<SEC-DOCUMENT>0001493152-21-005653.txt : 20210309
<SEC-HEADER>0001493152-21-005653.hdr.sgml : 20210309
<ACCEPTANCE-DATETIME>20210309121605
ACCESSION NUMBER:		0001493152-21-005653
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		127
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210309
DATE AS OF CHANGE:		20210309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Orgenesis Inc.
		CENTRAL INDEX KEY:			0001460602
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980583166
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38416
		FILM NUMBER:		21724867

	BUSINESS ADDRESS:	
		STREET 1:		20271 GOLDENROD LANE
		CITY:			GERMANTOWN
		STATE:			MD
		ZIP:			20876
		BUSINESS PHONE:		(480) 659-6404

	MAIL ADDRESS:	
		STREET 1:		20271 GOLDENROD LANE
		CITY:			GERMANTOWN
		STATE:			MD
		ZIP:			20876

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Orgenesis, Inc.
		DATE OF NAME CHANGE:	20110902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Business Outsourcing Service, Inc.
		DATE OF NAME CHANGE:	20090401
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ORGS="http://orgenesis.com/20201231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_ORGS_orgenesis.com_20201231 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20201231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001460602 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityFilerCategory_Non%2Daccelerated Filer -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_071_XDX_Z%2D%2D\XBRL OPERATIONS 2020\ORGENESIS INC\20201231 10K FY DFN%2DiXBRL\Client\form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_070_SO_Z%2D%2D\XBRL OPERATIONS 2020\ORGENESIS INC\20201231 10K FY DFN%2DiXBRL\Client\form10%2Dk.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_060_Percentage_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_Segment_0_Segment -->
<!-- Field: Set; Name: xdx; ID: xdx_065_EUR_0_iso4217%2D%2DEUR -->
<!-- Field: Set; Name: xdx; ID: xdx_064_KRW_0_iso4217%2D%2DKRW -->
<!-- Field: Set; Name: xdx; ID: xdx_063_NIS_0_iso4217%2D%2DILS -->
<body>
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityCentralIndexKey">0001460602</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityFilerCategory">Non-accelerated Filer</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2020-12-31" id="xdx2ixbrl0070" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:DueFromRelatedPartiesNoncurrent" contextRef="AsOf2020-12-31" id="xdx2ixbrl0082" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2019-12-31" id="xdx2ixbrl0086" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2019-12-31" id="xdx2ixbrl0122" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2019-12-31" id="xdx2ixbrl0137" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2020-12-31" id="xdx2ixbrl0145" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="AsOf2020-12-31" id="xdx2ixbrl0163" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2019-12-31" id="xdx2ixbrl0167" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:RedeemableNoncontrollingInterestOfDiscontinuedOperation" contextRef="AsOf2020-12-31" id="xdx2ixbrl0181" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2019-12-31" id="xdx2ixbrl0213" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:ShareInNetIncomeOfAssociatedCompanies" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0366" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0375" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:IssuanceOfSharesAndWarrantsShares" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0392" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0401" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0418" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:StockbasedCompensationToStrategicCollaborations" contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0430" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans" contextRef="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans" contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0435" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp" contextRef="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0440" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp" contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0449" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0454" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0455" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0476" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0486" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0487" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0488" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0490" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0495" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0506" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0507" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0508" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement" contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0517" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0518" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0519" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0521" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0526" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0528" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0529" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0530" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0532" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:IssuanceOfSharesAndWarrants" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0535" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:IssuanceOfSharesAndWarrants" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0537" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:IssuanceOfSharesAndWarrants" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0538" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:IssuanceOfSharesAndWarrants" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0539" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:IssuanceOfSharesAndWarrants" contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0541" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0548" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0549" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0550" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0552" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0557" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0559" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0560" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0561" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember" id="xdx2ixbrl0562" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0566" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0568" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0569" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0570" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0572" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0575" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0576" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0577" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0579" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0581" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0586" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0587" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0589" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:ShareBasedCompensationOne" contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl0620" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:ShareBasedCompensationTwo" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0624" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GainOrLossOnSaleOfStockInSubsidiary" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0630" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:ShareInNetIncomeOfAssociatedCompanies" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0633" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0690" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0699" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0702" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:PaymentsForInvestments" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0705" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:RepaymentOfTreasuryStock" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0717" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProceedsFromMinorityShareholders" contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl0719" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0723" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0729" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl0734" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl0755" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl0758" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl0773" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:AcquisitionOfOtherAssetInExchangeForCommonStocks" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0777" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0780" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0958" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal" contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl0960" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0962" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0966" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="From2020-01-012020-12-31_custom_TechTransferServicesMember" id="xdx2ixbrl1048" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="From2020-01-012020-12-31_custom_CellManufacturingServicesMember" id="xdx2ixbrl1052" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_custom_AdvancePaymentMember" id="xdx2ixbrl1187" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2019-12-31_country_BE" id="xdx2ixbrl1209" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2019-12-31_country_US" id="xdx2ixbrl1221" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl1232" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_custom_KyslecelTechnologyMember" id="xdx2ixbrl1258" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_custom_IPResearchAndDevelopmentMember" id="xdx2ixbrl1262" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansTwoMember" id="xdx2ixbrl1314" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansThreeMember" id="xdx2ixbrl1326" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" contextRef="From2019-01-012019-12-31_custom_ConvertibleLoansTwoMember" id="xdx2ixbrl1356" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:DebtInstrumentConvertibleRepaidBeneficialConversionFeature" contextRef="From2020-01-012020-12-31_custom_SixPercentageConvertibleLoansTwoMember" id="xdx2ixbrl1382" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:DebtInstrumentConvertibleRepaidBeneficialConversionFeature" contextRef="From2020-01-012020-12-31_custom_EightPercetageConvertibleLoansTwoMember" id="xdx2ixbrl1394" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonNumeric contextRef="AsOf2020-12-31_custom_ConvertibleLoansOneMember" id="xdx2ixbrl1403" name="us-gaap:WarrantsAndRightsOutstandingTerm">P3Y</ix:nonNumeric>
    <ix:nonNumeric contextRef="AsOf2020-12-31_custom_ConvertibleLoansTwoMember" id="xdx2ixbrl1417" name="us-gaap:WarrantsAndRightsOutstandingTerm">P3Y</ix:nonNumeric>
    <ix:nonNumeric contextRef="AsOf2019-04-30_custom_ConvertibleLoanAgreementMember_us-gaap_InvestorMember_custom_ConvertibleLoansOneMember" id="xdx2ixbrl1432" name="us-gaap:WarrantsAndRightsOutstandingTerm">P3Y</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:DebtCurrent" contextRef="AsOf2020-12-31_custom_ShortTermLoanOneMember_currency_KRW" id="xdx2ixbrl1630" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:DebtCurrent" contextRef="AsOf2020-12-31_custom_ShortTermLoansTwoMember_currency_KRW" id="xdx2ixbrl1636" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:DebtCurrent" contextRef="AsOf2019-12-31_custom_ShortTermLoansThreeMember" id="xdx2ixbrl1644" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2019-12-31_country_US" id="xdx2ixbrl1762" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="AsOf2019-12-31" id="xdx2ixbrl1988" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:TreasuryStockShare" contextRef="AsOf2019-12-31" id="xdx2ixbrl2064" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:WeightedAveragePriceNumberOfSharesTreasuryStock" contextRef="AsOf2019-12-31" id="xdx2ixbrl2066" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember" id="xdx2ixbrl2221" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember" id="xdx2ixbrl2223" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember" id="xdx2ixbrl2224" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember" id="xdx2ixbrl2225" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember" id="xdx2ixbrl2247" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember" id="xdx2ixbrl2249" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixMember" id="xdx2ixbrl2314" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSevenMember" id="xdx2ixbrl2321" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSevenMember" id="xdx2ixbrl2322" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSevenMember" id="xdx2ixbrl2323" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEightMember" id="xdx2ixbrl2328" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEightMember" id="xdx2ixbrl2329" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEightMember" id="xdx2ixbrl2330" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineMember" id="xdx2ixbrl2335" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTenMember" id="xdx2ixbrl2342" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceElevenMember" id="xdx2ixbrl2349" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwelveMember" id="xdx2ixbrl2356" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThirteenMember" id="xdx2ixbrl2363" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourteenMember" id="xdx2ixbrl2370" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFifteenMember" id="xdx2ixbrl2377" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixteenMember" id="xdx2ixbrl2384" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSeventeenMember" id="xdx2ixbrl2391" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEighteenMember" id="xdx2ixbrl2398" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineteenMember" id="xdx2ixbrl2405" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwentyMember" id="xdx2ixbrl2412" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember" id="xdx2ixbrl2494" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember" id="xdx2ixbrl2495" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember" id="xdx2ixbrl2499" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember" id="xdx2ixbrl2501" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember" id="xdx2ixbrl2505" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember" id="xdx2ixbrl2507" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceOneMember" id="xdx2ixbrl2531" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceOneMember" id="xdx2ixbrl2533" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwoMember" id="xdx2ixbrl2539" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwoMember" id="xdx2ixbrl2540" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixMember" id="xdx2ixbrl2566" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixMember" id="xdx2ixbrl2567" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixMember" id="xdx2ixbrl2568" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSevenMember" id="xdx2ixbrl2573" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSevenMember" id="xdx2ixbrl2574" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSevenMember" id="xdx2ixbrl2575" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEightMember" id="xdx2ixbrl2580" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineMember" id="xdx2ixbrl2587" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTenMember" id="xdx2ixbrl2594" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceElevenMember" id="xdx2ixbrl2601" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwelveMember" id="xdx2ixbrl2608" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThirteenMember" id="xdx2ixbrl2615" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThirteenMember" id="xdx2ixbrl2616" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThirteenMember" id="xdx2ixbrl2617" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourteenMember" id="xdx2ixbrl2622" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFifteenMember" id="xdx2ixbrl2629" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixteenMember" id="xdx2ixbrl2636" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSeventeenMember" id="xdx2ixbrl2643" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEighteenMember" id="xdx2ixbrl2650" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineteenMember" id="xdx2ixbrl2657" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonNumeric contextRef="AsOf2018-11-30_custom_SeveralConsultantsMember" id="xdx2ixbrl2755" name="us-gaap:WarrantsAndRightsOutstandingTerm">P3Y</ix:nonNumeric>
    <ix:nonNumeric contextRef="AsOf2018-01-31_custom_ConsultingAgreementMember_custom_ConsultantMember" id="xdx2ixbrl2763" name="us-gaap:WarrantsAndRightsOutstandingTerm">P3Y</ix:nonNumeric>
    <ix:nonNumeric contextRef="AsOf2018-07-31_custom_ConsultingAgreementMember_custom_ConsultantMember" id="xdx2ixbrl2772" name="us-gaap:WarrantsAndRightsOutstandingTerm">P3Y</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2019-12-31" id="xdx2ixbrl2841" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:DeferredTaxAssetsLeasesAsset" contextRef="AsOf2019-12-31" id="xdx2ixbrl2847" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:DeferredTaxAssetsLeaseLiability" contextRef="AsOf2019-12-31" id="xdx2ixbrl2850" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2020-12-31" id="xdx2ixbrl2861" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_custom_CustomerBMember" id="xdx2ixbrl2904" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:AccountsReceivableAcquisitionOfKoligo" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl2922" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue" contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl2984" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" contextRef="From2019-01-012019-12-31_us-gaap_SegmentContinuingOperationsMember" id="xdx2ixbrl3024" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="ORGS:DueFromRelatedPartiesNoncurrent1" contextRef="AsOf2020-12-31" id="xdx2ixbrl3051" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2019-12-31" id="xdx2ixbrl3057" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="AsOf2020-12-31" id="xdx2ixbrl3059" unitRef="USD" xs:nil="true"></ix:nonFraction>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="orgs-20201231.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-01-01to2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_EquityAttributedToOrgenesisIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ORGS:EquityAttributedToOrgenesisIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_EquityAttributedToOrgenesisIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ORGS:EquityAttributedToOrgenesisIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_EquityAttributedToOrgenesisIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ORGS:EquityAttributedToOrgenesisIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ORGS:EquityAttributedToOrgenesisIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_EquityAttributedToOrgenesisIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ORGS:EquityAttributedToOrgenesisIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-29_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:MasthercellMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-012020-02-29_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:MasthercellMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-01</xbrli:startDate>
        <xbrli:endDate>2020-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CureCellCoLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:CureCellCoLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:TamirBiotechnologyIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:TamirPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-06</xbrli:startDate>
        <xbrli:endDate>2020-04-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-092020-02-10_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:MasthercellMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-09</xbrli:startDate>
        <xbrli:endDate>2020-02-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-192020-01-20_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-19</xbrli:startDate>
        <xbrli:endDate>2020-01-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ProductionFacilityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:ProductionFacilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ProductionFacilityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:ProductionFacilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_EquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_EquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_KnowhowMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ORGS:KnowhowMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_TechnologyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ORGS:TechnologyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_AccountingStandardsUpdate201912Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-02_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:MasthercellMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-012020-02-02_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:MasthercellMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-01</xbrli:startDate>
        <xbrli:endDate>2020-02-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-092020-02-10_custom_MasthercellSAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:MasthercellSAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-09</xbrli:startDate>
        <xbrli:endDate>2020-02-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_country_BE">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CellProcessDevelopmentServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:CellProcessDevelopmentServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CellProcessDevelopmentServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:CellProcessDevelopmentServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_TechTransferServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:TechTransferServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_TechTransferServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:TechTransferServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CellManufacturingServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:CellManufacturingServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CellManufacturingServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:CellManufacturingServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:TamirBiotechnologyIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:TamirPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-142020-10-15_custom_KoligoTherapeuticsIncMember_custom_MaterialDefinitiveAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:KoligoTherapeuticsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:MaterialDefinitiveAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-14</xbrli:startDate>
        <xbrli:endDate>2020-10-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-142020-10-15_custom_MaximaGroupLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:MaximaGroupLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-14</xbrli:startDate>
        <xbrli:endDate>2020-10-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-10-15_custom_KoligoTherapeuticsIncMember_custom_MaterialDefinitiveAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:KoligoTherapeuticsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:MaterialDefinitiveAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-10-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-142020-10-15_custom_LongHillAndMaximGroupLLCMember_custom_RegistrationRightsandLockUpAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:LongHillAndMaximGroupLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:RegistrationRightsandLockUpAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-14</xbrli:startDate>
        <xbrli:endDate>2020-10-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_KyslecelTechnologyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ORGS:KyslecelTechnologyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_IPResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ORGS:IPResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_KyslecelTechnologyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ORGS:KyslecelTechnologyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_KoligoTherapeuticsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:KoligoTherapeuticsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_KoligoTherapeuticsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:KoligoTherapeuticsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-062019-08-07_custom_TransferAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:TransferAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-06</xbrli:startDate>
        <xbrli:endDate>2019-08-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ProductionFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:ProductionFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ProductionFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:ProductionFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OfficeFurnitureAndComputersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:OfficeFurnitureAndComputersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_OfficeFurnitureAndComputersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:OfficeFurnitureAndComputersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_LabEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:LabEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_LabEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:LabEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_AdvancePaymentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:AdvancePaymentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_AdvancePaymentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:AdvancePaymentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_country_BE">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_country_KR">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_country_KR">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_country_IL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_country_IL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_KnowhowMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ORGS:KnowhowMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_KnowhowMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ORGS:KnowhowMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_KyslecelTechnologyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ORGS:KyslecelTechnologyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_IPResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ORGS:IPResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleLoansOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ConvertibleLoansOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleLoansTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ConvertibleLoansTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleLoansTwoMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleLoansTwoMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ConvertibleLoansTwoMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ConvertibleLoansTwoMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleLoansThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ConvertibleLoansThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleLoansMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ConvertibleLoansOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_ConvertibleLoansOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ConvertibleLoansTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_ConvertibleLoansTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ConvertibleLoansTwoMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ConvertibleLoansTwoMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_ConvertibleLoansTwoMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_ConvertibleLoansTwoMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ConvertibleLoansMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_TwoPercentageConvertibleLoansTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:TwoPercentageConvertibleLoansTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_TwoPercentageConvertibleLoansTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:TwoPercentageConvertibleLoansTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_SixPercentageConvertibleLoansTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:SixPercentageConvertibleLoansTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SixPercentageConvertibleLoansTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:SixPercentageConvertibleLoansTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_EightPercetageConvertibleLoansTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:EightPercetageConvertibleLoansTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_EightPercetageConvertibleLoansTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:EightPercetageConvertibleLoansTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ConvertibleLoansMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleLoansOneMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_HemogenyxCelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:HemogenyxCelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ImmugenyxLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:ImmugenyxLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleLoansTwoMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-04-30_custom_ConvertibleLoanAgreementMember_us-gaap_InvestorMember_custom_ConvertibleLoansOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ConvertibleLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-30_custom_ConvertibleLoanAgreementMember_us-gaap_InvestorMember_custom_ConvertibleLoansOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ConvertibleLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-012019-05-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:PrivatePlacementSubscriptionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-01</xbrli:startDate>
        <xbrli:endDate>2019-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-05-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:PrivatePlacementSubscriptionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-05-31_custom_SixPercentageConvertibleLoanAgreementMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:SixPercentageConvertibleLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-012019-05-31_custom_SixPercentageConvertibleLoanAgreementMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:SixPercentageConvertibleLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-01</xbrli:startDate>
        <xbrli:endDate>2019-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-30_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:PrivatePlacementSubscriptionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:PrivatePlacementSubscriptionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-012019-11-30_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-01</xbrli:startDate>
        <xbrli:endDate>2019-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-012019-11-30_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-01</xbrli:startDate>
        <xbrli:endDate>2019-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-012019-11-30_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-01</xbrli:startDate>
        <xbrli:endDate>2019-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-012019-11-30_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-01</xbrli:startDate>
        <xbrli:endDate>2019-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-012019-11-30_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-01</xbrli:startDate>
        <xbrli:endDate>2019-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-012019-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-01-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-012020-02-29_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-01</xbrli:startDate>
        <xbrli:endDate>2020-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-012019-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-012019-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-012019-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-012019-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-01-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-01-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-01-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-01-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-012020-02-29_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-01</xbrli:startDate>
        <xbrli:endDate>2020-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-012020-02-29_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-01</xbrli:startDate>
        <xbrli:endDate>2020-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-012020-02-29_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-01</xbrli:startDate>
        <xbrli:endDate>2020-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-012020-02-29_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-01</xbrli:startDate>
        <xbrli:endDate>2020-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CreditLineAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CreditLineAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CreditLineAgreementsMember_custom_InvestorOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CreditLineAgreementsMember_custom_InvestorTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CreditLineAgreementsMember_custom_TwoOtherInvestorTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:TwoOtherInvestorTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CreditLineAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-012019-12-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:PrivatePlacementSubscriptionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:PrivatePlacementSubscriptionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-302020-01-03_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:PrivatePlacementSubscriptionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-30</xbrli:startDate>
        <xbrli:endDate>2020-01-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-02_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:PrivatePlacementSubscriptionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-12-012018-12-31_custom_ControlledEquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-12-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-11-012016-11-02_custom_ControlledEquityOfferingSalesAgreementMember_currency_ILS">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-11-01</xbrli:startDate>
        <xbrli:endDate>2016-11-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-11-012016-11-02_custom_ControlledEquityOfferingSalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-11-01</xbrli:startDate>
        <xbrli:endDate>2016-11-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-11-02_custom_ControlledEquityOfferingSalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-11-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_custom_ControlledEquityOfferingSalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-012018-04-30_custom_ControlledEquityOfferingSalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2018-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ShortTermLoanOneMember_currency_KRW">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">ORGS:ShortTermLoanOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:KRW</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ShortTermLoanOneMember_currency_KRW">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">ORGS:ShortTermLoanOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:KRW</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ShortTermLoansTwoMember_currency_KRW">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">ORGS:ShortTermLoansTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:KRW</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ShortTermLoansTwoMember_currency_KRW">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">ORGS:ShortTermLoansTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:KRW</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ShortTermLoansThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">ORGS:ShortTermLoansThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ShortTermLoansThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">ORGS:ShortTermLoansThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_ManufacturingFacilityMember_country_IL_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_ManufacturingFacilityMember_country_IL_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ResearchAndDevelopmentFacilitiesMember_country_KR_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:ResearchAndDevelopmentFacilitiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ResearchAndDevelopmentFacilitiesMember_country_KR_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:ResearchAndDevelopmentFacilitiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OfficesMember_country_IL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:OfficesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-06-30_custom_MarylandTechnologyDevelopmentCorporationMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:MarylandTechnologyDevelopmentCorporationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-11-17_custom_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-11-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-11-17_custom_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-11-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-11-17_custom_IndustrialResearchPartOfResearchProgramMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:IndustrialResearchPartOfResearchProgramMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-11-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-11-17_custom_IndustrialResearchPartOfResearchProgramMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:IndustrialResearchPartOfResearchProgramMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-11-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-11-17_custom_ExperimentalDevelopmentPartOfResearchProgramMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ExperimentalDevelopmentPartOfResearchProgramMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-11-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-11-17_custom_ExperimentalDevelopmentPartOfResearchProgramMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ExperimentalDevelopmentPartOfResearchProgramMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-11-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_custom_RevenueFromGrantsMember_custom_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:RevenueFromGrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-04-30_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:DevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-04-30_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:DevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-012016-04-30_custom_RevenueFromGrantsMember_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:RevenueFromGrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:DevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-012016-04-30_custom_RevenueFromGrantsMember_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:RevenueFromGrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:DevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_RevenueFromGrantsMember_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:RevenueFromGrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:DevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_RevenueFromGrantsMember_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:RevenueFromGrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:DevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:DevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:DevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-10-08_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-10-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-10-08_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-10-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-012016-10-08_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2016-10-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-012016-10-08_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2016-10-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-12-012016-12-19_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-12-01</xbrli:startDate>
        <xbrli:endDate>2016-12-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-12-012016-12-19_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-12-01</xbrli:startDate>
        <xbrli:endDate>2016-12-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_DeductionOfResearchAndDevelopmentExpensesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:DeductionOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchOnDermatitisTreatmentsAndWoundHealingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchOnDermatitisTreatmentsAndWoundHealingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchOnDermatitisTreatmentsAndWoundHealingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchOnDermatitisTreatmentsAndWoundHealingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchOnDermatitisTreatmentsAndWoundHealingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchOnDermatitisTreatmentsAndWoundHealingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-09_custom_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-09-012015-09-09_custom_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-09-01</xbrli:startDate>
        <xbrli:endDate>2015-09-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-05-26_custom_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:KoreaisraelIndustrialResearchAndDevelopmentFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-05-012016-05-26_custom_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:KoreaisraelIndustrialResearchAndDevelopmentFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-05-01</xbrli:startDate>
        <xbrli:endDate>2016-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:KoreaisraelIndustrialResearchAndDevelopmentFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-30_custom_BirdSecantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:BirdSecantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OBIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:OBIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_DeductionOfResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:DeductionOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-01-28_custom_AdvaBiotechnologyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:AdvaBiotechnologyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-01-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-262018-01-28_custom_AdvaBiotechnologyLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:AdvaBiotechnologyLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-26</xbrli:startDate>
        <xbrli:endDate>2018-01-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-02-012012-02-02_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-02-01</xbrli:startDate>
        <xbrli:endDate>2012-02-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-02_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-02_custom_OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-02_custom_OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-02_custom_OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-02_custom_OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-02_custom_WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-18_custom_HemogenyxPharmaceuticalsPLCMember_custom_SalesMilestoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:HemogenyxPharmaceuticalsPLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:SalesMilestoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-18_custom_HemogenyxPharmaceuticalsPLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:HemogenyxPharmaceuticalsPLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-232018-11-25_custom_HemogenyxPharmaceuticalsPLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:HemogenyxPharmaceuticalsPLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-11-23</xbrli:startDate>
        <xbrli:endDate>2018-11-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_HemogenyxPharmaceuticalsPLCMember_custom_ResearchAndDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:HemogenyxPharmaceuticalsPLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_HemogenyxPharmaceuticalsPLCMember_custom_ResearchAndDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:HemogenyxPharmaceuticalsPLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-152018-10-16_custom_ImmuAgreementMember_custom_ImmugenyxLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:ImmuAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:ImmugenyxLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-15</xbrli:startDate>
        <xbrli:endDate>2018-10-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-16_custom_ImmugenyxLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:ImmugenyxLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_ImmugenyxLLCMember_custom_ResearchAndDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:ImmugenyxLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ImmugenyxLLCMember_custom_ResearchAndDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:ImmugenyxLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-242018-11-25_custom_BgNegevTechnologiesAndApplicationsBgnMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:BgNegevTechnologiesAndApplicationsBgnMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-11-24</xbrli:startDate>
        <xbrli:endDate>2018-11-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-242018-11-25_custom_BgNegevTechnologiesAndApplicationsBgnMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:BgNegevTechnologiesAndApplicationsBgnMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-11-24</xbrli:startDate>
        <xbrli:endDate>2018-11-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-242018-11-25_custom_BgNegevTechnologiesAndApplicationsBgnMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:BgNegevTechnologiesAndApplicationsBgnMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-11-24</xbrli:startDate>
        <xbrli:endDate>2018-11-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-11-25_custom_BgNegevTechnologiesAndApplicationsBgnMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:BgNegevTechnologiesAndApplicationsBgnMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CollaborationAgreementMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CollaborationAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:CollaborationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CollaborationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:CollaborationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CollaborationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:CollaborationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_SponsoredResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:SponsoredResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ColumbiaLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:ColumbiaLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_MarylandSubsidiaryMember_custom_AIPCellsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">ORGS:MarylandSubsidiaryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:AIPCellsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CaliforniaUniversityJointResearchAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:CaliforniaUniversityJointResearchAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CaerusTherapeuticsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">ORGS:CaerusTherapeuticsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CaerusTherapeuticsIncMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">ORGS:CaerusTherapeuticsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CaerusTherapeuticsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">ORGS:CaerusTherapeuticsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_custom_ExtracellularVesicleMember_custom_EVAmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ORGS:ExtracellularVesicleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:EVAmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-07_srt_MaximumMember_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:TamirBiotechnologyIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:TamirPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-062020-04-07_srt_MaximumMember_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:TamirBiotechnologyIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:TamirPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-06</xbrli:startDate>
        <xbrli:endDate>2020-04-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_TissueGenesisLLCMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:TissueGenesisLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-292020-12-31_custom_TissueGenesisLLCMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:TissueGenesisLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-29</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_BroadenJointVentureAgreementMember_custom_MarylandSubsidiaryMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:BroadenJointVentureAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:MarylandSubsidiaryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_BroadenJointVentureAgreementMember_custom_MarylandSubsidiaryMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:BroadenJointVentureAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:MarylandSubsidiaryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_BroadenJointVentureAgreementMember_custom_MarylandSubsidiaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:BroadenJointVentureAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:MarylandSubsidiaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_srt_MinimumMember_custom_BroadenJointVentureAgreementMember_custom_MarylandSubsidiaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:BroadenJointVentureAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:MarylandSubsidiaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_JointVentureAgreementMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:JointVentureAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_JointVentureAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:JointVentureAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-312022-01-01_custom_JointVentureAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:JointVentureAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-31</xbrli:startDate>
        <xbrli:endDate>2022-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_JointVentureAgreementMember_custom_KinerjapayCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:JointVentureAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:KinerjapayCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-12-31_custom_SBHSciencesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:SBHSciencesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-10-31_custom_TLABSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:TLABSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-10-31_custom_ButterflyBiosciencesSarlMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:ButterflyBiosciencesSarlMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-10-31_custom_KidneyCureJVAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:KidneyCureJVAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-20_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-192020-01-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-19</xbrli:startDate>
        <xbrli:endDate>2020-01-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-242020-09-26_custom_MergerAgreementMember_custom_KoligoTherapeuticsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:MergerAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:KoligoTherapeuticsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-24</xbrli:startDate>
        <xbrli:endDate>2020-09-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-26_custom_MergerAgreementMember_custom_KoligoTherapeuticsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:MergerAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:KoligoTherapeuticsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsAndWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ORGS:OptionsAndWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_SharesUponConversionOfConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ORGS:SharesUponConversionOfConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-05-11_custom_TwoZeroOneSevenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ORGS:TwoZeroOneSevenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-05-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-05-092017-05-11_srt_MaximumMember_custom_TwoZeroOneSevenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ORGS:TwoZeroOneSevenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-05-09</xbrli:startDate>
        <xbrli:endDate>2017-05-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-05-092017-05-11_custom_TwoZeroOneSevenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ORGS:TwoZeroOneSevenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-05-09</xbrli:startDate>
        <xbrli:endDate>2017-05-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_TwoZeroOneSevenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ORGS:TwoZeroOneSevenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_TwoZeroOneSevenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ORGS:TwoZeroOneSevenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-05-23_custom_GlobalShareIncentivePlanTwoZeroOneTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ORGS:GlobalShareIncentivePlanTwoZeroOneTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-05-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-05-212012-05-23_srt_MaximumMember_custom_GlobalShareIncentivePlanTwoZeroOneTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ORGS:GlobalShareIncentivePlanTwoZeroOneTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-05-21</xbrli:startDate>
        <xbrli:endDate>2012-05-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_GlobalShareIncentivePlanTwoZeroOneTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ORGS:GlobalShareIncentivePlanTwoZeroOneTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_GlobalShareIncentivePlanTwoZeroOneTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ORGS:GlobalShareIncentivePlanTwoZeroOneTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_OneYearAnniversaryMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ORGS:OneYearAnniversaryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ThreeEqualInstallmentsMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ORGS:ThreeEqualInstallmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_srt_MaximumMember_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_srt_MaximumMember_custom_OptionsGrantedToEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_srt_MaximumMember_custom_OptionsGrantedToEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_OptionsGrantedToEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_OptionsGrantedToEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSeventeenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSeventeenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSeventeenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSeventeenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceNineteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceNineteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_MasthercellGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:MasthercellGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_MasthercellGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:MasthercellGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_MasthercellGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:MasthercellGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_OptionsGrantedToNonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_OptionsGrantedToNonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSeventeenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSeventeenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSeventeenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSeventeenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceNineteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceNineteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-02_custom_PrivatePlacementSubscriptionAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:PrivatePlacementSubscriptionAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-01-02_custom_PrivatePlacementSubscriptionAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:PrivatePlacementSubscriptionAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_NonEmployeesMember_custom_SeveralConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:NonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeveralConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_NonEmployeesMember_custom_ConvertibleNotesAndPrivateInvestmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:NonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ORGS:ConvertibleNotesAndPrivateInvestmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_SeveralConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:SeveralConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_srt_MinimumMember_custom_SeveralConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:SeveralConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_srt_MaximumMember_custom_SeveralConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:SeveralConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_SuccessFeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ORGS:SuccessFeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-012019-09-30_custom_InvestorRelationContactMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-012019-09-30_custom_HeldUntilSixMonthsAnniversaryMember_custom_InvestorRelationContactMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ORGS:HeldUntilSixMonthsAnniversaryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-012019-09-30_custom_HeldUntilOneYearAnniversaryMember_custom_InvestorRelationContactMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ORGS:HeldUntilOneYearAnniversaryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-092019-09-30_custom_InvestorRelationContactMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-09</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-03-012019-03-31_custom_FirstChoiceInternationalCompanyIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:FirstChoiceInternationalCompanyIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-03-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_FirstChoiceInternationalCompanyIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:FirstChoiceInternationalCompanyIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-12-012018-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-12-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_VestedOnSigningDateMember_custom_InvestorRelationContactMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ORGS:VestedOnSigningDateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_VestMonthlyOver3MonthsMember_custom_InvestorRelationContactMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ORGS:VestMonthlyOver3MonthsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-012019-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-12-012018-12-31_custom_SeparateInvestorRelationsContactMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeparateInvestorRelationsContactMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-12-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_VestedOnSigningDateMember_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ORGS:VestedOnSigningDateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeparateInvestorRelationContactMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_VestMonthlyOver3MonthsMember_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ORGS:VestMonthlyOver3MonthsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeparateInvestorRelationContactMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeparateInvestorRelationContactMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-012019-12-31_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeparateInvestorRelationContactMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeparateInvestorRelationContactMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-11-30_custom_SeveralConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeveralConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-292018-11-30_custom_SeveralConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeveralConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-11-29</xbrli:startDate>
        <xbrli:endDate>2018-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-01-31_custom_ConsultingAgreementMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-01-31_custom_ConsultingAgreementMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-012018-07-31_custom_ConsultingAgreementMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_custom_ConsultingAgreementMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-012017-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_VestedOnSigningDateMember_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ORGS:VestedOnSigningDateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeparateInvestorRelationContactMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_VestMonthlyOver3MonthsMember_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ORGS:VestMonthlyOver3MonthsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeparateInvestorRelationContactMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_country_IL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_country_IL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_country_BE_custom_TwoThousandTwentyOneToTwoThousandTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ORGS:TwoThousandTwentyOneToTwoThousandTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_country_BE">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_country_BE_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_country_KR_custom_TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">ORGS:TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_country_KR_custom_UpToKrwTwoZeroBillionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">ORGS:UpToKrwTwoZeroBillionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_country_KR_custom_UpToKrwThreeZeroZeroBillionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">ORGS:UpToKrwThreeZeroZeroBillionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_country_KR_custom_TaxBaseAboveKrwThreeZeroZeroBillionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">ORGS:TaxBaseAboveKrwThreeZeroZeroBillionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_country_KR_custom_SouthKoreanWonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ORGS:SouthKoreanWonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_country_KR">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_PointOfCareServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:PointOfCareServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_PointOfCareServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:PointOfCareServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_MasterServicesAgreementsMember_custom_JointVenturePartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:MasterServicesAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:JointVenturePartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CustomerAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ORGS:CustomerAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CustomerAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ORGS:CustomerAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CustomerBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ORGS:CustomerBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CustomerBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ORGS:CustomerBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CustomerCRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ORGS:CustomerCRelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CustomerCRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ORGS:CustomerCRelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CustomerDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ORGS:CustomerDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CustomerDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ORGS:CustomerDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_SegmentContinuingOperationsMember_srt_ExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_SegmentContinuingOperationsMember_srt_ExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_BoardMembersMember_us-gaap_SegmentContinuingOperationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:BoardMembersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_SegmentContinuingOperationsMember_custom_BoardMembersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:BoardMembersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_SegmentContinuingOperationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_SegmentContinuingOperationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CaerusTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:CaerusTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_CaerusTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:CaerusTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_SegmentDiscontinuedOperationsMember_srt_ExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_srt_ExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_srt_ExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NonexecutiveDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:NonexecutiveDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_NonexecutiveDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460602</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:NonexecutiveDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Percentage">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>ORGS:Segment</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="EUR">
      <xbrli:measure>iso4217:EUR</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="KRW">
      <xbrli:measure>iso4217:KRW</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="NIS">
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unit>
    <ix:relationship fromRefs="Fact000502" toRefs="Footnote000606"></ix:relationship>
    <ix:relationship fromRefs="Fact001095" toRefs="Footnote001102"></ix:relationship>
    <ix:relationship fromRefs="Fact001116" toRefs="Footnote001143"></ix:relationship>
    <ix:relationship fromRefs="Fact001118" toRefs="Footnote001143"></ix:relationship>
    <ix:relationship fromRefs="Fact001122" toRefs="Footnote001150"></ix:relationship>
    <ix:relationship fromRefs="Fact001296" toRefs="Footnote001397"></ix:relationship>
    <ix:relationship fromRefs="Fact001338" toRefs="Footnote001397"></ix:relationship>
    <ix:relationship fromRefs="Fact001312" toRefs="Footnote001411"></ix:relationship>
    <ix:relationship fromRefs="Fact001354" toRefs="Footnote001411"></ix:relationship>
    <ix:relationship fromRefs="Fact001324" toRefs="Footnote001424"></ix:relationship>
    <ix:relationship fromRefs="Fact002053" toRefs="Footnote002060"></ix:relationship>
    <ix:relationship fromRefs="Fact002055" toRefs="Footnote002060"></ix:relationship>
    <ix:relationship fromRefs="Fact002057" toRefs="Footnote002060"></ix:relationship>
    <ix:relationship fromRefs="Fact002059" toRefs="Footnote002060"></ix:relationship>
    <ix:relationship fromRefs="Fact002950" toRefs="Footnote002961"></ix:relationship>
    <ix:relationship fromRefs="Fact002952" toRefs="Footnote002961"></ix:relationship>
    <ix:relationship fromRefs="Fact003007" toRefs="Footnote003029"></ix:relationship>
    <ix:relationship fromRefs="Fact003009" toRefs="Footnote003029"></ix:relationship>
    </ix:resources>
  </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>FORM
<span id="xdx_905_edei--DocumentType_c20200101__20201231_ztnLqmetB4M9"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Mark
One)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_edei--DocumentAnnualReport_c20200101__20201231_zFhQm7GAs9yf"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span>
</span><span style="font: 10pt Times New Roman, Times, Serif"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For
the fiscal year ended <b><span style="text-decoration: underline"><span id="xdx_90D_edei--DocumentPeriodEndDate_c20200101__20201231_zBhlEEiNV6Qi"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 31, 2020</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_edei--DocumentTransitionReport_c20200101__20201231_zUyNeQMwSOj7"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
<b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For
the transition period from __________________________ to __________________________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Commission
file number <b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityFileNumber_c20200101__20201231_zz4gaJHDg6gg"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityFileNumber">001-38416</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><img src="form10-k_001.jpg" alt="" style="height: 55px; width: 182px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_90C_edei--EntityRegistrantName_c20200101__20201231_zaOba2TDnKLc"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityRegistrantName">ORGENESIS
INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20200101__20201231_zoHWyATNA4o4"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20200101__20201231_zW585yMKqKF2"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityTaxIdentificationNumber">98-0583166</ix:nonNumeric></span></span></b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">State
    or other jurisdiction</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(I.R.S.
    Employer</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">of
    incorporation or organization</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Identification
    No.)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_906_edei--EntityAddressAddressLine1_c20200101__20201231_zVRQpHbYKCb8"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityAddressAddressLine1">20271
Goldenrod Lane</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressCityOrTown_c20200101__20201231_zDR3PhLP6OF4"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityAddressCityOrTown">Germantown</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressStateOrProvince_c20200101__20201231_zImDyXzswPqd"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityAddressStateOrProvince">MD</ix:nonNumeric></span> <span id="xdx_909_edei--EntityAddressPostalZipCode_c20200101__20201231_zODTPruF7Rme"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityAddressPostalZipCode">20876</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Address
of Principal Executive Offices) (Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Registrant&#8217;s
telephone number, including area code: <b><span style="text-decoration: underline"><span id="xdx_906_edei--CityAreaCode_c20200101__20201231_zHOYqdgQaFv4"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:CityAreaCode">(480)</ix:nonNumeric></span> <span id="xdx_90D_edei--LocalPhoneNumber_c20200101__20201231_zRGpFA4Pnpt"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:LocalPhoneNumber">659-6404</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name
    of each exchange on which registered</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_903_edei--Security12bTitle_c20200101__20201231_zwShKfDDDhTd"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:Security12bTitle">Common
    Stock, par value $0.0001 per share</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_901_edei--TradingSymbol_c20200101__20201231_zNsyKpCtyYA9"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:TradingSymbol">ORGS</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>The
    <span id="xdx_90C_edei--SecurityExchangeName_c20200101__20201231_zrycq28sqVq2"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(g) of the Act: <b><span style="text-decoration: underline">None</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_90A_edei--EntityWellKnownSeasonedIssuer_c20200101__20201231_zG8DVJ9nq7r2"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span>
&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744;
<span id="xdx_90B_edei--EntityVoluntaryFilers_c20200101__20201231_zXpzY3FISkK6"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. <span id="xdx_90A_edei--EntityCurrentReportingStatus_c20200101__20201231_zyjEycyY3JSe"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files). <span id="xdx_901_edei--EntityInteractiveDataCurrent_c20200101__20201231_zJxD2raxfWae"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">Accelerated
    filer &#9744;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Non-accelerated
    filer <b>&#9746;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Smaller
reporting company </span><span id="xdx_903_edei--EntitySmallBusiness_c20200101__20201231_z7Ve0v0tjMel"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Emerging
    growth company <span id="xdx_902_edei--EntityEmergingGrowthCompany_c20200101__20201231_zIBebmRRgsnc"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes <b>&#9744;</b> <span id="xdx_908_edei--EntityShellCompany_c20200101__20201231_zummIdCM8Ju6"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
registrant had <span id="xdx_909_edei--EntityCommonStockSharesOutstanding_iI_c20210309_zaVUmpNFmsB9"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2021-03-09" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,199,674</ix:nonFraction></span> shares of common stock outstanding as of March 9, 2021. The aggregate market value of the common
stock held by non-affiliates of the registrant as of the last business day of the registrant&#8217;s most recently completed second
fiscal quarter (June 30, 2020) was $<span id="xdx_90F_edei--EntityPublicFloat_iI_c20200630_zs8jbt2V0Mle"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,399,427</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">,
as computed by reference to the closing price of such common stock on The Nasdaq Capital Market on such date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ORGENESIS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020
FORM 10-K ANNUAL REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Page</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#a_001">PART I</a></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_002">ITEM 1. BUSINESS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">5<span style="font: 10pt Times New Roman, Times, Serif"></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_003">ITEM 1A. RISK FACTORS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">21</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_004">ITEM 1B. UNRESOLVED STAFF COMMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">42<span style="font: 10pt Times New Roman, Times, Serif"></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_005">ITEM 2. PROPERTIES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">42</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_006">ITEM 3. LEGAL PROCEEDINGS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">43</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_007">ITEM 4. MINE SAFETY DISCLOSURES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">43</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#a_008">PART II</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_009">ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">43<span style="font: 10pt Times New Roman, Times, Serif"></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_010">ITEM 6. SELECTED FINANCIAL DATA</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">45</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_011">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">45<span style="font: 10pt Times New Roman, Times, Serif"></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_012">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">61</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_013">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">61</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_014">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">61</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_015">ITEM 9A. CONTROLS AND PROCEDURES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">61</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_016">ITEM 9B. OTHER INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">62<span style="font: 10pt Times New Roman, Times, Serif"></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#a_017">PART III</a></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_018">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">62</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_019">ITEM 11. EXECUTIVE COMPENSATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">67</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_020">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">73<span style="font: 10pt Times New Roman, Times, Serif"></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_021">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">76</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_022">ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">77<span style="font: 10pt Times New Roman, Times, Serif"></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#a_023">PART IV</a></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_024">ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">78</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_025">ITEM 16. FORM 10-K SUMMARY</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">81</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_026">SIGNATURES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">82</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>FORWARD-LOOKING
STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">CAUTIONARY
STATEMENT FOR PURPOSES OF THE &#8220;SAFE HARBOR&#8221; PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following discussion should be read in conjunction with the financial statements and related notes contained elsewhere in this
Annual Report on Form 10-K. Certain statements made in this discussion are &#8220;forward-looking statements&#8221; within the
meaning of 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities
Exchange Act of 1934, as amended. These statements are based upon beliefs of, and information currently available to, the Company&#8217;s
management as well as estimates and assumptions made by the Company&#8217;s management. Readers are cautioned not to place undue
reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. When used herein,
the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221;
&#8220;future,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221;
&#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221;
or the negative of these terms and similar expressions as they relate to the Company or the Company&#8217;s management identify
forward-looking statements. Such statements reflect the current view of the Company with respect to future events and are subject
to risks, uncertainties, assumptions, and other factors, including the risks relating to the Company&#8217;s business, industry,
and the Company&#8217;s operations and results of operations. Should one or more of these risks or uncertainties materialize,
or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed,
estimated, expected, intended, or planned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Although
the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee
future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities
laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements
to actual results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
financial statements are prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;).
These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments
and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments
and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities
as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented.
Our financial statements would be affected to the extent there are material differences between these estimates and actual results.
The following discussion should be read in conjunction with our financial statements and notes thereto appearing elsewhere in
this report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Unless
otherwise indicated or the context requires otherwise, the words &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company,&#8221;
&#8220;our Company&#8221; or &#8220;Orgenesis&#8221; refer to Orgenesis Inc., a Nevada corporation, and our majority or wholly-owned
subsidiaries, Orgenesis Korea Co. Ltd. (the &#8220;Korean Subsidiary&#8221;), (formerly known as CureCell); Orgenesis Belgium
SRL, a Belgian-based entity (the &#8220;Belgian Subsidiary&#8221;); Orgenesis Ltd., an Israeli corporation (the &#8220;Israeli
Subsidiary&#8221;); Orgenesis Maryland Inc., a Maryland corporation (the &#8220;U.S. Subsidiary&#8221;); Orgenesis Switzerland
Sarl, which was incorporated in October 2020 (the &#8220;Swiss Subsidiary&#8221;); Orgenesis Biotech Israel Ltd. (formerly known
as Atvio Biotech Ltd.) (&#8220;OBI&#8221;); Koligo Therapeutics Inc., a Kentucky corporation, purchased in 2020 (&#8220;Koligo&#8221;);
Masthercell Global Inc. (&#8220;Masthercell&#8221;) and its wholly owned subsidiaries Cell Therapy Holdings S.A., MaSTherCell,
S.A. (&#8220;MaSTherCell&#8221;), a Belgian-based subsidiary and a Contract Development and Manufacturing Organization (&#8220;CDMO&#8221;)
specialized in cell therapy development and manufacturing for advanced medicinal products, and Masthercell U.S., LLC (&#8220;Masthercell
U.S.&#8221;), a U.S.-based CDMO (collectively, &#8220;Masthercell&#8221;). The Company sold all of its equity interests in Masthercell
and its subsidiaries on February 20, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Forward-looking
statements made in this Annual Report on Form 10-K include statements about:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Corporate
and Financial</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    ability to increase revenues;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    ability to achieve profitability;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    ability to manage our research and development programs that are based on novel technologies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    ability to grow the size and capabilities of our organization through further collaboration and strategic alliances to expand
    our point-of-care cell therapy business;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    ability to control key elements relating to the development and commercialization of therapeutic product candidates with third
    parties;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    ability to manage potential disruptions as a result of the coronavirus outbreak;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    ability to manage the growth of our company;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    ability to attract and retain key scientific or management personnel and to expand our management team;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    accuracy of estimates regarding expenses, future revenue, capital requirements, profitability, and needs for additional financing;
    and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    belief that our therapeutic related developments have competitive advantages and can compete favorably and profitably in the
    cell and gene therapy industry.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Cell
&amp; Gene Therapy Business (&#8220;CGT&#8221;)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160; </span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    ability to adequately fund and scale our various collaboration, license, partnership and joint venture agreements for the
    development of therapeutic products and technologies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    ability to advance our therapeutic collaborations in terms of industrial development, clinical development, regulatory challenges,
    commercial partners and manufacturing availability;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    ability to implement our point-of-care cell therapy (&#8220;POC&#8221;) strategy in order to further develop and advance autologous
    therapies to reach patients;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">expectations
    regarding our ability to obtain additional and maintain existing intellectual property protection for our technologies and
    therapies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    ability to commercialize products in light of the intellectual property rights of others;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    ability to obtain funding necessary to start and complete such clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    ability to further our CGT development projects, either directly or through our JV partner agreements, and to fulfill our
    obligations under such agreements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    belief that our systems and therapies are as at least as safe and as effective as other options;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    Subsidiary&#8217;s relationship with Tel Hashomer Medical Research Infrastructure and Services Ltd. (&#8220;THM&#8221;) and
    the risk that THM may cancel or, at the very least continue to challenge, the License Agreement with Orgenesis Ltd. as we
    continue to expand our focus to other therapies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    license agreements with other institutions;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">expenditures
    not resulting in commercially successful products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    dependence on the financial results of our POC business; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    ability to grow our POC business and to develop additional joint venture relationships in order to produce demonstrable revenues.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">These
statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks in the
section entitled &#8220;Risk Factors&#8221; set forth in this Annual Report on Form 10-K for the year ended December 31, 2020,
any of which may cause our Company&#8217;s or our industry&#8217;s actual results, levels of activity, performance or achievements
to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these
forward-looking statements. These risks may cause the Company&#8217;s or its industry&#8217;s actual results, levels of activity
or performance to be materially different from any future results, levels of activity or performance expressed or implied by these
forward looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity or performance. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness
of these forward-looking statements. The Company is under no duty to update any forward-looking statements after the date of this
report to conform these statements to actual results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_001"></span>PART
I</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_002"></span>ITEM
1. BUSINESS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Business
Overview</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
Inc., a Nevada corporation, is a global biotech company working to unlock the potential of cell and gene therapies in an affordable
and accessible format (&#8220;CGTs&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">CGTs
can be centered on autologous (using the patient&#8217;s own cells) or allogenic (using master banked donor cells) and are part
of a class of medicines referred to as advanced therapy medicinal products (ATMPs). We mostly focus on autologous therapies, with
processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated
for compliant production near the patient at their point of care for treatment of the patient. This approach has the potential
to overcome the limitations of traditional commercial manufacturing methods that do not translate well to commercial production
of advanced therapies due to their cost prohibitive nature and complex logistics to deliver the treatments to patients (ultimately
limiting the number of patients that can have access to, or can afford, these therapies).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">To
achieve these goals, we have developed a Point of Care Platform comprised of three enabling components: a pipeline of licensed
<b>POCare Therapies</b> that are designed to be processed and produced in closed, automated <b>POCare Technology</b> systems across
a collaborative <b>POCare Network</b>. Via a combination of science, technology, engineering, and networking, we are working to
provide a more efficient and scalable pathway for advanced therapies to reach patients more rapidly at lowered costs. We also
draw on extensive medical expertise to identify promising new autologous therapies to leverage within the POCare Platform either
via ownership or licensing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
POCare Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide with a goal of
achieving harmonized, regulated clinical development and production of the therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><img src="form10-k_002.jpg" alt="" style="height: 249px; width: 571px" /></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>POCare
Platform Operations via Subsidiaries</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
currently conduct our core business operations ourselves and through our subsidiaries which are all wholly-owned except as otherwise
stated below (collectively, the &#8220;Subsidiaries&#8221;). The Subsidiaries are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>United
States</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
    Maryland Inc. (the &#8220;U.S. Subsidiary&#8221;) is the center of activity in North America and is currently focused on setting
    up the POCare Network.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Koligo
    Therapeutics Inc. (&#8220;Koligo&#8221;) is a Kentucky corporation that we acquired in 2020 and is currently focused on developing
    the POCare network and therapies. .</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Europe</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
    Belgium SRL (the &#8220;Belgian Subsidiary&#8221;) is the center of activity in Europe and is currently focused on process
    development and the preparation of European clinical trials.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
    Switzerland Sarl (the &#8220;Swiss Subsidiary&#8221;), was incorporated in October 2020, and is currently focused on providing
    management services to us.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: 10pt Times New Roman, Times, Serif"><b>Asia</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
    Ltd. in Israel (the &#8220;Israeli Subsidiary&#8221;) is a provider of regulatory, clinical and pre-clinical services.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
    Biotech Israel Ltd. (&#8220;OBI&#8221;), is a provider of cell-processing services in Israel.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Korea:
    Orgenesis Korea Co. Ltd. (the &#8220;Korean Subsidiary&#8221;), is a provider of processing and pre-clinical services in Korea.
    We own 94.12% of the Korean Subsidiary.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Discontinued
Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Until
December 31, 2019, we operated the POCare Platform as one of two business separate business segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Historically,
the second separate business segment was operated as a Contract Development and Manufacturing Organization (&#8220;CDMO&#8221;)
platform, providing contract manufacturing and development services for biopharmaceutical companies (the &#8220;CDMO Business&#8221;).
The CDMO platform was historically operated mainly through majority owned Masthercell Global (which consisted of the following
two subsidiaries: MaSTherCell S.A. in Belgium (&#8220;MaSTherCell&#8221;), and Masthercell U.S., LLC in the United States (&#8220;Masthercell
U.S.&#8221;) (collectively, the &#8220;Masthercell Global Subsidiaries&#8221;)).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
February 2020, we and GPP-II Masthercell LLC (&#8220;GPP&#8221;) sold 100% of the outstanding equity interests of Masthercell
(the &#8220;Masthercell Business&#8221;), which comprised the majority of our CDMO Business, to Catalent Pharma Solutions, Inc.
for an aggregate nominal purchase price of $315 million, subject to customary adjustments (the &#8220;Masthercell Sale&#8221;).
After accounting for GPP&#8217;s liquidation preference and equity stake in Masthercell as well as other investor interests in
our Belgian subsidiary MaSTherCell, distributions to Masthercell option holders and transaction costs, we received approximately
$126.7 million. We incurred an additional approximately $5.6 million in transaction costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
determined that the Masthercell Business (&#8220;Discontinued Operation&#8221;) meets the criteria to be classified as a discontinued
operation as of the first quarter of 2020. The Discontinued Operation includes the vast majority of the previous CDMO Business,
including majority-owned Masthercell, including MaSTherCell, Masthercell U.S. and all of the Masthercell Global Subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Since
the Masthercell Sale, we entered into new joint venture agreements with new partners in various jurisdictions. This has allowed
us to grow our infrastructure and expand our processing sites into new markets and jurisdictions. In addition, we have engaged
some of these joint venture partners to perform research and development services to further develop and adapt our systems and
devices for specific purposes. We have been investing manpower and financial resources to focus on developing, manufacturing and
rolling out several types of OMPULs to be used and/or distributed through our POCare Network of partners, collaborators, and joint
ventures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Chief Executive Officer
(&#8220;CEO&#8221;) is the Company&#8217;s chief operating decision-maker who reviews financial information prepared on a consolidated
basis. Effective from the first quarter of 2020, all of our continuing operations are in the point-of-care business via our
POCare Platform. Therefore, no segment report has been presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Advanced
Therapy Medicinal Products (ATMPs) Overview</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Advanced
Therapy Medicinal Product (&#8220;ATMP&#8221;) means one of any of the following medicinal products that are developed and commercialized
for human use:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
    <i>somatic cell therapy medicinal product</i> (&#8220;STMP&#8221;) that contains cells or tissues that have been manipulated
    to change their biological characteristics or cells or tissues not intended to be used for the same essential functions in
    the body.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
    <i>tissue engineered produc</i>t (&#8220;TEP&#8221;) that contains cells or tissues that have been modified so that they can
    be used to repair, regenerate, or replace human tissue.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
    <i>gene therapy medicinal product</i> (&#8220;GTMP&#8221;) that engineers genes that lead to a therapeutic, prophylactic,
    or diagnostic effect and, in many cases, work by inserting &#8220;recombinant&#8221; genes into the body, usually to treat
    a variety of diseases, including genetic disorders, cancer, or long-term diseases. In this case, a recombinant gene is a stretch
    of DNA that is created in the laboratory, bringing together DNA from different sources.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">It
is important to note that although STMPs and GTMPs currently dominate the market, in order to access the market potential and
trends in the future, other cell products are likely to be essential in all of these categories.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
believe that autologous therapies represent a substantial segment of the ATMP market. Autologous therapies are produced from a
patient&#8217;s own cells versus allogeneic therapies that are mass-cultivated from donor cells via the construction of master
and working cell banks, are then produced on a large scale. Developers and manufacturers of ATMPs (both autologous and allogeneic)
currently rely heavily on production using traditional centralized supply chains and manufacturing sites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">CGTs
are costly and complex to produce. We also refer to CGTs as &#8220;living&#8221; drugs since they are based on maintaining the
cells vitality. Therefore, there is no possibility to sterilize the products, since such a process involves killing any living
organism. Many of these therapies require sourcing of the patient&#8217;s cells, engineering them in a sterile environment and
then transplanting them back to the patient (so-called &#8220;autologous&#8221; CGT). This presents multiple logistic challenges
as each patient requires its own production batch, and the current processes involve complex laboratory-based types of manipulations
requiring highly trained lab technicians. We are leveraging a unique approach to therapy production using the POCare Platform
to potentially overcome some of the development and supply chain challenges of affordably bringing autologous therapies to patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Allogeneic
therapies are costly and complex to produce because autologous therapies are derived from the treated patient and manufactured
through a defined protocol before re-administration. We are leveraging a unique approach to therapy production using the POCare
Platform to potentially overcome some of the development and supply chain challenges of bringing autologous therapies to patients
affordably.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Our
Therapies</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Products
in Clinical Use</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">KYSLECEL&#174;
(autologous Pancreatic Islets)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">KYSLECEL
is made from a patient&#8217;s own pancreatic islets &#8211; the cells that make insulin to regulate blood sugar. KYSLECEL is
intended to preserve insulin secretory capacity in chronic or acute recurrent pancreatitis patients after total pancreatectomy
(TP-IAT). KYSLECEL is a minimally manipulated autologous cell-based product available in the United States and regulated by the
Food and Drug Administration (&#8220;FDA&#8221;). KYSLECEL is produced according to current good tissue practices (cGTP) and in
compliance with federal and state regulations. Prior to being acquired by us, Koligo treated approximately 40 patients with KYSLECEL
at six U.S. hospitals through a commercial pilot program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Tissue
Genesis Icellator&#174; for Cell Assisted Lipotransfer</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Tissue Genesis Icellator is a point-of-care medical device that isolates stromal and vascular fraction cells (&#8220;SVF&#8221;)
from a patient&#8217;s own (autologous) adipose tissue (fat). The Icellator is commercially available in Korea through a medical
device distributor. The SVF obtained from the Icellator is for use in cell-assisted lipotransfer, a plastic surgery procedure
intended to improve fat engraftments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">It
is expected that the Icellator may also become commercially available in Japan in 2021 for use in cell assisted lipotransfer,
pending review and approval by the Japanese Pharmaceuticals and Medical Devices Agency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Cartil-S
Autologous Products for the Treatment of Osteoarthritis</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Cartil-S
is a cell therapy for Osteoarthritis. This product is produced by performing a minimally invasive biopsy of adipose (fat) tissue
from a patient, followed by isolation and expansion of adipose-derived stem cells (ADSCs), to be injected arthroscopically. The
autologous injectable product helps delay/stop the progression of osteoarthritis, involving the patient&#8217;s own stem cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Chondroseal
Autologous Products for the Treatment of Cartilage Defects (Osteoarthritis)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Chondroseal
is a cell therapy for cartilage defects. Following collection of adipose tissue by minimally invasive biopsy that is composed
of ADSCs, the cells are combined with a natural gel serving as a scaffold for local cartilage regeneration in the joint.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Products
in Clinical Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following chart depicts our therapeutic development pipeline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><img src="form10-k_003.jpg" alt="" style="height: 296px; width: 670px" /><br /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Products
in Clinical Trials</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">RanTop,
Ranpirnase Topical Formulation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
are currently developing a novel topical formulation of an active RNA-degrading enzyme, called Ranpirnase. Ranpirnase combats
viral infections by targeting double-stranded RNA including miRNA precursors, via RNA degradation catalysis. It acts through a
dual mechanism: 1) Inhibition of viral replication; and 2) induction of host cell apoptosis. Ranpirnase was previously developed
for the treatment of <span style="color: #202124; background-color: white">human papillomavirus</span> (HPV)-related pathologies
such as external genital warts (EGW) and anal dysplasia. It has demonstrated clinical efficacy and good tolerability in a Phase
IIa clinical study for the treatment of HPV-associated EGW. The initiation of a clinical Phase IIb for EGW is planned for 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Tissue
Geneseis Icellator&#174; for Erectile Dysfunction and COVID-19 (SVF-CLI-ED)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
safety of the Tissue Genesis Icellator, and use of SVF produced by the Icellator, has previously been tested in a number of pilot
clinical trials in the United States. Orgenesis has prioritized the clinical development of the Icellator for potential use in
the treatment of erectile dysfunction and COVID-19 related respiratory complications. Pending review and approval of the FDA of
the clinical trials, we expect to start a phase 2 trial in erectile dysfunction and a phase 1 trial for COVID -19 in 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Tissue Genesis Icellator is also being used by research collaborators in FDA-regulated clinical trials to test the use of SVF
during rotator cuff surgery. These trials are investigator sponsored initiatives that Orgenesis will continue to support.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Products
in IND Enabling Studies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
are</span><span style="font: 10pt Times New Roman, Times, Serif"> engaged in the following IND-enabling studies:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Generation
of Autologous Insulin-Producing Cells (AIPs) from Adult Liver Cells (&#8220;Trans-differentiation technology&#8221;)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
Ltd. has trans-differentiation in-vitro technology that has demonstrated in animal models the capacity to induce a shift
in the developmental fate of cells from the liver or other tissues, transdifferentiating them into &#8220;pancreatic beta cell-like&#8221;
AIP cells for patients with Type 1 Diabetes (&#8220;T1D&#8221;), acute pancreatitis and other insulin deficient diseases.
           For the treatment of diabetes, cells are derived from the liver
or other adult tissue and are trans-differentiated to become AIP cells. This technology, which has yet to be proven in human clinical
trials, has shown in relevant animal models that the human derived AIP cells produce insulin in a glucose-sensitive manner. No
adverse effects were observed in any of the animal studies. This trans-differentiation technology is licensed by the Israeli Subsidiary
and is based on the work of Prof. Sarah Ferber, a researcher at Tel Hashomer Medical Research Infrastructure and Services Ltd.
(&#8220;THM&#8221;) in Israel. The development plan calls for conducting additional pre-clinical safety and efficacy studies with
respect to diabetes and other potential indications prior to initiating human clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">With
respect to the trans-differentiation technology, we have exclusive rights to seven (7) United States and twelve (12) foreign issued
patents, five (5) pending patent applications in the United States, twenty four (24) pending patent applications in foreign jurisdictions,
including, Australia, Brazil, Canada, China, Europe, India, Israel, Panama, South Korea, and Singapore. These patents and patent
applications relate, among others, to the trans-differentiation of cells (including hepatic cells) to cells having pancreatic
&#946;-cell-like phenotype and function and to their use in the treatment of degenerative pancreatic disorders, including diabetes,
pancreatic cancer and pancreatitis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
June 11, 2019, the FDA granted Orphan Drug Designation for our AIP cells as a cell replacement therapy for the treatment of severe
hypoglycemia-prone diabetes resulting from total pancreatectomy (&#8220;TP&#8221;) due to chronic pancreatitis. The incidence
of diabetes following TP is 100%, resulting in immediate and lifelong insulin-dependence with the loss of both endogenous insulin
secretion and that of the counter-regulatory hormone, glucagon. Glycemic control after TP is notoriously difficult with conventional
insulin therapy due to complete insulin dependence and loss of glucagon-dependent counter-regulation. Patients with this condition
experience both severe hyperglycemic and hypoglycemic episodes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
April 29, 2019, we received Institutional Review Board (&#8220;IRB&#8221;) approval to collect liver biopsies from patients at
Rambam Medical Center located in Haifa, Israel for a planned study to confirm the suitability of liver cells for personalized
cell replacement therapy for patients with insulin-dependent diabetes resulting from total or partial pancreatectomy. The first
patients were enrolled during 2020. The goal of the proposed study, entitled &#8220;Collection of Human Liver Biopsy and Whole
Blood Samples from Type 1 Diabetes Mellitus (T1DM), Total or Partial Pancreatectomy Patients for Potential use as an Autologous
Source for Insulin Producing Cells in Future Clinical Studies,&#8221; is to confirm the suitability of the liver cells for personalized
cell replacement therapy, as well as eligibility of patients to participate in a future clinical study, as defined by successful
AIP cell production from their own liver biopsy. The secondary objective of the study is to evaluate patients&#8217; immune response
to AIPs based on the patient&#8217;s blood samples and followed by subcutaneous implantation into the patients&#8217; arm which
would represent the first human trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
trans-differentiation technology is from a licensing agreement entered into as of February 2, 2012 by the Israeli Subsidiary and
THM pursuant to which the Israeli Subsidiary, Orgenesis Ltd, was granted a worldwide royalty bearing and exclusive license (the
&#8220;THM License Agreement&#8221;). By using therapeutic agents that efficiently convert a sub-population of liver cells into
pancreatic islets phenotype and function, this approach allows the diabetic patient to be the donor of his own therapeutic tissue.
While we believe that this provides a major competitive advantage to the cell transformation technology of the Israeli Subsidiary,
we also believe that our expanded focus to other therapies and business activities may continue to prompt THM to inquire of such
activities as they may relate to our compliance with the terms or direction in regards to the THM License Agreement. While
we have not received any notice of cancellation of the THM License Agreement, we have received an allegation regarding the scope
of the rights by THM that may present future challenges for our Israeli Subsidiary to continue to develop, manufacture, sell and
market the products pursuant to the milestones and time schedule specified in the development plan of the THM License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">ORG-CAR19,
Autologous CD-19 CAR-T</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Chimeric
antigen receptor T cells (also known as CAR-T cells) are T cells that have been genetically engineered to produce an artificial
T-cell receptor for use in immunotherapy. CAR-T cell therapy uses T cells engineered with CARs for cancer therapy. The premise
of CAR-T immunotherapy is to modify T cells to recognize cancer cells in order to more effectively target and destroy them. Physicians
harvest T cells from patients, genetically alter them, then infuse the resulting CAR-T cells into patients to attack their tumors.
CAR-T cells can be either derived from T cells in a patient&#8217;s own blood (autologous) or derived from the T cells of another
healthy donor (allogeneic). Once isolated from a person, these T cells are genetically engineered to express a specific CAR, which
programs them to target an antigen that is present on the surface of tumors. After CAR-T cells are infused into a patient, they
act as a &#8220;living drug&#8221; against cancer cells. When they come in contact with their targeted antigen on a cell, CAR-T
cells bind to it and become activated, then proceed to proliferate and become cytotoxic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
are developing a new and advanced anti-CD19 CAR-T therapy for treating B-cell Acute lymphoblastic leukemia (B-ALL) and lymphoma
patients, based on a clinically used CAR-T therapy licensed from Kecellitics Biotech. B-ALL is driven by malignant B-cell, expressing
the B-cell surface protein, CD19. Orgenesis is also working on combining the CD19 with CD22 CAR on a single, bi-specific CD19/22
CAR-T that can target both antigens simultaneously for the treatment of blood cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Dual
Cellular vaccine (DUVAC), Therapy for Pancreatic Cancer</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The DUVAC cell-based immunotherapy,
licensed from Columbia University, is based on autologous dendritic cells and macrophages. These cells are key coordinators of
the innate and adaptive immune system and have critical roles in the induction of antitumor immunity. The cells are exposed to
whole cancer cells constitute the most comprehensive source of cancer antigens and by so boosting the patient immune system and
direct it against the tumor. The DUVAC vaccine can be a developed for a wide range of solid tumor, but our initial focus is
on pancreatic cancer. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Metabolically
Optimized T-Cells (MOTC): Therapy for melanoma and lung cancer</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
the early stages of cancer, some lymphocytes successfully attack and infiltrate the tumor microenvironment, surround the tumor
cells, and mount an anti-tumor response. TIL therapy is a clinically validated personalized cancer treatment based on infusion
of autologous TILs expanded <i>ex vivo</i> from tumors. Once expanded, the TILs are infused back into the patient where they attack
the cancer cells with a high degree of specificity. Orgenesis is developing an advanced cellular biomanufacturing platform integrated
with metabolic control. The expanded TILs possess an optimized metabolic state referred to as MOTC (Metabolically Optimized T-Cells),
which can potentially lead to a more robust therapeutic response, especially for solid tumors such as lung cancer and melanoma.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Products
in Pre-Clinical Studies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">CAR-NK,
Therapy for Solid Tumors</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have licensed from Caerus Therapeutics (a related party) a unique CAR platform that contains additional immunological effectors
that aim to address significant challenges emerged in the development process of CAR technologies such as: safety, viability,
immunosuppression by tumor microenvironment and dense desmoplastic stroma. Orgenesis aims target this CAR platform Natural Killer
Cells (CAR-NK) platform for the treatment of solid tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Autologous
Cell-Based Vaccine for protecting against SARS-CoV-2</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
are working on developing a cell-based vaccine platform for the prevention of viral diseases. The initial target for the platform
is SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2, the causative agent of COVID-19). This cell-based vaccine platform
utilizes an autologous approach. The goal is to enable the COVID-19 engineered cells will have the ability to activate an endogenous
immune response and induce the production of neutralizing antibodies as well as cellular response.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Bioxomes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Exosomes
are small, membrane-enclosed extracellular vesicles implicated in cell-to-cell communication. Exosomes may serve as a valuable
therapeutic modality because of their ability to transfer a wide variety of therapeutic payloads among cells that can influence
a cell in multiple ways, and they can be designed to reach specific cell types. We are developing a proprietary manufacturing
process for exosome like structures, termed Bioxomes. Bioxomes can carry specific therapeutic cargo into target cells. Orgenesis
is developing this platform technology to treat liver fibrosis, dermatology, and other indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #0E1F2D"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">MSCP</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
is developing a personalized cell-based therapy product for wound healing and psoriasis. The product is based on Adipose-Derived
Stem Cells (ADSCs). Following expansion, the ADSCs are formulated with Topiramate, a well-known substrate used in other indications,
and a commercially available hyaluronic acid (HA), a well-known dermal filler, for topical treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Muscle-derived
Mesenchymal Stem Cells for Human Regenerative Medicine</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">An
innovative and patented technology licensed by Revatis that enables the isolation of pluripotent adult Mesenchymal Stem Cells
(MSCs) from a minimally invasive muscle micro-biopsy. The isolated autologously undifferentiated muscle-derived MSCs are developed
to explore autologous therapeutics fields in humans such as Urine Incontinence</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #0E1F2D"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Kidney
Disease</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #0E1F2D"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
are also developing multiple Proprietary cell and cell derived products therapies for treating kidney failure and End-Stage Renal
Disease (ESRD).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">KT-DM-103
and KT-CP-203 (3D-Printed Pancreatic Islets)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Koligo
had exclusively licensed patents and technology from the University of Louisville Research Foundation related to the revascularization
and 3D printing of cell and tissue for transplant (&#8220;3D-V&#8221; technology platform). Orgenesis is developing this technology
for potential autologous and allogeneic pancreatic islet transplant to treat type 1 diabetes (KT-DM-103) and chronic pancreatitis
(KT-CP-203). The 3D-V technology platform may also support improved transplantation of other cell and tissue types in additional
to pancreatic islets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>POCare
Platform Strategy</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
aim is to provide a pathway to bring ATMPs in the cell and gene therapy industry from research to patients worldwide through our
POCare Platform. We define point of care as a process of collecting, processing, and administering cells within the patient care
environment, namely through academic partnerships in a hospital setting. We believe that this approach is an attractive proposition
for personalized medicine because of our strategic partnerships with suppliers that help us to customize closed systems into effective
mobile clean room facilities. This will potentially help to minimize or eliminate the need for cell transportation, which is a
high-risk and costly aspect of the supply chain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
aim to build value in various aspects of our company ranging from supply related processes including development and distribution
systems, clinical and regulatory services, engineering and devices such as OMPULs discussed below, delivery systems, therapies
including immuno-oncology, anti-aging, anti-viral, metabolic, nephrology, dermatology, orthopedic, as well as regenerative technologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Over
time, we have worked to develop and validate POCare Technologies that can be combined within mobile production units for advanced
therapies. In 2020, we made significant investments in the development of several types of Orgenesis Mobile Processing
Units and Labs (OMPULs) with the expectation of use and/or distribution through our POCare Network of partners, collaborators,
and joint ventures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
2020 we made significant investments in the development of several types of OMPULs and have made significant progress in the validation,
risk analysis, regulatory and other related tasks relating to the OMPULS. We anticipate distributing and using the OMPULS through
our POCare Network of partners, collaborators, and joint ventures. OMPULs are designed for the purpose of validation, development,
performance of clinical trials, manufacturing and/or processing of potential or approved cell and gene therapy products in a safe,
reliable, and cost-effective manner at the point of care, as well as the manufacturing of such CGTs in a consistent and standardized
manner in all locations. The design delivers a potential industrial solution for us to deliver CGTs to most clinical institutions
at the point of care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><img src="form10-k_004.jpg" alt="A picture containing graphical user interface&#10;&#10;Description automatically generated" style="height: 240px; width: 619px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">*For
illustrative purposes only</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Currently,
we are finalizing the development over 30 OMPUL-based POC processing locations worldwide and, with the assistance of our partners,
we are adapting the local requirements of each partner with the target of achieving a capacity to process and supply CGTs to as
many as 2,000 patients annually. The responsibility for setting up the OMPULS falls on the joint venture partners, who are also
responsible for marketing and distribution worldwide. As we expand operations, the OMPUL setup cost is expected to decline proportionately.
Most of our POC revenue to date is in support of the implementation of our technologies and therapies in our partners&#8217; POC
activities, which will be the basis for future royalties and supply revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have embarked on a strategy of collaborative arrangements with strategically situated regional joint venture partners around the
world. We believe that these parties have the expertise, experience and strategic location to advance our POCare Platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>Strategic
CGT Therapeutics Collaborations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Collaborations,
partnerships, joint ventures and license agreements are a key component of our POC strategy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our POC technology collaborators
and partners include Mircod, , Cure Therapeutics, Columbia University in the City of New York, Caerus Therapeutics Corporation,
Sescom Ltd., UC Davis, SBH Sciences, Inc., The Johns Hopkins University and others.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, we have collaborations and joint ventures for setting up POCare Platform operations facilities in jurisdictions throughout
the world, including various countries in North America, Europe, Latin America, Asia, the Middle East, and Australia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
more information, see Note 11, &#8220;Collaboration and Licensing Agreements&#8221; of the &#8220;Notes to the Financial Statements&#8221;
included in Item 8.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>CDMO
Business</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Regarding
the Masthercell Sale, see Note 3 to Item 8 of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Current
Development Facilities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>OBI</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">OBI
is a specialized process and technology development wholly owned subsidiary focused on custom-made process development, upscaling
design from lab to industry innovation and automation procedures, which are extremely essential in the cell therapy industry.
OBI is located in Bar-Lev Industrial Park utilizing the exclusive Israeli innovative ecosystem and highly experienced and talented
associates including Ph.D. holders and biotechnology engineers. The center provides end to end solutions to cell therapy industrialization,
process development capabilities and proficiency, custom-made engineering and a unique platform for creative design and process
optimization. OBI occupies 1300 square meters of labs and offices resulting in an efficient and unique environment for cell therapy
development. In connection with the Masthercell Sale, for a period of 3 years in the European Union and five years in the United
States and the rest of the world from the closing date of the Masthercell Sale, we agreed that OBI will not manufacture
products on a contract basis for third-party customers in any jurisdiction other than the State of Israel, but it may
conduct such CDMO business in the State of Israel, solely for customers located within the State of Israel or with respect to
therapies intended for distribution solely within the State of Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>The
Korean Subsidiary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Korean Subsidiary has a particular focus on developing innovative cell therapies. Together, with promising in-house research programs,
the technologies are currently under development for the rapidly growing Korean market offering the most favorable environment
for the cell therapy industry in the world. Through close collaboration with leading medical and academic facilities, the Korean
Subsidiary is accelerating the development of foreign technologies in Korea. In connection with the Masthercell Sale, for a period
of 3 years in the European Union and five years in the United States and the rest of the world from the closing date of the Masthercell
Sale, we agreed that the Korean Subsidiary will not manufacture cell and gene products on a contract basis for third-party
customers in any jurisdiction other than South Korea, but it may conduct CDMO business in South Korea, solely for customers
located within South Korea and with respect to therapies intended for distribution solely within South Korea.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Koligo</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Koligo
maintains commercial production facilities for KYSLECEL at an FDA-registered establishment in Indiana. The Tissue Genesis Icellators,
and associated reagents and kits, are made by contract manufacturers and warehoused at our facility in Texas. Koligo also maintains
development labs at the Indiana and Texas locations to support continued development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>The
Belgian subsidiary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Belgian subsidiary specializes in developing and validating proprietary and licensed advanced cell and gene therapies. The subsidiary
benefits both from its central position in Europe and its being in the leading Walloon biotech cluster. Located near Namur, at
Novalis Science Park, the Belgian subsidiary collaborates with leading medical and academic facilities which enables it to cover
the drug product life cycle from research to clinical stage through pre-clinical and quality control. It occupies innovative
facilities for the development and quality control of therapies in R&amp;D and GMP grades.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Its
talented and highly experienced staff and collaborators, including Ph.D. holders, quality assurance experts and biotechnology
manufacturing engineers, contribute to the POCare platform development and roll-out. The subsidiary provides quality assurance
and supply activities for the global POCare network. It has developed smart and agile methodologies to ensure compliant and harmonized
decentralization operations at POCare.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Notable
2020 Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
April 7, 2020, we entered into an Asset Purchase Agreement (the &#8220;Tamir Purchase Agreement&#8221;) with Tamir Biotechnology,
Inc. (&#8220;Tamir&#8221; or &#8220;Seller&#8221;), pursuant to which we agreed to acquire certain assets and liabilities of Tamir
related to the discovery, development and testing of therapeutic products for the treatment of diseases and conditions in humans,
including all rights to ranpirnase and use for antiviral therapy (collectively, the &#8220;Purchased Assets and Assumed Liabilities&#8221;
and such acquisition, the &#8220;Tamir Transaction&#8221;). The Tamir Transaction closed on April 23, 2020. We paid $2.5 million
in cash and issued an aggregate of 3,400,000 shares (the &#8220;Shares&#8221;) of our common stock to Tamir resulting in a total
consideration of $20.2 million. In November 2020, we filed a registration statement on Form S-3 to register the resale of the
Shares as required by the Tamir Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
September 26, 2020, we entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) with
Orgenesis Merger Sub, Inc., a Delaware corporation and our wholly-owned subsidiary (&#8220;Merger Sub&#8221;), Koligo Therapeutics
Inc., a Kentucky corporation (&#8220;Koligo&#8221;), the shareholders of Koligo (collectively, the &#8220;Shareholders&#8221;)
and Long Hill Capital V, LLC, solely in its capacity as the representative, agent and attorney-in-fact of the Shareholders. The
Merger Agreement provided for the acquisition of Koligo by us through the merger of Merger Sub with and into Koligo, with Koligo
surviving as our wholly-owned subsidiary (the &#8220;Merger&#8221;). The Merger closed on October 15, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Koligo&#8217;s
operations include (a) the manufacture and sale of KYSLECEL&#174; (autologous pancreatic islets) for chronic and acute recurrent
pancreatitis diseases in the United States; (b) development and commercialization of the Tissue Genesis Icellator&#174; platform,
a cell isolation system acquired by Koligo from Tissue Genesis, LLC prior to our acquisition of Koligo; and (c) preclinical development
of the &#8220;3D-V&#8221; technology platform, a system exclusively licensed by Koligo from the University of Louisville Research
Foundation intended for the revascularization and 3D printing of cell and tissue for transplant applications. Koligo maintains
facilities in Indiana and Texas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Tissue Genesis assets acquired by Koligo included the entire inventory of Tissue Genesis Icellator&#174; devices, related kits
and reagents, a broad patent portfolio to protect the technology, registered trademarks, clinical data, and existing business
relationships for commercial and development stage use of the Icellator technology</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the terms of the Merger Agreement, an aggregate of 2,061,713 shares of our common stock were issued to Koligo&#8217;s Shareholders
who were accredited investors (with certain Shareholders who were not accredited investors being paid solely in cash in the amount
of approximately $20 thousand) in accordance with the terms of the Merger Agreement. In connection with the Merger, we assumed
an aggregate of approximately $1.9 million of Koligo&#8217;s liabilities, which were substantially all of Koligo&#8217;s liabilities
at the closing of the Merger. In addition, we issued 66,910 shares to Maxim Group LLC for advisory services in connection with
the Merger. In November 2020, we filed a registration statement on Form S-3 to register the resale of 1,425,962 shares of
our common stock as required by the Merger Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, according to the agreement between the parties, we also funded an additional cash consideration of $500 thousand (with
$100 thousand of such reducing the ultimate consideration payable to Koligo) for the acquisition of the assets of Tissue Genesis,
LLC (&#8220;Tissue Genesis&#8221;) by Koligo that was consummated on October 14, 2020. The Tissue Genesis assets include the entire
inventory of Tissue Genesis Icellator&#174; devices, related kits and reagents, a broad patent portfolio to protect the technology,
registered trademarks, clinical data, and existing business relationships for commercial and development stage use of the Icellator
technology. The Icellator device is already commercially available in Korea and the Bahamas, and is expected to gain regulatory
approval in Japan during the first quarter of 2021, subject to completion of manufacturing tests requested by the Japanese Pharmaceutics
and Medical Devices Agency. Tissue Genesis already initiated U.S. FDA IDE Phase 1 pilot trials SVF cells in the treatment of erectile
dysfunction, critical limb ischemia, tissue repair, and other therapeutic indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Revenue
Model, Business Development and Licenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Orgenesis Point of Care (POCare) Platform is comprised of three enabling components: a multitude of licensed cell based POCare
Therapeutics that are produced in closed, automated POCare Technology systems across a collaborative POCare Network. Our
therapies include, but are not limited to, autologous, cell-based immunotherapies, therapeutics for metabolic diseases, anti-viral
diseases, and tissue regeneration. We are establishing and positioning the business to bring point-of-care therapies to patients
in a scalable way working directly with hospitals and through regional JV partners and JVs active in autologous cell therapy product
development, including facilities in various countries in North America, Europe, Latin America, Asia, the Middle East, and Australia.
The POCare Platform&#8217;s goal is to enable a rapid, globally harmonized pathway for these therapies to reach large numbers
of patients at lowered costs through efficient, and decentralized production. The Network brings together industry partners, research
institutes and hospitals worldwide to achieve harmonized, regulated clinical development and production of the therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
are focused on technology in licensing and therapeutic collaborations, and we out license therapies marketing rights and manufacturing
rights to partners and / or to the JVs. In many cases, the JVs are responsible for the preparation of clinical trials, local regulatory
approvals and regional marketing activities. Such licensing includes exclusive or nonexclusive, sublicensable, royalty bearing
rights and license to the Orgenesis Background IP as required solely to manufacture, distribute and market and sell Orgenesis
Products within the relevant territories. In consideration of the rights and the licenses so granted, we receive a royalty
in the range of ten percent of the net sales generated by the JV Entity and/or its sublicensees (as applicable) with respect to
the Orgenesis Products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, in many cases, once the JV entities become profitable, we are entitled (in addition to any of its rights as holder
of the JV Entity and prior to any other distributions of dividends by the JV Entity to shareholders of the JV Entity) and in addition
to any royalties to which we may be entitled pursuant to a Orgenesis License Agreement, to receive from the JV entity royalties
at a range of 10 to 15 percent of the JV entity&#8217;s audited US GAAP profit after tax.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Further
to revenues generated from out licenses we generate revenues from POCare services and sales which is comprised of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">R&amp;D
    services provided to out licensing partners</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has signed POCare Master Services Agreements (&#8220;MSAs&#8221;) with its JV partners. In terms of the MSAs, we provide
certain broadly defined development services that relate to our licensed therapies designed to develop or enhance the therapy
with the objective of preparing it for clinical use. Such services, per therapy, include regulatory services, pre-clinical studies,
intellectual property services, development services, and GMP process translation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Hospital
    supply</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Hospital
services includes the sale or lease of products and the performance of processing services to our POCare hospitals or other medical
providers. We either work directly with hospitals or receive payments through our regional JV partnerships.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Cell
    process development revenue</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
provide cell process development services in some regions to third party customers. Those services are unique to the customers
who retain the ownership of the intellectual property created through the process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
POCare therapy revenue is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">Revenue stream:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; padding-left: 10pt; text-align: left">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">POC and hospital services</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,068</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,109</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cell process development services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,584</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">790</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,652</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,899</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Cost
of Research and Development and Research and Development Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
incurred $83,986 and $14,014 thousand in cost of sales, research and development and research and development services in the
fiscal years ended December 31, 2020 and December 31, 2019, respectively, of which $196 and $812 thousand was covered by grant
funding. Part of the expense was funded by share issues. Our research and development scope was expanded to the evaluation and
development of new cell therapies related technologies in the field of immuno-oncology, liver pathologies and tissue regeneration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Competition
in the Cell Therapy Field</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
biopharmaceutical industry is intensely competitive. There is continuous demand for innovation and speed, and as the cell-based
therapies market evolves, there is always the risk that a competitor may be able to develop other compounds or drugs that are
able to achieve similar or better results for indications. Potential competition includes major multinational pharmaceutical companies,
established biotechnology companies, specialty pharmaceutical companies, universities, and other research institutions. Many of
these competitors have substantially greater financial, technical, and other resources, such as larger research and development
staff and experienced marketing and manufacturing organizations with established sales forces. Smaller or early-stage companies
may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Currently,
we are not aware of any other companies pursuing a business model similar to what we are developing under our POCare Platform.
However, our competitors in the CGT field who are significantly larger and better capitalized than us could undertake strategies
similar to what we are pursuing and even develop them at a much more rapid rate. These potential competitors include the same
multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities,
and other research institutions that are operating in the CGT field. In that respect, smaller or early-stage companies may also
prove to be significant competitors, particularly through collaborative arrangements with large, established companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Intellectual
Property</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
will be able to protect our technology and products from unauthorized use by third parties only to the extent it is covered by
valid and enforceable claims of our patents or is effectively maintained as trade secrets. Patents and other proprietary rights
are thus an essential element of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
success will depend in part on our ability to obtain and maintain proprietary protection for our product candidates, technology,
and know-how, to operate without infringing on the proprietary rights of others, and to prevent others from infringing our proprietary
rights. Our policy is to seek to protect our proprietary position by, among other methods, filing U.S. and foreign patent applications
related to our proprietary technology, inventions, and improvements that are important to the development of our business. We
also rely on trade secrets, know-how, continuing technological innovation, and in-licensing opportunities to develop and maintain
our proprietary position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, we own or
have exclusive rights to twenty eight (28) United States patents, thirty six (36) foreign-issued patents, twenty five (25) pending
patent applications in the United States, forty five (45) pending patent applications in foreign jurisdictions, including Australia,
Brazil, Canada, China, Europe, Hong Kong, India, Israel, Japan, Mexico, New Zealand, North Korea, Russia, Singapore, South Africa,
and South Korea, and two (2) international Patent Cooperation Treaty (&#8220;PCT&#8221;) patent applications. These patents and
patent applications relate, among others, to (1) dendritic and macrophages based vaccines, and their use for treating cancer and
viral diseases; (2) compositions comprising ranpirnase and other ribonucleases for treating viral diseases; (3)
tumor infiltrating lymphocytes (TILs) and their use for treating cancer; (4) compositions comprising immune cells, ribonucleases,
or antibodies for treating COVID-19; (5) whole-cell antiviral vaccines; (6) therapeutic compositions comprising
exosomes, bioxomes, and redoxomes; (7) bioreactors for cell cultureand automated devices for supporting cell therapies:
and (8) scaffolds, including alginate and sulfated alginate scaffolds, polysaccharides thereof, and scaffolds for use for cell
propagation, transplantations, and in the treatment of autoimmune diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have a pending U.S. patent applications directed, among others, to dendritic and macrophages based vaccines, and their use for
treating cancer and viral diseases. If issued, this application would expire in 2038.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have pending U.S. patent applications directed, among others, to compositions comprising ranpirnase and other ribonucleases for
treating viral diseases. If issued, these applications would expire between 2039 and 2040. Counterpart patents applications were
filed in Australia, Canada, China, Europe, Hong Kong, Japan, Mexico, New Zealand, North Korea, Russian Federation, Singapore,
South Africa, and were also filed as International (&#8220;PCT&#8221;) applications. If issued, these applications would expire
between 2035 and 2037. These expiration dates do not include any patent term extensions that might be available following the
grant of marketing authorizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have pending U.S. patent applications directed, among others, to therapeutic compositions comprising exosomes, bioxomes, and redoxomes.
If issued, these applications would expire in 2040. Counterpart patents applications were filed in Australia, Brazil, Canada,
China, Europe, India, Israel, India, Japan and South Korea. If issued, these applications would expire in 2039. These expiration
dates do not include any patent term extensions that might be available following the grant of marketing authorizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have pending U.S. patent applications directed, among others, to automated devices for supporting cell therapies. If issued, these
applications would expire between 2035 and 2038.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have a pending U.S. provisional patent application directed, among others, to tumor infiltrating lymphocytes (TILs) and their
use for treating cancer. If converted into a non-provisional application and issued, this application would expire in 2041, without
including any patent term extensions that might be available following the grant of marketing authorizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have pending U.S. provisional patent applications directed, among
others, to compositions comprising immune cells, ribonucleases, or antibodies for treating COVID-19. If converted into a non-provisional
application and issued, this application would expire in 2041, without including any patent term extensions that might be available
following the grant of marketing authorizations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Granted
U.S. patents, which are directed among others to scaffolds, including alginate and sulfated alginate scaffolds, polysaccharides
thereof, and scaffolds for use for cell propagation, transplantations, and in the treatment of autoimmune diseases, will expire
between 2025 and 2036. Counterpart patents granted in Australia, France, Germany, Israel, Switzerland, and the United Kingdom,
will expire between 2026 and 2035. These expiration dates do not include any patent term extensions that might be available following
the grant of marketing authorizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have pending U.S.
patent applications directed, among others, to bioconjugates comprising sulfated polysaccharides and diverse bioactive peptides,
and their use in the treatment of inflammatory conditions. If issued, these applications would expire in 2038. Counterpart patents
applications were filed in China, Europe, Israel, Japan, and South Korea. If issued, these applications would expire between 2026
and 2038. These expiration dates do not include any patent term extensions that might be available following the grant of marketing
authorizations</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
Ltd, has exclusive rights to six (6) United States patents, fourteen (14) foreign-issued patents, five (5) pending patent applications
in the United States, twenty six (26) pending patent applications in foreign jurisdictions, including Australia, Brazil, Canada,
China, Europe, India, Israel, Japan, Mexico, Panama, Singapore, and South Korea. These patents and patent applications relate,
among others, to the trans-differentiation of cells (including hepatic cells) to cells having pancreatic &#946;-cell-like phenotype
and function and to their use in the treatment of degenerative pancreatic disorders, including diabetes, pancreatic cancer and
pancreatitis. Granted U.S. patents, which are directed among others to trans-differentiation to pancreatic &#946;-cell-like phenotype
and function cells and to their use in the treatment of degenerative pancreatic disorders, including diabetes, pancreatic cancer
and pancreatitis, will expire between 2024 and 2035. Counterpart patents granted in Australia, France, Germany, Israel, Switzerland,
and the United Kingdom, will expire between 2024 and 2035. These expiration dates do not include any patent term extensions that
might be available following the grant of marketing authorizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
Ltd, has pending U.S. patent applications directed, among others, to the trans-differentiation of cells, to cells having pancreatic
&#946;-cell-like phenotype and function and to their use in the treatment of degenerative pancreatic disorders, including diabetes,
pancreatic cancer and pancreatitis. If issued, these applications would expire between 2038 and 2040. Counterpart patents applications
were filed in Australia, Brazil, Canada, China, Europe, India, Israel, Mexico, Panama, Singapore, South Korea, and were also filed
as International (&#8220;PCT&#8221;) applications. If issued, these applications would expire between 2034 and 2039. These expiration
dates do not include any patent term extensions that might be available following the grant of marketing authorizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Government
Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Development
Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
are required to comply with the regulatory requirements of various local, state, national and international regulatory bodies
having jurisdiction in the countries or localities where we manufacture products or where our customers&#8217; products are distributed.
In particular, we are subject to laws and regulations concerning research and development, testing, manufacturing processes, equipment
and facilities, including compliance with cGMPs, labeling and distribution, import and export, facility registration or licensing,
and product registration and listing. As a result, our facilities are subject to regulation in Israel and South Korea. We are
also required to comply with environmental, health and safety laws and regulations, as discussed below. These regulatory requirements
impact many aspects of our operations, including manufacturing, developing, labeling, packaging, storage, distribution, import
and export and record keeping related to customers&#8217; products. Noncompliance with any applicable regulatory requirements
can result in government refusal to approve facilities for manufacturing products or products for commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
customers&#8217; products must undergo pre-clinical and clinical evaluations relating to product safety and efficacy before they
are approved as commercial therapeutic products. The regulatory authorities that have jurisdiction in the countries in which our
customers intend to market their products may delay or put on hold clinical trials, delay approval of a product or determine that
the product is not approvable. The regulatory agencies can delay approval of a drug if our manufacturing facilities are not able
to demonstrate compliance with cGTPs, pass other aspects of pre-approval inspections (i.e., compliance with filed submissions)
or properly scale up to produce commercial supplies. The government authorities having jurisdiction in the countries in which
our customers intend to market their products have the authority to withdraw product approval or suspend manufacture if there
are significant problems with raw materials or supplies, quality control and assurance or the product is deemed adulterated or
misbranded. In addition, if new legislation or regulations are enacted or existing legislation or regulations are amended or are
interpreted or enforced differently, we may be required to obtain additional approvals or operate according to different manufacturing
or operating standards or pay additional fees. This may require a change in our manufacturing techniques or additional capital
investments in our facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Certain
products manufactured by us involve the use, storage and transportation of toxic and hazardous materials. Our operations are subject
to extensive laws and regulations relating to the storage, handling, emission, transportation and discharge of materials into
the environment and the maintenance of safe working conditions. We maintain environmental and industrial safety and health compliance
programs and training at our facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Prevailing
legislation tends to hold companies primarily responsible for the proper disposal of their waste even after transfer to third
party waste disposal facilities. Other future developments, such as increasingly strict environmental, health and safety laws
and regulations, and enforcement policies, could result in substantial costs and liabilities to us and could subject the handling,
manufacture, use, reuse or disposal of substances or pollutants at our facilities to more rigorous scrutiny than at present.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
development operations involve the controlled use of hazardous materials and chemicals. Although we believe that our procedures
for using, handling, storing and disposing of these materials comply with legally prescribed standards, we may incur significant
additional costs to comply with applicable laws in the future. Also, even if we are in compliance with applicable laws, we cannot
completely eliminate the risk of contamination or injury resulting from hazardous materials or chemicals. As a result of any such
contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials
and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines,
and the liability could exceed our resources. Compliance with applicable environmental laws and regulations is expensive, and
current or future environmental regulations may impair our contract manufacturing operations, which could materially harm our
business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
costs associated with complying with the various applicable local, state, national and international regulations could be significant
and the failure to comply with such legal requirements could have an adverse effect on our results of operations and financial
condition. See &#8220;Risk Factors &#8212; Risks Related to Development and Regulatory Approval of Our Therapies and Product Candidates
&#8212; Extensive industry regulation has had, and will continue to have, a significant impact on our business, especially our
product development, manufacturing and distribution capabilities.&#8221; for additional discussion of the costs associated with
complying with the various regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>POCare
Therapies Portfolio</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
therapeutic portfolio pipeline is diverse and addresses various unmet clinical needs. It is predominantly comprised of novel autologous
cell therapies, implying that patients receive cells that originate from their own body, virtually eliminating the risk of an
immune response and rejection and thus easing various regulatory hurdles. In addition, by leveraging Orgenesis&#8217; vast experience
and proven track record in developing and optimizing cell processing, these selective therapies are adapted to be produced in
closed, automated technology systems, reducing the need for high grade cleanroom environments. The systems enable each stage of
the manufacturing process (cell sorting, expansion, genetic modifications, quality control) to be optimized in order to substantially
reduce the cost burden for patients and making the therapies widely accessible. Notably, our therapeutic pipeline is developed
by researchers from our network and are subsequently outlicensed and validated in multi-center clinical trials conducted across
point of care partner sites leveraging the robustness of the Orgenesis network. Once approved these therapies are distributed
to leading medical institutions globally within the our network and thus granting the inventors a royalty-based commercialization
horizon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Regulatory
Process in the United States</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
potential product candidates are subject to regulation as a biological product under the Public Health Service Act and the Food,
Drug and Cosmetic Act. The FDA generally requires the following steps for pre-market approval or licensure of a new biological
product:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-clinical
    laboratory and animal tests conducted in compliance with the Good Laboratory Practice, or GLP, requirements to assess a drug&#8217;s
    biological activity and to identify potential safety problems, and to characterize and document the product&#8217;s chemistry,
    manufacturing controls, formulation, and stability;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Submission
    to the FDA of an Investigational New Drug, or IND, application, which must become effective before clinical testing in humans
    can start;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Obtaining
    approval of Institutional Review Boards, or IRBs, of research institutions or other clinical sites to introduce a first human
    biologic drug candidate into humans in clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Conducting
    adequate and well-controlled human clinical trials to establish the safety and efficacy of the product for its intended indication
    conducted in compliance with Good Clinical Practice, or GCP, requirements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Compliance
    with current Good Manufacturing Practices (&#8220;cGMP&#8221;) regulations and standards;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Submission
    to the FDA of a Biologics License Application (&#8220;BLA&#8221;) for marketing that includes adequate results of pre-clinical
    testing and clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    FDA reviews the marketing application in order to determine, among other things, whether the product is safe, effective and
    potent for its intended uses; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Obtaining
    FDA approval of the BLA, including inspection and approval of the product manufacturing facility as compliant with cGMP requirements,
    prior to any commercial sale or shipment of the pharmaceutical agent. The FDA may also require post marketing testing and
    surveillance of approved products or place other conditions on the approvals.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Regulatory
Process in Europe</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
European Union (&#8220;EU&#8221;) has approved a regulation specific to cell and tissue therapy products, the Advanced Therapy
Medicinal Product (&#8220;ATMP&#8221;) regulation. For products that are regulated as an ATMP, the EU directive requires:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Compliance
    with current cGMP regulations and standards, pre-clinical laboratory and animal testing;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Filing
    a Clinical Trial Application (&#8220;CTA&#8221;) with the various member states or a centralized procedure;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Voluntary
    Harmonization Procedure (&#8220;VHP&#8221;), a procedure which makes it possible to obtain a coordinated assessment of an
    application for a clinical trial that is to take place in several European countries;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Obtaining
    approval of ethic committees of research institutions or other clinical sites to introduce the AIP into humans in clinical
    trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Adequate
    and well-controlled clinical trials to establish the safety and efficacy of the product for its intended use;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Submission
    to EMEA for a Marketing Authorization (&#8220;MA&#8221;); and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Review
    and approval of the MAA (&#8220;Marketing Authorization Application&#8221;).</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
in the U.S., prior to the general regulatory process of a new biologic products, we will prosecute an Orphan Drug Designation
for treatment of Patients with Established Diabetes Mellitus (&#8220;DM&#8221;) Induced by Total pancreatectomy. In the EU, in
order to be qualified, the prevalence must be below 5 per 10,000 of the EU population, except where the expected return on investment
is insufficient to justify the investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Authorized
orphan medicines benefit from 10 years of protection from market competition with similar medicines with similar indications once
they are approved. Companies applying for designated orphan medicines pay reduced fees for regulatory activities. This includes
reduced fees for protocol assistance, marketing-authorization applications, inspections before authorization, applications for
changes to marketing authorizations made after approval, and reduced annual fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Clinical
Trials</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Typically,
both in the U.S. and the EU, clinical testing involves a three-phase process, although the phases may overlap. In Phase I, clinical
trials are conducted with a small number of healthy volunteers or patients and are designed to provide information about product
safety and to evaluate the pattern of drug distribution and metabolism within the body. In Phase II, clinical trials are conducted
with groups of patients afflicted with a specific disease in order to determine preliminary efficacy, optimal dosages and expanded
evidence of safety. In some cases, an initial trial is conducted in diseased patients to assess both preliminary efficacy and
preliminary safety and patterns of drug metabolism and distribution, in which case it is referred to as a Phase I/II trial. Phase
III clinical trials are generally large-scale, multi-center, comparative trials conducted with patients afflicted with a target
disease in order to provide statistically valid proof of efficacy, as well as safety and potency. In some circumstances, the FDA
or EMA may require Phase IV or post-marketing trials if it feels that additional information needs to be collected about the drug
after it is on the market. During all phases of clinical development, regulatory agencies require extensive monitoring and auditing
of all clinical activities, clinical data, as well as clinical trial investigators. An agency may, at its discretion, re-evaluate,
alter, suspend, or terminate the testing based upon the data that have been accumulated to that point and its assessment of the
risk/benefit ratio to the patient. Monitoring all aspects of the study to minimize risks is a continuing process. All adverse
events must be reported to the FDA or EMA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
FDA has granted Orphan Drug designation for our AIP cells as a cell replacement therapy for the treatment of severe hypoglycemia-prone
diabetes resulting from TP due to chronic pancreatitis. The FDA&#8217;s Orphan Drug Designation Program provides orphan status
to drugs and biologics which are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare
diseases/disorders that affect fewer than 200,000 people in the United States. Orphan designation qualifies the sponsor of the
drug for various development incentives, including eligibility for seven years of market exclusivity upon regulatory approval,
exemption from FDA application fees, tax credits for qualified clinical trials, and other potential assistance in the drug development
process<i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Employees</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, we had an aggregate of 111 employees working at our company and subsidiaries. In addition, we retain the
services of outside consultants for various functions including clinical work, finance, accounting and business development services.
Most of our senior management and professional employees have had prior experience in pharmaceutical or biotechnology companies.
None of our employees are covered by collective bargaining agreements. We believe that we have good relations with our employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Corporate
and Available Information</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and all amendments to those reports are
available free of charge though our website (<i>http://www.orgenesis.com</i>) as soon as practicable after such material is electronically
filed with, or furnished to, the Securities and Exchange Commission (the &#8220;SEC&#8221;). Except as otherwise stated in these
documents, the information contained on our website or available by hyperlink from our website is not incorporated by reference
into this report or any other documents we file, with or furnish to, the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
common stock is listed and traded on the Nasdaq Capital Market under the symbol &#8220;ORGS.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
used in this Annual Report on Form 10-K and unless otherwise indicated, the term &#8220;Company&#8221; refers to Orgenesis Inc.
and its Subsidiaries. Unless otherwise specified, all amounts are expressed in United States Dollars.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_003"></span>ITEM
1A. RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Summary
of Risk Factors</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Below
is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not
address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks
that we face, can be found below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with
other information in this Annual Report on Form 10-K and our other filings with the SEC, before making an investment decision
regarding our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    failure to effectively utilize the proceeds from the sale of Masthercell to scale our POC business to show demonstrable revenue
    may adversely affect our business.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
    research and development efforts on novel technology using cell-based therapy and our future success is highly dependent on
    the successful development of that technology.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
    have entered into collaborations and may form or seek collaborations or strategic alliances or enter into additional licensing
    arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
    success will depend on strategic collaborations with third parties to develop and commercialize therapeutic product candidates,
    and we may not have control over a number of key elements relating to the development and commercialization of any such product
    candidate.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    coronavirus outbreak has the potential to cause disruptions in our business, including our clinical development activities.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
    success depends on our ability to protect our intellectual property and our proprietary technologies.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
    product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization
    of our product candidates.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
    are increasingly dependent on information technology and our systems and infrastructure face certain risks, including cybersecurity
    and data storage risks.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
    can be no assurance that we will be able to develop in-house sales and commercial distribution capabilities or establish or
    maintain relationships with third-party collaborators to successfully commercialize any product in the United States or overseas,
    and as a result, we may not be able to generate product revenue.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
    product candidates may cause undesirable side effects or have other properties that could halt their clinical development,
    prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
    product candidates are biologics and the manufacture of our product candidates is complex and we may encounter difficulties
    in production, particularly with respect to process development or scaling-out of our manufacturing capabilities.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cell-based
    therapies rely on the availability of reagents, specialized equipment, and other specialty materials, which may not be available
    to us on acceptable terms or at all. For some of these reagents, equipment, and materials, we rely or may rely on sole source
    vendors or a limited number of vendors, which could impair our ability to manufacture and supply our products.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
    currently have no marketing and sales organization and have no experience in marketing therapeutic products. If we are unable
    to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates,
    we may not be able to generate product revenue.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
    can be no assurance that we will be able to develop in-house sales and commercial distribution capabilities or establish or
    maintain relationships with third-party collaborators to successfully commercialize any product in the United States or overseas,
    and as a result, we may not be able to generate product revenue.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
    face significant competition from other biotechnology and pharmaceutical companies, many of which have substantially greater
    financial, technical and other resources, and our operating results will suffer if we fail to compete effectively.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
    are highly dependent on key personnel who would be difficult to replace, and our business plans will likely be harmed if we
    lose their services or cannot hire additional qualified personnel.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Extensive
    industry regulation has had, and will continue to have, a significant impact on our business, especially our product development,
    manufacturing and distribution capabilities.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Third
    parties to whom we may license or transfer development and commercialization rights for products covered by intellectual property
    rights may not be successful in their efforts and, as a result, we may not receive future royalty or other milestone payments
    relating to those products or rights.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Risk
Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">An
investment in our common stock involves a number of very significant risks. You should carefully consider the following risks
and uncertainties in addition to other information in this report in evaluating our company and its business before purchasing
shares of our company&#8217;s common stock. Our business, operating results and financial condition could be seriously harmed
due to any of the following risks. You could lose all or part of your investment due to any of these risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Risks
Related to Our Company and POC Business</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>We
will need to deploy our capital from the sale of Masthercell in a manner to scale our POC business to show demonstrable revenue
and market value for our shareholders, the failure of which could adversely impact our operations and the price of our stock.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
February 2, 2020, we entered into a Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with GPP-II Masthercell LLC
(&#8220;GPP&#8221; and together with Orgenesis, the &#8220;Sellers&#8221;), Masthercell Global Inc. (&#8220;Masthercell&#8221;)
and Catalent Pharma Solutions, Inc. (the &#8220;Buyer&#8221;). Pursuant to the terms and conditions of the Purchase Agreement,
on February 10, 2020, the Sellers sold 100% of the outstanding equity interests of Masthercell to Buyer (the &#8220;Sale&#8221;)
for an aggregate nominal purchase price of $315 million, subject to customary adjustments. After accounting for GPP&#8217;s liquidation
preference and equity stake in Masthercell as well as SFPI - FPIM&#8217;s interest in MaSTherCell S.A., distributions to Masthercell
option holders and transaction costs, we received approximately $126.7 million at the closing of the Sale transaction, of which
$7.2 million was used for the repayment of intercompany loans and payables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
proceeds from the sale of Masthercell were received by us and not our shareholders. We used or will use a portion of the proceeds
to repay certain outstanding indebtedness and to pay for certain additional transaction costs associated with the sale. We will
also be paying taxes on the proceeds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
expect to use the remainder of net proceeds from the sale of Masthercell, at the discretion of our Board of Directors, for working
capital and other general corporate purposes, including to continue to grow our POC cell therapy business and to further the development
of ATMPs. Although we now have sufficient capital resources for the next 12 months and the foreseeable future, we may not be able
to implement our POC business and commence clinical trials for our diabetes solution or respond to competitive pressures due to
other non-financial factors beyond our control. Our failure to effectively utilize the proceeds from the sale of Masthercell could
adversely affect our ability to successfully grow our POC business and develop cell therapy product candidates, which could cause
the value of your investment in Orgenesis to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>We
are not profitable as of</b></span><b> <span style="font: 10pt Times New Roman, Times, Serif">December 31, 2020<span style="background-color: white">,
</span>have limited cash flow and, unless we increase revenues and take advantage of any commercial opportunities that arise to
expand our POC business, the perceived value of our company may decrease and our stock price could be affected accordingly.</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
the fiscal year ended December 31, 2020 and as of the date of this report, we assessed our financial condition and concluded that
we have sufficient resources for the next 12 months from the date of the report as a result of the receipt of the net proceeds
from the sale of Masthercell. Our auditor&#8217;s report for the year ended December 31, 2020 does not include a going concern
opinion on the matter. However, management is unable to predict if and when we will be able to generate significant revenues or
achieve profitability. Our plan regarding these matters is to continue improving the net results in our POC business into fiscal
year 2021. There can be no assurance that we will be successful in increasing revenues, improving our POC results or that the
perceived value of our company will increase. In the event that we are unable to generate significant revenues in our POC business,
our stock price could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Our
research and development programs are based on novel technologies and are inherently risky.</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
are subject to the risks of failure inherent in the development of products based on new technologies. The novel nature of our
cell therapy technology creates significant challenges with respect to product development and optimization, manufacturing, government
regulation and approval, third-party reimbursement and market acceptance. For example, the FDA and EMA have relatively limited
experience with the development and regulation of cell therapy products and, therefore, the pathway to marketing approval for
our cell therapy product candidates may accordingly be more complex, lengthy and uncertain than for a more conventional product
candidate. The indications of use for which we choose to pursue development may have clinical effectiveness endpoints that have
not previously been reviewed or validated by the FDA or EMA, which may complicate or delay our effort to ultimately obtain FDA
or EMA approval. Because this is a new approach to treating diseases, developing and commercializing our product candidates subjects
us to a number of challenges, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">obtaining
    regulatory approval from the FDA, EMA and other regulatory authorities that have very limited experience with the commercial
    development of our technology for treating different diseases;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">developing
    and deploying consistent and reliable processes for removing the cells from the patient engineering cells ex vivo and infusing
    the engineered cells back into the patient;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">developing
    processes for the safe administration of these products, including long-term follow-up for all patients who receive our products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">sourcing
    clinical and, if approved, commercial supplies for the materials used to manufacture and process our products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">developing
    a manufacturing process and distribution network with a cost of goods that allows for an attractive return on investment;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">establishing
    sales and marketing capabilities after obtaining any regulatory approval to gain market acceptance; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">maintaining
    a system of post marketing surveillance and risk assessment programs to identify adverse events that did not appear during
    the drug approval process.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
efforts to overcome these challenges may not prove successful, and any product candidate we seek to develop may not be successfully
developed or commercialized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Kyslecel may not
achieve patient or market acceptance, which could have a material adverse effect on our business.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
commercialization strategy for Kyslecel relies on medical specialists, medical facilities and patients adopting TP-IAT with Kyslecel
as an accepted treatment for chronic pancreatitis. However, medical specialists are historically slow to adopt new treatments,
regardless of perceived merits, when older treatments continue to be supported by established providers. Overcoming such resistance
often requires significant marketing expenditure or definitive product performance and/or pricing superiority. The cost of allocating
resources for such requirements might severely impact the potential for profitability of Kyslecel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">There
is no guarantee that physician or patient acceptance of TP-IAT with Kyslecel will be substantial. Further, there is no guarantee
that Koligo will be able to achieve patient acceptance or obtain enough customers (clinical providers) to meet its sales objectives.
If we do not meet our sales objectives, our business prospects and financial performance will be materially
and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Further,
we are  partially reliant on published clinical trials and scientific research conducted by third parties to justify
the patient benefit and safety of TP-IAT with Kyslecel and, as such, we rely, in part, on the accuracy and integrity of
those third-parties to have reported the results and correctly collected and interpreted the data from all clinical trials conducted
to date. If published data turn out to later be incorrect or incomplete, our business prospects and financial performance
may be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>The
                                         therapeutic efficacy of ranpirnase and our other product candidates is unproven in humans,
                                         and we may not be able to successfully develop and commercialize ranpirnase or any of
                                         our other product candidates.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Ranpirnase
and our other product candidates are novel compounds and their potential benefit as antiviral drugs or immunotherapies is unproven.
Ranpirnase and our other product candidates may not prove to be effective against the indications for which they are being designed
to act and may not demonstrate in clinical trials any or all of the pharmacological effects that have been observed in preclinical
studies. As a result, our clinical trial results may not be indicative of the results of future clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Ranpirnase
and our other product candidates may interact with human biological systems in unforeseen, ineffective or harmful ways. If ranpirnase
or any of our other product candidates is associated with undesirable side effects or have characteristics that are unexpected,
we may need to abandon the development of such product candidate or limit development to certain uses or subpopulations in which
the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective.
Because of these and other risks described herein that are inherent in the development of novel therapeutic agents, we may never
successfully develop or commercialize ranpirnase or any of our other product candidates, in which case our business will be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>We
will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, we had 111 employees. As our development and commercialization plans and strategies develop, we must add
a significant number of additional managerial, operational, sales, marketing, financial, and other personnel. Future growth will
impose significant added responsibilities on members of management, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">identifying,
    recruiting, integrating, maintaining, and motivating additional employees;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">managing
    our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while
    complying with our contractual obligations to contractors and other third parties; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">improving
    our operational, financial and management controls, reporting systems, and procedures.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively
manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day
activities in order to devote a substantial amount of time to managing these growth activities. This lack of long-term experience
working together may adversely impact our senior management team&#8217;s ability to effectively manage our business and growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations,
advisors and consultants to provide certain services. There can be no assurance that the services of these independent organizations,
advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements.
In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided
by consultants is compromised for any reason, our clinical trials may be extended, delayed, or terminated, and we may not be able
to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will
be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable
terms, if at all. If we are not able to effectively expand our organization by hiring new employees and expanding our groups of
consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize
our product candidates and, accordingly, may not achieve our research, development, and commercialization goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Currency
exchange fluctuations may impact the results of our operations.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
provision of services by our former subsidiary, Masthercell Global, were usually transacted in U.S. dollars and European currencies
during the year ended December 31, 2020. Our results of operations are affected by fluctuations in currency exchange rates in
both sourcing and selling locations. Our results of operations may still be impacted by foreign currency exchange rates, primarily,
the euro-to-U.S. dollar exchange rate. In recent years, the euro-to-U.S. dollar exchange rate has been subject to substantial
volatility which may continue, particularly in light of recent political events regarding the European Union, or EU. Because we
do not hedge against all of our foreign currency exposure, our business will continue to be susceptible to foreign currency fluctuations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>We
have entered into collaborations and may form or seek collaborations or strategic alliances or enter into additional licensing
arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have entered into collaborations and joint ventures and may form or seek strategic alliances, create joint ventures or collaborations,
or enter into additional licensing arrangements with third parties that we believe will complement or augment our development
and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any
of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures,
issue securities that dilute our existing stockholders, or disrupt our management and business. In addition, we face significant
competition in seeking appropriate strategic partners for which the negotiation process is time-consuming and complex. Moreover,
we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product
candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties
may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. Further, collaborations
involving our product candidates, such as our collaborations with third-party research institutions, are subject to numerous risks,
which may include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">collaborators
    have significant discretion in determining the efforts and resources that they will apply to a collaboration;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">collaborators
    may not perform their obligations as expected;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">collaborators
    may not pursue development and commercialization of our product candidates or may elect not to continue or renew development
    or commercialization programs based on clinical trial results, changes in their strategic focus due to the acquisition of
    competitive products, availability of funding, or other external factors, such as a business combination that diverts resources
    or creates competing priorities;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">collaborators
    may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate,
    repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">collaborators
    could fail to make timely regulatory submissions for a product candidate;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">collaborators
    may not comply with all applicable regulatory requirements or may fail to report safety data in accordance with all applicable
    regulatory requirements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">collaborators
    could independently develop, or develop with third parties, products that compete directly or indirectly with our products
    or product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">product
    candidates developed in collaboration with us may be viewed by our collaborators as competitive with their own product candidates
    or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a
    collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing
    and distribution;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">collaborators
    may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information
    in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property
    or proprietary information or expose us to potential liability;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">disputes
    may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization
    of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">collaborations
    may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization
    of the applicable product candidates; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">collaborators
    may own or co-own intellectual property covering our products that results from our collaborating with them and, in such cases,
    we would not have the exclusive right to commercialize such intellectual property.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
a result, if we enter into collaboration agreements and strategic partnerships or license our products or businesses, we may not
be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations
and company culture, which could delay our timelines or otherwise adversely affect our business. The success of our existing and
future collaboration arrangements and strategic partnerships, which include research and development services by our collaborators
to improve our intellectual property, will depend heavily on the efforts and activities of our collaborators and may not be successful.
We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income
that justifies such transaction. Any delays in entering into new collaborations or strategic partnership agreements related to
our product candidates could delay the development and commercialization of our product candidates in certain geographies for
certain indications, which would harm our business prospects, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Our
success will depend on strategic collaborations with third parties to develop and commercialize therapeutic product candidates,
and we may not have control over a number of key elements relating to the development and commercialization of any such product
candidate.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.6pt"><span style="font: 10pt Times New Roman, Times, Serif">A
key aspect of our strategy is to seek collaborations with partners, such as a large pharmaceutical organization, that are willing
to further develop and commercialize a selected product candidate. To date, we have entered into a number of collaborative arrangements
with cell therapy organizations. By entering into any such strategic collaborations, we may rely on our partner for financial
resources and for development, regulatory and commercialization expertise. Our partner may fail to develop or effectively commercialize
our product candidate because they:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">do
    not have sufficient resources or decide not to devote the necessary resources due to internal constraints such as limited
    cash or human resources;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">decide
    to pursue a competitive potential product developed outside of the collaboration;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">cannot
    obtain the necessary regulatory approvals;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">determine
    that the market opportunity is not attractive; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">cannot
    manufacture or obtain the necessary materials in sufficient quantities from multiple sources or at a reasonable cost.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
may not be able to enter into additional collaborations on acceptable terms, if at all. We face competition in our search for
partners from other organizations worldwide, many of whom are larger and are able to offer more attractive deals in terms of financial
commitments, contribution of human resources, or development, manufacturing, regulatory or commercial expertise and support. If
we are not successful in attracting a partner and entering into a collaboration on acceptable terms, we may not be able to complete
development of or commercialize any product candidate. In such event, our ability to generate revenues and achieve or sustain
profitability would be significantly hindered and we may not be able to continue operations as proposed, requiring us to modify
our business plan, curtail various aspects of our operations or cease operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>The
coronavirus outbreak has the potential to cause disruptions in our business, including our clinical development activities</b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
outbreak of the novel strain of coronavirus, or COVID-19, has currently impacted and may continue to impact our business, including
our preclinical studies and clinical trials. COVID-19 has spread to multiple countries, including the United States and Israel,
where we conduct most of our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Efforts
to contain the spread of COVID-19 have intensified and the United States and Israel, among other countries, have implemented and
may continue to implement severe travel restrictions, shelter in place orders, social distancing and delays or cancellations of
elective surgeries. These and other disruptions have caused, and may continue to cause, a delay in the supply of consumable goods,
which could result in further delays, increased costs to source alternative suppliers and affect our ability to commercialize
and develop our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
spread of an infectious disease, including COVID-19, may also result in a period of business disruption, and in reduced operations,
including employee absenteeism and delays in payments from our customers, any of which could materially affect our business, financial
condition and results of operations. Although, as of the date of this Annual Report on Form 10-K, we do not expect any material
impact on our long-term activity, the extent to which COVID-19 impacts our business will depend on future developments, which
are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and
the actions to contain COVID-19 or treat its impact, among others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Our
success depends on our ability to protect our intellectual property and our proprietary technologies.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our
product candidates, proprietary technologies, and their uses as well as our ability to operate without infringing upon the proprietary
rights of others. We can provide no assurance that our patent applications or those of our licensors will result in additional
patents being issued or that issued patents will afford sufficient protection against competitors with similar technologies, nor
can there be any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Even
issued patents may later be found unenforceable or may be modified or revoked in proceedings instituted by third parties before
various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection
may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. Composition-of-matter
patents on the biological or chemical active pharmaceutical ingredients are generally considered to offer the strongest protection
of intellectual property and provide the broadest scope of patent protection for pharmaceutical products, as such patents provide
protection without regard to any method of use or any method of manufacturing. While we have issued patents in the United States
we cannot be certain that the claims in our issued patent will not be found invalid or unenforceable if challenged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
cannot be certain that the claims in our issued United States methods of use patents will not be found invalid or unenforceable
if challenged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
cannot be certain that the pending applications covering among others the bioconjugates comprising sulfated polysaccharides; ranpirnase
and other ribonucleases for treating viral diseases; therapeutic compositions comprising exosomes, bioxomes, and redoxomes; automated
devices for supporting cell therapies; immune cells, ribonucleases, or antibodies for treating COVID-19; chimeric antigen receptors
(CARs); or cell-conditioned medium will be considered patentable by the United States Patent and Trademark Office (USPTO),
and courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims
in our issued patents will not be found invalid or unenforceable if challenged. Even if our patent applications covering these
inventions issue as patents, the patents protect specific products and may not be enforced against competitors making and marketing
a product that has the same activity. Method-of-use patents protect the use of a product for the specified method or for treatment
of a particular indication. These type of patents may not be enforced against competitors making and marketing a product
that provides the same activity but is used for a method not included in the patent. Moreover, even if competitors do not actively
promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although
off-label prescriptions may infringe or contribute to the infringement of method-of-use patents, the practice is common and such
infringement is difficult to prevent or prosecute.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, we</span><span style="font: 10pt Times New Roman, Times, Serif"> own or have exclusive rights to twenty eight (28)
United States patents, thirty six (36) foreign-issued patents, twenty five (25) pending patent applications in the United States,
forty five (45) pending patent applications in foreign jurisdictions, including Australia, Brazil, Canada, China, Europe, Hong
Kong, India, Israel, Japan, Mexico, New Zealand, North Korea, Russia, Singapore, South Africa, and South Korea, and two (2) international
Patent Cooperation Treaty (&#8220;PCT&#8221;) patent applications. These patents and patent applications relate, among others,
to (1) dendritic and macrophages based vaccines, and their use for treating cancer and viral diseases; (2) compositions comprising
ranpirnase and other ribonucleases for treating viral diseases; (3) tumor infiltrating lymphocytes (TILs) and their use for treating
cancer; (4) compositions comprising immune cells, ribonucleases, or antibodies for treating COVID-19; (5) whole-cell antiviral
vaccines; (6) therapeutic compositions comprising exosomes, bioxomes, and redoxomes; (7)bioreactors for cell culture and automated
systems and devices for supporting cell therapies; and(8) scaffolds, including alginate and sulfated alginate scaffolds, polysaccharides
thereof, and scaffolds for use for cell propagation, transplantations, and in the treatment of autoimmune diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have pending U.S. patent applications directed, among others, to dendritic and macrophages based vaccines, and their use for
treating cancer and viral diseases. If issued, this application would expire in 2038.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have pending U.S. patent applications directed, among others, to compositions comprising ranpirnase and other ribonucleases for
treating viral diseases. If issued, these applications would expire between 2039 and 2040. Counterpart patents applications were
filed in Australia, Canada, China, Europe, Hong Kong, Japan, Mexico, New Zealand, North Korea, Russian Federation, Singapore,
South Africa, and were also filed as International (&#8220;PCT&#8221;) applications. If issued, these applications would expire
between 2035 and 2037. These expiration dates do not include any patent term extensions that might be available following the
grant of marketing authorizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have pending U.S. patent applications directed, among others, to therapeutic compositions comprising exosomes, bioxomes, and redoxomes.
If issued, these applications would expire in 2040. Counterpart patents applications were filed in Australia, Brazil, Canada,
China, Europe, India, Israel, India, Japan and South Korea. If issued, these applications would expire in 2039. These expiration
dates do not include any patent term extensions that might be available following the grant of marketing authorizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have pending U.S. patent applications directed, among others, to automated devices for supporting cell therapies. If issued, these
applications would expire between 2035 and 2038.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have a pending U.S. provisional patent application directed, among others, to tumor infiltrating lymphocytes (TILs) and their
use for treating cancer. If converted into a non-provisional application and issued, this application would expire in 2041, without
including any patent term extensions that might be available following the grant of marketing authorizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have pending U.S. provisional patent applications directed, among others, to compositions comprising immune cells, ribonucleases,
or antibodies for treating COVID-19. If converted into a non-provisional application and issued, this application would expire
in 2041, without including any patent term extensions that might be available following the grant of marketing authorizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Granted U.S. patents,
which are directed among others to scaffolds, including alginate and sulfated alginate scaffolds, polysaccharides thereof, and
scaffolds for use for cell propagation, transplantations, and in the treatment of autoimmune diseases, will expire between 2025
and 2036. Counterpart patents granted in Australia, France, Germany, Israel, Switzerland, and the United Kingdom, will expire
between 2026 and 2035. <span style="font: 10pt Times New Roman, Times, Serif">These expiration dates do not
include any patent term extensions that might be available following the grant of marketing authorizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have pending U.S.
patent applications directed, among others, to bioconjugates comprising sulfated polysaccharides and diverse bioactive peptides,
and their use in the treatment of inflammatory conditions. If issued, these applications would expire in 2038. Counterpart patents
applications were filed in China, Europe, Israel, Japan, and South Korea. If issued, these applications would expire between 2026
and 2038. These expiration dates do not include any patent term extensions that might be available following the grant of marketing
authorizations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
Ltd, has exclusive rights to six (6) United States patents, fourteen (14) foreign-issued patents, five (5) pending patent applications
in the United States, twenty six (26) pending patent applications in foreign jurisdictions, including Australia, Brazil, Canada,
China, Europe, India, Israel, Japan, Mexico, Panama, Singapore, and South Korea. These patents and patent applications relate,
among others, to the trans-differentiation of cells (including hepatic cells) to cells having pancreatic &#946;-cell-like phenotype
and function and to their use in the treatment of degenerative pancreatic disorders, including diabetes, pancreatic cancer and
pancreatitis. Granted U.S. patents, which are directed among others to trans-differentiation to pancreatic &#946;-cell-like phenotype
and function cells and to their use in the treatment of degenerative pancreatic disorders, including diabetes, pancreatic cancer
and pancreatitis, will expire between 2024 and 2035. Counterpart patents granted in Australia, France, Germany, Israel, Switzerland,
and the United Kingdom, will expire between 2024 and 2035. These expiration dates do not include any patent term extensions that
might be available following the grant of marketing authorizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
Ltd, has pending U.S. patent applications directed, among others, to the trans-differentiation of cells, to cells having pancreatic
&#946;-cell-like phenotype and function and to their use in the treatment of degenerative pancreatic disorders, including diabetes,
pancreatic cancer and pancreatitis. If issued, these applications would expire between 2038 and 2040. Counterpart patents applications
were filed in Australia, Brazil, Canada, China, Europe, India, Israel, Mexico, Panama, Singapore, South Korea, and were also filed
as International (&#8220;PCT&#8221;) applications. If issued, these applications would expire between 2034 and 2039. These expiration
dates do not include any patent term extensions that might be available following the grant of marketing authorizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our
future development partners will be successful in protecting our product candidates by obtaining and defending patents. These
risks and uncertainties include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment
    and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse
    of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In
    such an event, competitors might be able to enter the market earlier than would otherwise have been the case;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">patent
    applications may not result in any patents being issued;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">patents
    that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable
    or otherwise may not provide any competitive advantage;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    competitors, many of whom have substantially greater resources and many of whom have made significant investments in competing
    technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make,
    use, and sell our potential product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">there
    may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection
    both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding
    worldwide health concerns; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">countries
    other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign
    competitors a better opportunity to create, develop and market competing product candidates.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, we rely on the protection of our trade secrets and proprietary know-how. Although we have taken steps to protect our
trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential
information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that all such
agreements have been duly executed, and third parties may still obtain this information or may come upon this or similar information
independently. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient
recourse against third parties for misappropriating its trade secrets. If any of these events occurs or if we otherwise lose protection
for our trade secrets or proprietary know-how, our business may be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>If
product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization
of our product candidates.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even
greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to
cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product
liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent
in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection
acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be
required to limit commercialization of our product candidates. Even a successful defense would require significant financial and
management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">decreased
    demand for our products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">injury
    to our reputation;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">withdrawal
    of clinical trial participants and inability to continue clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">initiation
    of investigations by regulators;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">costs
    to defend the related litigation;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a
    diversion of management&#8217;s time and our resources;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">substantial
    monetary awards to trial participants or patients;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">product
    recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">loss
    of revenue;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">exhaustion
    of any available insurance and our capital resources;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    inability to commercialize any product candidate; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a
    decline in our share price.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Because
most of our products have not reached commercial stage, we do not currently need to carry clinical trial or extensive product
liability insurance. In the future, our inability to obtain additional sufficient product liability insurance at an acceptable
cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop,
alone or with collaborators. Such insurance policies may also have various exclusions, and we may be subject to a product liability
claim for which we have no coverage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>It
may be difficult to enforce a U.S. judgment against us, our officers and directors and the foreign persons named in this Annual
Report on Form 10-K in the United States or in foreign countries, or to assert U.S. securities laws claims in foreign countries
or serve process on our officers and directors and these experts.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">While
we are incorporated in the State of Nevada, currently a majority of our directors and executive officers are not residents of
the United States, and the foreign persons named in this Annual Report on Form 10-K are located outside of the United States.
The majority of our assets are located outside the United States. Therefore, it may be difficult for an investor, or any other
person or entity, to enforce a U.S. court judgment based upon the civil liability provisions of the U.S. federal securities laws
against us or any of these persons in a U.S. or foreign court, or to effect service of process upon these persons in the United
States. Additionally, it may be difficult for an investor, or any other person or entity, to assert U.S. securities law claims
in original actions instituted in foreign countries in which we operate. Foreign courts may refuse to hear a claim based on a
violation of U.S. securities laws on the grounds that foreign countries are not necessary the most appropriate forum in which
to bring such a claim. Even if a foreign court agrees to hear a claim, it may determine that foreign law and not U.S. law is applicable
to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be
a time-consuming and costly process. Certain matters of procedure will also be governed by foreign countries law. There is little
binding case law in foreign countries addressing the matters described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>We
may be subject to numerous and varying privacy and security laws, and our failure to comply could result in penalties and reputational
damage.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
are subject to laws and regulations covering data privacy and the protection of personal information, including health information.
The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing
focus on privacy and data protection issues which may affect our business. In the U.S., numerous federal and state laws and regulations,
including state security breach notification laws, state health information privacy laws, and federal and state consumer protection
laws, govern the collection, use, disclosure, and protection of personal information. Each of these laws is subject to varying
interpretations by courts and government agencies, creating complex compliance issues for us. If we fail to comply with applicable
laws and regulations we could be subject to penalties or sanctions, including criminal penalties if we knowingly obtain or disclose
individually identifiable health information from a covered entity in a manner that is not authorized or permitted by the Health
Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical
Health Act, or HIPAA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Numerous
other countries have, or are developing, laws governing the collection, use and transmission of personal information as well.
The EU and other jurisdictions have adopted data protection laws and regulations, which impose significant compliance obligations.
In the EU, for example, effective May 25, 2018, the GDPR replaced the prior EU Data Protection Directive (95/46) that governed
the processing of personal data in the European Union. The GDPR imposes significant obligations on controllers and processors
of personal data, including, as compared to the prior directive, higher standards for obtaining consent from individuals to process
their personal data, more robust notification requirements to individuals about the processing of their personal data, a strengthened
individual data rights regime, mandatory data breach notifications, limitations on the retention of personal data and increased
requirements pertaining to health data, and strict rules and restrictions on the transfer of personal data outside of the EU,
including to the U.S. The GDPR also imposes additional obligations on, and required contractual provisions to be included in,
contracts between companies subject to the GDPR and their third-party processors that relate to the processing of personal data.
The GDPR allows EU member states to make additional laws and regulations further limiting the processing of genetic, biometric
or health data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Adoption
of the GDPR increased our responsibility and liability in relation to personal data that we process and may require us to put
in place additional mechanisms to ensure compliance. Any failure to comply with the requirements of GDPR and applicable national
data protection laws of EU member states, could lead to regulatory enforcement actions and significant administrative and/or financial
penalties against us (fines of up to Euro 20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial
year, whichever is higher), and could adversely affect our business, financial condition, cash flows and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>We
are increasingly dependent on information technology and our systems and infrastructure face certain risks, including cybersecurity
and data storage risks.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Significant
disruptions to our information technology systems or breaches of information security could adversely affect our business. In
the ordinary course of business, we collect, store and transmit confidential information, and it is critical that we do so in
a secure manner in order to maintain the confidentiality and integrity of such confidential information. Our information technology
systems are potentially vulnerable to service interruptions and security breaches from inadvertent or intentional actions by our
employees, partners, vendors, or from attacks by malicious third parties. Maintaining the secrecy of this confidential, proprietary,
and/or trade secret information is important to our competitive business position. While we have taken steps to protect such information
and invested in information technology, there can be no assurance that our efforts will prevent service interruptions or security
breaches in our systems or the unauthorized or inadvertent wrongful access or disclosure of confidential information that could
adversely affect our business operations or result in the loss, dissemination, or misuse of critical or sensitive information.
A breach of our security measures or the accidental loss, inadvertent disclosure, unapproved dissemination or misappropriation
or misuse of trade secrets, proprietary information, or other confidential information, whether as a result of theft, hacking,
or other forms of deception, or for any other cause, could enable others to produce competing products, use our proprietary technology
and/or adversely affect our business position. Further, any such interruption, security breach, loss or disclosure of confidential
information could result in financial, legal, business, and reputational harm to us and could have a material effect on our business,
financial position, results of operations and/or cash flow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>There
can be no assurance that we will be able to develop in-house sales and commercial distribution capabilities or establish or maintain
relationships with third-party collaborators to successfully commercialize any product in the United States or overseas, and as
a result, we may not be able to generate product revenue.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
variety of risks associated with operating our business internationally could materially adversely affect our business. We plan
to seek regulatory approval of our product candidates outside of the United States and, accordingly, we expect that we, and any
potential collaborators in those jurisdictions, will be subject to additional risks related to operating in foreign countries,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">differing
    regulatory requirements in foreign countries, unexpected changes in tariffs, trade barriers, price and exchange controls,
    and other regulatory requirements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">economic
    weakness, including inflation, or political instability in particular foreign economies and markets;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">compliance
    with tax, employment, immigration, and labor laws for employees living or traveling abroad;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">foreign
    taxes, including withholding of payroll taxes;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">foreign
    currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident
    to doing business in another country;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">difficulties
    staffing and managing foreign operations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">workforce
    uncertainty in countries where labor unrest is more common than in the United States;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">potential
    liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign laws;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">challenges
    enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and
    protect intellectual property rights to the same extent as the United States;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">production
    shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">business
    interruptions resulting from geo-political actions, including war, and terrorism or disease outbreaks (such as the recent
    outbreak of COVID-19, or the novel coronavirus).</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">These
and other risks associated with our planned international operations may materially adversely affect our ability to attain or
maintain profitable operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>If
we are unable to integrate acquired businesses effectively, our operating results may be adversely affected.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">From
time to time, we seek to expand our business through acquisitions. We may not be able to successfully integrate acquired businesses
and, where desired, their product portfolios into ours, and therefore we may not be able to realize the intended benefits. If
we fail to successfully integrate acquisitions or product portfolios, or if they fail to perform as we anticipate, our existing
businesses and our revenue and operating results could be adversely affected. If the due diligence of the operations of acquired
businesses performed by us and by third parties on our behalf is inadequate or flawed, or if we later discover unforeseen financial
or business liabilities, acquired businesses and their assets may not perform as expected. Additionally, acquisitions could result
in difficulties assimilating acquired operations and, where deemed desirable, transitioning overlapping products into a single
product line and the diversion of capital and management&#8217;s attention away from other business issues and opportunities.
The failure to integrate acquired businesses effectively may adversely impact our business, results of operations or financial
condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Risks
Related to Our Trans-Differentiation Technologies for Diabetes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>THM
is entitled to cancel the THM License Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the terms of the THM License Agreement with THM, Orgenesis Ltd, the Israeli Subsidiary, must develop, manufacture, sell and
market the products pursuant to the milestones and time schedule specified in the development plan. In the event the Israeli Subsidiary
fails to fulfill the terms of the development plan under the THM License Agreement, THM shall be entitled to terminate the THM
License Agreement by providing the Israeli Subsidiary with written notice of such a breach and if the Israeli Subsidiary does
not cure such breach within one year of receiving the notice. THM may also terminate the THM License Agreement if the Israeli
Subsidiary breaches an obligation contained in the THM License Agreement and does not cure it within 180 days of receiving notice
of the breach. We also run the risk that THM may attempt cancel or, at the very least challenge, the License Agreement with Orgenesis
Ltd. as we continue to expand our focus to other therapies and business activities. We believe that our expanded focus to such
other therapies and business activities may continue to prompt THM to inquire of such activities as they may relate to our compliance
with the terms or direction of resources toward the THM License Agreement. While we have not received any notice of cancellation
of the THM License Agreement, we have received an allegation regarding the scope of the rights by THM that may present future
challenges for our Israeli Subsidiary to continue to develop, manufacture, sell and market the products pursuant to the milestones
and time schedule specified in the development plan of the THM License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have developed a technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver
and differentiating (converting) them into &#8220;pancreatic beta cell-like&#8221; insulin-producing cells for patients with diabetes.
Our intention is to develop our technology to the clinical stage for regeneration of functional insulin-producing cells, thus
enabling normal glucose regulated insulin secretion, via cell therapy. By using therapeutic agents that efficiently convert a
sub-population of liver cells into pancreatic islets phenotype and function, this approach allows the diabetic patient to be the
donor of his/her own therapeutic tissue and to start producing his/her own insulin in a glucose-responsive manner, thereby eliminating
the need for insulin injections. Because this is a new approach to treating diabetes, developing and commercializing our product
candidates subjects us to a number of challenges, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">obtaining
    regulatory approval from the FDA, EMA and other regulatory authorities that have very limited experience with the commercial
    development of our technology for diabetes;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">developing
    and deploying consistent and reliable processes for engineering a patient&#8217;s liver cells ex vivo and infusing the engineered
    cells back into the patient;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">developing
    processes for the safe administration of these products, including long-term follow-up for all patients who receive our products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">sourcing
    clinical and, if approved, commercial supplies for the materials used to manufacture and process our products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">developing
    a manufacturing process and distribution network with a cost of goods that allows for an attractive return on investment;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">establishing
    sales and marketing capabilities after obtaining any regulatory approval to gain market acceptance; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">maintaining
    a system of post marketing surveillance and risk assessment programs to identify adverse events that did not appear during
    the drug approval process.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Risks
Related to Development and Regulatory Approval of Our Therapies and Product Candidates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Research
and development of biopharmaceutical products is inherently risky.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
may not be successful in our efforts to use and enhance our technology platform to create a pipeline of product candidates and
develop commercially successful products. Furthermore, we may expend our limited resources on programs that do not yield a successful
product candidate and fail to capitalize on product candidates or diseases that may be more profitable or for which there is a
greater likelihood of success. If we fail to develop additional product candidates, our commercial opportunity will be limited.
Even if we are successful in continuing to build our pipeline, obtaining regulatory approvals and commercializing additional product
candidates will require substantial additional funding and are prone to the risks of failure inherent in medical product development.
Investment in biopharmaceutical product development involves significant risk that any potential product candidate will fail to
demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, and become commercially viable. We cannot
provide you any assurance that we will be able to successfully advance any of these additional product candidates through the
development process. Our research programs may initially show promise in identifying potential product candidates, yet fail to
yield product candidates for clinical development or commercialization for many reasons, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    platform may not be successful in identifying additional product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">we
    may not be able or willing to assemble sufficient resources to acquire or discover additional product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    product candidates may not succeed in preclinical or clinical testing;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a
    product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is
    unlikely to be effective or otherwise does not meet applicable regulatory criteria;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">competitors
    may develop alternatives that render our product candidates obsolete or less attractive;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">product
    candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    market for a product candidate may change during our program so that the continued development of that product candidate is
    no longer reasonable;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a
    product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a
    product candidate may not be accepted as safe and effective by patients, the medical community or third- party payers, if
    applicable.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">If
any of these events occur, we may be forced to abandon our development efforts for a program or programs, or we may not be able
to identify, discover, develop, or commercialize additional product candidates, which would have a material adverse effect on
our business and could potentially cause us to cease operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Extensive
industry regulation has had, and will continue to have, a significant impact on our business, especially our product development,
manufacturing and distribution capabilities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">All
pharmaceutical companies are subject to extensive, complex, costly and evolving government regulation. For the U.S., this is principally
administered by the FDA and to a lesser extent by the Drug Enforcement Administration (&#8220;DEA&#8221;) and state government
agencies, as well as by varying regulatory agencies in foreign countries where products or product candidates are being manufactured
and/or marketed. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other federal statutes and regulations,
and similar foreign statutes and regulations, govern or influence the testing, manufacturing, packing, labeling, storing, record
keeping, safety, approval, advertising, promotion, sale and distribution of our future products. Under these regulations, we may
become subject to periodic inspection of our facilities, procedures and operations and/or the testing of our future products by
the FDA, the DEA and other authorities, which conduct periodic inspections to confirm that we are in compliance with all applicable
regulations. In addition, the FDA and foreign regulatory agencies conduct pre-approval and post-approval reviews and plant inspections
to determine whether our systems and processes are in compliance with current good manufacturing practice (&#8220;cGMP&#8221;)
and other regulations. Following such inspections, the FDA or other agency may issue observations, notices, citations and/or warning
letters that could cause us to modify certain activities identified during the inspection. FDA guidelines specify that a warning
letter is issued only for violations of &#8220;regulatory significance&#8221; for which the failure to adequately and promptly
achieve correction may be expected to result in an enforcement action. We may also be required to report adverse events associated
with our future products to FDA and other regulatory authorities. Unexpected or serious health or safety concerns would result
in labeling changes, recalls, market withdrawals or other regulatory actions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
range of possible sanctions includes, among others, FDA issuance of adverse publicity, product recalls or seizures, fines, total
or partial suspension of production and/or distribution, suspension of the FDA&#8217;s review of product applications, enforcement
actions, injunctions, and civil or criminal prosecution. Any such sanctions, if imposed, could have a material adverse effect
on our business, operating results, financial condition and cash flows. Under certain circumstances, the FDA also has the authority
to revoke previously granted drug approvals. Similar sanctions as detailed above may be available to the FDA under a consent decree,
depending upon the actual terms of such decree. If internal compliance programs do not meet regulatory agency standards or if
compliance is deemed deficient in any significant way, it could materially harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
European Medicines Agency (&#8220;EMA&#8221;) will regulate our future products in Europe. Regulatory approval by the EMA will
be subject to the evaluation of data relating to the quality, efficacy and safety of our future products for its proposed use.
The time taken to obtain regulatory approval varies between countries. Different regulators may impose their own requirements
and may refuse to grant, or may require additional data before granting, an approval, notwithstanding that regulatory approval
may have been granted by other regulators.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Regulatory
approval may be delayed, limited or denied for a number of reasons, including insufficient clinical data, the product not meeting
safety or efficacy requirements or any relevant manufacturing processes or facilities not meeting applicable requirements.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Further
trials and other costly and time-consuming assessments of the product may be required to obtain or maintain regulatory approval.
Medicinal products are generally subject to lengthy and rigorous pre-clinical and clinical trials and other extensive, costly
and time-consuming procedures mandated by regulatory authorities. We may be required to conduct additional trials beyond those
currently planned, which could require significant time and expense. In addition, even after the technology approval, both in
the U.S. and Europe, we will be required to maintain post marketing surveillance of potential adverse and risk assessment programs
to identify adverse events that did not appear during the clinical studies and drug approval process. All of the foregoing could
require an investment of significant time and expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>We
have generated limited revenue from therapeutic product sales, and our ability to generate any significant revenue from product
sales and become profitable depends significantly on our success in a number of factors.</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have a limited number of therapeutic products approved for commercial sale, and we have generated only limited revenue from product
sales. Our ability to generate revenue of more significant scale and achieve profitability depends significantly on our success
in many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">completing
    research regarding, and nonclinical and clinical development of, our product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">obtaining
    regulatory approvals and marketing authorizations for product candidates for which we complete clinical studies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">developing
    a sustainable and scalable manufacturing process for our product candidates, including establishing and maintaining commercially
    viable supply relationships with third parties and establishing our own manufacturing capabilities and infrastructure;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">launching
    and commercializing product candidates for which we obtain regulatory approvals and marketing authorizations, either directly
    or with a collaborator or distributor;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">obtaining
    market acceptance of our product candidates as viable treatment options;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">addressing
    any competing technological and market developments;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">identifying,
    assessing, acquiring and/or developing new product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">negotiating
    favorable terms in any collaboration, licensing, or other arrangements into which we may enter;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">maintaining,
    protecting, and expanding our portfolio of intellectual property rights, including patents, trade secrets, and know-how; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">attracting,
    hiring, and retaining qualified personnel.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Even
if more of the product candidates that we develop are approved for commercial sale, we anticipate incurring significant costs
associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required
by the U.S. Food and Drug Administration, or the FDA, or other regulatory agencies, domestic or foreign, to change our manufacturing
processes or assays, or to perform clinical, nonclinical, or other types of studies in addition to those that we currently anticipate.
If we are successful in obtaining regulatory approvals to market more of our product candidates, our revenue will be dependent,
in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product,
the ability to get reimbursement at any price, and whether we own the commercial rights for that territory. If the number of our
addressable disease patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower
than we expect, or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment
guidelines, we may not generate significant revenue from sales of such products, even if approved. If we are not able to generate
revenue from the sale of any approved products, we may never become profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>When
we commence any clinical trials, we may not be able to conduct our trials on the timelines we expect.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Clinical
testing is expensive, time consuming, and subject to uncertainty. We cannot guarantee that any clinical studies will be conducted
as planned or completed on schedule, if at all. We expect that our early clinical work will help support the filing with the FDA
of an IND for our product in fiscal 2020. However, we cannot be sure that we will be able to submit an IND in this time-frame,
and we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin. Moreover, even if these
trials begin, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical studies
can occur at any stage of testing, and our future clinical studies may not be successful. Events that may prevent successful or
timely completion of clinical development include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    inability to generate sufficient preclinical or other in vivo or in vitro data to support the initiation of clinical studies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">delays
    in reaching a consensus with regulatory agencies on study design;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">delays
    in establishing CMC (Chemistry, Manufacturing, and Controls) which is a cornerstone in clinical study submission and later
    on, the regulatory approval;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    FDA not allowing us to use the clinical trial data from a research institution to support an IND if we cannot demonstrate
    the comparability of our product candidates with the product candidate used by the relevant research institution in its clinical
    studies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">delays
    in obtaining required Institutional Review Board, or IRB, approval at each clinical study site;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">imposition
    of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND
    application or amendment, or equivalent application or amendment;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a
    result of a new safety finding that presents unreasonable risk to clinical trial participants;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a
    negative finding from an inspection of our clinical study operations or study sites;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">developments
    on trials conducted by competitors for related technology that raises FDA concerns about risk to patients of the technology
    broadly;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">if
    the FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">delays
    in recruiting suitable patients to participate in our clinical studies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">difficulty
    collaborating with patient groups and investigators;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">failure
    to perform in accordance with the FDA&#8217;s current good clinical practices, or cGCPs, requirements, or applicable regulatory
    guidelines in other countries;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">delays
    in having patients&#8217; complete participation in a study or return for post-treatment follow-up;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">patients
    dropping out of a study;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">occurrence
    of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">changes
    in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">changes
    in the standard of care on which a clinical development plan was based, which may require new or additional trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    cost of clinical studies of our product candidates being greater than we anticipate;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">clinical
    studies of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators
    requiring us, to conduct additional clinical studies or abandon product development programs; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">delays
    in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates
    for use in clinical studies or the inability to do any of the foregoing.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Any
inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability
to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required
to, or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical study
delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring
products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm
our business and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
clinical trial results may also not support approval, whether accelerated approval, conditional marketing authorizations, or regular
approval. The results of preclinical and clinical studies may not be predictive of the results of later-stage clinical trials,
and product candidates in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed
through preclinical studies and initial clinical trials. In addition, our product candidates could fail to receive regulatory
approval for many reasons, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full population
    for which we seek approval;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">we
    may be unable to demonstrate that our product candidates&#8217; risk-benefit ratios for their proposed indications are acceptable;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory
    authorities for approval;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">we
    may be unable to demonstrate that the clinical and other benefits of our product candidates outweigh their safety risks;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or
    clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable
    foreign regulatory authorities to obtain regulatory approval in the United States or elsewhere;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, our own manufacturing facilities,
    or our third-party manufacturers&#8217; facilities with which we contract for clinical and commercial supplies; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner
    rendering our clinical data insufficient for approval.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Further,
failure to obtain approval for any of the above reasons may be made more likely by the fact that the FDA and other regulatory
authorities have very limited experience with commercial development of our cell therapy for the treatment of Type 1 Diabetes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Our
product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent
their regulatory approval, limit their commercial potential, or result in significant negative consequences.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
with most biological drug products, use of our product candidates could be associated with side effects or adverse events which
can vary in severity from minor reactions to death and in frequency from infrequent to prevalent. Any of these occurrences may
materially and adversely harm our business, financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Our
product candidates are biologics and the manufacture of our product candidates is complex and we may encounter difficulties in
production, particularly with respect to process development or scaling-out of our manufacturing capabilities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">If
we encounter such difficulties, our ability to provide supply of our product candidates for clinical trials or our products for
patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure. Our
product candidates are biologics and the process of manufacturing our products is complex, highly regulated and subject to multiple
risks. As a result of the complexities, the cost to manufacture biologics is generally higher than traditional small molecule
chemical compounds, and the manufacturing process is less reliable and is more difficult to reproduce.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
manufacturing process will be susceptible to product loss or failure due to logistical issues associated with the collection of
liver cells, or starting material, from the patient, shipping such material to the manufacturing site, shipping the final product
back to the patient, and infusing the patient with the product, manufacturing issues associated with the differences in patient
starting materials, interruptions in the manufacturing process, contamination, equipment or reagent failure, improper installation
or operation of equipment, vendor or operator error, inconsistency in cell growth, failures in process testing and variability
in product characteristics. Even minor deviations from normal manufacturing processes could result in reduced production yields,
product defects, and other supply disruptions. If for any reason we lose a patient&#8217;s starting material or later-developed
product at any point in the process, the manufacturing process for that patient will need to be restarted and the resulting delay
may adversely affect that patient&#8217;s outcome. If microbial, viral, or other contaminations are discovered in our product
candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need
to be closed for an extended period of time to investigate and remedy the contamination. Because our product candidates are manufactured
for each particular patient, we will be required to maintain a chain of identity and tractability of all reagents and viruses
involved in the process with respect to materials as they move from the patient to the manufacturing facility, through the manufacturing
process, and back to the patient. Maintaining such a chain of identity is difficult and complex, and failure to do so could result
in adverse patient outcomes, loss of product, or regulatory action including withdrawal of our products from the market. Further,
as product candidates are developed through preclinical to late stage clinical trials towards approval and commercialization,
it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort
to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of
these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other
future clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Although
we are working to develop commercially viable processes, doing so is a difficult and uncertain task, and there are risks associated
with scaling to the level required for advanced clinical trials or commercialization, including, among others, cost overruns,
potential problems with process scale-out, process reproducibility, stability issues, lot consistency, and timely availability
of reagents or raw materials. We may ultimately be unable to reduce the cost of goods for our product candidates to levels that
will allow for an attractive return on investment if and when those product candidates are commercialized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, the manufacturing process for any products that we may develop is subject to FDA and foreign regulatory authority approval
process, and we will need to contract with manufacturers who can meet all applicable FDA and foreign regulatory authority requirements
on an ongoing basis. If we are unable to reliably produce products to specifications acceptable to the FDA or other regulatory
authorities, we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory
approval for any of our product candidates, there is no assurance that either we or our subsidiaries and joint ventures will be
able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it
in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand.
Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or
more clinical trials, increase clinical trial costs, delay approval of our product candidate, impair commercialization efforts,
increase our cost of goods, and have an adverse effect on our business, financial condition, results of operations and growth
prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
manufacture of biological drug products is complex and requires significant expertise and capital investment, including the development
of advanced manufacturing techniques and process controls. Manufacturers of biologic products often encounter difficulties in
production, particularly in scaling up or out, validating the production process, and assuring high reliability of the manufacturing
process (including the absence of contamination). These problems include logistics and shipping, difficulties with production
costs and yields, quality control, including stability of the product, product testing, operator error, availability of qualified
personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if contaminants are
discovered in our supply of our product candidates or in the manufacturing facilities, such manufacturing facilities may need
to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability
failures or other issues relating to the manufacture of our product candidates will not occur in the future. Additionally, our
manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable
political environments. If our manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their
contractual obligations, our ability to provide our product candidate to patients in clinical trials would be jeopardized. Any
delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs
associated with maintaining clinical trial programs and, depending upon the period of delay, require us to begin new clinical
trials at additional expense or terminate clinical trials completely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Cell-based
therapies rely on the availability of reagents, specialized equipment, and other specialty materials, which may not be available
to us on acceptable terms or at all. For some of these reagents, equipment, and materials, we rely or may rely on sole source
vendors or a limited number of vendors, which could impair our ability to manufacture and supply our products.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Manufacturing
our product candidates will require many reagents and viruses, which are substances used in our manufacturing processes to bring
about chemical or biological reactions, and other specialty materials and equipment, some of which are manufactured or supplied
by small companies with limited resources and experience to support commercial biologics production. We currently depend on a
limited number of vendors for certain materials and equipment used in the manufacture of our product candidates. Some of these
suppliers may not have the capacity to support commercial products manufactured under GMP by biopharmaceutical firms or may otherwise
be ill-equipped to support our needs. We also do not have supply contracts with many of these suppliers and may not be able to
obtain supply contracts with them on acceptable terms or at all. Accordingly, we may experience delays in receiving key materials
and equipment to support clinical or commercial manufacturing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
some of these reagents, viruses, equipment, and materials, we rely and may in the future rely on sole source vendors or a limited
number of vendors. An inability to continue to source product from any of these suppliers, which could be due to regulatory actions
or requirements affecting the supplier, adverse financial or other strategic developments experienced by a supplier, labor disputes
or shortages, unexpected demands, or quality issues, could adversely affect our ability to satisfy demand for our product candidates,
which could adversely and materially affect our product sales and operating results or our ability to conduct clinical trials,
either of which could significantly harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
we continue to develop and scale our manufacturing process, we expect that we will need to obtain rights to and supplies of certain
materials and equipment to be used as part of that process. We may not be able to obtain rights to such materials on commercially
reasonable terms, or at all, and if we are unable to alter our process in a commercially viable manner to avoid the use of such
materials or find a suitable substitute, it would have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>There
can be no assurance that we will be able to further develop in-house sales and commercial distribution capabilities or establish
or maintain relationships with third-party collaborators to successfully commercialize any product in the United States or overseas,
and as a result, we may not be able to generate product revenue.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
variety of risks associated with operating our business internationally could materially adversely affect our business. We plan
to seek regulatory approval of our product candidates outside of the United States and, accordingly, we expect that we, and any
potential collaborators in those jurisdictions, will be subject to additional risks related to operating in foreign countries,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">differing
    regulatory requirements in foreign countries, unexpected changes in tariffs, trade barriers, price and exchange controls,
    and other regulatory requirements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">economic
    weakness, including inflation, or political instability in particular foreign economies and markets;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">compliance
    with tax, employment, immigration, and labor laws for employees living or traveling abroad;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">foreign
    taxes, including withholding of payroll taxes;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">foreign
    currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident
    to doing business in another country;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">difficulties
    staffing and managing foreign operations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">workforce
    uncertainty in countries where labor unrest is more common than in the United States;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">potential
    liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign laws;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">challenges
    enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and
    protect intellectual property rights to the same extent as the United States;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">production
    shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">business
    interruptions resulting from geo-political actions, including war and terrorism.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">These
and other risks associated with our planned international operations may materially adversely affect our ability to attain or
maintain profitable operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>We
face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we
fail to compete effectively.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
biopharmaceutical industry, and the rapidly evolving market for developing cell-based therapies is characterized by intense competition
and rapid innovation. Our competitors may be able to develop other compounds or drugs that are able to achieve similar or better
results. Our potential competitors include major multinational pharmaceutical companies, established biotechnology companies,
specialty pharmaceutical companies, universities, and other research institutions. Many of our competitors have substantially
greater financial, technical and other resources, such as larger research and development staff and experienced marketing and
manufacturing organizations as well as established sales forces. Smaller or early-stage companies may also prove to be significant
competitors, particularly through collaborative arrangements with large, established companies. Mergers and acquisitions in the
biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition
may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital
for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring
or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized, or less
costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the
development of our technologies and products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>We
are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified
personnel, we may not be able to successfully implement our business strategy.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract,
motivate and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our senior management,
particularly our Chief Executive Officer, Vered Caplan. The loss of the services of any of our executive officers, other key employees,
and other scientific and medical advisors, and our inability to find suitable replacements, could result in delays in product
development and harm our business. Competition for skilled personnel is intense and the turnover rate can be high, which may limit
our ability to hire and retain highly qualified personnel on acceptable terms or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">To
induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock option grants
that vest over time. The value to employees of these equity grants that vest over time may be significantly affected by movements
in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other
companies. Although we have employment agreements with our key employees, most these employment agreements provide for at-will
employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain
&#8220;key man&#8221; insurance policies on the lives of all of these individuals or the lives of any of our other employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Risks
Related to our Common Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>If
we issue additional shares in the future, it will result in the dilution of our existing stockholders.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
articles of incorporation authorizes the issuance of up to 145,833,334 shares of our common stock with a par value of $0.0001
per share. Our Board of Directors may choose to issue some or all of such shares to acquire one or more companies or products
and to fund our overhead and general operating requirements. The issuance of any such shares will reduce the book value per share
and may contribute to a reduction in the market price of the outstanding shares of our common stock. If we issue any such additional
shares, such issuance will reduce the proportionate ownership and voting power of all current stockholders. Further, such issuance
may result in a change of control of our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Our
stock price and trading volume may be volatile, which could result in losses for our stockholders.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
equity trading markets have recently experienced high volatility resulting in highly variable and unpredictable pricing of equity
securities. If the turmoil in the equity trading markets continues, the market for our common stock could change in ways that
may not be related to our business, our industry or our operating performance and financial condition. In addition, the trading
volume in our common stock may fluctuate and cause significant price variations to occur. Some of the factors that could negatively
affect our share price or result in fluctuations in the price or trading volume of our common stock include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">actual
    or anticipated quarterly variations in our operating results;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">changes
    in expectations as to our future financial performance or changes in financial estimates, if any;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">announcements
    relating to our business;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">conditions
    generally affecting the biotechnology industry;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">the
    success of our operating strategy; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">the
    operating and stock performance of other comparable companies.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Many
of these factors are beyond our control, and we cannot predict their potential effects on the price of our common stock. In addition,
the stock market is subject to extreme price and volume fluctuations. During the past 52 weeks ended December 31, 2020, our stock
price has fluctuated from a low of $2.76 to a high of $7.84. This volatility has had a significant effect on the market price
of securities issued by many companies for reasons unrelated to their operating performance and could have the same effect on
our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">No
assurance can be provided that a purchaser of our common stock will be able to resell their shares of common stock at or above
the price that they acquired those shares. We can provide no assurances that the market price of common stock will increase or
that the market price of common stock will not fluctuate or decline significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>We
do not intend to pay dividends on any investment in the shares of stock of our company.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have never paid any cash dividends, and currently do not intend to pay any dividends for the foreseeable future. The Board of
Directors has not directed the payment of any dividends and does not anticipate paying dividends on the shares for the foreseeable
future and intends to retain any future earnings to the extent necessary to develop and expand our business. Payment of cash dividends,
if any, will depend, among other factors, on our earnings, capital requirements, and the general operating and financial condition,
and will be subject to legal limitations on the payment of dividends out of paid-in capital. Because we do not intend to declare
dividends, any gain on an investment in our company will need to come through an increase in the stock&#8217;s price. This may
never happen, and investors may lose all of their investment in our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_004"></span>ITEM
1B. UNRESOLVED STAFF COMMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_005"></span>ITEM
2. PROPERTIES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
do not own any real property. A description of the leased premises we utilize in several of our facilities is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Entity</span></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Property
                                         Description</span></b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
        Inc./Orgenesis Maryland Inc.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">These
                                         are our principal offices:</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.3pt; text-align: justify; text-indent: -13.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;Located at 20271 Goldenrod Lane, Germantown, MD 20876.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.3pt; text-align: justify; text-indent: -13.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;Occupy office space at the Germantown Innovation Center.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.3pt; text-indent: -13.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;Cost is $200 per month on a month-to-month contract.</span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
    Ltd.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.3pt; text-align: justify; text-indent: -13.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;The development lab is located in the Bar Lev Industrial Park M.P. MISGAV, Israel.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.3pt; text-indent: -13.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;Offices
        are in the science park of Ness Ziona. Monthly costs are approximately $5 thousand.</span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
        Korea</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.15pt; text-align: justify; text-indent: -13.15pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;Operational production and Office area represent approximately 2,234 square meters.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.15pt; text-align: justify; text-indent: -13.15pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;Monthly costs are approximately 21,232 thousand KRW, or approximately $19 thousand.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.15pt; text-indent: -13.15pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;Lease agreement for the office and operational production area expires on January 1, 2023.</span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Koligo
    Therapeutics Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.25pt; text-align: justify; text-indent: -13.25pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;Production facility and development labs in New Albany, Indiana &#8211; approximately
                                         4170 square feet (388 square meter) at monthly costs of about $5400</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.25pt; text-indent: -13.25pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;Medical device maintenance and development labs in Leander, Texas &#8211; approximately 2000 square feet (186 square meter)
        at monthly costs of about $2500</span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
                                         Biotech Israel (previously Atvio Biotech)</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.15pt; text-align: justify; text-indent: -13.15pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;Located in the Bar Lev Industrial Park M.P. MISGAV, Israel.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.15pt; text-align: justify; text-indent: -13.15pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;Operational production and Office area represent +/-1,264 m&#178;.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.15pt; text-align: justify; text-indent: -13.15pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;Monthly costs are approximately $10.5 thousand.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.15pt; text-indent: -13.15pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;Lease agreement for the office and operational production area expires on July 31, 2023.</span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
    Belgium</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.15pt; text-align: justify; text-indent: -13.15pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;Located near Namur, at Novalis Science Park, Orgenesis Belgium</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
believe that our facilities are generally in good condition and suitable to carry on our business. We also believe that, if required,
suitable alternative or additional space will be available to us on commercially reasonable terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_006"></span>ITEM
3. LEGAL PROCEEDINGS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
are not involved in any pending legal proceedings that we anticipate would result in a material adverse effect on our business
or operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_007"></span>ITEM
4. MINE SAFETY DISCLOSURES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_008"></span>PART
II</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_009"></span>ITEM
5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Market
Information</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Until
March 13, 2018, our common shares were traded under OTC Market Group&#8217;s OTCQB. Since March 13, 2018, our common
stock has been listed for trading on the Nasdaq Capital Market (&#8220;Nasdaq CM&#8221;) under the symbol &#8220;ORGS.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 9, 2021, there were 205 holders of record of our common stock, and the last reported sale price of our
common stock on the NasdaqCM on March 8, 2021 was $7.26. A significant number of shares of our common stock are
held in either nominee name or street name brokerage accounts, and consequently, we are unable to determine the total number
of beneficial owners of our stock.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Dividend
Policy</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">To
date, we have paid no dividends on our common stock and do not expect to pay cash dividends in the foreseeable future. We plan
to retain all earnings to provide funds for the operations of our company. In the future, our Board of Directors will decide whether
to declare and pay dividends based upon our earnings, financial condition, capital requirements, and other factors that our Board
of Directors may consider relevant. We are not under any contractual restriction as to present or future ability to pay dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Unregistered
Sales of Equity Securities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the fiscal year ended December 31, 2020, our financing activities consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
January 20, 2020, we entered into a Securities Purchase Agreement with certain investors pursuant to which we issued and sold,
in a private placement (the &#8220;Offering&#8221;), 2,200,000 shares of Common Stock at a purchase price of $4.20 per share and
warrants to purchase up to 1,000,000 shares of Common Stock at an exercise price of $5.50 per share, which are exercisable between
June 2021 and January 2023. We received gross proceeds of approximately $9.24 million before deducting related offering expenses
in the amount of $0.8 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
April 7, 2020, we entered into an Asset Purchase Agreement (the &#8220;Tamir Purchase Agreement&#8221;) with Tamir Biotechnology,
Inc. (&#8220;Tamir&#8221;), pursuant to which we agreed to acquire certain assets and liabilities of Tamir related to the discovery,
development and testing of therapeutic products for the treatment of diseases and conditions in humans, including all rights to
ranpirnase and use for antiviral therapy (collectively, the &#8220;Purchased Assets and Assumed Liabilities&#8221; and such acquisition,
the &#8220;Tamir Transaction&#8221;). The Tamir Transaction closed on April 23, 2020. As aggregate consideration for the acquisition,
we paid $2.5 million in cash and issued an aggregate of 3,400,000 shares of common stock to Tamir resulting in a total consideration
of $20.2 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
September 26, 2020, we entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) by
and among the Company, Orgenesis Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (&#8220;Merger
Sub&#8221;), Koligo Therapeutics Inc., a Kentucky corporation (&#8220;Koligo&#8221;), the shareholders of Koligo (collectively,
the &#8220;Shareholders&#8221;) and Long Hill Capital V, LLC, solely in its capacity as the representative, agent and attorney-in-fact
of the Shareholders. The Merger Agreement provided for the acquisition of Koligo by the Company through the merger of Merger Sub
with and into Koligo, with Koligo surviving as a wholly-owned subsidiary of the Company (the &#8220;Merger&#8221;). The Merger
closed on October 15, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the terms of the Merger Agreement, an aggregate of 2,061,713 shares of Company common stock were issued to Koligo&#8217;s Shareholders
who were accredited investors (with certain Shareholders who were not accredited investors being paid solely in cash in the amount
of approximately $20 thousand) in accordance with the terms of the Merger Agreement. In connection with the Merger, the Company
assumed an aggregate of approximately $1.9 million of Koligo&#8217;s liabilities, which were substantially all of Koligo&#8217;s
liabilities at the closing of the Merger. In addition, we issued 66,910 shares to Maxim Group LLC for advisory services in
connection with the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">All
of the securities issued in the transactions described above were issued without registration under the Securities Act in reliance
upon the exemptions provided in Section 4(2) or Regulation S of the Securities Act. Except with respect to securities sold pursuant
to Regulation S, the recipients of securities in each such transaction acquired the securities for investment only and not with
a view to or for sale in connection with any distribution thereof. Appropriate legends were affixed to the share certificates
issued in all of the above transactions. Each of the recipients also represented that they were &#8220;accredited investors&#8221;
within the meaning of Rule 501(a) of Regulation D under the Securities Act or had such knowledge and experience in financial and
business matters as to be able to evaluate the merits and risks of an investment in its common stock. All recipients had adequate
access, through their relationships with the Company and its officers and directors, to information about the Company. None of
the transactions described above involved general solicitation or advertising.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Issuer
Purchases of Equity Securities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt"><span style="font: 10pt Times New Roman, Times, Serif">On
May 14, 2020, our Board of Directors approved the stock repurchase plan (the &#8220;Stock Repurchase Plan&#8221;) pursuant to
which we may, from time to time, purchase up to $10 million of our outstanding shares of common stock. The shares may be repurchased
from time to time in privately negotiated transactions or the open market, including pursuant to Rule 10b5-1 trading plans, and
in accordance with applicable regulations of the SEC. The timing and exact amount of any repurchases will depend on various factors
including, general and business market conditions, corporate and regulatory requirements, share price, alternative investment
opportunities and other factors. The Repurchase Plan commenced on May 29, 2020 and does not obligate us to acquire any specific
number of shares in any period, and may be expanded, extended, modified, suspended or discontinued by the Board of Directors at
any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the share repurchase activity from the inception of the Stock Repurchase Plan through December 31,
2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Number of Shares <br /> Purchased</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average Price <br /> Paid per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Maximum Value that May Yet Be Purchased Under the Plans or Programs</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 19%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">October 2020</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">8,807</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">4.47</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">8,807</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,960</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">November 2020</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,960</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">December 2020</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46,401</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.47</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46,401</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,750</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">55,309</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4.47</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">55,309</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,750</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_010"></span>ITEM
6. SELECTED FINANCIAL DATA</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_011"></span>ITEM
7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is intended to provide information
necessary to understand our audited consolidated financial statements for the fiscal years ended December 31, 2020 and December
31, 2019 and highlight certain other information which, in the opinion of management, will enhance a reader&#8217;s understanding
of our financial condition, changes in financial condition and results of operations. In particular, the discussion is intended
to provide an analysis of significant trends and material changes in our financial position and the operating results of our business
during the year ended December 31, 2020, as compared to the fiscal year ended December 31, 2019. This discussion should be read
in conjunction with our consolidated financial statements for the fiscal years ended December 31, 2020 and December 31, 2019 and
related notes included elsewhere in this Annual Report on Form 10-K. These historical financial statements may not be indicative
of our future performance. This Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contains
numerous forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties
and risks described throughout this filing, particularly in &#8220;Item 1A. Risk Factors.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial
condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning
COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and
international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements, and although
there is currently no major impact, there may be changes to those estimates in future periods. Actual results may differ from
these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Corporate
Overview</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
Inc., a Nevada corporation, is a global biotech company working to unlock the potential of cell and gene therapies in an affordable
and accessible format (&#8220;CGTs&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">CGTs
can be centered on autologous (using the patient&#8217;s own cells) or allogenic (using master banked donor cells) and are part
of a class of medicines referred to as advanced therapy medicinal products (ATMPs). We mostly focus on autologous therapies, with
processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated
for compliant production near the patient at their point of care for the treatment of patients. This approach has the potential
to overcome the limitations of traditional commercial manufacturing methods that do not translate well to commercial production
of advanced therapies due to their cost prohibitive nature and complex logistics to deliver the treatments to patients (ultimately
limiting the number of patients that can have access to, or can afford, these therapies).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">To
achieve these goals, we have developed a Point of Care Platform comprised of three enabling components: a pipeline of licensed
<b>POCare Therapies</b> that are designed to be processed and produced in closed, automated <b>POCare Technology</b> systems across
a collaborative <b>POCare Network</b>. Via a combination of science, technology, engineering, and networking, we are working to
provide a more efficient and scalable pathway for advanced therapies to reach patients more rapidly at lowered costs. We also
draw on extensive medical expertise to identify promising new autologous therapies to leverage within the POCare Platform either
via ownership or licensing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
POCare Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide with a goal of
achieving harmonized, regulated clinical development and production of the therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>POCare
Platform Operations via Subsidiaries</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
currently conduct our core business operations ourselves and through our subsidiaries which are all wholly-owned except as otherwise
stated below (collectively, the &#8220;Subsidiaries&#8221;). The Subsidiaries are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>United
States</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
    Maryland Inc. (the &#8220;U.S. Subsidiary&#8221;) is the center of activity in North America and is currently focused on setting
    up the POCare Network.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Koligo
    Therapeutics Inc. (&#8220;Koligo&#8221;) is a Kentucky corporation that we acquired in 2020 and is currently focused on developing
    the POCare network and therapies. .</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Europe</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
    Belgium SRL (the &#8220;Belgian Subsidiary&#8221;) is the center of activity in Europe and is currently focused on process
    development and the preparation of European clinical trials.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
    Switzerland Sarl (the &#8220;Swiss Subsidiary&#8221;), was incorporated in October 2020, and is currently focused on providing
    management services to us.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: 10pt Times New Roman, Times, Serif"><b>Asia</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
    Ltd. in Israel (the &#8220;Israeli Subsidiary&#8221;) is a provider of regulatory, clinical and pre-clinical services.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
    Biotech Israel Ltd. (&#8220;OBI&#8221;), is a provider of cell-processing services in Israel.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Korea:
    Orgenesis Korea Co. Ltd. (the &#8220;Korean Subsidiary&#8221;), is a provider of processing and pre-clinical services in Korea.
    We own 94.12% of the Korean Subsidiary.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Corporate
History</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
were incorporated in the state of Nevada on June 5, 2008 under the name Business Outsourcing Services, Inc. Effective August 31,
2011, we completed a merger with our subsidiary, Orgenesis Inc., a Nevada corporation, which was incorporated solely to effect
a change in its name. As a result, we changed our name from &#8220;Business Outsourcing Services, Inc.&#8221; to &#8220;Orgenesis
Inc.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
October 11, 2011, we incorporated Orgenesis Ltd. as our wholly-owned subsidiary under the laws of Israel. On February 2, 2012,
Orgenesis Ltd. signed and closed a definitive agreement to license from Tel Hashomer - Medical Research, Infrastructure and Services
Ltd. (&#8220;THM&#8221;), a private company duly incorporated under the laws of Israel for the development of AIP (Autologous
Insulin Producing) cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
November 6, 2014, we entered into an agreement with the shareholders of MaSTherCell S.A. to acquire MaSTherCell S.A. On March
2, 2015, we closed on the acquisition of MaSTherCell whereby it became an independent, and wholly-owned subsidiary of Orgenesis
INC. Through MaSTherCell, we became engaged in the CDMO business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
June 28, 2018, we, Masthercell Global, Great Point Partners, LLC, a manager of private equity funds focused on growing small to
medium sized heath care companies (&#8220;Great Point&#8221;), and certain of Great Point&#8217;s affiliates, entered into a series
of definitive strategic agreements intended to finance, strengthen and expand our CDMO business. In connection therewith, we,
Masthercell Global and GPP-II Masthercell, LLC, a Delaware limited liability company (&#8220;GPP-II&#8221;) and an affiliate of
Great Point, entered into a Stock Purchase Agreement (the &#8220;SPA&#8221;) pursuant to which GPP-II purchased 378,000 shares
of newly designated Series A Preferred Stock of Masthercell Global (the &#8220;Masthercell Global Preferred Stock&#8221;), representing
37.8% of the issued and outstanding share capital of Masthercell Global, for cash consideration to be paid into Masthercell Global
of up to $25 million, subject to certain adjustments (the &#8220;Consideration&#8221;). At such time, we held 622,000 shares of
Masthercell Global&#8217;s Common Stock, representing 62.2% of the issued and outstanding equity share capital of Masthercell
Global. An initial cash payment of $11.8 million of the Consideration was remitted at closing by GPP-II, with a follow up payment
of $6,600,000 made in each of years 2018 and 2019, or an aggregate of $13.2 million (the &#8220;Future Payments&#8221;), if (a)
Masthercell Global achieved specified EBITDA and revenues targets during each of these years, and (b) the Orgenesis&#8217; shareholders
approved certain provisions of the Stockholders&#8217; Agreement referred to below on or before December 31, 2020. Both of these
conditions were met and we received both milestone payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Contemporaneous
with the execution of the SPA, we and Masthercell Global entered into a Contribution, Assignment and Assumption Agreement pursuant
to which we contributed to Masthercell Global our assets relating to the CDMO Business (as defined below), including the CDMO
subsidiaries (the &#8220;Corporate Reorganization&#8221;). In furtherance thereof, Masthercell Global, as our assignee, acquired
all of the issued and outstanding share capital of OBI, our Israel based CDMO partner since May 2016, and 94.12% of the share
capital of the Korean Subsidiary, our Korea based CDMO partner since March 2016.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
August 7, 2019, we, Masthercell Global and GPP (the &#8220;Parties&#8221;) entered into a Transfer Agreement (the &#8220;Transfer
Agreement&#8221;). As a result of the Transfer Agreement, Masthercell Global transferred all of its equity interests of OBI and
the Korean Subsidiary to us in exchange for one dollar ($1.00). The Transfer Agreement also contains agreements made with respect
to certain intercompany loans. We accounted for the Transfer Agreement as a transaction with non-controlling interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Discontinued
Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Until
December 31, 2019, we operated the POCare Platform as one of two business separate business segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Historically,
the second separate business segment was operated as a Contract Development and Manufacturing Organization (&#8220;CDMO&#8221;)
platform, providing third party contract manufacturing and development services for biopharmaceutical companies (the &#8220;CDMO
Business&#8221;). The CDMO platform was historically operated mainly through majority owned Masthercell Global (which consisted
of the following two subsidiaries: MaSTherCell S.A. in Belgium (&#8220;MaSTherCell&#8221;), and Masthercell U.S., LLC in the United
States (&#8220;Masthercell U.S.&#8221;) (collectively, the &#8220;Masthercell Global Subsidiaries&#8221;)).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
February 2020, we and GPP-II Masthercell LLC (&#8220;GPP&#8221;) sold 100% of the outstanding equity interests of Masthercell
(the &#8220;Masthercell Business&#8221;), which comprised the majority of our CDMO Business, to Catalent Pharma Solutions, Inc.
for an aggregate nominal purchase price of $315 million, subject to customary adjustments (the &#8220;Masthercell Sale&#8221;).
After accounting for GPP&#8217;s liquidation preference and equity stake in Masthercell as well as other investor interests in
our Belgian subsidiary MaSTherCell, distributions to Masthercell option holders and transaction costs, we received approximately
$126.7 million. We incurred an additional approximately $5.6 million in transaction costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
determined that the Masthercell Business (&#8220;Discontinued Operation&#8221;) meets the criteria to be classified as a discontinued
operation as of the first quarter of 2020. The Discontinued Operation includes the vast majority of the previous CDMO Business,
including majority-owned Masthercell, including MaSTherCell, Masthercell U.S. and all of the Masthercell Global Subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Since
the Masthercell Sale, we entered into new joint venture agreements with new partners in various jurisdictions. This has allowed
us to grow our infrastructure and expand our processing sites into new markets and jurisdictions. In addition, we have engaged
some of these joint venture partners to perform research and development services to further develop and adapt our systems and
devices for specific purposes. We have been investing manpower and financial resources to focus on developing, manufacturing and
rolling out several types of OMPULs to be used and/or distributed through our POCare Network of partners, collaborators, and joint
ventures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Chief Executive Officer (&#8220;CEO&#8221;) is our chief operating decision-maker who reviews financial information
prepared on a consolidated basis. Effective from the first quarter of 2020, all of our continuing operations are in the point-of-care
business via our POCare Platform. Therefore, no segment report has been presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
Inc., a Nevada corporation, is a global biotech company working to unlock the potential of cell and gene therapies (&#8220;CGT&#8221;s)
in an affordable and accessible format.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">CGTs
can be centered on autologous (using the patient&#8217;s own cells) or allogenic (using master banked donor cells) and are part
of a class of medicines referred to as advanced therapy medicinal products (ATMP). We mostly focus on autologous therapies, with
processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated
for compliant production near the patient at their point of care. This approach has the potential to overcome the limitations
of traditional commercial manufacturing methods that do not translate well to commercial production of advanced therapies due
to their cost prohibitive nature and complex logistics to deliver the treatments to patients (ultimately limiting the number of
patients that can have access to, or can afford, these therapies).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">To
achieve these goals, we have developed a Point of Care Platform comprised of three enabling components: a pipeline of licensed
<b>POCare Therapies</b> that are designed to be processed and produced in closed, automated <b>POCare Technology</b> systems across
a collaborative <b>POCare Network</b>. Via a combination of science, technology, engineering, and networking, we are working to
provide a more efficient and scalable pathway for advanced therapies to reach patients more rapidly at lowered costs. We also
draw on extensive medical expertise to identify promising new autologous therapies to leverage within the POCare Platform either
via ownership or licensing. The POCare Network brings together patients, doctors, industry partners, research institutes and hospitals
worldwide with a goal of achieving harmonized, regulated clinical development and production of the therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Material
Developments During Fiscal 2020</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Acquisitions
and Dispositions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
mentioned above, on February 2, 2020, we entered into a Purchase Agreement with GPP, Masthercell and Catalent Pharma Solutions,
Inc. pursuant to which the Sellers sold 100% of the outstanding equity interests of our Masthercell Business for an aggregate
nominal purchase price of $315 million, subject to customary adjustments. After accounting for GPP&#8217;s liquidation preference
and equity stake in Masthercell as well as other investor interests in its Belgian subsidiary MaSTherCell, S.A. (&#8220;MaSTherCell&#8221;),
distributions to Masthercell option holders and transaction costs, we received approximately $126.7 million. We incurred an additional
approximately $5.6 million in transaction costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
April 7, 2020, we entered into an Asset Purchase Agreement (the &#8220;Tamir Purchase Agreement&#8221;) with Tamir Biotechnology,
Inc. (&#8220;Tamir&#8221; or &#8220;Seller&#8221;), pursuant to which we agreed to acquire certain assets and liabilities of Tamir
related to the discovery, development and testing of therapeutic products for the treatment of diseases and conditions in humans,
including all rights to ranpirnase and use for antiviral therapy (collectively, the &#8220;Purchased Assets and Assumed Liabilities&#8221;
and such acquisition, the &#8220;Tamir Transaction&#8221;). The Tamir Transaction closed on April 23, 2020. As aggregate consideration
for the acquisition, we paid $2.5 million in cash and issued an aggregate of 3,400,000 shares (the &#8220;Shares&#8221;) of Common
Stock to Tamir resulting in a total consideration of $20.2 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
September 26, 2020, we entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) by
and among ourselves, Orgenesis Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (&#8220;Merger
Sub&#8221;), Koligo Therapeutics Inc., a Kentucky corporation (&#8220;Koligo&#8221;), the shareholders of Koligo (collectively,
the &#8220;Shareholders&#8221;), and Long Hill Capital V, LLC (&#8220;Long Hill&#8221;), solely in its capacity as the representative,
agent and attorney-in-fact of the Shareholders. The Merger Agreement provides for the acquisition of Koligo by us through the
merger of Merger Sub with and into Koligo, with Koligo surviving as our wholly-owned subsidiary (the &#8220;Merger&#8221;). The
Merger was announced in a Current Report on Form 8-K filed with the Securities and Exchange Commission on October 1, 2020, to
which a copy of the Merger Agreement, along with copies of certain other ancillary agreements, were annexed as exhibits. The Merger
closed on October 15, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Koligo
was a privately-held US regenerative medicine company. Koligo&#8217;s first commercial product is KYSLECEL&#174; (autologous pancreatic
islets) for chronic and acute recurrent pancreatitis. Koligo&#8217;s 3D-V technology platform incorporates the use of advanced
3D bioprinting techniques and vascular endothelial cells to support development of transformational cell and tissue products for
serious diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, according to the agreement between the parties, we also funded an additional cash consideration of $500 thousand (with
$100 thousand of such reducing the ultimate consideration payable to Koligo) for the acquisition of the assets of Tissue Genesis,
LLC (&#8220;Tissue Genesis&#8221;) by Koligo that was consummated on October 14, 2020. The Tissue Genesis assets include the entire
inventory of Tissue Genesis Icellator&#174; devices, related kits and reagents, a broad patent portfolio to protect the technology,
registered trademarks, clinical data, and existing business relationships for commercial and development stage use of the Icellator
technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Private
Placement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
January 20, 2020, we entered into a Securities Purchase Agreement with certain investors pursuant to which we issued and sold,
in a private placement, 2,200,000 shares of Common Stock at a purchase price of $4.20 per share and warrants to purchase up to
1,000,000 shares of Common Stock at an exercise price of $5.50 per share which are exercisable between June 2021 and January 2023.
We received gross proceeds of approximately $9.24 million before deducting related offering expenses in the amount of $0.8 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Other
Developments and Agreements During Fiscal 2020</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Joint
Ventures, Collaborations and License Agreements During Fiscal 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
2020, we entered into joint venture agreements (&#8220;JVA&#8221;) or amended existing JVAs (&#8220;AJVA&#8221;) (which superseded
previous JVAs), master service agreements for POC development revenue (&#8220;MSA DEV&#8221;) and master service agreements for
procured services (&#8220;MSA PS&#8221;), with third parties as per the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 34%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name
    of Party (and country of origin)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 14%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Nature
                                         of</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Agreement</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 34%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Territory</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 12%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Theracell
    Advanced Biotechnology</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">AJVA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Greece,
    Turkey, Cyprus, Israel, and Balkans</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Broaden
    Bioscience and Technology Corp</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">AJVA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Certain
    projects in China and the Middle East</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Mircod
                                         LLC</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">(US)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">JVA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Russia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Image
                                         Securities FZC (UAE)</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">(a
        related party)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">AJVA
                                         &amp;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">MSA
        PS</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">India</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Cure
    Therapeutics</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">JVA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Korea
    and Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Kidney
    Cure Ltd</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">JVA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">N/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(5)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Sescom
    Ltd</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">JVA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">N/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(6)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Educell
                                         D.O.O</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">(Slovenia)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">AJVA
                                         &amp;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">MSA
        PS &amp;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">MSA
        DEV</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Croatia,
    Serbia and Slovenia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Med
                                         Centre for Gene and</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Cell
        Therapy FZ-LLC (UAE)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">AJVA
                                         &amp;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">MSA
        PS &amp;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">MSA
        DEV</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">UAE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Mida
    Biotech B.V. (Netherlands)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">AJVA
                                         &amp;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">MSA
        PS &amp;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">MSA
        DEV</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Netherlands,
                                         Lithuania, Spain, Switzerland,</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Germany,
        Belgium and other countries</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">within
        West Europe</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(7)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Butterfly
    Biosciences Sarl</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">JVA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">N/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(8)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Notes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(1)
The parties will collaborate in POC processing, regulatory and therapy development including the setting up one or more point
of care processing facilities in institutions or hospitals in the territory, the supply of our products and services within the
Territory, and the clinical development and commercialization of the relevant third-party products worldwide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(2)
The parties will collaborate in POC processing, regulatory and therapy development including the setting up one or more point
of care processing facilities in institutions or hospitals in the territory, the supply of our products and services within the
Territory and clinical, regulatory, development and commercialization of cell and gene therapies in the Territory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(5)
The parties will collaborate in the (i) implementation of a point-of-care strategy; (ii) assessment of the options for development
and manufacture of various cell-based types (including kidney derived cells, MSC cells, exosomes, gene therapies) development;
and (iii) development of protocols and tests for kidney therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(6)
The parties will collaborate in (i) the assessment of relevant tools and technologies to be used in our information security system
(the &#8220;ISS&#8221;); (ii) the implementation of the ISS within the Company and in our point-of-care network; and (iii) the
operation and maintenance of the ISS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(7)
The parties will collaborate in POC processing, regulatory and therapy development including the setting up one or more point
of care processing facilities in institutions or hospitals in the territory and the establishment of an induced pluripotent stem
cells R&amp;D and automation platforms and other early-stage development activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(8)
We and Kidney Cure Ltd own 49% and 51%, respectively, of Butterfly Biosciences Sarl (&#8220;BB&#8221;). BB is the entity
through which the Kidney Cure JVA activities will be completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Other
License Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
are now working on the completion of all the IND enabling requirements in order to get into Phase I studies under the Sponsored
Research Agreement (the &#8220;SRA&#8221;) and Exclusive License Agreement between ourselves and the Trustees of Columbia University
in the City of New York, a New York corporation (&#8220;Columbia University&#8221;). In 2019, we entered into an SRA with Columbia
University whereby we will provide financial support for studying the utility of serological tumor marker for tumor dynamics monitoring.
Also in 2019, we and Columbia University entered into an Exclusive License Agreement (the &#8220;Columbia License Agreement&#8221;)
whereby Columbia University granted to us an exclusive license to discover, develop, manufacture and sell product in the field
of cancer therapy. In consideration of the licenses granted under the Columbia License Agreement, we shall pay to Columbia University
(i) a royalty of 5% of net sales of any patented product sold and (ii) 2.5% of net sales of other products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
May 15, 2019, we entered into a Joint Venture Agreement with SBH Sciences, Inc., a Massachusetts corporation (&#8220;SBH&#8221;),
for the establishment of a joint venture with SBH for the purpose of collaborating in the field of gene and cell therapy development,
process and services of bio-exosome therapy products and services in the areas of diabetes, liver cells and skin applications,
including wound healing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2019, we concluded a license agreement with Caerus Therapeutics Corporation (a related party), a Virginia company (&#8220;Caerus&#8221;),
pursuant to which Caerus granted us, among others, an exclusive license to all Caerus IP relating to Advance Chemeric Antigen
Vectors for Targeting Tumors for the development and/or commercialization of certain licensed products. In consideration for the
license granted to us under this agreement, we shall pay Caerus feasibility fees, annual maintenance fees and royalties of sales
of up to 5% and up to 18% of sub-license fees. Through this joint venture, the parties co-develop a novel CART and CAR-NK platform
for the treatment of solid tumors. The development is at a pre-clinical stage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
December 20, 2019, we and the Regents of the University of California (&#8220;University&#8221;) entered into a joint research
agreement in the field of therapies and processing technologies according to an agreed upon work plan. According to the agreement,
we will pay the University royalties of up to 5% (or up to 20% of sub-licensing sales) in the event of sales that includes certain
types of University owned IP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the third quarter of 2020, we purchased the IP and related EV technology from a service provider (the &#8220;Service Provider&#8221;)
pursuant to an EV agreement (the &#8220;EV agreement&#8221;). According to the EV agreement, the Service Provider sold to us all
of its rights in the EV technology that it had produced, in the amount of $500 thousand, to be paid in installments over the next
12 months from September 2020. In addition, the Service Provider granted us an exclusive worldwide license to use the EV IP technology
for any purpose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Included
in the purchased assets of the Tamir Biotechnology Inc. acquisition was the assumption by us of a worldwide license to a private
company of certain Tamir technologies in the field of treatment, amelioration, mitigation or prevention of diseases or conditions
of the eye and its adnexa in return for certain development and sales milestone payments to be paid to Tamir. This license fee
and the right to receive future milestone payments (of up to $11 million assuming that certain milestones are reached) and royalties
(of up to $35 million based on net sales milestones), were assumed by us in connection with the Tamir Purchase Agreement together
with a less than 10% share interest. To date, no milestones have been reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
mentioned above, included in the Koligo acquisition were the assets of Tissue Genesis, LLC (&#8220;Tissue Genesis&#8221;). We
are committed to paying the previous owners of Tissue Genesis up to $500 thousand upon the achievement of certain performance
milestones and earn-out payments on future sales provided that in no event will the aggregate of the earn-out payments exceed
$4 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><i>Results
of Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Comparison
of the Year Ended December 31, 2020 to the Year Ended December 31, 2019.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
financial results for the year ended December 31, 2020 are summarized as follows in comparison to the year ended December 31,
2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended December 31,</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,177</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,629</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Revenues from related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,475</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,270</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses and Research and development service expenses, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,986</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,014</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amortization of intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">478</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">430</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Selling, general and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,973</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,451</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share in income of associated company</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(106</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Financial expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,061</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">843</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss from continuing operation before income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">96,736</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,818</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Revenues</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table shows our revenues by major revenue streams:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Revenue stream:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify">POC and hospital services</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,068</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,109</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cell process development services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,584</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">790</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,652</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,899</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
revenues for the year ended December 31, 2020 were $7,652 thousand, as compared to $3,899 thousand for the year ended December
31, 2019, representing an increase of 96%. The increase in revenues for the year ended December 31, 2020 compared to the year
ended December 31, 2019 is mainly attributable to increased POC services revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">POC
services are mainly the result of agreements between us and our joint venture partners (See note 11). Pursuant to the agreements,
we provide certain services in support of partners&#8217; activity. We have signed master services agreements partners in the
aggregate amount of over $38 million for services to be provided from 2021 to 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">A
breakdown of the revenues per customer that constituted at least 10% of revenues is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Revenue earned:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify">Customer A</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,857</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,420</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Customer B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,577</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Customer C &#8211; related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,475</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,270</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Customer D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,412</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">857</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Research
and Development and Research and Development Services, net:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Salaries and related expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,175</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,064</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">481</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">776</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees and consulting services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,463</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,419</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lab expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,348</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,229</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">First Choice JVA (See Note 11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,741</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tamir Purchase Agreement (See Note 4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,225</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation expenses, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">603</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">521</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,887</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,076</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less &#8211; grant</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(196</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(812</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">83,986</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development expenses for the year ended December 31, 2020 were $83,986 thousand, as compared to $14,014 thousand for the year
ended December 31, 2019, representing an increase of 499%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
increase is mainly attributable to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">expansion
    of our pipeline of licensed CGTs with a harmonized pathway for regulatory approval;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">expansion
of our POC capacity globally;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">investment
in automated processing units &amp; processes;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">developing
owned and licensed advanced therapies to enable commercial production;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">works
with partners to enable efficient closed processing system technologies addressing POCare needs;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">an
    increase in salaries and related expenses and other research and development expenses. Additional R&amp;D staff were hired
    as we expanded our research and development to the evaluation and development of new cell therapies and related
    technologies in the field of immune-oncology (our novel CD19 CAR-T and CD19.22 CAR-T programs, cellular vaccination for solid
    cancers, advanced tumor infiltrating lymphocyte, NK-based therapies, etc.), liver pathologies, stem cell-based therapies and
    other cell-based technologies such as the novel delivery system, Bioxomes. We invested in converting biological processes
    to GMP-compliant processes as these therapies progress to clinical stage;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
    2020 we made significant investments in the development of several types of Orgenesis Mobile Processing Units and Labs (OMPULs)
    with the expectation of use and/or distribution through our POCare Network of partners, collaborators, and joint ventures.
    OMPULs are designed for the purpose of validation, development, performance of clinical trials, manufacturing and/or processing
    of potential or approved cell and gene therapy products in a safe, reliable, and cost-effective manner at the point of care,
    as well as the manufacturing of such CGTs in a consistent and standardized manner in all locations. The design delivers a
    potential industrial solution for us to deliver CGTs to practically any clinical institution at the point of care;
    and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Tamir purchase agreement (See Note 4).</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Selling,
General and Administrative Expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2019</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Salaries and related expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,379</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,332</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,915</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,855</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounting and legal fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,946</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,388</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,571</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,553</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Rent and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">407</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">214</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Business development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,477</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,148</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expenses related to collaboration with Theracell</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">689</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Depreciation expenses, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">113</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other general and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,177</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,159</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,973</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,451</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Selling,
general and administrative expenses for the year ended December 31, 2020 were $18,973 thousand, as compared to $11,451 thousand
for the year ended December 31, 2019, representing an increase of 66%. The increase for the year ended December 31, 2020 is primarily
attributable to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An
    increase in salaries and related expenses of $1,047 thousand, as a result of additional managerial appointments and increased
    salaries;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An
    increase in accounting and legal fees of $4,558 thousand, which is mainly attributable to additional legal fees incurred for
    recent business and collaboration agreements; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An
    increase in business development of $2,329 thousand, as a result of increased activities to establish our presence in new
    markets.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Financial
Expenses, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2019</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Decrease in fair value financial liabilities and assets measured at fair value</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">63</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense on convertible loans and loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,254</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">498</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign exchange loss, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">160</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">395</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(353</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(113</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,061</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">843</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Financial
expenses, net for the year ended December 31, 2020 were $1,061 thousand, as compared to $843 thousand for the year ended December
31, 2019, representing an increase of 26%. The increase for the year ended December 31, 2020 is primarily attributable to an increase
in interest expense on convertible loans and loans of $756 thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Tax
income</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-bottom: 1.5pt">Tax income</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">1,609</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">229</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,609</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">229</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Tax
income, net for the year ended December 31, 2020 were $1,609 thousand, as compared to $229 thousand for the year ended
December 31, 2019, representing an increase of 603%.&#160; The increase for the year ended December 31, 2020 is primarily
attributable due to the release of a tax asset up to the amount of Koligo&#8217;s net tax liability. See
Note 4.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 2.55pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Discontinued
Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 2.55pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 2.55pt 0 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Discontinued
operations relate to the Masthercell Business. The following table presents the financial results associated with the Masthercell
Business operation as reflected in our Consolidated Comprehensive loss:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 2.55pt 0 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 2.55pt 0 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">OPERATIONS</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands):</td><td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,556</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">31,053</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,482</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,318</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cost of research and development and research and development services, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amortization of intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,631</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Selling, general and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,896</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,886</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Other (income) expenses, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">305</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(207</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,271</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,629</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Financial expenses, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,242</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,660</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Tax expenses (income)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(30</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">792</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Net loss from discontinuing operation, net of tax</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,212</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,452</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 2.55pt 0 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 2.55pt 0 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Revenues
are attributable to the extension of existing customer service contracts with biotechnology clients and from revenues generated
from existing manufacturing agreements. Cost of revenues were in line with the growth in revenues and employment of additional
operational staff. Selling, general and administrative expenses included additional managerial appointments, increased professional
fees, additional rental space including in the U.S., and an increase of business development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Working
Capital </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Current assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">50,077</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">78,348</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,285</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,434</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Working capital</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33,792</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">35,914</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Current
assets decreased by $28,271 thousand between December 31, 2019 and December 31, 2020, which was primarily attributable to the
following: (i) an increase in cash and cash equivalents due the Masthercell sale; and (ii) an increase in accounts receivable
as a result of POC revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Current
liabilities decreased by $26,149 thousand between December 31, 2019 and December 31, 2020, which was primarily attributable to
the following: (i) an increase in accounts payable and accrued expenses due to expanded operations, (ii) an increase in current
maturities of convertible loans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended December 31,</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">579</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(26,041</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(78,046</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,220</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash provided by (used in) investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105,610</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,778</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,881</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24,098</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net change in cash and cash equivalents and restricted cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33,445</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,900</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
February 2, 2020, we entered into a Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with GPP-II Masthercell LLC
(&#8220;GPP&#8221; and together with us, the &#8220;Sellers&#8221;), Masthercell Global Inc. (&#8220;Masthercell&#8221;) and Catalent
Pharma Solutions, Inc. (the &#8220;Buyer&#8221;). Pursuant to the terms and conditions of the Purchase Agreement, on February
10, 2020 the Sellers sold 100% of the outstanding equity interests of Masthercell to Buyer (the &#8220;Masthercell Sale&#8221;)
for an aggregate nominal purchase price of $315 million, subject to customary adjustments. After accounting for GPP&#8217;s liquidation
preference and equity stake in Masthercell as well as SFPI &#8211; FPIM&#8217;s interest in MaSTherCell S.A., distributions to
Masthercell option holders and transaction costs, we received approximately $126.7 million, of which $7.2 million was used for
the repayment of intercompany loans and payables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Net
cash used in operating activities for the year ended December 31, 2020 was approximately $78 million, as compared to net cash
used in operating activities of approximately $13 million for the year ended December 31, 2019. Since the Masthercell Sale, we
entered into new joint venture agreements with new partners in various jurisdictions. This has allowed us to grow our infrastructure
and expand our processing sites into new markets and jurisdictions. In addition, we engaged some of these joint venture partners
to perform research and development services to further develop and adapt our systems and devices for specific purposes. We invested
manpower and financial resources to focus on developing, manufacturing and rolling out several types of OMPULs to be used and/or
distributed through our POCare Network of partners, collaborators, and joint ventures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Net
cash provided by investing activities for the year ended December 31, 2020 was approximately $106 million, as compared to net
cash used in investing activities of approximately $14 million for the year ended December 31, 2019. This was mainly attributable
to the Masthercell sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Liquidity
and Capital Resources Outlook</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Based
on our current cash resources and commitments, we believe that we will be able to maintain our current planned activities and
expected level of expenditures for at least 12 months from the date of the issuance of the financial statements. If increases
are incurred in operating costs in general and administrative expenses for facilities expansion, research and development, commercial
and clinical activity or if we experience decreases in revenues from customers, we may need to seek additional
financing. In addition, additional funds may be necessary to finance some of our collaborations and joint ventures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2018, we entered into a Controlled Equity Offering Sales Agreement, or Sales Agreement, with Cantor Fitzgerald &amp;
Co., or Cantor, pursuant to which we may offer and sell, from time to time through Cantor, shares of our common stock having an
aggregate offering price of up to $25.0 million. We will pay Cantor a commission rate equal to 3.0% of the aggregate gross proceeds
from each sale. Shares sold under the Sales Agreement will be offered and sold pursuant to our Shelf Registration Statement on
Form S-3 (Registration No. 333-223777) that was declared effective by the Securities and Exchange Commission on March 28, 2018,
or the Shelf Registration Statement, and a prospectus supplement and accompanying base prospectus that we filed with the Securities
and Exchange Commission on December 20, 2018. We have not yet sold any shares of our common stock pursuant to the Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Critical
Accounting Policies and Estimates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
significant accounting policies are more fully described in the notes to our financial statements included in this Annual Report
on Form 10-K for the fiscal year ended December 31, 2020. We believe that the accounting policies below are critical for one to
fully understand and evaluate our financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Business
Combination</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
allocate the purchase price of an acquired business to the tangible and intangible assets acquired and liabilities assumed based
upon our estimated fair values on the acquisition date. Any excess of the purchase price over the fair value of the net assets
acquired is recorded as goodwill. Acquired in-process backlog, customer relations, brand name know, technology and IPR&amp;D how
are recognized at fair value. The purchase price allocation process requires management to make significant estimates and assumptions,
especially at the acquisition date with respect to intangible assets. Direct transaction costs associated with the business combination
are expensed as incurred. The allocation of the consideration transferred in certain cases may be subject to revision based on
the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. We
include the results of operations of the business that we have acquired in our consolidated results prospectively from the date
of acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">If
the business combination is achieved in stages, the acquisition date carrying value of the acquirer&#8217;s previously held equity
interest in the acquiree is re-measured to fair value at the acquisition date; any gains or losses arising from such re-measurement
are recognized in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Goodwill</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Goodwill
represents the excess of consideration transferred over the value assigned to the net tangible and identifiable intangible assets
of businesses acquired. Goodwill is allocated to reporting units expected to benefit from the business combination. Goodwill
is not amortized but rather tested for impairment at least annually in the fourth quarter, or more frequently
if events or changes in circumstances indicate that goodwill may be impaired. Following the sale of Masthercell, we
manage the business as one operating segment and one reporting unit. Goodwill impairment is recognized when the quantitative
assessment results in the carrying value exceeding the fair value, in which case an impairment charge is recorded to the
extent the carrying value exceeds the fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">There
were no impairment charges to goodwill during the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Impairment
of Long-lived Assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
will periodically evaluate the carrying value of long-lived assets to be held and used when events and circumstances warrant such
a review. The carrying value of a long-lived asset is considered impaired when the anticipated undiscounted
cash flow from such asset is separately identifiable and is less than its carrying value. In that event, a loss is recognized
based on the amount by which the carrying value exceeds the fair value of the long-lived asset. Fair value is determined primarily
using the anticipated cash flows discounted at a rate commensurate with the risk involved. Losses on long-lived assets to be disposed
of are determined in a similar manner, except that fair values are reduced for the cost to dispose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Income
Taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
income tax assets and liabilities are computed for differences between the financial statement and tax basis of assets and liabilities
that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods
in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce
deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period
plus or minus the change during the period in deferred tax assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, our management performs an evaluation of all uncertain income tax positions taken or expected to be taken in the course
of preparing our income tax returns to determine whether the income tax positions meet a &#8220;more likely than not&#8221; standard
of being sustained under examination by the applicable taxing authorities. This evaluation is required to be performed for all
open tax years, as defined by the various statutes of limitations, for federal and state purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>ASC
606 - Revenue from Contracts with Customers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
agreements are primarily service contracts that range in duration. We recognize revenue when control of these services is transferred
to the customer for an amount, referred to as the transaction price, which reflects the consideration to which we are expected
to be entitled in exchange for those goods or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
contract with a customer exists only when:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
parties to the contract have approved it and are committed to perform their respective obligations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">we
can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;);</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">we
can determine the transaction price for the goods or services to be transferred; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
contract has commercial substance and it is probable that we will collect the consideration to which it will be entitled in exchange
for the goods or services that will be transferred to the customer.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
the majority of our contracts, we receive non-refundable upfront payments. We do not adjust the promised amount of consideration
for the effects of a significant financing component since we expect, at contract inception, that the period between the time
of transfer of the promised goods or services to the customer and the time the customer pays for these goods or services to be
generally one year or less. Our credit terms to customers are in average between thirty and ninety days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
do not disclose the value of unsatisfied performance obligations for contracts with original expected duration of one year or
less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Disaggregation
of Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table disaggregates our revenues by major revenue streams:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">Revenue stream:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">POC and hospital services</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,068</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,109</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cell process development services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,584</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">790</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,652</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,899</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Nature
of Revenue Streams</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have two main revenue streams being cell process development services and POC development services which includes and hospital
supplies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 2.55pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>POC
Development Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Revenue
recognized under contracts for POC development services may, in some contracts, represent multiple performance obligations (where
promises to the customers are distinct) in circumstances in which the <span style="background-color: white">work packages are
not interrelated or the customer is able to complete the services performed.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">For
arrangements that include multiple performance obligations, the transaction price is allocated to the identified performance obligations
based on their relative standalone selling prices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We
recognize revenue when, or as, it satisfies a performance obligation. At contract inception, we determine whether the services
are transferred over time or at a point in time. Performance obligations that have no alternative use and that we have the right
to payment for performance completed to date, at all times during the contract term, are recognized over time. All other Performance
obligations are recognized as revenues by the company at point of time (upon completion)<span style="background-color: white">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 2.55pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Included
in POC development services is hospital supplies revenue which is derived principally from the sale or lease of products
and the performance of services to hospitals or other medical providers. Revenue is earned and recognized when product and services
are received by the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 2.55pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 2.55pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Significant
Judgement and Estimates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 2.55pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 2.55pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Significant
judgment is required to</span> identifying the distinct performance obligations and estimating the standalone selling price of
each distinct performance obligation, and identifying which performance obligations create assets with alternative use to us,
which results in revenue recognized upon completion, and which performance obligations are transferred to the customer over time.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 2.55pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>Cell
Process Development Services (mainly discontinued operations)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Revenue
recognized under contracts for cell process development services may, in some contracts, represent multiple performance obligations
(where promises to the customers are distinct) in circumstances in which the <span style="background-color: white">work packages
and milestones are not interrelated or the customer is able to complete the services performed independently or by using our competitors.
In other contracts when the above circumstances are not met, the promises are not considered distinct and the contract represents
one performance obligation. </span>All performance obligations are satisfied over time, as there is no alternative use to the
services it performs, since, in nature, those services are unique to the customer, which retain the ownership of the intellectual
property created through the process. Additionally, due to the non-refundable upfront payment the customer pays, together with
the payment term and cancellation fine, it has a right to payment (which include a reasonable margin), at all times, for work
completed to date, which is enforceable by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">For
arrangements that include multiple performance obligations, the transaction price is allocated to the identified performance obligations
based on their relative standalone selling prices. For these contracts, the standalone selling prices are based on our normal
pricing practices when sold separately with consideration of market conditions and other factors, including customer demographics
and geographic location.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We
measure the revenue to be recognized over time on a contract by contract basis, determining the use of <span style="background-color: white">either
a cost-based input method or output method, depending on whichever best depicts the transfer of control over the life of the performance
obligation.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>Tech
Transfer Services (discontinued operations)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Revenue
recognized under contracts for tech transfer services are considered a single performance obligation, as all work packages (including
data collection, GMP documentation, validation runs) and milestones are interrelated. Additionally, the customer is unable to
complete services of work performed independently or by using our competitors. Revenue is recognized <span style="background-color: white">over
time using a cost-based input method where progress on the performance obligation is measured by the proportion of actual costs
incurred to the total costs expected to complete the contract.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>Cell
Manufacturing Services </b></span><b><span style="font: 10pt Times New Roman, Times, Serif">(discontinued operations)</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Revenues
from cell manufacturing services represent</span> <span style="font: 10pt Times New Roman, Times, Serif">a single
performance obligation which is recognized over time. The progress towards completion will continue to be measured on an output
measure based on direct measurement of the value transferred to the customer (units produced).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Reimbursed
Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
include reimbursed expenses in revenues and costs of revenue as we are primarily responsible for fulfilling the promise to provide
the specified service, including the integration of the related services into a combined output to the customer, which are inseparable
from the integrated service. These costs include such items as consumable, reagents, transportation and travel expenses, over
which we have discretion in establishing prices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Change
Orders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Changes
in the scope of work are common and can result in a change in transaction price, equipment used and payment terms. Change orders
are evaluated on a contract-by-contract basis to determine if they should be accounted for as a new contract or as part of the
existing contract. Generally, services from change orders are not distinct from the original performance obligation. As a result,
the effect that the contract modification has on the contract revenue, and measure of progress, is recognized as an adjustment
to revenue when they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Costs
of Revenue (Discontinued Operations)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Costs
of revenue include (i) compensation and benefits for billable employees and personnel involved in production, data management
and delivery, and the costs of acquiring and processing data for our information offerings; (ii) costs of staff directly involved
with delivering services offerings and engagements; (iii) consumables used for the services; and (iv) other expenses directly
related to service contracts such as courier fees, laboratory supplies, professional services and travel expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Contract
Assets and Liabilities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Contract
assets are mainly comprised of trade receivables net of allowance for doubtful debts, which includes amounts billed and currently
due from customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
activity for trade receivables is comprised of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Balance as of beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,831</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">129</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Acquisition of Koligo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">228</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,997</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,079</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Collections</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,982</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(364</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Exchange rate differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance as of end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,831</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
activity for contract liabilities is comprised of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Balance as of beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">325</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">56</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">597</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,126</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Realizations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(862</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(854</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Exchange rate differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">59</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">325</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">See
note 2(z).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">See
note (x).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">See
note 2(y).</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Off-Balance
Sheet Arrangements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital
resources that is material to stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_012"></span>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_013"></span>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
information called for by Item 8 is included following the &#8220;Index to Financial Statements&#8221; on page F-1 contained in
this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_014"></span>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_015"></span>ITEM
9A. CONTROLS AND PROCEDURES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Evaluation
of Disclosure Controls and Procedures</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Our
management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness
of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act and
regulations promulgated thereunder) as of</span> <span style="font: 10pt Times New Roman, Times, Serif">December
31, 2020<span style="background-color: white">, or the Evaluation Date. Based on such evaluation, our Chief Executive Officer
and Chief Financial Officer have concluded that, as of the Evaluation Date, our disclosure controls and procedures are effective.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Management&#8217;s
Report on Internal Control over Financial Reporting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
management, under the supervision of the <span style="background-color: white">Chief Executive Officer and Chief Financial Officer</span>,
is responsible for establishing and maintaining adequate internal control over financial reporting for our company. Internal control
over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by,
or under the supervision of, the company&#8217;s principal executive and principal financial officers and effected by the company&#8217;s
board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with GAAP and includes those policies and procedures
that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and
dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit
preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures
of our company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our company&#8217;s
assets that could have a material effect on the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Koligo acquisition which was completed in October 2020 was excluded from management&#8217;s evaluation of internal control over
financial reporting as of December 31, 2020 because the business was acquired in a transaction accounted for as a business combination
during 2020. Koligo, represents approximately 2% of our total consolidated assets and approximately 3% of our total consolidated
revenues as of and for the year ended December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
management, with the participation of our <span style="background-color: white">Chief Executive Officer and Chief Financial Officer</span>,
evaluated the effectiveness of our internal control over financial reporting as of December 31, 2020. In making this evaluation,
our management used the criteria set forth in the Internal Control &#8212; Integrated Framework (2013) issued by the Committee
of Sponsoring Organizations of the Treadway Commission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Based
on this evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2020
based on those criteria.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">This
annual report does not include an attestation report of our registered public accounting firm on internal control over financial
reporting because we are is a smaller reporting company and non-accelerated filer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Changes
in Internal Control Over Financial Reporting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">There
were no changes in our internal control over financial reporting that occurred during the quarter ended December 31, 2020 that
have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_016"></span>ITEM
9B. OTHER INFORMATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_017"></span>PART
III</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_018"></span>ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The
following table sets forth certain information regarding our each of our current Directors and Executive Officers as of March
9, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">&#160;</span></span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">&#160;</span></span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 44%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Position</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Vered
    Caplan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Chief
    Executive Officer and Chairperson of the Board of Directors</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Neil
    Reithinger</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Chief
    Financial Officer, Secretary and Treasurer</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">David
    Sidransky <sup>(1) (2) (4)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">60</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Guy
    Yachin <sup>(1) (2) (3) (4)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">53</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Yaron
    Adler <sup>(2) (3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Ashish
    Nanda <sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">55</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Mario
    Philips <sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 5%"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 95%"><span style="font: 10pt Times New Roman, Times, Serif">A
    member on the audit committee.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
    member on the compensation committee.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
    member on the nominating and corporate governance committee.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(4)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
    member of the research and development committee.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Our
Executive Officers</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Vered
Caplan &#8211; Chief Executive Officer and Chairperson of the Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Ms.
Caplan has served as our CEO and Chairperson of the Board of Directors since August 14, 2014, prior to which she served as Interim
President and CEO commencing on December 23, 2013. She joined our Board of Directors in February 2012. She has 26 <span style="background-color: white">years
of industry experience, previously holding positions as </span>CEO of Kamedis Ltd. <span style="background-color: white">from
2009 to 2014</span>, CEO of GammaCan International Inc. from 2004 to 2007. She also served as a director of the following companies:
Opticul Ltd., Inmotion Ltd., Nehora Photonics Ltd., Ocure Ltd., Eve Medical Ltd., and Biotech Investment Corp. Ms. Caplan holds
a M.Sc. in biomedical engineering from Tel Aviv University specializing in signal processing; management for engineers from Tel
Aviv University specializing in business development; and a B.Sc. in mechanical engineering from the Technion&#8211; Israel Institute
of Technology specialized in software and cad systems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Neil
Reithinger &#8211; Chief Financial Officer, Secretary and Treasurer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Mr.
Reithinger was appointed Chief Financial Officer, Secretary and Treasurer on August 1, 2014. Mr. Reithinger is the Founder and
President of Eventus Advisory Group, LLC, a private, CFO-services firm incorporated in Arizona, which specializes in capital advisory
and SEC compliance for publicly-traded and emerging growth companies. He is also the President of Eventus Consulting, P.C., a
registered CPA firm in Arizona. Prior to forming Eventus, Mr. Reithinger was Chief Operating Officer &amp; CFO from March 2009
to December 2009 of New Leaf Brands, Inc., a branded beverage company, CEO of Nutritional Specialties, Inc. from April 2007 to
October 2009, a nationally distributed nutritional supplement company that was acquired by Nutraceutical International, Inc.,
Chairman, CEO, President and director of Baywood International, Inc. from January 1998 to March 2009, a publicly-traded nutraceutical
company and Controller of Baywood International, Inc. from December 1994 to January 1998. Mr. Reithinger earned a B.S. in Accounting
from the University of Arizona and is a Certified Public Accountant. He is a Member of the American Institute of Certified Public
Accountants and the Arizona Society of Certified Public Accountants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Our
Directors</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Dr.
David Sidransky &#8211; Director</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Dr.
Sidransky has served as a director since his appointment on July 18, 2013. Dr. Sidransky is a renowned oncologist and research
scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his
work with early detection of cancer. Since 1994, Dr. Sidransky has been the Director of the Head and Neck Cancer Research Division
at Johns Hopkins University School of Medicine&#8217;s Department of Otolaryngology and Professor of Oncology, Cellular &amp;
Molecular Medicine, Urology, Genetics, and Pathology at the John Hopkins University School of Medicine. Dr. Sidransky is one of
the most highly cited researchers in clinical and medical journals in the world in the field of oncology during the past decade,
with over 560 peer reviewed publications. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous
biotechnology patents. Dr. Sidransky has served as Vice Chairman of the board of directors, and was, until the merger with Eli
Lilly, a director of ImClone Systems, Inc., a global biopharmaceutical company committed to advancing oncology care. He is currently
on the board of Directors of Galmed and Champions Oncology. and chairs the board of directors of Advaxis and Ayala . Dr. Sidransky
served as Director from 2005 until 2008 of the American Association for Cancer Research (AACR). He was the chairperson of AACR
International Conferences during the years 2006 and 2007 on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing
Opportunities for Personalized Treatment. Dr. Sidransky is the recipient of a number of awards and honors, including the 1997
Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and
Health by the American College of Chest Physicians, and the 2004 Richard and Hinda Rosenthal Award from the American Association
of Cancer Research. Dr. Sidransky received his BS in Chemistry from Brandies University and his medical degree from Baylor College
of medicine where he also completed his residency in internal medicine. His specialty in Medical Oncology was completed at Johns
Hopkins University and Hospital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
believe Dr. Sidransky is qualified to serve on our Board of Directors because of his education, medical background, experience
within the life science industry and his business acumen in the public markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Guy
Yachin &#8211; Director</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Mr.
Yachin has served as a director since his appointment on April 2, 2012. Mr. Yachin has served as the President and CEO of Serpin
Pharma, a clinical stage Virginia-based company focused on the development of anti-inflammatory drugs, since April 2013. Mr. Yachin
is the CEO of Oasis Management, a Maryland-based consulting company, since 2010. Mr. Yachin is the CEO of NasVax Ltd., a company
focused on the development of improved immunotherapeutics and vaccines. Prior to joining NasVax, Mr. Yachin served as CEO of MultiGene
Vascular Systems Ltd., a cell therapy company focused on blood vessels disorders, leading the company through clinical studies
in the U.S. and Israel, financial rounds, and a keystone strategic agreement with Teva Pharmaceuticals Industries Ltd. He was
CEO and founder of Chiasma Inc., a biotechnology company focused on the oral delivery of macromolecule drugs, where he built the
company&#8217;s presence in Israel and the U.S., concluded numerous financial rounds, and guided the company&#8217;s strategy
and operation for over six years. Earlier, he was CEO of Naiot Technological Center Ltd., and provided seed funding and guidance
to more than a dozen biomedical startups such as Remon Medical Technologies Ltd., Enzymotec Ltd. and NanoPass Technologies Ltd.
He holds a BSc. in Industrial Engineering and Management and an MBA from the Technion &#8211; Israel Institute of Technology.
Mr. Yachin served on the board of Peak Pharmaceuticals, Inc. from March 2014 to April 2016.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
believe Mr. Yachin is qualified to serve on our Board of Directors because of his education, experience within the life science
industry and his business acumen in the public markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Yaron
Adler &#8211; Director</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Mr.
Adler has served as a director since his appointment on April 17, 2012. Mr. Adler is the co-founder of a startup incubator, We
Group Ltd. In 1999, Mr. Adler co-founded IncrediMail Ltd. and served as its CEO until 2008 and President until 2009. In 1999,
prior to founding IncrediMail, Mr. Adler consulted Israeli startup companies regarding Internet products, services and technologies.
Mr. Adler served as a product manager from 1997 to 1999, and as a software engineer from 1994 to 1997, at Tecnomatix Technologies
Ltd., a software company that develops and markets production engineering solutions to complex automated manufacturing lines that
fill the gap between product design and production, and which was acquired by UGS Corp. in April 2005. In 1993, Mr. Adler held
a software engineer position at Intel Israel Ltd. He has a B.A. in computer sciences and economics from Tel Aviv University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
believe Mr. Adler is qualified to serve on our Board of Directors because of his education, success with early-stage enterprises
and his business acumen in the public markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Ashish
Nanda &#8211; Director</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Mr.
Nanda has served as a director since his appointment on February 22, 2017. Since 1998, Mr. Nanda has been the Managing Director
of Innovations Group, one of the largest outsourcing companies in the financial sector that employs close to 14,000 people working
across various financial sectors. Since 1992, Mr. Nanda has served as the Managing Partner of Capstone Insurance Brokers LLC and,
since 2009, has served as Managing Partner of Dive Tech Marine Engineering Services L.L.C. From 1991 to 1994, Mr. Nanda held the
position of Asst. Manager Corporate Banking at Emirates Banking Group where he was involved in establishing relationships with
business houses owned by UAE nationals and expatriates in order to set up banking limits and also where he managed portfolios
of USD $26 billion. Mr. Nanda holds a Chartered Accountancy from the Institute of Chartered Accountants from India.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
believe that Mr. Nanda is qualified to serve on our Board of Directors because of his business experience and strategic understanding
of advancing the valuation of companies in emerging industries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">There
are no family relationships between any of the above executive officers or directors or any other person nominated or chosen to
become an executive officer or a director. Pursuant to an agreement entered into between us and Image Securities fzc. (&#8220;Image&#8221;),
for <span style="background-color: white">so long as Image&#8217;s ownership of our company is 10% or greater, it </span>was granted
the right to nominate a director to our Board of Directors. Mr. Nanda was nominated for a directorship at the 2017 annual meeting
in compliance with our contractual undertakings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Mario
Philips &#8211; Director</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Mr.
Philips has served as a director since his appointment on January 9, 2020. Since November 2020, Mr. Philips has been Chief Executive
Officer of Polyplus, a leading Biotech supplier of transfection reagents for cell &amp; gene therapy as well as the research life
sciences market. Mario is also chairmen of the Board of PLL Therapeutics, a drug company based in France that has developed a
diagnostic platform technology for neurodegenerative diseases in combination with a therapy to cure neurodegenerative diseases
such as ALS and Parkinson&#8217;s.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Prior
to that Mario acted as VP/GM for Danaher Pall Biotech business with full P&amp;L responsibility for a $1,3B business unit. Mario
joined Pall in February 2014, as part of the Pall acquisition of ATMI Life Sciences, and was appointed to Vice President and General
Manager to lead the Single-Use Technologies BU. In this role he was responsible for leading and executing an aggressive investment
and growth strategy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Mario
joined ATMI in 1999 with ATMI&#8217;s acquisition of MST Analytics, Inc., serving as European Sales Manager for ATMI Analytical
Systems. In 2004, Mario was appointed to General Manager of ATMI Packaging, a role he held through 2010 when he was promoted to
the position of Senior Vice President and General Manager, ATMI Life Sciences. In that role, he was responsible for developing
and executing all business strategies, including the introduction of new products and service solutions for the Life Sciences
industry. A strong leading innovative IP portfolio was created, Pall acquired the business in 2014.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Mario
also held in the past several board member positions in the life sciences industry with Clean Biologics, Austar Life Sciences
(China), Disposable Lab (France) and Artelis (Belgium).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
believe that Mr. Philips is qualified to serve on our Board of Directors because of his business experience and strategic understanding
of advancing the valuation of companies in emerging industries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Board
of Directors</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
Board of Directors currently consists of six (6) members. All directors hold office until the next annual meeting of stockholders.
At each annual meeting of stockholders, the successors to directors whose terms then expire are elected to serve from the time
of election and qualification until the next annual meeting following election.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Management
has been delegated the responsibility for meeting defined corporate objectives, implementing approved strategic and operating
plans, carrying on our business in the ordinary course, managing cash flow, evaluating new business opportunities, recruiting
staff and complying with applicable regulatory requirements. The Board of Directors exercises its supervision over management
by reviewing and approving long-term strategic, business and capital plans, material contracts and business transactions, and
all debt and equity financing transactions and stock issuances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
Board of Directors is comprised of a majority of independent directors. In determining director independence, the Company uses
the definition of independence in Rule 5605(a)(2) of the listing standards of The Nasdaq Stock Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Board has concluded that each of Dr. Sidransky, and Messrs. Yachin, Adler, Philips and Nanda is &#8220;independent&#8221; based
on the listing standards of the Nasdaq Stock Market, having concluded that any relationship between such director and our company,
in its opinion, does not interfere with the exercise of independent judgment in carrying out the responsibilities of a director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Board
Committees </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Our
Board of Directors has established an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee,
with each comprised of independent directors in accordance with the rules of The Nasdaq Stock Market and applicable federal securities
laws and regulations. The members of the Audit Committee are Dr. Sidransky and Messrs. Yachin and Philips. The members of the
Compensation Committee are Dr. Sidransky and Messrs. Adler and Yachin. The members of the Nominating and Corporate Governance
Committee are Messrs. Nanda, Adler and Yachin. The members of the Research and Development Committee are Mr. Yachin and Dr. Sidransky.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Each
committee operates under a written charter that has been approved by our Board of Directors. Copies of our committee charters
are available on the investor relations section of our website, which is located at http://www.orgenesis.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Audit
Committee </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Audit Committee (a) assists the Board of Directors in fulfilling its oversight of: (i) the quality and integrity of our financial
statements&#894; (ii) our compliance with legal and regulatory requirements relating to our financial statements and related disclosures&#894;
(iii) the qualifications and independence of our independent auditors&#894; and (iv) the performance of our independent auditors&#894;
and (b) prepares any reports that the rules of the SEC require be included in our proxy statement for our annual meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Audit Committee held 9 meetings in fiscal 2020. In addition, the Audit Committee reviewed and approved various corporate items
by way of written consent during the fiscal year 2020. The Board has determined that each member of the Audit Committee is an
independent director in accordance with the rules of The Nasdaq Stock Market and applicable federal securities laws and regulations.
In addition, the Board has determined that Dr. Sidransky is an &#8220;audit committee financial expert&#8221; within the meaning
of Item 407(d)(5) of Regulation S-K and has designated him to fill that role. See &#8220;Directors, Executive Officers and Corporate
Governance &#8211; Directors&#8221; above for descriptions of the relevant education and experience of each member of the Audit
Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">At
no time since the commencement of our most recently completed fiscal year was a recommendation of the Audit Committee to nominate
or compensate an external auditor not adopted by the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Audit Committee is responsible for the oversight of our financial reporting process on behalf of the Board of Directors and such
other matters as specified in the Audit Committee&#8217;s charter or as directed by the Board of Directors. Our Audit Committee
is directly responsible for the appointment, compensation, retention and oversight of the work of any registered public accounting
firm engaged by us for the purpose of preparing or issuing an audit report or performing other audit, review or attest services
for us (or to nominate the independent registered public accounting firm for stockholder approval), and each such registered public
accounting firm must report directly to the Audit Committee. Our Audit Committee must approve in advance all audit, review and
attest services and all non-audit services (including, in each case, the engagement and terms thereof) to be performed by our
independent auditors, in accordance with applicable laws, rules and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Compensation
Committee</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Compensation Committee (i) assists the Board of Directors in discharging its responsibilities with respect to compensation of
our executive officers and directors, (ii) evaluates the performance of our executive officers, and (iii) administers our stock
and incentive compensation plans and recommends changes in such plans to the Board as needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Compensation Committee acted by unanimous written consent or held 5 meetings in fiscal 2020. In addition, the Compensation Committee
reviewed and approved various corporate items by way of written consent during the fiscal year 2019. The Board of Directors has
determined that each member of the Compensation Committee is an independent director in accordance with the rules of The Nasdaq
Stock Market and applicable federal securities laws and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Nominating
and Corporate Governance Committee</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Nominating and Corporate Governance Committee assists the Board in (i) identifying qualified individuals to become directors,
(ii) determining the composition of the Board and its committees, (iii) developing succession plans for executive officers, (iv)
monitoring a process to assess Board effectiveness, and (v) developing and implementing our corporate governance procedures and
policies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Nominating and Corporate Governance Committee acted by unanimous written consent or held 4 meeting in fiscal 2020. The Board has
determined that each member of the Nominating and Corporate Governance Committee is an independent director in accordance with
the rules of The Nasdaq Stock Market and applicable federal securities laws and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Research
and Development Committee</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Research and Development Committee assists the Board in fulfilling the Board&#8217;s responsibilities to oversee the Company&#8217;s
research and development programs, and strategies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Research and Development Committee was established in January 2021. The Board has determined that each member of the Research
and Development Committee is an independent director in accordance with the rules of The Nasdaq Stock Market and applicable federal
securities laws and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>DELINQUENT
SECTION 16(a) REPORTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Section
16(a) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), requires officers and directors of
the Company and persons who beneficially own more than ten percent (10%) of the Common Stock outstanding to file initial statements
of beneficial ownership of Common Stock (Form 3) and statements of changes in beneficial ownership of Common Stock (Forms 4 or
5) with the SEC. Officers, directors and greater than 10% stockholders are required by SEC regulation to furnish us with copies
of all such forms they file.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
records reflect that all reports which were required to be filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
as amended, were filed on a timely basis, except that two reports, covering an aggregate of five transactions, were filed late
by David Sidransky, one report, covering an aggregate of one transaction, was filed late by Yaron Adler, one report, covering
an aggregate of one transaction, was filed late by Guy Yachin, and one report, covering an aggregate of one transaction, was filed
late by Ashish Nanda.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Corporate
Code of Conduct and Ethics</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
Board of Directors has adopted a written code of business conduct and ethics that applies to our directors, officers and employees,
including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons
performing similar functions. Copies of our corporate code of conduct and ethics are available, without charge, upon request in
writing to Orgenesis Inc., 20271 Goldenrod Lane, Germantown, MD, 20876, Attn: Secretary and are posted on the investor relations
section of our website, which is located at www.orgenesis.com. The inclusion of our website address in this Annual Report on Form
10-K does not include or incorporate by reference the information on our website into this Annual Report on Form 10-K. We also
intend to disclose any amendments to the Corporate Code of Conduct and Ethics, or any waivers of its requirements, on our website.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_019"></span>ITEM
11. EXECUTIVE COMPENSATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table shows the total compensation paid or accrued during the last two fiscal years ended December 31, 2020 to our Chief
Executive Officer and Chief Financial Officer. As of December 31, 2020, there were no other executive officers who earned
more than $100,000 during the fiscal year ended December 31, 2020 and were serving as executive officers as of such date (the
&#8220;named executive officers&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Summary
Compensation Table</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name and</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Principal</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Position</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Year</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Salary</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Bonus</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Awards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Awards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>($) <sup>(1)</sup></b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Non-Equity</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Incentive</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Plan</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Compensa-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>tion</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Non-qualified</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Deferred</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Earnings</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>All Other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Compensa-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>tion</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>($) <sup>(2)</sup></b></span></p></td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Total <br />
($)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-style: italic; text-align: left">Vered Caplan <br /></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">2020</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">250,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">400,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">163,239</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">215,640</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">1,028,879</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CEO(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2019</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">871,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,398,056</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Neil Reithinger <i>CFO, Treasurer &amp; </i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">255,231</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,331</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">512,562</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Secretary</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2019</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">213,653</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,970</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">236,623</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 5%"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 95%"><span style="font: 10pt Times New Roman, Times, Serif">In
    accordance with SEC rules, the amounts in this column reflect the fair value on the grant date of the option awards granted
    to the named executive, calculated in accordance with ASC Topic 718. Stock options were valued using the Black-Scholes model.
    The grant-date fair value does not necessarily reflect the value of shares which may be received in the future with respect
    to these awards. The grant-date fair value of the stock options in this column is a non-cash expense for the Company that
    reflects the fair value of the stock options on the grant date and therefore does not affect our cash balance. The fair value
    of the stock options will likely vary from the actual value the holder receives because the actual value depends on the number
    of options exercised and the market price of our Common Stock on the date of exercise. For a discussion of the assumptions
    made in the valuation of the stock options, see Note 15 to this Annual Report on Form 10-K for the year ended &#160;December
    31, 2020.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For
    2020 and 2019, represents the compensation as described under the caption &#8220;All Other Compensation&#8221; below.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>All
Other Compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table provides information regarding each component of compensation for fiscal years 2020 and 2019 included in the All
Other Compensation column in the Summary Compensation Table above. Represents amounts paid in New Israeli Shekels (NIS) or Swiss
Franks and converted at average exchange rates for the year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Name</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Automobile and Communication</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Related</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Expenses</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>$
                                         (1)</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Social</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Benefits</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>$
                                         (2)</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Vered Caplan</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">2020</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">13,172</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">202,468</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">215,640</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2019</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,876</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,144</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,020</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 5%"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 95%"><span style="font: 10pt Times New Roman, Times, Serif">Represents
    for Ms. Caplan, a leased automobile and communication expenses.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">These
    are comprised of contributions by the Company to savings, severance, pension, disability and insurance plans generally provided
    in Israel and Switzerland, including education funds and managerial insurance funds, and redeemed vacation pay. This amount
    represents Israeli and Swiss severance fund payments, managerial insurance funds, disability insurance, supplemental education
    fund contribution and social securities. See discussion below under &#8220;Narrative Disclosure to Summary Compensation Table
    &#8211; Vered Caplan.&#8221;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Outstanding
Equity Awards at December 31, 2020</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the outstanding equity awards held by each named executive officer of our company as of December 31,
2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Name</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Grant Date</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares<br />
    Underlying<br />
    Unexercised<br />
    Options (#)<br />
    Exercisable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares<br />
    Underlying<br />
    Unexercised<br />
    Options (#)<br />
    Unexercisable</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Option<br />
    Exercise<br />
    Price ($)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Option<br />
    Expiration<br />
    Date</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center">Vered Caplan</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">02-Feb-12<i><sup>(1)</sup></i></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right">278,191</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right">0.012</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center">02-Feb-22</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">22-Aug-14<i><sup>(1)</sup></i></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">230,189</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0012</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">22-Aug-24</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">09-Dec-16<i><sup>(1)</sup></i></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">166,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.80</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">09-Dec-26</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">06-Jun-17<i><sup>(1)</sup></i></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">83,334</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7.20</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">06-Jun-27</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">28-Jun-18<i><sup>(1)</sup></i></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">250,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8.36</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">28-Jun-28</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">22-Oct-18<i><sup>(3)</sup></i></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">42,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">42,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5.99</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">22-Oct-28</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">19-Mar-20<i><sup>(2)</sup></i></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">31,875</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">53,125</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2.99</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">18-Mar-30</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Neil Reithinger</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">09-Dec-16<i><sup>(1)</sup></i></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">83,334</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.80</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">09-Dec-26</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">08-Mar-19<i><sup>(2)</sup></i></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,250</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">18,750</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5.07</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">08-Mar-29</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">19-Mar-20<i><sup>(2)</sup></i></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,625</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,375</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2.99</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">18-Mar-30</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The
    options were fully vested as of</span> <span style="font: 10pt Times New Roman, Times, Serif">December 31,
    2020<span style="background-color: white">.</span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The
    options vest on a quarterly basis over a period of two years from the date of grant.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The
    options vest on a quarterly basis over a period of four years from the date of grant.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">There
were no option exercises by our named executive officers during our fiscal year ended December 31, 2019 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Narrative
Disclosure to Summary Compensation Table</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Vered
Caplan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
August 14, 2014, our Board of Directors confirmed that Ms. Vered Caplan, who had served as our President and Chief Executive Officer
on an interim basis since December 23, 2013, was appointed as our President and Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
March 30, 2017, we and Ms. Caplan entered into an employment agreement replacing a previous employment agreement dated August
22, 2014 (the &#8220;Amended Caplan Employment Agreement&#8221;). Under the Amended Caplan Employment Agreement, which took effect
April 1, 2017, Ms. Caplan&#8217;s annual salary continued at $160,000 per annum, subject to adjustment to $250,000 per annum upon
the listing of the Company&#8217;s securities on an Exchange. On May 10, 2017, we and Ms. Caplan further amended the Amended Caplan
Employment Agreement pursuant to which Ms. Caplan became entitled to a grant under the 2017 of options (the &#8220;Initial Option&#8221;)
to purchase 83,334 shares of the Company&#8217;s common stock at a per share exercise price equal to the Fair Market Value (as
defined in our 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;)) of the Company&#8217;s common stock on the date of grant.
The amendment further provided that beginning in fiscal 2018, subject to approval by the compensation committee, Ms. Caplan became
entitled to an additional option (the &#8220;Additional Option&#8221;; together with the Initial Option, the &#8220;Options&#8221;)
under the 2017 Plan for up to 250,000 shares of common stock of the Company to be awarded in such amounts per fiscal year as shall
be consistent with the Plan, in each case at a per share exercise price equal to the Fair Market Value (as defined in the Plan)
of the Company&#8217;s common stock on the date of grant. In 2018, following the listing of the Company&#8217;s securities on
Nasdaq, Ms. Caplan&#8217;s annual salary was raised to $250,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
additional information regarding Ms. Caplan&#8217;s stock options awards, see the Outstanding Equity Awards table above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
November 19, 2020, we and Ms. Caplan entered into an executive directorship agreement, effective as of October 1, (the &#8220;Executive
Directorship Agreement&#8221;), that supersedes and replaces the Amended Caplan Employment Agreement (the &#8220;Prior Agreement&#8221;).
Pursuant to the Executive Directorship Agreement, Ms. Caplan will continue to serve the Company as its Chairperson of the Board
of Directors (the &#8220;Board&#8221;) and shall receive in consideration for her serving as Chairperson of the Board an annual
regular Board fee in the amount of $75,000 payable by the Company in equal quarterly installments in advance. In addition, Ms.
Caplan may be eligible for non-recurring special Board fees as reviewed and approved by the Compensation Committee of the Board
(the &#8220;Compensation Committee&#8221;) and then reviewed and ratified by the Board. In addition, Ms. Caplan may be granted
option awards from time to time at the discretion of the Compensation Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Ms.
Caplan&#8217;s position as Chairperson of the Board under the Executive Directorship Agreement may be terminated for any reason
by either Ms. Caplan or the Company upon 90 days prior written notice (the &#8220;Notice Period&#8221;), provided that the Company
may terminate such appointment as Chairperson at any time during the Notice Period subject to certain conditions. Such termination
as Chairperson of the Board will be deemed a termination even if Ms. Caplan remains as a regular director of the Board. Upon termination
by the Company of Ms. Caplan&#8217;s employment other than for cause or by Ms. Caplan for any reason whatsoever, in addition to
any Accrued Obligations (as defined therein) she shall be entitled to receive a lump sum payment equal to the sum of (i) the annual
regular Board fee (the &#8220;Board Fee&#8221;) and (ii) the greater of actual or target annual performance bonus to which she
may have been entitled to as of the termination date (in each case, less all customary and required taxes and related deductions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Ms.
Caplan&#8217;s position under the Executive Directorship Agreement may be terminated in the event of a Change of Control (as defined
therein) by the Company other than for cause or by Ms. Caplan for any reason whatsoever. In the event of a Change of Control and
if, within one year following such Change of Control, employment under the Executive Directorship Agreement is terminated by the
Company other than for cause or by Ms. Caplan for any reason whatsoever, in addition to any Accrued Obligations, she shall be
entitled to receive a lump sum payment equal to one and a half times the sum of (i) the Board Fee and (ii) the target annual performance
remuneration to which she may have been entitled as of the termination date (in each case, less all customary and required taxes
and related deductions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, on November 19, 2020, Orgenesis Services S&#224;rl, a Swiss corporation and wholly-owned, direct subsidiary of the
Company (&#8220;Orgenesis Services&#8221;), and Ms. Caplan entered into a personal employment agreement (the &#8220;Swiss Employment
Agreement&#8221; and together with the Executive Directorship Agreement, the &#8220;Agreements&#8221;), pursuant to which Ms.
Caplan will serve as Chief Executive Officer, President and Chairperson of the Board of Directors of Orgenesis Services and will
be a material provider of services to the Company pursuant to a services agreement between the Company and Orgenesis Services.
The Swiss Employment Agreement provides that Ms. Caplan is entitled to a monthly base salary of CHF 13,345.05 (equivalent to $14,583
based on the current exchange rate at signing), and an annual representation fee of CHF 24,000 (equivalent to $26,226 based on
the current exchange rate at signing), payable in monthly installments of CHF 2,000. Ms. Caplan is eligible to receive a bonus
at the absolute discretion of Orgenesis Services and its compensation committee. Ms. Caplan may also be granted option awards
from time to time, as per the recommendation of the compensation committee of Orgenesis Services as reviewed and approved by the
Compensation Committee. Under the Swiss Employment Agreement, Ms. Caplan is entitled to paid annual vacation days, monthly travel
allowance, sick leave, expenses reimbursement and a mobile phone. The Swiss Employment Agreement has an effective date as of October
1, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Employment
under the Swiss Employment Agreement may be terminated for any reason by Ms. Caplan or by Orgenesis Services other than for just
cause (as defined therein) upon six months prior written notice or by Orgenesis Services other than for just cause in the event
of a Change of Control (as defined therein) of the Company upon at least 12 months prior written notice. Upon termination by Orgenesis
Services of Ms. Caplan&#8217;s employment without just cause or by Ms. Caplan for any reason whatsoever, in addition to any Accrued
Obligations (as defined therein), she shall be entitled to receive a lump sum payment equal to the sum of (i) her Base Salary
(as defined therein) at the rate in effect as of the termination date and (ii) the greater of actual or target annual performance
bonus to which she may have been entitled to for the year in which employment terminates (in each case, less all customary and
required taxes and employment-related deductions). In the event of a Change of Control and if, within one year following such
Change of Control, employment is terminated by Orgenesis Services other than for cause or by Ms. Caplan for any reason whatsoever,
in addition to any Accrued Obligations she shall be entitled to receive a lump sum payment equal to one and a half times the sum
of (i) her Base Salary and (ii) the target annual performance bonus to which she may have been entitled to for the year in which
employment terminates (in each case, less all customary and required taxes and employment-related deductions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Swiss Employment Agreement provides for customary protections of Orgenesis Services&#8217; confidential information and intellectual
property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
November 19, 2020, the Compensation Committee approved a special remuneration of $400,000 to Ms. Caplan for her outstanding service
in the business development of the Company and its affiliates. The payment of such remuneration was made at the time of entry
into the Agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Neil
Reithinger</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Mr.
Reithinger was appointed Chief Financial Officer, Treasurer and Secretary on August 1, 2014. Mr. Reithinger&#8217;s employment
agreement stipulates a monthly salary of $1,500; payment of an annual bonus as determined by the Company in its sole discretion,
participation in the Company&#8217;s pension plan; grant of stock options as determined by the Company; and reimbursement of expenses.
In addition, on August 1, 2014, the Company entered into a financial consulting agreement with Eventus Consulting, P.C., an Arizona
professional corporation, of which Mr. Reithinger is the sole shareholder (&#8220;Eventus&#8221;), pursuant to which Eventus has
agreed to provide financial consulting services to the Company. In consideration for Eventus&#8217; services, the Company agreed
to pay Eventus according to its standard hourly rate structure. The term of the consulting agreement was for a period of one year
from August 1, 2014 and automatically renews for additional one-year periods upon the expiration of the term unless otherwise
terminated. Eventus is owned and controlled by Mr. Reithinger. On December 16, 2020, the Compensation Committee of the Board of
Directors of the Company, approved a special one-time bonus of $200,000 was paid prior to December 31, 2020. As of December 31,
2020, Eventus was owed $28 thousand for accrued and unpaid services under the financial consulting agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Potential
Payments upon Change of Control or Termination following a Change of Control</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
employment agreements with our named executive officers provide incremental compensation in the event of termination, as described
herein. Generally, we currently do not provide any severance specifically upon a change in control nor do we provide for accelerated
vesting upon change in control. Termination of employment also impacts outstanding stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Due
to the factors that may affect the amount of any benefits provided upon the events described below, any actual amounts paid or
payable may be different than those shown in this table. Factors that could affect these amounts include the basis for the termination,
the date the termination event occurs, the base salary of an executive on the date of termination of employment and the price
of our common stock when the termination event occurs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth the compensation that would have been received by each of the Company&#8217;s executive officers had
they been terminated as of December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Name</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Salary</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Continuation</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: center">Vered Caplan</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center">*</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>(*)
Termination by Company without cause: $250,000</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Termination
without cause following a change in control: $375,000 </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Director
Compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth for each non-employee director that served as a director during the year ended December 31, 2020 certain
information concerning his or her compensation for the year ended December 31, 2020 and the December 2018 transition period:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Year
Ended December 31, 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Name</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Fees</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Earned</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>or</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Paid
                                         in</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Cash</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>($)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Awards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>($)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Awards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>($)
                                         <sup>(1)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Non-equity</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Incentive
                                         Plan</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>($)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Nonqualified</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Deferred</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Earnings</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>($)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>All
                                         Other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>($)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>($)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Guy
    Yachin</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">52,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">45,462
    <sup>(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">97,962</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Yaron
    Adler</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">46,250</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">45,306
    <sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">91,556</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Dr.
    David Sidransky</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">75,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">45,518
    </span><span style="font: 10pt Times New Roman, Times, Serif"><sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">120,518</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Ashish
    Nanda</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">52,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">45,257
    <sup>(5)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">97,757</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Mario
    Philips</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">37,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">27,514
    <sup>(6)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">65,014</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
    accordance with SEC rules, the amounts in this column reflect the fair value on the grant date of the option awards granted
    to the named executive, calculated in accordance with ASC Topic 718.&#160;&#160;Stock options were valued using the Black-Scholes
    model.&#160;&#160;The grant-date fair value does not necessarily reflect the value of shares which may be received in the
    future with respect to these awards.&#160;&#160;The grant-date fair value of the stock options in this column is a non-cash
    expense for the Company that reflects the fair value of the stock options on the grant date and therefore does not affect
    our cash balance.&#160;&#160;The fair value of the stock options will likely vary from the actual value the holder receives
    because the actual value depends on the number of options exercised and the market price of our common stock on the date of
    exercise.&#160;&#160;For a discussion of the assumptions made in the valuation of the stock options, see Note 15 (Stock Based
    Compensation) to our financial statements, which are included in this Annual Report on Form 10-K.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Aggregate
                                         number of option awards outstanding as of December 31, 2020 was 150,934 of which (i)
                                         122,184 options are exercisable as of December 31, 2020, (ii) 12,500 options are exercisable
                                         on April 1, 2021 and (iii) 16,250 options are exercisable on December 17, 2021. Does
                                         not include $192 thousand related to options held by Caerus Therapeutics LLC over which
                                         Mr. Yachin does not have beneficial control.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Aggregate
                                         number of option awards outstanding as of December 31, 2020 was 169,325 of which (i)
                                         141,825 options are exercisable as of December 31, 2020, (ii) 12,500 options are exercisable
                                         as of April 1, 2021 and (iii) 15,000 options are exercisable on December 17, 2021.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(4)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Aggregate
                                         number of option awards outstanding as of December 31, 2020 was 133,401 of which (i)
                                         104,201 options are exercisable as of December 31, 2020, (ii) 12,500 options are exercisable
                                         on April 1, 2021 and (iii) 16,700 options are exercisable on December 17, 2021.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(5)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Aggregate
    number of option awards outstanding as of December 31, 2020 was 66,700 of which (i) 39,600 options are exercisable as of December
    31, 2020, (ii) 12,500 options are exercisable on April 1, 2021 and (ii) 14,600 options are exercisable on December 17, 2021.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(6)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Aggregate
    number of option awards outstanding as of December 31, 2020 was 32,500 of which (i) 2,083 options are exercisable on
    January 9, 2021 (ii) 12,500 options are exercisable on April 1, 2021 (iii) 13,750 options are exercisable on December 17,
    2021 (iv) 2,084 options are exercisable on January 9, 2022 and (v) 2,084 options are exercisable on January
    9, 2023.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">All
directors receive reimbursement for reasonable out of pocket expenses in attending Board of Directors meetings and for participating
in our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Compensation
Policy for Non-Employee Directors.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2018, the Board of Directors adopted a compensation policy for non-employee directors which replaced the non-employee
director compensation terms discussed above. By its terms, the policy became effective November 2018. Under the adopted policy,
each director is to receive an annual cash compensation of $30,000 and the Chairman and Vice Chairman is paid an additional $15,000
per annum. Each committee member will be paid an additional $7,500 per annum and each committee chairman is to receive $15,000
per annum. Cash compensation will be made on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">All
newly appointed directors also receive options to purchase up to 6,250 shares of the Company&#8217;s common stock. All directors
are entitled on an annual bonus of options for 12,500 shares and each committee member is entitled to a further option to purchase
up to 1,250 shares of common stock and each committee chairperson to options for an additional 2,100 shares of common stock. In
addition, the Chairman and Vice Chairman shall be granted an option to purchase 4,200 shares of the Company&#8217;s ordinary shares.
In all cases, the options are granted at a per share exercise price equal to the closing price of the Company&#8217;s publicly
traded stock on the date of grant and the vesting schedule is determined by the compensation committee at the time of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<!-- Field: Page; Sequence: 72; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Compensation
Committee Interlocks and Insider Participation </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">None
of our executive officers has served as a member of the Board of Directors, or as a member of the compensation or similar committee,
of any entity that has one or more executive officers who served on our Board of Directors or Compensation Committee during the
fiscal year ended December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_020"></span>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth certain information with respect to the beneficial ownership of our common stock as of March 9, 2021
for (a) the named executive officers, (b) each of our directors, (c) all of our current directors and executive officers as a
group and (d) each stockholder known by us to own beneficially more than 5% of our common stock. Beneficial ownership is determined
in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. We deem shares
of common stock that may be acquired by an individual or group within 60 days of March 9, 2021 pursuant to the exercise of options
or warrants to be outstanding for the purpose of computing the percentage ownership of such individual or group but are not deemed
to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table. Except as indicated
in footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power with respect
to all shares of common stock shown to be beneficially owned by them based on information provided to us by these stockholders.
Percentage of ownership is based on 24,199,674 shares of common stock outstanding on March 9, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Security
Ownership of Greater than 5% Beneficial Owners</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name
                                         and Address of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Beneficial
                                         Owner</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Amount
                                         and Nature of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Beneficial
                                         Ownership <sup>(1)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><sup>&#160;</sup></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Percent<sup>(1)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: center">Image Securities fzc. <br />2310, 23rd floor, Tiffany <br />Towers, JLT <br />Dubai,
    UAE</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">3,126,434</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><sup>(2)</sup></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">12.92</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Yehuda Nir<br /> c/o Orgenesis Inc. <br />20271 Goldenrod Lane <br />Germantown, MD 20876</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,175,152</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(3)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8.99</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Gakasa Holding, LLC <br />c/o Knoll Capital Management <br />5 East 44th Street <br />New York, NY
    10017</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,316,364</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(4)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5.44</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Security
Ownership of Directors and Executive Officers</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name
                                         and Address of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Beneficial
                                         Owner</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Amount
                                         and Nature of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Beneficial
                                         Ownership <sup>(1)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><sup>&#160;</sup></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Percent<sup>(1)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: center">Vered Caplan <br />c/o Orgenesis Inc. <br />20271 Goldenrod Lane <br />Germantown, MD
    20876</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,104,006</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><sup>(5)</sup></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">4.56</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Neil Reithinger <br />14201 N. Hayden Road, Suite A-1 <br />Scottsdale, AZ 85260</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">112,709</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(6)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&lt;1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Guy Yachin <br />c/o Orgenesis Inc. <br />20271 Goldenrod Lane <br />Germantown, MD 20876</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">134,684</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(7)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&lt;1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Dr. David Sidransky <br />c/o Orgenesis Inc. <br />20271 Goldenrod Lane <br />Germantown, MD 20876</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">116,701</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(8)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&lt;1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Yaron Adler <br />c/o Orgenesis Inc. <br />20271 Goldenrod Lane <br />Germantown, MD 20876</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">217,629</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(9)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&lt;1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Ashish Nanda <br />c/o Orgenesis Inc. <br />20271 Goldenrod Lane <br />Germantown, MD 20876</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">52,100</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(10)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&lt;1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Mario Philips <br />c/o Orgenesis Inc. <br />20271 Goldenrod Lane <br />Germantown, MD 20876</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,583</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(11)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&lt;1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Directors &amp; Executive Officers as a Group (7 persons)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,752,412</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>&#160;</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7.24</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Notes:</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Percentage
    of ownership is based on 24,167,784 shares of our common stock outstanding as of March 9, 2021.&#160;&#160;Except as otherwise
    indicated, we believe that the beneficial owners of the common stock listed above, based on information furnished by such
    owners, have sole investment and voting power with respect to such shares, subject to community property laws where applicable.&#160;&#160;Beneficial
    ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect
    to securities.&#160;&#160;Shares of common stock subject to options or warrants currently exercisable or exercisable within
    60 days, are deemed outstanding for purposes of computing the percentage ownership of the person holding such option or warrants
    but are not deemed outstanding for purposes of computing the percentage ownership of any other person.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Consists
    of (i) 1,494,217 <span style="background-color: white">ordinary shares and (ii)</span> 1,832,538 <span style="background-color: white">ordinary
    shares issuable upon exercise of outstanding warrants at a price of </span>$6.24 per share. The warrants are exercisable over
    a three-year period from the date of issuance.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Consists
    of (i) 309,464 <span style="background-color: white">ordinary shares issuable upon exercise of outstanding warrants at a price
    of </span>$6.24 per share, exercisable until June 30, 2021, (ii) 153,846 <span style="background-color: white">ordinary shares
    issuable upon exercise of outstanding warrants at a price of </span>$6.24 per share, exercisable until June 9, 2021, (iii)
    50,000 <span style="background-color: white">ordinary shares issuable upon exercise of outstanding warrants at a price of
    </span>$7.00 per share, exercisable until October 3, 2022, and (iv) 1,661,842 <span style="background-color: white">ordinary
    shares issuable upon exercise of convertible debt at a price of </span>$7.00 <span style="background-color: white">per share.</span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(4)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Consists
    of 1,316,364 <span style="background-color: white">ordinary share</span>s.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(5)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0">Consists of (i) 278,191
                                         <span style="background-color: white">ordinary shares issuable upon exercise of outstanding
                                         options at a price of </span>$0.012 <span style="background-color: white">per share,
                                         </span>(<span style="background-color: white">ii</span>) 230,189 <span style="background-color: white">ordinary
                                         shares issuable upon exercise of outstanding options at a price of </span>$0.0012 <span style="background-color: white">per
                                         share, (iii) </span>166,667 <span style="background-color: white">ordinary shares issuable
                                         upon exercise of outstanding options at a price of </span>$4.80 <span style="background-color: white">per
                                         share, </span>(iv) 83,334 <span style="background-color: white">ordinary shares issuable
                                         upon exercise of outstanding options at a price of </span>$7.20 per share, (vi) 250,000
                                         <span style="background-color: white">ordinary shares issuable upon exercise of outstanding
                                         options at a price of </span>$8.36 <span style="background-color: white">per share </span>and
                                         (v) 53,125 <span style="background-color: white">ordinary shares issuable upon exercise
                                         of outstanding options at a price of </span>$5.99 <span style="background-color: white">per
                                         share and(vii) 42,500 ordinary shares issuable upon exercise of outstanding options at
                                         a price of $2.99 per share. </span>Does not include (i) options for 31,875 shares of
                                         common stock with an exercise price of $5.99 per share <span style="background-color: white">that
                                         are exercisable quarterly after April 22, 2021 and (ii) option for 42,500 shares of common
                                         stock with an exercise price of $2.99 per share that are exercisable quarterly after
                                         March 31, 2021.</span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(6)</sup></span></td>
    <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Consists
                                         of (i) 83,334 <span style="background-color: white">ordinary shares issuable upon exercise
                                         of outstanding options at a price of </span>$4.80 <span style="background-color: white">per
                                         share a</span>nd (ii) 21,875 <span style="background-color: white">ordinary shares
                                         issuable upon exercise of outstanding options at a price of </span>$5.07 <span style="background-color: white">per
                                         share (iii) 7,500 ordinary shares issuable upon exercise of outstanding options
                                         at a price of $2.99 per share.</span> Does not include (i) options for 3,125 shares
                                         of common stock with an exercise price of $5.07 per share <span style="background-color: white">that
                                         are exercisable quarterly after April 1, 2021 and (ii) option for 7,500
                                         shares of common stock with an exercise price of $2.99 per share that are exercisable
                                         quarterly after March 31, 2021.</span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(7)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Consists
                                         of (i) 39,267 <span style="background-color: white">ordinary shares issuable upon
                                         exercise of outstanding options at a price of </span>$10.2 per share and (ii) 41,667
                                         <span style="background-color: white">ordinary shares issuable upon exercise of outstanding
                                         options at a price of </span>$4.80 per share and (iii) 28,750 <span style="background-color: white">ordinary
                                         shares issuable upon exercise of outstanding options at a price of </span>$5.99
                                         per share and (iv) 25,000 ordinary shares issuable upon exercise of
                                         outstanding options at a price of $2.99 per share. Does not include options exercisable
                                         at a price per share of $7.00 into 70,000 ordinary shares held by Caerus Therapeutics
                                         LLC for which Mr. Yachin does not have beneficial control.</p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(8)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Consists
                                         of (i) 20,834 <span style="background-color: white">ordinary shares issuable upon
                                         exercise of outstanding options at a price of </span>$9 per share and (ii) 41,667
                                         <span style="background-color: white">ordinary shares issuable upon exercise of outstanding
                                         options at a price of </span>$4.80 per share and (iii) 29,200 <span style="background-color: white">ordinary
                                         shares issuable upon exercise of outstanding options at a price of </span>$5.99 per share
                                         and (iv) 25,000 ordinary shares issuable upon exercise of outstanding options at a price
                                         of $2.99 per share.</p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(9)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Consists
                                         of (i) 63,304 <span style="background-color: white">ordinary shares,</span> (ii) 58,908
                                         <span style="background-color: white">ordinary shares issuable upon exercise of outstanding
                                         options at a price of </span>$9.48 per share and (iii) 41,667 <span style="background-color: white">ordinary
                                         shares issuable upon exercise of outstanding options at a price of </span>$4.80 per share
                                         and (iv) 28,750 <span style="background-color: white">ordinary shares issuable
                                         upon exercise of outstanding options at a price of </span>$5.99 per share and (iiv)
                                         25,000 ordinary shares issuable upon exercise of outstanding options at a price of
                                         $2.99 per share.</p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(10)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0">Consists of (i) 27,100
                                         ordinary shares issuable upon exercise of outstanding options at a price of $5.99 per
                                         share and (ii) 25,000 ordinary shares issuable upon exercise of outstanding options
                                         at a price of $2.99 per share.</p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(11)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Consists
    of (i) 2,083 ordinary shares issuable upon exercise of outstanding options at a price of $4.7 per share and (ii) 12,500 ordinary
    shares issuable upon exercise of outstanding options at a price of $2.99 per share. Does not include options for 4,167 shares
    of common stock with an exercise price of $4.70 per share that are exercisable in three equal instalments over three anniversaries
    <span style="background-color: white">starting on January 9, 2022.</span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Securities
Authorized for Issuance Under Existing Equity Compensation Plans</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes certain information regarding our equity compensation plans as of December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Plan Category</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number
                                         of Securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>to
                             be Issued Upon</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise
                                         of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding
                                         Options</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted-Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise
                                         Price of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding
                                         Options</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number
                                         of Securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Remaining
                                         Available for</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Future
                                         Issuance Under</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Equity
                                         Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Plans
                                         (Excluding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Securities
                                         Reflected in</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Column
                                         (a))</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(a)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(b)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(c)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Equity
    compensation plans approved by security holders <sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">2,503,002</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">4.64</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">1,496,998</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Equity compensation plans not approved by security holders</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">963,806</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3.55</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">141,668</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Total</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,466,808</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.34</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,638,666</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Consists
                                         of the 2017 Equity Incentive Plan and the Global Share Incentive Plan (2012). For a short
                                         description of those plans, see Note 15 to our 2020 Consolidated Financial Statements
                                         included in this Annual Report on Form 10-K for the year ended December 31, 2020.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_021"></span>ITEM
13. CERTAIN RELATIONSHIPS<span style="font-weight: normal">&#160;</span> AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Transactions
with Related Persons</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Except
as set out below, as of December 31, 2020, there have been no transactions, or currently proposed transactions, in which we were
or are to be a participant and the amount involved exceeds the lesser of $120,000 or one percent of the average of our total assets
at year-end for the last two completed fiscal years, and in which any of the following persons had or will have a direct or indirect
material interest:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">any
                                         director or executive officer of our company;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">any
                                         person who beneficially owns, directly or indirectly, shares carrying more than 5% of
                                         the voting rights attached to our outstanding shares of common stock;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">any
                                         promoters and control persons; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">any
                                         member of the immediate family (including spouse, parents, children, siblings and in
                                         laws) of any of the foregoing persons.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
September 15, 2014, the Company received a loan in the principal amount of $100,000 from Yaron Adler Investments (1999) Ltd.,
an entity of which Mr. Yaron Adler, one of the Company&#8217;s non-employee director, is the sole shareholder. The loan, with
an original interest rate of 6% per annum, was repayable on or before March 15, 2015. The Loan currently bears a default interest
rate of 24% per annum and, as of November 30, 2017, the outstanding balance on the note was $166,581. The loan was converted into
our common stock in 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
January 2017, the Company entered into definitive agreements with Image Securities fzc. (&#8220;Image&#8221;) for the private
placement of 2,564,115 units of the Company&#8217;s securities for aggregate subscription proceeds to the Company of $16 million
at $6.24 price per unit. In July 2018, the Company entered into definitive agreements with assignees of Image whereby these assignees
remitted $4.6 million in respect of the units available under the original subscription agreement that have not been subscribed
for, entitling such investors to 702,307 units, with each unit being comprised of (i) one share of the Company&#8217;s common
stock and (ii) one three-year warrant to purchase up to an additional one share of the Company&#8217;s common stock at a per share
exercise price of $6.24.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2018, the Company entered into definitive agreements with assignees of Image whereby these assignees remitted $4.6 million
in respect of the units available under the original subscription agreement that have not been subscribed for, entitling such
investors to 702,307 units, with each unit being comprised of (i) one share of the Company&#8217;s common stock and (ii) one three-year
warrant to purchase up to an additional one share of the Company&#8217;s common stock at a per share exercise price of $6.24.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
2018, the Company raised $6.9 million from Image entitling it to 1,111,380 shares of Common Stock and three-year warrants for
an additional 1,111,380 shares of the Company&#8217;s Common Stock at a per share exercise price of $6.24. Following this remittance
and those referred to in the previous paragraph, the Company received a total of $16 million out of the committed $16 million
subscription proceeds under such agreement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to an agreement entered into between the Company and Image, <span style="background-color: white">so long as Image&#8217;s ownership
of the company is 10% or greater, it </span>is entitled to nominate a director to the Company&#8217;s Board of Directors. Mr.
Nanda was nominated for a directorship at the 2018 annual meeting in compliance with our contractual undertakings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to our Audit Committee charter adopted in March 2017, the Audit Committee is responsible for reviewing and approving, prior to
our entry into any such transaction, all transactions in which we are a participant and in which any parties related to us have
or will have a direct or indirect material interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Pursuant to
agreements with Image, the Company procured services from Image in the amount of $4.8 million during the year ended December 31,
2020, and earned revenues from Image in the amount of $1.5 million and $1.3 million for the years ended December 31, 2020
and December 31, 2019, respectively. In addition, the company earned interest income in the amount of $169 thousand
and $112 thousand for the years ended December 31, 2020 and December 31, 2019, respectively.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Named
Executive Officers and Current Directors</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
information regarding compensation for our named executive officers and current directors, see &#8220;Executive Compensation.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Director
Independence</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">See
&#8220;Directors, Executive Officers and Corporate Governance &#8211; Director Independence&#8221; and &#8220;Directors, Executive
Officers and Corporate Governance &#8211; Board Committees&#8221; in Item 10 above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_022"></span>ITEM
14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">The
Board <span style="letter-spacing: -0.35pt">of Directors of the Company </span>has appointed Kesselman &amp; Kesselman, a member
firm of PricewaterhouseCoopers International Limited (&#8220;PwC&#8221;) as our independent registered public accounting firm
(the &#8220;Independent Auditor&#8221;) for the fiscal year end<span style="letter-spacing: -0.4pt">ed</span> December 31, 2020.
The following table sets forth the fees billed to the Company for professional services rendered by PwC for the years ended December
31, 2020 and December 31, 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Services:</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2019</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Audit Fees (1)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">267,231</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">426,040</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Audit-Related Fees (2)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">67,405</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">26,900</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Tax Fees (3)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">18,300</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">All Other Fees</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">49,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total fees</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">357,136</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">520,740</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Audit
                                         fees consisted of audit work performed in the preparation of financial statements, as
                                         well as work generally only the independent registered public accounting firm can reasonably
                                         be expected to provide, such as statutory audits.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Audit
                                         related fees consisted principally of audits of employee benefit plans and special procedures
                                         related to regulatory filings in 2020.</span></td></tr>                                                                                                <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
                                         tax fees were paid for reviewing various tax related matters.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Policy
on Audit Committee Pre-Approval of Audit and Permissible Non-audit Services of Independent Public Accountant</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Consistent
with SEC policies regarding auditor independence, the Audit Committee has responsibility for appointing, setting compensation
and overseeing the work of our independent registered public accounting firm. In recognition of this responsibility, the Audit
Committee has established a policy to pre-approve all audit and permissible non-audit services provided by our independent registered
public accounting firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Prior
to engagement of an independent registered public accounting firm for the next year&#8217;s audit, management will submit an aggregate
of services expected to be rendered during that year for each of four categories of services to the Audit Committee for approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">1.
<b><i>Audit </i></b>services include audit work performed in the preparation of financial statements, as well as work that generally
only an independent registered public accounting firm can reasonably be expected to provide, including comfort letters, statutory
audits, and attest services and consultation regarding financial accounting and/or reporting standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">2.
<b><i>Audit-Related </i></b>services are for assurance and related services that are traditionally performed by an independent
registered public accounting firm, including due diligence related to mergers and acquisitions, employee benefit plan audits,
and special procedures required to meet certain regulatory requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">3.
<b><i>Tax </i></b>services include all services performed by an independent registered public accounting firm&#8217;s tax personnel
except those services specifically related to the audit of the financial statements, and includes fees in the areas of tax compliance,
tax planning, and tax advice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">4.
<b><i>Other Fees</i></b> are those associated with services not captured in the other categories. The Company generally does not
request such services from our independent registered public accounting firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Prior
to engagement, the Audit Committee pre-approves these services by category of service. The fees are budgeted and the Audit Committee
requires our independent registered public accounting firm and management to report actual fees versus the budget periodically
throughout the year by category of service. During the year, circumstances may arise when it may become necessary to engage our
independent registered public accounting firm for additional services not contemplated in the original pre-approval. In those
instances, the Audit Committee requires specific pre-approval before engaging our independent registered public accounting firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Audit Committee may delegate pre-approval authority to one or more of its members. The member to whom such authority is delegated
must report, for informational purposes only, any pre-approval decisions to the Audit Committee at its next scheduled meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_023"></span>PART
IV</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_024"></span>ITEM
15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">c.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Financial
                                         Statements</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
consolidated financial statements are set forth in Part II, Item 8 of this Annual Report on Form 10-K and are incorporated herein
by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">d.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Financial
                                         Statement Schedules</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">No
financial statement schedules have been filed as part of this Annual Report on Form 10-K because they are not applicable or are
not required or because the information is otherwise included herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 78; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">e.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Exhibits
                                         required by Regulation S-K</span></td></tr></table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299320000415/exhibit2-1.htm" style="-sec-extract: exhibit">Stock Purchase Agreement, dated February 2, 2020, by and among Orgenesis, Inc., GPP-II Masthercell LLC, Masthercell Global Inc. and Catalent Pharma Solutions, Inc.(incorporated by reference to Exhibit 2.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on February 3, 2020).</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000149315220018712/ex2-1.htm" style="-sec-extract: exhibit">Agreement and Plan of Merger and Reorganization, dated as of September 26, 2020 by and among Orgenesis Inc., Orgenesis Merger Sub, Inc., Koligo Therapeutics Inc., the Shareholders of Koligo and Long Hill Capital V, LLC, solely in its capacity as representative of the Shareholders (incorporated by reference to an exhibit to our current report on Form 8-K, filed on October 2, 2020)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000149315220014941/ex4-2.htm" style="-sec-extract: exhibit">Articles of Incorporation, as amended (incorporated by reference to an exhibit to our registration statement on Form S-8, filed on August 7, 2020)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000116552711000890/ex3-2.txt" style="-sec-extract: exhibit">Amended and Restated Bylaws (incorporated by reference to an exhibit to our current report on Form 8-K, filed on September 21, 2011)</a></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299320001299/exhibit4-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Description of Securities (incorporated by reference to an exhibit to our annual report on Form 10-K filed on March 9, 2020)</span></a></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299320000263/exhibit4-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Form of Warrant (incorporated by reference to an exhibit to our current report on Form 8-K, filed on January 22, 2020)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000149315220014941/ex4-4.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Form of Stock Option Agreement (incorporated by reference to an exhibit to our current report on Form S-8, filed on August 7, 2020)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299313006362/exhibit10-2.htm" style="-sec-extract: exhibit">Convertible Loan Agreement, dated December 6, 2013, with Mediapark A.G. (incorporated by reference to an exhibit to our current report on Form 8-K, filed on December 16, 2013)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299313006362/exhibit10-3.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Investment
Agreement, dated December 13, 2013, with Kodiak Capital Group, LLC (incorporated by reference to an exhibit to our current report
on Form 8-K, filed on December 16, 2013)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299313006362/exhibit10-4.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Registration Rights Agreement, dated December 13, 2013, with Kodiak Capital Group, LLC (incorporated by reference to an exhibit to our current report on Form 8-K, filed on December 16, 2013)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299314001108/exhibit10-1.htm" style="-sec-extract: exhibit">Form of subscription agreement (incorporated by reference to an exhibit to our current report on Form 8-K, filed on March 4, 2014)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299314001108/exhibit10-2.htm" style="-sec-extract: exhibit">Form of warrant (incorporated by reference to an exhibit to our current report on Form 8-K, filed on March 4, 2014)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299314001990/exhibit10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Consulting Agreement, dated April 3, 2014, with Aspen Agency Limited (incorporated by reference to an exhibit to our current report on Form 8-K, filed on April 7, 2014)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299314001990/exhibit10-2.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Stock Option Agreement, dated April 3, 2014, with Aspen Agency Limited (incorporated by reference to an exhibit to our current report on Form 8-K, filed on April 7, 2014)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299314002376/exhibit10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Form of subscription agreement with form of warrant (incorporated by reference to an exhibit to our current report on Form 8-K, filed on April 28, 2014)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299314003459/exhibit10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Convertible Loan Agreement, dated May 29, 2014, with Nine Investments Limited (incorporated by reference to an exhibit to our current report on Form 8-K, filed on May 30, 2014)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299314004051/exhibit10-1.htm" style="-sec-extract: exhibit">Service Agreement between Orgenesis SPRL and MaSTherCell S.A., dated July 3, 2014 (incorporated by reference to an exhibit to our current report on Form 8-K, filed on July 7, 2014)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299314004537/exhibit10-1.htm" style="-sec-extract: exhibit">Financial Consulting Agreement, dated August 1, 2014, with Eventus Consulting, P.C. (incorporated by reference to an exhibit to our current report on Form 8-K, filed on August 5, 2014)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299314004537/exhibit10-2.htm" style="-sec-extract: exhibit">Personal Employment Agreement, dated August 1, 2014, by and between Orgenesis Inc. and Neil Reithinger (incorporated by reference to an exhibit to our current report on Form 8-K, filed on August 5, 2014)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299317003366/exhibit10-1.htm" style="-sec-extract: exhibit">Executive Employment Agreement, dated March 30, 2017, between Orgenesis Inc. and Vered Caplan (incorporated by reference to an exhibit to our quarterly report on Form 10-Q, filed on July 24, 2017)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299317003366/exhibit10-2.htm" style="-sec-extract: exhibit">Amendment No. 1, dated May 10, 2017, to Executive Employment Agreement, dated as of March 30, 2017, between Orgenesis Inc. and Vered Caplan (incorporated by reference to an exhibit to our quarterly report on Form 10-Q, filed on July 24, 2017)</a></span></td></tr>
</table>
<p style="margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description</b></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299314006399/exhibit10-1.htm" style="-sec-extract: exhibit">Share Exchange Agreement, dated November 3, 2014, by and between Orgenesis Inc. and MaSTherCell S.A. and Cell Therapy Holding SA (collectively &#8220;MaSTherCell&#8221;) and each of the shareholders of MaSTherCell (incorporated by reference to an exhibit to our current report on Form 8-K, filed on November 10, 2014)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299315001187/exhibit10-1.htm" style="-sec-extract: exhibit">Addendum No. 1, dated March 2, 2015, to Share Exchange Agreement, dated November 3, 2014, by and between Orgenesis Inc., MaSTherCell, and each of the shareholders of MaSTherCell (incorporated by reference to an exhibit to our current report on Form 8-K, filed on March 5, 2015)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299315001187/exhibit10-2.htm" style="-sec-extract: exhibit">Escrow Agreement, dated February 27, 2015, by and between Orgenesis Inc., the shareholders of MaSTherCell S.A. and Cell Therapy Holding SA, the bondholders of MaSTherCell S.A. and Securities Transfer Corporation (incorporated by reference to an exhibit to our current report on Form 8-K, filed on March 5, 2015)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299315001366/exhibit10-1.htm" style="-sec-extract: exhibit">Orgenesis Inc. Board of Advisors Consulting Agreement, dated March 16, 2015 (incorporated by reference to an exhibit to our current report on Form 8-K, filed on March 17, 2015)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299315006113/exhibit10-1.htm" style="-sec-extract: exhibit">Addendum No. 2, dated November 12, 2015, to Share Exchange Agreement, dated November 3, 2014, by and between Orgenesis Inc., MaSTherCell, and each of the shareholders of MaSTherCell (incorporated by reference to an exhibit our current report on Form 8-K, filed on November 13, 2015)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299317001138/exhibit10-25.htm" style="-sec-extract: exhibit">Joint Venture Agreement, dated March 14, 2016, by and between Orgenesis Inc. and CureCell Co., Ltd. (incorporated by reference to an exhibit to our annual report on Form 10-K, filed on February 28, 2017)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299317001962/exhibit10-1.htm" style="-sec-extract: exhibit">Joint Venture Agreement, dated May 10, 2016, by and between Orgenesis Inc. and Atvio Biotech Ltd. (incorporated by reference to an exhibit to our quarterly report on Form 10-Q, filed on April 19, 2017)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299317001962/exhibit10-2.htm" style="-sec-extract: exhibit">Private Placement Subscription Agreement, dated January 26, 2017, between Orgenesis Inc. and Image Securities FZC (incorporated by reference to an exhibit to our quarterly report on Form 10-Q, filed on April 19, 2017)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299317001962/exhibit10-3.htm" style="-sec-extract: exhibit">Amendment No. 1, dated February 9, 2017, to the Private Placement Subscription Agreement, dated January 26, 2017, between Orgenesis Inc. and Image Securities FZC (incorporated by reference to an exhibit to our quarterly report on Form 10-Q, filed on April 19, 2017)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; padding-right: 2.25pt; padding-left: 2.25pt"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299317001570/scheddef14a.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">2017 Equity Incentive Plan (incorporated by reference to an exhibit to our definitive proxy statement on Schedule 14A, filed on March 30, 2017)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.25</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299318004065/exhibit10-1.htm" style="-sec-extract: exhibit">Collaboration and License Agreement, dated as of June 8, 2018, between Orgenesis Inc. and Mircod Limited (incorporated by reference to an exhibit to our quarterly report on Form 10-Q, filed on October 12, 2018)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.26</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299318004773/exhibit10-1.htm" style="-sec-extract: exhibit">Private Placement Subscription Agreement, dated November 13, 2018, between Orgenesis Inc. and Avner Sonnino (incorporated by reference to an exhibit to our current report on Form 8-K, filed on November 20, 2018)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299318004773/exhibit10-2.htm" style="-sec-extract: exhibit">Private Placement Subscription Agreement, dated November 21, 2018, between Orgenesis Inc. and an accredited investor (incorporated by reference to an exhibit to our current report on Form 8-K, filed on November 28, 2018)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.28</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299318004930/exhibit10-1.htm" style="-sec-extract: exhibit">Private Placement Subscription Agreement, dated November 30, 2018, between Orgenesis Inc. and an accredited investor (incorporated by reference to an exhibit to our current report on Form 8-K, filed on December 6, 2018)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.29</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299318005056/exhibit10-1.htm" style="-sec-extract: exhibit">Private Placement Subscription Agreement, dated December 10, 2018, between Orgenesis Inc. and an accredited investor (incorporated by reference to an exhibit to our current report on Form 8-K, filed on December 14, 2018)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.30</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299318005125/exhibit10-1.htm" style="-sec-extract: exhibit">Controlled Equity Offering Sales Agreement, dated December 20, 2018, between Orgenesis Inc. and Cantor Fitzgerald &amp; Co. (incorporated by reference to an exhibit to our current report on Form 8-K, filed on December 20, 2018)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.31</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299319002066/exhibit10-1.htm" style="-sec-extract: exhibit">Joint Venture Agreement between the Company and First Choice International Company, Inc. dated March 12, 2019 (incorporated by reference to an exhibit to our quarterly report on Form 10-Q, filed on May 8, 2019)</a></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description</b></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.32</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299319002066/exhibit10-2.htm" style="-sec-extract: exhibit">Convertible Loan Agreement between Orgenesis Maryland Inc. and Yosef Ram dated April 12, 2019 (incorporated by reference to an exhibit to our quarterly report on Form 10-Q, filed on May 8, 2019)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.33</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299319002066/exhibit10-3.htm" style="-sec-extract: exhibit">Joint Venture Agreement between the Company and KinerjaPay Corp. dated May 6, 2019&#160;&#160;(incorporated by reference to an exhibit to our quarterly report on Form 10-Q, filed on May 8, 2019)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.34</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299319004217/exhibit10-1.htm" style="-sec-extract: exhibit">Convertible Loan Agreement, dated April 10, 2019, by and between the Company and Investor (incorporated by reference to an exhibit to our quarterly report on form 10-Q, filed on November 7, 2019)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.35</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299319004217/exhibit10-2.htm" style="-sec-extract: exhibit">Form of Subscription Agreement, dated May 17, 2019, by and between the Company and Investor (incorporated by reference to an exhibit to our quarterly report on form 10-Q, filed on November 7, 2019)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.36</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299319004217/exhibit10-3.htm" style="-sec-extract: exhibit">Form of Subscription Agreement, dated May 30, 2019, by and between the Company and Investor (incorporated by reference to an exhibit to our quarterly report on form 10-Q, filed on November 7, 2019)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.37</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299319004217/exhibit10-4.htm" style="-sec-extract: exhibit">Form of Subscription Agreement, dated June 6, 2019, by and between the Company and Investor (incorporated by reference to an exhibit to our quarterly report on Form 10-Q, filed on November 7, 2019)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.38</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299319003348/exhibit10-1.htm" style="-sec-extract: exhibit">Transfer Agreement, dated as of August 7, 2019 by and among Masthercell Global, Orgenesis Inc. and GPP-II Masthercell, LLC (incorporated by reference to our current report on Form 8-K, filed on August 13, 2019)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.39</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299317001570/scheddef14a.htm" style="-sec-extract: exhibit">2017 Equity Incentive Plan (incorporated by reference to an exhibit to our definitive proxy statement on Schedule 14A, filed on March 30, 2017)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.40</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299320000263/exhibit10-1.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated January 20, 2020, by and among the Company and the Investors (incorporated by reference to an exhibit to our current report on Form 8-K, filed on January 22, 2020)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.41</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299320000263/exhibit10-2.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated January 20, 2020, by and among the Company and the Investors (incorporated by reference to an exhibit to our current report on Form 8-K, filed on January 22, 2020)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.42</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299320001770/exhibit10-1.htm" style="-sec-extract: exhibit">Asset Purchase Agreement by and between Orgenesis Inc. and Tamir Biotechnology, Inc, dated April 12, 2020 (incorporated by reference to an exhibit to our current report on Form 8-K, filed on April 13, 2020)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.43</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000149315220018712/ex10-1.htm" style="-sec-extract: exhibit">Form of Registration Rights and Lock-Up Agreement between the Company, Long Hill Capital V, LLC and Maxim Group, LLC (incorporated by reference to an exhibit to our current report on Form 8-K, filed on October 1, 2020)</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.44</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000149315220018712/ex10-2.htm" style="-sec-extract: exhibit">Form of Shareholders Lock-Up Agreement between the Company and Shareholders other than Long Hill Capital V, LLC (incorporated by reference to an exhibit to our current report on Form 8-K, filed on October 1, 2020)</a></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.45*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex10-45.htm"><span style="font: 10pt Times New Roman, Times, Serif">Executive Directorship Agreement between the Company and Vered Caplan dated November 19, 2020</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">10.46*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex10-46.htm"><span style="font: 10pt Times New Roman, Times, Serif">Swiss Employment Agreement between the Company and Vered Caplan dated November 19, 2020</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">21.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex21-1.htm">List of Subsidiaries of Orgenesis Inc.</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex23-1.htm">Consent of independent registered public accounting firm</a></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex31-1.htm">Certification Statement of the Chief Executive Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex31-2.htm">Certification Statement of the Chief Financial Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">32.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex32-1.htm">Certification Statement of the Chief Executive Officer pursuant to Section 906 of the Sarbanes Oxley Act of 2002</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">32.2**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex32-2.htm">Certification Statement of the Chief Financial Officer pursuant to Section 906 of the Sarbanes Oxley Act of 2002</a></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299312001978/exhibit99-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Global Share Incentive Plan (2012) (incorporated by reference to an exhibit to our current report on Form 8-K, filed on May 31, 2012)</span></a></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">99.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1460602/000106299312001978/exhibit99-2.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Appendix &#8211; Israeli Taxpayers Global Share Incentive Plan (2012) (incorporated by reference to an exhibit to our current report on Form 8-K, filed on May 31, 2012)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">101.INS*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Instance Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">101.SCH*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Schema Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">101.CAL*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Calculation Linkbase Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">101.DEF*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Definition Linkbase Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">101.LAB*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Label Linkbase Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">101.PRE*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Presentation Linkbase Document</span></td></tr>
</table>
<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">*Filed
herewith</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">**Furnished
herewith</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_025"></span>ITEM
16. FORM 10-K SUMMARY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 81; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_026"></span>SIGNATURES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>ORGENESIS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Vered Caplan</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Vered
    Caplan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Chief
    Executive Officer and Chairperson of the Board of Directors (Principal Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Date:&#160;&#160;March
    9, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Neil Reithinger</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Neil
    Reithinger</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Chief
                                         Financial Officer, Treasurer and Secretary</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">(Principal
        Financial and Accounting Officer)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Date:&#160;&#160;March
    9, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Vered Caplan</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Vered
    Caplan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Chief
    Executive Officer and Chairperson of the Board of Directors (Principal Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Date:&#160;&#160;March
    9, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Neil Reithinger</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Neil
    Reithinger</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Chief
    Financial Officer, Treasurer and Secretary (Principal Financial and Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Date:&#160;&#160;March
    9, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Guy Yachin</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Guy
    Yachin</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Date:&#160;&#160;March
    9, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    David Sidransky</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">David
    Sidransky</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Date:&#160;&#160;March
    9, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Yaron Adler</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Yaron
    Adler</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Date:&#160;&#160;March
    9, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font: 10pt Times New Roman, Times, Serif">/<i>s/
    Ashish Nanda</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Ashish
    Nanda</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Date:&#160;&#160;March
    9, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font: 10pt Times New Roman, Times, Serif">/<i>s/
    Mario Philips</i></span></td>
    <td style="width: 50%">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Mario
    Philips</span></td>
    <td>&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td>&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Date:&#160;&#160;March
    9, 2021</span></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 82; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_027"></span>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ORGENESIS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CONSOLIDATED
FINANCIAL STATEMENTS AS OF DECEMBER 31, 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">TABLE
OF CONTENTS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Page</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_028">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">F-2</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">CONSOLIDATED FINANCIAL STATEMENTS:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_029">Consolidated Balance Sheets</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">F-3</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_031"><span style="font: 10pt Times New Roman, Times, Serif">Consolidated
    Statements of Comprehensive Loss (Income)</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">F-5</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_032">Consolidated Statements of Changes in Equity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">F-6</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_034">Consolidated Statements of Cash Flows</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">F-8</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_035">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">F-9
    to F-52</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 83; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_028"></span><b>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">To
the Board of Directors and shareholders of Orgenesis Inc.:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Opinion
</i></b></span><span style="font: 10pt Times New Roman, Times, Serif"><b><i>on the Financial Statements </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Orgenesis Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2020 and 2019, and the related
consolidated statements of comprehensive loss (income), changes in equity and cash flows for the years then ended, including the
related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated
financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and
2019, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally
accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Changes in Accounting Principle </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As discussed in Note 2(x) to the consolidated
financial statements, the Company changed the manner in which it accounts for leases in 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Basis for Opinion</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements
are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audits of these consolidated
financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether
due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over
financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting
but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.
Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our audits included performing procedures
to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and
disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe
that our audits provide a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Critical Audit Matters</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The critical audit matter communicated
below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required
to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated
financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical
audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not,
by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts
or disclosures to which it relates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Revenue Recognition - Point-of-Care
(&#8220;POC&#8221;) Cell Therapy Platform</i></p>

<p style="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify; color: red"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As described in Notes 1 and 2(w) to the
consolidated financial statements, the Company generated approximately $5.9 million in revenue from POC services for the year
ended December 31, 2020. The transaction price from those POC services is allocated by management to each distinct performance
obligation based on its relative standalone selling price. The Company recognizes revenue when, or as, it satisfies a performance
obligation. At contract inception, the Company determines whether the services are transferred over time or at a point in time.
Revenue related to performance obligations that have no alternative use and that the Company has the right to payment for performance
completed to date, at all times during the contract term, are recognized over time. Revenue from all other performance obligations
are recognized as revenues by the Company at point of time (upon completion).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The principal
considerations for our determination that performing procedures relating to revenue recognition - POC cell therapy platform is
a critical audit matter are that there was significant judgment by management in (1) identifying the distinct performance obligations
and estimating the standalone selling price of each distinct performance obligation, and (2) identifying which performance obligations
create assets with alternative use to the Company, which results in revenue recognized upon completion, and which performance
obligations are transferred to the customer over time. This in turn led to significant auditor judgment and effort in performing
procedures to evaluate management&#8217;s significant judgment in identifying distinct performance obligations and determining
whether those performance obligations create assets with alternative use to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Addressing the
matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated
financial statements. These procedures included testing the effectiveness of controls relating to the revenue recognition process.
These procedures also included, among others, on a test basis, testing the completeness and accuracy of management&#8217;s identification
of the distinct performance obligations by evaluating customer arrangements; and testing management&#8217;s process for determining
the appropriate amount of revenue recognition based on the performance obligations identified in relevant contracts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>/s/ Kesselman &amp; Kesselman</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certified Public Accountants (Isr.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A member firm of PricewaterhouseCoopers
International Limited</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Tel-Aviv, Israel</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">March 9, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have served as the Company&#8217;s auditor
since 2012.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"><b><span id="a_029"></span>ORGENESIS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars, in thousands)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_111_pn3n3_zbsJlFmhTOmf" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20201231_zOvcNAKK4yXg" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20191231_zxFjkqerhqR5" style="font-weight: bold; text-align: center">2019</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AssetsAbstract_iB_z38BuQTfObUb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; font-weight: bold">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--AssetsCurrentAbstract_i01B_zKfuxi9oKt8g" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCznBp_zs2WHbchKXk9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44,923</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">107</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--RestrictedCashCurrent_i02I_maCznBp_zjQPe9Zbu0k1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">645</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">467</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AccountsReceivableNetCurrent_i02I_maCznBp_z83RTZXN9Gi4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,085</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,831</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCznBp_zVB5FdQpaCqe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,070</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">382</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--GrantsReceivableCurrent_i02I_maCznBp_zRrTHzcVmv1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Grants receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrantsReceivableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">169</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrantsReceivableCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">204</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--InventoryNet_i02I_maCznBp_zhgEEO6j2cc7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">185</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">136</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_maCznBp_zqvBYGyhnF61" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Current assets of discontinued operations (See Note 3)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0070">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75,221</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AssetsCurrent_i02TI_mtCznBp_maCz049_zhpxhtpVKknj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50,077</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">78,348</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--AssetsNoncurrentAbstract_i01B_zx93Jr7wZGw8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">NON CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--DepositsAssetsNoncurrent_i02I_maCzgdW_z1P7htsQAzV4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Deposits</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">296</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">299</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--DueFromRelatedPartiesNoncurrent_i02I_maCzgdW_zzvYYwqtpwB4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loan to related party </td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0082">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DueFromRelatedPartiesNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,623</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--Investments_i02I_maCzgdW_zmwcQxH1dol8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Investments in associates, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">175</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0086">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_i02I_maCzgdW_zpktSsPIyH3h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Property, plants and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,073</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,305</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_maCzgdW_zKVP4ldUwAkc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,023</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,348</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maCzgdW_zXdonnKJZsl2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,474</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">725</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--Goodwill_i02I_maCzgdW_zFUr8SJopzE" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,745</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,812</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OtherAssetsNoncurrent_i02I_maCzgdW_z0PNT3z1O1xg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">821</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--AssetsNoncurrent_i02TI_mtCzgdW_maCz049_zdZTvE3U8MVi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,607</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,147</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--Assets_i01TI_mtCz049_zCiB3KSkF1Oc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">77,684</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">92,495</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_030"></span>ORGENESIS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars, in thousands)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zjyxGfMByFyf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Liabilities and equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--LiabilitiesCurrentAbstract_i01B_zr9rUm4Hqlg5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AccountsPayableCurrent_i02I_maCzYRr_zn6u8Q0u7kG3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: justify">Accounts payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,649</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,549</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--AccruedExpensesAndOtherPayablesCurrent_i02I_maCzYRr_zZIgZdEvsPA9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Accrued expenses and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:AccruedExpensesAndOtherPayablesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">792</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:AccruedExpensesAndOtherPayablesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,615</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--AccruedIncomeTaxesCurrent_i02I_maCzYRr_zG85FteBktJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Income tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0122">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--EmployeeRelatedLiabilitiesCurrent_i02I_maCzYRr_zf3XsalYqXA" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Employees and related payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,463</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,672</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_ecustom--AdvancePaymentsOnAccountOfGrant_i02I_maCzYRr_zn7EcL4VfUqf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Advance payments on account of grant</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:AdvancePaymentsOnAccountOfGrant" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">692</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:AdvancePaymentsOnAccountOfGrant" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">523</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--OtherLiabilitiesCurrent_i02I_maCzYRr_zMuP415oxqki" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Short-term loans and current maturities of long-term loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">145</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">391</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--ContractWithCustomerLiabilityCurrent_i02I_maCzYRr_zfEkByyjIL0h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Contract liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">59</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">325</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--FinanceLeaseLiabilityCurrent_i02I_maCzYRr_zIJJGaOKIlXc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Current maturities of finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0137">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzYRr_zep0PKTFnxc4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Current maturities of operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">485</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">357</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--ConvertibleDebtCurrent_i02I_maCzYRr_zm9rOiko4FMi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Current maturities of convertible loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebtCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,974</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebtCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">416</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_maCzYRr_zkvfB1jRsh07" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Current liabilities of discontinued operations (See Note 3)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0145">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31,586</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--LiabilitiesCurrent_i02TI_mtCzYRr_maCzXkd_zVu71IQDWLJc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">TOTAL CURRENT LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,285</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42,434</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zG7L8AW6zjOd" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">LONG-TERM LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maCzPiW_zbw1MZP1Aojl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: justify">Non-current operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,020</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">455</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--ConvertibleDebtNoncurrent_i02I_maCzPiW_zEMa3HWWiKH4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Convertible loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebtNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebtNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,143</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_i02I_maCzPiW_zLwB8wEGokna" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Retirement benefits obligation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">74</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--DeferredIncomeTaxLiabilitiesNet_i02I_maCzPiW_z6vWijaihqR4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Deferred taxes</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0163">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityNoncurrent_i02I_maCzPiW_zzvUAfwI7Ig1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Long-term debt and finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0167">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--OtherLiabilitiesNoncurrent_i02I_maCzPiW_zTwBmX6Qbvgc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Other long-term liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">313</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">331</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--LiabilitiesNoncurrent_i02TI_mtCzPiW_maCzXkd_zEcjMvF1lN5e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">TOTAL LONG-TERM LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,671</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,028</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--Liabilities_i01TI_mtCzXkd_maCzQCq_zJ01H50IJfnj" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">TOTAL LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,956</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">55,462</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--CommitmentsAndContingencies_i01I_maCzQCq_zD50VSkzqUHk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">COMMITMENTS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--RedeemableNoncontrollingInterestOfDiscontinuedOperation_i01I_maCzQCq_z5QKuIx7qdTf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">REDEEMABLE NON CONTROLLING INTEREST OF DISCONTINUED OPERATIONS (See Note 3)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0181">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ORGS:RedeemableNoncontrollingInterestOfDiscontinuedOperation" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,955</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--StockholdersEquityAbstract_i01B_zKeM0qLNxzia" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">EQUITY:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--CommonStockValue_i02I_maCzPVM_zIPAWkoYCcpi" style="vertical-align: bottom; background-color: White">
    <td>Common stock of $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20201231_zrQnYrSeHxXh" title="Common stock, par value"><span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20191231_zaTrxUk1rqE9" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_c20201231_pii" title="Common stock, shares authorized"><span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_c20191231_pii" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">145,833,334</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_c20201231_pii" title="Common stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_c20201231_pii" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,223,093</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_c20191231_pii" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_c20191231_pii" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,140,962</ix:nonFraction></ix:nonFraction></span></span> shares issued as of December 31, 2020 and December 31, 2019, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_maCzPVM_zpUX6jMEGCm9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">140,397</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">94,691</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_maCzPVM_zEs0bA92Pnp" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accumulated other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">748</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">213</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--TreasuryStockValue_i02NI_di_msCzPVM_zz1BkAsu2EG7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Treasury stock at December 31, 2020 <span id="xdx_907_eus-gaap--TreasuryStockShares_iI_pii_c20201231_zeskWwGB8319" title="Treasury stock, shares"><ix:nonFraction name="us-gaap:TreasuryStockShares" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,309</ix:nonFraction></span> shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0213">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzPVM_zlPh5M1lMwNl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">88,319</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">89,429</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr id="xdx_40D_eus-gaap--StockholdersEquity_i02TI_mtCzPVM_maCzSCx_zhI4NHYqXSP9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: justify">Equity attributable to Orgenesis Inc.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">52,579</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,477</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--MinorityInterest_i02I_maCzSCx_zzNxv4eupXu8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Non-controlling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">149</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">601</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_mtCzSCx_maCzQCq_zhhlZ4NUKHH" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">TOTAL EQUITY</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">52,728</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,078</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtCzQCq_zEqksUHMrzIj" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND EQUITY</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">77,684</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">92,495</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_031"></span>ORGENESIS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENTS OF COMPREHENSIVE LOSS</b></span><b> (INCOME)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars, in thousands, except share and per share amounts)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_113_pn3n3_zxChfX9aClTk" summary="xdx: Statement - Consolidated Statements of Comprehensive Loss (Income)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20200101__20201231_zxZ44Z3QLeQg" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20190101__20191231_zFpukmPwlyLd" style="font-weight: bold; text-align: center">2019</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maCz3Yu_zfbYBQirIOol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,177</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,629</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--RevenueFromRelatedParties_maCz3Yu_zSOqptXBXOx3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Revenues from related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromRelatedParties" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,475</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromRelatedParties" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,270</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--Revenues_iT_mtCz3Yu_maCzmS3_zyCHTOOf6Lej" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,652</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,899</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_msCzmS3_zl9RaSDXhQR6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cost of research and development and research and development services, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83,986</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,014</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AmortizationOfIntangibleAssets_msCzmS3_zdTvIRv0eef7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amortization of intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">478</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">430</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--SellingGeneralAndAdministrativeExpense_msCzmS3_zj792HLmJyih" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling, general and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,973</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,451</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--OtherOperatingIncome_iN_di_maCzmS3_zZwlj8g3Aa4d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherOperatingIncome" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherOperatingIncome" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr id="xdx_400_eus-gaap--OperatingIncomeLoss_iT_mtCzmS3_maCzwgO_maILFCOzwwN_zJk0jSW7clVh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">95,781</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,975</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--OtherNonoperatingIncomeExpense_maCzwgO_maILFCOzwwN_zu3jwQd7PRN3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial expenses, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,061</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">843</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--ShareInNetIncomeOfAssociatedCompanies_iN_di_msCzwgO_maILFCOzwwN_zgmyXu5I04J3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Share in net income of associated companies</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ORGS:ShareInNetIncomeOfAssociatedCompanies" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">106</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0260">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_maCzfir_mtILFCOzwwN_zrQdKwk8wPah" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from continuing operation before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">96,736</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,818</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msCzfir_zO9k5TOmH9wg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,609</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">229</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_iT_mtCzfir_maCzLoM_zXGcIhp34K6f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss from continuing operation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">95,127</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,589</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_maCzLoM_zuQqrAjx6KUj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss (income) from discontinued operations, net of tax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">95,706</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,452</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--ProfitLoss_iT_mtCzLoM_maCzZHG_zAO0wyAGbzY3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss (income)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">579</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,041</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_iN_di_msCzZHG_zTjouwEoPTf2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss attributable to non-controlling interests (including redeemable) from continuing operation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">99</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40C_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_iN_di_msCzZHG_zeUOc84okxbf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss attributable to non-controlling interests (including redeemable) from discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">492</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,821</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr id="xdx_40C_eus-gaap--NetIncomeLoss_iT_mtCzZHG_zyHt8l4nPSd7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss (income) attributable to Orgenesis Inc.</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,110</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,121</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--EarningsPerShareAbstract_iB_z0PMkrg4unQi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Loss (income) per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_i01_pii_zb1s1yw7s2Xc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted from continuing operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.46</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.41</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_i01_pii_zJLykOI5Eph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted from discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">4.75</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.36</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAndDiluted_i01_pii_za70PjyyeOX3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.29</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.77</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_z5OTVM2MpTg8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Weighted average number of shares used in computation of Basic and Diluted loss per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i01_z5fd7fvkKrOf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">21,320,314</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">15,907,995</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--ComprehensiveIncomeNetOfTaxAbstract_iB_zm2TYSmrvNI9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Comprehensive loss (income):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests_i01_zoTuSRfLKTqb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Net loss from Continuing Operation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ORGS:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">95,127</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ORGS:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,589</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_ecustom--IncomeLossesFromDiscontinuedOperationNetOfTax_i01_zl9Z4Tydt87f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net loss (income) from Discontinued Operations, Net of Tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ORGS:IncomeLossesFromDiscontinuedOperationNetOfTax" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">95,706</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:IncomeLossesFromDiscontinuedOperationNetOfTax" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,452</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_i01_zPXVqTiAR4F1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other Comprehensive (income) loss &#8211; Translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">341</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">456</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_ecustom--OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary_i01_zafFlZ4JMWwl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Release of translation adjustment due to sale of subsidiary</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ORGS:OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">194</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0317">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_400_ecustom--ComprehensiveIncomeNetOfTaxes_zeIBAa7z53j7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Comprehensive loss (income)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ORGS:ComprehensiveIncomeNetOfTaxes" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,114</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ORGS:ComprehensiveIncomeNetOfTaxes" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,497</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40A_ecustom--ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations_i01_zUNFxCoUJnL2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Comprehensive loss attributed to non-controlling interests (including redeemable)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ORGS:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">39</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ORGS:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">99</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40E_ecustom--ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations_i01_zA4gbg8am3u8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Comprehensive loss attributed to non-controlling interests (including redeemable) from discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ORGS:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">492</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ORGS:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,821</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--ComprehensiveIncomeNetOfTax_i01_z7FOeOZcYX7c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Comprehensive loss (income) attributed to Orgenesis Inc.</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,645</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,577</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_032"></span>ORGENESIS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN EQUITY </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars, in thousands, except share amounts)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_309_114_pn3n3_zPb0vSY7XH7i" summary="xdx: Statement - Consolidated Statements of Changes in Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><b>1</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zXBaFsMQFDO8" style="font-weight: bold; text-align: center">2</td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zuyDkNvGf409" style="font-weight: bold; text-align: center">3</td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zq0iA6TtdOTh" style="font-weight: bold; text-align: center">4</td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zG8MNTxi3H19" style="font-weight: bold; text-align: center">5</td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_custom--EquityAttributedToOrgenesisIncMember_zw5dOd1SdRr4" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>
                                                                                                                                                                        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">6</p></td><td style="text-align: center"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_zp5yxMIBvHG" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>7
</b></span></p></td><td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" id="xdx_4BE_zOTdQTbOY9Fc" style="font-weight: bold; text-align: center"><b>Total</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Common Stock</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Accumulated<br />
    Other</b></td><td style="text-align: center"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Equity<br />
    Attributable</b></span></td><td style="text-align: center"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Number</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Par Value</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Additional Paid-in Capital</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Comprehensive Income<br />
    (loss)</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Accumulated Deficit</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>
                                                                                                                                                                        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>to<br />
                                         Orgenesis Inc.</b></p></td><td style="text-align: center"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Non-
                                         Controlling</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Interest
                                         </b></span></p></td><td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Total</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td></tr>
<tr id="xdx_430_c20190101__20191231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zENI6QxznY7d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold">BALANCE AT JANUARY 1, 2019</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEOP9cBErZXk" title="Beginning balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,540,333</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90,597</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2018-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">669</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">65,163</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2018-12-31_custom_EquityAttributedToOrgenesisIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,105</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2018-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">645</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,750</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Changes during the Year ended December 31, 2019:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z9VWxrhnbVR5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation to employees and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0341">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,106</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0343">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-12-31_custom_EquityAttributedToOrgenesisIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,106</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,164</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zshJjfn1ephd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation to service providers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNiCMYQwnzfa" title="Stock-based compensation to service providers, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,629</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_F29_zV8SDma94jyg" style="font: 10pt Times New Roman, Times, Serif">*-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">893</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0351">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2019-01-012019-12-31_custom_EquityAttributedToOrgenesisIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">893</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0354">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">893</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement_i_pn3n3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation for Tamir purchase agreement (See Note 3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYu6Ch9V6O19" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_i_pn3n3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zu5Wu44qhvu2" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_i_pn3n3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Beneficial conversion <br />feature of convertible loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--IssuanceOfSharesAndWarrants_i_pn3n3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of shares and warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--IssuanceOfSharesAndWarrantsShares_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY4BAQrCYAW8" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0392">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_i_pn3n3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of shares related to acquisition of Koligo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1FL2DUNvoR9" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0401">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_iN_pn3n3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sale of subsidiaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--StockRepurchasedDuringPeriodValue_iN_di_zMuaNyPeelB" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Repurchase of treasury stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockRepurchasedDuringPeriodShares_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaoosJBgIOnk" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--StockbasedCompensationToStrategicCollaborations_zopvfUVAt0w4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation to strategic collaborations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--StockbasedCompensationToStrategicCollaborationsShares_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Stock-based compensation to strategic collaborations, shares" style="text-align: right"><ix:nonFraction name="ORGS:StockbasedCompensationToStrategicCollaborationsShares" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">525,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_F2E_z2unOoqFSOld" style="font: 10pt Times New Roman, Times, Serif">*-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:StockbasedCompensationToStrategicCollaborations" contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,641</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:StockbasedCompensationToStrategicCollaborations" contextRef="From2019-01-012019-12-31_custom_EquityAttributedToOrgenesisIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,641</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0425">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:StockbasedCompensationToStrategicCollaborations" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,641</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans_zqMmCE53L58e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance and modification of warrants and Beneficial conversion feature of convertible loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0430">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans" contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">515</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0432">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ORGS:IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans" contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">145</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans" contextRef="From2019-01-012019-12-31_custom_EquityAttributedToOrgenesisIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">370</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0435">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">370</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_ecustom--AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp_zcMQp5KrzYM3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Transaction with non-controlling interest GPP (See Note 1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0438">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp" contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,034</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0440">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp" contextRef="From2019-01-012019-12-31_custom_EquityAttributedToOrgenesisIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,034</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0443">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,034</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Adjustment to redemption value of redeemable non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0446">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,095</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0448">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0449">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2019-01-012019-12-31_custom_EquityAttributedToOrgenesisIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,095</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0451">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,095</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40B_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_zDgUNYNfwOD2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Comprehensive loss for the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0454">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0455">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">456</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">24,121</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2019-01-012019-12-31_custom_EquityAttributedToOrgenesisIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">24,577</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">102</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">24,679</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr id="xdx_43B_c20190101__20191231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zbLYMrmC9wOd" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">BALANCE AT DECEMBER 31, 2019</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZFiJOWU0F14" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,140,962</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">94,691</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">213</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">89,429</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_custom_EquityAttributedToOrgenesisIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,477</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">601</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,078</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span id="xdx_F05_zvPiFrQZTeFd" style="font: 10pt Times New Roman, Times, Serif">*</span></td>
    <td><span id="xdx_F15_zspKWB45RqV2" style="font: 10pt Times New Roman, Times, Serif"><ix:footnote id="Footnote000471" xml:lang="en-US">Represents an amount lower than $1
    thousand</ix:footnote></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated financial statement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_033"></span>ORGENESIS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN EQUITY </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars, in thousands, except share amounts)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>1</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_ziyOJo2sb8F6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zHjk4HElWze7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zyOQ2cJ7b6Fj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">4</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockMember_zXfNVxc28RR1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>5</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zza3zktV0i25" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>6</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_custom--EquityAttributedToOrgenesisIncMember_zrwhi94aBADk" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>7</b></p></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_zj3GFVCSZkig" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>8
</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_4B9_zz7EbQ3x4Ho1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Common Stock</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Accumulated Other</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Equity
    Attributable</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Number</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Par Value</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Additional Paid-in Capital</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Comprehensive Income <br />
    (loss)</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Treasury Shares</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Accumulated Deficit</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>to</b></p>
                                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Orgenesis<br />
                                         Inc.</b></p></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Non-
                                         Controlling</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Interest
                                         </b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Par Value</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td></tr>
<tr id="xdx_432_c20200101__20201231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zIdz9eTDy9a7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold">BALANCE AT JANUARY 1, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBe9hIOOBJp4" title="Beginning balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,140,962</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">94,691</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">213</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0476">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">89,429</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_custom_EquityAttributedToOrgenesisIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,477</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">601</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,078</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Changes during the Year ended &#160;December 31, 2020:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zO6ynAnngz88" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation to employees and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0484">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,470</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0486">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0487">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0488">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,470</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0490">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,470</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zGk4GHuZxSRg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation to <br />service providers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKio___z1rqx2UA0Fqb" title="Stock-based compensation to service providers, shares" style="text-align: right">**<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="Fact000502" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">270,174</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,376</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0495">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0496">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0497">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,377</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0499">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,377</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement_zKzHvBQizVH2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation for Tamir purchase agreement (See Note 4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNkXpH4r6pv7" title="Stock-based compensation for Tamir purchase agreement (See Note 3), shares" style="text-align: right"><ix:nonFraction name="ORGS:StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,400,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_F28_zKpTm1SqoLi4" style="font: 10pt Times New Roman, Times, Serif">*-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,748</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0506">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0507">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0508">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement" contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,748</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0510">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,748</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zR9fGD9qaMZk" style="vertical-align: bottom; background-color: White">
    <td>Exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4pHu31pOhB2" title="Exercise of options, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">83,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_F2B_zeqrSIZYX4d6" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">*-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0517">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0518">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0519">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0521">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_z4DIVhzLELOc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Beneficial conversion <br />feature of convertible loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0526">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0528">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0529">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0530">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0532">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--IssuanceOfSharesAndWarrants_zUGvqDSiRXma" style="vertical-align: bottom; background-color: White">
    <td>Issuance of shares and warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--IssuanceOfSharesAndWarrantsShares_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zezG9vkTYTx4" title="Issuance of shares and warrants, shares" style="text-align: right"><ix:nonFraction name="ORGS:IssuanceOfSharesAndWarrantsShares" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,200,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0535">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:IssuanceOfSharesAndWarrants" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,438</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0537">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0538">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0539">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:IssuanceOfSharesAndWarrants" contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,438</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0541">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:IssuanceOfSharesAndWarrants" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,438</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_zbxzRvVy7Drk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of shares related to acquisition of Koligo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbFuBvmGNmu4" title="Issuance of shares related to acquisition of Koligo, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,128,623</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_F27_zUzYKtOFhBxh" style="font: 10pt Times New Roman, Times, Serif">*-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,172</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0548">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0549">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0550">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,172</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0552">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,172</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_iN_pn3n3_di_zrjQZu03Wvog" style="vertical-align: bottom; background-color: White">
    <td>Sale of subsidiaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0557">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0558">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0559">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0560">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0561">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0562">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">413</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">413</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_zFEdMyPlRYK7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustment to redemption value of redeemable non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0566">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,160</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0568">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0569">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0570">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,160</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0572">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,160</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--StockRepurchasedDuringPeriodValue_iN_di_z44wlxfXwbi1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Repurchase of treasury stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockRepurchasedDuringPeriodShares_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCsdk7zDSxs9" title="Repurchase of treasury stock, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">55,309</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0575">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0576">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0577">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0579">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0581">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_400_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_zGhabDkBIglg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Comprehensive income (loss) for the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0586">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0587">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">535</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0589">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,110</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,645</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">39</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,606</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_432_c20200101__20201231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zxVVaTMkrW1f" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">BALANCE AT DECEMBER 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zE20PMio2Bj5" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,167,784</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">140,397</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">748</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">250</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">88,319</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_custom_EquityAttributedToOrgenesisIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">52,579</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">149</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">52,728</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top">
    <td><span id="xdx_F00_zsUdsecnKfcb" style="font-family: Times New Roman, Times, Serif">*</span></td>
    <td><span id="xdx_F1D_zjJGM0bfjim8" style="font-family: Times New Roman, Times, Serif"><ix:footnote id="Footnote000605" xml:lang="en-US">Represents an amount lower than $1 thousand</ix:footnote></span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="width: 2%"><span id="xdx_F01_zGuTcsEMhiA8" style="font: 10pt Times New Roman, Times, Serif">**</span></td>
    <td style="width: 98%"><span id="xdx_F14_zI3PJ7FVEuu5" style="font: 10pt Times New Roman, Times, Serif"><ix:footnote id="Footnote000606" xml:lang="en-US">out of which 30,000 shares
    have additional restrictions on transfer until services have been provided.</ix:footnote></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_034"></span>ORGENESIS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS(*)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(U.S.
Dollars, in thousands)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_112_pn3n3_zf7TBtmkiai" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20200101__20201231_zcaGmNlXem0f" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20190101__20191231_zCJV0MI5AwWe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_F53_zzk5lyU4hc3h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_F5B_zGHrngTazrrc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zCiXwWrBrH02" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--ProfitLoss_i01N_di_maOp1_zkCVsncx2D47" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: justify">Net income (loss)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">579</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,041</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zfMS31CzgDe1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments required to reconcile net income (loss) to net cash used
    in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--ShareBasedCompensation_i02_maOp1_zhgsixIyPpi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,847</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,057</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_ecustom--ShareBasedCompensationOne_i02_maOp1_zHvgZXTp8LT" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Stock-based compensation for strategic collaborations</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0620">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:ShareBasedCompensationOne" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,641</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--ShareBasedCompensationTwo_i02_maOp1_zCftzbTxytOe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Stock-based compensation for Tamir Purchase Agreement (See Notes 4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:ShareBasedCompensationTwo" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,048</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0624">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_i02N_di_msOp1_zhxSzvizg5U4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Capital loss (gain), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_409_eus-gaap--GainOrLossOnSaleOfStockInSubsidiary_i02N_di_msOp1_zuycq4n8UNPa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Gain on disposal of subsidiaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainOrLossOnSaleOfStockInSubsidiary" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">96,918</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0630">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_ecustom--ShareInNetIncomeOfAssociatedCompanies_i02N_di_msOp1_zApPTTG6OZib" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Share in income of associated company</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ORGS:ShareInNetIncomeOfAssociatedCompanies" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">106</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0633">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DepreciationAndAmortization_i02_maOp1_zwoYf1SQjvG2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Depreciation and amortization expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,435</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,806</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_ecustom--IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances_i02_maOp1_z3HIjYmLOnLk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Effect of exchange differences on inter-company balances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ORGS:IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">618</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">214</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--NetChangesInOperatingLeases_i02N_di_msOp1_zGR46RyLVKuh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Net changes in operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:NetChangesInOperatingLeases" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ORGS:NetChangesInOperatingLeases" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">339</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--InterestExpenseShortTermBorrowings_i02_maOp1_zqGpVEPTD45k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Interest expense accrued on loans and convertible loans (including amortization of beneficial conversion feature)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpenseShortTermBorrowings" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">927</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpenseShortTermBorrowings" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">387</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zg94Dqp6NwK6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">&#160;&#160;&#160;&#160;&#160;Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msOp1_z9vKh2i1VKKf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Increase in accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,350</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,308</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--IncreaseDecreaseInInventories_i03N_di_msOp1_zdaTXP5I9Qu2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Increase in inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">414</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_405_eus-gaap--IncreaseDecreaseInOtherCurrentAssets_i03N_di_msOp1_zLKH5JJdaH4f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Increase in other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_409_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msOp1_zrnPediQgwqb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Increase in prepaid expenses, other accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,073</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maOp1_zboK2Lc62vO" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Increase in accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,985</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,626</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--IncreaseDecreaseInAccuredExpensesAndOtherPayables_i03_maOp1_zn3nApl6ldk7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Increase (decrease) in accrued expenses and other payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ORGS:IncreaseDecreaseInAccuredExpensesAndOtherPayables" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,156</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:IncreaseDecreaseInAccuredExpensesAndOtherPayables" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">271</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--IncreaseDecreaseInEmployeeRelatedLiabilities_i03_maOp1_zd8f2CwzqqA6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Increase (decrease) in employee and related payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">170</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">474</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--IncreaseDecreaseInContractWithCustomerLiability_i03_maOp1_zVakyl3xs7ff" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Increase (decrease) in contract liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">166</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,536</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant_i03_maOp1_zgkhs1mHYpL8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in advance payments and receivables on account of grant, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">140</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ORGS:IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">247</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_408_eus-gaap--IncreaseDecreaseInDeferredIncomeTaxes_i03N_di_msOp1_zJBQ9LqgvRij" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Increase (decrease) in deferred taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,378</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">304</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtOp1_maCz6tt_zEdpmuOz9l0i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Net cash used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">78,046</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,220</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zNUzcWKxL9C3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--ProceedsFromPaymentsForLongTermLoansForRelatedParties_i01_maCz9lB_z2t9zpj56ZI9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Increase in loan to JV partner, a related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProceedsFromPaymentsForLongTermLoansForRelatedParties" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProceedsFromPaymentsForLongTermLoansForRelatedParties" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,500</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_400_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_i01_maCz9lB_zYKjM2Fu8Pw4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Repayment in loan to JV partner, a related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0690">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_i01_maCz9lB_z2DJGdXVadb6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Sale of property, plants and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">79</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCz9lB_z4kMxNxL9Bx4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Purchase of property, plants and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,525</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,129</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_i01N_di_msCz9lB_z4QHSAD370gh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Acquisition of Koligo, net of cash acquired (See Note 4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">955</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0699">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_i01_maCz9lB_zcU4nGHP4avb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Proceed from sale of subsidiaries, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">105,634</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0702">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--PaymentsForInvestments_i01N_di_msCz9lB_zG79lCsnNR44" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Investment in associated company</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ORGS:PaymentsForInvestments" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">69</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0705">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--PaymentsForProceedsFromInvestments_i01N_di_msCz9lB_ze9c04EFGGZ5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Repayment (investment) in short term deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PaymentsForProceedsFromInvestments" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForProceedsFromInvestments" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">228</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCz9lB_maCz6tt_zr2qXCzrDXpl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Net cash provided by (used) in investing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">105,610</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,778</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zODPPvM6hvfh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--RepaymentOfTreasuryStock_i01N_di_msCz4RU_zkEurgLxDKp4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Repurchase of treasury stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ORGS:RepaymentOfTreasuryStock" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0717">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--ProceedsFromMinorityShareholders_i01_maCz4RU_zal1okIE0xX1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Increase in redeemable non-controlling interests received from GPP</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0719">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromMinorityShareholders" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,200</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_i01_maCz4RU_zkW9gwgeqybc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of shares, warrants and exercise of options
    (net of transaction costs)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,738</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0723">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--ProceedsFromConvertibleDebt_i01_maCz4RU_zGz8HDL4KNVe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of convertible loans (net of transaction costs)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--RepaymentsOfConvertibleDebt_i01N_di_msCz4RU_zgcMFJvA4eJa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Repayment of convertible loans and convertible bonds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,400</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0729">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--RepaymentsOfDebt_i01N_di_msCz4RU_zqoLsgYn5zWi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Repayment of short and long-term debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">457</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">772</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_405_eus-gaap--ProceedsFromIssuanceOfDebt_i01_maCz4RU_zoDaPaCm7np2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Proceeds from issuance of loans payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0734">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">270</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCz4RU_maCz6tt_z1UjwnZXpdOh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,881</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,098</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCz6tt_ztvZTQSN8NEd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33,445</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,900</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_408_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_zWk5cNuAKAt" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">58</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zbBbjeUXJ3Pi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF YEAR</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,041</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,999</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zpa5gN1uL60e" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF YEAR</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45,568</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,041</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--SupplementalCashFlowInformationAbstract_iB_ztvTyl8PK8Hc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">SUPPLEMENTAL DISCLOSURE OF CASH FLOW TRANSACTIONS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--InterestPaidNet_i01_z4kXlzUbD7d7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest paid in cash during the year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0755">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">157</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--IncomeTaxesPaidNet_i01_ziL9tuQGl2le" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Income taxes, net of refunds paid in cash during the year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0758">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">156</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zCvfg3zPjuz4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">SUPPLEMENTAL NON-CASH FINANCING AND INVESTING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_ecustom--FinanceLeasesOfPropertyPlantAndEquipment_i01_z6ZsJuewvgr" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Finance Leases of property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ORGS:FinanceLeasesOfPropertyPlantAndEquipment" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">366</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ORGS:FinanceLeasesOfPropertyPlantAndEquipment" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">355</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_ecustom--RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities_i01_z5dVRUvmkrW7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Right-of-use assets acquired in exchange for right-of-use liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ORGS:RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">967</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ORGS:RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,229</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable_i01_zbNGEGcFo0F4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Purchase of property, plant and equipment included in accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ORGS:PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">241</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ORGS:PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,584</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_i01_zJyx7SjBgEO3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Transaction costs of issuance of convertible loans</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0773">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">546</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_ecustom--AcquisitionOfOtherAssetInExchangeForCommonStocks_i01_zAXWcndUDyDc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Acquisition of other asset in exchange for common stocks</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ORGS:AcquisitionOfOtherAssetInExchangeForCommonStocks" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">700</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0777">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_ecustom--IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo_i01_zQGtJa8rcHf9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of common
    stocks in connection with the acquisition of Koligo</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="ORGS:IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,172</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0780">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span id="xdx_F05_zb0OeXGUiYL4" style="font: 10pt Times New Roman, Times, Serif">(*)</span></td>
    <td><span id="xdx_F19_zgiRFFEJQ3wf" style="font: 10pt Times New Roman, Times, Serif"><ix:footnote id="Footnote000781" xml:lang="en-US">See Note 3 for information regarding the discontinued operations.</ix:footnote></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_035"></span>ORGENESIS
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_809_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z1wFQBsa56jj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
1 &#8211; <span id="xdx_82E_zKn9KP3uNTw5">DESCRIPTION OF BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>a.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>General</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
Inc., a Nevada corporation, is a global biotech company working to unlock the potential of cell and gene therapies in an affordable
and accessible format (&#8220;CGTs&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">CGTs
can be centered on autologous (using the patient&#8217;s own cells) or allogenic (using master banked donor cells) and are part
of a class of medicines referred to as advanced therapy medicinal products (ATMP). The Company mostly focusses on autologous therapies,
with processes and systems that are developed for each therapy using a closed and automated processing system approach that is
validated for compliant production near the patient at their point of care for treatment of the patient. This approach has the
potential to overcome the limitations of traditional commercial manufacturing methods that do not translate well to commercial
production of advanced therapies due to their cost prohibitive nature and complex logistics to deliver the treatments to patients
(ultimately limiting the number of patients that can have access to, or can afford, these therapies).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">To
achieve these goals, the Company has developed a Point of Care Platform comprised of three enabling components: a pipeline of
licensed <b>POCare Therapies</b> that are designed to be processed and produced in closed, automated <b>POCare Technology</b>
systems across a collaborative <b>POCare Network</b>. Via a combination of science, technology, engineering, and networking, the
Company is working to provide a more efficient and scalable pathway for advanced therapies to reach patients more rapidly at lowered
costs. The Company also draws on extensive medical expertise to identify promising new autologous therapies to leverage within
the POCare Platform either via ownership or licensing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
POCare Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide with a goal of
achieving harmonized, regulated clinical development and production of the therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Over
time, the Company has worked to develop and validate POCare Technologies that can be combined within mobile production units for
advanced therapies. In 2020, the Company made significant investments in the development of several types of Orgenesis Mobile
Processing Units and Labs (OMPULs) with the expectation of use and/or distribution through our POCare Network of partners, collaborators,
and joint ventures. As of the date of this report, the OMPULs are still in the development stage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">OMPULs
are designed for the purpose of validation, development, performance of clinical trials, manufacturing and/or processing of potential
or approved cell and gene therapy products in a safe, reliable, and cost-effective manner at the point of care, as well as the
manufacturing of such CGTs in a consistent and standardized manner in all locations. The design delivers a potential industrial
solution for the Company to deliver CGTs to practically any clinical institution at the point of care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Until
December 31, 2019, the Company operated the POCare Platform as one of two business separate business segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Historically,
the second separate business segment was operated as a Contract Development and Manufacturing Organization (&#8220;CDMO&#8221;)
platform, providing contract manufacturing and development services for biopharmaceutical companies (the &#8220;CDMO Business&#8221;).
The CDMO platform was historically operated mainly through majority owned Masthercell Global (which consisted of the following
two subsidiaries: MaSTherCell S.A. in Belgium (&#8220;MaSTherCell&#8221;), and Masthercell U.S., LLC in the United States (&#8220;Masthercell
U.S.&#8221;) (collectively, the &#8220;Masthercell Global Subsidiaries&#8221;)).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
February 2020, the Company and GPP-II Masthercell LLC (&#8220;GPP&#8221;) sold <span id="xdx_90F_ecustom--PercentageOfOutstandingEquityInterests_iI_pii_dp_uPercentage_c20200229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zc8EpBAWrAUa" title="Percentage of outstanding equity interests"><ix:nonFraction name="ORGS:PercentageOfOutstandingEquityInterests" contextRef="AsOf2020-02-29_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">100</ix:nonFraction>%</span> of the outstanding equity interests of Masthercell
(the &#8220;Masthercell Business&#8221;), which comprised the majority of the Company&#8217;s CDMO Business, to Catalent Pharma
Solutions, Inc. for an aggregate nominal purchase price of $<span id="xdx_907_ecustom--AggregateNominalPurchasePrice_pn5n6_c20200201__20200229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z7YHP7JDTwFk" title="Aggregate nominal purchase price of outstanding equity interests"><ix:nonFraction name="ORGS:AggregateNominalPurchasePrice" contextRef="From2020-02-012020-02-29_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">315</ix:nonFraction></span> million, (the &#8220;Masthercell Sale&#8221;). After accounting
for GPP&#8217;s liquidation preference and equity stake in Masthercell as well as other investor interests in our Belgian subsidiary
MaSTherCell, distributions to Masthercell option holders and transaction costs, the company received approximately $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20200201__20200229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zhYswqhZwNic" title="Proceeds from Issuance or Sale of Equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2020-02-012020-02-29_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">126.7</ix:nonFraction></span> million.
The Company incurred an additional approximately $<span id="xdx_906_ecustom--TransactionCostIncurred_pn5n6_c20200201__20200229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zV1ELPSMkbZ3" title="Transaction cost incurred"><ix:nonFraction name="ORGS:TransactionCostIncurred" contextRef="From2020-02-012020-02-29_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.6</ix:nonFraction></span> million in transaction costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 91; Options: NewSection; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company determined that the Masthercell Business (&#8220;Discontinued Operation&#8221;) meets the criteria to be classified as
a discontinued operation as of the first quarter of 2020. The Discontinued Operation includes the vast majority of the previous
CDMO Business, including majority-owned Masthercell, including MaSTherCell, Masthercell U.S. and all of the Masthercell Global
Subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Since
the Masthercell Sale, the Company has entered into new joint venture agreements with new partners in various jurisdictions. This
has allowed the Company to grow its infrastructure and expand its processing sites into new markets and jurisdictions. In addition,
the Company has engaged some of these joint venture partners to perform research and development services to further develop and
adapt its systems and devices for specific purposes. The Company has been investing manpower and financial resources to focus
on developing, manufacturing and rolling out several types of OMPULs to be used and/or distributed through our POCare Network
of partners, collaborators, and joint ventures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Chief Executive Officer (&#8220;CEO&#8221;) is the Company&#8217;s chief operating decision-maker who reviews financial
information prepared on a consolidated basis. Effective from the first quarter of 2020, all of our continuing operations
are in one segment, being the point-of-care business via our POCare Platform. Therefore, no segment report has been
presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company currently conducts its core CGT business operations through itself and its subsidiaries which are all wholly-owned except
as otherwise stated (collectively, the &#8220;Subsidiaries&#8221;). The Subsidiaries are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">United
    States: Orgenesis Maryland Inc. (the &#8220;U.S. Subsidiary&#8221;) is the center of activity in North America currently focused
    on setting up of the POCare Network.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Koligo
    Therapeutics Inc. (&#8220;Koligo&#8221;) is a Kentucky corporation that was acquired in 2020 and is currently focused on developing
    the POCare network and therapies (See Note 4 for the acquisition of Koligo).</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">European
    Union: Orgenesis Belgium SRL (the &#8220;Belgian Subsidiary&#8221;) is the center of activity in Europe currently focused
    on process development and preparation of European clinical trials.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
    Switzerland Sarl (the &#8220;Swiss subsidiary) incorporated in October 2020 is currently focused on providing management services
    to the Company.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Israel:
    Orgenesis Ltd. (the &#8220;Israeli Subsidiary&#8221;) is a provider of regulatory, clinical and pre-clinical services, and
    Orgenesis Biotech Israel Ltd. (&#8220;OBI&#8221;) previously known as Atvio Biotech Ltd. (&#8220;Atvio&#8221;) is a provider
    of cell-processing services in Israel.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Korea:
    Orgenesis Korea Co. Ltd. (the &#8220;Korean Subsidiary&#8221;), previously known as CureCell Co. Ltd., is a provider of processing
    and pre-clinical services in Korea. The Company owns <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CureCellCoLtdMember_zg6wD7RHx4Pb" title="Equity Method Investment, Ownership Percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2020-12-31_custom_CureCellCoLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">94.12</ix:nonFraction>%</span> of the Korean Subsidiary.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">These
consolidated financial statements include the accounts of Orgenesis Inc. and its subsidiaries including the Discontinued Operation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
April 7, 2020, the Company entered into an Asset Purchase Agreement (the &#8220;Tamir Purchase Agreement&#8221;) with Tamir Biotechnology,
Inc. (&#8220;Tamir&#8221; or &#8220;Seller&#8221;), pursuant to which the Company agreed to acquire certain assets and liabilities
of Tamir related to the discovery, development and testing of therapeutic products for the treatment of diseases and conditions
in humans, including all rights to Ranpirnase and use for antiviral therapy (collectively, the &#8220;Purchased Assets and Assumed
Liabilities&#8221; and such acquisition, the &#8220;Tamir Transaction&#8221;). The Tamir Transaction closed on April 23, 2020.
As aggregate consideration for the acquisition, the Company paid $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pn5n6_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zd5O51mhgaTc" title="Stock issued during period value acquisitions"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million in cash and issued an aggregate of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_pii" title="Shares issued, acquisition"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,400,000</ix:nonFraction></span> shares
(the &#8220;Shares&#8221;) of Common Stock to Tamir resulting in a total consideration of $<span id="xdx_90F_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zJNhl0Q0aX61" title="Business Combination, Consideration Transferred"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">20.2</ix:nonFraction></span> million (See Note 4).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 92; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s common stock, par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_c20201231_pii" title="Common Stock, Par or Stated Value Per Share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share (the &#8220;Common Stock&#8221;) is listed and traded on the Nasdaq
Capital Market under the symbol &#8220;ORGS.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
used in this report and unless otherwise indicated, the term &#8220;Company&#8221; refers to Orgenesis Inc. and its Subsidiaries.
Unless otherwise specified, all amounts are expressed in United States Dollars.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>b.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Liquidity</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020 ,the Company has accumulated losses of approximately $<span id="xdx_900_ecustom--AccumulatedDeficit_iI_pn5n6_c20201231_zdiUdTmPhuKi" title="Accumulated losses"><ix:nonFraction name="ORGS:AccumulatedDeficit" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">88</ix:nonFraction></span> Million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
February 10, 2020, the Company received approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20200209__20200210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zzFiFZu6z6j7"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2020-02-092020-02-10_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">126.7</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million, of which $<span id="xdx_90B_ecustom--RepaymentOfIntercompanyLoansAndPayables_pn5n6_c20200209__20200210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z49SNnFE192l"><ix:nonFraction name="ORGS:RepaymentOfIntercompanyLoansAndPayables" contextRef="From2020-02-092020-02-10_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.2</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million was used for the repayment of
intercompany loans and payables, from the Masthercell Sale (See Note 3). In addition, on January 20, 2020, the Company
entered into a Securities Purchase Agreement with certain investors pursuant to which the Company received gross proceeds of approximately
$<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn4n6_uUSD_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zf3ZAztQ34Ul"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2020-01-192020-01-20_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">9.24</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million before deducting related offering
expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company invested significant resources in research and development and research and development services in 2020. The Company
believes that these investments will enable it to substantially increase revenues in the next 12 months. Based on its current
cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and
expected level of expenditures for at least 12 months from the date of the issuance of these financial statements. If there are
further increases in operating costs for facilities expansion, research and development, commercial and clinical activity or decreases
in revenues from customers, the Company may decide to seek additional financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zJBSMdfeMNv7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
2 - <span><span id="xdx_829_z2Cc0yIxfPkf">SIGNIFICANT ACCOUNTING POLICIES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements are prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_845_eus-gaap--UseOfEstimates_zoTqjeGUG1E3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>a.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86F_zmuEvKVDb2R9">Use of Estimates in the Preparation of Financial Statements</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30.6pt"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation of our consolidated financial statements in conformity with U.S. GAAP requires us to make estimates, judgments
and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure
of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, judgments and methodologies. We base our
estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form
the basis for making judgments about the carrying values of assets, liabilities and equity, the amount of revenues and expenses
and determining whether an acquisition is a business combination or a purchase of asset. Actual results could differ from those
estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial
condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning
COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and
international customers and markets. We examined the impact of COVID-19 on our financial statements, and although there is currently
no major impact, there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:BusinessCombinationsPolicy"><p id="xdx_84F_eus-gaap--BusinessCombinationsPolicy_zASBMmgcRifh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>b.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_864_zIV8aZ9zoWC7">Business Combination</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company allocates the purchase price of an acquired business to the tangible and intangible assets acquired and liabilities assumed
based upon their estimated fair values on the acquisition date. Any excess of the purchase price over the fair value of the net
assets acquired is recorded as goodwill. Acquired in-process backlog, customer relations, technology, IPR&amp;D, brand name and
know how are recognized at fair value. The purchase price allocation process requires management to make significant estimates
and assumptions, especially at the acquisition date with respect to intangible assets. Direct transaction costs associated with
the business combination are expensed as incurred. The allocation of the consideration transferred in certain cases may be subject
to revision based on the final determination of fair values during the measurement period, which may be up to one year from the
acquisition date. The Company includes the results of operations of the business that it has acquired in its consolidated results
prospectively from the date of acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 93; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">If
the business combination is achieved in stages, the acquisition date carrying value of the acquirer&#8217;s previously held equity
interest in the acquire is re-measured to fair value at the acquisition date; any gains or losses arising from such re-measurement
are recognized in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:OtherInvestmentsPolicyTextBlock"><p id="xdx_849_ecustom--OtherInvestmentsPolicyTextBlock_zxa4jeXJtTJ5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>c.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_862_zEX2xcZFX5Og">Other Investments</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
other investments, the Company applies the measurement alternative upon the adoption of ASU 2016-01, and elected to record equity
investments without readily determinable fair values at cost, less impairment, adjusted for subsequent observable price changes.
In this measurement alternative method, changes in the carrying value of the equity investments are reflected in current earnings.
Changes in the carrying value of the equity investment are required to be made whenever there are observable price changes in
orderly transactions for the identical or similar investment of the same issuer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:DiscontinuedOperationsPolicyTextBlock"><p id="xdx_848_eus-gaap--DiscontinuedOperationsPolicyTextBlock_z0tAJNQJEqF6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>d.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_866_zT2nEPd7Xj7l">Discontinued operations</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Upon
divestiture of a business, the Company classifies such business as a discontinued operation, if the divested business represents
a strategic shift that has (or will have) a major effect on an entity&#8217;s operations and financial results. For disposals
other than by sale such as abandonment, the results of operations of a business would not be recorded as a discontinued operation
until the period in which the business is actually abandoned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Masthercell Business divestiture qualifies as a discontinued operation and therefore has been presented as such.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
results of businesses that have qualified as a discontinued operation have been presented as such for all reporting periods. Results
of discontinued operations include all revenues and expenses directly derived from such businesses; general corporate overhead
is not allocated to discontinued operations. Any loss or gain that arose from the divestiture of a business that qualifies as
discontinued operations is included within the results of the discontinued operations. The Company included information regarding
cash flows from discontinued operations (See Note 3).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zGbbnJW7W7Ok" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>e.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_864_z5uAMJlNwL1">Cash Equivalents</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company considers cash equivalents to be all short-term, highly liquid investments, which include money market instruments, that
are not restricted as to withdrawal or use, and short-term bank deposits with original maturities of three months or less from
the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"><p id="xdx_841_eus-gaap--ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_z0k9DUhdcDQ3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>f.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_865_zd0MD2bxejCe">Cost of research and development and research and development services, net </span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Cost
of research and development and research and development services include costs directly attributable to the conduct of research
and development activities, including the cost of salaries, stock-based compensation expenses, payroll taxes and other employees&#8217;
benefits, lab expenses, consumable equipment, courier fees, travel expenses, professional fees and consulting fees. All costs
associated with research and developments are expensed as incurred. Participation from government departments and from research
foundations for development of approved projects is recognized as a reduction of expense as the related costs are incurred. Research
and development in-process acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative
future use, is expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_84D_eus-gaap--ConsolidationPolicyTextBlock_z58jOYQ7GVW2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>g.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86B_zFu2oE6YT6Md">Principles of Consolidation</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
consolidated financial statements include the accounts of the Company and its Subsidiaries. All intercompany transactions and
balances have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 94; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:EquityMethodInvestmentsPolicy"><p id="xdx_849_eus-gaap--EquityMethodInvestmentsPolicy_z6a50xTL5SCf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>h.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_869_zNyNwcNiwFv5">Non-Marketable Equity Investments</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s investments in certain non-marketable equity securities in which it has the ability to exercise significant influence,
but it does not control through variable interests or voting interests. These are accounted for under the equity method of accounting
and presented as Investment in associates, net, in the Company&#8217;s consolidated balance sheets. Under the equity method, the
Company recognizes its proportionate share of the comprehensive income or loss of the investee. The Company&#8217;s share of income
and losses from equity method investments is included in share in losses of associated company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company reviews its investments accounted for under the equity method for possible impairment, which generally involves an analysis
of the facts and changes in circumstances influencing the investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:FunctionalCurrencyPolicyTextBlock"><p id="xdx_840_ecustom--FunctionalCurrencyPolicyTextBlock_zoWTiL5Cyoh8" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>i.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86E_zugML1cnvI3l">Functional Currency</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
currency of the primary economic environment in which the operations of the Company and part of its Subsidiaries are conducted
is the U.S. dollar (&#8220;$&#8221; or &#8220;dollar&#8221;). The functional currency of the Belgian Subsidiaries is the Euro
(&#8220;&#8364;&#8221; or &#8220;Euro&#8221;). The functional currency of Orgenesis Korea is the Won (&#8220;KRW&#8221;). Most
of the Company&#8217;s expenses are incurred in dollars, and the source of the Company&#8217;s financing has been provided in
dollars. Thus, the functional currency of the Company and its other subsidiaries is the dollar. Transactions and balances originally
denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using
historical and current exchange rates for nonmonetary and monetary balances, respectively. For foreign transactions and other
items reflected in the statements of operations, the following exchange rates are used: (1) for transactions &#8211; exchange
rates at transaction dates or average rates and (2) for other items (derived from nonmonetary balance sheet items such as depreciation)
&#8211; historical exchange rates. The resulting transaction gains or losses are recorded as financial income or expenses. The
financial statements of the Belgian Subsidiaries and Orgenesis Korea are included in the consolidated financial statements, translated
into U.S. dollars. Assets and liabilities are translated at year-end exchange rates, while revenues and expenses are translated
at yearly average exchange rates during the year. Differences resulting from translation of assets and liabilities are presented
as other comprehensive income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zbJ1zWty11Zh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>j.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86A_zLI2WVvdPIy5">Inventory</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s inventory consists of raw material for use for the services provided. The Company periodically evaluates the quantities
on hand. Cost of the raw materials is determined using the weighted average cost method. The inventory is recorded at the lower
of cost or net realizable value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrb5SiWXpmAg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>k.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_868_z7qU0zEBmU38">Property, plant and Equipment</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Property,
plant and equipment are recorded at cost and depreciated by the straight-line method over the estimated useful lives of the related
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock"><p id="xdx_890_ecustom--ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock_zh1n2tVBzNya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Annual
rates of depreciation are presented in the table below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BF_z2zA03goEqb4" style="display: none">SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Useful Life (Years)</b></span></p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Production facility</td><td style="width: 2%">&#160;</td>
    <td style="width: 32%; text-align: center"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember__srt--RangeAxis__srt--MinimumMember_zrZKyWqXBHH3" title="Weighted Average Useful Life"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_ProductionFacilityMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> - <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember__srt--RangeAxis__srt--MaximumMember_zvU9vrNQ1Hj2" title="Weighted Average Useful Life"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_ProductionFacilityMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zxVC4f2PFcZh" title="Weighted Average Useful Life"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_EquipmentMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">2</ix:nonNumeric></span> - <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zY76Fk7sDRRg" title="Weighted Average Useful Life"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_EquipmentMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office equipment and computers</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zN3XZviUAKbe" title="Weighted Average Useful Life"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span> - <span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zZhJXWuhWnrf" title="Weighted Average Useful Life"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">17</ix:nonNumeric></span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A2_z9w1ZtH7Elsl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_845_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zMSnFezUZica" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>l.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_863_zJ3WcX5X9dV7">Intangible assets</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock"><p id="xdx_898_ecustom--ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock_zbOYS9vpY4p6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Intangible
assets and their useful lives are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B8_zEKSONEQ5FDi" style="display: none">SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful Life (Years)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Amortization Recorded at Comprehensive</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Loss Line Item</p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Customer Relationships</td><td style="width: 2%">&#160;</td>
    <td style="width: 22%; text-align: center"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zO06hxwW9q0a" title="Intangible assets and useful lives (Years)"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_CustomerRelationshipsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">10</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 44%; text-align: center">Amortization of intangible assets</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Know-How</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowhowMember_zcXooVGZJTe5" title="Intangible assets and useful lives (Years)"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_KnowhowMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">12</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: center">Amortization of intangible assets</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Technology</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TechnologyMember_zEsA4tuODn0k" title="Intangible assets and useful lives (Years)"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_TechnologyMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">15</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: center">Amortization of intangible assets</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A6_z9WCdJJlXZr2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 95; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Intangible
assets are recorded at acquisition less accumulated amortization and impairment. Definite lived intangible assets are amortized
over their estimated useful life using the straight-line method, which is determined by identifying the period over which the
cash flows from the asset are expected to be generated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock"><p id="xdx_843_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zi7iV6mHs2b9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>m.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_865_zd6VISbnwa5e">Goodwill</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Goodwill represents
the excess of consideration transferred over the value assigned to the net tangible and identifiable intangible assets of businesses
acquired. Goodwill is allocated to reporting units expected to benefit from the business combination. Goodwill is not amortized
but rather tested for impairment at least annually in the fourth quarter, or more frequently if events
or changes in circumstances indicate that goodwill may be impaired. Following the sale of Masthercell the Company manages
the business as one operating segment and one reporting unit. Goodwill impairment is recognized when the quantitative assessment
results in the carrying value exceeding the fair value, in which case an impairment charge is recorded to the extent the
carrying value exceeds the fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">There
were <span id="xdx_90E_eus-gaap--GoodwillImpairmentLoss_pn5n6_do_c20200101__20201231_zPR5LqcFQzkg"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2020-01-01to2020-12-31" format="ixt-sec:numwordsen" decimals="-5" scale="6" unitRef="USD">no</ix:nonFraction></span></span> <span style="font: 10pt Times New Roman, Times, Serif">impairment
charges to goodwill during the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zrrNaOitkMu6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>n.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_866_zOv0AtkRWS3g">Impairment of Long-lived Assets</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company reviews its property, plants and equipment, intangible assets subject to amortization and other long-lived assets for
impairment whenever events or changes in circumstances indicate that the carrying amount of an asset class may not be recoverable.
Indicators of potential impairment include: an adverse change in legal factors or in the business climate that could affect the
value of the asset; an adverse change in the extent or manner in which the asset is used or is expected to be used, or in its
physical condition; and current or forecasted operating or cash flow losses that demonstrate continuing losses associated with
the use of the asset. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying
value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected
cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is
written down to fair value, based on the related estimated discounted cash flows. There were <span id="xdx_906_eus-gaap--AssetImpairmentCharges_pn5n6_do_c20200101__20201231_z1wGWkiwhMsg" title="Impairment of long-lived asset"><span id="xdx_904_eus-gaap--AssetImpairmentCharges_pn5n6_do_c20190101__20191231_zrB1t9GtR964" title="Impairment of long-lived asset"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2020-01-01to2020-12-31" format="ixt-sec:numwordsen" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2019-01-012019-12-31" format="ixt-sec:numwordsen" decimals="-5" scale="6" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> impairment charges in the year
ended December 31, 2020 and 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_843_eus-gaap--IncomeTaxPolicyTextBlock_zYJB765LFvch" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>o.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86D_zJoBX6muei4">Income Taxes</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">1)
With respect to deferred taxes, income taxes are computed using the asset and liability method. Under the asset and liability
method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and
tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is
recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">2)
The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the
tax position for recognition by determining if the available evidence indicates that it is more likely than not that the position
will be sustained on examination. If this threshold is met, the second step is to measure the tax position as the largest amount
that is greater than <span id="xdx_90E_ecustom--IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent_pii_dp_uPercentage_c20200101__20201231_zXxFP1WFAnW7" title="Income tax examination, likelihood of unfavorable settlement percent"><ix:nonFraction name="ORGS:IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">50</ix:nonFraction></span>% likely of being realized upon ultimate settlement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">3)
Taxes that would apply in the event of disposal of investment in Subsidiaries have not been taken into account in computing the
deferred income taxes, as it is the Company&#8217;s intention to hold these investments and not realize them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 96; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zSIop9rtFqEe" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>p.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_865_zPzQrxQKQuEf">Stock-based Compensation</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes
stock-based compensation for the estimated fair value of share-based awards. The Company measures compensation expense for share-based
awards based on estimated fair values on the date of grant using the Black-Scholes option-pricing model. This option pricing model
requires estimates as to the option&#8217;s expected term and the price volatility of the underlying stock. The Company amortizes
the value of share-based awards to expense over the vesting period on a straight-line basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:RedeemableNoncontrollingInterestPolicyTextBlock"><p id="xdx_848_ecustom--RedeemableNoncontrollingInterestPolicyTextBlock_zsEnUDcEFlxj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>q.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_866_zgCh5Z6OyJih">Redeemable Non-controlling Interest</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Non-controlling
interests with embedded redemption features, whose settlement is not at the Company&#8217;s discretion, are considered redeemable
non-controlling interest. Redeemable non-controlling interests are considered to be temporary equity and are therefore presented
as a mezzanine section between liabilities and equity on the Company&#8217;s consolidated balance sheets. Subsequent adjustment
of the amount presented in temporary equity is required only if the Company&#8217;s management estimates that it is probable that
the instrument will become redeemable. Adjustments of redeemable non-controlling interest to its redemption value are recorded
through additional paid-in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zNJx6RzESn1i" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>r.
<span id="xdx_867_zU7V6Xvszvll">Loss (income) per Share of Common Stock</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Basic
net loss (income) per share is computed by dividing the net loss (income) for the period by the weighted average
number of shares of common stock outstanding for each period. Diluted net loss (income) per share is based upon the weighted
average number of common shares and of common shares equivalents outstanding when dilutive. Common share equivalents include:
(i) outstanding stock options and warrants which are included under the treasury share method when dilutive, and (ii) common shares
to be issued under the assumed conversion of the Company&#8217;s outstanding convertible loans and debt, which are included under
the if-converted method when dilutive (See Note 14).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_z9iIMxbJLEt3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>s.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86C_zAOs2P028xn">Concentration of Credit Risk</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Financial
instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents,
bank deposits and certain receivables. The Company held these instruments with highly rated financial institutions and the Company
has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant
credit risk on these instruments apart of accounts receivable. The Company performs ongoing credit evaluations of its customers
for the purpose of determining the appropriate allowance for doubtful accounts. An appropriate allowance for doubtful accounts
is included in the accounts and netted against accounts receivable. In the year ended December 31, 2020 the Company has not experienced
any material credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Bad
debt allowance is created when objective evidence exists of inability to collect all sums owed it under the original terms of
the debit balances. Material customer difficulties, the probability of their going bankrupt or undergoing economic reorganization
and insolvency or material delays in payments are all considered indicative of reduced debtor balance value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:TreasurySharesPolicyTextBlock"><p id="xdx_84E_ecustom--TreasurySharesPolicyTextBlock_zLbbSVa2voY4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>t.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86D_zCEKwbqlGi5h">Treasury shares</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company repurchases its ordinary shares from time to time on the open market and holds such shares as treasury stock. The Company
presents the cost to repurchase treasury stock as a reduction of shareholders&#8217; equity. During the years ended December 31,
2020, the Company repurchased <span id="xdx_90D_eus-gaap--TreasuryStockShares_iI_pii_c20201231_zSfcLu6T32ck"><ix:nonFraction name="us-gaap:TreasuryStockShares" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,309</ix:nonFraction></span></span>
<span style="font: 10pt Times New Roman, Times, Serif">shares. The Company did not reissue nor cancel treasury
shares during the year ended December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:BeneficialConversionFeatureBcfPolicyTextBlock"><p id="xdx_84E_ecustom--BeneficialConversionFeatureBcfPolicyTextBlock_zcdFRGpqeFm1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>u.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_861_zwdTIHksyfce">Beneficial Conversion Feature (&#8220;BCF&#8221;)</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">When
the Company issues convertible debt, if the stock price is greater than the effective conversion price (after allocation of the
total proceeds) on the measurement date, the conversion feature is considered &#8220;beneficial&#8221; to the holder. If there
is no contingency, this difference is treated as issued equity and reduces the carrying value of the host debt; the discount is
accreted as deemed interest on the debt (See Note 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 97; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_84C_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zqsBQb7xNxJc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>v.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_862_zmJDopxvL1Jk">Other Comprehensive Loss</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other
comprehensive loss represents adjustments of foreign currency translation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_841_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zI8Vwp6qBLh4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>w.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_864_zmzvFYMGY2lf">Revenue from Contracts with Customers</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes revenue from contracts with customers according to ASC 606, <i>Revenue from Contracts with Customers</i> and
the related amendments (&#8220;New Revenue Standard&#8221;) to all contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s agreements are primarily service contracts that range in duration from a few months to one year. The Company recognizes
revenue when control of these services is transferred to the customer for an amount, referred to as the transaction price, which
reflects the consideration to which the Company is expected to be entitled in exchange for those goods or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
contract with a customer exists only when:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    parties to the contract have approved it and are committed to perform their respective obligations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance
    obligations&#8221;);</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company can determine the transaction price for the goods or services to be transferred; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled
    in exchange for the goods or services that will be transferred to the customer.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company does not adjust the promised amount of consideration for the effects of a significant financing component since the Company
expects, at contract inception, that the period between the time of transfer of the promised goods or services to the customer
and the time the customer pays for these goods or services to be generally one year or less. The Company&#8217;s credit terms
to customers are in average between thirty and one hundred and fifty days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Nature
of Revenue Streams</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s main revenue streams from continuing operation are POC development services and Cell Process Development
Services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>POC
Development Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Revenue
recognized under contracts for POC development services may, in some contracts, represent multiple performance obligations (where
promises to the customers are distinct) in circumstances in which the work packages are not interrelated or the customer is able
to complete the services performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">For
arrangements that include multiple performance obligations, the transaction price is allocated to the identified performance obligations
based on their relative standalone selling prices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes revenue when, or as, it satisfies a performance obligation. At contract inception, the Company determines whether
the services are transferred over time or at a point in time. Performance obligations that have no alternative use and that the
Company has the right to payment for performance completed to date, at all times during the contract term, are recognized over
time. All other Performance obligations are recognized as revenues by the company at point of time (upon completion).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Included
in POC development services is Hospital supplies revenue which is derived principally from the sale or lease of products and the
performance of services to hospitals or other medical providers. Revenue is earned and recognized when product and services are
received by the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;Significant
Judgement and Estimates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Significant
judgment is required to</span> identifying the distinct performance obligations and estimating the standalone selling price of
each distinct performance obligation, and identifying which performance obligations create assets with alternative use to the
Company, which results in revenue recognized upon completion, and which performance obligations are transferred to the customer
over time.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Practical
Expedients</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">As
part of ASC 606, the Company has adopted several practical expedients including the Company&#8217;s determination that it need
not adjust the promised amount of consideration for the effects of a significant financing component since the Company expects,
at contract inception, that the period between when the Company transfers a promised service to the customer and when the customer
pays for that service will be one year or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 98; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>Cell
Process Development Services (mainly discontinued operations)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Revenue
recognized under contracts for cell process development services may, in some contracts, represent multiple performance obligations
(where promises to the customers are distinct) in circumstances in which the work packages and milestones are not interrelated
or the customer is able to complete the services performed independently or by using competitors of the Company. In other contracts
when the above circumstances are not met, the promises are not considered distinct and the contract represents one performance
obligation. All performance obligations are satisfied over time, as there is no alternative use to the services it performs, since,
in nature, those services are unique to the customer, which retain the ownership of the intellectual property created through
the process. Additionally, due to the non-refundable upfront payment the customer pays, together with the payment term and cancellation
fine, it has a right to payment (which include a reasonable margin), at all times, for work completed to date, which is enforceable
by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
arrangements that include multiple performance obligations, the transaction price is allocated to the identified performance obligations
based on their relative standalone selling prices. For these contracts, the standalone selling prices are based on the Company&#8217;s
normal pricing practices when sold separately with consideration of market conditions and other factors, including customer demographics
and geographic location.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company measures the revenue to be recognized over time on a contract by contract basis, determining the use of either a cost-based
input method or output method, depending on whichever best depicts the transfer of control over the life of the performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>Tech
Transfer Services (discontinued operations)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Revenue
recognized under contracts for tech transfer services are considered a single performance obligation, as all work packages (including
data collection, GMP documentation, validation runs) and milestones are interrelated. Additionally, the customer is unable to
complete services of work performed independently or by using competitors of the Company. Revenue is recognized over time using
a cost-based based input method where progress on the performance obligation is measured by the proportion of actual costs incurred
to the total costs expected to complete the contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>Cell
Manufacturing Services (discontinued operations)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Revenues
from cell manufacturing services represent a single performance obligation which is recognized over time. The progress towards
completion will continue to be measured on an output measure based on direct measurement of the value transferred to the customer
(units produced).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>Reimbursed
Expenses (discontinued operations)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company includes reimbursed expenses in revenues and costs of revenue as the Company is primarily responsible for fulfilling the
promise to provide the specified service, including the integration of the related services into a combined output to the customer,
which are inseparable from the integrated service. These costs include such items as consumable, reagents, transportation and
travel expenses, over which the Company has discretion in establishing prices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 99; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Change
Orders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Changes
in the scope of work are common and can result in a change in transaction price, equipment used and payment terms. Change orders
are evaluated on a contract-by-contract basis to determine if they should be accounted for as a new contract or as part of the
existing contract. Generally, services from change orders are not distinct from the original performance obligation. As a result,
the effect that the contract modification has on the contract revenue, and measure of progress, is recognized as an adjustment
to revenue when they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Costs
of Revenue (discontinued operations)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Costs
of revenue include (i) compensation and benefits for billable employees and personnel involved in production, data management
and delivery, and the costs of acquiring and processing data for the Company&#8217;s information offerings; (ii) costs of staff
directly involved with delivering services offerings and engagements; (iii) consumables used for the services; and (iv) other
expenses directly related to service contracts such as courier fees, laboratory supplies, professional services and travel expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zM949RtKzIP9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>x.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_864_zoYBMzuMVFJe">Leases</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company adopted
the new lease standard ASC 842 and all the related amendments on January 1, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2.
If any of these five criteria is met, The Company classifies the lease as a finance lease; otherwise, the Company classifies the
lease as an operating lease. <span id="xdx_904_ecustom--LeaseClassificationDiscription_c20200101__20201231" title="Lease classification discription"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="ORGS:LeaseClassificationDiscription">When determining lease classification, the Company&#8217;s approach in assessing two of the mentioned
criteria is: (i) generally 75% or more of the remaining economic life of the underlying asset is a major part of the remaining
economic life of that underlying asset; and (ii) generally 90% or more of the fair value of the underlying asset comprises substantially
all of the fair value of the underlying asset.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Operating
leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the consolidated
balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">ROU
assets represent Orgenesis&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation
to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date
based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the
information available at the commencement date to determine the present value of the lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
standard also provides practical expedients for an entity&#8217;s ongoing accounting. The Company elected the short-term lease
recognition exemption for all leases with a term shorter than 12 months. This means that for those leases, the Company does not
recognize ROU assets or lease liabilities, including not recognizing ROU assets or lease liabilities for existing short-term leases
of those assets in transition, but recognizes lease expenses over the lease term on a straight-line basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Lease
terms will include options to extend or terminate the lease when it is reasonably certain that Orgenesis will exercise or not
exercise the option to renew or terminate the lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock"><p id="xdx_84F_ecustom--RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zUdPYL8yJYz5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>y.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86B_zlPuyTRD20wc">Recently issued accounting pronouncements, not yet adopted</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2016, the FASB issued ASU 2016-13 &#8220;Financial Instruments&#8212;Credit Losses&#8212;Measurement of Credit Losses on
Financial Instruments.&#8221; This guidance replaces the current incurred loss impairment methodology with a methodology that
reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform
credit loss estimates. The guidance will be effective for Smaller Reporting Companies (SRCs, as defined by the SEC) for the fiscal
year beginning on January 1, 2023, including interim periods within that year. The Company is currently evaluating this guidance
to determine the impact it may have on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 100; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, Debt with Conversion and Other Options (Subtopic
470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments
and Contracts in an Entity&#8217;s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation
models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument
with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required
for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it.
The ASU also simplifies the diluted net income per share calculation in certain areas. The new guidance is effective for annual
and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years beginning after December
15, 2020, and interim periods within those fiscal years. The Company is currently evaluating the impact that this new guidance
will have on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zA9T2OUm4Tfi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">z.</span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86D_zHRjqYLmA3cc">Newly issued and recently adopted accounting pronouncements</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company early adopted ASU 2019-12 on January 1, 2020, which did not have a material impact on the Consolidated Financial Statements
except for the removal of the exception related to intra-period tax allocations. Commencing from January 1, 2020, the Company
followed the general intra-period allocation of tax expenses. The Company had incurred a loss from continuing operations and subsequent
to the adoption of ASU 2019-12, the Company determined the amount attributable to continuing operations without regard to the
tax effect of other items. The ASU 2019-12 amendment related to the intra-period tax allocation was applied prospectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Had
the Company not adopted ASU 2019-12, an approximately $<span id="xdx_902_eus-gaap--IncomeTaxExpenseBenefit_pn5n6_c20200101__20201231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201912Member_zgebC0H9Ojm1" title="Income Tax Expense (Benefit)"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-01-012020-12-31_us-gaap_AccountingStandardsUpdate201912Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">20</ix:nonFraction></span> million tax benefit would have been recognized along with corresponding
decreases to net loss from continuing operations with a corresponding increase in tax expenses and decrease in net income resulting
from discontinued operations. The Company had no intra-period tax allocation items in prior years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_84D_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zhAsVeCQvSik" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>aa.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86C_z1U2luzhxRDl">Reclassifications</span> </i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Certain
reclassifications have been made to the prior years&#8217; financial statements to conform to the current year presentation. These
reclassifications had no net effect on previously reported results of operations.</span></p>

</ix:nonNumeric><p id="xdx_852_zoOFYUCTqTvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"><p id="xdx_805_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_z5kixiFfTK2e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
3 &#8211; <span id="xdx_82A_zgDFcvg3IEmk">DISCONTINUED OPERATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
February 2, 2020, the Company entered into a Purchase Agreement with GPP, Masthercell and the Buyer. Pursuant to the terms and
conditions of the Purchase Agreement, Sellers agreed to sell <span id="xdx_909_ecustom--PercentageOfOutstandingEquityInterests_iI_pii_dp_c20200202__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zvcmOPmYYGjk" title="Percentage of outstanding equity interests"><ix:nonFraction name="ORGS:PercentageOfOutstandingEquityInterests" contextRef="AsOf2020-02-02_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">100</ix:nonFraction>%</span> of the outstanding equity interests of Masthercell to Buyer
for an aggregate nominal purchase price of $<span id="xdx_90A_ecustom--AggregateNominalPurchasePrice_pn5n6_c20200201__20200202__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zBxUQgH60ZFg" title="Aggregate nominal purchase price of outstanding equity interests"><ix:nonFraction name="ORGS:AggregateNominalPurchasePrice" contextRef="From2020-02-012020-02-02_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">315</ix:nonFraction></span> million. The Company has determined that the Masthercell Business meets the criteria
to be classified as discontinued operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
February 10, 2020, the Masthercell Sale was consummated in accordance with the terms of the Purchase Agreement. After accounting
for GPP&#8217;s liquidation preference and equity stake in Masthercell, as well as SFPI &#8211; FPIM&#8217;s interest in MaSTherCell,
distributions to Masthercell option holders and transaction costs, the Company received approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20200209__20200210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zXXsIlh7t9H2" title="Proceeds from Issuance or Sale of Equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2020-02-092020-02-10_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">126.7</ix:nonFraction></span> million at the closing
of the Masthercell Sale, of which $<span id="xdx_90E_ecustom--RepaymentOfIntercompanyLoansAndPayables_pn5n6_c20200209__20200210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zTNolHBnENQe" title="Repayment of intercompany loans and payables"><ix:nonFraction name="ORGS:RepaymentOfIntercompanyLoansAndPayables" contextRef="From2020-02-092020-02-10_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.2</ix:nonFraction></span> million was used for the repayment of intercompany loans and payables, including $<span id="xdx_900_ecustom--RepaymentOfIntercompanyLoansAndPayables_pn5n6_c20200209__20200210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellSAMember_zPLBGhlZ7rM6" title="Repayment of intercompany loans and payables"><ix:nonFraction name="ORGS:RepaymentOfIntercompanyLoansAndPayables" contextRef="From2020-02-092020-02-10_custom_MasthercellSAMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.6</ix:nonFraction></span> million
of payables to MaSTherCell.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Due
to the sale of the controlling interest in Masthercell, the Company retrospectively reclassified the assets and liabilities of
these entities as assets and liabilities of discontinued operations and included the financial results of these entities as discontinued
operations in the Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Discontinued
operations relate to the Masthercell Business. The comprehensive loss and balance sheet for this operation are separately reported
as discontinued operations for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 101; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zmkQyrHutPYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
financial results of the Masthercell Business are presented as income (loss) from discontinued operations, net of income taxes
on the Company&#8217;s consolidated statement of comprehensive loss. The following table presents the financial results associated
with the Masthercell Business operation as reflected in the Company&#8217;s Consolidated Comprehensive loss (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;<span id="xdx_8B6_zpoTCAyl7kKi" style="display: none">SCHEDULE OF DISCONTINUED OPERATION AND BALANCE SHEETS</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">OPERATIONS</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231_zeOdHvQTFCM3" title="Revenues" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,556</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231_zDshnLGkj0M8" title="Revenues" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31,053</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c20200101__20201231_pn3n3" title="Cost of revenues" style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,482</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c20190101__20191231_pn3n3" title="Cost of revenues" style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,318</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cost of research and development and research and development services, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet_c20200101__20201231_pn3n3" title="Cost of research and development and research and development services, net" style="text-align: right"><ix:nonFraction name="ORGS:CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet_c20190101__20191231_pn3n3" title="Cost of research and development and research and development services, net" style="text-align: right"><ix:nonFraction name="ORGS:CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amortization of intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DepreciationAndAmortizationDiscontinuedOperations_c20200101__20201231_pn3n3" title="Amortization of intangible assets" style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">137</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DepreciationAndAmortizationDiscontinuedOperations_c20190101__20191231_pn3n3" title="Amortization of intangible assets" style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,631</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling, general and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c20200101__20201231_pn3n3" title="Selling, general and administrative expenses" style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,896</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c20190101__20191231_pn3n3" title="Selling, general and administrative expenses" style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,886</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other (income) expenses, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherExpenses_c20200101__20201231_pn3n3" title="Other (income) expenses, net" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ORGS:DisposalGroupIncludingDiscontinuedOperationOtherExpenses" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">305</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherExpenses_c20190101__20191231_pn3n3" title="Other (income) expenses, net" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ORGS:DisposalGroupIncludingDiscontinuedOperationOtherExpenses" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">207</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_c20200101__20201231_pn3n3" title="Operating loss" style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,271</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_c20190101__20191231_pn3n3" title="Operating loss" style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,629</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Financial expenses (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet_pn3n3_c20200101__20201231_zGXmlGGliLjl" title="Financial expenses (income), net" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ORGS:DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet_pn3n3_c20190101__20191231_ztHwbrb670Ki" title="Financial expenses (income), net" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ORGS:DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_c20200101__20201231_pn3n3" title="Loss before income taxes" style="text-align: right"><ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,242</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_c20190101__20191231_pn3n3" title="Loss before income taxes" style="text-align: right"><ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,660</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax expenses (income)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DiscontinuedOperationTaxEffectOfDiscontinuedOperation_c20200101__20201231_pn3n3" title="Tax expenses (income)" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">30</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DiscontinuedOperationTaxEffectOfDiscontinuedOperation_c20190101__20191231_pn3n3" title="Tax expenses (income)" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">792</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss from discontinuing operation, net of tax</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_ecustom--IncomeLossFromDiscontinuedOperationNetOfTax_c20200101__20201231_pn3n3" title="Net loss from discontinuing operation, net of tax" style="text-align: right"><ix:nonFraction name="ORGS:IncomeLossFromDiscontinuedOperationNetOfTax" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,212</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--IncomeLossFromDiscontinuedOperationNetOfTax_c20190101__20191231_pn3n3" title="Net loss from discontinuing operation, net of tax" style="text-align: right"><ix:nonFraction name="ORGS:IncomeLossFromDiscontinuedOperationNetOfTax" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,452</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">DISPOSAL</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on disposal before income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_c20200101__20201231_pn3n3" title="Gain on disposal before income taxes" style="text-align: right"><ix:nonFraction name="us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">96,918</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_c20190101__20191231_pn3n3" title="Gain on disposal before income taxes" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0958">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Provision for income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal_c20200101__20201231_pn3n3" title="Provision for income taxes" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0960">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal_c20190101__20191231_pn3n3" title="Provision for income taxes" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0962">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on disposal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_c20200101__20201231_pn3n3" title="Gain on disposal" style="text-align: right"><ix:nonFraction name="us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">96,918</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_c20190101__20191231_pn3n3" title="Gain on disposal" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0966">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net profit (loss) from discontinuing operation, net of tax</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--NetProfitLossFromDiscontinuingOperationNetOfTax_c20200101__20201231_pn3n3" title="Net profit (loss) from discontinuing operation, net of tax" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ORGS:NetProfitLossFromDiscontinuingOperationNetOfTax" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">95,706</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--NetProfitLossFromDiscontinuingOperationNetOfTax_c20190101__20191231_pn3n3" title="Net profit (loss) from discontinuing operation, net of tax" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="ORGS:NetProfitLossFromDiscontinuingOperationNetOfTax" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,452</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table is a summary of the assets and liabilities of discontinued operations (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 78%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_pn3n3_c20191231_zVVTRihLJ2J2" title="Cash and cash equivalents" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,281</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--DisposalGroupIncludingDiscontinuedOperationRestrictedCash_c20191231_pn3n3" title="Restricted cash" style="text-align: right"><ix:nonFraction name="ORGS:DisposalGroupIncludingDiscontinuedOperationRestrictedCash" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">186</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_c20191231_pn3n3" title="Accounts receivable, net" style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,654</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_c20191231_pn3n3" title="Prepaid expenses and other receivables" style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">845</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Grants receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--DisposalGroupIncludingDiscontinuedOperationGrantsReceivable_c20191231_pn3n3" title="Grants receivable" style="text-align: right"><ix:nonFraction name="ORGS:DisposalGroupIncludingDiscontinuedOperationGrantsReceivable" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,979</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DisposalGroupIncludingDiscontinuedOperationInventory1_c20191231_pn3n3" title="Inventory" style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,907</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--DisposalGroupIncludingDiscontinuedOperationsDeposits_c20191231_pn3n3" title="Deposits" style="text-align: right"><ix:nonFraction name="ORGS:DisposalGroupIncludingDiscontinuedOperationsDeposits" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">326</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_c20191231_pn3n3" title="Property and equipment, net" style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,149</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Intangible assets, net (mainly Know How)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_iI_pn3n3_c20191231_zGQWzg7mr6C4" title="Intangible assets, net (mainly Know How)" style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,858</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets_c20191231_pn3n3" title="Operating lease right-of-use assets" style="text-align: right"><ix:nonFraction name="ORGS:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,860</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGoodwill1_c20191231_pn3n3" title="Goodwill" style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,129</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherAssets_c20191231_pn3n3" title="Other assets" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">47</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL CURRENT ASSETS OF DISCONTINUED OPERATIONS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperation_iI_pn3n3_c20191231_z50nh6viLcIc" title="TOTAL CURRENT ASSETS OF DISCONTINUED OPERATIONS" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75,221</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 78%; text-align: left">Accounts payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayable_c20191231_pn3n3" title="Accounts payable" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,756</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_c20191231_pn3n3" title="Accrued expenses and other payables" style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">372</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Employees and related payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables_c20191231_pn3n3" title="Employees and related payables" style="text-align: right"><ix:nonFraction name="ORGS:DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,047</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Advance payments on account of grant</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant_c20191231_pn3n3" title="Advance payments on account of grant" style="text-align: right"><ix:nonFraction name="ORGS:DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,227</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Short-term loans and current maturities of long- term loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans_c20191231_pn3n3" title="Short-term loans and current maturities of long- term loans" style="text-align: right"><ix:nonFraction name="ORGS:DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">372</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Contract liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_c20191231_pn3n3" title="Contract liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,301</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Current maturities of long-term finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases_c20191231_pn3n3" title="Current maturities of long-term finance leases" style="text-align: right"><ix:nonFraction name="ORGS:DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">291</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Current maturities of operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases_c20191231_pn3n3" title="Current maturities of operating leases" style="text-align: right"><ix:nonFraction name="ORGS:DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,365</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Non-current operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases_c20191231_pn3n3" title="Non-current operating leases" style="text-align: right"><ix:nonFraction name="ORGS:DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,069</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loans payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--DisposalGroupIncludingDiscontinuedOperationLoansPayable_c20191231_pn3n3" title="Loans payable" style="text-align: right"><ix:nonFraction name="ORGS:DisposalGroupIncludingDiscontinuedOperationLoansPayable" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,230</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Deferred taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_c20191231_pn3n3" title="Deferred taxes" style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,868</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Long-term finance leases</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases_c20191231_pn3n3" title="Long-term finance leases" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ORGS:DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">688</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL CURRENT LIABILITIES OF DISCONTINUED OPERATIONS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c20191231_pn3n3" title="TOTAL CURRENT LIABILITIES OF DISCONTINUED OPERATIONS" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31,586</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 102; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Property,
plants and equipment, net and right-of-use assets by geographical location were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--PropertyPlantAndEquipmentNetAndRightOfUseAssets_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--US_zphmKqdJ6fB6" title="Property, plants and equipment, net and right-of-use assets" style="width: 26%; text-align: right"><ix:nonFraction name="ORGS:PropertyPlantAndEquipmentNetAndRightOfUseAssets" contextRef="AsOf2019-12-31_country_US" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,707</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Belgium</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--PropertyPlantAndEquipmentNetAndRightOfUseAssets_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--BE_zrqOc8vCk7Rc" title="Property, plants and equipment, net and right-of-use assets" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ORGS:PropertyPlantAndEquipmentNetAndRightOfUseAssets" contextRef="AsOf2019-12-31_country_BE" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,302</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--PropertyPlantAndEquipmentNetAndRightOfUseAssets_iI_pn3n3_c20191231_zJ5y9rAN0zs2" title="Property, plants and equipment, net and right-of-use assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ORGS:PropertyPlantAndEquipmentNetAndRightOfUseAssets" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31,009</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table represents the components of the cash flows from discontinued operations (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net cash flows used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_pn3n3_c20200101__20201231_zacoQ03y73D4" title="Net cash flows provided by (used in) operating activities" style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,409</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_c20190101__20191231_pn3n3" title="Net cash flows provided by (used in) operating activities" style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,248</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash flows used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_c20200101__20201231_pn3n3" title="Net cash flows used in investing activities" style="text-align: right">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">579</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_c20190101__20191231_pn3n3" title="Net cash flows used in investing activities" style="text-align: right">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,621</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash flows (used in) provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_c20200101__20201231_pn3n3" title="Net cash flows (used in) provided by financing activities" style="text-align: right">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">51</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_c20190101__20191231_pn3n3" title="Net cash flows (used in) provided by financing activities" style="text-align: right"><ix:nonFraction name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,570</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AB_zMbRXlROwq2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Disaggregation
of Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock"><p id="xdx_896_ecustom--ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock_zCO9x69k1qOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table disaggregates the Company&#8217;s revenues by major revenue streams related to discontinued operations (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zm80mblxonAi" style="display: none">SCHEDULE OF DISAGGREGATION OF REVENUE RELATED TO DISCONTINUED OPERATIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Revenue stream:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Cell process development services</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesMember_zmYvscrkc938" title="Disposal Group, Including Discontinued Operation, Revenue" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="From2020-01-012020-12-31_custom_CellProcessDevelopmentServicesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,556</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231__srt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesMember_zi8SlHnnKwZ1" title="Disposal Group, Including Discontinued Operation, Revenue" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="From2019-01-012019-12-31_custom_CellProcessDevelopmentServicesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,834</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Tech transfer services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--TechTransferServicesMember_zcAyJvlL4sxc" title="Disposal Group, Including Discontinued Operation, Revenue" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1048">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231__srt--ProductOrServiceAxis__custom--TechTransferServicesMember_zbf29ju37tFf" title="Disposal Group, Including Discontinued Operation, Revenue" style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="From2019-01-012019-12-31_custom_TechTransferServicesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,396</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Cell manufacturing services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--CellManufacturingServicesMember_zdo3UKetmdie" title="Disposal Group, Including Discontinued Operation, Revenue" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231__srt--ProductOrServiceAxis__custom--CellManufacturingServicesMember_zo6KYpAjIKDb" title="Disposal Group, Including Discontinued Operation, Revenue" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="From2019-01-012019-12-31_custom_CellManufacturingServicesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,823</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231_zDS1Tqq4vpk3" title="Disposal Group, Including Discontinued Operation, Revenue" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,556</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231_z3CT2nlfEL76" title="Disposal Group, Including Discontinued Operation, Revenue" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31,053</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AE_zdgAKf1XHhVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Redeemable
Non-Controlling Interest of Discontinued Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>a.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Subscription
    and Shareholders Agreement with Belgian Sovereign Funds Soci&#233;t&#233; F&#233;d&#233;rale de Participations et
    d&#8217;Investissement (&#8220;SFPI&#8221;).</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
November 15, 2017, the Company, MaSTherCell and SFPI entered into a Subscription and Shareholders Agreement (&#8220;SFPI Agreement&#8221;)
pursuant to which SFPI made an equity investment in MaSTherCell.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Due
to the embedded redemption feature of the SPFI agreement whose settlement was not at the Company discretion, the Company had accounted
for the investment made by GPP as a redeemable non-controlling interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 103; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>b.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Stock
    Purchase Agreement and Stockholders&#8217; Agreement with Great Point Partners, LLC (&#8220;GPP&#8221;)</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
June 28, 2018, the Company, Masthercell Global GPP, and certain of GPP&#8217;s affiliates, entered into a series of
definitive strategic agreements intended to finance, strengthen and expand Orgenesis&#8217; CDMO business. Due to the
embedded redemption feature of the GPP agreement whose settlement was not at the Company discretion, the Company had
accounted for the investment made by GPP as a redeemable non-controlling interest.</span></p>
<!-- Field: Split-Segment; Name: Split 1 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:AcquisitionAndReorganizationTextBlock"><p id="xdx_805_ecustom--AcquisitionAndReorganizationTextBlock_zApP4DXnF3ge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
4 &#8211; <span id="xdx_82F_zNMSOub0OWC3">ACQUISITION AND REORGANIZATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Tamir
Biotechnology, Inc.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
April 7, 2020, the Company entered into the Tamir Purchase Agreement with Tamir, pursuant to which the Company agreed to acquire
certain assets and liabilities of Tamir related to the discovery, development and testing of therapeutic products for the treatment
of diseases and conditions in humans, including all rights to Ranpirnase and use for antiviral therapy. The Tamir Transaction
closed on April 23, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
aggregate consideration for the acquisition, the Company paid $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pn5n6_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zBxjUOcsNzRi" title="Stock issued during period value acquisitions"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million in cash and issued an aggregate of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pii_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zbTMUQ8HNTBi" title="Shares issued, acquisition"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,400,000</ix:nonFraction></span> shares
(the &#8220;Shares&#8221;) of Common Stock to Tamir resulting in a total consideration of $<span id="xdx_90D_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zAvLQRdRVvGe" title="Business Combination, Consideration Transferred"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">20.2</ix:nonFraction></span> million based on the Company&#8217;s
share price at the closing date. $<span id="xdx_907_eus-gaap--EscrowDeposit_iI_pn3n3_c20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zKluibrst0Wd" title="Escrow Deposit"><ix:nonFraction name="us-gaap:EscrowDeposit" contextRef="AsOf2020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">59</ix:nonFraction></span> thousand and <span id="xdx_901_ecustom--NumberOfSharesDepositInEscrowAccount_pii_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zRn641sDS4g2" title="Number of shares deposit in escrow account"><ix:nonFraction name="ORGS:NumberOfSharesDepositInEscrowAccount" contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">340,000</ix:nonFraction></span> Shares are being held in an escrow account for a period of 18 months
from closing to secure indemnification obligations of Tamir pursuant to the terms of the Tamir Purchase Agreement. $<span id="xdx_900_ecustom--BusinessCombinationConsiderationTransferred_pn5n6_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zTibqOyYTWCf" title="Total consideration"><ix:nonFraction name="ORGS:BusinessCombinationConsiderationTransferred" contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.5</ix:nonFraction></span> million
of the consideration was attributable to research and development related inventory and most of the remaining amount reflected
the cost of intangible assets. The Shares were registered for resale by the Company in November 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s acquired right to Tamir&#8217;s intellectual property represents a single identifiable asset sourced from the
agreement. Because substantially all (more than 90%) of the fair value of the gross assets acquired are concentrated in a single
asset being the right to Tamir&#8217;s intellectual property and related assets (&#8220;IPR&amp;D&#8221;), the Company determined
that the acquisition is not considered a business in accordance with ASC 805-10-55-5A. Therefore, the Company accounted the transaction
as an asset acquisition. The fair value associated with Tamir&#8217;s IPR&amp;D in the amount of $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_z0ewOEClv3wl" title="Research and Development Expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">19.5</ix:nonFraction></span> million was charged to
research and development expenses under ASC 730. The remaining amount was attributed to the above-mentioned share in a private
company, which is presented in the balance sheet as long term &#8220;other assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Description
of Koligo Acquisition during 2020</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
September 26, 2020, the Company entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;)
by and among the Company, Orgenesis Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (&#8220;Merger
Sub&#8221;), Koligo Therapeutics Inc., a Kentucky corporation (&#8220;Koligo&#8221;), the shareholders of Koligo (collectively,
the &#8220;Shareholders&#8221;), and Long Hill Capital V, LLC (&#8220;Long Hill&#8221;), solely in its capacity as the representative,
agent and attorney-in-fact of the Shareholders. The Merger Agreement provides for the acquisition of Koligo by the Company through
the merger of Merger Sub with and into Koligo, with Koligo surviving as a wholly-owned subsidiary of the Company (the &#8220;Merger&#8221;).
The acquisition was completed on October 15, 2020 (the &#8220;Effective Time&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Koligo
is a privately-held US regenerative medicine company. Koligo&#8217;s first commercial product is KYSLECEL&#174; (autologous pancreatic
islets) for chronic and acute recurrent pancreatitis. Koligo&#8217;s 3D-V technology platform incorporates the use of advanced
3D bioprinting techniques and vascular endothelial cells to support development of transformational cell and tissue products for
serious diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the terms of the Merger Agreement, at the Effective Time, the shares of capital stock of Koligo that were issued and outstanding
immediately prior to the Effective Time were automatically cancelled and converted into the right to receive, subject to customary
adjustments, an aggregate of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pii_c20201014__20201015__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--MaterialDefinitiveAgreementMember_zGcVmhNbUwB3"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2020-10-142020-10-15_custom_KoligoTherapeuticsIncMember_custom_MaterialDefinitiveAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,061,713</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Company common stock which
have been issued to Koligo&#8217;s accredited investors (with certain non-accredited investors being paid solely in cash in
the amount of approximately $<span id="xdx_905_ecustom--CashPaidToAccreditedInvestors_pn3n3_c20201014__20201015__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--MaterialDefinitiveAgreementMember_zGpx3FcbLVmk" title="Cash paid to accredited investors"><ix:nonFraction name="ORGS:CashPaidToAccreditedInvestors" contextRef="From2020-10-142020-10-15_custom_KoligoTherapeuticsIncMember_custom_MaterialDefinitiveAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand). In addition, we issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20201014__20201015__dei--LegalEntityAxis__custom--MaximaGroupLLCMember_zpCXUCeVXnr4"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2020-10-142020-10-15_custom_MaximaGroupLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,910</ix:nonFraction></span>
shares to Maxim Group LLC for advisory services</span><span style="font: 10pt Times New Roman, Times, Serif"> in connection
with the Merger. The share price was $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pii_c20201015__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--MaterialDefinitiveAgreementMember_zm7taXrIMAj7"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-10-15_custom_KoligoTherapeuticsIncMember_custom_MaterialDefinitiveAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.26</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">at the day of the closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 104; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Merger Agreement contains customary indemnification provisions whereby the Shareholders of Koligo will indemnify the Company and
certain affiliated parties for any losses arising out of breaches of the representations, warranties and covenants of Koligo and
the Shareholders under the Merger Agreement. As partial security for the indemnification and purchase price adjustment obligations
of Koligo shareholders under the Merger Agreement, $<span id="xdx_90F_eus-gaap--EscrowDeposit_iI_pn3n3_c20201015__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--MaterialDefinitiveAgreementMember_z40mcdEKpc7a" title="Cash held in escrow account"><ix:nonFraction name="us-gaap:EscrowDeposit" contextRef="AsOf2020-10-15_custom_KoligoTherapeuticsIncMember_custom_MaterialDefinitiveAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></span> thousand in cash and <span id="xdx_909_ecustom--SharesHeldInEscrow_pii_c20201014__20201015__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--MaterialDefinitiveAgreementMember_zd5VTQj77s6g" title="Shares held in escrow"><ix:nonFraction name="ORGS:SharesHeldInEscrow" contextRef="From2020-10-142020-10-15_custom_KoligoTherapeuticsIncMember_custom_MaterialDefinitiveAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">328,587</ix:nonFraction></span> shares of Company common stock of the merger
consideration otherwise payable in the Merger to the Shareholders were placed in a third party escrow account. The aggregate indemnification
obligations of the Koligo shareholders under the Merger Agreement is capped at the amounts in escrow, subject to certain limited
exceptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, according to the agreement between the parties, the Company has also funded an additional cash consideration of $<span id="xdx_900_ecustom--AdditionalCashConsideration_pn3n3_c20201014__20201015__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--MaterialDefinitiveAgreementMember_zbdhd01wAtwh" title="Additional cash consideration"><ix:nonFraction name="ORGS:AdditionalCashConsideration" contextRef="From2020-10-142020-10-15_custom_KoligoTherapeuticsIncMember_custom_MaterialDefinitiveAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></span>
thousand (with $<span id="xdx_90D_ecustom--ReductionInConsiderationPayable_pn3n3_c20201014__20201015__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--MaterialDefinitiveAgreementMember_zLTXPNlbeaGa" title="Reduction in consideration payable"><ix:nonFraction name="ORGS:ReductionInConsiderationPayable" contextRef="From2020-10-142020-10-15_custom_KoligoTherapeuticsIncMember_custom_MaterialDefinitiveAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></span> thousand of such reducing the ultimate consideration payable to Koligo) for the acquisition of the assets
of Tissue Genesis, LLC (&#8220;Tissue Genesis&#8221;) by Koligo that was consummated on October 14, 2020. The Tissue Genesis assets
include the entire inventory of Tissue Genesis Icellator&#174; devices, related kits and reagents, a broad patent portfolio to
protect the technology, registered trademarks, clinical data, and existing business relationships for commercial and development
stage use of the Icellator technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with the Merger Agreement, the Company, Long Hill and Maxim Group LLC (&#8220;Maxim&#8221;) entered into a Registration
Rights and Lock-Up Agreement pursuant to which Long Hill will have one demand registration right to require the registration of
the shares of Company common stock received by Long Hill in the Merger and Long Hill and Maxim will have certain piggyback registration
rights. In addition, Long Hill agreed with the Company that, during the applicable Restriction Period (as defined below), it shall
not sell or transfer, subject to certain limited exceptions, the portion of the shares received in the Merger during the applicable
Restriction Period, subject to a limitation on the number of shares sold per any trading day not to exceed <span id="xdx_90D_ecustom--RestrictionOnSaleOfSharesPercentage_pii_dp_uPercentage_c20201014__20201015__dei--LegalEntityAxis__custom--LongHillAndMaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsandLockUpAgreementMember_z32ak6MQfMZ2" title="Restriction on sale of shares percentage"><ix:nonFraction name="ORGS:RestrictionOnSaleOfSharesPercentage" contextRef="From2020-10-142020-10-15_custom_LongHillAndMaximGroupLLCMember_custom_RegistrationRightsandLockUpAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">10</ix:nonFraction></span>% of the average
daily trading volume of the Common Stock, as reported by Bloomberg Financial L.P. &#8220;Restriction Period&#8221; means <span id="xdx_904_ecustom--RestrictionPeriodDescription_c20201014__20201015__dei--LegalEntityAxis__custom--LongHillAndMaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsandLockUpAgreementMember_z1Y7fRHKmZ3b" title="Restriction period, description"><ix:nonNumeric contextRef="From2020-10-142020-10-15_custom_LongHillAndMaximGroupLLCMember_custom_RegistrationRightsandLockUpAgreementMember" name="ORGS:RestrictionPeriodDescription">(a) in
relation to 70% of all of the shares received in the Merger that Long Hill is entitled to receive under or in connection with
the Merger Agreement, the period beginning on the date of the closing and ending on the date that is the four month anniversary
thereof, and (b) in relation to the remaining 30% of all of the shares received in the Merger that Long Hill is entitled to receive
under or in connection with the Merger Agreement, the period beginning on the date of the closing and ending on the date that
is the twelve month anniversary thereof</ix:nonNumeric></span>. All of the shares required to be registered by the Company pursuant to the Registration
Rights and Lock-Up Agreement were registered by the Company in November 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, pursuant to separate Lock-Up Agreements entered into by the Shareholders other than Long Hill with the Company (the
&#8220;Shareholders Lock-Up Agreement&#8221;), such Shareholders agreed that they will not transfer any of their shares received
in the Merger except in accordance with the following lock-up release schedule whereby one fifth of such holder&#8217;s respective
shares will be released from such restriction every six months, starting six months from the closing of the Merger. Each holder&#8217;s
sales of such shares are subject to a resale limit of its pro rata portion of 10% of the average daily trading volume, allocated
to the Shareholders other than Long Hill pro-rata.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
acquisition was accounted in accordance with Accounting Standards Codification Topic 805, &#8220;Business Combinations&#8221;.
The allocation of the consideration transferred in certain cases may be subject to revision based on the final determination of
fair values during the measurement period, which may be up to one year from the acquisition date. The Company includes the results
of operations of the business that it has acquired in its consolidated results prospectively from the date of acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Fair
Value of Consideration Transferred</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zWeonuaKo7se" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the allocation of purchase price to the fair values of the assets acquired and liabilities assumed
as of the transaction date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B2_z8408OO7tIP9" style="display: none">SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20201231_z1qrVyAOpNob" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued_iI_pn3n3_maBCRIAzxgu_zpZljblX2cRk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%">Fair value of <span id="xdx_90A_ecustom--FairValuePercentageofSharesIssued_iI_pii_dp_uPercentage_c20201231_zmr08iQJvnDa" title="Fair value percentage of shares issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="ORGS:FairValuePercentageofSharesIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">8.8</ix:nonFraction></span>% of shared issued *</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"><span id="xdx_F47_zz9L2sR0yq73" style="display: none; font-family: Times New Roman, Times, Serif">*</span></td><td style="width: 18%; text-align: right"><ix:nonFraction name="ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued" contextRef="AsOf2020-12-31" id="Fact001095" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,172</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments_iI_pn3n3_maBCRIAzxgu_ziNdtG7LgITh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash payment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,115</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_pn3n3_mtBCRIAzxgu_zxQF4lTwThg8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total consideration transferred</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,287</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td id="xdx_F01_zLuqe2CpwNid" style="width: 1.2%">*</td>
    <td id="xdx_F1F_zSzpzffwMp64" style="width: 50%"><ix:footnote id="Footnote001102" xml:lang="en-US">Fair value of the consideration is based on the company&#8217;s market share price.</ix:footnote></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 105; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Total assets acquired:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 78%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pn3n3_c20201231_zaA0VUMeje8b" title="Cash and cash equivalents" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Restricted Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_iI_pn3n3_c20201231_zzdW7jHhqefd" title="Restricted Cash" style="text-align: right"><ix:nonFraction name="ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">152</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts Receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_pn3n3_c20201231_zmNyRNKuCKLk" title="Accounts Receivable" style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">228</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iI_pn3n3_c20201231_zq9T4Dy5pkpl" title="Inventory" style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_iI_pn3n3_c20201231_ztTVWWU6d3Td" title="Other assets" style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Property, plants and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pn3n3_c20201231_zYmz0iITYuui" title="Property, plants and equipment, net" style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">482</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Kyslecel Technology (a)</td><td id="xdx_F46_zu1500R9cTqk" style="display: none">(a)</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_fYQ_____zKffF8VCEZO7" title="Other intangible assets" style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="AsOf2020-12-31_custom_KyslecelTechnologyMember" id="Fact001116" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,340</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">IPR&amp;D (a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_fYQ_____zidQJTdSBsef" title="Other intangible assets" style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="AsOf2020-12-31_custom_IPResearchAndDevelopmentMember" id="Fact001118" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">641</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_iI_pn3n3_c20201231_z9LX9XnVFREh" title="Operating lease right-of-use assets" style="text-align: right"><ix:nonFraction name="ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">238</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Goodwill (b)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill_iI_pn3n3_c20201231_fYg_____zAz3kQsaxVRf" title="Goodwill" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill" contextRef="AsOf2020-12-31" id="Fact001122" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,704</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_pn3n3_c20201231_zRe9GSXqKHJ" title="Total assets" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,852</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Total liabilities assumed:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease_iI_pn3n3_c20201231_zKR13To8FmJ7" title="Operating leases" style="text-align: right"><ix:nonFraction name="ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">238</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_pn3n3_c20201231_ze56KYhWrkt5" title="Accounts Payable" style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">216</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_iI_pn3n3_c20201231_zgv0xezpFr98" title="Accrued Expenses" style="text-align: right"><ix:nonFraction name="ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Orgenesis Inc loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability_iI_pn3n3_c20201231_zuLlfxIelzwa" title="Orgenesis Inc loan" style="text-align: right"><ix:nonFraction name="ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">651</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Deferred taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_iI_pn3n3_c20201231_zu8WyHo2SLR9" title="Deferred taxes" style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,293</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Notes Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_iI_pn3n3_c20201231_zvF4ICtmkrCe" title="Notes Payable" style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">162</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_iI_pn3n3_c20201231_zWoir7e4LwZ3" title="Other liabilities" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_pn3n3_c20201231_zcqPJQYzOgd3" title="Total liabilities" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,565</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; padding-bottom: 2.5pt">Total consideration transferred</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pn3n3_c20201231_zIIXbRMFwIa4" title="Total consideration transferred" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,287</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1.2%; text-align: right"><span id="xdx_F0D_zmsOFibs8cqa" style="font: 10pt Times New Roman, Times, Serif">a.</span></td><td style="text-align: justify; width: 50%"><span id="xdx_F16_zzszZc7HaF43" style="font: 10pt Times New Roman, Times, Serif"><ix:footnote id="Footnote001143" xml:lang="en-US">The
                                         allocation of the purchase price to the net assets acquired and liabilities assumed resulted
                                         in the recognition of other intangible assets which comprised of: Kyslecel Technology
                                         of $<span id="xdx_905_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_zkEyoPQjdj0e" title="Other intangible assets" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="AsOf2020-12-31_custom_KyslecelTechnologyMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,340</ix:nonFraction></span> and IPR&amp;D of <span id="xdx_905_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_zbaY6aSbgAC8" title="Other intangible assets" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="AsOf2020-12-31_custom_IPResearchAndDevelopmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">641</ix:nonFraction></span>. Kyslecel Technology has a useful life of <span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_zYRTWIzaNSq8" title="Useful life" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_KyslecelTechnologyMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">15</ix:nonNumeric></span> years. The
                                         useful life of these intangible assets for amortization purposes was determined considering
                                         the period of expected cash flows generated by the assets used to measure the fair value
                                         of the intangible assets adjusted as appropriate for the entity-specific factors, including
                                         legal, regulatory, contractual, competitive, economic or other factors that may limit
                                         the useful life of intangible assets.</ix:footnote></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">These
intangible assets were estimated using a discounted cash flow method with the application of the multi-period excess earnings
method. Under this method, an intangible asset&#8217;s fair value is equal to the present value of the incremental after-tax cash
flows attributable only to the subject intangible asset after deducting contributory asset charges. An income and expenses forecast
were built based upon revenue and expense estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1.2%; text-align: right"><span id="xdx_F08_zwXN3l4aZ3rl" style="font: 10pt Times New Roman, Times, Serif">b.</span></td><td style="text-align: justify; width: 50%"><span id="xdx_F14_zGdT76xRwTL" style="font: 10pt Times New Roman, Times, Serif"><ix:footnote id="Footnote001150" xml:lang="en-US">The primary
items that generate goodwill include the value of the synergies between the acquired company and the Company and the acquired
assembled workforce, neither of which qualifies for recognition as an intangible asset. The Goodwill is not deductible for tax
purposes.</ix:footnote></span></td>
</tr></table>

</ix:nonNumeric><p id="xdx_8AF_znSjyyQGYlq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Pro
forma Impact of Business Combination</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
unaudited pro forma financial results have been prepared using the acquisition method of accounting and are based on the historical
financial information of the Company and Koligo. The unaudited pro forma condensed financial results have been prepared for illustrative
purposes only and do not purport to be indicative of the results of operations that actually would have resulted had the acquisition
of Koligo occurred at the beginning of the fiscal year, or of future results of the combined entities. The unaudited pro forma
condensed financial information does not reflect any operating efficiencies and expected realization of cost savings or synergies
associated with the acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock"><p id="xdx_89A_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_z7erDNuy7OUf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Unaudited
supplemental pro forma combined results of operations (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8B1_zNvvKHaYkemd" style="display: none">SCHEDULE OF UNAUDITED SUPPLEMENTAL PRO FORMA</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20200101__20201231__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_zZnB1kWTVapb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20190101__20191231__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_zdjNqHXzKmgd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zQkIcQPJ7PDk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 2.5pt">Revenues</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_custom_KoligoTherapeuticsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,239</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_custom_KoligoTherapeuticsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,398</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--ProfitLoss_pn3n3_zeJXVLbN19e9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-01-012020-12-31_custom_KoligoTherapeuticsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">318</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2019-01-012019-12-31_custom_KoligoTherapeuticsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,263</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Loss per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--EarningsPerShareBasic_pii_zas48cbihrHe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Basic</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2020-01-012020-12-31_custom_KoligoTherapeuticsIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.05</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2019-01-012019-12-31_custom_KoligoTherapeuticsIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.91</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A7_zcChthqUgVvf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Koligo&#8217;s
related actual results from the date of acquisition to December 31, 2020 resulted in a loss of $<span id="xdx_90E_eus-gaap--NetIncomeLoss_pn3n3_c20200101__20201231__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_zViwJXPQHkK4" title="Net Loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_custom_KoligoTherapeuticsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">513</ix:nonFraction></span> thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i></i></span></p>

<ix:exclude><!-- Field: Page; Sequence: 106; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Koligo&#8217;s
Acquisition-related Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Acquisition-related
expenses consist of transaction costs which represent external costs directly related to the acquisition of Koligo and primarily
include expenditures for professional fees such as legal, accounting and other directly related incremental costs incurred to
close the acquisition by both the Company and Koligo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Acquisition-related
expenses for the year ended December 31, 2020 were $<span id="xdx_90B_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_pn3n3_c20200101__20201231__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_zzU5VvHDY1f7" title="Acquisition-related expenses"><ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="From2020-01-012020-12-31_custom_KoligoTherapeuticsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">682</ix:nonFraction></span> thousand. These expenses were recorded to selling and general administrative
expense in the consolidated statements of comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Cooperate
reorganization, description of the Transactions Korea and OBI during 2019</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
August 7, 2019, the Company, Masthercell Global and GPP-II Masthercell, LLC, a Delaware limited liability company (&#8220;GPP-II&#8221;),
(the &#8220;Parties&#8221;) entered into a Transfer Agreement (the &#8220;Transfer Agreement&#8221;). As a result of the Transfer
Agreement, Masthercell Global transferred all of its equity interests of OBI and the Korean Subsidiary to Orgenesis Inc in exchange
for one dollar ($<span id="xdx_906_eus-gaap--BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_pp0p0_c20190806__20190807__us-gaap--TypeOfArrangementAxis__custom--TransferAgreementMember_zZtK8opGDRxb" title="Transfer of equity interests"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" contextRef="From2019-08-062019-08-07_custom_TransferAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1.00</ix:nonFraction></span>). The Transfer Agreement also contained agreements made with respect to certain intercompany loans. The
Company accounted for the Transfer Agreement as a transaction with non-controlling interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zJKxz2PJM8F6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
5 &#8211; <span id="xdx_827_z4crzAehKnS">PROPERTY, PLANTS AND EQUIPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_890_eus-gaap--PropertyPlantAndEquipmentTextBlock_zDHQPVL1geg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table represents the components of property, plants and equipment:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BC_z2GFvj6gaFHk" style="display: none">SCHEDULE OF COMPONENTS OF PROPERTY, PLANTS AND EQUIPMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cost:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Production facility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember_zWYVxVDMQvGc" title="Cost" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_custom_ProductionFacilityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,801</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember_pn3n3" title="Cost" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_custom_ProductionFacilityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,481</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and computers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndComputersMember_zgcO2T8iYmK7" title="Cost" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_custom_OfficeFurnitureAndComputersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">697</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndComputersMember_z0y9NA1IfI65" title="Cost" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_custom_OfficeFurnitureAndComputersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">606</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lab equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zczCPRXCNbLl" title="Cost" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_custom_LabEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,483</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zL1npMPfGEH9" title="Cost" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_custom_LabEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">656</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Advance payment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancePaymentMember_pn3n3" title="Cost" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_custom_AdvancePaymentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">281</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancePaymentMember_zkxBffHbarbg" title="Cost" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231_zHLOZ4Rnt6ce" title="Cost" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,262</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20191231_pn3n3" title="Cost" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,743</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less &#8211; accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20201231_zLFFAiqJWJz4" title="Less accumulated depreciation" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,189</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20191231_zV8Gha4ReO47" title="Less accumulated depreciation" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,438</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_c20201231_pn3n3" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,073</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_c20191231_pn3n3" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,305</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A8_zOGJHQuedg2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Depreciation
expense for the years ended December 31, 2020 and December 31, 2019 were $ <span id="xdx_90D_eus-gaap--Depreciation_pn3n3_c20200101__20201231_zzJYb6SVla56" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">705</ix:nonFraction></span> thousand and $<span id="xdx_90B_eus-gaap--Depreciation_pn3n3_c20190101__20191231_zaQMBO8KTPCl" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">634</ix:nonFraction></span> thousand, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock"><p id="xdx_893_ecustom--ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock_zHA5Muxbbcp" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Property,
plants and equipment, net by geographical location were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;<span id="xdx_8BB_zNFBcntFHRU8" style="display: none">SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT BY GEOGRAPHICAL LOCATION</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Belgium</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--BE_z3FrDJDpS0dk" title="Property, plants and equipment, net" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31_country_BE" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">358</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--BE_zwfZfgF2Jwx4" title="Property, plants and equipment, net" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1209">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Korea</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--KR_zlTQHJXo3AB5" title="Property, plants and equipment, net" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31_country_KR" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">839</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--KR_zAqptTq2mcBl" title="Property, plants and equipment, net" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2019-12-31_country_KR" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">983</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Israel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--IL_zoo1isOf3lTe" title="Property, plants and equipment, net" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31_country_IL" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,386</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--IL_zLDcfeYHoMyc" title="Property, plants and equipment, net" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2019-12-31_country_IL" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,322</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">U.S.</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--US_z6HzmHQklp0h" title="Property, plants and equipment, net" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31_country_US" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">490</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--US_zteNa7ACv2q1" title="Property, plants and equipment, net" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1221">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231_zHod0TYdk5Yh" title="Property, plants and equipment, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,073</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231_zXe9lKeMKkqi" title="Property, plants and equipment, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,305</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AA_z7TYMSt04WBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 107; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock"><p id="xdx_807_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zcFooncd3e82" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
6 &#8211; <span id="xdx_829_zqOazwDyQHXc">INTANGIBLE ASSETS AND GOODWILL</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfGoodwillTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfGoodwillTextBlock_zzQN5PNTZYI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Changes
in the carrying amount of the Company&#8217;s goodwill for the years ended December 31, 2020 and 2019 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B4_zJh07DxpbKv" style="display: none">SCHEDULE OF GOODWILL</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%">Goodwill as of December 31, 2018</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--Goodwill_iS_pn3n3_c20190101__20191231_zP0kjS9gsqp2" style="width: 22%; text-align: right"><span title="Goodwill, Beginning Balance"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,942</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Goodwill as acquired, (Koligo) see note 4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Goodwill as acquired" id="xdx_987_eus-gaap--GoodwillAcquiredDuringPeriod_c20190101__20191231_pn3n3" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1232">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Translation differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td title="Translation differences" id="xdx_988_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">130</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Goodwill as of December 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">$</td><td title="Goodwill, Ending Balance" id="xdx_98B_eus-gaap--Goodwill_iE_pn3n3_c20190101__20191231_zJv4Jb2X2twb" style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,812</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Goodwill as of December 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">$</td><td title="Goodwill, Beginning Balance" id="xdx_98A_eus-gaap--Goodwill_iS_pn3n3_c20200101__20201231_zitu3wy1HRq9" style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,812</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Goodwill as acquired, (Koligo) see note 4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Goodwill as acquired" id="xdx_986_eus-gaap--GoodwillAcquiredDuringPeriod_c20200101__20201231_pn3n3" style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,704</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Translation differences</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td title="Translation differences" id="xdx_98B_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">229</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Goodwill as of December 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td title="Goodwill, Ending Balance" id="xdx_987_eus-gaap--Goodwill_iE_pn3n3_c20200101__20201231_zFIXFDKo4AJ" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,745</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AD_z1AC6UZDaZuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Goodwill
Impairment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">See
Note 2(m) for the Company&#8217;s goodwill impairment analysis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Other
Intangible Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zReGqiIAAmG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Other
intangible assets consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B6_zOKwaLRlcl2" style="display: none">SCHEDULE OF OTHER INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Gross Carrying Amount:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Know How</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowhowMember_zqboipEQbCYh" title="Gross Carrying Amount" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-12-31_custom_KnowhowMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,170</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowhowMember_pn3n3" title="Gross Carrying Amount" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_custom_KnowhowMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,991</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Customer relationships</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z7884oqAwQ25" title="Gross Carrying Amount" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-12-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">886</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" title="Gross Carrying Amount" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">895</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Kyslecel Technology</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_pn3n3" title="Gross Carrying Amount" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-12-31_custom_KyslecelTechnologyMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_pn3n3" title="Gross Carrying Amount" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1258">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">IPR&amp;D</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_pn3n3" title="Gross Carrying Amount" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-12-31_custom_IPResearchAndDevelopmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">641</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_pn3n3" title="Gross Carrying Amount" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1262">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231_pn3n3" title="Gross Carrying Amount" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,037</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231_pn3n3" title="Gross Carrying Amount" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,886</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less &#8211; Accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_c20201231_zacFdX1Y6U27" title="Accumulated amortization" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,014</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_c20191231_zDlaRNPO6mWb" title="Accumulated amortization" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">538</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net carrying amount of other intangible assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_c20201231_pn3n3" title="Net carrying amount of other intangible assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,023</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_c20191231_pn3n3" title="Net carrying amount of other intangible assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,348</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A2_zkYJzhcRqgk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Intangible
assets amortization expenses were approximately $<span id="xdx_900_ecustom--AmortizationOfIntangibleAsset_pn3n3_c20200101__20201231_zLmIfKr0POxl"><ix:nonFraction name="ORGS:AmortizationOfIntangibleAsset" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">478</ix:nonFraction> </span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand
and $<span id="xdx_90F_ecustom--AmortizationOfIntangibleAsset_pn3n3_c20190101__20191231_zbCZmQsUiNpl"><ix:nonFraction name="ORGS:AmortizationOfIntangibleAsset" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">430</ix:nonFraction></span> thousand for the years ended December 31, 2020 and December 31, 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zbdoR2gR6af2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Estimated
aggregate amortization expenses for the five succeeding years ending on December 31<sup>st</sup> are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B2_zh9tGtGOqTY9" style="display: none">SCHEDULE OF ESTIMATED AGGREGATE AMORTIZATION EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 to 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Amortization expenses</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_c20201231_z73g2F3IBPG5" title="Amortization expenses, 2021" style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">965</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive_iI_pn3n3_c20201231_zCHhoDKXPeGf" title="Amortization expenses, 2022  to 2025" style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right"><ix:nonFraction name="ORGS:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,910</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A2_zsqOQYGrAS07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 108; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_za5Tuv2xnZU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
7 &#8211; <span id="xdx_823_z5Kds0JuJvy3">CONVERTIBLE LOANS</span></b></span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ConvertibleDebtTableTextBlock"><p id="xdx_898_eus-gaap--ConvertibleDebtTableTextBlock_zkusSwVXQFmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8B5_z8MbVmB5xC1k" style="display: none">SCHEDULE OF LONG TERM CONVERTIBLE LOANS</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Long
    term convertible loans outstanding as of&#160;December 31, 2020 and December 31, 2019 are as follows:</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Principal</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Amount</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Issuance</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Year</p></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Interest</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Rate</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maturity Period</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>BCF</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b></b></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">(in thousands)</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">(Years)</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="14" style="font-style: normal; font-weight: normal">Convertible Loans Outstanding as of <span style="font-style: normal; font-weight: normal">December
    31, 2020</span></td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zDFw3ZPfrvd7" title="Principal Amount" style="width: 17%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-12-31_custom_ConvertibleLoansOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td id="xdx_98A_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember" title="Issuance Year" style="width: 16%; text-align: center"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansOneMember" name="ORGS:DebtInstrumentIssuanceYear">2018</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zHPp0UkM80Yg" title="Interest Rate" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-12-31_custom_ConvertibleLoansOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">2</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td id="xdx_987_eus-gaap--DebtInstrumentTerm_dtY_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zeg6ar17UK5g" title="Maturity Period" style="width: 14%; text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansOneMember" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm">3</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_fKDEp_zb4zf47LSFJi" title="Exercise Price" style="width: 14%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2020-12-31_custom_ConvertibleLoansOneMember" id="Fact001296" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span></td><td style="width: 1%; text-align: left">(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_pn3n3" title="BCF" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">71</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zDA1sBqe1EXi" title="Principal Amount" style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-12-31_custom_ConvertibleLoansTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_980_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember" title="Issuance Year" style="text-align: center"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansTwoMember" name="ORGS:DebtInstrumentIssuanceYear">2019</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MinimumMember_zSPSlDj6sNgc" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-12-31_custom_ConvertibleLoansTwoMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">6</ix:nonFraction></span>%-<span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MaximumMember_z6yMje78exYf" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-12-31_custom_ConvertibleLoansTwoMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">8</ix:nonFraction></span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MinimumMember_zV50gcduFWV4" title="Maturity Period"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansTwoMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm">2</ix:nonNumeric></span>-<span id="xdx_906_eus-gaap--DebtInstrumentTerm_dtY_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MaximumMember_z7xBBiTsS0Nk" title="Maturity Period"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansTwoMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm">5</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_fKDIp_z6v86nbfHkbe" title="Exercise Price" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2020-12-31_custom_ConvertibleLoansTwoMember" id="Fact001312" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span></td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pn3n3" title="BCF" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1314">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zyv1bKnywRHj" title="Principal Amount" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-12-31_custom_ConvertibleLoansThreeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td id="xdx_987_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember" title="Issuance Year" style="padding-bottom: 1.5pt; text-align: center"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansThreeMember" name="ORGS:DebtInstrumentIssuanceYear">2020</ix:nonNumeric></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_z5xJOBpnNrOb" title="Interest Rate" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-12-31_custom_ConvertibleLoansThreeMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">8</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td id="xdx_98A_eus-gaap--DebtInstrumentTerm_dtY_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zAxR13De8uzi" title="Maturity Period" style="padding-bottom: 1.5pt; text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansThreeMember" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm">2</ix:nonNumeric></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_fKDMp_zt8CAYylZ5w2" title="Exercise Price" style="padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2020-12-31_custom_ConvertibleLoansThreeMember" id="Fact001324" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">(3)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_pn3n3" title="BCF" style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1326">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DebtInstrumentFaceAmount_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansMember_pn3n3" title="Principal Amount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-12-31_custom_ConvertibleLoansMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,750</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="18" style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Convertible
    Loans Outstanding as of </b><span style="font-style: normal; font-weight: normal">December 31, 2019</span></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_pn3n3" title="Principal Amount" style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2019-12-31_custom_ConvertibleLoansOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_989_ecustom--DebtInstrumentIssuanceYear_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember" title="Issuance Year" style="text-align: center"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_ConvertibleLoansOneMember" name="ORGS:DebtInstrumentIssuanceYear">2018</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zle1KDDZKZqk" title="Interest Rate" style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2019-12-31_custom_ConvertibleLoansOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">2</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td id="xdx_987_eus-gaap--DebtInstrumentTerm_dtY_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zYwCOa0umj1c" title="Maturity Period" style="text-align: right"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_ConvertibleLoansOneMember" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm">3</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_fKDEp_zxqPtxnJs8sb" title="Exercise Price" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2019-12-31_custom_ConvertibleLoansOneMember" id="Fact001338" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span></td><td id="xdx_F20_z1eDrS0SelJf" style="text-align: left">(1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn3n3_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zT8CBWNXlY6j" title="BCF" style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" contextRef="From2019-01-012019-12-31_custom_ConvertibleLoansOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">124</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pn3n3" title="Principal Amount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2019-12-31_custom_ConvertibleLoansTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,400</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td id="xdx_98E_ecustom--DebtInstrumentIssuanceYear_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember" title="Issuance Year" style="padding-bottom: 2.5pt; text-align: center"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_ConvertibleLoansTwoMember" name="ORGS:DebtInstrumentIssuanceYear">2019</ix:nonNumeric></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MinimumMember_zHMFCnuTzZxg" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2019-12-31_custom_ConvertibleLoansTwoMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">6</ix:nonFraction></span>%-<span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MaximumMember_zBK65LqIf8w" title="Interest Rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2019-12-31_custom_ConvertibleLoansTwoMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">8</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90D_eus-gaap--DebtInstrumentTerm_dtY_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MinimumMember_zyUY8X127l2h" title="Maturity Period"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_ConvertibleLoansTwoMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm">2</ix:nonNumeric></span>-<span id="xdx_90A_eus-gaap--DebtInstrumentTerm_dtY_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MaximumMember_zeuAtuVShXIf" title="Maturity Period"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_ConvertibleLoansTwoMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm">5</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_fKDIp_zx9JV7VEjKQ3" title="Exercise Price" style="padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2019-12-31_custom_ConvertibleLoansTwoMember" id="Fact001354" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span></td><td id="xdx_F2B_zfU9bW8ArPui" style="padding-bottom: 2.5pt; text-align: left">(2)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pn3n3" title="BCF" style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1356">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtInstrumentFaceAmount_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansMember_pn3n3" title="Principal Amount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2019-12-31_custom_ConvertibleLoansMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,900</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td colspan="18" style="text-align: left; font-weight: bold">Convertible Loans repaid during the year ended <span style="font-style: normal; font-weight: normal">December
    31, 2020</span></td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Principal</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Amount</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Issuance</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Year</p></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Interest</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Rate</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maturity Period</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>BCF</b></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 1%; text-align: center">&#160;</td><td id="xdx_984_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zIHKBs5PcDRf" title="Repaid, Principal Amount" style="width: 17%; text-align: right"><ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2020-01-012020-12-31_custom_TwoPercentageConvertibleLoansTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 1%">&#160;</td>
    <td id="xdx_98D_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zkow0ZZaa3H6" title="Issuance Year" style="width: 16%; text-align: center"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_TwoPercentageConvertibleLoansTwoMember" name="ORGS:DebtInstrumentIssuanceYear">2018</ix:nonNumeric></td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td id="xdx_98C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zBotYCYosfuk" title="Interest Rate" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-12-31_custom_TwoPercentageConvertibleLoansTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">2</ix:nonFraction></td><td style="width: 1%; text-align: center">%</td><td style="text-align: center; width: 1%">&#160;</td>
    <td id="xdx_989_ecustom--DebtInstrumentRemainingTerm_dtM_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_z7cvCx8z5JW6" title="Repaid, Maturity Period" style="width: 14%; text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_TwoPercentageConvertibleLoansTwoMember" format="ixt-sec:durmonth" name="ORGS:DebtInstrumentRemainingTerm">0.87</ix:nonNumeric></td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">$</td><td id="xdx_987_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zK7dopUg33n6" title="Exercise Price" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2020-12-31_custom_TwoPercentageConvertibleLoansTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7</ix:nonFraction></td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td id="xdx_983_ecustom--DebtInstrumentConvertibleRepaidBeneficialConversionFeature_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zrQIEMx9Rx7k" title="Repaid, BCF" style="width: 10%; text-align: right"><ix:nonFraction name="ORGS:DebtInstrumentConvertibleRepaidBeneficialConversionFeature" contextRef="From2020-01-012020-12-31_custom_TwoPercentageConvertibleLoansTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">53</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td id="xdx_98D_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_zdo7o6rInVL6" title="Repaid, Principal Amount" style="text-align: right"><ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2020-01-012020-12-31_custom_SixPercentageConvertibleLoansTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td id="xdx_980_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember" title="Issuance Year" style="text-align: center"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_SixPercentageConvertibleLoansTwoMember" name="ORGS:DebtInstrumentIssuanceYear">2019</ix:nonNumeric></td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_98A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_zaVwMTYQyCE2" title="Interest Rate" style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-12-31_custom_SixPercentageConvertibleLoansTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">6</ix:nonFraction></td><td style="text-align: center">%</td><td style="text-align: center">&#160;</td>
    <td id="xdx_986_ecustom--DebtInstrumentRemainingTerm_dtM_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_zvPfHqd4CFpe" title="Repaid, Maturity Period" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_SixPercentageConvertibleLoansTwoMember" format="ixt-sec:durmonth" name="ORGS:DebtInstrumentRemainingTerm">0.28</ix:nonNumeric></td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_zJcBzqlsDTrj" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2020-12-31_custom_SixPercentageConvertibleLoansTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7</ix:nonFraction></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_986_ecustom--DebtInstrumentConvertibleRepaidBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_pn3n3" title="Repaid, BCF" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1382">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td id="xdx_98B_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_zAKr0TKD3mxg" title="Repaid, Principal Amount" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2020-01-012020-12-31_custom_EightPercetageConvertibleLoansTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,400</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td id="xdx_987_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_zdeDPXfx1Bn2" title="Issuance Year" style="padding-bottom: 1.5pt; text-align: center"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_EightPercetageConvertibleLoansTwoMember" name="ORGS:DebtInstrumentIssuanceYear">2019</ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td id="xdx_986_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_zM9WocadbgL7" title="Interest Rate" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-12-31_custom_EightPercetageConvertibleLoansTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">8</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: center">%</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td id="xdx_980_ecustom--DebtInstrumentRemainingTerm_dtMp_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_zibWRPZBRSmg" title="Repaid, Maturity Period" style="padding-bottom: 1.5pt; text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_EightPercetageConvertibleLoansTwoMember" format="ixt-sec:durmonth" name="ORGS:DebtInstrumentRemainingTerm">0.76</ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td id="xdx_98E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_z6FdnJQRu7Dc" title="Exercise Price" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2020-12-31_custom_EightPercetageConvertibleLoansTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td id="xdx_98D_ecustom--DebtInstrumentConvertibleRepaidBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_pn3n3" title="Repaid, BCF" style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1394">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td id="xdx_981_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansMember_zRR7XZAJBEHa" title="Repaid, Principal Amount" style="text-align: right"><ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,400</ix:nonFraction></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Apart
from the items mentioned below there were no repayments of convertible loans during the fiscal years ended December 31, 2019 and
December 31, 2020. In addition, there were no conversions during the fiscal years ended December 31, 2019 and December 31,
2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F08_zpSgWyVib4Qg" style="font: 10pt Times New Roman, Times, Serif">(1)</span></td><td style="text-align: justify"><span id="xdx_F12_zNRKLWCftCS9" style="font: 10pt Times New Roman, Times, Serif"><ix:footnote id="Footnote001397" xml:lang="en-US">The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_pii" title="Stock issued during period, conversion of convertible securities" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">148,838</ix:nonFraction></span> shares
and <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zfQ3X7ZtgEv7" title="Number of warrant may be converted" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2020-12-31_custom_ConvertibleLoansOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">148,838</ix:nonFraction></span> <span title="Warrants exercise, term"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_z2olYqVdp0gb" title="Warrants exercise, term::XDX::P3Y" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><span style="-sec-ix-hidden: xdx2ixbrl1403">three-year</span></span></span> warrants to purchase up to an additional <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxws5Qrjrwp2" title="Number of warrant may be converted" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2020-12-31_custom_ConvertibleLoansOneMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">148,838</ix:nonFraction></span> shares of the Company&#8217;s common stock at a per share
exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zHp9sXQK5nwg" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-31_custom_ConvertibleLoansOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7</ix:nonFraction></span>. <span>In the initial two years, the holders have the right to convert the outstanding principal amount and accrued
interest into shares of capital stock of Hemogenyx-Cell or Immugenyx, LLC according under the relevant note agreement, subsidiaries
of Hemogenyx Pharmaceuticals Plc, at a price per share based on a pre-money valuation of Hemogenyx-Cell or Immugenyx, LLC of $<span id="xdx_901_ecustom--PreMoneyValuation_iI_pn6n6_c20201231__dei--LegalEntityAxis__custom--HemogenyxCelMember_zkLtkIqsJWR" title="Pre-money valuation" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="ORGS:PreMoneyValuation" contextRef="AsOf2020-12-31_custom_HemogenyxCelMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">12</ix:nonFraction></span>
million and $<span id="xdx_900_ecustom--PreMoneyValuation_iI_pn6n6_c20201231__dei--LegalEntityAxis__custom--ImmugenyxLLCMember_zqO6fr0KZyMe" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="ORGS:PreMoneyValuation" contextRef="AsOf2020-12-31_custom_ImmugenyxLLCMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">8</ix:nonFraction></span> million, respectively, pursuant to the collaboration agreement with Hemogenyx Pharmaceuticals Plc and Immugenyx,
LLC.</span> As of December 31, 2020, the loans are presented in current maturities of convertible notes in the balance sheet (See Notes
11(c) and 11(d).</ix:footnote></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F0E_z5oVRsJ6GJOj" style="font: 10pt Times New Roman, Times, Serif">(2)</span></td><td style="text-align: justify"><span id="xdx_F15_zprCsjdBN534" style="font: 10pt Times New Roman, Times, Serif"><ix:footnote id="Footnote001411" xml:lang="en-US">The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pii" title="Stock issued during period, conversion of convertible securities" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,443,734</ix:nonFraction></span> shares
and <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pii" title="Number of warrant may be converted" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2020-12-31_custom_ConvertibleLoansTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,053,503</ix:nonFraction></span> <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zRDvnnKx88Ag" title="Warrants exercise, term::XDX::P3Y" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><span style="-sec-ix-hidden: xdx2ixbrl1417">three-year</span></span> warrants to purchase up to an additional <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Number of warrant may be converted" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2020-12-31_custom_ConvertibleLoansTwoMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,053,503</ix:nonFraction></span> shares of the Company&#8217;s common stock at a per
share exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pii" title="Warrants exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-31_custom_ConvertibleLoansTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7</ix:nonFraction></span>. As of December 31, 2020, $<span id="xdx_90B_eus-gaap--ConvertibleDebtCurrent_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zScnFXulvOp2" title="Current maturities of convertible loans" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:ConvertibleDebtCurrent" contextRef="AsOf2020-12-31_custom_ConvertibleLoansTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,500</ix:nonFraction></span> thousand of the principal amount is included in current maturities
of convertible loans in the balance sheet and the remainder in long-term convertible loans. See also Notes 7(b), 7(c), 7(e), 7(f)
and 7(g).</ix:footnote></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F07_zKcMdD3eXmG9" style="width: 15pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td><td style="text-align: justify"><span id="xdx_F19_zABI8xDlieZ9" style="font: 10pt Times New Roman, Times, Serif"><ix:footnote id="Footnote001424" xml:lang="en-US">The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_pii" title="Stock issued during period, conversion of convertible securities" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,559</ix:nonFraction></span> shares
at a per share exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zEMHD8sLnPdi" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-31_custom_ConvertibleLoansThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7</ix:nonFraction></span>. As of December 31, 2020, all the principal amount is included in long-term convertible loans
in the balance sheet See also Notes 7(h).</ix:footnote></span></td>
</tr></table>

</ix:nonNumeric><p id="xdx_8AC_zLHNdcivKyDi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">b.
During April 2019, the Company entered into a convertible loan agreement with an offshore investor for an aggregate amount of
$<span id="xdx_902_eus-gaap--ProceedsFromConvertibleDebt_pn3n3_c20190401__20190430__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_z69O0G3tVKJk" title="Proceeds from Convertible Debt"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2019-04-012019-04-30_custom_ConvertibleLoanAgreementMember_us-gaap_InvestorMember_custom_ConvertibleLoansOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></span> thousand into the U.S. Subsidiary. The investor, at its option, may convert the outstanding principal amount and accrued
interest under this note into shares and <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20190430__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_z7n6mMUDIHE6" title="Warrants exercise, term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl1432">three-year</span></span> warrants to purchase shares of the Company&#8217;s common stock at a per share
exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20190430__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_pii" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-04-30_custom_ConvertibleLoanAgreementMember_us-gaap_InvestorMember_custom_ConvertibleLoansOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span>; or into shares of the U.S. Subsidiary at a valuation of the U.S. Subsidiary of $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn6n6_c20190401__20190430__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zcRY4Opjzscf" title="Valuation of shares"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2019-04-012019-04-30_custom_ConvertibleLoanAgreementMember_us-gaap_InvestorMember_custom_ConvertibleLoansOneMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">50</ix:nonFraction></span> million. During February
2020 the company repaid this convertible loan to the investor in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 109; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">c.
During May 2019, the Company entered into a private placement subscription agreement with an investor for $<span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn6n6_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zKQ4Zzo0IKrj" title="Aggregate amount of debt"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2019-05-012019-05-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million. The lender
shall be entitled, at any time prior to or no later than the maturity date, to convert the outstanding amount, into units of (1)
shares of common stock of the Company at a conversion price per share equal to $<span title="Convertible warrant exercise price"><span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20190531__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zV5pGv4Se0P2" title="Convertible warrant exercise price into common stock"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2019-05-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span></span> and (2) warrants to purchase an equal number
of additional shares of the Company&#8217;s common stock at a price of $<span title="Conversion price per share"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20190531__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zW7aCDryPHCh" title="Warrant exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-05-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
transaction costs were approximately $<span id="xdx_902_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zk6UVIe2To5a" title="Transaction costs"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2019-05-012019-05-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">497</ix:nonFraction></span> thousand, out of which $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z0DLIX3eIO3k" title="Allocated share-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-05-012019-05-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">97</ix:nonFraction></span> thousand are stock-based compensation due to issuance of
warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">d.
In May 2019, the Company had agreed to enter into a <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20190531__us-gaap--TypeOfArrangementAxis__custom--SixPercentageConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zHEYF4XfkfIh" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2019-05-31_custom_SixPercentageConvertibleLoanAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">6</ix:nonFraction></span>% convertible loan agreement with an investor for an aggregate amount of
$<span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn6n6_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--SixPercentageConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z0bvHabdnThh" title="Aggregate amount of debt"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2019-05-012019-05-31_custom_SixPercentageConvertibleLoanAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million. The lender shall be entitled, at any time prior to or no later than the maturity date, to convert the outstanding
amount, into units of (1) shares of stock of the Company at a conversion price per share equal to $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20190531__us-gaap--TypeOfArrangementAxis__custom--SixPercentageConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zTiIhuplX0h6" title="Convertible warrant exercise price into common stock"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2019-05-31_custom_SixPercentageConvertibleLoanAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span> and (2) warrants to purchase
an equal number of additional shares of the Company&#8217;s common stock at a price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20190531__us-gaap--TypeOfArrangementAxis__custom--SixPercentageConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zrHb12bwPml8" title="Warrant exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-05-31_custom_SixPercentageConvertibleLoanAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span> per share. As of the date of the
filing of this Annual Report on Form 10-K, the loan had not yet been received by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">e.
In June 2019, the Company entered into private placement subscription agreements with investors for an aggregate amount of $<span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn6n6_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zpurUKFq14na" title="Aggregate amount of debt"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2019-06-012019-06-30_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span>
million. The lenders shall be entitled, at any time prior to or no later than the maturity date, to convert the outstanding amount,
into units of (1) shares of common stock of the Company at a conversion price per share equal to $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20190630__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zuliYvtAThb6" title="Convertible warrant exercise price into common stock"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2019-06-30_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span> and (2) warrants to purchase
an equal number of additional shares of the Company&#8217;s common stock at a price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20190630__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zUPP9yQegI1k" title="Warrant exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-06-30_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">f.
During October 2019, the Company entered into a Private Placement Subscription Agreement and Convertible Credit Line Agreement
(collectively, the &#8220;Credit Line Agreements&#8221;) with four non-U.S. investors (the &#8220;Lenders&#8221;), pursuant to
which the Lenders furnished to the Company access to an aggregate $<span title="Aggregate credit line amount"><span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_zcjuaMXMr04c"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5</ix:nonFraction></span>.0</span> million credit line (which consists of $<span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_zUuI9OIxOmo2" title="Aggregate credit line amount"><span id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_z3MyOSmjrq59" title="Aggregate credit line amount"><span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_z8UUtvwWvQrj" title="Aggregate credit line amount"><span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_zWymxtcelJLd" title="Aggregate credit line amount"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">1.25</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> million from
each Lender) (collectively, the &#8220;Credit Line&#8221;). Pursuant to the Credit Line Agreements, the Company is entitled to
draw down an aggregate of $<span title="Proceeds from lines of credit"><span id="xdx_90A_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_zaPyjOXVPFU5" title="Proceeds from lines of credit"><span id="xdx_901_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20191101__20191130__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_zitzrlT2jfn3" title="Proceeds from lines of credit"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-10-012019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-11-012019-11-30_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction></ix:nonFraction></span></span></span> million (consisting of $<span title="Proceeds from lines of credit"><span id="xdx_909_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_zWjb1tdLhk62" title="Proceeds from lines of credit"><span id="xdx_904_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_zCexVgm8IXNd" title="Proceeds from lines of credit"><span id="xdx_906_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_zw24EX7Nx9Z7" title="Proceeds from lines of credit"><span id="xdx_907_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_zdCQdwaFdnwc" title="Proceeds from lines of credit"><span id="xdx_902_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191101__20191130__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_zezWyrEqHisl" title="Proceeds from lines of credit"><span id="xdx_90D_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191101__20191130__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_zm2F3SqPrmlc" title="Proceeds from lines of credit"><span id="xdx_905_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191101__20191130__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_znQSaazoCaDb" title="Proceeds from lines of credit"><span id="xdx_90D_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191101__20191130__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_zymaoZ7Qbk5g" title="Proceeds from lines of credit"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-10-012019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-10-012019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-10-012019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-10-012019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-11-012019-11-30_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-11-012019-11-30_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-11-012019-11-30_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-11-012019-11-30_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span></span></span></span></span></span> thousand from each Lender) of the Credit Line in each of October 2019
and November 2019. In each of December 2019, January 2020 and February 2020, the Company may draw down an additional aggregate
of $<span title="Proceeds from lines of credit"><span id="xdx_90B_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_z1r7z6cMtRbj" title="Proceeds from lines of credit"><span id="xdx_908_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_zB0QdMgwrfec" title="Proceeds from lines of credit"><span id="xdx_90F_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_zQZC92nW2BE2" title="Proceeds from lines of credit"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-12-012019-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2020-01-012020-01-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2020-02-012020-02-29_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> million (consisting of $<span title="Proceeds from lines of credit"><span id="xdx_905_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_z6Bw4wZHB7Al" title="Proceeds from lines of credit"><span id="xdx_909_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_z4LDdXOcIfd4" title="Proceeds from lines of credit"><span id="xdx_90D_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_zJEFVNtTRf9a" title="Proceeds from lines of credit"><span id="xdx_905_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_z55ZFm2vjlzi" title="Proceeds from lines of credit"><span id="xdx_903_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_z1jhgobBxpZc" title="Proceeds from lines of credit"><span id="xdx_908_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_zKRyE2bR8XCd" title="Proceeds from lines of credit"><span id="xdx_90F_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_z8csag846ioh" title="Proceeds from lines of credit"><span id="xdx_90E_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_zsFaN90115w5" title="Proceeds from lines of credit"><span id="xdx_901_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_zfEXCZRUReLk" title="Proceeds from lines of credit"><span id="xdx_900_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_zkiCMDD8vf34" title="Proceeds from lines of credit"><span id="xdx_90C_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_zIAVVEyOlkl7" title="Proceeds from lines of credit"><span id="xdx_901_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_z8ceT8CzTIOh" title="Proceeds from lines of credit"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-12-012019-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-12-012019-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-12-012019-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-12-012019-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2020-01-012020-01-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2020-01-012020-01-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2020-01-012020-01-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2020-01-012020-01-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2020-02-012020-02-29_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2020-02-012020-02-29_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2020-02-012020-02-29_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2020-02-012020-02-29_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span></span></span></span></span></span></span></span></span></span> thousand from each Lender), until the total amount drawn down under the Credit Line reaches
an aggregate of $<span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_zW6lx0PuaOha" title="Aggregate credit line amount"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5</ix:nonFraction></span> million (consisting of $<span id="xdx_90F_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_zEVMX3fEW0kd" title="Aggregate credit line amount"><span id="xdx_900_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_zYpzfkrlPyhk" title="Aggregate credit line amount"><span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_zOZKMacdpBC6" title="Aggregate credit line amount"><span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_z5SDJgoHqgH5" title="Aggregate credit line amount"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">1.25</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> million from each Lender), subject to the approval of the Lenders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the terms of the Credit Line Agreements and the Notes, the total loan amount, and all accrued but unpaid interest thereon,
shall become due and payable on the second anniversary of the Effective Date (the &#8220;Maturity Date&#8221;). The Maturity Date
may be extended by each Lender in its sole discretion and shall be in writing signed by the Company and the Lender. Interest on
any amount that has been drawn down under the Credit Line accrues at a per annum rate of eight percent (<span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zZJUkLpt2qGj" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">8</ix:nonFraction></span>%). At any time prior
to or on the Maturity Date, by providing written notice to the Company, each of the Lenders is entitled to convert its respective
drawdown amounts and all accrued interest, into shares of the Company&#8217;s common stock, par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zwSUsnpyt1md" title="Common stock, par value"><span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zatdvznLc6Ji" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> per share (the &#8220;Common
Stock&#8221;), at a conversion price equal to $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zjgrLDl3JEU5" title="Conversion price per share"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Furthermore,
upon the drawdown of $<span id="xdx_904_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_z6phx8coXCwf" title="Proceeds from lines of credit"><span id="xdx_903_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_zzz6tqDI2Xna" title="Proceeds from lines of credit"><span id="xdx_90C_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_zb2cTMQKoN6l" title="Proceeds from lines of credit"><span id="xdx_90F_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_zYdKUBTBiNX2" title="Proceeds from lines of credit"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2020-12-012020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2020-12-012020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2020-12-012020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2020-12-012020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> thousand from each Lender and, together with the other Lenders, a drawdown of an aggregate of $<span id="xdx_90B_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_zi0HTrgMuR1d" title="Proceeds from lines of credit"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2020-12-012020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span> million
under the Credit Line, the existing warrants of the Lenders to purchase shares of Common Stock shall be amended to extend their
exercise date to June 30, 2021 and the Company will issue to each of the Lenders warrants to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_pii" title="Number of warrant to purchase"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_pii" title="Number of warrant to purchase"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_pii" title="Number of warrant to purchase"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_pii" title="Number of warrant to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares of Common
Stock at an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_pii" title="Warrants exercise price"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_pii" title="Warrants exercise price"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_pii" title="Warrants exercise price"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_pii" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> per share. The new warrants will be exercisable for three (<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_zgdXXTXftPKj" title="Warrants exercise, term"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_zPfkchNgbST7" title="Warrants exercise, term"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_z6xdvaAGX202" title="Warrants exercise, term"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_zKDnZs4JEHF3" title="Warrants exercise, term"><ix:nonNumeric contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm"><ix:nonNumeric contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm"><ix:nonNumeric contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm"><ix:nonNumeric contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">3</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></span></span></span>) years from the Effective Date.
During October 2019, such drawdown was reached and the warrants were issued. The modification of the existing warrants in the
amount of $<span title="Transaction costs"><span id="xdx_90F_ecustom--ModificationOfExistingWarrants_iI_pn3n3_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zP7ls0iJyzUd" title="Modification of the existing warrants"><ix:nonFraction name="ORGS:ModificationOfExistingWarrants" contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">145</ix:nonFraction></span></span> thousands was recorded against the accumulated deficit and the value of the new warrants in the amount of $<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_z3xEr6nPszll" title="Warrants amount"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">370</ix:nonFraction></span>
thousands was offset against the convertible loan amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
lender shall be entitled, at any time prior to or no later than the maturity date, to convert the outstanding amount, into units
of shares of common stock of the Company at a conversion price per share equal to $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zljxqb0hyRxg" title="Conversion price per share"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
at December 31, 2019, the Company had received $<span id="xdx_901_eus-gaap--ProceedsFromLinesOfCredit_pn3n6_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_ztDQtFSEVnda"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-01-012019-12-31_custom_CreditLineAgreementsMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">3.65</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million from the Convertible Credit
Line investment comprised of $<span id="xdx_905_eus-gaap--ProceedsFromLinesOfCredit_pn4n6_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorOneMember_zkli2RKtYWPb"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-01-012019-12-31_custom_CreditLineAgreementsMember_custom_InvestorOneMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">1.15</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million from one investor, $<span id="xdx_905_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorTwoMember_zV1I2zV9YHxa"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-01-012019-12-31_custom_CreditLineAgreementsMember_custom_InvestorTwoMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million from a second investor, and $<span id="xdx_90A_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoOtherInvestorTwoMember_zTHnt9KwW958"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-01-012019-12-31_custom_CreditLineAgreementsMember_custom_TwoOtherInvestorTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">750</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand from two of the other lenders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 110; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
transaction costs were approximately $<span id="xdx_90E_ecustom--ModificationOfExistingWarrants_iI_pn3n3_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zsLO4oYJWIB7"><ix:nonFraction name="ORGS:ModificationOfExistingWarrants" contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">145</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 2020 the company repaid principal amount of $<span id="xdx_905_eus-gaap--RepaymentsOfLinesOfCredit_pn3n3_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zvAkWqq8xlFl" title="Repayments of lines o credit"><ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="From2020-01-012020-12-31_custom_CreditLineAgreementsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,400</ix:nonFraction></span> thousand and a total interest amount of $<span id="xdx_90F_eus-gaap--InterestExpenseDebt_pn3n3_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zH49qumtG5Hf" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2020-01-012020-12-31_custom_CreditLineAgreementsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">372</ix:nonFraction></span> thousand
to certain of the credit line investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">g.
In December 2019, the Company entered into private placement subscription agreements with investors for an aggregate amount of
$<span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn3n3_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zMsWBG02UWQ" title="Aggregate amount of debt"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2019-12-012019-12-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></span> thousand. The lenders shall be entitled, at any time prior to or no later than the maturity date, to convert the outstanding
amount, into units of 1 share of common stock of the Company at a conversion price per share equal to $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20191231__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_pii" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-12-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span> and warrants to purchase
<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20191231__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zUa5os2B7M3j" title="Number of warrant to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2019-12-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">183,481</ix:nonFraction></span> additional shares of the Company&#8217;s common stock at a price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20191231__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z6Pw4KchltVg" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-12-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span> per share. The fair value of the warrants was
$<span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20191231__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z52UVplQdXbl" title="Warrants amount"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2019-12-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">124</ix:nonFraction></span> thousand using the fair value of the shares on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">h.
On January 2, 2020, the Company entered into private placement subscription agreements with investors for an aggregate amount
of $<span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn3n3_c20191230__20200103__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zoIQtR4YckW" title="Aggregate amount of debt"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2019-12-302020-01-03_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></span> thousand of convertible loans. The lenders shall be entitled, at any time prior to or no later than the maturity date,
to convert the outstanding amount, into shares of Common Stock of the Company at a conversion price per share equal to $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_pii" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-01-02_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span>.
In addition, the Company granted the investors <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_pii" title="Number of warrant to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2020-01-02_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">151,428</ix:nonFraction></span> warrants to purchase an equal number of additional shares of Common Stock
at a price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zmheJnSvGEd9" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-01-02_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">i.
In December 2018, the Company entered into a Controlled Equity Offering Sales Agreement, or Sales Agreement, with Cantor Fitzgerald
&amp; Co., or Cantor, pursuant to which the Company may offer and sell, from time to time through Cantor, shares of its common
stock having an aggregate offering price of up to $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zlMtfVU4VtSg" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2018-12-012018-12-31_custom_ControlledEquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">25.0</ix:nonFraction></span> million. The Company will pay Cantor a commission rate equal to <span id="xdx_904_ecustom--PercentageOfCommission_pii_dp_uPercentage_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zhWvdCpBPosk" title="Percentage of commission"><ix:nonFraction name="ORGS:PercentageOfCommission" contextRef="From2018-12-012018-12-31_custom_ControlledEquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">3.0</ix:nonFraction></span>% of
the aggregate gross proceeds from each sale. Shares sold under the Sales Agreement will be offered and sold pursuant to the Company&#8217;s
Shelf Registration Statement on Form S-3 (Registration No. 333-223777) that was declared effective by the Securities and Exchange
Commission on March 28, 2018, or the Shelf Registration Statement, and a prospectus supplement and accompanying base prospectus
that the Company filed with the Securities and Exchange Commission on December 20, 2018. The Company has not yet sold any shares
of its common stock pursuant to the Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">j.
On November 2, 2016, the Company entered into unsecured convertible note agreements with accredited or offshore investors for
an aggregate amount of NIS <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn6n6_uNIS_c20161101__20161102__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember__srt--CurrencyAxis__currency--ILS_zPreb3R8Nm9g" title="Aggregate amount of debt"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2016-11-012016-11-02_custom_ControlledEquityOfferingSalesAgreementMember_currency_ILS" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="NIS">1</ix:nonFraction></span> million ($<span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn3n3_c20161101__20161102__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember_zmz9g9CfIoD6" title="Aggregate amount of debt"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2016-11-012016-11-02_custom_ControlledEquityOfferingSalesAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">280</ix:nonFraction></span> thousand). The loan bears a monthly interest rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20161102__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember_zjANP8kHV3pb" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2016-11-02_custom_ControlledEquityOfferingSalesAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">2</ix:nonFraction></span>% and mature on <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20161101__20161102__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember_zZ8BnkI6oK82" title="Debt instrument, maturity date"><ix:nonNumeric contextRef="From2016-11-012016-11-02_custom_ControlledEquityOfferingSalesAgreementMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">May 1, 2017</ix:nonNumeric></span>,
unless converted earlier. On April 27, 2017 and November 2, 2017, the Company entered into extension agreements through November
2, 2017 and May 2, 2018, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
March 2018, the investor submitted a notice of its intention to convert into shares of the Company&#8217;s common stock the principal
amount and accrued interest of approximately $<span id="xdx_902_eus-gaap--ConvertibleDebt_iI_pn3n3_c20180331__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember_znUx3t8cIbqh" title="Convertible debt"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2018-03-31_custom_ControlledEquityOfferingSalesAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">383</ix:nonFraction></span> thousand outstanding. A related party of such investor at the same time, exercised
warrants issued in November 2016 to purchase shares of the Company&#8217;s Common Stock. The exercise price of the warrants and
conversion price were fixed at $<span id="xdx_902_ecustom--DebtInstrumentConvertibleWarrantExercisePrice_iI_pii_uUSDPShares_c20180331__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember_zxOnUi2aIdp8" title="Convertible warrant exercise price"><ix:nonFraction name="ORGS:DebtInstrumentConvertibleWarrantExercisePrice" contextRef="AsOf2018-03-31_custom_ControlledEquityOfferingSalesAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.52</ix:nonFraction></span> per share (pre-reverse stock split implemented by the Company in November 2017). There is
a significant disagreement between the Company and these two entities as to the number of shares of Common Stock issuable to these
entities, and they contend that the number of shares of Common Stock issuable to them should not consider the reverse stock split.
The Company rejects these contentions in their entirety and, based on the advice of specially retained counsel, believes that
these claims are without legal merit and not made in good faith. The Company intends to vigorously defend its interests and pursue
other avenues of legal address. Through its counsel, the Company has advised these entities that unless they withdraw their request
within a specified period, the Company will cancel the above referenced agreements and these parties&#8217; right to receive any
shares of the Company&#8217;s Common Stock. In April 2018, the Company withdrew the agreements and deposited the shares in total
amount of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180401__20180430__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember_pii" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2018-04-012018-04-30_custom_ControlledEquityOfferingSalesAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">107,985</ix:nonFraction></span> issued under those agreements and the principal amount and accrued interest of the loan in escrow account. The
deposit of the principal amount and accrued interest presented as restricted cash in the balance sheet as of December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 111; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:LoansTextBlock"><p id="xdx_800_ecustom--LoansTextBlock_zjrO7ATL8kll" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
8 &#8211; <span id="xdx_824_ztd02ZE3btW2">LOANS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfDebtTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfDebtTableTextBlock_zAYEB7Q4VzU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Terms
of Short-term Loans</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_8BF_z8OljQQ2hCri" style="display: none">SCHEDULE OF LOANS</span></i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Currency</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Interest Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 42%; text-align: left">Short term loans</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center">KRW</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoanOneMember__srt--CurrencyAxis__currency--KRW_zIsn6CtImNi3" title="Interest Rate" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-12-31_custom_ShortTermLoanOneMember_currency_KRW" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">3.61</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--DebtCurrent_iI_pn3n3_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoanOneMember__srt--CurrencyAxis__currency--KRW_z6t9YdpT77kf" title="Total loans" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1630">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtCurrent_iI_pn3n3_c20191231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoanOneMember__srt--CurrencyAxis__currency--KRW_zNr3uHWNlib8" title="Total loans" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="AsOf2019-12-31_custom_ShortTermLoanOneMember_currency_KRW" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">260</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short term loans</td><td>&#160;</td>
    <td style="text-align: center">KRW</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansTwoMember__srt--CurrencyAxis__currency--KRW_zMC4UvRNnTJl" title="Interest Rate" style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-12-31_custom_ShortTermLoansTwoMember_currency_KRW" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">6.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtCurrent_iI_pn3n3_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansTwoMember__srt--CurrencyAxis__currency--KRW_zgLnnldJsKOg" title="Total loans" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1636">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--DebtCurrent_iI_pn3n3_c20191231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansTwoMember__srt--CurrencyAxis__currency--KRW_zL8Jg8cz0a31" title="Total loans" style="text-align: right"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="AsOf2019-12-31_custom_ShortTermLoansTwoMember_currency_KRW" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">131</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short term loans</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">USD</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansThreeMember_zETCATVnI7qh" title="Interest Rate" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-12-31_custom_ShortTermLoansThreeMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">1.00</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--DebtCurrent_iI_pn3n3_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansThreeMember_zsvIRslKMeI2" title="Total loans" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="AsOf2020-12-31_custom_ShortTermLoansThreeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">145</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--DebtCurrent_iI_pn3n3_c20191231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansThreeMember_zrBmTvcLXsgg" title="Total loans" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1644">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DebtCurrent_iI_pn3n3_c20201231_zYcK5lHR21sh" title="Total loans" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">145</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--DebtCurrent_iI_pn3n3_c20191231_ztWvQaA4gr9h" title="Total loans" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">391</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A7_zXo7VmyNKFee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:LeasesOfLesseeDisclosureTextBlock"><p id="xdx_80E_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zr0ZpGQpiJUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
9 &#8211; <span id="xdx_82C_zRZf20zOsyz8">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company leases research and development facilities, equipment and offices under finance and operating leases. For leases with
terms greater than 12 months, the Company record the related asset and obligation at the present value of lease payments over
the term. Many of the leases include rental escalation clauses, renewal options and/or termination options that are factored into
the determination of lease payments when appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s leases do not provide a readily determinable implicit rate. Therefore, the Company estimated the incremental borrowing
rate to discount the lease payments based on information available at lease commencement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Manufacturing
facilities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company leases space for its manufacturing facilities in Israel under operating lease agreements. The leasing contracts are for
a period of <span id="xdx_903_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ManufacturingFacilityMember__srt--StatementGeographicalAxis__country--IL__srt--RangeAxis__srt--MinimumMember_zGQAXTREGjQa" title="Leasing contracts period"><ix:nonNumeric contextRef="AsOf2020-12-31_us-gaap_ManufacturingFacilityMember_country_IL_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract">3</ix:nonNumeric></span> - <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ManufacturingFacilityMember__srt--StatementGeographicalAxis__country--IL__srt--RangeAxis__srt--MaximumMember_zZSthrCW7jG5" title="Leasing contracts period"><ix:nonNumeric contextRef="AsOf2020-12-31_us-gaap_ManufacturingFacilityMember_country_IL_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract">5</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Research
and Development facilities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company leases space for its research and development facilities in South Korea under an operating lease agreement. The leasing
contracts are for a period of <span id="xdx_900_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchAndDevelopmentFacilitiesMember__srt--StatementGeographicalAxis__country--KR__srt--RangeAxis__srt--MinimumMember_zbob8PMMPKHc" title="Leasing contracts period"><ix:nonNumeric contextRef="AsOf2020-12-31_custom_ResearchAndDevelopmentFacilitiesMember_country_KR_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract">2</ix:nonNumeric></span> &#8211; <span id="xdx_900_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchAndDevelopmentFacilitiesMember__srt--StatementGeographicalAxis__country--KR__srt--RangeAxis__srt--MaximumMember_zWy4x1Grp6Ml" title="Leasing contracts period"><ix:nonNumeric contextRef="AsOf2020-12-31_custom_ResearchAndDevelopmentFacilitiesMember_country_KR_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract">5</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Offices</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company leases space for offices in Israel under operating leases. The leasing contracts are valid for terms of <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficesMember__srt--StatementGeographicalAxis__country--IL_zR0orHrT7INg" title="Leasing contracts period"><ix:nonNumeric contextRef="AsOf2020-12-31_custom_OfficesMember_country_IL" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract">5</ix:nonNumeric></span> years. These
contracts are considered as operational leasing and under operating lease right-of-use assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Lease
Position</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock"><p id="xdx_890_ecustom--LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock_z1FhRdiiGaR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
table below presents the lease-related assets and liabilities recorded on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8B0_zZdKgRAHa2p5" style="display: none">SCHEDULE OF LEASE-RELATED ASSETS AND LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Operating Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Operating lease right-of-use assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231_zqRWSm2h1JEc" title="Operating lease right-of-use assets" style="width: 22%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,474</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property, plants and equipment, gross</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_iI_pn3n3_c20201231_zJOUqZ8y7xm8" title="Property, plants and equipment, gross" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">99</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_iNI_pn3n3_di_c20201231_zWnCpv4ev9o7" title="Accumulated depreciation" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_iI_pn3n3_c20201231_zvbDrAEhCeBj" title="Property and equipment, net" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current maturities of operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20201231_zWljfSHKPXta" title="Current maturities of operating leases" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">485</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current maturities of long-term finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityCurrent_iI_pn3n3_c20201231_zYVkaOFfyVm9" title="Current maturities of long-term finance leases" style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Long-term liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_zvKMPRRBlAfi" title="Non-current operating leases" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,020</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long-term finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_z5cnGBu7KYX4" title="Long-term finance leases" style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Weighted Average Remaining Lease Term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Weighted Average Remaining Lease Term, Operating leases" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zqn7w1LZqLPc" title="Weighted Average Remaining Lease Term, Operating leases"><ix:nonNumeric contextRef="AsOf2020-12-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">3.4</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_90C_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zFXvyLnurfwl" title="Weighted Average Remaining Lease Term, Finance leases"><ix:nonNumeric contextRef="AsOf2020-12-31" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1">4.2</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average Discount Rate</b></span></p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercentage_c20201231_zKy8r14AXkhk" title="Weighted Average Discount Rate, Operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">6.7</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercentage_c20201231_zuyJmNY7djsb" title="Weighted Average Discount Rate, Finance leases" style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">2.0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A2_zGn7PpLH9Mbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 112; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Lease
Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_893_eus-gaap--LeaseCostTableTextBlock_z67WrxGKHnM5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
table below presents certain information related to lease costs and finance and operating leases during the year ended December
31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8BA_zuaKHrU7aoml" style="display: none">SCHEDULE OF LEASE COSTS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20200101__20201231_z0Sk6zz48Erk" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeaseCost_pn3n3_zexRgjt0MFr2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Operating lease cost:</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 18%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">547</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Finance lease cost:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_pn3n3_maFLCzuMa_zmKVHsTFM7V3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amortization of leased assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--FinanceLeaseInterestExpense_pn3n3_maFLCzuMa_zbwkMID5of0e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Interest on lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_400_ecustom--FinanceLeaseCost_iT_pn3n3_mtFLCzuMa_zPKF1ljciKzb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total finance lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ORGS:FinanceLeaseCost" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A7_z8Ud03dG2pu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zJyqjoP69R92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
table below presents supplemental cash flow information related to leases during the year ended December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8B1_z4qX6smYrA7h" style="display: none">SCHEDULE OF SUPPLEMENTAL CASHFLOW INFORMATION</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20200101__20201231_zl3kxCon0LI8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>December 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in Thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid for amounts included in the measurement of leases liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--OperatingLeasePayments_pn3n3_zSuJywrS7kae" style="vertical-align: bottom; background-color: White">
    <td style="width: 78%; text-align: left">Operating leases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">515</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--FinanceLeaseInterestPaymentOnLiability_pn3n3_zfrprXkaNqL7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_zZZo1JoAWpwc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">967</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_pn3n3_zFFFu9SrcNN" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">366</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AC_zVemCYsqNhWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Undiscounted
Cash Flows</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:LesseeLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89C_ecustom--LesseeLeaseLiabilityMaturityTableTextBlock_zPoAow1Vgmpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining years to the finance
lease liabilities and operating lease liabilities recorded on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8B7_zOMZCS7jzl36" style="display: none">SCHEDULE OF FINANCE LEASE LIABILITIES AND OPERATING LEASE LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Operating</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Leases</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Finance<br /> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; font-weight: bold">Year ended December 31,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20201231_z6tF4FvykiI8" title="Operating Leases, 2021" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">526</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20201231_zBaLYRgihj6" title="Finance Lease, 2021" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20201231_zg24sOWglx32" title="Operating Leases, 2022" style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">528</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20201231_zTxAWvVV5xtb" title="Finance Lease, 2022" style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20201231_zHETN0cgwm34" title="Operating Leases, 2023" style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">342</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20201231_zq4qcR8EzRKh" title="Finance Lease, 2023" style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20201231_zFeR4t2KR6h" title="Operating Leases, 2024" style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">188</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20201231_zwNV9GhUi5K3" title="Finance Lease, 2024" style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20201231_zsJhVL2uRgn7" title="Operating Leases, 2025" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">59</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20201231_zuz522hVdfpj" title="Finance Lease, 2025" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total minimum lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3_c20201231_zBMnPMPIbkLk" title="Operating Leases, Total minimum lease payments" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,643</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_pn3n3_c20201231_zC1UR28KG7Mk" title="Finance Leases, Total minimum lease payments" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: amount of lease payments representing interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20201231_ztGz3nCYll8h" title="Operating Leases, Less: amount of lease payments representing interest" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">138</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20201231_zHT9XriD7Lrl" title="Finance Lease, Less: amount of lease payments representing interest" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Present value of future minimum lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20201231_zuJcxwl9X6Rg" title="Operating Leases, Present value of future minimum lease payments" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,505</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20201231_zsOll1AEozka" title="Finance Lease, Present value of future minimum lease payments" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Current leases obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_c20201231_znjuy2SLuqd1" title="Operating Leases, Less: Current leases obligations" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">485</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_pn3n3_di_c20201231_z95tzskdOep5" title="Finance Lease, Less: Current leases obligations" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Long-term leases obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_zgG7HPpfTkOe" title="Operating Leases, Long-term leases obligations" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,020</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_zkdo2MEdckRc" title="Finance Lease, Long-term leases obligations" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A1_zOc9cENU1w82" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 113; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:ScheduleOfRightofuseAssetsByGeographicalLocation"><p id="xdx_895_ecustom--ScheduleOfRightofuseAssetsByGeographicalLocation_zGSgBueRb6dk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Right-of-use
assets by geographical location were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8B9_ziuqXQcrRCB3" style="display: none">SCHEDULE OF RIGHT-OF-USE ASSETS BY GEOGRAPHICAL LOCATION</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Korea</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--KR_zlXuLOn79WM6" title="Operating lease right-of-use assets" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-12-31_country_KR" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">683</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--KR_zmzTrc2PUWRl" title="Operating lease right-of-use assets" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2019-12-31_country_KR" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">145</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Israel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--IL_z19Lr1NnxPye" title="Operating lease right-of-use assets" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-12-31_country_IL" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">496</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--IL_zcOn8zhaNaCb" title="Operating lease right-of-use assets" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2019-12-31_country_IL" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">580</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">U.S.</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--US_z4mX8BUG13c9" title="Operating lease right-of-use assets" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-12-31_country_US" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">295</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--US_z76UwFBhrWG" title="Operating lease right-of-use assets" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1762">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231_zg2SXZvncJul" title="Operating lease right-of-use assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,474</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20191231_zhAh91WpnK6b" title="Operating lease right-of-use assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">725</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A4_zCsttVJJ5FFd" style="margin-top: 0; margin-bottom: 0">&#160;</p>
<!-- Field: Split-Segment; Name: Split 2 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:CommitmentsDisclosureTextBlock"><p id="xdx_80F_eus-gaap--CommitmentsDisclosureTextBlock_zAn7Qlnnjvtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
10 &#8211; <span id="xdx_82E_zDzDwqP4TG81">COMMITMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">See
Note 11 for additional commitments for funding of the ventures of the company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>a.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Maryland
    Technology Development Corporation</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
June 30, 2014, the Company&#8217;s U.S. Subsidiary entered into a grant agreement with Maryland Technology Development Corporation
(&#8220;TEDCO&#8221;). TEDCO was created by the Maryland State Legislature in 1998 to facilitate the transfer and commercialization
of technology from Maryland&#8217;s research universities and federal labs into the marketplace and to assist in the creation
and growth of technology-based businesses in all regions of the State. Under the agreement, TEDCO paid to the U.S Subsidiary an
amount of $<span id="xdx_90D_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_c20140630__us-gaap--RelatedPartyTransactionAxis__custom--MarylandTechnologyDevelopmentCorporationMember__srt--RangeAxis__srt--MaximumMember_z61OWaxT90nb" title="Grants receivable, noncurrent"><ix:nonFraction name="us-gaap:GrantsReceivableNoncurrent" contextRef="AsOf2014-06-30_custom_MarylandTechnologyDevelopmentCorporationMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">406</ix:nonFraction></span> thousand (the &#8220;Grant&#8221;). On June 21, 2016 TEDCO has approved an extension until June 30, 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>b.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Department
    De La Gestion Financiere Direction De L&#8217;analyse Financiere (&#8220;DGO6&#8221;)</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">(1)
On November 17, 2014, the Belgian Subsidiary, received the formal approval from the DGO6 for a Euro <span id="xdx_900_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_uEUR_c20141117__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zpNwyBMCRF6h" title="Grants receivable, noncurrent"><ix:nonFraction name="us-gaap:GrantsReceivableNoncurrent" contextRef="AsOf2014-11-17_custom_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="EUR">2</ix:nonFraction></span> million ($<span id="xdx_900_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_uUSD_c20141117__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zxBTCocFltT" title="Grants receivable, noncurrent"><ix:nonFraction name="us-gaap:GrantsReceivableNoncurrent" contextRef="AsOf2014-11-17_custom_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.4</ix:nonFraction></span> million) support
program for the research and development of a potential cure for Type 1 Diabetes. The financial support was composed of Euro <span id="xdx_90F_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_uEUR_c20141117__us-gaap--OtherCommitmentsAxis__custom--IndustrialResearchPartOfResearchProgramMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zxlOqLLITAx2" title="Grants receivable, noncurrent"><ix:nonFraction name="us-gaap:GrantsReceivableNoncurrent" contextRef="AsOf2014-11-17_custom_IndustrialResearchPartOfResearchProgramMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="EUR">1,085</ix:nonFraction></span>
thousand (<span id="xdx_90C_ecustom--GrantsReceivablePercentageOfBudgetedCosts_iI_pii_dp_uPercentage_c20141117__us-gaap--OtherCommitmentsAxis__custom--IndustrialResearchPartOfResearchProgramMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zQwJabUpFY3" title="Grants receivable, percentage of budgeted costs"><ix:nonFraction name="ORGS:GrantsReceivablePercentageOfBudgetedCosts" contextRef="AsOf2014-11-17_custom_IndustrialResearchPartOfResearchProgramMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">70</ix:nonFraction></span>% of budgeted costs) grant for the industrial research part of the research program and a further recoverable advance
of Euro <span id="xdx_907_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_uEUR_c20141117__us-gaap--OtherCommitmentsAxis__custom--ExperimentalDevelopmentPartOfResearchProgramMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zBOhOf3nRpw8" title="Grants receivable, noncurrent"><ix:nonFraction name="us-gaap:GrantsReceivableNoncurrent" contextRef="AsOf2014-11-17_custom_ExperimentalDevelopmentPartOfResearchProgramMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="EUR">930</ix:nonFraction></span> thousand (<span id="xdx_901_ecustom--GrantsReceivablePercentageOfBudgetedCosts_iI_pii_dp_uPercentage_c20141117__us-gaap--OtherCommitmentsAxis__custom--ExperimentalDevelopmentPartOfResearchProgramMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zxIWdncDV2d9" title="Grants receivable, percentage of budgeted costs"><ix:nonFraction name="ORGS:GrantsReceivablePercentageOfBudgetedCosts" contextRef="AsOf2014-11-17_custom_ExperimentalDevelopmentPartOfResearchProgramMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">60</ix:nonFraction></span>% of budgeted costs) of the experimental development part of the research program. In December 2014, the
Belgian Subsidiary received advance payment of Euro <span id="xdx_90C_ecustom--AdvancePaymentsOnAccountOfGrant_iI_pn3n3_uEUR_c20141231__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zVKbZnE8j15e" title="Advance payments on account of grant"><ix:nonFraction name="ORGS:AdvancePaymentsOnAccountOfGrant" contextRef="AsOf2014-12-31_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="EUR">1,209</ix:nonFraction></span> thousand under the grant. The grants are subject to certain conditions
with respect to the Belgian Subsidiary&#8217;s work in the Walloon Region. In addition, the DGO6 is also entitled to a royalty
upon revenue being generated from any commercial application of the technology. In 2017 the Company received by the DGO6 final
approval for Euro <span id="xdx_908_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_uEUR_c20171231__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zyEBoHcF3IB9" title="Grants receivable, noncurrent"><ix:nonFraction name="us-gaap:GrantsReceivableNoncurrent" contextRef="AsOf2017-12-31_custom_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="EUR">1.8</ix:nonFraction></span> million costs invested in the project out of which Euro <span id="xdx_905_eus-gaap--Revenues_pn5n6_c20170101__20171231__srt--ProductOrServiceAxis__custom--RevenueFromGrantsMember__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zwbh06oQeVx2" title="Revenues, total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2017-01-012017-12-31_custom_RevenueFromGrantsMember_custom_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million funded by the DGO6. As of December 31,
2020, the Company repaid to the DGO6 a total amount of $<span id="xdx_90F_eus-gaap--OtherExpenses_pn3n3_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zuJ1klvKPF3b" title="Other expenses"><ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2020-01-012020-12-31_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">118</ix:nonFraction></span> thousand (Euro <span id="xdx_904_eus-gaap--OtherExpenses_pn3n3_uEUR_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zqDcUUNqk98e" title="Other expenses"><ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2020-01-012020-12-31_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="EUR">96</ix:nonFraction></span> thousand) and amount of $<span id="xdx_905_eus-gaap--OtherCommitment_iI_pn3n3_c20201231__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zChk3zy27KRd" title="Other payables"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2020-12-31_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">106</ix:nonFraction></span> thousand was recorded
in other payables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">(2)
In April 2016, the Belgian Subsidiary received the formal approval from DGO6 for a Euro <span id="xdx_906_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_uEUR_c20160430__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zwckrLTpKrOc"><ix:nonFraction name="us-gaap:GrantsReceivableNoncurrent" contextRef="AsOf2016-04-30_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="EUR">1.3</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million ($<span id="xdx_903_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_c20160430__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zcyDSi8mIuC2"><ix:nonFraction name="us-gaap:GrantsReceivableNoncurrent" contextRef="AsOf2016-04-30_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million) support program for the development
of a potential cure for Type 1 Diabetes. The financial support was awarded to the Belgium Subsidiary as a recoverable advance
payment at <span id="xdx_90F_ecustom--GrantsReceivablePercentageOfBudgetedCosts_iI_dp_uPercentage_c20160430__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zkYAYh5F1O06"><ix:nonFraction name="ORGS:GrantsReceivablePercentageOfBudgetedCosts" contextRef="AsOf2016-04-30_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">55</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of budgeted costs, or for a total of Euro <span id="xdx_90D_eus-gaap--Revenues_pn3n3_uEUR_c20160401__20160430__srt--ProductOrServiceAxis__custom--RevenueFromGrantsMember__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zsgyX91xQ0Lh"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2016-04-012016-04-30_custom_RevenueFromGrantsMember_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="EUR">717</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand ($<span id="xdx_909_eus-gaap--Revenues_pn3n3_c20160401__20160430__srt--ProductOrServiceAxis__custom--RevenueFromGrantsMember__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_z3OUrZmJYRT8"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2016-04-012016-04-30_custom_RevenueFromGrantsMember_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">800</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand). The grant will be paid over
the project period. The Belgian Subsidiary received advance payment of Euro <span id="xdx_90B_eus-gaap--Revenues_pn3n3_uEUR_c20200101__20201231__srt--ProductOrServiceAxis__custom--RevenueFromGrantsMember__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_z00ID9zTlD19"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-12-31_custom_RevenueFromGrantsMember_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="EUR">438</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand ($<span id="xdx_905_eus-gaap--Revenues_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--RevenueFromGrantsMember__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zvPwZ8jIz1Ag"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-12-31_custom_RevenueFromGrantsMember_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">537</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand). Up through December 31,
2020, an amount of Euro <span id="xdx_903_ecustom--DeductionOfResearchAndDevelopmentExpenses_pn3n3_uEUR_c20200101__20201231__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zKrgXmU9kBO"><ix:nonFraction name="ORGS:DeductionOfResearchAndDevelopmentExpenses" contextRef="From2020-01-012020-12-31_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="EUR">358</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand ($<span id="xdx_901_ecustom--DeductionOfResearchAndDevelopmentExpenses_pn3n3_c20200101__20201231__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zeOcc5Wz7Axc"><ix:nonFraction name="ORGS:DeductionOfResearchAndDevelopmentExpenses" contextRef="From2020-01-012020-12-31_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">437</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand) was recorded as deduction of
research and development expenses and an amount of Euro <span id="xdx_90E_ecustom--AdvancePaymentsOnAccountOfGrant_iI_pn3n3_uEUR_c20201231__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_z3HPJnLeeree"><ix:nonFraction name="ORGS:AdvancePaymentsOnAccountOfGrant" contextRef="AsOf2020-12-31_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="EUR">80</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand was recorded as advance payments
on account of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 114; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">(3)
On October 8, 2016, the Belgian Subsidiary received the formal approval from the DGO6 for a Euro <span id="xdx_907_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_uEUR_c20161008__us-gaap--OtherCommitmentsAxis__custom--GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zQ351sqZpTCh" title="Grants receivable, noncurrent"><ix:nonFraction name="us-gaap:GrantsReceivableNoncurrent" contextRef="AsOf2016-10-08_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="EUR">12.3</ix:nonFraction> </span>million ($<span id="xdx_902_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_c20161008__us-gaap--OtherCommitmentsAxis__custom--GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zUtbRlRMhrlk" title="Grants receivable, noncurrent"><ix:nonFraction name="us-gaap:GrantsReceivableNoncurrent" contextRef="AsOf2016-10-08_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.8</ix:nonFraction></span> million)
support program for the GMP production of AIP cells for two clinical trials that will be performed in Germany and Belgium. The
project will be conducted during a period of three years commencing January 1, 2017. The financial support is awarded to the Belgium
subsidiary at<span id="xdx_906_ecustom--GrantsReceivablePercentageOfBudgetedCosts_iI_dp_uPercentage_c20161008__us-gaap--OtherCommitmentsAxis__custom--GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zCAmTg3EXiOc" title="Grants receivable, percentage of budgeted costs"> <ix:nonFraction name="ORGS:GrantsReceivablePercentageOfBudgetedCosts" contextRef="AsOf2016-10-08_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">55</ix:nonFraction></span>% of budgeted costs, a total of Euro <span id="xdx_90E_eus-gaap--Revenues_pn5n6_uEUR_c20161001__20161008__us-gaap--OtherCommitmentsAxis__custom--GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zdAUZJBCegKj" title="Revenues, total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2016-10-012016-10-08_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="EUR">6.8</ix:nonFraction></span> million ($<span id="xdx_904_eus-gaap--Revenues_pn5n6_c20161001__20161008__us-gaap--OtherCommitmentsAxis__custom--GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zMVclOX9uG67" title="Revenues, total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2016-10-012016-10-08_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7</ix:nonFraction></span> million). The grant will be paid over the project period.
On December 19, 2016, the Belgian Subsidiary received a first payment of Euro <span id="xdx_909_eus-gaap--Revenues_pn5n6_uEUR_c20161201__20161219__us-gaap--OtherCommitmentsAxis__custom--GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zvG5mrnrBYTc" title="Revenues, total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2016-12-012016-12-19_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="EUR">1.7</ix:nonFraction></span> million ($<span id="xdx_900_eus-gaap--Revenues_pn5n6_c20161201__20161219__us-gaap--OtherCommitmentsAxis__custom--GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zW6uSLNowGCg" title="Revenues, total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2016-12-012016-12-19_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2</ix:nonFraction></span> million). Up through December 31,
2020, an amount of Euro <span id="xdx_902_ecustom--DeductionOfResearchAndDevelopmentExpenses_pn5n6_c20200101__20201231__us-gaap--OtherCommitmentsAxis__custom--DeductionOfResearchAndDevelopmentExpensesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zOyIMtsiFh6" title="Deduction of research and development expenses"><ix:nonFraction name="ORGS:DeductionOfResearchAndDevelopmentExpenses" contextRef="From2020-01-012020-12-31_custom_DeductionOfResearchAndDevelopmentExpensesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.7</ix:nonFraction></span> million was recorded as deduction of research and development expenses and an amount of Euro <span id="xdx_900_ecustom--DeductionOfResearchAndDevelopmentExpenses_pn3n3_uEUR_c20200101__20201231__us-gaap--OtherCommitmentsAxis__custom--DeductionOfResearchAndDevelopmentExpensesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_z2oNMdoqLROj" title="Deduction of research and development expenses"><ix:nonFraction name="ORGS:DeductionOfResearchAndDevelopmentExpenses" contextRef="From2020-01-012020-12-31_custom_DeductionOfResearchAndDevelopmentExpensesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="EUR">53</ix:nonFraction></span> thousand
was recorded as receivable on account of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><span style="font: 10pt Times New Roman, Times, Serif">(4)
In December 2020, the Belgian Subsidiary received the formal approval from DGO6 for a Euro <span id="xdx_901_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_uEUR_c20201231__us-gaap--OtherCommitmentsAxis__custom--ResearchOnDermatitisTreatmentsAndWoundHealingMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_z9uGjXhpGRB6" title="Grants receivable, noncurrent"><ix:nonFraction name="us-gaap:GrantsReceivableNoncurrent" contextRef="AsOf2020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="EUR">2.9</ix:nonFraction></span> million ($<span id="xdx_908_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_c20201231__us-gaap--OtherCommitmentsAxis__custom--ResearchOnDermatitisTreatmentsAndWoundHealingMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zWmYSsiAhZL3" title="Grants receivable, noncurrent"><ix:nonFraction name="us-gaap:GrantsReceivableNoncurrent" contextRef="AsOf2020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.5</ix:nonFraction></span> million) support
program for research on Dermatitis Treatments and Wound Healing Using Cell Regenerative Technologies. The financial support was
awarded to the Belgium Subsidiary as a recoverable advance payment at <span id="xdx_908_ecustom--GrantsReceivablePercentageOfBudgetedCosts_iI_pii_dp_uPercentage_c20201231__us-gaap--OtherCommitmentsAxis__custom--ResearchOnDermatitisTreatmentsAndWoundHealingMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_ztxwQsGzHb75" title="Grants receivable, percentage of budgeted costs"><ix:nonFraction name="ORGS:GrantsReceivablePercentageOfBudgetedCosts" contextRef="AsOf2020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">60</ix:nonFraction></span>% of budgeted costs, or for a total of Euro <span id="xdx_905_eus-gaap--Revenues_pn5n6_uEUR_c20201201__20201231__us-gaap--OtherCommitmentsAxis__custom--ResearchOnDermatitisTreatmentsAndWoundHealingMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zahfsZHia256" title="Revenues, total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-12-012020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="EUR">1.7</ix:nonFraction></span> million
($<span id="xdx_90E_eus-gaap--Revenues_pn5n6_c20201201__20201231__us-gaap--OtherCommitmentsAxis__custom--ResearchOnDermatitisTreatmentsAndWoundHealingMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zxDQaPfMmVV7" title="Revenues, total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-12-012020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.1</ix:nonFraction> </span>million). The grant will be paid over the project period. The Belgian Subsidiary received an advance payment of Euro <span id="xdx_907_eus-gaap--Revenues_pn3n3_uEUR_c20200101__20201231__us-gaap--OtherCommitmentsAxis__custom--ResearchOnDermatitisTreatmentsAndWoundHealingMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zH6NmnKczsj1" title="Revenues, total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="EUR">301</ix:nonFraction></span>
thousand ($<span id="xdx_902_eus-gaap--Revenues_pn3n3_c20200101__20201231__us-gaap--OtherCommitmentsAxis__custom--ResearchOnDermatitisTreatmentsAndWoundHealingMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zqq9gnukmmSb" title="Revenues, total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">366</ix:nonFraction></span> thousand) in December 2020. The research program is to be started in 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>c.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Israel-U.S.
    Binational Industrial Research and Development Foundation (&#8220;BIRD&#8221;)</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
September 9, 2015, the Israeli Subsidiary entered into a pharma Cooperation and Project Funding Agreement (CPFA) with BIRD and
Pall Corporation, a U.S. company. BIRD awarded a conditional grant of $<span id="xdx_908_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_c20150909__us-gaap--RelatedPartyTransactionAxis__custom--IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember_zxoTJz8FASMl" title="Grants receivable, noncurrent"><ix:nonFraction name="us-gaap:GrantsReceivableNoncurrent" contextRef="AsOf2015-09-09_custom_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">400</ix:nonFraction></span> thousand each (according to terms defined in the agreement),
for a joint research and development project for the use Autologous Insulin Producing (AIP) Cells for the Treatment of Diabetes
(the &#8220;Project&#8221;). The Project started on March 1, 2015. Upon the conclusion of product development, the grant shall
be repaid at the rate of <span id="xdx_904_ecustom--RepaymentsOfGrantPercentageOfGrossSales_pii_dp_uPercentage_c20150901__20150909__us-gaap--RelatedPartyTransactionAxis__custom--IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember_zGZjuaY4Bu61" title="Repayments of grant, percentage of gross sales"><ix:nonFraction name="ORGS:RepaymentsOfGrantPercentageOfGrossSales" contextRef="From2015-09-012015-09-09_custom_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">5</ix:nonFraction></span>% of gross sales. The grant will be used solely to finance the costs to conduct the research of the
project during a period of 18 months starting on March 1, 2015. On July 28, 2016, BIRD approved an extension for the project period
until May 31, 2017 and the final report was submitted to BIRD. As of December 31, 2020, the Israeli Subsidiary received a total
amount of $<span id="xdx_90E_eus-gaap--Revenues_pn3n3_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember_zlikKsnB5QBe" title="Revenues, total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-12-31_custom_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">299</ix:nonFraction></span> thousand under the grant and the project was completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>d.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Korea-Israel
    Industrial Research and Development Foundation (&#8220;KORIL&#8221;)</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
May 26, 2016, the Israeli Subsidiary and the Korean Subsidiary entered into a pharma Cooperation and Project Funding Agreement
(CPFA) with KORIL. KORIL will give a conditional grant of up to $<span title="Grants receivable, noncurrent"><span id="xdx_905_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_c20160526__us-gaap--RelatedPartyTransactionAxis__custom--KoreaisraelIndustrialResearchAndDevelopmentFoundationMember_zWQSCLNRjLn" title="Grants receivable, noncurrent"><ix:nonFraction name="us-gaap:GrantsReceivableNoncurrent" contextRef="AsOf2016-05-26_custom_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">400</ix:nonFraction></span></span> thousand each (according to terms defined in the agreement),
for a joint research and development project for the use of AIP Cells for the Treatment of Diabetes (the &#8220;Project&#8221;).
The Project started on June 1, 2016. Upon the conclusion of product development, the grant shall be repaid at the yearly rate
of <span id="xdx_90F_ecustom--RepaymentsOfGrantPercentageOfGrossSales_pii_dp_uPercentage_c20160501__20160526__us-gaap--RelatedPartyTransactionAxis__custom--KoreaisraelIndustrialResearchAndDevelopmentFoundationMember_zlSFd6mGeR41" title="Repayments of grant, percentage of gross sales"><ix:nonFraction name="ORGS:RepaymentsOfGrantPercentageOfGrossSales" contextRef="From2016-05-012016-05-26_custom_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">2.5</ix:nonFraction></span>% of gross sales. The grant will be used solely to finance the costs to conduct the research of the project during a period
of 18 months starting. On July 26, 2018 KORIL approved extension for the project period till May 31, 2019 and was further extended
to May 2020. During 2019, the grant was assigned to Cure Therapeutics from the Korean Subsidiary. As of December 31, 2020, the
Israeli Subsidiary and the Korean Subsidiary received $<span id="xdx_907_eus-gaap--Revenues_pn3n3_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--KoreaisraelIndustrialResearchAndDevelopmentFoundationMember_zzaKlScIBE09" title="Revenues, total"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-12-31_custom_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">440</ix:nonFraction></span> thousand under the grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>e.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">BIRD
    Secant</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
July 30, 2018, Orgenesis Inc and OBI entered into a collaboration agreement with Secant Group LLC (&#8220;Secant&#8221;). Under
the agreement, Secant will engineer and prototype 3D scaffolds based on novel biomaterials and technologies involving bioresorbable
polymer microparticles, while OBI will provide expertise in cell coatings, cell production, process development and support services.
Under the agreement, Orgenesis is authorized to utilize the jointly developed technology for its autologous cell therapy platform,
including its Autologous Insulin Producing (&#8220;AIP&#8221;) cell technology for patients with Type 1 Diabetes, acute pancreatitis
and other insulin deficient diseases. In the beginning of 2018, OBI entered into a Cooperation and Project Funding Agreement (CPFA)
with BIRD and Secant. BIRD will give a conditional grant up to $<span id="xdx_90A_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_c20180730__us-gaap--RelatedPartyTransactionAxis__custom--BirdSecantMember_zansRgRUxYM4" title="Grants receivable, noncurrent"><ix:nonFraction name="us-gaap:GrantsReceivableNoncurrent" contextRef="AsOf2018-07-30_custom_BirdSecantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">450</ix:nonFraction></span> thousand each to support the joint project (according to terms
defined in the agreement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, OBI received a total amount of $<span id="xdx_90E_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_c20201231__us-gaap--RelatedPartyTransactionAxis__custom--OBIMember_zi6QxgMyqHLb" title="Grants receivable, noncurrent"><ix:nonFraction name="us-gaap:GrantsReceivableNoncurrent" contextRef="AsOf2020-12-31_custom_OBIMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">425</ix:nonFraction></span> thousand under the grant. For the year ended December 31, 2020, an amount
of $<span id="xdx_906_ecustom--DeductionOfResearchAndDevelopmentExpenses_c20200101__20201231__us-gaap--OtherCommitmentsAxis__custom--DeductionOfResearchAndDevelopmentExpensesMember_pn3n3" title="Deduction of research and development expenses"><ix:nonFraction name="ORGS:DeductionOfResearchAndDevelopmentExpenses" contextRef="From2020-01-012020-12-31_custom_DeductionOfResearchAndDevelopmentExpensesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28</ix:nonFraction></span> thousand was recorded as deduction of research and development expenses.</span></p>

</ix:nonNumeric><p id="xdx_811_zh1pBOGx2zG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 115; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:CollaborationsLicenseAgreementsAndCommitmentsTextBlock"><p id="xdx_80D_ecustom--CollaborationsLicenseAgreementsAndCommitmentsTextBlock_zAO0ynzstave" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
11 &#8211; <span id="xdx_82B_z4GMuU7NLpCh">COLLABORATION AND LICENSE AGREEMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>a.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Adva
    Biotechnology Ltd.</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
January 28, 2018, the Company and Adva Biotechnology Ltd. (&#8220;Adva&#8221;), entered into a Master Services Agreement (&#8220;MSA&#8221;),
under which the Company and/or its affiliates are to provide certain services relating to development of products to Adva, as
may be agreed between the parties from time to time. Under the MSA, the Company undertook to provide Adva with in kind funding
in the form of materials and services having an aggregate value of approximately $<span id="xdx_901_eus-gaap--OtherCommitment_iI_pn3n3_c20180128__custom--CollaborationAndLicenseAgreementsAxis__custom--AdvaBiotechnologyLtdMember_zl0mHKSUG3J9" title="Commitment"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2018-01-28_custom_AdvaBiotechnologyLtdMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">760</ix:nonFraction></span> thousand at the Company&#8217;s own cost
in accordance with a project schedule and related mutually acceptable project budget. The Company entered into an agreement with
Orgenesis Biotech Israel (previously Atvio), to fulfill its obligations pursuant this MSA and it completed its contractual obligations
under the contract during 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
consideration for and subject to the fulfillment by the Company of such in-kind funding commitment, Adva agreed that upon completion
of the development of the products, the Company and/or its affiliates and Adva shall enter into a supply agreement pursuant to
which for a period of eight (8) years following execution of such supply agreement, the Company and/or its affiliates (as applicable)
is entitled (on a non-exclusive basis) to purchase the products from Adva at a specified discount pricing from their then standard
pricing. The Company and/or its affiliates were also granted a non-exclusive worldwide right to distribute such products, directly
or indirectly. <span id="xdx_90E_ecustom--TerminationDescription_c20180126__20180128__custom--CollaborationAndLicenseAgreementsAxis__custom--AdvaBiotechnologyLtdMember" title="Termination description"><ix:nonNumeric contextRef="From2018-01-262018-01-28_custom_AdvaBiotechnologyLtdMember" name="ORGS:TerminationDescription">The MSA shall remain in effect for 10 years unless earlier terminated in accordance with its terms.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>b.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Tel
    Hashomer Medical Research, Infrastructure and Services Ltd (&#8220;THM&#8221;).</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
February 2, 2012, the Company&#8217;s Israeli Subsidiary entered into a licensing agreement with THM. According to the agreement,
the Israeli Subsidiary was granted a worldwide, royalty bearing, exclusive license to trans-differentiation of cells to insulin
producing cells, including the population of insulin producing cells, methods of making this population, and methods of using
this population of cells for cell therapy or diabetes treatment developed by Dr. Sarah Ferber of THM.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
consideration for the license, the Israeli Subsidiary will pay the following to THM:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">1)</span></td>
    <td colspan="3"><span style="font: 10pt Times New Roman, Times, Serif">A royalty of <span id="xdx_901_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20120201__20120202__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zPH6e54yVUwa" title="Royalty of net sales, percentage"><ix:nonFraction name="ORGS:RoyaltyOfNetSalesPercentage" contextRef="From2012-02-012012-02-02_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">3.5</ix:nonFraction></span>% of net sales;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2)</span></td>
    <td colspan="3"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_ecustom--SublicensingFeesPercentage_pii_dp_uPercentage_c20120201__20120202__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zJkV0kE3qAJg" title="Sublicensing fees, percentage"><ix:nonFraction name="ORGS:SublicensingFeesPercentage" contextRef="From2012-02-012012-02-02_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">16</ix:nonFraction></span>% of all sublicensing fees received;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">3)</span></td>
    <td colspan="3" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An annual license fee of $<span id="xdx_908_eus-gaap--OtherCommitment_iI_pn3n3_c20120202__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zHgkyJiYWSCe" title="Commitment"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2012-02-02_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></span> thousand, which commenced on January 1, 2012 and shall be paid once every year thereafter. The annual fee is non-refundable, but it shall be paid each year against the royalty noted above, to the extent that such are payable, during that year; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">4)</span></td>
    <td colspan="3"><span style="font: 10pt Times New Roman, Times, Serif">Milestone payments as follows:</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">$<span id="xdx_90E_eus-gaap--OtherCommitment_iI_pn3n3_c20120202__us-gaap--OtherCommitmentsAxis__custom--OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zNC2gLJnbjO8" title="Commitment"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2012-02-02_custom_OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></span>
    thousand on the date of initiation of Phase I clinical trials in human subjects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">$<span id="xdx_903_eus-gaap--OtherCommitment_iI_pn3n3_c20120202__us-gaap--OtherCommitmentsAxis__custom--OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_z5sCowqt1tzf" title="Commitment"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2012-02-02_custom_OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></span>
    thousand on the date of initiation of Phase II clinical trials in human subjects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">c.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">$<span id="xdx_900_eus-gaap--OtherCommitment_iI_pn3n3_c20120202__us-gaap--OtherCommitmentsAxis__custom--OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zkpYvuhXP3Sd" title="Commitment"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2012-02-02_custom_OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></span>
    thousand on the date of initiation of Phase III clinical trials in human subjects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">d.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">$<span id="xdx_90A_eus-gaap--OtherCommitment_iI_pn3n3_c20120202__us-gaap--OtherCommitmentsAxis__custom--OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zjYrwyDrPJfc" title="Commitment"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2012-02-02_custom_OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">750</ix:nonFraction></span>
    thousand on the date of initiation of issuance of an approval for marketing of the first product by the FDA; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">e.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">$<span id="xdx_903_eus-gaap--OtherCommitment_iI_pin6_c20120202__us-gaap--OtherCommitmentsAxis__custom--WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zSrPM8kKujtg" title="Commitment"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2012-02-02_custom_WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">2</ix:nonFraction></span>
    million when worldwide net sales of Products (as defined in the agreement) have reached the amount of $<span id="xdx_90B_eus-gaap--ConvertibleDebt_iI_pin6_c20181018__dei--LegalEntityAxis__custom--HemogenyxPharmaceuticalsPLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesMilestoneMember_zwf65DEtjjLg" title="Convertible loan"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2018-10-18_custom_HemogenyxPharmaceuticalsPLCMember_custom_SalesMilestoneMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">150</ix:nonFraction></span> million for the
    first time, (the &#8220;Sales Milestone&#8221;).</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, the Israeli Subsidiary had not reached any of these milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><span style="font: 10pt Times New Roman, Times, Serif">In
the event of closing of an acquisition of all of the issued and outstanding share capital of the Israeli Subsidiary and/or consolidation
of the Israeli Subsidiary or the Company into or with another corporation (&#8220;Exit&#8221;), the THM shall be entitled to choose
whether to receive from the Israeli Subsidiary a one-time payment based, as applicable, on the value of either <span id="xdx_90E_ecustom--CommitmentSharesOfCommonStock_c20120202__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_pii" title="Commitment, shares of common stock"><ix:nonFraction name="ORGS:CommitmentSharesOfCommonStock" contextRef="AsOf2012-02-02_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">463,651</ix:nonFraction></span> shares
of common stock of the Company at the time of the Exit or the value of <span id="xdx_900_ecustom--CommitmentSharesOfCommonStockOfSubsidiary_c20120202__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_pii" title="Commitment, shares of common stock of Israeli subsidiary"><ix:nonFraction name="ORGS:CommitmentSharesOfCommonStockOfSubsidiary" contextRef="AsOf2012-02-02_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></span> shares of common stock of the Israeli Subsidiary
at the time of the Exit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 116; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>c.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Hemogenyx
    Pharmaceuticals PLC.</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
October 18, 2018, the Company and Hemogenyx Pharmaceuticals PLC., a corporation with its registered office in the United Kingdom
and Hemogenyx-Cell (&#8220;H-Cell&#8221;), a corporation with its registered office in Belgium (together &#8220;Hemo&#8221;),
who are engaged in the development of cell replacement bone marrow therapy technology, entered into a Collaboration Agreement
(the &#8220;Hemo Agreement&#8221;) pursuant to which the parties will collaborate in the funding, continued development, and commercialization
of the Hemo technology via Hemo. Pursuant to the Hemo agreement the Company and Hemogenyx LLC (&#8220;Hemo-LLC&#8221;) (a wholly
owned US subsidiary of Hemo) entered into a loan agreement on November 7, 2018 according to which the Company agreed to loan Hemo-LLC
not less than $<span id="xdx_907_eus-gaap--ConvertibleDebt_iI_pn5n6_c20181018__dei--LegalEntityAxis__custom--HemogenyxPharmaceuticalsPLCMember_z3oC1AMftN38"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2018-10-18_custom_HemogenyxPharmaceuticalsPLCMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million by way of a convertible loan.
On November 25, 2018 the Company and Hemo entered into a License and Distribution agreement according to which Company received
the worldwide rights to market the products under the agreement in consideration for the payment of a <span id="xdx_907_ecustom--ReductionRateOfRoyaltyPercentage_pii_dp_uPercentage_c20181123__20181125__dei--LegalEntityAxis__custom--HemogenyxPharmaceuticalsPLCMember_zWPMYzAt6mEg"><ix:nonFraction name="ORGS:ReductionRateOfRoyaltyPercentage" contextRef="From2018-11-232018-11-25_custom_HemogenyxPharmaceuticalsPLCMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">12</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
royalty all subject to the terms of the agreement. On November 25, 2018, the Company and H-Cell signed an Exclusive Manufacturing
agreement according to which the Company will receive the exclusive right to manufacture certain of H-Cell products. During 2018
and 2020 the Company advanced $<span id="xdx_90F_eus-gaap--ConvertibleDebt_iI_pn4n6_c20181231__dei--LegalEntityAxis__custom--HemogenyxPharmaceuticalsPLCMember__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentCostsMember_zh6QmUhapDl8"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2018-12-31_custom_HemogenyxPharmaceuticalsPLCMember_custom_ResearchAndDevelopmentCostsMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.75</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million and $<span id="xdx_90A_eus-gaap--ConvertibleDebt_iI_pn4n6_c20201231__dei--LegalEntityAxis__custom--HemogenyxPharmaceuticalsPLCMember__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentCostsMember_zt5E6z96iXYi"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2020-12-31_custom_HemogenyxPharmaceuticalsPLCMember_custom_ResearchAndDevelopmentCostsMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.25</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million, respectively,</span><span style="font: 10pt Times New Roman, Times, Serif">
to Hemo as a convertible loan and the entire loan was charged to expenses under ASC 730-10-50 and 20-50 and presented as research
and development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">See
Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>d.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Immugenyx
    LLC.</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
October 16, 2018, the Company and Immugenyx LLC., a corporation with its registered office in the USA (&#8220;Immu&#8221;), who
is engaged in the development of technology related to the production and use of humanized mice entered into a Collaboration Agreement
(the &#8220;Immu Agreement&#8221;) pursuant to which the parties will collaborate in the funding, continued development, and commercialization
of the Immu technology. Pursuant to the agreement, the Company received the worldwide rights to market the products under the
agreement in consideration for the payment of a <span id="xdx_90B_ecustom--ReductionRateOfRoyaltyPercentage_pii_dp_uPercentage_c20181015__20181016__custom--CollaborationAndLicenseAgreementsAxis__custom--ImmuAgreementMember__dei--LegalEntityAxis__custom--ImmugenyxLLCMember_zemHS3SecARd"><ix:nonFraction name="ORGS:ReductionRateOfRoyaltyPercentage" contextRef="From2018-10-152018-10-16_custom_ImmuAgreementMember_custom_ImmugenyxLLCMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">12</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
royalty all subject to the terms of the agreement. Pursuant to the Immu agreement the Company and Immu entered into a loan agreement
on November 7, 2018 according to which the Company agreed to loan Immu not less than US$<span id="xdx_900_eus-gaap--ConvertibleDebt_iI_pn5n6_c20181016__dei--LegalEntityAxis__custom--ImmugenyxLLCMember_zuOVZyQekvyj"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2018-10-16_custom_ImmugenyxLLCMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">Million by way of a convertible loan.
During 2018 and 2020 the Company advanced $<span id="xdx_90F_eus-gaap--ConvertibleDebt_iI_pn4n6_c20181231__dei--LegalEntityAxis__custom--ImmugenyxLLCMember__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentCostsMember_zZMMGiDr48Nf"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2018-12-31_custom_ImmugenyxLLCMember_custom_ResearchAndDevelopmentCostsMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.75</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million and $<span id="xdx_90F_eus-gaap--ConvertibleDebt_iI_pn4n6_c20201231__dei--LegalEntityAxis__custom--ImmugenyxLLCMember__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentCostsMember_zuuKQOo3fw09"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2020-12-31_custom_ImmugenyxLLCMember_custom_ResearchAndDevelopmentCostsMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.25</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million, respectively,</span><span style="font: 10pt Times New Roman, Times, Serif">
to Immu as a convertible loan and the entire loan was charged to expenses under ASC 730-10-50 and 20-50 and presented as research
and development</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>e.
    </i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">BG
    Negev Technologies and Applications (&#8220;BGN&#8221;).</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
August 2, 2018, the Company&#8217;s U.S. Subsidiary entered into a licensing agreement with BGN. According to the agreement, the
U.S. Subsidiary was granted a worldwide, royalty bearing, exclusive license to develop and commercialize a novel alginate scaffold
technology for cell transplantation focused on autoimmune diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
November 25, 2018, the Company&#8217;s U.S. Subsidiary entered into a further licensing agreement with BGN. According to the agreement,
the U.S. Subsidiary was granted a worldwide, royalty bearing, exclusive license to develop and commercialize technology directed
to RAFT modification of polysaccharides and use of a bioreactor for supporting cell constructs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
consideration for the licenses, the U.S. Subsidiary will pay royalties of between <span id="xdx_90B_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20181124__20181125__custom--CollaborationAndLicenseAgreementsAxis__custom--BgNegevTechnologiesAndApplicationsBgnMember__srt--RangeAxis__srt--MinimumMember_zqWgvHHdLYjh" title="Royalty of net sales, percentage"><ix:nonFraction name="ORGS:RoyaltyOfNetSalesPercentage" contextRef="From2018-11-242018-11-25_custom_BgNegevTechnologiesAndApplicationsBgnMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">4</ix:nonFraction></span>% and <span id="xdx_909_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20181124__20181125__custom--CollaborationAndLicenseAgreementsAxis__custom--BgNegevTechnologiesAndApplicationsBgnMember__srt--RangeAxis__srt--MaximumMember_zxWcD51E429a" title="Royalty of net sales, percentage"><ix:nonFraction name="ORGS:RoyaltyOfNetSalesPercentage" contextRef="From2018-11-242018-11-25_custom_BgNegevTechnologiesAndApplicationsBgnMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">7</ix:nonFraction></span>% (subject to rate reductions to <span id="xdx_90D_ecustom--ReductionRateOfRoyaltyPercentage_pii_dp_uPercentage_c20181124__20181125__custom--CollaborationAndLicenseAgreementsAxis__custom--BgNegevTechnologiesAndApplicationsBgnMember__srt--RangeAxis__srt--MaximumMember_zVuLkYAhTSV7" title="Reduction rate of royalty percentage"><ix:nonFraction name="ORGS:ReductionRateOfRoyaltyPercentage" contextRef="From2018-11-242018-11-25_custom_BgNegevTechnologiesAndApplicationsBgnMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">5</ix:nonFraction></span>%
and <span id="xdx_903_ecustom--ReductionRateOfRoyaltyPercentage_pii_dp_uPercentage_c20181124__20181125__custom--CollaborationAndLicenseAgreementsAxis__custom--BgNegevTechnologiesAndApplicationsBgnMember__srt--RangeAxis__srt--MinimumMember_zEet3ELPDQk5" title="Reduction rate of royalty percentage"><ix:nonFraction name="ORGS:ReductionRateOfRoyaltyPercentage" contextRef="From2018-11-242018-11-25_custom_BgNegevTechnologiesAndApplicationsBgnMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">4</ix:nonFraction></span>%, respectively, in specific circumstances) of net sales of the licensed product, sub-license fees of <span id="xdx_901_ecustom--SublicensingFeesPercentage_pii_dp_uPercentage_c20181124__20181125__custom--CollaborationAndLicenseAgreementsAxis__custom--BgNegevTechnologiesAndApplicationsBgnMember_zd2gKaDZMjK2" title="Sublicensing fees, percentage"><ix:nonFraction name="ORGS:SublicensingFeesPercentage" contextRef="From2018-11-242018-11-25_custom_BgNegevTechnologiesAndApplicationsBgnMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">20</ix:nonFraction></span>% of sub-license
income received, license fees of $<span id="xdx_901_eus-gaap--OtherCommitment_c20181125__custom--CollaborationAndLicenseAgreementsAxis__custom--BgNegevTechnologiesAndApplicationsBgnMember_pp0p0" title="Commitment"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2018-11-25_custom_BgNegevTechnologiesAndApplicationsBgnMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000</ix:nonFraction></span> per year per license, and milestone and budget payments according to agreed upon work
plans to BGN.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 117; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>f.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Collaboration
    Agreement with Tarus Therapeutics, Inc.</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
February 27, 2019, the Company and Tarus Therapeutics Inc., a Delaware corporation, (&#8220;Tarus&#8221;) entered into a Collaboration
Agreement (the &#8220;Tarus Agreement&#8221;) for the collaboration in the funding, development and commercialization of certain
technologies, products and patents of Tarus in the areas of therapeutics for cancer and other diseases in the field of cell therapies
and their combination with checkpoint inhibitors comprised of Adenosine Receptor Antagonists. Under the terms of the Tarus Agreement
and subject to final due diligence and approved financing of the Company, the Company and/or one or more qualified investors (the
&#8220;Investors&#8221;) shall advance to Tarus a convertible loan in an amount of not less than $<span id="xdx_90A_eus-gaap--NotesReceivableNet_iI_pn3n3_c20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CollaborationAgreementMember__srt--RangeAxis__srt--MinimumMember_zHPmYRxJk323" title="Loans receivable net"><ix:nonFraction name="us-gaap:NotesReceivableNet" contextRef="AsOf2020-12-31_custom_CollaborationAgreementMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,750</ix:nonFraction></span> thousand and up to $<span id="xdx_902_eus-gaap--NotesReceivableNet_iI_pn3n3_c20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CollaborationAgreementMember__srt--RangeAxis__srt--MaximumMember_zCCxlFU7M1Hi" title="Loans receivable net"><ix:nonFraction name="us-gaap:NotesReceivableNet" contextRef="AsOf2020-12-31_custom_CollaborationAgreementMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></span>
thousand (the &#8220;Loan Agreement&#8221;). As of December 31, 2020, the loan agreements have not been concluded, nor has any
financing been made to Tarus. As part of such Loan Agreement, and subject to approval by the board of directors of the Company,
the Investors shall have the right, within two years of the date of the Loan Agreement, to convert the outstanding convertible
loan into either (i) shares of Tarus at a price per share based on a pre- money valuation of $<span id="xdx_906_ecustom--PreMoneyValuation_iI_pn3n3_c20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CollaborationAgreementMember_z4v84TGEQ3a6" title="Pre-money valuation"><ix:nonFraction name="ORGS:PreMoneyValuation" contextRef="AsOf2020-12-31_custom_CollaborationAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,500</ix:nonFraction></span> thousand or (ii) shares of
the Company&#8217;s common stock at a price per share set in accordance with an approved financing of the Company, with such terms
as approved by the Company in its sole discretion. In the event the Investors elect to convert into shares of the Company&#8217;s
common stock, the Company shall have the right upon notice to Tarus to receive the same number of shares of capital stock of Tarus
that the Investors would have received had the Investors converted their convertible loans into shares of Tarus. Further, as part
of the Loan Agreement, the Company shall advance to Tarus up to $<span id="xdx_907_ecustom--AdditionalFundsInvest_iI_pn3n3_c20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CollaborationAgreementMember__srt--RangeAxis__srt--MinimumMember_zKcZnbLsBRrk" title="Additional Funds Invest"><ix:nonFraction name="ORGS:AdditionalFundsInvest" contextRef="AsOf2020-12-31_custom_CollaborationAgreementMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></span> thousand within fourteen days of execution of the Loan Agreement.
Subject to the closing of the Loan Agreement, the Company and/or the Investors shall have an option, exercisable by sending written
notice to Tarus at any time through the second anniversary of the closing of the Loan Agreement, to invest additional funds in
an amount of up to $<span id="xdx_908_ecustom--AdditionalFundsInvest_iI_pn3n3_c20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CollaborationAgreementMember__srt--RangeAxis__srt--MaximumMember_zMc08MlHqtJ6" title="Additional Funds Invest"><ix:nonFraction name="ORGS:AdditionalFundsInvest" contextRef="AsOf2020-12-31_custom_CollaborationAgreementMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,250</ix:nonFraction></span> thousand and not less than $<span id="xdx_905_eus-gaap--ProceedsFromGrantors_pn3n3_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CollaborationAgreementMember_znoS8pAsopBf" title="Proceeds from advance payment of grant"><ix:nonFraction name="us-gaap:ProceedsFromGrantors" contextRef="From2020-01-012020-12-31_custom_CollaborationAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></span> thousand in Tarus. The Company will also have the right to appoint and/or
replace one member of board of directors of Tarus. Upon and subject to the execution of a definitive development and manufacturing
agreement between the Company and Tarus (&#8220;Manufacturing and Supply Agreement&#8221;), the Company, or one or more of its
affiliates, shall manufacture and supply to Tarus and any of its affiliates, licensees, assignees of interest all requirements
for all cell therapy elements of any combination therapy incorporating the technology of Tarus. Following the conclusion of the
clinical development stage of each product emanating from the technology of Tarus, the cell therapy component of any such product
borne out of the technology of Tarus shall be exclusively supplied by the Company under the Manufacturing and Supply Agreement.
If the Company and Tarus fail to sign such Manufacturing and Supply Agreement for any given Tarus product, Tarus shall pay the
Company an amount equal to four percent (<span id="xdx_906_ecustom--PercentageOfGrossRevenues_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CollaborationAgreementMember_ztrZuKxNxkvf" title="Percentage of gross revenues"><ix:nonFraction name="ORGS:PercentageOfGrossRevenues" contextRef="From2020-01-012020-12-31_custom_CollaborationAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">4</ix:nonFraction></span>%) of gross revenues derived by Tarus from such Tarus products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Apart
from the above, there was no activity in the Tarus collaboration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>g.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Sponsored
    Research and Exclusive License Agreement with Columbia University</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Effective
April 2, 2019, the Company and The Trustees of Columbia University in the City of New York, a New York corporation, (&#8220;Columbia&#8221;)
entered into a Sponsored Research Agreement (the &#8220;SRA&#8221;) whereby the Company will provide financial support for studying
the utility of serological tumor marker for tumor dynamics monitoring. Under the terms of the SRA, the Company shall pay $<span id="xdx_906_ecustom--PaymentForFinancialSupportToTrustForStudy_pn3n3_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--SponsoredResearchAgreementMember_zdTOfRjwJtMk" title="Payment for financial support to trust for study"><ix:nonFraction name="ORGS:PaymentForFinancialSupportToTrustForStudy" contextRef="From2020-01-012020-12-31_custom_SponsoredResearchAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">300</ix:nonFraction></span>
thousand per year for three years, or for a total of $<span id="xdx_906_ecustom--PaymentForFinancialSupportCumulativeAmountToTrustForStudy_pn3n3_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--SponsoredResearchAgreementMember_z60cQnMRYDS9" title="Payment for financial support cumulative amount to trust for study"><ix:nonFraction name="ORGS:PaymentForFinancialSupportCumulativeAmountToTrustForStudy" contextRef="From2020-01-012020-12-31_custom_SponsoredResearchAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">900</ix:nonFraction></span> thousand, with payments of $<span id="xdx_905_ecustom--PaymentForFinancialSupportToTrustForStudyDueEverySixMonths_pn3n3_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--SponsoredResearchAgreementMember_zQceikMC5Y1j" title="Payment for financial support to trust for study due every six months"><ix:nonFraction name="ORGS:PaymentForFinancialSupportToTrustForStudyDueEverySixMonths" contextRef="From2020-01-012020-12-31_custom_SponsoredResearchAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></span> thousand due every six months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Effective
April 2, 2019, the Company and Columbia entered into an Exclusive License Agreement (the &#8220;Columbia License Agreement&#8221;)
whereby Columbia granted to the Company an exclusive license to discover, develop, manufacture, sell, and otherwise distribute
certain product in the field of cancer therapy. In consideration of the licenses granted under the Columbia License Agreement,
the Company shall pay to Columbia (i) a royalty of <span id="xdx_909_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--ColumbiaLicenseAgreementMember_zxjZ2yTPKBpc" title="Royalty of net sales, percentage"><ix:nonFraction name="ORGS:RoyaltyOfNetSalesPercentage" contextRef="From2020-01-012020-12-31_custom_ColumbiaLicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">5</ix:nonFraction></span>% of net sales of any product sold which incorporates a licensed Columbia
patent and (ii) <span id="xdx_90B_ecustom--RoyaltyOfNetSalesOfOtherProductsPercentage_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--ColumbiaLicenseAgreementMember_zL4KLpOLHNMb" title="Royalty of net sales of other product percentage"><ix:nonFraction name="ORGS:RoyaltyOfNetSalesOfOtherProductsPercentage" contextRef="From2020-01-012020-12-31_custom_ColumbiaLicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">2.5</ix:nonFraction></span>% of net sales of other products. In addition, the Company shall pay a flat $<span id="xdx_904_ecustom--PaymentOfFeeUponAchievementOfEachRegulatoryMilestone_pn3n3_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--ColumbiaLicenseAgreementMember_zhNWLXIZRyyd" title="Payment of fee upon the achievement of each regulatory milestone"><ix:nonFraction name="ORGS:PaymentOfFeeUponAchievementOfEachRegulatoryMilestone" contextRef="From2020-01-012020-12-31_custom_ColumbiaLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></span> thousand fee to Columbia upon
the achievement of each regulatory milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>h.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>IRB
    Approval for Liver Cell Collection</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
April 29, 2019, the Company received Institutional Review Board (&#8220;IRB&#8221;) approval to collect liver biopsies from patients
at Rambam Medical Center located in Haifa, Israel for a planned study to confirm the suitability of liver cells for personalized
cell replacement therapy for patients with insulin-dependent diabetes resulting from total or partial pancreatectomy. The liver
cells are intended to be bio-banked for potential future clinical use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
goal of the proposed study, entitled &#8220;Collection of Human Liver Biopsy and Whole Blood Samples from Type 1 Diabetes Mellitus
(T1DM), Total or Partial Pancreatectomy Patients for Potential use as an Autologous Source for Insulin Producing Cells in Future
Clinical Studies,&#8221; is to confirm the suitability of the liver cells for personalized cell replacement therapy, as well as
eligibility of patients to participate in a future clinical study, as defined by successful AIP cell production from their own
liver biopsy. The secondary objective of the study is to evaluate patients&#8217; immune response to AIPs based on the patient&#8217;s
blood samples and followed by subcutaneous implantation into the patients&#8217; arm which would represent the first human trial.
The Company has developed a novel technology based on technology licensed from Tel Hashomer Medical Research Infrastructure and
Services Ltd., utilizing liver cells as a source for AIP cells as replacement therapy for islet transplantation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the study, liver samples will be collected and then processed and stored in specialized, clinical grade, tissue banks for potential
clinical use. The propagated cells will be maintained in a tissue bank and are intended to be utilized in a future clinical study,
in which the cells will be transdifferentiated and administered back to the patients as a potential treatment. This personalized
autologous process will be performed under our POC platform in which the patient liver samples are processed, cryopreserved and
potentially re-injected, all in the medical center under clinical grade/GMP level conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 118; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2019, the Company received additional Institutional Review Board (&#8220;IRB&#8221;) approval to collect liver biopsies from
patients at a leading medical center in USA for a planned study to confirm the suitability of liver cells for personalized cell
replacement therapy for patients with insulin-dependent diabetes resulting from total pancreatectomy (the granted Orphan Drug
Designation indication). The liver cells are intended to be bio-banked at the New York Blood Center, NYC for potential future
clinical use. In October 2019, a liver sample from the first recruited patient was collected and processed and stored at the New
York Blood Center, NYC in specialized, clinical grade, tissue banks for potential clinical use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>i.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>FDA
    Approval for Orphan Drug Designation for AIP Cells</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
June 11, 2019, the FDA granted Orphan Drug Designation for the Company&#8217;s AIP cells as a cell replacement therapy for the
treatment of severe hypoglycemia-prone diabetes resulting from total pancreatectomy (&#8220;TP&#8221;) due to chronic pancreatitis.
The incidence of diabetes following TP is <span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pii_dp_uPercentage_c20201231__srt--OwnershipAxis__custom--MarylandSubsidiaryMember__custom--CollaborationAndLicenseAgreementsAxis__custom--AIPCellsMember_zraQWOEaILP3" title="Percentage of ownership"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2020-12-31_custom_MarylandSubsidiaryMember_custom_AIPCellsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">100</ix:nonFraction></span>%, resulting in immediate and lifelong insulin-dependence with the loss of both endogenous
insulin secretion and that of the counter-regulatory hormone, glucagon. Glycemic control after TP is notoriously difficult with
conventional insulin therapy due to complete insulin dependence and loss of glucagon-dependent counter-regulation. Patients with
this condition experience both severe hyperglycemic and hypoglycemic episodes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>j.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Regents
    of the University of California</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, the Company and the Regents of the University of California (&#8220;University&#8221;) entered into a joint research
agreement in the field of therapies and processing technologies according to an agreed upon work plan. According to the agreement,
the Company will pay the University royalties of up to <span id="xdx_901_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CaliforniaUniversityJointResearchAgreementMember__srt--RangeAxis__srt--MaximumMember_z7PbVj9GvJS8" title="Royalty of net sales, percentage"><ix:nonFraction name="ORGS:RoyaltyOfNetSalesPercentage" contextRef="From2020-01-012020-12-31_custom_CaliforniaUniversityJointResearchAgreementMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">5</ix:nonFraction></span>% (or up to <span id="xdx_90B_ecustom--SublicensingFeesPercentage_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CaliforniaUniversityJointResearchAgreementMember__srt--RangeAxis__srt--MaximumMember_zbuTfjASQFHk" title="Sublicensing fees, percentage"><ix:nonFraction name="ORGS:SublicensingFeesPercentage" contextRef="From2020-01-012020-12-31_custom_CaliforniaUniversityJointResearchAgreementMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">20</ix:nonFraction></span>% of sub-licensing sales) in the event of sales that includes
certain types of University owned IP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>k.
    </i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Caerus
    Therapeutics Inc (a related party)</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2019, the Company and Caerus Therapeutics (&#8220;Caerus&#8221;), a Virginia company, concluded a license agreement whereby
Caerus granted the Company an exclusive license to all Caerus IP relating to Advance Chemeric Antigen Vectors for Targeting Tumors
for the development and/or commercialization of certain licensed products. In consideration for the License granted to the Company
under this Agreement, the Company shall pay Caerus feasibility fees (including the grant to purchase <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231__srt--OwnershipAxis__custom--CaerusTherapeuticsIncMember_pii" title="Number of options issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-012020-12-31_custom_CaerusTherapeuticsIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,000</ix:nonFraction></span> options in the Company,
annual maintenance fees and royalties of sales of up to <span id="xdx_904_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20200101__20201231__srt--OwnershipAxis__custom--CaerusTherapeuticsIncMember__srt--RangeAxis__srt--MaximumMember_zZUw2eJZY7Gc" title="Royalty of net sales, percentage"><ix:nonFraction name="ORGS:RoyaltyOfNetSalesPercentage" contextRef="From2020-01-012020-12-31_custom_CaerusTherapeuticsIncMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">5</ix:nonFraction></span>% and up to <span id="xdx_90B_ecustom--SublicensingFeesPercentage_pii_dp_uPercentage_c20200101__20201231__srt--OwnershipAxis__custom--CaerusTherapeuticsIncMember__srt--RangeAxis__srt--MaximumMember_zJHtmnyCjaSi" title="Sublicensing fees, percentage"><ix:nonFraction name="ORGS:SublicensingFeesPercentage" contextRef="From2020-01-012020-12-31_custom_CaerusTherapeuticsIncMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">18</ix:nonFraction></span>% of sub-license fees. Expenses in the amount of approximately
$<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200101__20201231__srt--OwnershipAxis__custom--CaerusTherapeuticsIncMember_zALt5XPUoLB7" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-012020-12-31_custom_CaerusTherapeuticsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></span> thousand including the fair value of the options granted were recorded as research and development expenses. The Company
also has the right to instruct Caerus to transfer the license, development, development results and any other rights and licenses
granted to the Company to a joint venture (&#8220;JV&#8221;) in which Company shall have a <span id="xdx_904_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pii_dp_uPercentage_c20201231__srt--OwnershipAxis__custom--CaerusTherapeuticsIncMember_z3UaTBN68y08" title="Percentage of ownership"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2020-12-31_custom_CaerusTherapeuticsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">51</ix:nonFraction></span>% controlling ownership stake in
the JV Entity. Upon Company&#8217;s election of such option, the development shall be carried out by Caerus for the JV and the
royalty, sublicense fees and annual maintenance fee shall be terminated. Company may provide requisite funding for the JV Entity
as determined by the Company and Caerus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>l.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Extracellular
    Vesicle (&#8220;EV&#8221;) Technology License</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the third quarter of 2020, the Company purchased the IP and related EV technology from a service provider (the &#8220;Service
Provider&#8221;) pursuant to an EV agreement (the &#8220;EV agreement&#8221;). According to the EV agreement, the Service Provider
sold to the Company all of its rights in the EV technology that it had produced, in the amount of $500 thousand, to be paid in
installments over the next 12 months from September 2020. The $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20201001__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ExtracellularVesicleMember__custom--CollaborationAndLicenseAgreementsAxis__custom--EVAmentMember_zJQDYFWWaCH2" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-10-012020-12-31_custom_ExtracellularVesicleMember_custom_EVAmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></span> thousand was recorded in R&amp;D expenses. In addition, the
Service Provider granted the Company an exclusive worldwide license to use the EV IP technology for any purpose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 119; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>m.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Tamir
    Biotechnology acquisition</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Included
in the purchased assets of the Tamir Biotechnology Inc acquisition (See Note 4) was the assumption by the Company of a worldwide
license to a private company of certain Tamir technologies in the field of treatment, amelioration, mitigation or prevention of
diseases or conditions of the eye and its adnexa in return for certain development and sales milestone payments to be paid to
Tamir. This license fee and the right to receive future milestone payments (of up to $<span id="xdx_907_ecustom--FutureMilestonePayments_iI_pin6_c20200407__srt--RangeAxis__srt--MaximumMember__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_z17N0ufaqVYg" title="Future milestone payments"><ix:nonFraction name="ORGS:FutureMilestonePayments" contextRef="AsOf2020-04-07_srt_MaximumMember_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">11</ix:nonFraction></span> million assuming that certain milestones
are reached) and royalties (of up to $<span id="xdx_906_eus-gaap--RoyaltyExpense_pin6_c20200406__20200407__srt--RangeAxis__srt--MaximumMember__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zeDpymxqdJHj" title="Royalty Expense"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2020-04-062020-04-07_srt_MaximumMember_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">35</ix:nonFraction></span> million based on net sales milestones), were assumed by the Company in connection with
the Tamir Purchase Agreement together with a less than <span id="xdx_902_ecustom--RoyaltyPercentage_iI_pii_dp_uPercentage_c20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zrdusZxTjA9l" title="Royalty percentage"><ix:nonFraction name="ORGS:RoyaltyPercentage" contextRef="AsOf2020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">10</ix:nonFraction></span>% share interest. To date, no milestones have been reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>n.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Tissue
    Genesis, LLC (&#8220;Tissue Genesis&#8221;)</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Included
in the Koligo acquisition (See Note 4) were the assets of Tissue Genesis. The Company is committed to paying the previous owners
of Tissue Genesis up to $<span id="xdx_90C_ecustom--FutureMilestonePayments_iI_pn3n3_c20201231__us-gaap--BusinessAcquisitionAxis__custom--TissueGenesisLLCMember__srt--RangeAxis__srt--MaximumMember_zf3DbvEYPCOl" title="Future milestone payments"><ix:nonFraction name="ORGS:FutureMilestonePayments" contextRef="AsOf2020-12-31_custom_TissueGenesisLLCMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></span> thousand upon the achievement of certain performance milestones and earn-out payments on future sales
provided that in no event will the aggregate of the earn-out payments exceed $<span id="xdx_901_eus-gaap--RoyaltyExpense_pn5n6_c20201229__20201231__us-gaap--BusinessAcquisitionAxis__custom--TissueGenesisLLCMember__srt--RangeAxis__srt--MaximumMember_zUb1PGRVHhLl" title="Royalty Expense"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2020-12-292020-12-31_custom_TissueGenesisLLCMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4</ix:nonFraction></span> million. To date, no milestones have been reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>o.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Joint
    venture agreements</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Additionally,
the Company has entered into joint venture agreements (&#8220;JVAs&#8221;) with its joint venture partners (Company and partner
are referred to as &#8220;parties&#8221;) to facilitate the collaboration in the field of CGT development and development of the
Company&#8217;s worldwide POCare network. The provisos and the table below summarize the major agreements. CGT and POCare activities
covered by the JVAs include the development, marketing, clinical development, and commercialization of the Company&#8217;s and
/ or partner&#8217;s products within defined territories. The extent of the collaboration is set out in each agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Unless
otherwise stated in the table below the JVAs include the following provisos (&#8220;Provisos&#8221;):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    incorporation of a joint venture entity (&#8220;JVE&#8221;) in which the Company will hold between <span id="xdx_90D_ecustom--InterestInJointVenture_iI_pii_dp_uPercentage_c20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--BroadenJointVentureAgreementMember__dei--LegalEntityAxis__custom--MarylandSubsidiaryMember__srt--RangeAxis__srt--MinimumMember_zNSbZAJGnWlf" title="Interest in joint venture"><ix:nonFraction name="ORGS:InterestInJointVenture" contextRef="AsOf2020-12-31_custom_BroadenJointVentureAgreementMember_custom_MarylandSubsidiaryMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">49</ix:nonFraction></span>% and <span id="xdx_908_ecustom--InterestInJointVenture_iI_pii_dp_uPercentage_c20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--BroadenJointVentureAgreementMember__dei--LegalEntityAxis__custom--MarylandSubsidiaryMember__srt--RangeAxis__srt--MaximumMember_zzEeoNyOYN5" title="Interest in joint venture"><ix:nonFraction name="ORGS:InterestInJointVenture" contextRef="AsOf2020-12-31_custom_BroadenJointVentureAgreementMember_custom_MarylandSubsidiaryMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">50</ix:nonFraction></span> % of the equity.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    partner will manage the joint venture activities until the JVE is incorporated.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    JVE will be managed by a steering committee consisting of 3 members which will act as the entity&#8217;s board of directors.
    The Company is entitled to appoint 1 member, the partner is entitled to appoint 1 member, and Company and partner will jointly
    appoint the third member.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    Company has the right to exercise a call option to acquire the partner&#8217;s share in the JVE based on the occurrence of
    certain events and according to an agreed upon mechanism.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    funding of the parties&#8217; investment in the joint venture share may be made in the form of cash investment and / or in-kind
    services. The Company&#8217;s cash investment may be in the form of additional shares, a convertible loan, and/or procured
    services.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Each
    of the parties may agree to provide additional funding to the JVE to cover the operation costs and such additional funding
    may be in the form of in-kind contributions. The Company&#8217;s investments may be made in the form of a cash investment
    for additional shares, a convertible loan, and/or procured services. Procured services refer to certain services that the
    Company has engaged the partner or the JVE to provide the Company with, in support of Company&#8217;s activity. All results
    of these procured services shall be owned by Company.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
    appropriate, the parties will grant to the JVE an exclusive or nonexclusive, sublicensable, royalty-bearing, right and license
    to the relevant party&#8217;s background IP as required solely to manufacture, distribute and market and sell the party&#8217;s
    products within the territory. Each party shall receive royalties in an amount of ten percent (<span id="xdx_906_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--BroadenJointVentureAgreementMember__dei--LegalEntityAxis__custom--MarylandSubsidiaryMember_zwmlyMD2ISV4" title="Royalty of net sales, percentage"><ix:nonFraction name="ORGS:RoyaltyOfNetSalesPercentage" contextRef="From2020-01-012020-12-31_custom_BroadenJointVentureAgreementMember_custom_MarylandSubsidiaryMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">10</ix:nonFraction></span>%) of the net sales generated
    by the JVE and/or its sublicensees.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Once
    the JVE is profitable, the Company will be entitled (in addition to any of its rights as the holder of the JVE) to an additional
    share of fifteen percent (<span id="xdx_901_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__custom--CollaborationAndLicenseAgreementsAxis__custom--BroadenJointVentureAgreementMember__dei--LegalEntityAxis__custom--MarylandSubsidiaryMember_zJOSHZxgIH3b" title="Royalty of net sales, percentage"><ix:nonFraction name="ORGS:RoyaltyOfNetSalesPercentage" contextRef="From2020-01-012020-12-31_srt_MinimumMember_custom_BroadenJointVentureAgreementMember_custom_MarylandSubsidiaryMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">15</ix:nonFraction></span>%) of the JVE&#8217;s GAAP profit after tax, over and above all rights granted pursuant to Company&#8217;s
    participating interest in the JVE.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 120; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name
    of party (and country of origin)</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Territory</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Theracell
    Advanced Biotechnology</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Greece,
    Turkey, Cyprus, Israel and Balkans</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Broaden
    Bioscience and Technology Corp</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Certain
    projects in China and the Middle East</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Mircod
                                         LLC</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(US)</span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Russia</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Image
    Securities FZC (UAE) (a related party)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">India</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cure
    Therapeutics</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Korea
    and Japan</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Kidney
    Cure Ltd</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Worldwide</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Sescom
    Ltd</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Worldwide</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(4)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Educell
                                         D.O.O</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(Slovenia)</span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Croatia,
    Serbia and Slovenia</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Med
                                         Centre for Gene and Cell Therapy FZ-LLC</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(UAE)</span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">UAE</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Mida
                                         Biotech B.V.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(Netherlands)</span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Netherlands,
    Lithuania, Spain, Switzerland, Germany, Belgium or any other countries within West Europe</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(5)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">First
                                         Choice International Company, Inc</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Panama
    and certain other Latin American countries</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(6)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">KinerjaPay
    Corp</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Singapore</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(7)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">SBH
    Sciences Inc</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Worldwide</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(8)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">HekaBio
    KK</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Japan</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(9)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    Theracell JVE was incorporated in Greece under the name of Theracell Laboratories Ltd. (See Note 12).</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
    the Mircod JVA, provisos 7 and 8 do not apply. Subject to payment by the Company ORGS of the contribution amount, the JVA
    will grant Company an exclusive, perpetual, irrevocable, royalty free and fully paid up and sublicensable license to use the
    Project IP for research and development and for the manufacturing, processing, supplying, and use of products based on point
    of care manufacturing and/or processing of treatments for patients and for use in hospitals, medical centers and academic
    institution settings solely outside the territory. The parties also, following proviso 6, concluded a convertible loan agreement
    pursuant to which Company shall lend Mircod up to $<span id="xdx_90D_ecustom--ConvertibleLoanAdvancedToJointVenture_pin6_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--JointVentureAgreementMember__srt--RangeAxis__srt--MinimumMember_zemq4si86All" title="Convertible loan advanced to joint venture"><ix:nonFraction name="ORGS:ConvertibleLoanAdvancedToJointVenture" contextRef="From2020-01-012020-12-31_custom_JointVentureAgreementMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">5</ix:nonFraction></span> million based upon a development plan to be agreed upon. The loan bears
    simple interest in the amount of <span id="xdx_908_ecustom--ConvertibleLoanAdvancedToJointVentureInterestRate_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--JointVentureAgreementMember_zn2eHUwvtpOe" title="Convertible loan advanced to joint venture, interest rate"><ix:nonFraction name="ORGS:ConvertibleLoanAdvancedToJointVentureInterestRate" contextRef="From2020-01-012020-12-31_custom_JointVentureAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">6</ix:nonFraction></span>% annually. As at December 31, 2020, the development plan had not been finalized and no
    transfers under the loan agreement were made.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
    to the Kidney Cure JVA, the parties will collaborate in the (i) implementation of a point-of-care strategy; (ii) assessment
    of the options for development and manufacture of various cell-based types (including kidney derived cells, MSC cells, exosomes,
    gene therapies) development; and (iii) development of protocols and tests for kidney therapies (the &#8220;Project&#8221;).
    Provisos 7 and 8 do not apply to the Kidney Cure JVA. The Kidney Cure JVE was incorporated in Switzerland under the name of
    Butterfly Biosciences Sarl (See Note 12).</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
    the Sescom JVA, the parties will collaborate in the field of the assessment of relevant tools and technologies to be used
    in the Company&#8217;s information security system (the &#8220;ISS&#8221;); (ii) the implementation of the ISS within the
    Company and in the Company&#8217;s point-of-care network; and (iii) the operation and maintenance of the ISS. Provisos 7 and
    8 do not apply to this JVA. Company has agreed to provide the Sescom JVE with: (a) a non-exclusive, not transferable and non-sublicensable
    worldwide royalty-free license to use its background IP to the extent required for carrying out certain activities by the
    Sescom JVE; and (b) access to its point-of-care network and relevant data to be used for the certain activities.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
    the Mida JVA, commencing January 1, 2022 and thereafter Mida shall have the right to sell to Company its then issued and outstanding
    shares in the JVA, and if the JVA was not yet set up, its assets, contracts and liabilities relating to the project, for a
    consideration to be agreed between the parties in good faith, provided that such consideration is not lower than $<span id="xdx_909_eus-gaap--PaymentForContingentConsiderationLiabilityInvestingActivities_pn3n3_c20211231__20220101__custom--CollaborationAndLicenseAgreementsAxis__custom--JointVentureAgreementMember__srt--RangeAxis__srt--MaximumMember_zmMDqUsvnE44" title="Payment for consideration"><ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" contextRef="From2021-12-312022-01-01_custom_JointVentureAgreementMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></span> thousand.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
    the First Choice JVA, each party shall, subject to fulfilment of the party&#8217;s JVA, grant the Panama JV Entity an exclusive
    license to certain intellectual property of the part to develop and commercialize the party&#8217;s products in the territory,
    subject to minimum sales obligations. In consideration of such license, the Panama JV shall pay the relevant part royalties
    at the rate of 15% of the Panama JVE net sales of party&#8217;s products sold in the territory.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 121; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">No
    activities have taken place since the JVA was signed. According to the JVA, Company was eligible to receive <span id="xdx_90E_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--JointVentureAgreementMember__dei--LegalEntityAxis__custom--KinerjapayCorpMember_zNDhJ53IA2Ti" title="Royalty of net sales, percentage"><ix:nonFraction name="ORGS:RoyaltyOfNetSalesPercentage" contextRef="From2020-01-012020-12-31_custom_JointVentureAgreementMember_custom_KinerjapayCorpMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">51</ix:nonFraction></span>% of the equity
    and <span id="xdx_900_ecustom--RoyaltyOfNetSalesOfOtherProductsPercentage_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--JointVentureAgreementMember__dei--LegalEntityAxis__custom--KinerjapayCorpMember_zqrpDxVw2r2e" title="Royalty of net sales of other product percentage"><ix:nonFraction name="ORGS:RoyaltyOfNetSalesOfOtherProductsPercentage" contextRef="From2020-01-012020-12-31_custom_JointVentureAgreementMember_custom_KinerjapayCorpMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">10</ix:nonFraction></span>% royalties on sales of products. The steering committee was to compromise 5 members of which Company could appoint
    2, and a third member to be an industry expert, to be appointed by Orgenesis. The JVA did not include the proviso 8.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
    to the SBH JVA the parties will collaborate in the field of gene and cell therapy development, process and services of bio-exosome
    therapy products and services in the areas of diabetes, liver cells and skin applications, including wound healing. The SBH
    JVE has not yet been incorporated. According to the JVA, the board of directors of the SBH JVE shall be comprised of three
    directors with one appointed by SBH and two appointed by the Company. All intellectual property conceived or developed resulting
    from the business of the SBH JV Entity, that is not SBH&#8217;s or the Company&#8217;s background intellectual property, shall
    be owned exclusively by the SBH JV Entity, although the Company shall be granted the right to exclusively license any intellectual
    property arriving from the development activities of the SBH JV Entity, or exclusively distribute products based thereon.
    Provisos 7 and 8 do not apply to the SBH JVA.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
    the third quarter of 2019, the Company transferred $<span id="xdx_900_eus-gaap--TransferToInvestments_pn3n3_c20191001__20191231__dei--LegalEntityAxis__custom--SBHSciencesIncMember_zrvWxhpaG5Qh" title="Transfer for prior establishment"><ix:nonFraction name="us-gaap:TransferToInvestments" contextRef="From2019-10-012019-12-31_custom_SBHSciencesIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></span> thousand to SBH. Apart from the above, there was no material activity
    in the SBH Collaboration and the SBH JV entity had not been incorporated as at December 31, 2020.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
    the third quarter of 2020, the Company and HB agreed to terminate the license agreement. As of December 31, 2020, no activity
    had begun in the said JV and no investments were made therein.</span></td></tr>
</table>
</ix:nonNumeric><p id="xdx_81D_zKjYXAQk2C1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock"><p id="xdx_80C_eus-gaap--InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock_zgkjvWqzjWV1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
12 &#8211;<span id="xdx_824_z0OkBUWj5wUj"> INVESTMENTS IN ASSOCIATES, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Theracell
    Laboratories Private Company</span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">During
October 2020, the Company and Theracell, pursuant to the Greek JVA (See Note 11) incorporated the Greek JVA entity known as Theracell
Laboratories Private Company (&#8220;TLABS&#8221;). The Theracell Project activities will be run through TLABS. The Company and
Theracell each hold a <span id="xdx_901_ecustom--InvestmentsInAssociatePercentageOfOwnership_iI_pii_dp_uPercentage_c20201031__dei--LegalEntityAxis__custom--TLABSMember_zCbE0weqp0i6" title="Investments in associate percentage of ownership"><ix:nonFraction name="ORGS:InvestmentsInAssociatePercentageOfOwnership" contextRef="AsOf2020-10-31_custom_TLABSMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">50</ix:nonFraction></span>% participating interest in TLABS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Butterfly
    Biosciences Sarl</span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">During
October 2020, the Company and Kidney Cure, pursuant to the Kidney Cure JVA (See Note 11) incorporated the KC JV Entity known as
Butterfly Biosciences Sarl (&#8220;BB&#8221;) in Switzerland. BB will be involved in the (i) implementation of a point-of-care
strategy; (ii) assessment of the options for development and manufacture of various cell-based types (including kidney derived
cells, MSC cells, exosomes, gene therapies) development; and (iii) development of protocols and tests for kidney therapies (the
&#8220;BB Project&#8221;). The Company holds a <span id="xdx_906_ecustom--InvestmentsInAssociatePercentageOfOwnership_iI_pii_dp_uPercentage_c20201031__dei--LegalEntityAxis__custom--ButterflyBiosciencesSarlMember_zpeP14qqdOad" title="Investments in associate percentage of ownership"><ix:nonFraction name="ORGS:InvestmentsInAssociatePercentageOfOwnership" contextRef="AsOf2020-10-31_custom_ButterflyBiosciencesSarlMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">49</ix:nonFraction></span>% participating interest on BB and Kidney Cure holds the remaining <span id="xdx_900_ecustom--InvestmentsInAssociatePercentageOfOwnership_iI_pii_dp_uPercentage_c20201031__dei--LegalEntityAxis__custom--KidneyCureJVAMember_zUdTmFSDZTm7" title="Investments in associate percentage of ownership"><ix:nonFraction name="ORGS:InvestmentsInAssociatePercentageOfOwnership" contextRef="AsOf2020-10-31_custom_KidneyCureJVAMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">51</ix:nonFraction></span>%.</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock"><p id="xdx_898_eus-gaap--InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_zmRmGgVbBzQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">c.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    table below sets forth a summary of the changes in the investments for the year ended&#160;December 31, 2020:</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B6_z5jPxicOzBo6" style="display: none">SCHEDULE OF CHANGES IN INVESTMENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20200101__20201231_zCZPdhPHQcI2" style="font-weight: bold; text-align: center">December 30,</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(In thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--EquityMethodInvestments_iS_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Opening balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1988">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--PaymentsToAcquireEquityMethodInvestments_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="width: 71%; text-align: left">Investments during the period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 25%; text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">69</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--IncomeLossFromEquityMethodInvestments_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Share in net income of associated companies</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">106</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--EquityMethodInvestments_iE_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Ending balance</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">175</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 122; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zCWfL8IlyhK2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
13 &#8211; <span id="xdx_823_zOXiRXZlnMvg">EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Financings</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
January 20, 2020, the Company entered into a Securities Purchase Agreement (the &#8220;January Purchase Agreement&#8221;) with
certain investors pursuant to which the Company issued and sold, in a private placement (the &#8220;Offering&#8221;), <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pii" title="Sale of Stock, Number of Shares Issued in Transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2020-01-192020-01-20_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,200,000</ix:nonFraction></span>
shares of Common Stock at a purchase price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_c20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pii" title="Sale of Stock, Price Per Share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2020-01-20_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.20</ix:nonFraction></span> per share (the &#8220;Shares&#8221;) and warrants to purchase up to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_znkdBizq9Ap7" title="Warrant to purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2020-01-20_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span>
shares of Common Stock at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pii" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-01-20_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.50</ix:nonFraction></span> per share (the &#8220;Warrants&#8221;) which are <span id="xdx_90A_ecustom--WarrantExercisableDescription_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember" title="Warrant exercisable, description"><ix:nonNumeric contextRef="From2020-01-192020-01-20_custom_SecuritiesPurchaseAgreementMember" name="ORGS:WarrantExercisableDescription">exercisable between June
2021 and January 2023.</ix:nonNumeric></span> The Company received gross proceeds of approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn4n6_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zmILN4Kjidt1" title="Proceeds from Issuance of Private Placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2020-01-192020-01-20_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">9.24</ix:nonFraction></span> million before deducting related offering expenses
in the amount of $<span id="xdx_90C_ecustom--OfferingExpenses_pn5n6_c20200119__20200120_zEAiaVypijU7" title="Offering expenses"><ix:nonFraction name="ORGS:OfferingExpenses" contextRef="From2020-01-192020-01-20" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>b.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Tamir
    Biotechnology, Inc.</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
the acquisition of Tamir, see Note 4.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
aggregate consideration for the acquisition, the Company paid $<span id="xdx_90E_eus-gaap--Cash_iI_pn5n6_c20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zcN3btyYhyof" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million in cash and issued an aggregate of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pii_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zYhzVXccQFJh" title="Stock Issued During Period, Shares, Acquisitions"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,400,000</ix:nonFraction></span> shares
(the &#8220;Shares&#8221;) of Common Stock to Tamir resulting in a total consideration of $<span id="xdx_906_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zP1lwZBdHHaf" title="Business Combination, Consideration Transferred"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">20.2</ix:nonFraction></span> million based on the Company&#8217;s
share price at the closing date. $<span id="xdx_901_eus-gaap--EscrowDeposit_iI_pn3n3_c20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zHhrr4v1e1V9" title="Escrow Deposit"><ix:nonFraction name="us-gaap:EscrowDeposit" contextRef="AsOf2020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">59</ix:nonFraction></span> thousand and <span id="xdx_901_ecustom--NumberOfSharesDepositInEscrowAccount_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_pii" title="Number of shares deposit in escrow account"><ix:nonFraction name="ORGS:NumberOfSharesDepositInEscrowAccount" contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">340,000</ix:nonFraction></span> Shares are being held in an escrow account for a period of 18 months
from closing to secure indemnification obligations of Tamir pursuant to the terms of the Tamir Purchase Agreement. The share price
was $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_c20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_pii" title="Shares Issued, Price Per Share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.26</ix:nonFraction></span> at the day of the closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>c.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Koligo
    Therapeutics Inc.</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
the acquisition of Koligo, see Note 4.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the terms of the Merger Agreement, at the Effective Time, the shares of capital stock of Koligo that were issued and outstanding
immediately prior to the Effective Time were automatically cancelled and converted into the right to receive, subject to customary
adjustments, an aggregate of <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20200924__20200926__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_pii"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2020-09-242020-09-26_custom_MergerAgreementMember_custom_KoligoTherapeuticsIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,063,713</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Company common stock which
have been issued to Koligo&#8217;s accredited investors (with certain non-accredited investors being paid solely in cash in
the amount of approximately $<span id="xdx_906_eus-gaap--Cash_iI_pn3n3_c20200926__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_ztN69wJlqo8f"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2020-09-26_custom_MergerAgreementMember_custom_KoligoTherapeuticsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand). In addition, we issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20201014__20201015__dei--LegalEntityAxis__custom--MaximaGroupLLCMember_zV4CliG3nq01"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2020-10-142020-10-15_custom_MaximaGroupLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,910</ix:nonFraction></span>
shares to Maxim Group LLC for advisory services</span><span style="font: 10pt Times New Roman, Times, Serif"> in connection
with the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>d.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Warrants</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:ScheduleOfWarrantsActivity"><p id="xdx_892_ecustom--ScheduleOfWarrantsActivity_zYqchtHnoERa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the Company&#8217;s warrants granted to investors and as finder&#8217;s fees as of December 31, 2020, and December
31, 2019 and changes for the periods then ended is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zM9rIJbKhFS7" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Warrants </b></span></p> </div></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p> </div></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Warrants </b></span></p> </div></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p> </div></td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Warrants </b>outstanding at the</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">beginning of the period</span></p></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pii_c20200101__20201231_zy7hqsLWzaWe" title="Number of Warrants - Warrants outstanding at the beginning of the period" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,010,087</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231_zFSaEvQVhSc5" title="Weighted Average Exercise Price - Warrants outstanding at the beginning of the period" style="width: 14%; text-align: right"><ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.35</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pii_c20190101__20191231_zQls2BU5AEg9" title="Number of Warrants - Warrants outstanding at the beginning of the period" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,286,351</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pii_c20190101__20191231_zgeuftkOQsZf" title="Weighted Average Exercise Price - Warrants outstanding at the beginning of the period" style="width: 14%; text-align: right"><ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.29</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes during the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231_pii" title="Number of Warrants - Issued" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,344,606</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_c20200101__20201231_pii" title="Weighted Average Exercise Price - Issued" style="text-align: right"><ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.64</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20190101__20191231_pii" title="Number of Warrants - Issued" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">471,980</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_c20190101__20191231_pii" title="Weighted Average Exercise Price - Issued" style="text-align: right"><ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.95</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pii_di_c20200101__20201231_zIeUTF8pAYnl" title="Number of Warrants - Expired" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">284,452</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_c20200101__20201231_pii" title="Weighted Average Exercise Price - Expired" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.53</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pii_di_c20190101__20191231_z2bpJ9Ke5kE9" title="Number of Warrants - Expired" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">748,244</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_c20190101__20191231_pii" title="Weighted Average Exercise Price - Expired" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.24</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><b>Warrants</b> outstanding and exercisable at end of the period*</td><td style="padding-bottom: 2.5pt"><span id="xdx_F45_zkzKE0sZlZCe" style="font: 10pt Times New Roman, Times, Serif; display: none">*</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pii_c20200101__20201231_fKg_____zR6NfaZmUFu3" title="Number of Warrants - Warrants outstanding and exercisable at the end of the period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" contextRef="AsOf2020-12-31" id="Fact002053" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,070,241</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice_iE_pii_c20200101__20201231_fKg_____z8LdBEn42ePi" title="Weighted Average Exercise Price - Warrants outstanding and exercisable at the end of the period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice" contextRef="AsOf2020-12-31" id="Fact002055" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.20</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pii_c20190101__20191231_fKg_____zUMeCU4HGJp6" title="Number of Warrants - Warrants outstanding and exercisable at the end of the period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" contextRef="AsOf2019-12-31" id="Fact002057" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,010,087</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice_iE_pii_c20190101__20191231_fKg_____zDnl7acqCJ1h" title="Weighted Average Exercise Price - Warrants outstanding and exercisable at the end of the period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice" contextRef="AsOf2019-12-31" id="Fact002059" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.35</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td id="xdx_F03_zyyC5iZXAPy1" style="width: 1%">*</td>
    <td id="xdx_F12_zEo56LSDClG5"><ix:footnote id="Footnote002060" xml:lang="en-US">As
of December 31, 2020 and December 31, 2019, there are no warrants that are subject to exercise price adjustments.</ix:footnote></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

</ix:nonNumeric><p id="xdx_8AC_zFYvy87s8xN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 123; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>e.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Treasury
    shares</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:ScheduleOfTreasuryShares"><p id="xdx_89E_ecustom--ScheduleOfTreasuryShares_z9FHh3sxwB8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the Company&#8217;s treasury shares purchased as of December 31, 2020 and changes for the period then ended is presented
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BA_zE0KGUTQTGYi" style="display: none">S<span>CHEDULE
OF TREASURY SHARES</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Treasury Shares </b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price Paid</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Treasury Shares at the beginning of the period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--TreasuryStockShare_iS_pii_c20200101__20201231_zCALmNDnKKKf" title="Number of Treasury Shares at the beginning of the period" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2064">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--WeightedAveragePriceNumberOfSharesTreasuryStock_iS_pii_c20200101__20201231_z5s3B29Wptf2" title="Weighted Average Price Paid Treasury Shares at the beginning of the period" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2066">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes during the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 56%; padding-bottom: 1.5pt">Purchased</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--TreasuryStockSharesAcquired_c20200101__20201231_pii" title="Number of Treasury Shares Purchased" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right"><ix:nonFraction name="us-gaap:TreasuryStockSharesAcquired" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,309</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--WeightedAveragePriceNumberOfSharesTreasuryStockPurchased_c20200101__20201231_pii" title="Weighted Average Price Paid Treasury Shares Purchased" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right"><ix:nonFraction name="ORGS:WeightedAveragePriceNumberOfSharesTreasuryStockPurchased" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.47</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Shares at end of the period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_ecustom--TreasuryStockShare_iE_pii_c20200101__20201231_zX5xyPjyZQt9" title="Number of Treasury Shares at end of the period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ORGS:TreasuryStockShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">53,309</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_ecustom--WeightedAveragePriceNumberOfSharesTreasuryStock_iE_pii_c20200101__20201231_zNaro5lNGmN9" title="Weighted Average Price Paid Treasury Shares at end of the period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ORGS:WeightedAveragePriceNumberOfSharesTreasuryStock" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.47</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AB_zXvFBZTcCjGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_808_eus-gaap--EarningsPerShareTextBlock_zMOXj1KiIjXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
14 &#8211; <span id="xdx_826_z9nVLXal8zkh">INCOME (LOSS) PER SHARE</span></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zLfgzUn45W49" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth the calculation of basic and diluted loss per share for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B4_zW1mjJ0gKzSk" style="display: none">SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20200101__20201231_zWx4jwAIP616" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20190101__20191231_z79mK5xdaI01" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands, except per share data)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Basic and diluted:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net loss from continuing operations attributable to Orgenesis Inc.</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">95,088</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,490</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net (income) loss from discontinued operations attributable to Orgenesis Inc. for loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">96,198</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,631</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Adjustment of redeemable non-controlling interest to redemption amount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ORGS:AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,160</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ORGS:AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,095</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zL6pxqPyyqvd" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif">Basic: Net income (loss) available to common stockholders</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">101,358</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,726</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--NetIncomeLossToParentCompany_zFQJa5eUc912" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net (income) loss attributable to Orgenesis Inc. for loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ORGS:NetIncomeLossToParentCompany" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,270</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:NetIncomeLossToParentCompany" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,216</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i_pii" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Weighted average number of common shares outstanding</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">21,320,314</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">15,907,995</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pii_zUMbTmX4h8l1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss per common share from continuing operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.46</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.41</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_pii_zcRAfqAQwP8e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net (income) loss common share from discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">4.75</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.36</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--EarningsPerShareBasic_pii_uUSDPShares_zEEhZlScEMna" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Net (income) loss per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.29</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.77</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AB_z9AMcNjIP1Qc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
the year ended December 31, 2020, and December 31, 2019, all outstanding convertible notes, options and warrants have been excluded
from the calculation of the diluted net loss per share since their effect was anti-dilutive. Diluted loss per share does not include
<span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsAndWarrantsMember_zJs3Bb4BH4J9" title="Antidilutive securities excluded from computation of earnings per share amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-12-31_custom_OptionsAndWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,212,789</ix:nonFraction></span> shares underlying outstanding options and warrants and <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesUponConversionOfConvertibleNotesMember_zt6AFC85gL54" title="Antidilutive securities excluded from computation of earnings per share amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-12-31_custom_SharesUponConversionOfConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,630,857</ix:nonFraction></span> shares upon conversion of convertible loans for the
year ended December 31, 2020, because the effect of their inclusion in the computation would be anti-dilutive.</span></p>
<!-- Field: Split-Segment; Name: Split 3 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 124; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_800_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zsPEWaOODBTl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
15 &#8211; <span id="xdx_823_ziOCQJv1z6Sa">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>a.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Global
    Share Incentive Plan</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
May 11, 2017, the annual meeting of the Company&#8217;s stockholders approved the 2017 Equity Incentive Plan (the &#8220;2017
Plan&#8221;) under which, the Company had reserved a pool of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_c20170511__us-gaap--PlanNameAxis__custom--TwoZeroOneSevenEquityIncentivePlanMember_z2As6VSfKaFd" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2017-05-11_custom_TwoZeroOneSevenEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,750,000</ix:nonFraction></span> shares of the Company&#8217;s common stock, which may be
issued at the discretion of the Company&#8217;s board of directors from time to time. Under this Plan, each option is exercisable
into one share of common stock of the Company. The options may be exercised after vesting and in accordance with the vesting schedule
that will be determined by the Company&#8217;s board of directors for each grant. The maximum contractual life term of the options
is <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20170509__20170511__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoZeroOneSevenEquityIncentivePlanMember_zw9xbN8LIZ45" title="Share-based compensation, shares authorized under stock option plans, exercise price range, outstanding options, weighted average remaining contractual term"><ix:nonNumeric contextRef="From2017-05-092017-05-11_srt_MaximumMember_custom_TwoZeroOneSevenEquityIncentivePlanMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">10</ix:nonNumeric></span> years. At the Company&#8217;s annual meeting of stockholders on November 26, 2019 the Company&#8217;s stockholders approved
an amendment to increase the number of shares authorized for issuance of awards under the Company&#8217;s 2017 Equity Incentive
Plan from <span>1,750,000</span> shares to an aggregate of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pii_c20170509__20170511__us-gaap--PlanNameAxis__custom--TwoZeroOneSevenEquityIncentivePlanMember_z9b3mV53BZ4j" title="Share-based compensation arrangement by share-based payment award, number of additional shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2017-05-092017-05-11_custom_TwoZeroOneSevenEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000</ix:nonFraction></span> shares of Common Stock. As of December 31, 2020, total options granted
under this plan are <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--TwoZeroOneSevenEquityIncentivePlanMember_ze4AO8PDT6e7" title="Share-based compensation arrangement by share-based payment award, options, outstanding, number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-012020-12-31_custom_TwoZeroOneSevenEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,362,133</ix:nonFraction></span> and the total options that are available for grants under this plan are <span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--TwoZeroOneSevenEquityIncentivePlanMember_zFTUyslIemka" title="Share-based compensation arrangement by share-based payment award, options, available for grants"><ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants" contextRef="AsOf2020-12-31_custom_TwoZeroOneSevenEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,724,966</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
May 23, 2012, the Company&#8217;s board of directors adopted the Global Share Incentive Plan 2012 (the &#8220;2012 Plan&#8221;)
under which, the Company had reserved a pool of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_c20120523__us-gaap--PlanNameAxis__custom--GlobalShareIncentivePlanTwoZeroOneTwoMember_zClNYU8Q0NB1" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2012-05-23_custom_GlobalShareIncentivePlanTwoZeroOneTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of the Company&#8217;s common stock, which may be issued at the
discretion of the Company&#8217;s board of directors from time to time. Under this plan, each option is exercisable into one share
of common stock of the Company. The options may be exercised after vesting and in accordance with the vesting schedule that will
be determined by the Company&#8217;s board of directors for each grant. The maximum contractual life term of the options is <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20120521__20120523__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--GlobalShareIncentivePlanTwoZeroOneTwoMember_zXXYQyCIc3m6" title="Share-based compensation, shares authorized under stock option plans, exercise price range, outstanding options, weighted average remaining contractual term"><ix:nonNumeric contextRef="From2012-05-212012-05-23_srt_MaximumMember_custom_GlobalShareIncentivePlanTwoZeroOneTwoMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">10</ix:nonNumeric></span>
years. As of December 31, 2020, total options granted under this plan are <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--GlobalShareIncentivePlanTwoZeroOneTwoMember_zjksD69k25pb" title="Share-based compensation arrangement by share-based payment award, options, outstanding, number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-012020-12-31_custom_GlobalShareIncentivePlanTwoZeroOneTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,183,182</ix:nonFraction></span> and the total options that are available for
grants under this plan are <span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--GlobalShareIncentivePlanTwoZeroOneTwoMember_zvSDZoIywWE4" title="Share-based compensation arrangement by share-based payment award, options, available for grants"><ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants" contextRef="AsOf2020-12-31_custom_GlobalShareIncentivePlanTwoZeroOneTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">248,024</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>b.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Options
    Granted to Employees and Directors</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember" escape="true" name="us-gaap:ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZpsYXnnwH74" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Below
is a table summarizing all of the options grants to employees and Directors made during the years ended December 31, 2020, and
December 31, 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8BE_z2wZ5VoapHK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE
OF EMPLOYEE STOCK OWNERSHIP PLAN DISCLOSURES<span style="font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of options <br /> granted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Vesting period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Fair value at grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>(in thousands)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Expiration <br /> period</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%; text-align: center">Employees</td><td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: center">December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zK84ovmWCrVj" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">531,450</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">$<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember__srt--RangeAxis__srt--MinimumMember_zjlMlT6Y8Hp3" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.99</ix:nonFraction></span>-$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember__srt--RangeAxis__srt--MaximumMember_z2N5Xc2nwZHd"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.84</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 28%; text-align: center">Quarterly over a period of <span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zOHsvZG0LJx4" title="Stock options vesting period description"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember" name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description">two years</ix:nonNumeric></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_znd3sUJFCZqi" title="Fair value at grant" style="width: 12%; text-align: right"><ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,312</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zbvht2A920S9"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember" format="ixt-sec:duryear" name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod">10</ix:nonNumeric></span> years</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Directors</td><td>&#160;</td>
    <td style="text-align: center">December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zK3VPNSsvJ0f" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">145,050</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">$<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember__srt--RangeAxis__srt--MinimumMember_z5KfV2P0CSb" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.99</ix:nonFraction></span>-$<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember__srt--RangeAxis__srt--MaximumMember_zUuysBuwVFX8"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.7</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90C_ecustom--StockOptionsGrantVestingPeriodPercentage_pii_dp_uPercentage_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--StatementScenarioAxis__custom--OneYearAnniversaryMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z6PmhEs4a4td"><ix:nonFraction name="ORGS:StockOptionsGrantVestingPeriodPercentage" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_OneYearAnniversaryMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">96</ix:nonFraction></span>%
on the one-year anniversary, <span>and
the remaining </span><span id="xdx_902_ecustom--StockOptionsGrantVestingPeriodPercentage_pii_dp_uPercentage_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--StatementScenarioAxis__custom--ThreeEqualInstallmentsMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z5aJKhTktsA3"><ix:nonFraction name="ORGS:StockOptionsGrantVestingPeriodPercentage" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ThreeEqualInstallmentsMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">4</ix:nonFraction></span><span>%
in three equal instalments on the first, second and third year anniversaries</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zAUSql0z2lgg" title="Fair value at grant" style="text-align: right"><ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">377</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z9CKhxzGeRSa"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember" format="ixt-sec:duryear" name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod">10</ix:nonNumeric></span> years</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Employees</td><td>&#160;</td>
    <td style="text-align: center">December 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zi9F5VeJtsja" title="No. of options granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">94,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zE36mXHDmjW4" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.14</ix:nonFraction></span>-$<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zXVuc9s05iJh" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_srt_MaximumMember_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.07</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Quarterly over a period of <span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zIYrSjtXl9m9" title="Stock options vesting period description"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember" name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description">two years</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zFxHlKP0XU9a" title="Fair value at grant" style="text-align: right"><ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">322</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z78KDbNzJeK6" title="Expiration period"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember" format="ixt-sec:duryear" name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod">10</ix:nonNumeric></span> years</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Directors</td><td>&#160;</td>
    <td style="text-align: center">December 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zVqCz3kgOwPk" title="No. of options granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zZyCgN1R4yXh" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.99</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zjOfThQtSbe6"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember" name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description">One-year</ix:nonNumeric></span> anniversary</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zQJe3aZ6xA1i" title="Fair value at grant" style="text-align: right"><ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">103</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zNiZVk9vlFY6" title="Expiration period"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember" format="ixt-sec:duryear" name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod">10</ix:nonNumeric></span> years</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A0_zb0bzOVrWTg8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value of each stock option grant is estimated at the date of grant using a Black Scholes option pricing model. The volatility
is based on historical volatility of the Company, by statistical analysis of the weekly share price for past periods based on
expected term. The expected option term is calculated using the simplified method<i>, </i>as the Company concludes that its historical
share option exercise experience does not provide a reasonable basis to estimate its expected option term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zarrDrkXzyxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The fair value of each
option grant is based on the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8BB_zu5YXeodfKUg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify">SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value of one common share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zxAkFRvFYom7" title="Value of one common share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.99</ix:nonFraction></span>-$<span id="xdx_905_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z1eFWEp56oF4" title="Value of one common share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.84</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zG7neHReUXf4" title="Value of one common share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2019-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.99</ix:nonFraction></span>-$<span id="xdx_90E_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zQ5y9tjhJhr2" title="Value of one common share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2019-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.07</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">Dividend yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_uPercentage_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zReH2dtA3zh4" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_uPercentage_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZebSolkkqrl" title="Dividend yield" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected stock price volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zsS5PwD0W1D7"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-01-012020-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">80</ix:nonFraction></span>%-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zYePs3g60htc"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-01-012020-12-31_srt_MaximumMember_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">86</ix:nonFraction></span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zNar8RrjmwB8" title="Expected stock price volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2019-01-012019-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">83</ix:nonFraction></span>%-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zEDf0maq53rk" title="Expected stock price volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2019-01-012019-12-31_srt_MaximumMember_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">88</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zOy9G7xKVGLf"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-01-012020-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">0.36</ix:nonFraction></span>%-<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zYye4pMhEvIe"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-01-012020-12-31_srt_MaximumMember_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">1.71</ix:nonFraction></span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zLyjUsMQiYx4" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2019-01-012019-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">1.45</ix:nonFraction></span>%-<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zjDBWHGiJmW1" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2019-01-012019-12-31_srt_MaximumMember_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">2.47</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_ze3gE7h0Rb49"><ix:nonNumeric contextRef="From2020-01-012020-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.50</ix:nonNumeric></span>-<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zW6K9Y35RD4k"><ix:nonNumeric contextRef="From2020-01-012020-12-31_srt_MaximumMember_custom_OptionsGrantedToEmployeesMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.00</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zKAv9fglXGY2" title="Expected term (years)"><ix:nonNumeric contextRef="From2019-01-012019-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.38</ix:nonNumeric></span>-<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zleGTKeRrgcj" title="Expected term (years)"><ix:nonNumeric contextRef="From2019-01-012019-12-31_srt_MaximumMember_custom_OptionsGrantedToEmployeesMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.56</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A8_zLejcaFxNxp1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 125; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zS3l2Iqv4Uv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the Company&#8217;s stock options granted to employees and directors as of December 31, 2020 and December 31, 2019
is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8BD_zoETxj5WpTca" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify">SCHEDULE OF STOCK OPTIONS ACTIVITY<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify">Options outstanding at the beginning of the period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pp0i_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zS0jFjN6KED9" title="Number of Options - Options outstanding at the beginning of the year" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,465,522</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z66PjItUwiM7" title="Weighted Average Exercise Price - Options outstanding at the beginning of the year" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.44</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z1XpzuJYcAm4" title="Number of Options - Options outstanding at the beginning of the year" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2018-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,376,427</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zwin3PHg5uH5" title="Weighted Average Exercise Price - Options outstanding at the beginning of the year" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2018-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.51</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes during the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" title="Number of Options - Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">676,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" title="Weighted Average Exercise Price - Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.74</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zpPLI0D0IsI7" title="Number of Options - Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">144,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zXaY3QgzSlJd" title="Weighted Average Exercise Price - Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.15</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zkbmQpBqp9b8" title="Number of Options - Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2221">-</span></td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zKYCsHeYQgBf" title="Weighted Average Exercise Price - Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2223">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_ztjVax01M9gf" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2224">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zi0koaWyMNhj" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2225">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zcE59Ue5eEM1" title="Number of Options - Expired" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,876</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" title="Weighted Average Exercise Price - Expired" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.88</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zsvXWdYt2eEh" title="Number of Options - Expired" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,750</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zOgPNHGEJ0pc" title="Weighted Average Exercise Price - Expired" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.01</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zx0am2zNCkf6" title="Number of Options - Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">57,042</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" title="Weighted Average Exercise Price - Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.52</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zBs5z1ppkm2d" title="Number of Options - Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,655</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zL30qNRjUlL" title="Weighted Average Exercise Price - Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.11</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zK1f3mUQl6Cc" title="Number of Options - Cancelled" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">155,437</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" title="Weighted Average Exercise Price - Cancelled" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.38</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zHUFGhJj1qua" title="Number of Options - Cancelled" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2247">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zyudtFueAWS" title="Weighted Average Exercise Price - Cancelled" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2249">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Options outstanding at end of the period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z024hYqGeUMe" title="Number of Options - Options outstanding at the end of the year" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,917,667</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zFoCUILK0Q8c" title="Weighted Average Exercise Price - Options outstanding at the end of the year" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.05</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zKrFiK6LLwvg" title="Number of Options - Options outstanding at the end of the year" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,465,522</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zyCEU8TRgmZi" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.44</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Options exercisable at end of the period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pp0i_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZ2pJpCKwoxc" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,299,937</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zpUpqlzns8x4" title="Weighted Average Exercise Price - Options exercisable at end of the year" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.03</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZ0SvcxgDS9g" title="Number of Options - Options exercisable at end of the year" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2019-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,112,567</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zK7aIyGVpPbc" title="Weighted Average Exercise Price - Options exercisable at end of the year" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.21</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A9_zLojcCy90UR7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember" escape="true" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"><p id="xdx_892_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zxdA6Hu4y6M3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table presents summary information concerning the options granted and exercisable to employees and directors outstanding
as of December 31, 2020 (in thousands, except per share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8B5_z4X3q6LgMLN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify">SCHEDULE OF STOCK OPTIONS EXERCISABLE<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Life</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Value $</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(in thousands)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zGEALbelDWwh" title="Exercise Price" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0012</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z6TqKbUflO2j" title="Number of Outstanding Options" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">230,189</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zuf78fMwa3f5" title="Weighted Average Remaining Contractual Life" style="width: 13%; text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceOneMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.64</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zY4WOMnLvNb6" title="Aggregate Intrinsic Value" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,036</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zAWBgIjsGEXb" title="Number of Exercisable Options" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">230,189</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_d0_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z0iITGcIcg7i" title="Aggregate Exercisable Options Value" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceOneMember" format="ixt:zerodash" decimals="-3" scale="3" sign="-" unitRef="USD">-</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zsnXse1mShx5" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.012</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zYWnvvAxbePf" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">510,017</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zgtr2LszQ8T" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwoMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">1.09</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z7pAURfpw0B5" title="Aggregate Intrinsic Value" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,289</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zosR9KYJuJl9" title="Number of Exercisable Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">510,017</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z2evfla7Qt4" title="Aggregate Exercisable Options Value" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z8lU7wP9IYhf" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.99</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zZe7CuN7ybP6" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">445,013</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zLhTnNHFK0j" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThreeMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.15</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zwDNvdMzi6s2" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">672</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zNIKw2DIiwW6" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">174,208</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z1TXSnL3ru7k" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">521</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zziuggCyAbF3" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zXpaNqHvtX13" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvuZtvKy57B3" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.27</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zE3q69EIIDYc" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zSICuphcB5Ug" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,875</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zAxaQYg9prC5" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zzgKfDknX7re" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zHDBhdy1z2e8" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zz9bcZ1HDAA" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFiveMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.93</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zAfiKgfooTsa" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zbM0gX99XZy7" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTCxm0HfXDb9" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">221</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zua5M9f5Kwjc" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zbIxZC0xCdFb" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJJhg7ViLdEk" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.47</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zxPzOGqt9tAf" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2314">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zKYpcnIP3CA2" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,938</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zuR3G4xzwGo8" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">108</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zrtz3nBOVSl4" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zi1Jq9uNwzg5" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">185,300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zNdSHSEvJXUh" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSevenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.96</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zqwyKX6tAvol" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2321">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zaB4oP2vrV6i" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2322">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_z3KEJ7E6TB4g" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2323">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zGoq2SXn28Vj" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pp0i_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zTtdkdMRF9D5" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEightMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zSVe3QPTBTk9" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEightMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.03</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zB5WBQL6dIUl" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2328">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z8M4560m5oEb" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2329">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z54JqtlcFFnd" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2330">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zaXCRz6LmYI9" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zByoI54r79j6" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">483,337</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zX6XYi0wSKS2" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.94</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z1RW0WBc41G6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2335">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zLUJ1ygYDy8i" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">483,337</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zhXjTw0gsvgl" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,320</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zfFNf1Lmh8yf" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.07</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zMF2XZBxa3jl" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">53,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zzonyXwmtLAe" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.08</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zZ5sgYFnjkY" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2342">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zBTf2tpIvD94" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zU7QOoLUpS2a" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTenMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">202</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z6jBUGwNk8v6" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zBZdet3rU6Yh" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zRHJmugJkFck" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceElevenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.68</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zhXZzATa9Ss8" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2349">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zHilCuwxGo84" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,875</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zcodATh9AaOk" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceElevenMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z86G3JEOVNr9" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwelveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.99</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zwNp4pEw8fQ2" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwelveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">352,550</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zfHNOptExar2" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwelveMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.26</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zA1mWFNXcNJ6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2356">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zP1LLSF4Mtuc" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwelveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">290,488</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zMpNwJzHG4Gd" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwelveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,740</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zuUYwnC0X5fa" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThirteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zVwS6ErCiyTa" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThirteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zSyQu6yR305h" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThirteenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.59</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z9tAjFEecGda" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2363">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zlZ9fmmDFEIc" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThirteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z39Brmi8we8l" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThirteenMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zv7NHJLAmtw8" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.84</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zVulO9w8euh5" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z8RNlxcC2W1i" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourteenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.38</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zKnH7yGsrxn9" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2370">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zmIYUBzMpcYd" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zqlLmFqB3qi2" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourteenMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zw8ubJhwHO17" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFifteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zONbllM7nOLc" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFifteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">83,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zFDNG2zRevn7" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFifteenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.43</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_znOihXEN96jl" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2377">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zBumwNDfbY28" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFifteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">83,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zj1GmtxQcMYc" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFifteenMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">600</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zyrN5fuMbMU2" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.36</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zAcZWJKzTXu" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zDILxQGP3fzd" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixteenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.50</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_ztmamPyTtELk" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2384">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zsXyj2NXlY1i" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zpJuHxdUimm6" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixteenMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,090</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_z76gvrXQeJdf" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSeventeenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.91</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zDhBuuQ0yyL8" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSeventeenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_z74nX1crcePc" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSeventeenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.46</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_z7RM1Jq3y8Ah" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2391">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zXjHdoUuI6sd" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSeventeenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zQ3jAXaGiuv" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSeventeenMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">134</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_z79o78OrNJ36" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEighteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zfO8tkwF6Zn" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEighteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,834</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_ztIvFWPvSzhi" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEighteenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">2.54</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zvOuCFgoJyLe" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2398">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zUwzO0SsLsCi" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEighteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,834</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zm81PGWFTiC5" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEighteenMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">187</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zLDbWwX6rgF8" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.48</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_z0aoY4XPQdl9" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">58,908</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zzp1y3zqife6" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineteenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">1.52</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zNV3bqMD055k" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2405">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zOL8AZY6jqni" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">58,908</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zma966NkxPvl" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineteenMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">558</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zGbmSBYIOg61" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwentyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zgzKvQiMO9w6" title="Number of Outstanding Options" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwentyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,267</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_z0i0XGzTN3O6" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwentyMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">1.42</ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zgRRK1mvqLH2" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2412">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zbdB8XmT3Tx3" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwentyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,267</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zbyxob0ZdTu4" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwentyMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">401</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zsDbzHu4diyh" title="Number of Outstanding Options" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,917,667</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zx7nbitDplPd" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.98</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zdZNhbLeERj6" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,006</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z6RenwmsaOAi" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,299,937</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_ztKD6Ozzb14f" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,263</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A8_zy1aHQkP142g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Costs
incurred with respect to stock-based compensation for employees and directors for the years ended December 31, 2020 and December
31, 2019 were $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesAndDirectorsMember_zSI8D6O7pIsg"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesAndDirectorsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,470</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pn3n3_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesAndDirectorsMember_z3SS4NEX4755"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesAndDirectorsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,107</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand, respectively,</span><span style="font: 10pt Times New Roman, Times, Serif">
out of which <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20201231__dei--LegalEntityAxis__custom--MasthercellGlobalMember_z5y3Qqm3LChk">$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-012020-12-31_custom_MasthercellGlobalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">450</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand</span><span style="font: 10pt Times New Roman, Times, Serif">
and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20190101__20191231__dei--LegalEntityAxis__custom--MasthercellGlobalMember_zpVzsmy5ta04">$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2019-01-012019-12-31_custom_MasthercellGlobalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">360</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand</span><span style="font: 10pt Times New Roman, Times, Serif">
related to options granted to employees of Masthercell Global, respectively, and presented as part of net loss from discontinued
operations in the consolidated statements of comprehensive loss. As of December 31, 2020, there was $<span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--MasthercellGlobalMember_zXKOSiT2ndna"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2020-12-31_custom_MasthercellGlobalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,594</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousands of unrecognized compensation
costs related to non-vested employees and directors stock options, to be recorded over the next <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20200101__20201231__dei--LegalEntityAxis__custom--MasthercellGlobalMember_zS5SsYoLX809"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_MasthercellGlobalMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">2.02</ix:nonNumeric>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 126; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>c.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Options
    Granted to Consultants and service providers</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zrZwCVhUAEB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Below
is a table summarizing all the compensation granted to consultants and service providers during the years ended December 31, 2020
and December 31, 2019 and for the one-month period ended December 31, 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8BE_zyaIvRYNcubb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify">SCHEDULE OF STOCK OPTIONS GRANTED TO CONSULTANTS<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><br />Year
    of grant</b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><br />No.
    of options <br /> granted</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><br />Exercise
    price</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Vesting period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Fair
                                         value at grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(in
                                         thousands)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"><b><br />Expiration
    <br /> period</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 8%; text-align: center">Non-employees <br /></td><td style="width: 2%">&#160;</td>
    <td style="width: 8%; text-align: center">2020 <br /></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zq9DlXJrIeng" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zanjnW2R8tDb"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.99</ix:nonFraction></span>-$<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z725VBpqLdzi"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.84</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 30%; text-align: center">Quarterly over a period of <span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zgFWgaOCBvi" title="Vesting peirod description"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember" name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription">two</ix:nonNumeric></span> years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pp0p0_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z3QNkvR0SEUh" style="width: 14%; text-align: right"><ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">209</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 10%; text-align: center"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zStftzty8WEh"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt-sec:duryear" name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod">10</ix:nonNumeric></span> years</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Non-employees <br /></td><td>&#160;</td>
    <td style="text-align: center">2019 <br /></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_ztq9TlnZkUz1" title="No. of options granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">128,336</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z7jIjxUbX6rj" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.14</ix:nonFraction></span>-$<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zfRWQwgfkdrg" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Vest immediately-<span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zJCsrnJgG7mi" title="Vesting period"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt-sec:duryear" name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod">5</ix:nonNumeric></span> years</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pp0p0_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zyvsGmIXHucc" title="Fair value at grant" style="text-align: right"><ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">394</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zklPJev0kWDb" title="Expiration period"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt-sec:duryear" name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod">10</ix:nonNumeric></span> years</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><p id="xdx_8AD_zmELaunstzi7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value of options granted during 2020 and 2019 to consultants and service providers, was computed using the Black-Scholes
model. The fair value of each stock option grant is estimated at the date of grant using a Black Scholes option pricing model.
The volatility is based on historical volatility of the Company, by statistical analysis of the weekly share price for past periods
based on the expected term period, the expected term is the contractual term of each grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zcIP9njEhfD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The underlying data used for computing
the fair value of the options are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8B0_zJxkjABIydHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify">SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value of one common share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_907_eus-gaap--SharePrice_iI_pii_c20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zJVigMTWX45k" title="Value of one common share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.99</ix:nonFraction></span>-$<span id="xdx_90A_eus-gaap--SharePrice_iI_pii_c20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zpRisG2jihca" title="Value of one common share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.84</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharePrice_iI_pii_c20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z4CFsUrPPvgd" title="Value of one common share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2019-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.14</ix:nonFraction></span>-$<span id="xdx_908_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z7Q6Fqa6nU5j" title="Value of one common share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2019-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.07</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">Dividend yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_uPercentage_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zCGG4SGYztWj" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_uPercentage_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zIlUev5sQYfi" title="Dividend yield" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected stock price volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zEEBmNX0ugFa"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-01-012020-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">86</ix:nonFraction></span>%-<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zzpOwg9Ve8De"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-01-012020-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">89</ix:nonFraction></span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zqbMIBHnVT39" title="Expected stock price volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2019-01-012019-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">89</ix:nonFraction></span>%-<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zrpQJcpmFPL" title="Expected stock price volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2019-01-012019-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">92</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zhYmeOySrEn9"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-01-012020-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">0.73</ix:nonFraction></span>%-<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zKnvypQfvKO4"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-01-012020-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">1.12</ix:nonFraction></span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z4OaZ4mRlzf9" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2019-01-012019-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">1.52</ix:nonFraction></span>%-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z3gtBPyAed2" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2019-01-012019-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">2.62</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zvBH53H5zF08"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zzioggVFdog1" title="Expected term (years)"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A2_z57grP2rydpi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zbftw2pPvn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the Company&#8217;s stock options granted to consultants and service providers as of December 31, 2020, and December
31, 2019 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8BC_z5scIwsT27yf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify">SCHEDULE OF STOCK OPTIONS ACTIVITY<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify">Options outstanding at the <br />beginning of the year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zMWWzXlkuf8b" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">598,310</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zMYVJ1dtg8vj" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.76</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zQmxTi4o8My7" title="Number of Options - Options outstanding at the end of the year" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2018-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">469,974</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zLPGxTYap2vd" title="Weighted Average Exercise Price - Options outstanding at the end of the year" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2018-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.75</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes during the year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zsacUEIZps54" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z4m6jLMYhn81" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.97</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zjo8psJ0w978" title="Number of Options - Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">128,336</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zD3WK7ymPaak" title="Weighted Average Exercise Price - Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.65</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zFGF3564i5qi" title="Number of Options - Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">83,334</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zz9Bi03JMrgg" title="Weighted Average Exercise Price - Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.60</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zhSTkn5jm4vg" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2494">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zrhFkiUYRuvl" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2495">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zwKkzH5fQzUl" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,335</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_ziOnnSoUSsUd" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.99</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zEmJt048ziR4" title="Number of Options - Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2499">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zDuFasT03jK" title="Weighted Average Exercise Price - Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2501">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zsYlJ5gHpanj" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">20,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_ziXt3pWgbXe5" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.30</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zbuZYe0hVNbb" title="Number of Options - Cancelled" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2505">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zBmtnPDCceha" title="Weighted Average Exercise Price - Cancelled" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2507">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Options outstanding at end of the year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zDPWZoMW9KL1" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">549,141</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zBAZt4xBqfrl" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.89</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zL0TkJctr6g4" title="Number of Options - Options outstanding at the end of the year" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">598,310</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z5X4sq1uxk27" title="Weighted Average Exercise Price - Options outstanding at the end of the year" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.76</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Options exercisable at end of the year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zxZ8ISpM5Qkj" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">450,972</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zdHwM1ea4Ft1" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.28</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zO82XaWp8604" title="Number of Options - Options exercisable at end of the year" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2019-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">539,515</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zCtk9ECpLhS3" title="Weighted Average Exercise Price - Options exercisable at end of the year" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.88</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A0_zNJjV3QAxgKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 127; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember" escape="true" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"><p id="xdx_897_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zldnSpYcVwvi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table presents summary information concerning the options granted and exercisable to consultants and service providers
outstanding as of December 31, 2020 (in thousands, except per share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8B1_zvQLz8p6E7L2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify">SCHEDULE OF STOCK OPTIONS EXERCISABLE</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Life</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Value*</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Value $</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(in thousands)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zjm9KeYw0zgf" title="Exercise Price" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.99</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zFsNJSwDApWg" title="Number of Outstanding Options" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zq3ZDJf4kH2" title="Weighted Average Remaining Contractual Life" style="width: 13%; text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceOneMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.22</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zpIV6M23tDhk" title="Aggregate Intrinsic Value" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">53</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zonnfsenO1Ad" title="Number of Exercisable Options" style="width: 13%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2531">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zvZhiXuQEK13" title="Aggregate Exercisable Options Value" style="width: 13%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2533">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zoWEcxO26Xr2" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z3K4Q79OQqbg" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zVNabox3ktg7" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwoMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.91</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z9j6eSh0jVIa" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zxoEyxXqf6yg" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2539">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zaSf0MMFK0hi" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2540">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zktbC9NK4TW6" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.36</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zCMVcnDHKi9f" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">136,775</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zmtPk5bUnJpd" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThreeMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.32</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zn0bDOAAafo4" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">156</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zIIhm7y6zio7" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">136,775</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zFHyytHLrxG4" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThreeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">460</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zOxNEUsbX702" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.09</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zgTFDIoUL233" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zNJ3aWMz8Xl7" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.76</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zeEVsV31T7f3" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zFOYn8Ir6nej" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbZxy4FxBHnf" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">102</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zWeNDczB3e78" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zeQON0tYgVP6" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,325</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zdbqxxK1uYqg" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFiveMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.93</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zSqHe0Ao7EQd" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zR2WFvpSqTpl" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,325</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zhm9J98AUeX2" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFiveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zkcADpZSds4k" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zd5lv0i429O5" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,335</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJSz7E0E76ob" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.53</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zBooPwUqqhOg" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2566">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zeeWGjZPl6y1" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2567">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_znd3nMZECIQ4" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2568">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zrP3TyPWJbJk" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zi0nUliJ5sgk" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zJs5hiyQ5Q2f" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSevenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.96</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zHHcqEqVmkIg" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2573">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zkzM1mNSEw66" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2574">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zVqIafo7IUal" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2575">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zaieSMzFpVql" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zurwOxk9DNCl" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,668</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zbWd7Mk8IIWj" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEightMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.94</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zSN3DyjkCwC8" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2580">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z9RaK704MHoj" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,668</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zY2FbABfI1Vg" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEightMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">80</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zEg461Ebhqr5" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.07</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_ztlx2ItVxahe" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zO104xrrhPwg" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.19</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z1rZAmEh70Lk" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2587">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zI6fMwT3gUIf" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zjw3S2bpxcR" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zNrlRTalEVHj" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zvkzRwm5Bruj" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zAbI3yY5QC2e" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.70</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zEnyWF57eaU9" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2594">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z4Kpm9VUq672" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zVwvRKv5DJ3d" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTenMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">80</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zgWb0dUriad6" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.99</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z1ji04xSMPxl" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,670</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z3axaAYQ4rx8" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceElevenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.81</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_znaPAL9XofZ" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2601">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zxJraIVcjY8k" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,670</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zgI0vgGH2Y77" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceElevenMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zZPMsU8ReXG1" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwelveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zqO7LylWwdV4" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwelveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">90,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_ze9lgJeZooXc" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwelveMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.59</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zs0u9hDogXC" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2608">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zv9YQJLUgJmd" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwelveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">90,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zcF8hGPpjWG1" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwelveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">540</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zsQhIelhGvsf" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThirteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.84</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zAiTLyxIz4zb" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThirteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zjP14kh3Zcs" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThirteenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.38</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z7xRGhD5QDO5" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2615">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zqZETXPG2fUj" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2616">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z52vcHID7zy1" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2617">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z8BknISK8yNa" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zlGerKsKT0Kb" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z82nupvXIEC9" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourteenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.83</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z7Qs3uB9N123" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2622">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zi3znQaa68cd" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zftRam9AvoSb" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourteenMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">490</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zw4q5x4zBfXa" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFifteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.32</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z4zo18qwcyS6" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFifteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z6B57Re75uD2" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFifteenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">1.89</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z4NJZnHEe9W4" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2629">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zJFfvXx4XJCh" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFifteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zGdeGtxb7y5e" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFifteenMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_z0Ic6KJ8XcU8" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.34</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zeNExxZhoBk6" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zJY5o9pyAd51" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixteenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.52</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_z31WZzfFzHle" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2636">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zDb2jKC1BLPa" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zLz7ySnhSeEa" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixteenMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">72</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zfaV4M7ePToa" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSeventeenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_znuZvBMVskeg" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSeventeenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,333</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zgFzWN7WAT8e" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSeventeenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.05</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zp69PYYZoIUh" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2643">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zc90HE6kBMUg" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSeventeenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,999</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zg0koyS616p4" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSeventeenMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zttaeVMJ2mmc" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEighteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.52</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_z6ojrK2VDqe" title="Number of Outstanding Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEighteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zrmW1ph8Acba" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEighteenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">2.26</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zBIQUnU5xsl" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2650">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zIgegUeSGUC" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEighteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_z2cgXQaWRDM" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEighteenMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">96</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zmFRHLn4lQU8" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.8</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zpWfNgNoTnra" title="Number of Outstanding Options" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,267</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zpcmqwo8y4k4" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineteenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">1.28</ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zAjvcELcwlfa" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2657">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zYAWvkc5Qpv8" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,267</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zvMnWacbflx2" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineteenMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">660</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zXPtMpBpMvO4" title="Number of Outstanding Options" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">549,141</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z4hKvDKamxN2" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.18</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z7jEda9Q4WG8" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">240</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zJN4C00E9KHf" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">450,972</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zAMCvEmSYO3" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,834</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AC_znVadZXHR6yf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Costs
incurred with respect to options granted to consultants and service providers for the years ended December 31, 2020 and December
31, 2019 were $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zfzTc7v9MyA8"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">113</ix:nonFraction></span> thousand and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pn3n3_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zTNhbHPzQjij" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">330</ix:nonFraction></span> thousand, respectively. As of December 31, 2020, there was $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z7kubgqN0Mtj"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">231</ix:nonFraction></span> thousands of unrecognized
compensation costs related to non-vested consultants and service providers, to be recorded over the next <span><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zAgzhiocscYi"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">4.58</ix:nonNumeric></span></span> years.<br />
<br /></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>d.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Warrants
    and Shares Issued to Non-Employees</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">The
fair value of Common Stock issued was the share price of the shares issued at the day of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">1)
On January 20, 2020, the Company entered into a Securities Purchase Agreement (the &#8220;January Purchase Agreement&#8221;) with
certain investors pursuant to which the Company issued and sold, in a private placement (the &#8220;Offering&#8221;), <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pii_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zGgaZxQiban3" title="Number of shares issued"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2020-01-192020-01-20_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,200,000</ix:nonFraction></span>
shares of Common Stock at a purchase price of $<span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_pii_c20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zqAUx3s3jtF3" title="Share issued price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2020-01-20_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.20</ix:nonFraction></span> per share (the &#8220;Shares&#8221;) and warrants to purchase up to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z1rqvrI0qa5" title="Number of warrants granted to purchase an equal number of additional shares of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2020-01-20_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span>
shares of Common Stock at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z4fF0eCNDWb1" title="Warrants exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-01-20_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.50</ix:nonFraction></span> per share (the &#8220;Warrants&#8221;) which are <span id="xdx_909_ecustom--WarrantExercisableDescription_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYrwZqyDlgT4"><ix:nonNumeric contextRef="From2020-01-192020-01-20_custom_SecuritiesPurchaseAgreementMember" name="ORGS:WarrantExercisableDescription">exercisable between June
2021 and January 2023.</ix:nonNumeric></span> The Company received gross proceeds of approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zK01S5AP0ag9" title="Proceeds from issuance of private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2020-01-192020-01-20_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">9.2</ix:nonFraction></span> million before deducting related offering expenses
in the amount of $<span id="xdx_907_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z0GuOIhqqxO9" title="Offering expenses"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2020-01-20_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million. The fair value of those warrants as of the date of grant using the Black-Scholes valuation model
was $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zX1pH7Qz3im6" title="Warrants fair value"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2020-01-192020-01-20_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,911</ix:nonFraction></span> thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">2)
On January 2, 2020, the Company entered into private placement subscription agreements with investors for an aggregate amount
of $<span id="xdx_90B_ecustom--AggregateAmountOfSubscriptionAgreement_iI_pn3n3_c20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementsMember_zkXsyYGJbKrd" title="Aggregate amount of subscription agreement"><ix:nonFraction name="ORGS:AggregateAmountOfSubscriptionAgreement" contextRef="AsOf2020-01-02_custom_PrivatePlacementSubscriptionAgreementsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></span> thousand of convertible loans. The lenders shall be entitled, at any time prior to or no later than the maturity date,
to convert the outstanding amount, into shares of Common Stock of the Company at a conversion price per share equal to $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementsMember_zTN8O4MeTSca" title="Conversion price per share"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2020-01-02_custom_PrivatePlacementSubscriptionAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span>.
In addition, the Company granted the investors <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementsMember_zxKxt3202ijl" title="Number of warrants granted to purchase an equal number of additional shares of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2020-01-02_custom_PrivatePlacementSubscriptionAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">151,428</ix:nonFraction></span> warrants to purchase an equal number of additional shares of the Company&#8217;s
Common Stock at a price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementsMember_pii" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-01-02_custom_PrivatePlacementSubscriptionAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span> per share. The fair value of those warrants as of the date of grant using the Black-Scholes valuation
model was $<span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20200101__20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementsMember_zZuxOd1WxtQ4"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2020-01-012020-01-02_custom_PrivatePlacementSubscriptionAgreementsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">210</ix:nonFraction></span> thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">3)
During the year ended December 31, 2020, the Company granted to several consultants <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20201231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_zw3LmohdRPAk" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-012020-12-31_custom_NonEmployeesMember_custom_SeveralConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">193,178</ix:nonFraction></span> warrants each exercisable between
$<span id="xdx_90B_eus-gaap--WarrantExercisePriceDecrease_c20200101__20201231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_pii" title="Warrant, Exercise Price, Decrease"><ix:nonFraction name="us-gaap:WarrantExercisePriceDecrease" contextRef="From2020-01-012020-12-31_custom_NonEmployeesMember_custom_SeveralConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.14</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--WarrantExercisePriceIncrease_c20200101__20201231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_pii" title="Warrant, Exercise Price, Increase"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2020-01-012020-12-31_custom_NonEmployeesMember_custom_SeveralConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.34</ix:nonFraction></span> per share for <span id="xdx_904_ecustom--WarrantsAndRightsOutstandingTermDescription_c20200101__20201231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember" title="Warrants term"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_NonEmployeesMember_custom_SeveralConsultantsMember" name="ORGS:WarrantsAndRightsOutstandingTermDescription">three years</ix:nonNumeric></span>. The fair value of those options as of the date of grant using the Black-Scholes valuation
model was $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20200101__20201231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_zLZWMYD6u1Oh" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2020-01-012020-12-31_custom_NonEmployeesMember_custom_SeveralConsultantsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">378</ix:nonFraction></span> thousand, out of which $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20200101__20201231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesAndPrivateInvestmentMember_zn9yzulEQCTb"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2020-01-012020-12-31_custom_NonEmployeesMember_custom_ConvertibleNotesAndPrivateInvestmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">350</ix:nonFraction></span> thousand is related to <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20201231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesAndPrivateInvestmentMember_zMnNdbdHsQZa"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-012020-12-31_custom_NonEmployeesMember_custom_ConvertibleNotesAndPrivateInvestmentMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">179,428</ix:nonFraction></span> warrants granted as a success fee with respect to the
issuance of the convertible notes and private Investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 128; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">4)
During the year ended December 31, 2019, the Company granted to several consultants <span id="xdx_907_ecustom--ClassOfWarrantOrRightGrantsInPeriod_pii_c20190101__20191231__srt--TitleOfIndividualAxis__custom--SeveralConsultantsMember_z38o6pCisXWa" title="Number of warrants - issued"><ix:nonFraction name="ORGS:ClassOfWarrantOrRightGrantsInPeriod" contextRef="From2019-01-012019-12-31_custom_SeveralConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,499</ix:nonFraction></span> warrants each exercisable between $<span id="xdx_902_ecustom--ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__srt--TitleOfIndividualAxis__custom--SeveralConsultantsMember_zUmPEII3LERa" title="Weighted Average Exercise Price - Issued"><ix:nonFraction name="ORGS:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_srt_MinimumMember_custom_SeveralConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.3</ix:nonFraction></span>
and $<span id="xdx_901_ecustom--ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__srt--TitleOfIndividualAxis__custom--SeveralConsultantsMember_zSwNtPytmdxj" title="Weighted Average Exercise Price - Issued"><ix:nonFraction name="ORGS:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_srt_MaximumMember_custom_SeveralConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span> per share for three years. The fair value of those options as of the date of grant using the Black-Scholes valuation
model was $<span id="xdx_909_ecustom--ClassOfWarrantOrRightGrantsInPeriodFairValue_pn3n3_c20190101__20191231__srt--TitleOfIndividualAxis__custom--SeveralConsultantsMember_zJNuZDCPnpOj" title="Class of warrant or right, grants in period, fair value"><ix:nonFraction name="ORGS:ClassOfWarrantOrRightGrantsInPeriodFairValue" contextRef="From2019-01-012019-12-31_custom_SeveralConsultantsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">155</ix:nonFraction></span> thousand, out of which $<span id="xdx_909_ecustom--ClassOfWarrantOrRightGrantsInPeriodFairValue_pn3n3_c20190101__20191231__us-gaap--AwardTypeAxis__custom--SuccessFeeMember_z0WGCbdKgHA9" title="Class of warrant or right, grants in period, fair value"><ix:nonFraction name="ORGS:ClassOfWarrantOrRightGrantsInPeriodFairValue" contextRef="From2019-01-012019-12-31_custom_SuccessFeeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">97</ix:nonFraction></span> thousand is related to <span id="xdx_908_ecustom--ClassOfWarrantOrRightGrantsInPeriod_pii_c20190101__20191231__us-gaap--AwardTypeAxis__custom--SuccessFeeMember_z75y90cjcXh5" title="Number of warrants - issued"><ix:nonFraction name="ORGS:ClassOfWarrantOrRightGrantsInPeriod" contextRef="From2019-01-012019-12-31_custom_SuccessFeeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">57,142</ix:nonFraction></span> warrants granted as a success fee with respect to the
issuance of the convertible notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">5)
In September 2019, the Company entered into an investor relation services, marketing and related services agreement. Under the
terms of the agreement, the Company agreed to issue the consultant <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pii_c20190901__20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember_zBrAJ1D5qcSf"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2019-09-012019-09-30_custom_InvestorRelationContactMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,174</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">shares of restricted
common stock, of which the first <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pii_c20190901__20190930__us-gaap--VestingAxis__custom--HeldUntilSixMonthsAnniversaryMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember_zIFtiRK2GhCc"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2019-09-012019-09-30_custom_HeldUntilSixMonthsAnniversaryMember_custom_InvestorRelationContactMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,087</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">shares will be
held in escrow by the Company until the six months anniversary of the agreement and <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pii_c20190901__20190930__us-gaap--VestingAxis__custom--HeldUntilOneYearAnniversaryMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember_zMwrXjnDdaij"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2019-09-012019-09-30_custom_HeldUntilOneYearAnniversaryMember_custom_InvestorRelationContactMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,087</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">shares will be
issued on the six months anniversary of the agreement to be held in escrow by the company until the one-year anniversary of the
agreement. The fair value of the shares was $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn3n3_c20190909__20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember_z27lpOlmmtD2"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2019-09-092019-09-30_custom_InvestorRelationContactMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">178</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">thousand using
the fair value of the shares on the grant date. $<span id="xdx_905_ecustom--FairValueOfSharesRecognizedOnGrantDate_iI_pn3n3_c20201231_zI6pjGp1Yf59"><ix:nonFraction name="ORGS:FairValueOfSharesRecognizedOnGrantDate" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">96</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">and <span id="xdx_904_ecustom--FairValueOfSharesRecognizedOnGrantDate_iI_pn3n3_c20191231_zMsklUcFte4b"><ix:nonFraction name="ORGS:FairValueOfSharesRecognizedOnGrantDate" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">thousand was recognized
during the year ended December 31, 2020 and December 31, 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">6)
In March 2019, the Company issued First Choice <span id="xdx_90B_ecustom--JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted_pii_c20190301__20190331__dei--LegalEntityAxis__custom--FirstChoiceInternationalCompanyIncMember_zV1gWUHfRjle" title="Joint venture agreement, shares issued for compensation of work already completed"><ix:nonFraction name="ORGS:JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted" contextRef="From2019-03-012019-03-31_custom_FirstChoiceInternationalCompanyIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">525,000</ix:nonFraction></span> shares of Common Stock. The value of Common Stock issued in the amount
of $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20190101__20191231__dei--LegalEntityAxis__custom--FirstChoiceInternationalCompanyIncMember_z48GvTEwiqIl" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-01-012019-12-31_custom_FirstChoiceInternationalCompanyIncMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.6</ix:nonFraction></span> million were charged to research and development expenses during the year ended December 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">7)
In December 2018, the Company entered into an investor relation services, marketing and related services agreement. Under the
terms of the agreement, the Company agreed to issue the consultant <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20181201__20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zs2Wvc0x5Cyd" title="Stock issued during period, shares, restricted stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2018-12-012018-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares of restricted common stock, of which the first
<span id="xdx_90F_ecustom--NumberOfVestedShares_iI_pii_c20181231__us-gaap--VestingAxis__custom--VestedOnSigningDateMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zuTQasQOik18" title="Number of vested shares"><ix:nonFraction name="ORGS:NumberOfVestedShares" contextRef="AsOf2018-12-31_custom_VestedOnSigningDateMember_custom_InvestorRelationContactMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500</ix:nonFraction></span> shares vested on the signing date, and <span id="xdx_901_ecustom--NumberOfVestedShares_iI_pp0i_c20181231__us-gaap--VestingAxis__custom--VestMonthlyOver3MonthsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zI8ZVcqcj5F3" title="Number of vested shares"><ix:nonFraction name="ORGS:NumberOfVestedShares" contextRef="AsOf2018-12-31_custom_VestMonthlyOver3MonthsMember_custom_InvestorRelationContactMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">7,500</ix:nonFraction></span> shares are to vest monthly over 3 months commencing January 2019. As of December
31, 2019, <span id="xdx_90F_ecustom--NumberOfVestedShares_iI_pii_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zHu65hMXBPb9" title="Number of vested shares"><ix:nonFraction name="ORGS:NumberOfVestedShares" contextRef="AsOf2019-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares were fully vested. The fair value of the shares was $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn3n3_c20191201__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zbTATAZto1kj" title="Stock issued during period, value, issued for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2019-12-012019-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51</ix:nonFraction></span> thousand using the fair value of the shares on
the vesting dates. $<span id="xdx_90B_ecustom--FairValueOfSharesOnVestingDatesRecognizedDuringYear_pn3n3_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zJyRPF4wQirh" title="Fair value of shares on vesting dates recognized during year"><ix:nonFraction name="ORGS:FairValueOfSharesOnVestingDatesRecognizedDuringYear" contextRef="From2019-01-012019-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37</ix:nonFraction></span> thousand was recognized during the year ended December 30, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">8)
In December 2018, the Company entered into a separate investor relations services, marketing and related services agreement. Under
the terms of the agreement, the Company agreed to issue the consultant <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20181201__20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationsContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zmLwbrAhBk88" title="Stock issued during period, shares, restricted stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2018-12-012018-12-31_custom_SeparateInvestorRelationsContactMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span> shares of restricted common stock, of which the
first <span id="xdx_908_ecustom--NumberOfVestedShares_iI_pii_c20181231__us-gaap--VestingAxis__custom--VestedOnSigningDateMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zQFuM1QM4ZW6"><ix:nonFraction name="ORGS:NumberOfVestedShares" contextRef="AsOf2018-12-31_custom_VestedOnSigningDateMember_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,667</ix:nonFraction></span> shares vested on the signing date, and <span id="xdx_903_ecustom--NumberOfVestedShares_iI_pp0i_c20181231__us-gaap--VestingAxis__custom--VestMonthlyOver3MonthsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zimv2xMOMZcb"><ix:nonFraction name="ORGS:NumberOfVestedShares" contextRef="AsOf2018-12-31_custom_VestMonthlyOver3MonthsMember_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">33,333</ix:nonFraction></span> shares vested monthly over five months commencing January 2019. As of
December 31, 2019, <span id="xdx_908_ecustom--NumberOfVestedShares_iI_pii_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zYjFXWrQxLW1"><ix:nonFraction name="ORGS:NumberOfVestedShares" contextRef="AsOf2019-12-31_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span> shares were fully vested. The fair value of the shares was $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn3n3_c20191201__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_z6rz8wsWwo77"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2019-12-012019-12-31_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></span> thousand using the fair value of the
shares at the vesting dates. $<span id="xdx_907_ecustom--FairValueOfSharesOnVestingDatesRecognizedDuringYear_pn3n3_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zfwB15vDhaX3"><ix:nonFraction name="ORGS:FairValueOfSharesOnVestingDatesRecognizedDuringYear" contextRef="From2019-01-012019-12-31_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">163</ix:nonFraction></span> thousand was recognized during the year ended December 30, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">9)
During the year ended November 30, 2018, the Company granted to several consultants <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_zv3Vyqf154q1" title="Number of warrants shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2018-11-30_custom_SeveralConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,782</ix:nonFraction></span> warrants each exercisable between $<span id="xdx_903_eus-gaap--WarrantExercisePriceDecrease_c20181129__20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_zaUy9CQtXmM8" title="Warrant, exercise price, decrease"><ix:nonFraction name="us-gaap:WarrantExercisePriceDecrease" contextRef="From2018-11-292018-11-30_custom_SeveralConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.24</ix:nonFraction></span>
and $<span id="xdx_90F_eus-gaap--WarrantExercisePriceIncrease_c20181129__20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_z1kBFaQUrea3" title="Warrant, exercise price, increase"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2018-11-292018-11-30_custom_SeveralConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.41</ix:nonFraction></span> per share for <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtxL_c20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_z8dp5Nk1tCb5" title="Warrant term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl2755">three</span></span> years. The fair value of those warrants as of the date of grant using the Black-Scholes valuation
model was $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20181129__20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_za1cOu0l2cN9" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2018-11-292018-11-30_custom_SeveralConsultantsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">350</ix:nonFraction></span> thousand. The warrants granted as a success fee with respect to private placement and the issuance of convertible
loans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">10)
In January 2018, the Company entered into a consulting agreement with a financial advisor for a period of one year. Under the
terms of the agreement, the consultant was entitled to receive $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20180101__20180131__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zNSdiF9VL1I7" title="Number of common stock for services, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2018-01-012018-01-31_custom_ConsultingAgreementMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60</ix:nonFraction></span> thousand and <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pii_c20180101__20180131__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_z4FiHJj0Bn4c" title="Number of common stock for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2018-01-012018-01-31_custom_ConsultingAgreementMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,000</ix:nonFraction></span> units of the Company securities. Each unit
is comprised of (i) one share of the Company&#8217;s common stock and (ii) a <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtxL_c20180131__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zcniQxloDrF3" title="Warrant term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl2763">three</span></span>-year warrant to purchase up to an additional
one share of the Company&#8217;s Common Stock at a per share exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20180131__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zkvmPiTNsOVf" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2018-01-31_custom_ConsultingAgreementMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.24</ix:nonFraction></span>. The fair value of the units as of the date
of grant was $<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20180101__20180131__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_ze0x5BBacvIf" title="Fair value of granted"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2018-01-012018-01-31_custom_ConsultingAgreementMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">171</ix:nonFraction></span> thousand, out of which $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20180101__20180131__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zCb0671DJAQ2" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2018-01-012018-01-31_custom_ConsultingAgreementMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">62</ix:nonFraction></span> thousand reflect the fair value of the warrants using the Black-Scholes valuation
model. In July 2018, the board approved an additional issuance of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180701__20180731__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zfLMK3gqVDG6" title="Number of common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2018-07-012018-07-31_custom_ConsultingAgreementMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,629</ix:nonFraction></span> shares and <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtxL_c20180731__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zxRaOQdO1T87" title="::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl2772">three</span></span>-year warrants to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20180731__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zkWvMiLL0GB" title="Number of warrants shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2018-07-31_custom_ConsultingAgreementMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,629</ix:nonFraction></span>
shares of the Company&#8217;s Common Stock at a per share exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20180731__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zBFFLzb7Wzk8" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2018-07-31_custom_ConsultingAgreementMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.24</ix:nonFraction></span>. The fair value of the units as of the date
of grant was $<span id="xdx_900_eus-gaap--FairValueAdjustmentOfWarrants_c20180701__20180731__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zLNjkl2Zy4b1" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2018-07-012018-07-31_custom_ConsultingAgreementMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88</ix:nonFraction></span> thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">11)
In December 2017, the Company entered into investor relations services, marketing and related services agreements. Under the terms
of the agreement, the Company agreed to grant the consultants a total of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20171201__20171231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zaVThk1Qtvj7" title="Stock issued during period, shares, restricted stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2017-12-012017-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">195,000</ix:nonFraction></span> shares of restricted common stock, out of which
the first <span id="xdx_90E_ecustom--NumberOfVestedShares_iI_pii_c20171231__us-gaap--VestingAxis__custom--VestedOnSigningDateMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zHFwRjEQ7kwf"><ix:nonFraction name="ORGS:NumberOfVestedShares" contextRef="AsOf2017-12-31_custom_VestedOnSigningDateMember_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares will vest after 30 days from the signing date, and <span id="xdx_902_ecustom--NumberOfVestedShares_iI_pp0i_c20171231__us-gaap--VestingAxis__custom--VestMonthlyOver3MonthsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_z5y4wtROY3G8"><ix:nonFraction name="ORGS:NumberOfVestedShares" contextRef="AsOf2017-12-31_custom_VestMonthlyOver3MonthsMember_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">145,000</ix:nonFraction></span> shares are to vest monthly over 15 months commencing
February 2018. As of December 31, 2019, all shares were vested. The fair value of the shares as of the date of grant was $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20171201__20171231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zCHKCtFxVbXb" title="Stock issued during period, value, restricted stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2017-12-012017-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,439</ix:nonFraction></span>
thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">12)
During the twelve months ended December 31, 2020, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk9Sya5NOXuk" title="Number of common stock for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">270,174</ix:nonFraction></span> shares of common stock to service providers. As of
December 31, 2020, <span id="xdx_90B_ecustom--NumberOfAdditionalSharesRestrictionsOnTransfer_pii_c20200101__20201231_zTNluHLhUpT3" title="Number of additional shares restrictions on transfer"><ix:nonFraction name="ORGS:NumberOfAdditionalSharesRestrictionsOnTransfer" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000</ix:nonFraction></span> shares have additional restrictions on transfer until such services have been provide.</span></p>
<!-- Field: Split-Segment; Name: Split 4 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 129; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_zgc6SFYi2Hbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
16 &#8211; <span id="xdx_823_zdBFmTGxF39h">TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>a.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Corporate
    taxation in the U.S.</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
corporate U.S. Federal Income tax rate applicable to the Company and its US subsidiaries is <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercentage_c20200101__20201231__srt--StatementGeographicalAxis__country--US_zvSqlUnoCDo5" title="Effective income tax rate reconciliation, at income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2020-01-012020-12-31_country_US" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">21</ix:nonFraction>%</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, the Company has an accumulated tax loss carryforward of approximately $ <span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20201231_zvnQWbP5ivVg"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">18</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million (as of December 31, 2019,
approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20191231_zYrfI1zw54xj"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">34</ix:nonFraction></span></span> <span style="font: 10pt Times New Roman, Times, Serif">million).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20200101__20201231__srt--StatementGeographicalAxis__country--US" title="Operating loss carryforwards, limitations on use"><ix:nonNumeric contextRef="From2020-01-012020-12-31_country_US" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse">For
U.S. federal income tax purposes, net operating losses (&#8220;NOLs&#8221;) arising in tax years beginning after December 31,
2017, the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) limits the ability to utilize NOL carryforwards to
80% of taxable income in tax years beginning after December 31, 2020.</ix:nonNumeric></span> In addition, NOLs arising in tax years ending after December
31, 2017 can be carried forward indefinitely, but carryback is generally prohibited. NOLs generated in tax years beginning before
January 1, 2018 will not be subject to the taxable income limitation, and NOLs generated in tax years ending before January 1,
2018 will continue to have a two-year carryback and twenty-year carryforward period. Deferred tax assets for NOLs will need to
be measured at the applicable tax rate in effect when the NOL is expected to be utilized. The changes in the carryforward/carryback
periods as well as the new limitation on use of NOLs may significantly impact the Company&#8217;s valuation allowance assessments
for NOLs generated after December 31, 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, utilization of the NOLs may be subject to substantial annual limitation under Section 382 of the Code due to an &#8220;ownership
change&#8221; within the meaning of Section 382(g) of the Code. An ownership change, subjects pre-ownership change NOLs carryforwards
to an annual limitation, which significantly restricts the ability to use them to offset taxable income in periods following the
ownership change. In general, the annual use limitation equals the aggregate value of the Company&#8217;s stock at the time of
the ownership change multiplied by a specified tax-exempt interest rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the &#8220;CARES Act&#8221;) was enacted into law. The
CARES Act is aimed at providing emergency relief and health care for individuals and businesses affected by the COVID-19 pandemic.
The CARES Act, among other things, includes provisions related to refundable payroll tax credits, deferral of the employer portion
of social security payments, expanded net operating loss application, modifications to the net interest deduction limitations,
and technical corrections to tax depreciation methods for qualified improvement property. The CARES act allowed the Company to
utilize 100% of NOLs arising in tax years after December 31, 2017. The Company assess all other provisions of the CARES Act and
notes no other material impact to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>b.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Corporate
    taxation in Israel</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Israeli Subsidiaries are taxed in accordance with Israeli tax laws. The corporate tax rate applicable to 2020 and 2019 are <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercentage_c20200101__20201231__srt--StatementGeographicalAxis__country--IL_zfC2oMpOFwfl" title="Effective income tax rate reconciliation, at income tax rate"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercentage_c20190101__20191231__srt--StatementGeographicalAxis__country--IL_z9mE9zgMWA27" title="Effective income tax rate reconciliation, at income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2020-01-012020-12-31_country_IL" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2019-01-012019-12-31_country_IL" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">23</ix:nonFraction></ix:nonFraction>%</span></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, the Israeli Subsidiaries has an accumulated tax loss carryforward of approximately $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pin6_c20201231__srt--StatementGeographicalAxis__country--IL_zA26Da8kwIp8" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2020-12-31_country_IL" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">11</ix:nonFraction></span> million (as of December
31, 2019, approximately $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pin6_c20191231__srt--StatementGeographicalAxis__country--IL_zao3Ibx3Xfhe" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2019-12-31_country_IL" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">10</ix:nonFraction></span> million). Under the Israeli tax laws, carryforward tax losses have no expiration date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>c.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Corporate
taxation in Belgium</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Belgian Subsidiary are taxed according to Belgian tax laws. The corporate tax rates applicable to  2020, 2019
are <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercentage_c20200101__20201231__srt--StatementGeographicalAxis__country--BE__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyOneToTwoThousandTwentyMember_zPzwHLKe2y0h"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2020-01-012020-12-31_country_BE_custom_TwoThousandTwentyOneToTwoThousandTwentyMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">25</ix:nonFraction>%
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercentage_c20190101__20191231__srt--StatementGeographicalAxis__country--BE_zvMZu66v1zF5"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2019-01-012019-12-31_country_BE" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">29.58</ix:nonFraction>%,
</span></span><span style="font: 10pt Times New Roman, Times, Serif">respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, the Belgian Subsidiary has an accumulated tax loss carryforward of approximately $ <span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pin6_c20201231__srt--StatementGeographicalAxis__country--BE_ztKmAzH7EHcf"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2020-12-31_country_BE" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">8</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million (&#8364; <span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pin6_uEUR_c20201231__srt--StatementGeographicalAxis__country--BE__us-gaap--AwardTypeAxis__srt--EuropeMember_z64hQwO0QK2i"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2020-12-31_country_BE_srt_EuropeMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="EUR">6</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million), (as of December 31, 2019 $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pin6_c20191231__srt--StatementGeographicalAxis__country--BE_zhnpymgbxTc4"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2019-12-31_country_BE" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">6</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million). Under the Belgian tax laws there
are limitation on accumulated tax loss carryforward deductions of Euro <span id="xdx_905_ecustom--AccumulatedTaxLossCarryforwardDeductions_iI_pin6_uEUR_c20201231__srt--StatementGeographicalAxis__country--BE__us-gaap--AwardTypeAxis__srt--EuropeMember_z6nV2q6VzjY4"><ix:nonFraction name="ORGS:AccumulatedTaxLossCarryforwardDeductions" contextRef="AsOf2020-12-31_country_BE_srt_EuropeMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="EUR">1</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million per year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 130; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>d.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Corporate
    taxation in Korea</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
basic Korean corporate tax rates are currently: <span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember_zlmYfvNcz0y" title="Effective income tax rate reconciliation, at income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2020-01-012020-12-31_country_KR_custom_TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">10</ix:nonFraction>%</span> on the first KRW 200 million of the tax base, <span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--UpToKrwTwoZeroBillionMember_znQrRJ88tJP5" title="Effective income tax rate reconciliation, at income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2020-01-012020-12-31_country_KR_custom_UpToKrwTwoZeroBillionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">20</ix:nonFraction>%</span> up to KRW 20 billion, <span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--UpToKrwThreeZeroZeroBillionMember_zKLZJPdoTzW7" title="Effective income tax rate reconciliation, at income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2020-01-012020-12-31_country_KR_custom_UpToKrwThreeZeroZeroBillionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">22</ix:nonFraction>%</span>
up to KRW 300 billion and <span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--TaxBaseAboveKrwThreeZeroZeroBillionMember_zFjZ2f7e5r0l" title="Effective income tax rate reconciliation, at income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2020-01-012020-12-31_country_KR_custom_TaxBaseAboveKrwThreeZeroZeroBillionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">25</ix:nonFraction>%</span> for tax base above KRW 300 billion. In addition, the local income tax rate is <span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercentage_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember_zRBrOoNLT9f" title="Effective income tax rate reconciliation, at local income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2020-01-012020-12-31_country_KR_custom_TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">1</ix:nonFraction>%</span> on the first KRW
200 million of taxable income, <span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercentage_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--UpToKrwTwoZeroBillionMember_z1LZEOs8cNjd" title="Effective income tax rate reconciliation, at local income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2020-01-012020-12-31_country_KR_custom_UpToKrwTwoZeroBillionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">2</ix:nonFraction>%</span> on taxable income over KRW 200 million up to KRW 20 billion, <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercentage_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--UpToKrwThreeZeroZeroBillionMember_zO7j5qn1X9Sb" title="Effective income tax rate reconciliation, at local income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2020-01-012020-12-31_country_KR_custom_UpToKrwThreeZeroZeroBillionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">2.2</ix:nonFraction>%</span> of taxable income over KRW
20 billion up to 300 billion and <span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercentage_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--TaxBaseAboveKrwThreeZeroZeroBillionMember_zLHLaSVq83Tk" title="Effective income tax rate reconciliation, at local income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2020-01-012020-12-31_country_KR_custom_TaxBaseAboveKrwThreeZeroZeroBillionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percentage">2.5</ix:nonFraction>%</span> on taxable income over KRW 300 billion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, the Korean subsidiary has an accumulated tax loss carryforward of approximately $ <span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_pin6_c20201231__srt--StatementGeographicalAxis__country--KR_zvKetHp1cF9l"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2020-12-31_country_KR" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">4</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million (KRW <span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pin6_uKRW_c20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--AwardTypeAxis__custom--SouthKoreanWonMember_zeUF2PMi5vZ9"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2020-12-31_country_KR_custom_SouthKoreanWonMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="KRW">3,813</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million), (as of December 31, 2019,
approximately $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pin6_c20191231__srt--StatementGeographicalAxis__country--KR_zOzKCiGFCds5"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2019-12-31_country_KR" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">3</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million). Under the Korean tax laws accumulated
tax loss can be carry forwarded for <span id="xdx_90B_ecustom--AccumulatedTaxLossCarryForwardedPeriod_dtY_c20200101__20201231__srt--StatementGeographicalAxis__country--KR_zQEcnKBSHTHb"><ix:nonNumeric contextRef="From2020-01-012020-12-31_country_KR" format="ixt-sec:duryear" name="ORGS:AccumulatedTaxLossCarryForwardedPeriod">15</ix:nonNumeric>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>e.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Deferred
    Taxes</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zeqE89lKRzJ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table presents summary of information concerning the Company&#8217;s deferred taxes as of the years ending December
31, 2019 and December 31, 2019 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B1_z766Or12sSuc" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20201231_zXZFQuv0fVj3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20191231_zDgTmK3N8vic" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(U.S. dollars in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_msDTLztYm_zgBPVCDGywNa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Net operating loss carry forwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,606</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,033</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_msDTLztYm_zCrXy6rt04M4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,684</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,358</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_msDTLztYm_zTg18Jn9qUm6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity compensation </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,747</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl2841">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_iI_pn3n3_msDTLztYm_zXn3SAkGPgU6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Employee benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">252</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">228</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--DeferredTaxAssetsLeasesAsset_iI_pn3n3_msDTLztYm_z11i1Jih1eP9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leases asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:DeferredTaxAssetsLeasesAsset" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">533</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl2847">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--DeferredTaxAssetsLeaseLiability_iNI_pn3n3_di_maDTLztYm_zjVBpvnsc7q9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ORGS:DeferredTaxAssetsLeaseLiability" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">324</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl2850">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_pn3n3_di_maDTLztYm_zwCugWd6HsWa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,863</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">737</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_msDTLztYm_zkJGG3QCpJbc" style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">297</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_maDTLztYm_zcpm0JO7Gs46" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,932</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,939</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxLiabilities_iNTI_pn3n3_di_mtDTLztYm_zMJuAwQKEokj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2861">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A4_z1DdpOkxSl4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Realization
of deferred tax assets is contingent upon sufficient future taxable income during the period that deductible temporary differences
and carry forwards losses are expected to be available to reduce taxable income. As the achievement of required future taxable
income is not considered more likely than not achievable, the Company and all its subsidiaries except the Korean Subsidiary (previously
CureCell) have recorded full valuation allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:SummaryOfValuationAllowanceTextBlock"><p id="xdx_891_eus-gaap--SummaryOfValuationAllowanceTextBlock_zaZcptbl3pD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
changes in valuation allowance are comprised as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BF_zI2Sac4A7VW4" style="display: none">SCHEDULE OF VALUATION ALLOWANCE, ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(U.S dollars in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Balance at the beginning of year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20200101__20201231_z4UsOo810krg" title="Balance at the beginning of year" style="width: 18%; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,939</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20190101__20191231_zj5TStugVh28" title="Balance at the beginning of year" style="width: 18%; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,254</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20200101__20201231_zUge94j55QWg" title="Change during the year" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,007</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20190101__20191231_zjtjNj8oM515" title="Change during the year" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,685</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Balance at end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20200101__20201231_zKy9h85KJWOe" title="Balance at end of year" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,932</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20190101__20191231_z0lEzw0xdTTf" title="Balance at end of year" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,939</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AC_zaPljoTAvhri" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>f.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Reconciliation
    of the Theoretical Tax Expense to Actual Tax Expense</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
main reconciling item between the statutory tax rate of the Company and the effective rate is the provision for valuation allowance
with respect to tax benefits from carry forward tax losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>g.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Uncertain
    Tax Provisions</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">ASC
Topic 740, &#8220;Income Taxes&#8221; requires significant judgment in determining what constitutes an individual tax position
as well as assessing the outcome of each tax position. Changes in judgment as to recognition or measurement of tax positions can
materially affect the estimate of the effective tax rate and consequently, affect the operating results of the Company. As of
December 31, 2020, the Company has not accrued a provision for uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 131; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:RevenueFromContractWithCustomerTextBlock"><p id="xdx_802_eus-gaap--RevenueFromContractWithCustomerTextBlock_zatR1J2qiMTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
17 &#8211; <span id="xdx_822_zc9Tws1gKm7a">REVENUES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Disaggregation
of Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><p id="xdx_899_eus-gaap--DisaggregationOfRevenueTableTextBlock_zciVtxWIG3Cl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table disaggregates the Company&#8217;s revenues by major revenue streams.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B6_z1gyYh8uIJzf" style="display: none">SCHEDULE OF DISAGGREGATION OF REVENUE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Revenue stream:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">POC and hospital services</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--PointOfCareServicesMember_zhFWJCKZmbgk" title="Total" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-12-31_custom_PointOfCareServicesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,068</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Revenues_c20190101__20191231__srt--ProductOrServiceAxis__custom--PointOfCareServicesMember_pn3n3" title="Total" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-12-31_custom_PointOfCareServicesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,109</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cell process development services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--Revenues_c20200101__20201231__srt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesMember_pn3n3" title="Total" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-12-31_custom_CellProcessDevelopmentServicesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,584</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--Revenues_c20190101__20191231__srt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesMember_pn3n3" title="Total" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-12-31_custom_CellProcessDevelopmentServicesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">790</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_c20200101__20201231_pn3n3" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,652</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--Revenues_c20190101__20191231_pn3n3" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,899</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AB_z22QlsUJnVD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">POC
development services are the result of agreements between Company and its partners (See Note 11). The Company provides certain
services in support of the partners&#8217; clinical activity. The Company has signed Master Services Agreements with joint venture
partners in the aggregate amount of over $<span id="xdx_90B_eus-gaap--Revenues_pin6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JointVenturePartnersMember_zrXXa7x58lKa" title="Revenue"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-12-31_custom_MasterServicesAgreementsMember_custom_JointVenturePartnersMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">38</ix:nonFraction></span> million for services to be provided from 2021 to 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:ScheduleOfBreakdownOfRevenuesPerCustomer"><p id="xdx_898_ecustom--ScheduleOfBreakdownOfRevenuesPerCustomer_zY1gLtJVUKwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">A
breakdown of the revenues per customer what constituted at least 10% of revenues is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B2_zm38Kgu5iW3i" style="display: none">SCHEDULE OF BREAKDOWN OF REVENUES PER CUSTOMER</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Revenue earned:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: justify">Customer A</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerAMember_pn3n3" title="Revenues" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_custom_CustomerAMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,857</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--MajorCustomersAxis__custom--CustomerAMember_pn3n3" title="Revenues" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_custom_CustomerAMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,420</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Customer B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerBMember_pn3n3" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_custom_CustomerBMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,577</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--MajorCustomersAxis__custom--CustomerBMember_pn3n3" title="Revenues" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2904">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Customer C &#8211; related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerCRelatedPartyMember_pn3n3" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_custom_CustomerCRelatedPartyMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,475</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--MajorCustomersAxis__custom--CustomerCRelatedPartyMember_pn3n3" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_custom_CustomerCRelatedPartyMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,270</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Customer D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerDMember_pn3n3" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_custom_CustomerDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,412</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--MajorCustomersAxis__custom--CustomerDMember_pn3n3" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_custom_CustomerDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">857</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A7_zxdqTJw6Pdu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Contract
Assets and Liabilities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Contract
assets are mainly comprised of trade receivables net of allowance for doubtful debts, which includes amounts billed and currently
due from customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock"><p id="xdx_89A_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zEx5HF4APUu1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
activity for trade receivables is comprised of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><span><span id="xdx_8B3_zKMopYhtwfci" style="display: none">SCHEDULE OF ACTIVITY FOR TRADE RECEIVABLES</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%">Balance as of beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AccountsReceivableNetCurrent_iS_pn3n3_c20200101__20201231_zgIuXzD8VVu3" title="Balance as of beginning of period" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,831</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AccountsReceivableNetCurrent_iS_pn3n3_c20190101__20191231_zeumEvjYPYj7" title="Balance as of beginning of period" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">129</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Acquisition of Koligo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--AccountsReceivableAcquisitionOfKoligo_c20200101__20201231_pn3n3" title="Acquisition of Koligo" style="text-align: right"><ix:nonFraction name="ORGS:AccountsReceivableAcquisitionOfKoligo" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">228</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--AccountsReceivableAcquisitionOfKoligo_c20190101__20191231_pn3n3" title="Acquisition of Koligo" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2922">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--AccountsReceivableAdditions_c20200101__20201231_pn3n3" title="Additions" style="text-align: right"><ix:nonFraction name="ORGS:AccountsReceivableAdditions" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,997</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--AccountsReceivableAdditions_c20190101__20191231_pn3n3" title="Additions" style="text-align: right"><ix:nonFraction name="ORGS:AccountsReceivableAdditions" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,079</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Collections</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--AccountsReceivableCollections_c20200101__20201231_pn3n3" title="Collections" style="text-align: right">(<ix:nonFraction name="ORGS:AccountsReceivableCollections" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,982</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--AccountsReceivableCollections_c20190101__20191231_pn3n3" title="Collections" style="text-align: right">(<ix:nonFraction name="ORGS:AccountsReceivableCollections" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">364</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Exchange rate differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ExchangeRateDifferencesOfAccountsReceivable_c20200101__20201231_pn3n3" title="Exchange rate differences" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ORGS:ExchangeRateDifferencesOfAccountsReceivable" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ExchangeRateDifferencesOfAccountsReceivable_c20190101__20191231_pn3n3" title="Exchange rate differences" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ORGS:ExchangeRateDifferencesOfAccountsReceivable" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance as of end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AccountsReceivableNetCurrent_iE_pn3n3_c20200101__20201231_z5EzxrYt23w8" title="Balance as of end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,085</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AccountsReceivableNetCurrent_iE_pn3n3_c20190101__20191231_zqbnSQSPLjwf" title="Balance as of end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,831</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A4_z4gg2OJ5ms8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 132; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock"><p id="xdx_89D_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_z7ZGBpL1HCgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
activity for contract liabilities is comprised of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B4_zWL501wjCgnk" style="display: none">SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%">Balance as of beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ContractWithCustomerLiabilityCurrent_iS_pn3n3_c20200101__20201231_zPJ5G2h1xHhl" title="Balance as of beginning of period" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">325</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ContractWithCustomerLiabilityCurrent_iS_pn3n3_c20190101__20191231_zJNOYDwWAI32" title="Balance as of beginning of period" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">56</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ContractWithCustomerLiabilityAddition_c20200101__20201231_pn3n3" title="Additions" style="text-align: right"><ix:nonFraction name="ORGS:ContractWithCustomerLiabilityAddition" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">597</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ContractWithCustomerLiabilityAddition_c20190101__20191231_pn3n3" title="Additions" style="text-align: right"><ix:nonFraction name="ORGS:ContractWithCustomerLiabilityAddition" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,126</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F43_z0M5U3m6Pdc7" style="padding-left: 10pt">Realizations*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ContractWithCustomerLiabilityRealizations_pn3n3_c20200101__20201231_fKg_____zl72xmE3vlo9" title="Realizations" style="text-align: right">(<ix:nonFraction name="ORGS:ContractWithCustomerLiabilityRealizations" contextRef="From2020-01-01to2020-12-31" id="Fact002950" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">862</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ContractWithCustomerLiabilityRealizations_pn3n3_c20190101__20191231_fKg_____zx18NKmAlo2j" title="Realizations" style="text-align: right">(<ix:nonFraction name="ORGS:ContractWithCustomerLiabilityRealizations" contextRef="From2019-01-012019-12-31" id="Fact002952" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">854</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Exchange rate differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--ContractWithCustomerLiabilityExchangeRateDifferences_c20200101__20201231_pn3n3" title="Exchange rate differences" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ORGS:ContractWithCustomerLiabilityExchangeRateDifferences" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--ContractWithCustomerLiabilityExchangeRateDifferences_c20190101__20191231_pn3n3" title="Exchange rate differences" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ORGS:ContractWithCustomerLiabilityExchangeRateDifferences" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ContractWithCustomerLiabilityCurrent_iE_pn3n3_c20200101__20201231_zGOvVzvolUrf" title="Balance as of end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">59</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ContractWithCustomerLiabilityCurrent_iE_pn3n3_c20190101__20191231_zOKMpkkMhpv5" title="Balance as of end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">325</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td id="xdx_F06_zZk6RCpAn0lg" style="width: 3%">*</td>
    <td id="xdx_F1F_zKmYLsKShpMl" style="width: 97%"><ix:footnote id="Footnote002961" xml:lang="en-US">Out of which $ <span id="xdx_90F_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn3n3_c20191231_zMzilnHXUcB9" title="Contract with customer liability" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDVElWSVRZIEZPUiBDT05UUkFDVCBMSUFCSUxJVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">325</ix:nonFraction></span> thousand were realized from the beginning of the period for the year ended December 31, 2020.</ix:footnote></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric><p id="xdx_8AF_zgh8DGPfK7ic" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"><p id="xdx_802_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zWlXHw6dGYq" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
18 &#8211; <span id="xdx_824_zMcviMJeQtY9">COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET</span></b></span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_z3cLO8fhyhdh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BC_zV30xjyeSrsl" style="display: none">SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Total expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--OtherResearchAndDevelopmentExpense_c20200101__20201231_pn3n3" title="Total expenses" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84,182</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--OtherResearchAndDevelopmentExpense_c20190101__20191231_pn3n3" title="Total expenses" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,826</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less grants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--GrantsIncome_pn3n3_c20200101__20201231_zLkNeA3LKiB4" title="Less grants" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ORGS:GrantsIncome" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">196</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--GrantsIncome_pn3n3_c20190101__20191231_zWqsZuYCF5S3" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ORGS:GrantsIncome" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">812</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231_pn3n3" title="COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83,986</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20191231_pn3n3" title="COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,014</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A6_zBvXs2JHb9gf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:FinancialExpensesNetTextBlock"><p id="xdx_806_ecustom--FinancialExpensesNetTextBlock_zzoFwE69I6Xb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
19 &#8211; <span id="xdx_82C_zutiiOuEq0C3">FINANCIAL EXPENSES, NET</span></b></span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:ScheduleOfFinancialExpensesTableTextBlock"><p id="xdx_89B_ecustom--ScheduleOfFinancialExpensesTableTextBlock_zn2kLRrF00z3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B8_zNbPtYGts483" style="display: none">SCHEDULE OF FINANCIAL EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20200101_20201231" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20190101_20191231" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_40B_ecustom--IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue_maTFEzElv_zsM3s6BwG0hi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Increase in fair value of warrants and financial liabilities measured at fair value</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2984">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="ORGS:IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">63</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--InterestExpenseOnConvertibleLoans_maTFEzElv_zsyyLXxCWzI" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense on convertible loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:InterestExpenseOnConvertibleLoans" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,254</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:InterestExpenseOnConvertibleLoans" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">498</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--ForeignCurrencyTransactionsGainLossRealized_pn3n3_maTFEzElv_zBTjU4qtGp5a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign exchange loss, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:ForeignCurrencyTransactionsGainLossRealized" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">160</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ORGS:ForeignCurrencyTransactionsGainLossRealized" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">395</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OtherIncome_iN_pn3n3_di_msTFEzElv_zVEnpzdXTn2c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherIncome" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">353</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherIncome" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">113</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr id="xdx_402_ecustom--TotalFinancialExpenses_iT_mtTFEzElv_zqPwqivVUB6c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ORGS:TotalFinancialExpenses" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,061</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ORGS:TotalFinancialExpenses" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">843</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A6_zKCcIilTYR59" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80A_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zmDO0XMqZorh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
20 &#8211; <span id="xdx_820_zciW7f3HFWe7">RELATED PARTIES TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>a.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Related
    Parties presented in the consolidated statements of comprehensive loss</span></i></span></td></tr>
</table>
<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_z0I8RBOqbpe4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_z38wGFN32fS9" style="display: none">SCHEDULE OF RELATED PARTY TRANSACTIONS</span></span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold">(in thousands)</td><td style="font-size: 11pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Continuing operations:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left; padding-bottom: 2.5pt">Stock-based compensation expenses to executive officers</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_pn3n3" title="Stock Based Compensation" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-12-31_us-gaap_SegmentContinuingOperationsMember_srt_ExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">221</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zScrlX5LwUYc" title="Stock Based Compensation" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-012019-12-31_us-gaap_SegmentContinuingOperationsMember_srt_ExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">898</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F4D_zDj1uemAftSe" style="text-align: left; padding-bottom: 2.5pt">Stock-based compensation expenses to Board Members*</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_fKg_____z5oDhlnYaApj" title="Stock Based Compensation" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-12-31_custom_BoardMembersMember_us-gaap_SegmentContinuingOperationsMember" id="Fact003007" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">209</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember_fKg_____zbufEPXtHTL9" title="Stock Based Compensation" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-012019-12-31_us-gaap_SegmentContinuingOperationsMember_custom_BoardMembersMember" id="Fact003009" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">414</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Compensation of executive officers</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--OfficersCompensation_pn3n3_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zeXQ9O2OeORf" title="Compensation" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2020-01-012020-12-31_us-gaap_SegmentContinuingOperationsMember_srt_ExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,321</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--OfficersCompensation_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zDt1hvYywZ2a" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2019-01-012019-12-31_us-gaap_SegmentContinuingOperationsMember_srt_ExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">812</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Management and consulting fees to Board Members</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pn3n3" title="Management and consulting fees" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2020-01-012020-12-31_custom_BoardMembersMember_us-gaap_SegmentContinuingOperationsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">264</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember_zZ5ZrtfncJ67" title="Management and consulting fees" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2019-01-012019-12-31_us-gaap_SegmentContinuingOperationsMember_custom_BoardMembersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">233</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Revenues from customer</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromRelatedParties_pn3n3_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zWmRrjlj5Fk2" title="Revenues from customer" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromRelatedParties" contextRef="From2020-01-012020-12-31_us-gaap_SegmentContinuingOperationsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,475</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromRelatedParties_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_z3S6kt0Y6JN8" title="Revenues from customer" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromRelatedParties" contextRef="From2019-01-012019-12-31_us-gaap_SegmentContinuingOperationsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,270</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Cost of research and development and research and development services, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet_pn3n3_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zMEkarZwPlOh" title="Cost of research and development and research and development services, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ORGS:CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" contextRef="From2020-01-012020-12-31_us-gaap_SegmentContinuingOperationsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,772</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pn3n3" title="Cost of research and development and research and development services, net" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3024">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Financial income</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--FinancialIncome_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pn3n3" title="Financial income" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ORGS:FinancialIncome" contextRef="From2020-01-012020-12-31_us-gaap_SegmentContinuingOperationsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">169</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--FinancialIncome_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pn3n3" title="Financial income" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ORGS:FinancialIncome" contextRef="From2019-01-012019-12-31_us-gaap_SegmentContinuingOperationsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td id="xdx_F08_zUmcncmQEk2b" style="width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td>
    <td style="width: 95%"><span id="xdx_F14_zdm5QhoDOrPa" style="font: 10pt Times New Roman, Times, Serif"><ix:footnote id="Footnote003029" xml:lang="en-US">Does not include $<span id="xdx_904_eus-gaap--StockOptionPlanExpense_pn3n3_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaerusTherapeuticsLLCMember_zwN4HCMuUKA8" title="Stock Based Compensation expenses for options exercisable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEFURUQgUEFSVFkgVFJBTlNBQ1RJT05TIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="From2019-01-012019-12-31_custom_CaerusTherapeuticsLLCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">192</ix:nonFraction></span> thousand
    for the year ended December 31, 2019 related to Stock Based Compensation expenses for options exercisable at an exercise price
    of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaerusTherapeuticsLLCMember_pii" title="Exercise price per share of options exercisable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEFURUQgUEFSVFkgVFJBTlNBQ1RJT05TIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_custom_CaerusTherapeuticsLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.00</ix:nonFraction></span> per share into <span id="xdx_90F_ecustom--NumberOfOrdinarySharesHeld_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaerusTherapeuticsLLCMember_pii" title="Number of ordinary shares held" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEFURUQgUEFSVFkgVFJBTlNBQ1RJT05TIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="ORGS:NumberOfOrdinarySharesHeld" contextRef="From2019-01-012019-12-31_custom_CaerusTherapeuticsLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,000</ix:nonFraction></span> ordinary shares held by Caerus Therapeutics LLC for which the director does not have beneficial
    control.</ix:footnote></span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>


<ix:exclude><!-- Field: Page; Sequence: 133; Value: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Year ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">December 31,</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2019</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(in thousands)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Discontinued operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F46_zSsDanWIU0i8" style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left; padding-bottom: 2.5pt">Stock-based compensation expenses to executive officers</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_pn3n3" title="Stock Based Compensation" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-012019-12-31_us-gaap_SegmentDiscontinuedOperationsMember_srt_ExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">76</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Compensation of executive officers</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--OfficersCompensation_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_z3PQzKHltDNa" title="Compensation" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2019-01-012019-12-31_us-gaap_SegmentDiscontinuedOperationsMember_srt_ExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">685</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AE_zt0eY1Dvex6j" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Related
    Parties presented in the consolidated balance sheets</span></i></span></td></tr>
</table>
<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="ORGS:ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock_z4a2KVSbG4S7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BC_zMe02VSe5zki" style="display: none">SCHEDULE OF RELATED PARTIES PRESENTED IN CONSOLIDATED BALANCE SHEETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Continuing operations:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left; padding-bottom: 2.5pt">Executive officers&#8217; payables</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_c20201231__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zKL8yC3duZL5" title="Due to Related Parties" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2020-12-31_srt_ExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">170</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_c20191231__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_pn3n3" title="Due to Related Parties" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2019-12-31_srt_ExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,251</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Non-executive directors&#8217; payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_c20201231__us-gaap--RelatedPartyTransactionAxis__custom--NonexecutiveDirectorsMember_zY02Lb952nXi" title="Due to Related Parties" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2020-12-31_custom_NonexecutiveDirectorsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_c20191231__us-gaap--RelatedPartyTransactionAxis__custom--NonexecutiveDirectorsMember_zN7cd3dfFGGj" title="Due to Related Parties" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2019-12-31_custom_NonexecutiveDirectorsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">202</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F4F_zU60oWJU4a1j" style="text-align: left; padding-bottom: 2.5pt">Loan to Related Party </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--DueFromRelatedPartiesNoncurrent1_iI_pn3n3_c20201231_fKg_____zEKOY0rnIym3" title="Loan to related party" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3051">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--DueFromRelatedPartiesNoncurrent1_iI_pn3n3_c20191231_fKg_____zQFt3aaF0ufj" title="Loan to related party" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ORGS:DueFromRelatedPartiesNoncurrent1" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,623</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Accounts receivable, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AccountsReceivableNet_c20201231_pn3n3" title="Accounts receivable, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">744</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AccountsReceivableNet_c20191231_pn3n3" title="Accounts receivable, net" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3057">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Contract liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ContractWithCustomerLiability_c20201231_pn3n3" title="Contract liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3059">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ContractWithCustomerLiability_c20191231_pn3n3" title="Contract liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">230</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AB_zgA9qYDvZ32e" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0"></p>


<ix:exclude><!-- Field: Page; Sequence: 134; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</ix:nonNumeric></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.45
<SEQUENCE>2
<FILENAME>ex10-45.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.45</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>EXECUTIVE
DIRECTORSHIP AGREEMENT</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Executive Directorship Agreement (the &ldquo;<B><U>Agreement</U></B>&rdquo;) is made and entered into as of November 19, 2020,
by and between Orgenesis Inc., a Nevada corporation (&ldquo;<B><U>Company</U></B>&rdquo;) and Vered Caplan (&ldquo;<B><U>Director</U></B>&rdquo;
or &ldquo;<B><U>Chairperson</U></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS,
</B>Director and Company are currently parties to an Executive Employment Agreement dated March 30, 2017 (the &ldquo;<B><U>Prior
Agreement</U></B>&rdquo;), pursuant to which Director serves on behalf of the Company as (i) Chairperson of the Board of Directors,
(ii) Chief Executive Officer, and (iii) President;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
Company and Director desire to enter into this Agreement pursuant to which Director will continue to serve as Chairperson of the
Board of Directors of the Company (the &ldquo;<B><U>Board</U></B>&rdquo;); and,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
this Agreement will supersede and replace in its entirety the Prior Agreement (and any related secondment or similar agreements
Director entered into while the Prior Agreement was in effect), and as a result the Prior Agreement (and any related secondment
or similar agreements Director entered into while the Prior Agreement was in effect), shall be of no further force or effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B>, in consideration of the mutual promises, terms, provisions, and conditions contained herein, the parties agree
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Roles
                                         and Duties</U><FONT STYLE="font-weight: normal">.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Chairperson
                                         of the Board of Directors</U>. Subject to the terms and conditions of this Agreement,
                                         Company shall continue to appoint Director as its Chairperson of the Board.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Duties</U>.
                                         The duties and responsibilities of Director shall include the duties and responsibilities
                                         for the position as Chairperson as set forth in the Company&rsquo;s bylaws, and such
                                         other duties and responsibilities as the Board may from time to time reasonably assign
                                         to Director.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Classification</U>.
                                         Director in her capacity of Chairperson of the Board shall be classified as an independent
                                         contractor of the Company for Federal income tax purposes.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
                                         Conflicting Obligation</U>. Director represents and warrants to Company that she is under
                                         no obligations or commitments, whether contractual or otherwise, that are inconsistent
                                         with her obligations under this Agreement.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Chairperson
                                         Term and Termination</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Term</U>.
                                         This Agreement shall be in effect commencing as of October __, 2020 (the &ldquo;<B><U>Commencement
                                         Date</U></B>&rdquo;) and shall continue in full force and effect until terminated pursuant
                                         to the terms hereof.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Termination</U>.
                                         Director&rsquo;s appointment as Chairperson may be terminated by either party, at any
                                         time, pursuant to the delivery of ninety (90) days prior written notice (the &ldquo;<B><U>Notice
                                         Period</U></B>&rdquo;); provided however, if Company terminates Director as the Chairperson
                                         of the Board but she remains as a regular Director, such termination of only the Chairperson
                                         position shall nonetheless be treated as a termination event under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                         the Notice Period and unless otherwise determined by Company, Director shall continue
                                         to perform her duties as Chairperson until the conclusion of the Notice Period, and cooperate
                                         with the Company in assisting the integration of the person who will assume Chairperson&rsquo;s
                                         responsibilities.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
                                         the aforementioned, Company shall have the right not to take advantage of the full Notice
                                         Period and may terminate Director&rsquo;s appointment as the Chairperson at any time
                                         during the Notice Period (regardless of whether notice of termination was delivered by
                                         the Company or whether such notice was delivered by Director). In the event of such termination,
                                         Company shall pay Director her Chairperson level Board fees due to her hereunder as she
                                         would have been entitled to receive for the remaining period of the Notice Period.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
                                         Upon Termination:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">a.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                         the purposes of this Agreement, <B>&ldquo;Accrued Obligations&rdquo;</B> means: (i) the
                                         portion of Director&rsquo;s fee that has accrued, prior to the end of the present Agreement
                                         and has not yet been paid or compensated; and (ii) the amount of any expenses properly
                                         incurred by Director on behalf of Company prior to the end of the present Agreement and
                                         not yet reimbursed. Director&rsquo;s entitlement to any other compensation or benefit
                                         under any plan of Company shall be governed by and determined in accordance with the
                                         terms of such plans, except as otherwise specified in this Agreement.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">b.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                         used herein, a <B>&ldquo;Change of Control&rdquo;</B> shall mean the occurrence of any
                                         of the following events: (A) The approval by shareholders of the Company of a merger
                                         or consolidation of the Company with any other corporation, other than a merger or consolidation
                                         which would result in the voting securities of the Company outstanding immediately prior
                                         thereto continuing to represent (either by remaining outstanding or by being converted
                                         into voting securities of the surviving entity) more than fifty percent (50%) of the
                                         total voting power represented by the voting securities of the Company or such surviving
                                         entity outstanding immediately after such merger or consolidation; or (B). The approval
                                         by the shareholders of the Company of a plan of complete liquidation of the Company or
                                         an agreement for the sale or disposition by the Company of all or substantially all of
                                         the Company&rsquo;s assets.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">c.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                         the event of termination of this Agreement by Company other than for cause or by Director
                                         for any reason whatsoever, Director shall be entitled to receive, in addition to the
                                         Accrued Obligations, a lump sum payment equal to the sum of (x) Director&rsquo;s annual
                                         regular Board fee at the rate in effect as of the termination date (i.e., as of the last
                                         day of the Notice Period), and (y) the greater of actual or target annual performance
                                         bonus if so approved by the compensation committee to which Director may have been entitled
                                         as of the termination date (i.e., as of the last day of the Notice Period), in each case
                                         less all customary and required taxes and related deductions.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">d.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                         the event that a Change of Control (as defined above) occurs and that, within a period
                                         of one (1) year following the Change of Control, then this Agreement is terminated either
                                         by Company other than for cause, or by Director for any reason whatsoever, then, in addition
                                         to the Accrued Obligations, Director shall receive a lump sum payment equal to one and
                                         a half times the sum of (x) Director&rsquo;s annual regular Board fee at the rate in
                                         effect as of the termination date (i.e., as of the last day of the Notice Period), and
                                         (y) the target annual performance remuneration to which Director may have been entitled
                                         as of the termination date (i.e., as of the last day of the Notice Period), in each case
                                         less all customary and required taxes and related deductions as approved by the compensation
                                         committee.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compensation</U><FONT STYLE="font-weight: normal">.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Board
                                         Fees</U>. Director shall receive in consideration for her serving as Chairperson of the
                                         Board an annual regular Board fee in the amount of $75,000 payable by Company in equal
                                         quarterly installments in advance. In addition, Director may be eligible for non-recurring
                                         special Board fees as reviewed and approved by Company&rsquo;s Compensation Committee
                                         and then reviewed and ratified by the Board.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Reimbursement
                                         of Expenses</U>. Company shall reimburse Director for all ordinary and reasonable out-of-pocket
                                         business expenses incurred by Director in furtherance of the Board&rsquo;s business in
                                         accordance with Company&rsquo;s policies with respect thereto as in effect from time
                                         to time. Director must submit any request for reimbursement no later than ninety (90)
                                         days following the date that such business expense is incurred.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Stock
                                         Options</U>. Director may be granted options awards from time to time, as per the discretion
                                         of the compensation committee of Company.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Miscellaneous
                                         Provisions</U><FONT STYLE="font-weight: normal">.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notice</U>.
                                         Notices and all other communications contemplated by this Agreement shall be in writing
                                         and shall be deemed to have been duly given when personally delivered or when mailed
                                         by U.S. registered or certified mail, return receipt requested and postage prepaid. In
                                         the case of Director, mailed notices shall be addressed to her at the home address, which
                                         she most recently communicated to Company in writing. In the case of Company, mailed
                                         notices shall be addressed to its corporate headquarters, and all notices shall be directed
                                         to the attention of its Secretary.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Modifications
                                         and Waivers</U>. No provision of this Agreement shall be modified, waived or discharged
                                         unless the modification, waiver or discharge is agreed to in writing and signed by Director
                                         and by an authorized officer of the Company (other than Director). No waiver by either
                                         party of any breach of, or of compliance with, any condition or provision of this Agreement
                                         by the other party shall be considered a waiver of any other condition or provision or
                                         of the same condition or provision at another time.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Whole
                                         Agreement</U>. This Agreement contains the entire understanding of the parties with respect
                                         to the subject matter hereof. No other agreements, representations or understandings
                                         (whether oral or written and whether express or implied) which are not expressly set
                                         forth in such agreements have been made or entered into by either party with respect
                                         to the subject matter hereof.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Withholding
                                         Taxes</U>. All payments made under this Agreement shall be subject to reduction to reflect
                                         taxes or other charges required to be withheld by law.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Choice
                                         of Law and Severability</U>. This Agreement shall be interpreted in accordance with the
                                         laws of the State of Nevada. If any provision of this Agreement becomes or is deemed
                                         invalid, illegal or unenforceable in any jurisdiction by reason of the scope, extent
                                         or duration of its coverage, then such provision shall be deemed amended to the extent
                                         necessary to conform to applicable law so as to be valid and enforceable or, if such
                                         provision cannot be so amended without materially altering the intention of the parties,
                                         then such provision shall be stricken and the remainder of this Agreement shall continue
                                         in full force and effect. Should there ever occur any conflict between any provision
                                         contained in this Agreement and any present or future statute, law, ordinance or regulation
                                         contrary to which the parties have no legal right to contract, then the latter shall
                                         prevail but the provision of this Agreement affected thereby shall be curtailed and limited
                                         only to the extent necessary to bring it into compliance with applicable law. All the
                                         other terms and provisions of this Agreement shall continue in full force and effect
                                         without impairment or limitation. To the extent applicable, the payments under this Agreement
                                         are intended to be exempt from the application of, or to comply with the requirements
                                         of, Section 409A and Section 457A of the Internal Revenue Code of 1986, as amended, and
                                         to the extent permitted this Agreement, and any ambiguity herein, shall be interpreted,
                                         construed and administered in accordance with such intent.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Arbitration</U>.
                                         Any controversy or claim arising out of or relating to this Agreement or the breach thereof,
                                         or the Director&rsquo;s appointment as Chairperson or the termination thereof, shall
                                         be settled in New York, New York, by arbitration in accordance with the National Rules
                                         of the American Arbitration Association. The decision of the arbitrator shall be final
                                         and binding on the parties, and judgment on the award rendered by the arbitrator may
                                         be entered in any court having jurisdiction thereof. The parties hereby agree that the
                                         arbitrator shall be empowered to enter an equitable decree mandating specific enforcement
                                         of the terms of this Agreement. Company and the Director shall share equally all fees
                                         and expenses of the arbitrator. Director hereby consents to personal jurisdiction of
                                         the state and federal courts located in the State of New York for any action or proceeding
                                         arising from or relating to this Agreement or relating to any arbitration in which the
                                         parties are participants.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Counterparts</U>.
                                         This Agreement may be executed in two or more counterparts, each of which shall be deemed
                                         an original, but all of which together shall constitute one and the same instrument.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Signature
Page to Follow]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">VERED CAPLAN</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ORGENESIS INC</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 38%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.46
<SEQUENCE>3
<FILENAME>ex10-46.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.46</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>PERSONAL
EMPLOYMENT AGREEMENT</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 78.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
AGREEMENT </B>(&ldquo;<B>Agreement</B>&rdquo;) is made and entered into November 19, 2020 and is effective as of October 1, 2020
(&ldquo;<B>Effective Date</B>&rdquo;), by and between Orgenesis Services S&agrave;rl, a Swiss corporation (the &ldquo;<B>Company</B>&rdquo;),
and <B>Vered Caplan </B>(the &ldquo;<B>Employee</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS,
</B>the Company is a wholly-owned, direct subsidiary of Orgenesis, Inc. (&ldquo;<B>Parent</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS,
</B>it is intended that the Company will enter into a services agreement with Parent to provide strategic services to the Parent
pursuant to a Services Agreement dated as of November 10, 2020; (&ldquo;<B>Services Agreement</B>&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS,
</B>Employee will be a material provider of services in the Services Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS,
</B>the Employee, pursuant to a separate appointment by the Parent, will continue as the Chairperson and a member of the board
of directors of Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B>, in consideration of the mutual premises, covenants and undertakings contained herein, the parties hereto have hereby
agreed as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Employment,
                                         Position And Duties.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 32.9pt; text-align: justify; text-indent: -32.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.65in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Position</U>.
                                         Effective as of October 1, 2020 (the &ldquo;<B>Start Date</B>&rdquo;), the Employee will
                                         serve as the Chief Executive Officer (&ldquo;<B>CEO</B>&rdquo;) and President of the
                                         Company and, in such other related capacity as the Company may from time to time reasonably
                                         require. The Employee will also continue to serve as the Chairperson of the Board of
                                         Directors of the Company (the &ldquo;<B>Company Board</B>&rdquo;).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Duties</U>.
                                         The Employee will perform such duties as are regularly and customarily performed by the
                                         CEO and President of a company, including but not limited to, being accountable and responsible
                                         for overall direction, strategy, research, development and operations of the Company,
                                         including fundraising and regulatory compliance.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Location</U>.
                                         The Employee will carry out her work from her home office in Switzerland or out of the
                                         offices of the Company in Switzerland, at her discretion. The Employee acknowledges that
                                         she may be required to travel in connection with the performance her duties for the Company
                                         and in her capacity as Chairperson of Parent.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Reporting</U>.
                                         The Employee shall take directions from the Company&rsquo;s Board.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Time
                                         and Efforts</U>. During the Employee&rsquo;s employment with the Company, the Employee
                                         will:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 79.35pt; text-align: justify; text-indent: -32.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diligently,
                                         honestly and faithfully serve the Company and use her best efforts to promote and advance
                                         the interests of the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">devote
                                         significant time and effort and attention to the business and affairs of the Company
                                         and its affiliates and subsidiaries; and,</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">perform
                                         her duties in accordance with applicable laws and in accordance with the policies and
                                         procedures of the Company as the same may be established and revised by the Company from
                                         time to time.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 120.7pt; text-align: justify; text-indent: -41.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 12.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remuneration,
                                         Expenses And Other Benefits</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.65in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Salary</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                         fulfilment of the Employee&rsquo;s obligations as CEO and President of the Company under
                                         this Agreement, commencing October 1, 2020, the Company shall pay the Employee a gross
                                         monthly salary of CHF 13,345.05 (the &ldquo;<B>Base Salary</B>&rdquo;), payable in accordance
                                         with the Company&rsquo;s payroll practices, but in no event less frequently than monthly.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee acknowledges that the Base Salary includes all compensation for overtime. Thus,
                                         no overtime shall be paid or compensated.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee agrees and acknowledges that her position is one that requires a special measure
                                         of personal trust and loyalty and constitutes a high leadership position according to
                                         Article 3 <I>lit</I>. d of the Swiss Federal Act of March 13, 1964 on Work in Industry,
                                         Trade and Commerce (<B>LTr</B>).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                         employment relationship in the Company is built on trust and on work during flexible
                                         hours. According to this principle, the Employee&rsquo;s work and rest hours are determined
                                         according to the Company&rsquo;s needs, taking into consideration the Employee&rsquo;s
                                         needs and the needs of the Company. Therefore, insofar as this shall be required by virtue
                                         of work needs, the Employee shall be expected to be available to the Company also during
                                         irregular and exceptional hours, beyond the normal workday in Company.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Base Salary includes the last cost of living allowance that has been paid before signing
                                         this Agreement. The Base Salary shall be updated according to the cost of living allowance
                                         that shall be in force from time to time, and it shall be paid to the Employee not later
                                         than the ninth day of each month, for the previous month.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 114pt; text-align: justify; text-indent: -41.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.65in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representation
                                         fees</U>. The Company will pay Employee CHF 24,000 annual representation fees in monthly
                                         instalments of CHF 2,000 per month.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Pension
                                         plan</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 76.65pt; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                         the work performed for the Company, the Employee shall participate in the Company&rsquo;s
                                         pension plan. The contributions and the benefits are determined by the rules and regulations
                                         of the pension plan, as amended from time to time. The Employee&rsquo;s contributions
                                         are deducted by the Company from the gross Salary.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.65in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Cellular
                                         Phone and Internet Services</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 76.65pt; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Company shall provide the Employee with a cellular phone (the &ldquo;<B>Cellular Phone</B>&rdquo;)
                                         to be placed at the Employee&rsquo;s disposal for her use in the course of performing
                                         her obligations under this Agreement, provided that the Company&rsquo;s procedures in
                                         respect thereof are followed.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee shall return the Cellular Phone (together with any other equipment supplied)
                                         to the Company&rsquo;s principal office upon termination of her employment under this
                                         Agreement. The Employee shall have no property rights with respect to the Cellular Phone
                                         and/or any of said other equipment.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee shall bear any taxes levied in connection with the Cellular Phone and/or the
                                         use thereof.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Company shall pay for internet services provided to the Employee for her home computer.
                                         The Employee shall bear any taxes that may be levied in connection therewith.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 114pt; text-align: justify; text-indent: -41.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.65in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Travel
                                         allowance</U>. The Company shall provide the Employee with a travel allowance of CHF
                                         1,200 per month, which shall be paid monthly in accordance with the Company&rsquo;s payroll
                                         practices.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Stock
                                         Options</U>. The Employee may be granted options awards from time to time, as per the
                                         discretion of the compensation committee of Parent.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Bonus</U>.
                                         Any bonus payable to the Employee for any year is at the absolute discretion of the Company
                                         and its compensation committee. In particular, the eligibility criteria as well as any
                                         payment under the bonus plan, if applicable, will be determined by the Company and its
                                         compensation committee at their absolute discretion. The Company may modify or repeal
                                         the discretionary bonus plan, if applicable, at its discretion at any time. Furthermore,
                                         any bonus payment for one or more years does not grant a right to any future bonuses.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Expenses</U>.
                                         The Company will reimburse the Employee for expenses reasonably and properly incurred
                                         by her in the performance of her duties and responsibilities under this Agreement, in
                                         accordance with a budget that will be pre-approved.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Vacation</U>.
                                         The Employee will be entitled to five (5) weeks paid vacation each calendar year to be
                                         taken at such time or times as the Employee may select and as the Company Board may reasonably
                                         approve, having regard to the business affairs and operations of the Company.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Indemnity
                                         and D&amp;O Insurance</U>. The Company agrees to arrange to allow the Employee to benefit
                                         from any director and officer liability insurance coverage policy carried by either of
                                         them. In addition, the Company shall provide Employee with an indemnification agreement
                                         at least as favorable as those provided to other senior executive officers and directors
                                         of Parent.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Employment
                                         Period and Termination Thereof.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.65in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee&rsquo;s employment by the Company shall commence on the date specified in this
                                         Agreement, and shall not be limited in time.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee&rsquo;s employment may be terminated by either party subject to the delivery
                                         of prior written notice by the terminating party, as follows: (i) at least six (6) months
                                         in advance if the termination is by the the Employee for any reason or by the Company
                                         other than for just cause according to Article 337 Swiss Code of Obligations (<B>SCO</B>)
                                         as described in Appendix A hereto &ldquo;Just Cause&rdquo;); and (ii) at least twelve
                                         (12) months in advance, if termination is by the Company following a Change of Control
                                         (as defined below) other than for Just Cause and (iii) on the day of termination if the
                                         termination is for Just Cause (the &ldquo;<B>Notice Period</B>&rdquo;).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         provisions of Section 2 of <B>Appendix A </B>attached hereto shall apply to the terms
                                         of termination of Employee&rsquo;s employment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 70.9pt; text-align: justify; text-indent: -21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Social
                                         Security Contributions.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Employee and the Company shall each pay half of the contributions, which are owed as a matter of law for AVS (Old Age and Survivors&rsquo;
Insurance), AI (Invalidity Insurance), APG (Loss of Earnings Insurance), AC (Unemployment Insurance). The Employee&rsquo;s contributions
are deducted by the Company from the gross Salary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Sick
                                         Leave</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case the Employee is unable to perform her duties under this Agreement due to illness, the Company&rsquo;s obligation to continue
to pay the Employee&rsquo;s salary is determined by Article 324<I>a</I> of the SCO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 42.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Payments
                                         upon Termination.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.65in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Definition
                                         of Accrued Obligations</U>. For the purposes of this Agreement, &ldquo;<B>Accrued Obligations</B>&rdquo;
                                         means: (i) the portion of the Employee&rsquo;s Base Salary that has accrued, including
                                         vacation time, prior to the end of the present Agreement and has not yet been paid or
                                         compensated; and (ii) the amount of any expenses properly incurred by the Employee on
                                         behalf of the Company prior to the end of the present Agreement and not yet reimbursed.
                                         The Employee&rsquo;s entitlement to any other compensation or benefit under any plan
                                         of the Company shall be governed by and determined in accordance with the terms of such
                                         plans, except as otherwise specified in this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.65in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Definition
                                         of Change of Control</U>. As used herein, a &ldquo;<B>Change of Control</B>&rdquo; shall
                                         mean the occurrence of any of the following events: (A) The approval by shareholders
                                         of the Parent of a merger or consolidation of the Parent with any other corporation,
                                         other than a merger or consolidation which would result in the voting securities of the
                                         Parent outstanding immediately prior thereto continuing to represent (either by remaining
                                         outstanding or by being converted into voting securities of the surviving entity) more
                                         than fifty percent (50%) of the total voting power represented by the voting securities
                                         of the Parent or such surviving entity outstanding immediately after such merger or consolidation;
                                         or (B) The approval by the shareholders of the Parent of a plan of complete liquidation
                                         of the Parent or an agreement for the sale or disposition by the Parent of all or substantially
                                         all of the Parent&rsquo;s assets.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Severance
                                         Payment in the Case of Termination by Company Without Cause or by the Employee</U>. In
                                         the event of termination of this Agreement by the Company other than for cause or by
                                         the Employee for any reason whatsoever, the Employee shall be entitled to receive, in
                                         addition to the Accrued Obligations, a lump sum payment equal to the sum of (x) the Employee&rsquo;s
                                         annual Base Salary at the rate in effect as of the termination date, and (y) the greater
                                         of actual or target Annual Performance Bonus to which the Employee may have been entitled
                                         for the year in which the Employee&rsquo;s employment terminates, in each case less all
                                         customary and required taxes and employment-related deductions and subject to the terms
                                         and conditions described in Section 6.5 (including the Employee&rsquo;s execution of
                                         a release of claims).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Severance
                                         Payment in the Case of Termination by Company Without Cause or by the Employee Following
                                         a Change of Control</U>. In the event that a Change of Control (as defined in Section
                                         6.2) occurs and that, within a period of one (1) year following the Change of Control,
                                         the present Agreement is terminated either by the Company other than for cause, or by
                                         the Employee for any reason whatsoever, then, in addition to the Accrued Obligations,
                                         the Employee shall receive a lump sum payment equal to one and a half times the sum of
                                         (x) the Employee&rsquo;s annual Base Salary at the rate in effect as of the termination
                                         date, and (y) the target Annual Performance Bonus to which the Employee may have been
                                         entitled for the year in which the Employee&rsquo;s employment terminates, in each case
                                         less all customary and required taxes and employment-related deductions and subject to
                                         the terms and conditions described in Section 6.5 (including the Employee&rsquo;s execution
                                         of a release of claims).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Execution
                                         of Release of Claims</U>. The Company shall not be obligated to pay the Employee any
                                         of the severance payments under Sections 6.3 and 6.4 unless and until the Employee has
                                         executed (without revocation) a timely release of claims in a form that is acceptable
                                         to the Company, and which includes standard and reasonable terms regarding items such
                                         as mutual non-disparagement, confidentiality, cooperation and the like, which must be
                                         provided to the Employee after thirty (30) days following separation from service, and
                                         must be effective and irrevocable prior to the 60th day following the Employee&rsquo;s
                                         separation from service (the &ldquo;<B>Review Period</B>&rdquo;), and which shall include
                                         a general release of claims against Company and its affiliated entities and each of their
                                         officers, directors, employees and others associated with the Company and its affiliated
                                         entities. If the Employee fails or refuses to return such agreement, or revokes the agreement,
                                         within the Review Period, the Employee&rsquo;s severance payments hereunder and benefits
                                         shall be forfeited.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Confidentiality,
                                         Non-Competition, Non-solicitation and Intellectual Property.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49.65pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee hereby declares that she is obliged to the provisions of the Confidentiality,
                                         Non-Competition, Non-solicitation and Assignment of Intellectual Property clause, as
                                         described in Section 3 of Appendix A attached hereto.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                         addition to the terms and conditions specified above, the other terms and conditions
                                         of the Employee&rsquo;s employment shall be in accordance with the provisions of Appendix
                                         A attached hereto, and the policies of the Company, as may be amended from time to time.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 70.9pt; text-align: justify; text-indent: -21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>General.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49.65pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 21.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Amendment</U>.
                                         No provision in this Agreement may be amended unless such amendment is agreed to in writing
                                         and signed by the Employee and an authorized officer of the Company.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compliance
                                         with Policies and Laws</U>. The Employee agrees to abide by all the policies and procedures,
                                         including without limitation, the code of conduct the Company. The Employee also agrees
                                         to abide by all laws applicable to the Company, in each jurisdiction in which the aforementioned
                                         do business.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Governing
                                         Law and Venue</U>. This Agreement and all rights and duties of the parties hereunder
                                         shall be exclusively governed by and interpreted in accordance with the laws of Switzerland.
                                         The competent courts of Lausanne, canton of Vaud, Switzerland, shall have the exclusive
                                         jurisdiction over the parties with regard to this Agreement, its execution, interpretation
                                         and performance.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notices</U>.
                                         Any notice given or required to be given under this Agreement will be in writing and
                                         signed by or on behalf of the party giving it. Such notice may be served personally and
                                         in either case may be sent by priority post to the addresses of the parties noted on
                                         page one of this Agreement, or by fax, email or other electronic transmission. Any notice
                                         served personally will be deemed served immediately, and if mailed by priority post will
                                         be deemed served seventy two (72) hours after the time of posting, and if by electronic
                                         transmission, upon successful transmission.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Severability</U>.
                                         If any provision contained herein is determined to be void or unenforceable for any reason,
                                         in whole or in part, it will not be deemed to affect or impair the validity of any other
                                         provision contained herein and the remaining provisions will remain in full force and
                                         effect to the fullest extent permissible by law.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Assignment
                                         of Rights. </U>The Company will have the right to assign this Agreement to another party.
                                         The Employee shall not assign the Employees rights under this Agreement or delegate to
                                         others any of the Employees&rsquo; functions and duties under this Agreement, without
                                         the prior express written consent of the Company, which consent may be withheld at the
                                         sole discretion of the Company.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.7.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Entire
                                         Agreement</U>. This Agreement contains the entire understanding and agreement between
                                         the parties concerning the subject matter hereof and supersedes all prior agreements,
                                         understandings, discussions, negotiations and undertakings, whether written or oral,
                                         between the parties with respect thereto.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.8.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Headings</U>.
                                         The headings contained herein are for reference purposes only and will not in any way
                                         affect the construction or interpretation of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
page to follow.]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INTENDING
TO BE LEGALLY BOUND</B>, the parties hereunto have signed this Agreement as of the November 19, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 13.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
ORGENESIS SERVICES SARL</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>__________________________</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
<U>[NAME]</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized
Signatory</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
[TITLE]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 13.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNED
by <B>VERED CAPLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 13.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>__________________________</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 13.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>APPENDIX
A TO PERSONAL EMPLOYMENT AGREEMENT</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 79.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>General</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 78.35pt; text-align: justify; text-indent: -39.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">                                                                                                                                                                                                                                                                                                                                                                                                                              <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                         agreement constitutes an integral part of the personal employment agreement dated October
                                         1, 2020 between Ms. Vered Caplan (the &ldquo;<B>Employee</B>&rdquo;) and Orgenesis Services
                                         S&agrave;rl (the &ldquo;<B>Company</B>&rdquo;) (the &ldquo;<B>Agreement</B>&rdquo;).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee warrants, confirms and undertakes that she is entitled to enter into this Agreement
                                         and to assume all the obligations pursuant hereto, that there is no contractual or other
                                         impediment to her entering into this Agreement.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee hereby warrants that she has no medical or other problems, which might prevent
                                         her from performing her obligations to work for the Company. The Employee shall notify
                                         the Company of any change in her state of health.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 112.15pt; text-align: justify; text-indent: -32.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Employment
                                         Period and Termination Thereof</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 78.35pt; text-align: justify; text-indent: -39.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                         the Notice Period as described in Section 3 of the Agreement, the Employee shall continue
                                         to render services to the Company until the end of the Notice Period, unless otherwise
                                         instructed by the Company. Nevertheless, the Company shall have the right to put the
                                         Employee on garden leave at any time during the Notice Period. In the event of such termination,
                                         the Company shall pay the Employee her Salary during the remainder of the Notice Period.
                                         If the Employee is put on garden leave, she shall continue to provide her services to
                                         the extent deemed necessary by the Company to ensure a smooth transition of her duties
                                         and continuation of the Company&rsquo;s activities. Any severance due the Employee following
                                         or upon the termination of employment shall be due following the expiration of the applicable
                                         Notice Period.</FONT></TD></TR>                                                                                                                                                                                                                        <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                         the avoidance of any doubt, it is hereby expressed that the Company reserves this right
                                         in both the event the notice of termination of employment was delivered by it or in the
                                         event that it was delivered by the Employee, and a latter case shall not constitute a
                                         dismissal of employment by the Company.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
                                         the foregoing, the Company may also terminate the employment without notice for just
                                         cause according to Article 337 SCO. Just cause exists in particular in, but not limited
                                         to, the case of a breach of her fiduciary duty by the Employee, including but not limited
                                         to a commission of a felonious crime connected with her employment and/or in the case
                                         of a breach of her obligations regarding confidentiality, non-competition and intellectual
                                         property, as defined in Section 3 henceforth.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 112.15pt; text-align: justify; text-indent: -32.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee undertakes that immediately upon the termination of her employment with the
                                         Company (which is effective immediately following the expiration of the applicable Notice
                                         Period), for any reason, or prior thereto, as per the Company&rsquo;s instructions, she
                                         shall act as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 112.15pt; text-align: justify; text-indent: -32.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">She
                                         shall deliver and/or return to the Company all the documents, diskettes or other magnetic
                                         media, letters, notes, reports and other papers in her possession and relating to her
                                         employment with the Company, as well as any equipment and/or other property belonging
                                         to the Company which was placed at her disposal;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">She
                                         shall delete any information relating to the Company or its business from her personal
                                         computer, if any;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">She
                                         shall coordinate her resignation with the Company Board and shareholders of the Company
                                         according to the timetable determined by her supervisors, and she shall hand over her
                                         duties in an orderly fashion and in accordance with the Company procedures, the documents
                                         and all the other matters dealt with by her to whomever the Company instructs, and all
                                         to the satisfaction of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 144.95pt; text-align: justify; text-indent: -32.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Confidentiality,
                                         Non-Competition/Non-solicitation and Intellectual Property</U></B></FONT></TD></TR>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee warrants and undertakes that for as long as she is employed by the Company,
                                         and after the termination of such employment, for any reason, she shall maintain in complete
                                         confidence any matters that relate to the Company the affairs and/or business thereof,
                                         including regarding the terms and conditions of her employment pursuant to this Agreement,
                                         and that she shall not harm the goodwill or reputation of the Company and she agrees
                                         to the provisions of the confidentiality, non-competition, non- solicitation and intellectual
                                         property clauses as specified below.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee&rsquo;s obligations pursuant to this Section derive from her status and her
                                         position in the Company, along with all matters connected therewith, and the terms and
                                         conditions of the Employee&rsquo;s employment pursuant to this Agreement, including her
                                         Salary, have been determined in part, inter alia, in consideration of this undertaking
                                         and constitute sufficient consideration for her obligations hereunder.</FONT></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 78.35pt; text-align: justify; text-indent: -39.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">                                                                                                                                      <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Confidentiality</U></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee undertakes to maintain the Confidential Information (as defined below) of the
                                         Company, including its Parent and their affiliates, during the term of her employment
                                         with the Company and after the termination of such employment, for any reason.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
                                         derogating from the generality of the foregoing, the Employee hereby agrees that she
                                         shall not, directly or indirectly, disclose or transfer to any person or entity, at any
                                         time, either during or subsequent to her employment period, any trade secrets or other
                                         confidential information, whether patentable or not, of the Company and/or Parent and/or
                                         their affiliates, including but not limited to, any (i) processes, formulas, trade secrets,
                                         innovations, inventions, discoveries, improvements, research or development and test
                                         results, survey, specifications, data and know-how; (ii) marketing plans, business plans,
                                         strategies, forecasts, unpublished financial information, budgets, projections, product
                                         plans and pricing; (iii) personnel information, including organizational structure, salary,
                                         and qualifications of Employees; (iv) customer and supplier information, including identities,
                                         product sales and purchase history or forecasts and agreements; and (v) any other information
                                         which is not known to the public (collectively, &ldquo;<B>Confidential Information</B>&rdquo;),
                                         of which the Employee is or becomes informed or aware during the employment period, whether
                                         or not developed by the Employee.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee undertakes not to directly or indirectly give and/or transfer, directly or indirectly,
                                         to any person or entity, any material and/or raw material and/or product and/or part
                                         of a product and/or model and/or document and/or diskette and/or other information storage
                                         media and/or photocopied and/or printed and/or duplicated object containing any or all
                                         of the Confidential Information.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee undertakes not to make any use, including duplication, production, sale, transfer,
                                         imitation and distribution, of all or any of the Confidential Information, without the
                                         prior written consent of the Company.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee will not use or disclose any confidential information or trade secrets, if any,
                                         of any former employer or any third party or any information in respect of which the
                                         Employee has confidentiality obligations, and will not bring onto the premises of the
                                         Company any such information, unless express written consent was provided by such former
                                         employer or third party.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                         the event the Employee is in breach of any of her above obligations, she shall be liable
                                         to indemnify, compensate and hold the Company harmless in respect of all damages and/or
                                         expenses incurred by the Company as a result of such breach, including trial costs and
                                         legal fees and applicable taxes, and such being without derogating from any other relief
                                         and/or remedy available to the Company by virtue of any law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 145pt; text-align: justify; text-indent: -32.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">3.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Non-Competition/
                                         Non-Solicitation</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 112.15pt; text-align: justify; text-indent: -26.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee undertakes that during the period of her employment with the Company and for
                                         a period of twelve (12) months after the termination thereof, for any reason, she shall
                                         not, anywhere in the world, do business, as an employee, independent contractor, consultant
                                         or otherwise, and shall not directly or indirectly participate in or accept any position,
                                         proposal or job offer that may directly or indirectly compete with or harm the Company,
                                         Parent, or their affiliates, or in the field in which the Company engages, is engaged
                                         or is about to engaged (the &ldquo;<B>Competitive Occupation</B>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 145pt; text-align: justify; text-indent: -32.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">                                                                                                                                                <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         foregoing shall apply irrespective of whether the Competitive Occupation is carried out
                                         by the Employee alone or in cooperation with others and shall apply to the participation
                                         of the Employee in a Competitive Occupation, whether as a controlling shareholder or
                                         as an interested party.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">3.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Intellectual
                                         Property, Copyright and Patents</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 112.15pt; text-align: justify; text-indent: -33.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee hereby acknowledges and agrees that the Company owns and shall own any and all
                                         Intellectual Property Rights created, made or discovered by the Employee or employee
                                         or personal that reports to Employee either: during the term of employment; and/or in
                                         connection therewith; and/or in connection with the Company, its business (actual and/or
                                         contemplated), products, technology and/or know how or that of Parent (&ldquo;<B>Company
                                         IPR</B>&rdquo;). Intellectual Property Rights means all worldwide (a) patents, patent
                                         applications and patent rights; (b) rights associated with works of authorship, including
                                         copyrights, copyrights applications, copyrights restrictions, mask work rights, mask
                                         work applications and mask work registrations; (c) rights relating to the protection
                                         of trade secrets and confidential information; (d) moral rights; (e) rights analogous
                                         to those set forth herein and any other proprietary rights relating to intangible property
                                         including ideas; and (f) divisions, continuations, renewals, reissues and extensions
                                         of the foregoing (as applicable) now existing or hereafter filed, issued, or acquired.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee hereby assigns to the Company and/or its designee, all right, title and interest
                                         in and to Company IPR upon its creation. The Employee will assist the Company to obtain,
                                         and from time to time enforce, any Company IPR worldwide, including without limitation,
                                         executing, verifying and delivering such documents and performing such other acts as
                                         the Company may reasonably request for use in applying for, obtaining, perfecting, evidencing,
                                         sustaining and enforcing such Company IPR. Such obligation shall remain in effect beyond
                                         the termination of the Employee&rsquo;s relationship with the Company, all for no additional
                                         consideration provided that Employee shall not be required to bear any expenses as a
                                         result of such assignment. In the event the Company is unable for any reason, after reasonable
                                         effort, to secure Employee&rsquo;s signature on any document required, Employee hereby
                                         irrevocably designates and appoints the Company and its duly authorized officers and
                                         agents as its agent and attorney in fact to act for and in its behalf to further the
                                         above purposes.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee hereby waives, releases and forever discharges any claims and/or demands whatsoever,
                                         whether in law, in equity or otherwise, in relation to the Company IPR, including without
                                         limitation any moral rights and rights to receive royalties in connection therewith and
                                         expressly waive any rights to receive royalties under Swiss law.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee represents and warrants that upon execution hereof it has not created and does
                                         not have any right, title or interest in and to any Intellectual Property Rights related
                                         and/or similar to Company&rsquo;s business, products or Intellectual Property Rights.
                                         The Employee undertakes not to incorporate any prior inventions in any Company IPR.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee undertakes to immediately inform and deliver to the Company, written notice
                                         of any Company IPR conceived/ invented by her and/or personal of the Company and/or its
                                         successors who are subordinate to her, immediately upon the discovery thereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 145pt; text-align: justify; text-indent: -32.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee&rsquo;s obligations pursuant to this Section shall survive the termination of
                                         her employment with the Company and/or its successors and assigns with respect to inventions
                                         conceived by her during the term of her employment or as a result of her employment with
                                         the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 145pt; text-align: justify; text-indent: -32.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
                                         acknowledges that the restricted period of specified hereunder are reasonable, in view
                                         of her position and the nature of the business in which the Company is engaged, the Employee&rsquo;s
                                         knowledge of the Company&rsquo;s business and the compensation she receives. Notwithstanding
                                         anything contained herein to the contrary, if the period of time specified herein should
                                         be determined to be unreasonable in any judicial proceeding, then the period of time
                                         and area of the restriction shall be reduced so that this Agreement may be enforced in
                                         such area and during such period of time as shall be determined to be reasonable by such
                                         judicial proceeding. The Employee acknowledges that the compensation and benefits granted
                                         to her by the Company under this Agreement were determined, inter alia, in consideration
                                         for her obligations under this Section 3.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 103.3pt; text-align: justify; text-indent: -32.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Taxes</U></B></FONT></TD></TR>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employee shall bear all the taxes deriving from the rights and benefits received by her
                                         pursuant to this Agreement. It is hereby expressed that all the amounts specified in
                                         this contract are gross and statutory tax shall be deducted from them.</FONT></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 79.35pt; text-align: justify; text-indent: -40.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 13.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have carefully read this agreement and its appendices thereto, I have understood the contents, the terms and conditions included
therein and undertake to perform all the thereof and I agree to the obligations therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 13.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee&rsquo;s
    name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vered
    Caplan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[date]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 13.65pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>ex21-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
21.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: transparent"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ORGENESIS
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>List
of Subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orgenesis
    Korea Co. Ltd.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orgenesis
    Belgiuim SRL</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orgenesis
    Ltd.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orgenesis
    Maryland Inc.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orgenesis
    Switzerland Sarl</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orgenesis
    Biotech Israel Ltd.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Koligo
    Therapeutics Inc.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex23-1_001.jpg" ALT="" STYLE="height: 116px; width: 200px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-223777, No. 333-237261 and
333-250127) and Form S-8 (No. 333-242195) of Orgenesis Inc. of our report dated March 9, 2021 relating to the consolidated financial
statements, which appears in this Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Kesselman &amp; Kesselman</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certified
Public Accountants (Isr.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
member firm of PricewaterhouseCoopers International Limited</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel-Aviv,
Israel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
9, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 28.35pt; text-align: justify; color: red"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 28.35pt; text-align: justify; color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ORGENESIS
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CEO
CERTIFICATE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO SECTION 302</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Vered Caplan, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Annual Report on Form 10-K for the year ended&nbsp;December 31, 2020 of Orgenesis Inc.;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and
    procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
    in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the Registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the Registrant&rsquo;s internal control over financial reporting that occurred during the Registrant&rsquo;s
    most recent fiscal quarter (the Registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the Registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the Registrant&rsquo;s auditors and the audit committee of the Registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the Registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    9, 2021</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Vered Caplan</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vered
    Caplan</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer (Principal Executive Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ORGENESIS
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CFO
CERTIFICATE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO SECTION 302</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Neil Reithinger, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Annual Report on Form 10-K for the year ended&nbsp;December 31, 2020 of Orgenesis Inc.;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and
    procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
    in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the Registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the Registrant&rsquo;s internal control over financial reporting that occurred during the Registrant&rsquo;s
    most recent fiscal quarter (the Registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the Registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the Registrant&rsquo;s auditors and the audit committee of the Registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the Registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    9, 2021</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Neil Reithinger</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neil
    Reithinger</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer, Secretary and Treasurer (Principal Financial Officer and Principal Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ORGENESIS
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B><BR>
<B>18 U.S.C. SECTION 1350</B><BR>
<B>AS ADOPTED PURSUANT TO</B><BR>
<B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this Annual Report on Form 10-K of Orgenesis Inc. (the &ldquo;Company&rdquo;) for the year ended December 31,
2020 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned, in the
capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that to her knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operation
    of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    9, 2021</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Vered Caplan</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vered
    Caplan</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer (Principal Executive Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ORGENESIS
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this Annual Report on Form 10-K of Orgenesis Inc. (the &ldquo;Company&rdquo;) for the year ended December 31,
2020 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned, in the
capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operation
    of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    9, 2021</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Neil Reithinger</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neil
    Reithinger</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer, Secretary and Treasurer (Principal Financial Officer and Principal Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  W +8# 2(  A$! Q$!_\0
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(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Y CL# 2(  A$! Q$!_\0
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M\CYE"X&%_BW<9--"9K_\()X/_P"A4T/_ ,%T/_Q-'_"">#_^A4T/_P %T/\
M\363X?.M":"WFN+I$M=-2=+20+ND9I)0BR,03D(J C/7K6?#X@OEDTYK369K
M_49[>>2ZTYXEPDRPLP3 4-'AQC:3D_@318+G3?\ "">#_P#H5-#_ /!=#_\
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M'_XFC_A!/!__ $*FA_\ @NA_^)JIX1OKZ[NKH2:G;WUJ(D8%;E9G20DYY6-
M 1CY3D@CWK)T;7;J=K"6/6Y+W4)KUX9]/*(%6(.X)P%W+M !WDX/3N*+!<Z'
M_A!/!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:P]/U2]O)-.2'7)IM
M1O0Z7UGY:?Z%\C98+MRFQ]J_,3NSWSFH[/Q!XAO;RW@DCDA6^D6T0B( PR0G
M-RY)&,,-X7/]P>M%@N=!_P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\
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M4IPKZF]NS^4F+.W6=D+@8Y.T#YFR!UQ@46"YJ?\ "">#_P#H5-#_ /!=#_\
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M5+PUH]]IU_)+=1!$:V\L$.#\WGS/V_V74_C6?=^&=2D&K6J1QM8Q6]P=,3>
M3).IW CMM.X+[2'TH [/S85<)O178;MI(!(]<4LKQQQEI654[ES@5PFJ>'[R
M<WT)T-;N\FOH[B'43)&-D0=#C).X%5!7:!@_B:W?$%A)<:E87<FF_P!J6<*2
MJ]IE,AVV[9 KD*V &7DY&[([T6"YT VM@C!QTJHFI6DNHBR20//Y1F&WD!0=
MIY]<GI7/66AWZ> +G2HH%L;J0W!C@$V0BM*S*F\>JD#(Z9]JR;OPY>7LU\^G
M:"-)BDL8X2@DB4S%9E9DVJ2HRH9<GKGGBBP7._\ -A>$R"1&BP26R"N/K0TT
M(C5VE0(V K%A@YZ8KAH?#EQ%;><-.N9K?[:DT^G3F!!,JQE<JD>$!#%6P3\V
MP>U.U;P_<7DUI/%I$L5BL$L8T^)+9C$[/G<5?*#<.ZG(_$T6"YW.]%8)N4$\
M!<U5M-3M+Y;@PR@BWF:&3/&&7K7(/X0N/LNI,+7S;SR;1;.XFD5I0T2KD[^S
M9!R1C-6%\)^9.BS:=;M VM2WDRX7#QF.0*6'\7S,.#ZT6079UYDA!$1>,$KD
M)D=/IZ54M=6M+M6,1=8UW@NZ%5&US&1D\9W*>*Y+4?#]U++=0_V&MU=R:C'<
MQ:B9$&R(2*P&2=P*J-NT#!Q[FGRZ+JULE]+'I4-ZTL4L<<,K(R$M=22!B&."
M K!L=^G!HL%SM?M$(B\TS1B/^_N&/SK)UK3+"<23WUW=I 8R);=+EE290"2"
MF>>.H&,CKFN:F\,2K8:5';:9=):6OG":V*VSR/(^T^<58F,Y^<=01NXXXIDO
MAFY@L)[:71)-6\[3T@M3/-$6M6 ;*,Q(VC+ [D!Z8["G85SL+C6[&TTVVNV,
MA2Y"_9XHXRTDA(R%51SG'/L <U"/$EBMC-=7$=U:^4ZQM%/;LLA9ONA1@[R>
MVW-4IM-U"VM]!O8+<7%QIT/E36V\*75D56*L>-P*CK@$9&12WZZKJD5M>QZ6
M8);"[6>&WN)EW3KL96!VDA#ASMY/(&<4AEV+7HWM)YAIFIHT17="UJ0[;CU7
MLWO@\=Z;X9NK"[T>*33;2YM[3K%]HC*EU;YLC/)'S54TBWU-]=O+R6*^MK&2
M' M[RY$A,I;)*JK,%4#CK^%6M'L+BS\&VFGSPYN8K(1/$LFW+!,8W#I]: -=
M'B?YHV1MQQE2#DBAIHD +RHH)P"6 YKAM*TC5=,6RECTE_L]C=$QP PI.\;0
ME"6VD(Q#8&<@D<GGK3M]+>#7DBU#P\FIR_V<[M"'C;R3)<2N!\Y"GK@L.F/0
MT6"YZ*TD4;@.Z*S$*,D D]A4,%_!<7EU:QL?-MF59 1CDJ&&/7@BO/H-(ECU
M&ZL[W0UUBZCTFU@,GF(?*?\ >\9<@@=/G&6^7ITJ[=Z=JFAV4VJ-MN;^UFM3
M 2__ !]-Y*0NOJ-Q)Z]P#18+G=@H 2NT#)SCU[U4EU2SCN;:W:52;E7:-ARI
M"XW9/3N*Q[W0)X_"5OIMN!=/%)'+<QLVW[7\^^4$G^\=QYX/0\&JXT&#4-2T
MR5_#\5I80-<&2WE6/!9E0*Q125.<$=^F: .J=XHPJ.R*&.U0Q S["HUNHFDE
M3)7RL99EPIR,\'H>/2N&3P]>PV,<>H:$-68Z:EK"C2H?L[J7R,L> 05^9<GY
M?85+I_A2[,^FKJ-E%);PO;M*CN'7Y+-HSD=\.0/UHL%SL-0O[73;(WMTX6%"
MHW8SRQ"C]32VVH6UU/<0Q/F2"3RW!XR=JMQZC##FN<G\/3R>"Y](-I$Y%VS0
MP,5*K%]HW*!G@ )T';I22^&6-_>7L=C$+DZK;36\H(#+ @B5L'^$860;>X^M
M%D&IU7F0^:RAT\P ;AD9 [9J#3;^UU2Q2\LV#0R9(.,<YP<UQMOX>NTNM*C?
M0U-W:W[376J&1/WR'?ELYWL3N&5(P/P%:EEH%U:_#^72+:.*SO7AD7$9"C<2
M>Z],C R.1^%%@N;MUJ5G8V;7#R+Y*,$/E_-@E@N,#W(J9+J)XA(28U+F,>:-
MA)!([_3CUKA)?#US<WSS6'AM-+B^R1PLOF1+O<3QOT0D8"JWS'D_E27-I'IE
MXKZO96=[&T5SY=M/<Q*8=UQ(^_$A PRLF6'(VCCFBP7._+Q;ERR;CPN2,_A2
MAT+L@=2ZX+*#R,UYUIGA:6]\+O,]A&UR^B6L5DSM\T<JAS\I/*D%D^;@UNZ7
MIM[:>+[NY33_ "K:X\QIYY3&Q+97;Y;#Y\''*L,#'!HL%R]/J6C7<]NLC%FM
MK\P1XR DPC8\X[;2W7BMD/&JKAE .-O/7TQ7'GPJ9+AO,TZW,4FN&\E'RX>+
MRF +>OS'H?4U)I7AAH-<MIKFRA^RV@N_LP)#"+?<!X]H[?*#CTZ<4:!J=8&B
M+O&K(6'+J",C/J*5)$?<$=6VG:VTYP?0UY]I_A/5(I'#FZBU!8KE?MX,"QR.
MX8!BRCS6!)#8;H5'H*U/".A2Z;>-/):W=JPME@97\A8W(.<@1#+$<X9N?F-%
M@N=)87]MJ5LEW;G*.652PP3M8J?U%6$ECD4,DB,"< JP/->?VWA;78=(U.U;
M:T]Y!(L$P<*;=?-+>3W^5P<[ASDG=T%/.COI.C:GJJV]Q:RVQBNH8I_(C5GB
MR2 L/ + F,D\D$>@HL%SO\@Y&0<<&F)+"8V9)$*)D$@C"X_E6 -&OCX-N[2.
M01:G>H\TK[B/WK\E<CH!]T$= !5"?23<:?&+7PPMG%%<127%D6B7[6BAAM^4
ME3M)##<0#C%%@N==YL)C63?&8_O!LC'US3O,3+#>N5QD9Z9Z5Q=MX:EN=2@F
MFTF.WTPW[3BQD*$1+]G9-Q4$K\SD':,^O4FL;5/#,NE>$D;[#&KBRE@NL2 &
M1FFB,:LPY/ 8 \[118+GIB2QRJ6C=74$@E3D TB2PM'YB/&48YW*1@_C7$SZ
M!=W7VV2RT9=.M6C@1[ NB"[*2[G!V$J 5RF3][.#P*'\-RW]X)8]%2RTYKRV
MD:R=D /E[]\A525&=R+@$YV\T6"YV[31)&)&D18SC#%@!STYH9XPRAF4-G"Y
M/.:X*\\+7J3KMLW?3HKFY:.T@6!]HDV%6"2_)CB08X(W<<$U(?!TCZ??J]F9
MK@:5!!927$BM(DJ^8<;AP""R?,,=!Z46079V-OJ=I<O>+',N;.7RIMQP%;:&
M_+#"K6%)#8!(Z&N-OO#;-:ZN3IA=[O4DN ;;R@[*J)AB'^5P'#95NN2>M;N@
MV]Y#9Q-?6L%O<&WB1UAD.T%<\!/NK@8Z$YS["@#6I H48  'H*6BD,0* NT
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M$>]+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4M=!0 4444 %%%% !1110 4444 %%%% !1110!6O[V#3;">]NI!'! A=V/8
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MX+2TAB>01&9S-(4&W.,# //Z#\:I6VOW%RL=Q]BC2U+0HQ\[+9D1&X &" 7
MZ\]:TIK6QU1%:>!)@AX\Q"",@9'//ID4[R;* Q6PBB3S""B!0,E ,8^@ _(4
M 9EKJE[<ZAII>.&.UNXGE0+)N8@!2-PQ[YXZ=*=+J]V+N>"WMDE,9E8F67:
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MR1COM/?CBD.MWR02/)8;?+9=TA60($())P5W'& #@8^8'UK8-K;L ##&0"S
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MO^P5:_\ HI:Z"N?\"?\ )//#7_8*M?\ T4M=!0 4444 %%%% !1110 4444
M%%%-DD2*-I'8*B@DL3@ >M '(?$CQ6/"_AF1H7 OKG,5N.X..6_ ?KBOF5B6
M8LQ)).23WKI_'WBE_%7B::Y1C]CA_=6RG^X#][ZD\_EZ5R]?HN38#ZIAUS+W
MI:O]%\OSN<TY<S"K6GZ?=:K?1V=G&'GDR0"P48 )))/ P :JUH:+<6EMJ6;]
MIEM9(989&A4,ZAT*Y /7K7J5')0;CN0CH_#OA>ZM/$VGRW<L:I'+O8)'*QP
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KY ^-O_)7M=_[=_\ TGCKZ_KY ^-O_)7M=_[=_P#TGCH ^G_
MG_)//#7_ &"K7_T4M=!7/^!/^2>>&O\ L%6O_HI:Z"@ HHHH **** "BBB@
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M+M@</SZ!>/2II=(MI%0*98F0OAXI"K88Y89'8GFGH+4I'Q+&Q!@L;J9"8TW
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M:4[WYE]Z_P R7*F]VOP,HP^E1F(BMG^Q-5_Z!MW_ -^&_P */[$U7_H&W?\
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MPRI-=W#O.?WKG9EP!@#&W QVP 0><TRWT$+&8[B[GDC\Z658=PVJ69B#G&>
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'Z\_HH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_003.jpg
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" $D I4# 2(  A$! Q$!_\0
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MT 6R,@CUI$79&J^@ JK\W_/63\Z/F_YZR?G0!<HJG\W_ #UD_.CYO^>LGYT
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MU[_2K=SKL-M-=1-$Y>WA$K<@ DXRH/J-RD_[PJ2<VKM;I'&\C^6QB%N=I"#
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M_P#K4 65UNP;(6?)"[C\C# / R<<9R,9]:+?6[.XMXY?,*%T#E&4Y0$ Y/'
M^8<].:J&ST=+EIVG0(T05HS(0I"\Y//HO?TI]S%I-I;QSR+^ZD:.WW(Q((("
MJ&Y^[@+G- %A-<T]R<7& !G+(P'?N1_LG'KBK5M=17:.T+$A',;94J0PZC!K
M)A_L2XBD"JNR*1H<,Q&XID?+SR/G.#[_ $JS:7^EVT(\NY1/./G$22$L2V.N
M>_(&* -*BJS:E9H"6NH0  <[QT.,?S'YBD_M6Q\EI?MD'EKU;?P.,_RI#+5%
M (8 @Y!&01WHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH 4#)Q7'S?%+PQ!/)#)=7 >-BC 6['D'!KKZPY+;PJ9&\R+0]^3NW"'.>^?>
MMZ/L]?:)OT$[F3_PMCPK_P _=S_X#-1_PMCPK_S]W/\ X#-6K]E\)?\ /+0?
MRAH^R^$O^>6@_E#6]L-_)+[U_D+4RO\ A;'A7_G[N?\ P&:C_A;'A7_G[N?_
M  &:M7[+X2_YY:#^4-'V7PE_SRT'\H:+8;^27WK_ "#4RO\ A;'A7_G[N?\
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M$4 4)M.L9U:[FDE*#]ZS,=O*@ MC&>BXJ%-.MTO;::&Y"Q2W!G5<DF63:_\
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M5[3[-=/LH[9#N"9RV,;B23D_G2 L4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% "@X(-<1/\ "7PS<7$DT@O-\C%VQ<#J3GTKMP<$'TKSZY^#6FW-
MU+.VJ:DK2N7( 7 R<^E=6&GR-_O''T5R9+R)_P#A3_A;TO?_  ('^%'_  I_
MPMZ7O_@0/\*I_P#"E-,_Z"NI_DO^%'_"E-,_Z"NI_DO^%=?MU_T$/[G_ )BM
MY%S_ (4_X6]+W_P('^%'_"G_  MZ7O\ X$#_  JG_P *4TS_ *"NI_DO^%!^
M"NECKJVI#_OG_"CVZ_Z"']S_ ,PMY%S_ (4_X6]+W_P('^%'_"G_  MZ7O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH_)C_N_K1Y,?]W]: ),48J/R8_[OZT>3'_=_6@"3%&*C\F/^[^M'DQ_W?UH
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M/W-ZG\ZQ[+5U=XK=8Y#)*PV!W!.WYMQZ=%*$>_'K6O03Z"[CZFDHHH ****
M"BBB@ HHHH **** "J^H7)LM.N+E5#-$A8*>AJQ4%_/';6,TLL?F(HY3^]DX
M Y]S0!G2:S<&_:VM[8.1(5 *L&( C/X??/)]*L:=J;WUP\31JIB_=RX/W9<G
M*_3 !_X$*<9)4OEA%I!]J=6DW!^-HV@\XSDD@?A5,:["(R\=H!(Z^>%R 678
M2S9QV*%?R]:8B4:XB1133[56<E8HU4EB=VW!/3/J.U-D\1P)_P L)ERZQ@N
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MNSV-/_H&G][_ /D17?<R_P#A;VA?\^]__P!\)_\ %4?\+>T+_GWO_P#OA/\
MXJM3_A./"/\ T$+/_OPW_P 31_PG'A'_ *"%G_WX;_XFCV-/_H&G][_^1"[[
MF7_PM[0O^?>__P"^$_\ BJ/^%O:%_P ^]_\ ]\)_\56I_P )QX1_Z"%G_P!^
M&_\ B:/^$X\(_P#00L_^_#?_ !-'L:?_ $#3^]__ "(7?<R_^%O:%_S[W_\
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MO_B:/^$X\(C_ )B%G_WX;_XFCV-/_H&G][_^1"[[F7_PM[0O^?>__P"^$_\
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MVMYCL0.4SP<Y^Z1GZTV+1Y(71D$6%97VEV(9E)*D\=MQ_*F#0F6U,$82-2)
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MV?\ WR?\:/\ A"/#?_0%L_\ OD_XUN44?6J_\[^]A9&'_P (1X;_ .@+9_\
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MY4>9_L/^5/HH 9YG^P_Y4>9_L/\ E3Z* &>9_L/^5'F?[#_E3Z* &>9_L/\
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M_P"AF7\V_P */^$;\7?]#,OYM_A1]E\??\_MC_XY_P#$T?9?'W_/[8_^.?\
MQ-'-/^>'X?Y!>7\T?Z^0?\(WXN_Z&9?S;_"C_A&_%W_0S+^;?X4?9?'W_/[8
M_P#CG_Q-'V7Q]_S^V/\ XY_\31S3_GA^'^07E_-'^OD'_"-^+O\ H9E_-O\
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M,24M2$+!0[DKMYQN8=0#UK9R?6C)]: .?A\2R2Q1L;0!I%!&&.T<'))P,<C
M^HK3L;]KN6>.2+RVBVG .>#ZGIG.>*NY/J:,TAB4444 %%%% !1110 4444
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MZ7 ",C9QM(SUY!&.".]%@N:U%4)=9L(4D>74;)%C;8Y:0 *WH>?8_D:4ZO9
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M!"]S:Q;Y)/,W;"1*,,,L,;2, >@ K>N8UFM9HG7<CH59<XR".>>U8T\4E];
M23)((XV ;S(R I4J21T/U]OS+V&HN7_#D(T31M/O?M"7MQ'/\TF4E!&T8##
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M]3\O6M&&,PP1QEVD**%WMU;'<TACZ*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHK,_L*/_ )[S?I5147\3L4DGNS3HK,_L*/\ Y^)OTH_L*/\
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MJPH^UA(SEL==RE6X^A/XT-HZ-#!$9G"0XV[54'COGL>QQU%7]Z_WE_.C>O\
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0OY4M%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_004.jpg
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #P FL# 2(  A$! Q$!_\0
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M=RH25US'.:]X0\,//%=V%C81+-QY'V1%5<<9Z5F6WAK1+3SDO-/TN1Q( O\
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MC@:WH_4@1CH,^M=GXMDCDTBW"L#DC^55*S:B*#:YI>9YV&;[<,2-M6WXRH)
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MQDC1CR5&T_TK.6)GL5'#4]SU";XFRGA90/\ <MP/YFL[4OB'?O;P_9[VXC+
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MQ8\?,WYU(CL8)ERW\+=?0_\ UZT^LS!T('2'Q3=FX8[HPF>-L" X_*M.#QA
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M./\ GH?\:A;4;AOO7%P?JY_QKI[.+37T.)FCT\V?V1C<3,P%PEP,X &<]=N
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M\^U!XU9V4J0K8Y7*@!L>H%8HQS]^H:LRD[C_ #'_ +@Z4X22[6^1:AX_VJ4
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M]ZV;2.*WL0]]"[S-PZ>4/RXK*O))9+EFMM/6.'C:K1 GZUO./+32TN_O_P"
M2G=E I:Y/SRC_@ _QHVVX4[9'SR.4Q_6K#/.#\UE$?\ MD::\I*$-9Q+_M!6
M!'ZUSE,B6.VX_P!(;_OV:4Q0Y/\ I8'_  %J<EQ$%&ZQC^N]A3S/:[CFR_*8
MT: 1B*+:<7B?^/?X4>2O:]C_ .^F']*D$MD0?]%E'TE_^M1OT\]8;D?1U/\
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MZ47,[:EI=G):R.$A0QR+O"D'CAOEJD=)C;J[#TQQBE@T]+=FVW4RJWW@O?\
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MU/;2]20#-M/[_+FH&MKU/O0S#ZQFBXR4S6.X[K.4<_PS?_6IROII/^INU/\
MOJ?Z55?S58Y7\UI%=MP&U,_2BX6+0&EGJ]VO_ %/]:>L6EG.+R<<?Q0?_7JC
MYG_3-?P-.5UR?W?;UH M?9-.8#&IJ/\ ?@85<TK3[,:O9LFIVS$3H0NU@3\P
MXZ5D;H\#Y&'XU<T@Q?VU8_?S]HC[?[0H O:QI2RZY?.+^R!:X<[6EVD?,>#Q
M5>/1+C<"EU9M_NW*U%K0A.OZ@2YS]ID_A_VC5-4AW??4_A0P1IC0]6'^K(;G
M^"Y4_P!:>-)\0(1M2[_X#+G^1K(\I.TB=?6GB-@1MD_)Z -9H/$L3'']I 8[
M%C3#<>(X_O2:@/\ >5C_ $JB'O$8^7<S 8XVRG_&I5O]60?+?78_[:FBX6)V
MU36TCR\T^?\ ;B']152YO[VZ*^?(#MZ?NP/Z5:.M:TD8(O[G\3FJUUJ%_>,I
MN9VDV?=RHX_2B_F.WD1;WEE#-C. .!BD+,"XP#[D<T[SGDFW.5R?8"F^<?G&
M$/OBH9H)N/\ ='Y54F.96. /85<$G'W$Z53G.9F. /84X[D3V/8-&@L5T#3F
M<+N-K$3]=HJV9[*/A8P?^ UC:4Z_V+8 O_R[Q]_]D5:)3^^/SK90;,')(LO>
MQ?P0K^50/<%ND:C\*C)C_OC\Z3='_>%4J9/.,8ENH'Y4PQY]*F^3^\*7Y/6J
MY$+F*IBH%OFK68Z7<E/E0N8JBV%*(0.PJUE/\FF[D]OSIV%<K^6!V%'E;OX1
M5D#/0"G^9Y0X S3L%RGY '51^536NFM=S!$7'J<5-"LE[.(PV,UU-E816D0
M(+=VK.4K;%QB4;;1+6SP?+WOW9AQ5\6T; CY<>RU,8TSG//UJ*[G%I;$@9=^
M!@]*R;-+&/=R!B41$VCC..M4&MT/2&,U9<$G)/6F@^IJTB&QMO;('4>4@'H!
M6Y!&BC"Q8]\5DPM^^4=\UT:8VCU]Z3&BA>QJ\# E@!_=%8316W0O*?H!75NC
M," 5P1C%<U-'Y,K*PP0:$$BN([7^[-^8I=EJ.?+E/U84UG_NBFX=OX6_(U5B
M16:V _U+_P#?=1&2'H(,_P# S4@@D;_EFY_X":=]FFQQ;R#Z+1H&I6+QXY@3
M_OHTTO$.EO%^M6397!Z0/^.*C-A< _ZO'U84M!V96:8 \0P_]\T@U">/@*N/
M0"IVLI^YC'_ Q4?V-N\D(/\ OT:!J2)J$,HQ(I5O]KD431,ZYA<+^ Q5=K0$
M\W$(_$T)'Y!^6[3'H%)% %.X%['G+MCU6LN>.6; ,L@P<_*>IQBNJ2[A.%=P
M3WP.*<^GVMT,@#)_B'^-(#B)+($ ,9"!Q]\U5?3(C_>_.NSFT98N<L_T(K/E
MMX8VP\,P/N0*+#.6;3@OW7(I%M98W5EE/!!ZFNB>*W_YY/\ ]]5&T4(Z0?FQ
MI6"YA%)UFW.[>3ORV#_#GFNRT7Q+IMA>2W$Q9(G7:BCYB.G]*QML?_/NGYFC
M [11CVQ5)M;":3/0[7Q=H4^,7R*3V;BM6+4].G7,=Y"W_ J\D9<]883]4!J%
MH5SQ$JG_ &/E_E6BK/JB/9KN>TJ\3XVR(WT84XIGM7B:B:,YCN;A/]V4U9CU
M35H!^[U2X&.S8-4JRZHGV;[GK[1]>*Q=5C$6K:5/ZR-$?Q&?Z5PL?BWQ!#C%
MW'(/1U(J9_&^IR1B.XBC^\&'EKDG'/?IS3]I%H7)),]),0STI!"/2N+@^(%P
MS_O=,RO^PV36A%X_T\?\?%K<1?53_A34X=P<9=CIA ,=*3R!Z5D0>-]!FX^U
M!#_M5H1:]I,XRE]%^)JEROJ3JB7R!CI2&W![5-'=6LH^2XB;Z,*E 5NA!^AI
M\J#F*#6H)/%(+49'%7]G7BDV\TN0.8Y?P_:C[!-'CF.YE3_QXUIBR7'2H]%3
M9=:O%_=O&(_$ _UK6V"H4-"W(S/L2GM5+4K=K>T+Q_*V>N ?YUT(2J&L0LU@
M0J%N>0%S0Z8*9Q@U"\#X+QD?[48_H*Z#3[=KNW+RJN?]D8KGRNR;#?+SW.VN
MST--UBQSGGUS6:A<MRL8VHK'9.%-NCC&>3C^AK.6:QF;#Z:ASW&#_,"MSQ"A
M$V 0!@=\5BVRXD'RYYZE=U)PU&IEU/#NFW4'F?8(@#ZH,_I56Z\,:) <2VBI
MD?PAOZ5V-A$#8I\H&?05G:]",KA3T[#-#IJP*HSE/^$6\.S#Y69/^!L/YU+:
M^"=,CN([FWGE)B8. '##@YJQ'% K\_>_ 5TNG1+]AG8$D!#UY[5*@AN;..NO
M $-]<RW0O)4:9VD(V C).:K'X:2@Y34!_P "B_\ KUW]S IT>$D#E1UQZ>]8
MBVS!L+)_WRY_H*'3&JC.2?X::B/N7ELWU#"J[_#K6E8;?LK_ $DQ_,5Z-9PW
M"R+F67;Z%F_J:Z06HR.*7LQ^T/#)? ?B!&8BQ##_ &)5/]:K/X0\0Q==+NO^
M \_R->U7CW$,S+$/E![IG_"JZZA<(?F2)O\ @.W_ -FJ7 KG/%I=%UJ!1NL;
MY3W_ ';56;[?;L0_GH1V9"/YBOH*QG>[?:8E4>JL3_2N?\40E-24 _\ +,']
M34N#&IGF]EXOUNS@CM@]L\,:X03V<;\?4KDT_P#X3B\<'SM+T*;GG=8(/Y8K
MZ!TRWM_['LUDM4;]ROWD![4LVA:3<#,FE6+^H>V3_"HN::'S^/%MFX_?^$M"
MD]UC=/Y-7+:G<1W6HS3Q6L5K&^,0Q$[4X'3//O7TW)X)\,3GY]"L!GTCVG]*
M^=_&EG;:?XPU*ULXUCMXY $13P!M!JHD3L=SI%AOT6P;'6WC/_CHJ[_9@/7
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M<3HV1(W/>NA;1G'_ "T%4;W262,9=3GI3YHARR,8WESQB9_PI/MMV3@7$O\
MWU5M=,DSRP-/&EMS\PHO$+,H&ZNAUN)3_P "-1&YG/\ RVD)_P!\UI-IC$<N
M,U&=*;'#"G="LS.,\V0/,<_\"J,R3'/[QOSK3_LJ3^]^0IG]E29SOHN@LS-+
MR?WFIOF29^^WYUI?V3)C[_Z4QM*?^^,T7069G-))G&]A33))_?;\ZT?[+?GY
MA3?[*?\ O"BZ"S,YG?\ OM^="7%Q$<QS./QJ_P#V7)TW"F?V9)V9:5T%F1KJ
M4A_UK-D=P:G\YYU^^67ZYJ(Z5*3US]!3ETFZ!R@8'M@&C0>I#+9[ONRE3Z9X
MJA-:W,>2=Q'JIK?CT^]8;9(VP/XE&#5Q-'E&#YI(]"M*Z"S.)8R#/S&F%Y!_
M&:[6?P^LX.Y1GU P:S)?"EQN_=R+C_:I70[,YLR/_>;\Z0R2#^,UT'_"*SMU
MG3\%-._X1&7O<?D*6@[,YOS)/[QIIDD_OFNE_P"$5"?>G_-@*C;P];)]Z9/Q
MDHT#4YTR/_>-,+O_ 'C70MI-G'UDB/\ P(FH_L]FG3RS]%HT#4P#))_?-2+=
M72C"ROCTK88P#.U <?[-1&08^6(\>]&@:F>;JXD&)(5D'^U'31#%)UM70^J<
M5>:>7( B7\336DN3R$2EH/4KBVF09AN9D]MQJ>*ZUB'_ %>H2KCU;-,)N3W4
M?A2%;H]7Q3$:D/B'Q#!TOT?V8&KT?C77HOOQPR >C?XU@*ERIYVL/>I/)WC]
MY'C/]TTU-KJ+E78Z%/B!=Q7$CM:"4D $ <+CW[]:OP_$BSX^T6DD?KP:Y!=.
M5_N2[?9J?_8]T/N;6'L:?M)=P]FCOK?Q_H<IP9"GUK4M_%6C3?=O%'UKRI]-
MN$XDMP??;4/]GH3S"H]^E5[9D^S1[5'JNGSCY;N)A[M5B-[<J?*>+!_ND5XB
MNFN,&,RKG^[(:LQVVHH3Y-_.,=CS3]MW0O9^9[)/I]K=\S0ASZAB/Y&JG_"-
MZ;NRJ2J?:0G^>:\TAN?$4/$=\&]F!!_2K\/B3Q-"!DQR#VDQ_,4>TB]T')(]
M/AMT@@6)"2HZ9ZU4U+26O\%)40@8PRD_UKC(O&6N)Q-I\AQW4*W\C5V/Q^ZD
M"XL9$SW:)A5<\&+EDB]_PB]^CY26W<>SE?\ V6M:WLIK33+L3(H/EMC#9[5D
M0^/M-D(#;%/_ %TQ_.K[^*M,GLY5+/M9"#@@]OK0N7HQ-RZHMR1.^B6VQ'8^
M6OW02>GM7-S1R*Y\Q)%_WU8?SQ73:=KFFM9PHEQ@*@'S*>*U(M1LY.%NXC[;
M\4^2X<UCEM)"FX0*R]>Q7^F:[$1_,/I3D\F3D>6_N,&I@HW?A34+!S7.8U.0
MQW# 8Z^W_P!>J273YP5)'MG_  %=7/I%I=,6D20,>I25E_D<55;PM9,<K-<*
M?<JW\UJ'!E*95T=0UQG&/Q_^N:QO%<>=6QZ1#^M=A8Z2ME)N6=G'H5 _E_A7
M.>)(=^K,<=$45G-6B7!W9TEH9?L-LJ3$8B48 'I4C&\)RMRN/]J,<46^C7BQ
M1E<8*C\.*NII%XP 9A^5<=T=6I2)U,@E9XO^_8KYO^(MNUKX\U.%SE@8R>,=
M8U/]:^H5TF_S\KH,=\8KYI^+$+P?$S5XY&W./)R?^V*5<63)'HGA[2Y)?#FE
MN!PUI$?_ !P5J_V(V,DT[PU,R^%-' /2QA_] %79+M\8W?K78HJQRN6IDR:5
ML[$U"UG&O48J_)*SGEZK/M'\6:=D*Y5-O$*C:.(= 2:G9L]"*;D+SF@"..VC
M8Y? %5KK6((,Q64*,PZR,./PJ+5;YB@@1L9Y8CT]*S((3/*J;TC4_P#+23(5
M?J0#7KX+!QE'VE3Y(];!8*,H^UJ_)#Y;^ZF)+SO] <"HA-(#G>WXFMB/PU/)
M%',M]9O'(3L\HN[-CJ0H7)'OTI)_#=Q&H\F996)PJ-&T98^BD\$^V<UW_N/A
MLON_X!Z5J.UE]W_ )M*\0^1B&X10O]]1T^HKIXYUF4,K @\C%><D%6*L""#@
M@C!!K;\/WS)+]F=N.J>WJ*\O,,NA&#JTE:VZ_P CDQ6$BH\]/[CKBH/4FD C
MC!=B@ [,<9H7+*"&_,5D7TSM*5+*0/05X*5SS&[$=]=R7DO(147IM%5?;BAG
M)[<TP YR1BM$K&3=QQ&WDX ]:H3ZF$)2  _[;?T%-U.<@B!3CC+?X55L[.6]
MF,<950JEY)'.%C4=6)]*]O X"#A[6M\D>IA,'%Q]I4!KZZ8_\?$@_P!TX_E3
MH]2O8B"MS)]"<C]:OVEGI]W<?8[..6YF*D^?-,((QCN%P3CZG/M5*2&W::2(
M;K:17;Y7?>@ ' W 9)SWZ5ZBA1?N\B^Y'HJ-/;E_ U;+Q"681W8 S_RT7I^(
MK5O(UGM/,3YL>E<7)&\4C1R(R.IPRL,$'WK<T+4C&K6TA)7&5^GI7DYAE\80
M]M1Z;K]4<&+PD5'G@3+#(?NHWX"GBRG;I&WY5J#5X%7&P_\ ?-(-9CS@1?B:
M\6[/*LC/&G3GCRS^-*-*N3_ /SJZ=9;H(P!]:A;69^@1:+L-"$Z5-&A>0HJ
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M8=/UQ6E2T,.^?L_U*E[M)\W8]%MO">JSVF8A ?3<]5&^'NNLQ)-J2?\ ;_\
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M ($_Y)YX:_[!5K_Z*6N@IB"BBB@ HHHH PO%?AFW\4:.UI*1',AWP2XSL;_
M]Z^?M7T6_P!#OGM-0MVBD7H3]UAZ@]Q7T]534-+L=6MC;W]K%<1?W9%SCW![
M?A7HX+,)8?W6KQ_+T.O#8MT?=>J/EW ]*0 #H*]PO?A)H-PY:WFN[;/\*N&'
MZC/ZU%;_  AT:)\S7=W./[I(4?H*]?\ M;#6O=_<>A]?HVZ_<>.V5C<ZC<I;
MVD+2RMT"C^?I7MG@GP<NBV@:;#3R8:1\?D!["NCTOPWI>CQ>79VL<8[X')^I
MZFM4  8 P*\G&YC+$+DBK1_,X,3BW5]U:(4# P****\TXPHHHH YWQCX5@\4
MZ3Y!(CNXLM;RGL>X/L:\!U32KW1KU[2_MWAF0]&'!'J#W'O7U!5+4](T_6+?
MR-0M(KB/MO'*_0]1^%>E@LPEAUR25X_D=F&Q;I>Z]4?,B7,Z*JK*VU7$B@\@
M-ZU)=:A>7V/M5S)*!T5C\H^@Z"O9+OX1Z%.Y:WN+NW']T,&'ZC/ZTVV^$6BP
MN&FN;J<#^$L%'Z"O4_M3"_%K?T.[Z]0W_0\>T_3;O5+I;:SA:61O0< >I/85
M[AX,\(IH=BH?YI6^:1\?>/\ @*W],\/Z;I$(BL[6.)?]D=?J>]:@&!@5Y6-S
M"6(]V*M'\_4X,3BW6]U:(.E%%%><<@4444 <MXW\(1^*=,'EE8[^#)@D/0^J
MGV/Z5X)?Z?=Z7>/:7L#PSH<%7&/_ -8KZDK/U70],UN#R=1LXIU'W2P^9?H1
MR*]/!9C+#KDFKQ_([<-BW27++5'SAI^J3Z<)8U2*>VFQYMM.NZ-\="1V(]1S
M4-]?7&HW37-U)OD(P,# 51T51T 'H*]DNOA#H<S[H+J\@']W<K#]1FEM/A)H
M<#AIYKFXQV9@H_05Z?\ :>%7O*]_0[/KM!>]U]#R'2M'O=9O%M[.(NQ^\W\*
MCU)KW;PEX8AT/3XX@,L/F9B.6;N:V-.T2PTN$16EM'$@[*N*T.E>1C<?+$^Z
ME:/];G!B<5*MHM$%%%%<!RA1110!Q?C[P4/$MHMW9A5U*!<+G@2K_=)]?0UX
MM#-?>']2D5X-DP5H9H)TX=3P58>AKZ=K+UCP[I.O1[-1LHYB!A7Z.OT8<UZ>
M#S%TH^SJ*\?R.W#XOV:Y)JZ/G'4-0EU*=))4BC6.,1111+M2-!T4#\3^=6[+
MQ#>6-G';QQV[M"7-O-)'NDM]WWMA[9]\X->J7'P@T61RT%Y>0C^[E6_I4MG\
M)M"MG#327%SCL[ #]!7I2S+"<MM7Y6_X)V/&4.6WZ'D6BZ%>ZY=K!:1$C/SR
M$?*@]S7O'A?PY#HFGQ0HOW1G)ZL>Y-:MAI%EIL*Q6MO'$B]%5< 5>KR,;CI8
MEVVBNG^9P8G%2K.VR"BBBN$Y0HHHH X3XA>!SXAA&HZ>H&HQ+@IT\Y1V^H[?
ME7EEIXAU70T.GRP1LL.5$5Q&0T9SG&1@XSGY3QSTKZ.K(UGPSH^OKC4;*.1P
M,"4?*X_X$.:]/"Y@H0]E67-'\4=M#%J,>2HKH^<;^]GU*Z^T73*TFT(-J!0J
MCH !P!5;:OH/RKVJ?X/Z-))NAOKR)?[IVM_2K%C\*-"M7#S-/=$=I&P/R&*]
M3^U<-&/NW]+';]>HI:7^X\ET30+_ ,0WBQ0*YC7"O*V2J+Z?X"O>?#F@0:-8
M10QKA4&!GJ3W)]S6C9:79Z?"L5M D:+P%5< 5<KQ<9C9XEVVBNAYV(Q,JS[(
M****XCF"BBB@#SSXB>!'UK.K:6@-\BXEB'_+8#H1_M#]:\?%S?V3&$7%S 4.
M#'O9=I^G:OJ.L76O">BZ_P#-?V2-+C'G)\K_ )CK^->M@\R]E%4ZJNOR._#X
MSD7)-71\\?VOJ7_00NO^_IIDFHWTH(DO;E@>"#*V#^M>OS?![1W<F*_O(U_N
MG:?Z5<L/A7H%FX>4371'_/9N/R&*[WFF%2NE^!U/&T$KK\CRCPYX8O?$%VHC
M1DM@?WDQ' ]AZFO>M$T>'2K..&- JHH51Z"KMK86UG&L<$2(JC "C %6:\;&
M8R>)EKHELCSL1B)5GKH@HHHKC.<**** /+_B+X"FO)I-;TB(O*W-S;J.6_VU
M]3ZC\:\C92K%64A@<$'M7U96!K7@S0M><R7EDHG/6:(['/U(Z_CFO8P>:.E%
M0JJZ77J>AA\=R+EGJCP*TUN\LH88H?((A8O$TD*LT9)R2I(XY&:SCR23R2<U
M[/)\'=(9R8]0O$7T.T_TJ_I_PNT"QD#R))=,/^>S9'Y# KM>:86*O&]_0Z7C
MJ*U7Y'E?ACPG>>(+I&,;1V8/SR$?>]E]37O.D:7%IMJD<:!0JA54=@*M6]E!
M:H$AC5548  P!5BO%Q>,GB97>B6R/.Q&(E6=WL%%%%<ASA1110 5\@?&W_DK
MVN_]N_\ Z3QU]?U\@?&W_DKVN_\ ;O\ ^D\= 'T_X$_Y)YX:_P"P5:_^BEKH
M*Y_P)_R3SPU_V"K7_P!%+704 %%%% !6!<:Y=1^*$TP):PPD(5-P[*\X.=WE
MG&"5].I]JWZQ=0T%]1NPTFHSBS,L<K6I52-R$$;6(RHR!G'OTS30F0Z;XLM+
MM=MT'MI-TX#M&PC81,P;#D8) 7)_'TJ3_A*],6"6:;[3;QQPFX!FMV7S(QC+
M+QSU''7D<4K^&+.6TM[:621XHGG8@D#=YN_<#]-YQ]!4$GA4W<31ZAJES=8@
M:"$E$4QJV,G@?,QV@9/Y<T:!J3Q>(/.U^UTY;.Y6.>U:X$DD3*5(8+@@]/Q]
MO6K!U^P6[O;=GD462[KB8H?+C^4-@MZX(-6#I\9U=-1WMYBP- %[8+!L_7BL
MJ^\*0:EJ4US=W4CQ2Q/$8E15.UEP5+@98#J <X-&@:D-[XSM(=/FGMH+B2>)
MH28'B8.4D<*' [CD_CP:UO[;L?+9S(P"7*6C H<B5MN%_P#'A6;;^$H(K.>W
MDG1O-:([XK:.)@$<, =H&<D<Y_2II/#:2:DTXO9EM7NDO'M0JX:90,'=C(&5
M4X]11H&HZP\4:;J,D"P_:%CN25@FE@9(Y6&<A6(Z\'ZX.,UM5R^A>&+JULM,
M34M0EF6R_>1VV%VI)@@?,!E@ QP/YXKJ*&""BBBD,*P+O7+J'Q-'IBQVL43!
M"K7+LK7&<[A&0,97T/)]NM;]8NIZ"^IW/[S49ULV>.1[;:I&Y""-K$97D#./
MTIH3(SXNTSSC$B7DCEI$0):N?,9#APO')&#FG3^+=*@@\]6N)X%@%Q))! SB
M*,C(+8'' /'6IK?0(+>:UD6:0FVEGE4'')E))!^F>*SO^$/\FRDL[+5;JUAG
M@$%P%1&,@"[0P)'RMCC(]!1H&I8MO$+W.N)8K"GE/(ZK)DY(6*-P<>_F?I6_
M6/:^';>TU&*\2:4O&6(4XQS&B?RC!_$UL4@04444#"BBB@ K(O\ 4KS^U%TO
M3886N/)\^66X)"1H25' Y))!],8K7K,U#2&NKR.^M+R2SO$C,1E10P=,YVLI
MX.#R.XR?6@"-M9>QBABU& M?R;B(+)6EW*O5\8! Y'7N<<TL/B/3KFYM+>W:
M69[E/,79$QVKG;EO[O((.>A'-0OH-P7@N8]7N%U"-6C:Y:-&WHQ!*E<8 ! Q
MCI[U"_A*,_8E6^F$=L_FG*(7>3?O9@^,J6)YQP1Q3T%J7M"U8ZS8R7#6\D!2
M>6+:Z%<[7*@C/7I^>:U*JZ?8II]L8(V9E,LDN6]7<L1^9JU2&%%%% !1110!
MQT'CH/X:NKZ2R(U*(LL5D&YF^]L93_=(4DGMM;TK4'BFSCMH7F2=G^SI<7'D
M0M(L"L,Y8@<#K[X&:=#X6TZ*RBA,>^:*WEMH[E@/,5)"2P'YU$_A<HK)9ZG<
M6L<L"07 558R!%V@@D?*VWC(]N.*>@M1NM>+K33;*[EMHY;IK= 6>.-FB5F
M*AG' R"#[ C-7Y-<LDMVD60G_2&M5!4\RKGC]#S6=<^$4DM[BSL]1N+*PN0H
MEMXE4YPJK\K$9&550?IVS4Q\,(;YI#>S?93<-=BUVK@2L""V[&<9)./7\J-
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M      Z 4M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M110 4444 %%%% !1110 5\@?&W_DKVN_]N__ *3QU]?U\@?&W_DKVN_]N_\
MZ3QT ?3_ ($_Y)YX:_[!5K_Z*6N@K@_!?C3PK:^!?#UO<>)=&AGBTRV22.2_
MB5D81*"""V00>,5N?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\
M!C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4
M?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\
M^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8
MP_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '
M045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#P
MG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]
M#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_
M /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)W
MX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT
M/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\
MQ5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S
M_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@_
M_H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\
M!C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4
M?\)WX/\ ^AKT/_P8P_\ Q5 '045S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\
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..1L01@X8<'!!'X4 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex23-1_001.jpg
<TEXT>
begin 644 ex23-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !; (H# 2(  A$! Q$!_\0
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MQ=133E!QE'V<[RC)SY?WV":<E&DVD]4KVU3M>SM_*E_P7$C0_M4?#YV;+?\
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M*%*C2K5%AZ;J4:<J.)KPJ3A2M5DX)1BFTY<Z<(]31117]7GXR%%%% !1110
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MFFQ&B0P[V+,VV-!N.!N9?RE_X/BO^15_X)R_]C!^T_\ ^FSX)UX)_P $0O\
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MSA5#,P3RPS,!DL(_D!))"?*#MXI]% !_G\^M-"(-N$4;0 N% V@= O' '8#
M%.HH :$0,S!5#/@,P4!F & &.,G X&<X'2EP..!\O3@<<$<>G!(X[$CO2T4
?(         !@ #@  <  =!2T44 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>orgs-20201231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWayEabP9z5Z8WekhvWB6bcl6HyUuFGfvICfJW2+mMW4D -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ORGS="http://orgenesis.com/20201231" elementFormDefault="qualified" targetNamespace="http://orgenesis.com/20201231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://orgenesis.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/StatementsOfComprehensiveLossIncome" id="StatementsOfComprehensiveLossIncome">
	  <link:definition>00000004 - Statement - Consolidated Statements of Comprehensive Loss (Income)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/StatementsOfChangesInEquity" id="StatementsOfChangesInEquity">
	  <link:definition>00000005 - Statement - Consolidated Statements of Changes in Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/DescriptionOfBusiness" id="DescriptionOfBusiness">
	  <link:definition>00000007 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/DiscontinuedOperation" id="DiscontinuedOperation">
	  <link:definition>00000009 - Disclosure - DISCONTINUED OPERATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/AcquisitionAndReorganization" id="AcquisitionAndReorganization">
	  <link:definition>00000010 - Disclosure - ACQUISITION AND REORGANIZATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/PropertyPlantsAndEquipment" id="PropertyPlantsAndEquipment">
	  <link:definition>00000011 - Disclosure - PROPERTY, PLANTS AND EQUIPMENT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/IntangibleAssetsAndGoodwill" id="IntangibleAssetsAndGoodwill">
	  <link:definition>00000012 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ConvertibleLoans" id="ConvertibleLoans">
	  <link:definition>00000013 - Disclosure - CONVERTIBLE LOANS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/Loans" id="Loans">
	  <link:definition>00000014 - Disclosure - LOANS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/Leases" id="Leases">
	  <link:definition>00000015 - Disclosure - LEASES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/Commitments" id="Commitments">
	  <link:definition>00000016 - Disclosure - COMMITMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/CollaborationAndLicenseAgreements" id="CollaborationAndLicenseAgreements">
	  <link:definition>00000017 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/InvestmentsInAssociatesNet" id="InvestmentsInAssociatesNet">
	  <link:definition>00000018 - Disclosure - INVESTMENTS IN ASSOCIATES, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/Equity" id="Equity">
	  <link:definition>00000019 - Disclosure - EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/IncomeLossPerShare" id="IncomeLossPerShare">
	  <link:definition>00000020 - Disclosure - INCOME (LOSS) PER SHARE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
	  <link:definition>00000021 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/Taxes" id="Taxes">
	  <link:definition>00000022 - Disclosure - TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/Revenues" id="Revenues">
	  <link:definition>00000023 - Disclosure - REVENUES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" id="CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet">
	  <link:definition>00000024 - Disclosure - COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/FinancialExpensesNet" id="FinancialExpensesNet">
	  <link:definition>00000025 - Disclosure - FINANCIAL EXPENSES, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/RelatedPartiesTransactions" id="RelatedPartiesTransactions">
	  <link:definition>00000026 - Disclosure - RELATED PARTIES TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
	  <link:definition>00000027 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
	  <link:definition>00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/DiscontinuedOperationTables" id="DiscontinuedOperationTables">
	  <link:definition>00000029 - Disclosure - DISCONTINUED OPERATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/AcquisitionAndReorganizationTables" id="AcquisitionAndReorganizationTables">
	  <link:definition>00000030 - Disclosure - ACQUISITION AND REORGANIZATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/PropertyPlantsAndEquipmentTables" id="PropertyPlantsAndEquipmentTables">
	  <link:definition>00000031 - Disclosure - PROPERTY, PLANTS AND EQUIPMENT (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/IntangibleAssetsAndGoodwillTables" id="IntangibleAssetsAndGoodwillTables">
	  <link:definition>00000032 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ConvertibleLoansTables" id="ConvertibleLoansTables">
	  <link:definition>00000033 - Disclosure - CONVERTIBLE LOANS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/LoansTables" id="LoansTables">
	  <link:definition>00000034 - Disclosure - LOANS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000035 - Disclosure - LEASES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/InvestmentsInAssociatesNetTables" id="InvestmentsInAssociatesNetTables">
	  <link:definition>00000036 - Disclosure - INVESTMENTS IN ASSOCIATES, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/EquityTables" id="EquityTables">
	  <link:definition>00000037 - Disclosure - EQUITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/IncomeLossPerShareTables" id="IncomeLossPerShareTables">
	  <link:definition>00000038 - Disclosure - INCOME (LOSS) PER SHARE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
	  <link:definition>00000039 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/TaxesTables" id="TaxesTables">
	  <link:definition>00000040 - Disclosure - TAXES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/RevenuesTables" id="RevenuesTables">
	  <link:definition>00000041 - Disclosure - REVENUES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNetTables" id="CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNetTables">
	  <link:definition>00000042 - Disclosure - COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/FinancialExpensesNetTables" id="FinancialExpensesNetTables">
	  <link:definition>00000043 - Disclosure - FINANCIAL EXPENSES, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/RelatedPartiesTransactionsTables" id="RelatedPartiesTransactionsTables">
	  <link:definition>00000044 - Disclosure - RELATED PARTIES TRANSACTIONS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative" id="DescriptionOfBusinessDetailsNarrative">
	  <link:definition>00000045 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails" id="ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails">
	  <link:definition>00000046 - Disclosure - SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfIntangibleAssetsAndTheirUsefulLiveDetails" id="ScheduleOfIntangibleAssetsAndTheirUsefulLiveDetails">
	  <link:definition>00000047 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/SignificantAccountingPoliciesDetailsNarrative" id="SignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000048 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails" id="ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails">
	  <link:definition>00000049 - Disclosure - SCHEDULE OF DISCONTINUED OPERATION AND BALANCE SHEETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsDetails" id="ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsDetails">
	  <link:definition>00000050 - Disclosure - SCHEDULE OF DISAGGREGATION OF REVENUE RELATED TO DISCONTINUED OPERATIONS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative" id="DiscontinuedOperationDetailsNarrative">
	  <link:definition>00000051 - Disclosure - DISCONTINUED OPERATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" id="SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails">
	  <link:definition>00000052 - Disclosure - SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical" id="SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical">
	  <link:definition>00000053 - Disclosure - SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfUnauditedSupplementalProFormaDetails" id="ScheduleOfUnauditedSupplementalProFormaDetails">
	  <link:definition>00000054 - Disclosure - SCHEDULE OF UNAUDITED SUPPLEMENTAL PRO FORMA (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative" id="AcquisitionAndReorganizationDetailsNarrative">
	  <link:definition>00000055 - Disclosure - ACQUISITION AND REORGANIZATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails" id="ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails">
	  <link:definition>00000056 - Disclosure - SCHEDULE OF COMPONENTS OF PROPERTY, PLANTS AND EQUIPMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails" id="ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails">
	  <link:definition>00000057 - Disclosure - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT BY GEOGRAPHICAL LOCATION (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/PropertyPlantsAndEquipmentDetailsNarrative" id="PropertyPlantsAndEquipmentDetailsNarrative">
	  <link:definition>00000058 - Disclosure - PROPERTY, PLANTS AND EQUIPMENT (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfGoodwillDetails" id="ScheduleOfGoodwillDetails">
	  <link:definition>00000059 - Disclosure - SCHEDULE OF GOODWILL (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfOtherIntangibleAssetsDetails" id="ScheduleOfOtherIntangibleAssetsDetails">
	  <link:definition>00000060 - Disclosure - SCHEDULE OF OTHER INTANGIBLE ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfEstimatedAggregateAmortizationExpensesDetails" id="ScheduleOfEstimatedAggregateAmortizationExpensesDetails">
	  <link:definition>00000061 - Disclosure - SCHEDULE OF ESTIMATED AGGREGATE AMORTIZATION EXPENSES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" id="IntangibleAssetsAndGoodwillDetailsNarrative">
	  <link:definition>00000062 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails" id="ScheduleOfLongTermConvertibleLoansDetails">
	  <link:definition>00000063 - Disclosure - SCHEDULE OF LONG TERM CONVERTIBLE LOANS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical" id="ScheduleOfLongTermConvertibleLoansDetailsParenthetical">
	  <link:definition>00000064 - Disclosure - SCHEDULE OF LONG TERM CONVERTIBLE LOANS (Details) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ConvertibleLoansDetailsNarrative" id="ConvertibleLoansDetailsNarrative">
	  <link:definition>00000065 - Disclosure - CONVERTIBLE LOANS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfLoansDetails" id="ScheduleOfLoansDetails">
	  <link:definition>00000066 - Disclosure - SCHEDULE OF LOANS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfLease-relatedAssetsAndLiabilitiesDetails" id="ScheduleOfLease-relatedAssetsAndLiabilitiesDetails">
	  <link:definition>00000067 - Disclosure - SCHEDULE OF LEASE-RELATED ASSETS AND LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfLeaseCostsDetails" id="ScheduleOfLeaseCostsDetails">
	  <link:definition>00000068 - Disclosure - SCHEDULE OF LEASE COSTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfSupplementalCashflowInformationDetails" id="ScheduleOfSupplementalCashflowInformationDetails">
	  <link:definition>00000069 - Disclosure - SCHEDULE OF SUPPLEMENTAL CASHFLOW INFORMATION (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails" id="ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails">
	  <link:definition>00000070 - Disclosure - SCHEDULE OF FINANCE LEASE LIABILITIES AND OPERATING LEASE LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfRight-of-useAssetsByGeographicalLocationDetails" id="ScheduleOfRight-of-useAssetsByGeographicalLocationDetails">
	  <link:definition>00000071 - Disclosure - SCHEDULE OF RIGHT-OF-USE ASSETS BY GEOGRAPHICAL LOCATION (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
	  <link:definition>00000072 - Disclosure - LEASES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/CommitmentsDetailsNarrative" id="CommitmentsDetailsNarrative">
	  <link:definition>00000073 - Disclosure - COMMITMENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative" id="CollaborationAndLicenseAgreementsDetailsNarrative">
	  <link:definition>00000074 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfChangesInInvestmentsDetails" id="ScheduleOfChangesInInvestmentsDetails">
	  <link:definition>00000075 - Disclosure - SCHEDULE OF CHANGES IN INVESTMENTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/InvestmentsInAssociatesNetDetailsNarrative" id="InvestmentsInAssociatesNetDetailsNarrative">
	  <link:definition>00000076 - Disclosure - INVESTMENTS IN ASSOCIATES, NET (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfWarrantsActivityDetails" id="ScheduleOfWarrantsActivityDetails">
	  <link:definition>00000077 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfTreasurySharesDetails" id="ScheduleOfTreasurySharesDetails">
	  <link:definition>00000078 - Disclosure - SCHEDULE OF TREASURY SHARES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/EquityDetailsNarrative" id="EquityDetailsNarrative">
	  <link:definition>00000079 - Disclosure - EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfBasicAndDilutedLossPerShareDetails" id="ScheduleOfBasicAndDilutedLossPerShareDetails">
	  <link:definition>00000080 - Disclosure - SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/IncomeLossPerShareDetailsNarrative" id="IncomeLossPerShareDetailsNarrative">
	  <link:definition>00000081 - Disclosure - INCOME (LOSS) PER SHARE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails" id="ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails">
	  <link:definition>00000082 - Disclosure - SCHEDULE OF EMPLOYEE STOCK OWNERSHIP PLAN DISCLOSURES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" id="ScheduleOfStockOptionsValuationAssumptionsDetails">
	  <link:definition>00000083 - Disclosure - SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails" id="ScheduleOfStockOptionsActivityDetails">
	  <link:definition>00000084 - Disclosure - SCHEDULE OF STOCK OPTIONS ACTIVITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails" id="ScheduleOfStockOptionsExercisableDetails">
	  <link:definition>00000085 - Disclosure - SCHEDULE OF STOCK OPTIONS EXERCISABLE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails" id="ScheduleOfStockOptionsGrantedToConsultantsDetails">
	  <link:definition>00000086 - Disclosure - SCHEDULE OF STOCK OPTIONS GRANTED TO CONSULTANTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
	  <link:definition>00000087 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails" id="ScheduleOfDeferredTaxAssetsDetails">
	  <link:definition>00000088 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfValuationAllowanceActivityDetails" id="ScheduleOfValuationAllowanceActivityDetails">
	  <link:definition>00000089 - Disclosure - SCHEDULE OF VALUATION ALLOWANCE, ACTIVITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/TaxesDetailsNarrative" id="TaxesDetailsNarrative">
	  <link:definition>00000090 - Disclosure - TAXES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueDetails" id="ScheduleOfDisaggregationOfRevenueDetails">
	  <link:definition>00000091 - Disclosure - SCHEDULE OF DISAGGREGATION OF REVENUE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfBreakdownOfRevenuesPerCustomerDetails" id="ScheduleOfBreakdownOfRevenuesPerCustomerDetails">
	  <link:definition>00000092 - Disclosure - SCHEDULE OF BREAKDOWN OF REVENUES PER CUSTOMER (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfActivityForTradeReceivablesDetails" id="ScheduleOfActivityForTradeReceivablesDetails">
	  <link:definition>00000093 - Disclosure - SCHEDULE OF ACTIVITY FOR TRADE RECEIVABLES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetails" id="ScheduleOfActivityForContractLiabilitiesDetails">
	  <link:definition>00000094 - Disclosure - SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetailsParenthetical" id="ScheduleOfActivityForContractLiabilitiesDetailsParenthetical">
	  <link:definition>00000095 - Disclosure - SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES (Details) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/RevenuesDetailsNarrative" id="RevenuesDetailsNarrative">
	  <link:definition>00000096 - Disclosure - REVENUES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" id="ScheduleOfResearchAndDevelopmentExpensesDetails">
	  <link:definition>00000097 - Disclosure - SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfFinancialExpensesDetails" id="ScheduleOfFinancialExpensesDetails">
	  <link:definition>00000098 - Disclosure - SCHEDULE OF FINANCIAL EXPENSES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails" id="ScheduleOfRelatedPartyTransactionsDetails">
	  <link:definition>00000099 - Disclosure - SCHEDULE OF RELATED PARTY TRANSACTIONS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical" id="ScheduleOfRelatedPartyTransactionsDetailsParenthetical">
	  <link:definition>00000100 - Disclosure - SCHEDULE OF RELATED PARTY TRANSACTIONS (Details) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://orgenesis.com/role/ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails" id="ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails">
	  <link:definition>00000101 - Disclosure - SCHEDULE OF RELATED PARTIES PRESENTED IN CONSOLIDATED BALANCE SHEETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="orgs-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="orgs-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="orgs-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="orgs-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
    <element id="ORGS_EquityAttributedToOrgenesisIncMember" name="EquityAttributedToOrgenesisIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_MasthercellMember" name="MasthercellMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_CureCellCoLtdMember" name="CureCellCoLtdMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_TamirBiotechnologyIncMember" name="TamirBiotechnologyIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_TamirPurchaseAgreementMember" name="TamirPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ProductionFacilityMember" name="ProductionFacilityMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_KnowhowMember" name="KnowhowMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_TechnologyMember" name="TechnologyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_MasthercellSAMember" name="MasthercellSAMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_CellProcessDevelopmentServicesMember" name="CellProcessDevelopmentServicesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_TechTransferServicesMember" name="TechTransferServicesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_CellManufacturingServicesMember" name="CellManufacturingServicesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_KoligoTherapeuticsIncMember" name="KoligoTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_MaterialDefinitiveAgreementMember" name="MaterialDefinitiveAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_MaximaGroupLLCMember" name="MaximaGroupLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_LongHillAndMaximGroupLLCMember" name="LongHillAndMaximGroupLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_RegistrationRightsandLockUpAgreementMember" name="RegistrationRightsandLockUpAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_KyslecelTechnologyMember" name="KyslecelTechnologyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_IPResearchAndDevelopmentMember" name="IPResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_TransferAgreementMember" name="TransferAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_OfficeFurnitureAndComputersMember" name="OfficeFurnitureAndComputersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_LabEquipmentMember" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_AdvancePaymentMember" name="AdvancePaymentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ConvertibleLoansOneMember" name="ConvertibleLoansOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ConvertibleLoansTwoMember" name="ConvertibleLoansTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ConvertibleLoansThreeMember" name="ConvertibleLoansThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ConvertibleLoansMember" name="ConvertibleLoansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_TwoPercentageConvertibleLoansTwoMember" name="TwoPercentageConvertibleLoansTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_SixPercentageConvertibleLoansTwoMember" name="SixPercentageConvertibleLoansTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_EightPercetageConvertibleLoansTwoMember" name="EightPercetageConvertibleLoansTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_HemogenyxCelMember" name="HemogenyxCelMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ImmugenyxLLCMember" name="ImmugenyxLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ConvertibleLoanAgreementMember" name="ConvertibleLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_PrivatePlacementSubscriptionAgreementMember" name="PrivatePlacementSubscriptionAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_SixPercentageConvertibleLoanAgreementMember" name="SixPercentageConvertibleLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_CreditLineAgreementsMember" name="CreditLineAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_NonUSInvestorMember" name="NonUSInvestorMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_NonUSInvestorThreeMember" name="NonUSInvestorThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_NonUSInvestorOneMember" name="NonUSInvestorOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_NonUSInvestorTwoMember" name="NonUSInvestorTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_NonUSInvestorFourMember" name="NonUSInvestorFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_InvestorOneMember" name="InvestorOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_InvestorTwoMember" name="InvestorTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_TwoOtherInvestorTwoMember" name="TwoOtherInvestorTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ControlledEquityOfferingSalesAgreementMember" name="ControlledEquityOfferingSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_CantorFitzgeraldAndCoMember" name="CantorFitzgeraldAndCoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ShortTermLoanOneMember" name="ShortTermLoanOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ShortTermLoansTwoMember" name="ShortTermLoansTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ShortTermLoansThreeMember" name="ShortTermLoansThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ResearchAndDevelopmentFacilitiesMember" name="ResearchAndDevelopmentFacilitiesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_OfficesMember" name="OfficesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_MarylandTechnologyDevelopmentCorporationMember" name="MarylandTechnologyDevelopmentCorporationMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember" name="ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" name="DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_IndustrialResearchPartOfResearchProgramMember" name="IndustrialResearchPartOfResearchProgramMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExperimentalDevelopmentPartOfResearchProgramMember" name="ExperimentalDevelopmentPartOfResearchProgramMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_RevenueFromGrantsMember" name="RevenueFromGrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DevelopmentOfPotentialCureForTypeOneDiabetesMember" name="DevelopmentOfPotentialCureForTypeOneDiabetesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember" name="GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DeductionOfResearchAndDevelopmentExpensesMember" name="DeductionOfResearchAndDevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ResearchOnDermatitisTreatmentsAndWoundHealingMember" name="ResearchOnDermatitisTreatmentsAndWoundHealingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember" name="IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember" name="KoreaisraelIndustrialResearchAndDevelopmentFoundationMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_BirdSecantMember" name="BirdSecantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_OBIMember" name="OBIMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_AdvaBiotechnologyLtdMember" name="AdvaBiotechnologyLtdMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember" name="TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember" name="OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember" name="OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember" name="OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember" name="OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember" name="WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_HemogenyxPharmaceuticalsPLCMember" name="HemogenyxPharmaceuticalsPLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_SalesMilestoneMember" name="SalesMilestoneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ResearchAndDevelopmentCostsMember" name="ResearchAndDevelopmentCostsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ImmuAgreementMember" name="ImmuAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_BgNegevTechnologiesAndApplicationsBgnMember" name="BgNegevTechnologiesAndApplicationsBgnMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_CollaborationAgreementMember" name="CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_SponsoredResearchAgreementMember" name="SponsoredResearchAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ColumbiaLicenseAgreementMember" name="ColumbiaLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_MarylandSubsidiaryMember" name="MarylandSubsidiaryMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_AIPCellsMember" name="AIPCellsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_CaliforniaUniversityJointResearchAgreementMember" name="CaliforniaUniversityJointResearchAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_CaerusTherapeuticsIncMember" name="CaerusTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExtracellularVesicleMember" name="ExtracellularVesicleMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_EVAmentMember" name="EVAmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_TissueGenesisLLCMember" name="TissueGenesisLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_BroadenJointVentureAgreementMember" name="BroadenJointVentureAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_JointVentureAgreementMember" name="JointVentureAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_KinerjapayCorpMember" name="KinerjapayCorpMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_SBHSciencesIncMember" name="SBHSciencesIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_TLABSMember" name="TLABSMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ButterflyBiosciencesSarlMember" name="ButterflyBiosciencesSarlMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_KidneyCureJVAMember" name="KidneyCureJVAMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_MergerAgreementMember" name="MergerAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_OptionsAndWarrantsMember" name="OptionsAndWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_SharesUponConversionOfConvertibleNotesMember" name="SharesUponConversionOfConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_TwoZeroOneSevenEquityIncentivePlanMember" name="TwoZeroOneSevenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_GlobalShareIncentivePlanTwoZeroOneTwoMember" name="GlobalShareIncentivePlanTwoZeroOneTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_OptionsGrantedToEmployeesMember" name="OptionsGrantedToEmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_OneYearAnniversaryMember" name="OneYearAnniversaryMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ThreeEqualInstallmentsMember" name="ThreeEqualInstallmentsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_OptionsGrantedToNonEmployeesMember" name="OptionsGrantedToNonEmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExercisePriceOneMember" name="ExercisePriceOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExercisePriceTwoMember" name="ExercisePriceTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExercisePriceThreeMember" name="ExercisePriceThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExercisePriceFourMember" name="ExercisePriceFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExercisePriceFiveMember" name="ExercisePriceFiveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExercisePriceSixMember" name="ExercisePriceSixMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExercisePriceSevenMember" name="ExercisePriceSevenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExercisePriceEightMember" name="ExercisePriceEightMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExercisePriceNineMember" name="ExercisePriceNineMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExercisePriceTenMember" name="ExercisePriceTenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExercisePriceElevenMember" name="ExercisePriceElevenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExercisePriceTwelveMember" name="ExercisePriceTwelveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExercisePriceThirteenMember" name="ExercisePriceThirteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExercisePriceFourteenMember" name="ExercisePriceFourteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExercisePriceFifteenMember" name="ExercisePriceFifteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExercisePriceSixteenMember" name="ExercisePriceSixteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExercisePriceSeventeenMember" name="ExercisePriceSeventeenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExercisePriceEighteenMember" name="ExercisePriceEighteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExercisePriceNineteenMember" name="ExercisePriceNineteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExercisePriceTwentyMember" name="ExercisePriceTwentyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_OptionsGrantedToEmployeesAndDirectorsMember" name="OptionsGrantedToEmployeesAndDirectorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_MasthercellGlobalMember" name="MasthercellGlobalMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_PrivatePlacementSubscriptionAgreementsMember" name="PrivatePlacementSubscriptionAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_NonEmployeesMember" name="NonEmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_SeveralConsultantsMember" name="SeveralConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ConvertibleNotesAndPrivateInvestmentMember" name="ConvertibleNotesAndPrivateInvestmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_SuccessFeeMember" name="SuccessFeeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_InvestorRelationContactMember" name="InvestorRelationContactMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_HeldUntilSixMonthsAnniversaryMember" name="HeldUntilSixMonthsAnniversaryMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_HeldUntilOneYearAnniversaryMember" name="HeldUntilOneYearAnniversaryMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_FirstChoiceInternationalCompanyIncMember" name="FirstChoiceInternationalCompanyIncMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ConsultantMember" name="ConsultantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_VestedOnSigningDateMember" name="VestedOnSigningDateMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_VestMonthlyOver3MonthsMember" name="VestMonthlyOver3MonthsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_SeparateInvestorRelationsContactMember" name="SeparateInvestorRelationsContactMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_SeparateInvestorRelationContactMember" name="SeparateInvestorRelationContactMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ConsultingAgreementMember" name="ConsultingAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_TwoThousandTwentyOneToTwoThousandTwentyMember" name="TwoThousandTwentyOneToTwoThousandTwentyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember" name="TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_UpToKrwTwoZeroBillionMember" name="UpToKrwTwoZeroBillionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_UpToKrwThreeZeroZeroBillionMember" name="UpToKrwThreeZeroZeroBillionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_TaxBaseAboveKrwThreeZeroZeroBillionMember" name="TaxBaseAboveKrwThreeZeroZeroBillionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_SouthKoreanWonMember" name="SouthKoreanWonMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_PointOfCareServicesMember" name="PointOfCareServicesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_MasterServicesAgreementsMember" name="MasterServicesAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_JointVenturePartnersMember" name="JointVenturePartnersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_CustomerAMember" name="CustomerAMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_CustomerBMember" name="CustomerBMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_CustomerCRelatedPartyMember" name="CustomerCRelatedPartyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_CustomerDMember" name="CustomerDMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_BoardMembersMember" name="BoardMembersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_CaerusTherapeuticsLLCMember" name="CaerusTherapeuticsLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_NonexecutiveDirectorsMember" name="NonexecutiveDirectorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_AccruedExpensesAndOtherPayablesCurrent" name="AccruedExpensesAndOtherPayablesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_AdvancePaymentsOnAccountOfGrant" name="AdvancePaymentsOnAccountOfGrant" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_RedeemableNoncontrollingInterestOfDiscontinuedOperation" name="RedeemableNoncontrollingInterestOfDiscontinuedOperation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ShareInNetIncomeOfAssociatedCompanies" name="ShareInNetIncomeOfAssociatedCompanies" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests" name="IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_IncomeLossesFromDiscontinuedOperationNetOfTax" name="IncomeLossesFromDiscontinuedOperationNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary" name="OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ComprehensiveIncomeNetOfTaxes" name="ComprehensiveIncomeNetOfTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations" name="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations" name="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement" name="StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares" name="StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_IssuanceOfSharesAndWarrants" name="IssuanceOfSharesAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_IssuanceOfSharesAndWarrantsShares" name="IssuanceOfSharesAndWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_StockbasedCompensationToStrategicCollaborations" name="StockbasedCompensationToStrategicCollaborations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_StockbasedCompensationToStrategicCollaborationsShares" name="StockbasedCompensationToStrategicCollaborationsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans" name="IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp" name="AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ShareBasedCompensationOne" name="ShareBasedCompensationOne" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ShareBasedCompensationTwo" name="ShareBasedCompensationTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances" name="IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_NetChangesInOperatingLeases" name="NetChangesInOperatingLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_IncreaseDecreaseInAccuredExpensesAndOtherPayables" name="IncreaseDecreaseInAccuredExpensesAndOtherPayables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant" name="IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_PaymentsForInvestments" name="PaymentsForInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_RepaymentOfTreasuryStock" name="RepaymentOfTreasuryStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_FinanceLeasesOfPropertyPlantAndEquipment" name="FinanceLeasesOfPropertyPlantAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities" name="RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable" name="PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_AcquisitionOfOtherAssetInExchangeForCommonStocks" name="AcquisitionOfOtherAssetInExchangeForCommonStocks" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo" name="IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DisclosureAcquisitionAndReorganizationAbstract" name="DisclosureAcquisitionAndReorganizationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_AcquisitionAndReorganizationTextBlock" name="AcquisitionAndReorganizationTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DisclosureLoansAbstract" name="DisclosureLoansAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_LoansTextBlock" name="LoansTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DisclosureCollaborationAndLicenseAgreementsAbstract" name="DisclosureCollaborationAndLicenseAgreementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_CollaborationsLicenseAgreementsAndCommitmentsTextBlock" name="CollaborationsLicenseAgreementsAndCommitmentsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DisclosureFinancialExpensesNetAbstract" name="DisclosureFinancialExpensesNetAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_FinancialExpensesNetTextBlock" name="FinancialExpensesNetTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_OtherInvestmentsPolicyTextBlock" name="OtherInvestmentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_FunctionalCurrencyPolicyTextBlock" name="FunctionalCurrencyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_RedeemableNoncontrollingInterestPolicyTextBlock" name="RedeemableNoncontrollingInterestPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_TreasurySharesPolicyTextBlock" name="TreasurySharesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_BeneficialConversionFeatureBcfPolicyTextBlock" name="BeneficialConversionFeatureBcfPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock" name="ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock" name="ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock" name="ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock" name="LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_LesseeLeaseLiabilityMaturityTableTextBlock" name="LesseeLeaseLiabilityMaturityTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ScheduleOfRightofuseAssetsByGeographicalLocation" name="ScheduleOfRightofuseAssetsByGeographicalLocation" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ScheduleOfWarrantsActivity" name="ScheduleOfWarrantsActivity" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ScheduleOfTreasuryShares" name="ScheduleOfTreasuryShares" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ScheduleOfBreakdownOfRevenuesPerCustomer" name="ScheduleOfBreakdownOfRevenuesPerCustomer" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ScheduleOfFinancialExpensesTableTextBlock" name="ScheduleOfFinancialExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock" name="ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_PercentageOfOutstandingEquityInterests" name="PercentageOfOutstandingEquityInterests" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_AggregateNominalPurchasePrice" name="AggregateNominalPurchasePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_TransactionCostIncurred" name="TransactionCostIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_AccumulatedDeficit" name="AccumulatedDeficit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_RepaymentOfIntercompanyLoansAndPayables" name="RepaymentOfIntercompanyLoansAndPayables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent" name="IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_LeaseClassificationDiscription" name="LeaseClassificationDiscription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet" name="CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DisposalGroupIncludingDiscontinuedOperationOtherExpenses" name="DisposalGroupIncludingDiscontinuedOperationOtherExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet" name="DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_IncomeLossFromDiscontinuedOperationNetOfTax" name="IncomeLossFromDiscontinuedOperationNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_NetProfitLossFromDiscontinuingOperationNetOfTax" name="NetProfitLossFromDiscontinuingOperationNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" name="DisposalGroupIncludingDiscontinuedOperationRestrictedCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DisposalGroupIncludingDiscontinuedOperationGrantsReceivable" name="DisposalGroupIncludingDiscontinuedOperationGrantsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DisposalGroupIncludingDiscontinuedOperationsDeposits" name="DisposalGroupIncludingDiscontinuedOperationsDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets" name="DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables" name="DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant" name="DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans" name="DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases" name="DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases" name="DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases" name="DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DisposalGroupIncludingDiscontinuedOperationLoansPayable" name="DisposalGroupIncludingDiscontinuedOperationLoansPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases" name="DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_PropertyPlantAndEquipmentNetAndRightOfUseAssets" name="PropertyPlantAndEquipmentNetAndRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_FairValuePercentageofSharesIssued" name="FairValuePercentageofSharesIssued" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_NumberOfSharesDepositInEscrowAccount" name="NumberOfSharesDepositInEscrowAccount" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_BusinessCombinationConsiderationTransferred" name="BusinessCombinationConsiderationTransferred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_CashPaidToAccreditedInvestors" name="CashPaidToAccreditedInvestors" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_SharesHeldInEscrow" name="SharesHeldInEscrow" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_AdditionalCashConsideration" name="AdditionalCashConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ReductionInConsiderationPayable" name="ReductionInConsiderationPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_RestrictionOnSaleOfSharesPercentage" name="RestrictionOnSaleOfSharesPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_RestrictionPeriodDescription" name="RestrictionPeriodDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive" name="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_AmortizationOfIntangibleAsset" name="AmortizationOfIntangibleAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DebtInstrumentIssuanceYear" name="DebtInstrumentIssuanceYear" nillable="true" xbrli:periodType="duration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DebtInstrumentRemainingTerm" name="DebtInstrumentRemainingTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DebtInstrumentConvertibleRepaidBeneficialConversionFeature" name="DebtInstrumentConvertibleRepaidBeneficialConversionFeature" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_PreMoneyValuation" name="PreMoneyValuation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ModificationOfExistingWarrants" name="ModificationOfExistingWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_PercentageOfCommission" name="PercentageOfCommission" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DebtInstrumentConvertibleWarrantExercisePrice" name="DebtInstrumentConvertibleWarrantExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_FinanceLeaseCost" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_GrantsReceivablePercentageOfBudgetedCosts" name="GrantsReceivablePercentageOfBudgetedCosts" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DeductionOfResearchAndDevelopmentExpenses" name="DeductionOfResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_RepaymentsOfGrantPercentageOfGrossSales" name="RepaymentsOfGrantPercentageOfGrossSales" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_CollaborationAndLicenseAgreementsAxis" name="CollaborationAndLicenseAgreementsAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="ORGS_CollaborationAndLicenseAgreementsDomain" name="CollaborationAndLicenseAgreementsDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_TerminationDescription" name="TerminationDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_RoyaltyOfNetSalesPercentage" name="RoyaltyOfNetSalesPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_SublicensingFeesPercentage" name="SublicensingFeesPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_CommitmentSharesOfCommonStock" name="CommitmentSharesOfCommonStock" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_CommitmentSharesOfCommonStockOfSubsidiary" name="CommitmentSharesOfCommonStockOfSubsidiary" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ReductionRateOfRoyaltyPercentage" name="ReductionRateOfRoyaltyPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_AdditionalFundsInvest" name="AdditionalFundsInvest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_PercentageOfGrossRevenues" name="PercentageOfGrossRevenues" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_PaymentForFinancialSupportToTrustForStudy" name="PaymentForFinancialSupportToTrustForStudy" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_PaymentForFinancialSupportCumulativeAmountToTrustForStudy" name="PaymentForFinancialSupportCumulativeAmountToTrustForStudy" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_PaymentForFinancialSupportToTrustForStudyDueEverySixMonths" name="PaymentForFinancialSupportToTrustForStudyDueEverySixMonths" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_RoyaltyOfNetSalesOfOtherProductsPercentage" name="RoyaltyOfNetSalesOfOtherProductsPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_PaymentOfFeeUponAchievementOfEachRegulatoryMilestone" name="PaymentOfFeeUponAchievementOfEachRegulatoryMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_FutureMilestonePayments" name="FutureMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_RoyaltyPercentage" name="RoyaltyPercentage" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_InterestInJointVenture" name="InterestInJointVenture" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ConvertibleLoanAdvancedToJointVenture" name="ConvertibleLoanAdvancedToJointVenture" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ConvertibleLoanAdvancedToJointVentureInterestRate" name="ConvertibleLoanAdvancedToJointVentureInterestRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_InvestmentsInAssociatePercentageOfOwnership" name="InvestmentsInAssociatePercentageOfOwnership" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_TreasuryStockShare" name="TreasuryStockShare" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock" name="WeightedAveragePriceNumberOfSharesTreasuryStock" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStockPurchased" name="WeightedAveragePriceNumberOfSharesTreasuryStockPurchased" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_WarrantExercisableDescription" name="WarrantExercisableDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_OfferingExpenses" name="OfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount" name="AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_NetIncomeLossToParentCompany" name="NetIncomeLossToParentCompany" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_StockOptionsGrantVestingPeriodPercentage" name="StockOptionsGrantVestingPeriodPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_AggregateAmountOfSubscriptionAgreement" name="AggregateAmountOfSubscriptionAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_WarrantsAndRightsOutstandingTermDescription" name="WarrantsAndRightsOutstandingTermDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ClassOfWarrantOrRightGrantsInPeriod" name="ClassOfWarrantOrRightGrantsInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice" name="ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ClassOfWarrantOrRightGrantsInPeriodFairValue" name="ClassOfWarrantOrRightGrantsInPeriodFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_FairValueOfSharesRecognizedOnGrantDate" name="FairValueOfSharesRecognizedOnGrantDate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted" name="JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_NumberOfVestedShares" name="NumberOfVestedShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_FairValueOfSharesOnVestingDatesRecognizedDuringYear" name="FairValueOfSharesOnVestingDatesRecognizedDuringYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_NumberOfAdditionalSharesRestrictionsOnTransfer" name="NumberOfAdditionalSharesRestrictionsOnTransfer" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DeferredTaxAssetsLeasesAsset" name="DeferredTaxAssetsLeasesAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_AccumulatedTaxLossCarryforwardDeductions" name="AccumulatedTaxLossCarryforwardDeductions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_AccumulatedTaxLossCarryForwardedPeriod" name="AccumulatedTaxLossCarryForwardedPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_AccountsReceivableAcquisitionOfKoligo" name="AccountsReceivableAcquisitionOfKoligo" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_AccountsReceivableAdditions" name="AccountsReceivableAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_AccountsReceivableCollections" name="AccountsReceivableCollections" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ExchangeRateDifferencesOfAccountsReceivable" name="ExchangeRateDifferencesOfAccountsReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ContractWithCustomerLiabilityAddition" name="ContractWithCustomerLiabilityAddition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ContractWithCustomerLiabilityRealizations" name="ContractWithCustomerLiabilityRealizations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ContractWithCustomerLiabilityExchangeRateDifferences" name="ContractWithCustomerLiabilityExchangeRateDifferences" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_GrantsIncome" name="GrantsIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue" name="IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_InterestExpenseOnConvertibleLoans" name="InterestExpenseOnConvertibleLoans" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_ForeignCurrencyTransactionsGainLossRealized" name="ForeignCurrencyTransactionsGainLossRealized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_TotalFinancialExpenses" name="TotalFinancialExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" name="CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_FinancialIncome" name="FinancialIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_NumberOfOrdinarySharesHeld" name="NumberOfOrdinarySharesHeld" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_DueFromRelatedPartiesNoncurrent1" name="DueFromRelatedPartiesNoncurrent1" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_CommitmentsByPartyAxis" name="CommitmentsByPartyAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="ORGS_EmployeeRangesAxis" name="EmployeeRangesAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="ORGS_StockbasedCompensationTransactionsAxis" name="StockbasedCompensationTransactionsAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="ORGS_EmployeeOneMember" name="EmployeeOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_IncomeTaxBracketsAxis" name="IncomeTaxBracketsAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="ORGS_ContractWithCustomerLiabilityRealizationsAsOfDate" name="ContractWithCustomerLiabilityRealizationsAsOfDate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_Compensation" name="Compensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_RevenuesFromCustomer" name="RevenuesFromCustomer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_FinanceIncome" name="FinanceIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_AdditionalRestrictionsOnTransferForServices" name="AdditionalRestrictionsOnTransferForServices" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_FirstAnniversaryMember" name="FirstAnniversaryMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ORGS_StockIssuedDuringPeriodSharesStockOptionExercised" name="StockIssuedDuringPeriodSharesStockOptionExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>orgs-20201231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://orgenesis.com/role/Cover" xlink:href="orgs-20201231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/BalanceSheets" xlink:href="orgs-20201231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/BalanceSheetsParenthetical" xlink:href="orgs-20201231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/StatementsOfComprehensiveLossIncome" xlink:href="orgs-20201231.xsd#StatementsOfComprehensiveLossIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/StatementsOfChangesInEquity" xlink:href="orgs-20201231.xsd#StatementsOfChangesInEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/StatementsOfCashFlows" xlink:href="orgs-20201231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/DescriptionOfBusiness" xlink:href="orgs-20201231.xsd#DescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/SignificantAccountingPolicies" xlink:href="orgs-20201231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/DiscontinuedOperation" xlink:href="orgs-20201231.xsd#DiscontinuedOperation" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/AcquisitionAndReorganization" xlink:href="orgs-20201231.xsd#AcquisitionAndReorganization" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/PropertyPlantsAndEquipment" xlink:href="orgs-20201231.xsd#PropertyPlantsAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/IntangibleAssetsAndGoodwill" xlink:href="orgs-20201231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ConvertibleLoans" xlink:href="orgs-20201231.xsd#ConvertibleLoans" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Loans" xlink:href="orgs-20201231.xsd#Loans" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Leases" xlink:href="orgs-20201231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Commitments" xlink:href="orgs-20201231.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/CollaborationAndLicenseAgreements" xlink:href="orgs-20201231.xsd#CollaborationAndLicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/InvestmentsInAssociatesNet" xlink:href="orgs-20201231.xsd#InvestmentsInAssociatesNet" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Equity" xlink:href="orgs-20201231.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/IncomeLossPerShare" xlink:href="orgs-20201231.xsd#IncomeLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Stock-basedCompensation" xlink:href="orgs-20201231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Taxes" xlink:href="orgs-20201231.xsd#Taxes" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Revenues" xlink:href="orgs-20201231.xsd#Revenues" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" xlink:href="orgs-20201231.xsd#CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/FinancialExpensesNet" xlink:href="orgs-20201231.xsd#FinancialExpensesNet" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/RelatedPartiesTransactions" xlink:href="orgs-20201231.xsd#RelatedPartiesTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/SignificantAccountingPoliciesPolicies" xlink:href="orgs-20201231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/SignificantAccountingPoliciesTables" xlink:href="orgs-20201231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/DiscontinuedOperationTables" xlink:href="orgs-20201231.xsd#DiscontinuedOperationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/AcquisitionAndReorganizationTables" xlink:href="orgs-20201231.xsd#AcquisitionAndReorganizationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/PropertyPlantsAndEquipmentTables" xlink:href="orgs-20201231.xsd#PropertyPlantsAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="orgs-20201231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ConvertibleLoansTables" xlink:href="orgs-20201231.xsd#ConvertibleLoansTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/LoansTables" xlink:href="orgs-20201231.xsd#LoansTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/LeasesTables" xlink:href="orgs-20201231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/InvestmentsInAssociatesNetTables" xlink:href="orgs-20201231.xsd#InvestmentsInAssociatesNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/EquityTables" xlink:href="orgs-20201231.xsd#EquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/IncomeLossPerShareTables" xlink:href="orgs-20201231.xsd#IncomeLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Stock-basedCompensationTables" xlink:href="orgs-20201231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/TaxesTables" xlink:href="orgs-20201231.xsd#TaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/RevenuesTables" xlink:href="orgs-20201231.xsd#RevenuesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNetTables" xlink:href="orgs-20201231.xsd#CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/FinancialExpensesNetTables" xlink:href="orgs-20201231.xsd#FinancialExpensesNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/RelatedPartiesTransactionsTables" xlink:href="orgs-20201231.xsd#RelatedPartiesTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative" xlink:href="orgs-20201231.xsd#DescriptionOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails" xlink:href="orgs-20201231.xsd#ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfIntangibleAssetsAndTheirUsefulLiveDetails" xlink:href="orgs-20201231.xsd#ScheduleOfIntangibleAssetsAndTheirUsefulLiveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="orgs-20201231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative" xlink:href="orgs-20201231.xsd#DiscontinuedOperationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="orgs-20201231.xsd#SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical" xlink:href="orgs-20201231.xsd#SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfUnauditedSupplementalProFormaDetails" xlink:href="orgs-20201231.xsd#ScheduleOfUnauditedSupplementalProFormaDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative" xlink:href="orgs-20201231.xsd#AcquisitionAndReorganizationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails" xlink:href="orgs-20201231.xsd#ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails" xlink:href="orgs-20201231.xsd#ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/PropertyPlantsAndEquipmentDetailsNarrative" xlink:href="orgs-20201231.xsd#PropertyPlantsAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfGoodwillDetails" xlink:href="orgs-20201231.xsd#ScheduleOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfOtherIntangibleAssetsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfOtherIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfEstimatedAggregateAmortizationExpensesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfEstimatedAggregateAmortizationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:href="orgs-20201231.xsd#IntangibleAssetsAndGoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails" xlink:href="orgs-20201231.xsd#ScheduleOfLongTermConvertibleLoansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical" xlink:href="orgs-20201231.xsd#ScheduleOfLongTermConvertibleLoansDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ConvertibleLoansDetailsNarrative" xlink:href="orgs-20201231.xsd#ConvertibleLoansDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfLoansDetails" xlink:href="orgs-20201231.xsd#ScheduleOfLoansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfLease-relatedAssetsAndLiabilitiesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfLease-relatedAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfLeaseCostsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfLeaseCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfSupplementalCashflowInformationDetails" xlink:href="orgs-20201231.xsd#ScheduleOfSupplementalCashflowInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfRight-of-useAssetsByGeographicalLocationDetails" xlink:href="orgs-20201231.xsd#ScheduleOfRight-of-useAssetsByGeographicalLocationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/LeasesDetailsNarrative" xlink:href="orgs-20201231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/CommitmentsDetailsNarrative" xlink:href="orgs-20201231.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative" xlink:href="orgs-20201231.xsd#CollaborationAndLicenseAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfChangesInInvestmentsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfChangesInInvestmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/InvestmentsInAssociatesNetDetailsNarrative" xlink:href="orgs-20201231.xsd#InvestmentsInAssociatesNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="orgs-20201231.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfTreasurySharesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfTreasurySharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/EquityDetailsNarrative" xlink:href="orgs-20201231.xsd#EquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfBasicAndDilutedLossPerShareDetails" xlink:href="orgs-20201231.xsd#ScheduleOfBasicAndDilutedLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/IncomeLossPerShareDetailsNarrative" xlink:href="orgs-20201231.xsd#IncomeLossPerShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails" xlink:href="orgs-20201231.xsd#ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails" xlink:href="orgs-20201231.xsd#ScheduleOfStockOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails" xlink:href="orgs-20201231.xsd#ScheduleOfStockOptionsExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfStockOptionsGrantedToConsultantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="orgs-20201231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfValuationAllowanceActivityDetails" xlink:href="orgs-20201231.xsd#ScheduleOfValuationAllowanceActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/TaxesDetailsNarrative" xlink:href="orgs-20201231.xsd#TaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:href="orgs-20201231.xsd#ScheduleOfDisaggregationOfRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfBreakdownOfRevenuesPerCustomerDetails" xlink:href="orgs-20201231.xsd#ScheduleOfBreakdownOfRevenuesPerCustomerDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfActivityForTradeReceivablesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfActivityForTradeReceivablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfActivityForContractLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetailsParenthetical" xlink:href="orgs-20201231.xsd#ScheduleOfActivityForContractLiabilitiesDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/RevenuesDetailsNarrative" xlink:href="orgs-20201231.xsd#RevenuesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfFinancialExpensesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfFinancialExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfRelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical" xlink:href="orgs-20201231.xsd#ScheduleOfRelatedPartyTransactionsDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaapGrantsReceivableCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapGrantsReceivableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesNoncurrent" xlink:label="loc_us-gaapDueFromRelatedPartiesNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDueFromRelatedPartiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AccruedExpensesAndOtherPayablesCurrent" xlink:label="loc_ORGSAccruedExpensesAndOtherPayablesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_ORGSAccruedExpensesAndOtherPayablesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdvancePaymentsOnAccountOfGrant" xlink:label="loc_ORGSAdvancePaymentsOnAccountOfGrant" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_ORGSAdvancePaymentsOnAccountOfGrant" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaapConvertibleDebtCurrent" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleDebtCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaapConvertibleDebtNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapConvertibleDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="loc_us-gaapPensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapPensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RedeemableNoncontrollingInterestOfDiscontinuedOperation" xlink:label="loc_ORGSRedeemableNoncontrollingInterestOfDiscontinuedOperation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_ORGSRedeemableNoncontrollingInterestOfDiscontinuedOperation" xlink:type="arc" weight="1" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/StatementsOfComprehensiveLossIncome" xlink:title="00000004 - Statement - Consolidated Statements of Comprehensive Loss (Income)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRevenues" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaapRevenueFromRelatedParties" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRevenues" xlink:to="loc_us-gaapRevenueFromRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome" xlink:label="loc_us-gaapOtherOperatingIncome" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOtherOperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareInNetIncomeOfAssociatedCompanies" xlink:label="loc_ORGSShareInNetIncomeOfAssociatedCompanies" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_ORGSShareInNetIncomeOfAssociatedCompanies" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/StatementsOfChangesInEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationOne" xlink:label="loc_ORGSShareBasedCompensationOne" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ORGSShareBasedCompensationOne" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationTwo" xlink:label="loc_ORGSShareBasedCompensationTwo" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ORGSShareBasedCompensationTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:label="loc_us-gaapGainOrLossOnSaleOfStockInSubsidiary" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainOrLossOnSaleOfStockInSubsidiary" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareInNetIncomeOfAssociatedCompanies" xlink:label="loc_ORGSShareInNetIncomeOfAssociatedCompanies" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ORGSShareInNetIncomeOfAssociatedCompanies" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances" xlink:label="loc_ORGSIncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ORGSIncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NetChangesInOperatingLeases" xlink:label="loc_ORGSNetChangesInOperatingLeases" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ORGSNetChangesInOperatingLeases" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseShortTermBorrowings" xlink:label="loc_us-gaapInterestExpenseShortTermBorrowings" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInterestExpenseShortTermBorrowings" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncreaseDecreaseInAccuredExpensesAndOtherPayables" xlink:label="loc_ORGSIncreaseDecreaseInAccuredExpensesAndOtherPayables" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ORGSIncreaseDecreaseInAccuredExpensesAndOtherPayables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant" xlink:label="loc_ORGSIncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ORGSIncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredIncomeTaxes" />
      <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForLongTermLoansForRelatedParties" xlink:label="loc_us-gaapProceedsFromPaymentsForLongTermLoansForRelatedParties" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromPaymentsForLongTermLoansForRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaapProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PaymentsForInvestments" xlink:label="loc_ORGSPaymentsForInvestments" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_ORGSPaymentsForInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaapPaymentsForProceedsFromInvestments" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsForProceedsFromInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RepaymentOfTreasuryStock" xlink:label="loc_ORGSRepaymentOfTreasuryStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ORGSRepaymentOfTreasuryStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_us-gaapProceedsFromMinorityShareholders" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromMinorityShareholders" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/DescriptionOfBusiness" xlink:title="00000007 - Disclosure - DESCRIPTION OF BUSINESS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/SignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/DiscontinuedOperation" xlink:title="00000009 - Disclosure - DISCONTINUED OPERATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/AcquisitionAndReorganization" xlink:title="00000010 - Disclosure - ACQUISITION AND REORGANIZATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/PropertyPlantsAndEquipment" xlink:title="00000011 - Disclosure - PROPERTY, PLANTS AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/IntangibleAssetsAndGoodwill" xlink:title="00000012 - Disclosure - INTANGIBLE ASSETS AND GOODWILL" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ConvertibleLoans" xlink:title="00000013 - Disclosure - CONVERTIBLE LOANS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Loans" xlink:title="00000014 - Disclosure - LOANS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Leases" xlink:title="00000015 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Commitments" xlink:title="00000016 - Disclosure - COMMITMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/CollaborationAndLicenseAgreements" xlink:title="00000017 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/InvestmentsInAssociatesNet" xlink:title="00000018 - Disclosure - INVESTMENTS IN ASSOCIATES, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Equity" xlink:title="00000019 - Disclosure - EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/IncomeLossPerShare" xlink:title="00000020 - Disclosure - INCOME (LOSS) PER SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Stock-basedCompensation" xlink:title="00000021 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Taxes" xlink:title="00000022 - Disclosure - TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Revenues" xlink:title="00000023 - Disclosure - REVENUES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" xlink:title="00000024 - Disclosure - COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/FinancialExpensesNet" xlink:title="00000025 - Disclosure - FINANCIAL EXPENSES, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/RelatedPartiesTransactions" xlink:title="00000026 - Disclosure - RELATED PARTIES TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000027 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/SignificantAccountingPoliciesTables" xlink:title="00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/DiscontinuedOperationTables" xlink:title="00000029 - Disclosure - DISCONTINUED OPERATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/AcquisitionAndReorganizationTables" xlink:title="00000030 - Disclosure - ACQUISITION AND REORGANIZATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/PropertyPlantsAndEquipmentTables" xlink:title="00000031 - Disclosure - PROPERTY, PLANTS AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="00000032 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ConvertibleLoansTables" xlink:title="00000033 - Disclosure - CONVERTIBLE LOANS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/LoansTables" xlink:title="00000034 - Disclosure - LOANS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/LeasesTables" xlink:title="00000035 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/InvestmentsInAssociatesNetTables" xlink:title="00000036 - Disclosure - INVESTMENTS IN ASSOCIATES, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/EquityTables" xlink:title="00000037 - Disclosure - EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/IncomeLossPerShareTables" xlink:title="00000038 - Disclosure - INCOME (LOSS) PER SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Stock-basedCompensationTables" xlink:title="00000039 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/TaxesTables" xlink:title="00000040 - Disclosure - TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/RevenuesTables" xlink:title="00000041 - Disclosure - REVENUES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNetTables" xlink:title="00000042 - Disclosure - COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/FinancialExpensesNetTables" xlink:title="00000043 - Disclosure - FINANCIAL EXPENSES, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/RelatedPartiesTransactionsTables" xlink:title="00000044 - Disclosure - RELATED PARTIES TRANSACTIONS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative" xlink:title="00000045 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfIntangibleAssetsAndTheirUsefulLiveDetails" xlink:title="00000047 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000048 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF DISCONTINUED OPERATION AND BALANCE SHEETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsDetails" xlink:title="00000050 - Disclosure - SCHEDULE OF DISAGGREGATION OF REVENUE RELATED TO DISCONTINUED OPERATIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative" xlink:title="00000051 - Disclosure - DISCONTINUED OPERATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:title="00000052 - Disclosure - SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued" xlink:label="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments" xlink:label="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical" xlink:title="00000053 - Disclosure - SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfUnauditedSupplementalProFormaDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF UNAUDITED SUPPLEMENTAL PRO FORMA (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative" xlink:title="00000055 - Disclosure - ACQUISITION AND REORGANIZATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails" xlink:title="00000056 - Disclosure - SCHEDULE OF COMPONENTS OF PROPERTY, PLANTS AND EQUIPMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails" xlink:title="00000057 - Disclosure - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT BY GEOGRAPHICAL LOCATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/PropertyPlantsAndEquipmentDetailsNarrative" xlink:title="00000058 - Disclosure - PROPERTY, PLANTS AND EQUIPMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfGoodwillDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF GOODWILL (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfOtherIntangibleAssetsDetails" xlink:title="00000060 - Disclosure - SCHEDULE OF OTHER INTANGIBLE ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfEstimatedAggregateAmortizationExpensesDetails" xlink:title="00000061 - Disclosure - SCHEDULE OF ESTIMATED AGGREGATE AMORTIZATION EXPENSES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:title="00000062 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails" xlink:title="00000063 - Disclosure - SCHEDULE OF LONG TERM CONVERTIBLE LOANS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical" xlink:title="00000064 - Disclosure - SCHEDULE OF LONG TERM CONVERTIBLE LOANS (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ConvertibleLoansDetailsNarrative" xlink:title="00000065 - Disclosure - CONVERTIBLE LOANS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfLoansDetails" xlink:title="00000066 - Disclosure - SCHEDULE OF LOANS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfLease-relatedAssetsAndLiabilitiesDetails" xlink:title="00000067 - Disclosure - SCHEDULE OF LEASE-RELATED ASSETS AND LIABILITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfLeaseCostsDetails" xlink:title="00000068 - Disclosure - SCHEDULE OF LEASE COSTS (Details)">
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FinanceLeaseCost" xlink:label="loc_ORGSFinanceLeaseCost" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ORGSFinanceLeaseCost" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ORGSFinanceLeaseCost" xlink:to="loc_us-gaapFinanceLeaseInterestExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfSupplementalCashflowInformationDetails" xlink:title="00000069 - Disclosure - SCHEDULE OF SUPPLEMENTAL CASHFLOW INFORMATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails" xlink:title="00000070 - Disclosure - SCHEDULE OF FINANCE LEASE LIABILITIES AND OPERATING LEASE LIABILITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfRight-of-useAssetsByGeographicalLocationDetails" xlink:title="00000071 - Disclosure - SCHEDULE OF RIGHT-OF-USE ASSETS BY GEOGRAPHICAL LOCATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/LeasesDetailsNarrative" xlink:title="00000072 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/CommitmentsDetailsNarrative" xlink:title="00000073 - Disclosure - COMMITMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative" xlink:title="00000074 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfChangesInInvestmentsDetails" xlink:title="00000075 - Disclosure - SCHEDULE OF CHANGES IN INVESTMENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/InvestmentsInAssociatesNetDetailsNarrative" xlink:title="00000076 - Disclosure - INVESTMENTS IN ASSOCIATES, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000077 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfTreasurySharesDetails" xlink:title="00000078 - Disclosure - SCHEDULE OF TREASURY SHARES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/EquityDetailsNarrative" xlink:title="00000079 - Disclosure - EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfBasicAndDilutedLossPerShareDetails" xlink:title="00000080 - Disclosure - SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/IncomeLossPerShareDetailsNarrative" xlink:title="00000081 - Disclosure - INCOME (LOSS) PER SHARE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails" xlink:title="00000082 - Disclosure - SCHEDULE OF EMPLOYEE STOCK OWNERSHIP PLAN DISCLOSURES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:title="00000083 - Disclosure - SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails" xlink:title="00000084 - Disclosure - SCHEDULE OF STOCK OPTIONS ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails" xlink:title="00000085 - Disclosure - SCHEDULE OF STOCK OPTIONS EXERCISABLE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails" xlink:title="00000086 - Disclosure - SCHEDULE OF STOCK OPTIONS GRANTED TO CONSULTANTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000087 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="00000088 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DeferredTaxAssetsLeasesAsset" xlink:label="loc_ORGSDeferredTaxAssetsLeasesAsset" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_ORGSDeferredTaxAssetsLeasesAsset" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DeferredTaxAssetsLeaseLiability" xlink:label="loc_ORGSDeferredTaxAssetsLeaseLiability" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_ORGSDeferredTaxAssetsLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfValuationAllowanceActivityDetails" xlink:title="00000089 - Disclosure - SCHEDULE OF VALUATION ALLOWANCE, ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/TaxesDetailsNarrative" xlink:title="00000090 - Disclosure - TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:title="00000091 - Disclosure - SCHEDULE OF DISAGGREGATION OF REVENUE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfBreakdownOfRevenuesPerCustomerDetails" xlink:title="00000092 - Disclosure - SCHEDULE OF BREAKDOWN OF REVENUES PER CUSTOMER (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfActivityForTradeReceivablesDetails" xlink:title="00000093 - Disclosure - SCHEDULE OF ACTIVITY FOR TRADE RECEIVABLES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetails" xlink:title="00000094 - Disclosure - SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetailsParenthetical" xlink:title="00000095 - Disclosure - SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/RevenuesDetailsNarrative" xlink:title="00000096 - Disclosure - REVENUES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:title="00000097 - Disclosure - SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfFinancialExpensesDetails" xlink:title="00000098 - Disclosure - SCHEDULE OF FINANCIAL EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TotalFinancialExpenses" xlink:label="loc_ORGSTotalFinancialExpenses" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue" xlink:label="loc_ORGSIncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ORGSTotalFinancialExpenses" xlink:to="loc_ORGSIncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_InterestExpenseOnConvertibleLoans" xlink:label="loc_ORGSInterestExpenseOnConvertibleLoans" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ORGSTotalFinancialExpenses" xlink:to="loc_ORGSInterestExpenseOnConvertibleLoans" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ForeignCurrencyTransactionsGainLossRealized" xlink:label="loc_ORGSForeignCurrencyTransactionsGainLossRealized" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ORGSTotalFinancialExpenses" xlink:to="loc_ORGSForeignCurrencyTransactionsGainLossRealized" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ORGSTotalFinancialExpenses" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:title="00000099 - Disclosure - SCHEDULE OF RELATED PARTY TRANSACTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical" xlink:title="00000100 - Disclosure - SCHEDULE OF RELATED PARTY TRANSACTIONS (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails" xlink:title="00000101 - Disclosure - SCHEDULE OF RELATED PARTIES PRESENTED IN CONSOLIDATED BALANCE SHEETS (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>orgs-20201231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://orgenesis.com/role/Cover" xlink:href="orgs-20201231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/BalanceSheets" xlink:href="orgs-20201231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/BalanceSheetsParenthetical" xlink:href="orgs-20201231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/StatementsOfComprehensiveLossIncome" xlink:href="orgs-20201231.xsd#StatementsOfComprehensiveLossIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/StatementsOfChangesInEquity" xlink:href="orgs-20201231.xsd#StatementsOfChangesInEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/StatementsOfCashFlows" xlink:href="orgs-20201231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/DescriptionOfBusiness" xlink:href="orgs-20201231.xsd#DescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/SignificantAccountingPolicies" xlink:href="orgs-20201231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/DiscontinuedOperation" xlink:href="orgs-20201231.xsd#DiscontinuedOperation" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/AcquisitionAndReorganization" xlink:href="orgs-20201231.xsd#AcquisitionAndReorganization" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/PropertyPlantsAndEquipment" xlink:href="orgs-20201231.xsd#PropertyPlantsAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/IntangibleAssetsAndGoodwill" xlink:href="orgs-20201231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ConvertibleLoans" xlink:href="orgs-20201231.xsd#ConvertibleLoans" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Loans" xlink:href="orgs-20201231.xsd#Loans" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Leases" xlink:href="orgs-20201231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Commitments" xlink:href="orgs-20201231.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/CollaborationAndLicenseAgreements" xlink:href="orgs-20201231.xsd#CollaborationAndLicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/InvestmentsInAssociatesNet" xlink:href="orgs-20201231.xsd#InvestmentsInAssociatesNet" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Equity" xlink:href="orgs-20201231.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/IncomeLossPerShare" xlink:href="orgs-20201231.xsd#IncomeLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Stock-basedCompensation" xlink:href="orgs-20201231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Taxes" xlink:href="orgs-20201231.xsd#Taxes" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Revenues" xlink:href="orgs-20201231.xsd#Revenues" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" xlink:href="orgs-20201231.xsd#CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/FinancialExpensesNet" xlink:href="orgs-20201231.xsd#FinancialExpensesNet" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/RelatedPartiesTransactions" xlink:href="orgs-20201231.xsd#RelatedPartiesTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/SignificantAccountingPoliciesPolicies" xlink:href="orgs-20201231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/SignificantAccountingPoliciesTables" xlink:href="orgs-20201231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/DiscontinuedOperationTables" xlink:href="orgs-20201231.xsd#DiscontinuedOperationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/AcquisitionAndReorganizationTables" xlink:href="orgs-20201231.xsd#AcquisitionAndReorganizationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/PropertyPlantsAndEquipmentTables" xlink:href="orgs-20201231.xsd#PropertyPlantsAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="orgs-20201231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ConvertibleLoansTables" xlink:href="orgs-20201231.xsd#ConvertibleLoansTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/LoansTables" xlink:href="orgs-20201231.xsd#LoansTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/LeasesTables" xlink:href="orgs-20201231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/InvestmentsInAssociatesNetTables" xlink:href="orgs-20201231.xsd#InvestmentsInAssociatesNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/EquityTables" xlink:href="orgs-20201231.xsd#EquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/IncomeLossPerShareTables" xlink:href="orgs-20201231.xsd#IncomeLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Stock-basedCompensationTables" xlink:href="orgs-20201231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/TaxesTables" xlink:href="orgs-20201231.xsd#TaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/RevenuesTables" xlink:href="orgs-20201231.xsd#RevenuesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNetTables" xlink:href="orgs-20201231.xsd#CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/FinancialExpensesNetTables" xlink:href="orgs-20201231.xsd#FinancialExpensesNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/RelatedPartiesTransactionsTables" xlink:href="orgs-20201231.xsd#RelatedPartiesTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative" xlink:href="orgs-20201231.xsd#DescriptionOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails" xlink:href="orgs-20201231.xsd#ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfIntangibleAssetsAndTheirUsefulLiveDetails" xlink:href="orgs-20201231.xsd#ScheduleOfIntangibleAssetsAndTheirUsefulLiveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="orgs-20201231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative" xlink:href="orgs-20201231.xsd#DiscontinuedOperationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="orgs-20201231.xsd#SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical" xlink:href="orgs-20201231.xsd#SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfUnauditedSupplementalProFormaDetails" xlink:href="orgs-20201231.xsd#ScheduleOfUnauditedSupplementalProFormaDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative" xlink:href="orgs-20201231.xsd#AcquisitionAndReorganizationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails" xlink:href="orgs-20201231.xsd#ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails" xlink:href="orgs-20201231.xsd#ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/PropertyPlantsAndEquipmentDetailsNarrative" xlink:href="orgs-20201231.xsd#PropertyPlantsAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfGoodwillDetails" xlink:href="orgs-20201231.xsd#ScheduleOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfOtherIntangibleAssetsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfOtherIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfEstimatedAggregateAmortizationExpensesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfEstimatedAggregateAmortizationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:href="orgs-20201231.xsd#IntangibleAssetsAndGoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails" xlink:href="orgs-20201231.xsd#ScheduleOfLongTermConvertibleLoansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical" xlink:href="orgs-20201231.xsd#ScheduleOfLongTermConvertibleLoansDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ConvertibleLoansDetailsNarrative" xlink:href="orgs-20201231.xsd#ConvertibleLoansDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfLoansDetails" xlink:href="orgs-20201231.xsd#ScheduleOfLoansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfLease-relatedAssetsAndLiabilitiesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfLease-relatedAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfLeaseCostsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfLeaseCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfSupplementalCashflowInformationDetails" xlink:href="orgs-20201231.xsd#ScheduleOfSupplementalCashflowInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfRight-of-useAssetsByGeographicalLocationDetails" xlink:href="orgs-20201231.xsd#ScheduleOfRight-of-useAssetsByGeographicalLocationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/LeasesDetailsNarrative" xlink:href="orgs-20201231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/CommitmentsDetailsNarrative" xlink:href="orgs-20201231.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative" xlink:href="orgs-20201231.xsd#CollaborationAndLicenseAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfChangesInInvestmentsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfChangesInInvestmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/InvestmentsInAssociatesNetDetailsNarrative" xlink:href="orgs-20201231.xsd#InvestmentsInAssociatesNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="orgs-20201231.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfTreasurySharesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfTreasurySharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/EquityDetailsNarrative" xlink:href="orgs-20201231.xsd#EquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfBasicAndDilutedLossPerShareDetails" xlink:href="orgs-20201231.xsd#ScheduleOfBasicAndDilutedLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/IncomeLossPerShareDetailsNarrative" xlink:href="orgs-20201231.xsd#IncomeLossPerShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails" xlink:href="orgs-20201231.xsd#ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails" xlink:href="orgs-20201231.xsd#ScheduleOfStockOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails" xlink:href="orgs-20201231.xsd#ScheduleOfStockOptionsExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfStockOptionsGrantedToConsultantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="orgs-20201231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfValuationAllowanceActivityDetails" xlink:href="orgs-20201231.xsd#ScheduleOfValuationAllowanceActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/TaxesDetailsNarrative" xlink:href="orgs-20201231.xsd#TaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:href="orgs-20201231.xsd#ScheduleOfDisaggregationOfRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfBreakdownOfRevenuesPerCustomerDetails" xlink:href="orgs-20201231.xsd#ScheduleOfBreakdownOfRevenuesPerCustomerDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfActivityForTradeReceivablesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfActivityForTradeReceivablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfActivityForContractLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetailsParenthetical" xlink:href="orgs-20201231.xsd#ScheduleOfActivityForContractLiabilitiesDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/RevenuesDetailsNarrative" xlink:href="orgs-20201231.xsd#RevenuesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfFinancialExpensesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfFinancialExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfRelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical" xlink:href="orgs-20201231.xsd#ScheduleOfRelatedPartyTransactionsDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/StatementsOfComprehensiveLossIncome" xlink:title="00000004 - Statement - Consolidated Statements of Comprehensive Loss (Income)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/StatementsOfChangesInEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_EquityAttributedToOrgenesisIncMember" xlink:label="loc_ORGSEquityAttributedToOrgenesisIncMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ORGSEquityAttributedToOrgenesisIncMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapNoncontrollingInterestMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaapTreasuryStockMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement" xlink:label="loc_ORGSStockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ORGSStockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares" xlink:label="loc_ORGSStockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ORGSStockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IssuanceOfSharesAndWarrants" xlink:label="loc_ORGSIssuanceOfSharesAndWarrants_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ORGSIssuanceOfSharesAndWarrants_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IssuanceOfSharesAndWarrantsShares" xlink:label="loc_ORGSIssuanceOfSharesAndWarrantsShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ORGSIssuanceOfSharesAndWarrantsShares_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_90" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_90" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:label="loc_us-gaapNoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_90" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue_90" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_90" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_StockbasedCompensationToStrategicCollaborations" xlink:label="loc_ORGSStockbasedCompensationToStrategicCollaborations_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ORGSStockbasedCompensationToStrategicCollaborations_90" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_StockbasedCompensationToStrategicCollaborationsShares" xlink:label="loc_ORGSStockbasedCompensationToStrategicCollaborationsShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ORGSStockbasedCompensationToStrategicCollaborationsShares_90" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans" xlink:label="loc_ORGSIssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ORGSIssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans_90" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp" xlink:label="loc_ORGSAdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ORGSAdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp_90" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_90" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_90" xlink:type="arc" order="23" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/DescriptionOfBusiness" xlink:title="00000007 - Disclosure - DESCRIPTION OF BUSINESS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/SignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/DiscontinuedOperation" xlink:title="00000009 - Disclosure - DISCONTINUED OPERATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/AcquisitionAndReorganization" xlink:title="00000010 - Disclosure - ACQUISITION AND REORGANIZATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/PropertyPlantsAndEquipment" xlink:title="00000011 - Disclosure - PROPERTY, PLANTS AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/IntangibleAssetsAndGoodwill" xlink:title="00000012 - Disclosure - INTANGIBLE ASSETS AND GOODWILL" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ConvertibleLoans" xlink:title="00000013 - Disclosure - CONVERTIBLE LOANS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Loans" xlink:title="00000014 - Disclosure - LOANS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Leases" xlink:title="00000015 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Commitments" xlink:title="00000016 - Disclosure - COMMITMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/CollaborationAndLicenseAgreements" xlink:title="00000017 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/InvestmentsInAssociatesNet" xlink:title="00000018 - Disclosure - INVESTMENTS IN ASSOCIATES, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Equity" xlink:title="00000019 - Disclosure - EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/IncomeLossPerShare" xlink:title="00000020 - Disclosure - INCOME (LOSS) PER SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Stock-basedCompensation" xlink:title="00000021 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Taxes" xlink:title="00000022 - Disclosure - TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Revenues" xlink:title="00000023 - Disclosure - REVENUES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" xlink:title="00000024 - Disclosure - COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/FinancialExpensesNet" xlink:title="00000025 - Disclosure - FINANCIAL EXPENSES, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/RelatedPartiesTransactions" xlink:title="00000026 - Disclosure - RELATED PARTIES TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000027 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/SignificantAccountingPoliciesTables" xlink:title="00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/DiscontinuedOperationTables" xlink:title="00000029 - Disclosure - DISCONTINUED OPERATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/AcquisitionAndReorganizationTables" xlink:title="00000030 - Disclosure - ACQUISITION AND REORGANIZATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/PropertyPlantsAndEquipmentTables" xlink:title="00000031 - Disclosure - PROPERTY, PLANTS AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="00000032 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ConvertibleLoansTables" xlink:title="00000033 - Disclosure - CONVERTIBLE LOANS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/LoansTables" xlink:title="00000034 - Disclosure - LOANS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/LeasesTables" xlink:title="00000035 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/InvestmentsInAssociatesNetTables" xlink:title="00000036 - Disclosure - INVESTMENTS IN ASSOCIATES, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/EquityTables" xlink:title="00000037 - Disclosure - EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/IncomeLossPerShareTables" xlink:title="00000038 - Disclosure - INCOME (LOSS) PER SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Stock-basedCompensationTables" xlink:title="00000039 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToEmployeesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToEmployeesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToNonEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToNonEmployeesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToNonEmployeesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/TaxesTables" xlink:title="00000040 - Disclosure - TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/RevenuesTables" xlink:title="00000041 - Disclosure - REVENUES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNetTables" xlink:title="00000042 - Disclosure - COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/FinancialExpensesNetTables" xlink:title="00000043 - Disclosure - FINANCIAL EXPENSES, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/RelatedPartiesTransactionsTables" xlink:title="00000044 - Disclosure - RELATED PARTIES TRANSACTIONS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative" xlink:title="00000045 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:label="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MasthercellMember" xlink:label="loc_ORGSMasthercellMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSMasthercellMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CureCellCoLtdMember" xlink:label="loc_ORGSCureCellCoLtdMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSCureCellCoLtdMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SecuritiesPurchaseAgreementMember" xlink:label="loc_ORGSSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TamirPurchaseAgreementMember" xlink:label="loc_ORGSTamirPurchaseAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSTamirPurchaseAgreementMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TamirBiotechnologyIncMember" xlink:label="loc_ORGSTamirBiotechnologyIncMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ORGSTamirBiotechnologyIncMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PercentageOfOutstandingEquityInterests" xlink:label="loc_ORGSPercentageOfOutstandingEquityInterests_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_ORGSPercentageOfOutstandingEquityInterests_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AggregateNominalPurchasePrice" xlink:label="loc_ORGSAggregateNominalPurchasePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_ORGSAggregateNominalPurchasePrice_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TransactionCostIncurred" xlink:label="loc_ORGSTransactionCostIncurred_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_ORGSTransactionCostIncurred_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AccumulatedDeficit" xlink:label="loc_ORGSAccumulatedDeficit_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_ORGSAccumulatedDeficit_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RepaymentOfIntercompanyLoansAndPayables" xlink:label="loc_ORGSRepaymentOfIntercompanyLoansAndPayables_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_ORGSRepaymentOfIntercompanyLoansAndPayables_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_80" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ProductionFacilityMember" xlink:label="loc_ORGSProductionFacilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ORGSProductionFacilityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfIntangibleAssetsAndTheirUsefulLiveDetails" xlink:title="00000047 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KnowhowMember" xlink:label="loc_ORGSKnowhowMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ORGSKnowhowMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TechnologyMember" xlink:label="loc_ORGSTechnologyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ORGSTechnologyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000048 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="loc_us-gaapAccountingStandardsUpdate201912Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTypeOfAdoptionMember" xlink:to="loc_us-gaapAccountingStandardsUpdate201912Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLoss_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent" xlink:label="loc_ORGSIncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_ORGSIncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaapTreasuryStockShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapTreasuryStockShares_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_LeaseClassificationDiscription" xlink:label="loc_ORGSLeaseClassificationDiscription_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_ORGSLeaseClassificationDiscription_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF DISCONTINUED OPERATION AND BALANCE SHEETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MortgageLoansOnRealEstateLineItems" xlink:label="loc_srtMortgageLoansOnRealEstateLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_countryUS_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_BE" xlink:label="loc_countryBE_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryBE_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationRevenue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationRevenue_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet" xlink:label="loc_ORGSCostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSCostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:label="loc_us-gaapDepreciationAndAmortizationDiscontinuedOperations_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDepreciationAndAmortizationDiscontinuedOperations_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationOtherExpenses" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationOtherExpenses_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationOtherExpenses_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaapDiscontinuedOperationTaxEffectOfDiscontinuedOperation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDiscontinuedOperationTaxEffectOfDiscontinuedOperation_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncomeLossFromDiscontinuedOperationNetOfTax" xlink:label="loc_ORGSIncomeLossFromDiscontinuedOperationNetOfTax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSIncomeLossFromDiscontinuedOperationNetOfTax_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax" xlink:label="loc_us-gaapDiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal" xlink:label="loc_us-gaapDiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaapDiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NetProfitLossFromDiscontinuingOperationNetOfTax" xlink:label="loc_ORGSNetProfitLossFromDiscontinuingOperationNetOfTax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSNetProfitLossFromDiscontinuingOperationNetOfTax_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationRestrictedCash_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationRestrictedCash_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationGrantsReceivable" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationGrantsReceivable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationGrantsReceivable_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationInventory1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationInventory1_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationsDeposits" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationsDeposits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationsDeposits_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_60" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationIntangibleAssets_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationIntangibleAssets_60" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets_60" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGoodwill1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGoodwill1_60" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOtherAssets_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOtherAssets_60" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperation_60" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayable_60" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_60" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables_60" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant_60" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans_60" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOtherLiabilities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOtherLiabilities_60" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases_60" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases_60" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases_60" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationLoansPayable" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationLoansPayable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationLoansPayable_60" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_60" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases_60" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_60" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PropertyPlantAndEquipmentNetAndRightOfUseAssets" xlink:label="loc_ORGSPropertyPlantAndEquipmentNetAndRightOfUseAssets_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSPropertyPlantAndEquipmentNetAndRightOfUseAssets_60" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaapCashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapCashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_60" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaapCashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapCashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_60" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaapCashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapCashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_60" xlink:type="arc" order="44" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsDetails" xlink:title="00000050 - Disclosure - SCHEDULE OF DISAGGREGATION OF REVENUE RELATED TO DISCONTINUED OPERATIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:label="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CellProcessDevelopmentServicesMember" xlink:label="loc_ORGSCellProcessDevelopmentServicesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_ORGSCellProcessDevelopmentServicesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TechTransferServicesMember" xlink:label="loc_ORGSTechTransferServicesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_ORGSTechTransferServicesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CellManufacturingServicesMember" xlink:label="loc_ORGSCellManufacturingServicesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_ORGSCellManufacturingServicesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationRevenue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationRevenue_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative" xlink:title="00000051 - Disclosure - DISCONTINUED OPERATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:label="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MasthercellMember" xlink:label="loc_ORGSMasthercellMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSMasthercellMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MasthercellSAMember" xlink:label="loc_ORGSMasthercellSAMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSMasthercellSAMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SecuritiesPurchaseAgreementMember" xlink:label="loc_ORGSSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PercentageOfOutstandingEquityInterests" xlink:label="loc_ORGSPercentageOfOutstandingEquityInterests_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_ORGSPercentageOfOutstandingEquityInterests_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AggregateNominalPurchasePrice" xlink:label="loc_ORGSAggregateNominalPurchasePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_ORGSAggregateNominalPurchasePrice_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RepaymentOfIntercompanyLoansAndPayables" xlink:label="loc_ORGSRepaymentOfIntercompanyLoansAndPayables_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_ORGSRepaymentOfIntercompanyLoansAndPayables_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:title="00000052 - Disclosure - SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KyslecelTechnologyMember" xlink:label="loc_ORGSKyslecelTechnologyMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ORGSKyslecelTechnologyMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IPResearchAndDevelopmentMember" xlink:label="loc_ORGSIPResearchAndDevelopmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ORGSIPResearchAndDevelopmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued" xlink:label="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments" xlink:label="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:label="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill" xlink:label="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease" xlink:label="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability" xlink:label="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_40" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical" xlink:title="00000053 - Disclosure - SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KyslecelTechnologyMember" xlink:label="loc_ORGSKyslecelTechnologyMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ORGSKyslecelTechnologyMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IPResearchAndDevelopmentMember" xlink:label="loc_ORGSIPResearchAndDevelopmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ORGSIPResearchAndDevelopmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FairValuePercentageofSharesIssued" xlink:label="loc_ORGSFairValuePercentageofSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSFairValuePercentageofSharesIssued_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfUnauditedSupplementalProFormaDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF UNAUDITED SUPPLEMENTAL PRO FORMA (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KoligoTherapeuticsIncMember" xlink:label="loc_ORGSKoligoTherapeuticsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ORGSKoligoTherapeuticsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapProfitLoss_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative" xlink:title="00000055 - Disclosure - ACQUISITION AND REORGANIZATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TamirBiotechnologyIncMember" xlink:label="loc_ORGSTamirBiotechnologyIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ORGSTamirBiotechnologyIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KoligoTherapeuticsIncMember" xlink:label="loc_ORGSKoligoTherapeuticsIncMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ORGSKoligoTherapeuticsIncMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TamirPurchaseAgreementMember" xlink:label="loc_ORGSTamirPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSTamirPurchaseAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MaterialDefinitiveAgreementMember" xlink:label="loc_ORGSMaterialDefinitiveAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSMaterialDefinitiveAgreementMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RegistrationRightsandLockUpAgreementMember" xlink:label="loc_ORGSRegistrationRightsandLockUpAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSRegistrationRightsandLockUpAgreementMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TransferAgreementMember" xlink:label="loc_ORGSTransferAgreementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSTransferAgreementMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MaximaGroupLLCMember" xlink:label="loc_ORGSMaximaGroupLLCMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSMaximaGroupLLCMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_LongHillAndMaximGroupLLCMember" xlink:label="loc_ORGSLongHillAndMaximGroupLLCMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSLongHillAndMaximGroupLLCMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapEscrowDeposit_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NumberOfSharesDepositInEscrowAccount" xlink:label="loc_ORGSNumberOfSharesDepositInEscrowAccount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSNumberOfSharesDepositInEscrowAccount_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationConsiderationTransferred" xlink:label="loc_ORGSBusinessCombinationConsiderationTransferred_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSBusinessCombinationConsiderationTransferred_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CashPaidToAccreditedInvestors" xlink:label="loc_ORGSCashPaidToAccreditedInvestors_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSCashPaidToAccreditedInvestors_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SharesHeldInEscrow" xlink:label="loc_ORGSSharesHeldInEscrow_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSSharesHeldInEscrow_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdditionalCashConsideration" xlink:label="loc_ORGSAdditionalCashConsideration_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSAdditionalCashConsideration_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ReductionInConsiderationPayable" xlink:label="loc_ORGSReductionInConsiderationPayable_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSReductionInConsiderationPayable_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RestrictionOnSaleOfSharesPercentage" xlink:label="loc_ORGSRestrictionOnSaleOfSharesPercentage_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSRestrictionOnSaleOfSharesPercentage_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RestrictionPeriodDescription" xlink:label="loc_ORGSRestrictionPeriodDescription_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSRestrictionPeriodDescription_90" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapNetIncomeLoss_90" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts_90" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_90" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails" xlink:title="00000056 - Disclosure - SCHEDULE OF COMPONENTS OF PROPERTY, PLANTS AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ProductionFacilityMember" xlink:label="loc_ORGSProductionFacilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ORGSProductionFacilityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OfficeFurnitureAndComputersMember" xlink:label="loc_ORGSOfficeFurnitureAndComputersMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ORGSOfficeFurnitureAndComputersMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_LabEquipmentMember" xlink:label="loc_ORGSLabEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ORGSLabEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdvancePaymentMember" xlink:label="loc_ORGSAdvancePaymentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ORGSAdvancePaymentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_110" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails" xlink:title="00000057 - Disclosure - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT BY GEOGRAPHICAL LOCATION (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MortgageLoansOnRealEstateLineItems" xlink:label="loc_srtMortgageLoansOnRealEstateLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_BE" xlink:label="loc_countryBE_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryBE_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_KR" xlink:label="loc_countryKR_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryKR_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:label="loc_countryIL_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIL_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_countryUS_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/PropertyPlantsAndEquipmentDetailsNarrative" xlink:title="00000058 - Disclosure - PROPERTY, PLANTS AND EQUIPMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfGoodwillDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF GOODWILL (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfOtherIntangibleAssetsDetails" xlink:title="00000060 - Disclosure - SCHEDULE OF OTHER INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KnowhowMember" xlink:label="loc_ORGSKnowhowMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ORGSKnowhowMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KyslecelTechnologyMember" xlink:label="loc_ORGSKyslecelTechnologyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ORGSKyslecelTechnologyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IPResearchAndDevelopmentMember" xlink:label="loc_ORGSIPResearchAndDevelopmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ORGSIPResearchAndDevelopmentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_110" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfEstimatedAggregateAmortizationExpensesDetails" xlink:title="00000061 - Disclosure - SCHEDULE OF ESTIMATED AGGREGATE AMORTIZATION EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:title="00000062 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails" xlink:title="00000063 - Disclosure - SCHEDULE OF LONG TERM CONVERTIBLE LOANS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoansOneMember" xlink:label="loc_ORGSConvertibleLoansOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSConvertibleLoansOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoansTwoMember" xlink:label="loc_ORGSConvertibleLoansTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSConvertibleLoansTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoansThreeMember" xlink:label="loc_ORGSConvertibleLoansThreeMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSConvertibleLoansThreeMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoansMember" xlink:label="loc_ORGSConvertibleLoansMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSConvertibleLoansMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TwoPercentageConvertibleLoansTwoMember" xlink:label="loc_ORGSTwoPercentageConvertibleLoansTwoMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSTwoPercentageConvertibleLoansTwoMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SixPercentageConvertibleLoansTwoMember" xlink:label="loc_ORGSSixPercentageConvertibleLoansTwoMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSSixPercentageConvertibleLoansTwoMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_EightPercetageConvertibleLoansTwoMember" xlink:label="loc_ORGSEightPercetageConvertibleLoansTwoMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSEightPercetageConvertibleLoansTwoMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_280" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DebtInstrumentIssuanceYear" xlink:label="loc_ORGSDebtInstrumentIssuanceYear_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ORGSDebtInstrumentIssuanceYear_280" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_280" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm_280" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_280" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_280" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt_280" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DebtInstrumentRemainingTerm" xlink:label="loc_ORGSDebtInstrumentRemainingTerm_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ORGSDebtInstrumentRemainingTerm_280" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DebtInstrumentConvertibleRepaidBeneficialConversionFeature" xlink:label="loc_ORGSDebtInstrumentConvertibleRepaidBeneficialConversionFeature_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ORGSDebtInstrumentConvertibleRepaidBeneficialConversionFeature_280" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_280" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical" xlink:title="00000064 - Disclosure - SCHEDULE OF LONG TERM CONVERTIBLE LOANS (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoansOneMember" xlink:label="loc_ORGSConvertibleLoansOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSConvertibleLoansOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoansTwoMember" xlink:label="loc_ORGSConvertibleLoansTwoMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSConvertibleLoansTwoMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoansThreeMember" xlink:label="loc_ORGSConvertibleLoansThreeMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSConvertibleLoansThreeMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_HemogenyxCelMember" xlink:label="loc_ORGSHemogenyxCelMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSHemogenyxCelMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ImmugenyxLLCMember" xlink:label="loc_ORGSImmugenyxLLCMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSImmugenyxLLCMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PreMoneyValuation" xlink:label="loc_ORGSPreMoneyValuation_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ORGSPreMoneyValuation_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaapConvertibleDebtCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapConvertibleDebtCurrent_100" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ConvertibleLoansDetailsNarrative" xlink:title="00000065 - Disclosure - CONVERTIBLE LOANS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoanAgreementMember" xlink:label="loc_ORGSConvertibleLoanAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSConvertibleLoanAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PrivatePlacementSubscriptionAgreementMember" xlink:label="loc_ORGSPrivatePlacementSubscriptionAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSPrivatePlacementSubscriptionAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SixPercentageConvertibleLoanAgreementMember" xlink:label="loc_ORGSSixPercentageConvertibleLoanAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSSixPercentageConvertibleLoanAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CreditLineAgreementsMember" xlink:label="loc_ORGSCreditLineAgreementsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSCreditLineAgreementsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ControlledEquityOfferingSalesAgreementMember" xlink:label="loc_ORGSControlledEquityOfferingSalesAgreementMember_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSControlledEquityOfferingSalesAgreementMember_570" xlink:type="arc" order="571" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NonUSInvestorMember" xlink:label="loc_ORGSNonUSInvestorMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSNonUSInvestorMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NonUSInvestorThreeMember" xlink:label="loc_ORGSNonUSInvestorThreeMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSNonUSInvestorThreeMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NonUSInvestorOneMember" xlink:label="loc_ORGSNonUSInvestorOneMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSNonUSInvestorOneMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NonUSInvestorTwoMember" xlink:label="loc_ORGSNonUSInvestorTwoMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSNonUSInvestorTwoMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NonUSInvestorFourMember" xlink:label="loc_ORGSNonUSInvestorFourMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSNonUSInvestorFourMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_InvestorOneMember" xlink:label="loc_ORGSInvestorOneMember_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSInvestorOneMember_490" xlink:type="arc" order="492" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_InvestorTwoMember" xlink:label="loc_ORGSInvestorTwoMember_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSInvestorTwoMember_500" xlink:type="arc" order="502" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TwoOtherInvestorTwoMember" xlink:label="loc_ORGSTwoOtherInvestorTwoMember_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSTwoOtherInvestorTwoMember_510" xlink:type="arc" order="512" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoansOneMember" xlink:label="loc_ORGSConvertibleLoansOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSConvertibleLoansOneMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CantorFitzgeraldAndCoMember" xlink:label="loc_ORGSCantorFitzgeraldAndCoMember_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSCantorFitzgeraldAndCoMember_570" xlink:type="arc" order="572" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_ILS" xlink:label="loc_currencyILS_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyILS_580" xlink:type="arc" order="582" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt_640" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_640" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_640" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_640" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_640" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_640" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_640" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_640" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_640" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_640" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromLinesOfCredit_640" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_640" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_640" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ModificationOfExistingWarrants" xlink:label="loc_ORGSModificationOfExistingWarrants_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ORGSModificationOfExistingWarrants_640" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_640" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit_640" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_640" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_640" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PercentageOfCommission" xlink:label="loc_ORGSPercentageOfCommission_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ORGSPercentageOfCommission_640" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_640" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapConvertibleDebt_640" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DebtInstrumentConvertibleWarrantExercisePrice" xlink:label="loc_ORGSDebtInstrumentConvertibleWarrantExercisePrice_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ORGSDebtInstrumentConvertibleWarrantExercisePrice_640" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_640" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfLoansDetails" xlink:title="00000066 - Disclosure - SCHEDULE OF LOANS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtLineItems" xlink:label="loc_us-gaapExtinguishmentOfDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:label="loc_us-gaapScheduleOfExtinguishmentOfDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapExtinguishmentOfDebtLineItems" xlink:to="loc_us-gaapScheduleOfExtinguishmentOfDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="loc_us-gaapExtinguishmentOfDebtAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfExtinguishmentOfDebtTable" xlink:to="loc_us-gaapExtinguishmentOfDebtAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaapExtinguishmentOfDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapExtinguishmentOfDebtAxis" xlink:to="loc_us-gaapExtinguishmentOfDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaapExtinguishmentOfDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapExtinguishmentOfDebtAxis" xlink:to="loc_us-gaapExtinguishmentOfDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShortTermLoanOneMember" xlink:label="loc_ORGSShortTermLoanOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapExtinguishmentOfDebtTypeDomain" xlink:to="loc_ORGSShortTermLoanOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShortTermLoansTwoMember" xlink:label="loc_ORGSShortTermLoansTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapExtinguishmentOfDebtTypeDomain" xlink:to="loc_ORGSShortTermLoansTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShortTermLoansThreeMember" xlink:label="loc_ORGSShortTermLoansThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapExtinguishmentOfDebtTypeDomain" xlink:to="loc_ORGSShortTermLoansThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfExtinguishmentOfDebtTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_KRW" xlink:label="loc_currencyKRW_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyKRW_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapExtinguishmentOfDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaapDebtCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapExtinguishmentOfDebtLineItems" xlink:to="loc_us-gaapDebtCurrent_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfLease-relatedAssetsAndLiabilitiesDetails" xlink:title="00000067 - Disclosure - SCHEDULE OF LEASE-RELATED ASSETS AND LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfLeaseCostsDetails" xlink:title="00000068 - Disclosure - SCHEDULE OF LEASE COSTS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfSupplementalCashflowInformationDetails" xlink:title="00000069 - Disclosure - SCHEDULE OF SUPPLEMENTAL CASHFLOW INFORMATION (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails" xlink:title="00000070 - Disclosure - SCHEDULE OF FINANCE LEASE LIABILITIES AND OPERATING LEASE LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfRight-of-useAssetsByGeographicalLocationDetails" xlink:title="00000071 - Disclosure - SCHEDULE OF RIGHT-OF-USE ASSETS BY GEOGRAPHICAL LOCATION (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MortgageLoansOnRealEstateLineItems" xlink:label="loc_srtMortgageLoansOnRealEstateLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_KR" xlink:label="loc_countryKR_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryKR_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:label="loc_countryIL_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIL_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_countryUS_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/LeasesDetailsNarrative" xlink:title="00000072 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaapLesseeLeaseDescriptionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="loc_us-gaapManufacturingFacilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapManufacturingFacilityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ResearchAndDevelopmentFacilitiesMember" xlink:label="loc_ORGSResearchAndDevelopmentFacilitiesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ORGSResearchAndDevelopmentFacilitiesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OfficesMember" xlink:label="loc_ORGSOfficesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ORGSOfficesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:label="loc_countryIL_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIL_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_KR" xlink:label="loc_countryKR_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryKR_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_60" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/CommitmentsDetailsNarrative" xlink:title="00000073 - Disclosure - COMMITMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MarylandTechnologyDevelopmentCorporationMember" xlink:label="loc_ORGSMarylandTechnologyDevelopmentCorporationMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_ORGSMarylandTechnologyDevelopmentCorporationMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" xlink:label="loc_ORGSDepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_ORGSDepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember" xlink:label="loc_ORGSIsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_ORGSIsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember" xlink:label="loc_ORGSKoreaisraelIndustrialResearchAndDevelopmentFoundationMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_ORGSKoreaisraelIndustrialResearchAndDevelopmentFoundationMember_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BirdSecantMember" xlink:label="loc_ORGSBirdSecantMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_ORGSBirdSecantMember_410" xlink:type="arc" order="411" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OBIMember" xlink:label="loc_ORGSOBIMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_ORGSOBIMember_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember" xlink:label="loc_ORGSResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IndustrialResearchPartOfResearchProgramMember" xlink:label="loc_ORGSIndustrialResearchPartOfResearchProgramMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSIndustrialResearchPartOfResearchProgramMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExperimentalDevelopmentPartOfResearchProgramMember" xlink:label="loc_ORGSExperimentalDevelopmentPartOfResearchProgramMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSExperimentalDevelopmentPartOfResearchProgramMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DevelopmentOfPotentialCureForTypeOneDiabetesMember" xlink:label="loc_ORGSDevelopmentOfPotentialCureForTypeOneDiabetesMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSDevelopmentOfPotentialCureForTypeOneDiabetesMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember" xlink:label="loc_ORGSGmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSGmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DeductionOfResearchAndDevelopmentExpensesMember" xlink:label="loc_ORGSDeductionOfResearchAndDevelopmentExpensesMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSDeductionOfResearchAndDevelopmentExpensesMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ResearchOnDermatitisTreatmentsAndWoundHealingMember" xlink:label="loc_ORGSResearchOnDermatitisTreatmentsAndWoundHealingMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSResearchOnDermatitisTreatmentsAndWoundHealingMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="loc_srtEuropeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_srtEuropeMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RevenueFromGrantsMember" xlink:label="loc_ORGSRevenueFromGrantsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_ORGSRevenueFromGrantsMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivableNoncurrent" xlink:label="loc_us-gaapGrantsReceivableNoncurrent_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapGrantsReceivableNoncurrent_450" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_GrantsReceivablePercentageOfBudgetedCosts" xlink:label="loc_ORGSGrantsReceivablePercentageOfBudgetedCosts_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_ORGSGrantsReceivablePercentageOfBudgetedCosts_450" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdvancePaymentsOnAccountOfGrant" xlink:label="loc_ORGSAdvancePaymentsOnAccountOfGrant_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_ORGSAdvancePaymentsOnAccountOfGrant_450" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRevenues_450" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherExpenses_450" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherCommitment_450" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DeductionOfResearchAndDevelopmentExpenses" xlink:label="loc_ORGSDeductionOfResearchAndDevelopmentExpenses_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_ORGSDeductionOfResearchAndDevelopmentExpenses_450" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RepaymentsOfGrantPercentageOfGrossSales" xlink:label="loc_ORGSRepaymentsOfGrantPercentageOfGrossSales_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_ORGSRepaymentsOfGrantPercentageOfGrossSales_450" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative" xlink:title="00000074 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CollaborationAndLicenseAgreementsAxis" xlink:label="loc_ORGSCollaborationAndLicenseAgreementsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_ORGSCollaborationAndLicenseAgreementsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CollaborationAndLicenseAgreementsDomain" xlink:label="loc_ORGSCollaborationAndLicenseAgreementsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsAxis" xlink:to="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CollaborationAndLicenseAgreementsDomain" xlink:label="loc_ORGSCollaborationAndLicenseAgreementsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsAxis" xlink:to="loc_ORGSCollaborationAndLicenseAgreementsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdvaBiotechnologyLtdMember" xlink:label="loc_ORGSAdvaBiotechnologyLtdMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSAdvaBiotechnologyLtdMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember" xlink:label="loc_ORGSTelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSTelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ImmuAgreementMember" xlink:label="loc_ORGSImmuAgreementMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSImmuAgreementMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BgNegevTechnologiesAndApplicationsBgnMember" xlink:label="loc_ORGSBgNegevTechnologiesAndApplicationsBgnMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSBgNegevTechnologiesAndApplicationsBgnMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CollaborationAgreementMember" xlink:label="loc_ORGSCollaborationAgreementMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSCollaborationAgreementMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SponsoredResearchAgreementMember" xlink:label="loc_ORGSSponsoredResearchAgreementMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSSponsoredResearchAgreementMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ColumbiaLicenseAgreementMember" xlink:label="loc_ORGSColumbiaLicenseAgreementMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSColumbiaLicenseAgreementMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AIPCellsMember" xlink:label="loc_ORGSAIPCellsMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSAIPCellsMember_280" xlink:type="arc" order="282" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CaliforniaUniversityJointResearchAgreementMember" xlink:label="loc_ORGSCaliforniaUniversityJointResearchAgreementMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSCaliforniaUniversityJointResearchAgreementMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_EVAmentMember" xlink:label="loc_ORGSEVAmentMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSEVAmentMember_330" xlink:type="arc" order="332" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BroadenJointVentureAgreementMember" xlink:label="loc_ORGSBroadenJointVentureAgreementMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSBroadenJointVentureAgreementMember_390" xlink:type="arc" order="391" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_JointVentureAgreementMember" xlink:label="loc_ORGSJointVentureAgreementMember_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSJointVentureAgreementMember_430" xlink:type="arc" order="431" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember" xlink:label="loc_ORGSOnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSOnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember" xlink:label="loc_ORGSOnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSOnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember" xlink:label="loc_ORGSOnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSOnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember" xlink:label="loc_ORGSOnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSOnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember" xlink:label="loc_ORGSWhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSWhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ResearchAndDevelopmentCostsMember" xlink:label="loc_ORGSResearchAndDevelopmentCostsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSResearchAndDevelopmentCostsMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_HemogenyxPharmaceuticalsPLCMember" xlink:label="loc_ORGSHemogenyxPharmaceuticalsPLCMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSHemogenyxPharmaceuticalsPLCMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ImmugenyxLLCMember" xlink:label="loc_ORGSImmugenyxLLCMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSImmugenyxLLCMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MarylandSubsidiaryMember" xlink:label="loc_ORGSMarylandSubsidiaryMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSMarylandSubsidiaryMember_390" xlink:type="arc" order="392" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KinerjapayCorpMember" xlink:label="loc_ORGSKinerjapayCorpMember_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSKinerjapayCorpMember_460" xlink:type="arc" order="462" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SBHSciencesIncMember" xlink:label="loc_ORGSSBHSciencesIncMember_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSSBHSciencesIncMember_470" xlink:type="arc" order="471" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SalesMilestoneMember" xlink:label="loc_ORGSSalesMilestoneMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSSalesMilestoneMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TamirPurchaseAgreementMember" xlink:label="loc_ORGSTamirPurchaseAgreementMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSTamirPurchaseAgreementMember_340" xlink:type="arc" order="343" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srtOwnershipAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtOwnershipAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MarylandSubsidiaryMember" xlink:label="loc_ORGSMarylandSubsidiaryMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_ORGSMarylandSubsidiaryMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CaerusTherapeuticsIncMember" xlink:label="loc_ORGSCaerusTherapeuticsIncMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_ORGSCaerusTherapeuticsIncMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExtracellularVesicleMember" xlink:label="loc_ORGSExtracellularVesicleMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ORGSExtracellularVesicleMember_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TamirBiotechnologyIncMember" xlink:label="loc_ORGSTamirBiotechnologyIncMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ORGSTamirBiotechnologyIncMember_340" xlink:type="arc" order="342" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TissueGenesisLLCMember" xlink:label="loc_ORGSTissueGenesisLLCMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ORGSTissueGenesisLLCMember_370" xlink:type="arc" order="371" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapOtherCommitment_490" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TerminationDescription" xlink:label="loc_ORGSTerminationDescription_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSTerminationDescription_490" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RoyaltyOfNetSalesPercentage" xlink:label="loc_ORGSRoyaltyOfNetSalesPercentage_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSRoyaltyOfNetSalesPercentage_490" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SublicensingFeesPercentage" xlink:label="loc_ORGSSublicensingFeesPercentage_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSSublicensingFeesPercentage_490" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapConvertibleDebt_490" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CommitmentSharesOfCommonStock" xlink:label="loc_ORGSCommitmentSharesOfCommonStock_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSCommitmentSharesOfCommonStock_490" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CommitmentSharesOfCommonStockOfSubsidiary" xlink:label="loc_ORGSCommitmentSharesOfCommonStockOfSubsidiary_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSCommitmentSharesOfCommonStockOfSubsidiary_490" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ReductionRateOfRoyaltyPercentage" xlink:label="loc_ORGSReductionRateOfRoyaltyPercentage_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSReductionRateOfRoyaltyPercentage_490" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableNet" xlink:label="loc_us-gaapNotesReceivableNet_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapNotesReceivableNet_490" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PreMoneyValuation" xlink:label="loc_ORGSPreMoneyValuation_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSPreMoneyValuation_490" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdditionalFundsInvest" xlink:label="loc_ORGSAdditionalFundsInvest_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSAdditionalFundsInvest_490" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromGrantors" xlink:label="loc_us-gaapProceedsFromGrantors_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapProceedsFromGrantors_490" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PercentageOfGrossRevenues" xlink:label="loc_ORGSPercentageOfGrossRevenues_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSPercentageOfGrossRevenues_490" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PaymentForFinancialSupportToTrustForStudy" xlink:label="loc_ORGSPaymentForFinancialSupportToTrustForStudy_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSPaymentForFinancialSupportToTrustForStudy_490" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PaymentForFinancialSupportCumulativeAmountToTrustForStudy" xlink:label="loc_ORGSPaymentForFinancialSupportCumulativeAmountToTrustForStudy_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSPaymentForFinancialSupportCumulativeAmountToTrustForStudy_490" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PaymentForFinancialSupportToTrustForStudyDueEverySixMonths" xlink:label="loc_ORGSPaymentForFinancialSupportToTrustForStudyDueEverySixMonths_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSPaymentForFinancialSupportToTrustForStudyDueEverySixMonths_490" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RoyaltyOfNetSalesOfOtherProductsPercentage" xlink:label="loc_ORGSRoyaltyOfNetSalesOfOtherProductsPercentage_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSRoyaltyOfNetSalesOfOtherProductsPercentage_490" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PaymentOfFeeUponAchievementOfEachRegulatoryMilestone" xlink:label="loc_ORGSPaymentOfFeeUponAchievementOfEachRegulatoryMilestone_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSPaymentOfFeeUponAchievementOfEachRegulatoryMilestone_490" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaapMinorityInterestOwnershipPercentageByParent_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapMinorityInterestOwnershipPercentageByParent_490" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_490" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_490" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FutureMilestonePayments" xlink:label="loc_ORGSFutureMilestonePayments_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSFutureMilestonePayments_490" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapRoyaltyExpense_490" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RoyaltyPercentage" xlink:label="loc_ORGSRoyaltyPercentage_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSRoyaltyPercentage_490" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_InterestInJointVenture" xlink:label="loc_ORGSInterestInJointVenture_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSInterestInJointVenture_490" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoanAdvancedToJointVenture" xlink:label="loc_ORGSConvertibleLoanAdvancedToJointVenture_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSConvertibleLoanAdvancedToJointVenture_490" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoanAdvancedToJointVentureInterestRate" xlink:label="loc_ORGSConvertibleLoanAdvancedToJointVentureInterestRate_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSConvertibleLoanAdvancedToJointVentureInterestRate_490" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaapPaymentForContingentConsiderationLiabilityInvestingActivities_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapPaymentForContingentConsiderationLiabilityInvestingActivities_490" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferToInvestments" xlink:label="loc_us-gaapTransferToInvestments_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapTransferToInvestments_490" xlink:type="arc" order="28" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfChangesInInvestmentsDetails" xlink:title="00000075 - Disclosure - SCHEDULE OF CHANGES IN INVESTMENTS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/InvestmentsInAssociatesNetDetailsNarrative" xlink:title="00000076 - Disclosure - INVESTMENTS IN ASSOCIATES, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="loc_us-gaapScheduleOfInvestmentsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="loc_us-gaapScheduleOfInvestmentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapScheduleOfInvestmentsLineItems" xlink:to="loc_us-gaapScheduleOfInvestmentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfInvestmentsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TLABSMember" xlink:label="loc_ORGSTLABSMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSTLABSMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ButterflyBiosciencesSarlMember" xlink:label="loc_ORGSButterflyBiosciencesSarlMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSButterflyBiosciencesSarlMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KidneyCureJVAMember" xlink:label="loc_ORGSKidneyCureJVAMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSKidneyCureJVAMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_InvestmentsInAssociatePercentageOfOwnership" xlink:label="loc_ORGSInvestmentsInAssociatePercentageOfOwnership_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScheduleOfInvestmentsLineItems" xlink:to="loc_ORGSInvestmentsInAssociatePercentageOfOwnership_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000077 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfTreasurySharesDetails" xlink:title="00000078 - Disclosure - SCHEDULE OF TREASURY SHARES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/EquityDetailsNarrative" xlink:title="00000079 - Disclosure - EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SecuritiesPurchaseAgreementMember" xlink:label="loc_ORGSSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TamirPurchaseAgreementMember" xlink:label="loc_ORGSTamirPurchaseAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSTamirPurchaseAgreementMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MergerAgreementMember" xlink:label="loc_ORGSMergerAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSMergerAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TamirBiotechnologyIncMember" xlink:label="loc_ORGSTamirBiotechnologyIncMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ORGSTamirBiotechnologyIncMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KoligoTherapeuticsIncMember" xlink:label="loc_ORGSKoligoTherapeuticsIncMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ORGSKoligoTherapeuticsIncMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MaximaGroupLLCMember" xlink:label="loc_ORGSMaximaGroupLLCMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSMaximaGroupLLCMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_WarrantExercisableDescription" xlink:label="loc_ORGSWarrantExercisableDescription_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ORGSWarrantExercisableDescription_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OfferingExpenses" xlink:label="loc_ORGSOfferingExpenses_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ORGSOfferingExpenses_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCash_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapEscrowDeposit_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NumberOfSharesDepositInEscrowAccount" xlink:label="loc_ORGSNumberOfSharesDepositInEscrowAccount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ORGSNumberOfSharesDepositInEscrowAccount_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_90" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfBasicAndDilutedLossPerShareDetails" xlink:title="00000080 - Disclosure - SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/IncomeLossPerShareDetailsNarrative" xlink:title="00000081 - Disclosure - INCOME (LOSS) PER SHARE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsAndWarrantsMember" xlink:label="loc_ORGSOptionsAndWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ORGSOptionsAndWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SharesUponConversionOfConvertibleNotesMember" xlink:label="loc_ORGSSharesUponConversionOfConvertibleNotesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ORGSSharesUponConversionOfConvertibleNotesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails" xlink:title="00000082 - Disclosure - SCHEDULE OF EMPLOYEE STOCK OWNERSHIP PLAN DISCLOSURES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToEmployeesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToEmployeesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_EmployeesMember" xlink:label="loc_ORGSEmployeesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ORGSEmployeesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OneYearAnniversaryMember" xlink:label="loc_ORGSOneYearAnniversaryMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ORGSOneYearAnniversaryMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ThreeEqualInstallmentsMember" xlink:label="loc_ORGSThreeEqualInstallmentsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ORGSThreeEqualInstallmentsMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_StockOptionsGrantVestingPeriodPercentage" xlink:label="loc_ORGSStockOptionsGrantVestingPeriodPercentage_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_ORGSStockOptionsGrantVestingPeriodPercentage_130" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:title="00000083 - Disclosure - SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToEmployeesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToEmployeesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToNonEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToNonEmployeesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToNonEmployeesMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_190" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails" xlink:title="00000084 - Disclosure - SCHEDULE OF STOCK OPTIONS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToEmployeesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToEmployeesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToNonEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToNonEmployeesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToNonEmployeesMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_110" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_110" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails" xlink:title="00000085 - Disclosure - SCHEDULE OF STOCK OPTIONS EXERCISABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToEmployeesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToEmployeesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToNonEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToNonEmployeesMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToNonEmployeesMember_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceOneMember" xlink:label="loc_ORGSExercisePriceOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceOneMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceTwoMember" xlink:label="loc_ORGSExercisePriceTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceTwoMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceThreeMember" xlink:label="loc_ORGSExercisePriceThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceThreeMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceFourMember" xlink:label="loc_ORGSExercisePriceFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceFourMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceFiveMember" xlink:label="loc_ORGSExercisePriceFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceFiveMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceSixMember" xlink:label="loc_ORGSExercisePriceSixMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceSixMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceSevenMember" xlink:label="loc_ORGSExercisePriceSevenMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceSevenMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceEightMember" xlink:label="loc_ORGSExercisePriceEightMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceEightMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceNineMember" xlink:label="loc_ORGSExercisePriceNineMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceNineMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceTenMember" xlink:label="loc_ORGSExercisePriceTenMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceTenMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceElevenMember" xlink:label="loc_ORGSExercisePriceElevenMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceElevenMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceTwelveMember" xlink:label="loc_ORGSExercisePriceTwelveMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceTwelveMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceThirteenMember" xlink:label="loc_ORGSExercisePriceThirteenMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceThirteenMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceFourteenMember" xlink:label="loc_ORGSExercisePriceFourteenMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceFourteenMember_260" xlink:type="arc" order="262" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceFifteenMember" xlink:label="loc_ORGSExercisePriceFifteenMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceFifteenMember_280" xlink:type="arc" order="282" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceSixteenMember" xlink:label="loc_ORGSExercisePriceSixteenMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceSixteenMember_300" xlink:type="arc" order="302" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceSeventeenMember" xlink:label="loc_ORGSExercisePriceSeventeenMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceSeventeenMember_320" xlink:type="arc" order="322" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceEighteenMember" xlink:label="loc_ORGSExercisePriceEighteenMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceEighteenMember_340" xlink:type="arc" order="342" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceNineteenMember" xlink:label="loc_ORGSExercisePriceNineteenMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceNineteenMember_360" xlink:type="arc" order="362" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceTwentyMember" xlink:label="loc_ORGSExercisePriceTwentyMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceTwentyMember_380" xlink:type="arc" order="382" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_830" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_830" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_830" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_830" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_830" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_830" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails" xlink:title="00000086 - Disclosure - SCHEDULE OF STOCK OPTIONS GRANTED TO CONSULTANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToNonEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToNonEmployeesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToNonEmployeesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000087 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TwoZeroOneSevenEquityIncentivePlanMember" xlink:label="loc_ORGSTwoZeroOneSevenEquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ORGSTwoZeroOneSevenEquityIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_GlobalShareIncentivePlanTwoZeroOneTwoMember" xlink:label="loc_ORGSGlobalShareIncentivePlanTwoZeroOneTwoMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ORGSGlobalShareIncentivePlanTwoZeroOneTwoMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToEmployeesAndDirectorsMember" xlink:label="loc_ORGSOptionsGrantedToEmployeesAndDirectorsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToEmployeesAndDirectorsMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToNonEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToNonEmployeesMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToNonEmployeesMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MasthercellGlobalMember" xlink:label="loc_ORGSMasthercellGlobalMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSMasthercellGlobalMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FirstChoiceInternationalCompanyIncMember" xlink:label="loc_ORGSFirstChoiceInternationalCompanyIncMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSFirstChoiceInternationalCompanyIncMember_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SecuritiesPurchaseAgreementMember" xlink:label="loc_ORGSSecuritiesPurchaseAgreementMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSSecuritiesPurchaseAgreementMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PrivatePlacementSubscriptionAgreementsMember" xlink:label="loc_ORGSPrivatePlacementSubscriptionAgreementsMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSPrivatePlacementSubscriptionAgreementsMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConsultingAgreementMember" xlink:label="loc_ORGSConsultingAgreementMember_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSConsultingAgreementMember_490" xlink:type="arc" order="491" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NonEmployeesMember" xlink:label="loc_ORGSNonEmployeesMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ORGSNonEmployeesMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SeveralConsultantsMember" xlink:label="loc_ORGSSeveralConsultantsMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ORGSSeveralConsultantsMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConsultantMember" xlink:label="loc_ORGSConsultantMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ORGSConsultantMember_350" xlink:type="arc" order="352" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SeveralConsultantsMember" xlink:label="loc_ORGSSeveralConsultantsMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSSeveralConsultantsMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_InvestorRelationContactMember" xlink:label="loc_ORGSInvestorRelationContactMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSInvestorRelationContactMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SeparateInvestorRelationsContactMember" xlink:label="loc_ORGSSeparateInvestorRelationsContactMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSSeparateInvestorRelationsContactMember_410" xlink:type="arc" order="411" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SeparateInvestorRelationContactMember" xlink:label="loc_ORGSSeparateInvestorRelationContactMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSSeparateInvestorRelationContactMember_420" xlink:type="arc" order="422" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleNotesAndPrivateInvestmentMember" xlink:label="loc_ORGSConvertibleNotesAndPrivateInvestmentMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_ORGSConvertibleNotesAndPrivateInvestmentMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SuccessFeeMember" xlink:label="loc_ORGSSuccessFeeMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ORGSSuccessFeeMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_HeldUntilSixMonthsAnniversaryMember" xlink:label="loc_ORGSHeldUntilSixMonthsAnniversaryMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_ORGSHeldUntilSixMonthsAnniversaryMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_HeldUntilOneYearAnniversaryMember" xlink:label="loc_ORGSHeldUntilOneYearAnniversaryMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_ORGSHeldUntilOneYearAnniversaryMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_VestedOnSigningDateMember" xlink:label="loc_ORGSVestedOnSigningDateMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_ORGSVestedOnSigningDateMember_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_VestMonthlyOver3MonthsMember" xlink:label="loc_ORGSVestMonthlyOver3MonthsMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_ORGSVestMonthlyOver3MonthsMember_370" xlink:type="arc" order="371" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_590" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_590" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_590" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_590" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants_590" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_590" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_590" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_590" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_590" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_590" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_590" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_590" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_WarrantExercisableDescription" xlink:label="loc_ORGSWarrantExercisableDescription_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSWarrantExercisableDescription_590" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_590" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts_590" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_590" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AggregateAmountOfSubscriptionAgreement" xlink:label="loc_ORGSAggregateAmountOfSubscriptionAgreement_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSAggregateAmountOfSubscriptionAgreement_590" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_590" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaapWarrantExercisePriceDecrease_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantExercisePriceDecrease_590" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease_590" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_WarrantsAndRightsOutstandingTermDescription" xlink:label="loc_ORGSWarrantsAndRightsOutstandingTermDescription_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSWarrantsAndRightsOutstandingTermDescription_590" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_590" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ClassOfWarrantOrRightGrantsInPeriod" xlink:label="loc_ORGSClassOfWarrantOrRightGrantsInPeriod_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSClassOfWarrantOrRightGrantsInPeriod_590" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_ORGSClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice_590" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ClassOfWarrantOrRightGrantsInPeriodFairValue" xlink:label="loc_ORGSClassOfWarrantOrRightGrantsInPeriodFairValue_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSClassOfWarrantOrRightGrantsInPeriodFairValue_590" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_590" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_590" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FairValueOfSharesRecognizedOnGrantDate" xlink:label="loc_ORGSFairValueOfSharesRecognizedOnGrantDate_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSFairValueOfSharesRecognizedOnGrantDate_590" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted" xlink:label="loc_ORGSJointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSJointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted_590" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_590" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_590" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NumberOfVestedShares" xlink:label="loc_ORGSNumberOfVestedShares_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSNumberOfVestedShares_590" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FairValueOfSharesOnVestingDatesRecognizedDuringYear" xlink:label="loc_ORGSFairValueOfSharesOnVestingDatesRecognizedDuringYear_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSFairValueOfSharesOnVestingDatesRecognizedDuringYear_590" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_590" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_590" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_590" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_590" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NumberOfAdditionalSharesRestrictionsOnTransfer" xlink:label="loc_ORGSNumberOfAdditionalSharesRestrictionsOnTransfer_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSNumberOfAdditionalSharesRestrictionsOnTransfer_590" xlink:type="arc" order="37" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="00000088 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfValuationAllowanceActivityDetails" xlink:title="00000089 - Disclosure - SCHEDULE OF VALUATION ALLOWANCE, ACTIVITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/TaxesDetailsNarrative" xlink:title="00000090 - Disclosure - TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:label="loc_countryIL_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIL_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_BE" xlink:label="loc_countryBE_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryBE_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_KR" xlink:label="loc_countryKR_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryKR_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TwoThousandTwentyOneToTwoThousandTwentyMember" xlink:label="loc_ORGSTwoThousandTwentyOneToTwoThousandTwentyMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ORGSTwoThousandTwentyOneToTwoThousandTwentyMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="loc_srtEuropeMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_srtEuropeMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SouthKoreanWonMember" xlink:label="loc_ORGSSouthKoreanWonMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ORGSSouthKoreanWonMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember" xlink:label="loc_ORGSTheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_ORGSTheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_UpToKrwTwoZeroBillionMember" xlink:label="loc_ORGSUpToKrwTwoZeroBillionMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_ORGSUpToKrwTwoZeroBillionMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_UpToKrwThreeZeroZeroBillionMember" xlink:label="loc_ORGSUpToKrwThreeZeroZeroBillionMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_ORGSUpToKrwThreeZeroZeroBillionMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TaxBaseAboveKrwThreeZeroZeroBillionMember" xlink:label="loc_ORGSTaxBaseAboveKrwThreeZeroZeroBillionMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_ORGSTaxBaseAboveKrwThreeZeroZeroBillionMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AccumulatedTaxLossCarryforwardDeductions" xlink:label="loc_ORGSAccumulatedTaxLossCarryforwardDeductions_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_ORGSAccumulatedTaxLossCarryforwardDeductions_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AccumulatedTaxLossCarryForwardedPeriod" xlink:label="loc_ORGSAccumulatedTaxLossCarryForwardedPeriod_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_ORGSAccumulatedTaxLossCarryForwardedPeriod_210" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:title="00000091 - Disclosure - SCHEDULE OF DISAGGREGATION OF REVENUE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PointOfCareServicesMember" xlink:label="loc_ORGSPointOfCareServicesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_ORGSPointOfCareServicesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CellProcessDevelopmentServicesMember" xlink:label="loc_ORGSCellProcessDevelopmentServicesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_ORGSCellProcessDevelopmentServicesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenues_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfBreakdownOfRevenuesPerCustomerDetails" xlink:title="00000092 - Disclosure - SCHEDULE OF BREAKDOWN OF REVENUES PER CUSTOMER (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CustomerAMember" xlink:label="loc_ORGSCustomerAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ORGSCustomerAMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CustomerBMember" xlink:label="loc_ORGSCustomerBMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ORGSCustomerBMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CustomerCRelatedPartyMember" xlink:label="loc_ORGSCustomerCRelatedPartyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ORGSCustomerCRelatedPartyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CustomerDMember" xlink:label="loc_ORGSCustomerDMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ORGSCustomerDMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfActivityForTradeReceivablesDetails" xlink:title="00000093 - Disclosure - SCHEDULE OF ACTIVITY FOR TRADE RECEIVABLES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetails" xlink:title="00000094 - Disclosure - SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetailsParenthetical" xlink:title="00000095 - Disclosure - SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES (Details) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/RevenuesDetailsNarrative" xlink:title="00000096 - Disclosure - REVENUES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MasterServicesAgreementsMember" xlink:label="loc_ORGSMasterServicesAgreementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSMasterServicesAgreementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_JointVenturePartnersMember" xlink:label="loc_ORGSJointVenturePartnersMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSJointVenturePartnersMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRevenues_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:title="00000097 - Disclosure - SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfFinancialExpensesDetails" xlink:title="00000098 - Disclosure - SCHEDULE OF FINANCIAL EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:title="00000099 - Disclosure - SCHEDULE OF RELATED PARTY TRANSACTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaapStatementOperatingActivitiesSegmentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementOperatingActivitiesSegmentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaapSegmentOperatingActivitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementOperatingActivitiesSegmentAxis" xlink:to="loc_us-gaapSegmentOperatingActivitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaapSegmentOperatingActivitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementOperatingActivitiesSegmentAxis" xlink:to="loc_us-gaapSegmentOperatingActivitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentContinuingOperationsMember" xlink:label="loc_us-gaapSegmentContinuingOperationsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentOperatingActivitiesDomain" xlink:to="loc_us-gaapSegmentContinuingOperationsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaapSegmentDiscontinuedOperationsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentOperatingActivitiesDomain" xlink:to="loc_us-gaapSegmentDiscontinuedOperationsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srtExecutiveOfficerMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_srtExecutiveOfficerMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BoardMembersMember" xlink:label="loc_ORGSBoardMembersMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_ORGSBoardMembersMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensation_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOfficersCompensation_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaapRevenueFromRelatedParties_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRevenueFromRelatedParties_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" xlink:label="loc_ORGSCostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_ORGSCostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FinancialIncome" xlink:label="loc_ORGSFinancialIncome_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_ORGSFinancialIncome_80" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical" xlink:title="00000100 - Disclosure - SCHEDULE OF RELATED PARTY TRANSACTIONS (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CaerusTherapeuticsLLCMember" xlink:label="loc_ORGSCaerusTherapeuticsLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSCaerusTherapeuticsLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockOptionPlanExpense_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NumberOfOrdinarySharesHeld" xlink:label="loc_ORGSNumberOfOrdinarySharesHeld_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_ORGSNumberOfOrdinarySharesHeld_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails" xlink:title="00000101 - Disclosure - SCHEDULE OF RELATED PARTIES PRESENTED IN CONSOLIDATED BALANCE SHEETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srtExecutiveOfficerMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_srtExecutiveOfficerMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NonexecutiveDirectorsMember" xlink:label="loc_ORGSNonexecutiveDirectorsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_ORGSNonexecutiveDirectorsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrentAndNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrentAndNoncurrent_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DueFromRelatedPartiesNoncurrent1" xlink:label="loc_ORGSDueFromRelatedPartiesNoncurrent1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_ORGSDueFromRelatedPartiesNoncurrent1_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaapAccountsReceivableNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsReceivableNet_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaapContractWithCustomerLiability_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapContractWithCustomerLiability_70" xlink:type="arc" order="3" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>orgs-20201231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_EquityAttributedToOrgenesisIncMember" xlink:label="ORGS_EquityAttributedToOrgenesisIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_EquityAttributedToOrgenesisIncMember" xlink:to="ORGS_EquityAttributedToOrgenesisIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_EquityAttributedToOrgenesisIncMember_lbl" xml:lang="en-US">Equity Attributed To Orgenesis Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US">Treasury Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MasthercellMember" xlink:label="ORGS_MasthercellMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_MasthercellMember" xlink:to="ORGS_MasthercellMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_MasthercellMember_lbl" xml:lang="en-US">Masthercell [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SecuritiesPurchaseAgreementMember" xlink:label="ORGS_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SecuritiesPurchaseAgreementMember" xlink:to="ORGS_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CureCellCoLtdMember" xlink:label="ORGS_CureCellCoLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CureCellCoLtdMember" xlink:to="ORGS_CureCellCoLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_CureCellCoLtdMember_lbl" xml:lang="en-US">CureCell Co. Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TamirBiotechnologyIncMember" xlink:label="ORGS_TamirBiotechnologyIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TamirBiotechnologyIncMember" xlink:to="ORGS_TamirBiotechnologyIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_TamirBiotechnologyIncMember_lbl" xml:lang="en-US">Tamir Biotechnology Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TamirPurchaseAgreementMember" xlink:label="ORGS_TamirPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TamirPurchaseAgreementMember" xlink:to="ORGS_TamirPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_TamirPurchaseAgreementMember_lbl" xml:lang="en-US">Tamir Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ProductionFacilityMember" xlink:label="ORGS_ProductionFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ProductionFacilityMember" xlink:to="ORGS_ProductionFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ProductionFacilityMember_lbl" xml:lang="en-US">Production Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="us-gaap_CustomerRelationshipsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerRelationshipsMember_lbl" xml:lang="en-US">Customer Relationships [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KnowhowMember" xlink:label="ORGS_KnowhowMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_KnowhowMember" xlink:to="ORGS_KnowhowMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_KnowhowMember_lbl" xml:lang="en-US">Know-How [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TechnologyMember" xlink:label="ORGS_TechnologyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TechnologyMember" xlink:to="ORGS_TechnologyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_TechnologyMember_lbl" xml:lang="en-US">Technology [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201912Member" xlink:to="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xml:lang="en-US">Accounting Standards Update 2019-12 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MasthercellSAMember" xlink:label="ORGS_MasthercellSAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_MasthercellSAMember" xlink:to="ORGS_MasthercellSAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_MasthercellSAMember_lbl" xml:lang="en-US">Masthercell S A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_BE" xlink:label="country_BE" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BE" xlink:to="country_BE_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BE_lbl" xml:lang="en-US">BELGIUM</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CellProcessDevelopmentServicesMember" xlink:label="ORGS_CellProcessDevelopmentServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CellProcessDevelopmentServicesMember" xlink:to="ORGS_CellProcessDevelopmentServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_CellProcessDevelopmentServicesMember_lbl" xml:lang="en-US">Cell Process Development Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TechTransferServicesMember" xlink:label="ORGS_TechTransferServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TechTransferServicesMember" xlink:to="ORGS_TechTransferServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_TechTransferServicesMember_lbl" xml:lang="en-US">Tech Transfer Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CellManufacturingServicesMember" xlink:label="ORGS_CellManufacturingServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CellManufacturingServicesMember" xlink:to="ORGS_CellManufacturingServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_CellManufacturingServicesMember_lbl" xml:lang="en-US">Cell Manufacturing Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KoligoTherapeuticsIncMember" xlink:label="ORGS_KoligoTherapeuticsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_KoligoTherapeuticsIncMember" xlink:to="ORGS_KoligoTherapeuticsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_KoligoTherapeuticsIncMember_lbl" xml:lang="en-US">Koligo Therapeutics Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MaterialDefinitiveAgreementMember" xlink:label="ORGS_MaterialDefinitiveAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_MaterialDefinitiveAgreementMember" xlink:to="ORGS_MaterialDefinitiveAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_MaterialDefinitiveAgreementMember_lbl" xml:lang="en-US">Material Definitive Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MaximaGroupLLCMember" xlink:label="ORGS_MaximaGroupLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_MaximaGroupLLCMember" xlink:to="ORGS_MaximaGroupLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_MaximaGroupLLCMember_lbl" xml:lang="en-US">Maxima Group L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_LongHillAndMaximGroupLLCMember" xlink:label="ORGS_LongHillAndMaximGroupLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_LongHillAndMaximGroupLLCMember" xlink:to="ORGS_LongHillAndMaximGroupLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_LongHillAndMaximGroupLLCMember_lbl" xml:lang="en-US">Long Hill And Maxim Group L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RegistrationRightsandLockUpAgreementMember" xlink:label="ORGS_RegistrationRightsandLockUpAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RegistrationRightsandLockUpAgreementMember" xlink:to="ORGS_RegistrationRightsandLockUpAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_RegistrationRightsandLockUpAgreementMember_lbl" xml:lang="en-US">Registration Rightsand Lock Up Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KyslecelTechnologyMember" xlink:label="ORGS_KyslecelTechnologyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_KyslecelTechnologyMember" xlink:to="ORGS_KyslecelTechnologyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_KyslecelTechnologyMember_lbl" xml:lang="en-US">Kyslecel Technology [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IPResearchAndDevelopmentMember" xlink:label="ORGS_IPResearchAndDevelopmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IPResearchAndDevelopmentMember" xlink:to="ORGS_IPResearchAndDevelopmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_IPResearchAndDevelopmentMember_lbl" xml:lang="en-US">IPR&amp;D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TransferAgreementMember" xlink:label="ORGS_TransferAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TransferAgreementMember" xlink:to="ORGS_TransferAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_TransferAgreementMember_lbl" xml:lang="en-US">Transfer Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OfficeFurnitureAndComputersMember" xlink:label="ORGS_OfficeFurnitureAndComputersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OfficeFurnitureAndComputersMember" xlink:to="ORGS_OfficeFurnitureAndComputersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_OfficeFurnitureAndComputersMember_lbl" xml:lang="en-US">Office Furniture and Computers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_LabEquipmentMember" xlink:label="ORGS_LabEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_LabEquipmentMember" xlink:to="ORGS_LabEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_LabEquipmentMember_lbl" xml:lang="en-US">Lab Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdvancePaymentMember" xlink:label="ORGS_AdvancePaymentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AdvancePaymentMember" xlink:to="ORGS_AdvancePaymentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_AdvancePaymentMember_lbl" xml:lang="en-US">Advance Payment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_KR" xlink:label="country_KR" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KR" xlink:to="country_KR_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_KR_lbl" xml:lang="en-US">KOREA, REPUBLIC OF</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:label="country_IL" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_IL_lbl" xml:lang="en-US">ISRAEL</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoansOneMember" xlink:label="ORGS_ConvertibleLoansOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ConvertibleLoansOneMember" xlink:to="ORGS_ConvertibleLoansOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ConvertibleLoansOneMember_lbl" xml:lang="en-US">Convertible Loans One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoansTwoMember" xlink:label="ORGS_ConvertibleLoansTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ConvertibleLoansTwoMember" xlink:to="ORGS_ConvertibleLoansTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ConvertibleLoansTwoMember_lbl" xml:lang="en-US">Convertible Loans Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoansThreeMember" xlink:label="ORGS_ConvertibleLoansThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ConvertibleLoansThreeMember" xlink:to="ORGS_ConvertibleLoansThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ConvertibleLoansThreeMember_lbl" xml:lang="en-US">Convertible Loans Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoansMember" xlink:label="ORGS_ConvertibleLoansMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ConvertibleLoansMember" xlink:to="ORGS_ConvertibleLoansMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ConvertibleLoansMember_lbl" xml:lang="en-US">Convertible Loans [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TwoPercentageConvertibleLoansTwoMember" xlink:label="ORGS_TwoPercentageConvertibleLoansTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TwoPercentageConvertibleLoansTwoMember" xlink:to="ORGS_TwoPercentageConvertibleLoansTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_TwoPercentageConvertibleLoansTwoMember_lbl" xml:lang="en-US">Two Percentage Convertible Loans Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SixPercentageConvertibleLoansTwoMember" xlink:label="ORGS_SixPercentageConvertibleLoansTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SixPercentageConvertibleLoansTwoMember" xlink:to="ORGS_SixPercentageConvertibleLoansTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_SixPercentageConvertibleLoansTwoMember_lbl" xml:lang="en-US">Six Percentage Convertible Loans Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_EightPercetageConvertibleLoansTwoMember" xlink:label="ORGS_EightPercetageConvertibleLoansTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_EightPercetageConvertibleLoansTwoMember" xlink:to="ORGS_EightPercetageConvertibleLoansTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_EightPercetageConvertibleLoansTwoMember_lbl" xml:lang="en-US">Eight Percetage Convertible Loans Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_HemogenyxCelMember" xlink:label="ORGS_HemogenyxCelMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_HemogenyxCelMember" xlink:to="ORGS_HemogenyxCelMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_HemogenyxCelMember_lbl" xml:lang="en-US">Hemogenyx Cel [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ImmugenyxLLCMember" xlink:label="ORGS_ImmugenyxLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ImmugenyxLLCMember" xlink:to="ORGS_ImmugenyxLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ImmugenyxLLCMember_lbl" xml:lang="en-US">Immugenyx, Llc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoanAgreementMember" xlink:label="ORGS_ConvertibleLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ConvertibleLoanAgreementMember" xlink:to="ORGS_ConvertibleLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ConvertibleLoanAgreementMember_lbl" xml:lang="en-US">Convertible Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PrivatePlacementSubscriptionAgreementMember" xlink:label="ORGS_PrivatePlacementSubscriptionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PrivatePlacementSubscriptionAgreementMember" xlink:to="ORGS_PrivatePlacementSubscriptionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_PrivatePlacementSubscriptionAgreementMember_lbl" xml:lang="en-US">Private Placement Subscription Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SixPercentageConvertibleLoanAgreementMember" xlink:label="ORGS_SixPercentageConvertibleLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SixPercentageConvertibleLoanAgreementMember" xlink:to="ORGS_SixPercentageConvertibleLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_SixPercentageConvertibleLoanAgreementMember_lbl" xml:lang="en-US">Six Percentage Convertible Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CreditLineAgreementsMember" xlink:label="ORGS_CreditLineAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CreditLineAgreementsMember" xlink:to="ORGS_CreditLineAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_CreditLineAgreementsMember_lbl" xml:lang="en-US">Credit Line Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NonUSInvestorMember" xlink:label="ORGS_NonUSInvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NonUSInvestorMember" xlink:to="ORGS_NonUSInvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_NonUSInvestorMember_lbl" xml:lang="en-US">Non U S Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NonUSInvestorThreeMember" xlink:label="ORGS_NonUSInvestorThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NonUSInvestorThreeMember" xlink:to="ORGS_NonUSInvestorThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_NonUSInvestorThreeMember_lbl" xml:lang="en-US">Non U S Investor Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NonUSInvestorOneMember" xlink:label="ORGS_NonUSInvestorOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NonUSInvestorOneMember" xlink:to="ORGS_NonUSInvestorOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_NonUSInvestorOneMember_lbl" xml:lang="en-US">Non U S Investor One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NonUSInvestorTwoMember" xlink:label="ORGS_NonUSInvestorTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NonUSInvestorTwoMember" xlink:to="ORGS_NonUSInvestorTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_NonUSInvestorTwoMember_lbl" xml:lang="en-US">Non U S Investor Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NonUSInvestorFourMember" xlink:label="ORGS_NonUSInvestorFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NonUSInvestorFourMember" xlink:to="ORGS_NonUSInvestorFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_NonUSInvestorFourMember_lbl" xml:lang="en-US">Non U S Investor Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_InvestorOneMember" xlink:label="ORGS_InvestorOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_InvestorOneMember" xlink:to="ORGS_InvestorOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_InvestorOneMember_lbl" xml:lang="en-US">Investor One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_InvestorTwoMember" xlink:label="ORGS_InvestorTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_InvestorTwoMember" xlink:to="ORGS_InvestorTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_InvestorTwoMember_lbl" xml:lang="en-US">Investor Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TwoOtherInvestorTwoMember" xlink:label="ORGS_TwoOtherInvestorTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TwoOtherInvestorTwoMember" xlink:to="ORGS_TwoOtherInvestorTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_TwoOtherInvestorTwoMember_lbl" xml:lang="en-US">Two Other Investor Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ControlledEquityOfferingSalesAgreementMember" xlink:label="ORGS_ControlledEquityOfferingSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ControlledEquityOfferingSalesAgreementMember" xlink:to="ORGS_ControlledEquityOfferingSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ControlledEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Controlled Equity Offering Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CantorFitzgeraldAndCoMember" xlink:label="ORGS_CantorFitzgeraldAndCoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CantorFitzgeraldAndCoMember" xlink:to="ORGS_CantorFitzgeraldAndCoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_CantorFitzgeraldAndCoMember_lbl" xml:lang="en-US">Cantor Fitzgerald &amp; Co. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_ILS" xlink:label="currency_ILS" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_ILS" xlink:to="currency_ILS_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_ILS_lbl" xml:lang="en-US">Israel, New Shekels</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="us-gaap_ExtinguishmentOfDebtAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtAxis_lbl" xml:lang="en-US">Extinguishment of Debt [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShortTermLoanOneMember" xlink:label="ORGS_ShortTermLoanOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShortTermLoanOneMember" xlink:to="ORGS_ShortTermLoanOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ShortTermLoanOneMember_lbl" xml:lang="en-US">Short Term Loan One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_KRW" xlink:label="currency_KRW" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_KRW" xlink:to="currency_KRW_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_KRW_lbl" xml:lang="en-US">Korea (South), Won</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShortTermLoansTwoMember" xlink:label="ORGS_ShortTermLoansTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShortTermLoansTwoMember" xlink:to="ORGS_ShortTermLoansTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ShortTermLoansTwoMember_lbl" xml:lang="en-US">Short Term Loans Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShortTermLoansThreeMember" xlink:label="ORGS_ShortTermLoansThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShortTermLoansThreeMember" xlink:to="ORGS_ShortTermLoansThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ShortTermLoansThreeMember_lbl" xml:lang="en-US">Short Term Loans Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="us-gaap_ManufacturingFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xml:lang="en-US">Manufacturing Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ResearchAndDevelopmentFacilitiesMember" xlink:label="ORGS_ResearchAndDevelopmentFacilitiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ResearchAndDevelopmentFacilitiesMember" xlink:to="ORGS_ResearchAndDevelopmentFacilitiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ResearchAndDevelopmentFacilitiesMember_lbl" xml:lang="en-US">Research And Development Facilities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OfficesMember" xlink:label="ORGS_OfficesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OfficesMember" xlink:to="ORGS_OfficesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_OfficesMember_lbl" xml:lang="en-US">Offices [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MarylandTechnologyDevelopmentCorporationMember" xlink:label="ORGS_MarylandTechnologyDevelopmentCorporationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_MarylandTechnologyDevelopmentCorporationMember" xlink:to="ORGS_MarylandTechnologyDevelopmentCorporationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_MarylandTechnologyDevelopmentCorporationMember_lbl" xml:lang="en-US">Maryland Technology Development Corporation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US">Other Commitments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember" xlink:label="ORGS_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember" xlink:to="ORGS_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_lbl" xml:lang="en-US">Research And Development Of Potential Cure For Type One Diabetes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" xlink:label="ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" xlink:to="ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_lbl" xml:lang="en-US">Department De La Gestion Financiere Direction De Lanalyse Financiere [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US">Europe [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IndustrialResearchPartOfResearchProgramMember" xlink:label="ORGS_IndustrialResearchPartOfResearchProgramMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IndustrialResearchPartOfResearchProgramMember" xlink:to="ORGS_IndustrialResearchPartOfResearchProgramMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_IndustrialResearchPartOfResearchProgramMember_lbl" xml:lang="en-US">Industrial research part of research program [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExperimentalDevelopmentPartOfResearchProgramMember" xlink:label="ORGS_ExperimentalDevelopmentPartOfResearchProgramMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExperimentalDevelopmentPartOfResearchProgramMember" xlink:to="ORGS_ExperimentalDevelopmentPartOfResearchProgramMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExperimentalDevelopmentPartOfResearchProgramMember_lbl" xml:lang="en-US">Experimental development part of research program [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RevenueFromGrantsMember" xlink:label="ORGS_RevenueFromGrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RevenueFromGrantsMember" xlink:to="ORGS_RevenueFromGrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_RevenueFromGrantsMember_lbl" xml:lang="en-US">Revenue from grants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DevelopmentOfPotentialCureForTypeOneDiabetesMember" xlink:label="ORGS_DevelopmentOfPotentialCureForTypeOneDiabetesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DevelopmentOfPotentialCureForTypeOneDiabetesMember" xlink:to="ORGS_DevelopmentOfPotentialCureForTypeOneDiabetesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DevelopmentOfPotentialCureForTypeOneDiabetesMember_lbl" xml:lang="en-US">Development Of Potential Cure For Type One Diabetes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember" xlink:label="ORGS_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember" xlink:to="ORGS_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_lbl" xml:lang="en-US">GMP production of AIP cells for two clinical trials that will be performed in Germany and Belgium [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DeductionOfResearchAndDevelopmentExpensesMember" xlink:label="ORGS_DeductionOfResearchAndDevelopmentExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DeductionOfResearchAndDevelopmentExpensesMember" xlink:to="ORGS_DeductionOfResearchAndDevelopmentExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DeductionOfResearchAndDevelopmentExpensesMember_lbl" xml:lang="en-US">Deduction Of Research And Development Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ResearchOnDermatitisTreatmentsAndWoundHealingMember" xlink:label="ORGS_ResearchOnDermatitisTreatmentsAndWoundHealingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ResearchOnDermatitisTreatmentsAndWoundHealingMember" xlink:to="ORGS_ResearchOnDermatitisTreatmentsAndWoundHealingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ResearchOnDermatitisTreatmentsAndWoundHealingMember_lbl" xml:lang="en-US">Research On Dermatitis Treatments And Wound Healing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember" xlink:label="ORGS_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember" xlink:to="ORGS_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember_lbl" xml:lang="en-US">Israelus Binational Industrial Research And Development Foundation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember" xlink:label="ORGS_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember" xlink:to="ORGS_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember_lbl" xml:lang="en-US">Koreaisrael Industrial Research And Development Foundation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BirdSecantMember" xlink:label="ORGS_BirdSecantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BirdSecantMember" xlink:to="ORGS_BirdSecantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_BirdSecantMember_lbl" xml:lang="en-US">BIRD Secant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OBIMember" xlink:label="ORGS_OBIMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OBIMember" xlink:to="ORGS_OBIMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_OBIMember_lbl" xml:lang="en-US">O B I [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CollaborationAndLicenseAgreementsAxis" xlink:label="ORGS_CollaborationAndLicenseAgreementsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CollaborationAndLicenseAgreementsAxis" xlink:to="ORGS_CollaborationAndLicenseAgreementsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_CollaborationAndLicenseAgreementsAxis_lbl" xml:lang="en-US">Collaboration and License Agreements [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdvaBiotechnologyLtdMember" xlink:label="ORGS_AdvaBiotechnologyLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AdvaBiotechnologyLtdMember" xlink:to="ORGS_AdvaBiotechnologyLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_AdvaBiotechnologyLtdMember_lbl" xml:lang="en-US">Adva Biotechnology Ltd. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember" xlink:label="ORGS_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember" xlink:to="ORGS_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_lbl" xml:lang="en-US">Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember" xlink:label="ORGS_OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember" xlink:to="ORGS_OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember_lbl" xml:lang="en-US">On the date of initiation of phase I clinical trials in human subjects [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember" xlink:label="ORGS_OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember" xlink:to="ORGS_OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember_lbl" xml:lang="en-US">On the date of initiation of phase II clinical trials in human subject [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember" xlink:label="ORGS_OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember" xlink:to="ORGS_OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember_lbl" xml:lang="en-US">On the date of initiation of phase III clinical trials in human subjects [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember" xlink:label="ORGS_OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember" xlink:to="ORGS_OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember_lbl" xml:lang="en-US">On the date of initiation of issuance of an approval for marketing of the first product by the FDA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember" xlink:label="ORGS_WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember" xlink:to="ORGS_WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember_lbl" xml:lang="en-US">When Worldwide Net Sales Of Products Have Reached The Amount Of One Five Zero Million For The First Time [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_HemogenyxPharmaceuticalsPLCMember" xlink:label="ORGS_HemogenyxPharmaceuticalsPLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_HemogenyxPharmaceuticalsPLCMember" xlink:to="ORGS_HemogenyxPharmaceuticalsPLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_HemogenyxPharmaceuticalsPLCMember_lbl" xml:lang="en-US">Hemogenyx Pharmaceuticals PLC. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SalesMilestoneMember" xlink:label="ORGS_SalesMilestoneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SalesMilestoneMember" xlink:to="ORGS_SalesMilestoneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_SalesMilestoneMember_lbl" xml:lang="en-US">Sales Milestone [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ResearchAndDevelopmentCostsMember" xlink:label="ORGS_ResearchAndDevelopmentCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ResearchAndDevelopmentCostsMember" xlink:to="ORGS_ResearchAndDevelopmentCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ResearchAndDevelopmentCostsMember_lbl" xml:lang="en-US">Research And Development Costs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ImmuAgreementMember" xlink:label="ORGS_ImmuAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ImmuAgreementMember" xlink:to="ORGS_ImmuAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ImmuAgreementMember_lbl" xml:lang="en-US">Immu Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BgNegevTechnologiesAndApplicationsBgnMember" xlink:label="ORGS_BgNegevTechnologiesAndApplicationsBgnMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BgNegevTechnologiesAndApplicationsBgnMember" xlink:to="ORGS_BgNegevTechnologiesAndApplicationsBgnMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_BgNegevTechnologiesAndApplicationsBgnMember_lbl" xml:lang="en-US">BG Negev Technologies and Applications (BGN) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CollaborationAgreementMember" xlink:label="ORGS_CollaborationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CollaborationAgreementMember" xlink:to="ORGS_CollaborationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_CollaborationAgreementMember_lbl" xml:lang="en-US">Collaboration agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SponsoredResearchAgreementMember" xlink:label="ORGS_SponsoredResearchAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SponsoredResearchAgreementMember" xlink:to="ORGS_SponsoredResearchAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_SponsoredResearchAgreementMember_lbl" xml:lang="en-US">Sponsored Research Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ColumbiaLicenseAgreementMember" xlink:label="ORGS_ColumbiaLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ColumbiaLicenseAgreementMember" xlink:to="ORGS_ColumbiaLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ColumbiaLicenseAgreementMember_lbl" xml:lang="en-US">Columbia License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MarylandSubsidiaryMember" xlink:label="ORGS_MarylandSubsidiaryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_MarylandSubsidiaryMember" xlink:to="ORGS_MarylandSubsidiaryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_MarylandSubsidiaryMember_lbl" xml:lang="en-US">Maryland Subsidiary [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AIPCellsMember" xlink:label="ORGS_AIPCellsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AIPCellsMember" xlink:to="ORGS_AIPCellsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_AIPCellsMember_lbl" xml:lang="en-US">A I P Cells [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CaliforniaUniversityJointResearchAgreementMember" xlink:label="ORGS_CaliforniaUniversityJointResearchAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CaliforniaUniversityJointResearchAgreementMember" xlink:to="ORGS_CaliforniaUniversityJointResearchAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_CaliforniaUniversityJointResearchAgreementMember_lbl" xml:lang="en-US">California University Joint Research Agreement [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CaerusTherapeuticsIncMember" xlink:label="ORGS_CaerusTherapeuticsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CaerusTherapeuticsIncMember" xlink:to="ORGS_CaerusTherapeuticsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_CaerusTherapeuticsIncMember_lbl" xml:lang="en-US">Caerus Therapeutics Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExtracellularVesicleMember" xlink:label="ORGS_ExtracellularVesicleMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExtracellularVesicleMember" xlink:to="ORGS_ExtracellularVesicleMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExtracellularVesicleMember_lbl" xml:lang="en-US">Extracellular Vesicle [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_EVAmentMember" xlink:label="ORGS_EVAmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_EVAmentMember" xlink:to="ORGS_EVAmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_EVAmentMember_lbl" xml:lang="en-US">E V Ament [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TissueGenesisLLCMember" xlink:label="ORGS_TissueGenesisLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TissueGenesisLLCMember" xlink:to="ORGS_TissueGenesisLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_TissueGenesisLLCMember_lbl" xml:lang="en-US">Tissue Genesis L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BroadenJointVentureAgreementMember" xlink:label="ORGS_BroadenJointVentureAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BroadenJointVentureAgreementMember" xlink:to="ORGS_BroadenJointVentureAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_BroadenJointVentureAgreementMember_lbl" xml:lang="en-US">Broaden Joint Venture Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_JointVentureAgreementMember" xlink:label="ORGS_JointVentureAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_JointVentureAgreementMember" xlink:to="ORGS_JointVentureAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_JointVentureAgreementMember_lbl" xml:lang="en-US">Joint Venture Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KinerjapayCorpMember" xlink:label="ORGS_KinerjapayCorpMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_KinerjapayCorpMember" xlink:to="ORGS_KinerjapayCorpMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_KinerjapayCorpMember_lbl" xml:lang="en-US">Kinerjapay Corp [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SBHSciencesIncMember" xlink:label="ORGS_SBHSciencesIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SBHSciencesIncMember" xlink:to="ORGS_SBHSciencesIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_SBHSciencesIncMember_lbl" xml:lang="en-US">SBH Sciences, Inc [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TLABSMember" xlink:label="ORGS_TLABSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TLABSMember" xlink:to="ORGS_TLABSMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_TLABSMember_lbl" xml:lang="en-US">T L A B S [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ButterflyBiosciencesSarlMember" xlink:label="ORGS_ButterflyBiosciencesSarlMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ButterflyBiosciencesSarlMember" xlink:to="ORGS_ButterflyBiosciencesSarlMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ButterflyBiosciencesSarlMember_lbl" xml:lang="en-US">Butterfly Biosciences Sarl [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KidneyCureJVAMember" xlink:label="ORGS_KidneyCureJVAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_KidneyCureJVAMember" xlink:to="ORGS_KidneyCureJVAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_KidneyCureJVAMember_lbl" xml:lang="en-US">Kidney Cure J V A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MergerAgreementMember" xlink:label="ORGS_MergerAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_MergerAgreementMember" xlink:to="ORGS_MergerAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_MergerAgreementMember_lbl" xml:lang="en-US">Merger Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsAndWarrantsMember" xlink:label="ORGS_OptionsAndWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OptionsAndWarrantsMember" xlink:to="ORGS_OptionsAndWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_OptionsAndWarrantsMember_lbl" xml:lang="en-US">Options and Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SharesUponConversionOfConvertibleNotesMember" xlink:label="ORGS_SharesUponConversionOfConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SharesUponConversionOfConvertibleNotesMember" xlink:to="ORGS_SharesUponConversionOfConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_SharesUponConversionOfConvertibleNotesMember_lbl" xml:lang="en-US">Shares Upon Conversion of Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TwoZeroOneSevenEquityIncentivePlanMember" xlink:label="ORGS_TwoZeroOneSevenEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TwoZeroOneSevenEquityIncentivePlanMember" xlink:to="ORGS_TwoZeroOneSevenEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_TwoZeroOneSevenEquityIncentivePlanMember_lbl" xml:lang="en-US">2017 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_GlobalShareIncentivePlanTwoZeroOneTwoMember" xlink:label="ORGS_GlobalShareIncentivePlanTwoZeroOneTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_GlobalShareIncentivePlanTwoZeroOneTwoMember" xlink:to="ORGS_GlobalShareIncentivePlanTwoZeroOneTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_GlobalShareIncentivePlanTwoZeroOneTwoMember_lbl" xml:lang="en-US">Global Share Incentive Plan 2012 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_lbl" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToEmployeesMember" xlink:label="ORGS_OptionsGrantedToEmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OptionsGrantedToEmployeesMember" xlink:to="ORGS_OptionsGrantedToEmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_OptionsGrantedToEmployeesMember_lbl" xml:lang="en-US">Options Granted To Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_EmployeesMember" xlink:label="ORGS_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_EmployeesMember" xlink:to="ORGS_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OneYearAnniversaryMember" xlink:label="ORGS_OneYearAnniversaryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OneYearAnniversaryMember" xlink:to="ORGS_OneYearAnniversaryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_OneYearAnniversaryMember_lbl" xml:lang="en-US">One Year Anniversary [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ThreeEqualInstallmentsMember" xlink:label="ORGS_ThreeEqualInstallmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ThreeEqualInstallmentsMember" xlink:to="ORGS_ThreeEqualInstallmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ThreeEqualInstallmentsMember_lbl" xml:lang="en-US">Three Equal Installments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToNonEmployeesMember" xlink:label="ORGS_OptionsGrantedToNonEmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OptionsGrantedToNonEmployeesMember" xlink:to="ORGS_OptionsGrantedToNonEmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_OptionsGrantedToNonEmployeesMember_lbl" xml:lang="en-US">Options Granted To Non Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceOneMember" xlink:label="ORGS_ExercisePriceOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceOneMember" xlink:to="ORGS_ExercisePriceOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceTwoMember" xlink:label="ORGS_ExercisePriceTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceTwoMember" xlink:to="ORGS_ExercisePriceTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceThreeMember" xlink:label="ORGS_ExercisePriceThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceThreeMember" xlink:to="ORGS_ExercisePriceThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceFourMember" xlink:label="ORGS_ExercisePriceFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceFourMember" xlink:to="ORGS_ExercisePriceFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceFiveMember" xlink:label="ORGS_ExercisePriceFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceFiveMember" xlink:to="ORGS_ExercisePriceFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceSixMember" xlink:label="ORGS_ExercisePriceSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceSixMember" xlink:to="ORGS_ExercisePriceSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExercisePriceSixMember_lbl" xml:lang="en-US">Exercise Price Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceSevenMember" xlink:label="ORGS_ExercisePriceSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceSevenMember" xlink:to="ORGS_ExercisePriceSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExercisePriceSevenMember_lbl" xml:lang="en-US">Exercise Price Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceEightMember" xlink:label="ORGS_ExercisePriceEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceEightMember" xlink:to="ORGS_ExercisePriceEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExercisePriceEightMember_lbl" xml:lang="en-US">Exercise Price Eighteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceNineMember" xlink:label="ORGS_ExercisePriceNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceNineMember" xlink:to="ORGS_ExercisePriceNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExercisePriceNineMember_lbl" xml:lang="en-US">Exercise Price Nine [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceTenMember" xlink:label="ORGS_ExercisePriceTenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceTenMember" xlink:to="ORGS_ExercisePriceTenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExercisePriceTenMember_lbl" xml:lang="en-US">Exercise Price Ten [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceElevenMember" xlink:label="ORGS_ExercisePriceElevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceElevenMember" xlink:to="ORGS_ExercisePriceElevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExercisePriceElevenMember_lbl" xml:lang="en-US">Exercise Price Eleven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceTwelveMember" xlink:label="ORGS_ExercisePriceTwelveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceTwelveMember" xlink:to="ORGS_ExercisePriceTwelveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExercisePriceTwelveMember_lbl" xml:lang="en-US">Exercise Price Twelve [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceThirteenMember" xlink:label="ORGS_ExercisePriceThirteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceThirteenMember" xlink:to="ORGS_ExercisePriceThirteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExercisePriceThirteenMember_lbl" xml:lang="en-US">Exercise Price Thirteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceFourteenMember" xlink:label="ORGS_ExercisePriceFourteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceFourteenMember" xlink:to="ORGS_ExercisePriceFourteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExercisePriceFourteenMember_lbl" xml:lang="en-US">Exercise Price Fourteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceFifteenMember" xlink:label="ORGS_ExercisePriceFifteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceFifteenMember" xlink:to="ORGS_ExercisePriceFifteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExercisePriceFifteenMember_lbl" xml:lang="en-US">Exercise Price Fifteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceSixteenMember" xlink:label="ORGS_ExercisePriceSixteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceSixteenMember" xlink:to="ORGS_ExercisePriceSixteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExercisePriceSixteenMember_lbl" xml:lang="en-US">Exercise Price Sixteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceSeventeenMember" xlink:label="ORGS_ExercisePriceSeventeenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceSeventeenMember" xlink:to="ORGS_ExercisePriceSeventeenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExercisePriceSeventeenMember_lbl" xml:lang="en-US">Exercise Price Seventeen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceEighteenMember" xlink:label="ORGS_ExercisePriceEighteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceEighteenMember" xlink:to="ORGS_ExercisePriceEighteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ORGS_ExercisePriceEighteenMember_lbl" xml:lang="en-US">Exercise Price Eighteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceNineteenMember" xlink:label="ORGS_ExercisePriceNineteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceNineteenMember" xlink:to="ORGS_ExercisePriceNineteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExercisePriceNineteenMember_lbl" xml:lang="en-US">Exercise Price Nineteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceTwentyMember" xlink:label="ORGS_ExercisePriceTwentyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceTwentyMember" xlink:to="ORGS_ExercisePriceTwentyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExercisePriceTwentyMember_lbl" xml:lang="en-US">Exercise Price Twenty [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToEmployeesAndDirectorsMember" xlink:label="ORGS_OptionsGrantedToEmployeesAndDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OptionsGrantedToEmployeesAndDirectorsMember" xlink:to="ORGS_OptionsGrantedToEmployeesAndDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_OptionsGrantedToEmployeesAndDirectorsMember_lbl" xml:lang="en-US">Options Granted to Employees and Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MasthercellGlobalMember" xlink:label="ORGS_MasthercellGlobalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_MasthercellGlobalMember" xlink:to="ORGS_MasthercellGlobalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_MasthercellGlobalMember_lbl" xml:lang="en-US">Masthercell Global [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PrivatePlacementSubscriptionAgreementsMember" xlink:label="ORGS_PrivatePlacementSubscriptionAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PrivatePlacementSubscriptionAgreementsMember" xlink:to="ORGS_PrivatePlacementSubscriptionAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_PrivatePlacementSubscriptionAgreementsMember_lbl" xml:lang="en-US">Private Placement Subscription Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NonEmployeesMember" xlink:label="ORGS_NonEmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NonEmployeesMember" xlink:to="ORGS_NonEmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_NonEmployeesMember_lbl" xml:lang="en-US">Non-Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SeveralConsultantsMember" xlink:label="ORGS_SeveralConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SeveralConsultantsMember" xlink:to="ORGS_SeveralConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_SeveralConsultantsMember_lbl" xml:lang="en-US">Several Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleNotesAndPrivateInvestmentMember" xlink:label="ORGS_ConvertibleNotesAndPrivateInvestmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ConvertibleNotesAndPrivateInvestmentMember" xlink:to="ORGS_ConvertibleNotesAndPrivateInvestmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ConvertibleNotesAndPrivateInvestmentMember_lbl" xml:lang="en-US">Convertible Notes And Private Investment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SuccessFeeMember" xlink:label="ORGS_SuccessFeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SuccessFeeMember" xlink:to="ORGS_SuccessFeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_SuccessFeeMember_lbl" xml:lang="en-US">Success fee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_InvestorRelationContactMember" xlink:label="ORGS_InvestorRelationContactMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_InvestorRelationContactMember" xlink:to="ORGS_InvestorRelationContactMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_InvestorRelationContactMember_lbl" xml:lang="en-US">Investor Relation Contact [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_HeldUntilSixMonthsAnniversaryMember" xlink:label="ORGS_HeldUntilSixMonthsAnniversaryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_HeldUntilSixMonthsAnniversaryMember" xlink:to="ORGS_HeldUntilSixMonthsAnniversaryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_HeldUntilSixMonthsAnniversaryMember_lbl" xml:lang="en-US">Held Until Six Months Anniversary [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_HeldUntilOneYearAnniversaryMember" xlink:label="ORGS_HeldUntilOneYearAnniversaryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_HeldUntilOneYearAnniversaryMember" xlink:to="ORGS_HeldUntilOneYearAnniversaryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_HeldUntilOneYearAnniversaryMember_lbl" xml:lang="en-US">Held Until One Year Anniversary [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FirstChoiceInternationalCompanyIncMember" xlink:label="ORGS_FirstChoiceInternationalCompanyIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FirstChoiceInternationalCompanyIncMember" xlink:to="ORGS_FirstChoiceInternationalCompanyIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_FirstChoiceInternationalCompanyIncMember_lbl" xml:lang="en-US">First Choice International Company, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConsultantMember" xlink:label="ORGS_ConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ConsultantMember" xlink:to="ORGS_ConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ConsultantMember_lbl" xml:lang="en-US">Consultant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_VestedOnSigningDateMember" xlink:label="ORGS_VestedOnSigningDateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_VestedOnSigningDateMember" xlink:to="ORGS_VestedOnSigningDateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_VestedOnSigningDateMember_lbl" xml:lang="en-US">vested on signing date[Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_VestMonthlyOver3MonthsMember" xlink:label="ORGS_VestMonthlyOver3MonthsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_VestMonthlyOver3MonthsMember" xlink:to="ORGS_VestMonthlyOver3MonthsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_VestMonthlyOver3MonthsMember_lbl" xml:lang="en-US">Vest Monthly Over 3 Months [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SeparateInvestorRelationsContactMember" xlink:label="ORGS_SeparateInvestorRelationsContactMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SeparateInvestorRelationsContactMember" xlink:to="ORGS_SeparateInvestorRelationsContactMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_SeparateInvestorRelationsContactMember_lbl" xml:lang="en-US">Separate Investor Relations Contact [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SeparateInvestorRelationContactMember" xlink:label="ORGS_SeparateInvestorRelationContactMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SeparateInvestorRelationContactMember" xlink:to="ORGS_SeparateInvestorRelationContactMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_SeparateInvestorRelationContactMember_lbl" xml:lang="en-US">Separate Investor Relation Contact [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConsultingAgreementMember" xlink:label="ORGS_ConsultingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ConsultingAgreementMember" xlink:to="ORGS_ConsultingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TwoThousandTwentyOneToTwoThousandTwentyMember" xlink:label="ORGS_TwoThousandTwentyOneToTwoThousandTwentyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TwoThousandTwentyOneToTwoThousandTwentyMember" xlink:to="ORGS_TwoThousandTwentyOneToTwoThousandTwentyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_TwoThousandTwentyOneToTwoThousandTwentyMember_lbl" xml:lang="en-US">2021-2020 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember" xlink:label="ORGS_TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember" xlink:to="ORGS_TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember_lbl" xml:lang="en-US">The First KRW 200 Million Of The Tax Base [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_UpToKrwTwoZeroBillionMember" xlink:label="ORGS_UpToKrwTwoZeroBillionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_UpToKrwTwoZeroBillionMember" xlink:to="ORGS_UpToKrwTwoZeroBillionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_UpToKrwTwoZeroBillionMember_lbl" xml:lang="en-US">Up To KRW 20 Billion [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_UpToKrwThreeZeroZeroBillionMember" xlink:label="ORGS_UpToKrwThreeZeroZeroBillionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_UpToKrwThreeZeroZeroBillionMember" xlink:to="ORGS_UpToKrwThreeZeroZeroBillionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_UpToKrwThreeZeroZeroBillionMember_lbl" xml:lang="en-US">Up To KRW 300 Billion [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TaxBaseAboveKrwThreeZeroZeroBillionMember" xlink:label="ORGS_TaxBaseAboveKrwThreeZeroZeroBillionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TaxBaseAboveKrwThreeZeroZeroBillionMember" xlink:to="ORGS_TaxBaseAboveKrwThreeZeroZeroBillionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_TaxBaseAboveKrwThreeZeroZeroBillionMember_lbl" xml:lang="en-US">Tax Base Above KRW 300 Billion [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SouthKoreanWonMember" xlink:label="ORGS_SouthKoreanWonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SouthKoreanWonMember" xlink:to="ORGS_SouthKoreanWonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_SouthKoreanWonMember_lbl" xml:lang="en-US">South Korean Won [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PointOfCareServicesMember" xlink:label="ORGS_PointOfCareServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PointOfCareServicesMember" xlink:to="ORGS_PointOfCareServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_PointOfCareServicesMember_lbl" xml:lang="en-US">POC and Hospital Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MasterServicesAgreementsMember" xlink:label="ORGS_MasterServicesAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_MasterServicesAgreementsMember" xlink:to="ORGS_MasterServicesAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_MasterServicesAgreementsMember_lbl" xml:lang="en-US">Master Services Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_JointVenturePartnersMember" xlink:label="ORGS_JointVenturePartnersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_JointVenturePartnersMember" xlink:to="ORGS_JointVenturePartnersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_JointVenturePartnersMember_lbl" xml:lang="en-US">Joint Venture Partners [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CustomerAMember" xlink:label="ORGS_CustomerAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CustomerAMember" xlink:to="ORGS_CustomerAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_CustomerAMember_lbl" xml:lang="en-US">Customer A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CustomerBMember" xlink:label="ORGS_CustomerBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CustomerBMember" xlink:to="ORGS_CustomerBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_CustomerBMember_lbl" xml:lang="en-US">Customer B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CustomerCRelatedPartyMember" xlink:label="ORGS_CustomerCRelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CustomerCRelatedPartyMember" xlink:to="ORGS_CustomerCRelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_CustomerCRelatedPartyMember_lbl" xml:lang="en-US">Customer C Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CustomerDMember" xlink:label="ORGS_CustomerDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CustomerDMember" xlink:to="ORGS_CustomerDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_CustomerDMember_lbl" xml:lang="en-US">Customer D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis_lbl" xml:lang="en-US">Operating Activities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentContinuingOperationsMember" xlink:label="us-gaap_SegmentContinuingOperationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentContinuingOperationsMember" xlink:to="us-gaap_SegmentContinuingOperationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentContinuingOperationsMember_lbl" xml:lang="en-US">Continuing Operations [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ExecutiveOfficerMember_lbl" xml:lang="en-US">Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BoardMembersMember" xlink:label="ORGS_BoardMembersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BoardMembersMember" xlink:to="ORGS_BoardMembersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_BoardMembersMember_lbl" xml:lang="en-US">Board Members [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CaerusTherapeuticsLLCMember" xlink:label="ORGS_CaerusTherapeuticsLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CaerusTherapeuticsLLCMember" xlink:to="ORGS_CaerusTherapeuticsLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_CaerusTherapeuticsLLCMember_lbl" xml:lang="en-US">Caerus Therapeutics LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember_lbl" xml:lang="en-US">Discontinued Operations [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NonexecutiveDirectorsMember" xlink:label="ORGS_NonexecutiveDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NonexecutiveDirectorsMember" xlink:to="ORGS_NonexecutiveDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_NonexecutiveDirectorsMember_lbl" xml:lang="en-US">Nonexecutive Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US">Grants receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Current assets of discontinued operations (See Note 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON CURRENT ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesNoncurrent" xlink:label="us-gaap_DueFromRelatedPartiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesNoncurrent" xlink:to="us-gaap_DueFromRelatedPartiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedPartiesNoncurrent_lbl" xml:lang="en-US">Loan to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Investments_lbl" xml:lang="en-US">Investments in associates, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plants and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AccruedExpensesAndOtherPayablesCurrent" xlink:label="ORGS_AccruedExpensesAndOtherPayablesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AccruedExpensesAndOtherPayablesCurrent" xlink:to="ORGS_AccruedExpensesAndOtherPayablesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_AccruedExpensesAndOtherPayablesCurrent_lbl" xml:lang="en-US">Accrued expenses and other payables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Income tax payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employees and related payables</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdvancePaymentsOnAccountOfGrant" xlink:label="ORGS_AdvancePaymentsOnAccountOfGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AdvancePaymentsOnAccountOfGrant" xlink:to="ORGS_AdvancePaymentsOnAccountOfGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_AdvancePaymentsOnAccountOfGrant_lbl" xml:lang="en-US">Advance payments on account of grant</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Short-term loans and current maturities of long-term loans</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current maturities of finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current maturities of operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Current maturities of convertible loans</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Current liabilities of discontinued operations (See Note 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG-TERM LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Non-current operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible loans</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Retirement benefits obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US">Deferred taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term debt and finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other long-term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">TOTAL LONG-TERM LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RedeemableNoncontrollingInterestOfDiscontinuedOperation" xlink:label="ORGS_RedeemableNoncontrollingInterestOfDiscontinuedOperation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RedeemableNoncontrollingInterestOfDiscontinuedOperation" xlink:to="ORGS_RedeemableNoncontrollingInterestOfDiscontinuedOperation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_RedeemableNoncontrollingInterestOfDiscontinuedOperation_lbl" xml:lang="en-US">REDEEMABLE NON CONTROLLING INTEREST OF DISCONTINUED OPERATIONS (See Note 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">EQUITY:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock of $0.0001 par value, 145,833,334 shares authorized, 24,223,093 and 16,140,962 shares issued as of December 31, 2020 and December 31, 2019, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock at December 31, 2020 55,309 shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Equity attributable to Orgenesis Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Non-controlling interests</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">TOTAL EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US">Treasury stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xml:lang="en-US">Revenues from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Cost of research and development and research and development services, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome" xlink:label="us-gaap_OtherOperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncome" xlink:to="us-gaap_OtherOperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherOperatingIncome_lbl" xml:lang="en-US">Other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Financial expenses, net</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareInNetIncomeOfAssociatedCompanies" xlink:label="ORGS_ShareInNetIncomeOfAssociatedCompanies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareInNetIncomeOfAssociatedCompanies" xlink:to="ORGS_ShareInNetIncomeOfAssociatedCompanies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ORGS_ShareInNetIncomeOfAssociatedCompanies_lbl" xml:lang="en-US">Share in net income of associated companies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss from continuing operation before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Tax income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net loss from continuing operation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xml:lang="en-US">Net loss (income) from discontinued operations, net of tax</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss (income)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl" xml:lang="en-US">Net loss attributable to non-controlling interests (including redeemable) from continuing operation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net loss attributable to non-controlling interests (including redeemable) from discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss (income) attributable to Orgenesis Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss (income) per share:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xml:lang="en-US">Basic and diluted from continuing operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_lbl" xml:lang="en-US">Basic and diluted from discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of shares used in computation of Basic and Diluted loss per share:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Comprehensive loss (income):</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests" xlink:label="ORGS_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests" xlink:to="ORGS_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Net loss from Continuing Operation</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncomeLossesFromDiscontinuedOperationNetOfTax" xlink:label="ORGS_IncomeLossesFromDiscontinuedOperationNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IncomeLossesFromDiscontinuedOperationNetOfTax" xlink:to="ORGS_IncomeLossesFromDiscontinuedOperationNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_IncomeLossesFromDiscontinuedOperationNetOfTax_lbl" xml:lang="en-US">Net loss (income) from Discontinued Operations, Net of Tax</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Other Comprehensive (income) loss &#8211; Translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary" xlink:label="ORGS_OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary" xlink:to="ORGS_OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary_lbl" xml:lang="en-US">Release of translation adjustment due to sale of subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ComprehensiveIncomeNetOfTaxes" xlink:label="ORGS_ComprehensiveIncomeNetOfTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ComprehensiveIncomeNetOfTaxes" xlink:to="ORGS_ComprehensiveIncomeNetOfTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ComprehensiveIncomeNetOfTaxes_lbl" xml:lang="en-US">Comprehensive loss (income)</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations" xlink:label="ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations" xlink:to="ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations_lbl" xml:lang="en-US">Comprehensive loss attributed to non-controlling interests (including redeemable)</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations" xlink:label="ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations" xlink:to="ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations_lbl" xml:lang="en-US">Comprehensive loss attributed to non-controlling interests (including redeemable) from discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss (income) attributed to Orgenesis Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation to employees and directors</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock-based compensation to service providers</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock-based compensation to service providers, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement" xlink:label="ORGS_StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement" xlink:to="ORGS_StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement_lbl" xml:lang="en-US">Stock-based compensation for Tamir purchase agreement (See Note 4)</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares" xlink:label="ORGS_StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares" xlink:to="ORGS_StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares_lbl" xml:lang="en-US">Stock-based compensation for Tamir purchase agreement (See Note 3), shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xml:lang="en-US">Beneficial conversion feature of convertible loans</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IssuanceOfSharesAndWarrants" xlink:label="ORGS_IssuanceOfSharesAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IssuanceOfSharesAndWarrants" xlink:to="ORGS_IssuanceOfSharesAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_IssuanceOfSharesAndWarrants_lbl" xml:lang="en-US">Issuance of shares and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IssuanceOfSharesAndWarrantsShares" xlink:label="ORGS_IssuanceOfSharesAndWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IssuanceOfSharesAndWarrantsShares" xlink:to="ORGS_IssuanceOfSharesAndWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_IssuanceOfSharesAndWarrantsShares_lbl" xml:lang="en-US">Issuance of shares and warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Issuance of shares related to acquisition of Koligo</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Issuance of shares related to acquisition of Koligo, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:label="us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:to="us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_lbl" xml:lang="en-US">Sale of subsidiaries</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">Repurchase of treasury stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Repurchase of treasury stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_StockbasedCompensationToStrategicCollaborations" xlink:label="ORGS_StockbasedCompensationToStrategicCollaborations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_StockbasedCompensationToStrategicCollaborations" xlink:to="ORGS_StockbasedCompensationToStrategicCollaborations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_StockbasedCompensationToStrategicCollaborations_lbl" xml:lang="en-US">Stock-based compensation to strategic collaborations</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_StockbasedCompensationToStrategicCollaborationsShares" xlink:label="ORGS_StockbasedCompensationToStrategicCollaborationsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_StockbasedCompensationToStrategicCollaborationsShares" xlink:to="ORGS_StockbasedCompensationToStrategicCollaborationsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_StockbasedCompensationToStrategicCollaborationsShares_lbl" xml:lang="en-US">Stock-based compensation to strategic collaborations, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans" xlink:label="ORGS_IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans" xlink:to="ORGS_IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans_lbl" xml:lang="en-US">Issuance and modification of warrants and Beneficial conversion feature of convertible loans</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp" xlink:label="ORGS_AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp" xlink:to="ORGS_AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp_lbl" xml:lang="en-US">Transaction with non-controlling interest GPP (See Note 1)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Adjustment to redemption value of redeemable non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Comprehensive income (loss) for the period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net income (loss) to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationOne" xlink:label="ORGS_ShareBasedCompensationOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationOne" xlink:to="ORGS_ShareBasedCompensationOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ShareBasedCompensationOne_lbl" xml:lang="en-US">Stock-based compensation for strategic collaborations</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationTwo" xlink:label="ORGS_ShareBasedCompensationTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationTwo" xlink:to="ORGS_ShareBasedCompensationTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ShareBasedCompensationTwo_lbl" xml:lang="en-US">Stock-based compensation for Tamir Purchase Agreement (See Notes 4)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Capital loss (gain), net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:label="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:to="us-gaap_GainOrLossOnSaleOfStockInSubsidiary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainOrLossOnSaleOfStockInSubsidiary_lbl" xml:lang="en-US">Gain on disposal of subsidiaries</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareInNetIncomeOfAssociatedCompanies" xlink:to="ORGS_ShareInNetIncomeOfAssociatedCompanies_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ORGS_ShareInNetIncomeOfAssociatedCompanies_2_lbl" xml:lang="en-US">Share in income of associated company</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances" xlink:label="ORGS_IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances" xlink:to="ORGS_IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances_lbl" xml:lang="en-US">Effect of exchange differences on inter-company balances</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NetChangesInOperatingLeases" xlink:label="ORGS_NetChangesInOperatingLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NetChangesInOperatingLeases" xlink:to="ORGS_NetChangesInOperatingLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ORGS_NetChangesInOperatingLeases_lbl" xml:lang="en-US">Net changes in operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseShortTermBorrowings" xlink:label="us-gaap_InterestExpenseShortTermBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseShortTermBorrowings" xlink:to="us-gaap_InterestExpenseShortTermBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseShortTermBorrowings_lbl" xml:lang="en-US">Interest expense accrued on loans and convertible loans (including amortization of beneficial conversion feature)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">&#160;&#160;&#160;&#160;&#160;Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase in accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase in inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Increase in other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase in prepaid expenses, other accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncreaseDecreaseInAccuredExpensesAndOtherPayables" xlink:label="ORGS_IncreaseDecreaseInAccuredExpensesAndOtherPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IncreaseDecreaseInAccuredExpensesAndOtherPayables" xlink:to="ORGS_IncreaseDecreaseInAccuredExpensesAndOtherPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_IncreaseDecreaseInAccuredExpensesAndOtherPayables_lbl" xml:lang="en-US">Increase (decrease) in accrued expenses and other payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in employee and related payables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (decrease) in contract liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant" xlink:label="ORGS_IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant" xlink:to="ORGS_IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant_lbl" xml:lang="en-US">Change in advance payments and receivables on account of grant, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xml:lang="en-US">Increase (decrease) in deferred taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForLongTermLoansForRelatedParties" xlink:label="us-gaap_ProceedsFromPaymentsForLongTermLoansForRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForLongTermLoansForRelatedParties" xlink:to="us-gaap_ProceedsFromPaymentsForLongTermLoansForRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromPaymentsForLongTermLoansForRelatedParties_lbl" xml:lang="en-US">Increase in loan to JV partner, a related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayment in loan to JV partner, a related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Sale of property, plants and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property, plants and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Acquisition of Koligo, net of cash acquired (See Note 4)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:label="us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:to="us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_lbl" xml:lang="en-US">Proceed from sale of subsidiaries, net</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PaymentsForInvestments" xlink:label="ORGS_PaymentsForInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PaymentsForInvestments" xlink:to="ORGS_PaymentsForInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ORGS_PaymentsForInvestments_lbl" xml:lang="en-US">Investment in associated company</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_lbl" xml:lang="en-US">Repayment (investment) in short term deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used) in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RepaymentOfTreasuryStock" xlink:label="ORGS_RepaymentOfTreasuryStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RepaymentOfTreasuryStock" xlink:to="ORGS_RepaymentOfTreasuryStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ORGS_RepaymentOfTreasuryStock_lbl" xml:lang="en-US">Repurchase of treasury stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="us-gaap_ProceedsFromMinorityShareholders" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMinorityShareholders" xlink:to="us-gaap_ProceedsFromMinorityShareholders_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromMinorityShareholders_lbl" xml:lang="en-US">Increase in redeemable non-controlling interests received from GPP</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from issuance of shares, warrants and exercise of options (net of transaction costs)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of convertible loans (net of transaction costs)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Repayment of convertible loans and convertible bonds</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayment of short and long-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from issuance of loans payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF YEAR</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF YEAR</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW TRANSACTIONS:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid in cash during the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes, net of refunds paid in cash during the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL NON-CASH FINANCING AND INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FinanceLeasesOfPropertyPlantAndEquipment" xlink:label="ORGS_FinanceLeasesOfPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FinanceLeasesOfPropertyPlantAndEquipment" xlink:to="ORGS_FinanceLeasesOfPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_FinanceLeasesOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Finance Leases of property, plant and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities" xlink:label="ORGS_RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities" xlink:to="ORGS_RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities_lbl" xml:lang="en-US">Right-of-use assets acquired in exchange for right-of-use liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable" xlink:label="ORGS_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable" xlink:to="ORGS_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable_lbl" xml:lang="en-US">Purchase of property, plant and equipment included in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US">Transaction costs of issuance of convertible loans</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AcquisitionOfOtherAssetInExchangeForCommonStocks" xlink:label="ORGS_AcquisitionOfOtherAssetInExchangeForCommonStocks" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AcquisitionOfOtherAssetInExchangeForCommonStocks" xlink:to="ORGS_AcquisitionOfOtherAssetInExchangeForCommonStocks_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_AcquisitionOfOtherAssetInExchangeForCommonStocks_lbl" xml:lang="en-US">Acquisition of other asset in exchange for common stocks</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo" xlink:label="ORGS_IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo" xlink:to="ORGS_IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo_lbl" xml:lang="en-US">Issuance of common stocks in connection with the acquisition of Koligo</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US">DISCONTINUED OPERATION</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisclosureAcquisitionAndReorganizationAbstract" xlink:label="ORGS_DisclosureAcquisitionAndReorganizationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisclosureAcquisitionAndReorganizationAbstract" xlink:to="ORGS_DisclosureAcquisitionAndReorganizationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DisclosureAcquisitionAndReorganizationAbstract_lbl" xml:lang="en-US">Acquisition And Reorganization</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AcquisitionAndReorganizationTextBlock" xlink:label="ORGS_AcquisitionAndReorganizationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AcquisitionAndReorganizationTextBlock" xlink:to="ORGS_AcquisitionAndReorganizationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_AcquisitionAndReorganizationTextBlock_lbl" xml:lang="en-US">ACQUISITION AND REORGANIZATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY, PLANTS AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS AND GOODWILL</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE LOANS</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisclosureLoansAbstract" xlink:label="ORGS_DisclosureLoansAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisclosureLoansAbstract" xlink:to="ORGS_DisclosureLoansAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DisclosureLoansAbstract_lbl" xml:lang="en-US">Loans</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_LoansTextBlock" xlink:label="ORGS_LoansTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_LoansTextBlock" xlink:to="ORGS_LoansTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_LoansTextBlock_lbl" xml:lang="en-US">LOANS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisclosureCollaborationAndLicenseAgreementsAbstract" xlink:label="ORGS_DisclosureCollaborationAndLicenseAgreementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisclosureCollaborationAndLicenseAgreementsAbstract" xlink:to="ORGS_DisclosureCollaborationAndLicenseAgreementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DisclosureCollaborationAndLicenseAgreementsAbstract_lbl" xml:lang="en-US">Collaboration And License Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CollaborationsLicenseAgreementsAndCommitmentsTextBlock" xlink:label="ORGS_CollaborationsLicenseAgreementsAndCommitmentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CollaborationsLicenseAgreementsAndCommitmentsTextBlock" xlink:to="ORGS_CollaborationsLicenseAgreementsAndCommitmentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_CollaborationsLicenseAgreementsAndCommitmentsTextBlock_lbl" xml:lang="en-US">COLLABORATION AND LICENSE AGREEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:label="us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:to="us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract_lbl" xml:lang="en-US">Investments in and Advances to Affiliates [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:label="us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:to="us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock_lbl" xml:lang="en-US">INVESTMENTS IN ASSOCIATES, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">EQUITY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_2_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">INCOME (LOSS) PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">REVENUES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and Development [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisclosureFinancialExpensesNetAbstract" xlink:label="ORGS_DisclosureFinancialExpensesNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisclosureFinancialExpensesNetAbstract" xlink:to="ORGS_DisclosureFinancialExpensesNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DisclosureFinancialExpensesNetAbstract_lbl" xml:lang="en-US">Financial Expenses Net</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FinancialExpensesNetTextBlock" xlink:label="ORGS_FinancialExpensesNetTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FinancialExpensesNetTextBlock" xlink:to="ORGS_FinancialExpensesNetTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_FinancialExpensesNetTextBlock_lbl" xml:lang="en-US">FINANCIAL EXPENSES, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates in the Preparation of Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US">Business Combination</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OtherInvestmentsPolicyTextBlock" xlink:label="ORGS_OtherInvestmentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OtherInvestmentsPolicyTextBlock" xlink:to="ORGS_OtherInvestmentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_OtherInvestmentsPolicyTextBlock_lbl" xml:lang="en-US">Other Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:to="us-gaap_DiscontinuedOperationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock_lbl" xml:lang="en-US">Discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xml:lang="en-US">Cost of research and development and research and development services, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xml:lang="en-US">Non-Marketable Equity Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FunctionalCurrencyPolicyTextBlock" xlink:label="ORGS_FunctionalCurrencyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FunctionalCurrencyPolicyTextBlock" xlink:to="ORGS_FunctionalCurrencyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_FunctionalCurrencyPolicyTextBlock_lbl" xml:lang="en-US">Functional Currency</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, plant and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:label="ORGS_RedeemableNoncontrollingInterestPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:to="ORGS_RedeemableNoncontrollingInterestPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_RedeemableNoncontrollingInterestPolicyTextBlock_lbl" xml:lang="en-US">Redeemable Non-controlling Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss (income) per Share of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TreasurySharesPolicyTextBlock" xlink:label="ORGS_TreasurySharesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TreasurySharesPolicyTextBlock" xlink:to="ORGS_TreasurySharesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_TreasurySharesPolicyTextBlock_lbl" xml:lang="en-US">Treasury shares</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BeneficialConversionFeatureBcfPolicyTextBlock" xlink:label="ORGS_BeneficialConversionFeatureBcfPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BeneficialConversionFeatureBcfPolicyTextBlock" xlink:to="ORGS_BeneficialConversionFeatureBcfPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_BeneficialConversionFeatureBcfPolicyTextBlock_lbl" xml:lang="en-US">Beneficial Conversion Feature (&#8220;BCF&#8221;)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Other Comprehensive Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue from Contracts with Customers</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="ORGS_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="ORGS_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US">Recently issued accounting pronouncements, not yet adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Newly issued and recently adopted accounting pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassifications</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock" xlink:label="ORGS_ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock" xlink:to="ORGS_ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock" xlink:label="ORGS_ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock" xlink:to="ORGS_ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DISCONTINUED OPERATION AND BALANCE SHEETS</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock" xlink:label="ORGS_ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock" xlink:to="ORGS_ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DISAGGREGATION OF REVENUE RELATED TO DISCONTINUED OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xml:lang="en-US">SCHEDULE OF UNAUDITED SUPPLEMENTAL PRO FORMA</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF COMPONENTS OF PROPERTY, PLANTS AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock" xlink:label="ORGS_ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock" xlink:to="ORGS_ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT BY GEOGRAPHICAL LOCATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xml:lang="en-US">SCHEDULE OF GOODWILL</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OTHER INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ESTIMATED AGGREGATE AMORTIZATION EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF LONG TERM CONVERTIBLE LOANS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF LOANS</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock" xlink:label="ORGS_LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock" xlink:to="ORGS_LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF LEASE-RELATED ASSETS AND LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF LEASE COSTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF SUPPLEMENTAL CASHFLOW INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:label="ORGS_LesseeLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:to="ORGS_LesseeLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_LesseeLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FINANCE LEASE LIABILITIES AND OPERATING LEASE LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ScheduleOfRightofuseAssetsByGeographicalLocation" xlink:label="ORGS_ScheduleOfRightofuseAssetsByGeographicalLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ScheduleOfRightofuseAssetsByGeographicalLocation" xlink:to="ORGS_ScheduleOfRightofuseAssetsByGeographicalLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ScheduleOfRightofuseAssetsByGeographicalLocation_lbl" xml:lang="en-US">SCHEDULE OF RIGHT-OF-USE ASSETS BY GEOGRAPHICAL LOCATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:label="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:to="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF CHANGES IN INVESTMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ScheduleOfWarrantsActivity" xlink:label="ORGS_ScheduleOfWarrantsActivity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ScheduleOfWarrantsActivity" xlink:to="ORGS_ScheduleOfWarrantsActivity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ScheduleOfWarrantsActivity_lbl" xml:lang="en-US">SCHEDULE OF WARRANTS ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ScheduleOfTreasuryShares" xlink:label="ORGS_ScheduleOfTreasuryShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ScheduleOfTreasuryShares" xlink:to="ORGS_ScheduleOfTreasuryShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ScheduleOfTreasuryShares_lbl" xml:lang="en-US">SCHEDULE OF TREASURY SHARES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_lbl" xml:lang="en-US">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_lbl" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock_lbl" xml:lang="en-US">SCHEDULE OF EMPLOYEE STOCK OWNERSHIP PLAN DISCLOSURES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTIONS ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTIONS EXERCISABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTIONS GRANTED TO CONSULTANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEFERRED TAX ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US">SCHEDULE OF VALUATION ALLOWANCE, ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DISAGGREGATION OF REVENUE</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ScheduleOfBreakdownOfRevenuesPerCustomer" xlink:label="ORGS_ScheduleOfBreakdownOfRevenuesPerCustomer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ScheduleOfBreakdownOfRevenuesPerCustomer" xlink:to="ORGS_ScheduleOfBreakdownOfRevenuesPerCustomer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ScheduleOfBreakdownOfRevenuesPerCustomer_lbl" xml:lang="en-US">SCHEDULE OF BREAKDOWN OF REVENUES PER CUSTOMER</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACTIVITY FOR TRADE RECEIVABLES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ScheduleOfFinancialExpensesTableTextBlock" xlink:label="ORGS_ScheduleOfFinancialExpensesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ScheduleOfFinancialExpensesTableTextBlock" xlink:to="ORGS_ScheduleOfFinancialExpensesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ScheduleOfFinancialExpensesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FINANCIAL EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="ORGS_ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock" xlink:to="ORGS_ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RELATED PARTIES PRESENTED IN CONSOLIDATED BALANCE SHEETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:label="srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems_lbl" xml:lang="en-US">Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PercentageOfOutstandingEquityInterests" xlink:label="ORGS_PercentageOfOutstandingEquityInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PercentageOfOutstandingEquityInterests" xlink:to="ORGS_PercentageOfOutstandingEquityInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_PercentageOfOutstandingEquityInterests_lbl" xml:lang="en-US">Percentage of outstanding equity interests</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AggregateNominalPurchasePrice" xlink:label="ORGS_AggregateNominalPurchasePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AggregateNominalPurchasePrice" xlink:to="ORGS_AggregateNominalPurchasePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_AggregateNominalPurchasePrice_lbl" xml:lang="en-US">Aggregate nominal purchase price of outstanding equity interests</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TransactionCostIncurred" xlink:label="ORGS_TransactionCostIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TransactionCostIncurred" xlink:to="ORGS_TransactionCostIncurred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_TransactionCostIncurred_lbl" xml:lang="en-US">Transaction cost incurred</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_2_lbl" xml:lang="en-US">Stock issued during period value acquisitions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2_lbl" xml:lang="en-US">Shares issued, acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AccumulatedDeficit" xlink:label="ORGS_AccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AccumulatedDeficit" xlink:to="ORGS_AccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_AccumulatedDeficit_lbl" xml:lang="en-US">Accumulated losses</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RepaymentOfIntercompanyLoansAndPayables" xlink:label="ORGS_RepaymentOfIntercompanyLoansAndPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RepaymentOfIntercompanyLoansAndPayables" xlink:to="ORGS_RepaymentOfIntercompanyLoansAndPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_RepaymentOfIntercompanyLoansAndPayables_lbl" xml:lang="en-US">Repayment of intercompany loans and payables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Weighted Average Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Intangible assets and useful lives (Years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment of long-lived asset</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent" xlink:label="ORGS_IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent" xlink:to="ORGS_IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent_lbl" xml:lang="en-US">Income tax examination, likelihood of unfavorable settlement percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TreasuryStockShares_2_lbl" xml:lang="en-US">Treasury Stock, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_LeaseClassificationDiscription" xlink:label="ORGS_LeaseClassificationDiscription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_LeaseClassificationDiscription" xlink:to="ORGS_LeaseClassificationDiscription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_LeaseClassificationDiscription_lbl" xml:lang="en-US">Lease classification discription</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MortgageLoansOnRealEstateLineItems" xlink:label="srt_MortgageLoansOnRealEstateLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateLineItems" xlink:to="srt_MortgageLoansOnRealEstateLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MortgageLoansOnRealEstateLineItems_lbl" xml:lang="en-US">SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet" xlink:label="ORGS_CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet" xlink:to="ORGS_CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ORGS_CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet_lbl" xml:lang="en-US">Cost of research and development and research and development services, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:label="us-gaap_DepreciationAndAmortizationDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:to="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationOtherExpenses" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationOtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationOtherExpenses" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationOtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationOtherExpenses_lbl" xml:lang="en-US">Other (income) expenses, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet_lbl" xml:lang="en-US">Financial expenses (income), net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_lbl" xml:lang="en-US">Tax expenses (income)</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncomeLossFromDiscontinuedOperationNetOfTax" xlink:label="ORGS_IncomeLossFromDiscontinuedOperationNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IncomeLossFromDiscontinuedOperationNetOfTax" xlink:to="ORGS_IncomeLossFromDiscontinuedOperationNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_IncomeLossFromDiscontinuedOperationNetOfTax_lbl" xml:lang="en-US">Net loss from discontinuing operation, net of tax</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax" xlink:label="us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax" xlink:to="us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_lbl" xml:lang="en-US">Gain on disposal before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal" xlink:label="us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal" xlink:to="us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:to="us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_lbl" xml:lang="en-US">Gain on disposal</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NetProfitLossFromDiscontinuingOperationNetOfTax" xlink:label="ORGS_NetProfitLossFromDiscontinuingOperationNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NetProfitLossFromDiscontinuingOperationNetOfTax" xlink:to="ORGS_NetProfitLossFromDiscontinuingOperationNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_NetProfitLossFromDiscontinuingOperationNetOfTax_lbl" xml:lang="en-US">Net profit (loss) from discontinuing operation, net of tax</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationGrantsReceivable" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationGrantsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationGrantsReceivable" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationGrantsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationGrantsReceivable_lbl" xml:lang="en-US">Grants receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationsDeposits" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationsDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationsDeposits" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationsDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationsDeposits_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl" xml:lang="en-US">Intangible assets, net (mainly Know How)</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS OF DISCONTINUED OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other payables</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables_lbl" xml:lang="en-US">Employees and related payables</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant_lbl" xml:lang="en-US">Advance payments on account of grant</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans_lbl" xml:lang="en-US">Short-term loans and current maturities of long- term loans</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_lbl" xml:lang="en-US">Contract liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases_lbl" xml:lang="en-US">Current maturities of long-term finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases_lbl" xml:lang="en-US">Current maturities of operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases_lbl" xml:lang="en-US">Non-current operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationLoansPayable" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationLoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationLoansPayable" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationLoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationLoansPayable_lbl" xml:lang="en-US">Loans payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_lbl" xml:lang="en-US">Deferred taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases_lbl" xml:lang="en-US">Long-term finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES OF DISCONTINUED OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PropertyPlantAndEquipmentNetAndRightOfUseAssets" xlink:label="ORGS_PropertyPlantAndEquipmentNetAndRightOfUseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PropertyPlantAndEquipmentNetAndRightOfUseAssets" xlink:to="ORGS_PropertyPlantAndEquipmentNetAndRightOfUseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_PropertyPlantAndEquipmentNetAndRightOfUseAssets_lbl" xml:lang="en-US">Property, plants and equipment, net and right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US">Net cash flows provided by (used in) operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US">Net cash flows used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US">Net cash flows (used in) provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:label="srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:to="srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems_lbl" xml:lang="en-US">SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued" xlink:to="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued_lbl" xml:lang="en-US">Fair value of 8.8% of shared issued *</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments" xlink:to="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments_lbl" xml:lang="en-US">Cash payment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Total consideration transferred</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:to="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property, plants and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xml:lang="en-US">Other intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:to="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill" xlink:to="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease" xlink:to="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease_lbl" xml:lang="en-US">Operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US">Accounts Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_lbl" xml:lang="en-US">Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability" xlink:to="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability_lbl" xml:lang="en-US">Orgenesis Inc loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xml:lang="en-US">Deferred taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xml:lang="en-US">Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2_lbl" xml:lang="en-US">Total consideration transferred</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FairValuePercentageofSharesIssued" xlink:label="ORGS_FairValuePercentageofSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FairValuePercentageofSharesIssued" xlink:to="ORGS_FairValuePercentageofSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_FairValuePercentageofSharesIssued_lbl" xml:lang="en-US">Fair value percentage of shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_2_lbl" xml:lang="en-US">Useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Acquired Indefinite-lived Intangible Assets [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="us-gaap_EscrowDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDeposit" xlink:to="us-gaap_EscrowDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EscrowDeposit_lbl" xml:lang="en-US">Cash held in escrow account</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NumberOfSharesDepositInEscrowAccount" xlink:label="ORGS_NumberOfSharesDepositInEscrowAccount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NumberOfSharesDepositInEscrowAccount" xlink:to="ORGS_NumberOfSharesDepositInEscrowAccount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_NumberOfSharesDepositInEscrowAccount_lbl" xml:lang="en-US">Number of shares deposit in escrow account</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationConsiderationTransferred" xlink:label="ORGS_BusinessCombinationConsiderationTransferred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BusinessCombinationConsiderationTransferred" xlink:to="ORGS_BusinessCombinationConsiderationTransferred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_BusinessCombinationConsiderationTransferred_lbl" xml:lang="en-US">Total consideration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and Development Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CashPaidToAccreditedInvestors" xlink:label="ORGS_CashPaidToAccreditedInvestors" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CashPaidToAccreditedInvestors" xlink:to="ORGS_CashPaidToAccreditedInvestors_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_CashPaidToAccreditedInvestors_lbl" xml:lang="en-US">Cash paid to accredited investors</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SharesHeldInEscrow" xlink:label="ORGS_SharesHeldInEscrow" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SharesHeldInEscrow" xlink:to="ORGS_SharesHeldInEscrow_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_SharesHeldInEscrow_lbl" xml:lang="en-US">Shares held in escrow</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdditionalCashConsideration" xlink:label="ORGS_AdditionalCashConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AdditionalCashConsideration" xlink:to="ORGS_AdditionalCashConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_AdditionalCashConsideration_lbl" xml:lang="en-US">Additional cash consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ReductionInConsiderationPayable" xlink:label="ORGS_ReductionInConsiderationPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ReductionInConsiderationPayable" xlink:to="ORGS_ReductionInConsiderationPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ReductionInConsiderationPayable_lbl" xml:lang="en-US">Reduction in consideration payable</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RestrictionOnSaleOfSharesPercentage" xlink:label="ORGS_RestrictionOnSaleOfSharesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RestrictionOnSaleOfSharesPercentage" xlink:to="ORGS_RestrictionOnSaleOfSharesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_RestrictionOnSaleOfSharesPercentage_lbl" xml:lang="en-US">Restriction on sale of shares percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RestrictionPeriodDescription" xlink:label="ORGS_RestrictionPeriodDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RestrictionPeriodDescription" xlink:to="ORGS_RestrictionPeriodDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_RestrictionPeriodDescription_lbl" xml:lang="en-US">Restriction period, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US">Acquisition-related expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xml:lang="en-US">Transfer of equity interests</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Goodwill_2_lbl" xml:lang="en-US">Goodwill, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="us-gaap_GoodwillAcquiredDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod_lbl" xml:lang="en-US">Goodwill as acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss_lbl" xml:lang="en-US">Translation differences</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Goodwill_3_lbl" xml:lang="en-US">Goodwill, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Net carrying amount of other intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">Amortization expenses, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive" xlink:label="ORGS_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive" xlink:to="ORGS_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive_lbl" xml:lang="en-US">Amortization expenses, 2022 to 2025</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AmortizationOfIntangibleAsset" xlink:label="ORGS_AmortizationOfIntangibleAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AmortizationOfIntangibleAsset" xlink:to="ORGS_AmortizationOfIntangibleAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_AmortizationOfIntangibleAsset_lbl" xml:lang="en-US">Amortization of Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DebtInstrumentIssuanceYear" xlink:label="ORGS_DebtInstrumentIssuanceYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DebtInstrumentIssuanceYear" xlink:to="ORGS_DebtInstrumentIssuanceYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DebtInstrumentIssuanceYear_lbl" xml:lang="en-US">Issuance Year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Maturity Period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xml:lang="en-US">BCF</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_2_lbl" xml:lang="en-US">Repaid, Principal Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DebtInstrumentRemainingTerm" xlink:label="ORGS_DebtInstrumentRemainingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DebtInstrumentRemainingTerm" xlink:to="ORGS_DebtInstrumentRemainingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DebtInstrumentRemainingTerm_lbl" xml:lang="en-US">Repaid, Maturity Period</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DebtInstrumentConvertibleRepaidBeneficialConversionFeature" xlink:label="ORGS_DebtInstrumentConvertibleRepaidBeneficialConversionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DebtInstrumentConvertibleRepaidBeneficialConversionFeature" xlink:to="ORGS_DebtInstrumentConvertibleRepaidBeneficialConversionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DebtInstrumentConvertibleRepaidBeneficialConversionFeature_lbl" xml:lang="en-US">Repaid, BCF</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock issued during period, conversion of convertible securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrant may be converted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants exercise, term</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PreMoneyValuation" xlink:label="ORGS_PreMoneyValuation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PreMoneyValuation" xlink:to="ORGS_PreMoneyValuation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_PreMoneyValuation_lbl" xml:lang="en-US">Pre-money valuation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_2_lbl" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Valuation of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Aggregate amount of debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_2_lbl" xml:lang="en-US">Conversion price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated share-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Aggregate credit line amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from lines of credit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Number of warrant to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ModificationOfExistingWarrants" xlink:label="ORGS_ModificationOfExistingWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ModificationOfExistingWarrants" xlink:to="ORGS_ModificationOfExistingWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ModificationOfExistingWarrants_lbl" xml:lang="en-US">Modification of the existing warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Repayments of lines o credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PercentageOfCommission" xlink:label="ORGS_PercentageOfCommission" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PercentageOfCommission" xlink:to="ORGS_PercentageOfCommission_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_PercentageOfCommission_lbl" xml:lang="en-US">Percentage of commission</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt instrument, maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DebtInstrumentConvertibleWarrantExercisePrice" xlink:label="ORGS_DebtInstrumentConvertibleWarrantExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DebtInstrumentConvertibleWarrantExercisePrice" xlink:to="ORGS_DebtInstrumentConvertibleWarrantExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DebtInstrumentConvertibleWarrantExercisePrice_lbl" xml:lang="en-US">Convertible warrant exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:label="us-gaap_ScheduleOfExtinguishmentOfDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:to="us-gaap_ScheduleOfExtinguishmentOfDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfExtinguishmentOfDebtTable_lbl" xml:lang="en-US">Schedule of Extinguishment of Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtLineItems" xlink:label="us-gaap_ExtinguishmentOfDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtLineItems_lbl" xml:lang="en-US">Extinguishment of Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_DebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtCurrent_lbl" xml:lang="en-US">Total loans</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US">Property, plants and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Current maturities of long-term finance leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Long-term finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Lease Term, Operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Lease Term, Finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted Average Discount Rate, Operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted Average Discount Rate, Finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of leased assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FinanceLeaseCost" xlink:label="ORGS_FinanceLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FinanceLeaseCost" xlink:to="ORGS_FinanceLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ORGS_FinanceLeaseCost_lbl" xml:lang="en-US">Total finance lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US">Finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US">Finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Operating Leases, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Finance Lease, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Operating Leases, 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Finance Lease, 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Operating Leases, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Finance Lease, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Operating Leases, 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Finance Lease, 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Operating Leases, 2025</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Finance Lease, 2025</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Operating Leases, Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Finance Leases, Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Operating Leases, Less: amount of lease payments representing interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Finance Lease, Less: amount of lease payments representing interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Leases, Present value of future minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Finance Lease, Present value of future minimum lease payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Operating Leases, Less: Current leases obligations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_3_lbl" xml:lang="en-US">Finance Lease, Less: Current leases obligations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating Leases, Long-term leases obligations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_3_lbl" xml:lang="en-US">Finance Lease, Long-term leases obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Leasing contracts period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivableNoncurrent" xlink:label="us-gaap_GrantsReceivableNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableNoncurrent" xlink:to="us-gaap_GrantsReceivableNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivableNoncurrent_lbl" xml:lang="en-US">Grants receivable, noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_GrantsReceivablePercentageOfBudgetedCosts" xlink:label="ORGS_GrantsReceivablePercentageOfBudgetedCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_GrantsReceivablePercentageOfBudgetedCosts" xlink:to="ORGS_GrantsReceivablePercentageOfBudgetedCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_GrantsReceivablePercentageOfBudgetedCosts_lbl" xml:lang="en-US">Grants receivable, percentage of budgeted costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenues, total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Other expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US">Other payables</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DeductionOfResearchAndDevelopmentExpenses" xlink:label="ORGS_DeductionOfResearchAndDevelopmentExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DeductionOfResearchAndDevelopmentExpenses" xlink:to="ORGS_DeductionOfResearchAndDevelopmentExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DeductionOfResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Deduction of research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RepaymentsOfGrantPercentageOfGrossSales" xlink:label="ORGS_RepaymentsOfGrantPercentageOfGrossSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RepaymentsOfGrantPercentageOfGrossSales" xlink:to="ORGS_RepaymentsOfGrantPercentageOfGrossSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_RepaymentsOfGrantPercentageOfGrossSales_lbl" xml:lang="en-US">Repayments of grant, percentage of gross sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="dei_EntityListingsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityListingsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingsLineItems_lbl" xml:lang="en-US">Entity Listings [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherCommitment_2_lbl" xml:lang="en-US">Commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TerminationDescription" xlink:label="ORGS_TerminationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TerminationDescription" xlink:to="ORGS_TerminationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_TerminationDescription_lbl" xml:lang="en-US">Termination description</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RoyaltyOfNetSalesPercentage" xlink:label="ORGS_RoyaltyOfNetSalesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RoyaltyOfNetSalesPercentage" xlink:to="ORGS_RoyaltyOfNetSalesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_RoyaltyOfNetSalesPercentage_lbl" xml:lang="en-US">Royalty of net sales, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SublicensingFeesPercentage" xlink:label="ORGS_SublicensingFeesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SublicensingFeesPercentage" xlink:to="ORGS_SublicensingFeesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_SublicensingFeesPercentage_lbl" xml:lang="en-US">Sublicensing fees, percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleDebt_2_lbl" xml:lang="en-US">Convertible loan</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CommitmentSharesOfCommonStock" xlink:label="ORGS_CommitmentSharesOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CommitmentSharesOfCommonStock" xlink:to="ORGS_CommitmentSharesOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_CommitmentSharesOfCommonStock_lbl" xml:lang="en-US">Commitment, shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CommitmentSharesOfCommonStockOfSubsidiary" xlink:label="ORGS_CommitmentSharesOfCommonStockOfSubsidiary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CommitmentSharesOfCommonStockOfSubsidiary" xlink:to="ORGS_CommitmentSharesOfCommonStockOfSubsidiary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_CommitmentSharesOfCommonStockOfSubsidiary_lbl" xml:lang="en-US">Commitment, shares of common stock of Israeli subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ReductionRateOfRoyaltyPercentage" xlink:label="ORGS_ReductionRateOfRoyaltyPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ReductionRateOfRoyaltyPercentage" xlink:to="ORGS_ReductionRateOfRoyaltyPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ReductionRateOfRoyaltyPercentage_lbl" xml:lang="en-US">Reduction rate of royalty percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableNet" xlink:label="us-gaap_NotesReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableNet" xlink:to="us-gaap_NotesReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesReceivableNet_lbl" xml:lang="en-US">Loans receivable net</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdditionalFundsInvest" xlink:label="ORGS_AdditionalFundsInvest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AdditionalFundsInvest" xlink:to="ORGS_AdditionalFundsInvest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_AdditionalFundsInvest_lbl" xml:lang="en-US">Additional Funds Invest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromGrantors" xlink:label="us-gaap_ProceedsFromGrantors" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromGrantors" xlink:to="us-gaap_ProceedsFromGrantors_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromGrantors_lbl" xml:lang="en-US">Proceeds from advance payment of grant</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PercentageOfGrossRevenues" xlink:label="ORGS_PercentageOfGrossRevenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PercentageOfGrossRevenues" xlink:to="ORGS_PercentageOfGrossRevenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_PercentageOfGrossRevenues_lbl" xml:lang="en-US">Percentage of gross revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PaymentForFinancialSupportToTrustForStudy" xlink:label="ORGS_PaymentForFinancialSupportToTrustForStudy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PaymentForFinancialSupportToTrustForStudy" xlink:to="ORGS_PaymentForFinancialSupportToTrustForStudy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_PaymentForFinancialSupportToTrustForStudy_lbl" xml:lang="en-US">Payment for financial support to trust for study</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PaymentForFinancialSupportCumulativeAmountToTrustForStudy" xlink:label="ORGS_PaymentForFinancialSupportCumulativeAmountToTrustForStudy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PaymentForFinancialSupportCumulativeAmountToTrustForStudy" xlink:to="ORGS_PaymentForFinancialSupportCumulativeAmountToTrustForStudy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_PaymentForFinancialSupportCumulativeAmountToTrustForStudy_lbl" xml:lang="en-US">Payment for financial support cumulative amount to trust for study</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PaymentForFinancialSupportToTrustForStudyDueEverySixMonths" xlink:label="ORGS_PaymentForFinancialSupportToTrustForStudyDueEverySixMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PaymentForFinancialSupportToTrustForStudyDueEverySixMonths" xlink:to="ORGS_PaymentForFinancialSupportToTrustForStudyDueEverySixMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_PaymentForFinancialSupportToTrustForStudyDueEverySixMonths_lbl" xml:lang="en-US">Payment for financial support to trust for study due every six months</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RoyaltyOfNetSalesOfOtherProductsPercentage" xlink:label="ORGS_RoyaltyOfNetSalesOfOtherProductsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RoyaltyOfNetSalesOfOtherProductsPercentage" xlink:to="ORGS_RoyaltyOfNetSalesOfOtherProductsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_RoyaltyOfNetSalesOfOtherProductsPercentage_lbl" xml:lang="en-US">Royalty of net sales of other product percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PaymentOfFeeUponAchievementOfEachRegulatoryMilestone" xlink:label="ORGS_PaymentOfFeeUponAchievementOfEachRegulatoryMilestone" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PaymentOfFeeUponAchievementOfEachRegulatoryMilestone" xlink:to="ORGS_PaymentOfFeeUponAchievementOfEachRegulatoryMilestone_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_PaymentOfFeeUponAchievementOfEachRegulatoryMilestone_lbl" xml:lang="en-US">Payment of fee upon the achievement of each regulatory milestone</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Percentage of ownership</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_3_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FutureMilestonePayments" xlink:label="ORGS_FutureMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FutureMilestonePayments" xlink:to="ORGS_FutureMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_FutureMilestonePayments_lbl" xml:lang="en-US">Future milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RoyaltyPercentage" xlink:label="ORGS_RoyaltyPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RoyaltyPercentage" xlink:to="ORGS_RoyaltyPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_RoyaltyPercentage_lbl" xml:lang="en-US">Royalty percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_InterestInJointVenture" xlink:label="ORGS_InterestInJointVenture" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_InterestInJointVenture" xlink:to="ORGS_InterestInJointVenture_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_InterestInJointVenture_lbl" xml:lang="en-US">Interest in joint venture</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoanAdvancedToJointVenture" xlink:label="ORGS_ConvertibleLoanAdvancedToJointVenture" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ConvertibleLoanAdvancedToJointVenture" xlink:to="ORGS_ConvertibleLoanAdvancedToJointVenture_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ConvertibleLoanAdvancedToJointVenture_lbl" xml:lang="en-US">Convertible loan advanced to joint venture</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoanAdvancedToJointVentureInterestRate" xlink:label="ORGS_ConvertibleLoanAdvancedToJointVentureInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ConvertibleLoanAdvancedToJointVentureInterestRate" xlink:to="ORGS_ConvertibleLoanAdvancedToJointVentureInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ConvertibleLoanAdvancedToJointVentureInterestRate_lbl" xml:lang="en-US">Convertible loan advanced to joint venture, interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_lbl" xml:lang="en-US">Payment for consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferToInvestments" xlink:label="us-gaap_TransferToInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransferToInvestments" xlink:to="us-gaap_TransferToInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransferToInvestments_lbl" xml:lang="en-US">Transfer for prior establishment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US">Opening balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl" xml:lang="en-US">Investments during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Share in net income of associated companies</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_EquityMethodInvestments_2_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="us-gaap_ScheduleOfInvestmentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_ScheduleOfInvestmentsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInvestmentsTable_lbl" xml:lang="en-US">Schedule of Investments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfInvestmentsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems_lbl" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_InvestmentsInAssociatePercentageOfOwnership" xlink:label="ORGS_InvestmentsInAssociatePercentageOfOwnership" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_InvestmentsInAssociatePercentageOfOwnership" xlink:to="ORGS_InvestmentsInAssociatePercentageOfOwnership_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_InvestmentsInAssociatePercentageOfOwnership_lbl" xml:lang="en-US">Investments in associate percentage of ownership</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Warrants - Warrants outstanding at the beginning of the period</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price - Warrants outstanding at the beginning of the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Warrants - Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price - Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Number of Warrants - Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price - Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_lbl" xml:lang="en-US">Number of Warrants - Warrants outstanding and exercisable at the end of the period</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price - Warrants outstanding and exercisable at the end of the period</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TreasuryStockShare" xlink:label="ORGS_TreasuryStockShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TreasuryStockShare" xlink:to="ORGS_TreasuryStockShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ORGS_TreasuryStockShare_lbl" xml:lang="en-US">Number of Treasury Shares at the beginning of the period</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock" xlink:label="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock" xlink:to="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock_lbl" xml:lang="en-US">Weighted Average Price Paid Treasury Shares at the beginning of the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesAcquired" xlink:to="us-gaap_TreasuryStockSharesAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xml:lang="en-US">Number of Treasury Shares Purchased</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_WeightedAveragePriceNumberOfSharesTreasuryStockPurchased" xlink:label="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStockPurchased" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStockPurchased" xlink:to="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStockPurchased_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStockPurchased_lbl" xml:lang="en-US">Weighted Average Price Paid Treasury Shares Purchased</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TreasuryStockShare" xlink:to="ORGS_TreasuryStockShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ORGS_TreasuryStockShare_2_lbl" xml:lang="en-US">Number of Treasury Shares at end of the period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock" xlink:to="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock_2_lbl" xml:lang="en-US">Weighted Average Price Paid Treasury Shares at end of the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Warrant to purchase of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_WarrantExercisableDescription" xlink:label="ORGS_WarrantExercisableDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_WarrantExercisableDescription" xlink:to="ORGS_WarrantExercisableDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_WarrantExercisableDescription_lbl" xml:lang="en-US">Warrant exercisable, description</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OfferingExpenses" xlink:label="ORGS_OfferingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OfferingExpenses" xlink:to="ORGS_OfferingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_OfferingExpenses_lbl" xml:lang="en-US">Offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_3_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDeposit" xlink:to="us-gaap_EscrowDeposit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EscrowDeposit_2_lbl" xml:lang="en-US">Escrow Deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:label="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:to="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_lbl" xml:lang="en-US">Net loss from continuing operations attributable to Orgenesis Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" xlink:label="us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" xlink:to="us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_lbl" xml:lang="en-US">Net (income) loss from discontinued operations attributable to Orgenesis Inc. for loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount" xlink:label="ORGS_AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount" xlink:to="ORGS_AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount_lbl" xml:lang="en-US">Adjustment of redeemable non-controlling interest to redemption amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Basic: Net income (loss) available to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NetIncomeLossToParentCompany" xlink:label="ORGS_NetIncomeLossToParentCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NetIncomeLossToParentCompany" xlink:to="ORGS_NetIncomeLossToParentCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_NetIncomeLossToParentCompany_lbl" xml:lang="en-US">Net (income) loss attributable to Orgenesis Inc. for loss per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US">Loss per common share from continuing operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_lbl" xml:lang="en-US">Net (income) loss common share from discontinued operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Net (income) loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">No. of options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_lbl" xml:lang="en-US">Stock options vesting period description</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_lbl" xml:lang="en-US">Fair value at grant</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_lbl" xml:lang="en-US">Expiration period</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_StockOptionsGrantVestingPeriodPercentage" xlink:label="ORGS_StockOptionsGrantVestingPeriodPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_StockOptionsGrantVestingPeriodPercentage" xlink:to="ORGS_StockOptionsGrantVestingPeriodPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_StockOptionsGrantVestingPeriodPercentage_lbl" xml:lang="en-US">Stock options grant vesting period percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Value of one common share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected stock price volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options - Options outstanding at the end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price - Options outstanding at the end of the year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Number of Options - Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price - Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of Options - Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price - Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of Options - Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price - Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Options - Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price - Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_lbl" xml:lang="en-US">Number of Options - Cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price - Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Options - Options outstanding at the end of the year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price - Options outstanding at the end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options - Options exercisable at end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price - Options exercisable at end of the year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of Outstanding Options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Number of Exercisable Options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Exercisable Options Value</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription_lbl" xml:lang="en-US">Vesting peirod description</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod_lbl" xml:lang="en-US">Vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, number of shares authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Share-based compensation, shares authorized under stock option plans, exercise price range, outstanding options, weighted average remaining contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, number of additional shares authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, available for grants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_2_lbl" xml:lang="en-US">Share issued price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_WarrantExercisableDescription" xlink:to="ORGS_WarrantExercisableDescription_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ORGS_WarrantExercisableDescription_2_lbl" xml:lang="en-US">[custom:WarrantExercisableDescription]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2_lbl" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AggregateAmountOfSubscriptionAgreement" xlink:label="ORGS_AggregateAmountOfSubscriptionAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AggregateAmountOfSubscriptionAgreement" xlink:to="ORGS_AggregateAmountOfSubscriptionAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_AggregateAmountOfSubscriptionAgreement_lbl" xml:lang="en-US">Aggregate amount of subscription agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xml:lang="en-US">Warrant, exercise price, decrease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="us-gaap_WarrantExercisePriceIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Warrant, exercise price, increase</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_WarrantsAndRightsOutstandingTermDescription" xlink:label="ORGS_WarrantsAndRightsOutstandingTermDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_WarrantsAndRightsOutstandingTermDescription" xlink:to="ORGS_WarrantsAndRightsOutstandingTermDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_WarrantsAndRightsOutstandingTermDescription_lbl" xml:lang="en-US">Warrants term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Fair value of granted</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ClassOfWarrantOrRightGrantsInPeriod" xlink:label="ORGS_ClassOfWarrantOrRightGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ClassOfWarrantOrRightGrantsInPeriod" xlink:to="ORGS_ClassOfWarrantOrRightGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ClassOfWarrantOrRightGrantsInPeriod_lbl" xml:lang="en-US">Number of warrants - issued</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ORGS_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice" xlink:to="ORGS_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ORGS_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price - Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ClassOfWarrantOrRightGrantsInPeriodFairValue" xlink:label="ORGS_ClassOfWarrantOrRightGrantsInPeriodFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ClassOfWarrantOrRightGrantsInPeriodFairValue" xlink:to="ORGS_ClassOfWarrantOrRightGrantsInPeriodFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ClassOfWarrantOrRightGrantsInPeriodFairValue_lbl" xml:lang="en-US">Class of warrant or right, grants in period, fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xml:lang="en-US">Number of common stock for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xml:lang="en-US">Number of common stock for services, value</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FairValueOfSharesRecognizedOnGrantDate" xlink:label="ORGS_FairValueOfSharesRecognizedOnGrantDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FairValueOfSharesRecognizedOnGrantDate" xlink:to="ORGS_FairValueOfSharesRecognizedOnGrantDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_FairValueOfSharesRecognizedOnGrantDate_lbl" xml:lang="en-US">[custom:FairValueOfSharesRecognizedOnGrantDate-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted" xlink:label="ORGS_JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted" xlink:to="ORGS_JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted_lbl" xml:lang="en-US">Joint venture agreement, shares issued for compensation of work already completed</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock issued during period, shares, restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NumberOfVestedShares" xlink:label="ORGS_NumberOfVestedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NumberOfVestedShares" xlink:to="ORGS_NumberOfVestedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_NumberOfVestedShares_lbl" xml:lang="en-US">Number of vested shares</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FairValueOfSharesOnVestingDatesRecognizedDuringYear" xlink:label="ORGS_FairValueOfSharesOnVestingDatesRecognizedDuringYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FairValueOfSharesOnVestingDatesRecognizedDuringYear" xlink:to="ORGS_FairValueOfSharesOnVestingDatesRecognizedDuringYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_FairValueOfSharesOnVestingDatesRecognizedDuringYear_lbl" xml:lang="en-US">Fair value of shares on vesting dates recognized during year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Number of warrants shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Warrant term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock issued during period, value, restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NumberOfAdditionalSharesRestrictionsOnTransfer" xlink:label="ORGS_NumberOfAdditionalSharesRestrictionsOnTransfer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NumberOfAdditionalSharesRestrictionsOnTransfer" xlink:to="ORGS_NumberOfAdditionalSharesRestrictionsOnTransfer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_NumberOfAdditionalSharesRestrictionsOnTransfer_lbl" xml:lang="en-US">Number of additional shares restrictions on transfer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forwards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Equity compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_lbl" xml:lang="en-US">Employee benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DeferredTaxAssetsLeasesAsset" xlink:label="ORGS_DeferredTaxAssetsLeasesAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DeferredTaxAssetsLeasesAsset" xlink:to="ORGS_DeferredTaxAssetsLeasesAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DeferredTaxAssetsLeasesAsset_lbl" xml:lang="en-US">Leases asset</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DeferredTaxAssetsLeaseLiability" xlink:label="ORGS_DeferredTaxAssetsLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DeferredTaxAssetsLeaseLiability" xlink:to="ORGS_DeferredTaxAssetsLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ORGS_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Net deferred tax liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Balance at the beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Change during the year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_3_lbl" xml:lang="en-US">Balance at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective income tax rate reconciliation, at income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xml:lang="en-US">Operating loss carryforwards, limitations on use</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AccumulatedTaxLossCarryforwardDeductions" xlink:label="ORGS_AccumulatedTaxLossCarryforwardDeductions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AccumulatedTaxLossCarryforwardDeductions" xlink:to="ORGS_AccumulatedTaxLossCarryforwardDeductions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_AccumulatedTaxLossCarryforwardDeductions_lbl" xml:lang="en-US">[custom:AccumulatedTaxLossCarryforwardDeductions-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective income tax rate reconciliation, at local income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AccumulatedTaxLossCarryForwardedPeriod" xlink:label="ORGS_AccumulatedTaxLossCarryForwardedPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AccumulatedTaxLossCarryForwardedPeriod" xlink:to="ORGS_AccumulatedTaxLossCarryForwardedPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_AccumulatedTaxLossCarryForwardedPeriod_lbl" xml:lang="en-US">[custom:AccumulatedTaxLossCarryForwardedPeriod]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_3_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_2_lbl" xml:lang="en-US">Balance as of beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AccountsReceivableAcquisitionOfKoligo" xlink:label="ORGS_AccountsReceivableAcquisitionOfKoligo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AccountsReceivableAcquisitionOfKoligo" xlink:to="ORGS_AccountsReceivableAcquisitionOfKoligo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_AccountsReceivableAcquisitionOfKoligo_lbl" xml:lang="en-US">Acquisition of Koligo</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AccountsReceivableAdditions" xlink:label="ORGS_AccountsReceivableAdditions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AccountsReceivableAdditions" xlink:to="ORGS_AccountsReceivableAdditions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_AccountsReceivableAdditions_lbl" xml:lang="en-US">Additions</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AccountsReceivableCollections" xlink:label="ORGS_AccountsReceivableCollections" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AccountsReceivableCollections" xlink:to="ORGS_AccountsReceivableCollections_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_AccountsReceivableCollections_lbl" xml:lang="en-US">Collections</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExchangeRateDifferencesOfAccountsReceivable" xlink:label="ORGS_ExchangeRateDifferencesOfAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExchangeRateDifferencesOfAccountsReceivable" xlink:to="ORGS_ExchangeRateDifferencesOfAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExchangeRateDifferencesOfAccountsReceivable_lbl" xml:lang="en-US">Exchange rate differences</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_3_lbl" xml:lang="en-US">Balance as of end of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_2_lbl" xml:lang="en-US">Balance as of beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ContractWithCustomerLiabilityAddition" xlink:label="ORGS_ContractWithCustomerLiabilityAddition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ContractWithCustomerLiabilityAddition" xlink:to="ORGS_ContractWithCustomerLiabilityAddition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ORGS_ContractWithCustomerLiabilityAddition_lbl" xml:lang="en-US">Additions</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ContractWithCustomerLiabilityRealizations" xlink:label="ORGS_ContractWithCustomerLiabilityRealizations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ContractWithCustomerLiabilityRealizations" xlink:to="ORGS_ContractWithCustomerLiabilityRealizations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ContractWithCustomerLiabilityRealizations_lbl" xml:lang="en-US">Realizations</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ContractWithCustomerLiabilityExchangeRateDifferences" xlink:label="ORGS_ContractWithCustomerLiabilityExchangeRateDifferences" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ContractWithCustomerLiabilityExchangeRateDifferences" xlink:to="ORGS_ContractWithCustomerLiabilityExchangeRateDifferences_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ORGS_ContractWithCustomerLiabilityExchangeRateDifferences_lbl" xml:lang="en-US">Exchange rate differences</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_3_lbl" xml:lang="en-US">Balance as of end of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_4_lbl" xml:lang="en-US">Contract with customer liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_4_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Total expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_GrantsIncome" xlink:label="ORGS_GrantsIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_GrantsIncome" xlink:to="ORGS_GrantsIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_GrantsIncome_lbl" xml:lang="en-US">Less grants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisclosureFinancialExpensesNetAbstract" xlink:to="ORGS_DisclosureFinancialExpensesNetAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ORGS_DisclosureFinancialExpensesNetAbstract_2_lbl" xml:lang="en-US">Schedule Of Financial Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue" xlink:label="ORGS_IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue" xlink:to="ORGS_IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue_lbl" xml:lang="en-US">Increase in fair value of warrants and financial liabilities measured at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_InterestExpenseOnConvertibleLoans" xlink:label="ORGS_InterestExpenseOnConvertibleLoans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_InterestExpenseOnConvertibleLoans" xlink:to="ORGS_InterestExpenseOnConvertibleLoans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_InterestExpenseOnConvertibleLoans_lbl" xml:lang="en-US">Interest expense on convertible loans</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ForeignCurrencyTransactionsGainLossRealized" xlink:label="ORGS_ForeignCurrencyTransactionsGainLossRealized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ForeignCurrencyTransactionsGainLossRealized" xlink:to="ORGS_ForeignCurrencyTransactionsGainLossRealized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ForeignCurrencyTransactionsGainLossRealized_lbl" xml:lang="en-US">Foreign exchange loss, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TotalFinancialExpenses" xlink:label="ORGS_TotalFinancialExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TotalFinancialExpenses" xlink:to="ORGS_TotalFinancialExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ORGS_TotalFinancialExpenses_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_lbl" xml:lang="en-US">Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Management and consulting fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromRelatedParties_2_lbl" xml:lang="en-US">Revenues from customer</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" xlink:label="ORGS_CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" xlink:to="ORGS_CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ORGS_CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet_lbl" xml:lang="en-US">Cost of research and development and research and development services, net</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FinancialIncome" xlink:label="ORGS_FinancialIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FinancialIncome" xlink:to="ORGS_FinancialIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_FinancialIncome_lbl" xml:lang="en-US">Financial income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Stock Based Compensation expenses for options exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Exercise price per share of options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NumberOfOrdinarySharesHeld" xlink:label="ORGS_NumberOfOrdinarySharesHeld" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NumberOfOrdinarySharesHeld" xlink:to="ORGS_NumberOfOrdinarySharesHeld_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_NumberOfOrdinarySharesHeld_lbl" xml:lang="en-US">Number of ordinary shares held</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Due to Related Parties</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DueFromRelatedPartiesNoncurrent1" xlink:label="ORGS_DueFromRelatedPartiesNoncurrent1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DueFromRelatedPartiesNoncurrent1" xlink:to="ORGS_DueFromRelatedPartiesNoncurrent1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ORGS_DueFromRelatedPartiesNoncurrent1_lbl" xml:lang="en-US">Loan to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Contract liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AccruedExpensesAndOtherPayablesCurrent" xlink:to="ORGS_AccruedExpensesAndOtherPayablesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_AccruedExpensesAndOtherPayablesCurrent_doc" xml:lang="en-US">Accrued expenses and other payables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AdvancePaymentsOnAccountOfGrant" xlink:to="ORGS_AdvancePaymentsOnAccountOfGrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_AdvancePaymentsOnAccountOfGrant_doc" xml:lang="en-US">Advance payments on account of grant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RedeemableNoncontrollingInterestOfDiscontinuedOperation" xlink:to="ORGS_RedeemableNoncontrollingInterestOfDiscontinuedOperation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_RedeemableNoncontrollingInterestOfDiscontinuedOperation_doc" xml:lang="en-US">Redeemable non-controlling interest of discontinued operation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_EquityAttributedToOrgenesisIncMember" xlink:to="ORGS_EquityAttributedToOrgenesisIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_EquityAttributedToOrgenesisIncMember_doc" xml:lang="en-US">Equity Attributed To Orgenesis Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_StockbasedCompensationToStrategicCollaborations" xlink:to="ORGS_StockbasedCompensationToStrategicCollaborations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_StockbasedCompensationToStrategicCollaborations_doc" xml:lang="en-US">Stock-based compensation to strategic collaborations.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans" xlink:to="ORGS_IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans_doc" xml:lang="en-US">Issuance and modification of warrants and beneficial conversion feature of convertible loans.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp" xlink:to="ORGS_AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp_doc" xml:lang="en-US">Adjustments to Additional Paid in Capital, Transaction With noncontrolling interest GPP.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement" xlink:to="ORGS_StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement_doc" xml:lang="en-US">Stock-based compensation for Tamir purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IssuanceOfSharesAndWarrants" xlink:to="ORGS_IssuanceOfSharesAndWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_IssuanceOfSharesAndWarrants_doc" xml:lang="en-US">Issuance of shares and warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_StockbasedCompensationToStrategicCollaborationsShares" xlink:to="ORGS_StockbasedCompensationToStrategicCollaborationsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_StockbasedCompensationToStrategicCollaborationsShares_doc" xml:lang="en-US">Stock-based compensation to strategic collaborations, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares" xlink:to="ORGS_StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares_doc" xml:lang="en-US">Stock-based compensation for Tamir purchase agreement, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IssuanceOfSharesAndWarrantsShares" xlink:to="ORGS_IssuanceOfSharesAndWarrantsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_IssuanceOfSharesAndWarrantsShares_doc" xml:lang="en-US">Issuance of shares and warrants, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PercentageOfOutstandingEquityInterests" xlink:to="ORGS_PercentageOfOutstandingEquityInterests_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_PercentageOfOutstandingEquityInterests_doc" xml:lang="en-US">Percentage of outstanding equity interests.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_MasthercellMember" xlink:to="ORGS_MasthercellMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_MasthercellMember_doc" xml:lang="en-US">MaSTherCell [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SecuritiesPurchaseAgreementMember" xlink:to="ORGS_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AggregateNominalPurchasePrice" xlink:to="ORGS_AggregateNominalPurchasePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_AggregateNominalPurchasePrice_doc" xml:lang="en-US">Amount of aggregate nominal purchase price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TransactionCostIncurred" xlink:to="ORGS_TransactionCostIncurred_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_TransactionCostIncurred_doc" xml:lang="en-US">Transaction cost incurred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CureCellCoLtdMember" xlink:to="ORGS_CureCellCoLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_CureCellCoLtdMember_doc" xml:lang="en-US">CureCell Co. Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TamirBiotechnologyIncMember" xlink:to="ORGS_TamirBiotechnologyIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_TamirBiotechnologyIncMember_doc" xml:lang="en-US">Tamir Biotechnology, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TamirPurchaseAgreementMember" xlink:to="ORGS_TamirPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_TamirPurchaseAgreementMember_doc" xml:lang="en-US">Tamir Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AccumulatedDeficit" xlink:to="ORGS_AccumulatedDeficit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_AccumulatedDeficit_doc" xml:lang="en-US">Accumulated losses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RepaymentOfIntercompanyLoansAndPayables" xlink:to="ORGS_RepaymentOfIntercompanyLoansAndPayables_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_RepaymentOfIntercompanyLoansAndPayables_doc" xml:lang="en-US">Repayment of intercompany loans and payables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_LeaseClassificationDiscription" xlink:to="ORGS_LeaseClassificationDiscription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_LeaseClassificationDiscription_doc" xml:lang="en-US">Lease classification discription.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ProductionFacilityMember" xlink:to="ORGS_ProductionFacilityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ProductionFacilityMember_doc" xml:lang="en-US">Production Facility [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet" xlink:to="ORGS_CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet_doc" xml:lang="en-US">Cost of research and development and research and development services, net to discontinued operation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationOtherExpenses" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationOtherExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationOtherExpenses_doc" xml:lang="en-US">Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet_doc" xml:lang="en-US">Discontinued operation financial (income) expenses, net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IncomeLossFromDiscontinuedOperationNetOfTax" xlink:to="ORGS_IncomeLossFromDiscontinuedOperationNetOfTax_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_IncomeLossFromDiscontinuedOperationNetOfTax_doc" xml:lang="en-US">Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NetProfitLossFromDiscontinuingOperationNetOfTax" xlink:to="ORGS_NetProfitLossFromDiscontinuingOperationNetOfTax_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_NetProfitLossFromDiscontinuingOperationNetOfTax_doc" xml:lang="en-US">Net profit (loss) from discontinuing operation, net of tax.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_doc" xml:lang="en-US">Amount classified as restricted cash equivalents attributable to disposal group held for sale or disposed of.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationGrantsReceivable" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationGrantsReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationGrantsReceivable_doc" xml:lang="en-US">Disposal group, including discontinued operation receivable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationsDeposits" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationsDeposits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationsDeposits_doc" xml:lang="en-US">Deposits of discontinued operations.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets_doc" xml:lang="en-US">Operating lease right-of-use assets to disposal group.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables_doc" xml:lang="en-US">Employees and related payables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant_doc" xml:lang="en-US">Advance payments on account of grant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans_doc" xml:lang="en-US">Short-term loans and current maturities of long- term loans.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases_doc" xml:lang="en-US">Current maturities of long-term finance leases.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases_doc" xml:lang="en-US">Current maturities of operating leases.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases_doc" xml:lang="en-US">Non-current operating leases.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationLoansPayable" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationLoansPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationLoansPayable_doc" xml:lang="en-US">Disposal group, including discontinued operation loans payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases_doc" xml:lang="en-US">Long-term finance leases.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PropertyPlantAndEquipmentNetAndRightOfUseAssets" xlink:to="ORGS_PropertyPlantAndEquipmentNetAndRightOfUseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_PropertyPlantAndEquipmentNetAndRightOfUseAssets_doc" xml:lang="en-US">Property, plants and equipment, net and right-of-use assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OptionsGrantedToEmployeesMember" xlink:to="ORGS_OptionsGrantedToEmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_OptionsGrantedToEmployeesMember_doc" xml:lang="en-US">Options Granted To Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CommitmentsByPartyAxis" xlink:label="ORGS_CommitmentsByPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CommitmentsByPartyAxis" xlink:to="ORGS_CommitmentsByPartyAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_CommitmentsByPartyAxis_doc" xml:lang="en-US">Commitments by party</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_EmployeeRangesAxis" xlink:label="ORGS_EmployeeRangesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_EmployeeRangesAxis" xlink:to="ORGS_EmployeeRangesAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_EmployeeRangesAxis_doc" xml:lang="en-US">Employee Ranges</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_GrantsReceivablePercentageOfBudgetedCosts" xlink:to="ORGS_GrantsReceivablePercentageOfBudgetedCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_GrantsReceivablePercentageOfBudgetedCosts_doc" xml:lang="en-US">Grants receivable, percentage of budgeted costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TechnologyMember" xlink:to="ORGS_TechnologyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_TechnologyMember_doc" xml:lang="en-US">Technology [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_MasthercellSAMember" xlink:to="ORGS_MasthercellSAMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_MasthercellSAMember_doc" xml:lang="en-US">Masthercell SA [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CellProcessDevelopmentServicesMember" xlink:to="ORGS_CellProcessDevelopmentServicesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_CellProcessDevelopmentServicesMember_doc" xml:lang="en-US">Cell Process Development Services [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TechTransferServicesMember" xlink:to="ORGS_TechTransferServicesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_TechTransferServicesMember_doc" xml:lang="en-US">Tech Transfer Services [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CellManufacturingServicesMember" xlink:to="ORGS_CellManufacturingServicesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_CellManufacturingServicesMember_doc" xml:lang="en-US">Cell Manufacturing Services [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock" xlink:to="ORGS_ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock_doc" xml:lang="en-US">Schedule of Disaggregation of Revenue Related to Discontinued Operations [Table Text ]Block</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock" xlink:to="ORGS_ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock_doc" xml:lang="en-US">Schedule of Annual Depreciation Rates Property and Equipment [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock" xlink:to="ORGS_ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock_doc" xml:lang="en-US">Schedule of Intangible Assets Useful Lives [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_KnowhowMember" xlink:to="ORGS_KnowhowMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_KnowhowMember_doc" xml:lang="en-US">Know How [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AcquisitionAndReorganizationTextBlock" xlink:to="ORGS_AcquisitionAndReorganizationTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_AcquisitionAndReorganizationTextBlock_doc" xml:lang="en-US">Acquisition and Reorganization [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_doc" xml:lang="en-US">Fair value at grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_doc" xml:lang="en-US">Expiration period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DeductionOfResearchAndDevelopmentExpenses" xlink:to="ORGS_DeductionOfResearchAndDevelopmentExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DeductionOfResearchAndDevelopmentExpenses_doc" xml:lang="en-US">Deduction of research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_StockbasedCompensationTransactionsAxis" xlink:label="ORGS_StockbasedCompensationTransactionsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_StockbasedCompensationTransactionsAxis" xlink:to="ORGS_StockbasedCompensationTransactionsAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_StockbasedCompensationTransactionsAxis_doc" xml:lang="en-US">Stockbased Compensation Transactions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TwoZeroOneSevenEquityIncentivePlanMember" xlink:to="ORGS_TwoZeroOneSevenEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_TwoZeroOneSevenEquityIncentivePlanMember_doc" xml:lang="en-US">2017 Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_MarylandTechnologyDevelopmentCorporationMember" xlink:to="ORGS_MarylandTechnologyDevelopmentCorporationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_MarylandTechnologyDevelopmentCorporationMember_doc" xml:lang="en-US">Maryland Technology Development Corporation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember" xlink:to="ORGS_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_doc" xml:lang="en-US">Research and development of a potential cure for Type 1 Diabetes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" xlink:to="ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_doc" xml:lang="en-US">Department De La Gestion Financiere Direction De Lanalyse Financiere [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_EmployeeOneMember" xlink:label="ORGS_EmployeeOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_EmployeeOneMember" xlink:to="ORGS_EmployeeOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_EmployeeOneMember_doc" xml:lang="en-US">Employee 1 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IndustrialResearchPartOfResearchProgramMember" xlink:to="ORGS_IndustrialResearchPartOfResearchProgramMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_IndustrialResearchPartOfResearchProgramMember_doc" xml:lang="en-US">Industrial research part of the research program [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExperimentalDevelopmentPartOfResearchProgramMember" xlink:to="ORGS_ExperimentalDevelopmentPartOfResearchProgramMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExperimentalDevelopmentPartOfResearchProgramMember_doc" xml:lang="en-US">Experimental development part of the research program [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_EmployeesMember" xlink:to="ORGS_EmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_EmployeesMember_doc" xml:lang="en-US">Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareInNetIncomeOfAssociatedCompanies" xlink:to="ORGS_ShareInNetIncomeOfAssociatedCompanies_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ShareInNetIncomeOfAssociatedCompanies_doc" xml:lang="en-US">Share in net income of associated companies.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary" xlink:to="ORGS_OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary_doc" xml:lang="en-US">Net loss (income) from discontinued operations, net of tax.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations" xlink:to="ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations_doc" xml:lang="en-US">Comprehensive income attributed to non-controlling interests (including redeemable) from continuing operation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations" xlink:to="ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations_doc" xml:lang="en-US">Comprehensive income attributed to non-controlling interests (including redeemable) from discontinued operation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationOne" xlink:to="ORGS_ShareBasedCompensationOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ShareBasedCompensationOne_doc" xml:lang="en-US">Stock-based compensation to for strategic collaborations.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationTwo" xlink:to="ORGS_ShareBasedCompensationTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ShareBasedCompensationTwo_doc" xml:lang="en-US">Stock-based compensation for Tamir Purchase Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances" xlink:to="ORGS_IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances_doc" xml:lang="en-US">Effect of exchange differences on inter-company balances.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NetChangesInOperatingLeases" xlink:to="ORGS_NetChangesInOperatingLeases_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_NetChangesInOperatingLeases_doc" xml:lang="en-US">Net changes in operating leases.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IncreaseDecreaseInAccuredExpensesAndOtherPayables" xlink:to="ORGS_IncreaseDecreaseInAccuredExpensesAndOtherPayables_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_IncreaseDecreaseInAccuredExpensesAndOtherPayables_doc" xml:lang="en-US">Increase in accrued expenses and other payables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant" xlink:to="ORGS_IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant_doc" xml:lang="en-US">Increase (decrease) in advance payments and receivables on account of grant, net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PaymentsForInvestments" xlink:to="ORGS_PaymentsForInvestments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_PaymentsForInvestments_doc" xml:lang="en-US">Investment in associated company</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RepaymentOfTreasuryStock" xlink:to="ORGS_RepaymentOfTreasuryStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_RepaymentOfTreasuryStock_doc" xml:lang="en-US">Repurchase of treasury stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FinanceLeasesOfPropertyPlantAndEquipment" xlink:to="ORGS_FinanceLeasesOfPropertyPlantAndEquipment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_FinanceLeasesOfPropertyPlantAndEquipment_doc" xml:lang="en-US">Finance leases of property, plant and equipment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities" xlink:to="ORGS_RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities_doc" xml:lang="en-US">Right-of-use assets acquired in exchange for right-of-use liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable" xlink:to="ORGS_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable_doc" xml:lang="en-US">Purchase of property, plant and equipment included in accounts payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AcquisitionOfOtherAssetInExchangeForCommonStocks" xlink:to="ORGS_AcquisitionOfOtherAssetInExchangeForCommonStocks_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_AcquisitionOfOtherAssetInExchangeForCommonStocks_doc" xml:lang="en-US">Acquisition of other asset in exchange for common stocks.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo" xlink:to="ORGS_IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo_doc" xml:lang="en-US">Issuance of common stocks in connection with the acquisition of Koligo.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OtherInvestmentsPolicyTextBlock" xlink:to="ORGS_OtherInvestmentsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_OtherInvestmentsPolicyTextBlock_doc" xml:lang="en-US">Other Investments [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FunctionalCurrencyPolicyTextBlock" xlink:to="ORGS_FunctionalCurrencyPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_FunctionalCurrencyPolicyTextBlock_doc" xml:lang="en-US">Functional Currency [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:to="ORGS_RedeemableNoncontrollingInterestPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_RedeemableNoncontrollingInterestPolicyTextBlock_doc" xml:lang="en-US">Redeemable Noncontrolling Interest [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TreasurySharesPolicyTextBlock" xlink:to="ORGS_TreasurySharesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_TreasurySharesPolicyTextBlock_doc" xml:lang="en-US">Treasury Shares [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BeneficialConversionFeatureBcfPolicyTextBlock" xlink:to="ORGS_BeneficialConversionFeatureBcfPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_BeneficialConversionFeatureBcfPolicyTextBlock_doc" xml:lang="en-US">Beneficial Conversion Feature [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="ORGS_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_doc" xml:lang="en-US">Recently Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RevenueFromGrantsMember" xlink:to="ORGS_RevenueFromGrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_RevenueFromGrantsMember_doc" xml:lang="en-US">Revenue from grants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DevelopmentOfPotentialCureForTypeOneDiabetesMember" xlink:to="ORGS_DevelopmentOfPotentialCureForTypeOneDiabetesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DevelopmentOfPotentialCureForTypeOneDiabetesMember_doc" xml:lang="en-US">Development of a potential cure for Type 1 Diabetes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants_doc" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Available for grants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_GlobalShareIncentivePlanTwoZeroOneTwoMember" xlink:to="ORGS_GlobalShareIncentivePlanTwoZeroOneTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_GlobalShareIncentivePlanTwoZeroOneTwoMember_doc" xml:lang="en-US">Global share incentive plan (2012) [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember" xlink:to="ORGS_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_doc" xml:lang="en-US">GMP production of AIP cells for two clinical trials that will be performed in Germany and Belgium</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_LoansTextBlock" xlink:to="ORGS_LoansTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_LoansTextBlock_doc" xml:lang="en-US">Loans.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock" xlink:to="ORGS_LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock_doc" xml:lang="en-US">Schedule of Lease-Related Assets and Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:to="ORGS_LesseeLeaseLiabilityMaturityTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_LesseeLeaseLiabilityMaturityTableTextBlock_doc" xml:lang="en-US">Schedule of Finance Lease Liabilities and Operating Lease Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ScheduleOfRightofuseAssetsByGeographicalLocation" xlink:to="ORGS_ScheduleOfRightofuseAssetsByGeographicalLocation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ScheduleOfRightofuseAssetsByGeographicalLocation_doc" xml:lang="en-US">Schedule of Right-of-use Assets by Geographical Location [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NumberOfSharesDepositInEscrowAccount" xlink:to="ORGS_NumberOfSharesDepositInEscrowAccount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_NumberOfSharesDepositInEscrowAccount_doc" xml:lang="en-US">Number of shares deposit in escrow account.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember" xlink:to="ORGS_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember_doc" xml:lang="en-US">Israel-U.S Binational Industrial Research and Development Foundation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BusinessCombinationConsiderationTransferred" xlink:to="ORGS_BusinessCombinationConsiderationTransferred_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_BusinessCombinationConsiderationTransferred_doc" xml:lang="en-US">Business combination consideration transferred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RepaymentsOfGrantPercentageOfGrossSales" xlink:to="ORGS_RepaymentsOfGrantPercentageOfGrossSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_RepaymentsOfGrantPercentageOfGrossSales_doc" xml:lang="en-US">Repayments of grant, percentage of gross sales</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember" xlink:to="ORGS_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember_doc" xml:lang="en-US">Korea-Israel Industrial Research and Development Foundation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BirdSecantMember" xlink:to="ORGS_BirdSecantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_BirdSecantMember_doc" xml:lang="en-US">BIRD Secant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_KoligoTherapeuticsIncMember" xlink:to="ORGS_KoligoTherapeuticsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_KoligoTherapeuticsIncMember_doc" xml:lang="en-US">Koligo therapeutics inc.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_MaterialDefinitiveAgreementMember" xlink:to="ORGS_MaterialDefinitiveAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_MaterialDefinitiveAgreementMember_doc" xml:lang="en-US">Material dewfinitive agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CashPaidToAccreditedInvestors" xlink:to="ORGS_CashPaidToAccreditedInvestors_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_CashPaidToAccreditedInvestors_doc" xml:lang="en-US">Cash paid to accredited investors.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_doc" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Cancellations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Cancellations in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceTwoMember" xlink:to="ORGS_ExercisePriceTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExercisePriceTwoMember_doc" xml:lang="en-US">Exercise Price 2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SharesHeldInEscrow" xlink:to="ORGS_SharesHeldInEscrow_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_SharesHeldInEscrow_doc" xml:lang="en-US">Shares held in escrow.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AdditionalCashConsideration" xlink:to="ORGS_AdditionalCashConsideration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_AdditionalCashConsideration_doc" xml:lang="en-US">Additional cash consideration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ReductionInConsiderationPayable" xlink:to="ORGS_ReductionInConsiderationPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ReductionInConsiderationPayable_doc" xml:lang="en-US">Reduction in consideration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RestrictionOnSaleOfSharesPercentage" xlink:to="ORGS_RestrictionOnSaleOfSharesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_RestrictionOnSaleOfSharesPercentage_doc" xml:lang="en-US">Restriction on sale of shares percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_LongHillAndMaximGroupLLCMember" xlink:to="ORGS_LongHillAndMaximGroupLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_LongHillAndMaximGroupLLCMember_doc" xml:lang="en-US">Long hill and maximum group.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RegistrationRightsandLockUpAgreementMember" xlink:to="ORGS_RegistrationRightsandLockUpAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_RegistrationRightsandLockUpAgreementMember_doc" xml:lang="en-US">Registration rights and lock up agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TerminationDescription" xlink:to="ORGS_TerminationDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_TerminationDescription_doc" xml:lang="en-US">Termination description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CollaborationAndLicenseAgreementsAxis" xlink:to="ORGS_CollaborationAndLicenseAgreementsAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_CollaborationAndLicenseAgreementsAxis_doc" xml:lang="en-US">Collaboration and License Agreements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AdvaBiotechnologyLtdMember" xlink:to="ORGS_AdvaBiotechnologyLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_AdvaBiotechnologyLtdMember_doc" xml:lang="en-US">Adva Biotechnology Ltd.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RoyaltyOfNetSalesPercentage" xlink:to="ORGS_RoyaltyOfNetSalesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_RoyaltyOfNetSalesPercentage_doc" xml:lang="en-US">Royalty of net sales, percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember" xlink:to="ORGS_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_doc" xml:lang="en-US">Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SublicensingFeesPercentage" xlink:to="ORGS_SublicensingFeesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_SublicensingFeesPercentage_doc" xml:lang="en-US">Sublicensing fees, percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceOneMember" xlink:to="ORGS_ExercisePriceOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExercisePriceOneMember_doc" xml:lang="en-US">Exercise Price 1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember" xlink:to="ORGS_OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember_doc" xml:lang="en-US">On the date of initiation of phase I clinical trials in human subjects</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember" xlink:to="ORGS_OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember_doc" xml:lang="en-US">On the date of initiation of phase II clinical trials in human subject</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_KyslecelTechnologyMember" xlink:to="ORGS_KyslecelTechnologyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_KyslecelTechnologyMember_doc" xml:lang="en-US">Kyslecel Technology [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember" xlink:to="ORGS_OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember_doc" xml:lang="en-US">On the date of initiation of phase III clinical trials in human subjects</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IPResearchAndDevelopmentMember" xlink:to="ORGS_IPResearchAndDevelopmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_IPResearchAndDevelopmentMember_doc" xml:lang="en-US">IPR&amp;D [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember" xlink:to="ORGS_OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember_doc" xml:lang="en-US">On the date of initiation of issuance of an approval for marketing of the first product by the FDA</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember" xlink:to="ORGS_WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember_doc" xml:lang="en-US">When worldwide net sales of Products have reached the amount of $150 million for the first time</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_HemogenyxPharmaceuticalsPLCMember" xlink:to="ORGS_HemogenyxPharmaceuticalsPLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_HemogenyxPharmaceuticalsPLCMember_doc" xml:lang="en-US">Hemogenyx Pharmaceuticals PLC. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CommitmentSharesOfCommonStock" xlink:to="ORGS_CommitmentSharesOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_CommitmentSharesOfCommonStock_doc" xml:lang="en-US">Commitment, shares of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CommitmentSharesOfCommonStockOfSubsidiary" xlink:to="ORGS_CommitmentSharesOfCommonStockOfSubsidiary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_CommitmentSharesOfCommonStockOfSubsidiary_doc" xml:lang="en-US">Commitment, shares of common stock of subsidiary</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ReductionRateOfRoyaltyPercentage" xlink:to="ORGS_ReductionRateOfRoyaltyPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ReductionRateOfRoyaltyPercentage_doc" xml:lang="en-US">Reduction rate of royalty percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ResearchAndDevelopmentCostsMember" xlink:to="ORGS_ResearchAndDevelopmentCostsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ResearchAndDevelopmentCostsMember_doc" xml:lang="en-US">Research And Development Costs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ImmugenyxLLCMember" xlink:to="ORGS_ImmugenyxLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ImmugenyxLLCMember_doc" xml:lang="en-US">Immugenyx, LLC</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ImmuAgreementMember" xlink:to="ORGS_ImmuAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ImmuAgreementMember_doc" xml:lang="en-US">Immu Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BgNegevTechnologiesAndApplicationsBgnMember" xlink:to="ORGS_BgNegevTechnologiesAndApplicationsBgnMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_BgNegevTechnologiesAndApplicationsBgnMember_doc" xml:lang="en-US">BG Negev Technologies and Applications (BGN)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued" xlink:to="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued_doc" xml:lang="en-US">Fair value of shared issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments" xlink:to="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments_doc" xml:lang="en-US">Cash payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:to="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_doc" xml:lang="en-US">Restricted Cash.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:to="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_doc" xml:lang="en-US">Operating lease right-of-use assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill" xlink:to="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill_doc" xml:lang="en-US">Goodwill.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease" xlink:to="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease_doc" xml:lang="en-US">Operating leases.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_doc" xml:lang="en-US">Accrued Expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability" xlink:to="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability_doc" xml:lang="en-US">Loan liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CollaborationAgreementMember" xlink:to="ORGS_CollaborationAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_CollaborationAgreementMember_doc" xml:lang="en-US">Collaboration agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceSeventeenMember" xlink:to="ORGS_ExercisePriceSeventeenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExercisePriceSeventeenMember_doc" xml:lang="en-US">Exercise Price Seventeen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceEighteenMember" xlink:to="ORGS_ExercisePriceEighteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExercisePriceEighteenMember_doc" xml:lang="en-US">Exercise Price Eighteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceNineteenMember" xlink:to="ORGS_ExercisePriceNineteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExercisePriceNineteenMember_doc" xml:lang="en-US">Exercise Price Nineteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceTwentyMember" xlink:to="ORGS_ExercisePriceTwentyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExercisePriceTwentyMember_doc" xml:lang="en-US">Exercise Price Twenty [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PreMoneyValuation" xlink:to="ORGS_PreMoneyValuation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_PreMoneyValuation_doc" xml:lang="en-US">Pre-money valuation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AdditionalFundsInvest" xlink:to="ORGS_AdditionalFundsInvest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_AdditionalFundsInvest_doc" xml:lang="en-US">Represents additional amount invested in company.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PercentageOfGrossRevenues" xlink:to="ORGS_PercentageOfGrossRevenues_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_PercentageOfGrossRevenues_doc" xml:lang="en-US">Percentage of gross revenues.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceThreeMember" xlink:to="ORGS_ExercisePriceThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExercisePriceThreeMember_doc" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceFourMember" xlink:to="ORGS_ExercisePriceFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExercisePriceFourMember_doc" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceFiveMember" xlink:to="ORGS_ExercisePriceFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExercisePriceFiveMember_doc" xml:lang="en-US">Exercise Price Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceSixMember" xlink:to="ORGS_ExercisePriceSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExercisePriceSixMember_doc" xml:lang="en-US">Exercise Price Six [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceSevenMember" xlink:to="ORGS_ExercisePriceSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExercisePriceSevenMember_doc" xml:lang="en-US">Exercise Price Seven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceEightMember" xlink:to="ORGS_ExercisePriceEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExercisePriceEightMember_doc" xml:lang="en-US">Exercise Price Eighteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceNineMember" xlink:to="ORGS_ExercisePriceNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExercisePriceNineMember_doc" xml:lang="en-US">Exercise Price Nine [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceTenMember" xlink:to="ORGS_ExercisePriceTenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExercisePriceTenMember_doc" xml:lang="en-US">Exercise Price Ten [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceElevenMember" xlink:to="ORGS_ExercisePriceElevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExercisePriceElevenMember_doc" xml:lang="en-US">Exercise Price Eleven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceTwelveMember" xlink:to="ORGS_ExercisePriceTwelveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExercisePriceTwelveMember_doc" xml:lang="en-US">Exercise Price Twelve [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceThirteenMember" xlink:to="ORGS_ExercisePriceThirteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExercisePriceThirteenMember_doc" xml:lang="en-US">Exercise Price Thirteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceFourteenMember" xlink:to="ORGS_ExercisePriceFourteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExercisePriceFourteenMember_doc" xml:lang="en-US">Exercise Price Fourteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceFifteenMember" xlink:to="ORGS_ExercisePriceFifteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExercisePriceFifteenMember_doc" xml:lang="en-US">Exercise Price Fifteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceSixteenMember" xlink:to="ORGS_ExercisePriceSixteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExercisePriceSixteenMember_doc" xml:lang="en-US">Exercise Price Sixteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FairValuePercentageofSharesIssued" xlink:to="ORGS_FairValuePercentageofSharesIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_FairValuePercentageofSharesIssued_doc" xml:lang="en-US">Fair Value Percentage of Shares Issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PaymentForFinancialSupportToTrustForStudy" xlink:to="ORGS_PaymentForFinancialSupportToTrustForStudy_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_PaymentForFinancialSupportToTrustForStudy_doc" xml:lang="en-US">Represents amount of financial support provided to trust for study.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SponsoredResearchAgreementMember" xlink:to="ORGS_SponsoredResearchAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_SponsoredResearchAgreementMember_doc" xml:lang="en-US">Sponsored Research Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PaymentForFinancialSupportCumulativeAmountToTrustForStudy" xlink:to="ORGS_PaymentForFinancialSupportCumulativeAmountToTrustForStudy_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_PaymentForFinancialSupportCumulativeAmountToTrustForStudy_doc" xml:lang="en-US">Represents amount of cumulative financial support provided to trust for study.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PaymentForFinancialSupportToTrustForStudyDueEverySixMonths" xlink:to="ORGS_PaymentForFinancialSupportToTrustForStudyDueEverySixMonths_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_PaymentForFinancialSupportToTrustForStudyDueEverySixMonths_doc" xml:lang="en-US">Represents amount of financial support to trust for study due in six month.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RoyaltyOfNetSalesOfOtherProductsPercentage" xlink:to="ORGS_RoyaltyOfNetSalesOfOtherProductsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_RoyaltyOfNetSalesOfOtherProductsPercentage_doc" xml:lang="en-US">Percentage of royalty of net sales of other products.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ColumbiaLicenseAgreementMember" xlink:to="ORGS_ColumbiaLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ColumbiaLicenseAgreementMember_doc" xml:lang="en-US">Columbia License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PaymentOfFeeUponAchievementOfEachRegulatoryMilestone" xlink:to="ORGS_PaymentOfFeeUponAchievementOfEachRegulatoryMilestone_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_PaymentOfFeeUponAchievementOfEachRegulatoryMilestone_doc" xml:lang="en-US">Represents amount of payment of fee to Columbia upon the achievement of each regulatory milestone.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OptionsGrantedToEmployeesAndDirectorsMember" xlink:to="ORGS_OptionsGrantedToEmployeesAndDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_OptionsGrantedToEmployeesAndDirectorsMember_doc" xml:lang="en-US">Options Granted to Employees and Directors</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_MasthercellGlobalMember" xlink:to="ORGS_MasthercellGlobalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_MasthercellGlobalMember_doc" xml:lang="en-US">Masthercell Global [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_MarylandSubsidiaryMember" xlink:to="ORGS_MarylandSubsidiaryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_MarylandSubsidiaryMember_doc" xml:lang="en-US">Maryland Subsidiary [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AIPCellsMember" xlink:to="ORGS_AIPCellsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_AIPCellsMember_doc" xml:lang="en-US">AIP Cells [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CaliforniaUniversityJointResearchAgreementMember" xlink:to="ORGS_CaliforniaUniversityJointResearchAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_CaliforniaUniversityJointResearchAgreementMember_doc" xml:lang="en-US">California University Joint Research Agreement [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CaerusTherapeuticsIncMember" xlink:to="ORGS_CaerusTherapeuticsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_CaerusTherapeuticsIncMember_doc" xml:lang="en-US">Caerus Therapeutics Inc [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExtracellularVesicleMember" xlink:to="ORGS_ExtracellularVesicleMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExtracellularVesicleMember_doc" xml:lang="en-US">Extracellular Vesicle [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_EVAmentMember" xlink:to="ORGS_EVAmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_EVAmentMember_doc" xml:lang="en-US">EV Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FutureMilestonePayments" xlink:to="ORGS_FutureMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_FutureMilestonePayments_doc" xml:lang="en-US">Future milestone.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RoyaltyPercentage" xlink:to="ORGS_RoyaltyPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_RoyaltyPercentage_doc" xml:lang="en-US">Royalty percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod_doc" xml:lang="en-US">Vesting period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TissueGenesisLLCMember" xlink:to="ORGS_TissueGenesisLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_TissueGenesisLLCMember_doc" xml:lang="en-US">Tissue Genesis, LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_InterestInJointVenture" xlink:to="ORGS_InterestInJointVenture_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_InterestInJointVenture_doc" xml:lang="en-US">Interest in joint venture</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BroadenJointVentureAgreementMember" xlink:to="ORGS_BroadenJointVentureAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_BroadenJointVentureAgreementMember_doc" xml:lang="en-US">Broaden Joint Venture Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ConvertibleLoanAdvancedToJointVenture" xlink:to="ORGS_ConvertibleLoanAdvancedToJointVenture_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ConvertibleLoanAdvancedToJointVenture_doc" xml:lang="en-US">Convertible loan advanced to joint venture</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_JointVentureAgreementMember" xlink:to="ORGS_JointVentureAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_JointVentureAgreementMember_doc" xml:lang="en-US">Joint Venture Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ConvertibleLoanAdvancedToJointVentureInterestRate" xlink:to="ORGS_ConvertibleLoanAdvancedToJointVentureInterestRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ConvertibleLoanAdvancedToJointVentureInterestRate_doc" xml:lang="en-US">Convertible loan advanced to joint venture, interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_KinerjapayCorpMember" xlink:to="ORGS_KinerjapayCorpMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_KinerjapayCorpMember_doc" xml:lang="en-US">KinerjaPay Corp member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SBHSciencesIncMember" xlink:to="ORGS_SBHSciencesIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_SBHSciencesIncMember_doc" xml:lang="en-US">SBH Sciences, Inc [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive" xlink:to="ORGS_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive_doc" xml:lang="en-US">Amortization expenses, 2022  to 2025.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_InvestmentsInAssociatePercentageOfOwnership" xlink:to="ORGS_InvestmentsInAssociatePercentageOfOwnership_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_InvestmentsInAssociatePercentageOfOwnership_doc" xml:lang="en-US">Investments in associate percentage of ownership.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TLABSMember" xlink:to="ORGS_TLABSMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_TLABSMember_doc" xml:lang="en-US">TLABS [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ButterflyBiosciencesSarlMember" xlink:to="ORGS_ButterflyBiosciencesSarlMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ButterflyBiosciencesSarlMember_doc" xml:lang="en-US">Butterfly Biosciences Sarl [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_KidneyCureJVAMember" xlink:to="ORGS_KidneyCureJVAMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_KidneyCureJVAMember_doc" xml:lang="en-US">Kidney Cure JVA [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ScheduleOfWarrantsActivity" xlink:to="ORGS_ScheduleOfWarrantsActivity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ScheduleOfWarrantsActivity_doc" xml:lang="en-US">Schedule of Warrants Activity [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TwoThousandTwentyOneToTwoThousandTwentyMember" xlink:to="ORGS_TwoThousandTwentyOneToTwoThousandTwentyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_TwoThousandTwentyOneToTwoThousandTwentyMember_doc" xml:lang="en-US">2021-2020 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AccumulatedTaxLossCarryforwardDeductions" xlink:to="ORGS_AccumulatedTaxLossCarryforwardDeductions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_AccumulatedTaxLossCarryforwardDeductions_doc" xml:lang="en-US">Accumulated tax loss carryforward deductions.</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncomeTaxBracketsAxis" xlink:label="ORGS_IncomeTaxBracketsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IncomeTaxBracketsAxis" xlink:to="ORGS_IncomeTaxBracketsAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_IncomeTaxBracketsAxis_doc" xml:lang="en-US">Income tax brackets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember" xlink:to="ORGS_TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember_doc" xml:lang="en-US">The First KRW 200 Million Of The Tax Base [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_UpToKrwTwoZeroBillionMember" xlink:to="ORGS_UpToKrwTwoZeroBillionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_UpToKrwTwoZeroBillionMember_doc" xml:lang="en-US">Up to KRW 20 billion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_UpToKrwThreeZeroZeroBillionMember" xlink:to="ORGS_UpToKrwThreeZeroZeroBillionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_UpToKrwThreeZeroZeroBillionMember_doc" xml:lang="en-US">Up to KRW 300 billion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TaxBaseAboveKrwThreeZeroZeroBillionMember" xlink:to="ORGS_TaxBaseAboveKrwThreeZeroZeroBillionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_TaxBaseAboveKrwThreeZeroZeroBillionMember_doc" xml:lang="en-US">Tax Base Above KRW 300 Billion [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ScheduleOfTreasuryShares" xlink:to="ORGS_ScheduleOfTreasuryShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ScheduleOfTreasuryShares_doc" xml:lang="en-US">Schedule of Treasury Shares [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_WarrantExercisableDescription" xlink:to="ORGS_WarrantExercisableDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_WarrantExercisableDescription_doc" xml:lang="en-US">Warrant exercisable description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OfferingExpenses" xlink:to="ORGS_OfferingExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_OfferingExpenses_doc" xml:lang="en-US">Offering expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_MergerAgreementMember" xlink:to="ORGS_MergerAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_MergerAgreementMember_doc" xml:lang="en-US">Merger Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SouthKoreanWonMember" xlink:to="ORGS_SouthKoreanWonMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_SouthKoreanWonMember_doc" xml:lang="en-US">KRW [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AccumulatedTaxLossCarryForwardedPeriod" xlink:to="ORGS_AccumulatedTaxLossCarryForwardedPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_AccumulatedTaxLossCarryForwardedPeriod_doc" xml:lang="en-US">Accumulated tax loss carry forwarded period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DeferredTaxAssetsLeasesAsset" xlink:to="ORGS_DeferredTaxAssetsLeasesAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DeferredTaxAssetsLeasesAsset_doc" xml:lang="en-US">Leases asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DeferredTaxAssetsLeaseLiability" xlink:to="ORGS_DeferredTaxAssetsLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DeferredTaxAssetsLeaseLiability_doc" xml:lang="en-US">Lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FinanceLeaseCost" xlink:to="ORGS_FinanceLeaseCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_FinanceLeaseCost_doc" xml:lang="en-US">Total finance lease cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_doc" xml:lang="en-US">Number of Warrants - Warrants outstanding and exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price - warrants outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price - warrants granted in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price - warrants expiration in periods.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise pPrice - warrants outstanding and exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock" xlink:to="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock_doc" xml:lang="en-US">Weighted Average Price Paid Treasury Shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStockPurchased" xlink:to="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStockPurchased_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStockPurchased_doc" xml:lang="en-US">Weighted Average Price Paid Treasury Shares Purchased.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount" xlink:to="ORGS_AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount_doc" xml:lang="en-US">Adjustment of redeemable non-controlling interest to redemption amount.</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ContractWithCustomerLiabilityRealizationsAsOfDate" xlink:label="ORGS_ContractWithCustomerLiabilityRealizationsAsOfDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ContractWithCustomerLiabilityRealizationsAsOfDate" xlink:to="ORGS_ContractWithCustomerLiabilityRealizationsAsOfDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ContractWithCustomerLiabilityRealizationsAsOfDate_doc" xml:lang="en-US">Realization of contract with customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DebtInstrumentIssuanceYear" xlink:to="ORGS_DebtInstrumentIssuanceYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DebtInstrumentIssuanceYear_doc" xml:lang="en-US">Debt instrument, issuance year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ConvertibleLoansMember" xlink:to="ORGS_ConvertibleLoansMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ConvertibleLoansMember_doc" xml:lang="en-US">Convertible Loans [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PointOfCareServicesMember" xlink:to="ORGS_PointOfCareServicesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_PointOfCareServicesMember_doc" xml:lang="en-US">POC and Hospital Services [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CustomerAMember" xlink:to="ORGS_CustomerAMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_CustomerAMember_doc" xml:lang="en-US">Customers A [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CustomerBMember" xlink:to="ORGS_CustomerBMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_CustomerBMember_doc" xml:lang="en-US">Customers B [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CustomerCRelatedPartyMember" xlink:to="ORGS_CustomerCRelatedPartyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_CustomerCRelatedPartyMember_doc" xml:lang="en-US">Customers C - Related Party [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CustomerDMember" xlink:to="ORGS_CustomerDMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_CustomerDMember_doc" xml:lang="en-US">Customers D [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AccountsReceivableAcquisitionOfKoligo" xlink:to="ORGS_AccountsReceivableAcquisitionOfKoligo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_AccountsReceivableAcquisitionOfKoligo_doc" xml:lang="en-US">Amount of accounts receivable acquisition of Koligo.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AccountsReceivableAdditions" xlink:to="ORGS_AccountsReceivableAdditions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_AccountsReceivableAdditions_doc" xml:lang="en-US">Amount of accounts receivable additions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AccountsReceivableCollections" xlink:to="ORGS_AccountsReceivableCollections_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_AccountsReceivableCollections_doc" xml:lang="en-US">Amount of accounts receivable collections.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExchangeRateDifferencesOfAccountsReceivable" xlink:to="ORGS_ExchangeRateDifferencesOfAccountsReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ExchangeRateDifferencesOfAccountsReceivable_doc" xml:lang="en-US">Exchange rate differences.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ContractWithCustomerLiabilityAddition" xlink:to="ORGS_ContractWithCustomerLiabilityAddition_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ContractWithCustomerLiabilityAddition_doc" xml:lang="en-US">Amount of addition of contract with customer liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ContractWithCustomerLiabilityRealizations" xlink:to="ORGS_ContractWithCustomerLiabilityRealizations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ContractWithCustomerLiabilityRealizations_doc" xml:lang="en-US">Amount of revenue from contract with customer liability realizations.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ContractWithCustomerLiabilityExchangeRateDifferences" xlink:to="ORGS_ContractWithCustomerLiabilityExchangeRateDifferences_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ContractWithCustomerLiabilityExchangeRateDifferences_doc" xml:lang="en-US">Amount of revenue from contract with customer liability exchange rate differences.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AggregateAmountOfSubscriptionAgreement" xlink:to="ORGS_AggregateAmountOfSubscriptionAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_AggregateAmountOfSubscriptionAgreement_doc" xml:lang="en-US">Aggregate amount of subscription agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PrivatePlacementSubscriptionAgreementsMember" xlink:to="ORGS_PrivatePlacementSubscriptionAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_PrivatePlacementSubscriptionAgreementsMember_doc" xml:lang="en-US">Private Placement Subscription Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NonEmployeesMember" xlink:to="ORGS_NonEmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_NonEmployeesMember_doc" xml:lang="en-US">Non-Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SeveralConsultantsMember" xlink:to="ORGS_SeveralConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_SeveralConsultantsMember_doc" xml:lang="en-US">Several Consultants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_WarrantsAndRightsOutstandingTermDescription" xlink:to="ORGS_WarrantsAndRightsOutstandingTermDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_WarrantsAndRightsOutstandingTermDescription_doc" xml:lang="en-US">Warrants term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DebtInstrumentRemainingTerm" xlink:to="ORGS_DebtInstrumentRemainingTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DebtInstrumentRemainingTerm_doc" xml:lang="en-US">Repaid maturity period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ClassOfWarrantOrRightGrantsInPeriod" xlink:to="ORGS_ClassOfWarrantOrRightGrantsInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ClassOfWarrantOrRightGrantsInPeriod_doc" xml:lang="en-US">Class of Warrant or Right, Grants in Period, Net of Forfeitures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice" xlink:to="ORGS_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Class of Warrant or Right, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ClassOfWarrantOrRightGrantsInPeriodFairValue" xlink:to="ORGS_ClassOfWarrantOrRightGrantsInPeriodFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ClassOfWarrantOrRightGrantsInPeriodFairValue_doc" xml:lang="en-US">Class of Warrant or Right, Grants in Period, Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SuccessFeeMember" xlink:to="ORGS_SuccessFeeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_SuccessFeeMember_doc" xml:lang="en-US">Success fee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DebtInstrumentConvertibleRepaidBeneficialConversionFeature" xlink:to="ORGS_DebtInstrumentConvertibleRepaidBeneficialConversionFeature_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DebtInstrumentConvertibleRepaidBeneficialConversionFeature_doc" xml:lang="en-US">Debt instrument, convertible, repaid beneficial conversion feature.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_HeldUntilSixMonthsAnniversaryMember" xlink:to="ORGS_HeldUntilSixMonthsAnniversaryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_HeldUntilSixMonthsAnniversaryMember_doc" xml:lang="en-US">Represents information of shares held until six months anniversary.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_HeldUntilOneYearAnniversaryMember" xlink:to="ORGS_HeldUntilOneYearAnniversaryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_HeldUntilOneYearAnniversaryMember_doc" xml:lang="en-US">Represents information of shares held until one year anniversary.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted" xlink:to="ORGS_JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted_doc" xml:lang="en-US">Joint venture agreement, shares issued for compensation of work already completed</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FirstChoiceInternationalCompanyIncMember" xlink:to="ORGS_FirstChoiceInternationalCompanyIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_FirstChoiceInternationalCompanyIncMember_doc" xml:lang="en-US">First Choice International Company, Inc.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue" xlink:to="ORGS_IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue_doc" xml:lang="en-US">Decrease in fair value of warrants and financial liabilities measured at fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_InterestExpenseOnConvertibleLoans" xlink:to="ORGS_InterestExpenseOnConvertibleLoans_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_InterestExpenseOnConvertibleLoans_doc" xml:lang="en-US">Interest expense on convertible loans</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TotalFinancialExpenses" xlink:to="ORGS_TotalFinancialExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_TotalFinancialExpenses_doc" xml:lang="en-US">Total financial expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NumberOfVestedShares" xlink:to="ORGS_NumberOfVestedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_NumberOfVestedShares_doc" xml:lang="en-US">Number of vested shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_VestedOnSigningDateMember" xlink:to="ORGS_VestedOnSigningDateMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_VestedOnSigningDateMember_doc" xml:lang="en-US">Vested on the signing date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_VestMonthlyOver3MonthsMember" xlink:to="ORGS_VestMonthlyOver3MonthsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_VestMonthlyOver3MonthsMember_doc" xml:lang="en-US">Represents information of Vest Monthly Over 3 Months.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FairValueOfSharesOnVestingDatesRecognizedDuringYear" xlink:to="ORGS_FairValueOfSharesOnVestingDatesRecognizedDuringYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_FairValueOfSharesOnVestingDatesRecognizedDuringYear_doc" xml:lang="en-US">Represents amount of fair value of shares on vesting dates recognized during year .</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DebtInstrumentConvertibleWarrantExercisePrice" xlink:to="ORGS_DebtInstrumentConvertibleWarrantExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DebtInstrumentConvertibleWarrantExercisePrice_doc" xml:lang="en-US">Debt Instrument, Convertible, Warrant Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ModificationOfExistingWarrants" xlink:to="ORGS_ModificationOfExistingWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ModificationOfExistingWarrants_doc" xml:lang="en-US">Modification of the existing warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CantorFitzgeraldAndCoMember" xlink:to="ORGS_CantorFitzgeraldAndCoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_CantorFitzgeraldAndCoMember_doc" xml:lang="en-US">Cantor Fitzgerald &amp; Co. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PercentageOfCommission" xlink:to="ORGS_PercentageOfCommission_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_PercentageOfCommission_doc" xml:lang="en-US">Percentage of commission.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BoardMembersMember" xlink:to="ORGS_BoardMembersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_BoardMembersMember_doc" xml:lang="en-US">Board Members</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_Compensation" xlink:label="ORGS_Compensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_Compensation" xlink:to="ORGS_Compensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_Compensation_doc" xml:lang="en-US">Compensation.</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RevenuesFromCustomer" xlink:label="ORGS_RevenuesFromCustomer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RevenuesFromCustomer" xlink:to="ORGS_RevenuesFromCustomer_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_RevenuesFromCustomer_doc" xml:lang="en-US">Revenues from customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" xlink:to="ORGS_CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet_doc" xml:lang="en-US">The aggregate cost of research and development and research and development services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FinancialIncome" xlink:to="ORGS_FinancialIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_FinancialIncome_doc" xml:lang="en-US">Financial income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CaerusTherapeuticsLLCMember" xlink:to="ORGS_CaerusTherapeuticsLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_CaerusTherapeuticsLLCMember_doc" xml:lang="en-US">Caerus Therapeutics LLC</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NumberOfOrdinarySharesHeld" xlink:to="ORGS_NumberOfOrdinarySharesHeld_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_NumberOfOrdinarySharesHeld_doc" xml:lang="en-US">Represents the number of ordinary shares held.</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FinanceIncome" xlink:label="ORGS_FinanceIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FinanceIncome" xlink:to="ORGS_FinanceIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_FinanceIncome_doc" xml:lang="en-US">Represents amount of finance income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NonexecutiveDirectorsMember" xlink:to="ORGS_NonexecutiveDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_NonexecutiveDirectorsMember_doc" xml:lang="en-US">Non-executive directors</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SeparateInvestorRelationsContactMember" xlink:to="ORGS_SeparateInvestorRelationsContactMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_SeparateInvestorRelationsContactMember_doc" xml:lang="en-US">Separate Investor Relations Contact [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_InvestorRelationContactMember" xlink:to="ORGS_InvestorRelationContactMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_InvestorRelationContactMember_doc" xml:lang="en-US">Investor Relation Contact [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SeparateInvestorRelationContactMember" xlink:to="ORGS_SeparateInvestorRelationContactMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_SeparateInvestorRelationContactMember_doc" xml:lang="en-US">Separate Investor Relation Contact [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdditionalRestrictionsOnTransferForServices" xlink:label="ORGS_AdditionalRestrictionsOnTransferForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AdditionalRestrictionsOnTransferForServices" xlink:to="ORGS_AdditionalRestrictionsOnTransferForServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_AdditionalRestrictionsOnTransferForServices_doc" xml:lang="en-US">Additional restrictions on transfer for services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ConsultingAgreementMember" xlink:to="ORGS_ConsultingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ConsultingAgreementMember_doc" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ConsultantMember" xlink:to="ORGS_ConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ConsultantMember_doc" xml:lang="en-US">Consultant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NetIncomeLossToParentCompany" xlink:to="ORGS_NetIncomeLossToParentCompany_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_NetIncomeLossToParentCompany_doc" xml:lang="en-US">Net Income Loss To Parent Company.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests" xlink:to="ORGS_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests_doc" xml:lang="en-US">Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ComprehensiveIncomeNetOfTaxes" xlink:to="ORGS_ComprehensiveIncomeNetOfTaxes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ComprehensiveIncomeNetOfTaxes_doc" xml:lang="en-US">Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TreasuryStockShare" xlink:to="ORGS_TreasuryStockShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_TreasuryStockShare_doc" xml:lang="en-US">Shares repurchased.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_AmortizationOfIntangibleAsset" xlink:to="ORGS_AmortizationOfIntangibleAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_AmortizationOfIntangibleAsset_doc" xml:lang="en-US">Amortization of Intangible Assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_IncomeLossesFromDiscontinuedOperationNetOfTax" xlink:to="ORGS_IncomeLossesFromDiscontinuedOperationNetOfTax_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_IncomeLossesFromDiscontinuedOperationNetOfTax_doc" xml:lang="en-US">Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OfficeFurnitureAndComputersMember" xlink:to="ORGS_OfficeFurnitureAndComputersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_OfficeFurnitureAndComputersMember_doc" xml:lang="en-US">Office Furniture and Computers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_LabEquipmentMember" xlink:to="ORGS_LabEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_LabEquipmentMember_doc" xml:lang="en-US">Lab Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OptionsAndWarrantsMember" xlink:to="ORGS_OptionsAndWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_OptionsAndWarrantsMember_doc" xml:lang="en-US">Options and Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_SharesUponConversionOfConvertibleNotesMember" xlink:to="ORGS_SharesUponConversionOfConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_SharesUponConversionOfConvertibleNotesMember_doc" xml:lang="en-US">Shares Upon Conversion of Convertible Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_StockOptionsGrantVestingPeriodPercentage" xlink:to="ORGS_StockOptionsGrantVestingPeriodPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_StockOptionsGrantVestingPeriodPercentage_doc" xml:lang="en-US">Stock options grant vesting period percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_OneYearAnniversaryMember" xlink:to="ORGS_OneYearAnniversaryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_OneYearAnniversaryMember_doc" xml:lang="en-US">One Year Anniversary [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FirstAnniversaryMember" xlink:label="ORGS_FirstAnniversaryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FirstAnniversaryMember" xlink:to="ORGS_FirstAnniversaryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_FirstAnniversaryMember_doc" xml:lang="en-US">First Anniversary [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ThreeEqualInstallmentsMember" xlink:to="ORGS_ThreeEqualInstallmentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ThreeEqualInstallmentsMember_doc" xml:lang="en-US">Three Equal Installments [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DueFromRelatedPartiesNoncurrent1" xlink:to="ORGS_DueFromRelatedPartiesNoncurrent1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_DueFromRelatedPartiesNoncurrent1_doc" xml:lang="en-US">Aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due after one year (or one business cycle).</link:label>
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_StockIssuedDuringPeriodSharesStockOptionExercised" xlink:label="ORGS_StockIssuedDuringPeriodSharesStockOptionExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_StockIssuedDuringPeriodSharesStockOptionExercised" xlink:to="ORGS_StockIssuedDuringPeriodSharesStockOptionExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_StockIssuedDuringPeriodSharesStockOptionExercised_doc" xml:lang="en-US">Number of share options (or share units) exercised during the current period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ForeignCurrencyTransactionsGainLossRealized" xlink:to="ORGS_ForeignCurrencyTransactionsGainLossRealized_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ORGS_ForeignCurrencyTransactionsGainLossRealized_doc" xml:lang="en-US">Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ExercisePriceEighteenMember" xlink:to="ORGS_ExercisePriceEighteenMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ExercisePriceEighteenMember_3_lbl" xml:lang="en-US">Exercise Price Eighteen [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_2_lbl" xml:lang="en-US">Treasury Stock, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncome" xlink:to="us-gaap_OtherOperatingIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncome_2_lbl" xml:lang="en-US">Other Operating Income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareInNetIncomeOfAssociatedCompanies" xlink:to="ORGS_ShareInNetIncomeOfAssociatedCompanies_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ShareInNetIncomeOfAssociatedCompanies_4_lbl" xml:lang="en-US">ShareInNetIncomeOfAssociatedCompanies</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:to="us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_2_lbl" xml:lang="en-US">Noncontrolling Interest, Increase from Sale of Parent Equity Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_2_lbl" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:to="us-gaap_GainOrLossOnSaleOfStockInSubsidiary_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainOrLossOnSaleOfStockInSubsidiary_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Stock in Subsidiary</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_NetChangesInOperatingLeases" xlink:to="ORGS_NetChangesInOperatingLeases_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_NetChangesInOperatingLeases_3_lbl" xml:lang="en-US">NetChangesInOperatingLeases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2_lbl" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_PaymentsForInvestments" xlink:to="ORGS_PaymentsForInvestments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_PaymentsForInvestments_3_lbl" xml:lang="en-US">PaymentsForInvestments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_2_lbl" xml:lang="en-US">Payments for (Proceeds from) Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_RepaymentOfTreasuryStock" xlink:to="ORGS_RepaymentOfTreasuryStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_RepaymentOfTreasuryStock_3_lbl" xml:lang="en-US">RepaymentOfTreasuryStock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_2_lbl" xml:lang="en-US">Repayments of Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_2_lbl" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_2_lbl" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_2_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet" xlink:to="ORGS_CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet_3_lbl" xml:lang="en-US">CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:to="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_2_lbl" xml:lang="en-US">Depreciation and Amortization, Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_3_lbl" xml:lang="en-US">repayment of intercompany loans and payables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationGrantsReceivable" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationGrantsReceivable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationGrantsReceivable_3_lbl" xml:lang="en-US">DisposalGroupIncludingDiscontinuedOperationGrantsReceivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationsDeposits" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationsDeposits_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationsDeposits_3_lbl" xml:lang="en-US">DisposalGroupIncludingDiscontinuedOperationsDeposits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets_3_lbl" xml:lang="en-US">DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables_3_lbl" xml:lang="en-US">DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant_3_lbl" xml:lang="en-US">DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases_3_lbl" xml:lang="en-US">DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases" xlink:to="ORGS_DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases_3_lbl" xml:lang="en-US">DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:to="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_3_lbl" xml:lang="en-US">BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill" xlink:to="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill_3_lbl" xml:lang="en-US">BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_2_lbl" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_2_lbl" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_FinanceLeaseCost" xlink:to="ORGS_FinanceLeaseCost_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_FinanceLeaseCost_3_lbl" xml:lang="en-US">Finance Lease Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_2_lbl" xml:lang="en-US">Operating Lease, Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_2_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestments_3_lbl" xml:lang="en-US">Equity Method Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice" xlink:to="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TreasuryStockShare" xlink:to="ORGS_TreasuryStockShare_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_TreasuryStockShare_4_lbl" xml:lang="en-US">Shares repurchased</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock" xlink:to="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock_4_lbl" xml:lang="en-US">WeightedAveragePriceNumberOfSharesTreasuryStock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_2_lbl" xml:lang="en-US">Deferred Offering Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice" xlink:to="ORGS_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Class Of Warrant Or Right Grants In Period Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DeferredTaxAssetsLeaseLiability" xlink:to="ORGS_DeferredTaxAssetsLeaseLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DeferredTaxAssetsLeaseLiability_3_lbl" xml:lang="en-US">DeferredTaxAssetsLeaseLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_4_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ContractWithCustomerLiabilityAddition" xlink:to="ORGS_ContractWithCustomerLiabilityAddition_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ContractWithCustomerLiabilityAddition_3_lbl" xml:lang="en-US">ContractWithCustomerLiabilityAddition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_ContractWithCustomerLiabilityExchangeRateDifferences" xlink:to="ORGS_ContractWithCustomerLiabilityExchangeRateDifferences_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_ContractWithCustomerLiabilityExchangeRateDifferences_3_lbl" xml:lang="en-US">ContractWithCustomerLiabilityExchangeRateDifferences</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_2_lbl" xml:lang="en-US">Other Income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_TotalFinancialExpenses" xlink:to="ORGS_TotalFinancialExpenses_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_TotalFinancialExpenses_3_lbl" xml:lang="en-US">Total Financial Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" xlink:to="ORGS_CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet_3_lbl" xml:lang="en-US">Cost of research and development and research and development services net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ORGS_DueFromRelatedPartiesNoncurrent1" xlink:to="ORGS_DueFromRelatedPartiesNoncurrent1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ORGS_DueFromRelatedPartiesNoncurrent1_3_lbl" xml:lang="en-US">Loan to Related Party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_2_lbl" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_2_lbl" xml:lang="en-US">Contract with Customer, Liability</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>orgs-20201231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://orgenesis.com/role/Cover" xlink:href="orgs-20201231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/BalanceSheets" xlink:href="orgs-20201231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/BalanceSheetsParenthetical" xlink:href="orgs-20201231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/StatementsOfComprehensiveLossIncome" xlink:href="orgs-20201231.xsd#StatementsOfComprehensiveLossIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/StatementsOfChangesInEquity" xlink:href="orgs-20201231.xsd#StatementsOfChangesInEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/StatementsOfCashFlows" xlink:href="orgs-20201231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/DescriptionOfBusiness" xlink:href="orgs-20201231.xsd#DescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/SignificantAccountingPolicies" xlink:href="orgs-20201231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/DiscontinuedOperation" xlink:href="orgs-20201231.xsd#DiscontinuedOperation" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/AcquisitionAndReorganization" xlink:href="orgs-20201231.xsd#AcquisitionAndReorganization" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/PropertyPlantsAndEquipment" xlink:href="orgs-20201231.xsd#PropertyPlantsAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/IntangibleAssetsAndGoodwill" xlink:href="orgs-20201231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ConvertibleLoans" xlink:href="orgs-20201231.xsd#ConvertibleLoans" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Loans" xlink:href="orgs-20201231.xsd#Loans" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Leases" xlink:href="orgs-20201231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Commitments" xlink:href="orgs-20201231.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/CollaborationAndLicenseAgreements" xlink:href="orgs-20201231.xsd#CollaborationAndLicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/InvestmentsInAssociatesNet" xlink:href="orgs-20201231.xsd#InvestmentsInAssociatesNet" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Equity" xlink:href="orgs-20201231.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/IncomeLossPerShare" xlink:href="orgs-20201231.xsd#IncomeLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Stock-basedCompensation" xlink:href="orgs-20201231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Taxes" xlink:href="orgs-20201231.xsd#Taxes" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Revenues" xlink:href="orgs-20201231.xsd#Revenues" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" xlink:href="orgs-20201231.xsd#CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/FinancialExpensesNet" xlink:href="orgs-20201231.xsd#FinancialExpensesNet" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/RelatedPartiesTransactions" xlink:href="orgs-20201231.xsd#RelatedPartiesTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/SignificantAccountingPoliciesPolicies" xlink:href="orgs-20201231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/SignificantAccountingPoliciesTables" xlink:href="orgs-20201231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/DiscontinuedOperationTables" xlink:href="orgs-20201231.xsd#DiscontinuedOperationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/AcquisitionAndReorganizationTables" xlink:href="orgs-20201231.xsd#AcquisitionAndReorganizationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/PropertyPlantsAndEquipmentTables" xlink:href="orgs-20201231.xsd#PropertyPlantsAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="orgs-20201231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ConvertibleLoansTables" xlink:href="orgs-20201231.xsd#ConvertibleLoansTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/LoansTables" xlink:href="orgs-20201231.xsd#LoansTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/LeasesTables" xlink:href="orgs-20201231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/InvestmentsInAssociatesNetTables" xlink:href="orgs-20201231.xsd#InvestmentsInAssociatesNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/EquityTables" xlink:href="orgs-20201231.xsd#EquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/IncomeLossPerShareTables" xlink:href="orgs-20201231.xsd#IncomeLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Stock-basedCompensationTables" xlink:href="orgs-20201231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/TaxesTables" xlink:href="orgs-20201231.xsd#TaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/RevenuesTables" xlink:href="orgs-20201231.xsd#RevenuesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNetTables" xlink:href="orgs-20201231.xsd#CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/FinancialExpensesNetTables" xlink:href="orgs-20201231.xsd#FinancialExpensesNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/RelatedPartiesTransactionsTables" xlink:href="orgs-20201231.xsd#RelatedPartiesTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative" xlink:href="orgs-20201231.xsd#DescriptionOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails" xlink:href="orgs-20201231.xsd#ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfIntangibleAssetsAndTheirUsefulLiveDetails" xlink:href="orgs-20201231.xsd#ScheduleOfIntangibleAssetsAndTheirUsefulLiveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="orgs-20201231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative" xlink:href="orgs-20201231.xsd#DiscontinuedOperationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="orgs-20201231.xsd#SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical" xlink:href="orgs-20201231.xsd#SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfUnauditedSupplementalProFormaDetails" xlink:href="orgs-20201231.xsd#ScheduleOfUnauditedSupplementalProFormaDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative" xlink:href="orgs-20201231.xsd#AcquisitionAndReorganizationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails" xlink:href="orgs-20201231.xsd#ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails" xlink:href="orgs-20201231.xsd#ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/PropertyPlantsAndEquipmentDetailsNarrative" xlink:href="orgs-20201231.xsd#PropertyPlantsAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfGoodwillDetails" xlink:href="orgs-20201231.xsd#ScheduleOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfOtherIntangibleAssetsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfOtherIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfEstimatedAggregateAmortizationExpensesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfEstimatedAggregateAmortizationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:href="orgs-20201231.xsd#IntangibleAssetsAndGoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails" xlink:href="orgs-20201231.xsd#ScheduleOfLongTermConvertibleLoansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical" xlink:href="orgs-20201231.xsd#ScheduleOfLongTermConvertibleLoansDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ConvertibleLoansDetailsNarrative" xlink:href="orgs-20201231.xsd#ConvertibleLoansDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfLoansDetails" xlink:href="orgs-20201231.xsd#ScheduleOfLoansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfLease-relatedAssetsAndLiabilitiesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfLease-relatedAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfLeaseCostsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfLeaseCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfSupplementalCashflowInformationDetails" xlink:href="orgs-20201231.xsd#ScheduleOfSupplementalCashflowInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfRight-of-useAssetsByGeographicalLocationDetails" xlink:href="orgs-20201231.xsd#ScheduleOfRight-of-useAssetsByGeographicalLocationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/LeasesDetailsNarrative" xlink:href="orgs-20201231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/CommitmentsDetailsNarrative" xlink:href="orgs-20201231.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative" xlink:href="orgs-20201231.xsd#CollaborationAndLicenseAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfChangesInInvestmentsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfChangesInInvestmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/InvestmentsInAssociatesNetDetailsNarrative" xlink:href="orgs-20201231.xsd#InvestmentsInAssociatesNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="orgs-20201231.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfTreasurySharesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfTreasurySharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/EquityDetailsNarrative" xlink:href="orgs-20201231.xsd#EquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfBasicAndDilutedLossPerShareDetails" xlink:href="orgs-20201231.xsd#ScheduleOfBasicAndDilutedLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/IncomeLossPerShareDetailsNarrative" xlink:href="orgs-20201231.xsd#IncomeLossPerShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails" xlink:href="orgs-20201231.xsd#ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails" xlink:href="orgs-20201231.xsd#ScheduleOfStockOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails" xlink:href="orgs-20201231.xsd#ScheduleOfStockOptionsExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfStockOptionsGrantedToConsultantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="orgs-20201231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfValuationAllowanceActivityDetails" xlink:href="orgs-20201231.xsd#ScheduleOfValuationAllowanceActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/TaxesDetailsNarrative" xlink:href="orgs-20201231.xsd#TaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:href="orgs-20201231.xsd#ScheduleOfDisaggregationOfRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfBreakdownOfRevenuesPerCustomerDetails" xlink:href="orgs-20201231.xsd#ScheduleOfBreakdownOfRevenuesPerCustomerDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfActivityForTradeReceivablesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfActivityForTradeReceivablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfActivityForContractLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetailsParenthetical" xlink:href="orgs-20201231.xsd#ScheduleOfActivityForContractLiabilitiesDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/RevenuesDetailsNarrative" xlink:href="orgs-20201231.xsd#RevenuesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfFinancialExpensesDetails" xlink:href="orgs-20201231.xsd#ScheduleOfFinancialExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfRelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical" xlink:href="orgs-20201231.xsd#ScheduleOfRelatedPartyTransactionsDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://orgenesis.com/role/ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails" xlink:href="orgs-20201231.xsd#ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaapGrantsReceivableCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapGrantsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesNoncurrent" xlink:label="loc_us-gaapDueFromRelatedPartiesNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapDueFromRelatedPartiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AccruedExpensesAndOtherPayablesCurrent" xlink:label="loc_ORGSAccruedExpensesAndOtherPayablesCurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_ORGSAccruedExpensesAndOtherPayablesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdvancePaymentsOnAccountOfGrant" xlink:label="loc_ORGSAdvancePaymentsOnAccountOfGrant" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_ORGSAdvancePaymentsOnAccountOfGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaapConvertibleDebtCurrent" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaapConvertibleDebtNoncurrent" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapConvertibleDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="loc_us-gaapPensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapPensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RedeemableNoncontrollingInterestOfDiscontinuedOperation" xlink:label="loc_ORGSRedeemableNoncontrollingInterestOfDiscontinuedOperation" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_ORGSRedeemableNoncontrollingInterestOfDiscontinuedOperation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaapTreasuryStockShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapTreasuryStockShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/StatementsOfComprehensiveLossIncome" xlink:title="00000004 - Statement - Consolidated Statements of Comprehensive Loss (Income)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaapRevenueFromRelatedParties" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome" xlink:label="loc_us-gaapOtherOperatingIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherOperatingIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareInNetIncomeOfAssociatedCompanies" xlink:label="loc_ORGSShareInNetIncomeOfAssociatedCompanies" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_ORGSShareInNetIncomeOfAssociatedCompanies" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_ORGSIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_ORGSIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncomeLossesFromDiscontinuedOperationNetOfTax" xlink:label="loc_ORGSIncomeLossesFromDiscontinuedOperationNetOfTax" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_ORGSIncomeLossesFromDiscontinuedOperationNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary" xlink:label="loc_ORGSOtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_ORGSOtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ComprehensiveIncomeNetOfTaxes" xlink:label="loc_ORGSComprehensiveIncomeNetOfTaxes" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_ORGSComprehensiveIncomeNetOfTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations" xlink:label="loc_ORGSComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_ORGSComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations" xlink:label="loc_ORGSComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_ORGSComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/StatementsOfChangesInEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_EquityAttributedToOrgenesisIncMember" xlink:label="loc_ORGSEquityAttributedToOrgenesisIncMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_ORGSEquityAttributedToOrgenesisIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapNoncontrollingInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaapTreasuryStockMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapTreasuryStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement" xlink:label="loc_ORGSStockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ORGSStockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares" xlink:label="loc_ORGSStockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ORGSStockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IssuanceOfSharesAndWarrants" xlink:label="loc_ORGSIssuanceOfSharesAndWarrants" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ORGSIssuanceOfSharesAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IssuanceOfSharesAndWarrantsShares" xlink:label="loc_ORGSIssuanceOfSharesAndWarrantsShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ORGSIssuanceOfSharesAndWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:label="loc_us-gaapNoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_StockbasedCompensationToStrategicCollaborations" xlink:label="loc_ORGSStockbasedCompensationToStrategicCollaborations" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ORGSStockbasedCompensationToStrategicCollaborations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_StockbasedCompensationToStrategicCollaborationsShares" xlink:label="loc_ORGSStockbasedCompensationToStrategicCollaborationsShares" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ORGSStockbasedCompensationToStrategicCollaborationsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans" xlink:label="loc_ORGSIssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ORGSIssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp" xlink:label="loc_ORGSAdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ORGSAdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationOne" xlink:label="loc_ORGSShareBasedCompensationOne" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ORGSShareBasedCompensationOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationTwo" xlink:label="loc_ORGSShareBasedCompensationTwo" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ORGSShareBasedCompensationTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:label="loc_us-gaapGainOrLossOnSaleOfStockInSubsidiary" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainOrLossOnSaleOfStockInSubsidiary" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareInNetIncomeOfAssociatedCompanies" xlink:label="loc_ORGSShareInNetIncomeOfAssociatedCompanies" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ORGSShareInNetIncomeOfAssociatedCompanies" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances" xlink:label="loc_ORGSIncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ORGSIncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NetChangesInOperatingLeases" xlink:label="loc_ORGSNetChangesInOperatingLeases" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ORGSNetChangesInOperatingLeases" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseShortTermBorrowings" xlink:label="loc_us-gaapInterestExpenseShortTermBorrowings" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapInterestExpenseShortTermBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncreaseDecreaseInAccuredExpensesAndOtherPayables" xlink:label="loc_ORGSIncreaseDecreaseInAccuredExpensesAndOtherPayables" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_ORGSIncreaseDecreaseInAccuredExpensesAndOtherPayables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant" xlink:label="loc_ORGSIncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_ORGSIncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredIncomeTaxes" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForLongTermLoansForRelatedParties" xlink:label="loc_us-gaapProceedsFromPaymentsForLongTermLoansForRelatedParties" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromPaymentsForLongTermLoansForRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaapProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PaymentsForInvestments" xlink:label="loc_ORGSPaymentsForInvestments" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_ORGSPaymentsForInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaapPaymentsForProceedsFromInvestments" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForProceedsFromInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RepaymentOfTreasuryStock" xlink:label="loc_ORGSRepaymentOfTreasuryStock" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ORGSRepaymentOfTreasuryStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_us-gaapProceedsFromMinorityShareholders" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromMinorityShareholders" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FinanceLeasesOfPropertyPlantAndEquipment" xlink:label="loc_ORGSFinanceLeasesOfPropertyPlantAndEquipment" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ORGSFinanceLeasesOfPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities" xlink:label="loc_ORGSRightofuseAssetsAcquiredInExchangeForRightofuseLiabilities" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ORGSRightofuseAssetsAcquiredInExchangeForRightofuseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable" xlink:label="loc_ORGSPurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ORGSPurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaapDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AcquisitionOfOtherAssetInExchangeForCommonStocks" xlink:label="loc_ORGSAcquisitionOfOtherAssetInExchangeForCommonStocks" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ORGSAcquisitionOfOtherAssetInExchangeForCommonStocks" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo" xlink:label="loc_ORGSIssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ORGSIssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/DescriptionOfBusiness" xlink:title="00000007 - Disclosure - DESCRIPTION OF BUSINESS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/SignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/DiscontinuedOperation" xlink:title="00000009 - Disclosure - DISCONTINUED OPERATION">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/AcquisitionAndReorganization" xlink:title="00000010 - Disclosure - ACQUISITION AND REORGANIZATION">
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisclosureAcquisitionAndReorganizationAbstract" xlink:label="loc_ORGSDisclosureAcquisitionAndReorganizationAbstract" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AcquisitionAndReorganizationTextBlock" xlink:label="loc_ORGSAcquisitionAndReorganizationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSDisclosureAcquisitionAndReorganizationAbstract" xlink:to="loc_ORGSAcquisitionAndReorganizationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/PropertyPlantsAndEquipment" xlink:title="00000011 - Disclosure - PROPERTY, PLANTS AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/IntangibleAssetsAndGoodwill" xlink:title="00000012 - Disclosure - INTANGIBLE ASSETS AND GOODWILL">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ConvertibleLoans" xlink:title="00000013 - Disclosure - CONVERTIBLE LOANS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Loans" xlink:title="00000014 - Disclosure - LOANS">
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisclosureLoansAbstract" xlink:label="loc_ORGSDisclosureLoansAbstract" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_LoansTextBlock" xlink:label="loc_ORGSLoansTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSDisclosureLoansAbstract" xlink:to="loc_ORGSLoansTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Leases" xlink:title="00000015 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Commitments" xlink:title="00000016 - Disclosure - COMMITMENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/CollaborationAndLicenseAgreements" xlink:title="00000017 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS">
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisclosureCollaborationAndLicenseAgreementsAbstract" xlink:label="loc_ORGSDisclosureCollaborationAndLicenseAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CollaborationsLicenseAgreementsAndCommitmentsTextBlock" xlink:label="loc_ORGSCollaborationsLicenseAgreementsAndCommitmentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSDisclosureCollaborationAndLicenseAgreementsAbstract" xlink:to="loc_ORGSCollaborationsLicenseAgreementsAndCommitmentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/InvestmentsInAssociatesNet" xlink:title="00000018 - Disclosure - INVESTMENTS IN ASSOCIATES, NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:label="loc_us-gaapInvestmentsInAndAdvancesToAffiliatesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:label="loc_us-gaapInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsInAndAdvancesToAffiliatesAbstract" xlink:to="loc_us-gaapInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Equity" xlink:title="00000019 - Disclosure - EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/IncomeLossPerShare" xlink:title="00000020 - Disclosure - INCOME (LOSS) PER SHARE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Stock-basedCompensation" xlink:title="00000021 - Disclosure - STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Taxes" xlink:title="00000022 - Disclosure - TAXES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Revenues" xlink:title="00000023 - Disclosure - REVENUES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" xlink:title="00000024 - Disclosure - COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/FinancialExpensesNet" xlink:title="00000025 - Disclosure - FINANCIAL EXPENSES, NET">
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisclosureFinancialExpensesNetAbstract" xlink:label="loc_ORGSDisclosureFinancialExpensesNetAbstract" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FinancialExpensesNetTextBlock" xlink:label="loc_ORGSFinancialExpensesNetTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSDisclosureFinancialExpensesNetAbstract" xlink:to="loc_ORGSFinancialExpensesNetTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/RelatedPartiesTransactions" xlink:title="00000026 - Disclosure - RELATED PARTIES TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000027 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaapBusinessCombinationsPolicy" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessCombinationsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OtherInvestmentsPolicyTextBlock" xlink:label="loc_ORGSOtherInvestmentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ORGSOtherInvestmentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="loc_us-gaapDiscontinuedOperationsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDiscontinuedOperationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="loc_us-gaapResearchDevelopmentAndComputerSoftwarePolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaapEquityMethodInvestmentsPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FunctionalCurrencyPolicyTextBlock" xlink:label="loc_ORGSFunctionalCurrencyPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ORGSFunctionalCurrencyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:label="loc_ORGSRedeemableNoncontrollingInterestPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ORGSRedeemableNoncontrollingInterestPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TreasurySharesPolicyTextBlock" xlink:label="loc_ORGSTreasurySharesPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ORGSTreasurySharesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BeneficialConversionFeatureBcfPolicyTextBlock" xlink:label="loc_ORGSBeneficialConversionFeatureBcfPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ORGSBeneficialConversionFeatureBcfPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_ORGSRecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ORGSRecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/SignificantAccountingPoliciesTables" xlink:title="00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock" xlink:label="loc_ORGSScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ORGSScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock" xlink:label="loc_ORGSScheduleOfIntangibleAssetsUsefulLivesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ORGSScheduleOfIntangibleAssetsUsefulLivesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/DiscontinuedOperationTables" xlink:title="00000029 - Disclosure - DISCONTINUED OPERATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaapScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock" xlink:label="loc_ORGSScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_ORGSScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/AcquisitionAndReorganizationTables" xlink:title="00000030 - Disclosure - ACQUISITION AND REORGANIZATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisclosureAcquisitionAndReorganizationAbstract" xlink:label="loc_ORGSDisclosureAcquisitionAndReorganizationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSDisclosureAcquisitionAndReorganizationAbstract" xlink:to="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaapBusinessAcquisitionProFormaInformationTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSDisclosureAcquisitionAndReorganizationAbstract" xlink:to="loc_us-gaapBusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/PropertyPlantsAndEquipmentTables" xlink:title="00000031 - Disclosure - PROPERTY, PLANTS AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock" xlink:label="loc_ORGSScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_ORGSScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="00000032 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaapScheduleOfGoodwillTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfGoodwillTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ConvertibleLoansTables" xlink:title="00000033 - Disclosure - CONVERTIBLE LOANS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaapConvertibleDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapConvertibleDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/LoansTables" xlink:title="00000034 - Disclosure - LOANS (Tables)">
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisclosureLoansAbstract" xlink:label="loc_ORGSDisclosureLoansAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSDisclosureLoansAbstract" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/LeasesTables" xlink:title="00000035 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock" xlink:label="loc_ORGSLeasesOfLesseeBalanceSheetDisclosuresTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_ORGSLeasesOfLesseeBalanceSheetDisclosuresTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_ORGSLesseeLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_ORGSLesseeLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ScheduleOfRightofuseAssetsByGeographicalLocation" xlink:label="loc_ORGSScheduleOfRightofuseAssetsByGeographicalLocation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_ORGSScheduleOfRightofuseAssetsByGeographicalLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/InvestmentsInAssociatesNetTables" xlink:title="00000036 - Disclosure - INVESTMENTS IN ASSOCIATES, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:label="loc_us-gaapInvestmentsInAndAdvancesToAffiliatesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:label="loc_us-gaapInvestmentHoldingsScheduleOfInvestmentsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsInAndAdvancesToAffiliatesAbstract" xlink:to="loc_us-gaapInvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/EquityTables" xlink:title="00000037 - Disclosure - EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ScheduleOfWarrantsActivity" xlink:label="loc_ORGSScheduleOfWarrantsActivity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ORGSScheduleOfWarrantsActivity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ScheduleOfTreasuryShares" xlink:label="loc_ORGSScheduleOfTreasuryShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ORGSScheduleOfTreasuryShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/IncomeLossPerShareTables" xlink:title="00000038 - Disclosure - INCOME (LOSS) PER SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Stock-basedCompensationTables" xlink:title="00000039 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToEmployeesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToNonEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToNonEmployeesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToNonEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/TaxesTables" xlink:title="00000040 - Disclosure - TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaapSummaryOfValuationAllowanceTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapSummaryOfValuationAllowanceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/RevenuesTables" xlink:title="00000041 - Disclosure - REVENUES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ScheduleOfBreakdownOfRevenuesPerCustomer" xlink:label="loc_ORGSScheduleOfBreakdownOfRevenuesPerCustomer" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_ORGSScheduleOfBreakdownOfRevenuesPerCustomer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="loc_us-gaapAccountsReceivableAllowanceForCreditLossTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapAccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaapContractWithCustomerAssetAndLiabilityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNetTables" xlink:title="00000042 - Disclosure - COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:label="loc_us-gaapScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/FinancialExpensesNetTables" xlink:title="00000043 - Disclosure - FINANCIAL EXPENSES, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisclosureFinancialExpensesNetAbstract" xlink:label="loc_ORGSDisclosureFinancialExpensesNetAbstract" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ScheduleOfFinancialExpensesTableTextBlock" xlink:label="loc_ORGSScheduleOfFinancialExpensesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSDisclosureFinancialExpensesNetAbstract" xlink:to="loc_ORGSScheduleOfFinancialExpensesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/RelatedPartiesTransactionsTables" xlink:title="00000044 - Disclosure - RELATED PARTIES TRANSACTIONS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_ORGSScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_ORGSScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative" xlink:title="00000045 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:label="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MasthercellMember" xlink:label="loc_ORGSMasthercellMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSMasthercellMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CureCellCoLtdMember" xlink:label="loc_ORGSCureCellCoLtdMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSCureCellCoLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SecuritiesPurchaseAgreementMember" xlink:label="loc_ORGSSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TamirPurchaseAgreementMember" xlink:label="loc_ORGSTamirPurchaseAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSTamirPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TamirBiotechnologyIncMember" xlink:label="loc_ORGSTamirBiotechnologyIncMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ORGSTamirBiotechnologyIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PercentageOfOutstandingEquityInterests" xlink:label="loc_ORGSPercentageOfOutstandingEquityInterests" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_ORGSPercentageOfOutstandingEquityInterests" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AggregateNominalPurchasePrice" xlink:label="loc_ORGSAggregateNominalPurchasePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_ORGSAggregateNominalPurchasePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TransactionCostIncurred" xlink:label="loc_ORGSTransactionCostIncurred" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_ORGSTransactionCostIncurred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AccumulatedDeficit" xlink:label="loc_ORGSAccumulatedDeficit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_ORGSAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RepaymentOfIntercompanyLoansAndPayables" xlink:label="loc_ORGSRepaymentOfIntercompanyLoansAndPayables" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_ORGSRepaymentOfIntercompanyLoansAndPayables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ProductionFacilityMember" xlink:label="loc_ORGSProductionFacilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ORGSProductionFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfIntangibleAssetsAndTheirUsefulLiveDetails" xlink:title="00000047 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KnowhowMember" xlink:label="loc_ORGSKnowhowMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ORGSKnowhowMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TechnologyMember" xlink:label="loc_ORGSTechnologyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ORGSTechnologyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000048 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="loc_us-gaapAccountingStandardsUpdate201912Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfAdoptionMember" xlink:to="loc_us-gaapAccountingStandardsUpdate201912Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent" xlink:label="loc_ORGSIncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_ORGSIncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaapTreasuryStockShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapTreasuryStockShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_LeaseClassificationDiscription" xlink:label="loc_ORGSLeaseClassificationDiscription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_ORGSLeaseClassificationDiscription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF DISCONTINUED OPERATION AND BALANCE SHEETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MortgageLoansOnRealEstateLineItems" xlink:label="loc_srtMortgageLoansOnRealEstateLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtMortgageLoansOnRealEstateLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_BE" xlink:label="loc_countryBE" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryBE" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet" xlink:label="loc_ORGSCostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSCostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:label="loc_us-gaapDepreciationAndAmortizationDiscontinuedOperations" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDepreciationAndAmortizationDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationOtherExpenses" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationOtherExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationOtherExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaapDiscontinuedOperationTaxEffectOfDiscontinuedOperation" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncomeLossFromDiscontinuedOperationNetOfTax" xlink:label="loc_ORGSIncomeLossFromDiscontinuedOperationNetOfTax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSIncomeLossFromDiscontinuedOperationNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax" xlink:label="loc_us-gaapDiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal" xlink:label="loc_us-gaapDiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaapDiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NetProfitLossFromDiscontinuingOperationNetOfTax" xlink:label="loc_ORGSNetProfitLossFromDiscontinuingOperationNetOfTax" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSNetProfitLossFromDiscontinuingOperationNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationRestrictedCash" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationGrantsReceivable" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationGrantsReceivable" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationGrantsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationInventory1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationInventory1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationsDeposits" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationsDeposits" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationsDeposits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationIntangibleAssets" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGoodwill1" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOtherAssets" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperation" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayable" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOtherLiabilities" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationLoansPayable" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationLoansPayable" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationLoansPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases" xlink:label="loc_ORGSDisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSDisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PropertyPlantAndEquipmentNetAndRightOfUseAssets" xlink:label="loc_ORGSPropertyPlantAndEquipmentNetAndRightOfUseAssets" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_ORGSPropertyPlantAndEquipmentNetAndRightOfUseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaapCashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapCashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaapCashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapCashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaapCashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapCashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsDetails" xlink:title="00000050 - Disclosure - SCHEDULE OF DISAGGREGATION OF REVENUE RELATED TO DISCONTINUED OPERATIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:label="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CellProcessDevelopmentServicesMember" xlink:label="loc_ORGSCellProcessDevelopmentServicesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_ORGSCellProcessDevelopmentServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TechTransferServicesMember" xlink:label="loc_ORGSTechTransferServicesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_ORGSTechTransferServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CellManufacturingServicesMember" xlink:label="loc_ORGSCellManufacturingServicesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_ORGSCellManufacturingServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative" xlink:title="00000051 - Disclosure - DISCONTINUED OPERATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:label="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MasthercellMember" xlink:label="loc_ORGSMasthercellMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSMasthercellMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MasthercellSAMember" xlink:label="loc_ORGSMasthercellSAMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSMasthercellSAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SecuritiesPurchaseAgreementMember" xlink:label="loc_ORGSSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PercentageOfOutstandingEquityInterests" xlink:label="loc_ORGSPercentageOfOutstandingEquityInterests" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_ORGSPercentageOfOutstandingEquityInterests" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AggregateNominalPurchasePrice" xlink:label="loc_ORGSAggregateNominalPurchasePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_ORGSAggregateNominalPurchasePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RepaymentOfIntercompanyLoansAndPayables" xlink:label="loc_ORGSRepaymentOfIntercompanyLoansAndPayables" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_ORGSRepaymentOfIntercompanyLoansAndPayables" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:title="00000052 - Disclosure - SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details)">
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisclosureAcquisitionAndReorganizationAbstract" xlink:label="loc_ORGSDisclosureAcquisitionAndReorganizationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSDisclosureAcquisitionAndReorganizationAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KyslecelTechnologyMember" xlink:label="loc_ORGSKyslecelTechnologyMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ORGSKyslecelTechnologyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IPResearchAndDevelopmentMember" xlink:label="loc_ORGSIPResearchAndDevelopmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ORGSIPResearchAndDevelopmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued" xlink:label="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments" xlink:label="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:label="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill" xlink:label="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease" xlink:label="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability" xlink:label="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical" xlink:title="00000053 - Disclosure - SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisclosureAcquisitionAndReorganizationAbstract" xlink:label="loc_ORGSDisclosureAcquisitionAndReorganizationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSDisclosureAcquisitionAndReorganizationAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KyslecelTechnologyMember" xlink:label="loc_ORGSKyslecelTechnologyMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ORGSKyslecelTechnologyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IPResearchAndDevelopmentMember" xlink:label="loc_ORGSIPResearchAndDevelopmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ORGSIPResearchAndDevelopmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FairValuePercentageofSharesIssued" xlink:label="loc_ORGSFairValuePercentageofSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSFairValuePercentageofSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfUnauditedSupplementalProFormaDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF UNAUDITED SUPPLEMENTAL PRO FORMA (Details)">
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisclosureAcquisitionAndReorganizationAbstract" xlink:label="loc_ORGSDisclosureAcquisitionAndReorganizationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSDisclosureAcquisitionAndReorganizationAbstract" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KoligoTherapeuticsIncMember" xlink:label="loc_ORGSKoligoTherapeuticsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ORGSKoligoTherapeuticsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative" xlink:title="00000055 - Disclosure - ACQUISITION AND REORGANIZATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisclosureAcquisitionAndReorganizationAbstract" xlink:label="loc_ORGSDisclosureAcquisitionAndReorganizationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSDisclosureAcquisitionAndReorganizationAbstract" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TamirBiotechnologyIncMember" xlink:label="loc_ORGSTamirBiotechnologyIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ORGSTamirBiotechnologyIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KoligoTherapeuticsIncMember" xlink:label="loc_ORGSKoligoTherapeuticsIncMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ORGSKoligoTherapeuticsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TamirPurchaseAgreementMember" xlink:label="loc_ORGSTamirPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSTamirPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MaterialDefinitiveAgreementMember" xlink:label="loc_ORGSMaterialDefinitiveAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSMaterialDefinitiveAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RegistrationRightsandLockUpAgreementMember" xlink:label="loc_ORGSRegistrationRightsandLockUpAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSRegistrationRightsandLockUpAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TransferAgreementMember" xlink:label="loc_ORGSTransferAgreementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSTransferAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MaximaGroupLLCMember" xlink:label="loc_ORGSMaximaGroupLLCMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSMaximaGroupLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_LongHillAndMaximGroupLLCMember" xlink:label="loc_ORGSLongHillAndMaximGroupLLCMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSLongHillAndMaximGroupLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapEscrowDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NumberOfSharesDepositInEscrowAccount" xlink:label="loc_ORGSNumberOfSharesDepositInEscrowAccount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSNumberOfSharesDepositInEscrowAccount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BusinessCombinationConsiderationTransferred" xlink:label="loc_ORGSBusinessCombinationConsiderationTransferred" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSBusinessCombinationConsiderationTransferred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CashPaidToAccreditedInvestors" xlink:label="loc_ORGSCashPaidToAccreditedInvestors" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSCashPaidToAccreditedInvestors" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SharesHeldInEscrow" xlink:label="loc_ORGSSharesHeldInEscrow" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSSharesHeldInEscrow" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdditionalCashConsideration" xlink:label="loc_ORGSAdditionalCashConsideration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSAdditionalCashConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ReductionInConsiderationPayable" xlink:label="loc_ORGSReductionInConsiderationPayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSReductionInConsiderationPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RestrictionOnSaleOfSharesPercentage" xlink:label="loc_ORGSRestrictionOnSaleOfSharesPercentage" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSRestrictionOnSaleOfSharesPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RestrictionPeriodDescription" xlink:label="loc_ORGSRestrictionPeriodDescription" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_ORGSRestrictionPeriodDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails" xlink:title="00000056 - Disclosure - SCHEDULE OF COMPONENTS OF PROPERTY, PLANTS AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ProductionFacilityMember" xlink:label="loc_ORGSProductionFacilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ORGSProductionFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OfficeFurnitureAndComputersMember" xlink:label="loc_ORGSOfficeFurnitureAndComputersMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ORGSOfficeFurnitureAndComputersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_LabEquipmentMember" xlink:label="loc_ORGSLabEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ORGSLabEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdvancePaymentMember" xlink:label="loc_ORGSAdvancePaymentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ORGSAdvancePaymentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails" xlink:title="00000057 - Disclosure - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT BY GEOGRAPHICAL LOCATION (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MortgageLoansOnRealEstateLineItems" xlink:label="loc_srtMortgageLoansOnRealEstateLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtMortgageLoansOnRealEstateLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_BE" xlink:label="loc_countryBE" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryBE" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_KR" xlink:label="loc_countryKR" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryKR" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:label="loc_countryIL" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/PropertyPlantsAndEquipmentDetailsNarrative" xlink:title="00000058 - Disclosure - PROPERTY, PLANTS AND EQUIPMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfGoodwillDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF GOODWILL (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaapGoodwillAcquiredDuringPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillAcquiredDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaapGoodwillForeignCurrencyTranslationGainLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwill_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfOtherIntangibleAssetsDetails" xlink:title="00000060 - Disclosure - SCHEDULE OF OTHER INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KnowhowMember" xlink:label="loc_ORGSKnowhowMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ORGSKnowhowMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KyslecelTechnologyMember" xlink:label="loc_ORGSKyslecelTechnologyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ORGSKyslecelTechnologyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IPResearchAndDevelopmentMember" xlink:label="loc_ORGSIPResearchAndDevelopmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ORGSIPResearchAndDevelopmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfEstimatedAggregateAmortizationExpensesDetails" xlink:title="00000061 - Disclosure - SCHEDULE OF ESTIMATED AGGREGATE AMORTIZATION EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive" xlink:label="loc_ORGSFiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_ORGSFiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:title="00000062 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AmortizationOfIntangibleAsset" xlink:label="loc_ORGSAmortizationOfIntangibleAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_ORGSAmortizationOfIntangibleAsset" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails" xlink:title="00000063 - Disclosure - SCHEDULE OF LONG TERM CONVERTIBLE LOANS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoansOneMember" xlink:label="loc_ORGSConvertibleLoansOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSConvertibleLoansOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoansTwoMember" xlink:label="loc_ORGSConvertibleLoansTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSConvertibleLoansTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoansThreeMember" xlink:label="loc_ORGSConvertibleLoansThreeMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSConvertibleLoansThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoansMember" xlink:label="loc_ORGSConvertibleLoansMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSConvertibleLoansMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TwoPercentageConvertibleLoansTwoMember" xlink:label="loc_ORGSTwoPercentageConvertibleLoansTwoMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSTwoPercentageConvertibleLoansTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SixPercentageConvertibleLoansTwoMember" xlink:label="loc_ORGSSixPercentageConvertibleLoansTwoMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSSixPercentageConvertibleLoansTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_EightPercetageConvertibleLoansTwoMember" xlink:label="loc_ORGSEightPercetageConvertibleLoansTwoMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSEightPercetageConvertibleLoansTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DebtInstrumentIssuanceYear" xlink:label="loc_ORGSDebtInstrumentIssuanceYear" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ORGSDebtInstrumentIssuanceYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DebtInstrumentRemainingTerm" xlink:label="loc_ORGSDebtInstrumentRemainingTerm" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ORGSDebtInstrumentRemainingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DebtInstrumentConvertibleRepaidBeneficialConversionFeature" xlink:label="loc_ORGSDebtInstrumentConvertibleRepaidBeneficialConversionFeature" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ORGSDebtInstrumentConvertibleRepaidBeneficialConversionFeature" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical" xlink:title="00000064 - Disclosure - SCHEDULE OF LONG TERM CONVERTIBLE LOANS (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoansOneMember" xlink:label="loc_ORGSConvertibleLoansOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSConvertibleLoansOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoansTwoMember" xlink:label="loc_ORGSConvertibleLoansTwoMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSConvertibleLoansTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoansThreeMember" xlink:label="loc_ORGSConvertibleLoansThreeMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSConvertibleLoansThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_HemogenyxCelMember" xlink:label="loc_ORGSHemogenyxCelMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSHemogenyxCelMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ImmugenyxLLCMember" xlink:label="loc_ORGSImmugenyxLLCMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSImmugenyxLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PreMoneyValuation" xlink:label="loc_ORGSPreMoneyValuation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ORGSPreMoneyValuation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaapConvertibleDebtCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapConvertibleDebtCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ConvertibleLoansDetailsNarrative" xlink:title="00000065 - Disclosure - CONVERTIBLE LOANS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoanAgreementMember" xlink:label="loc_ORGSConvertibleLoanAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSConvertibleLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PrivatePlacementSubscriptionAgreementMember" xlink:label="loc_ORGSPrivatePlacementSubscriptionAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSPrivatePlacementSubscriptionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SixPercentageConvertibleLoanAgreementMember" xlink:label="loc_ORGSSixPercentageConvertibleLoanAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSSixPercentageConvertibleLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CreditLineAgreementsMember" xlink:label="loc_ORGSCreditLineAgreementsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSCreditLineAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ControlledEquityOfferingSalesAgreementMember" xlink:label="loc_ORGSControlledEquityOfferingSalesAgreementMember" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSControlledEquityOfferingSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NonUSInvestorMember" xlink:label="loc_ORGSNonUSInvestorMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSNonUSInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NonUSInvestorThreeMember" xlink:label="loc_ORGSNonUSInvestorThreeMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSNonUSInvestorThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NonUSInvestorOneMember" xlink:label="loc_ORGSNonUSInvestorOneMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSNonUSInvestorOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NonUSInvestorTwoMember" xlink:label="loc_ORGSNonUSInvestorTwoMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSNonUSInvestorTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NonUSInvestorFourMember" xlink:label="loc_ORGSNonUSInvestorFourMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSNonUSInvestorFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_InvestorOneMember" xlink:label="loc_ORGSInvestorOneMember" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSInvestorOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_InvestorTwoMember" xlink:label="loc_ORGSInvestorTwoMember" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSInvestorTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TwoOtherInvestorTwoMember" xlink:label="loc_ORGSTwoOtherInvestorTwoMember" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSTwoOtherInvestorTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoansOneMember" xlink:label="loc_ORGSConvertibleLoansOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_ORGSConvertibleLoansOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CantorFitzgeraldAndCoMember" xlink:label="loc_ORGSCantorFitzgeraldAndCoMember" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSCantorFitzgeraldAndCoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtCurrencyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_ILS" xlink:label="loc_currencyILS" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyILS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ModificationOfExistingWarrants" xlink:label="loc_ORGSModificationOfExistingWarrants" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ORGSModificationOfExistingWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PercentageOfCommission" xlink:label="loc_ORGSPercentageOfCommission" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ORGSPercentageOfCommission" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DebtInstrumentConvertibleWarrantExercisePrice" xlink:label="loc_ORGSDebtInstrumentConvertibleWarrantExercisePrice" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_ORGSDebtInstrumentConvertibleWarrantExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfLoansDetails" xlink:title="00000066 - Disclosure - SCHEDULE OF LOANS (Details)">
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisclosureLoansAbstract" xlink:label="loc_ORGSDisclosureLoansAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:label="loc_us-gaapScheduleOfExtinguishmentOfDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSDisclosureLoansAbstract" xlink:to="loc_us-gaapScheduleOfExtinguishmentOfDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtLineItems" xlink:label="loc_us-gaapExtinguishmentOfDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfExtinguishmentOfDebtTable" xlink:to="loc_us-gaapExtinguishmentOfDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="loc_us-gaapExtinguishmentOfDebtAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfExtinguishmentOfDebtTable" xlink:to="loc_us-gaapExtinguishmentOfDebtAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaapExtinguishmentOfDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapExtinguishmentOfDebtAxis" xlink:to="loc_us-gaapExtinguishmentOfDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShortTermLoanOneMember" xlink:label="loc_ORGSShortTermLoanOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapExtinguishmentOfDebtTypeDomain" xlink:to="loc_ORGSShortTermLoanOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShortTermLoansTwoMember" xlink:label="loc_ORGSShortTermLoansTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapExtinguishmentOfDebtTypeDomain" xlink:to="loc_ORGSShortTermLoansTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShortTermLoansThreeMember" xlink:label="loc_ORGSShortTermLoansThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapExtinguishmentOfDebtTypeDomain" xlink:to="loc_ORGSShortTermLoansThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfExtinguishmentOfDebtTable" xlink:to="loc_srtCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_KRW" xlink:label="loc_currencyKRW" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyKRW" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapExtinguishmentOfDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaapDebtCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapExtinguishmentOfDebtLineItems" xlink:to="loc_us-gaapDebtCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfLease-relatedAssetsAndLiabilitiesDetails" xlink:title="00000067 - Disclosure - SCHEDULE OF LEASE-RELATED ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfLeaseCostsDetails" xlink:title="00000068 - Disclosure - SCHEDULE OF LEASE COSTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FinanceLeaseCost" xlink:label="loc_ORGSFinanceLeaseCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_ORGSFinanceLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfSupplementalCashflowInformationDetails" xlink:title="00000069 - Disclosure - SCHEDULE OF SUPPLEMENTAL CASHFLOW INFORMATION (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails" xlink:title="00000070 - Disclosure - SCHEDULE OF FINANCE LEASE LIABILITIES AND OPERATING LEASE LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfRight-of-useAssetsByGeographicalLocationDetails" xlink:title="00000071 - Disclosure - SCHEDULE OF RIGHT-OF-USE ASSETS BY GEOGRAPHICAL LOCATION (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MortgageLoansOnRealEstateLineItems" xlink:label="loc_srtMortgageLoansOnRealEstateLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtMortgageLoansOnRealEstateLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_KR" xlink:label="loc_countryKR" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryKR" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:label="loc_countryIL" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMortgageLoansOnRealEstateLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/LeasesDetailsNarrative" xlink:title="00000072 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaapLesseeLeaseDescriptionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLesseeLeaseDescriptionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="loc_us-gaapManufacturingFacilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapManufacturingFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ResearchAndDevelopmentFacilitiesMember" xlink:label="loc_ORGSResearchAndDevelopmentFacilitiesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ORGSResearchAndDevelopmentFacilitiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OfficesMember" xlink:label="loc_ORGSOfficesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ORGSOfficesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_srtStatementGeographicalAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:label="loc_countryIL" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_KR" xlink:label="loc_countryKR" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryKR" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/CommitmentsDetailsNarrative" xlink:title="00000073 - Disclosure - COMMITMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MarylandTechnologyDevelopmentCorporationMember" xlink:label="loc_ORGSMarylandTechnologyDevelopmentCorporationMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_ORGSMarylandTechnologyDevelopmentCorporationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" xlink:label="loc_ORGSDepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_ORGSDepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember" xlink:label="loc_ORGSIsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_ORGSIsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember" xlink:label="loc_ORGSKoreaisraelIndustrialResearchAndDevelopmentFoundationMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_ORGSKoreaisraelIndustrialResearchAndDevelopmentFoundationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BirdSecantMember" xlink:label="loc_ORGSBirdSecantMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_ORGSBirdSecantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OBIMember" xlink:label="loc_ORGSOBIMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_ORGSOBIMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember" xlink:label="loc_ORGSResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IndustrialResearchPartOfResearchProgramMember" xlink:label="loc_ORGSIndustrialResearchPartOfResearchProgramMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSIndustrialResearchPartOfResearchProgramMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExperimentalDevelopmentPartOfResearchProgramMember" xlink:label="loc_ORGSExperimentalDevelopmentPartOfResearchProgramMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSExperimentalDevelopmentPartOfResearchProgramMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DevelopmentOfPotentialCureForTypeOneDiabetesMember" xlink:label="loc_ORGSDevelopmentOfPotentialCureForTypeOneDiabetesMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSDevelopmentOfPotentialCureForTypeOneDiabetesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember" xlink:label="loc_ORGSGmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSGmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DeductionOfResearchAndDevelopmentExpensesMember" xlink:label="loc_ORGSDeductionOfResearchAndDevelopmentExpensesMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSDeductionOfResearchAndDevelopmentExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ResearchOnDermatitisTreatmentsAndWoundHealingMember" xlink:label="loc_ORGSResearchOnDermatitisTreatmentsAndWoundHealingMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSResearchOnDermatitisTreatmentsAndWoundHealingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="loc_srtEuropeMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_srtEuropeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtProductOrServiceAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RevenueFromGrantsMember" xlink:label="loc_ORGSRevenueFromGrantsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_ORGSRevenueFromGrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivableNoncurrent" xlink:label="loc_us-gaapGrantsReceivableNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapGrantsReceivableNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_GrantsReceivablePercentageOfBudgetedCosts" xlink:label="loc_ORGSGrantsReceivablePercentageOfBudgetedCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_ORGSGrantsReceivablePercentageOfBudgetedCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdvancePaymentsOnAccountOfGrant" xlink:label="loc_ORGSAdvancePaymentsOnAccountOfGrant" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_ORGSAdvancePaymentsOnAccountOfGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherCommitment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DeductionOfResearchAndDevelopmentExpenses" xlink:label="loc_ORGSDeductionOfResearchAndDevelopmentExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_ORGSDeductionOfResearchAndDevelopmentExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RepaymentsOfGrantPercentageOfGrossSales" xlink:label="loc_ORGSRepaymentsOfGrantPercentageOfGrossSales" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_ORGSRepaymentsOfGrantPercentageOfGrossSales" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative" xlink:title="00000074 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisclosureCollaborationAndLicenseAgreementsAbstract" xlink:label="loc_ORGSDisclosureCollaborationAndLicenseAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSDisclosureCollaborationAndLicenseAgreementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiEntityListingsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CollaborationAndLicenseAgreementsAxis" xlink:label="loc_ORGSCollaborationAndLicenseAgreementsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_ORGSCollaborationAndLicenseAgreementsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CollaborationAndLicenseAgreementsDomain" xlink:label="loc_ORGSCollaborationAndLicenseAgreementsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsAxis" xlink:to="loc_ORGSCollaborationAndLicenseAgreementsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdvaBiotechnologyLtdMember" xlink:label="loc_ORGSAdvaBiotechnologyLtdMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSAdvaBiotechnologyLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember" xlink:label="loc_ORGSTelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSTelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ImmuAgreementMember" xlink:label="loc_ORGSImmuAgreementMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSImmuAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BgNegevTechnologiesAndApplicationsBgnMember" xlink:label="loc_ORGSBgNegevTechnologiesAndApplicationsBgnMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSBgNegevTechnologiesAndApplicationsBgnMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CollaborationAgreementMember" xlink:label="loc_ORGSCollaborationAgreementMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSCollaborationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SponsoredResearchAgreementMember" xlink:label="loc_ORGSSponsoredResearchAgreementMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSSponsoredResearchAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ColumbiaLicenseAgreementMember" xlink:label="loc_ORGSColumbiaLicenseAgreementMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSColumbiaLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AIPCellsMember" xlink:label="loc_ORGSAIPCellsMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSAIPCellsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CaliforniaUniversityJointResearchAgreementMember" xlink:label="loc_ORGSCaliforniaUniversityJointResearchAgreementMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSCaliforniaUniversityJointResearchAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_EVAmentMember" xlink:label="loc_ORGSEVAmentMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSEVAmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BroadenJointVentureAgreementMember" xlink:label="loc_ORGSBroadenJointVentureAgreementMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSBroadenJointVentureAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_JointVentureAgreementMember" xlink:label="loc_ORGSJointVentureAgreementMember" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSCollaborationAndLicenseAgreementsDomain" xlink:to="loc_ORGSJointVentureAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember" xlink:label="loc_ORGSOnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSOnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember" xlink:label="loc_ORGSOnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSOnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember" xlink:label="loc_ORGSOnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSOnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember" xlink:label="loc_ORGSOnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSOnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember" xlink:label="loc_ORGSWhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSWhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ResearchAndDevelopmentCostsMember" xlink:label="loc_ORGSResearchAndDevelopmentCostsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_ORGSResearchAndDevelopmentCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_HemogenyxPharmaceuticalsPLCMember" xlink:label="loc_ORGSHemogenyxPharmaceuticalsPLCMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSHemogenyxPharmaceuticalsPLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ImmugenyxLLCMember" xlink:label="loc_ORGSImmugenyxLLCMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSImmugenyxLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MarylandSubsidiaryMember" xlink:label="loc_ORGSMarylandSubsidiaryMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSMarylandSubsidiaryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KinerjapayCorpMember" xlink:label="loc_ORGSKinerjapayCorpMember" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSKinerjapayCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SBHSciencesIncMember" xlink:label="loc_ORGSSBHSciencesIncMember" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSSBHSciencesIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SalesMilestoneMember" xlink:label="loc_ORGSSalesMilestoneMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSSalesMilestoneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TamirPurchaseAgreementMember" xlink:label="loc_ORGSTamirPurchaseAgreementMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSTamirPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srtOwnershipAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtOwnershipAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MarylandSubsidiaryMember" xlink:label="loc_ORGSMarylandSubsidiaryMember_2" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_ORGSMarylandSubsidiaryMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CaerusTherapeuticsIncMember" xlink:label="loc_ORGSCaerusTherapeuticsIncMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_ORGSCaerusTherapeuticsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExtracellularVesicleMember" xlink:label="loc_ORGSExtracellularVesicleMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_ORGSExtracellularVesicleMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TamirBiotechnologyIncMember" xlink:label="loc_ORGSTamirBiotechnologyIncMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ORGSTamirBiotechnologyIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TissueGenesisLLCMember" xlink:label="loc_ORGSTissueGenesisLLCMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ORGSTissueGenesisLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapOtherCommitment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TerminationDescription" xlink:label="loc_ORGSTerminationDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSTerminationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RoyaltyOfNetSalesPercentage" xlink:label="loc_ORGSRoyaltyOfNetSalesPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSRoyaltyOfNetSalesPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SublicensingFeesPercentage" xlink:label="loc_ORGSSublicensingFeesPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSSublicensingFeesPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CommitmentSharesOfCommonStock" xlink:label="loc_ORGSCommitmentSharesOfCommonStock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSCommitmentSharesOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CommitmentSharesOfCommonStockOfSubsidiary" xlink:label="loc_ORGSCommitmentSharesOfCommonStockOfSubsidiary" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSCommitmentSharesOfCommonStockOfSubsidiary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ReductionRateOfRoyaltyPercentage" xlink:label="loc_ORGSReductionRateOfRoyaltyPercentage" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSReductionRateOfRoyaltyPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableNet" xlink:label="loc_us-gaapNotesReceivableNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapNotesReceivableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PreMoneyValuation" xlink:label="loc_ORGSPreMoneyValuation" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSPreMoneyValuation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdditionalFundsInvest" xlink:label="loc_ORGSAdditionalFundsInvest" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSAdditionalFundsInvest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromGrantors" xlink:label="loc_us-gaapProceedsFromGrantors" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapProceedsFromGrantors" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PercentageOfGrossRevenues" xlink:label="loc_ORGSPercentageOfGrossRevenues" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSPercentageOfGrossRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PaymentForFinancialSupportToTrustForStudy" xlink:label="loc_ORGSPaymentForFinancialSupportToTrustForStudy" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSPaymentForFinancialSupportToTrustForStudy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PaymentForFinancialSupportCumulativeAmountToTrustForStudy" xlink:label="loc_ORGSPaymentForFinancialSupportCumulativeAmountToTrustForStudy" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSPaymentForFinancialSupportCumulativeAmountToTrustForStudy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PaymentForFinancialSupportToTrustForStudyDueEverySixMonths" xlink:label="loc_ORGSPaymentForFinancialSupportToTrustForStudyDueEverySixMonths" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSPaymentForFinancialSupportToTrustForStudyDueEverySixMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RoyaltyOfNetSalesOfOtherProductsPercentage" xlink:label="loc_ORGSRoyaltyOfNetSalesOfOtherProductsPercentage" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSRoyaltyOfNetSalesOfOtherProductsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PaymentOfFeeUponAchievementOfEachRegulatoryMilestone" xlink:label="loc_ORGSPaymentOfFeeUponAchievementOfEachRegulatoryMilestone" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSPaymentOfFeeUponAchievementOfEachRegulatoryMilestone" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaapMinorityInterestOwnershipPercentageByParent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapMinorityInterestOwnershipPercentageByParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FutureMilestonePayments" xlink:label="loc_ORGSFutureMilestonePayments" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSFutureMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_RoyaltyPercentage" xlink:label="loc_ORGSRoyaltyPercentage" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSRoyaltyPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_InterestInJointVenture" xlink:label="loc_ORGSInterestInJointVenture" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSInterestInJointVenture" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoanAdvancedToJointVenture" xlink:label="loc_ORGSConvertibleLoanAdvancedToJointVenture" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSConvertibleLoanAdvancedToJointVenture" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleLoanAdvancedToJointVentureInterestRate" xlink:label="loc_ORGSConvertibleLoanAdvancedToJointVentureInterestRate" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_ORGSConvertibleLoanAdvancedToJointVentureInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaapPaymentForContingentConsiderationLiabilityInvestingActivities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapPaymentForContingentConsiderationLiabilityInvestingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferToInvestments" xlink:label="loc_us-gaapTransferToInvestments" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapTransferToInvestments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfChangesInInvestmentsDetails" xlink:title="00000075 - Disclosure - SCHEDULE OF CHANGES IN INVESTMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:label="loc_us-gaapInvestmentsInAndAdvancesToAffiliatesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaapEquityMethodInvestments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsInAndAdvancesToAffiliatesAbstract" xlink:to="loc_us-gaapEquityMethodInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaapPaymentsToAcquireEquityMethodInvestments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsInAndAdvancesToAffiliatesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireEquityMethodInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromEquityMethodInvestments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsInAndAdvancesToAffiliatesAbstract" xlink:to="loc_us-gaapIncomeLossFromEquityMethodInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaapEquityMethodInvestments_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsInAndAdvancesToAffiliatesAbstract" xlink:to="loc_us-gaapEquityMethodInvestments_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/InvestmentsInAssociatesNetDetailsNarrative" xlink:title="00000076 - Disclosure - INVESTMENTS IN ASSOCIATES, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract" xlink:label="loc_us-gaapInvestmentsInAndAdvancesToAffiliatesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="loc_us-gaapScheduleOfInvestmentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsInAndAdvancesToAffiliatesAbstract" xlink:to="loc_us-gaapScheduleOfInvestmentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="loc_us-gaapScheduleOfInvestmentsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentsTable" xlink:to="loc_us-gaapScheduleOfInvestmentsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentsTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TLABSMember" xlink:label="loc_ORGSTLABSMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSTLABSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ButterflyBiosciencesSarlMember" xlink:label="loc_ORGSButterflyBiosciencesSarlMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSButterflyBiosciencesSarlMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KidneyCureJVAMember" xlink:label="loc_ORGSKidneyCureJVAMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSKidneyCureJVAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_InvestmentsInAssociatePercentageOfOwnership" xlink:label="loc_ORGSInvestmentsInAssociatePercentageOfOwnership" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentsLineItems" xlink:to="loc_ORGSInvestmentsInAssociatePercentageOfOwnership" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000077 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfTreasurySharesDetails" xlink:title="00000078 - Disclosure - SCHEDULE OF TREASURY SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TreasuryStockShare" xlink:label="loc_ORGSTreasuryStockShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ORGSTreasuryStockShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock" xlink:label="loc_ORGSWeightedAveragePriceNumberOfSharesTreasuryStock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ORGSWeightedAveragePriceNumberOfSharesTreasuryStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaapTreasuryStockSharesAcquired" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapTreasuryStockSharesAcquired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_WeightedAveragePriceNumberOfSharesTreasuryStockPurchased" xlink:label="loc_ORGSWeightedAveragePriceNumberOfSharesTreasuryStockPurchased" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ORGSWeightedAveragePriceNumberOfSharesTreasuryStockPurchased" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TreasuryStockShare" xlink:label="loc_ORGSTreasuryStockShare_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ORGSTreasuryStockShare_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock" xlink:label="loc_ORGSWeightedAveragePriceNumberOfSharesTreasuryStock_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ORGSWeightedAveragePriceNumberOfSharesTreasuryStock_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/EquityDetailsNarrative" xlink:title="00000079 - Disclosure - EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SecuritiesPurchaseAgreementMember" xlink:label="loc_ORGSSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TamirPurchaseAgreementMember" xlink:label="loc_ORGSTamirPurchaseAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSTamirPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MergerAgreementMember" xlink:label="loc_ORGSMergerAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSMergerAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TamirBiotechnologyIncMember" xlink:label="loc_ORGSTamirBiotechnologyIncMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ORGSTamirBiotechnologyIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_KoligoTherapeuticsIncMember" xlink:label="loc_ORGSKoligoTherapeuticsIncMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ORGSKoligoTherapeuticsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MaximaGroupLLCMember" xlink:label="loc_ORGSMaximaGroupLLCMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSMaximaGroupLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_WarrantExercisableDescription" xlink:label="loc_ORGSWarrantExercisableDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ORGSWarrantExercisableDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OfferingExpenses" xlink:label="loc_ORGSOfferingExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ORGSOfferingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapEscrowDeposit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NumberOfSharesDepositInEscrowAccount" xlink:label="loc_ORGSNumberOfSharesDepositInEscrowAccount" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ORGSNumberOfSharesDepositInEscrowAccount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfBasicAndDilutedLossPerShareDetails" xlink:title="00000080 - Disclosure - SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:label="loc_us-gaapNetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" xlink:label="loc_us-gaapNetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount" xlink:label="loc_ORGSAdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_ORGSAdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NetIncomeLossToParentCompany" xlink:label="loc_ORGSNetIncomeLossToParentCompany" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_ORGSNetIncomeLossToParentCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:label="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/IncomeLossPerShareDetailsNarrative" xlink:title="00000081 - Disclosure - INCOME (LOSS) PER SHARE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsAndWarrantsMember" xlink:label="loc_ORGSOptionsAndWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ORGSOptionsAndWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SharesUponConversionOfConvertibleNotesMember" xlink:label="loc_ORGSSharesUponConversionOfConvertibleNotesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ORGSSharesUponConversionOfConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails" xlink:title="00000082 - Disclosure - SCHEDULE OF EMPLOYEE STOCK OWNERSHIP PLAN DISCLOSURES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToEmployeesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_EmployeesMember" xlink:label="loc_ORGSEmployeesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ORGSEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_srtStatementScenarioAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OneYearAnniversaryMember" xlink:label="loc_ORGSOneYearAnniversaryMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ORGSOneYearAnniversaryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ThreeEqualInstallmentsMember" xlink:label="loc_ORGSThreeEqualInstallmentsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ORGSThreeEqualInstallmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_StockOptionsGrantVestingPeriodPercentage" xlink:label="loc_ORGSStockOptionsGrantVestingPeriodPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_ORGSStockOptionsGrantVestingPeriodPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:title="00000083 - Disclosure - SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToEmployeesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToNonEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToNonEmployeesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToNonEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails" xlink:title="00000084 - Disclosure - SCHEDULE OF STOCK OPTIONS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToEmployeesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToNonEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToNonEmployeesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToNonEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails" xlink:title="00000085 - Disclosure - SCHEDULE OF STOCK OPTIONS EXERCISABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToEmployeesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToNonEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToNonEmployeesMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToNonEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceOneMember" xlink:label="loc_ORGSExercisePriceOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceTwoMember" xlink:label="loc_ORGSExercisePriceTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceThreeMember" xlink:label="loc_ORGSExercisePriceThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceFourMember" xlink:label="loc_ORGSExercisePriceFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceFiveMember" xlink:label="loc_ORGSExercisePriceFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceSixMember" xlink:label="loc_ORGSExercisePriceSixMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceSevenMember" xlink:label="loc_ORGSExercisePriceSevenMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceEightMember" xlink:label="loc_ORGSExercisePriceEightMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceNineMember" xlink:label="loc_ORGSExercisePriceNineMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceTenMember" xlink:label="loc_ORGSExercisePriceTenMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceTenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceElevenMember" xlink:label="loc_ORGSExercisePriceElevenMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceElevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceTwelveMember" xlink:label="loc_ORGSExercisePriceTwelveMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceTwelveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceThirteenMember" xlink:label="loc_ORGSExercisePriceThirteenMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceThirteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceFourteenMember" xlink:label="loc_ORGSExercisePriceFourteenMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceFourteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceFifteenMember" xlink:label="loc_ORGSExercisePriceFifteenMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceFifteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceSixteenMember" xlink:label="loc_ORGSExercisePriceSixteenMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceSixteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceSeventeenMember" xlink:label="loc_ORGSExercisePriceSeventeenMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceSeventeenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceEighteenMember" xlink:label="loc_ORGSExercisePriceEighteenMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceEighteenMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceNineteenMember" xlink:label="loc_ORGSExercisePriceNineteenMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceNineteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExercisePriceTwentyMember" xlink:label="loc_ORGSExercisePriceTwentyMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ORGSExercisePriceTwentyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails" xlink:title="00000086 - Disclosure - SCHEDULE OF STOCK OPTIONS GRANTED TO CONSULTANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToNonEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToNonEmployeesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToNonEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000087 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TwoZeroOneSevenEquityIncentivePlanMember" xlink:label="loc_ORGSTwoZeroOneSevenEquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ORGSTwoZeroOneSevenEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_GlobalShareIncentivePlanTwoZeroOneTwoMember" xlink:label="loc_ORGSGlobalShareIncentivePlanTwoZeroOneTwoMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ORGSGlobalShareIncentivePlanTwoZeroOneTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToEmployeesAndDirectorsMember" xlink:label="loc_ORGSOptionsGrantedToEmployeesAndDirectorsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToEmployeesAndDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_OptionsGrantedToNonEmployeesMember" xlink:label="loc_ORGSOptionsGrantedToNonEmployeesMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="loc_ORGSOptionsGrantedToNonEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MasthercellGlobalMember" xlink:label="loc_ORGSMasthercellGlobalMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSMasthercellGlobalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FirstChoiceInternationalCompanyIncMember" xlink:label="loc_ORGSFirstChoiceInternationalCompanyIncMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ORGSFirstChoiceInternationalCompanyIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SecuritiesPurchaseAgreementMember" xlink:label="loc_ORGSSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PrivatePlacementSubscriptionAgreementsMember" xlink:label="loc_ORGSPrivatePlacementSubscriptionAgreementsMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSPrivatePlacementSubscriptionAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConsultingAgreementMember" xlink:label="loc_ORGSConsultingAgreementMember" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NonEmployeesMember" xlink:label="loc_ORGSNonEmployeesMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ORGSNonEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SeveralConsultantsMember" xlink:label="loc_ORGSSeveralConsultantsMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ORGSSeveralConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConsultantMember" xlink:label="loc_ORGSConsultantMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ORGSConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SeveralConsultantsMember" xlink:label="loc_ORGSSeveralConsultantsMember_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSSeveralConsultantsMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_InvestorRelationContactMember" xlink:label="loc_ORGSInvestorRelationContactMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSInvestorRelationContactMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SeparateInvestorRelationsContactMember" xlink:label="loc_ORGSSeparateInvestorRelationsContactMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSSeparateInvestorRelationsContactMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SeparateInvestorRelationContactMember" xlink:label="loc_ORGSSeparateInvestorRelationContactMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSSeparateInvestorRelationContactMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ConvertibleNotesAndPrivateInvestmentMember" xlink:label="loc_ORGSConvertibleNotesAndPrivateInvestmentMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_ORGSConvertibleNotesAndPrivateInvestmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SuccessFeeMember" xlink:label="loc_ORGSSuccessFeeMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ORGSSuccessFeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapVestingAxis" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_HeldUntilSixMonthsAnniversaryMember" xlink:label="loc_ORGSHeldUntilSixMonthsAnniversaryMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_ORGSHeldUntilSixMonthsAnniversaryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_HeldUntilOneYearAnniversaryMember" xlink:label="loc_ORGSHeldUntilOneYearAnniversaryMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_ORGSHeldUntilOneYearAnniversaryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_VestedOnSigningDateMember" xlink:label="loc_ORGSVestedOnSigningDateMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_ORGSVestedOnSigningDateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_VestMonthlyOver3MonthsMember" xlink:label="loc_ORGSVestMonthlyOver3MonthsMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_ORGSVestMonthlyOver3MonthsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants" xlink:label="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_WarrantExercisableDescription" xlink:label="loc_ORGSWarrantExercisableDescription" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSWarrantExercisableDescription" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AggregateAmountOfSubscriptionAgreement" xlink:label="loc_ORGSAggregateAmountOfSubscriptionAgreement" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSAggregateAmountOfSubscriptionAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaapWarrantExercisePriceDecrease" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantExercisePriceDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_WarrantsAndRightsOutstandingTermDescription" xlink:label="loc_ORGSWarrantsAndRightsOutstandingTermDescription" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSWarrantsAndRightsOutstandingTermDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ClassOfWarrantOrRightGrantsInPeriod" xlink:label="loc_ORGSClassOfWarrantOrRightGrantsInPeriod" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSClassOfWarrantOrRightGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_ORGSClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ClassOfWarrantOrRightGrantsInPeriodFairValue" xlink:label="loc_ORGSClassOfWarrantOrRightGrantsInPeriodFairValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSClassOfWarrantOrRightGrantsInPeriodFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FairValueOfSharesRecognizedOnGrantDate" xlink:label="loc_ORGSFairValueOfSharesRecognizedOnGrantDate" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSFairValueOfSharesRecognizedOnGrantDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted" xlink:label="loc_ORGSJointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSJointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NumberOfVestedShares" xlink:label="loc_ORGSNumberOfVestedShares" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSNumberOfVestedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FairValueOfSharesOnVestingDatesRecognizedDuringYear" xlink:label="loc_ORGSFairValueOfSharesOnVestingDatesRecognizedDuringYear" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSFairValueOfSharesOnVestingDatesRecognizedDuringYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NumberOfAdditionalSharesRestrictionsOnTransfer" xlink:label="loc_ORGSNumberOfAdditionalSharesRestrictionsOnTransfer" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ORGSNumberOfAdditionalSharesRestrictionsOnTransfer" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="00000088 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DeferredTaxAssetsLeasesAsset" xlink:label="loc_ORGSDeferredTaxAssetsLeasesAsset" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ORGSDeferredTaxAssetsLeasesAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DeferredTaxAssetsLeaseLiability" xlink:label="loc_ORGSDeferredTaxAssetsLeaseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ORGSDeferredTaxAssetsLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfValuationAllowanceActivityDetails" xlink:title="00000089 - Disclosure - SCHEDULE OF VALUATION ALLOWANCE, ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/TaxesDetailsNarrative" xlink:title="00000090 - Disclosure - TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:label="loc_countryIL" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_BE" xlink:label="loc_countryBE" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryBE" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_KR" xlink:label="loc_countryKR" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryKR" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TwoThousandTwentyOneToTwoThousandTwentyMember" xlink:label="loc_ORGSTwoThousandTwentyOneToTwoThousandTwentyMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ORGSTwoThousandTwentyOneToTwoThousandTwentyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="loc_srtEuropeMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_srtEuropeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_SouthKoreanWonMember" xlink:label="loc_ORGSSouthKoreanWonMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ORGSSouthKoreanWonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember" xlink:label="loc_ORGSTheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_ORGSTheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_UpToKrwTwoZeroBillionMember" xlink:label="loc_ORGSUpToKrwTwoZeroBillionMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_ORGSUpToKrwTwoZeroBillionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_UpToKrwThreeZeroZeroBillionMember" xlink:label="loc_ORGSUpToKrwThreeZeroZeroBillionMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_ORGSUpToKrwThreeZeroZeroBillionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TaxBaseAboveKrwThreeZeroZeroBillionMember" xlink:label="loc_ORGSTaxBaseAboveKrwThreeZeroZeroBillionMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_ORGSTaxBaseAboveKrwThreeZeroZeroBillionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AccumulatedTaxLossCarryforwardDeductions" xlink:label="loc_ORGSAccumulatedTaxLossCarryforwardDeductions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_ORGSAccumulatedTaxLossCarryforwardDeductions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AccumulatedTaxLossCarryForwardedPeriod" xlink:label="loc_ORGSAccumulatedTaxLossCarryForwardedPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_ORGSAccumulatedTaxLossCarryForwardedPeriod" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:title="00000091 - Disclosure - SCHEDULE OF DISAGGREGATION OF REVENUE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapDisaggregationOfRevenueLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_PointOfCareServicesMember" xlink:label="loc_ORGSPointOfCareServicesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_ORGSPointOfCareServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CellProcessDevelopmentServicesMember" xlink:label="loc_ORGSCellProcessDevelopmentServicesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_ORGSCellProcessDevelopmentServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfBreakdownOfRevenuesPerCustomerDetails" xlink:title="00000092 - Disclosure - SCHEDULE OF BREAKDOWN OF REVENUES PER CUSTOMER (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapDisaggregationOfRevenueLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtMajorCustomersAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CustomerAMember" xlink:label="loc_ORGSCustomerAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ORGSCustomerAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CustomerBMember" xlink:label="loc_ORGSCustomerBMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ORGSCustomerBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CustomerCRelatedPartyMember" xlink:label="loc_ORGSCustomerCRelatedPartyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ORGSCustomerCRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CustomerDMember" xlink:label="loc_ORGSCustomerDMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ORGSCustomerDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfActivityForTradeReceivablesDetails" xlink:title="00000093 - Disclosure - SCHEDULE OF ACTIVITY FOR TRADE RECEIVABLES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AccountsReceivableAcquisitionOfKoligo" xlink:label="loc_ORGSAccountsReceivableAcquisitionOfKoligo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_ORGSAccountsReceivableAcquisitionOfKoligo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AccountsReceivableAdditions" xlink:label="loc_ORGSAccountsReceivableAdditions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_ORGSAccountsReceivableAdditions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_AccountsReceivableCollections" xlink:label="loc_ORGSAccountsReceivableCollections" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_ORGSAccountsReceivableCollections" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ExchangeRateDifferencesOfAccountsReceivable" xlink:label="loc_ORGSExchangeRateDifferencesOfAccountsReceivable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_ORGSExchangeRateDifferencesOfAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetails" xlink:title="00000094 - Disclosure - SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ContractWithCustomerLiabilityAddition" xlink:label="loc_ORGSContractWithCustomerLiabilityAddition" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_ORGSContractWithCustomerLiabilityAddition" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ContractWithCustomerLiabilityRealizations" xlink:label="loc_ORGSContractWithCustomerLiabilityRealizations" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_ORGSContractWithCustomerLiabilityRealizations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ContractWithCustomerLiabilityExchangeRateDifferences" xlink:label="loc_ORGSContractWithCustomerLiabilityExchangeRateDifferences" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_ORGSContractWithCustomerLiabilityExchangeRateDifferences" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetailsParenthetical" xlink:title="00000095 - Disclosure - SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/RevenuesDetailsNarrative" xlink:title="00000096 - Disclosure - REVENUES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_MasterServicesAgreementsMember" xlink:label="loc_ORGSMasterServicesAgreementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ORGSMasterServicesAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_JointVenturePartnersMember" xlink:label="loc_ORGSJointVenturePartnersMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSJointVenturePartnersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:title="00000097 - Disclosure - SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_GrantsIncome" xlink:label="loc_ORGSGrantsIncome" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_ORGSGrantsIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfFinancialExpensesDetails" xlink:title="00000098 - Disclosure - SCHEDULE OF FINANCIAL EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DisclosureFinancialExpensesNetAbstract" xlink:label="loc_ORGSDisclosureFinancialExpensesNetAbstract" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue" xlink:label="loc_ORGSIncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSDisclosureFinancialExpensesNetAbstract" xlink:to="loc_ORGSIncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_InterestExpenseOnConvertibleLoans" xlink:label="loc_ORGSInterestExpenseOnConvertibleLoans" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSDisclosureFinancialExpensesNetAbstract" xlink:to="loc_ORGSInterestExpenseOnConvertibleLoans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_ForeignCurrencyTransactionsGainLossRealized" xlink:label="loc_ORGSForeignCurrencyTransactionsGainLossRealized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSDisclosureFinancialExpensesNetAbstract" xlink:to="loc_ORGSForeignCurrencyTransactionsGainLossRealized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSDisclosureFinancialExpensesNetAbstract" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_TotalFinancialExpenses" xlink:label="loc_ORGSTotalFinancialExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ORGSDisclosureFinancialExpensesNetAbstract" xlink:to="loc_ORGSTotalFinancialExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:title="00000099 - Disclosure - SCHEDULE OF RELATED PARTY TRANSACTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="loc_us-gaapStatementOperatingActivitiesSegmentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementOperatingActivitiesSegmentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="loc_us-gaapSegmentOperatingActivitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOperatingActivitiesSegmentAxis" xlink:to="loc_us-gaapSegmentOperatingActivitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentContinuingOperationsMember" xlink:label="loc_us-gaapSegmentContinuingOperationsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentOperatingActivitiesDomain" xlink:to="loc_us-gaapSegmentContinuingOperationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="loc_us-gaapSegmentDiscontinuedOperationsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentOperatingActivitiesDomain" xlink:to="loc_us-gaapSegmentDiscontinuedOperationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srtExecutiveOfficerMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_srtExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_BoardMembersMember" xlink:label="loc_ORGSBoardMembersMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_ORGSBoardMembersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaapRevenueFromRelatedParties" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRevenueFromRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" xlink:label="loc_ORGSCostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_ORGSCostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_FinancialIncome" xlink:label="loc_ORGSFinancialIncome" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_ORGSFinancialIncome" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical" xlink:title="00000100 - Disclosure - SCHEDULE OF RELATED PARTY TRANSACTIONS (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_CaerusTherapeuticsLLCMember" xlink:label="loc_ORGSCaerusTherapeuticsLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ORGSCaerusTherapeuticsLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockOptionPlanExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NumberOfOrdinarySharesHeld" xlink:label="loc_ORGSNumberOfOrdinarySharesHeld" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_ORGSNumberOfOrdinarySharesHeld" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://orgenesis.com/role/ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails" xlink:title="00000101 - Disclosure - SCHEDULE OF RELATED PARTIES PRESENTED IN CONSOLIDATED BALANCE SHEETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srtExecutiveOfficerMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_srtExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_NonexecutiveDirectorsMember" xlink:label="loc_ORGSNonexecutiveDirectorsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_ORGSNonexecutiveDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrentAndNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="orgs-20201231.xsd#ORGS_DueFromRelatedPartiesNoncurrent1" xlink:label="loc_ORGSDueFromRelatedPartiesNoncurrent1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_ORGSDueFromRelatedPartiesNoncurrent1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaapAccountsReceivableNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsReceivableNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaapContractWithCustomerLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapContractWithCustomerLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ORGS="http://orgenesis.com/20201231"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="orgs-20201231.xsd" xlink:type="simple"/>
    <context id="From2020-01-01to2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
        </entity>
        <period>
            <instant>2021-03-09</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_EquityAttributedToOrgenesisIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ORGS:EquityAttributedToOrgenesisIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_EquityAttributedToOrgenesisIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ORGS:EquityAttributedToOrgenesisIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_EquityAttributedToOrgenesisIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ORGS:EquityAttributedToOrgenesisIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ORGS:EquityAttributedToOrgenesisIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_EquityAttributedToOrgenesisIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ORGS:EquityAttributedToOrgenesisIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-02-29_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:MasthercellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="From2020-02-012020-02-29_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:MasthercellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CureCellCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:CureCellCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:TamirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:TamirPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-06</startDate>
            <endDate>2020-04-07</endDate>
        </period>
    </context>
    <context id="From2020-02-092020-02-10_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:MasthercellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-09</startDate>
            <endDate>2020-02-10</endDate>
        </period>
    </context>
    <context id="From2020-01-192020-01-20_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-19</startDate>
            <endDate>2020-01-20</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ProductionFacilityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:ProductionFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ProductionFacilityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:ProductionFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_EquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_EquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_KnowhowMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ORGS:KnowhowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_TechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ORGS:TechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_AccountingStandardsUpdate201912Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-02-02_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:MasthercellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-02</instant>
        </period>
    </context>
    <context id="From2020-02-012020-02-02_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:MasthercellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-02</endDate>
        </period>
    </context>
    <context id="From2020-02-092020-02-10_custom_MasthercellSAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:MasthercellSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-09</startDate>
            <endDate>2020-02-10</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_country_BE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CellProcessDevelopmentServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:CellProcessDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CellProcessDevelopmentServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:CellProcessDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_TechTransferServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:TechTransferServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_TechTransferServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:TechTransferServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CellManufacturingServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:CellManufacturingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CellManufacturingServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:CellManufacturingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:TamirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:TamirPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-07</instant>
        </period>
    </context>
    <context id="From2020-10-142020-10-15_custom_KoligoTherapeuticsIncMember_custom_MaterialDefinitiveAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:KoligoTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:MaterialDefinitiveAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-14</startDate>
            <endDate>2020-10-15</endDate>
        </period>
    </context>
    <context id="From2020-10-142020-10-15_custom_MaximaGroupLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:MaximaGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-14</startDate>
            <endDate>2020-10-15</endDate>
        </period>
    </context>
    <context id="AsOf2020-10-15_custom_KoligoTherapeuticsIncMember_custom_MaterialDefinitiveAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:KoligoTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:MaterialDefinitiveAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-15</instant>
        </period>
    </context>
    <context id="From2020-10-142020-10-15_custom_LongHillAndMaximGroupLLCMember_custom_RegistrationRightsandLockUpAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:RegistrationRightsandLockUpAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:LongHillAndMaximGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-14</startDate>
            <endDate>2020-10-15</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_KyslecelTechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ORGS:KyslecelTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_IPResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ORGS:IPResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_KyslecelTechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ORGS:KyslecelTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_KoligoTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:KoligoTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_KoligoTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:KoligoTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-08-062019-08-07_custom_TransferAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:TransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-06</startDate>
            <endDate>2019-08-07</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ProductionFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:ProductionFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_ProductionFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:ProductionFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OfficeFurnitureAndComputersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:OfficeFurnitureAndComputersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_OfficeFurnitureAndComputersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:OfficeFurnitureAndComputersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_LabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_LabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_AdvancePaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:AdvancePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_AdvancePaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:AdvancePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_country_BE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_country_KR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_country_KR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_country_IL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_country_IL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_KnowhowMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ORGS:KnowhowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_KnowhowMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ORGS:KnowhowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_KyslecelTechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ORGS:KyslecelTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_IPResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ORGS:IPResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ConvertibleLoansOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ConvertibleLoansOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ConvertibleLoansTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ConvertibleLoansTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ConvertibleLoansTwoMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ConvertibleLoansTwoMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ConvertibleLoansTwoMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ConvertibleLoansTwoMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ConvertibleLoansThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ConvertibleLoansThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ConvertibleLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_ConvertibleLoansOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_ConvertibleLoansOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_ConvertibleLoansTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_ConvertibleLoansTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_ConvertibleLoansTwoMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_ConvertibleLoansTwoMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_ConvertibleLoansTwoMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_ConvertibleLoansTwoMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_ConvertibleLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_TwoPercentageConvertibleLoansTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:TwoPercentageConvertibleLoansTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_TwoPercentageConvertibleLoansTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:TwoPercentageConvertibleLoansTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_SixPercentageConvertibleLoansTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:SixPercentageConvertibleLoansTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SixPercentageConvertibleLoansTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:SixPercentageConvertibleLoansTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_EightPercetageConvertibleLoansTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:EightPercetageConvertibleLoansTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_EightPercetageConvertibleLoansTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:EightPercetageConvertibleLoansTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ConvertibleLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ConvertibleLoansOneMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_HemogenyxCelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:HemogenyxCelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ImmugenyxLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:ImmugenyxLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ConvertibleLoansTwoMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2019-04-012019-04-30_custom_ConvertibleLoanAgreementMember_us-gaap_InvestorMember_custom_ConvertibleLoansOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ConvertibleLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-04-30_custom_ConvertibleLoanAgreementMember_us-gaap_InvestorMember_custom_ConvertibleLoansOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ORGS:ConvertibleLoansOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ConvertibleLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="From2019-05-012019-05-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:PrivatePlacementSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-05-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:PrivatePlacementSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="AsOf2019-05-31_custom_SixPercentageConvertibleLoanAgreementMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:SixPercentageConvertibleLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="From2019-05-012019-05-31_custom_SixPercentageConvertibleLoanAgreementMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:SixPercentageConvertibleLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:PrivatePlacementSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-06-30_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:PrivatePlacementSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="From2019-10-012019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="From2019-11-012019-11-30_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="From2019-10-012019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="From2019-10-012019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="From2019-10-012019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="From2019-11-012019-11-30_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="From2019-11-012019-11-30_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="From2019-11-012019-11-30_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="From2019-11-012019-11-30_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="From2019-12-012019-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-01-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="From2020-02-012020-02-29_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="From2019-12-012019-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-12-012019-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-12-012019-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-12-012019-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-01-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-01-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-01-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-01-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="From2020-02-012020-02-29_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="From2020-02-012020-02-29_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="From2020-02-012020-02-29_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="From2020-02-012020-02-29_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CreditLineAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-12-012020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-12-012020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-12-012020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-12-012020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-12-012020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:NonUSInvestorFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CreditLineAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CreditLineAgreementsMember_custom_InvestorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CreditLineAgreementsMember_custom_InvestorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CreditLineAgreementsMember_custom_TwoOtherInvestorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:TwoOtherInvestorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CreditLineAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:CreditLineAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-12-012019-12-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:PrivatePlacementSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:PrivatePlacementSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-12-302020-01-03_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:PrivatePlacementSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="AsOf2020-01-02_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:PrivatePlacementSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-02</instant>
        </period>
    </context>
    <context id="From2018-12-012018-12-31_custom_ControlledEquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2016-11-012016-11-02_custom_ControlledEquityOfferingSalesAgreementMember_currency_ILS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-02</endDate>
        </period>
    </context>
    <context id="From2016-11-012016-11-02_custom_ControlledEquityOfferingSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-02</endDate>
        </period>
    </context>
    <context id="AsOf2016-11-02_custom_ControlledEquityOfferingSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-02</instant>
        </period>
    </context>
    <context id="AsOf2018-03-31_custom_ControlledEquityOfferingSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="From2018-04-012018-04-30_custom_ControlledEquityOfferingSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ShortTermLoanOneMember_currency_KRW">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:KRW</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">ORGS:ShortTermLoanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_ShortTermLoanOneMember_currency_KRW">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:KRW</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">ORGS:ShortTermLoanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ShortTermLoansTwoMember_currency_KRW">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:KRW</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">ORGS:ShortTermLoansTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_ShortTermLoansTwoMember_currency_KRW">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:KRW</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">ORGS:ShortTermLoansTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ShortTermLoansThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">ORGS:ShortTermLoansThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_ShortTermLoansThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">ORGS:ShortTermLoansThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_ManufacturingFacilityMember_country_IL_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_ManufacturingFacilityMember_country_IL_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ResearchAndDevelopmentFacilitiesMember_country_KR_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:ResearchAndDevelopmentFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ResearchAndDevelopmentFacilitiesMember_country_KR_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:ResearchAndDevelopmentFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OfficesMember_country_IL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ORGS:OfficesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2014-06-30_custom_MarylandTechnologyDevelopmentCorporationMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:MarylandTechnologyDevelopmentCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-06-30</instant>
        </period>
    </context>
    <context id="AsOf2014-11-17_custom_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-17</instant>
        </period>
    </context>
    <context id="AsOf2014-11-17_custom_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-17</instant>
        </period>
    </context>
    <context id="AsOf2014-11-17_custom_IndustrialResearchPartOfResearchProgramMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:IndustrialResearchPartOfResearchProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-17</instant>
        </period>
    </context>
    <context id="AsOf2014-11-17_custom_IndustrialResearchPartOfResearchProgramMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:IndustrialResearchPartOfResearchProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-17</instant>
        </period>
    </context>
    <context id="AsOf2014-11-17_custom_ExperimentalDevelopmentPartOfResearchProgramMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ExperimentalDevelopmentPartOfResearchProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-17</instant>
        </period>
    </context>
    <context id="AsOf2014-11-17_custom_ExperimentalDevelopmentPartOfResearchProgramMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ExperimentalDevelopmentPartOfResearchProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-17</instant>
        </period>
    </context>
    <context id="AsOf2014-12-31_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-12-31_custom_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_custom_RevenueFromGrantsMember_custom_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:RevenueFromGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2016-04-30_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:DevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="AsOf2016-04-30_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:DevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="From2016-04-012016-04-30_custom_RevenueFromGrantsMember_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:RevenueFromGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:DevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="From2016-04-012016-04-30_custom_RevenueFromGrantsMember_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:RevenueFromGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:DevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_RevenueFromGrantsMember_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:RevenueFromGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:DevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_RevenueFromGrantsMember_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:RevenueFromGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:DevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:DevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:DevelopmentOfPotentialCureForTypeOneDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2016-10-08_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-08</instant>
        </period>
    </context>
    <context id="AsOf2016-10-08_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-08</instant>
        </period>
    </context>
    <context id="From2016-10-012016-10-08_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-10-08</endDate>
        </period>
    </context>
    <context id="From2016-10-012016-10-08_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-10-08</endDate>
        </period>
    </context>
    <context id="From2016-12-012016-12-19_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-19</endDate>
        </period>
    </context>
    <context id="From2016-12-012016-12-19_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-19</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_DeductionOfResearchAndDevelopmentExpensesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:DeductionOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchOnDermatitisTreatmentsAndWoundHealingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchOnDermatitisTreatmentsAndWoundHealingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-12-012020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchOnDermatitisTreatmentsAndWoundHealingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-12-012020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchOnDermatitisTreatmentsAndWoundHealingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchOnDermatitisTreatmentsAndWoundHealingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchOnDermatitisTreatmentsAndWoundHealingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2015-09-09_custom_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-09</instant>
        </period>
    </context>
    <context id="From2015-09-012015-09-09_custom_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-09</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2016-05-26_custom_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:KoreaisraelIndustrialResearchAndDevelopmentFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-26</instant>
        </period>
    </context>
    <context id="From2016-05-012016-05-26_custom_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:KoreaisraelIndustrialResearchAndDevelopmentFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-01</startDate>
            <endDate>2016-05-26</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:KoreaisraelIndustrialResearchAndDevelopmentFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-07-30_custom_BirdSecantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:BirdSecantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OBIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:OBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_DeductionOfResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:DeductionOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-01-28_custom_AdvaBiotechnologyLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:AdvaBiotechnologyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-28</instant>
        </period>
    </context>
    <context id="From2018-01-262018-01-28_custom_AdvaBiotechnologyLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:AdvaBiotechnologyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-26</startDate>
            <endDate>2018-01-28</endDate>
        </period>
    </context>
    <context id="From2012-02-012012-02-02_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-02-01</startDate>
            <endDate>2012-02-02</endDate>
        </period>
    </context>
    <context id="AsOf2012-02-02_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-02-02</instant>
        </period>
    </context>
    <context id="AsOf2012-02-02_custom_OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-02-02</instant>
        </period>
    </context>
    <context id="AsOf2012-02-02_custom_OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-02-02</instant>
        </period>
    </context>
    <context id="AsOf2012-02-02_custom_OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-02-02</instant>
        </period>
    </context>
    <context id="AsOf2012-02-02_custom_OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-02-02</instant>
        </period>
    </context>
    <context id="AsOf2012-02-02_custom_WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-02-02</instant>
        </period>
    </context>
    <context id="AsOf2018-10-18_custom_HemogenyxPharmaceuticalsPLCMember_custom_SalesMilestoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:SalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:HemogenyxPharmaceuticalsPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-18</instant>
        </period>
    </context>
    <context id="AsOf2018-10-18_custom_HemogenyxPharmaceuticalsPLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:HemogenyxPharmaceuticalsPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-18</instant>
        </period>
    </context>
    <context id="From2018-11-232018-11-25_custom_HemogenyxPharmaceuticalsPLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:HemogenyxPharmaceuticalsPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-23</startDate>
            <endDate>2018-11-25</endDate>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_HemogenyxPharmaceuticalsPLCMember_custom_ResearchAndDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:HemogenyxPharmaceuticalsPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_HemogenyxPharmaceuticalsPLCMember_custom_ResearchAndDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:HemogenyxPharmaceuticalsPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2018-10-152018-10-16_custom_ImmuAgreementMember_custom_ImmugenyxLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:ImmuAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:ImmugenyxLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-16</endDate>
        </period>
    </context>
    <context id="AsOf2018-10-16_custom_ImmugenyxLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:ImmugenyxLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-16</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_ImmugenyxLLCMember_custom_ResearchAndDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:ImmugenyxLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ImmugenyxLLCMember_custom_ResearchAndDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ORGS:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:ImmugenyxLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2018-11-242018-11-25_custom_BgNegevTechnologiesAndApplicationsBgnMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:BgNegevTechnologiesAndApplicationsBgnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-24</startDate>
            <endDate>2018-11-25</endDate>
        </period>
    </context>
    <context id="From2018-11-242018-11-25_custom_BgNegevTechnologiesAndApplicationsBgnMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:BgNegevTechnologiesAndApplicationsBgnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-24</startDate>
            <endDate>2018-11-25</endDate>
        </period>
    </context>
    <context id="From2018-11-242018-11-25_custom_BgNegevTechnologiesAndApplicationsBgnMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:BgNegevTechnologiesAndApplicationsBgnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-24</startDate>
            <endDate>2018-11-25</endDate>
        </period>
    </context>
    <context id="AsOf2018-11-25_custom_BgNegevTechnologiesAndApplicationsBgnMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:BgNegevTechnologiesAndApplicationsBgnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-25</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CollaborationAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CollaborationAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_SponsoredResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:SponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ColumbiaLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:ColumbiaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_MarylandSubsidiaryMember_custom_AIPCellsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ORGS:MarylandSubsidiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:AIPCellsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CaliforniaUniversityJointResearchAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:CaliforniaUniversityJointResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CaerusTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ORGS:CaerusTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CaerusTherapeuticsIncMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ORGS:CaerusTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CaerusTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ORGS:CaerusTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_custom_ExtracellularVesicleMember_custom_EVAmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ORGS:ExtracellularVesicleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:EVAmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-04-07_srt_MaximumMember_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:TamirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:TamirPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-07</instant>
        </period>
    </context>
    <context id="From2020-04-062020-04-07_srt_MaximumMember_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:TamirBiotechnologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:TamirPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-06</startDate>
            <endDate>2020-04-07</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_TissueGenesisLLCMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:TissueGenesisLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-12-292020-12-31_custom_TissueGenesisLLCMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:TissueGenesisLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-29</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_BroadenJointVentureAgreementMember_custom_MarylandSubsidiaryMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:BroadenJointVentureAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:MarylandSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_BroadenJointVentureAgreementMember_custom_MarylandSubsidiaryMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:BroadenJointVentureAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:MarylandSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_BroadenJointVentureAgreementMember_custom_MarylandSubsidiaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:BroadenJointVentureAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:MarylandSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_srt_MinimumMember_custom_BroadenJointVentureAgreementMember_custom_MarylandSubsidiaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:BroadenJointVentureAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:MarylandSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_JointVentureAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:JointVentureAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_JointVentureAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:JointVentureAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-12-312022-01-01_custom_JointVentureAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:JointVentureAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_JointVentureAgreementMember_custom_KinerjapayCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ORGS:CollaborationAndLicenseAgreementsAxis">ORGS:JointVentureAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:KinerjapayCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-10-012019-12-31_custom_SBHSciencesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:SBHSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-10-31_custom_TLABSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:TLABSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="AsOf2020-10-31_custom_ButterflyBiosciencesSarlMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:ButterflyBiosciencesSarlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="AsOf2020-10-31_custom_KidneyCureJVAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:KidneyCureJVAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="AsOf2020-01-20_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-20</instant>
        </period>
    </context>
    <context id="From2020-01-192020-01-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
        </entity>
        <period>
            <startDate>2020-01-19</startDate>
            <endDate>2020-01-20</endDate>
        </period>
    </context>
    <context id="From2020-09-242020-09-26_custom_MergerAgreementMember_custom_KoligoTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:KoligoTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-24</startDate>
            <endDate>2020-09-26</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-26_custom_MergerAgreementMember_custom_KoligoTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ORGS:KoligoTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-26</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsAndWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ORGS:OptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_SharesUponConversionOfConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ORGS:SharesUponConversionOfConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2017-05-11_custom_TwoZeroOneSevenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ORGS:TwoZeroOneSevenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-11</instant>
        </period>
    </context>
    <context id="From2017-05-092017-05-11_srt_MaximumMember_custom_TwoZeroOneSevenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ORGS:TwoZeroOneSevenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-09</startDate>
            <endDate>2017-05-11</endDate>
        </period>
    </context>
    <context id="From2017-05-092017-05-11_custom_TwoZeroOneSevenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ORGS:TwoZeroOneSevenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-09</startDate>
            <endDate>2017-05-11</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_TwoZeroOneSevenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ORGS:TwoZeroOneSevenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_TwoZeroOneSevenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ORGS:TwoZeroOneSevenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2012-05-23_custom_GlobalShareIncentivePlanTwoZeroOneTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ORGS:GlobalShareIncentivePlanTwoZeroOneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-05-23</instant>
        </period>
    </context>
    <context id="From2012-05-212012-05-23_srt_MaximumMember_custom_GlobalShareIncentivePlanTwoZeroOneTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ORGS:GlobalShareIncentivePlanTwoZeroOneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-05-21</startDate>
            <endDate>2012-05-23</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_GlobalShareIncentivePlanTwoZeroOneTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ORGS:GlobalShareIncentivePlanTwoZeroOneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_GlobalShareIncentivePlanTwoZeroOneTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ORGS:GlobalShareIncentivePlanTwoZeroOneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_OneYearAnniversaryMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ORGS:OneYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ThreeEqualInstallmentsMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ORGS:ThreeEqualInstallmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_srt_MaximumMember_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_srt_MaximumMember_custom_OptionsGrantedToEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_srt_MaximumMember_custom_OptionsGrantedToEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_OptionsGrantedToEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_OptionsGrantedToEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFifteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFifteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSeventeenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSeventeenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSeventeenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSeventeenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEighteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEighteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToEmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_MasthercellGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:MasthercellGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_MasthercellGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:MasthercellGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_MasthercellGlobalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:MasthercellGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_OptionsGrantedToNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_OptionsGrantedToNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFifteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFifteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSeventeenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSeventeenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSeventeenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceSeventeenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEighteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEighteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">ORGS:OptionsGrantedToNonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ORGS:ExercisePriceNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-01-02_custom_PrivatePlacementSubscriptionAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:PrivatePlacementSubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-02</instant>
        </period>
    </context>
    <context id="From2020-01-012020-01-02_custom_PrivatePlacementSubscriptionAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:PrivatePlacementSubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-02</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_NonEmployeesMember_custom_SeveralConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeveralConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_NonEmployeesMember_custom_ConvertibleNotesAndPrivateInvestmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ORGS:ConvertibleNotesAndPrivateInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_SeveralConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:SeveralConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_srt_MinimumMember_custom_SeveralConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:SeveralConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_srt_MaximumMember_custom_SeveralConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:SeveralConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_SuccessFeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ORGS:SuccessFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-09-012019-09-30_custom_InvestorRelationContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-09-012019-09-30_custom_HeldUntilSixMonthsAnniversaryMember_custom_InvestorRelationContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ORGS:HeldUntilSixMonthsAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-09-012019-09-30_custom_HeldUntilOneYearAnniversaryMember_custom_InvestorRelationContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ORGS:HeldUntilOneYearAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-09-092019-09-30_custom_InvestorRelationContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-09</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-03-012019-03-31_custom_FirstChoiceInternationalCompanyIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:FirstChoiceInternationalCompanyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_FirstChoiceInternationalCompanyIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ORGS:FirstChoiceInternationalCompanyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-12-012018-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_VestedOnSigningDateMember_custom_InvestorRelationContactMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ORGS:VestedOnSigningDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_VestMonthlyOver3MonthsMember_custom_InvestorRelationContactMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ORGS:VestMonthlyOver3MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-12-012019-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-12-012018-12-31_custom_SeparateInvestorRelationsContactMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeparateInvestorRelationsContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_VestedOnSigningDateMember_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeparateInvestorRelationContactMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ORGS:VestedOnSigningDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_VestMonthlyOver3MonthsMember_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeparateInvestorRelationContactMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ORGS:VestMonthlyOver3MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeparateInvestorRelationContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-12-012019-12-31_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeparateInvestorRelationContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeparateInvestorRelationContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-11-30_custom_SeveralConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeveralConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="From2018-11-292018-11-30_custom_SeveralConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeveralConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-29</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-01-31_custom_ConsultingAgreementMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-01-31_custom_ConsultingAgreementMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="From2018-07-012018-07-31_custom_ConsultingAgreementMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-07-31_custom_ConsultingAgreementMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="From2017-12-012017-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:InvestorRelationContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2017-12-31_custom_VestedOnSigningDateMember_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeparateInvestorRelationContactMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ORGS:VestedOnSigningDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-12-31_custom_VestMonthlyOver3MonthsMember_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ORGS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:SeparateInvestorRelationContactMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ORGS:VestMonthlyOver3MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_country_IL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_country_IL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_country_BE_custom_TwoThousandTwentyOneToTwoThousandTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ORGS:TwoThousandTwentyOneToTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_country_BE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_country_BE_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_country_KR_custom_TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">ORGS:TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_country_KR_custom_UpToKrwTwoZeroBillionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">ORGS:UpToKrwTwoZeroBillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_country_KR_custom_UpToKrwThreeZeroZeroBillionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">ORGS:UpToKrwThreeZeroZeroBillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_country_KR_custom_TaxBaseAboveKrwThreeZeroZeroBillionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">ORGS:TaxBaseAboveKrwThreeZeroZeroBillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_country_KR_custom_SouthKoreanWonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ORGS:SouthKoreanWonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_country_KR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_PointOfCareServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:PointOfCareServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_PointOfCareServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ORGS:PointOfCareServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_MasterServicesAgreementsMember_custom_JointVenturePartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:JointVenturePartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ORGS:MasterServicesAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CustomerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ORGS:CustomerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CustomerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ORGS:CustomerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CustomerBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ORGS:CustomerBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CustomerBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ORGS:CustomerBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CustomerCRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ORGS:CustomerCRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CustomerCRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ORGS:CustomerCRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CustomerDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ORGS:CustomerDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CustomerDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ORGS:CustomerDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_SegmentContinuingOperationsMember_srt_ExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_SegmentContinuingOperationsMember_srt_ExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_BoardMembersMember_us-gaap_SegmentContinuingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:BoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_SegmentContinuingOperationsMember_custom_BoardMembersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:BoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_SegmentContinuingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_SegmentContinuingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CaerusTherapeuticsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:CaerusTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_CaerusTherapeuticsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ORGS:CaerusTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_SegmentDiscontinuedOperationsMember_srt_ExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_srt_ExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_srt_ExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_NonexecutiveDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:NonexecutiveDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_NonexecutiveDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460602</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ORGS:NonexecutiveDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Percentage">
        <measure>pure</measure>
    </unit>
    <unit id="Segment">
        <measure>ORGS:Segment</measure>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="KRW">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="NIS">
        <measure>iso4217:ILS</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-12-31">0001460602</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-12-31">false</dei:AmendmentFlag>
    <dei:EntityFilerCategory contextRef="From2020-01-01to2020-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-12-31">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0070"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueFromRelatedPartiesNoncurrent
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0082"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Investments
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl0086"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl0122"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl0137"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0145"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0163"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl0167"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:RedeemableNoncontrollingInterestOfDiscontinuedOperation
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0181"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl0213"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:ShareInNetIncomeOfAssociatedCompanies
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0366"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0375"
      unitRef="Shares"
      xsi:nil="true"/>
    <ORGS:IssuanceOfSharesAndWarrantsShares
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0392"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0401"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0418"
      unitRef="Shares"
      xsi:nil="true"/>
    <ORGS:StockbasedCompensationToStrategicCollaborations
      contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0430"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans
      contextRef="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans
      contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp
      contextRef="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp
      contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0454"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0488"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement
      contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0508"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0517"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0518"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0519"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0521"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0526"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0528"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0529"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0530"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0532"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:IssuanceOfSharesAndWarrants
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0535"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:IssuanceOfSharesAndWarrants
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:IssuanceOfSharesAndWarrants
      contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0538"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:IssuanceOfSharesAndWarrants
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0539"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:IssuanceOfSharesAndWarrants
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0541"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0548"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0549"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0550"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0552"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0557"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0559"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0560"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0561"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember"
      id="xdx2ixbrl0562"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0568"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0569"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0570"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0572"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0575"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0576"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0577"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0579"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0581"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0586"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0587"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0589"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:ShareBasedCompensationOne
      contextRef="From2020-01-01to2020-12-31"
      id="xdx2ixbrl0620"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:ShareBasedCompensationTwo
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0624"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0630"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:ShareInNetIncomeOfAssociatedCompanies
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0633"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0690"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0699"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0702"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:PaymentsForInvestments
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0705"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:RepaymentOfTreasuryStock
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0717"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="From2020-01-01to2020-12-31"
      id="xdx2ixbrl0719"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0723"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0729"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2020-01-01to2020-12-31"
      id="xdx2ixbrl0734"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2020-01-01to2020-12-31"
      id="xdx2ixbrl0755"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2020-01-01to2020-12-31"
      id="xdx2ixbrl0758"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="From2020-01-01to2020-12-31"
      id="xdx2ixbrl0773"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:AcquisitionOfOtherAssetInExchangeForCommonStocks
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0777"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0780"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0958"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal
      contextRef="From2020-01-01to2020-12-31"
      id="xdx2ixbrl0960"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0962"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0966"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="From2020-01-012020-12-31_custom_TechTransferServicesMember"
      id="xdx2ixbrl1048"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="From2020-01-012020-12-31_custom_CellManufacturingServicesMember"
      id="xdx2ixbrl1052"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_custom_AdvancePaymentMember"
      id="xdx2ixbrl1187"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2019-12-31_country_BE"
      id="xdx2ixbrl1209"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2019-12-31_country_US"
      id="xdx2ixbrl1221"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl1232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_custom_KyslecelTechnologyMember"
      id="xdx2ixbrl1258"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_custom_IPResearchAndDevelopmentMember"
      id="xdx2ixbrl1262"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansTwoMember"
      id="xdx2ixbrl1314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansThreeMember"
      id="xdx2ixbrl1326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="From2019-01-012019-12-31_custom_ConvertibleLoansTwoMember"
      id="xdx2ixbrl1356"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:DebtInstrumentConvertibleRepaidBeneficialConversionFeature
      contextRef="From2020-01-012020-12-31_custom_SixPercentageConvertibleLoansTwoMember"
      id="xdx2ixbrl1382"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:DebtInstrumentConvertibleRepaidBeneficialConversionFeature
      contextRef="From2020-01-012020-12-31_custom_EightPercetageConvertibleLoansTwoMember"
      id="xdx2ixbrl1394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2020-12-31_custom_ConvertibleLoansOneMember"
      id="xdx2ixbrl1403">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2020-12-31_custom_ConvertibleLoansTwoMember"
      id="xdx2ixbrl1417">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2019-04-30_custom_ConvertibleLoanAgreementMember_us-gaap_InvestorMember_custom_ConvertibleLoansOneMember"
      id="xdx2ixbrl1432">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:DebtCurrent
      contextRef="AsOf2020-12-31_custom_ShortTermLoanOneMember_currency_KRW"
      id="xdx2ixbrl1630"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtCurrent
      contextRef="AsOf2020-12-31_custom_ShortTermLoansTwoMember_currency_KRW"
      id="xdx2ixbrl1636"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtCurrent
      contextRef="AsOf2019-12-31_custom_ShortTermLoansThreeMember"
      id="xdx2ixbrl1644"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2019-12-31_country_US"
      id="xdx2ixbrl1762"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl1988"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:TreasuryStockShare
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl2064"
      unitRef="Shares"
      xsi:nil="true"/>
    <ORGS:WeightedAveragePriceNumberOfSharesTreasuryStock
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl2066"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember"
      id="xdx2ixbrl2221"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember"
      id="xdx2ixbrl2223"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember"
      id="xdx2ixbrl2224"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember"
      id="xdx2ixbrl2225"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember"
      id="xdx2ixbrl2247"
      unitRef="Shares"
      xsi:nil="true"/>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember"
      id="xdx2ixbrl2249"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixMember"
      id="xdx2ixbrl2314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSevenMember"
      id="xdx2ixbrl2321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSevenMember"
      id="xdx2ixbrl2322"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSevenMember"
      id="xdx2ixbrl2323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEightMember"
      id="xdx2ixbrl2328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEightMember"
      id="xdx2ixbrl2329"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEightMember"
      id="xdx2ixbrl2330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineMember"
      id="xdx2ixbrl2335"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTenMember"
      id="xdx2ixbrl2342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceElevenMember"
      id="xdx2ixbrl2349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwelveMember"
      id="xdx2ixbrl2356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThirteenMember"
      id="xdx2ixbrl2363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourteenMember"
      id="xdx2ixbrl2370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFifteenMember"
      id="xdx2ixbrl2377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixteenMember"
      id="xdx2ixbrl2384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSeventeenMember"
      id="xdx2ixbrl2391"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEighteenMember"
      id="xdx2ixbrl2398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineteenMember"
      id="xdx2ixbrl2405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwentyMember"
      id="xdx2ixbrl2412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember"
      id="xdx2ixbrl2494"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember"
      id="xdx2ixbrl2495"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember"
      id="xdx2ixbrl2499"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember"
      id="xdx2ixbrl2501"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember"
      id="xdx2ixbrl2505"
      unitRef="Shares"
      xsi:nil="true"/>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember"
      id="xdx2ixbrl2507"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceOneMember"
      id="xdx2ixbrl2531"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceOneMember"
      id="xdx2ixbrl2533"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwoMember"
      id="xdx2ixbrl2539"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwoMember"
      id="xdx2ixbrl2540"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixMember"
      id="xdx2ixbrl2566"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixMember"
      id="xdx2ixbrl2567"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixMember"
      id="xdx2ixbrl2568"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSevenMember"
      id="xdx2ixbrl2573"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSevenMember"
      id="xdx2ixbrl2574"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSevenMember"
      id="xdx2ixbrl2575"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEightMember"
      id="xdx2ixbrl2580"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineMember"
      id="xdx2ixbrl2587"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTenMember"
      id="xdx2ixbrl2594"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceElevenMember"
      id="xdx2ixbrl2601"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwelveMember"
      id="xdx2ixbrl2608"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThirteenMember"
      id="xdx2ixbrl2615"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThirteenMember"
      id="xdx2ixbrl2616"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThirteenMember"
      id="xdx2ixbrl2617"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourteenMember"
      id="xdx2ixbrl2622"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFifteenMember"
      id="xdx2ixbrl2629"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixteenMember"
      id="xdx2ixbrl2636"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSeventeenMember"
      id="xdx2ixbrl2643"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEighteenMember"
      id="xdx2ixbrl2650"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineteenMember"
      id="xdx2ixbrl2657"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2018-11-30_custom_SeveralConsultantsMember"
      id="xdx2ixbrl2755">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2018-01-31_custom_ConsultingAgreementMember_custom_ConsultantMember"
      id="xdx2ixbrl2763">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2018-07-31_custom_ConsultingAgreementMember_custom_ConsultantMember"
      id="xdx2ixbrl2772">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl2841"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:DeferredTaxAssetsLeasesAsset
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl2847"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:DeferredTaxAssetsLeaseLiability
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl2850"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl2861"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_custom_CustomerBMember"
      id="xdx2ixbrl2904"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:AccountsReceivableAcquisitionOfKoligo
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl2922"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue
      contextRef="From2020-01-01to2020-12-31"
      id="xdx2ixbrl2984"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet
      contextRef="From2019-01-012019-12-31_us-gaap_SegmentContinuingOperationsMember"
      id="xdx2ixbrl3024"
      unitRef="USD"
      xsi:nil="true"/>
    <ORGS:DueFromRelatedPartiesNoncurrent1
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl3051"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl3057"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl3059"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2020-01-01to2020-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2020-01-01to2020-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2020-01-01to2020-12-31">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2020-01-01to2020-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2020-01-01to2020-12-31">001-38416</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2020-01-01to2020-12-31">ORGENESIS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-01-01to2020-12-31">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2020-01-01to2020-12-31">98-0583166</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2020-01-01to2020-12-31">20271 Goldenrod Lane</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2020-01-01to2020-12-31">Germantown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2020-01-01to2020-12-31">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2020-01-01to2020-12-31">20876</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2020-01-01to2020-12-31">(480)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2020-01-01to2020-12-31">659-6404</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2020-01-01to2020-12-31">Common     Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2020-01-01to2020-12-31">ORGS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2020-01-01to2020-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2020-01-01to2020-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2020-01-01to2020-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2020-01-01to2020-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2020-01-01to2020-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness contextRef="From2020-01-01to2020-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-01-01to2020-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2020-01-01to2020-12-31">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-03-09" decimals="INF" unitRef="Shares">24199674</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityPublicFloat contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">105399427</dei:EntityPublicFloat>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">44923000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">107000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">645000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">467000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">3085000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">1831000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1070000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">382000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:GrantsReceivableCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">169000</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">204000</us-gaap:GrantsReceivableCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">185000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">136000</us-gaap:InventoryNet>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">75221000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">50077000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">78348000</us-gaap:AssetsCurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">296000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">299000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DueFromRelatedPartiesNoncurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">2623000</us-gaap:DueFromRelatedPartiesNoncurrent>
    <us-gaap:Investments contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">175000</us-gaap:Investments>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">3073000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">2305000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">13023000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">3348000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1474000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">725000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">8745000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">4812000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">821000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">35000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">27607000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">14147000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">77684000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">92495000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">8649000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">5549000</us-gaap:AccountsPayableCurrent>
    <ORGS:AccruedExpensesAndOtherPayablesCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">792000</ORGS:AccruedExpensesAndOtherPayablesCurrent>
    <ORGS:AccruedExpensesAndOtherPayablesCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">1615000</ORGS:AccruedExpensesAndOtherPayablesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">7000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1463000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">1672000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <ORGS:AdvancePaymentsOnAccountOfGrant contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">692000</ORGS:AdvancePaymentsOnAccountOfGrant>
    <ORGS:AdvancePaymentsOnAccountOfGrant contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">523000</ORGS:AdvancePaymentsOnAccountOfGrant>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">145000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">391000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">59000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">325000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">19000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">485000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">357000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ConvertibleDebtCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">3974000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">416000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">31586000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">16285000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">42434000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1020000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">455000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">7200000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">12143000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">74000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">41000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">58000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">64000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">313000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">331000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">8671000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">13028000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">24956000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">55462000</us-gaap:Liabilities>
    <ORGS:RedeemableNoncontrollingInterestOfDiscontinuedOperation contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">30955000</ORGS:RedeemableNoncontrollingInterestOfDiscontinuedOperation>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2019-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">145833334</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">145833334</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">24223093</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">24223093</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">16140962</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">16140962</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">140397000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">94691000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">748000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">213000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockShares contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">55309</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">250000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">-88319000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">-89429000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">52579000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">5477000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">149000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">601000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">52728000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">6078000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">77684000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">92495000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">6177000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">2629000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromRelatedParties
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1475000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">1270000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:Revenues
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">7652000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">3899000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">83986000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">14014000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">478000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">430000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">18973000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">11451000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherOperatingIncome
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">4000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">21000</us-gaap:OtherOperatingIncome>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">95781000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">21975000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1061000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">843000</us-gaap:OtherNonoperatingIncomeExpense>
    <ORGS:ShareInNetIncomeOfAssociatedCompanies
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">106000</ORGS:ShareInNetIncomeOfAssociatedCompanies>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">96736000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">22818000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1609000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">229000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">95127000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">22589000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-95706000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">3452000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-579000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">26041000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">39000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">99000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">492000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">1821000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-1110000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">24121000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="USDPShares">4.46</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="USDPShares">1.41</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="USDPShares">-4.75</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="USDPShares">0.36</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.29</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="USDPShares">1.77</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="Shares">21320314000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="Shares">15907995000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <ORGS:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">95127000</ORGS:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests>
    <ORGS:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">22589000</ORGS:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests>
    <ORGS:IncomeLossesFromDiscontinuedOperationNetOfTax
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-95706000</ORGS:IncomeLossesFromDiscontinuedOperationNetOfTax>
    <ORGS:IncomeLossesFromDiscontinuedOperationNetOfTax
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">3452000</ORGS:IncomeLossesFromDiscontinuedOperationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-341000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">456000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <ORGS:OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-194000</ORGS:OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary>
    <ORGS:ComprehensiveIncomeNetOfTaxes
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-1114000</ORGS:ComprehensiveIncomeNetOfTaxes>
    <ORGS:ComprehensiveIncomeNetOfTaxes
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">26497000</ORGS:ComprehensiveIncomeNetOfTaxes>
    <ORGS:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-39000</ORGS:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations>
    <ORGS:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-99000</ORGS:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations>
    <ORGS:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-492000</ORGS:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations>
    <ORGS:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-1821000</ORGS:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-1645000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">24577000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2018-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15540333</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2018-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">90597000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2018-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">669000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-65163000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2018-12-31_custom_EquityAttributedToOrgenesisIncMember"
      decimals="-3"
      unitRef="USD">26105000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2018-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      unitRef="USD">645000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-12-31" decimals="-3" unitRef="USD">26750000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">2106000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-12-31_custom_EquityAttributedToOrgenesisIncMember"
      decimals="-3"
      unitRef="USD">2106000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      unitRef="USD">58000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">2164000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">75629</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">893000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-01-012019-12-31_custom_EquityAttributedToOrgenesisIncMember"
      decimals="-3"
      unitRef="USD">893000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">893000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <ORGS:StockbasedCompensationToStrategicCollaborationsShares
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">525000</ORGS:StockbasedCompensationToStrategicCollaborationsShares>
    <ORGS:StockbasedCompensationToStrategicCollaborations
      contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">2641000</ORGS:StockbasedCompensationToStrategicCollaborations>
    <ORGS:StockbasedCompensationToStrategicCollaborations
      contextRef="From2019-01-012019-12-31_custom_EquityAttributedToOrgenesisIncMember"
      decimals="-3"
      unitRef="USD">2641000</ORGS:StockbasedCompensationToStrategicCollaborations>
    <ORGS:StockbasedCompensationToStrategicCollaborations
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">2641000</ORGS:StockbasedCompensationToStrategicCollaborations>
    <ORGS:IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans
      contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">515000</ORGS:IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans>
    <ORGS:IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans
      contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-145000</ORGS:IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans>
    <ORGS:IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans
      contextRef="From2019-01-012019-12-31_custom_EquityAttributedToOrgenesisIncMember"
      decimals="-3"
      unitRef="USD">370000</ORGS:IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans>
    <ORGS:IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">370000</ORGS:IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans>
    <ORGS:AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp
      contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">2034000</ORGS:AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp>
    <ORGS:AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp
      contextRef="From2019-01-012019-12-31_custom_EquityAttributedToOrgenesisIncMember"
      decimals="-3"
      unitRef="USD">2034000</ORGS:AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp>
    <ORGS:AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">2034000</ORGS:AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">-4095000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2019-01-012019-12-31_custom_EquityAttributedToOrgenesisIncMember"
      decimals="-3"
      unitRef="USD">-4095000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-4095000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2019-01-012019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-456000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-24121000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2019-01-012019-12-31_custom_EquityAttributedToOrgenesisIncMember"
      decimals="-3"
      unitRef="USD">-24577000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      unitRef="USD">-102000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-24679000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">16140962</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">94691000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">213000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-89429000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_custom_EquityAttributedToOrgenesisIncMember"
      decimals="-3"
      unitRef="USD">5477000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      unitRef="USD">601000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">6078000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">16140962</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">94691000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">213000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-89429000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_custom_EquityAttributedToOrgenesisIncMember"
      decimals="-3"
      unitRef="USD">5477000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      unitRef="USD">601000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">6078000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">1470000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember"
      decimals="-3"
      unitRef="USD">1470000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1470000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000502"
      unitRef="Shares">270174</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">1376000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember"
      decimals="-3"
      unitRef="USD">1377000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1377000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <ORGS:StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3400000</ORGS:StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares>
    <ORGS:StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">17748000</ORGS:StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement>
    <ORGS:StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement
      contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember"
      decimals="-3"
      unitRef="USD">17748000</ORGS:StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement>
    <ORGS:StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">17748000</ORGS:StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">83334</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember"
      decimals="-3"
      unitRef="USD">300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">42000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember"
      decimals="-3"
      unitRef="USD">42000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">42000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <ORGS:IssuanceOfSharesAndWarrantsShares
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2200000</ORGS:IssuanceOfSharesAndWarrantsShares>
    <ORGS:IssuanceOfSharesAndWarrants
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">8438000</ORGS:IssuanceOfSharesAndWarrants>
    <ORGS:IssuanceOfSharesAndWarrants
      contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember"
      decimals="-3"
      unitRef="USD">8438000</ORGS:IssuanceOfSharesAndWarrants>
    <ORGS:IssuanceOfSharesAndWarrants
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">8438000</ORGS:IssuanceOfSharesAndWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2128623</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">11172000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember"
      decimals="-3"
      unitRef="USD">11172000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">11172000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      unitRef="USD">413000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">413000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">5160000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember"
      decimals="-3"
      unitRef="USD">5160000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">5160000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">-55309</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">250000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">535000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">1110000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-12-31_custom_EquityAttributedToOrgenesisIncMember"
      decimals="-3"
      unitRef="USD">1645000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      unitRef="USD">-39000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1606000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">24167784</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">3000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">140397000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">748000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember"
      decimals="-3"
      unitRef="USD">-250000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-88319000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_custom_EquityAttributedToOrgenesisIncMember"
      decimals="-3"
      unitRef="USD">52579000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      unitRef="USD">149000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">52728000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-579000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">26041000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">2847000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">3057000</us-gaap:ShareBasedCompensation>
    <ORGS:ShareBasedCompensationOne
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">2641000</ORGS:ShareBasedCompensationOne>
    <ORGS:ShareBasedCompensationTwo
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">17048000</ORGS:ShareBasedCompensationTwo>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-22000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">29000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">96918000</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
    <ORGS:ShareInNetIncomeOfAssociatedCompanies
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">106000</ORGS:ShareInNetIncomeOfAssociatedCompanies>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1435000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">3806000</us-gaap:DepreciationAndAmortization>
    <ORGS:IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-618000</ORGS:IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances>
    <ORGS:IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">214000</ORGS:IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances>
    <ORGS:NetChangesInOperatingLeases
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-14000</ORGS:NetChangesInOperatingLeases>
    <ORGS:NetChangesInOperatingLeases
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">339000</ORGS:NetChangesInOperatingLeases>
    <us-gaap:InterestExpenseShortTermBorrowings
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">927000</us-gaap:InterestExpenseShortTermBorrowings>
    <us-gaap:InterestExpenseShortTermBorrowings
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">387000</us-gaap:InterestExpenseShortTermBorrowings>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1350000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">5308000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">84000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">414000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">24000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">46000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1073000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">112000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1985000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">4626000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <ORGS:IncreaseDecreaseInAccuredExpensesAndOtherPayables
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-1156000</ORGS:IncreaseDecreaseInAccuredExpensesAndOtherPayables>
    <ORGS:IncreaseDecreaseInAccuredExpensesAndOtherPayables
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">271000</ORGS:IncreaseDecreaseInAccuredExpensesAndOtherPayables>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-170000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">474000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-166000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">3536000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <ORGS:IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">140000</ORGS:IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant>
    <ORGS:IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-247000</ORGS:IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1378000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-304000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-78046000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-13220000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromPaymentsForLongTermLoansForRelatedParties
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-500000</us-gaap:ProceedsFromPaymentsForLongTermLoansForRelatedParties>
    <us-gaap:ProceedsFromPaymentsForLongTermLoansForRelatedParties
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-1500000</us-gaap:ProceedsFromPaymentsForLongTermLoansForRelatedParties>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">3000000</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">7000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">79000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1525000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">12129000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">955000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">105634000</us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates>
    <ORGS:PaymentsForInvestments
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">69000</ORGS:PaymentsForInvestments>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-18000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">228000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">105610000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-13778000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <ORGS:RepaymentOfTreasuryStock
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">250000</ORGS:RepaymentOfTreasuryStock>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">13200000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">8738000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">250000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">11400000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">2400000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">457000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">772000</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">270000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">5881000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">24098000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">33445000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-2900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">82000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-58000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">12041000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2018-12-31" decimals="-3" unitRef="USD">14999000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">45568000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">12041000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">157000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">156000</us-gaap:IncomeTaxesPaidNet>
    <ORGS:FinanceLeasesOfPropertyPlantAndEquipment
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">366000</ORGS:FinanceLeasesOfPropertyPlantAndEquipment>
    <ORGS:FinanceLeasesOfPropertyPlantAndEquipment
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">355000</ORGS:FinanceLeasesOfPropertyPlantAndEquipment>
    <ORGS:RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">967000</ORGS:RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities>
    <ORGS:RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">8229000</ORGS:RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities>
    <ORGS:PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">241000</ORGS:PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable>
    <ORGS:PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">1584000</ORGS:PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">546000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <ORGS:AcquisitionOfOtherAssetInExchangeForCommonStocks
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">700000</ORGS:AcquisitionOfOtherAssetInExchangeForCommonStocks>
    <ORGS:IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">11172000</ORGS:IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_809_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z1wFQBsa56jj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
1 &#x2013; &lt;span id="xdx_82E_zKn9KP3uNTw5"&gt;DESCRIPTION OF BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;a.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;General&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Orgenesis
Inc., a Nevada corporation, is a global biotech company working to unlock the potential of cell and gene therapies in an affordable
and accessible format (&#x201c;CGTs&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;CGTs
can be centered on autologous (using the patient&#x2019;s own cells) or allogenic (using master banked donor cells) and are part
of a class of medicines referred to as advanced therapy medicinal products (ATMP). The Company mostly focusses on autologous therapies,
with processes and systems that are developed for each therapy using a closed and automated processing system approach that is
validated for compliant production near the patient at their point of care for treatment of the patient. This approach has the
potential to overcome the limitations of traditional commercial manufacturing methods that do not translate well to commercial
production of advanced therapies due to their cost prohibitive nature and complex logistics to deliver the treatments to patients
(ultimately limiting the number of patients that can have access to, or can afford, these therapies).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;To
achieve these goals, the Company has developed a Point of Care Platform comprised of three enabling components: a pipeline of
licensed &lt;b&gt;POCare Therapies&lt;/b&gt; that are designed to be processed and produced in closed, automated &lt;b&gt;POCare Technology&lt;/b&gt;
systems across a collaborative &lt;b&gt;POCare Network&lt;/b&gt;. Via a combination of science, technology, engineering, and networking, the
Company is working to provide a more efficient and scalable pathway for advanced therapies to reach patients more rapidly at lowered
costs. The Company also draws on extensive medical expertise to identify promising new autologous therapies to leverage within
the POCare Platform either via ownership or licensing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
POCare Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide with a goal of
achieving harmonized, regulated clinical development and production of the therapies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Over
time, the Company has worked to develop and validate POCare Technologies that can be combined within mobile production units for
advanced therapies. In 2020, the Company made significant investments in the development of several types of Orgenesis Mobile
Processing Units and Labs (OMPULs) with the expectation of use and/or distribution through our POCare Network of partners, collaborators,
and joint ventures. As of the date of this report, the OMPULs are still in the development stage.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;OMPULs
are designed for the purpose of validation, development, performance of clinical trials, manufacturing and/or processing of potential
or approved cell and gene therapy products in a safe, reliable, and cost-effective manner at the point of care, as well as the
manufacturing of such CGTs in a consistent and standardized manner in all locations. The design delivers a potential industrial
solution for the Company to deliver CGTs to practically any clinical institution at the point of care.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Until
December 31, 2019, the Company operated the POCare Platform as one of two business separate business segments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Historically,
the second separate business segment was operated as a Contract Development and Manufacturing Organization (&#x201c;CDMO&#x201d;)
platform, providing contract manufacturing and development services for biopharmaceutical companies (the &#x201c;CDMO Business&#x201d;).
The CDMO platform was historically operated mainly through majority owned Masthercell Global (which consisted of the following
two subsidiaries: MaSTherCell S.A. in Belgium (&#x201c;MaSTherCell&#x201d;), and Masthercell U.S., LLC in the United States (&#x201c;Masthercell
U.S.&#x201d;) (collectively, the &#x201c;Masthercell Global Subsidiaries&#x201d;)).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
February 2020, the Company and GPP-II Masthercell LLC (&#x201c;GPP&#x201d;) sold &lt;span id="xdx_90F_ecustom--PercentageOfOutstandingEquityInterests_iI_pii_dp_uPercentage_c20200229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zc8EpBAWrAUa" title="Percentage of outstanding equity interests"&gt;100%&lt;/span&gt; of the outstanding equity interests of Masthercell
(the &#x201c;Masthercell Business&#x201d;), which comprised the majority of the Company&#x2019;s CDMO Business, to Catalent Pharma
Solutions, Inc. for an aggregate nominal purchase price of $&lt;span id="xdx_907_ecustom--AggregateNominalPurchasePrice_pn5n6_c20200201__20200229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z7YHP7JDTwFk" title="Aggregate nominal purchase price of outstanding equity interests"&gt;315&lt;/span&gt; million, (the &#x201c;Masthercell Sale&#x201d;). After accounting
for GPP&#x2019;s liquidation preference and equity stake in Masthercell as well as other investor interests in our Belgian subsidiary
MaSTherCell, distributions to Masthercell option holders and transaction costs, the company received approximately $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20200201__20200229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zhYswqhZwNic" title="Proceeds from Issuance or Sale of Equity"&gt;126.7&lt;/span&gt; million.
The Company incurred an additional approximately $&lt;span id="xdx_906_ecustom--TransactionCostIncurred_pn5n6_c20200201__20200229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zV1ELPSMkbZ3" title="Transaction cost incurred"&gt;5.6&lt;/span&gt; million in transaction costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company determined that the Masthercell Business (&#x201c;Discontinued Operation&#x201d;) meets the criteria to be classified as
a discontinued operation as of the first quarter of 2020. The Discontinued Operation includes the vast majority of the previous
CDMO Business, including majority-owned Masthercell, including MaSTherCell, Masthercell U.S. and all of the Masthercell Global
Subsidiaries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Since
the Masthercell Sale, the Company has entered into new joint venture agreements with new partners in various jurisdictions. This
has allowed the Company to grow its infrastructure and expand its processing sites into new markets and jurisdictions. In addition,
the Company has engaged some of these joint venture partners to perform research and development services to further develop and
adapt its systems and devices for specific purposes. The Company has been investing manpower and financial resources to focus
on developing, manufacturing and rolling out several types of OMPULs to be used and/or distributed through our POCare Network
of partners, collaborators, and joint ventures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Chief Executive Officer (&#x201c;CEO&#x201d;) is the Company&#x2019;s chief operating decision-maker who reviews financial
information prepared on a consolidated basis. Effective from the first quarter of 2020, all of our continuing operations
are in one segment, being the point-of-care business via our POCare Platform. Therefore, no segment report has been
presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company currently conducts its core CGT business operations through itself and its subsidiaries which are all wholly-owned except
as otherwise stated (collectively, the &#x201c;Subsidiaries&#x201d;). The Subsidiaries are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;United
    States: Orgenesis Maryland Inc. (the &#x201c;U.S. Subsidiary&#x201d;) is the center of activity in North America currently focused
    on setting up of the POCare Network.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Koligo
    Therapeutics Inc. (&#x201c;Koligo&#x201d;) is a Kentucky corporation that was acquired in 2020 and is currently focused on developing
    the POCare network and therapies (See Note 4 for the acquisition of Koligo).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;European
    Union: Orgenesis Belgium SRL (the &#x201c;Belgian Subsidiary&#x201d;) is the center of activity in Europe currently focused
    on process development and preparation of European clinical trials.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Orgenesis
    Switzerland Sarl (the &#x201c;Swiss subsidiary) incorporated in October 2020 is currently focused on providing management services
    to the Company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Israel:
    Orgenesis Ltd. (the &#x201c;Israeli Subsidiary&#x201d;) is a provider of regulatory, clinical and pre-clinical services, and
    Orgenesis Biotech Israel Ltd. (&#x201c;OBI&#x201d;) previously known as Atvio Biotech Ltd. (&#x201c;Atvio&#x201d;) is a provider
    of cell-processing services in Israel.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Korea:
    Orgenesis Korea Co. Ltd. (the &#x201c;Korean Subsidiary&#x201d;), previously known as CureCell Co. Ltd., is a provider of processing
    and pre-clinical services in Korea. The Company owns &lt;span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CureCellCoLtdMember_zg6wD7RHx4Pb" title="Equity Method Investment, Ownership Percentage"&gt;94.12%&lt;/span&gt; of the Korean Subsidiary.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
consolidated financial statements include the accounts of Orgenesis Inc. and its subsidiaries including the Discontinued Operation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
April 7, 2020, the Company entered into an Asset Purchase Agreement (the &#x201c;Tamir Purchase Agreement&#x201d;) with Tamir Biotechnology,
Inc. (&#x201c;Tamir&#x201d; or &#x201c;Seller&#x201d;), pursuant to which the Company agreed to acquire certain assets and liabilities
of Tamir related to the discovery, development and testing of therapeutic products for the treatment of diseases and conditions
in humans, including all rights to Ranpirnase and use for antiviral therapy (collectively, the &#x201c;Purchased Assets and Assumed
Liabilities&#x201d; and such acquisition, the &#x201c;Tamir Transaction&#x201d;). The Tamir Transaction closed on April 23, 2020.
As aggregate consideration for the acquisition, the Company paid $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pn5n6_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zd5O51mhgaTc" title="Stock issued during period value acquisitions"&gt;2.5&lt;/span&gt; million in cash and issued an aggregate of &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_pii" title="Shares issued, acquisition"&gt;3,400,000&lt;/span&gt; shares
(the &#x201c;Shares&#x201d;) of Common Stock to Tamir resulting in a total consideration of $&lt;span id="xdx_90F_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zJNhl0Q0aX61" title="Business Combination, Consideration Transferred"&gt;20.2&lt;/span&gt; million (See Note 4).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s common stock, par value $&lt;span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_c20201231_pii" title="Common Stock, Par or Stated Value Per Share"&gt;0.0001&lt;/span&gt; per share (the &#x201c;Common Stock&#x201d;) is listed and traded on the Nasdaq
Capital Market under the symbol &#x201c;ORGS.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
used in this report and unless otherwise indicated, the term &#x201c;Company&#x201d; refers to Orgenesis Inc. and its Subsidiaries.
Unless otherwise specified, all amounts are expressed in United States Dollars.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;b.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of December 31, 2020 ,the Company has accumulated losses of approximately $&lt;span id="xdx_900_ecustom--AccumulatedDeficit_iI_pn5n6_c20201231_zdiUdTmPhuKi" title="Accumulated losses"&gt;88&lt;/span&gt; Million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
February 10, 2020, the Company received approximately $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20200209__20200210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zzFiFZu6z6j7"&gt;126.7
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million, of which $&lt;span id="xdx_90B_ecustom--RepaymentOfIntercompanyLoansAndPayables_pn5n6_c20200209__20200210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z49SNnFE192l"&gt;7.2
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million was used for the repayment of
intercompany loans and payables, from the Masthercell Sale (See Note 3). In addition, on January 20, 2020, the Company
entered into a Securities Purchase Agreement with certain investors pursuant to which the Company received gross proceeds of approximately
$&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn4n6_uUSD_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zf3ZAztQ34Ul"&gt;9.24
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million before deducting related offering
expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company invested significant resources in research and development and research and development services in 2020. The Company
believes that these investments will enable it to substantially increase revenues in the next 12 months. Based on its current
cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and
expected level of expenditures for at least 12 months from the date of the issuance of these financial statements. If there are
further increases in operating costs for facilities expansion, research and development, commercial and clinical activity or decreases
in revenues from customers, the Company may decide to seek additional financing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <ORGS:PercentageOfOutstandingEquityInterests
      contextRef="AsOf2020-02-29_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="Percentage">1</ORGS:PercentageOfOutstandingEquityInterests>
    <ORGS:AggregateNominalPurchasePrice
      contextRef="From2020-02-012020-02-29_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      unitRef="USD">315000000</ORGS:AggregateNominalPurchasePrice>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2020-02-012020-02-29_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      unitRef="USD">126700000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <ORGS:TransactionCostIncurred
      contextRef="From2020-02-012020-02-29_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      unitRef="USD">5600000</ORGS:TransactionCostIncurred>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2020-12-31_custom_CureCellCoLtdMember"
      decimals="INF"
      unitRef="Percentage">0.9412</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember"
      decimals="-5"
      unitRef="USD">2500000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">3400000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember"
      decimals="-5"
      unitRef="USD">20200000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <ORGS:AccumulatedDeficit contextRef="AsOf2020-12-31" decimals="-5" unitRef="USD">88000000</ORGS:AccumulatedDeficit>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2020-02-092020-02-10_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      unitRef="USD">126700000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <ORGS:RepaymentOfIntercompanyLoansAndPayables
      contextRef="From2020-02-092020-02-10_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      unitRef="USD">7200000</ORGS:RepaymentOfIntercompanyLoansAndPayables>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2020-01-192020-01-20_custom_SecuritiesPurchaseAgreementMember"
      decimals="-4"
      unitRef="USD">9240000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zJBSMdfeMNv7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
2 - &lt;span&gt;&lt;span id="xdx_829_z2Cc0yIxfPkf"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The consolidated financial
statements are prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--UseOfEstimates_zoTqjeGUG1E3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;a.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86F_zmuEvKVDb2R9"&gt;Use of Estimates in the Preparation of Financial Statements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30.6pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
preparation of our consolidated financial statements in conformity with U.S. GAAP requires us to make estimates, judgments
and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure
of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, judgments and methodologies. We base our
estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form
the basis for making judgments about the carrying values of assets, liabilities and equity, the amount of revenues and expenses
and determining whether an acquisition is a business combination or a purchase of asset. Actual results could differ from those
estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial
condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning
COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and
international customers and markets. We examined the impact of COVID-19 on our financial statements, and although there is currently
no major impact, there may be changes to those estimates in future periods. Actual results may differ from these estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--BusinessCombinationsPolicy_zASBMmgcRifh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;b.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_864_zIV8aZ9zoWC7"&gt;Business Combination&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company allocates the purchase price of an acquired business to the tangible and intangible assets acquired and liabilities assumed
based upon their estimated fair values on the acquisition date. Any excess of the purchase price over the fair value of the net
assets acquired is recorded as goodwill. Acquired in-process backlog, customer relations, technology, IPR&amp;amp;D, brand name and
know how are recognized at fair value. The purchase price allocation process requires management to make significant estimates
and assumptions, especially at the acquisition date with respect to intangible assets. Direct transaction costs associated with
the business combination are expensed as incurred. The allocation of the consideration transferred in certain cases may be subject
to revision based on the final determination of fair values during the measurement period, which may be up to one year from the
acquisition date. The Company includes the results of operations of the business that it has acquired in its consolidated results
prospectively from the date of acquisition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;If
the business combination is achieved in stages, the acquisition date carrying value of the acquirer&#x2019;s previously held equity
interest in the acquire is re-measured to fair value at the acquisition date; any gains or losses arising from such re-measurement
are recognized in profit or loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--OtherInvestmentsPolicyTextBlock_zxa4jeXJtTJ5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;c.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_862_zEX2xcZFX5Og"&gt;Other Investments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;For
other investments, the Company applies the measurement alternative upon the adoption of ASU 2016-01, and elected to record equity
investments without readily determinable fair values at cost, less impairment, adjusted for subsequent observable price changes.
In this measurement alternative method, changes in the carrying value of the equity investments are reflected in current earnings.
Changes in the carrying value of the equity investment are required to be made whenever there are observable price changes in
orderly transactions for the identical or similar investment of the same issuer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--DiscontinuedOperationsPolicyTextBlock_z0tAJNQJEqF6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;d.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_866_zT2nEPd7Xj7l"&gt;Discontinued operations&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Upon
divestiture of a business, the Company classifies such business as a discontinued operation, if the divested business represents
a strategic shift that has (or will have) a major effect on an entity&#x2019;s operations and financial results. For disposals
other than by sale such as abandonment, the results of operations of a business would not be recorded as a discontinued operation
until the period in which the business is actually abandoned.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Masthercell Business divestiture qualifies as a discontinued operation and therefore has been presented as such.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
results of businesses that have qualified as a discontinued operation have been presented as such for all reporting periods. Results
of discontinued operations include all revenues and expenses directly derived from such businesses; general corporate overhead
is not allocated to discontinued operations. Any loss or gain that arose from the divestiture of a business that qualifies as
discontinued operations is included within the results of the discontinued operations. The Company included information regarding
cash flows from discontinued operations (See Note 3).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zGbbnJW7W7Ok" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;e.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_864_z5uAMJlNwL1"&gt;Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company considers cash equivalents to be all short-term, highly liquid investments, which include money market instruments, that
are not restricted as to withdrawal or use, and short-term bank deposits with original maturities of three months or less from
the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_z0k9DUhdcDQ3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;f.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_865_zd0MD2bxejCe"&gt;Cost of research and development and research and development services, net &lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cost
of research and development and research and development services include costs directly attributable to the conduct of research
and development activities, including the cost of salaries, stock-based compensation expenses, payroll taxes and other employees&#x2019;
benefits, lab expenses, consumable equipment, courier fees, travel expenses, professional fees and consulting fees. All costs
associated with research and developments are expensed as incurred. Participation from government departments and from research
foundations for development of approved projects is recognized as a reduction of expense as the related costs are incurred. Research
and development in-process acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative
future use, is expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ConsolidationPolicyTextBlock_z58jOYQ7GVW2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;g.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86B_zFu2oE6YT6Md"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
consolidated financial statements include the accounts of the Company and its Subsidiaries. All intercompany transactions and
balances have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--EquityMethodInvestmentsPolicy_z6a50xTL5SCf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;h.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_869_zNyNwcNiwFv5"&gt;Non-Marketable Equity Investments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s investments in certain non-marketable equity securities in which it has the ability to exercise significant influence,
but it does not control through variable interests or voting interests. These are accounted for under the equity method of accounting
and presented as Investment in associates, net, in the Company&#x2019;s consolidated balance sheets. Under the equity method, the
Company recognizes its proportionate share of the comprehensive income or loss of the investee. The Company&#x2019;s share of income
and losses from equity method investments is included in share in losses of associated company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company reviews its investments accounted for under the equity method for possible impairment, which generally involves an analysis
of the facts and changes in circumstances influencing the investments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--FunctionalCurrencyPolicyTextBlock_zoWTiL5Cyoh8" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;i.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86E_zugML1cnvI3l"&gt;Functional Currency&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
currency of the primary economic environment in which the operations of the Company and part of its Subsidiaries are conducted
is the U.S. dollar (&#x201c;$&#x201d; or &#x201c;dollar&#x201d;). The functional currency of the Belgian Subsidiaries is the Euro
(&#x201c;&#x20ac;&#x201d; or &#x201c;Euro&#x201d;). The functional currency of Orgenesis Korea is the Won (&#x201c;KRW&#x201d;). Most
of the Company&#x2019;s expenses are incurred in dollars, and the source of the Company&#x2019;s financing has been provided in
dollars. Thus, the functional currency of the Company and its other subsidiaries is the dollar. Transactions and balances originally
denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using
historical and current exchange rates for nonmonetary and monetary balances, respectively. For foreign transactions and other
items reflected in the statements of operations, the following exchange rates are used: (1) for transactions &#x2013; exchange
rates at transaction dates or average rates and (2) for other items (derived from nonmonetary balance sheet items such as depreciation)
&#x2013; historical exchange rates. The resulting transaction gains or losses are recorded as financial income or expenses. The
financial statements of the Belgian Subsidiaries and Orgenesis Korea are included in the consolidated financial statements, translated
into U.S. dollars. Assets and liabilities are translated at year-end exchange rates, while revenues and expenses are translated
at yearly average exchange rates during the year. Differences resulting from translation of assets and liabilities are presented
as other comprehensive income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zbJ1zWty11Zh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;j.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86A_zLI2WVvdPIy5"&gt;Inventory&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s inventory consists of raw material for use for the services provided. The Company periodically evaluates the quantities
on hand. Cost of the raw materials is determined using the weighted average cost method. The inventory is recorded at the lower
of cost or net realizable value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrb5SiWXpmAg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;k.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_868_z7qU0zEBmU38"&gt;Property, plant and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Property,
plant and equipment are recorded at cost and depreciated by the straight-line method over the estimated useful lives of the related
assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_ecustom--ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock_zh1n2tVBzNya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Annual
rates of depreciation are presented in the table below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BF_z2zA03goEqb4" style="display: none"&gt;SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Useful Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Production facility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 32%; text-align: center"&gt;&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember__srt--RangeAxis__srt--MinimumMember_zrZKyWqXBHH3" title="Weighted Average Useful Life"&gt;5&lt;/span&gt; - &lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember__srt--RangeAxis__srt--MaximumMember_zvU9vrNQ1Hj2" title="Weighted Average Useful Life"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zxVC4f2PFcZh" title="Weighted Average Useful Life"&gt;2&lt;/span&gt; - &lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zY76Fk7sDRRg" title="Weighted Average Useful Life"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office equipment and computers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zN3XZviUAKbe" title="Weighted Average Useful Life"&gt;3&lt;/span&gt; - &lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zZhJXWuhWnrf" title="Weighted Average Useful Life"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A2_z9w1ZtH7Elsl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zMSnFezUZica" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;l.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_863_zJ3WcX5X9dV7"&gt;Intangible assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock_zbOYS9vpY4p6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible
assets and their useful lives are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B8_zEKSONEQ5FDi" style="display: none"&gt;SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Useful Life (Years)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortization Recorded at Comprehensive&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Loss Line Item&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left"&gt;Customer Relationships&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%; text-align: center"&gt;&lt;span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zO06hxwW9q0a" title="Intangible assets and useful lives (Years)"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 44%; text-align: center"&gt;Amortization of intangible assets&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Know-How&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowhowMember_zcXooVGZJTe5" title="Intangible assets and useful lives (Years)"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Amortization of intangible assets&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Technology&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TechnologyMember_zEsA4tuODn0k" title="Intangible assets and useful lives (Years)"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Amortization of intangible assets&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A6_z9WCdJJlXZr2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible
assets are recorded at acquisition less accumulated amortization and impairment. Definite lived intangible assets are amortized
over their estimated useful life using the straight-line method, which is determined by identifying the period over which the
cash flows from the asset are expected to be generated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zi7iV6mHs2b9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;m.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_865_zd6VISbnwa5e"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Goodwill represents
the excess of consideration transferred over the value assigned to the net tangible and identifiable intangible assets of businesses
acquired. Goodwill is allocated to reporting units expected to benefit from the business combination. Goodwill is not amortized
but rather tested for impairment at least annually in the fourth quarter, or more frequently if events
or changes in circumstances indicate that goodwill may be impaired. Following the sale of Masthercell the Company manages
the business as one operating segment and one reporting unit. Goodwill impairment is recognized when the quantitative assessment
results in the carrying value exceeding the fair value, in which case an impairment charge is recorded to the extent the
carrying value exceeds the fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;There
were &lt;span id="xdx_90E_eus-gaap--GoodwillImpairmentLoss_pn5n6_do_c20200101__20201231_zPR5LqcFQzkg"&gt;no&lt;/span&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;impairment
charges to goodwill during the periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zrrNaOitkMu6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;n.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_866_zOv0AtkRWS3g"&gt;Impairment of Long-lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company reviews its property, plants and equipment, intangible assets subject to amortization and other long-lived assets for
impairment whenever events or changes in circumstances indicate that the carrying amount of an asset class may not be recoverable.
Indicators of potential impairment include: an adverse change in legal factors or in the business climate that could affect the
value of the asset; an adverse change in the extent or manner in which the asset is used or is expected to be used, or in its
physical condition; and current or forecasted operating or cash flow losses that demonstrate continuing losses associated with
the use of the asset. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying
value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected
cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is
written down to fair value, based on the related estimated discounted cash flows. There were &lt;span id="xdx_906_eus-gaap--AssetImpairmentCharges_pn5n6_do_c20200101__20201231_z1wGWkiwhMsg" title="Impairment of long-lived asset"&gt;&lt;span id="xdx_904_eus-gaap--AssetImpairmentCharges_pn5n6_do_c20190101__20191231_zrB1t9GtR964" title="Impairment of long-lived asset"&gt;no&lt;/span&gt;&lt;/span&gt; impairment charges in the year
ended December 31, 2020 and 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--IncomeTaxPolicyTextBlock_zYJB765LFvch" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;o.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86D_zJoBX6muei4"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1)
With respect to deferred taxes, income taxes are computed using the asset and liability method. Under the asset and liability
method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and
tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is
recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2)
The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the
tax position for recognition by determining if the available evidence indicates that it is more likely than not that the position
will be sustained on examination. If this threshold is met, the second step is to measure the tax position as the largest amount
that is greater than &lt;span id="xdx_90E_ecustom--IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent_pii_dp_uPercentage_c20200101__20201231_zXxFP1WFAnW7" title="Income tax examination, likelihood of unfavorable settlement percent"&gt;50&lt;/span&gt;% likely of being realized upon ultimate settlement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3)
Taxes that would apply in the event of disposal of investment in Subsidiaries have not been taken into account in computing the
deferred income taxes, as it is the Company&#x2019;s intention to hold these investments and not realize them.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zSIop9rtFqEe" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;p.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_865_zPzQrxQKQuEf"&gt;Stock-based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company recognizes
stock-based compensation for the estimated fair value of share-based awards. The Company measures compensation expense for share-based
awards based on estimated fair values on the date of grant using the Black-Scholes option-pricing model. This option pricing model
requires estimates as to the option&#x2019;s expected term and the price volatility of the underlying stock. The Company amortizes
the value of share-based awards to expense over the vesting period on a straight-line basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--RedeemableNoncontrollingInterestPolicyTextBlock_zsEnUDcEFlxj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;q.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_866_zgCh5Z6OyJih"&gt;Redeemable Non-controlling Interest&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-controlling
interests with embedded redemption features, whose settlement is not at the Company&#x2019;s discretion, are considered redeemable
non-controlling interest. Redeemable non-controlling interests are considered to be temporary equity and are therefore presented
as a mezzanine section between liabilities and equity on the Company&#x2019;s consolidated balance sheets. Subsequent adjustment
of the amount presented in temporary equity is required only if the Company&#x2019;s management estimates that it is probable that
the instrument will become redeemable. Adjustments of redeemable non-controlling interest to its redemption value are recorded
through additional paid-in capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zNJx6RzESn1i" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;r.
&lt;span id="xdx_867_zU7V6Xvszvll"&gt;Loss (income) per Share of Common Stock&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basic
net loss (income) per share is computed by dividing the net loss (income) for the period by the weighted average
number of shares of common stock outstanding for each period. Diluted net loss (income) per share is based upon the weighted
average number of common shares and of common shares equivalents outstanding when dilutive. Common share equivalents include:
(i) outstanding stock options and warrants which are included under the treasury share method when dilutive, and (ii) common shares
to be issued under the assumed conversion of the Company&#x2019;s outstanding convertible loans and debt, which are included under
the if-converted method when dilutive (See Note 14).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_z9iIMxbJLEt3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;s.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86C_zAOs2P028xn"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Financial
instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents,
bank deposits and certain receivables. The Company held these instruments with highly rated financial institutions and the Company
has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant
credit risk on these instruments apart of accounts receivable. The Company performs ongoing credit evaluations of its customers
for the purpose of determining the appropriate allowance for doubtful accounts. An appropriate allowance for doubtful accounts
is included in the accounts and netted against accounts receivable. In the year ended December 31, 2020 the Company has not experienced
any material credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Bad
debt allowance is created when objective evidence exists of inability to collect all sums owed it under the original terms of
the debit balances. Material customer difficulties, the probability of their going bankrupt or undergoing economic reorganization
and insolvency or material delays in payments are all considered indicative of reduced debtor balance value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--TreasurySharesPolicyTextBlock_zLbbSVa2voY4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;t.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86D_zCEKwbqlGi5h"&gt;Treasury shares&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company repurchases its ordinary shares from time to time on the open market and holds such shares as treasury stock. The Company
presents the cost to repurchase treasury stock as a reduction of shareholders&#x2019; equity. During the years ended December 31,
2020, the Company repurchased &lt;span id="xdx_90D_eus-gaap--TreasuryStockShares_iI_pii_c20201231_zSfcLu6T32ck"&gt;55,309&lt;/span&gt;&lt;/span&gt;
&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;shares. The Company did not reissue nor cancel treasury
shares during the year ended December 31, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--BeneficialConversionFeatureBcfPolicyTextBlock_zcdFRGpqeFm1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;u.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_861_zwdTIHksyfce"&gt;Beneficial Conversion Feature (&#x201c;BCF&#x201d;)&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;When
the Company issues convertible debt, if the stock price is greater than the effective conversion price (after allocation of the
total proceeds) on the measurement date, the conversion feature is considered &#x201c;beneficial&#x201d; to the holder. If there
is no contingency, this difference is treated as issued equity and reduces the carrying value of the host debt; the discount is
accreted as deemed interest on the debt (See Note 7).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zqsBQb7xNxJc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;v.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_862_zmJDopxvL1Jk"&gt;Other Comprehensive Loss&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
comprehensive loss represents adjustments of foreign currency translation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zI8Vwp6qBLh4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;w.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_864_zmzvFYMGY2lf"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recognizes revenue from contracts with customers according to ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt; and
the related amendments (&#x201c;New Revenue Standard&#x201d;) to all contracts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s agreements are primarily service contracts that range in duration from a few months to one year. The Company recognizes
revenue when control of these services is transferred to the customer for an amount, referred to as the transaction price, which
reflects the consideration to which the Company is expected to be entitled in exchange for those goods or services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
contract with a customer exists only when:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;the
    parties to the contract have approved it and are committed to perform their respective obligations;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;the
    Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance
    obligations&#x201d;);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;the
    Company can determine the transaction price for the goods or services to be transferred; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;the
    contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled
    in exchange for the goods or services that will be transferred to the customer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company does not adjust the promised amount of consideration for the effects of a significant financing component since the Company
expects, at contract inception, that the period between the time of transfer of the promised goods or services to the customer
and the time the customer pays for these goods or services to be generally one year or less. The Company&#x2019;s credit terms
to customers are in average between thirty and one hundred and fifty days.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Nature
of Revenue Streams&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s main revenue streams from continuing operation are POC development services and Cell Process Development
Services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;POC
Development Services&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue
recognized under contracts for POC development services may, in some contracts, represent multiple performance obligations (where
promises to the customers are distinct) in circumstances in which the work packages are not interrelated or the customer is able
to complete the services performed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;For
arrangements that include multiple performance obligations, the transaction price is allocated to the identified performance obligations
based on their relative standalone selling prices.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recognizes revenue when, or as, it satisfies a performance obligation. At contract inception, the Company determines whether
the services are transferred over time or at a point in time. Performance obligations that have no alternative use and that the
Company has the right to payment for performance completed to date, at all times during the contract term, are recognized over
time. All other Performance obligations are recognized as revenues by the company at point of time (upon completion).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Included
in POC development services is Hospital supplies revenue which is derived principally from the sale or lease of products and the
performance of services to hospitals or other medical providers. Revenue is earned and recognized when product and services are
received by the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;Significant
Judgement and Estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="background-color: white"&gt;Significant
judgment is required to&lt;/span&gt; identifying the distinct performance obligations and estimating the standalone selling price of
each distinct performance obligation, and identifying which performance obligations create assets with alternative use to the
Company, which results in revenue recognized upon completion, and which performance obligations are transferred to the customer
over time.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Practical
Expedients&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
part of ASC 606, the Company has adopted several practical expedients including the Company&#x2019;s determination that it need
not adjust the promised amount of consideration for the effects of a significant financing component since the Company expects,
at contract inception, that the period between when the Company transfers a promised service to the customer and when the customer
pays for that service will be one year or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Cell
Process Development Services (mainly discontinued operations)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue
recognized under contracts for cell process development services may, in some contracts, represent multiple performance obligations
(where promises to the customers are distinct) in circumstances in which the work packages and milestones are not interrelated
or the customer is able to complete the services performed independently or by using competitors of the Company. In other contracts
when the above circumstances are not met, the promises are not considered distinct and the contract represents one performance
obligation. All performance obligations are satisfied over time, as there is no alternative use to the services it performs, since,
in nature, those services are unique to the customer, which retain the ownership of the intellectual property created through
the process. Additionally, due to the non-refundable upfront payment the customer pays, together with the payment term and cancellation
fine, it has a right to payment (which include a reasonable margin), at all times, for work completed to date, which is enforceable
by law.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;For
arrangements that include multiple performance obligations, the transaction price is allocated to the identified performance obligations
based on their relative standalone selling prices. For these contracts, the standalone selling prices are based on the Company&#x2019;s
normal pricing practices when sold separately with consideration of market conditions and other factors, including customer demographics
and geographic location.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company measures the revenue to be recognized over time on a contract by contract basis, determining the use of either a cost-based
input method or output method, depending on whichever best depicts the transfer of control over the life of the performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Tech
Transfer Services (discontinued operations)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue
recognized under contracts for tech transfer services are considered a single performance obligation, as all work packages (including
data collection, GMP documentation, validation runs) and milestones are interrelated. Additionally, the customer is unable to
complete services of work performed independently or by using competitors of the Company. Revenue is recognized over time using
a cost-based based input method where progress on the performance obligation is measured by the proportion of actual costs incurred
to the total costs expected to complete the contract.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Cell
Manufacturing Services (discontinued operations)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Revenues
from cell manufacturing services represent a single performance obligation which is recognized over time. The progress towards
completion will continue to be measured on an output measure based on direct measurement of the value transferred to the customer
(units produced).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Reimbursed
Expenses (discontinued operations)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company includes reimbursed expenses in revenues and costs of revenue as the Company is primarily responsible for fulfilling the
promise to provide the specified service, including the integration of the related services into a combined output to the customer,
which are inseparable from the integrated service. These costs include such items as consumable, reagents, transportation and
travel expenses, over which the Company has discretion in establishing prices.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Change
Orders&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Changes
in the scope of work are common and can result in a change in transaction price, equipment used and payment terms. Change orders
are evaluated on a contract-by-contract basis to determine if they should be accounted for as a new contract or as part of the
existing contract. Generally, services from change orders are not distinct from the original performance obligation. As a result,
the effect that the contract modification has on the contract revenue, and measure of progress, is recognized as an adjustment
to revenue when they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Costs
of Revenue (discontinued operations)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Costs
of revenue include (i) compensation and benefits for billable employees and personnel involved in production, data management
and delivery, and the costs of acquiring and processing data for the Company&#x2019;s information offerings; (ii) costs of staff
directly involved with delivering services offerings and engagements; (iii) consumables used for the services; and (iv) other
expenses directly related to service contracts such as courier fees, laboratory supplies, professional services and travel expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zM949RtKzIP9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;x.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_864_zoYBMzuMVFJe"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company adopted
the new lease standard ASC 842 and all the related amendments on January 1, 2019.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2.
If any of these five criteria is met, The Company classifies the lease as a finance lease; otherwise, the Company classifies the
lease as an operating lease. &lt;span id="xdx_904_ecustom--LeaseClassificationDiscription_c20200101__20201231" title="Lease classification discription"&gt;When determining lease classification, the Company&#x2019;s approach in assessing two of the mentioned
criteria is: (i) generally 75% or more of the remaining economic life of the underlying asset is a major part of the remaining
economic life of that underlying asset; and (ii) generally 90% or more of the fair value of the underlying asset comprises substantially
all of the fair value of the underlying asset.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Operating
leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities in the consolidated
balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;ROU
assets represent Orgenesis&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation
to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date
based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the
information available at the commencement date to determine the present value of the lease payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
standard also provides practical expedients for an entity&#x2019;s ongoing accounting. The Company elected the short-term lease
recognition exemption for all leases with a term shorter than 12 months. This means that for those leases, the Company does not
recognize ROU assets or lease liabilities, including not recognizing ROU assets or lease liabilities for existing short-term leases
of those assets in transition, but recognizes lease expenses over the lease term on a straight-line basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Lease
terms will include options to extend or terminate the lease when it is reasonably certain that Orgenesis will exercise or not
exercise the option to renew or terminate the lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zUdPYL8yJYz5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;y.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86B_zlPuyTRD20wc"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
June 2016, the FASB issued ASU 2016-13 &#x201c;Financial Instruments&#x2014;Credit Losses&#x2014;Measurement of Credit Losses on
Financial Instruments.&#x201d; This guidance replaces the current incurred loss impairment methodology with a methodology that
reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform
credit loss estimates. The guidance will be effective for Smaller Reporting Companies (SRCs, as defined by the SEC) for the fiscal
year beginning on January 1, 2023, including interim periods within that year. The Company is currently evaluating this guidance
to determine the impact it may have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
August 2020, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-06, Debt with Conversion and Other Options (Subtopic
470-20) and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments
and Contracts in an Entity&#x2019;s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation
models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument
with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required
for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it.
The ASU also simplifies the diluted net income per share calculation in certain areas. The new guidance is effective for annual
and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years beginning after December
15, 2020, and interim periods within those fiscal years. The Company is currently evaluating the impact that this new guidance
will have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zA9T2OUm4Tfi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;z.&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86D_zHRjqYLmA3cc"&gt;Newly issued and recently adopted accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company early adopted ASU 2019-12 on January 1, 2020, which did not have a material impact on the Consolidated Financial Statements
except for the removal of the exception related to intra-period tax allocations. Commencing from January 1, 2020, the Company
followed the general intra-period allocation of tax expenses. The Company had incurred a loss from continuing operations and subsequent
to the adoption of ASU 2019-12, the Company determined the amount attributable to continuing operations without regard to the
tax effect of other items. The ASU 2019-12 amendment related to the intra-period tax allocation was applied prospectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Had
the Company not adopted ASU 2019-12, an approximately $&lt;span id="xdx_902_eus-gaap--IncomeTaxExpenseBenefit_pn5n6_c20200101__20201231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201912Member_zgebC0H9Ojm1" title="Income Tax Expense (Benefit)"&gt;20&lt;/span&gt; million tax benefit would have been recognized along with corresponding
decreases to net loss from continuing operations with a corresponding increase in tax expenses and decrease in net income resulting
from discontinued operations. The Company had no intra-period tax allocation items in prior years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zhAsVeCQvSik" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;aa.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86C_z1U2luzhxRDl"&gt;Reclassifications&lt;/span&gt; &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Certain
reclassifications have been made to the prior years&#x2019; financial statements to conform to the current year presentation. These
reclassifications had no net effect on previously reported results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_852_zoOFYUCTqTvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_845_eus-gaap--UseOfEstimates_zoTqjeGUG1E3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;a.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86F_zmuEvKVDb2R9"&gt;Use of Estimates in the Preparation of Financial Statements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30.6pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
preparation of our consolidated financial statements in conformity with U.S. GAAP requires us to make estimates, judgments
and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure
of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, judgments and methodologies. We base our
estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form
the basis for making judgments about the carrying values of assets, liabilities and equity, the amount of revenues and expenses
and determining whether an acquisition is a business combination or a purchase of asset. Actual results could differ from those
estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial
condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning
COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and
international customers and markets. We examined the impact of COVID-19 on our financial statements, and although there is currently
no major impact, there may be changes to those estimates in future periods. Actual results may differ from these estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:BusinessCombinationsPolicy contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84F_eus-gaap--BusinessCombinationsPolicy_zASBMmgcRifh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;b.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_864_zIV8aZ9zoWC7"&gt;Business Combination&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company allocates the purchase price of an acquired business to the tangible and intangible assets acquired and liabilities assumed
based upon their estimated fair values on the acquisition date. Any excess of the purchase price over the fair value of the net
assets acquired is recorded as goodwill. Acquired in-process backlog, customer relations, technology, IPR&amp;amp;D, brand name and
know how are recognized at fair value. The purchase price allocation process requires management to make significant estimates
and assumptions, especially at the acquisition date with respect to intangible assets. Direct transaction costs associated with
the business combination are expensed as incurred. The allocation of the consideration transferred in certain cases may be subject
to revision based on the final determination of fair values during the measurement period, which may be up to one year from the
acquisition date. The Company includes the results of operations of the business that it has acquired in its consolidated results
prospectively from the date of acquisition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;If
the business combination is achieved in stages, the acquisition date carrying value of the acquirer&#x2019;s previously held equity
interest in the acquire is re-measured to fair value at the acquisition date; any gains or losses arising from such re-measurement
are recognized in profit or loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessCombinationsPolicy>
    <ORGS:OtherInvestmentsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_849_ecustom--OtherInvestmentsPolicyTextBlock_zxa4jeXJtTJ5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;c.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_862_zEX2xcZFX5Og"&gt;Other Investments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;For
other investments, the Company applies the measurement alternative upon the adoption of ASU 2016-01, and elected to record equity
investments without readily determinable fair values at cost, less impairment, adjusted for subsequent observable price changes.
In this measurement alternative method, changes in the carrying value of the equity investments are reflected in current earnings.
Changes in the carrying value of the equity investment are required to be made whenever there are observable price changes in
orderly transactions for the identical or similar investment of the same issuer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ORGS:OtherInvestmentsPolicyTextBlock>
    <us-gaap:DiscontinuedOperationsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_848_eus-gaap--DiscontinuedOperationsPolicyTextBlock_z0tAJNQJEqF6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;d.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_866_zT2nEPd7Xj7l"&gt;Discontinued operations&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Upon
divestiture of a business, the Company classifies such business as a discontinued operation, if the divested business represents
a strategic shift that has (or will have) a major effect on an entity&#x2019;s operations and financial results. For disposals
other than by sale such as abandonment, the results of operations of a business would not be recorded as a discontinued operation
until the period in which the business is actually abandoned.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Masthercell Business divestiture qualifies as a discontinued operation and therefore has been presented as such.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
results of businesses that have qualified as a discontinued operation have been presented as such for all reporting periods. Results
of discontinued operations include all revenues and expenses directly derived from such businesses; general corporate overhead
is not allocated to discontinued operations. Any loss or gain that arose from the divestiture of a business that qualifies as
discontinued operations is included within the results of the discontinued operations. The Company included information regarding
cash flows from discontinued operations (See Note 3).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DiscontinuedOperationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zGbbnJW7W7Ok" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;e.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_864_z5uAMJlNwL1"&gt;Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company considers cash equivalents to be all short-term, highly liquid investments, which include money market instruments, that
are not restricted as to withdrawal or use, and short-term bank deposits with original maturities of three months or less from
the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_841_eus-gaap--ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_z0k9DUhdcDQ3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;f.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_865_zd0MD2bxejCe"&gt;Cost of research and development and research and development services, net &lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cost
of research and development and research and development services include costs directly attributable to the conduct of research
and development activities, including the cost of salaries, stock-based compensation expenses, payroll taxes and other employees&#x2019;
benefits, lab expenses, consumable equipment, courier fees, travel expenses, professional fees and consulting fees. All costs
associated with research and developments are expensed as incurred. Participation from government departments and from research
foundations for development of approved projects is recognized as a reduction of expense as the related costs are incurred. Research
and development in-process acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative
future use, is expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84D_eus-gaap--ConsolidationPolicyTextBlock_z58jOYQ7GVW2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;g.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86B_zFu2oE6YT6Md"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
consolidated financial statements include the accounts of the Company and its Subsidiaries. All intercompany transactions and
balances have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_849_eus-gaap--EquityMethodInvestmentsPolicy_z6a50xTL5SCf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;h.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_869_zNyNwcNiwFv5"&gt;Non-Marketable Equity Investments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s investments in certain non-marketable equity securities in which it has the ability to exercise significant influence,
but it does not control through variable interests or voting interests. These are accounted for under the equity method of accounting
and presented as Investment in associates, net, in the Company&#x2019;s consolidated balance sheets. Under the equity method, the
Company recognizes its proportionate share of the comprehensive income or loss of the investee. The Company&#x2019;s share of income
and losses from equity method investments is included in share in losses of associated company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company reviews its investments accounted for under the equity method for possible impairment, which generally involves an analysis
of the facts and changes in circumstances influencing the investments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EquityMethodInvestmentsPolicy>
    <ORGS:FunctionalCurrencyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_840_ecustom--FunctionalCurrencyPolicyTextBlock_zoWTiL5Cyoh8" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;i.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86E_zugML1cnvI3l"&gt;Functional Currency&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
currency of the primary economic environment in which the operations of the Company and part of its Subsidiaries are conducted
is the U.S. dollar (&#x201c;$&#x201d; or &#x201c;dollar&#x201d;). The functional currency of the Belgian Subsidiaries is the Euro
(&#x201c;&#x20ac;&#x201d; or &#x201c;Euro&#x201d;). The functional currency of Orgenesis Korea is the Won (&#x201c;KRW&#x201d;). Most
of the Company&#x2019;s expenses are incurred in dollars, and the source of the Company&#x2019;s financing has been provided in
dollars. Thus, the functional currency of the Company and its other subsidiaries is the dollar. Transactions and balances originally
denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using
historical and current exchange rates for nonmonetary and monetary balances, respectively. For foreign transactions and other
items reflected in the statements of operations, the following exchange rates are used: (1) for transactions &#x2013; exchange
rates at transaction dates or average rates and (2) for other items (derived from nonmonetary balance sheet items such as depreciation)
&#x2013; historical exchange rates. The resulting transaction gains or losses are recorded as financial income or expenses. The
financial statements of the Belgian Subsidiaries and Orgenesis Korea are included in the consolidated financial statements, translated
into U.S. dollars. Assets and liabilities are translated at year-end exchange rates, while revenues and expenses are translated
at yearly average exchange rates during the year. Differences resulting from translation of assets and liabilities are presented
as other comprehensive income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ORGS:FunctionalCurrencyPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zbJ1zWty11Zh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;j.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86A_zLI2WVvdPIy5"&gt;Inventory&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s inventory consists of raw material for use for the services provided. The Company periodically evaluates the quantities
on hand. Cost of the raw materials is determined using the weighted average cost method. The inventory is recorded at the lower
of cost or net realizable value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrb5SiWXpmAg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;k.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_868_z7qU0zEBmU38"&gt;Property, plant and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Property,
plant and equipment are recorded at cost and depreciated by the straight-line method over the estimated useful lives of the related
assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_ecustom--ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock_zh1n2tVBzNya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Annual
rates of depreciation are presented in the table below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BF_z2zA03goEqb4" style="display: none"&gt;SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Useful Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Production facility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 32%; text-align: center"&gt;&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember__srt--RangeAxis__srt--MinimumMember_zrZKyWqXBHH3" title="Weighted Average Useful Life"&gt;5&lt;/span&gt; - &lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember__srt--RangeAxis__srt--MaximumMember_zvU9vrNQ1Hj2" title="Weighted Average Useful Life"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zxVC4f2PFcZh" title="Weighted Average Useful Life"&gt;2&lt;/span&gt; - &lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zY76Fk7sDRRg" title="Weighted Average Useful Life"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office equipment and computers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zN3XZviUAKbe" title="Weighted Average Useful Life"&gt;3&lt;/span&gt; - &lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zZhJXWuhWnrf" title="Weighted Average Useful Life"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A2_z9w1ZtH7Elsl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <ORGS:ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_890_ecustom--ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock_zh1n2tVBzNya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Annual
rates of depreciation are presented in the table below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BF_z2zA03goEqb4" style="display: none"&gt;SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Useful Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Production facility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 32%; text-align: center"&gt;&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember__srt--RangeAxis__srt--MinimumMember_zrZKyWqXBHH3" title="Weighted Average Useful Life"&gt;5&lt;/span&gt; - &lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember__srt--RangeAxis__srt--MaximumMember_zvU9vrNQ1Hj2" title="Weighted Average Useful Life"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zxVC4f2PFcZh" title="Weighted Average Useful Life"&gt;2&lt;/span&gt; - &lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zY76Fk7sDRRg" title="Weighted Average Useful Life"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office equipment and computers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zN3XZviUAKbe" title="Weighted Average Useful Life"&gt;3&lt;/span&gt; - &lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zZhJXWuhWnrf" title="Weighted Average Useful Life"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</ORGS:ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2020-01-012020-12-31_custom_ProductionFacilityMember_srt_MinimumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2020-01-012020-12-31_custom_ProductionFacilityMember_srt_MaximumMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2020-01-012020-12-31_us-gaap_EquipmentMember_srt_MinimumMember">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2020-01-012020-12-31_us-gaap_EquipmentMember_srt_MaximumMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2020-01-012020-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2020-01-012020-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember">P17Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_845_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zMSnFezUZica" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;l.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_863_zJ3WcX5X9dV7"&gt;Intangible assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock_zbOYS9vpY4p6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible
assets and their useful lives are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B8_zEKSONEQ5FDi" style="display: none"&gt;SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Useful Life (Years)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortization Recorded at Comprehensive&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Loss Line Item&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left"&gt;Customer Relationships&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%; text-align: center"&gt;&lt;span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zO06hxwW9q0a" title="Intangible assets and useful lives (Years)"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 44%; text-align: center"&gt;Amortization of intangible assets&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Know-How&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowhowMember_zcXooVGZJTe5" title="Intangible assets and useful lives (Years)"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Amortization of intangible assets&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Technology&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TechnologyMember_zEsA4tuODn0k" title="Intangible assets and useful lives (Years)"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Amortization of intangible assets&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A6_z9WCdJJlXZr2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible
assets are recorded at acquisition less accumulated amortization and impairment. Definite lived intangible assets are amortized
over their estimated useful life using the straight-line method, which is determined by identifying the period over which the
cash flows from the asset are expected to be generated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <ORGS:ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_898_ecustom--ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock_zbOYS9vpY4p6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible
assets and their useful lives are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B8_zEKSONEQ5FDi" style="display: none"&gt;SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Useful Life (Years)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortization Recorded at Comprehensive&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Loss Line Item&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left"&gt;Customer Relationships&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%; text-align: center"&gt;&lt;span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zO06hxwW9q0a" title="Intangible assets and useful lives (Years)"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 44%; text-align: center"&gt;Amortization of intangible assets&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Know-How&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowhowMember_zcXooVGZJTe5" title="Intangible assets and useful lives (Years)"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Amortization of intangible assets&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Technology&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TechnologyMember_zEsA4tuODn0k" title="Intangible assets and useful lives (Years)"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Amortization of intangible assets&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</ORGS:ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2020-01-012020-12-31_us-gaap_CustomerRelationshipsMember">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2020-01-012020-12-31_custom_KnowhowMember">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2020-01-012020-12-31_custom_TechnologyMember">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_843_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zi7iV6mHs2b9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;m.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_865_zd6VISbnwa5e"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Goodwill represents
the excess of consideration transferred over the value assigned to the net tangible and identifiable intangible assets of businesses
acquired. Goodwill is allocated to reporting units expected to benefit from the business combination. Goodwill is not amortized
but rather tested for impairment at least annually in the fourth quarter, or more frequently if events
or changes in circumstances indicate that goodwill may be impaired. Following the sale of Masthercell the Company manages
the business as one operating segment and one reporting unit. Goodwill impairment is recognized when the quantitative assessment
results in the carrying value exceeding the fair value, in which case an impairment charge is recorded to the extent the
carrying value exceeds the fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;There
were &lt;span id="xdx_90E_eus-gaap--GoodwillImpairmentLoss_pn5n6_do_c20200101__20201231_zPR5LqcFQzkg"&gt;no&lt;/span&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;impairment
charges to goodwill during the periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="-5"
      unitRef="USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zrrNaOitkMu6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;n.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_866_zOv0AtkRWS3g"&gt;Impairment of Long-lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company reviews its property, plants and equipment, intangible assets subject to amortization and other long-lived assets for
impairment whenever events or changes in circumstances indicate that the carrying amount of an asset class may not be recoverable.
Indicators of potential impairment include: an adverse change in legal factors or in the business climate that could affect the
value of the asset; an adverse change in the extent or manner in which the asset is used or is expected to be used, or in its
physical condition; and current or forecasted operating or cash flow losses that demonstrate continuing losses associated with
the use of the asset. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying
value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected
cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is
written down to fair value, based on the related estimated discounted cash flows. There were &lt;span id="xdx_906_eus-gaap--AssetImpairmentCharges_pn5n6_do_c20200101__20201231_z1wGWkiwhMsg" title="Impairment of long-lived asset"&gt;&lt;span id="xdx_904_eus-gaap--AssetImpairmentCharges_pn5n6_do_c20190101__20191231_zrB1t9GtR964" title="Impairment of long-lived asset"&gt;no&lt;/span&gt;&lt;/span&gt; impairment charges in the year
ended December 31, 2020 and 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2020-01-01to2020-12-31"
      decimals="-5"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2019-01-012019-12-31"
      decimals="-5"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_843_eus-gaap--IncomeTaxPolicyTextBlock_zYJB765LFvch" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;o.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86D_zJoBX6muei4"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1)
With respect to deferred taxes, income taxes are computed using the asset and liability method. Under the asset and liability
method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and
tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is
recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2)
The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the
tax position for recognition by determining if the available evidence indicates that it is more likely than not that the position
will be sustained on examination. If this threshold is met, the second step is to measure the tax position as the largest amount
that is greater than &lt;span id="xdx_90E_ecustom--IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent_pii_dp_uPercentage_c20200101__20201231_zXxFP1WFAnW7" title="Income tax examination, likelihood of unfavorable settlement percent"&gt;50&lt;/span&gt;% likely of being realized upon ultimate settlement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3)
Taxes that would apply in the event of disposal of investment in Subsidiaries have not been taken into account in computing the
deferred income taxes, as it is the Company&#x2019;s intention to hold these investments and not realize them.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <ORGS:IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Percentage">0.50</ORGS:IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zSIop9rtFqEe" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;p.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_865_zPzQrxQKQuEf"&gt;Stock-based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company recognizes
stock-based compensation for the estimated fair value of share-based awards. The Company measures compensation expense for share-based
awards based on estimated fair values on the date of grant using the Black-Scholes option-pricing model. This option pricing model
requires estimates as to the option&#x2019;s expected term and the price volatility of the underlying stock. The Company amortizes
the value of share-based awards to expense over the vesting period on a straight-line basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <ORGS:RedeemableNoncontrollingInterestPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_848_ecustom--RedeemableNoncontrollingInterestPolicyTextBlock_zsEnUDcEFlxj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;q.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_866_zgCh5Z6OyJih"&gt;Redeemable Non-controlling Interest&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-controlling
interests with embedded redemption features, whose settlement is not at the Company&#x2019;s discretion, are considered redeemable
non-controlling interest. Redeemable non-controlling interests are considered to be temporary equity and are therefore presented
as a mezzanine section between liabilities and equity on the Company&#x2019;s consolidated balance sheets. Subsequent adjustment
of the amount presented in temporary equity is required only if the Company&#x2019;s management estimates that it is probable that
the instrument will become redeemable. Adjustments of redeemable non-controlling interest to its redemption value are recorded
through additional paid-in capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ORGS:RedeemableNoncontrollingInterestPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zNJx6RzESn1i" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;r.
&lt;span id="xdx_867_zU7V6Xvszvll"&gt;Loss (income) per Share of Common Stock&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basic
net loss (income) per share is computed by dividing the net loss (income) for the period by the weighted average
number of shares of common stock outstanding for each period. Diluted net loss (income) per share is based upon the weighted
average number of common shares and of common shares equivalents outstanding when dilutive. Common share equivalents include:
(i) outstanding stock options and warrants which are included under the treasury share method when dilutive, and (ii) common shares
to be issued under the assumed conversion of the Company&#x2019;s outstanding convertible loans and debt, which are included under
the if-converted method when dilutive (See Note 14).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_z9iIMxbJLEt3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;s.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86C_zAOs2P028xn"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Financial
instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents,
bank deposits and certain receivables. The Company held these instruments with highly rated financial institutions and the Company
has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant
credit risk on these instruments apart of accounts receivable. The Company performs ongoing credit evaluations of its customers
for the purpose of determining the appropriate allowance for doubtful accounts. An appropriate allowance for doubtful accounts
is included in the accounts and netted against accounts receivable. In the year ended December 31, 2020 the Company has not experienced
any material credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Bad
debt allowance is created when objective evidence exists of inability to collect all sums owed it under the original terms of
the debit balances. Material customer difficulties, the probability of their going bankrupt or undergoing economic reorganization
and insolvency or material delays in payments are all considered indicative of reduced debtor balance value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <ORGS:TreasurySharesPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84E_ecustom--TreasurySharesPolicyTextBlock_zLbbSVa2voY4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;t.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86D_zCEKwbqlGi5h"&gt;Treasury shares&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company repurchases its ordinary shares from time to time on the open market and holds such shares as treasury stock. The Company
presents the cost to repurchase treasury stock as a reduction of shareholders&#x2019; equity. During the years ended December 31,
2020, the Company repurchased &lt;span id="xdx_90D_eus-gaap--TreasuryStockShares_iI_pii_c20201231_zSfcLu6T32ck"&gt;55,309&lt;/span&gt;&lt;/span&gt;
&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;shares. The Company did not reissue nor cancel treasury
shares during the year ended December 31, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</ORGS:TreasurySharesPolicyTextBlock>
    <us-gaap:TreasuryStockShares contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">55309</us-gaap:TreasuryStockShares>
    <ORGS:BeneficialConversionFeatureBcfPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84E_ecustom--BeneficialConversionFeatureBcfPolicyTextBlock_zcdFRGpqeFm1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;u.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_861_zwdTIHksyfce"&gt;Beneficial Conversion Feature (&#x201c;BCF&#x201d;)&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;When
the Company issues convertible debt, if the stock price is greater than the effective conversion price (after allocation of the
total proceeds) on the measurement date, the conversion feature is considered &#x201c;beneficial&#x201d; to the holder. If there
is no contingency, this difference is treated as issued equity and reduces the carrying value of the host debt; the discount is
accreted as deemed interest on the debt (See Note 7).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ORGS:BeneficialConversionFeatureBcfPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84C_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zqsBQb7xNxJc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;v.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_862_zmJDopxvL1Jk"&gt;Other Comprehensive Loss&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
comprehensive loss represents adjustments of foreign currency translation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_841_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zI8Vwp6qBLh4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;w.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_864_zmzvFYMGY2lf"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recognizes revenue from contracts with customers according to ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt; and
the related amendments (&#x201c;New Revenue Standard&#x201d;) to all contracts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s agreements are primarily service contracts that range in duration from a few months to one year. The Company recognizes
revenue when control of these services is transferred to the customer for an amount, referred to as the transaction price, which
reflects the consideration to which the Company is expected to be entitled in exchange for those goods or services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
contract with a customer exists only when:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;the
    parties to the contract have approved it and are committed to perform their respective obligations;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;the
    Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance
    obligations&#x201d;);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;the
    Company can determine the transaction price for the goods or services to be transferred; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;the
    contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled
    in exchange for the goods or services that will be transferred to the customer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company does not adjust the promised amount of consideration for the effects of a significant financing component since the Company
expects, at contract inception, that the period between the time of transfer of the promised goods or services to the customer
and the time the customer pays for these goods or services to be generally one year or less. The Company&#x2019;s credit terms
to customers are in average between thirty and one hundred and fifty days.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Nature
of Revenue Streams&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s main revenue streams from continuing operation are POC development services and Cell Process Development
Services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;POC
Development Services&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue
recognized under contracts for POC development services may, in some contracts, represent multiple performance obligations (where
promises to the customers are distinct) in circumstances in which the work packages are not interrelated or the customer is able
to complete the services performed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;For
arrangements that include multiple performance obligations, the transaction price is allocated to the identified performance obligations
based on their relative standalone selling prices.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recognizes revenue when, or as, it satisfies a performance obligation. At contract inception, the Company determines whether
the services are transferred over time or at a point in time. Performance obligations that have no alternative use and that the
Company has the right to payment for performance completed to date, at all times during the contract term, are recognized over
time. All other Performance obligations are recognized as revenues by the company at point of time (upon completion).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Included
in POC development services is Hospital supplies revenue which is derived principally from the sale or lease of products and the
performance of services to hospitals or other medical providers. Revenue is earned and recognized when product and services are
received by the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;Significant
Judgement and Estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="background-color: white"&gt;Significant
judgment is required to&lt;/span&gt; identifying the distinct performance obligations and estimating the standalone selling price of
each distinct performance obligation, and identifying which performance obligations create assets with alternative use to the
Company, which results in revenue recognized upon completion, and which performance obligations are transferred to the customer
over time.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Practical
Expedients&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
part of ASC 606, the Company has adopted several practical expedients including the Company&#x2019;s determination that it need
not adjust the promised amount of consideration for the effects of a significant financing component since the Company expects,
at contract inception, that the period between when the Company transfers a promised service to the customer and when the customer
pays for that service will be one year or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Cell
Process Development Services (mainly discontinued operations)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue
recognized under contracts for cell process development services may, in some contracts, represent multiple performance obligations
(where promises to the customers are distinct) in circumstances in which the work packages and milestones are not interrelated
or the customer is able to complete the services performed independently or by using competitors of the Company. In other contracts
when the above circumstances are not met, the promises are not considered distinct and the contract represents one performance
obligation. All performance obligations are satisfied over time, as there is no alternative use to the services it performs, since,
in nature, those services are unique to the customer, which retain the ownership of the intellectual property created through
the process. Additionally, due to the non-refundable upfront payment the customer pays, together with the payment term and cancellation
fine, it has a right to payment (which include a reasonable margin), at all times, for work completed to date, which is enforceable
by law.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;For
arrangements that include multiple performance obligations, the transaction price is allocated to the identified performance obligations
based on their relative standalone selling prices. For these contracts, the standalone selling prices are based on the Company&#x2019;s
normal pricing practices when sold separately with consideration of market conditions and other factors, including customer demographics
and geographic location.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company measures the revenue to be recognized over time on a contract by contract basis, determining the use of either a cost-based
input method or output method, depending on whichever best depicts the transfer of control over the life of the performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Tech
Transfer Services (discontinued operations)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue
recognized under contracts for tech transfer services are considered a single performance obligation, as all work packages (including
data collection, GMP documentation, validation runs) and milestones are interrelated. Additionally, the customer is unable to
complete services of work performed independently or by using competitors of the Company. Revenue is recognized over time using
a cost-based based input method where progress on the performance obligation is measured by the proportion of actual costs incurred
to the total costs expected to complete the contract.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Cell
Manufacturing Services (discontinued operations)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Revenues
from cell manufacturing services represent a single performance obligation which is recognized over time. The progress towards
completion will continue to be measured on an output measure based on direct measurement of the value transferred to the customer
(units produced).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Reimbursed
Expenses (discontinued operations)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company includes reimbursed expenses in revenues and costs of revenue as the Company is primarily responsible for fulfilling the
promise to provide the specified service, including the integration of the related services into a combined output to the customer,
which are inseparable from the integrated service. These costs include such items as consumable, reagents, transportation and
travel expenses, over which the Company has discretion in establishing prices.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Change
Orders&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Changes
in the scope of work are common and can result in a change in transaction price, equipment used and payment terms. Change orders
are evaluated on a contract-by-contract basis to determine if they should be accounted for as a new contract or as part of the
existing contract. Generally, services from change orders are not distinct from the original performance obligation. As a result,
the effect that the contract modification has on the contract revenue, and measure of progress, is recognized as an adjustment
to revenue when they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Costs
of Revenue (discontinued operations)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Costs
of revenue include (i) compensation and benefits for billable employees and personnel involved in production, data management
and delivery, and the costs of acquiring and processing data for the Company&#x2019;s information offerings; (ii) costs of staff
directly involved with delivering services offerings and engagements; (iii) consumables used for the services; and (iv) other
expenses directly related to service contracts such as courier fees, laboratory supplies, professional services and travel expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zM949RtKzIP9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;x.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_864_zoYBMzuMVFJe"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company adopted
the new lease standard ASC 842 and all the related amendments on January 1, 2019.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2.
If any of these five criteria is met, The Company classifies the lease as a finance lease; otherwise, the Company classifies the
lease as an operating lease. &lt;span id="xdx_904_ecustom--LeaseClassificationDiscription_c20200101__20201231" title="Lease classification discription"&gt;When determining lease classification, the Company&#x2019;s approach in assessing two of the mentioned
criteria is: (i) generally 75% or more of the remaining economic life of the underlying asset is a major part of the remaining
economic life of that underlying asset; and (ii) generally 90% or more of the fair value of the underlying asset comprises substantially
all of the fair value of the underlying asset.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Operating
leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities in the consolidated
balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;ROU
assets represent Orgenesis&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation
to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date
based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the
information available at the commencement date to determine the present value of the lease payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
standard also provides practical expedients for an entity&#x2019;s ongoing accounting. The Company elected the short-term lease
recognition exemption for all leases with a term shorter than 12 months. This means that for those leases, the Company does not
recognize ROU assets or lease liabilities, including not recognizing ROU assets or lease liabilities for existing short-term leases
of those assets in transition, but recognizes lease expenses over the lease term on a straight-line basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Lease
terms will include options to extend or terminate the lease when it is reasonably certain that Orgenesis will exercise or not
exercise the option to renew or terminate the lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <ORGS:LeaseClassificationDiscription contextRef="From2020-01-01to2020-12-31">When determining lease classification, the Company&#x2019;s approach in assessing two of the mentioned
criteria is: (i) generally 75% or more of the remaining economic life of the underlying asset is a major part of the remaining
economic life of that underlying asset; and (ii) generally 90% or more of the fair value of the underlying asset comprises substantially
all of the fair value of the underlying asset.</ORGS:LeaseClassificationDiscription>
    <ORGS:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84F_ecustom--RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zUdPYL8yJYz5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;y.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86B_zlPuyTRD20wc"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
June 2016, the FASB issued ASU 2016-13 &#x201c;Financial Instruments&#x2014;Credit Losses&#x2014;Measurement of Credit Losses on
Financial Instruments.&#x201d; This guidance replaces the current incurred loss impairment methodology with a methodology that
reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform
credit loss estimates. The guidance will be effective for Smaller Reporting Companies (SRCs, as defined by the SEC) for the fiscal
year beginning on January 1, 2023, including interim periods within that year. The Company is currently evaluating this guidance
to determine the impact it may have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
August 2020, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-06, Debt with Conversion and Other Options (Subtopic
470-20) and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments
and Contracts in an Entity&#x2019;s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation
models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument
with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required
for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it.
The ASU also simplifies the diluted net income per share calculation in certain areas. The new guidance is effective for annual
and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years beginning after December
15, 2020, and interim periods within those fiscal years. The Company is currently evaluating the impact that this new guidance
will have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ORGS:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zA9T2OUm4Tfi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;z.&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86D_zHRjqYLmA3cc"&gt;Newly issued and recently adopted accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company early adopted ASU 2019-12 on January 1, 2020, which did not have a material impact on the Consolidated Financial Statements
except for the removal of the exception related to intra-period tax allocations. Commencing from January 1, 2020, the Company
followed the general intra-period allocation of tax expenses. The Company had incurred a loss from continuing operations and subsequent
to the adoption of ASU 2019-12, the Company determined the amount attributable to continuing operations without regard to the
tax effect of other items. The ASU 2019-12 amendment related to the intra-period tax allocation was applied prospectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Had
the Company not adopted ASU 2019-12, an approximately $&lt;span id="xdx_902_eus-gaap--IncomeTaxExpenseBenefit_pn5n6_c20200101__20201231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201912Member_zgebC0H9Ojm1" title="Income Tax Expense (Benefit)"&gt;20&lt;/span&gt; million tax benefit would have been recognized along with corresponding
decreases to net loss from continuing operations with a corresponding increase in tax expenses and decrease in net income resulting
from discontinued operations. The Company had no intra-period tax allocation items in prior years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-01-012020-12-31_us-gaap_AccountingStandardsUpdate201912Member"
      decimals="-5"
      unitRef="USD">20000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84D_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zhAsVeCQvSik" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;aa.&lt;/i&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_86C_z1U2luzhxRDl"&gt;Reclassifications&lt;/span&gt; &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Certain
reclassifications have been made to the prior years&#x2019; financial statements to conform to the current year presentation. These
reclassifications had no net effect on previously reported results of operations.&lt;/span&gt;&lt;/p&gt;

</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_805_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_z5kixiFfTK2e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
3 &#x2013; &lt;span id="xdx_82A_zgDFcvg3IEmk"&gt;DISCONTINUED OPERATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
February 2, 2020, the Company entered into a Purchase Agreement with GPP, Masthercell and the Buyer. Pursuant to the terms and
conditions of the Purchase Agreement, Sellers agreed to sell &lt;span id="xdx_909_ecustom--PercentageOfOutstandingEquityInterests_iI_pii_dp_c20200202__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zvcmOPmYYGjk" title="Percentage of outstanding equity interests"&gt;100%&lt;/span&gt; of the outstanding equity interests of Masthercell to Buyer
for an aggregate nominal purchase price of $&lt;span id="xdx_90A_ecustom--AggregateNominalPurchasePrice_pn5n6_c20200201__20200202__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zBxUQgH60ZFg" title="Aggregate nominal purchase price of outstanding equity interests"&gt;315&lt;/span&gt; million. The Company has determined that the Masthercell Business meets the criteria
to be classified as discontinued operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
February 10, 2020, the Masthercell Sale was consummated in accordance with the terms of the Purchase Agreement. After accounting
for GPP&#x2019;s liquidation preference and equity stake in Masthercell, as well as SFPI &#x2013; FPIM&#x2019;s interest in MaSTherCell,
distributions to Masthercell option holders and transaction costs, the Company received approximately $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20200209__20200210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zXXsIlh7t9H2" title="Proceeds from Issuance or Sale of Equity"&gt;126.7&lt;/span&gt; million at the closing
of the Masthercell Sale, of which $&lt;span id="xdx_90E_ecustom--RepaymentOfIntercompanyLoansAndPayables_pn5n6_c20200209__20200210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zTNolHBnENQe" title="Repayment of intercompany loans and payables"&gt;7.2&lt;/span&gt; million was used for the repayment of intercompany loans and payables, including $&lt;span id="xdx_900_ecustom--RepaymentOfIntercompanyLoansAndPayables_pn5n6_c20200209__20200210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellSAMember_zPLBGhlZ7rM6" title="Repayment of intercompany loans and payables"&gt;4.6&lt;/span&gt; million
of payables to MaSTherCell.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Due
to the sale of the controlling interest in Masthercell, the Company retrospectively reclassified the assets and liabilities of
these entities as assets and liabilities of discontinued operations and included the financial results of these entities as discontinued
operations in the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Discontinued
operations relate to the Masthercell Business. The comprehensive loss and balance sheet for this operation are separately reported
as discontinued operations for all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zmkQyrHutPYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
financial results of the Masthercell Business are presented as income (loss) from discontinued operations, net of income taxes
on the Company&#x2019;s consolidated statement of comprehensive loss. The following table presents the financial results associated
with the Masthercell Business operation as reflected in the Company&#x2019;s Consolidated Comprehensive loss (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B6_zpoTCAyl7kKi" style="display: none"&gt;SCHEDULE OF DISCONTINUED OPERATION AND BALANCE SHEETS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"/&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;OPERATIONS&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231_zeOdHvQTFCM3" style="width: 14%; text-align: right" title="Revenues"&gt;2,556&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231_zDshnLGkj0M8" style="width: 14%; text-align: right" title="Revenues"&gt;31,053&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cost of revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c20200101__20201231_pn3n3" style="text-align: right" title="Cost of revenues"&gt;1,482&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c20190101__20191231_pn3n3" style="text-align: right" title="Cost of revenues"&gt;18,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Cost of research and development and research and development services, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet_c20200101__20201231_pn3n3" style="text-align: right" title="Cost of research and development and research and development services, net"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet_c20190101__20191231_pn3n3" style="text-align: right" title="Cost of research and development and research and development services, net"&gt;54&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Amortization of intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DepreciationAndAmortizationDiscontinuedOperations_c20200101__20201231_pn3n3" style="text-align: right" title="Amortization of intangible assets"&gt;137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DepreciationAndAmortizationDiscontinuedOperations_c20190101__20191231_pn3n3" style="text-align: right" title="Amortization of intangible assets"&gt;1,631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Selling, general and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c20200101__20201231_pn3n3" style="text-align: right" title="Selling, general and administrative expenses"&gt;1,896&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c20190101__20191231_pn3n3" style="text-align: right" title="Selling, general and administrative expenses"&gt;13,886&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other (income) expenses, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherExpenses_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other (income) expenses, net"&gt;305&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherExpenses_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other (income) expenses, net"&gt;(207&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_c20200101__20201231_pn3n3" style="text-align: right" title="Operating loss"&gt;1,271&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_c20190101__20191231_pn3n3" style="text-align: right" title="Operating loss"&gt;2,629&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Financial expenses (income), net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet_pn3n3_c20200101__20201231_zGXmlGGliLjl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Financial expenses (income), net"&gt;(29&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet_pn3n3_c20190101__20191231_ztHwbrb670Ki" style="border-bottom: Black 1.5pt solid; text-align: right" title="Financial expenses (income), net"&gt;31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss before income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_c20200101__20201231_pn3n3" style="text-align: right" title="Loss before income taxes"&gt;1,242&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_c20190101__20191231_pn3n3" style="text-align: right" title="Loss before income taxes"&gt;2,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Tax expenses (income)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DiscontinuedOperationTaxEffectOfDiscontinuedOperation_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Tax expenses (income)"&gt;(30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DiscontinuedOperationTaxEffectOfDiscontinuedOperation_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Tax expenses (income)"&gt;792&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss from discontinuing operation, net of tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--IncomeLossFromDiscontinuedOperationNetOfTax_c20200101__20201231_pn3n3" style="text-align: right" title="Net loss from discontinuing operation, net of tax"&gt;1,212&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--IncomeLossFromDiscontinuedOperationNetOfTax_c20190101__20191231_pn3n3" style="text-align: right" title="Net loss from discontinuing operation, net of tax"&gt;3,452&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;DISPOSAL&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gain on disposal before income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_c20200101__20201231_pn3n3" style="text-align: right" title="Gain on disposal before income taxes"&gt;96,918&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_c20190101__20191231_pn3n3" style="text-align: right" title="Gain on disposal before income taxes"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0958"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Provision for income taxes"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0960"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"/&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Provision for income taxes"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0962"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gain on disposal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_c20200101__20201231_pn3n3" style="text-align: right" title="Gain on disposal"&gt;96,918&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_c20190101__20191231_pn3n3" style="text-align: right" title="Gain on disposal"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0966"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net profit (loss) from discontinuing operation, net of tax&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--NetProfitLossFromDiscontinuingOperationNetOfTax_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net profit (loss) from discontinuing operation, net of tax"&gt;95,706&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--NetProfitLossFromDiscontinuingOperationNetOfTax_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net profit (loss) from discontinuing operation, net of tax"&gt;(3,452&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table is a summary of the assets and liabilities of discontinued operations (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;CURRENT ASSETS:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 78%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_pn3n3_c20191231_zVVTRihLJ2J2" style="width: 18%; text-align: right" title="Cash and cash equivalents"&gt;11,281&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Restricted cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--DisposalGroupIncludingDiscontinuedOperationRestrictedCash_c20191231_pn3n3" style="text-align: right" title="Restricted cash"&gt;186&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accounts receivable, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_c20191231_pn3n3" style="text-align: right" title="Accounts receivable, net"&gt;6,654&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Prepaid expenses and other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_c20191231_pn3n3" style="text-align: right" title="Prepaid expenses and other receivables"&gt;845&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Grants receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--DisposalGroupIncludingDiscontinuedOperationGrantsReceivable_c20191231_pn3n3" style="text-align: right" title="Grants receivable"&gt;1,979&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Inventory&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DisposalGroupIncludingDiscontinuedOperationInventory1_c20191231_pn3n3" style="text-align: right" title="Inventory"&gt;1,907&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--DisposalGroupIncludingDiscontinuedOperationsDeposits_c20191231_pn3n3" style="text-align: right" title="Deposits"&gt;326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Property and equipment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_c20191231_pn3n3" style="text-align: right" title="Property and equipment, net"&gt;22,149&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Intangible assets, net (mainly Know How)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_iI_pn3n3_c20191231_zGQWzg7mr6C4" style="text-align: right" title="Intangible assets, net (mainly Know How)"&gt;10,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets_c20191231_pn3n3" style="text-align: right" title="Operating lease right-of-use assets"&gt;8,860&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGoodwill1_c20191231_pn3n3" style="text-align: right" title="Goodwill"&gt;10,129&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Other assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherAssets_c20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other assets"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;TOTAL CURRENT ASSETS OF DISCONTINUED OPERATIONS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperation_iI_pn3n3_c20191231_z50nh6viLcIc" style="border-bottom: Black 2.5pt double; text-align: right" title="TOTAL CURRENT ASSETS OF DISCONTINUED OPERATIONS"&gt;75,221&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;CURRENT LIABILITIES:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 78%; text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayable_c20191231_pn3n3" style="width: 18%; text-align: right" title="Accounts payable"&gt;5,756&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accrued expenses and other payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_c20191231_pn3n3" style="text-align: right" title="Accrued expenses and other payables"&gt;372&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Employees and related payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables_c20191231_pn3n3" style="text-align: right" title="Employees and related payables"&gt;2,047&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Advance payments on account of grant&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant_c20191231_pn3n3" style="text-align: right" title="Advance payments on account of grant"&gt;2,227&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Short-term loans and current maturities of long- term loans&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans_c20191231_pn3n3" style="text-align: right" title="Short-term loans and current maturities of long- term loans"&gt;372&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Contract liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_c20191231_pn3n3" style="text-align: right" title="Contract liabilities"&gt;8,301&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Current maturities of long-term finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases_c20191231_pn3n3" style="text-align: right" title="Current maturities of long-term finance leases"&gt;291&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Current maturities of operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases_c20191231_pn3n3" style="text-align: right" title="Current maturities of operating leases"&gt;1,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Non-current operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases_c20191231_pn3n3" style="text-align: right" title="Non-current operating leases"&gt;7,069&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Loans payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--DisposalGroupIncludingDiscontinuedOperationLoansPayable_c20191231_pn3n3" style="text-align: right" title="Loans payable"&gt;1,230&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Deferred taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_c20191231_pn3n3" style="text-align: right" title="Deferred taxes"&gt;1,868&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Long-term finance leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases_c20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Long-term finance leases"&gt;688&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;TOTAL CURRENT LIABILITIES OF DISCONTINUED OPERATIONS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="TOTAL CURRENT LIABILITIES OF DISCONTINUED OPERATIONS"&gt;31,586&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Property,
plants and equipment, net and right-of-use assets by geographical location were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--PropertyPlantAndEquipmentNetAndRightOfUseAssets_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--US_zphmKqdJ6fB6" style="width: 26%; text-align: right" title="Property, plants and equipment, net and right-of-use assets"&gt;16,707&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Belgium&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--PropertyPlantAndEquipmentNetAndRightOfUseAssets_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--BE_zrqOc8vCk7Rc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property, plants and equipment, net and right-of-use assets"&gt;14,302&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--PropertyPlantAndEquipmentNetAndRightOfUseAssets_iI_pn3n3_c20191231_zJ5y9rAN0zs2" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, plants and equipment, net and right-of-use assets"&gt;31,009&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table represents the components of the cash flows from discontinued operations (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net cash flows used in operating activities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_pn3n3_c20200101__20201231_zacoQ03y73D4" style="width: 14%; text-align: right" title="Net cash flows provided by (used in) operating activities"&gt;(2,409&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_c20190101__20191231_pn3n3" style="width: 14%; text-align: right" title="Net cash flows provided by (used in) operating activities"&gt;(1,248&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net cash flows used in investing activities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_c20200101__20201231_pn3n3" style="text-align: right" title="Net cash flows used in investing activities"&gt;(579&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_c20190101__20191231_pn3n3" style="text-align: right" title="Net cash flows used in investing activities"&gt;(11,621&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net cash flows (used in) provided by financing activities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_c20200101__20201231_pn3n3" style="text-align: right" title="Net cash flows (used in) provided by financing activities"&gt;(51&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_c20190101__20191231_pn3n3" style="text-align: right" title="Net cash flows (used in) provided by financing activities"&gt;12,570&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AB_zMbRXlROwq2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Disaggregation
of Revenue&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_ecustom--ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock_zCO9x69k1qOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table disaggregates the Company&#x2019;s revenues by major revenue streams related to discontinued operations (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zm80mblxonAi" style="display: none"&gt;SCHEDULE OF DISAGGREGATION OF REVENUE RELATED TO DISCONTINUED OPERATIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Revenue stream:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: left"&gt;Cell process development services&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesMember_zmYvscrkc938" style="width: 14%; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue"&gt;2,556&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231__srt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesMember_zi8SlHnnKwZ1" style="width: 14%; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue"&gt;20,834&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Tech transfer services&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--TechTransferServicesMember_zcAyJvlL4sxc" style="text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1048"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231__srt--ProductOrServiceAxis__custom--TechTransferServicesMember_zbf29ju37tFf" style="text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue"&gt;5,396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Cell manufacturing services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--CellManufacturingServicesMember_zdo3UKetmdie" style="border-bottom: Black 1.5pt solid; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1052"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231__srt--ProductOrServiceAxis__custom--CellManufacturingServicesMember_zo6KYpAjIKDb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue"&gt;4,823&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231_zDS1Tqq4vpk3" style="border-bottom: Black 2.5pt double; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue"&gt;2,556&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231_z3CT2nlfEL76" style="border-bottom: Black 2.5pt double; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue"&gt;31,053&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AE_zdgAKf1XHhVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Redeemable
Non-Controlling Interest of Discontinued Operations&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;a.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Subscription
    and Shareholders Agreement with Belgian Sovereign Funds Soci&#xe9;t&#xe9; F&#xe9;d&#xe9;rale de Participations et
    d&#x2019;Investissement (&#x201c;SFPI&#x201d;).&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
November 15, 2017, the Company, MaSTherCell and SFPI entered into a Subscription and Shareholders Agreement (&#x201c;SFPI Agreement&#x201d;)
pursuant to which SFPI made an equity investment in MaSTherCell.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Due
to the embedded redemption feature of the SPFI agreement whose settlement was not at the Company discretion, the Company had accounted
for the investment made by GPP as a redeemable non-controlling interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;b.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Stock
    Purchase Agreement and Stockholders&#x2019; Agreement with Great Point Partners, LLC (&#x201c;GPP&#x201d;)&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
June 28, 2018, the Company, Masthercell Global GPP, and certain of GPP&#x2019;s affiliates, entered into a series of
definitive strategic agreements intended to finance, strengthen and expand Orgenesis&#x2019; CDMO business. Due to the
embedded redemption feature of the GPP agreement whose settlement was not at the Company discretion, the Company had
accounted for the investment made by GPP as a redeemable non-controlling interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <ORGS:PercentageOfOutstandingEquityInterests
      contextRef="AsOf2020-02-02_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="Percentage">1</ORGS:PercentageOfOutstandingEquityInterests>
    <ORGS:AggregateNominalPurchasePrice
      contextRef="From2020-02-012020-02-02_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      unitRef="USD">315000000</ORGS:AggregateNominalPurchasePrice>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2020-02-092020-02-10_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      unitRef="USD">126700000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <ORGS:RepaymentOfIntercompanyLoansAndPayables
      contextRef="From2020-02-092020-02-10_custom_MasthercellMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      unitRef="USD">7200000</ORGS:RepaymentOfIntercompanyLoansAndPayables>
    <ORGS:RepaymentOfIntercompanyLoansAndPayables
      contextRef="From2020-02-092020-02-10_custom_MasthercellSAMember"
      decimals="-5"
      unitRef="USD">4600000</ORGS:RepaymentOfIntercompanyLoansAndPayables>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zmkQyrHutPYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
financial results of the Masthercell Business are presented as income (loss) from discontinued operations, net of income taxes
on the Company&#x2019;s consolidated statement of comprehensive loss. The following table presents the financial results associated
with the Masthercell Business operation as reflected in the Company&#x2019;s Consolidated Comprehensive loss (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B6_zpoTCAyl7kKi" style="display: none"&gt;SCHEDULE OF DISCONTINUED OPERATION AND BALANCE SHEETS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"/&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;OPERATIONS&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231_zeOdHvQTFCM3" style="width: 14%; text-align: right" title="Revenues"&gt;2,556&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231_zDshnLGkj0M8" style="width: 14%; text-align: right" title="Revenues"&gt;31,053&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cost of revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c20200101__20201231_pn3n3" style="text-align: right" title="Cost of revenues"&gt;1,482&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c20190101__20191231_pn3n3" style="text-align: right" title="Cost of revenues"&gt;18,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Cost of research and development and research and development services, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet_c20200101__20201231_pn3n3" style="text-align: right" title="Cost of research and development and research and development services, net"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet_c20190101__20191231_pn3n3" style="text-align: right" title="Cost of research and development and research and development services, net"&gt;54&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Amortization of intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DepreciationAndAmortizationDiscontinuedOperations_c20200101__20201231_pn3n3" style="text-align: right" title="Amortization of intangible assets"&gt;137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DepreciationAndAmortizationDiscontinuedOperations_c20190101__20191231_pn3n3" style="text-align: right" title="Amortization of intangible assets"&gt;1,631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Selling, general and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c20200101__20201231_pn3n3" style="text-align: right" title="Selling, general and administrative expenses"&gt;1,896&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c20190101__20191231_pn3n3" style="text-align: right" title="Selling, general and administrative expenses"&gt;13,886&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other (income) expenses, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherExpenses_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other (income) expenses, net"&gt;305&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherExpenses_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other (income) expenses, net"&gt;(207&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_c20200101__20201231_pn3n3" style="text-align: right" title="Operating loss"&gt;1,271&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_c20190101__20191231_pn3n3" style="text-align: right" title="Operating loss"&gt;2,629&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Financial expenses (income), net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet_pn3n3_c20200101__20201231_zGXmlGGliLjl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Financial expenses (income), net"&gt;(29&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet_pn3n3_c20190101__20191231_ztHwbrb670Ki" style="border-bottom: Black 1.5pt solid; text-align: right" title="Financial expenses (income), net"&gt;31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss before income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_c20200101__20201231_pn3n3" style="text-align: right" title="Loss before income taxes"&gt;1,242&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_c20190101__20191231_pn3n3" style="text-align: right" title="Loss before income taxes"&gt;2,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Tax expenses (income)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DiscontinuedOperationTaxEffectOfDiscontinuedOperation_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Tax expenses (income)"&gt;(30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DiscontinuedOperationTaxEffectOfDiscontinuedOperation_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Tax expenses (income)"&gt;792&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss from discontinuing operation, net of tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--IncomeLossFromDiscontinuedOperationNetOfTax_c20200101__20201231_pn3n3" style="text-align: right" title="Net loss from discontinuing operation, net of tax"&gt;1,212&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--IncomeLossFromDiscontinuedOperationNetOfTax_c20190101__20191231_pn3n3" style="text-align: right" title="Net loss from discontinuing operation, net of tax"&gt;3,452&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;DISPOSAL&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gain on disposal before income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_c20200101__20201231_pn3n3" style="text-align: right" title="Gain on disposal before income taxes"&gt;96,918&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_c20190101__20191231_pn3n3" style="text-align: right" title="Gain on disposal before income taxes"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0958"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Provision for income taxes"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0960"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"/&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Provision for income taxes"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0962"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gain on disposal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_c20200101__20201231_pn3n3" style="text-align: right" title="Gain on disposal"&gt;96,918&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_c20190101__20191231_pn3n3" style="text-align: right" title="Gain on disposal"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0966"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net profit (loss) from discontinuing operation, net of tax&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--NetProfitLossFromDiscontinuingOperationNetOfTax_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net profit (loss) from discontinuing operation, net of tax"&gt;95,706&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--NetProfitLossFromDiscontinuingOperationNetOfTax_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net profit (loss) from discontinuing operation, net of tax"&gt;(3,452&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table is a summary of the assets and liabilities of discontinued operations (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;CURRENT ASSETS:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 78%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_pn3n3_c20191231_zVVTRihLJ2J2" style="width: 18%; text-align: right" title="Cash and cash equivalents"&gt;11,281&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Restricted cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--DisposalGroupIncludingDiscontinuedOperationRestrictedCash_c20191231_pn3n3" style="text-align: right" title="Restricted cash"&gt;186&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accounts receivable, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_c20191231_pn3n3" style="text-align: right" title="Accounts receivable, net"&gt;6,654&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Prepaid expenses and other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_c20191231_pn3n3" style="text-align: right" title="Prepaid expenses and other receivables"&gt;845&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Grants receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--DisposalGroupIncludingDiscontinuedOperationGrantsReceivable_c20191231_pn3n3" style="text-align: right" title="Grants receivable"&gt;1,979&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Inventory&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DisposalGroupIncludingDiscontinuedOperationInventory1_c20191231_pn3n3" style="text-align: right" title="Inventory"&gt;1,907&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--DisposalGroupIncludingDiscontinuedOperationsDeposits_c20191231_pn3n3" style="text-align: right" title="Deposits"&gt;326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Property and equipment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_c20191231_pn3n3" style="text-align: right" title="Property and equipment, net"&gt;22,149&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Intangible assets, net (mainly Know How)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_iI_pn3n3_c20191231_zGQWzg7mr6C4" style="text-align: right" title="Intangible assets, net (mainly Know How)"&gt;10,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets_c20191231_pn3n3" style="text-align: right" title="Operating lease right-of-use assets"&gt;8,860&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGoodwill1_c20191231_pn3n3" style="text-align: right" title="Goodwill"&gt;10,129&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Other assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherAssets_c20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other assets"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;TOTAL CURRENT ASSETS OF DISCONTINUED OPERATIONS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperation_iI_pn3n3_c20191231_z50nh6viLcIc" style="border-bottom: Black 2.5pt double; text-align: right" title="TOTAL CURRENT ASSETS OF DISCONTINUED OPERATIONS"&gt;75,221&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;CURRENT LIABILITIES:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 78%; text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayable_c20191231_pn3n3" style="width: 18%; text-align: right" title="Accounts payable"&gt;5,756&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accrued expenses and other payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_c20191231_pn3n3" style="text-align: right" title="Accrued expenses and other payables"&gt;372&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Employees and related payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables_c20191231_pn3n3" style="text-align: right" title="Employees and related payables"&gt;2,047&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Advance payments on account of grant&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant_c20191231_pn3n3" style="text-align: right" title="Advance payments on account of grant"&gt;2,227&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Short-term loans and current maturities of long- term loans&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans_c20191231_pn3n3" style="text-align: right" title="Short-term loans and current maturities of long- term loans"&gt;372&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Contract liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_c20191231_pn3n3" style="text-align: right" title="Contract liabilities"&gt;8,301&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Current maturities of long-term finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases_c20191231_pn3n3" style="text-align: right" title="Current maturities of long-term finance leases"&gt;291&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Current maturities of operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases_c20191231_pn3n3" style="text-align: right" title="Current maturities of operating leases"&gt;1,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Non-current operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases_c20191231_pn3n3" style="text-align: right" title="Non-current operating leases"&gt;7,069&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Loans payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--DisposalGroupIncludingDiscontinuedOperationLoansPayable_c20191231_pn3n3" style="text-align: right" title="Loans payable"&gt;1,230&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Deferred taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_c20191231_pn3n3" style="text-align: right" title="Deferred taxes"&gt;1,868&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Long-term finance leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases_c20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Long-term finance leases"&gt;688&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;TOTAL CURRENT LIABILITIES OF DISCONTINUED OPERATIONS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="TOTAL CURRENT LIABILITIES OF DISCONTINUED OPERATIONS"&gt;31,586&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Property,
plants and equipment, net and right-of-use assets by geographical location were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--PropertyPlantAndEquipmentNetAndRightOfUseAssets_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--US_zphmKqdJ6fB6" style="width: 26%; text-align: right" title="Property, plants and equipment, net and right-of-use assets"&gt;16,707&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Belgium&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--PropertyPlantAndEquipmentNetAndRightOfUseAssets_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--BE_zrqOc8vCk7Rc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property, plants and equipment, net and right-of-use assets"&gt;14,302&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--PropertyPlantAndEquipmentNetAndRightOfUseAssets_iI_pn3n3_c20191231_zJ5y9rAN0zs2" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, plants and equipment, net and right-of-use assets"&gt;31,009&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table represents the components of the cash flows from discontinued operations (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net cash flows used in operating activities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_pn3n3_c20200101__20201231_zacoQ03y73D4" style="width: 14%; text-align: right" title="Net cash flows provided by (used in) operating activities"&gt;(2,409&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_c20190101__20191231_pn3n3" style="width: 14%; text-align: right" title="Net cash flows provided by (used in) operating activities"&gt;(1,248&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net cash flows used in investing activities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_c20200101__20201231_pn3n3" style="text-align: right" title="Net cash flows used in investing activities"&gt;(579&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_c20190101__20191231_pn3n3" style="text-align: right" title="Net cash flows used in investing activities"&gt;(11,621&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net cash flows (used in) provided by financing activities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_c20200101__20201231_pn3n3" style="text-align: right" title="Net cash flows (used in) provided by financing activities"&gt;(51&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_c20190101__20191231_pn3n3" style="text-align: right" title="Net cash flows (used in) provided by financing activities"&gt;12,570&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">2556000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">31053000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1482000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">18318000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <ORGS:CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">7000</ORGS:CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet>
    <ORGS:CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">54000</ORGS:CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">137000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">1631000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1896000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">13886000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <ORGS:DisposalGroupIncludingDiscontinuedOperationOtherExpenses
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">305000</ORGS:DisposalGroupIncludingDiscontinuedOperationOtherExpenses>
    <ORGS:DisposalGroupIncludingDiscontinuedOperationOtherExpenses
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-207000</ORGS:DisposalGroupIncludingDiscontinuedOperationOtherExpenses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1271000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">2629000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <ORGS:DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-29000</ORGS:DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet>
    <ORGS:DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">31000</ORGS:DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1242000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">2660000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-30000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">792000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <ORGS:IncomeLossFromDiscontinuedOperationNetOfTax
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1212000</ORGS:IncomeLossFromDiscontinuedOperationNetOfTax>
    <ORGS:IncomeLossFromDiscontinuedOperationNetOfTax
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">3452000</ORGS:IncomeLossFromDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">96918000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">96918000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax>
    <ORGS:NetProfitLossFromDiscontinuingOperationNetOfTax
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">95706000</ORGS:NetProfitLossFromDiscontinuingOperationNetOfTax>
    <ORGS:NetProfitLossFromDiscontinuingOperationNetOfTax
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-3452000</ORGS:NetProfitLossFromDiscontinuingOperationNetOfTax>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">11281000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <ORGS:DisposalGroupIncludingDiscontinuedOperationRestrictedCash contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">186000</ORGS:DisposalGroupIncludingDiscontinuedOperationRestrictedCash>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">6654000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">845000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets>
    <ORGS:DisposalGroupIncludingDiscontinuedOperationGrantsReceivable contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">1979000</ORGS:DisposalGroupIncludingDiscontinuedOperationGrantsReceivable>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1 contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">1907000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
    <ORGS:DisposalGroupIncludingDiscontinuedOperationsDeposits contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">326000</ORGS:DisposalGroupIncludingDiscontinuedOperationsDeposits>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">22149000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">10858000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <ORGS:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">8860000</ORGS:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1 contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">10129000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">47000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">75221000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">5756000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">372000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities>
    <ORGS:DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">2047000</ORGS:DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables>
    <ORGS:DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">2227000</ORGS:DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant>
    <ORGS:DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">372000</ORGS:DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">8301000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities>
    <ORGS:DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">291000</ORGS:DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases>
    <ORGS:DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">1365000</ORGS:DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases>
    <ORGS:DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">7069000</ORGS:DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases>
    <ORGS:DisposalGroupIncludingDiscontinuedOperationLoansPayable contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">1230000</ORGS:DisposalGroupIncludingDiscontinuedOperationLoansPayable>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">1868000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities>
    <ORGS:DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">688000</ORGS:DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">31586000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <ORGS:PropertyPlantAndEquipmentNetAndRightOfUseAssets
      contextRef="AsOf2019-12-31_country_US"
      decimals="-3"
      unitRef="USD">16707000</ORGS:PropertyPlantAndEquipmentNetAndRightOfUseAssets>
    <ORGS:PropertyPlantAndEquipmentNetAndRightOfUseAssets
      contextRef="AsOf2019-12-31_country_BE"
      decimals="-3"
      unitRef="USD">14302000</ORGS:PropertyPlantAndEquipmentNetAndRightOfUseAssets>
    <ORGS:PropertyPlantAndEquipmentNetAndRightOfUseAssets contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">31009000</ORGS:PropertyPlantAndEquipmentNetAndRightOfUseAssets>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-2409000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-1248000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-579000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-11621000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-51000</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">12570000</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <ORGS:ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_896_ecustom--ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock_zCO9x69k1qOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table disaggregates the Company&#x2019;s revenues by major revenue streams related to discontinued operations (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zm80mblxonAi" style="display: none"&gt;SCHEDULE OF DISAGGREGATION OF REVENUE RELATED TO DISCONTINUED OPERATIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Revenue stream:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: left"&gt;Cell process development services&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesMember_zmYvscrkc938" style="width: 14%; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue"&gt;2,556&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231__srt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesMember_zi8SlHnnKwZ1" style="width: 14%; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue"&gt;20,834&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Tech transfer services&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--TechTransferServicesMember_zcAyJvlL4sxc" style="text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1048"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231__srt--ProductOrServiceAxis__custom--TechTransferServicesMember_zbf29ju37tFf" style="text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue"&gt;5,396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Cell manufacturing services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--CellManufacturingServicesMember_zdo3UKetmdie" style="border-bottom: Black 1.5pt solid; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1052"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231__srt--ProductOrServiceAxis__custom--CellManufacturingServicesMember_zo6KYpAjIKDb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue"&gt;4,823&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231_zDS1Tqq4vpk3" style="border-bottom: Black 2.5pt double; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue"&gt;2,556&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231_z3CT2nlfEL76" style="border-bottom: Black 2.5pt double; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue"&gt;31,053&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</ORGS:ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="From2020-01-012020-12-31_custom_CellProcessDevelopmentServicesMember"
      decimals="-3"
      unitRef="USD">2556000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="From2019-01-012019-12-31_custom_CellProcessDevelopmentServicesMember"
      decimals="-3"
      unitRef="USD">20834000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="From2019-01-012019-12-31_custom_TechTransferServicesMember"
      decimals="-3"
      unitRef="USD">5396000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="From2019-01-012019-12-31_custom_CellManufacturingServicesMember"
      decimals="-3"
      unitRef="USD">4823000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">2556000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">31053000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <ORGS:AcquisitionAndReorganizationTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_805_ecustom--AcquisitionAndReorganizationTextBlock_zApP4DXnF3ge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
4 &#x2013; &lt;span id="xdx_82F_zNMSOub0OWC3"&gt;ACQUISITION AND REORGANIZATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Tamir
Biotechnology, Inc.&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
April 7, 2020, the Company entered into the Tamir Purchase Agreement with Tamir, pursuant to which the Company agreed to acquire
certain assets and liabilities of Tamir related to the discovery, development and testing of therapeutic products for the treatment
of diseases and conditions in humans, including all rights to Ranpirnase and use for antiviral therapy. The Tamir Transaction
closed on April 23, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
aggregate consideration for the acquisition, the Company paid $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pn5n6_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zBxjUOcsNzRi" title="Stock issued during period value acquisitions"&gt;2.5&lt;/span&gt; million in cash and issued an aggregate of &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pii_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zbTMUQ8HNTBi" title="Shares issued, acquisition"&gt;3,400,000&lt;/span&gt; shares
(the &#x201c;Shares&#x201d;) of Common Stock to Tamir resulting in a total consideration of $&lt;span id="xdx_90D_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zAvLQRdRVvGe" title="Business Combination, Consideration Transferred"&gt;20.2&lt;/span&gt; million based on the Company&#x2019;s
share price at the closing date. $&lt;span id="xdx_907_eus-gaap--EscrowDeposit_iI_pn3n3_c20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zKluibrst0Wd" title="Escrow Deposit"&gt;59&lt;/span&gt; thousand and &lt;span id="xdx_901_ecustom--NumberOfSharesDepositInEscrowAccount_pii_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zRn641sDS4g2" title="Number of shares deposit in escrow account"&gt;340,000&lt;/span&gt; Shares are being held in an escrow account for a period of 18 months
from closing to secure indemnification obligations of Tamir pursuant to the terms of the Tamir Purchase Agreement. $&lt;span id="xdx_900_ecustom--BusinessCombinationConsiderationTransferred_pn5n6_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zTibqOyYTWCf" title="Total consideration"&gt;4.5&lt;/span&gt; million
of the consideration was attributable to research and development related inventory and most of the remaining amount reflected
the cost of intangible assets. The Shares were registered for resale by the Company in November 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s acquired right to Tamir&#x2019;s intellectual property represents a single identifiable asset sourced from the
agreement. Because substantially all (more than 90%) of the fair value of the gross assets acquired are concentrated in a single
asset being the right to Tamir&#x2019;s intellectual property and related assets (&#x201c;IPR&amp;amp;D&#x201d;), the Company determined
that the acquisition is not considered a business in accordance with ASC 805-10-55-5A. Therefore, the Company accounted the transaction
as an asset acquisition. The fair value associated with Tamir&#x2019;s IPR&amp;amp;D in the amount of $&lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_z0ewOEClv3wl" title="Research and Development Expense"&gt;19.5&lt;/span&gt; million was charged to
research and development expenses under ASC 730. The remaining amount was attributed to the above-mentioned share in a private
company, which is presented in the balance sheet as long term &#x201c;other assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Description
of Koligo Acquisition during 2020&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
September 26, 2020, the Company entered into an Agreement and Plan of Merger and Reorganization (the &#x201c;Merger Agreement&#x201d;)
by and among the Company, Orgenesis Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (&#x201c;Merger
Sub&#x201d;), Koligo Therapeutics Inc., a Kentucky corporation (&#x201c;Koligo&#x201d;), the shareholders of Koligo (collectively,
the &#x201c;Shareholders&#x201d;), and Long Hill Capital V, LLC (&#x201c;Long Hill&#x201d;), solely in its capacity as the representative,
agent and attorney-in-fact of the Shareholders. The Merger Agreement provides for the acquisition of Koligo by the Company through
the merger of Merger Sub with and into Koligo, with Koligo surviving as a wholly-owned subsidiary of the Company (the &#x201c;Merger&#x201d;).
The acquisition was completed on October 15, 2020 (the &#x201c;Effective Time&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Koligo
is a privately-held US regenerative medicine company. Koligo&#x2019;s first commercial product is KYSLECEL&#xae; (autologous pancreatic
islets) for chronic and acute recurrent pancreatitis. Koligo&#x2019;s 3D-V technology platform incorporates the use of advanced
3D bioprinting techniques and vascular endothelial cells to support development of transformational cell and tissue products for
serious diseases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant
to the terms of the Merger Agreement, at the Effective Time, the shares of capital stock of Koligo that were issued and outstanding
immediately prior to the Effective Time were automatically cancelled and converted into the right to receive, subject to customary
adjustments, an aggregate of &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pii_c20201014__20201015__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--MaterialDefinitiveAgreementMember_zGcVmhNbUwB3"&gt;2,061,713
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;shares of Company common stock which
have been issued to Koligo&#x2019;s accredited investors (with certain non-accredited investors being paid solely in cash in
the amount of approximately $&lt;span id="xdx_905_ecustom--CashPaidToAccreditedInvestors_pn3n3_c20201014__20201015__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--MaterialDefinitiveAgreementMember_zGpx3FcbLVmk" title="Cash paid to accredited investors"&gt;20
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;thousand). In addition, we issued &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20201014__20201015__dei--LegalEntityAxis__custom--MaximaGroupLLCMember_zpCXUCeVXnr4"&gt;66,910&lt;/span&gt;
shares to Maxim Group LLC for advisory services&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt; in connection
with the Merger. The share price was $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pii_c20201015__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--MaterialDefinitiveAgreementMember_zm7taXrIMAj7"&gt;5.26
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;at the day of the closing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Merger Agreement contains customary indemnification provisions whereby the Shareholders of Koligo will indemnify the Company and
certain affiliated parties for any losses arising out of breaches of the representations, warranties and covenants of Koligo and
the Shareholders under the Merger Agreement. As partial security for the indemnification and purchase price adjustment obligations
of Koligo shareholders under the Merger Agreement, $&lt;span id="xdx_90F_eus-gaap--EscrowDeposit_iI_pn3n3_c20201015__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--MaterialDefinitiveAgreementMember_z40mcdEKpc7a" title="Cash held in escrow account"&gt;7&lt;/span&gt; thousand in cash and &lt;span id="xdx_909_ecustom--SharesHeldInEscrow_pii_c20201014__20201015__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--MaterialDefinitiveAgreementMember_zd5VTQj77s6g" title="Shares held in escrow"&gt;328,587&lt;/span&gt; shares of Company common stock of the merger
consideration otherwise payable in the Merger to the Shareholders were placed in a third party escrow account. The aggregate indemnification
obligations of the Koligo shareholders under the Merger Agreement is capped at the amounts in escrow, subject to certain limited
exceptions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
addition, according to the agreement between the parties, the Company has also funded an additional cash consideration of $&lt;span id="xdx_900_ecustom--AdditionalCashConsideration_pn3n3_c20201014__20201015__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--MaterialDefinitiveAgreementMember_zbdhd01wAtwh" title="Additional cash consideration"&gt;500&lt;/span&gt;
thousand (with $&lt;span id="xdx_90D_ecustom--ReductionInConsiderationPayable_pn3n3_c20201014__20201015__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--MaterialDefinitiveAgreementMember_zLTXPNlbeaGa" title="Reduction in consideration payable"&gt;100&lt;/span&gt; thousand of such reducing the ultimate consideration payable to Koligo) for the acquisition of the assets
of Tissue Genesis, LLC (&#x201c;Tissue Genesis&#x201d;) by Koligo that was consummated on October 14, 2020. The Tissue Genesis assets
include the entire inventory of Tissue Genesis Icellator&#xae; devices, related kits and reagents, a broad patent portfolio to
protect the technology, registered trademarks, clinical data, and existing business relationships for commercial and development
stage use of the Icellator technology.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
connection with the Merger Agreement, the Company, Long Hill and Maxim Group LLC (&#x201c;Maxim&#x201d;) entered into a Registration
Rights and Lock-Up Agreement pursuant to which Long Hill will have one demand registration right to require the registration of
the shares of Company common stock received by Long Hill in the Merger and Long Hill and Maxim will have certain piggyback registration
rights. In addition, Long Hill agreed with the Company that, during the applicable Restriction Period (as defined below), it shall
not sell or transfer, subject to certain limited exceptions, the portion of the shares received in the Merger during the applicable
Restriction Period, subject to a limitation on the number of shares sold per any trading day not to exceed &lt;span id="xdx_90D_ecustom--RestrictionOnSaleOfSharesPercentage_pii_dp_uPercentage_c20201014__20201015__dei--LegalEntityAxis__custom--LongHillAndMaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsandLockUpAgreementMember_z32ak6MQfMZ2" title="Restriction on sale of shares percentage"&gt;10&lt;/span&gt;% of the average
daily trading volume of the Common Stock, as reported by Bloomberg Financial L.P. &#x201c;Restriction Period&#x201d; means &lt;span id="xdx_904_ecustom--RestrictionPeriodDescription_c20201014__20201015__dei--LegalEntityAxis__custom--LongHillAndMaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsandLockUpAgreementMember_z1Y7fRHKmZ3b" title="Restriction period, description"&gt;(a) in
relation to 70% of all of the shares received in the Merger that Long Hill is entitled to receive under or in connection with
the Merger Agreement, the period beginning on the date of the closing and ending on the date that is the four month anniversary
thereof, and (b) in relation to the remaining 30% of all of the shares received in the Merger that Long Hill is entitled to receive
under or in connection with the Merger Agreement, the period beginning on the date of the closing and ending on the date that
is the twelve month anniversary thereof&lt;/span&gt;. All of the shares required to be registered by the Company pursuant to the Registration
Rights and Lock-Up Agreement were registered by the Company in November 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
addition, pursuant to separate Lock-Up Agreements entered into by the Shareholders other than Long Hill with the Company (the
&#x201c;Shareholders Lock-Up Agreement&#x201d;), such Shareholders agreed that they will not transfer any of their shares received
in the Merger except in accordance with the following lock-up release schedule whereby one fifth of such holder&#x2019;s respective
shares will be released from such restriction every six months, starting six months from the closing of the Merger. Each holder&#x2019;s
sales of such shares are subject to a resale limit of its pro rata portion of 10% of the average daily trading volume, allocated
to the Shareholders other than Long Hill pro-rata.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
acquisition was accounted in accordance with Accounting Standards Codification Topic 805, &#x201c;Business Combinations&#x201d;.
The allocation of the consideration transferred in certain cases may be subject to revision based on the final determination of
fair values during the measurement period, which may be up to one year from the acquisition date. The Company includes the results
of operations of the business that it has acquired in its consolidated results prospectively from the date of acquisition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Fair
Value of Consideration Transferred&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zWeonuaKo7se" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the allocation of purchase price to the fair values of the assets acquired and liabilities assumed
as of the transaction date:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B2_z8408OO7tIP9" style="display: none"&gt;SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20201231_z1qrVyAOpNob" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued_iI_pn3n3_maBCRIAzxgu_zpZljblX2cRk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%"&gt;Fair value of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_ecustom--FairValuePercentageofSharesIssued_iI_pii_dp_uPercentage_c20201231_zmr08iQJvnDa" title="Fair value percentage of shares issued"&gt;8.8&lt;/span&gt;% of shared issued *&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span id="xdx_F47_zz9L2sR0yq73" style="display: none; font-family: Times New Roman, Times, Serif"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;11,172&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments_iI_pn3n3_maBCRIAzxgu_ziNdtG7LgITh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cash payment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,115&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_pn3n3_mtBCRIAzxgu_zxQF4lTwThg8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total consideration transferred&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;12,287&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td id="xdx_F01_zLuqe2CpwNid" style="width: 1.2%"&gt;*&lt;/td&gt;
    &lt;td id="xdx_F1F_zSzpzffwMp64" style="width: 50%"&gt;Fair value of the consideration is based on the company&#x2019;s market share price.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Total assets acquired:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 78%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pn3n3_c20201231_zaA0VUMeje8b" style="width: 18%; text-align: right" title="Cash and cash equivalents"&gt;8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Restricted Cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_iI_pn3n3_c20201231_zzdW7jHhqefd" style="text-align: right" title="Restricted Cash"&gt;152&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accounts Receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_pn3n3_c20201231_zmNyRNKuCKLk" style="text-align: right" title="Accounts Receivable"&gt;228&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Inventory&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iI_pn3n3_c20201231_zq9T4Dy5pkpl" style="text-align: right" title="Inventory"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Other assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_iI_pn3n3_c20201231_ztTVWWU6d3Td" style="text-align: right" title="Other assets"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Property, plants and equipment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pn3n3_c20201231_zYmz0iITYuui" style="text-align: right" title="Property, plants and equipment, net"&gt;482&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Kyslecel Technology (a)&lt;/td&gt;&lt;td id="xdx_F46_zu1500R9cTqk" style="display: none"&gt;(a)&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_fYQ_____zKffF8VCEZO7" style="text-align: right" title="Other intangible assets"&gt;9,340&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;IPR&amp;amp;D (a)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_fYQ_____zidQJTdSBsef" style="text-align: right" title="Other intangible assets"&gt;641&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_iI_pn3n3_c20201231_z9LX9XnVFREh" style="text-align: right" title="Operating lease right-of-use assets"&gt;238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Goodwill (b)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill_iI_pn3n3_c20201231_fYg_____zAz3kQsaxVRf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill"&gt;3,704&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_pn3n3_c20201231_zRe9GSXqKHJ" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total assets"&gt;14,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Total liabilities assumed:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease_iI_pn3n3_c20201231_zKR13To8FmJ7" style="text-align: right" title="Operating leases"&gt;238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accounts Payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_pn3n3_c20201231_ze56KYhWrkt5" style="text-align: right" title="Accounts Payable"&gt;216&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accrued Expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_iI_pn3n3_c20201231_zgv0xezpFr98" style="text-align: right" title="Accrued Expenses"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Orgenesis Inc loan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability_iI_pn3n3_c20201231_zuLlfxIelzwa" style="text-align: right" title="Orgenesis Inc loan"&gt;651&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Deferred taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_iI_pn3n3_c20201231_zu8WyHo2SLR9" style="text-align: right" title="Deferred taxes"&gt;1,293&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Notes Payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_iI_pn3n3_c20201231_zvF4ICtmkrCe" style="text-align: right" title="Notes Payable"&gt;162&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Other liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_iI_pn3n3_c20201231_zWoir7e4LwZ3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other liabilities"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_pn3n3_c20201231_zcqPJQYzOgd3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total liabilities"&gt;2,565&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: italic; text-align: left; padding-bottom: 2.5pt"&gt;Total consideration transferred&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pn3n3_c20201231_zIIXbRMFwIa4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred"&gt;12,287&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 1.2%; text-align: right"&gt;&lt;span id="xdx_F0D_zmsOFibs8cqa" style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 50%"&gt;&lt;span id="xdx_F16_zzszZc7HaF43" style="font: 10pt Times New Roman, Times, Serif"&gt;The
                                         allocation of the purchase price to the net assets acquired and liabilities assumed resulted
                                         in the recognition of other intangible assets which comprised of: Kyslecel Technology
                                         of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_zkEyoPQjdj0e" title="Other intangible assets"&gt;9,340&lt;/span&gt; and IPR&amp;amp;D of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_zbaY6aSbgAC8" title="Other intangible assets"&gt;641&lt;/span&gt;. Kyslecel Technology has a useful life of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_zYRTWIzaNSq8" title="Useful life"&gt;15&lt;/span&gt; years. The
                                         useful life of these intangible assets for amortization purposes was determined considering
                                         the period of expected cash flows generated by the assets used to measure the fair value
                                         of the intangible assets adjusted as appropriate for the entity-specific factors, including
                                         legal, regulatory, contractual, competitive, economic or other factors that may limit
                                         the useful life of intangible assets.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
intangible assets were estimated using a discounted cash flow method with the application of the multi-period excess earnings
method. Under this method, an intangible asset&#x2019;s fair value is equal to the present value of the incremental after-tax cash
flows attributable only to the subject intangible asset after deducting contributory asset charges. An income and expenses forecast
were built based upon revenue and expense estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 1.2%; text-align: right"&gt;&lt;span id="xdx_F08_zwXN3l4aZ3rl" style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 50%"&gt;&lt;span id="xdx_F14_zGdT76xRwTL" style="font: 10pt Times New Roman, Times, Serif"&gt;The primary
items that generate goodwill include the value of the synergies between the acquired company and the Company and the acquired
assembled workforce, neither of which qualifies for recognition as an intangible asset. The Goodwill is not deductible for tax
purposes.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AF_znSjyyQGYlq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Pro
forma Impact of Business Combination&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
unaudited pro forma financial results have been prepared using the acquisition method of accounting and are based on the historical
financial information of the Company and Koligo. The unaudited pro forma condensed financial results have been prepared for illustrative
purposes only and do not purport to be indicative of the results of operations that actually would have resulted had the acquisition
of Koligo occurred at the beginning of the fiscal year, or of future results of the combined entities. The unaudited pro forma
condensed financial information does not reflect any operating efficiencies and expected realization of cost savings or synergies
associated with the acquisition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_z7erDNuy7OUf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Unaudited
supplemental pro forma combined results of operations (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zNvvKHaYkemd" style="display: none"&gt;SCHEDULE OF UNAUDITED SUPPLEMENTAL PRO FORMA&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20200101__20201231__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_zZnB1kWTVapb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20190101__20191231__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_zdjNqHXzKmgd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zQkIcQPJ7PDk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; padding-bottom: 2.5pt"&gt;Revenues&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;8,239&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;4,398&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--ProfitLoss_pn3n3_zeJXVLbN19e9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;318&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;27,263&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Loss per share:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--EarningsPerShareBasic_pii_zas48cbihrHe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Basic&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.05&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.91&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A7_zcChthqUgVvf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Koligo&#x2019;s
related actual results from the date of acquisition to December 31, 2020 resulted in a loss of $&lt;span id="xdx_90E_eus-gaap--NetIncomeLoss_pn3n3_c20200101__20201231__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_zViwJXPQHkK4" title="Net Loss"&gt;513&lt;/span&gt; thousand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i/&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Koligo&#x2019;s
Acquisition-related Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Acquisition-related
expenses consist of transaction costs which represent external costs directly related to the acquisition of Koligo and primarily
include expenditures for professional fees such as legal, accounting and other directly related incremental costs incurred to
close the acquisition by both the Company and Koligo.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Acquisition-related
expenses for the year ended December 31, 2020 were $&lt;span id="xdx_90B_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_pn3n3_c20200101__20201231__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_zzU5VvHDY1f7" title="Acquisition-related expenses"&gt;682&lt;/span&gt; thousand. These expenses were recorded to selling and general administrative
expense in the consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Cooperate
reorganization, description of the Transactions Korea and OBI during 2019&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
August 7, 2019, the Company, Masthercell Global and GPP-II Masthercell, LLC, a Delaware limited liability company (&#x201c;GPP-II&#x201d;),
(the &#x201c;Parties&#x201d;) entered into a Transfer Agreement (the &#x201c;Transfer Agreement&#x201d;). As a result of the Transfer
Agreement, Masthercell Global transferred all of its equity interests of OBI and the Korean Subsidiary to Orgenesis Inc in exchange
for one dollar ($&lt;span id="xdx_906_eus-gaap--BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_pp0p0_c20190806__20190807__us-gaap--TypeOfArrangementAxis__custom--TransferAgreementMember_zZtK8opGDRxb" title="Transfer of equity interests"&gt;1.00&lt;/span&gt;). The Transfer Agreement also contained agreements made with respect to certain intercompany loans. The
Company accounted for the Transfer Agreement as a transaction with non-controlling interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ORGS:AcquisitionAndReorganizationTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember"
      decimals="-5"
      unitRef="USD">2500000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">3400000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember"
      decimals="-5"
      unitRef="USD">20200000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:EscrowDeposit
      contextRef="AsOf2020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember"
      decimals="-3"
      unitRef="USD">59000</us-gaap:EscrowDeposit>
    <ORGS:NumberOfSharesDepositInEscrowAccount
      contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">340000</ORGS:NumberOfSharesDepositInEscrowAccount>
    <ORGS:BusinessCombinationConsiderationTransferred
      contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember"
      decimals="-5"
      unitRef="USD">4500000</ORGS:BusinessCombinationConsiderationTransferred>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember"
      decimals="-5"
      unitRef="USD">19500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2020-10-142020-10-15_custom_KoligoTherapeuticsIncMember_custom_MaterialDefinitiveAgreementMember"
      decimals="INF"
      unitRef="Shares">2061713</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <ORGS:CashPaidToAccreditedInvestors
      contextRef="From2020-10-142020-10-15_custom_KoligoTherapeuticsIncMember_custom_MaterialDefinitiveAgreementMember"
      decimals="-3"
      unitRef="USD">20000</ORGS:CashPaidToAccreditedInvestors>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2020-10-142020-10-15_custom_MaximaGroupLLCMember"
      decimals="INF"
      unitRef="Shares">66910</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2020-10-15_custom_KoligoTherapeuticsIncMember_custom_MaterialDefinitiveAgreementMember"
      decimals="INF"
      unitRef="USDPShares">5.26</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:EscrowDeposit
      contextRef="AsOf2020-10-15_custom_KoligoTherapeuticsIncMember_custom_MaterialDefinitiveAgreementMember"
      decimals="-3"
      unitRef="USD">7000</us-gaap:EscrowDeposit>
    <ORGS:SharesHeldInEscrow
      contextRef="From2020-10-142020-10-15_custom_KoligoTherapeuticsIncMember_custom_MaterialDefinitiveAgreementMember"
      decimals="INF"
      unitRef="Shares">328587</ORGS:SharesHeldInEscrow>
    <ORGS:AdditionalCashConsideration
      contextRef="From2020-10-142020-10-15_custom_KoligoTherapeuticsIncMember_custom_MaterialDefinitiveAgreementMember"
      decimals="-3"
      unitRef="USD">500000</ORGS:AdditionalCashConsideration>
    <ORGS:ReductionInConsiderationPayable
      contextRef="From2020-10-142020-10-15_custom_KoligoTherapeuticsIncMember_custom_MaterialDefinitiveAgreementMember"
      decimals="-3"
      unitRef="USD">100000</ORGS:ReductionInConsiderationPayable>
    <ORGS:RestrictionOnSaleOfSharesPercentage
      contextRef="From2020-10-142020-10-15_custom_LongHillAndMaximGroupLLCMember_custom_RegistrationRightsandLockUpAgreementMember"
      decimals="INF"
      unitRef="Percentage">0.10</ORGS:RestrictionOnSaleOfSharesPercentage>
    <ORGS:RestrictionPeriodDescription contextRef="From2020-10-142020-10-15_custom_LongHillAndMaximGroupLLCMember_custom_RegistrationRightsandLockUpAgreementMember">(a) in
relation to 70% of all of the shares received in the Merger that Long Hill is entitled to receive under or in connection with
the Merger Agreement, the period beginning on the date of the closing and ending on the date that is the four month anniversary
thereof, and (b) in relation to the remaining 30% of all of the shares received in the Merger that Long Hill is entitled to receive
under or in connection with the Merger Agreement, the period beginning on the date of the closing and ending on the date that
is the twelve month anniversary thereof</ORGS:RestrictionPeriodDescription>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zWeonuaKo7se" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the allocation of purchase price to the fair values of the assets acquired and liabilities assumed
as of the transaction date:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B2_z8408OO7tIP9" style="display: none"&gt;SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20201231_z1qrVyAOpNob" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued_iI_pn3n3_maBCRIAzxgu_zpZljblX2cRk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%"&gt;Fair value of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_ecustom--FairValuePercentageofSharesIssued_iI_pii_dp_uPercentage_c20201231_zmr08iQJvnDa" title="Fair value percentage of shares issued"&gt;8.8&lt;/span&gt;% of shared issued *&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span id="xdx_F47_zz9L2sR0yq73" style="display: none; font-family: Times New Roman, Times, Serif"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;11,172&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments_iI_pn3n3_maBCRIAzxgu_ziNdtG7LgITh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cash payment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,115&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_pn3n3_mtBCRIAzxgu_zxQF4lTwThg8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total consideration transferred&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;12,287&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td id="xdx_F01_zLuqe2CpwNid" style="width: 1.2%"&gt;*&lt;/td&gt;
    &lt;td id="xdx_F1F_zSzpzffwMp64" style="width: 50%"&gt;Fair value of the consideration is based on the company&#x2019;s market share price.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Total assets acquired:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 78%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pn3n3_c20201231_zaA0VUMeje8b" style="width: 18%; text-align: right" title="Cash and cash equivalents"&gt;8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Restricted Cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_iI_pn3n3_c20201231_zzdW7jHhqefd" style="text-align: right" title="Restricted Cash"&gt;152&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accounts Receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_pn3n3_c20201231_zmNyRNKuCKLk" style="text-align: right" title="Accounts Receivable"&gt;228&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Inventory&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iI_pn3n3_c20201231_zq9T4Dy5pkpl" style="text-align: right" title="Inventory"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Other assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_iI_pn3n3_c20201231_ztTVWWU6d3Td" style="text-align: right" title="Other assets"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Property, plants and equipment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pn3n3_c20201231_zYmz0iITYuui" style="text-align: right" title="Property, plants and equipment, net"&gt;482&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Kyslecel Technology (a)&lt;/td&gt;&lt;td id="xdx_F46_zu1500R9cTqk" style="display: none"&gt;(a)&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_fYQ_____zKffF8VCEZO7" style="text-align: right" title="Other intangible assets"&gt;9,340&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;IPR&amp;amp;D (a)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_fYQ_____zidQJTdSBsef" style="text-align: right" title="Other intangible assets"&gt;641&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_iI_pn3n3_c20201231_z9LX9XnVFREh" style="text-align: right" title="Operating lease right-of-use assets"&gt;238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Goodwill (b)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill_iI_pn3n3_c20201231_fYg_____zAz3kQsaxVRf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill"&gt;3,704&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_pn3n3_c20201231_zRe9GSXqKHJ" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total assets"&gt;14,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Total liabilities assumed:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease_iI_pn3n3_c20201231_zKR13To8FmJ7" style="text-align: right" title="Operating leases"&gt;238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accounts Payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_pn3n3_c20201231_ze56KYhWrkt5" style="text-align: right" title="Accounts Payable"&gt;216&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accrued Expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_iI_pn3n3_c20201231_zgv0xezpFr98" style="text-align: right" title="Accrued Expenses"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Orgenesis Inc loan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability_iI_pn3n3_c20201231_zuLlfxIelzwa" style="text-align: right" title="Orgenesis Inc loan"&gt;651&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Deferred taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_iI_pn3n3_c20201231_zu8WyHo2SLR9" style="text-align: right" title="Deferred taxes"&gt;1,293&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Notes Payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_iI_pn3n3_c20201231_zvF4ICtmkrCe" style="text-align: right" title="Notes Payable"&gt;162&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Other liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_iI_pn3n3_c20201231_zWoir7e4LwZ3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other liabilities"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_pn3n3_c20201231_zcqPJQYzOgd3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total liabilities"&gt;2,565&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: italic; text-align: left; padding-bottom: 2.5pt"&gt;Total consideration transferred&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pn3n3_c20201231_zIIXbRMFwIa4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred"&gt;12,287&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 1.2%; text-align: right"&gt;&lt;span id="xdx_F0D_zmsOFibs8cqa" style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 50%"&gt;&lt;span id="xdx_F16_zzszZc7HaF43" style="font: 10pt Times New Roman, Times, Serif"&gt;The
                                         allocation of the purchase price to the net assets acquired and liabilities assumed resulted
                                         in the recognition of other intangible assets which comprised of: Kyslecel Technology
                                         of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_zkEyoPQjdj0e" title="Other intangible assets"&gt;9,340&lt;/span&gt; and IPR&amp;amp;D of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_zbaY6aSbgAC8" title="Other intangible assets"&gt;641&lt;/span&gt;. Kyslecel Technology has a useful life of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_zYRTWIzaNSq8" title="Useful life"&gt;15&lt;/span&gt; years. The
                                         useful life of these intangible assets for amortization purposes was determined considering
                                         the period of expected cash flows generated by the assets used to measure the fair value
                                         of the intangible assets adjusted as appropriate for the entity-specific factors, including
                                         legal, regulatory, contractual, competitive, economic or other factors that may limit
                                         the useful life of intangible assets.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
intangible assets were estimated using a discounted cash flow method with the application of the multi-period excess earnings
method. Under this method, an intangible asset&#x2019;s fair value is equal to the present value of the incremental after-tax cash
flows attributable only to the subject intangible asset after deducting contributory asset charges. An income and expenses forecast
were built based upon revenue and expense estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 1.2%; text-align: right"&gt;&lt;span id="xdx_F08_zwXN3l4aZ3rl" style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 50%"&gt;&lt;span id="xdx_F14_zGdT76xRwTL" style="font: 10pt Times New Roman, Times, Serif"&gt;The primary
items that generate goodwill include the value of the synergies between the acquired company and the Company and the acquired
assembled workforce, neither of which qualifies for recognition as an intangible asset. The Goodwill is not deductible for tax
purposes.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <ORGS:FairValuePercentageofSharesIssued
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="Percentage">0.088</ORGS:FairValuePercentageofSharesIssued>
    <ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact001095"
      unitRef="USD">11172000</ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued>
    <ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1115000</ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">12287000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">8000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">152000</ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">228000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">34000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">25000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">482000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="AsOf2020-12-31_custom_KyslecelTechnologyMember"
      decimals="-3"
      id="Fact001116"
      unitRef="USD">9340000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="AsOf2020-12-31_custom_IPResearchAndDevelopmentMember"
      decimals="-3"
      id="Fact001118"
      unitRef="USD">641000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">238000</ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
    <ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact001122"
      unitRef="USD">3704000</ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">14852000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">238000</ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">216000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">4000</ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">651000</ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1293000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">162000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">2565000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">12287000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="AsOf2020-12-31_custom_KyslecelTechnologyMember"
      decimals="-3"
      unitRef="USD">9340000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="AsOf2020-12-31_custom_IPResearchAndDevelopmentMember"
      decimals="-3"
      unitRef="USD">641000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2020-01-012020-12-31_custom_KyslecelTechnologyMember">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89A_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_z7erDNuy7OUf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Unaudited
supplemental pro forma combined results of operations (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zNvvKHaYkemd" style="display: none"&gt;SCHEDULE OF UNAUDITED SUPPLEMENTAL PRO FORMA&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20200101__20201231__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_zZnB1kWTVapb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20190101__20191231__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_zdjNqHXzKmgd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zQkIcQPJ7PDk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; padding-bottom: 2.5pt"&gt;Revenues&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;8,239&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;4,398&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--ProfitLoss_pn3n3_zeJXVLbN19e9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;318&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;27,263&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Loss per share:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--EarningsPerShareBasic_pii_zas48cbihrHe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Basic&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.05&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.91&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_custom_KoligoTherapeuticsIncMember"
      decimals="-3"
      unitRef="USD">8239000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_custom_KoligoTherapeuticsIncMember"
      decimals="-3"
      unitRef="USD">4398000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-12-31_custom_KoligoTherapeuticsIncMember"
      decimals="-3"
      unitRef="USD">318000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2019-01-012019-12-31_custom_KoligoTherapeuticsIncMember"
      decimals="-3"
      unitRef="USD">27263000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-01-012020-12-31_custom_KoligoTherapeuticsIncMember"
      decimals="INF"
      unitRef="USDPShares">0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2019-01-012019-12-31_custom_KoligoTherapeuticsIncMember"
      decimals="INF"
      unitRef="USDPShares">1.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_custom_KoligoTherapeuticsIncMember"
      decimals="-3"
      unitRef="USD">513000</us-gaap:NetIncomeLoss>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2020-01-012020-12-31_custom_KoligoTherapeuticsIncMember"
      decimals="-3"
      unitRef="USD">682000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="From2019-08-062019-08-07_custom_TransferAgreementMember"
      decimals="0"
      unitRef="USD">1.00</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zJKxz2PJM8F6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
5 &#x2013; &lt;span id="xdx_827_z4crzAehKnS"&gt;PROPERTY, PLANTS AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--PropertyPlantAndEquipmentTextBlock_zDHQPVL1geg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table represents the components of property, plants and equipment:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BC_z2GFvj6gaFHk" style="display: none"&gt;SCHEDULE OF COMPONENTS OF PROPERTY, PLANTS AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Production facility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember_zWYVxVDMQvGc" style="width: 14%; text-align: right" title="Cost"&gt;2,801&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember_pn3n3" style="width: 14%; text-align: right" title="Cost"&gt;2,481&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office furniture and computers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndComputersMember_zgcO2T8iYmK7" style="text-align: right" title="Cost"&gt;697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndComputersMember_z0y9NA1IfI65" style="text-align: right" title="Cost"&gt;606&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zczCPRXCNbLl" style="text-align: right" title="Cost"&gt;1,483&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zL1npMPfGEH9" style="text-align: right" title="Cost"&gt;656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Advance payment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancePaymentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost"&gt;281&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancePaymentMember_zkxBffHbarbg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1187"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231_zHLOZ4Rnt6ce" style="text-align: right" title="Cost"&gt;5,262&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20191231_pn3n3" style="text-align: right" title="Cost"&gt;3,743&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less &#x2013; accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20201231_zLFFAiqJWJz4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated depreciation"&gt;(2,189&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20191231_zV8Gha4ReO47" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated depreciation"&gt;(1,438&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;3,073&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;2,305&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A8_zOGJHQuedg2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Depreciation
expense for the years ended December 31, 2020 and December 31, 2019 were $ &lt;span id="xdx_90D_eus-gaap--Depreciation_pn3n3_c20200101__20201231_zzJYb6SVla56" title="Depreciation"&gt;705&lt;/span&gt; thousand and $&lt;span id="xdx_90B_eus-gaap--Depreciation_pn3n3_c20190101__20191231_zaQMBO8KTPCl" title="Depreciation"&gt;634&lt;/span&gt; thousand, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock_zHA5Muxbbcp" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Property,
plants and equipment, net by geographical location were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8BB_zNFBcntFHRU8" style="display: none"&gt;SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT BY GEOGRAPHICAL LOCATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Belgium&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--BE_z3FrDJDpS0dk" style="width: 14%; text-align: right" title="Property, plants and equipment, net"&gt;358&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--BE_zwfZfgF2Jwx4" style="width: 14%; text-align: right" title="Property, plants and equipment, net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1209"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Korea&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--KR_zlTQHJXo3AB5" style="text-align: right" title="Property, plants and equipment, net"&gt;839&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--KR_zAqptTq2mcBl" style="text-align: right" title="Property, plants and equipment, net"&gt;983&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Israel&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--IL_zoo1isOf3lTe" style="text-align: right" title="Property, plants and equipment, net"&gt;1,386&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--IL_zLDcfeYHoMyc" style="text-align: right" title="Property, plants and equipment, net"&gt;1,322&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;U.S.&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--US_z6HzmHQklp0h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property, plants and equipment, net"&gt;490&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--US_zteNa7ACv2q1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property, plants and equipment, net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1221"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231_zHod0TYdk5Yh" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, plants and equipment, net"&gt;3,073&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231_zXe9lKeMKkqi" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, plants and equipment, net"&gt;2,305&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AA_z7TYMSt04WBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_890_eus-gaap--PropertyPlantAndEquipmentTextBlock_zDHQPVL1geg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table represents the components of property, plants and equipment:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BC_z2GFvj6gaFHk" style="display: none"&gt;SCHEDULE OF COMPONENTS OF PROPERTY, PLANTS AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Production facility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember_zWYVxVDMQvGc" style="width: 14%; text-align: right" title="Cost"&gt;2,801&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember_pn3n3" style="width: 14%; text-align: right" title="Cost"&gt;2,481&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office furniture and computers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndComputersMember_zgcO2T8iYmK7" style="text-align: right" title="Cost"&gt;697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndComputersMember_z0y9NA1IfI65" style="text-align: right" title="Cost"&gt;606&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zczCPRXCNbLl" style="text-align: right" title="Cost"&gt;1,483&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zL1npMPfGEH9" style="text-align: right" title="Cost"&gt;656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Advance payment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancePaymentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost"&gt;281&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancePaymentMember_zkxBffHbarbg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1187"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231_zHLOZ4Rnt6ce" style="text-align: right" title="Cost"&gt;5,262&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20191231_pn3n3" style="text-align: right" title="Cost"&gt;3,743&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less &#x2013; accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20201231_zLFFAiqJWJz4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated depreciation"&gt;(2,189&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20191231_zV8Gha4ReO47" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated depreciation"&gt;(1,438&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;3,073&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;2,305&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_custom_ProductionFacilityMember"
      decimals="-3"
      unitRef="USD">2801000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_custom_ProductionFacilityMember"
      decimals="-3"
      unitRef="USD">2481000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_custom_OfficeFurnitureAndComputersMember"
      decimals="-3"
      unitRef="USD">697000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_custom_OfficeFurnitureAndComputersMember"
      decimals="-3"
      unitRef="USD">606000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_custom_LabEquipmentMember"
      decimals="-3"
      unitRef="USD">1483000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_custom_LabEquipmentMember"
      decimals="-3"
      unitRef="USD">656000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_custom_AdvancePaymentMember"
      decimals="-3"
      unitRef="USD">281000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">5262000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">3743000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">2189000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">1438000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">3073000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">2305000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">705000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">634000</us-gaap:Depreciation>
    <ORGS:ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_893_ecustom--ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock_zHA5Muxbbcp" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Property,
plants and equipment, net by geographical location were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8BB_zNFBcntFHRU8" style="display: none"&gt;SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT BY GEOGRAPHICAL LOCATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Belgium&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--BE_z3FrDJDpS0dk" style="width: 14%; text-align: right" title="Property, plants and equipment, net"&gt;358&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--BE_zwfZfgF2Jwx4" style="width: 14%; text-align: right" title="Property, plants and equipment, net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1209"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Korea&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--KR_zlTQHJXo3AB5" style="text-align: right" title="Property, plants and equipment, net"&gt;839&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--KR_zAqptTq2mcBl" style="text-align: right" title="Property, plants and equipment, net"&gt;983&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Israel&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--IL_zoo1isOf3lTe" style="text-align: right" title="Property, plants and equipment, net"&gt;1,386&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--IL_zLDcfeYHoMyc" style="text-align: right" title="Property, plants and equipment, net"&gt;1,322&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;U.S.&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--US_z6HzmHQklp0h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property, plants and equipment, net"&gt;490&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--US_zteNa7ACv2q1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property, plants and equipment, net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1221"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231_zHod0TYdk5Yh" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, plants and equipment, net"&gt;3,073&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231_zXe9lKeMKkqi" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, plants and equipment, net"&gt;2,305&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</ORGS:ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2020-12-31_country_BE"
      decimals="-3"
      unitRef="USD">358000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2020-12-31_country_KR"
      decimals="-3"
      unitRef="USD">839000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2019-12-31_country_KR"
      decimals="-3"
      unitRef="USD">983000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2020-12-31_country_IL"
      decimals="-3"
      unitRef="USD">1386000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2019-12-31_country_IL"
      decimals="-3"
      unitRef="USD">1322000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2020-12-31_country_US"
      decimals="-3"
      unitRef="USD">490000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">3073000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">2305000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_807_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zcFooncd3e82" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
6 &#x2013; &lt;span id="xdx_829_zqOazwDyQHXc"&gt;INTANGIBLE ASSETS AND GOODWILL&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfGoodwillTextBlock_zzQN5PNTZYI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Changes
in the carrying amount of the Company&#x2019;s goodwill for the years ended December 31, 2020 and 2019 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B4_zJh07DxpbKv" style="display: none"&gt;SCHEDULE OF GOODWILL&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%"&gt;Goodwill as of December 31, 2018&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Goodwill_iS_pn3n3_c20190101__20191231_zP0kjS9gsqp2" style="width: 22%; text-align: right"&gt;&lt;span title="Goodwill, Beginning Balance"&gt;4,942&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Goodwill as acquired, (Koligo) see note 4&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--GoodwillAcquiredDuringPeriod_c20190101__20191231_pn3n3" style="text-align: right" title="Goodwill as acquired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1232"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Translation differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Translation differences"&gt;(130&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Goodwill as of December 31, 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Goodwill_iE_pn3n3_c20190101__20191231_zJv4Jb2X2twb" style="text-align: right" title="Goodwill, Ending Balance"&gt;4,812&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Goodwill as of December 31, 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--Goodwill_iS_pn3n3_c20200101__20201231_zitu3wy1HRq9" style="text-align: right" title="Goodwill, Beginning Balance"&gt;4,812&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Goodwill as acquired, (Koligo) see note 4&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--GoodwillAcquiredDuringPeriod_c20200101__20201231_pn3n3" style="text-align: right" title="Goodwill as acquired"&gt;3,704&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Translation differences&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Translation differences"&gt;229&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Goodwill as of December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Goodwill_iE_pn3n3_c20200101__20201231_zFIXFDKo4AJ" style="border-bottom: Black 2.5pt double; text-align: right" title="Goodwill, Ending Balance"&gt;8,745&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AD_z1AC6UZDaZuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Goodwill
Impairment&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;See
Note 2(m) for the Company&#x2019;s goodwill impairment analysis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Other
Intangible Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zReGqiIAAmG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
intangible assets consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B6_zOKwaLRlcl2" style="display: none"&gt;SCHEDULE OF OTHER INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Gross Carrying Amount:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Know How&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowhowMember_zqboipEQbCYh" style="width: 14%; text-align: right" title="Gross Carrying Amount"&gt;3,170&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowhowMember_pn3n3" style="width: 14%; text-align: right" title="Gross Carrying Amount"&gt;2,991&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Customer relationships&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z7884oqAwQ25" style="text-align: right" title="Gross Carrying Amount"&gt;886&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Gross Carrying Amount"&gt;895&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Kyslecel Technology&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_pn3n3" style="text-align: right" title="Gross Carrying Amount"&gt;9,340&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_pn3n3" style="text-align: right" title="Gross Carrying Amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1258"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;IPR&amp;amp;D&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Carrying Amount"&gt;641&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Carrying Amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1262"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231_pn3n3" style="text-align: right" title="Gross Carrying Amount"&gt;14,037&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231_pn3n3" style="text-align: right" title="Gross Carrying Amount"&gt;3,886&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less &#x2013; Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_c20201231_zacFdX1Y6U27" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization"&gt;(1,014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_c20191231_zDlaRNPO6mWb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization"&gt;(538&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net carrying amount of other intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying amount of other intangible assets"&gt;13,023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying amount of other intangible assets"&gt;3,348&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A2_zkYJzhcRqgk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible
assets amortization expenses were approximately $&lt;span id="xdx_900_ecustom--AmortizationOfIntangibleAsset_pn3n3_c20200101__20201231_zLmIfKr0POxl"&gt;478 &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;thousand
and $&lt;span id="xdx_90F_ecustom--AmortizationOfIntangibleAsset_pn3n3_c20190101__20191231_zbCZmQsUiNpl"&gt;430&lt;/span&gt; thousand for the years ended December 31, 2020 and December 31, 2019, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zbdoR2gR6af2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated
aggregate amortization expenses for the five succeeding years ending on December 31&lt;sup&gt;st&lt;/sup&gt; are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B2_zh9tGtGOqTY9" style="display: none"&gt;SCHEDULE OF ESTIMATED AGGREGATE AMORTIZATION EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022 to 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 1.5pt"&gt;Amortization expenses&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_c20201231_z73g2F3IBPG5" style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right" title="Amortization expenses, 2021"&gt;965&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive_iI_pn3n3_c20201231_zCHhoDKXPeGf" style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right" title="Amortization expenses, 2022  to 2025"&gt;3,910&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A2_zsqOQYGrAS07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfGoodwillTextBlock_zzQN5PNTZYI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Changes
in the carrying amount of the Company&#x2019;s goodwill for the years ended December 31, 2020 and 2019 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B4_zJh07DxpbKv" style="display: none"&gt;SCHEDULE OF GOODWILL&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%"&gt;Goodwill as of December 31, 2018&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Goodwill_iS_pn3n3_c20190101__20191231_zP0kjS9gsqp2" style="width: 22%; text-align: right"&gt;&lt;span title="Goodwill, Beginning Balance"&gt;4,942&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Goodwill as acquired, (Koligo) see note 4&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--GoodwillAcquiredDuringPeriod_c20190101__20191231_pn3n3" style="text-align: right" title="Goodwill as acquired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1232"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Translation differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Translation differences"&gt;(130&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Goodwill as of December 31, 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Goodwill_iE_pn3n3_c20190101__20191231_zJv4Jb2X2twb" style="text-align: right" title="Goodwill, Ending Balance"&gt;4,812&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Goodwill as of December 31, 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--Goodwill_iS_pn3n3_c20200101__20201231_zitu3wy1HRq9" style="text-align: right" title="Goodwill, Beginning Balance"&gt;4,812&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Goodwill as acquired, (Koligo) see note 4&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--GoodwillAcquiredDuringPeriod_c20200101__20201231_pn3n3" style="text-align: right" title="Goodwill as acquired"&gt;3,704&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Translation differences&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Translation differences"&gt;229&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Goodwill as of December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Goodwill_iE_pn3n3_c20200101__20201231_zFIXFDKo4AJ" style="border-bottom: Black 2.5pt double; text-align: right" title="Goodwill, Ending Balance"&gt;8,745&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="AsOf2018-12-31" decimals="-3" unitRef="USD">4942000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-130000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">4812000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">4812000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">3704000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">229000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">8745000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89F_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zReGqiIAAmG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
intangible assets consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B6_zOKwaLRlcl2" style="display: none"&gt;SCHEDULE OF OTHER INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Gross Carrying Amount:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Know How&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowhowMember_zqboipEQbCYh" style="width: 14%; text-align: right" title="Gross Carrying Amount"&gt;3,170&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowhowMember_pn3n3" style="width: 14%; text-align: right" title="Gross Carrying Amount"&gt;2,991&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Customer relationships&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z7884oqAwQ25" style="text-align: right" title="Gross Carrying Amount"&gt;886&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Gross Carrying Amount"&gt;895&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Kyslecel Technology&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_pn3n3" style="text-align: right" title="Gross Carrying Amount"&gt;9,340&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_pn3n3" style="text-align: right" title="Gross Carrying Amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1258"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;IPR&amp;amp;D&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Carrying Amount"&gt;641&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Carrying Amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1262"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231_pn3n3" style="text-align: right" title="Gross Carrying Amount"&gt;14,037&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231_pn3n3" style="text-align: right" title="Gross Carrying Amount"&gt;3,886&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less &#x2013; Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_c20201231_zacFdX1Y6U27" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization"&gt;(1,014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_c20191231_zDlaRNPO6mWb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization"&gt;(538&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net carrying amount of other intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying amount of other intangible assets"&gt;13,023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying amount of other intangible assets"&gt;3,348&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-12-31_custom_KnowhowMember"
      decimals="-3"
      unitRef="USD">3170000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_custom_KnowhowMember"
      decimals="-3"
      unitRef="USD">2991000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      unitRef="USD">886000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      unitRef="USD">895000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-12-31_custom_KyslecelTechnologyMember"
      decimals="-3"
      unitRef="USD">9340000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-12-31_custom_IPResearchAndDevelopmentMember"
      decimals="-3"
      unitRef="USD">641000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">14037000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">3886000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1014000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">538000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">13023000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">3348000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ORGS:AmortizationOfIntangibleAsset
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">478000</ORGS:AmortizationOfIntangibleAsset>
    <ORGS:AmortizationOfIntangibleAsset
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">430000</ORGS:AmortizationOfIntangibleAsset>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_895_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zbdoR2gR6af2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated
aggregate amortization expenses for the five succeeding years ending on December 31&lt;sup&gt;st&lt;/sup&gt; are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B2_zh9tGtGOqTY9" style="display: none"&gt;SCHEDULE OF ESTIMATED AGGREGATE AMORTIZATION EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022 to 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 1.5pt"&gt;Amortization expenses&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_c20201231_z73g2F3IBPG5" style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right" title="Amortization expenses, 2021"&gt;965&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive_iI_pn3n3_c20201231_zCHhoDKXPeGf" style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right" title="Amortization expenses, 2022  to 2025"&gt;3,910&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">965000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <ORGS:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">3910000</ORGS:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_za5Tuv2xnZU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
7 &#x2013; &lt;span id="xdx_823_z5Kds0JuJvy3"&gt;CONVERTIBLE LOANS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ConvertibleDebtTableTextBlock_zkusSwVXQFmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_z8MbVmB5xC1k" style="display: none"&gt;SCHEDULE OF LONG TERM CONVERTIBLE LOANS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Long
    term convertible loans outstanding as of&#160;December 31, 2020 and December 31, 2019 are as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Principal&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Issuance&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Year&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Interest&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Rate&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Maturity Period&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;b&gt;BCF&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;b/&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;(Years)&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td colspan="14" style="font-style: normal; font-weight: normal"&gt;Convertible Loans Outstanding as of &lt;span style="font-style: normal; font-weight: normal"&gt;December
    31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zDFw3ZPfrvd7" style="width: 17%; text-align: right" title="Principal Amount"&gt;1,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember" style="width: 16%; text-align: center" title="Issuance Year"&gt;2018&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zHPp0UkM80Yg" style="width: 16%; text-align: right" title="Interest Rate"&gt;2&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--DebtInstrumentTerm_dtY_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zeg6ar17UK5g" style="width: 14%; text-align: right" title="Maturity Period"&gt;3&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_fKDEp_zb4zf47LSFJi" style="width: 14%; text-align: right" title="Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_pn3n3" style="width: 10%; text-align: right" title="BCF"&gt;71&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zDA1sBqe1EXi" style="text-align: right" title="Principal Amount"&gt;9,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember" style="text-align: center" title="Issuance Year"&gt;2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MinimumMember_zSPSlDj6sNgc" title="Interest Rate"&gt;6&lt;/span&gt;%-&lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MaximumMember_z6yMje78exYf" title="Interest Rate"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MinimumMember_zV50gcduFWV4" title="Maturity Period"&gt;2&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--DebtInstrumentTerm_dtY_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MaximumMember_z7xBBiTsS0Nk" title="Maturity Period"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_fKDIp_z6v86nbfHkbe" style="text-align: right" title="Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;(2)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pn3n3" style="text-align: right" title="BCF"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1314"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zyv1bKnywRHj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Principal Amount"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember" style="padding-bottom: 1.5pt; text-align: center" title="Issuance Year"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_z5xJOBpnNrOb" style="padding-bottom: 1.5pt; text-align: right" title="Interest Rate"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--DebtInstrumentTerm_dtY_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zAxR13De8uzi" style="padding-bottom: 1.5pt; text-align: right" title="Maturity Period"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_fKDMp_zt8CAYylZ5w2" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;(3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_pn3n3" style="padding-bottom: 1.5pt; text-align: right" title="BCF"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1326"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DebtInstrumentFaceAmount_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal Amount"&gt;10,750&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td colspan="18" style="font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Convertible
    Loans Outstanding as of &lt;/b&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;December 31, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_pn3n3" style="text-align: right" title="Principal Amount"&gt;1,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--DebtInstrumentIssuanceYear_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember" style="text-align: center" title="Issuance Year"&gt;2018&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zle1KDDZKZqk" style="text-align: right" title="Interest Rate"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--DebtInstrumentTerm_dtY_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zYwCOa0umj1c" style="text-align: right" title="Maturity Period"&gt;3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_fKDEp_zxqPtxnJs8sb" style="text-align: right" title="Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7.00&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_F20_z1eDrS0SelJf" style="text-align: left"&gt;(1)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn3n3_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zT8CBWNXlY6j" style="text-align: right" title="BCF"&gt;124&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal Amount"&gt;11,400&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--DebtInstrumentIssuanceYear_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember" style="padding-bottom: 2.5pt; text-align: center" title="Issuance Year"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MinimumMember_zHMFCnuTzZxg" title="Interest Rate"&gt;6&lt;/span&gt;%-&lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MaximumMember_zBK65LqIf8w" title="Interest Rate"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentTerm_dtY_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MinimumMember_zyUY8X127l2h" title="Maturity Period"&gt;2&lt;/span&gt;-&lt;span id="xdx_90A_eus-gaap--DebtInstrumentTerm_dtY_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MaximumMember_zeuAtuVShXIf" title="Maturity Period"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_fKDIp_zx9JV7VEjKQ3" style="padding-bottom: 2.5pt; text-align: right" title="Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7.00&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_F2B_zfU9bW8ArPui" style="padding-bottom: 2.5pt; text-align: left"&gt;(2)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pn3n3" style="padding-bottom: 2.5pt; text-align: right" title="BCF"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1356"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DebtInstrumentFaceAmount_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal Amount"&gt;12,900&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="18" style="text-align: left; font-weight: bold"&gt;Convertible Loans repaid during the year ended &lt;span style="font-style: normal; font-weight: normal"&gt;December
    31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Principal&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Issuance&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Year&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Interest&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Rate&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Maturity Period&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;b&gt;BCF&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zIHKBs5PcDRf" style="width: 17%; text-align: right" title="Repaid, Principal Amount"&gt;500&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zkow0ZZaa3H6" style="width: 16%; text-align: center" title="Issuance Year"&gt;2018&lt;/td&gt;&lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zBotYCYosfuk" style="width: 16%; text-align: right" title="Interest Rate"&gt;2&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;%&lt;/td&gt;&lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--DebtInstrumentRemainingTerm_dtM_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_z7cvCx8z5JW6" style="width: 14%; text-align: right" title="Repaid, Maturity Period"&gt;0.87&lt;/td&gt;&lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zK7dopUg33n6" style="width: 14%; text-align: right" title="Exercise Price"&gt;7&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--DebtInstrumentConvertibleRepaidBeneficialConversionFeature_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zrQIEMx9Rx7k" style="width: 10%; text-align: right" title="Repaid, BCF"&gt;53&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_zdo7o6rInVL6" style="text-align: right" title="Repaid, Principal Amount"&gt;500&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember" style="text-align: center" title="Issuance Year"&gt;2019&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_zaVwMTYQyCE2" style="text-align: right" title="Interest Rate"&gt;6&lt;/td&gt;&lt;td style="text-align: center"&gt;%&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--DebtInstrumentRemainingTerm_dtM_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_zvPfHqd4CFpe" style="text-align: right" title="Repaid, Maturity Period"&gt;0.28&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_zJcBzqlsDTrj" style="text-align: right" title="Exercise Price"&gt;7&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--DebtInstrumentConvertibleRepaidBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_pn3n3" style="text-align: right" title="Repaid, BCF"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1382"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_zAKr0TKD3mxg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Repaid, Principal Amount"&gt;1,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_zdeDPXfx1Bn2" style="padding-bottom: 1.5pt; text-align: center" title="Issuance Year"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_zM9WocadbgL7" style="padding-bottom: 1.5pt; text-align: right" title="Interest Rate"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--DebtInstrumentRemainingTerm_dtMp_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_zibWRPZBRSmg" style="padding-bottom: 1.5pt; text-align: right" title="Repaid, Maturity Period"&gt;0.76&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_z6FdnJQRu7Dc" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Price"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DebtInstrumentConvertibleRepaidBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_pn3n3" style="padding-bottom: 1.5pt; text-align: right" title="Repaid, BCF"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1394"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansMember_zRR7XZAJBEHa" style="text-align: right" title="Repaid, Principal Amount"&gt;2,400&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Apart
from the items mentioned below there were no repayments of convertible loans during the fiscal years ended December 31, 2019 and
December 31, 2020. In addition, there were no conversions during the fiscal years ended December 31, 2019 and December 31,
2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span id="xdx_F08_zpSgWyVib4Qg" style="font: 10pt Times New Roman, Times, Serif"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F12_zNRKLWCftCS9" style="font: 10pt Times New Roman, Times, Serif"&gt;The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_pii" title="Stock issued during period, conversion of convertible securities"&gt;148,838&lt;/span&gt; shares
and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zfQ3X7ZtgEv7" title="Number of warrant may be converted"&gt;148,838&lt;/span&gt; &lt;span title="Warrants exercise, term"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_z2olYqVdp0gb" title="Warrants exercise, term::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1403"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; warrants to purchase up to an additional &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxws5Qrjrwp2" title="Number of warrant may be converted"&gt;148,838&lt;/span&gt; shares of the Company&#x2019;s common stock at a per share
exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zHp9sXQK5nwg" title="Warrants exercise price"&gt;7&lt;/span&gt;. &lt;span&gt;In the initial two years, the holders have the right to convert the outstanding principal amount and accrued
interest into shares of capital stock of Hemogenyx-Cell or Immugenyx, LLC according under the relevant note agreement, subsidiaries
of Hemogenyx Pharmaceuticals Plc, at a price per share based on a pre-money valuation of Hemogenyx-Cell or Immugenyx, LLC of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_ecustom--PreMoneyValuation_iI_pn6n6_c20201231__dei--LegalEntityAxis__custom--HemogenyxCelMember_zkLtkIqsJWR" title="Pre-money valuation"&gt;12&lt;/span&gt;
million and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_ecustom--PreMoneyValuation_iI_pn6n6_c20201231__dei--LegalEntityAxis__custom--ImmugenyxLLCMember_zqO6fr0KZyMe"&gt;8&lt;/span&gt; million, respectively, pursuant to the collaboration agreement with Hemogenyx Pharmaceuticals Plc and Immugenyx,
LLC.&lt;/span&gt; As of December 31, 2020, the loans are presented in current maturities of convertible notes in the balance sheet (See Notes
11(c) and 11(d).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span id="xdx_F0E_z5oVRsJ6GJOj" style="font: 10pt Times New Roman, Times, Serif"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F15_zprCsjdBN534" style="font: 10pt Times New Roman, Times, Serif"&gt;The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pii" title="Stock issued during period, conversion of convertible securities"&gt;1,443,734&lt;/span&gt; shares
and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pii" title="Number of warrant may be converted"&gt;1,053,503&lt;/span&gt; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zRDvnnKx88Ag" title="Warrants exercise, term::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1417"&gt;three-year&lt;/span&gt;&lt;/span&gt; warrants to purchase up to an additional &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Number of warrant may be converted"&gt;1,053,503&lt;/span&gt; shares of the Company&#x2019;s common stock at a per
share exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pii" title="Warrants exercise price"&gt;7&lt;/span&gt;. As of December 31, 2020, $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--ConvertibleDebtCurrent_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zScnFXulvOp2" title="Current maturities of convertible loans"&gt;2,500&lt;/span&gt; thousand of the principal amount is included in current maturities
of convertible loans in the balance sheet and the remainder in long-term convertible loans. See also Notes 7(b), 7(c), 7(e), 7(f)
and 7(g).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F07_zKcMdD3eXmG9" style="width: 15pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F19_zABI8xDlieZ9" style="font: 10pt Times New Roman, Times, Serif"&gt;The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_pii" title="Stock issued during period, conversion of convertible securities"&gt;38,559&lt;/span&gt; shares
at a per share exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zEMHD8sLnPdi" title="Warrants exercise price"&gt;7&lt;/span&gt;. As of December 31, 2020, all the principal amount is included in long-term convertible loans
in the balance sheet See also Notes 7(h).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AC_zLHNdcivKyDi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;b.
During April 2019, the Company entered into a convertible loan agreement with an offshore investor for an aggregate amount of
$&lt;span id="xdx_902_eus-gaap--ProceedsFromConvertibleDebt_pn3n3_c20190401__20190430__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_z69O0G3tVKJk" title="Proceeds from Convertible Debt"&gt;500&lt;/span&gt; thousand into the U.S. Subsidiary. The investor, at its option, may convert the outstanding principal amount and accrued
interest under this note into shares and &lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20190430__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_z7n6mMUDIHE6" title="Warrants exercise, term::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1432"&gt;three-year&lt;/span&gt;&lt;/span&gt; warrants to purchase shares of the Company&#x2019;s common stock at a per share
exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20190430__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_pii" title="Warrants exercise price"&gt;7.00&lt;/span&gt;; or into shares of the U.S. Subsidiary at a valuation of the U.S. Subsidiary of $&lt;span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn6n6_c20190401__20190430__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zcRY4Opjzscf" title="Valuation of shares"&gt;50&lt;/span&gt; million. During February
2020 the company repaid this convertible loan to the investor in full.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;c.
During May 2019, the Company entered into a private placement subscription agreement with an investor for $&lt;span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn6n6_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zKQ4Zzo0IKrj" title="Aggregate amount of debt"&gt;5&lt;/span&gt; million. The lender
shall be entitled, at any time prior to or no later than the maturity date, to convert the outstanding amount, into units of (1)
shares of common stock of the Company at a conversion price per share equal to $&lt;span title="Convertible warrant exercise price"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20190531__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zV5pGv4Se0P2" title="Convertible warrant exercise price into common stock"&gt;7.00&lt;/span&gt;&lt;/span&gt; and (2) warrants to purchase an equal number
of additional shares of the Company&#x2019;s common stock at a price of $&lt;span title="Conversion price per share"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20190531__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zW7aCDryPHCh" title="Warrant exercise price per share"&gt;7.00&lt;/span&gt;&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
transaction costs were approximately $&lt;span id="xdx_902_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zk6UVIe2To5a" title="Transaction costs"&gt;497&lt;/span&gt; thousand, out of which $&lt;span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z0DLIX3eIO3k" title="Allocated share-based compensation expense"&gt;97&lt;/span&gt; thousand are stock-based compensation due to issuance of
warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;d.
In May 2019, the Company had agreed to enter into a &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20190531__us-gaap--TypeOfArrangementAxis__custom--SixPercentageConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zHEYF4XfkfIh" title="Interest rate"&gt;6&lt;/span&gt;% convertible loan agreement with an investor for an aggregate amount of
$&lt;span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn6n6_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--SixPercentageConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z0bvHabdnThh" title="Aggregate amount of debt"&gt;5&lt;/span&gt; million. The lender shall be entitled, at any time prior to or no later than the maturity date, to convert the outstanding
amount, into units of (1) shares of stock of the Company at a conversion price per share equal to $&lt;span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20190531__us-gaap--TypeOfArrangementAxis__custom--SixPercentageConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zTiIhuplX0h6" title="Convertible warrant exercise price into common stock"&gt;7.00&lt;/span&gt; and (2) warrants to purchase
an equal number of additional shares of the Company&#x2019;s common stock at a price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20190531__us-gaap--TypeOfArrangementAxis__custom--SixPercentageConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zrHb12bwPml8" title="Warrant exercise price per share"&gt;7.00&lt;/span&gt; per share. As of the date of the
filing of this Annual Report on Form 10-K, the loan had not yet been received by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;e.
In June 2019, the Company entered into private placement subscription agreements with investors for an aggregate amount of $&lt;span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn6n6_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zpurUKFq14na" title="Aggregate amount of debt"&gt;2&lt;/span&gt;
million. The lenders shall be entitled, at any time prior to or no later than the maturity date, to convert the outstanding amount,
into units of (1) shares of common stock of the Company at a conversion price per share equal to $&lt;span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20190630__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zuliYvtAThb6" title="Convertible warrant exercise price into common stock"&gt;7.00&lt;/span&gt; and (2) warrants to purchase
an equal number of additional shares of the Company&#x2019;s common stock at a price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20190630__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zUPP9yQegI1k" title="Warrant exercise price per share"&gt;7.00&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;f.
During October 2019, the Company entered into a Private Placement Subscription Agreement and Convertible Credit Line Agreement
(collectively, the &#x201c;Credit Line Agreements&#x201d;) with four non-U.S. investors (the &#x201c;Lenders&#x201d;), pursuant to
which the Lenders furnished to the Company access to an aggregate $&lt;span title="Aggregate credit line amount"&gt;&lt;span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_zcjuaMXMr04c"&gt;5&lt;/span&gt;.0&lt;/span&gt; million credit line (which consists of $&lt;span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_zUuI9OIxOmo2" title="Aggregate credit line amount"&gt;&lt;span id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_z3MyOSmjrq59" title="Aggregate credit line amount"&gt;&lt;span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_z8UUtvwWvQrj" title="Aggregate credit line amount"&gt;&lt;span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_zWymxtcelJLd" title="Aggregate credit line amount"&gt;1.25&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; million from
each Lender) (collectively, the &#x201c;Credit Line&#x201d;). Pursuant to the Credit Line Agreements, the Company is entitled to
draw down an aggregate of $&lt;span title="Proceeds from lines of credit"&gt;&lt;span id="xdx_90A_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_zaPyjOXVPFU5" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_901_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20191101__20191130__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_zitzrlT2jfn3" title="Proceeds from lines of credit"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; million (consisting of $&lt;span title="Proceeds from lines of credit"&gt;&lt;span id="xdx_909_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_zWjb1tdLhk62" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_904_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_zCexVgm8IXNd" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_906_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_zw24EX7Nx9Z7" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_907_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_zdCQdwaFdnwc" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_902_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191101__20191130__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_zezWyrEqHisl" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_90D_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191101__20191130__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_zm2F3SqPrmlc" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_905_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191101__20191130__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_znQSaazoCaDb" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_90D_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191101__20191130__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_zymaoZ7Qbk5g" title="Proceeds from lines of credit"&gt;250&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; thousand from each Lender) of the Credit Line in each of October 2019
and November 2019. In each of December 2019, January 2020 and February 2020, the Company may draw down an additional aggregate
of $&lt;span title="Proceeds from lines of credit"&gt;&lt;span id="xdx_90B_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_z1r7z6cMtRbj" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_908_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_zB0QdMgwrfec" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_90F_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_zQZC92nW2BE2" title="Proceeds from lines of credit"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; million (consisting of $&lt;span title="Proceeds from lines of credit"&gt;&lt;span id="xdx_905_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_z6Bw4wZHB7Al" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_909_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_z4LDdXOcIfd4" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_90D_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_zJEFVNtTRf9a" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_905_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_z55ZFm2vjlzi" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_903_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_z1jhgobBxpZc" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_908_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_zKRyE2bR8XCd" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_90F_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_z8csag846ioh" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_90E_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_zsFaN90115w5" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_901_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_zfEXCZRUReLk" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_900_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_zkiCMDD8vf34" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_90C_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_zIAVVEyOlkl7" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_901_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_z8ceT8CzTIOh" title="Proceeds from lines of credit"&gt;250&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; thousand from each Lender), until the total amount drawn down under the Credit Line reaches
an aggregate of $&lt;span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_zW6lx0PuaOha" title="Aggregate credit line amount"&gt;5&lt;/span&gt; million (consisting of $&lt;span id="xdx_90F_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_zEVMX3fEW0kd" title="Aggregate credit line amount"&gt;&lt;span id="xdx_900_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_zYpzfkrlPyhk" title="Aggregate credit line amount"&gt;&lt;span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_zOZKMacdpBC6" title="Aggregate credit line amount"&gt;&lt;span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_z5SDJgoHqgH5" title="Aggregate credit line amount"&gt;1.25&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; million from each Lender), subject to the approval of the Lenders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant
to the terms of the Credit Line Agreements and the Notes, the total loan amount, and all accrued but unpaid interest thereon,
shall become due and payable on the second anniversary of the Effective Date (the &#x201c;Maturity Date&#x201d;). The Maturity Date
may be extended by each Lender in its sole discretion and shall be in writing signed by the Company and the Lender. Interest on
any amount that has been drawn down under the Credit Line accrues at a per annum rate of eight percent (&lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zZJUkLpt2qGj" title="Interest rate"&gt;8&lt;/span&gt;%). At any time prior
to or on the Maturity Date, by providing written notice to the Company, each of the Lenders is entitled to convert its respective
drawdown amounts and all accrued interest, into shares of the Company&#x2019;s common stock, par value $&lt;span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zwSUsnpyt1md" title="Common stock, par value"&gt;&lt;span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zatdvznLc6Ji" title="Common stock, par value"&gt;0.0001&lt;/span&gt;&lt;/span&gt; per share (the &#x201c;Common
Stock&#x201d;), at a conversion price equal to $&lt;span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zjgrLDl3JEU5" title="Conversion price per share"&gt;7.00&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Furthermore,
upon the drawdown of $&lt;span id="xdx_904_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_z6phx8coXCwf" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_903_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_zzz6tqDI2Xna" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_90C_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_zb2cTMQKoN6l" title="Proceeds from lines of credit"&gt;&lt;span id="xdx_90F_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_zYdKUBTBiNX2" title="Proceeds from lines of credit"&gt;500&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; thousand from each Lender and, together with the other Lenders, a drawdown of an aggregate of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_zi0HTrgMuR1d" title="Proceeds from lines of credit"&gt;2&lt;/span&gt; million
under the Credit Line, the existing warrants of the Lenders to purchase shares of Common Stock shall be amended to extend their
exercise date to June 30, 2021 and the Company will issue to each of the Lenders warrants to purchase &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_pii" title="Number of warrant to purchase"&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_pii" title="Number of warrant to purchase"&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_pii" title="Number of warrant to purchase"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_pii" title="Number of warrant to purchase"&gt;50,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares of Common
Stock at an exercise price of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_pii" title="Warrants exercise price"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_pii" title="Warrants exercise price"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_pii" title="Warrants exercise price"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_pii" title="Warrants exercise price"&gt;7.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; per share. The new warrants will be exercisable for three (&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_zgdXXTXftPKj" title="Warrants exercise, term"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_zPfkchNgbST7" title="Warrants exercise, term"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_z6xdvaAGX202" title="Warrants exercise, term"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_zKDnZs4JEHF3" title="Warrants exercise, term"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;) years from the Effective Date.
During October 2019, such drawdown was reached and the warrants were issued. The modification of the existing warrants in the
amount of $&lt;span title="Transaction costs"&gt;&lt;span id="xdx_90F_ecustom--ModificationOfExistingWarrants_iI_pn3n3_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zP7ls0iJyzUd" title="Modification of the existing warrants"&gt;145&lt;/span&gt;&lt;/span&gt; thousands was recorded against the accumulated deficit and the value of the new warrants in the amount of $&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_z3xEr6nPszll" title="Warrants amount"&gt;370&lt;/span&gt;
thousands was offset against the convertible loan amount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
lender shall be entitled, at any time prior to or no later than the maturity date, to convert the outstanding amount, into units
of shares of common stock of the Company at a conversion price per share equal to $&lt;span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zljxqb0hyRxg" title="Conversion price per share"&gt;7.00&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
at December 31, 2019, the Company had received $&lt;span id="xdx_901_eus-gaap--ProceedsFromLinesOfCredit_pn3n6_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_ztDQtFSEVnda"&gt;3.65
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million from the Convertible Credit
Line investment comprised of $&lt;span id="xdx_905_eus-gaap--ProceedsFromLinesOfCredit_pn4n6_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorOneMember_zkli2RKtYWPb"&gt;1.15
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million from one investor, $&lt;span id="xdx_905_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorTwoMember_zV1I2zV9YHxa"&gt;1
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million from a second investor, and $&lt;span id="xdx_90A_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoOtherInvestorTwoMember_zTHnt9KwW958"&gt;750
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;thousand from two of the other lenders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
transaction costs were approximately $&lt;span id="xdx_90E_ecustom--ModificationOfExistingWarrants_iI_pn3n3_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zsLO4oYJWIB7"&gt;145
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;thousand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended December 2020 the company repaid principal amount of $&lt;span id="xdx_905_eus-gaap--RepaymentsOfLinesOfCredit_pn3n3_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zvAkWqq8xlFl" title="Repayments of lines o credit"&gt;2,400&lt;/span&gt; thousand and a total interest amount of $&lt;span id="xdx_90F_eus-gaap--InterestExpenseDebt_pn3n3_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zH49qumtG5Hf" title="Interest expense"&gt;372&lt;/span&gt; thousand
to certain of the credit line investors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;g.
In December 2019, the Company entered into private placement subscription agreements with investors for an aggregate amount of
$&lt;span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn3n3_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zMsWBG02UWQ" title="Aggregate amount of debt"&gt;250&lt;/span&gt; thousand. The lenders shall be entitled, at any time prior to or no later than the maturity date, to convert the outstanding
amount, into units of 1 share of common stock of the Company at a conversion price per share equal to $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20191231__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_pii" title="Warrants exercise price"&gt;7.00&lt;/span&gt; and warrants to purchase
&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20191231__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zUa5os2B7M3j" title="Number of warrant to purchase"&gt;183,481&lt;/span&gt; additional shares of the Company&#x2019;s common stock at a price of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20191231__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z6Pw4KchltVg" title="Warrants exercise price"&gt;7.00&lt;/span&gt; per share. The fair value of the warrants was
$&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20191231__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z52UVplQdXbl" title="Warrants amount"&gt;124&lt;/span&gt; thousand using the fair value of the shares on the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;h.
On January 2, 2020, the Company entered into private placement subscription agreements with investors for an aggregate amount
of $&lt;span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn3n3_c20191230__20200103__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zoIQtR4YckW" title="Aggregate amount of debt"&gt;250&lt;/span&gt; thousand of convertible loans. The lenders shall be entitled, at any time prior to or no later than the maturity date,
to convert the outstanding amount, into shares of Common Stock of the Company at a conversion price per share equal to $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_pii" title="Warrants exercise price"&gt;7.00&lt;/span&gt;.
In addition, the Company granted the investors &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_pii" title="Number of warrant to purchase"&gt;151,428&lt;/span&gt; warrants to purchase an equal number of additional shares of Common Stock
at a price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zmheJnSvGEd9" title="Warrants exercise price"&gt;7.00&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;i.
In December 2018, the Company entered into a Controlled Equity Offering Sales Agreement, or Sales Agreement, with Cantor Fitzgerald
&amp;amp; Co., or Cantor, pursuant to which the Company may offer and sell, from time to time through Cantor, shares of its common
stock having an aggregate offering price of up to $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zlMtfVU4VtSg" title="Proceeds from issuance of common stock"&gt;25.0&lt;/span&gt; million. The Company will pay Cantor a commission rate equal to &lt;span id="xdx_904_ecustom--PercentageOfCommission_pii_dp_uPercentage_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zhWvdCpBPosk" title="Percentage of commission"&gt;3.0&lt;/span&gt;% of
the aggregate gross proceeds from each sale. Shares sold under the Sales Agreement will be offered and sold pursuant to the Company&#x2019;s
Shelf Registration Statement on Form S-3 (Registration No. 333-223777) that was declared effective by the Securities and Exchange
Commission on March 28, 2018, or the Shelf Registration Statement, and a prospectus supplement and accompanying base prospectus
that the Company filed with the Securities and Exchange Commission on December 20, 2018. The Company has not yet sold any shares
of its common stock pursuant to the Sales Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;j.
On November 2, 2016, the Company entered into unsecured convertible note agreements with accredited or offshore investors for
an aggregate amount of NIS &lt;span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn6n6_uNIS_c20161101__20161102__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember__srt--CurrencyAxis__currency--ILS_zPreb3R8Nm9g" title="Aggregate amount of debt"&gt;1&lt;/span&gt; million ($&lt;span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn3n3_c20161101__20161102__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember_zmz9g9CfIoD6" title="Aggregate amount of debt"&gt;280&lt;/span&gt; thousand). The loan bears a monthly interest rate of &lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20161102__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember_zjANP8kHV3pb" title="Interest rate"&gt;2&lt;/span&gt;% and mature on &lt;span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20161101__20161102__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember_zZ8BnkI6oK82" title="Debt instrument, maturity date"&gt;May 1, 2017&lt;/span&gt;,
unless converted earlier. On April 27, 2017 and November 2, 2017, the Company entered into extension agreements through November
2, 2017 and May 2, 2018, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
March 2018, the investor submitted a notice of its intention to convert into shares of the Company&#x2019;s common stock the principal
amount and accrued interest of approximately $&lt;span id="xdx_902_eus-gaap--ConvertibleDebt_iI_pn3n3_c20180331__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember_znUx3t8cIbqh" title="Convertible debt"&gt;383&lt;/span&gt; thousand outstanding. A related party of such investor at the same time, exercised
warrants issued in November 2016 to purchase shares of the Company&#x2019;s Common Stock. The exercise price of the warrants and
conversion price were fixed at $&lt;span id="xdx_902_ecustom--DebtInstrumentConvertibleWarrantExercisePrice_iI_pii_uUSDPShares_c20180331__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember_zxOnUi2aIdp8" title="Convertible warrant exercise price"&gt;0.52&lt;/span&gt; per share (pre-reverse stock split implemented by the Company in November 2017). There is
a significant disagreement between the Company and these two entities as to the number of shares of Common Stock issuable to these
entities, and they contend that the number of shares of Common Stock issuable to them should not consider the reverse stock split.
The Company rejects these contentions in their entirety and, based on the advice of specially retained counsel, believes that
these claims are without legal merit and not made in good faith. The Company intends to vigorously defend its interests and pursue
other avenues of legal address. Through its counsel, the Company has advised these entities that unless they withdraw their request
within a specified period, the Company will cancel the above referenced agreements and these parties&#x2019; right to receive any
shares of the Company&#x2019;s Common Stock. In April 2018, the Company withdrew the agreements and deposited the shares in total
amount of &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180401__20180430__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember_pii" title="Number of shares issued"&gt;107,985&lt;/span&gt; issued under those agreements and the principal amount and accrued interest of the loan in escrow account. The
deposit of the principal amount and accrued interest presented as restricted cash in the balance sheet as of December 31, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_898_eus-gaap--ConvertibleDebtTableTextBlock_zkusSwVXQFmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_z8MbVmB5xC1k" style="display: none"&gt;SCHEDULE OF LONG TERM CONVERTIBLE LOANS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Long
    term convertible loans outstanding as of&#160;December 31, 2020 and December 31, 2019 are as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Principal&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Issuance&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Year&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Interest&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Rate&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Maturity Period&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;b&gt;BCF&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;b/&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;(Years)&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td colspan="14" style="font-style: normal; font-weight: normal"&gt;Convertible Loans Outstanding as of &lt;span style="font-style: normal; font-weight: normal"&gt;December
    31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zDFw3ZPfrvd7" style="width: 17%; text-align: right" title="Principal Amount"&gt;1,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember" style="width: 16%; text-align: center" title="Issuance Year"&gt;2018&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zHPp0UkM80Yg" style="width: 16%; text-align: right" title="Interest Rate"&gt;2&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--DebtInstrumentTerm_dtY_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zeg6ar17UK5g" style="width: 14%; text-align: right" title="Maturity Period"&gt;3&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_fKDEp_zb4zf47LSFJi" style="width: 14%; text-align: right" title="Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_pn3n3" style="width: 10%; text-align: right" title="BCF"&gt;71&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zDA1sBqe1EXi" style="text-align: right" title="Principal Amount"&gt;9,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember" style="text-align: center" title="Issuance Year"&gt;2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MinimumMember_zSPSlDj6sNgc" title="Interest Rate"&gt;6&lt;/span&gt;%-&lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MaximumMember_z6yMje78exYf" title="Interest Rate"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MinimumMember_zV50gcduFWV4" title="Maturity Period"&gt;2&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--DebtInstrumentTerm_dtY_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MaximumMember_z7xBBiTsS0Nk" title="Maturity Period"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_fKDIp_z6v86nbfHkbe" style="text-align: right" title="Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;(2)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pn3n3" style="text-align: right" title="BCF"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1314"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zyv1bKnywRHj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Principal Amount"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember" style="padding-bottom: 1.5pt; text-align: center" title="Issuance Year"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_z5xJOBpnNrOb" style="padding-bottom: 1.5pt; text-align: right" title="Interest Rate"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--DebtInstrumentTerm_dtY_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zAxR13De8uzi" style="padding-bottom: 1.5pt; text-align: right" title="Maturity Period"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_fKDMp_zt8CAYylZ5w2" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;(3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_pn3n3" style="padding-bottom: 1.5pt; text-align: right" title="BCF"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1326"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DebtInstrumentFaceAmount_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal Amount"&gt;10,750&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td colspan="18" style="font-weight: bold; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Convertible
    Loans Outstanding as of &lt;/b&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;December 31, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_pn3n3" style="text-align: right" title="Principal Amount"&gt;1,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--DebtInstrumentIssuanceYear_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember" style="text-align: center" title="Issuance Year"&gt;2018&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zle1KDDZKZqk" style="text-align: right" title="Interest Rate"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--DebtInstrumentTerm_dtY_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zYwCOa0umj1c" style="text-align: right" title="Maturity Period"&gt;3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_fKDEp_zxqPtxnJs8sb" style="text-align: right" title="Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7.00&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_F20_z1eDrS0SelJf" style="text-align: left"&gt;(1)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn3n3_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zT8CBWNXlY6j" style="text-align: right" title="BCF"&gt;124&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal Amount"&gt;11,400&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--DebtInstrumentIssuanceYear_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember" style="padding-bottom: 2.5pt; text-align: center" title="Issuance Year"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MinimumMember_zHMFCnuTzZxg" title="Interest Rate"&gt;6&lt;/span&gt;%-&lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MaximumMember_zBK65LqIf8w" title="Interest Rate"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentTerm_dtY_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MinimumMember_zyUY8X127l2h" title="Maturity Period"&gt;2&lt;/span&gt;-&lt;span id="xdx_90A_eus-gaap--DebtInstrumentTerm_dtY_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MaximumMember_zeuAtuVShXIf" title="Maturity Period"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_fKDIp_zx9JV7VEjKQ3" style="padding-bottom: 2.5pt; text-align: right" title="Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7.00&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_F2B_zfU9bW8ArPui" style="padding-bottom: 2.5pt; text-align: left"&gt;(2)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pn3n3" style="padding-bottom: 2.5pt; text-align: right" title="BCF"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1356"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DebtInstrumentFaceAmount_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal Amount"&gt;12,900&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="18" style="text-align: left; font-weight: bold"&gt;Convertible Loans repaid during the year ended &lt;span style="font-style: normal; font-weight: normal"&gt;December
    31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Principal&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Issuance&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Year&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Interest&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Rate&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Maturity Period&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;b&gt;BCF&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zIHKBs5PcDRf" style="width: 17%; text-align: right" title="Repaid, Principal Amount"&gt;500&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zkow0ZZaa3H6" style="width: 16%; text-align: center" title="Issuance Year"&gt;2018&lt;/td&gt;&lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zBotYCYosfuk" style="width: 16%; text-align: right" title="Interest Rate"&gt;2&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;%&lt;/td&gt;&lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--DebtInstrumentRemainingTerm_dtM_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_z7cvCx8z5JW6" style="width: 14%; text-align: right" title="Repaid, Maturity Period"&gt;0.87&lt;/td&gt;&lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zK7dopUg33n6" style="width: 14%; text-align: right" title="Exercise Price"&gt;7&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--DebtInstrumentConvertibleRepaidBeneficialConversionFeature_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zrQIEMx9Rx7k" style="width: 10%; text-align: right" title="Repaid, BCF"&gt;53&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_zdo7o6rInVL6" style="text-align: right" title="Repaid, Principal Amount"&gt;500&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember" style="text-align: center" title="Issuance Year"&gt;2019&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_zaVwMTYQyCE2" style="text-align: right" title="Interest Rate"&gt;6&lt;/td&gt;&lt;td style="text-align: center"&gt;%&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--DebtInstrumentRemainingTerm_dtM_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_zvPfHqd4CFpe" style="text-align: right" title="Repaid, Maturity Period"&gt;0.28&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_zJcBzqlsDTrj" style="text-align: right" title="Exercise Price"&gt;7&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--DebtInstrumentConvertibleRepaidBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_pn3n3" style="text-align: right" title="Repaid, BCF"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1382"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_zAKr0TKD3mxg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Repaid, Principal Amount"&gt;1,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_zdeDPXfx1Bn2" style="padding-bottom: 1.5pt; text-align: center" title="Issuance Year"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_zM9WocadbgL7" style="padding-bottom: 1.5pt; text-align: right" title="Interest Rate"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--DebtInstrumentRemainingTerm_dtMp_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_zibWRPZBRSmg" style="padding-bottom: 1.5pt; text-align: right" title="Repaid, Maturity Period"&gt;0.76&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_z6FdnJQRu7Dc" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Price"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DebtInstrumentConvertibleRepaidBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_pn3n3" style="padding-bottom: 1.5pt; text-align: right" title="Repaid, BCF"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1394"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansMember_zRR7XZAJBEHa" style="text-align: right" title="Repaid, Principal Amount"&gt;2,400&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Apart
from the items mentioned below there were no repayments of convertible loans during the fiscal years ended December 31, 2019 and
December 31, 2020. In addition, there were no conversions during the fiscal years ended December 31, 2019 and December 31,
2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span id="xdx_F08_zpSgWyVib4Qg" style="font: 10pt Times New Roman, Times, Serif"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F12_zNRKLWCftCS9" style="font: 10pt Times New Roman, Times, Serif"&gt;The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_pii" title="Stock issued during period, conversion of convertible securities"&gt;148,838&lt;/span&gt; shares
and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zfQ3X7ZtgEv7" title="Number of warrant may be converted"&gt;148,838&lt;/span&gt; &lt;span title="Warrants exercise, term"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_z2olYqVdp0gb" title="Warrants exercise, term::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1403"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; warrants to purchase up to an additional &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxws5Qrjrwp2" title="Number of warrant may be converted"&gt;148,838&lt;/span&gt; shares of the Company&#x2019;s common stock at a per share
exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zHp9sXQK5nwg" title="Warrants exercise price"&gt;7&lt;/span&gt;. &lt;span&gt;In the initial two years, the holders have the right to convert the outstanding principal amount and accrued
interest into shares of capital stock of Hemogenyx-Cell or Immugenyx, LLC according under the relevant note agreement, subsidiaries
of Hemogenyx Pharmaceuticals Plc, at a price per share based on a pre-money valuation of Hemogenyx-Cell or Immugenyx, LLC of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_ecustom--PreMoneyValuation_iI_pn6n6_c20201231__dei--LegalEntityAxis__custom--HemogenyxCelMember_zkLtkIqsJWR" title="Pre-money valuation"&gt;12&lt;/span&gt;
million and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_ecustom--PreMoneyValuation_iI_pn6n6_c20201231__dei--LegalEntityAxis__custom--ImmugenyxLLCMember_zqO6fr0KZyMe"&gt;8&lt;/span&gt; million, respectively, pursuant to the collaboration agreement with Hemogenyx Pharmaceuticals Plc and Immugenyx,
LLC.&lt;/span&gt; As of December 31, 2020, the loans are presented in current maturities of convertible notes in the balance sheet (See Notes
11(c) and 11(d).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span id="xdx_F0E_z5oVRsJ6GJOj" style="font: 10pt Times New Roman, Times, Serif"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F15_zprCsjdBN534" style="font: 10pt Times New Roman, Times, Serif"&gt;The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pii" title="Stock issued during period, conversion of convertible securities"&gt;1,443,734&lt;/span&gt; shares
and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pii" title="Number of warrant may be converted"&gt;1,053,503&lt;/span&gt; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zRDvnnKx88Ag" title="Warrants exercise, term::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1417"&gt;three-year&lt;/span&gt;&lt;/span&gt; warrants to purchase up to an additional &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Number of warrant may be converted"&gt;1,053,503&lt;/span&gt; shares of the Company&#x2019;s common stock at a per
share exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pii" title="Warrants exercise price"&gt;7&lt;/span&gt;. As of December 31, 2020, $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--ConvertibleDebtCurrent_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zScnFXulvOp2" title="Current maturities of convertible loans"&gt;2,500&lt;/span&gt; thousand of the principal amount is included in current maturities
of convertible loans in the balance sheet and the remainder in long-term convertible loans. See also Notes 7(b), 7(c), 7(e), 7(f)
and 7(g).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F07_zKcMdD3eXmG9" style="width: 15pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F19_zABI8xDlieZ9" style="font: 10pt Times New Roman, Times, Serif"&gt;The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_pii" title="Stock issued during period, conversion of convertible securities"&gt;38,559&lt;/span&gt; shares
at a per share exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zEMHD8sLnPdi" title="Warrants exercise price"&gt;7&lt;/span&gt;. As of December 31, 2020, all the principal amount is included in long-term convertible loans
in the balance sheet See also Notes 7(h).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-12-31_custom_ConvertibleLoansOneMember"
      decimals="-3"
      unitRef="USD">1000000</us-gaap:DebtInstrumentFaceAmount>
    <ORGS:DebtInstrumentIssuanceYear contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansOneMember">2018</ORGS:DebtInstrumentIssuanceYear>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2020-12-31_custom_ConvertibleLoansOneMember"
      decimals="INF"
      unitRef="Percentage">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansOneMember">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2020-12-31_custom_ConvertibleLoansOneMember"
      decimals="INF"
      id="Fact001296"
      unitRef="USDPShares">7.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansOneMember"
      decimals="-3"
      unitRef="USD">71000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-12-31_custom_ConvertibleLoansTwoMember"
      decimals="-3"
      unitRef="USD">9500000</us-gaap:DebtInstrumentFaceAmount>
    <ORGS:DebtInstrumentIssuanceYear contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansTwoMember">2019</ORGS:DebtInstrumentIssuanceYear>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2020-12-31_custom_ConvertibleLoansTwoMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Percentage">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2020-12-31_custom_ConvertibleLoansTwoMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Percentage">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansTwoMember_srt_MinimumMember">P2Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansTwoMember_srt_MaximumMember">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2020-12-31_custom_ConvertibleLoansTwoMember"
      decimals="INF"
      id="Fact001312"
      unitRef="USDPShares">7.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-12-31_custom_ConvertibleLoansThreeMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:DebtInstrumentFaceAmount>
    <ORGS:DebtInstrumentIssuanceYear contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansThreeMember">2020</ORGS:DebtInstrumentIssuanceYear>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2020-12-31_custom_ConvertibleLoansThreeMember"
      decimals="INF"
      unitRef="Percentage">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansThreeMember">P2Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2020-12-31_custom_ConvertibleLoansThreeMember"
      decimals="INF"
      id="Fact001324"
      unitRef="USDPShares">7.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-12-31_custom_ConvertibleLoansMember"
      decimals="-3"
      unitRef="USD">10750000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2019-12-31_custom_ConvertibleLoansOneMember"
      decimals="-3"
      unitRef="USD">1500000</us-gaap:DebtInstrumentFaceAmount>
    <ORGS:DebtInstrumentIssuanceYear contextRef="From2019-01-012019-12-31_custom_ConvertibleLoansOneMember">2018</ORGS:DebtInstrumentIssuanceYear>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2019-12-31_custom_ConvertibleLoansOneMember"
      decimals="INF"
      unitRef="Percentage">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm contextRef="From2019-01-012019-12-31_custom_ConvertibleLoansOneMember">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2019-12-31_custom_ConvertibleLoansOneMember"
      decimals="INF"
      id="Fact001338"
      unitRef="USDPShares">7.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="From2019-01-012019-12-31_custom_ConvertibleLoansOneMember"
      decimals="-3"
      unitRef="USD">124000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2019-12-31_custom_ConvertibleLoansTwoMember"
      decimals="-3"
      unitRef="USD">11400000</us-gaap:DebtInstrumentFaceAmount>
    <ORGS:DebtInstrumentIssuanceYear contextRef="From2019-01-012019-12-31_custom_ConvertibleLoansTwoMember">2019</ORGS:DebtInstrumentIssuanceYear>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2019-12-31_custom_ConvertibleLoansTwoMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Percentage">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2019-12-31_custom_ConvertibleLoansTwoMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Percentage">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm contextRef="From2019-01-012019-12-31_custom_ConvertibleLoansTwoMember_srt_MinimumMember">P2Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="From2019-01-012019-12-31_custom_ConvertibleLoansTwoMember_srt_MaximumMember">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2019-12-31_custom_ConvertibleLoansTwoMember"
      decimals="INF"
      id="Fact001354"
      unitRef="USDPShares">7.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2019-12-31_custom_ConvertibleLoansMember"
      decimals="-3"
      unitRef="USD">12900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2020-01-012020-12-31_custom_TwoPercentageConvertibleLoansTwoMember"
      decimals="-3"
      unitRef="USD">500000</us-gaap:RepaymentsOfConvertibleDebt>
    <ORGS:DebtInstrumentIssuanceYear contextRef="From2020-01-012020-12-31_custom_TwoPercentageConvertibleLoansTwoMember">2018</ORGS:DebtInstrumentIssuanceYear>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2020-12-31_custom_TwoPercentageConvertibleLoansTwoMember"
      decimals="INF"
      unitRef="Percentage">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ORGS:DebtInstrumentRemainingTerm contextRef="From2020-01-012020-12-31_custom_TwoPercentageConvertibleLoansTwoMember">P0M26D</ORGS:DebtInstrumentRemainingTerm>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2020-12-31_custom_TwoPercentageConvertibleLoansTwoMember"
      decimals="INF"
      unitRef="USDPShares">7</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <ORGS:DebtInstrumentConvertibleRepaidBeneficialConversionFeature
      contextRef="From2020-01-012020-12-31_custom_TwoPercentageConvertibleLoansTwoMember"
      decimals="-3"
      unitRef="USD">53000</ORGS:DebtInstrumentConvertibleRepaidBeneficialConversionFeature>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2020-01-012020-12-31_custom_SixPercentageConvertibleLoansTwoMember"
      decimals="-3"
      unitRef="USD">500000</us-gaap:RepaymentsOfConvertibleDebt>
    <ORGS:DebtInstrumentIssuanceYear contextRef="From2020-01-012020-12-31_custom_SixPercentageConvertibleLoansTwoMember">2019</ORGS:DebtInstrumentIssuanceYear>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2020-12-31_custom_SixPercentageConvertibleLoansTwoMember"
      decimals="INF"
      unitRef="Percentage">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ORGS:DebtInstrumentRemainingTerm contextRef="From2020-01-012020-12-31_custom_SixPercentageConvertibleLoansTwoMember">P0M8D</ORGS:DebtInstrumentRemainingTerm>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2020-12-31_custom_SixPercentageConvertibleLoansTwoMember"
      decimals="INF"
      unitRef="USDPShares">7</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2020-01-012020-12-31_custom_EightPercetageConvertibleLoansTwoMember"
      decimals="-3"
      unitRef="USD">1400000</us-gaap:RepaymentsOfConvertibleDebt>
    <ORGS:DebtInstrumentIssuanceYear contextRef="From2020-01-012020-12-31_custom_EightPercetageConvertibleLoansTwoMember">2019</ORGS:DebtInstrumentIssuanceYear>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2020-12-31_custom_EightPercetageConvertibleLoansTwoMember"
      decimals="INF"
      unitRef="Percentage">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ORGS:DebtInstrumentRemainingTerm contextRef="From2020-01-012020-12-31_custom_EightPercetageConvertibleLoansTwoMember">P0M23D</ORGS:DebtInstrumentRemainingTerm>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2020-12-31_custom_EightPercetageConvertibleLoansTwoMember"
      decimals="INF"
      unitRef="USDPShares">7</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansMember"
      decimals="-3"
      unitRef="USD">2400000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansOneMember"
      decimals="INF"
      unitRef="Shares">148838</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-12-31_custom_ConvertibleLoansOneMember"
      decimals="INF"
      unitRef="Shares">148838</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-12-31_custom_ConvertibleLoansOneMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">148838</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_custom_ConvertibleLoansOneMember"
      decimals="INF"
      unitRef="USDPShares">7</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ORGS:PreMoneyValuation
      contextRef="AsOf2020-12-31_custom_HemogenyxCelMember"
      decimals="-6"
      unitRef="USD">12000000</ORGS:PreMoneyValuation>
    <ORGS:PreMoneyValuation
      contextRef="AsOf2020-12-31_custom_ImmugenyxLLCMember"
      decimals="-6"
      unitRef="USD">8000000</ORGS:PreMoneyValuation>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansTwoMember"
      decimals="INF"
      unitRef="Shares">1443734</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-12-31_custom_ConvertibleLoansTwoMember"
      decimals="INF"
      unitRef="Shares">1053503</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-12-31_custom_ConvertibleLoansTwoMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1053503</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_custom_ConvertibleLoansTwoMember"
      decimals="INF"
      unitRef="USDPShares">7</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="AsOf2020-12-31_custom_ConvertibleLoansTwoMember"
      decimals="-3"
      unitRef="USD">2500000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2020-01-012020-12-31_custom_ConvertibleLoansThreeMember"
      decimals="INF"
      unitRef="Shares">38559</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_custom_ConvertibleLoansThreeMember"
      decimals="INF"
      unitRef="USDPShares">7</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2019-04-012019-04-30_custom_ConvertibleLoanAgreementMember_us-gaap_InvestorMember_custom_ConvertibleLoansOneMember"
      decimals="-3"
      unitRef="USD">500000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-04-30_custom_ConvertibleLoanAgreementMember_us-gaap_InvestorMember_custom_ConvertibleLoansOneMember"
      decimals="INF"
      unitRef="USDPShares">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2019-04-012019-04-30_custom_ConvertibleLoanAgreementMember_us-gaap_InvestorMember_custom_ConvertibleLoansOneMember"
      decimals="-6"
      unitRef="USD">50000000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2019-05-012019-05-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember"
      decimals="-6"
      unitRef="USD">5000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2019-05-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember"
      decimals="INF"
      unitRef="USDPShares">7.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-05-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember"
      decimals="INF"
      unitRef="USDPShares">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2019-05-012019-05-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember"
      decimals="-3"
      unitRef="USD">497000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-05-012019-05-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember"
      decimals="-3"
      unitRef="USD">97000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2019-05-31_custom_SixPercentageConvertibleLoanAgreementMember_us-gaap_InvestorMember"
      decimals="INF"
      unitRef="Percentage">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2019-05-012019-05-31_custom_SixPercentageConvertibleLoanAgreementMember_us-gaap_InvestorMember"
      decimals="-6"
      unitRef="USD">5000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2019-05-31_custom_SixPercentageConvertibleLoanAgreementMember_us-gaap_InvestorMember"
      decimals="INF"
      unitRef="USDPShares">7.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-05-31_custom_SixPercentageConvertibleLoanAgreementMember_us-gaap_InvestorMember"
      decimals="INF"
      unitRef="USDPShares">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2019-06-012019-06-30_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember"
      decimals="-6"
      unitRef="USD">2000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2019-06-30_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember"
      decimals="INF"
      unitRef="USDPShares">7.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-06-30_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember"
      decimals="INF"
      unitRef="USDPShares">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember"
      decimals="-5"
      unitRef="USD">5000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember"
      decimals="-4"
      unitRef="USD">1250000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember"
      decimals="-4"
      unitRef="USD">1250000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember"
      decimals="-4"
      unitRef="USD">1250000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember"
      decimals="-4"
      unitRef="USD">1250000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-10-012019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember"
      decimals="-6"
      unitRef="USD">1000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-11-012019-11-30_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember"
      decimals="-6"
      unitRef="USD">1000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-10-012019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-10-012019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-10-012019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-10-012019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-11-012019-11-30_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-11-012019-11-30_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-11-012019-11-30_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-11-012019-11-30_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-12-012019-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember"
      decimals="-6"
      unitRef="USD">1000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2020-01-012020-01-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember"
      decimals="-6"
      unitRef="USD">1000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2020-02-012020-02-29_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember"
      decimals="-6"
      unitRef="USD">1000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-12-012019-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-12-012019-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-12-012019-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-12-012019-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2020-01-012020-01-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2020-01-012020-01-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2020-01-012020-01-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2020-01-012020-01-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2020-02-012020-02-29_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2020-02-012020-02-29_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2020-02-012020-02-29_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2020-02-012020-02-29_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember"
      decimals="-5"
      unitRef="USD">5000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember"
      decimals="-4"
      unitRef="USD">1250000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember"
      decimals="-4"
      unitRef="USD">1250000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember"
      decimals="-4"
      unitRef="USD">1250000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-10-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember"
      decimals="-4"
      unitRef="USD">1250000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember"
      decimals="INF"
      unitRef="Percentage">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember"
      decimals="INF"
      unitRef="USDPShares">7.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2020-12-012020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember"
      decimals="-3"
      unitRef="USD">500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2020-12-012020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember"
      decimals="-3"
      unitRef="USD">500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2020-12-012020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember"
      decimals="-3"
      unitRef="USD">500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2020-12-012020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember"
      decimals="-3"
      unitRef="USD">500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2020-12-012020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorMember"
      decimals="-6"
      unitRef="USD">2000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember"
      decimals="INF"
      unitRef="USDPShares">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember"
      decimals="INF"
      unitRef="USDPShares">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember"
      decimals="INF"
      unitRef="USDPShares">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember"
      decimals="INF"
      unitRef="USDPShares">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorOneMember">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorTwoMember">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorThreeMember">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember_custom_NonUSInvestorFourMember">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ORGS:ModificationOfExistingWarrants
      contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember"
      decimals="-3"
      unitRef="USD">145000</ORGS:ModificationOfExistingWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember"
      decimals="-3"
      unitRef="USD">370000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember"
      decimals="INF"
      unitRef="USDPShares">7.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-01-012019-12-31_custom_CreditLineAgreementsMember"
      decimals="-3"
      unitRef="USD">3650000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-01-012019-12-31_custom_CreditLineAgreementsMember_custom_InvestorOneMember"
      decimals="-4"
      unitRef="USD">1150000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-01-012019-12-31_custom_CreditLineAgreementsMember_custom_InvestorTwoMember"
      decimals="-6"
      unitRef="USD">1000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-01-012019-12-31_custom_CreditLineAgreementsMember_custom_TwoOtherInvestorTwoMember"
      decimals="-3"
      unitRef="USD">750000</us-gaap:ProceedsFromLinesOfCredit>
    <ORGS:ModificationOfExistingWarrants
      contextRef="AsOf2020-12-31_custom_CreditLineAgreementsMember"
      decimals="-3"
      unitRef="USD">145000</ORGS:ModificationOfExistingWarrants>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="From2020-01-012020-12-31_custom_CreditLineAgreementsMember"
      decimals="-3"
      unitRef="USD">2400000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:InterestExpenseDebt
      contextRef="From2020-01-012020-12-31_custom_CreditLineAgreementsMember"
      decimals="-3"
      unitRef="USD">372000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2019-12-012019-12-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-12-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember"
      decimals="INF"
      unitRef="USDPShares">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2019-12-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember"
      decimals="INF"
      unitRef="Shares">183481</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-12-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember"
      decimals="INF"
      unitRef="USDPShares">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2019-12-31_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember"
      decimals="-3"
      unitRef="USD">124000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2019-12-302020-01-03_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember"
      decimals="-3"
      unitRef="USD">250000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-01-02_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember"
      decimals="INF"
      unitRef="USDPShares">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-01-02_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember"
      decimals="INF"
      unitRef="Shares">151428</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-01-02_custom_PrivatePlacementSubscriptionAgreementMember_us-gaap_InvestorMember"
      decimals="INF"
      unitRef="USDPShares">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2018-12-012018-12-31_custom_ControlledEquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="-5"
      unitRef="USD">25000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ORGS:PercentageOfCommission
      contextRef="From2018-12-012018-12-31_custom_ControlledEquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Percentage">0.030</ORGS:PercentageOfCommission>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2016-11-012016-11-02_custom_ControlledEquityOfferingSalesAgreementMember_currency_ILS"
      decimals="-6"
      unitRef="NIS">1000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2016-11-012016-11-02_custom_ControlledEquityOfferingSalesAgreementMember"
      decimals="-3"
      unitRef="USD">280000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2016-11-02_custom_ControlledEquityOfferingSalesAgreementMember"
      decimals="INF"
      unitRef="Percentage">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2016-11-012016-11-02_custom_ControlledEquityOfferingSalesAgreementMember">2017-05-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2018-03-31_custom_ControlledEquityOfferingSalesAgreementMember"
      decimals="-3"
      unitRef="USD">383000</us-gaap:ConvertibleDebt>
    <ORGS:DebtInstrumentConvertibleWarrantExercisePrice
      contextRef="AsOf2018-03-31_custom_ControlledEquityOfferingSalesAgreementMember"
      decimals="INF"
      unitRef="USDPShares">0.52</ORGS:DebtInstrumentConvertibleWarrantExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2018-04-012018-04-30_custom_ControlledEquityOfferingSalesAgreementMember"
      decimals="INF"
      unitRef="Shares">107985</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <ORGS:LoansTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_800_ecustom--LoansTextBlock_zjrO7ATL8kll" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
8 &#x2013; &lt;span id="xdx_824_ztd02ZE3btW2"&gt;LOANS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfDebtTableTextBlock_zAYEB7Q4VzU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Terms
of Short-term Loans&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_8BF_z8OljQQ2hCri" style="display: none"&gt;SCHEDULE OF LOANS&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Currency&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Interest Rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 42%; text-align: left"&gt;Short term loans&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center"&gt;KRW&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoanOneMember__srt--CurrencyAxis__currency--KRW_zIsn6CtImNi3" style="width: 12%; text-align: right" title="Interest Rate"&gt;3.61&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtCurrent_iI_pn3n3_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoanOneMember__srt--CurrencyAxis__currency--KRW_z6t9YdpT77kf" style="width: 10%; text-align: right" title="Total loans"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1630"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DebtCurrent_iI_pn3n3_c20191231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoanOneMember__srt--CurrencyAxis__currency--KRW_zNr3uHWNlib8" style="width: 10%; text-align: right" title="Total loans"&gt;260&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Short term loans&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;KRW&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansTwoMember__srt--CurrencyAxis__currency--KRW_zMC4UvRNnTJl" style="text-align: right" title="Interest Rate"&gt;6.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtCurrent_iI_pn3n3_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansTwoMember__srt--CurrencyAxis__currency--KRW_zgLnnldJsKOg" style="text-align: right" title="Total loans"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1636"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DebtCurrent_iI_pn3n3_c20191231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansTwoMember__srt--CurrencyAxis__currency--KRW_zL8Jg8cz0a31" style="text-align: right" title="Total loans"&gt;131&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short term loans&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansThreeMember_zETCATVnI7qh" style="padding-bottom: 1.5pt; text-align: right" title="Interest Rate"&gt;1.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DebtCurrent_iI_pn3n3_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansThreeMember_zsvIRslKMeI2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total loans"&gt;145&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DebtCurrent_iI_pn3n3_c20191231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansThreeMember_zrBmTvcLXsgg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total loans"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1644"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DebtCurrent_iI_pn3n3_c20201231_zYcK5lHR21sh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total loans"&gt;145&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DebtCurrent_iI_pn3n3_c20191231_ztWvQaA4gr9h" style="border-bottom: Black 2.5pt double; text-align: right" title="Total loans"&gt;391&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A7_zXo7VmyNKFee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ORGS:LoansTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_895_eus-gaap--ScheduleOfDebtTableTextBlock_zAYEB7Q4VzU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Terms
of Short-term Loans&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span id="xdx_8BF_z8OljQQ2hCri" style="display: none"&gt;SCHEDULE OF LOANS&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Currency&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Interest Rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 42%; text-align: left"&gt;Short term loans&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center"&gt;KRW&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoanOneMember__srt--CurrencyAxis__currency--KRW_zIsn6CtImNi3" style="width: 12%; text-align: right" title="Interest Rate"&gt;3.61&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtCurrent_iI_pn3n3_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoanOneMember__srt--CurrencyAxis__currency--KRW_z6t9YdpT77kf" style="width: 10%; text-align: right" title="Total loans"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1630"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DebtCurrent_iI_pn3n3_c20191231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoanOneMember__srt--CurrencyAxis__currency--KRW_zNr3uHWNlib8" style="width: 10%; text-align: right" title="Total loans"&gt;260&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Short term loans&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;KRW&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansTwoMember__srt--CurrencyAxis__currency--KRW_zMC4UvRNnTJl" style="text-align: right" title="Interest Rate"&gt;6.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtCurrent_iI_pn3n3_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansTwoMember__srt--CurrencyAxis__currency--KRW_zgLnnldJsKOg" style="text-align: right" title="Total loans"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1636"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DebtCurrent_iI_pn3n3_c20191231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansTwoMember__srt--CurrencyAxis__currency--KRW_zL8Jg8cz0a31" style="text-align: right" title="Total loans"&gt;131&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short term loans&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansThreeMember_zETCATVnI7qh" style="padding-bottom: 1.5pt; text-align: right" title="Interest Rate"&gt;1.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DebtCurrent_iI_pn3n3_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansThreeMember_zsvIRslKMeI2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total loans"&gt;145&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DebtCurrent_iI_pn3n3_c20191231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansThreeMember_zrBmTvcLXsgg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total loans"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1644"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DebtCurrent_iI_pn3n3_c20201231_zYcK5lHR21sh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total loans"&gt;145&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DebtCurrent_iI_pn3n3_c20191231_ztWvQaA4gr9h" style="border-bottom: Black 2.5pt double; text-align: right" title="Total loans"&gt;391&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2020-12-31_custom_ShortTermLoanOneMember_currency_KRW"
      decimals="INF"
      unitRef="Percentage">0.0361</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtCurrent
      contextRef="AsOf2019-12-31_custom_ShortTermLoanOneMember_currency_KRW"
      decimals="-3"
      unitRef="USD">260000</us-gaap:DebtCurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2020-12-31_custom_ShortTermLoansTwoMember_currency_KRW"
      decimals="INF"
      unitRef="Percentage">0.0600</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtCurrent
      contextRef="AsOf2019-12-31_custom_ShortTermLoansTwoMember_currency_KRW"
      decimals="-3"
      unitRef="USD">131000</us-gaap:DebtCurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2020-12-31_custom_ShortTermLoansThreeMember"
      decimals="INF"
      unitRef="Percentage">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtCurrent
      contextRef="AsOf2020-12-31_custom_ShortTermLoansThreeMember"
      decimals="-3"
      unitRef="USD">145000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">145000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">391000</us-gaap:DebtCurrent>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_80E_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zr0ZpGQpiJUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
9 &#x2013; &lt;span id="xdx_82C_zRZf20zOsyz8"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company leases research and development facilities, equipment and offices under finance and operating leases. For leases with
terms greater than 12 months, the Company record the related asset and obligation at the present value of lease payments over
the term. Many of the leases include rental escalation clauses, renewal options and/or termination options that are factored into
the determination of lease payments when appropriate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s leases do not provide a readily determinable implicit rate. Therefore, the Company estimated the incremental borrowing
rate to discount the lease payments based on information available at lease commencement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Manufacturing
facilities&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company leases space for its manufacturing facilities in Israel under operating lease agreements. The leasing contracts are for
a period of &lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ManufacturingFacilityMember__srt--StatementGeographicalAxis__country--IL__srt--RangeAxis__srt--MinimumMember_zGQAXTREGjQa" title="Leasing contracts period"&gt;3&lt;/span&gt; - &lt;span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ManufacturingFacilityMember__srt--StatementGeographicalAxis__country--IL__srt--RangeAxis__srt--MaximumMember_zZSthrCW7jG5" title="Leasing contracts period"&gt;5&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Research
and Development facilities&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company leases space for its research and development facilities in South Korea under an operating lease agreement. The leasing
contracts are for a period of &lt;span id="xdx_900_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchAndDevelopmentFacilitiesMember__srt--StatementGeographicalAxis__country--KR__srt--RangeAxis__srt--MinimumMember_zbob8PMMPKHc" title="Leasing contracts period"&gt;2&lt;/span&gt; &#x2013; &lt;span id="xdx_900_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchAndDevelopmentFacilitiesMember__srt--StatementGeographicalAxis__country--KR__srt--RangeAxis__srt--MaximumMember_zWy4x1Grp6Ml" title="Leasing contracts period"&gt;5&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Offices&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company leases space for offices in Israel under operating leases. The leasing contracts are valid for terms of &lt;span id="xdx_90C_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficesMember__srt--StatementGeographicalAxis__country--IL_zR0orHrT7INg" title="Leasing contracts period"&gt;5&lt;/span&gt; years. These
contracts are considered as operational leasing and under operating lease right-of-use assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Lease
Position&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_ecustom--LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock_z1FhRdiiGaR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
table below presents the lease-related assets and liabilities recorded on the balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zZdKgRAHa2p5" style="display: none"&gt;SCHEDULE OF LEASE-RELATED ASSETS AND LIABILITIES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Operating Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231_zqRWSm2h1JEc" style="width: 22%; text-align: right" title="Operating lease right-of-use assets"&gt;1,474&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property, plants and equipment, gross&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_iI_pn3n3_c20201231_zJOUqZ8y7xm8" style="text-align: right" title="Property, plants and equipment, gross"&gt;99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_iNI_pn3n3_di_c20201231_zWnCpv4ev9o7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated depreciation"&gt;(17&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_iI_pn3n3_c20201231_zvbDrAEhCeBj" style="text-align: right" title="Property and equipment, net"&gt;82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Current maturities of operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20201231_zWljfSHKPXta" style="text-align: right" title="Current maturities of operating leases"&gt;485&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current maturities of long-term finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FinanceLeaseLiabilityCurrent_iI_pn3n3_c20201231_zYVkaOFfyVm9" style="text-align: right" title="Current maturities of long-term finance leases"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Long-term liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-current operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_zvKMPRRBlAfi" style="text-align: right" title="Non-current operating leases"&gt;1,020&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Long-term finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_z5cnGBu7KYX4" style="text-align: right" title="Long-term finance leases"&gt;64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Weighted Average Remaining Lease Term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Weighted Average Remaining Lease Term, Operating leases"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zqn7w1LZqLPc" title="Weighted Average Remaining Lease Term, Operating leases"&gt;3.4&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_90C_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zFXvyLnurfwl" title="Weighted Average Remaining Lease Term, Finance leases"&gt;4.2&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b/&gt;&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted Average Discount Rate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercentage_c20201231_zKy8r14AXkhk" title="Weighted Average Discount Rate, Operating leases"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercentage_c20201231_zuyJmNY7djsb" style="text-align: right" title="Weighted Average Discount Rate, Finance leases"&gt;2.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A2_zGn7PpLH9Mbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Lease
Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--LeaseCostTableTextBlock_z67WrxGKHnM5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
table below presents certain information related to lease costs and finance and operating leases during the year ended December
31, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zuaKHrU7aoml" style="display: none"&gt;SCHEDULE OF LEASE COSTS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20200101__20201231_z0Sk6zz48Erk" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--OperatingLeaseCost_pn3n3_zexRgjt0MFr2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Operating lease cost:&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 18%; text-align: right"&gt;547&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Finance lease cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_pn3n3_maFLCzuMa_zmKVHsTFM7V3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Amortization of leased assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--FinanceLeaseInterestExpense_pn3n3_maFLCzuMa_zbwkMID5of0e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_ecustom--FinanceLeaseCost_iT_pn3n3_mtFLCzuMa_zPKF1ljciKzb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total finance lease cost&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A7_z8Ud03dG2pu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zJyqjoP69R92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
table below presents supplemental cash flow information related to leases during the year ended December 31, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_z4qX6smYrA7h" style="display: none"&gt;SCHEDULE OF SUPPLEMENTAL CASHFLOW INFORMATION&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20200101__20201231_zl3kxCon0LI8" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in Thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cash paid for amounts included in the measurement of leases liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--OperatingLeasePayments_pn3n3_zSuJywrS7kae" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;515&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--FinanceLeaseInterestPaymentOnLiability_pn3n3_zfrprXkaNqL7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_zZZo1JoAWpwc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;967&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_pn3n3_zFFFu9SrcNN" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;366&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AC_zVemCYsqNhWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Undiscounted
Cash Flows&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--LesseeLeaseLiabilityMaturityTableTextBlock_zPoAow1Vgmpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining years to the finance
lease liabilities and operating lease liabilities recorded on the balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zOMZCS7jzl36" style="display: none"&gt;SCHEDULE OF FINANCE LEASE LIABILITIES AND OPERATING LEASE LIABILITIES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Operating&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Finance&lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; font-weight: bold"&gt;Year ended December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: left"&gt;2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20201231_z6tF4FvykiI8" style="width: 14%; text-align: right" title="Operating Leases, 2021"&gt;526&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20201231_zBaLYRgihj6" style="width: 14%; text-align: right" title="Finance Lease, 2021"&gt;20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20201231_zg24sOWglx32" style="text-align: right" title="Operating Leases, 2022"&gt;528&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20201231_zTxAWvVV5xtb" style="text-align: right" title="Finance Lease, 2022"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20201231_zHETN0cgwm34" style="text-align: right" title="Operating Leases, 2023"&gt;342&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20201231_zq4qcR8EzRKh" style="text-align: right" title="Finance Lease, 2023"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20201231_zFeR4t2KR6h" style="text-align: right" title="Operating Leases, 2024"&gt;188&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20201231_zwNV9GhUi5K3" style="text-align: right" title="Finance Lease, 2024"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20201231_zsJhVL2uRgn7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, 2025"&gt;59&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20201231_zuz522hVdfpj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Lease, 2025"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3_c20201231_zBMnPMPIbkLk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Total minimum lease payments"&gt;1,643&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_pn3n3_c20201231_zC1UR28KG7Mk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Leases, Total minimum lease payments"&gt;84&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: amount of lease payments representing interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20201231_ztGz3nCYll8h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Less: amount of lease payments representing interest"&gt;(138&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20201231_zHT9XriD7Lrl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Lease, Less: amount of lease payments representing interest"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Present value of future minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20201231_zuJcxwl9X6Rg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Present value of future minimum lease payments"&gt;1,505&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20201231_zsOll1AEozka" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Lease, Present value of future minimum lease payments"&gt;83&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Current leases obligations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_c20201231_znjuy2SLuqd1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Less: Current leases obligations"&gt;(485&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_pn3n3_di_c20201231_z95tzskdOep5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Lease, Less: Current leases obligations"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Long-term leases obligations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_zgG7HPpfTkOe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Long-term leases obligations"&gt;1,020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_zkdo2MEdckRc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Lease, Long-term leases obligations"&gt;64&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A1_zOc9cENU1w82" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_ecustom--ScheduleOfRightofuseAssetsByGeographicalLocation_zGSgBueRb6dk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Right-of-use
assets by geographical location were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_ziuqXQcrRCB3" style="display: none"&gt;SCHEDULE OF RIGHT-OF-USE ASSETS BY GEOGRAPHICAL LOCATION&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Korea&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--KR_zlXuLOn79WM6" style="width: 14%; text-align: right" title="Operating lease right-of-use assets"&gt;683&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--KR_zmzTrc2PUWRl" style="width: 14%; text-align: right" title="Operating lease right-of-use assets"&gt;145&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Israel&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--IL_z19Lr1NnxPye" style="text-align: right" title="Operating lease right-of-use assets"&gt;496&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--IL_zcOn8zhaNaCb" style="text-align: right" title="Operating lease right-of-use assets"&gt;580&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;U.S.&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--US_z4mX8BUG13c9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating lease right-of-use assets"&gt;295&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--US_z76UwFBhrWG" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating lease right-of-use assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1762"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231_zg2SXZvncJul" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use assets"&gt;1,474&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20191231_zhAh91WpnK6b" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use assets"&gt;725&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A4_zCsttVJJ5FFd" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2020-12-31_us-gaap_ManufacturingFacilityMember_country_IL_srt_MinimumMember">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2020-12-31_us-gaap_ManufacturingFacilityMember_country_IL_srt_MaximumMember">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2020-12-31_custom_ResearchAndDevelopmentFacilitiesMember_country_KR_srt_MinimumMember">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2020-12-31_custom_ResearchAndDevelopmentFacilitiesMember_country_KR_srt_MaximumMember">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2020-12-31_custom_OfficesMember_country_IL">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ORGS:LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_890_ecustom--LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock_z1FhRdiiGaR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
table below presents the lease-related assets and liabilities recorded on the balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zZdKgRAHa2p5" style="display: none"&gt;SCHEDULE OF LEASE-RELATED ASSETS AND LIABILITIES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Operating Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231_zqRWSm2h1JEc" style="width: 22%; text-align: right" title="Operating lease right-of-use assets"&gt;1,474&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property, plants and equipment, gross&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_iI_pn3n3_c20201231_zJOUqZ8y7xm8" style="text-align: right" title="Property, plants and equipment, gross"&gt;99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_iNI_pn3n3_di_c20201231_zWnCpv4ev9o7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated depreciation"&gt;(17&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_iI_pn3n3_c20201231_zvbDrAEhCeBj" style="text-align: right" title="Property and equipment, net"&gt;82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Current maturities of operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20201231_zWljfSHKPXta" style="text-align: right" title="Current maturities of operating leases"&gt;485&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current maturities of long-term finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FinanceLeaseLiabilityCurrent_iI_pn3n3_c20201231_zYVkaOFfyVm9" style="text-align: right" title="Current maturities of long-term finance leases"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Long-term liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-current operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_zvKMPRRBlAfi" style="text-align: right" title="Non-current operating leases"&gt;1,020&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Long-term finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_z5cnGBu7KYX4" style="text-align: right" title="Long-term finance leases"&gt;64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Weighted Average Remaining Lease Term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Weighted Average Remaining Lease Term, Operating leases"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zqn7w1LZqLPc" title="Weighted Average Remaining Lease Term, Operating leases"&gt;3.4&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_90C_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zFXvyLnurfwl" title="Weighted Average Remaining Lease Term, Finance leases"&gt;4.2&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b/&gt;&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted Average Discount Rate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercentage_c20201231_zKy8r14AXkhk" title="Weighted Average Discount Rate, Operating leases"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercentage_c20201231_zuyJmNY7djsb" style="text-align: right" title="Weighted Average Discount Rate, Finance leases"&gt;2.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</ORGS:LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1474000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">99000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">17000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">82000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">485000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">19000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1020000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">64000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2020-12-31">P3Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2020-12-31">P4Y2M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="Percentage">0.067</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="Percentage">0.020</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_893_eus-gaap--LeaseCostTableTextBlock_z67WrxGKHnM5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
table below presents certain information related to lease costs and finance and operating leases during the year ended December
31, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zuaKHrU7aoml" style="display: none"&gt;SCHEDULE OF LEASE COSTS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20200101__20201231_z0Sk6zz48Erk" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--OperatingLeaseCost_pn3n3_zexRgjt0MFr2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Operating lease cost:&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 18%; text-align: right"&gt;547&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Finance lease cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_pn3n3_maFLCzuMa_zmKVHsTFM7V3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Amortization of leased assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--FinanceLeaseInterestExpense_pn3n3_maFLCzuMa_zbwkMID5of0e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_ecustom--FinanceLeaseCost_iT_pn3n3_mtFLCzuMa_zPKF1ljciKzb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total finance lease cost&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">547000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">17000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">3000</us-gaap:FinanceLeaseInterestExpense>
    <ORGS:FinanceLeaseCost
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">20000</ORGS:FinanceLeaseCost>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_895_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zJyqjoP69R92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
table below presents supplemental cash flow information related to leases during the year ended December 31, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_z4qX6smYrA7h" style="display: none"&gt;SCHEDULE OF SUPPLEMENTAL CASHFLOW INFORMATION&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20200101__20201231_zl3kxCon0LI8" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in Thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cash paid for amounts included in the measurement of leases liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--OperatingLeasePayments_pn3n3_zSuJywrS7kae" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;515&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--FinanceLeaseInterestPaymentOnLiability_pn3n3_zfrprXkaNqL7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_zZZo1JoAWpwc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;967&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_pn3n3_zFFFu9SrcNN" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;366&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">515000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">42000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">967000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">366000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <ORGS:LesseeLeaseLiabilityMaturityTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89C_ecustom--LesseeLeaseLiabilityMaturityTableTextBlock_zPoAow1Vgmpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining years to the finance
lease liabilities and operating lease liabilities recorded on the balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zOMZCS7jzl36" style="display: none"&gt;SCHEDULE OF FINANCE LEASE LIABILITIES AND OPERATING LEASE LIABILITIES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Operating&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Finance&lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; font-weight: bold"&gt;Year ended December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: left"&gt;2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20201231_z6tF4FvykiI8" style="width: 14%; text-align: right" title="Operating Leases, 2021"&gt;526&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20201231_zBaLYRgihj6" style="width: 14%; text-align: right" title="Finance Lease, 2021"&gt;20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20201231_zg24sOWglx32" style="text-align: right" title="Operating Leases, 2022"&gt;528&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20201231_zTxAWvVV5xtb" style="text-align: right" title="Finance Lease, 2022"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20201231_zHETN0cgwm34" style="text-align: right" title="Operating Leases, 2023"&gt;342&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20201231_zq4qcR8EzRKh" style="text-align: right" title="Finance Lease, 2023"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20201231_zFeR4t2KR6h" style="text-align: right" title="Operating Leases, 2024"&gt;188&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20201231_zwNV9GhUi5K3" style="text-align: right" title="Finance Lease, 2024"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20201231_zsJhVL2uRgn7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, 2025"&gt;59&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20201231_zuz522hVdfpj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Lease, 2025"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3_c20201231_zBMnPMPIbkLk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Total minimum lease payments"&gt;1,643&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_pn3n3_c20201231_zC1UR28KG7Mk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Leases, Total minimum lease payments"&gt;84&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: amount of lease payments representing interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20201231_ztGz3nCYll8h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Less: amount of lease payments representing interest"&gt;(138&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20201231_zHT9XriD7Lrl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Lease, Less: amount of lease payments representing interest"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Present value of future minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20201231_zuJcxwl9X6Rg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Present value of future minimum lease payments"&gt;1,505&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20201231_zsOll1AEozka" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Lease, Present value of future minimum lease payments"&gt;83&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Current leases obligations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_c20201231_znjuy2SLuqd1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Less: Current leases obligations"&gt;(485&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_pn3n3_di_c20201231_z95tzskdOep5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Lease, Less: Current leases obligations"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Long-term leases obligations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_zgG7HPpfTkOe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Long-term leases obligations"&gt;1,020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_zkdo2MEdckRc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Lease, Long-term leases obligations"&gt;64&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</ORGS:LesseeLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">526000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">20000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">528000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">20000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">342000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">20000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">188000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">20000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">59000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">4000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1643000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">84000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">138000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1505000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">83000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">485000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">19000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1020000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">64000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <ORGS:ScheduleOfRightofuseAssetsByGeographicalLocation contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_895_ecustom--ScheduleOfRightofuseAssetsByGeographicalLocation_zGSgBueRb6dk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Right-of-use
assets by geographical location were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_ziuqXQcrRCB3" style="display: none"&gt;SCHEDULE OF RIGHT-OF-USE ASSETS BY GEOGRAPHICAL LOCATION&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Korea&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--KR_zlXuLOn79WM6" style="width: 14%; text-align: right" title="Operating lease right-of-use assets"&gt;683&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--KR_zmzTrc2PUWRl" style="width: 14%; text-align: right" title="Operating lease right-of-use assets"&gt;145&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Israel&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--IL_z19Lr1NnxPye" style="text-align: right" title="Operating lease right-of-use assets"&gt;496&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--IL_zcOn8zhaNaCb" style="text-align: right" title="Operating lease right-of-use assets"&gt;580&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;U.S.&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--US_z4mX8BUG13c9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating lease right-of-use assets"&gt;295&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--US_z76UwFBhrWG" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating lease right-of-use assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1762"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231_zg2SXZvncJul" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use assets"&gt;1,474&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20191231_zhAh91WpnK6b" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use assets"&gt;725&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</ORGS:ScheduleOfRightofuseAssetsByGeographicalLocation>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2020-12-31_country_KR"
      decimals="-3"
      unitRef="USD">683000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2019-12-31_country_KR"
      decimals="-3"
      unitRef="USD">145000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2020-12-31_country_IL"
      decimals="-3"
      unitRef="USD">496000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2019-12-31_country_IL"
      decimals="-3"
      unitRef="USD">580000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2020-12-31_country_US"
      decimals="-3"
      unitRef="USD">295000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1474000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">725000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_80F_eus-gaap--CommitmentsDisclosureTextBlock_zAn7Qlnnjvtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
10 &#x2013; &lt;span id="xdx_82E_zDzDwqP4TG81"&gt;COMMITMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;See
Note 11 for additional commitments for funding of the ventures of the company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;a.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Maryland
    Technology Development Corporation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
June 30, 2014, the Company&#x2019;s U.S. Subsidiary entered into a grant agreement with Maryland Technology Development Corporation
(&#x201c;TEDCO&#x201d;). TEDCO was created by the Maryland State Legislature in 1998 to facilitate the transfer and commercialization
of technology from Maryland&#x2019;s research universities and federal labs into the marketplace and to assist in the creation
and growth of technology-based businesses in all regions of the State. Under the agreement, TEDCO paid to the U.S Subsidiary an
amount of $&lt;span id="xdx_90D_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_c20140630__us-gaap--RelatedPartyTransactionAxis__custom--MarylandTechnologyDevelopmentCorporationMember__srt--RangeAxis__srt--MaximumMember_z61OWaxT90nb" title="Grants receivable, noncurrent"&gt;406&lt;/span&gt; thousand (the &#x201c;Grant&#x201d;). On June 21, 2016 TEDCO has approved an extension until June 30, 2017.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;b.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Department
    De La Gestion Financiere Direction De L&#x2019;analyse Financiere (&#x201c;DGO6&#x201d;)&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(1)
On November 17, 2014, the Belgian Subsidiary, received the formal approval from the DGO6 for a Euro &lt;span id="xdx_900_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_uEUR_c20141117__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zpNwyBMCRF6h" title="Grants receivable, noncurrent"&gt;2&lt;/span&gt; million ($&lt;span id="xdx_900_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_uUSD_c20141117__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zxBTCocFltT" title="Grants receivable, noncurrent"&gt;2.4&lt;/span&gt; million) support
program for the research and development of a potential cure for Type 1 Diabetes. The financial support was composed of Euro &lt;span id="xdx_90F_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_uEUR_c20141117__us-gaap--OtherCommitmentsAxis__custom--IndustrialResearchPartOfResearchProgramMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zxlOqLLITAx2" title="Grants receivable, noncurrent"&gt;1,085&lt;/span&gt;
thousand (&lt;span id="xdx_90C_ecustom--GrantsReceivablePercentageOfBudgetedCosts_iI_pii_dp_uPercentage_c20141117__us-gaap--OtherCommitmentsAxis__custom--IndustrialResearchPartOfResearchProgramMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zQwJabUpFY3" title="Grants receivable, percentage of budgeted costs"&gt;70&lt;/span&gt;% of budgeted costs) grant for the industrial research part of the research program and a further recoverable advance
of Euro &lt;span id="xdx_907_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_uEUR_c20141117__us-gaap--OtherCommitmentsAxis__custom--ExperimentalDevelopmentPartOfResearchProgramMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zBOhOf3nRpw8" title="Grants receivable, noncurrent"&gt;930&lt;/span&gt; thousand (&lt;span id="xdx_901_ecustom--GrantsReceivablePercentageOfBudgetedCosts_iI_pii_dp_uPercentage_c20141117__us-gaap--OtherCommitmentsAxis__custom--ExperimentalDevelopmentPartOfResearchProgramMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zxIWdncDV2d9" title="Grants receivable, percentage of budgeted costs"&gt;60&lt;/span&gt;% of budgeted costs) of the experimental development part of the research program. In December 2014, the
Belgian Subsidiary received advance payment of Euro &lt;span id="xdx_90C_ecustom--AdvancePaymentsOnAccountOfGrant_iI_pn3n3_uEUR_c20141231__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zVKbZnE8j15e" title="Advance payments on account of grant"&gt;1,209&lt;/span&gt; thousand under the grant. The grants are subject to certain conditions
with respect to the Belgian Subsidiary&#x2019;s work in the Walloon Region. In addition, the DGO6 is also entitled to a royalty
upon revenue being generated from any commercial application of the technology. In 2017 the Company received by the DGO6 final
approval for Euro &lt;span id="xdx_908_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_uEUR_c20171231__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zyEBoHcF3IB9" title="Grants receivable, noncurrent"&gt;1.8&lt;/span&gt; million costs invested in the project out of which Euro &lt;span id="xdx_905_eus-gaap--Revenues_pn5n6_c20170101__20171231__srt--ProductOrServiceAxis__custom--RevenueFromGrantsMember__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zwbh06oQeVx2" title="Revenues, total"&gt;1.2&lt;/span&gt; million funded by the DGO6. As of December 31,
2020, the Company repaid to the DGO6 a total amount of $&lt;span id="xdx_90F_eus-gaap--OtherExpenses_pn3n3_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zuJ1klvKPF3b" title="Other expenses"&gt;118&lt;/span&gt; thousand (Euro &lt;span id="xdx_904_eus-gaap--OtherExpenses_pn3n3_uEUR_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zqDcUUNqk98e" title="Other expenses"&gt;96&lt;/span&gt; thousand) and amount of $&lt;span id="xdx_905_eus-gaap--OtherCommitment_iI_pn3n3_c20201231__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zChk3zy27KRd" title="Other payables"&gt;106&lt;/span&gt; thousand was recorded
in other payables.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(2)
In April 2016, the Belgian Subsidiary received the formal approval from DGO6 for a Euro &lt;span id="xdx_906_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_uEUR_c20160430__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zwckrLTpKrOc"&gt;1.3
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million ($&lt;span id="xdx_903_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_c20160430__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zcyDSi8mIuC2"&gt;1.5
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million) support program for the development
of a potential cure for Type 1 Diabetes. The financial support was awarded to the Belgium Subsidiary as a recoverable advance
payment at &lt;span id="xdx_90F_ecustom--GrantsReceivablePercentageOfBudgetedCosts_iI_dp_uPercentage_c20160430__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zkYAYh5F1O06"&gt;55&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
of budgeted costs, or for a total of Euro &lt;span id="xdx_90D_eus-gaap--Revenues_pn3n3_uEUR_c20160401__20160430__srt--ProductOrServiceAxis__custom--RevenueFromGrantsMember__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zsgyX91xQ0Lh"&gt;717
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;thousand ($&lt;span id="xdx_909_eus-gaap--Revenues_pn3n3_c20160401__20160430__srt--ProductOrServiceAxis__custom--RevenueFromGrantsMember__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_z3OUrZmJYRT8"&gt;800
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;thousand). The grant will be paid over
the project period. The Belgian Subsidiary received advance payment of Euro &lt;span id="xdx_90B_eus-gaap--Revenues_pn3n3_uEUR_c20200101__20201231__srt--ProductOrServiceAxis__custom--RevenueFromGrantsMember__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_z00ID9zTlD19"&gt;438
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;thousand ($&lt;span id="xdx_905_eus-gaap--Revenues_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--RevenueFromGrantsMember__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zvPwZ8jIz1Ag"&gt;537
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;thousand). Up through December 31,
2020, an amount of Euro &lt;span id="xdx_903_ecustom--DeductionOfResearchAndDevelopmentExpenses_pn3n3_uEUR_c20200101__20201231__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zKrgXmU9kBO"&gt;358
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;thousand ($&lt;span id="xdx_901_ecustom--DeductionOfResearchAndDevelopmentExpenses_pn3n3_c20200101__20201231__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zeOcc5Wz7Axc"&gt;437
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;thousand) was recorded as deduction of
research and development expenses and an amount of Euro &lt;span id="xdx_90E_ecustom--AdvancePaymentsOnAccountOfGrant_iI_pn3n3_uEUR_c20201231__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_z3HPJnLeeree"&gt;80
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;thousand was recorded as advance payments
on account of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(3)
On October 8, 2016, the Belgian Subsidiary received the formal approval from the DGO6 for a Euro &lt;span id="xdx_907_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_uEUR_c20161008__us-gaap--OtherCommitmentsAxis__custom--GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zQ351sqZpTCh" title="Grants receivable, noncurrent"&gt;12.3 &lt;/span&gt;million ($&lt;span id="xdx_902_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_c20161008__us-gaap--OtherCommitmentsAxis__custom--GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zUtbRlRMhrlk" title="Grants receivable, noncurrent"&gt;12.8&lt;/span&gt; million)
support program for the GMP production of AIP cells for two clinical trials that will be performed in Germany and Belgium. The
project will be conducted during a period of three years commencing January 1, 2017. The financial support is awarded to the Belgium
subsidiary at&lt;span id="xdx_906_ecustom--GrantsReceivablePercentageOfBudgetedCosts_iI_dp_uPercentage_c20161008__us-gaap--OtherCommitmentsAxis__custom--GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zCAmTg3EXiOc" title="Grants receivable, percentage of budgeted costs"&gt; 55&lt;/span&gt;% of budgeted costs, a total of Euro &lt;span id="xdx_90E_eus-gaap--Revenues_pn5n6_uEUR_c20161001__20161008__us-gaap--OtherCommitmentsAxis__custom--GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zdAUZJBCegKj" title="Revenues, total"&gt;6.8&lt;/span&gt; million ($&lt;span id="xdx_904_eus-gaap--Revenues_pn5n6_c20161001__20161008__us-gaap--OtherCommitmentsAxis__custom--GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zMVclOX9uG67" title="Revenues, total"&gt;7&lt;/span&gt; million). The grant will be paid over the project period.
On December 19, 2016, the Belgian Subsidiary received a first payment of Euro &lt;span id="xdx_909_eus-gaap--Revenues_pn5n6_uEUR_c20161201__20161219__us-gaap--OtherCommitmentsAxis__custom--GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zvG5mrnrBYTc" title="Revenues, total"&gt;1.7&lt;/span&gt; million ($&lt;span id="xdx_900_eus-gaap--Revenues_pn5n6_c20161201__20161219__us-gaap--OtherCommitmentsAxis__custom--GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zW6uSLNowGCg" title="Revenues, total"&gt;2&lt;/span&gt; million). Up through December 31,
2020, an amount of Euro &lt;span id="xdx_902_ecustom--DeductionOfResearchAndDevelopmentExpenses_pn5n6_c20200101__20201231__us-gaap--OtherCommitmentsAxis__custom--DeductionOfResearchAndDevelopmentExpensesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zOyIMtsiFh6" title="Deduction of research and development expenses"&gt;1.7&lt;/span&gt; million was recorded as deduction of research and development expenses and an amount of Euro &lt;span id="xdx_900_ecustom--DeductionOfResearchAndDevelopmentExpenses_pn3n3_uEUR_c20200101__20201231__us-gaap--OtherCommitmentsAxis__custom--DeductionOfResearchAndDevelopmentExpensesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_z2oNMdoqLROj" title="Deduction of research and development expenses"&gt;53&lt;/span&gt; thousand
was recorded as receivable on account of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(4)
In December 2020, the Belgian Subsidiary received the formal approval from DGO6 for a Euro &lt;span id="xdx_901_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_uEUR_c20201231__us-gaap--OtherCommitmentsAxis__custom--ResearchOnDermatitisTreatmentsAndWoundHealingMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_z9uGjXhpGRB6" title="Grants receivable, noncurrent"&gt;2.9&lt;/span&gt; million ($&lt;span id="xdx_908_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_c20201231__us-gaap--OtherCommitmentsAxis__custom--ResearchOnDermatitisTreatmentsAndWoundHealingMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zWmYSsiAhZL3" title="Grants receivable, noncurrent"&gt;3.5&lt;/span&gt; million) support
program for research on Dermatitis Treatments and Wound Healing Using Cell Regenerative Technologies. The financial support was
awarded to the Belgium Subsidiary as a recoverable advance payment at &lt;span id="xdx_908_ecustom--GrantsReceivablePercentageOfBudgetedCosts_iI_pii_dp_uPercentage_c20201231__us-gaap--OtherCommitmentsAxis__custom--ResearchOnDermatitisTreatmentsAndWoundHealingMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_ztxwQsGzHb75" title="Grants receivable, percentage of budgeted costs"&gt;60&lt;/span&gt;% of budgeted costs, or for a total of Euro &lt;span id="xdx_905_eus-gaap--Revenues_pn5n6_uEUR_c20201201__20201231__us-gaap--OtherCommitmentsAxis__custom--ResearchOnDermatitisTreatmentsAndWoundHealingMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zahfsZHia256" title="Revenues, total"&gt;1.7&lt;/span&gt; million
($&lt;span id="xdx_90E_eus-gaap--Revenues_pn5n6_c20201201__20201231__us-gaap--OtherCommitmentsAxis__custom--ResearchOnDermatitisTreatmentsAndWoundHealingMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zxDQaPfMmVV7" title="Revenues, total"&gt;2.1 &lt;/span&gt;million). The grant will be paid over the project period. The Belgian Subsidiary received an advance payment of Euro &lt;span id="xdx_907_eus-gaap--Revenues_pn3n3_uEUR_c20200101__20201231__us-gaap--OtherCommitmentsAxis__custom--ResearchOnDermatitisTreatmentsAndWoundHealingMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zH6NmnKczsj1" title="Revenues, total"&gt;301&lt;/span&gt;
thousand ($&lt;span id="xdx_902_eus-gaap--Revenues_pn3n3_c20200101__20201231__us-gaap--OtherCommitmentsAxis__custom--ResearchOnDermatitisTreatmentsAndWoundHealingMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zqq9gnukmmSb" title="Revenues, total"&gt;366&lt;/span&gt; thousand) in December 2020. The research program is to be started in 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;c.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Israel-U.S.
    Binational Industrial Research and Development Foundation (&#x201c;BIRD&#x201d;)&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
September 9, 2015, the Israeli Subsidiary entered into a pharma Cooperation and Project Funding Agreement (CPFA) with BIRD and
Pall Corporation, a U.S. company. BIRD awarded a conditional grant of $&lt;span id="xdx_908_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_c20150909__us-gaap--RelatedPartyTransactionAxis__custom--IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember_zxoTJz8FASMl" title="Grants receivable, noncurrent"&gt;400&lt;/span&gt; thousand each (according to terms defined in the agreement),
for a joint research and development project for the use Autologous Insulin Producing (AIP) Cells for the Treatment of Diabetes
(the &#x201c;Project&#x201d;). The Project started on March 1, 2015. Upon the conclusion of product development, the grant shall
be repaid at the rate of &lt;span id="xdx_904_ecustom--RepaymentsOfGrantPercentageOfGrossSales_pii_dp_uPercentage_c20150901__20150909__us-gaap--RelatedPartyTransactionAxis__custom--IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember_zGZjuaY4Bu61" title="Repayments of grant, percentage of gross sales"&gt;5&lt;/span&gt;% of gross sales. The grant will be used solely to finance the costs to conduct the research of the
project during a period of 18 months starting on March 1, 2015. On July 28, 2016, BIRD approved an extension for the project period
until May 31, 2017 and the final report was submitted to BIRD. As of December 31, 2020, the Israeli Subsidiary received a total
amount of $&lt;span id="xdx_90E_eus-gaap--Revenues_pn3n3_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember_zlikKsnB5QBe" title="Revenues, total"&gt;299&lt;/span&gt; thousand under the grant and the project was completed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;d.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Korea-Israel
    Industrial Research and Development Foundation (&#x201c;KORIL&#x201d;)&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
May 26, 2016, the Israeli Subsidiary and the Korean Subsidiary entered into a pharma Cooperation and Project Funding Agreement
(CPFA) with KORIL. KORIL will give a conditional grant of up to $&lt;span title="Grants receivable, noncurrent"&gt;&lt;span id="xdx_905_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_c20160526__us-gaap--RelatedPartyTransactionAxis__custom--KoreaisraelIndustrialResearchAndDevelopmentFoundationMember_zWQSCLNRjLn" title="Grants receivable, noncurrent"&gt;400&lt;/span&gt;&lt;/span&gt; thousand each (according to terms defined in the agreement),
for a joint research and development project for the use of AIP Cells for the Treatment of Diabetes (the &#x201c;Project&#x201d;).
The Project started on June 1, 2016. Upon the conclusion of product development, the grant shall be repaid at the yearly rate
of &lt;span id="xdx_90F_ecustom--RepaymentsOfGrantPercentageOfGrossSales_pii_dp_uPercentage_c20160501__20160526__us-gaap--RelatedPartyTransactionAxis__custom--KoreaisraelIndustrialResearchAndDevelopmentFoundationMember_zlSFd6mGeR41" title="Repayments of grant, percentage of gross sales"&gt;2.5&lt;/span&gt;% of gross sales. The grant will be used solely to finance the costs to conduct the research of the project during a period
of 18 months starting. On July 26, 2018 KORIL approved extension for the project period till May 31, 2019 and was further extended
to May 2020. During 2019, the grant was assigned to Cure Therapeutics from the Korean Subsidiary. As of December 31, 2020, the
Israeli Subsidiary and the Korean Subsidiary received $&lt;span id="xdx_907_eus-gaap--Revenues_pn3n3_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--KoreaisraelIndustrialResearchAndDevelopmentFoundationMember_zzaKlScIBE09" title="Revenues, total"&gt;440&lt;/span&gt; thousand under the grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;e.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;BIRD
    Secant&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
July 30, 2018, Orgenesis Inc and OBI entered into a collaboration agreement with Secant Group LLC (&#x201c;Secant&#x201d;). Under
the agreement, Secant will engineer and prototype 3D scaffolds based on novel biomaterials and technologies involving bioresorbable
polymer microparticles, while OBI will provide expertise in cell coatings, cell production, process development and support services.
Under the agreement, Orgenesis is authorized to utilize the jointly developed technology for its autologous cell therapy platform,
including its Autologous Insulin Producing (&#x201c;AIP&#x201d;) cell technology for patients with Type 1 Diabetes, acute pancreatitis
and other insulin deficient diseases. In the beginning of 2018, OBI entered into a Cooperation and Project Funding Agreement (CPFA)
with BIRD and Secant. BIRD will give a conditional grant up to $&lt;span id="xdx_90A_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_c20180730__us-gaap--RelatedPartyTransactionAxis__custom--BirdSecantMember_zansRgRUxYM4" title="Grants receivable, noncurrent"&gt;450&lt;/span&gt; thousand each to support the joint project (according to terms
defined in the agreement).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of December 31, 2020, OBI received a total amount of $&lt;span id="xdx_90E_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_c20201231__us-gaap--RelatedPartyTransactionAxis__custom--OBIMember_zi6QxgMyqHLb" title="Grants receivable, noncurrent"&gt;425&lt;/span&gt; thousand under the grant. For the year ended December 31, 2020, an amount
of $&lt;span id="xdx_906_ecustom--DeductionOfResearchAndDevelopmentExpenses_c20200101__20201231__us-gaap--OtherCommitmentsAxis__custom--DeductionOfResearchAndDevelopmentExpensesMember_pn3n3" title="Deduction of research and development expenses"&gt;28&lt;/span&gt; thousand was recorded as deduction of research and development expenses.&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:GrantsReceivableNoncurrent
      contextRef="AsOf2014-06-30_custom_MarylandTechnologyDevelopmentCorporationMember_srt_MaximumMember"
      decimals="-3"
      unitRef="USD">406000</us-gaap:GrantsReceivableNoncurrent>
    <us-gaap:GrantsReceivableNoncurrent
      contextRef="AsOf2014-11-17_custom_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember"
      decimals="-5"
      unitRef="EUR">2000000</us-gaap:GrantsReceivableNoncurrent>
    <us-gaap:GrantsReceivableNoncurrent
      contextRef="AsOf2014-11-17_custom_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember"
      decimals="-5"
      unitRef="USD">2400000</us-gaap:GrantsReceivableNoncurrent>
    <us-gaap:GrantsReceivableNoncurrent
      contextRef="AsOf2014-11-17_custom_IndustrialResearchPartOfResearchProgramMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember"
      decimals="-3"
      unitRef="EUR">1085000</us-gaap:GrantsReceivableNoncurrent>
    <ORGS:GrantsReceivablePercentageOfBudgetedCosts
      contextRef="AsOf2014-11-17_custom_IndustrialResearchPartOfResearchProgramMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember"
      decimals="INF"
      unitRef="Percentage">0.70</ORGS:GrantsReceivablePercentageOfBudgetedCosts>
    <us-gaap:GrantsReceivableNoncurrent
      contextRef="AsOf2014-11-17_custom_ExperimentalDevelopmentPartOfResearchProgramMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember"
      decimals="-3"
      unitRef="EUR">930000</us-gaap:GrantsReceivableNoncurrent>
    <ORGS:GrantsReceivablePercentageOfBudgetedCosts
      contextRef="AsOf2014-11-17_custom_ExperimentalDevelopmentPartOfResearchProgramMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember"
      decimals="INF"
      unitRef="Percentage">0.60</ORGS:GrantsReceivablePercentageOfBudgetedCosts>
    <ORGS:AdvancePaymentsOnAccountOfGrant
      contextRef="AsOf2014-12-31_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember"
      decimals="-3"
      unitRef="EUR">1209000</ORGS:AdvancePaymentsOnAccountOfGrant>
    <us-gaap:GrantsReceivableNoncurrent
      contextRef="AsOf2017-12-31_custom_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember"
      decimals="-5"
      unitRef="EUR">1800000</us-gaap:GrantsReceivableNoncurrent>
    <us-gaap:Revenues
      contextRef="From2017-01-012017-12-31_custom_RevenueFromGrantsMember_custom_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember"
      decimals="-5"
      unitRef="USD">1200000</us-gaap:Revenues>
    <us-gaap:OtherExpenses
      contextRef="From2020-01-012020-12-31_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember"
      decimals="-3"
      unitRef="USD">118000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="From2020-01-012020-12-31_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember"
      decimals="-3"
      unitRef="EUR">96000</us-gaap:OtherExpenses>
    <us-gaap:OtherCommitment
      contextRef="AsOf2020-12-31_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember"
      decimals="-3"
      unitRef="USD">106000</us-gaap:OtherCommitment>
    <us-gaap:GrantsReceivableNoncurrent
      contextRef="AsOf2016-04-30_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember"
      decimals="-5"
      unitRef="EUR">1300000</us-gaap:GrantsReceivableNoncurrent>
    <us-gaap:GrantsReceivableNoncurrent
      contextRef="AsOf2016-04-30_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember"
      decimals="-5"
      unitRef="USD">1500000</us-gaap:GrantsReceivableNoncurrent>
    <ORGS:GrantsReceivablePercentageOfBudgetedCosts
      contextRef="AsOf2016-04-30_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember"
      decimals="INF"
      unitRef="Percentage">0.55</ORGS:GrantsReceivablePercentageOfBudgetedCosts>
    <us-gaap:Revenues
      contextRef="From2016-04-012016-04-30_custom_RevenueFromGrantsMember_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember"
      decimals="-3"
      unitRef="EUR">717000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2016-04-012016-04-30_custom_RevenueFromGrantsMember_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember"
      decimals="-3"
      unitRef="USD">800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-12-31_custom_RevenueFromGrantsMember_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember"
      decimals="-3"
      unitRef="EUR">438000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-12-31_custom_RevenueFromGrantsMember_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember"
      decimals="-3"
      unitRef="USD">537000</us-gaap:Revenues>
    <ORGS:DeductionOfResearchAndDevelopmentExpenses
      contextRef="From2020-01-012020-12-31_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember"
      decimals="-3"
      unitRef="EUR">358000</ORGS:DeductionOfResearchAndDevelopmentExpenses>
    <ORGS:DeductionOfResearchAndDevelopmentExpenses
      contextRef="From2020-01-012020-12-31_custom_DevelopmentOfPotentialCureForTypeOneDiabetesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember"
      decimals="-3"
      unitRef="USD">437000</ORGS:DeductionOfResearchAndDevelopmentExpenses>
    <ORGS:AdvancePaymentsOnAccountOfGrant
      contextRef="AsOf2020-12-31_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember"
      decimals="-3"
      unitRef="EUR">80000</ORGS:AdvancePaymentsOnAccountOfGrant>
    <us-gaap:GrantsReceivableNoncurrent
      contextRef="AsOf2016-10-08_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember"
      decimals="-5"
      unitRef="EUR">12300000</us-gaap:GrantsReceivableNoncurrent>
    <us-gaap:GrantsReceivableNoncurrent
      contextRef="AsOf2016-10-08_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember"
      decimals="-5"
      unitRef="USD">12800000</us-gaap:GrantsReceivableNoncurrent>
    <ORGS:GrantsReceivablePercentageOfBudgetedCosts
      contextRef="AsOf2016-10-08_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember"
      decimals="INF"
      unitRef="Percentage">0.55</ORGS:GrantsReceivablePercentageOfBudgetedCosts>
    <us-gaap:Revenues
      contextRef="From2016-10-012016-10-08_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember"
      decimals="-5"
      unitRef="EUR">6800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2016-10-012016-10-08_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember"
      decimals="-5"
      unitRef="USD">7000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2016-12-012016-12-19_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember"
      decimals="-5"
      unitRef="EUR">1700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2016-12-012016-12-19_custom_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember"
      decimals="-5"
      unitRef="USD">2000000</us-gaap:Revenues>
    <ORGS:DeductionOfResearchAndDevelopmentExpenses
      contextRef="From2020-01-012020-12-31_custom_DeductionOfResearchAndDevelopmentExpensesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember"
      decimals="-5"
      unitRef="USD">1700000</ORGS:DeductionOfResearchAndDevelopmentExpenses>
    <ORGS:DeductionOfResearchAndDevelopmentExpenses
      contextRef="From2020-01-012020-12-31_custom_DeductionOfResearchAndDevelopmentExpensesMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember"
      decimals="-3"
      unitRef="EUR">53000</ORGS:DeductionOfResearchAndDevelopmentExpenses>
    <us-gaap:GrantsReceivableNoncurrent
      contextRef="AsOf2020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember"
      decimals="-5"
      unitRef="EUR">2900000</us-gaap:GrantsReceivableNoncurrent>
    <us-gaap:GrantsReceivableNoncurrent
      contextRef="AsOf2020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember"
      decimals="-5"
      unitRef="USD">3500000</us-gaap:GrantsReceivableNoncurrent>
    <ORGS:GrantsReceivablePercentageOfBudgetedCosts
      contextRef="AsOf2020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember"
      decimals="INF"
      unitRef="Percentage">0.60</ORGS:GrantsReceivablePercentageOfBudgetedCosts>
    <us-gaap:Revenues
      contextRef="From2020-12-012020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember"
      decimals="-5"
      unitRef="EUR">1700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-12-012020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember"
      decimals="-5"
      unitRef="USD">2100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_srt_EuropeMember"
      decimals="-3"
      unitRef="EUR">301000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-12-31_custom_ResearchOnDermatitisTreatmentsAndWoundHealingMember_custom_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember"
      decimals="-3"
      unitRef="USD">366000</us-gaap:Revenues>
    <us-gaap:GrantsReceivableNoncurrent
      contextRef="AsOf2015-09-09_custom_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember"
      decimals="-3"
      unitRef="USD">400000</us-gaap:GrantsReceivableNoncurrent>
    <ORGS:RepaymentsOfGrantPercentageOfGrossSales
      contextRef="From2015-09-012015-09-09_custom_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember"
      decimals="INF"
      unitRef="Percentage">0.05</ORGS:RepaymentsOfGrantPercentageOfGrossSales>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-12-31_custom_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember"
      decimals="-3"
      unitRef="USD">299000</us-gaap:Revenues>
    <us-gaap:GrantsReceivableNoncurrent
      contextRef="AsOf2016-05-26_custom_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember"
      decimals="-3"
      unitRef="USD">400000</us-gaap:GrantsReceivableNoncurrent>
    <ORGS:RepaymentsOfGrantPercentageOfGrossSales
      contextRef="From2016-05-012016-05-26_custom_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember"
      decimals="INF"
      unitRef="Percentage">0.025</ORGS:RepaymentsOfGrantPercentageOfGrossSales>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-12-31_custom_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember"
      decimals="-3"
      unitRef="USD">440000</us-gaap:Revenues>
    <us-gaap:GrantsReceivableNoncurrent
      contextRef="AsOf2018-07-30_custom_BirdSecantMember"
      decimals="-3"
      unitRef="USD">450000</us-gaap:GrantsReceivableNoncurrent>
    <us-gaap:GrantsReceivableNoncurrent
      contextRef="AsOf2020-12-31_custom_OBIMember"
      decimals="-3"
      unitRef="USD">425000</us-gaap:GrantsReceivableNoncurrent>
    <ORGS:DeductionOfResearchAndDevelopmentExpenses
      contextRef="From2020-01-012020-12-31_custom_DeductionOfResearchAndDevelopmentExpensesMember"
      decimals="-3"
      unitRef="USD">28000</ORGS:DeductionOfResearchAndDevelopmentExpenses>
    <ORGS:CollaborationsLicenseAgreementsAndCommitmentsTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_80D_ecustom--CollaborationsLicenseAgreementsAndCommitmentsTextBlock_zAO0ynzstave" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
11 &#x2013; &lt;span id="xdx_82B_z4GMuU7NLpCh"&gt;COLLABORATION AND LICENSE AGREEMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;a.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Adva
    Biotechnology Ltd.&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
January 28, 2018, the Company and Adva Biotechnology Ltd. (&#x201c;Adva&#x201d;), entered into a Master Services Agreement (&#x201c;MSA&#x201d;),
under which the Company and/or its affiliates are to provide certain services relating to development of products to Adva, as
may be agreed between the parties from time to time. Under the MSA, the Company undertook to provide Adva with in kind funding
in the form of materials and services having an aggregate value of approximately $&lt;span id="xdx_901_eus-gaap--OtherCommitment_iI_pn3n3_c20180128__custom--CollaborationAndLicenseAgreementsAxis__custom--AdvaBiotechnologyLtdMember_zl0mHKSUG3J9" title="Commitment"&gt;760&lt;/span&gt; thousand at the Company&#x2019;s own cost
in accordance with a project schedule and related mutually acceptable project budget. The Company entered into an agreement with
Orgenesis Biotech Israel (previously Atvio), to fulfill its obligations pursuant this MSA and it completed its contractual obligations
under the contract during 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
consideration for and subject to the fulfillment by the Company of such in-kind funding commitment, Adva agreed that upon completion
of the development of the products, the Company and/or its affiliates and Adva shall enter into a supply agreement pursuant to
which for a period of eight (8) years following execution of such supply agreement, the Company and/or its affiliates (as applicable)
is entitled (on a non-exclusive basis) to purchase the products from Adva at a specified discount pricing from their then standard
pricing. The Company and/or its affiliates were also granted a non-exclusive worldwide right to distribute such products, directly
or indirectly. &lt;span id="xdx_90E_ecustom--TerminationDescription_c20180126__20180128__custom--CollaborationAndLicenseAgreementsAxis__custom--AdvaBiotechnologyLtdMember" title="Termination description"&gt;The MSA shall remain in effect for 10 years unless earlier terminated in accordance with its terms.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;b.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Tel
    Hashomer Medical Research, Infrastructure and Services Ltd (&#x201c;THM&#x201d;).&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
February 2, 2012, the Company&#x2019;s Israeli Subsidiary entered into a licensing agreement with THM. According to the agreement,
the Israeli Subsidiary was granted a worldwide, royalty bearing, exclusive license to trans-differentiation of cells to insulin
producing cells, including the population of insulin producing cells, methods of making this population, and methods of using
this population of cells for cell therapy or diabetes treatment developed by Dr. Sarah Ferber of THM.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
consideration for the license, the Israeli Subsidiary will pay the following to THM:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1)&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A royalty of &lt;span id="xdx_901_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20120201__20120202__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zPH6e54yVUwa" title="Royalty of net sales, percentage"&gt;3.5&lt;/span&gt;% of net sales;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2)&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_ecustom--SublicensingFeesPercentage_pii_dp_uPercentage_c20120201__20120202__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zJkV0kE3qAJg" title="Sublicensing fees, percentage"&gt;16&lt;/span&gt;% of all sublicensing fees received;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3)&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;An annual license fee of $&lt;span id="xdx_908_eus-gaap--OtherCommitment_iI_pn3n3_c20120202__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zHgkyJiYWSCe" title="Commitment"&gt;15&lt;/span&gt; thousand, which commenced on January 1, 2012 and shall be paid once every year thereafter. The annual fee is non-refundable, but it shall be paid each year against the royalty noted above, to the extent that such are payable, during that year; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4)&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Milestone payments as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_90E_eus-gaap--OtherCommitment_iI_pn3n3_c20120202__us-gaap--OtherCommitmentsAxis__custom--OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zNC2gLJnbjO8" title="Commitment"&gt;50&lt;/span&gt;
    thousand on the date of initiation of Phase I clinical trials in human subjects;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_903_eus-gaap--OtherCommitment_iI_pn3n3_c20120202__us-gaap--OtherCommitmentsAxis__custom--OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_z5sCowqt1tzf" title="Commitment"&gt;50&lt;/span&gt;
    thousand on the date of initiation of Phase II clinical trials in human subjects;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_900_eus-gaap--OtherCommitment_iI_pn3n3_c20120202__us-gaap--OtherCommitmentsAxis__custom--OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zkpYvuhXP3Sd" title="Commitment"&gt;150&lt;/span&gt;
    thousand on the date of initiation of Phase III clinical trials in human subjects;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;d.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_90A_eus-gaap--OtherCommitment_iI_pn3n3_c20120202__us-gaap--OtherCommitmentsAxis__custom--OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zjYrwyDrPJfc" title="Commitment"&gt;750&lt;/span&gt;
    thousand on the date of initiation of issuance of an approval for marketing of the first product by the FDA; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;e.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_903_eus-gaap--OtherCommitment_iI_pin6_c20120202__us-gaap--OtherCommitmentsAxis__custom--WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zSrPM8kKujtg" title="Commitment"&gt;2&lt;/span&gt;
    million when worldwide net sales of Products (as defined in the agreement) have reached the amount of $&lt;span id="xdx_90B_eus-gaap--ConvertibleDebt_iI_pin6_c20181018__dei--LegalEntityAxis__custom--HemogenyxPharmaceuticalsPLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesMilestoneMember_zwf65DEtjjLg" title="Convertible loan"&gt;150&lt;/span&gt; million for the
    first time, (the &#x201c;Sales Milestone&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of December 31, 2020, the Israeli Subsidiary had not reached any of these milestones.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
the event of closing of an acquisition of all of the issued and outstanding share capital of the Israeli Subsidiary and/or consolidation
of the Israeli Subsidiary or the Company into or with another corporation (&#x201c;Exit&#x201d;), the THM shall be entitled to choose
whether to receive from the Israeli Subsidiary a one-time payment based, as applicable, on the value of either &lt;span id="xdx_90E_ecustom--CommitmentSharesOfCommonStock_c20120202__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_pii" title="Commitment, shares of common stock"&gt;463,651&lt;/span&gt; shares
of common stock of the Company at the time of the Exit or the value of &lt;span id="xdx_900_ecustom--CommitmentSharesOfCommonStockOfSubsidiary_c20120202__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_pii" title="Commitment, shares of common stock of Israeli subsidiary"&gt;1,000&lt;/span&gt; shares of common stock of the Israeli Subsidiary
at the time of the Exit.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;c.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Hemogenyx
    Pharmaceuticals PLC.&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
October 18, 2018, the Company and Hemogenyx Pharmaceuticals PLC., a corporation with its registered office in the United Kingdom
and Hemogenyx-Cell (&#x201c;H-Cell&#x201d;), a corporation with its registered office in Belgium (together &#x201c;Hemo&#x201d;),
who are engaged in the development of cell replacement bone marrow therapy technology, entered into a Collaboration Agreement
(the &#x201c;Hemo Agreement&#x201d;) pursuant to which the parties will collaborate in the funding, continued development, and commercialization
of the Hemo technology via Hemo. Pursuant to the Hemo agreement the Company and Hemogenyx LLC (&#x201c;Hemo-LLC&#x201d;) (a wholly
owned US subsidiary of Hemo) entered into a loan agreement on November 7, 2018 according to which the Company agreed to loan Hemo-LLC
not less than $&lt;span id="xdx_907_eus-gaap--ConvertibleDebt_iI_pn5n6_c20181018__dei--LegalEntityAxis__custom--HemogenyxPharmaceuticalsPLCMember_z3oC1AMftN38"&gt;1
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million by way of a convertible loan.
On November 25, 2018 the Company and Hemo entered into a License and Distribution agreement according to which Company received
the worldwide rights to market the products under the agreement in consideration for the payment of a &lt;span id="xdx_907_ecustom--ReductionRateOfRoyaltyPercentage_pii_dp_uPercentage_c20181123__20181125__dei--LegalEntityAxis__custom--HemogenyxPharmaceuticalsPLCMember_zWPMYzAt6mEg"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
royalty all subject to the terms of the agreement. On November 25, 2018, the Company and H-Cell signed an Exclusive Manufacturing
agreement according to which the Company will receive the exclusive right to manufacture certain of H-Cell products. During 2018
and 2020 the Company advanced $&lt;span id="xdx_90F_eus-gaap--ConvertibleDebt_iI_pn4n6_c20181231__dei--LegalEntityAxis__custom--HemogenyxPharmaceuticalsPLCMember__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentCostsMember_zh6QmUhapDl8"&gt;0.75
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million and $&lt;span id="xdx_90A_eus-gaap--ConvertibleDebt_iI_pn4n6_c20201231__dei--LegalEntityAxis__custom--HemogenyxPharmaceuticalsPLCMember__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentCostsMember_zt5E6z96iXYi"&gt;0.25
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million, respectively,&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;
to Hemo as a convertible loan and the entire loan was charged to expenses under ASC 730-10-50 and 20-50 and presented as research
and development costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;See
Note 7.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;d.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Immugenyx
    LLC.&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
October 16, 2018, the Company and Immugenyx LLC., a corporation with its registered office in the USA (&#x201c;Immu&#x201d;), who
is engaged in the development of technology related to the production and use of humanized mice entered into a Collaboration Agreement
(the &#x201c;Immu Agreement&#x201d;) pursuant to which the parties will collaborate in the funding, continued development, and commercialization
of the Immu technology. Pursuant to the agreement, the Company received the worldwide rights to market the products under the
agreement in consideration for the payment of a &lt;span id="xdx_90B_ecustom--ReductionRateOfRoyaltyPercentage_pii_dp_uPercentage_c20181015__20181016__custom--CollaborationAndLicenseAgreementsAxis__custom--ImmuAgreementMember__dei--LegalEntityAxis__custom--ImmugenyxLLCMember_zemHS3SecARd"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
royalty all subject to the terms of the agreement. Pursuant to the Immu agreement the Company and Immu entered into a loan agreement
on November 7, 2018 according to which the Company agreed to loan Immu not less than US$&lt;span id="xdx_900_eus-gaap--ConvertibleDebt_iI_pn5n6_c20181016__dei--LegalEntityAxis__custom--ImmugenyxLLCMember_zuOVZyQekvyj"&gt;1
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Million by way of a convertible loan.
During 2018 and 2020 the Company advanced $&lt;span id="xdx_90F_eus-gaap--ConvertibleDebt_iI_pn4n6_c20181231__dei--LegalEntityAxis__custom--ImmugenyxLLCMember__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentCostsMember_zZMMGiDr48Nf"&gt;0.75
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million and $&lt;span id="xdx_90F_eus-gaap--ConvertibleDebt_iI_pn4n6_c20201231__dei--LegalEntityAxis__custom--ImmugenyxLLCMember__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentCostsMember_zuuKQOo3fw09"&gt;0.25
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million, respectively,&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;
to Immu as a convertible loan and the entire loan was charged to expenses under ASC 730-10-50 and 20-50 and presented as research
and development&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;e.
    &lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;BG
    Negev Technologies and Applications (&#x201c;BGN&#x201d;).&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
August 2, 2018, the Company&#x2019;s U.S. Subsidiary entered into a licensing agreement with BGN. According to the agreement, the
U.S. Subsidiary was granted a worldwide, royalty bearing, exclusive license to develop and commercialize a novel alginate scaffold
technology for cell transplantation focused on autoimmune diseases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
November 25, 2018, the Company&#x2019;s U.S. Subsidiary entered into a further licensing agreement with BGN. According to the agreement,
the U.S. Subsidiary was granted a worldwide, royalty bearing, exclusive license to develop and commercialize technology directed
to RAFT modification of polysaccharides and use of a bioreactor for supporting cell constructs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
consideration for the licenses, the U.S. Subsidiary will pay royalties of between &lt;span id="xdx_90B_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20181124__20181125__custom--CollaborationAndLicenseAgreementsAxis__custom--BgNegevTechnologiesAndApplicationsBgnMember__srt--RangeAxis__srt--MinimumMember_zqWgvHHdLYjh" title="Royalty of net sales, percentage"&gt;4&lt;/span&gt;% and &lt;span id="xdx_909_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20181124__20181125__custom--CollaborationAndLicenseAgreementsAxis__custom--BgNegevTechnologiesAndApplicationsBgnMember__srt--RangeAxis__srt--MaximumMember_zxWcD51E429a" title="Royalty of net sales, percentage"&gt;7&lt;/span&gt;% (subject to rate reductions to &lt;span id="xdx_90D_ecustom--ReductionRateOfRoyaltyPercentage_pii_dp_uPercentage_c20181124__20181125__custom--CollaborationAndLicenseAgreementsAxis__custom--BgNegevTechnologiesAndApplicationsBgnMember__srt--RangeAxis__srt--MaximumMember_zVuLkYAhTSV7" title="Reduction rate of royalty percentage"&gt;5&lt;/span&gt;%
and &lt;span id="xdx_903_ecustom--ReductionRateOfRoyaltyPercentage_pii_dp_uPercentage_c20181124__20181125__custom--CollaborationAndLicenseAgreementsAxis__custom--BgNegevTechnologiesAndApplicationsBgnMember__srt--RangeAxis__srt--MinimumMember_zEet3ELPDQk5" title="Reduction rate of royalty percentage"&gt;4&lt;/span&gt;%, respectively, in specific circumstances) of net sales of the licensed product, sub-license fees of &lt;span id="xdx_901_ecustom--SublicensingFeesPercentage_pii_dp_uPercentage_c20181124__20181125__custom--CollaborationAndLicenseAgreementsAxis__custom--BgNegevTechnologiesAndApplicationsBgnMember_zd2gKaDZMjK2" title="Sublicensing fees, percentage"&gt;20&lt;/span&gt;% of sub-license
income received, license fees of $&lt;span id="xdx_901_eus-gaap--OtherCommitment_c20181125__custom--CollaborationAndLicenseAgreementsAxis__custom--BgNegevTechnologiesAndApplicationsBgnMember_pp0p0" title="Commitment"&gt;10,000&lt;/span&gt; per year per license, and milestone and budget payments according to agreed upon work
plans to BGN.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;f.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Collaboration
    Agreement with Tarus Therapeutics, Inc.&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
February 27, 2019, the Company and Tarus Therapeutics Inc., a Delaware corporation, (&#x201c;Tarus&#x201d;) entered into a Collaboration
Agreement (the &#x201c;Tarus Agreement&#x201d;) for the collaboration in the funding, development and commercialization of certain
technologies, products and patents of Tarus in the areas of therapeutics for cancer and other diseases in the field of cell therapies
and their combination with checkpoint inhibitors comprised of Adenosine Receptor Antagonists. Under the terms of the Tarus Agreement
and subject to final due diligence and approved financing of the Company, the Company and/or one or more qualified investors (the
&#x201c;Investors&#x201d;) shall advance to Tarus a convertible loan in an amount of not less than $&lt;span id="xdx_90A_eus-gaap--NotesReceivableNet_iI_pn3n3_c20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CollaborationAgreementMember__srt--RangeAxis__srt--MinimumMember_zHPmYRxJk323" title="Loans receivable net"&gt;1,750&lt;/span&gt; thousand and up to $&lt;span id="xdx_902_eus-gaap--NotesReceivableNet_iI_pn3n3_c20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CollaborationAgreementMember__srt--RangeAxis__srt--MaximumMember_zCCxlFU7M1Hi" title="Loans receivable net"&gt;3,000&lt;/span&gt;
thousand (the &#x201c;Loan Agreement&#x201d;). As of December 31, 2020, the loan agreements have not been concluded, nor has any
financing been made to Tarus. As part of such Loan Agreement, and subject to approval by the board of directors of the Company,
the Investors shall have the right, within two years of the date of the Loan Agreement, to convert the outstanding convertible
loan into either (i) shares of Tarus at a price per share based on a pre- money valuation of $&lt;span id="xdx_906_ecustom--PreMoneyValuation_iI_pn3n3_c20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CollaborationAgreementMember_z4v84TGEQ3a6" title="Pre-money valuation"&gt;12,500&lt;/span&gt; thousand or (ii) shares of
the Company&#x2019;s common stock at a price per share set in accordance with an approved financing of the Company, with such terms
as approved by the Company in its sole discretion. In the event the Investors elect to convert into shares of the Company&#x2019;s
common stock, the Company shall have the right upon notice to Tarus to receive the same number of shares of capital stock of Tarus
that the Investors would have received had the Investors converted their convertible loans into shares of Tarus. Further, as part
of the Loan Agreement, the Company shall advance to Tarus up to $&lt;span id="xdx_907_ecustom--AdditionalFundsInvest_iI_pn3n3_c20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CollaborationAgreementMember__srt--RangeAxis__srt--MinimumMember_zKcZnbLsBRrk" title="Additional Funds Invest"&gt;500&lt;/span&gt; thousand within fourteen days of execution of the Loan Agreement.
Subject to the closing of the Loan Agreement, the Company and/or the Investors shall have an option, exercisable by sending written
notice to Tarus at any time through the second anniversary of the closing of the Loan Agreement, to invest additional funds in
an amount of up to $&lt;span id="xdx_908_ecustom--AdditionalFundsInvest_iI_pn3n3_c20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CollaborationAgreementMember__srt--RangeAxis__srt--MaximumMember_zMc08MlHqtJ6" title="Additional Funds Invest"&gt;1,250&lt;/span&gt; thousand and not less than $&lt;span id="xdx_905_eus-gaap--ProceedsFromGrantors_pn3n3_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CollaborationAgreementMember_znoS8pAsopBf" title="Proceeds from advance payment of grant"&gt;500&lt;/span&gt; thousand in Tarus. The Company will also have the right to appoint and/or
replace one member of board of directors of Tarus. Upon and subject to the execution of a definitive development and manufacturing
agreement between the Company and Tarus (&#x201c;Manufacturing and Supply Agreement&#x201d;), the Company, or one or more of its
affiliates, shall manufacture and supply to Tarus and any of its affiliates, licensees, assignees of interest all requirements
for all cell therapy elements of any combination therapy incorporating the technology of Tarus. Following the conclusion of the
clinical development stage of each product emanating from the technology of Tarus, the cell therapy component of any such product
borne out of the technology of Tarus shall be exclusively supplied by the Company under the Manufacturing and Supply Agreement.
If the Company and Tarus fail to sign such Manufacturing and Supply Agreement for any given Tarus product, Tarus shall pay the
Company an amount equal to four percent (&lt;span id="xdx_906_ecustom--PercentageOfGrossRevenues_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CollaborationAgreementMember_ztrZuKxNxkvf" title="Percentage of gross revenues"&gt;4&lt;/span&gt;%) of gross revenues derived by Tarus from such Tarus products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Apart
from the above, there was no activity in the Tarus collaboration.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;g.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Sponsored
    Research and Exclusive License Agreement with Columbia University&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Effective
April 2, 2019, the Company and The Trustees of Columbia University in the City of New York, a New York corporation, (&#x201c;Columbia&#x201d;)
entered into a Sponsored Research Agreement (the &#x201c;SRA&#x201d;) whereby the Company will provide financial support for studying
the utility of serological tumor marker for tumor dynamics monitoring. Under the terms of the SRA, the Company shall pay $&lt;span id="xdx_906_ecustom--PaymentForFinancialSupportToTrustForStudy_pn3n3_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--SponsoredResearchAgreementMember_zdTOfRjwJtMk" title="Payment for financial support to trust for study"&gt;300&lt;/span&gt;
thousand per year for three years, or for a total of $&lt;span id="xdx_906_ecustom--PaymentForFinancialSupportCumulativeAmountToTrustForStudy_pn3n3_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--SponsoredResearchAgreementMember_z60cQnMRYDS9" title="Payment for financial support cumulative amount to trust for study"&gt;900&lt;/span&gt; thousand, with payments of $&lt;span id="xdx_905_ecustom--PaymentForFinancialSupportToTrustForStudyDueEverySixMonths_pn3n3_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--SponsoredResearchAgreementMember_zQceikMC5Y1j" title="Payment for financial support to trust for study due every six months"&gt;150&lt;/span&gt; thousand due every six months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Effective
April 2, 2019, the Company and Columbia entered into an Exclusive License Agreement (the &#x201c;Columbia License Agreement&#x201d;)
whereby Columbia granted to the Company an exclusive license to discover, develop, manufacture, sell, and otherwise distribute
certain product in the field of cancer therapy. In consideration of the licenses granted under the Columbia License Agreement,
the Company shall pay to Columbia (i) a royalty of &lt;span id="xdx_909_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--ColumbiaLicenseAgreementMember_zxjZ2yTPKBpc" title="Royalty of net sales, percentage"&gt;5&lt;/span&gt;% of net sales of any product sold which incorporates a licensed Columbia
patent and (ii) &lt;span id="xdx_90B_ecustom--RoyaltyOfNetSalesOfOtherProductsPercentage_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--ColumbiaLicenseAgreementMember_zL4KLpOLHNMb" title="Royalty of net sales of other product percentage"&gt;2.5&lt;/span&gt;% of net sales of other products. In addition, the Company shall pay a flat $&lt;span id="xdx_904_ecustom--PaymentOfFeeUponAchievementOfEachRegulatoryMilestone_pn3n3_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--ColumbiaLicenseAgreementMember_zhNWLXIZRyyd" title="Payment of fee upon the achievement of each regulatory milestone"&gt;100&lt;/span&gt; thousand fee to Columbia upon
the achievement of each regulatory milestone.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;h.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;IRB
    Approval for Liver Cell Collection&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
April 29, 2019, the Company received Institutional Review Board (&#x201c;IRB&#x201d;) approval to collect liver biopsies from patients
at Rambam Medical Center located in Haifa, Israel for a planned study to confirm the suitability of liver cells for personalized
cell replacement therapy for patients with insulin-dependent diabetes resulting from total or partial pancreatectomy. The liver
cells are intended to be bio-banked for potential future clinical use.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
goal of the proposed study, entitled &#x201c;Collection of Human Liver Biopsy and Whole Blood Samples from Type 1 Diabetes Mellitus
(T1DM), Total or Partial Pancreatectomy Patients for Potential use as an Autologous Source for Insulin Producing Cells in Future
Clinical Studies,&#x201d; is to confirm the suitability of the liver cells for personalized cell replacement therapy, as well as
eligibility of patients to participate in a future clinical study, as defined by successful AIP cell production from their own
liver biopsy. The secondary objective of the study is to evaluate patients&#x2019; immune response to AIPs based on the patient&#x2019;s
blood samples and followed by subcutaneous implantation into the patients&#x2019; arm which would represent the first human trial.
The Company has developed a novel technology based on technology licensed from Tel Hashomer Medical Research Infrastructure and
Services Ltd., utilizing liver cells as a source for AIP cells as replacement therapy for islet transplantation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the study, liver samples will be collected and then processed and stored in specialized, clinical grade, tissue banks for potential
clinical use. The propagated cells will be maintained in a tissue bank and are intended to be utilized in a future clinical study,
in which the cells will be transdifferentiated and administered back to the patients as a potential treatment. This personalized
autologous process will be performed under our POC platform in which the patient liver samples are processed, cryopreserved and
potentially re-injected, all in the medical center under clinical grade/GMP level conditions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
June 2019, the Company received additional Institutional Review Board (&#x201c;IRB&#x201d;) approval to collect liver biopsies from
patients at a leading medical center in USA for a planned study to confirm the suitability of liver cells for personalized cell
replacement therapy for patients with insulin-dependent diabetes resulting from total pancreatectomy (the granted Orphan Drug
Designation indication). The liver cells are intended to be bio-banked at the New York Blood Center, NYC for potential future
clinical use. In October 2019, a liver sample from the first recruited patient was collected and processed and stored at the New
York Blood Center, NYC in specialized, clinical grade, tissue banks for potential clinical use.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;i.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;FDA
    Approval for Orphan Drug Designation for AIP Cells&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
June 11, 2019, the FDA granted Orphan Drug Designation for the Company&#x2019;s AIP cells as a cell replacement therapy for the
treatment of severe hypoglycemia-prone diabetes resulting from total pancreatectomy (&#x201c;TP&#x201d;) due to chronic pancreatitis.
The incidence of diabetes following TP is &lt;span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pii_dp_uPercentage_c20201231__srt--OwnershipAxis__custom--MarylandSubsidiaryMember__custom--CollaborationAndLicenseAgreementsAxis__custom--AIPCellsMember_zraQWOEaILP3" title="Percentage of ownership"&gt;100&lt;/span&gt;%, resulting in immediate and lifelong insulin-dependence with the loss of both endogenous
insulin secretion and that of the counter-regulatory hormone, glucagon. Glycemic control after TP is notoriously difficult with
conventional insulin therapy due to complete insulin dependence and loss of glucagon-dependent counter-regulation. Patients with
this condition experience both severe hyperglycemic and hypoglycemic episodes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;j.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Regents
    of the University of California&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
December 2019, the Company and the Regents of the University of California (&#x201c;University&#x201d;) entered into a joint research
agreement in the field of therapies and processing technologies according to an agreed upon work plan. According to the agreement,
the Company will pay the University royalties of up to &lt;span id="xdx_901_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CaliforniaUniversityJointResearchAgreementMember__srt--RangeAxis__srt--MaximumMember_z7PbVj9GvJS8" title="Royalty of net sales, percentage"&gt;5&lt;/span&gt;% (or up to &lt;span id="xdx_90B_ecustom--SublicensingFeesPercentage_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CaliforniaUniversityJointResearchAgreementMember__srt--RangeAxis__srt--MaximumMember_zbuTfjASQFHk" title="Sublicensing fees, percentage"&gt;20&lt;/span&gt;% of sub-licensing sales) in the event of sales that includes
certain types of University owned IP.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;k.
    &lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Caerus
    Therapeutics Inc (a related party)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
October 2019, the Company and Caerus Therapeutics (&#x201c;Caerus&#x201d;), a Virginia company, concluded a license agreement whereby
Caerus granted the Company an exclusive license to all Caerus IP relating to Advance Chemeric Antigen Vectors for Targeting Tumors
for the development and/or commercialization of certain licensed products. In consideration for the License granted to the Company
under this Agreement, the Company shall pay Caerus feasibility fees (including the grant to purchase &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231__srt--OwnershipAxis__custom--CaerusTherapeuticsIncMember_pii" title="Number of options issued"&gt;70,000&lt;/span&gt; options in the Company,
annual maintenance fees and royalties of sales of up to &lt;span id="xdx_904_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20200101__20201231__srt--OwnershipAxis__custom--CaerusTherapeuticsIncMember__srt--RangeAxis__srt--MaximumMember_zZUw2eJZY7Gc" title="Royalty of net sales, percentage"&gt;5&lt;/span&gt;% and up to &lt;span id="xdx_90B_ecustom--SublicensingFeesPercentage_pii_dp_uPercentage_c20200101__20201231__srt--OwnershipAxis__custom--CaerusTherapeuticsIncMember__srt--RangeAxis__srt--MaximumMember_zJHtmnyCjaSi" title="Sublicensing fees, percentage"&gt;18&lt;/span&gt;% of sub-license fees. Expenses in the amount of approximately
$&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200101__20201231__srt--OwnershipAxis__custom--CaerusTherapeuticsIncMember_zALt5XPUoLB7" title="Research and development expense"&gt;200&lt;/span&gt; thousand including the fair value of the options granted were recorded as research and development expenses. The Company
also has the right to instruct Caerus to transfer the license, development, development results and any other rights and licenses
granted to the Company to a joint venture (&#x201c;JV&#x201d;) in which Company shall have a &lt;span id="xdx_904_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pii_dp_uPercentage_c20201231__srt--OwnershipAxis__custom--CaerusTherapeuticsIncMember_z3UaTBN68y08" title="Percentage of ownership"&gt;51&lt;/span&gt;% controlling ownership stake in
the JV Entity. Upon Company&#x2019;s election of such option, the development shall be carried out by Caerus for the JV and the
royalty, sublicense fees and annual maintenance fee shall be terminated. Company may provide requisite funding for the JV Entity
as determined by the Company and Caerus.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;l.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Extracellular
    Vesicle (&#x201c;EV&#x201d;) Technology License&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the third quarter of 2020, the Company purchased the IP and related EV technology from a service provider (the &#x201c;Service
Provider&#x201d;) pursuant to an EV agreement (the &#x201c;EV agreement&#x201d;). According to the EV agreement, the Service Provider
sold to the Company all of its rights in the EV technology that it had produced, in the amount of $500 thousand, to be paid in
installments over the next 12 months from September 2020. The $&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20201001__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ExtracellularVesicleMember__custom--CollaborationAndLicenseAgreementsAxis__custom--EVAmentMember_zJQDYFWWaCH2" title="Research and development expense"&gt;500&lt;/span&gt; thousand was recorded in R&amp;amp;D expenses. In addition, the
Service Provider granted the Company an exclusive worldwide license to use the EV IP technology for any purpose.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;m.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Tamir
    Biotechnology acquisition&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Included
in the purchased assets of the Tamir Biotechnology Inc acquisition (See Note 4) was the assumption by the Company of a worldwide
license to a private company of certain Tamir technologies in the field of treatment, amelioration, mitigation or prevention of
diseases or conditions of the eye and its adnexa in return for certain development and sales milestone payments to be paid to
Tamir. This license fee and the right to receive future milestone payments (of up to $&lt;span id="xdx_907_ecustom--FutureMilestonePayments_iI_pin6_c20200407__srt--RangeAxis__srt--MaximumMember__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_z17N0ufaqVYg" title="Future milestone payments"&gt;11&lt;/span&gt; million assuming that certain milestones
are reached) and royalties (of up to $&lt;span id="xdx_906_eus-gaap--RoyaltyExpense_pin6_c20200406__20200407__srt--RangeAxis__srt--MaximumMember__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zeDpymxqdJHj" title="Royalty Expense"&gt;35&lt;/span&gt; million based on net sales milestones), were assumed by the Company in connection with
the Tamir Purchase Agreement together with a less than &lt;span id="xdx_902_ecustom--RoyaltyPercentage_iI_pii_dp_uPercentage_c20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zrdusZxTjA9l" title="Royalty percentage"&gt;10&lt;/span&gt;% share interest. To date, no milestones have been reached.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;n.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Tissue
    Genesis, LLC (&#x201c;Tissue Genesis&#x201d;)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Included
in the Koligo acquisition (See Note 4) were the assets of Tissue Genesis. The Company is committed to paying the previous owners
of Tissue Genesis up to $&lt;span id="xdx_90C_ecustom--FutureMilestonePayments_iI_pn3n3_c20201231__us-gaap--BusinessAcquisitionAxis__custom--TissueGenesisLLCMember__srt--RangeAxis__srt--MaximumMember_zf3DbvEYPCOl" title="Future milestone payments"&gt;500&lt;/span&gt; thousand upon the achievement of certain performance milestones and earn-out payments on future sales
provided that in no event will the aggregate of the earn-out payments exceed $&lt;span id="xdx_901_eus-gaap--RoyaltyExpense_pn5n6_c20201229__20201231__us-gaap--BusinessAcquisitionAxis__custom--TissueGenesisLLCMember__srt--RangeAxis__srt--MaximumMember_zUb1PGRVHhLl" title="Royalty Expense"&gt;4&lt;/span&gt; million. To date, no milestones have been reached.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;o.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Joint
    venture agreements&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Additionally,
the Company has entered into joint venture agreements (&#x201c;JVAs&#x201d;) with its joint venture partners (Company and partner
are referred to as &#x201c;parties&#x201d;) to facilitate the collaboration in the field of CGT development and development of the
Company&#x2019;s worldwide POCare network. The provisos and the table below summarize the major agreements. CGT and POCare activities
covered by the JVAs include the development, marketing, clinical development, and commercialization of the Company&#x2019;s and
/ or partner&#x2019;s products within defined territories. The extent of the collaboration is set out in each agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Unless
otherwise stated in the table below the JVAs include the following provisos (&#x201c;Provisos&#x201d;):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
    incorporation of a joint venture entity (&#x201c;JVE&#x201d;) in which the Company will hold between &lt;span id="xdx_90D_ecustom--InterestInJointVenture_iI_pii_dp_uPercentage_c20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--BroadenJointVentureAgreementMember__dei--LegalEntityAxis__custom--MarylandSubsidiaryMember__srt--RangeAxis__srt--MinimumMember_zNSbZAJGnWlf" title="Interest in joint venture"&gt;49&lt;/span&gt;% and &lt;span id="xdx_908_ecustom--InterestInJointVenture_iI_pii_dp_uPercentage_c20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--BroadenJointVentureAgreementMember__dei--LegalEntityAxis__custom--MarylandSubsidiaryMember__srt--RangeAxis__srt--MaximumMember_zzEeoNyOYN5" title="Interest in joint venture"&gt;50&lt;/span&gt; % of the equity.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
    partner will manage the joint venture activities until the JVE is incorporated.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
    JVE will be managed by a steering committee consisting of 3 members which will act as the entity&#x2019;s board of directors.
    The Company is entitled to appoint 1 member, the partner is entitled to appoint 1 member, and Company and partner will jointly
    appoint the third member.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
    Company has the right to exercise a call option to acquire the partner&#x2019;s share in the JVE based on the occurrence of
    certain events and according to an agreed upon mechanism.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
    funding of the parties&#x2019; investment in the joint venture share may be made in the form of cash investment and / or in-kind
    services. The Company&#x2019;s cash investment may be in the form of additional shares, a convertible loan, and/or procured
    services.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Each
    of the parties may agree to provide additional funding to the JVE to cover the operation costs and such additional funding
    may be in the form of in-kind contributions. The Company&#x2019;s investments may be made in the form of a cash investment
    for additional shares, a convertible loan, and/or procured services. Procured services refer to certain services that the
    Company has engaged the partner or the JVE to provide the Company with, in support of Company&#x2019;s activity. All results
    of these procured services shall be owned by Company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
    appropriate, the parties will grant to the JVE an exclusive or nonexclusive, sublicensable, royalty-bearing, right and license
    to the relevant party&#x2019;s background IP as required solely to manufacture, distribute and market and sell the party&#x2019;s
    products within the territory. Each party shall receive royalties in an amount of ten percent (&lt;span id="xdx_906_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--BroadenJointVentureAgreementMember__dei--LegalEntityAxis__custom--MarylandSubsidiaryMember_zwmlyMD2ISV4" title="Royalty of net sales, percentage"&gt;10&lt;/span&gt;%) of the net sales generated
    by the JVE and/or its sublicensees.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;8.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Once
    the JVE is profitable, the Company will be entitled (in addition to any of its rights as the holder of the JVE) to an additional
    share of fifteen percent (&lt;span id="xdx_901_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__custom--CollaborationAndLicenseAgreementsAxis__custom--BroadenJointVentureAgreementMember__dei--LegalEntityAxis__custom--MarylandSubsidiaryMember_zJOSHZxgIH3b" title="Royalty of net sales, percentage"&gt;15&lt;/span&gt;%) of the JVE&#x2019;s GAAP profit after tax, over and above all rights granted pursuant to Company&#x2019;s
    participating interest in the JVE.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Name
    of party (and country of origin)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Territory&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Notes&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Theracell
    Advanced Biotechnology&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Greece,
    Turkey, Cyprus, Israel and Balkans&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Broaden
    Bioscience and Technology Corp&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Certain
    projects in China and the Middle East&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Mircod
                                         LLC&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(US)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Russia&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Image
    Securities FZC (UAE) (a related party)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;India&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cure
    Therapeutics&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Korea
    and Japan&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Kidney
    Cure Ltd&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Sescom
    Ltd&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Educell
                                         D.O.O&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(Slovenia)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Croatia,
    Serbia and Slovenia&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Med
                                         Centre for Gene and Cell Therapy FZ-LLC&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(UAE)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;UAE&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Mida
                                         Biotech B.V.&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(Netherlands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Netherlands,
    Lithuania, Spain, Switzerland, Germany, Belgium or any other countries within West Europe&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;First
                                         Choice International Company, Inc&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Panama
    and certain other Latin American countries&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;KinerjaPay
    Corp&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Singapore&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;SBH
    Sciences Inc&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;HekaBio
    KK&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Japan&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
    Theracell JVE was incorporated in Greece under the name of Theracell Laboratories Ltd. (See Note 12).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Under
    the Mircod JVA, provisos 7 and 8 do not apply. Subject to payment by the Company ORGS of the contribution amount, the JVA
    will grant Company an exclusive, perpetual, irrevocable, royalty free and fully paid up and sublicensable license to use the
    Project IP for research and development and for the manufacturing, processing, supplying, and use of products based on point
    of care manufacturing and/or processing of treatments for patients and for use in hospitals, medical centers and academic
    institution settings solely outside the territory. The parties also, following proviso 6, concluded a convertible loan agreement
    pursuant to which Company shall lend Mircod up to $&lt;span id="xdx_90D_ecustom--ConvertibleLoanAdvancedToJointVenture_pin6_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--JointVentureAgreementMember__srt--RangeAxis__srt--MinimumMember_zemq4si86All" title="Convertible loan advanced to joint venture"&gt;5&lt;/span&gt; million based upon a development plan to be agreed upon. The loan bears
    simple interest in the amount of &lt;span id="xdx_908_ecustom--ConvertibleLoanAdvancedToJointVentureInterestRate_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--JointVentureAgreementMember_zn2eHUwvtpOe" title="Convertible loan advanced to joint venture, interest rate"&gt;6&lt;/span&gt;% annually. As at December 31, 2020, the development plan had not been finalized and no
    transfers under the loan agreement were made.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant
    to the Kidney Cure JVA, the parties will collaborate in the (i) implementation of a point-of-care strategy; (ii) assessment
    of the options for development and manufacture of various cell-based types (including kidney derived cells, MSC cells, exosomes,
    gene therapies) development; and (iii) development of protocols and tests for kidney therapies (the &#x201c;Project&#x201d;).
    Provisos 7 and 8 do not apply to the Kidney Cure JVA. The Kidney Cure JVE was incorporated in Switzerland under the name of
    Butterfly Biosciences Sarl (See Note 12).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Under
    the Sescom JVA, the parties will collaborate in the field of the assessment of relevant tools and technologies to be used
    in the Company&#x2019;s information security system (the &#x201c;ISS&#x201d;); (ii) the implementation of the ISS within the
    Company and in the Company&#x2019;s point-of-care network; and (iii) the operation and maintenance of the ISS. Provisos 7 and
    8 do not apply to this JVA. Company has agreed to provide the Sescom JVE with: (a) a non-exclusive, not transferable and non-sublicensable
    worldwide royalty-free license to use its background IP to the extent required for carrying out certain activities by the
    Sescom JVE; and (b) access to its point-of-care network and relevant data to be used for the certain activities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(5)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Under
    the Mida JVA, commencing January 1, 2022 and thereafter Mida shall have the right to sell to Company its then issued and outstanding
    shares in the JVA, and if the JVA was not yet set up, its assets, contracts and liabilities relating to the project, for a
    consideration to be agreed between the parties in good faith, provided that such consideration is not lower than $&lt;span id="xdx_909_eus-gaap--PaymentForContingentConsiderationLiabilityInvestingActivities_pn3n3_c20211231__20220101__custom--CollaborationAndLicenseAgreementsAxis__custom--JointVentureAgreementMember__srt--RangeAxis__srt--MaximumMember_zmMDqUsvnE44" title="Payment for consideration"&gt;500&lt;/span&gt; thousand.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(6)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Under
    the First Choice JVA, each party shall, subject to fulfilment of the party&#x2019;s JVA, grant the Panama JV Entity an exclusive
    license to certain intellectual property of the part to develop and commercialize the party&#x2019;s products in the territory,
    subject to minimum sales obligations. In consideration of such license, the Panama JV shall pay the relevant part royalties
    at the rate of 15% of the Panama JVE net sales of party&#x2019;s products sold in the territory.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0"/&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(7)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;No
    activities have taken place since the JVA was signed. According to the JVA, Company was eligible to receive &lt;span id="xdx_90E_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--JointVentureAgreementMember__dei--LegalEntityAxis__custom--KinerjapayCorpMember_zNDhJ53IA2Ti" title="Royalty of net sales, percentage"&gt;51&lt;/span&gt;% of the equity
    and &lt;span id="xdx_900_ecustom--RoyaltyOfNetSalesOfOtherProductsPercentage_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--JointVentureAgreementMember__dei--LegalEntityAxis__custom--KinerjapayCorpMember_zqrpDxVw2r2e" title="Royalty of net sales of other product percentage"&gt;10&lt;/span&gt;% royalties on sales of products. The steering committee was to compromise 5 members of which Company could appoint
    2, and a third member to be an industry expert, to be appointed by Orgenesis. The JVA did not include the proviso 8.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(8)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant
    to the SBH JVA the parties will collaborate in the field of gene and cell therapy development, process and services of bio-exosome
    therapy products and services in the areas of diabetes, liver cells and skin applications, including wound healing. The SBH
    JVE has not yet been incorporated. According to the JVA, the board of directors of the SBH JVE shall be comprised of three
    directors with one appointed by SBH and two appointed by the Company. All intellectual property conceived or developed resulting
    from the business of the SBH JV Entity, that is not SBH&#x2019;s or the Company&#x2019;s background intellectual property, shall
    be owned exclusively by the SBH JV Entity, although the Company shall be granted the right to exclusively license any intellectual
    property arriving from the development activities of the SBH JV Entity, or exclusively distribute products based thereon.
    Provisos 7 and 8 do not apply to the SBH JVA.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
    the third quarter of 2019, the Company transferred $&lt;span id="xdx_900_eus-gaap--TransferToInvestments_pn3n3_c20191001__20191231__dei--LegalEntityAxis__custom--SBHSciencesIncMember_zrvWxhpaG5Qh" title="Transfer for prior establishment"&gt;50&lt;/span&gt; thousand to SBH. Apart from the above, there was no material activity
    in the SBH Collaboration and the SBH JV entity had not been incorporated as at December 31, 2020.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(9)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
    the third quarter of 2020, the Company and HB agreed to terminate the license agreement. As of December 31, 2020, no activity
    had begun in the said JV and no investments were made therein.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</ORGS:CollaborationsLicenseAgreementsAndCommitmentsTextBlock>
    <us-gaap:OtherCommitment
      contextRef="AsOf2018-01-28_custom_AdvaBiotechnologyLtdMember"
      decimals="-3"
      unitRef="USD">760000</us-gaap:OtherCommitment>
    <ORGS:TerminationDescription contextRef="From2018-01-262018-01-28_custom_AdvaBiotechnologyLtdMember">The MSA shall remain in effect for 10 years unless earlier terminated in accordance with its terms.</ORGS:TerminationDescription>
    <ORGS:RoyaltyOfNetSalesPercentage
      contextRef="From2012-02-012012-02-02_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember"
      decimals="INF"
      unitRef="Percentage">0.035</ORGS:RoyaltyOfNetSalesPercentage>
    <ORGS:SublicensingFeesPercentage
      contextRef="From2012-02-012012-02-02_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember"
      decimals="INF"
      unitRef="Percentage">0.16</ORGS:SublicensingFeesPercentage>
    <us-gaap:OtherCommitment
      contextRef="AsOf2012-02-02_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember"
      decimals="-3"
      unitRef="USD">15000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2012-02-02_custom_OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember"
      decimals="-3"
      unitRef="USD">50000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2012-02-02_custom_OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember"
      decimals="-3"
      unitRef="USD">50000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2012-02-02_custom_OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember"
      decimals="-3"
      unitRef="USD">150000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2012-02-02_custom_OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember"
      decimals="-3"
      unitRef="USD">750000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2012-02-02_custom_WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember"
      decimals="0"
      unitRef="USD">2000000</us-gaap:OtherCommitment>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2018-10-18_custom_HemogenyxPharmaceuticalsPLCMember_custom_SalesMilestoneMember"
      decimals="0"
      unitRef="USD">150000000</us-gaap:ConvertibleDebt>
    <ORGS:CommitmentSharesOfCommonStock
      contextRef="AsOf2012-02-02_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember"
      decimals="INF"
      unitRef="Shares">463651</ORGS:CommitmentSharesOfCommonStock>
    <ORGS:CommitmentSharesOfCommonStockOfSubsidiary
      contextRef="AsOf2012-02-02_custom_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember"
      decimals="INF"
      unitRef="Shares">1000</ORGS:CommitmentSharesOfCommonStockOfSubsidiary>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2018-10-18_custom_HemogenyxPharmaceuticalsPLCMember"
      decimals="-5"
      unitRef="USD">1000000</us-gaap:ConvertibleDebt>
    <ORGS:ReductionRateOfRoyaltyPercentage
      contextRef="From2018-11-232018-11-25_custom_HemogenyxPharmaceuticalsPLCMember"
      decimals="INF"
      unitRef="Percentage">0.12</ORGS:ReductionRateOfRoyaltyPercentage>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2018-12-31_custom_HemogenyxPharmaceuticalsPLCMember_custom_ResearchAndDevelopmentCostsMember"
      decimals="-4"
      unitRef="USD">750000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2020-12-31_custom_HemogenyxPharmaceuticalsPLCMember_custom_ResearchAndDevelopmentCostsMember"
      decimals="-4"
      unitRef="USD">250000</us-gaap:ConvertibleDebt>
    <ORGS:ReductionRateOfRoyaltyPercentage
      contextRef="From2018-10-152018-10-16_custom_ImmuAgreementMember_custom_ImmugenyxLLCMember"
      decimals="INF"
      unitRef="Percentage">0.12</ORGS:ReductionRateOfRoyaltyPercentage>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2018-10-16_custom_ImmugenyxLLCMember"
      decimals="-5"
      unitRef="USD">1000000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2018-12-31_custom_ImmugenyxLLCMember_custom_ResearchAndDevelopmentCostsMember"
      decimals="-4"
      unitRef="USD">750000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2020-12-31_custom_ImmugenyxLLCMember_custom_ResearchAndDevelopmentCostsMember"
      decimals="-4"
      unitRef="USD">250000</us-gaap:ConvertibleDebt>
    <ORGS:RoyaltyOfNetSalesPercentage
      contextRef="From2018-11-242018-11-25_custom_BgNegevTechnologiesAndApplicationsBgnMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Percentage">0.04</ORGS:RoyaltyOfNetSalesPercentage>
    <ORGS:RoyaltyOfNetSalesPercentage
      contextRef="From2018-11-242018-11-25_custom_BgNegevTechnologiesAndApplicationsBgnMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Percentage">0.07</ORGS:RoyaltyOfNetSalesPercentage>
    <ORGS:ReductionRateOfRoyaltyPercentage
      contextRef="From2018-11-242018-11-25_custom_BgNegevTechnologiesAndApplicationsBgnMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Percentage">0.05</ORGS:ReductionRateOfRoyaltyPercentage>
    <ORGS:ReductionRateOfRoyaltyPercentage
      contextRef="From2018-11-242018-11-25_custom_BgNegevTechnologiesAndApplicationsBgnMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Percentage">0.04</ORGS:ReductionRateOfRoyaltyPercentage>
    <ORGS:SublicensingFeesPercentage
      contextRef="From2018-11-242018-11-25_custom_BgNegevTechnologiesAndApplicationsBgnMember"
      decimals="INF"
      unitRef="Percentage">0.20</ORGS:SublicensingFeesPercentage>
    <us-gaap:OtherCommitment
      contextRef="AsOf2018-11-25_custom_BgNegevTechnologiesAndApplicationsBgnMember"
      decimals="0"
      unitRef="USD">10000</us-gaap:OtherCommitment>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2020-12-31_custom_CollaborationAgreementMember_srt_MinimumMember"
      decimals="-3"
      unitRef="USD">1750000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2020-12-31_custom_CollaborationAgreementMember_srt_MaximumMember"
      decimals="-3"
      unitRef="USD">3000000</us-gaap:NotesReceivableNet>
    <ORGS:PreMoneyValuation
      contextRef="AsOf2020-12-31_custom_CollaborationAgreementMember"
      decimals="-3"
      unitRef="USD">12500000</ORGS:PreMoneyValuation>
    <ORGS:AdditionalFundsInvest
      contextRef="AsOf2020-12-31_custom_CollaborationAgreementMember_srt_MinimumMember"
      decimals="-3"
      unitRef="USD">500000</ORGS:AdditionalFundsInvest>
    <ORGS:AdditionalFundsInvest
      contextRef="AsOf2020-12-31_custom_CollaborationAgreementMember_srt_MaximumMember"
      decimals="-3"
      unitRef="USD">1250000</ORGS:AdditionalFundsInvest>
    <us-gaap:ProceedsFromGrantors
      contextRef="From2020-01-012020-12-31_custom_CollaborationAgreementMember"
      decimals="-3"
      unitRef="USD">500000</us-gaap:ProceedsFromGrantors>
    <ORGS:PercentageOfGrossRevenues
      contextRef="From2020-01-012020-12-31_custom_CollaborationAgreementMember"
      decimals="INF"
      unitRef="Percentage">0.04</ORGS:PercentageOfGrossRevenues>
    <ORGS:PaymentForFinancialSupportToTrustForStudy
      contextRef="From2020-01-012020-12-31_custom_SponsoredResearchAgreementMember"
      decimals="-3"
      unitRef="USD">300000</ORGS:PaymentForFinancialSupportToTrustForStudy>
    <ORGS:PaymentForFinancialSupportCumulativeAmountToTrustForStudy
      contextRef="From2020-01-012020-12-31_custom_SponsoredResearchAgreementMember"
      decimals="-3"
      unitRef="USD">900000</ORGS:PaymentForFinancialSupportCumulativeAmountToTrustForStudy>
    <ORGS:PaymentForFinancialSupportToTrustForStudyDueEverySixMonths
      contextRef="From2020-01-012020-12-31_custom_SponsoredResearchAgreementMember"
      decimals="-3"
      unitRef="USD">150000</ORGS:PaymentForFinancialSupportToTrustForStudyDueEverySixMonths>
    <ORGS:RoyaltyOfNetSalesPercentage
      contextRef="From2020-01-012020-12-31_custom_ColumbiaLicenseAgreementMember"
      decimals="INF"
      unitRef="Percentage">0.05</ORGS:RoyaltyOfNetSalesPercentage>
    <ORGS:RoyaltyOfNetSalesOfOtherProductsPercentage
      contextRef="From2020-01-012020-12-31_custom_ColumbiaLicenseAgreementMember"
      decimals="INF"
      unitRef="Percentage">0.025</ORGS:RoyaltyOfNetSalesOfOtherProductsPercentage>
    <ORGS:PaymentOfFeeUponAchievementOfEachRegulatoryMilestone
      contextRef="From2020-01-012020-12-31_custom_ColumbiaLicenseAgreementMember"
      decimals="-3"
      unitRef="USD">100000</ORGS:PaymentOfFeeUponAchievementOfEachRegulatoryMilestone>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2020-12-31_custom_MarylandSubsidiaryMember_custom_AIPCellsMember"
      decimals="INF"
      unitRef="Percentage">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ORGS:RoyaltyOfNetSalesPercentage
      contextRef="From2020-01-012020-12-31_custom_CaliforniaUniversityJointResearchAgreementMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Percentage">0.05</ORGS:RoyaltyOfNetSalesPercentage>
    <ORGS:SublicensingFeesPercentage
      contextRef="From2020-01-012020-12-31_custom_CaliforniaUniversityJointResearchAgreementMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Percentage">0.20</ORGS:SublicensingFeesPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-012020-12-31_custom_CaerusTherapeuticsIncMember"
      decimals="INF"
      unitRef="Shares">70000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <ORGS:RoyaltyOfNetSalesPercentage
      contextRef="From2020-01-012020-12-31_custom_CaerusTherapeuticsIncMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Percentage">0.05</ORGS:RoyaltyOfNetSalesPercentage>
    <ORGS:SublicensingFeesPercentage
      contextRef="From2020-01-012020-12-31_custom_CaerusTherapeuticsIncMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Percentage">0.18</ORGS:SublicensingFeesPercentage>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-012020-12-31_custom_CaerusTherapeuticsIncMember"
      decimals="-3"
      unitRef="USD">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2020-12-31_custom_CaerusTherapeuticsIncMember"
      decimals="INF"
      unitRef="Percentage">0.51</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-10-012020-12-31_custom_ExtracellularVesicleMember_custom_EVAmentMember"
      decimals="-3"
      unitRef="USD">500000</us-gaap:ResearchAndDevelopmentExpense>
    <ORGS:FutureMilestonePayments
      contextRef="AsOf2020-04-07_srt_MaximumMember_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">11000000</ORGS:FutureMilestonePayments>
    <us-gaap:RoyaltyExpense
      contextRef="From2020-04-062020-04-07_srt_MaximumMember_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">35000000</us-gaap:RoyaltyExpense>
    <ORGS:RoyaltyPercentage
      contextRef="AsOf2020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember"
      decimals="INF"
      unitRef="Percentage">0.10</ORGS:RoyaltyPercentage>
    <ORGS:FutureMilestonePayments
      contextRef="AsOf2020-12-31_custom_TissueGenesisLLCMember_srt_MaximumMember"
      decimals="-3"
      unitRef="USD">500000</ORGS:FutureMilestonePayments>
    <us-gaap:RoyaltyExpense
      contextRef="From2020-12-292020-12-31_custom_TissueGenesisLLCMember_srt_MaximumMember"
      decimals="-5"
      unitRef="USD">4000000</us-gaap:RoyaltyExpense>
    <ORGS:InterestInJointVenture
      contextRef="AsOf2020-12-31_custom_BroadenJointVentureAgreementMember_custom_MarylandSubsidiaryMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Percentage">0.49</ORGS:InterestInJointVenture>
    <ORGS:InterestInJointVenture
      contextRef="AsOf2020-12-31_custom_BroadenJointVentureAgreementMember_custom_MarylandSubsidiaryMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Percentage">0.50</ORGS:InterestInJointVenture>
    <ORGS:RoyaltyOfNetSalesPercentage
      contextRef="From2020-01-012020-12-31_custom_BroadenJointVentureAgreementMember_custom_MarylandSubsidiaryMember"
      decimals="INF"
      unitRef="Percentage">0.10</ORGS:RoyaltyOfNetSalesPercentage>
    <ORGS:RoyaltyOfNetSalesPercentage
      contextRef="From2020-01-012020-12-31_srt_MinimumMember_custom_BroadenJointVentureAgreementMember_custom_MarylandSubsidiaryMember"
      decimals="INF"
      unitRef="Percentage">0.15</ORGS:RoyaltyOfNetSalesPercentage>
    <ORGS:ConvertibleLoanAdvancedToJointVenture
      contextRef="From2020-01-012020-12-31_custom_JointVentureAgreementMember_srt_MinimumMember"
      decimals="0"
      unitRef="USD">5000000</ORGS:ConvertibleLoanAdvancedToJointVenture>
    <ORGS:ConvertibleLoanAdvancedToJointVentureInterestRate
      contextRef="From2020-01-012020-12-31_custom_JointVentureAgreementMember"
      decimals="INF"
      unitRef="Percentage">0.06</ORGS:ConvertibleLoanAdvancedToJointVentureInterestRate>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities
      contextRef="From2021-12-312022-01-01_custom_JointVentureAgreementMember_srt_MaximumMember"
      decimals="-3"
      unitRef="USD">500000</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <ORGS:RoyaltyOfNetSalesPercentage
      contextRef="From2020-01-012020-12-31_custom_JointVentureAgreementMember_custom_KinerjapayCorpMember"
      decimals="INF"
      unitRef="Percentage">0.51</ORGS:RoyaltyOfNetSalesPercentage>
    <ORGS:RoyaltyOfNetSalesOfOtherProductsPercentage
      contextRef="From2020-01-012020-12-31_custom_JointVentureAgreementMember_custom_KinerjapayCorpMember"
      decimals="INF"
      unitRef="Percentage">0.10</ORGS:RoyaltyOfNetSalesOfOtherProductsPercentage>
    <us-gaap:TransferToInvestments
      contextRef="From2019-10-012019-12-31_custom_SBHSciencesIncMember"
      decimals="-3"
      unitRef="USD">50000</us-gaap:TransferToInvestments>
    <us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_80C_eus-gaap--InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock_zgkjvWqzjWV1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
12 &#x2013;&lt;span id="xdx_824_z0OkBUWj5wUj"&gt; INVESTMENTS IN ASSOCIATES, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Theracell
    Laboratories Private Company&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;During
October 2020, the Company and Theracell, pursuant to the Greek JVA (See Note 11) incorporated the Greek JVA entity known as Theracell
Laboratories Private Company (&#x201c;TLABS&#x201d;). The Theracell Project activities will be run through TLABS. The Company and
Theracell each hold a &lt;span id="xdx_901_ecustom--InvestmentsInAssociatePercentageOfOwnership_iI_pii_dp_uPercentage_c20201031__dei--LegalEntityAxis__custom--TLABSMember_zCbE0weqp0i6" title="Investments in associate percentage of ownership"&gt;50&lt;/span&gt;% participating interest in TLABS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Butterfly
    Biosciences Sarl&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;During
October 2020, the Company and Kidney Cure, pursuant to the Kidney Cure JVA (See Note 11) incorporated the KC JV Entity known as
Butterfly Biosciences Sarl (&#x201c;BB&#x201d;) in Switzerland. BB will be involved in the (i) implementation of a point-of-care
strategy; (ii) assessment of the options for development and manufacture of various cell-based types (including kidney derived
cells, MSC cells, exosomes, gene therapies) development; and (iii) development of protocols and tests for kidney therapies (the
&#x201c;BB Project&#x201d;). The Company holds a &lt;span id="xdx_906_ecustom--InvestmentsInAssociatePercentageOfOwnership_iI_pii_dp_uPercentage_c20201031__dei--LegalEntityAxis__custom--ButterflyBiosciencesSarlMember_zpeP14qqdOad" title="Investments in associate percentage of ownership"&gt;49&lt;/span&gt;% participating interest on BB and Kidney Cure holds the remaining &lt;span id="xdx_900_ecustom--InvestmentsInAssociatePercentageOfOwnership_iI_pii_dp_uPercentage_c20201031__dei--LegalEntityAxis__custom--KidneyCureJVAMember_zUdTmFSDZTm7" title="Investments in associate percentage of ownership"&gt;51&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_zmRmGgVbBzQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
    table below sets forth a summary of the changes in the investments for the year ended&#160;December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B6_z5jPxicOzBo6" style="display: none"&gt;SCHEDULE OF CHANGES IN INVESTMENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20200101__20201231_zCZPdhPHQcI2" style="font-weight: bold; text-align: center"&gt;December 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(In thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--EquityMethodInvestments_iS_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Opening balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1988"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--PaymentsToAcquireEquityMethodInvestments_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 71%; text-align: left"&gt;Investments during the period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 25%; text-align: right"&gt;69&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--IncomeLossFromEquityMethodInvestments_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Share in net income of associated companies&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;106&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--EquityMethodInvestments_iE_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;175&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock>
    <ORGS:InvestmentsInAssociatePercentageOfOwnership
      contextRef="AsOf2020-10-31_custom_TLABSMember"
      decimals="INF"
      unitRef="Percentage">0.50</ORGS:InvestmentsInAssociatePercentageOfOwnership>
    <ORGS:InvestmentsInAssociatePercentageOfOwnership
      contextRef="AsOf2020-10-31_custom_ButterflyBiosciencesSarlMember"
      decimals="INF"
      unitRef="Percentage">0.49</ORGS:InvestmentsInAssociatePercentageOfOwnership>
    <ORGS:InvestmentsInAssociatePercentageOfOwnership
      contextRef="AsOf2020-10-31_custom_KidneyCureJVAMember"
      decimals="INF"
      unitRef="Percentage">0.51</ORGS:InvestmentsInAssociatePercentageOfOwnership>
    <us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_898_eus-gaap--InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_zmRmGgVbBzQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
    table below sets forth a summary of the changes in the investments for the year ended&#160;December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B6_z5jPxicOzBo6" style="display: none"&gt;SCHEDULE OF CHANGES IN INVESTMENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20200101__20201231_zCZPdhPHQcI2" style="font-weight: bold; text-align: center"&gt;December 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(In thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--EquityMethodInvestments_iS_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Opening balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1988"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--PaymentsToAcquireEquityMethodInvestments_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 71%; text-align: left"&gt;Investments during the period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 25%; text-align: right"&gt;69&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--IncomeLossFromEquityMethodInvestments_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Share in net income of associated companies&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;106&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--EquityMethodInvestments_iE_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;175&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">69000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">106000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">175000</us-gaap:EquityMethodInvestments>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zCWfL8IlyhK2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
13 &#x2013; &lt;span id="xdx_823_zOXiRXZlnMvg"&gt;EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Financings&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
January 20, 2020, the Company entered into a Securities Purchase Agreement (the &#x201c;January Purchase Agreement&#x201d;) with
certain investors pursuant to which the Company issued and sold, in a private placement (the &#x201c;Offering&#x201d;), &lt;span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pii" title="Sale of Stock, Number of Shares Issued in Transaction"&gt;2,200,000&lt;/span&gt;
shares of Common Stock at a purchase price of $&lt;span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_c20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pii" title="Sale of Stock, Price Per Share"&gt;4.20&lt;/span&gt; per share (the &#x201c;Shares&#x201d;) and warrants to purchase up to &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_znkdBizq9Ap7" title="Warrant to purchase of common stock"&gt;1,000,000&lt;/span&gt;
shares of Common Stock at an exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pii" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;5.50&lt;/span&gt; per share (the &#x201c;Warrants&#x201d;) which are &lt;span id="xdx_90A_ecustom--WarrantExercisableDescription_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember" title="Warrant exercisable, description"&gt;exercisable between June
2021 and January 2023.&lt;/span&gt; The Company received gross proceeds of approximately $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn4n6_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zmILN4Kjidt1" title="Proceeds from Issuance of Private Placement"&gt;9.24&lt;/span&gt; million before deducting related offering expenses
in the amount of $&lt;span id="xdx_90C_ecustom--OfferingExpenses_pn5n6_c20200119__20200120_zEAiaVypijU7" title="Offering expenses"&gt;0.8&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;b.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Tamir
    Biotechnology, Inc.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;For
the acquisition of Tamir, see Note 4.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
aggregate consideration for the acquisition, the Company paid $&lt;span id="xdx_90E_eus-gaap--Cash_iI_pn5n6_c20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zcN3btyYhyof" title="Cash"&gt;2.5&lt;/span&gt; million in cash and issued an aggregate of &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pii_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zYhzVXccQFJh" title="Stock Issued During Period, Shares, Acquisitions"&gt;3,400,000&lt;/span&gt; shares
(the &#x201c;Shares&#x201d;) of Common Stock to Tamir resulting in a total consideration of $&lt;span id="xdx_906_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zP1lwZBdHHaf" title="Business Combination, Consideration Transferred"&gt;20.2&lt;/span&gt; million based on the Company&#x2019;s
share price at the closing date. $&lt;span id="xdx_901_eus-gaap--EscrowDeposit_iI_pn3n3_c20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zHhrr4v1e1V9" title="Escrow Deposit"&gt;59&lt;/span&gt; thousand and &lt;span id="xdx_901_ecustom--NumberOfSharesDepositInEscrowAccount_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_pii" title="Number of shares deposit in escrow account"&gt;340,000&lt;/span&gt; Shares are being held in an escrow account for a period of 18 months
from closing to secure indemnification obligations of Tamir pursuant to the terms of the Tamir Purchase Agreement. The share price
was $&lt;span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_c20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_pii" title="Shares Issued, Price Per Share"&gt;5.26&lt;/span&gt; at the day of the closing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;c.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Koligo
    Therapeutics Inc.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;For
the acquisition of Koligo, see Note 4.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant
to the terms of the Merger Agreement, at the Effective Time, the shares of capital stock of Koligo that were issued and outstanding
immediately prior to the Effective Time were automatically cancelled and converted into the right to receive, subject to customary
adjustments, an aggregate of &lt;span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20200924__20200926__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_pii"&gt;2,063,713
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;shares of Company common stock which
have been issued to Koligo&#x2019;s accredited investors (with certain non-accredited investors being paid solely in cash in
the amount of approximately $&lt;span id="xdx_906_eus-gaap--Cash_iI_pn3n3_c20200926__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_ztN69wJlqo8f"&gt;20
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;thousand). In addition, we issued &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20201014__20201015__dei--LegalEntityAxis__custom--MaximaGroupLLCMember_zV4CliG3nq01"&gt;66,910&lt;/span&gt;
shares to Maxim Group LLC for advisory services&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt; in connection
with the Merger.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;d.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfWarrantsActivity_zYqchtHnoERa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of the Company&#x2019;s warrants granted to investors and as finder&#x2019;s fees as of December 31, 2020, and December
31, 2019 and changes for the periods then ended is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zM9rIJbKhFS7" style="display: none"&gt;SCHEDULE OF WARRANTS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Warrants &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Warrants &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Warrants &lt;/b&gt;outstanding at the&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;beginning of the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pii_c20200101__20201231_zy7hqsLWzaWe" style="width: 14%; text-align: right" title="Number of Warrants - Warrants outstanding at the beginning of the period"&gt;6,010,087&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231_zFSaEvQVhSc5" style="width: 14%; text-align: right" title="Weighted Average Exercise Price - Warrants outstanding at the beginning of the period"&gt;6.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pii_c20190101__20191231_zQls2BU5AEg9" style="width: 14%; text-align: right" title="Number of Warrants - Warrants outstanding at the beginning of the period"&gt;6,286,351&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pii_c20190101__20191231_zgeuftkOQsZf" style="width: 14%; text-align: right" title="Weighted Average Exercise Price - Warrants outstanding at the beginning of the period"&gt;6.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Changes during the period:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231_pii" style="text-align: right" title="Number of Warrants - Issued"&gt;1,344,606&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_c20200101__20201231_pii" style="text-align: right" title="Weighted Average Exercise Price - Issued"&gt;5.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20190101__20191231_pii" style="text-align: right" title="Number of Warrants - Issued"&gt;471,980&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_c20190101__20191231_pii" style="text-align: right" title="Weighted Average Exercise Price - Issued"&gt;6.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pii_di_c20200101__20201231_zIeUTF8pAYnl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants - Expired"&gt;(284,452&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_c20200101__20201231_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price - Expired"&gt;6.53&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pii_di_c20190101__20191231_z2bpJ9Ke5kE9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants - Expired"&gt;(748,244&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_c20190101__20191231_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price - Expired"&gt;6.24&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;b&gt;Warrants&lt;/b&gt; outstanding and exercisable at end of the period*&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span id="xdx_F45_zkzKE0sZlZCe" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pii_c20200101__20201231_fKg_____zR6NfaZmUFu3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants - Warrants outstanding and exercisable at the end of the period"&gt;7,070,241&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice_iE_pii_c20200101__20201231_fKg_____z8LdBEn42ePi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Warrants outstanding and exercisable at the end of the period"&gt;6.20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pii_c20190101__20191231_fKg_____zUMeCU4HGJp6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants - Warrants outstanding and exercisable at the end of the period"&gt;6,010,087&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice_iE_pii_c20190101__20191231_fKg_____zDnl7acqCJ1h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Warrants outstanding and exercisable at the end of the period"&gt;6.35&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td id="xdx_F03_zyyC5iZXAPy1" style="width: 1%"&gt;*&lt;/td&gt;
    &lt;td id="xdx_F12_zEo56LSDClG5"&gt;As
of December 31, 2020 and December 31, 2019, there are no warrants that are subject to exercise price adjustments.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p id="xdx_8AC_zFYvy87s8xN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;e.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Treasury
    shares&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_ecustom--ScheduleOfTreasuryShares_z9FHh3sxwB8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of the Company&#x2019;s treasury shares purchased as of December 31, 2020 and changes for the period then ended is presented
below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BA_zE0KGUTQTGYi" style="display: none"&gt;S&lt;span&gt;CHEDULE
OF TREASURY SHARES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Treasury Shares &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price Paid&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Treasury Shares at the beginning of the period&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--TreasuryStockShare_iS_pii_c20200101__20201231_zCALmNDnKKKf" style="text-align: right" title="Number of Treasury Shares at the beginning of the period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2064"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--WeightedAveragePriceNumberOfSharesTreasuryStock_iS_pii_c20200101__20201231_z5s3B29Wptf2" style="text-align: right" title="Weighted Average Price Paid Treasury Shares at the beginning of the period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2066"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Changes during the period:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 56%; padding-bottom: 1.5pt"&gt;Purchased&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--TreasuryStockSharesAcquired_c20200101__20201231_pii" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Number of Treasury Shares Purchased"&gt;55,309&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--WeightedAveragePriceNumberOfSharesTreasuryStockPurchased_c20200101__20201231_pii" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Weighted Average Price Paid Treasury Shares Purchased"&gt;4.47&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Shares at end of the period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--TreasuryStockShare_iE_pii_c20200101__20201231_zX5xyPjyZQt9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Treasury Shares at end of the period"&gt;53,309&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--WeightedAveragePriceNumberOfSharesTreasuryStock_iE_pii_c20200101__20201231_zNaro5lNGmN9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Price Paid Treasury Shares at end of the period"&gt;4.47&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AB_zXvFBZTcCjGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2020-01-192020-01-20_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">2200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2020-01-20_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="USDPShares">4.20</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-01-20_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-01-20_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="USDPShares">5.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ORGS:WarrantExercisableDescription contextRef="From2020-01-192020-01-20_custom_SecuritiesPurchaseAgreementMember">exercisable between June
2021 and January 2023.</ORGS:WarrantExercisableDescription>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2020-01-192020-01-20_custom_SecuritiesPurchaseAgreementMember"
      decimals="-4"
      unitRef="USD">9240000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <ORGS:OfferingExpenses
      contextRef="From2020-01-192020-01-20"
      decimals="-5"
      unitRef="USD">800000</ORGS:OfferingExpenses>
    <us-gaap:Cash
      contextRef="AsOf2020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember"
      decimals="-5"
      unitRef="USD">2500000</us-gaap:Cash>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">3400000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember"
      decimals="-5"
      unitRef="USD">20200000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:EscrowDeposit
      contextRef="AsOf2020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember"
      decimals="-3"
      unitRef="USD">59000</us-gaap:EscrowDeposit>
    <ORGS:NumberOfSharesDepositInEscrowAccount
      contextRef="From2020-04-062020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">340000</ORGS:NumberOfSharesDepositInEscrowAccount>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2020-04-07_custom_TamirBiotechnologyIncMember_custom_TamirPurchaseAgreementMember"
      decimals="INF"
      unitRef="USDPShares">5.26</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2020-09-242020-09-26_custom_MergerAgreementMember_custom_KoligoTherapeuticsIncMember"
      decimals="INF"
      unitRef="Shares">2063713</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:Cash
      contextRef="AsOf2020-09-26_custom_MergerAgreementMember_custom_KoligoTherapeuticsIncMember"
      decimals="-3"
      unitRef="USD">20000</us-gaap:Cash>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2020-10-142020-10-15_custom_MaximaGroupLLCMember"
      decimals="INF"
      unitRef="Shares">66910</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <ORGS:ScheduleOfWarrantsActivity contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_892_ecustom--ScheduleOfWarrantsActivity_zYqchtHnoERa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of the Company&#x2019;s warrants granted to investors and as finder&#x2019;s fees as of December 31, 2020, and December
31, 2019 and changes for the periods then ended is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zM9rIJbKhFS7" style="display: none"&gt;SCHEDULE OF WARRANTS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Warrants &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Warrants &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Warrants &lt;/b&gt;outstanding at the&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;beginning of the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pii_c20200101__20201231_zy7hqsLWzaWe" style="width: 14%; text-align: right" title="Number of Warrants - Warrants outstanding at the beginning of the period"&gt;6,010,087&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231_zFSaEvQVhSc5" style="width: 14%; text-align: right" title="Weighted Average Exercise Price - Warrants outstanding at the beginning of the period"&gt;6.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pii_c20190101__20191231_zQls2BU5AEg9" style="width: 14%; text-align: right" title="Number of Warrants - Warrants outstanding at the beginning of the period"&gt;6,286,351&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pii_c20190101__20191231_zgeuftkOQsZf" style="width: 14%; text-align: right" title="Weighted Average Exercise Price - Warrants outstanding at the beginning of the period"&gt;6.29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Changes during the period:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231_pii" style="text-align: right" title="Number of Warrants - Issued"&gt;1,344,606&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_c20200101__20201231_pii" style="text-align: right" title="Weighted Average Exercise Price - Issued"&gt;5.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20190101__20191231_pii" style="text-align: right" title="Number of Warrants - Issued"&gt;471,980&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_c20190101__20191231_pii" style="text-align: right" title="Weighted Average Exercise Price - Issued"&gt;6.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pii_di_c20200101__20201231_zIeUTF8pAYnl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants - Expired"&gt;(284,452&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_c20200101__20201231_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price - Expired"&gt;6.53&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pii_di_c20190101__20191231_z2bpJ9Ke5kE9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants - Expired"&gt;(748,244&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_c20190101__20191231_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price - Expired"&gt;6.24&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;b&gt;Warrants&lt;/b&gt; outstanding and exercisable at end of the period*&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span id="xdx_F45_zkzKE0sZlZCe" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pii_c20200101__20201231_fKg_____zR6NfaZmUFu3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants - Warrants outstanding and exercisable at the end of the period"&gt;7,070,241&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice_iE_pii_c20200101__20201231_fKg_____z8LdBEn42ePi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Warrants outstanding and exercisable at the end of the period"&gt;6.20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pii_c20190101__20191231_fKg_____zUMeCU4HGJp6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants - Warrants outstanding and exercisable at the end of the period"&gt;6,010,087&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice_iE_pii_c20190101__20191231_fKg_____zDnl7acqCJ1h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Warrants outstanding and exercisable at the end of the period"&gt;6.35&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td id="xdx_F03_zyyC5iZXAPy1" style="width: 1%"&gt;*&lt;/td&gt;
    &lt;td id="xdx_F12_zEo56LSDClG5"&gt;As
of December 31, 2020 and December 31, 2019, there are no warrants that are subject to exercise price adjustments.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

</ORGS:ScheduleOfWarrantsActivity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">6010087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31"
      decimals="INF"
      unitRef="USDPShares">6.35</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2018-12-31" decimals="INF" unitRef="Shares">6286351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2018-12-31"
      decimals="INF"
      unitRef="USDPShares">6.29</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Shares">1344606</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="USDPShares">5.64</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Shares">471980</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="USDPShares">6.95</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Shares">284452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="USDPShares">6.53</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Shares">748244</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="USDPShares">6.24</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber
      contextRef="AsOf2020-12-31"
      decimals="INF"
      id="Fact002053"
      unitRef="Shares">7070241</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31"
      decimals="INF"
      id="Fact002055"
      unitRef="USDPShares">6.20</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber
      contextRef="AsOf2019-12-31"
      decimals="INF"
      id="Fact002057"
      unitRef="Shares">6010087</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31"
      decimals="INF"
      id="Fact002059"
      unitRef="USDPShares">6.35</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice>
    <ORGS:ScheduleOfTreasuryShares contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89E_ecustom--ScheduleOfTreasuryShares_z9FHh3sxwB8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of the Company&#x2019;s treasury shares purchased as of December 31, 2020 and changes for the period then ended is presented
below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BA_zE0KGUTQTGYi" style="display: none"&gt;S&lt;span&gt;CHEDULE
OF TREASURY SHARES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Treasury Shares &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price Paid&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Treasury Shares at the beginning of the period&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--TreasuryStockShare_iS_pii_c20200101__20201231_zCALmNDnKKKf" style="text-align: right" title="Number of Treasury Shares at the beginning of the period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2064"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--WeightedAveragePriceNumberOfSharesTreasuryStock_iS_pii_c20200101__20201231_z5s3B29Wptf2" style="text-align: right" title="Weighted Average Price Paid Treasury Shares at the beginning of the period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2066"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Changes during the period:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 56%; padding-bottom: 1.5pt"&gt;Purchased&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--TreasuryStockSharesAcquired_c20200101__20201231_pii" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Number of Treasury Shares Purchased"&gt;55,309&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--WeightedAveragePriceNumberOfSharesTreasuryStockPurchased_c20200101__20201231_pii" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Weighted Average Price Paid Treasury Shares Purchased"&gt;4.47&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Shares at end of the period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--TreasuryStockShare_iE_pii_c20200101__20201231_zX5xyPjyZQt9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Treasury Shares at end of the period"&gt;53,309&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--WeightedAveragePriceNumberOfSharesTreasuryStock_iE_pii_c20200101__20201231_zNaro5lNGmN9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Price Paid Treasury Shares at end of the period"&gt;4.47&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</ORGS:ScheduleOfTreasuryShares>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Shares">55309</us-gaap:TreasuryStockSharesAcquired>
    <ORGS:WeightedAveragePriceNumberOfSharesTreasuryStockPurchased
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="USDPShares">4.47</ORGS:WeightedAveragePriceNumberOfSharesTreasuryStockPurchased>
    <ORGS:TreasuryStockShare contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">53309</ORGS:TreasuryStockShare>
    <ORGS:WeightedAveragePriceNumberOfSharesTreasuryStock
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">4.47</ORGS:WeightedAveragePriceNumberOfSharesTreasuryStock>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_808_eus-gaap--EarningsPerShareTextBlock_zMOXj1KiIjXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
14 &#x2013; &lt;span id="xdx_826_z9nVLXal8zkh"&gt;INCOME (LOSS) PER SHARE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zLfgzUn45W49" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table sets forth the calculation of basic and diluted loss per share for the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B4_zW1mjJ0gKzSk" style="display: none"&gt;SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20200101__20201231_zWx4jwAIP616" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20190101__20191231_z79mK5xdaI01" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands, except per share data)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Basic and diluted:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net loss from continuing operations attributable to Orgenesis Inc.&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;95,088&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;22,490&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net (income) loss from discontinued operations attributable to Orgenesis Inc. for loss per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(96,198&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_ecustom--AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Adjustment of redeemable non-controlling interest to redemption amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,160&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zL6pxqPyyqvd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Basic: Net income (loss) available to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(101,358&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,726&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--NetIncomeLossToParentCompany_zFQJa5eUc912" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net (income) loss attributable to Orgenesis Inc. for loss per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,270&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,216&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i_pii" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Weighted average number of common shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,320,314&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,907,995&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pii_zUMbTmX4h8l1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Loss per common share from continuing operations&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4.46&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.41&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_pii_zcRAfqAQwP8e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net (income) loss common share from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(4.75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.36&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--EarningsPerShareBasic_pii_uUSDPShares_zEEhZlScEMna" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Net (income) loss per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.29&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.77&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AB_z9AMcNjIP1Qc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;For
the year ended December 31, 2020, and December 31, 2019, all outstanding convertible notes, options and warrants have been excluded
from the calculation of the diluted net loss per share since their effect was anti-dilutive. Diluted loss per share does not include
&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsAndWarrantsMember_zJs3Bb4BH4J9" title="Antidilutive securities excluded from computation of earnings per share amount"&gt;10,212,789&lt;/span&gt; shares underlying outstanding options and warrants and &lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesUponConversionOfConvertibleNotesMember_zt6AFC85gL54" title="Antidilutive securities excluded from computation of earnings per share amount"&gt;1,630,857&lt;/span&gt; shares upon conversion of convertible loans for the
year ended December 31, 2020, because the effect of their inclusion in the computation would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zLfgzUn45W49" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table sets forth the calculation of basic and diluted loss per share for the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B4_zW1mjJ0gKzSk" style="display: none"&gt;SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20200101__20201231_zWx4jwAIP616" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20190101__20191231_z79mK5xdaI01" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands, except per share data)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Basic and diluted:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net loss from continuing operations attributable to Orgenesis Inc.&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;95,088&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;22,490&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_i_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net (income) loss from discontinued operations attributable to Orgenesis Inc. for loss per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(96,198&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_ecustom--AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Adjustment of redeemable non-controlling interest to redemption amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,160&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zL6pxqPyyqvd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Basic: Net income (loss) available to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(101,358&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,726&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--NetIncomeLossToParentCompany_zFQJa5eUc912" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net (income) loss attributable to Orgenesis Inc. for loss per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,270&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,216&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i_pii" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Weighted average number of common shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,320,314&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,907,995&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pii_zUMbTmX4h8l1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Loss per common share from continuing operations&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4.46&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.41&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_pii_zcRAfqAQwP8e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net (income) loss common share from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(4.75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.36&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--EarningsPerShareBasic_pii_uUSDPShares_zEEhZlScEMna" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Net (income) loss per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.29&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.77&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">95088000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">22490000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-96198000</us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">1631000</us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic>
    <ORGS:AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-5160000</ORGS:AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount>
    <ORGS:AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">4095000</ORGS:AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-101358000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">5726000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <ORGS:NetIncomeLossToParentCompany
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-6270000</ORGS:NetIncomeLossToParentCompany>
    <ORGS:NetIncomeLossToParentCompany
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">28216000</ORGS:NetIncomeLossToParentCompany>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="Shares">21320314000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="Shares">15907995000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="USDPShares">4.46</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="USDPShares">1.41</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="USDPShares">-4.75</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="USDPShares">0.36</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="USDPShares">1.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-12-31_custom_OptionsAndWarrantsMember"
      decimals="INF"
      unitRef="Shares">10212789</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-12-31_custom_SharesUponConversionOfConvertibleNotesMember"
      decimals="INF"
      unitRef="Shares">1630857</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_800_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zsPEWaOODBTl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
15 &#x2013; &lt;span id="xdx_823_ziOCQJv1z6Sa"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;a.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Global
    Share Incentive Plan&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
May 11, 2017, the annual meeting of the Company&#x2019;s stockholders approved the 2017 Equity Incentive Plan (the &#x201c;2017
Plan&#x201d;) under which, the Company had reserved a pool of &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_c20170511__us-gaap--PlanNameAxis__custom--TwoZeroOneSevenEquityIncentivePlanMember_z2As6VSfKaFd" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;1,750,000&lt;/span&gt; shares of the Company&#x2019;s common stock, which may be
issued at the discretion of the Company&#x2019;s board of directors from time to time. Under this Plan, each option is exercisable
into one share of common stock of the Company. The options may be exercised after vesting and in accordance with the vesting schedule
that will be determined by the Company&#x2019;s board of directors for each grant. The maximum contractual life term of the options
is &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20170509__20170511__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoZeroOneSevenEquityIncentivePlanMember_zw9xbN8LIZ45" title="Share-based compensation, shares authorized under stock option plans, exercise price range, outstanding options, weighted average remaining contractual term"&gt;10&lt;/span&gt; years. At the Company&#x2019;s annual meeting of stockholders on November 26, 2019 the Company&#x2019;s stockholders approved
an amendment to increase the number of shares authorized for issuance of awards under the Company&#x2019;s 2017 Equity Incentive
Plan from &lt;span&gt;1,750,000&lt;/span&gt; shares to an aggregate of &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pii_c20170509__20170511__us-gaap--PlanNameAxis__custom--TwoZeroOneSevenEquityIncentivePlanMember_z9b3mV53BZ4j" title="Share-based compensation arrangement by share-based payment award, number of additional shares authorized"&gt;3,000,000&lt;/span&gt; shares of Common Stock. As of December 31, 2020, total options granted
under this plan are &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--TwoZeroOneSevenEquityIncentivePlanMember_ze4AO8PDT6e7" title="Share-based compensation arrangement by share-based payment award, options, outstanding, number"&gt;1,362,133&lt;/span&gt; and the total options that are available for grants under this plan are &lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--TwoZeroOneSevenEquityIncentivePlanMember_zFTUyslIemka" title="Share-based compensation arrangement by share-based payment award, options, available for grants"&gt;1,724,966&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
May 23, 2012, the Company&#x2019;s board of directors adopted the Global Share Incentive Plan 2012 (the &#x201c;2012 Plan&#x201d;)
under which, the Company had reserved a pool of &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_c20120523__us-gaap--PlanNameAxis__custom--GlobalShareIncentivePlanTwoZeroOneTwoMember_zClNYU8Q0NB1" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;1,000,000&lt;/span&gt; shares of the Company&#x2019;s common stock, which may be issued at the
discretion of the Company&#x2019;s board of directors from time to time. Under this plan, each option is exercisable into one share
of common stock of the Company. The options may be exercised after vesting and in accordance with the vesting schedule that will
be determined by the Company&#x2019;s board of directors for each grant. The maximum contractual life term of the options is &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20120521__20120523__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--GlobalShareIncentivePlanTwoZeroOneTwoMember_zXXYQyCIc3m6" title="Share-based compensation, shares authorized under stock option plans, exercise price range, outstanding options, weighted average remaining contractual term"&gt;10&lt;/span&gt;
years. As of December 31, 2020, total options granted under this plan are &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--GlobalShareIncentivePlanTwoZeroOneTwoMember_zjksD69k25pb" title="Share-based compensation arrangement by share-based payment award, options, outstanding, number"&gt;1,183,182&lt;/span&gt; and the total options that are available for
grants under this plan are &lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--GlobalShareIncentivePlanTwoZeroOneTwoMember_zvSDZoIywWE4" title="Share-based compensation arrangement by share-based payment award, options, available for grants"&gt;248,024&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;b.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Options
    Granted to Employees and Directors&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZpsYXnnwH74" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Below
is a table summarizing all of the options grants to employees and Directors made during the years ended December 31, 2020, and
December 31, 2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8BE_z2wZ5VoapHK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;SCHEDULE
OF EMPLOYEE STOCK OWNERSHIP PLAN DISCLOSURES&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;No. of options &lt;br/&gt; granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Vesting period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair value at grant&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Expiration &lt;br/&gt; period&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 10%; text-align: center"&gt;Employees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zK84ovmWCrVj" style="width: 10%; text-align: right"&gt;531,450&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember__srt--RangeAxis__srt--MinimumMember_zjlMlT6Y8Hp3" title="Exercise price"&gt;2.99&lt;/span&gt;-$&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember__srt--RangeAxis__srt--MaximumMember_z2N5Xc2nwZHd"&gt;6.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28%; text-align: center"&gt;Quarterly over a period of &lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zOHsvZG0LJx4" title="Stock options vesting period description"&gt;two years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_znd3sUJFCZqi" style="width: 12%; text-align: right" title="Fair value at grant"&gt;1,312&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: center"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zbvht2A920S9"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;Directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zK3VPNSsvJ0f" style="text-align: right"&gt;145,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember__srt--RangeAxis__srt--MinimumMember_z5KfV2P0CSb" title="Exercise price"&gt;2.99&lt;/span&gt;-$&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember__srt--RangeAxis__srt--MaximumMember_zUuysBuwVFX8"&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90C_ecustom--StockOptionsGrantVestingPeriodPercentage_pii_dp_uPercentage_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--StatementScenarioAxis__custom--OneYearAnniversaryMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z6PmhEs4a4td"&gt;96&lt;/span&gt;%
on the one-year anniversary, &lt;span&gt;and
the remaining &lt;/span&gt;&lt;span id="xdx_902_ecustom--StockOptionsGrantVestingPeriodPercentage_pii_dp_uPercentage_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--StatementScenarioAxis__custom--ThreeEqualInstallmentsMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z5aJKhTktsA3"&gt;4&lt;/span&gt;&lt;span&gt;%
in three equal instalments on the first, second and third year anniversaries&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zAUSql0z2lgg" style="text-align: right" title="Fair value at grant"&gt;377&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z9CKhxzGeRSa"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;Employees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;December 31, 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zi9F5VeJtsja" style="text-align: right" title="No. of options granted"&gt;94,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zE36mXHDmjW4" title="Exercise price"&gt;3.14&lt;/span&gt;-$&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zXVuc9s05iJh" title="Exercise price"&gt;5.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Quarterly over a period of &lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zIYrSjtXl9m9" title="Stock options vesting period description"&gt;two years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zFxHlKP0XU9a" style="text-align: right" title="Fair value at grant"&gt;322&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z78KDbNzJeK6" title="Expiration period"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;Directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;December 31, 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zVqCz3kgOwPk" style="text-align: right" title="No. of options granted"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zZyCgN1R4yXh" style="text-align: right" title="Exercise price"&gt;2.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zjOfThQtSbe6"&gt;One-year&lt;/span&gt; anniversary&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zQJe3aZ6xA1i" style="text-align: right" title="Fair value at grant"&gt;103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zNiZVk9vlFY6" title="Expiration period"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A0_zb0bzOVrWTg8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
fair value of each stock option grant is estimated at the date of grant using a Black Scholes option pricing model. The volatility
is based on historical volatility of the Company, by statistical analysis of the weekly share price for past periods based on
expected term. The expected option term is calculated using the simplified method&lt;i&gt;, &lt;/i&gt;as the Company concludes that its historical
share option exercise experience does not provide a reasonable basis to estimate its expected option term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zarrDrkXzyxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The fair value of each
option grant is based on the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8BB_zu5YXeodfKUg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify"&gt;SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value of one common share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zxAkFRvFYom7" title="Value of one common share"&gt;2.99&lt;/span&gt;-$&lt;span id="xdx_905_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z1eFWEp56oF4" title="Value of one common share"&gt;6.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zG7neHReUXf4" title="Value of one common share"&gt;2.99&lt;/span&gt;-$&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zQ5y9tjhJhr2" title="Value of one common share"&gt;5.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_uPercentage_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zReH2dtA3zh4" style="width: 18%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_uPercentage_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZebSolkkqrl" style="width: 18%; text-align: right" title="Dividend yield"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected stock price volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zsS5PwD0W1D7"&gt;80&lt;/span&gt;%-&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zYePs3g60htc"&gt;86&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zNar8RrjmwB8" title="Expected stock price volatility"&gt;83&lt;/span&gt;%-&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zEDf0maq53rk" title="Expected stock price volatility"&gt;88&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zOy9G7xKVGLf"&gt;0.36&lt;/span&gt;%-&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zYye4pMhEvIe"&gt;1.71&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zLyjUsMQiYx4" title="Risk free interest rate"&gt;1.45&lt;/span&gt;%-&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zjDBWHGiJmW1" title="Risk free interest rate"&gt;2.47&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_ze3gE7h0Rb49"&gt;5.50&lt;/span&gt;-&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zW6K9Y35RD4k"&gt;6.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zKAv9fglXGY2" title="Expected term (years)"&gt;5.38&lt;/span&gt;-&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zleGTKeRrgcj" title="Expected term (years)"&gt;5.56&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A8_zLejcaFxNxp1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zS3l2Iqv4Uv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of the Company&#x2019;s stock options granted to employees and directors as of December 31, 2020 and December 31, 2019
is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8BD_zoETxj5WpTca" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify"&gt;SCHEDULE OF STOCK OPTIONS ACTIVITY&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: justify"&gt;Options outstanding at the beginning of the period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pp0i_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zS0jFjN6KED9" style="width: 14%; text-align: right" title="Number of Options - Options outstanding at the beginning of the year"&gt;2,465,522&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z66PjItUwiM7" style="width: 14%; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the beginning of the year"&gt;4.44&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z1XpzuJYcAm4" style="width: 14%; text-align: right" title="Number of Options - Options outstanding at the beginning of the year"&gt;2,376,427&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zwin3PHg5uH5" style="width: 14%; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the beginning of the year"&gt;4.51&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Changes during the period:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" style="text-align: right" title="Number of Options - Granted"&gt;676,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" style="text-align: right" title="Weighted Average Exercise Price - Granted"&gt;3.74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zpPLI0D0IsI7" style="text-align: right" title="Number of Options - Granted"&gt;144,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zXaY3QgzSlJd" style="text-align: right" title="Weighted Average Exercise Price - Granted"&gt;4.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zkbmQpBqp9b8" style="text-align: right" title="Number of Options - Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2221"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"/&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zKYCsHeYQgBf" style="text-align: right" title="Weighted Average Exercise Price - Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2223"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_ztjVax01M9gf" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2224"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zi0koaWyMNhj" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2225"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zcE59Ue5eEM1" style="text-align: right" title="Number of Options - Expired"&gt;(11,876&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" style="text-align: right" title="Weighted Average Exercise Price - Expired"&gt;7.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zsvXWdYt2eEh" style="text-align: right" title="Number of Options - Expired"&gt;(16,750&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zOgPNHGEJ0pc" style="text-align: right" title="Weighted Average Exercise Price - Expired"&gt;6.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zx0am2zNCkf6" style="text-align: right" title="Number of Options - Forfeited"&gt;(57,042&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" style="text-align: right" title="Weighted Average Exercise Price - Forfeited"&gt;4.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zBs5z1ppkm2d" style="text-align: right" title="Number of Options - Forfeited"&gt;(38,655&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zL30qNRjUlL" style="text-align: right" title="Weighted Average Exercise Price - Forfeited"&gt;7.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zK1f3mUQl6Cc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options - Cancelled"&gt;(155,437&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price - Cancelled"&gt;8.38&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zHUFGhJj1qua" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options - Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2247"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zyudtFueAWS" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price - Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2249"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Options outstanding at end of the period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z024hYqGeUMe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options outstanding at the end of the year"&gt;2,917,667&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zFoCUILK0Q8c" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the end of the year"&gt;4.05&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zKrFiK6LLwvg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options outstanding at the end of the year"&gt;2,465,522&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zyCEU8TRgmZi" style="border-bottom: Black 2.5pt double; text-align: right"&gt;4.44&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Options exercisable at end of the period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pp0i_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZ2pJpCKwoxc" style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,299,937&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zpUpqlzns8x4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options exercisable at end of the year"&gt;4.03&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZ0SvcxgDS9g" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options exercisable at end of the year"&gt;2,112,567&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zK7aIyGVpPbc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options exercisable at end of the year"&gt;4.21&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A9_zLojcCy90UR7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zxdA6Hu4y6M3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table presents summary information concerning the options granted and exercisable to employees and directors outstanding
as of December 31, 2020 (in thousands, except per share data):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8B5_z4X3q6LgMLN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify"&gt;SCHEDULE OF STOCK OPTIONS EXERCISABLE&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Value $&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zGEALbelDWwh" style="width: 13%; text-align: right" title="Exercise Price"&gt;0.0012&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z6TqKbUflO2j" style="width: 13%; text-align: right" title="Number of Outstanding Options"&gt;230,189&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zuf78fMwa3f5" style="width: 13%; text-align: right" title="Weighted Average Remaining Contractual Life"&gt;3.64&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zY4WOMnLvNb6" style="width: 13%; text-align: right" title="Aggregate Intrinsic Value"&gt;1,036&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zAWBgIjsGEXb" style="width: 13%; text-align: right" title="Number of Exercisable Options"&gt;230,189&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_d0_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z0iITGcIcg7i" style="width: 13%; text-align: right" title="Aggregate Exercisable Options Value"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zsnXse1mShx5" style="text-align: right" title="Exercise Price"&gt;0.012&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zYWnvvAxbePf" style="text-align: right" title="Number of Outstanding Options"&gt;510,017&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zgtr2LszQ8T" style="text-align: right"&gt;1.09&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z7pAURfpw0B5" style="text-align: right" title="Aggregate Intrinsic Value"&gt;2,289&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zosR9KYJuJl9" style="text-align: right" title="Number of Exercisable Options"&gt;510,017&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z2evfla7Qt4" style="text-align: right" title="Aggregate Exercisable Options Value"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z8lU7wP9IYhf" style="text-align: right"&gt;2.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zZe7CuN7ybP6" style="text-align: right" title="Number of Outstanding Options"&gt;445,013&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zLhTnNHFK0j" style="text-align: right"&gt;9.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zwDNvdMzi6s2" style="text-align: right"&gt;672&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zNIKw2DIiwW6" style="text-align: right"&gt;174,208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z1TXSnL3ru7k" style="text-align: right"&gt;521&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zziuggCyAbF3" style="text-align: right"&gt;3.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zXpaNqHvtX13" style="text-align: right" title="Number of Outstanding Options"&gt;3,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvuZtvKy57B3" style="text-align: right"&gt;6.27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zE3q69EIIDYc" style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zSICuphcB5Ug" style="text-align: right"&gt;1,875&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zAxaQYg9prC5" style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zzgKfDknX7re" style="text-align: right"&gt;4.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zHDBhdy1z2e8" style="text-align: right" title="Number of Outstanding Options"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zz9bcZ1HDAA" style="text-align: right"&gt;6.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zAfiKgfooTsa" style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zbM0gX99XZy7" style="text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTCxm0HfXDb9" style="text-align: right"&gt;221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zua5M9f5Kwjc" style="text-align: right"&gt;4.5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zbIxZC0xCdFb" style="text-align: right" title="Number of Outstanding Options"&gt;34,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJJhg7ViLdEk" style="text-align: right"&gt;8.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zxPzOGqt9tAf" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2314"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zKYpcnIP3CA2" style="text-align: right"&gt;23,938&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zuR3G4xzwGo8" style="text-align: right"&gt;108&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zrtz3nBOVSl4" style="text-align: right"&gt;4.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zi1Jq9uNwzg5" style="text-align: right" title="Number of Outstanding Options"&gt;185,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zNdSHSEvJXUh" style="text-align: right"&gt;9.96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zqwyKX6tAvol" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2321"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zaB4oP2vrV6i" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2322"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_z3KEJ7E6TB4g" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2323"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zGoq2SXn28Vj" style="text-align: right"&gt;4.7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pp0i_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zTtdkdMRF9D5" style="text-align: right" title="Number of Outstanding Options"&gt;6,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zSVe3QPTBTk9" style="text-align: right"&gt;9.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zB5WBQL6dIUl" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2328"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z8M4560m5oEb" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2329"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z54JqtlcFFnd" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2330"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zaXCRz6LmYI9" style="text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zByoI54r79j6" style="text-align: right" title="Number of Outstanding Options"&gt;483,337&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zX6XYi0wSKS2" style="text-align: right"&gt;5.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z1RW0WBc41G6" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2335"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zLUJ1ygYDy8i" style="text-align: right"&gt;483,337&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zhXjTw0gsvgl" style="text-align: right"&gt;2,320&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zfFNf1Lmh8yf" style="text-align: right"&gt;5.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zMF2XZBxa3jl" style="text-align: right" title="Number of Outstanding Options"&gt;53,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zzonyXwmtLAe" style="text-align: right"&gt;8.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zZ5sgYFnjkY" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2342"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zBTf2tpIvD94" style="text-align: right"&gt;39,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zU7QOoLUpS2a" style="text-align: right"&gt;202&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z6jBUGwNk8v6" style="text-align: right"&gt;5.1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zBZdet3rU6Yh" style="text-align: right" title="Number of Outstanding Options"&gt;63,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zRHJmugJkFck" style="text-align: right"&gt;9.68&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zhXZzATa9Ss8" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2349"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zHilCuwxGo84" style="text-align: right"&gt;7,875&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zcodATh9AaOk" style="text-align: right"&gt;40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z86G3JEOVNr9" style="text-align: right"&gt;5.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zwNp4pEw8fQ2" style="text-align: right" title="Number of Outstanding Options"&gt;352,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zfHNOptExar2" style="text-align: right"&gt;7.26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zA1mWFNXcNJ6" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2356"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zP1LLSF4Mtuc" style="text-align: right"&gt;290,488&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zMpNwJzHG4Gd" style="text-align: right"&gt;1,740&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zuUYwnC0X5fa" style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zVwS6ErCiyTa" style="text-align: right" title="Number of Outstanding Options"&gt;16,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zSyQu6yR305h" style="text-align: right"&gt;3.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z9tAjFEecGda" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2363"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zlZ9fmmDFEIc" style="text-align: right"&gt;16,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z39Brmi8we8l" style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zv7NHJLAmtw8" style="text-align: right"&gt;6.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zVulO9w8euh5" style="text-align: right" title="Number of Outstanding Options"&gt;17,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z8RNlxcC2W1i" style="text-align: right"&gt;9.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zKnH7yGsrxn9" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2370"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zmIYUBzMpcYd" style="text-align: right"&gt;4,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zqlLmFqB3qi2" style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zw8ubJhwHO17" style="text-align: right"&gt;7.2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zONbllM7nOLc" style="text-align: right" title="Number of Outstanding Options"&gt;83,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zFDNG2zRevn7" style="text-align: right"&gt;6.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_znOihXEN96jl" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2377"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zBumwNDfbY28" style="text-align: right"&gt;83,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zj1GmtxQcMYc" style="text-align: right"&gt;600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zyrN5fuMbMU2" style="text-align: right"&gt;8.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zAcZWJKzTXu" style="text-align: right" title="Number of Outstanding Options"&gt;250,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zDILxQGP3fzd" style="text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_ztmamPyTtELk" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2384"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zsXyj2NXlY1i" style="text-align: right"&gt;250,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zpJuHxdUimm6" style="text-align: right"&gt;2,090&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_z76gvrXQeJdf" style="text-align: right"&gt;8.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zDhBuuQ0yyL8" style="text-align: right" title="Number of Outstanding Options"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_z74nX1crcePc" style="text-align: right"&gt;7.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_z7RM1Jq3y8Ah" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2391"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zXjHdoUuI6sd" style="text-align: right"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zQ3jAXaGiuv" style="text-align: right"&gt;134&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_z79o78OrNJ36" style="text-align: right"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zfO8tkwF6Zn" style="text-align: right" title="Number of Outstanding Options"&gt;20,834&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_ztIvFWPvSzhi" style="text-align: right"&gt;2.54&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zvOuCFgoJyLe" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2398"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zUwzO0SsLsCi" style="text-align: right"&gt;20,834&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zm81PGWFTiC5" style="text-align: right"&gt;187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zLDbWwX6rgF8" style="text-align: right"&gt;9.48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_z0aoY4XPQdl9" style="text-align: right" title="Number of Outstanding Options"&gt;58,908&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zzp1y3zqife6" style="text-align: right"&gt;1.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zNV3bqMD055k" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2405"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zOL8AZY6jqni" style="text-align: right"&gt;58,908&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zma966NkxPvl" style="text-align: right"&gt;558&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zGbmSBYIOg61" style="padding-bottom: 1.5pt; text-align: right"&gt;10.2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zgzKvQiMO9w6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Outstanding Options"&gt;39,267&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_z0i0XGzTN3O6" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1.42&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zgRRK1mvqLH2" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2412"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zbdB8XmT3Tx3" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,267&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zbyxob0ZdTu4" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;401&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zsDbzHu4diyh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding Options"&gt;2,917,667&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zx7nbitDplPd" style="border-bottom: Black 2.5pt double; text-align: right"&gt;5.98&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zdZNhbLeERj6" style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,006&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z6RenwmsaOAi" style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,299,937&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_ztKD6Ozzb14f" style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,263&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A8_zy1aHQkP142g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Costs
incurred with respect to stock-based compensation for employees and directors for the years ended December 31, 2020 and December
31, 2019 were $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesAndDirectorsMember_zSI8D6O7pIsg"&gt;1,470
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;thousand and $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_pn3n3_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesAndDirectorsMember_z3SS4NEX4755"&gt;2,107
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;thousand, respectively,&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;
out of which &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20201231__dei--LegalEntityAxis__custom--MasthercellGlobalMember_z5y3Qqm3LChk"&gt;$450
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;thousand&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;
and &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20190101__20191231__dei--LegalEntityAxis__custom--MasthercellGlobalMember_zpVzsmy5ta04"&gt;$360
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;thousand&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;
related to options granted to employees of Masthercell Global, respectively, and presented as part of net loss from discontinued
operations in the consolidated statements of comprehensive loss. As of December 31, 2020, there was $&lt;span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--MasthercellGlobalMember_zXKOSiT2ndna"&gt;1,594
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;thousands of unrecognized compensation
costs related to non-vested employees and directors stock options, to be recorded over the next &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20200101__20201231__dei--LegalEntityAxis__custom--MasthercellGlobalMember_zS5SsYoLX809"&gt;2.02
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;c.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Options
    Granted to Consultants and service providers&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zrZwCVhUAEB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Below
is a table summarizing all the compensation granted to consultants and service providers during the years ended December 31, 2020
and December 31, 2019 and for the one-month period ended December 31, 2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8BE_zyaIvRYNcubb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify"&gt;SCHEDULE OF STOCK OPTIONS GRANTED TO CONSULTANTS&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;br/&gt;Year
    of grant&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;br/&gt;No.
    of options &lt;br/&gt; granted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;br/&gt;Exercise
    price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Vesting period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair
                                         value at grant&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(in
                                         thousands)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;br/&gt;Expiration
    &lt;br/&gt; period&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 8%; text-align: center"&gt;Non-employees &lt;br/&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: center"&gt;2020 &lt;br/&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zq9DlXJrIeng" style="width: 6%; text-align: right"&gt;62,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zanjnW2R8tDb"&gt;2.99&lt;/span&gt;-$&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z725VBpqLdzi"&gt;6.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 30%; text-align: center"&gt;Quarterly over a period of &lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zgFWgaOCBvi" title="Vesting peirod description"&gt;two&lt;/span&gt; years&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pp0p0_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z3QNkvR0SEUh" style="width: 14%; text-align: right"&gt;209&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: center"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zStftzty8WEh"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;Non-employees &lt;br/&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2019 &lt;br/&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_ztq9TlnZkUz1" style="text-align: right" title="No. of options granted"&gt;128,336&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z7jIjxUbX6rj" title="Exercise price"&gt;3.14&lt;/span&gt;-$&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zfRWQwgfkdrg" title="Exercise price"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Vest immediately-&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zJCsrnJgG7mi" title="Vesting period"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pp0p0_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zyvsGmIXHucc" style="text-align: right" title="Fair value at grant"&gt;394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zklPJev0kWDb" title="Expiration period"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8AD_zmELaunstzi7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
fair value of options granted during 2020 and 2019 to consultants and service providers, was computed using the Black-Scholes
model. The fair value of each stock option grant is estimated at the date of grant using a Black Scholes option pricing model.
The volatility is based on historical volatility of the Company, by statistical analysis of the weekly share price for past periods
based on the expected term period, the expected term is the contractual term of each grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zcIP9njEhfD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The underlying data used for computing
the fair value of the options are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8B0_zJxkjABIydHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify"&gt;SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value of one common share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_907_eus-gaap--SharePrice_iI_pii_c20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zJVigMTWX45k" title="Value of one common share"&gt;2.99&lt;/span&gt;-$&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_pii_c20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zpRisG2jihca" title="Value of one common share"&gt;6.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_pii_c20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z4CFsUrPPvgd" title="Value of one common share"&gt;3.14&lt;/span&gt;-$&lt;span id="xdx_908_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z7Q6Fqa6nU5j" title="Value of one common share"&gt;5.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_uPercentage_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zCGG4SGYztWj" style="width: 18%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_uPercentage_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zIlUev5sQYfi" style="width: 18%; text-align: right" title="Dividend yield"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected stock price volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zEEBmNX0ugFa"&gt;86&lt;/span&gt;%-&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zzpOwg9Ve8De"&gt;89&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zqbMIBHnVT39" title="Expected stock price volatility"&gt;89&lt;/span&gt;%-&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zrpQJcpmFPL" title="Expected stock price volatility"&gt;92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zhYmeOySrEn9"&gt;0.73&lt;/span&gt;%-&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zKnvypQfvKO4"&gt;1.12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z4OaZ4mRlzf9" title="Risk free interest rate"&gt;1.52&lt;/span&gt;%-&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z3gtBPyAed2" title="Risk free interest rate"&gt;2.62&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zvBH53H5zF08"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zzioggVFdog1" title="Expected term (years)"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A2_z57grP2rydpi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zbftw2pPvn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of the Company&#x2019;s stock options granted to consultants and service providers as of December 31, 2020, and December
31, 2019 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8BC_z5scIwsT27yf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify"&gt;SCHEDULE OF STOCK OPTIONS ACTIVITY&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: justify"&gt;Options outstanding at the &lt;br/&gt;beginning of the year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zMWWzXlkuf8b" style="width: 12%; text-align: right"&gt;598,310&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zMYVJ1dtg8vj" style="width: 12%; text-align: right"&gt;5.76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zQmxTi4o8My7" style="width: 12%; text-align: right" title="Number of Options - Options outstanding at the end of the year"&gt;469,974&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zLPGxTYap2vd" style="width: 12%; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the end of the year"&gt;5.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Changes during the year:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zsacUEIZps54" style="text-align: right"&gt;62,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z4m6jLMYhn81" style="text-align: right"&gt;3.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zjo8psJ0w978" style="text-align: right" title="Number of Options - Granted"&gt;128,336&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zD3WK7ymPaak" style="text-align: right" title="Weighted Average Exercise Price - Granted"&gt;5.65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zFGF3564i5qi" style="text-align: right" title="Number of Options - Exercised"&gt;(83,334&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zz9Bi03JMrgg" style="text-align: right" title="Weighted Average Exercise Price - Exercised"&gt;3.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zhSTkn5jm4vg" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2494"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zrhFkiUYRuvl" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2495"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zwKkzH5fQzUl" style="text-align: right"&gt;(8,335&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_ziOnnSoUSsUd" style="text-align: right"&gt;5.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zEmJt048ziR4" style="text-align: right" title="Number of Options - Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2499"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zDuFasT03jK" style="text-align: right" title="Weighted Average Exercise Price - Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2501"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zsYlJ5gHpanj" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(20,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_ziXt3pWgbXe5" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5.30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zbuZYe0hVNbb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options - Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2505"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zBmtnPDCceha" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price - Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2507"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Options outstanding at end of the year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zDPWZoMW9KL1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;549,141&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zBAZt4xBqfrl" style="border-bottom: Black 2.5pt double; text-align: right"&gt;5.89&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zL0TkJctr6g4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options outstanding at the end of the year"&gt;598,310&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z5X4sq1uxk27" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the end of the year"&gt;5.76&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Options exercisable at end of the year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zxZ8ISpM5Qkj" style="border-bottom: Black 2.5pt double; text-align: right"&gt;450,972&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zdHwM1ea4Ft1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;6.28&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zO82XaWp8604" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options exercisable at end of the year"&gt;539,515&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zCtk9ECpLhS3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options exercisable at end of the year"&gt;5.88&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A0_zNJjV3QAxgKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zldnSpYcVwvi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table presents summary information concerning the options granted and exercisable to consultants and service providers
outstanding as of December 31, 2020 (in thousands, except per share data):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8B1_zvQLz8p6E7L2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify"&gt;SCHEDULE OF STOCK OPTIONS EXERCISABLE&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Value*&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Value $&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zjm9KeYw0zgf" style="width: 13%; text-align: right" title="Exercise Price"&gt;2.99&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zFsNJSwDApWg" style="width: 13%; text-align: right" title="Number of Outstanding Options"&gt;35,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zq3ZDJf4kH2" style="width: 13%; text-align: right" title="Weighted Average Remaining Contractual Life"&gt;9.22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zpIV6M23tDhk" style="width: 13%; text-align: right" title="Aggregate Intrinsic Value"&gt;53&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zonnfsenO1Ad" style="width: 13%; text-align: right" title="Number of Exercisable Options"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2531"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zvZhiXuQEK13" style="width: 13%; text-align: right" title="Aggregate Exercisable Options Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2533"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zoWEcxO26Xr2" style="text-align: right"&gt;3.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z3K4Q79OQqbg" style="text-align: right" title="Number of Outstanding Options"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zVNabox3ktg7" style="text-align: right"&gt;8.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z9j6eSh0jVIa" style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zxoEyxXqf6yg" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2539"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zaSf0MMFK0hi" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2540"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zktbC9NK4TW6" style="text-align: right"&gt;3.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zCMVcnDHKi9f" style="text-align: right" title="Number of Outstanding Options"&gt;136,775&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zmtPk5bUnJpd" style="text-align: right"&gt;5.32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zn0bDOAAafo4" style="text-align: right"&gt;156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zIIhm7y6zio7" style="text-align: right"&gt;136,775&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zFHyytHLrxG4" style="text-align: right"&gt;460&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zOxNEUsbX702" style="text-align: right"&gt;4.09&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zgTFDIoUL233" style="text-align: right" title="Number of Outstanding Options"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zNJ3aWMz8Xl7" style="text-align: right"&gt;8.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zeEVsV31T7f3" style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zFOYn8Ir6nej" style="text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbZxy4FxBHnf" style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zWeNDczB3e78" style="text-align: right"&gt;4.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zeQON0tYgVP6" style="text-align: right" title="Number of Outstanding Options"&gt;10,325&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zdbqxxK1uYqg" style="text-align: right"&gt;6.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zSqHe0Ao7EQd" style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zR2WFvpSqTpl" style="text-align: right"&gt;10,325&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zhm9J98AUeX2" style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zkcADpZSds4k" style="text-align: right"&gt;4.5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zd5lv0i429O5" style="text-align: right" title="Number of Outstanding Options"&gt;13,335&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJSz7E0E76ob" style="text-align: right"&gt;8.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zBooPwUqqhOg" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2566"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zeeWGjZPl6y1" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2567"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_znd3nMZECIQ4" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2568"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zrP3TyPWJbJk" style="text-align: right"&gt;4.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zi0nUliJ5sgk" style="text-align: right" title="Number of Outstanding Options"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zJs5hiyQ5Q2f" style="text-align: right"&gt;9.96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zHHcqEqVmkIg" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2573"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zkzM1mNSEw66" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2574"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zVqIafo7IUal" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2575"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zaieSMzFpVql" style="text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zurwOxk9DNCl" style="text-align: right" title="Number of Outstanding Options"&gt;16,668&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zbWd7Mk8IIWj" style="text-align: right"&gt;5.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zSN3DyjkCwC8" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2580"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z9RaK704MHoj" style="text-align: right"&gt;16,668&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zY2FbABfI1Vg" style="text-align: right"&gt;80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zEg461Ebhqr5" style="text-align: right"&gt;5.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_ztlx2ItVxahe" style="text-align: right" title="Number of Outstanding Options"&gt;5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zO104xrrhPwg" style="text-align: right"&gt;8.19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z1rZAmEh70Lk" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2587"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zI6fMwT3gUIf" style="text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zjw3S2bpxcR" style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zNrlRTalEVHj" style="text-align: right"&gt;5.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zvkzRwm5Bruj" style="text-align: right" title="Number of Outstanding Options"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zAbI3yY5QC2e" style="text-align: right"&gt;7.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zEnyWF57eaU9" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2594"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z4Kpm9VUq672" style="text-align: right"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zVwvRKv5DJ3d" style="text-align: right"&gt;80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zgWb0dUriad6" style="text-align: right"&gt;5.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z1ji04xSMPxl" style="text-align: right" title="Number of Outstanding Options"&gt;16,670&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z3axaAYQ4rx8" style="text-align: right"&gt;7.81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_znaPAL9XofZ" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2601"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zxJraIVcjY8k" style="text-align: right"&gt;16,670&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zgI0vgGH2Y77" style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zZPMsU8ReXG1" style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zqO7LylWwdV4" style="text-align: right" title="Number of Outstanding Options"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_ze9lgJeZooXc" style="text-align: right"&gt;3.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zs0u9hDogXC" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2608"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zv9YQJLUgJmd" style="text-align: right"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zcF8hGPpjWG1" style="text-align: right"&gt;540&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zsQhIelhGvsf" style="text-align: right"&gt;6.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zAiTLyxIz4zb" style="text-align: right" title="Number of Outstanding Options"&gt;7,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zjP14kh3Zcs" style="text-align: right"&gt;9.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z7xRGhD5QDO5" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2615"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zqZETXPG2fUj" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2616"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z52vcHID7zy1" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2617"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z8BknISK8yNa" style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zlGerKsKT0Kb" style="text-align: right" title="Number of Outstanding Options"&gt;70,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z82nupvXIEC9" style="text-align: right"&gt;8.83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z7Qs3uB9N123" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2622"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zi3znQaa68cd" style="text-align: right"&gt;70,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zftRam9AvoSb" style="text-align: right"&gt;490&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zw4q5x4zBfXa" style="text-align: right"&gt;7.32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z4zo18qwcyS6" style="text-align: right" title="Number of Outstanding Options"&gt;8,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z6B57Re75uD2" style="text-align: right"&gt;1.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z4NJZnHEe9W4" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2629"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zJFfvXx4XJCh" style="text-align: right"&gt;8,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zGdeGtxb7y5e" style="text-align: right"&gt;61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_z0Ic6KJ8XcU8" style="text-align: right"&gt;8.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zeNExxZhoBk6" style="text-align: right" title="Number of Outstanding Options"&gt;8,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zJY5o9pyAd51" style="text-align: right"&gt;7.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_z31WZzfFzHle" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2636"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zDb2jKC1BLPa" style="text-align: right"&gt;8,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zLz7ySnhSeEa" style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zfaV4M7ePToa" style="text-align: right"&gt;8.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_znuZvBMVskeg" style="text-align: right" title="Number of Outstanding Options"&gt;8,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zgFzWN7WAT8e" style="text-align: right"&gt;7.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zp69PYYZoIUh" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2643"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zc90HE6kBMUg" style="text-align: right"&gt;4,999&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zg0koyS616p4" style="text-align: right"&gt;42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zttaeVMJ2mmc" style="text-align: right"&gt;11.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_z6ojrK2VDqe" style="text-align: right" title="Number of Outstanding Options"&gt;8,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zrmW1ph8Acba" style="text-align: right"&gt;2.26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zBIQUnU5xsl" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2650"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zIgegUeSGUC" style="text-align: right"&gt;8,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_z2cgXQaWRDM" style="text-align: right"&gt;96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zmFRHLn4lQU8" style="padding-bottom: 1.5pt; text-align: right"&gt;16.8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zpWfNgNoTnra" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Outstanding Options"&gt;39,267&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zpcmqwo8y4k4" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1.28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zAjvcELcwlfa" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2657"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zYAWvkc5Qpv8" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,267&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zvMnWacbflx2" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;660&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zXPtMpBpMvO4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding Options"&gt;549,141&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z4hKvDKamxN2" style="border-bottom: Black 2.5pt double; text-align: right"&gt;6.18&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z7jEda9Q4WG8" style="border-bottom: Black 2.5pt double; text-align: right"&gt;240&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zJN4C00E9KHf" style="border-bottom: Black 2.5pt double; text-align: right"&gt;450,972&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zAMCvEmSYO3" style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,834&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AC_znVadZXHR6yf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Costs
incurred with respect to options granted to consultants and service providers for the years ended December 31, 2020 and December
31, 2019 were $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zfzTc7v9MyA8"&gt;113&lt;/span&gt; thousand and $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_pn3n3_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zTNhbHPzQjij" title="Stock-based compensation"&gt;330&lt;/span&gt; thousand, respectively. As of December 31, 2020, there was $&lt;span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z7kubgqN0Mtj"&gt;231&lt;/span&gt; thousands of unrecognized
compensation costs related to non-vested consultants and service providers, to be recorded over the next &lt;span&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zAgzhiocscYi"&gt;4.58&lt;/span&gt;&lt;/span&gt; years.&lt;br/&gt;
&lt;br/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;d.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Warrants
    and Shares Issued to Non-Employees&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;The
fair value of Common Stock issued was the share price of the shares issued at the day of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;1)
On January 20, 2020, the Company entered into a Securities Purchase Agreement (the &#x201c;January Purchase Agreement&#x201d;) with
certain investors pursuant to which the Company issued and sold, in a private placement (the &#x201c;Offering&#x201d;), &lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pii_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zGgaZxQiban3" title="Number of shares issued"&gt;2,200,000&lt;/span&gt;
shares of Common Stock at a purchase price of $&lt;span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_pii_c20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zqAUx3s3jtF3" title="Share issued price per share"&gt;4.20&lt;/span&gt; per share (the &#x201c;Shares&#x201d;) and warrants to purchase up to &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z1rqvrI0qa5" title="Number of warrants granted to purchase an equal number of additional shares of common stock"&gt;1,000,000&lt;/span&gt;
shares of Common Stock at an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z4fF0eCNDWb1" title="Warrants exercise price per share"&gt;5.50&lt;/span&gt; per share (the &#x201c;Warrants&#x201d;) which are &lt;span id="xdx_909_ecustom--WarrantExercisableDescription_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYrwZqyDlgT4"&gt;exercisable between June
2021 and January 2023.&lt;/span&gt; The Company received gross proceeds of approximately $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zK01S5AP0ag9" title="Proceeds from issuance of private placement"&gt;9.2&lt;/span&gt; million before deducting related offering expenses
in the amount of $&lt;span id="xdx_907_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z0GuOIhqqxO9" title="Offering expenses"&gt;0.8&lt;/span&gt; million. The fair value of those warrants as of the date of grant using the Black-Scholes valuation model
was $&lt;span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zX1pH7Qz3im6" title="Warrants fair value"&gt;1,911&lt;/span&gt; thousand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;2)
On January 2, 2020, the Company entered into private placement subscription agreements with investors for an aggregate amount
of $&lt;span id="xdx_90B_ecustom--AggregateAmountOfSubscriptionAgreement_iI_pn3n3_c20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementsMember_zkXsyYGJbKrd" title="Aggregate amount of subscription agreement"&gt;250&lt;/span&gt; thousand of convertible loans. The lenders shall be entitled, at any time prior to or no later than the maturity date,
to convert the outstanding amount, into shares of Common Stock of the Company at a conversion price per share equal to $&lt;span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementsMember_zTN8O4MeTSca" title="Conversion price per share"&gt;7.00&lt;/span&gt;.
In addition, the Company granted the investors &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementsMember_zxKxt3202ijl" title="Number of warrants granted to purchase an equal number of additional shares of common stock"&gt;151,428&lt;/span&gt; warrants to purchase an equal number of additional shares of the Company&#x2019;s
Common Stock at a price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementsMember_pii" title="Warrant exercise price"&gt;7.00&lt;/span&gt; per share. The fair value of those warrants as of the date of grant using the Black-Scholes valuation
model was $&lt;span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20200101__20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementsMember_zZuxOd1WxtQ4"&gt;210&lt;/span&gt; thousand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;3)
During the year ended December 31, 2020, the Company granted to several consultants &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20201231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_zw3LmohdRPAk" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross"&gt;193,178&lt;/span&gt; warrants each exercisable between
$&lt;span id="xdx_90B_eus-gaap--WarrantExercisePriceDecrease_c20200101__20201231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_pii" title="Warrant, Exercise Price, Decrease"&gt;3.14&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--WarrantExercisePriceIncrease_c20200101__20201231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_pii" title="Warrant, Exercise Price, Increase"&gt;5.34&lt;/span&gt; per share for &lt;span id="xdx_904_ecustom--WarrantsAndRightsOutstandingTermDescription_c20200101__20201231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember" title="Warrants term"&gt;three years&lt;/span&gt;. The fair value of those options as of the date of grant using the Black-Scholes valuation
model was $&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20200101__20201231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_zLZWMYD6u1Oh" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value"&gt;378&lt;/span&gt; thousand, out of which $&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20200101__20201231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesAndPrivateInvestmentMember_zn9yzulEQCTb"&gt;350&lt;/span&gt; thousand is related to &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20201231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesAndPrivateInvestmentMember_zMnNdbdHsQZa"&gt;179,428&lt;/span&gt; warrants granted as a success fee with respect to the
issuance of the convertible notes and private Investment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;4)
During the year ended December 31, 2019, the Company granted to several consultants &lt;span id="xdx_907_ecustom--ClassOfWarrantOrRightGrantsInPeriod_pii_c20190101__20191231__srt--TitleOfIndividualAxis__custom--SeveralConsultantsMember_z38o6pCisXWa" title="Number of warrants - issued"&gt;88,499&lt;/span&gt; warrants each exercisable between $&lt;span id="xdx_902_ecustom--ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__srt--TitleOfIndividualAxis__custom--SeveralConsultantsMember_zUmPEII3LERa" title="Weighted Average Exercise Price - Issued"&gt;4.3&lt;/span&gt;
and $&lt;span id="xdx_901_ecustom--ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__srt--TitleOfIndividualAxis__custom--SeveralConsultantsMember_zSwNtPytmdxj" title="Weighted Average Exercise Price - Issued"&gt;7.00&lt;/span&gt; per share for three years. The fair value of those options as of the date of grant using the Black-Scholes valuation
model was $&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRightGrantsInPeriodFairValue_pn3n3_c20190101__20191231__srt--TitleOfIndividualAxis__custom--SeveralConsultantsMember_zJNuZDCPnpOj" title="Class of warrant or right, grants in period, fair value"&gt;155&lt;/span&gt; thousand, out of which $&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRightGrantsInPeriodFairValue_pn3n3_c20190101__20191231__us-gaap--AwardTypeAxis__custom--SuccessFeeMember_z0WGCbdKgHA9" title="Class of warrant or right, grants in period, fair value"&gt;97&lt;/span&gt; thousand is related to &lt;span id="xdx_908_ecustom--ClassOfWarrantOrRightGrantsInPeriod_pii_c20190101__20191231__us-gaap--AwardTypeAxis__custom--SuccessFeeMember_z75y90cjcXh5" title="Number of warrants - issued"&gt;57,142&lt;/span&gt; warrants granted as a success fee with respect to the
issuance of the convertible notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;5)
In September 2019, the Company entered into an investor relation services, marketing and related services agreement. Under the
terms of the agreement, the Company agreed to issue the consultant &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pii_c20190901__20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember_zBrAJ1D5qcSf"&gt;40,174
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;shares of restricted
common stock, of which the first &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pii_c20190901__20190930__us-gaap--VestingAxis__custom--HeldUntilSixMonthsAnniversaryMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember_zIFtiRK2GhCc"&gt;20,087
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;shares will be
held in escrow by the Company until the six months anniversary of the agreement and &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pii_c20190901__20190930__us-gaap--VestingAxis__custom--HeldUntilOneYearAnniversaryMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember_zMwrXjnDdaij"&gt;20,087
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;shares will be
issued on the six months anniversary of the agreement to be held in escrow by the company until the one-year anniversary of the
agreement. The fair value of the shares was $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn3n3_c20190909__20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember_z27lpOlmmtD2"&gt;178
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;thousand using
the fair value of the shares on the grant date. $&lt;span id="xdx_905_ecustom--FairValueOfSharesRecognizedOnGrantDate_iI_pn3n3_c20201231_zI6pjGp1Yf59"&gt;96
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;and &lt;span id="xdx_904_ecustom--FairValueOfSharesRecognizedOnGrantDate_iI_pn3n3_c20191231_zMsklUcFte4b"&gt;82
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;thousand was recognized
during the year ended December 31, 2020 and December 31, 2019, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;6)
In March 2019, the Company issued First Choice &lt;span id="xdx_90B_ecustom--JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted_pii_c20190301__20190331__dei--LegalEntityAxis__custom--FirstChoiceInternationalCompanyIncMember_zV1gWUHfRjle" title="Joint venture agreement, shares issued for compensation of work already completed"&gt;525,000&lt;/span&gt; shares of Common Stock. The value of Common Stock issued in the amount
of $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20190101__20191231__dei--LegalEntityAxis__custom--FirstChoiceInternationalCompanyIncMember_z48GvTEwiqIl" title="Research and development expense"&gt;2.6&lt;/span&gt; million were charged to research and development expenses during the year ended December 31, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;7)
In December 2018, the Company entered into an investor relation services, marketing and related services agreement. Under the
terms of the agreement, the Company agreed to issue the consultant &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20181201__20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zs2Wvc0x5Cyd" title="Stock issued during period, shares, restricted stock"&gt;10,000&lt;/span&gt; shares of restricted common stock, of which the first
&lt;span id="xdx_90F_ecustom--NumberOfVestedShares_iI_pii_c20181231__us-gaap--VestingAxis__custom--VestedOnSigningDateMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zuTQasQOik18" title="Number of vested shares"&gt;2,500&lt;/span&gt; shares vested on the signing date, and &lt;span id="xdx_901_ecustom--NumberOfVestedShares_iI_pp0i_c20181231__us-gaap--VestingAxis__custom--VestMonthlyOver3MonthsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zI8ZVcqcj5F3" title="Number of vested shares"&gt;7,500&lt;/span&gt; shares are to vest monthly over 3 months commencing January 2019. As of December
31, 2019, &lt;span id="xdx_90F_ecustom--NumberOfVestedShares_iI_pii_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zHu65hMXBPb9" title="Number of vested shares"&gt;10,000&lt;/span&gt; shares were fully vested. The fair value of the shares was $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn3n3_c20191201__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zbTATAZto1kj" title="Stock issued during period, value, issued for services"&gt;51&lt;/span&gt; thousand using the fair value of the shares on
the vesting dates. $&lt;span id="xdx_90B_ecustom--FairValueOfSharesOnVestingDatesRecognizedDuringYear_pn3n3_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zJyRPF4wQirh" title="Fair value of shares on vesting dates recognized during year"&gt;37&lt;/span&gt; thousand was recognized during the year ended December 30, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;8)
In December 2018, the Company entered into a separate investor relations services, marketing and related services agreement. Under
the terms of the agreement, the Company agreed to issue the consultant &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20181201__20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationsContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zmLwbrAhBk88" title="Stock issued during period, shares, restricted stock"&gt;40,000&lt;/span&gt; shares of restricted common stock, of which the
first &lt;span id="xdx_908_ecustom--NumberOfVestedShares_iI_pii_c20181231__us-gaap--VestingAxis__custom--VestedOnSigningDateMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zQFuM1QM4ZW6"&gt;6,667&lt;/span&gt; shares vested on the signing date, and &lt;span id="xdx_903_ecustom--NumberOfVestedShares_iI_pp0i_c20181231__us-gaap--VestingAxis__custom--VestMonthlyOver3MonthsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zimv2xMOMZcb"&gt;33,333&lt;/span&gt; shares vested monthly over five months commencing January 2019. As of
December 31, 2019, &lt;span id="xdx_908_ecustom--NumberOfVestedShares_iI_pii_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zYjFXWrQxLW1"&gt;40,000&lt;/span&gt; shares were fully vested. The fair value of the shares was $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn3n3_c20191201__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_z6rz8wsWwo77"&gt;200&lt;/span&gt; thousand using the fair value of the
shares at the vesting dates. $&lt;span id="xdx_907_ecustom--FairValueOfSharesOnVestingDatesRecognizedDuringYear_pn3n3_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zfwB15vDhaX3"&gt;163&lt;/span&gt; thousand was recognized during the year ended December 30, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;9)
During the year ended November 30, 2018, the Company granted to several consultants &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_zv3Vyqf154q1" title="Number of warrants shares"&gt;78,782&lt;/span&gt; warrants each exercisable between $&lt;span id="xdx_903_eus-gaap--WarrantExercisePriceDecrease_c20181129__20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_zaUy9CQtXmM8" title="Warrant, exercise price, decrease"&gt;6.24&lt;/span&gt;
and $&lt;span id="xdx_90F_eus-gaap--WarrantExercisePriceIncrease_c20181129__20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_z1kBFaQUrea3" title="Warrant, exercise price, increase"&gt;15.41&lt;/span&gt; per share for &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtxL_c20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_z8dp5Nk1tCb5" title="Warrant term::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2755"&gt;three&lt;/span&gt;&lt;/span&gt; years. The fair value of those warrants as of the date of grant using the Black-Scholes valuation
model was $&lt;span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20181129__20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_za1cOu0l2cN9" title="Fair value of warrants"&gt;350&lt;/span&gt; thousand. The warrants granted as a success fee with respect to private placement and the issuance of convertible
loans.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;10)
In January 2018, the Company entered into a consulting agreement with a financial advisor for a period of one year. Under the
terms of the agreement, the consultant was entitled to receive $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20180101__20180131__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zNSdiF9VL1I7" title="Number of common stock for services, value"&gt;60&lt;/span&gt; thousand and &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pii_c20180101__20180131__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_z4FiHJj0Bn4c" title="Number of common stock for services"&gt;19,000&lt;/span&gt; units of the Company securities. Each unit
is comprised of (i) one share of the Company&#x2019;s common stock and (ii) a &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtxL_c20180131__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zcniQxloDrF3" title="Warrant term::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2763"&gt;three&lt;/span&gt;&lt;/span&gt;-year warrant to purchase up to an additional
one share of the Company&#x2019;s Common Stock at a per share exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20180131__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zkvmPiTNsOVf" title="Warrant exercise price"&gt;6.24&lt;/span&gt;. The fair value of the units as of the date
of grant was $&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20180101__20180131__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_ze0x5BBacvIf" title="Fair value of granted"&gt;171&lt;/span&gt; thousand, out of which $&lt;span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20180101__20180131__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zCb0671DJAQ2" title="Fair value of warrants"&gt;62&lt;/span&gt; thousand reflect the fair value of the warrants using the Black-Scholes valuation
model. In July 2018, the board approved an additional issuance of &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180701__20180731__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zfLMK3gqVDG6" title="Number of common stock issued"&gt;6,629&lt;/span&gt; shares and &lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtxL_c20180731__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zxRaOQdO1T87" title="::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2772"&gt;three&lt;/span&gt;&lt;/span&gt;-year warrants to purchase up to &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20180731__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zkWvMiLL0GB" title="Number of warrants shares"&gt;6,629&lt;/span&gt;
shares of the Company&#x2019;s Common Stock at a per share exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20180731__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zBFFLzb7Wzk8" title="Warrant exercise price"&gt;6.24&lt;/span&gt;. The fair value of the units as of the date
of grant was $&lt;span id="xdx_900_eus-gaap--FairValueAdjustmentOfWarrants_c20180701__20180731__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zLNjkl2Zy4b1" title="Fair value of warrants"&gt;88&lt;/span&gt; thousand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;11)
In December 2017, the Company entered into investor relations services, marketing and related services agreements. Under the terms
of the agreement, the Company agreed to grant the consultants a total of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20171201__20171231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zaVThk1Qtvj7" title="Stock issued during period, shares, restricted stock"&gt;195,000&lt;/span&gt; shares of restricted common stock, out of which
the first &lt;span id="xdx_90E_ecustom--NumberOfVestedShares_iI_pii_c20171231__us-gaap--VestingAxis__custom--VestedOnSigningDateMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zHFwRjEQ7kwf"&gt;50,000&lt;/span&gt; shares will vest after 30 days from the signing date, and &lt;span id="xdx_902_ecustom--NumberOfVestedShares_iI_pp0i_c20171231__us-gaap--VestingAxis__custom--VestMonthlyOver3MonthsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_z5y4wtROY3G8"&gt;145,000&lt;/span&gt; shares are to vest monthly over 15 months commencing
February 2018. As of December 31, 2019, all shares were vested. The fair value of the shares as of the date of grant was $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20171201__20171231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zCHKCtFxVbXb" title="Stock issued during period, value, restricted stock"&gt;1,439&lt;/span&gt;
thousand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"&gt;12)
During the twelve months ended December 31, 2020, the Company issued &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk9Sya5NOXuk" title="Number of common stock for services"&gt;270,174&lt;/span&gt; shares of common stock to service providers. As of
December 31, 2020, &lt;span id="xdx_90B_ecustom--NumberOfAdditionalSharesRestrictionsOnTransfer_pii_c20200101__20201231_zTNluHLhUpT3" title="Number of additional shares restrictions on transfer"&gt;30,000&lt;/span&gt; shares have additional restrictions on transfer until such services have been provide.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2017-05-11_custom_TwoZeroOneSevenEquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">1750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-05-092017-05-11_srt_MaximumMember_custom_TwoZeroOneSevenEquityIncentivePlanMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2017-05-092017-05-11_custom_TwoZeroOneSevenEquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-012020-12-31_custom_TwoZeroOneSevenEquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">1362133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants
      contextRef="AsOf2020-12-31_custom_TwoZeroOneSevenEquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">1724966</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2012-05-23_custom_GlobalShareIncentivePlanTwoZeroOneTwoMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2012-05-212012-05-23_srt_MaximumMember_custom_GlobalShareIncentivePlanTwoZeroOneTwoMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-012020-12-31_custom_GlobalShareIncentivePlanTwoZeroOneTwoMember"
      decimals="INF"
      unitRef="Shares">1183182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants
      contextRef="AsOf2020-12-31_custom_GlobalShareIncentivePlanTwoZeroOneTwoMember"
      decimals="INF"
      unitRef="Shares">248024</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants>
    <us-gaap:ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember">&lt;p id="xdx_89F_eus-gaap--ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZpsYXnnwH74" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Below
is a table summarizing all of the options grants to employees and Directors made during the years ended December 31, 2020, and
December 31, 2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8BE_z2wZ5VoapHK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;SCHEDULE
OF EMPLOYEE STOCK OWNERSHIP PLAN DISCLOSURES&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;No. of options &lt;br/&gt; granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Vesting period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair value at grant&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Expiration &lt;br/&gt; period&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 10%; text-align: center"&gt;Employees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zK84ovmWCrVj" style="width: 10%; text-align: right"&gt;531,450&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember__srt--RangeAxis__srt--MinimumMember_zjlMlT6Y8Hp3" title="Exercise price"&gt;2.99&lt;/span&gt;-$&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember__srt--RangeAxis__srt--MaximumMember_z2N5Xc2nwZHd"&gt;6.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28%; text-align: center"&gt;Quarterly over a period of &lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zOHsvZG0LJx4" title="Stock options vesting period description"&gt;two years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_znd3sUJFCZqi" style="width: 12%; text-align: right" title="Fair value at grant"&gt;1,312&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: center"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zbvht2A920S9"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;Directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zK3VPNSsvJ0f" style="text-align: right"&gt;145,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember__srt--RangeAxis__srt--MinimumMember_z5KfV2P0CSb" title="Exercise price"&gt;2.99&lt;/span&gt;-$&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember__srt--RangeAxis__srt--MaximumMember_zUuysBuwVFX8"&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90C_ecustom--StockOptionsGrantVestingPeriodPercentage_pii_dp_uPercentage_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--StatementScenarioAxis__custom--OneYearAnniversaryMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z6PmhEs4a4td"&gt;96&lt;/span&gt;%
on the one-year anniversary, &lt;span&gt;and
the remaining &lt;/span&gt;&lt;span id="xdx_902_ecustom--StockOptionsGrantVestingPeriodPercentage_pii_dp_uPercentage_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--StatementScenarioAxis__custom--ThreeEqualInstallmentsMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z5aJKhTktsA3"&gt;4&lt;/span&gt;&lt;span&gt;%
in three equal instalments on the first, second and third year anniversaries&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zAUSql0z2lgg" style="text-align: right" title="Fair value at grant"&gt;377&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z9CKhxzGeRSa"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;Employees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;December 31, 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zi9F5VeJtsja" style="text-align: right" title="No. of options granted"&gt;94,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zE36mXHDmjW4" title="Exercise price"&gt;3.14&lt;/span&gt;-$&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zXVuc9s05iJh" title="Exercise price"&gt;5.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Quarterly over a period of &lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zIYrSjtXl9m9" title="Stock options vesting period description"&gt;two years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zFxHlKP0XU9a" style="text-align: right" title="Fair value at grant"&gt;322&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z78KDbNzJeK6" title="Expiration period"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;Directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;December 31, 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zVqCz3kgOwPk" style="text-align: right" title="No. of options granted"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zZyCgN1R4yXh" style="text-align: right" title="Exercise price"&gt;2.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zjOfThQtSbe6"&gt;One-year&lt;/span&gt; anniversary&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zQJe3aZ6xA1i" style="text-align: right" title="Fair value at grant"&gt;103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zNiZVk9vlFY6" title="Expiration period"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember"
      decimals="INF"
      unitRef="Shares">531450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">2.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">6.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember">two years</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember"
      decimals="-3"
      unitRef="USD">1312000</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember">P10Y</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember"
      decimals="INF"
      unitRef="Shares">145050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">2.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">4.7</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ORGS:StockOptionsGrantVestingPeriodPercentage
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_OneYearAnniversaryMember_srt_DirectorMember"
      decimals="INF"
      unitRef="Percentage">0.96</ORGS:StockOptionsGrantVestingPeriodPercentage>
    <ORGS:StockOptionsGrantVestingPeriodPercentage
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ThreeEqualInstallmentsMember_srt_DirectorMember"
      decimals="INF"
      unitRef="Percentage">0.04</ORGS:StockOptionsGrantVestingPeriodPercentage>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember"
      decimals="-3"
      unitRef="USD">377000</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember">P10Y</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember"
      decimals="INF"
      unitRef="Shares">94500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember"
      decimals="INF"
      unitRef="USDPShares">3.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_srt_MaximumMember_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember"
      decimals="INF"
      unitRef="USDPShares">5.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember">two years</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember"
      decimals="-3"
      unitRef="USD">322000</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember">P10Y</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember"
      decimals="INF"
      unitRef="USDPShares">2.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember">One-year</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember"
      decimals="-3"
      unitRef="USD">103000</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember_srt_DirectorMember">P10Y</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember">&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zarrDrkXzyxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The fair value of each
option grant is based on the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8BB_zu5YXeodfKUg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify"&gt;SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value of one common share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zxAkFRvFYom7" title="Value of one common share"&gt;2.99&lt;/span&gt;-$&lt;span id="xdx_905_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z1eFWEp56oF4" title="Value of one common share"&gt;6.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zG7neHReUXf4" title="Value of one common share"&gt;2.99&lt;/span&gt;-$&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zQ5y9tjhJhr2" title="Value of one common share"&gt;5.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_uPercentage_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zReH2dtA3zh4" style="width: 18%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_uPercentage_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZebSolkkqrl" style="width: 18%; text-align: right" title="Dividend yield"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected stock price volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zsS5PwD0W1D7"&gt;80&lt;/span&gt;%-&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zYePs3g60htc"&gt;86&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zNar8RrjmwB8" title="Expected stock price volatility"&gt;83&lt;/span&gt;%-&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zEDf0maq53rk" title="Expected stock price volatility"&gt;88&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zOy9G7xKVGLf"&gt;0.36&lt;/span&gt;%-&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zYye4pMhEvIe"&gt;1.71&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zLyjUsMQiYx4" title="Risk free interest rate"&gt;1.45&lt;/span&gt;%-&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zjDBWHGiJmW1" title="Risk free interest rate"&gt;2.47&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_ze3gE7h0Rb49"&gt;5.50&lt;/span&gt;-&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zW6K9Y35RD4k"&gt;6.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zKAv9fglXGY2" title="Expected term (years)"&gt;5.38&lt;/span&gt;-&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zleGTKeRrgcj" title="Expected term (years)"&gt;5.56&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2020-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">2.99</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2020-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">6.84</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2019-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">2.99</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2019-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">5.07</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Percentage">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Percentage">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-012020-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Percentage">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-012020-12-31_srt_MaximumMember_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Percentage">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-01-012019-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Percentage">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-01-012019-12-31_srt_MaximumMember_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Percentage">0.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-012020-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Percentage">0.0036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-012020-12-31_srt_MaximumMember_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Percentage">0.0171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-01-012019-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Percentage">0.0145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-01-012019-12-31_srt_MaximumMember_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Percentage">0.0247</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-12-31_srt_MaximumMember_custom_OptionsGrantedToEmployeesMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-012019-12-31_srt_MinimumMember_custom_OptionsGrantedToEmployeesMember">P5Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-012019-12-31_srt_MaximumMember_custom_OptionsGrantedToEmployeesMember">P5Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember">&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zS3l2Iqv4Uv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of the Company&#x2019;s stock options granted to employees and directors as of December 31, 2020 and December 31, 2019
is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8BD_zoETxj5WpTca" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify"&gt;SCHEDULE OF STOCK OPTIONS ACTIVITY&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: justify"&gt;Options outstanding at the beginning of the period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pp0i_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zS0jFjN6KED9" style="width: 14%; text-align: right" title="Number of Options - Options outstanding at the beginning of the year"&gt;2,465,522&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z66PjItUwiM7" style="width: 14%; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the beginning of the year"&gt;4.44&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z1XpzuJYcAm4" style="width: 14%; text-align: right" title="Number of Options - Options outstanding at the beginning of the year"&gt;2,376,427&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zwin3PHg5uH5" style="width: 14%; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the beginning of the year"&gt;4.51&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Changes during the period:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" style="text-align: right" title="Number of Options - Granted"&gt;676,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" style="text-align: right" title="Weighted Average Exercise Price - Granted"&gt;3.74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zpPLI0D0IsI7" style="text-align: right" title="Number of Options - Granted"&gt;144,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zXaY3QgzSlJd" style="text-align: right" title="Weighted Average Exercise Price - Granted"&gt;4.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zkbmQpBqp9b8" style="text-align: right" title="Number of Options - Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2221"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"/&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zKYCsHeYQgBf" style="text-align: right" title="Weighted Average Exercise Price - Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2223"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_ztjVax01M9gf" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2224"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zi0koaWyMNhj" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2225"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zcE59Ue5eEM1" style="text-align: right" title="Number of Options - Expired"&gt;(11,876&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" style="text-align: right" title="Weighted Average Exercise Price - Expired"&gt;7.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zsvXWdYt2eEh" style="text-align: right" title="Number of Options - Expired"&gt;(16,750&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zOgPNHGEJ0pc" style="text-align: right" title="Weighted Average Exercise Price - Expired"&gt;6.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zx0am2zNCkf6" style="text-align: right" title="Number of Options - Forfeited"&gt;(57,042&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" style="text-align: right" title="Weighted Average Exercise Price - Forfeited"&gt;4.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zBs5z1ppkm2d" style="text-align: right" title="Number of Options - Forfeited"&gt;(38,655&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zL30qNRjUlL" style="text-align: right" title="Weighted Average Exercise Price - Forfeited"&gt;7.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zK1f3mUQl6Cc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options - Cancelled"&gt;(155,437&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price - Cancelled"&gt;8.38&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zHUFGhJj1qua" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options - Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2247"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zyudtFueAWS" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price - Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2249"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Options outstanding at end of the period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z024hYqGeUMe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options outstanding at the end of the year"&gt;2,917,667&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zFoCUILK0Q8c" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the end of the year"&gt;4.05&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zKrFiK6LLwvg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options outstanding at the end of the year"&gt;2,465,522&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zyCEU8TRgmZi" style="border-bottom: Black 2.5pt double; text-align: right"&gt;4.44&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Options exercisable at end of the period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pp0i_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZ2pJpCKwoxc" style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,299,937&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zpUpqlzns8x4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options exercisable at end of the year"&gt;4.03&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZ0SvcxgDS9g" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options exercisable at end of the year"&gt;2,112,567&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zK7aIyGVpPbc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options exercisable at end of the year"&gt;4.21&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="0"
      unitRef="Shares">2465522</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">4.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2018-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Shares">2376427</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2018-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">4.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Shares">676500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">3.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Shares">144500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">4.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Shares">11876</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">7.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Shares">16750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">6.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Shares">57042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">4.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Shares">38655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">7.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Shares">-155437</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">8.38</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Shares">2917667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">4.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Shares">2465522</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">4.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="0"
      unitRef="Shares">2299937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">4.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2019-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Shares">2112567</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">4.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember">&lt;p id="xdx_892_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zxdA6Hu4y6M3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table presents summary information concerning the options granted and exercisable to employees and directors outstanding
as of December 31, 2020 (in thousands, except per share data):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8B5_z4X3q6LgMLN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify"&gt;SCHEDULE OF STOCK OPTIONS EXERCISABLE&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Value $&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zGEALbelDWwh" style="width: 13%; text-align: right" title="Exercise Price"&gt;0.0012&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z6TqKbUflO2j" style="width: 13%; text-align: right" title="Number of Outstanding Options"&gt;230,189&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zuf78fMwa3f5" style="width: 13%; text-align: right" title="Weighted Average Remaining Contractual Life"&gt;3.64&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zY4WOMnLvNb6" style="width: 13%; text-align: right" title="Aggregate Intrinsic Value"&gt;1,036&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zAWBgIjsGEXb" style="width: 13%; text-align: right" title="Number of Exercisable Options"&gt;230,189&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_d0_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z0iITGcIcg7i" style="width: 13%; text-align: right" title="Aggregate Exercisable Options Value"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zsnXse1mShx5" style="text-align: right" title="Exercise Price"&gt;0.012&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zYWnvvAxbePf" style="text-align: right" title="Number of Outstanding Options"&gt;510,017&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zgtr2LszQ8T" style="text-align: right"&gt;1.09&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z7pAURfpw0B5" style="text-align: right" title="Aggregate Intrinsic Value"&gt;2,289&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zosR9KYJuJl9" style="text-align: right" title="Number of Exercisable Options"&gt;510,017&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z2evfla7Qt4" style="text-align: right" title="Aggregate Exercisable Options Value"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z8lU7wP9IYhf" style="text-align: right"&gt;2.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zZe7CuN7ybP6" style="text-align: right" title="Number of Outstanding Options"&gt;445,013&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zLhTnNHFK0j" style="text-align: right"&gt;9.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zwDNvdMzi6s2" style="text-align: right"&gt;672&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zNIKw2DIiwW6" style="text-align: right"&gt;174,208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z1TXSnL3ru7k" style="text-align: right"&gt;521&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zziuggCyAbF3" style="text-align: right"&gt;3.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zXpaNqHvtX13" style="text-align: right" title="Number of Outstanding Options"&gt;3,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvuZtvKy57B3" style="text-align: right"&gt;6.27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zE3q69EIIDYc" style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zSICuphcB5Ug" style="text-align: right"&gt;1,875&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zAxaQYg9prC5" style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zzgKfDknX7re" style="text-align: right"&gt;4.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zHDBhdy1z2e8" style="text-align: right" title="Number of Outstanding Options"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zz9bcZ1HDAA" style="text-align: right"&gt;6.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zAfiKgfooTsa" style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zbM0gX99XZy7" style="text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTCxm0HfXDb9" style="text-align: right"&gt;221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zua5M9f5Kwjc" style="text-align: right"&gt;4.5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zbIxZC0xCdFb" style="text-align: right" title="Number of Outstanding Options"&gt;34,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJJhg7ViLdEk" style="text-align: right"&gt;8.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zxPzOGqt9tAf" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2314"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zKYpcnIP3CA2" style="text-align: right"&gt;23,938&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zuR3G4xzwGo8" style="text-align: right"&gt;108&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zrtz3nBOVSl4" style="text-align: right"&gt;4.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zi1Jq9uNwzg5" style="text-align: right" title="Number of Outstanding Options"&gt;185,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zNdSHSEvJXUh" style="text-align: right"&gt;9.96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zqwyKX6tAvol" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2321"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zaB4oP2vrV6i" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2322"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_z3KEJ7E6TB4g" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2323"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zGoq2SXn28Vj" style="text-align: right"&gt;4.7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pp0i_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zTtdkdMRF9D5" style="text-align: right" title="Number of Outstanding Options"&gt;6,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zSVe3QPTBTk9" style="text-align: right"&gt;9.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zB5WBQL6dIUl" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2328"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z8M4560m5oEb" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2329"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z54JqtlcFFnd" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2330"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zaXCRz6LmYI9" style="text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zByoI54r79j6" style="text-align: right" title="Number of Outstanding Options"&gt;483,337&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zX6XYi0wSKS2" style="text-align: right"&gt;5.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z1RW0WBc41G6" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2335"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zLUJ1ygYDy8i" style="text-align: right"&gt;483,337&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zhXjTw0gsvgl" style="text-align: right"&gt;2,320&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zfFNf1Lmh8yf" style="text-align: right"&gt;5.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zMF2XZBxa3jl" style="text-align: right" title="Number of Outstanding Options"&gt;53,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zzonyXwmtLAe" style="text-align: right"&gt;8.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zZ5sgYFnjkY" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2342"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zBTf2tpIvD94" style="text-align: right"&gt;39,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zU7QOoLUpS2a" style="text-align: right"&gt;202&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z6jBUGwNk8v6" style="text-align: right"&gt;5.1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zBZdet3rU6Yh" style="text-align: right" title="Number of Outstanding Options"&gt;63,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zRHJmugJkFck" style="text-align: right"&gt;9.68&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zhXZzATa9Ss8" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2349"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zHilCuwxGo84" style="text-align: right"&gt;7,875&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zcodATh9AaOk" style="text-align: right"&gt;40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z86G3JEOVNr9" style="text-align: right"&gt;5.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zwNp4pEw8fQ2" style="text-align: right" title="Number of Outstanding Options"&gt;352,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zfHNOptExar2" style="text-align: right"&gt;7.26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zA1mWFNXcNJ6" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2356"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zP1LLSF4Mtuc" style="text-align: right"&gt;290,488&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zMpNwJzHG4Gd" style="text-align: right"&gt;1,740&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zuUYwnC0X5fa" style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zVwS6ErCiyTa" style="text-align: right" title="Number of Outstanding Options"&gt;16,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zSyQu6yR305h" style="text-align: right"&gt;3.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z9tAjFEecGda" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2363"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zlZ9fmmDFEIc" style="text-align: right"&gt;16,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z39Brmi8we8l" style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zv7NHJLAmtw8" style="text-align: right"&gt;6.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zVulO9w8euh5" style="text-align: right" title="Number of Outstanding Options"&gt;17,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z8RNlxcC2W1i" style="text-align: right"&gt;9.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zKnH7yGsrxn9" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2370"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zmIYUBzMpcYd" style="text-align: right"&gt;4,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zqlLmFqB3qi2" style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zw8ubJhwHO17" style="text-align: right"&gt;7.2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zONbllM7nOLc" style="text-align: right" title="Number of Outstanding Options"&gt;83,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zFDNG2zRevn7" style="text-align: right"&gt;6.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_znOihXEN96jl" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2377"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zBumwNDfbY28" style="text-align: right"&gt;83,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zj1GmtxQcMYc" style="text-align: right"&gt;600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zyrN5fuMbMU2" style="text-align: right"&gt;8.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zAcZWJKzTXu" style="text-align: right" title="Number of Outstanding Options"&gt;250,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zDILxQGP3fzd" style="text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_ztmamPyTtELk" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2384"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zsXyj2NXlY1i" style="text-align: right"&gt;250,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zpJuHxdUimm6" style="text-align: right"&gt;2,090&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_z76gvrXQeJdf" style="text-align: right"&gt;8.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zDhBuuQ0yyL8" style="text-align: right" title="Number of Outstanding Options"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_z74nX1crcePc" style="text-align: right"&gt;7.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_z7RM1Jq3y8Ah" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2391"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zXjHdoUuI6sd" style="text-align: right"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zQ3jAXaGiuv" style="text-align: right"&gt;134&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_z79o78OrNJ36" style="text-align: right"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zfO8tkwF6Zn" style="text-align: right" title="Number of Outstanding Options"&gt;20,834&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_ztIvFWPvSzhi" style="text-align: right"&gt;2.54&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zvOuCFgoJyLe" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2398"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zUwzO0SsLsCi" style="text-align: right"&gt;20,834&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zm81PGWFTiC5" style="text-align: right"&gt;187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zLDbWwX6rgF8" style="text-align: right"&gt;9.48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_z0aoY4XPQdl9" style="text-align: right" title="Number of Outstanding Options"&gt;58,908&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zzp1y3zqife6" style="text-align: right"&gt;1.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zNV3bqMD055k" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2405"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zOL8AZY6jqni" style="text-align: right"&gt;58,908&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zma966NkxPvl" style="text-align: right"&gt;558&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zGbmSBYIOg61" style="padding-bottom: 1.5pt; text-align: right"&gt;10.2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zgzKvQiMO9w6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Outstanding Options"&gt;39,267&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_z0i0XGzTN3O6" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1.42&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zgRRK1mvqLH2" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2412"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zbdB8XmT3Tx3" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,267&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zbyxob0ZdTu4" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;401&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zsDbzHu4diyh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding Options"&gt;2,917,667&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zx7nbitDplPd" style="border-bottom: Black 2.5pt double; text-align: right"&gt;5.98&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zdZNhbLeERj6" style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,006&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z6RenwmsaOAi" style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,299,937&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_ztKD6Ozzb14f" style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,263&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="USDPShares">0.0012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="Shares">230189</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceOneMember">P3Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceOneMember"
      decimals="-3"
      unitRef="USD">1036000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="Shares">230189</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceOneMember"
      decimals="-3"
      unitRef="USD">-0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="USDPShares">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="Shares">510017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwoMember">P1Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwoMember"
      decimals="-3"
      unitRef="USD">2289000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="Shares">510017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwoMember"
      decimals="-3"
      unitRef="USD">6000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="USDPShares">2.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="Shares">445013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThreeMember">P9Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThreeMember"
      decimals="-3"
      unitRef="USD">672000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="Shares">174208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThreeMember"
      decimals="-3"
      unitRef="USD">521000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourMember"
      decimals="INF"
      unitRef="USDPShares">3.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourMember"
      decimals="INF"
      unitRef="Shares">3750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourMember">P6Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourMember"
      decimals="-3"
      unitRef="USD">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourMember"
      decimals="INF"
      unitRef="Shares">1875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourMember"
      decimals="-3"
      unitRef="USD">6000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFiveMember"
      decimals="INF"
      unitRef="USDPShares">4.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFiveMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFiveMember">P6Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFiveMember"
      decimals="-3"
      unitRef="USD">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFiveMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFiveMember"
      decimals="-3"
      unitRef="USD">221000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixMember"
      decimals="INF"
      unitRef="USDPShares">4.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixMember"
      decimals="INF"
      unitRef="Shares">34000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixMember">P8Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixMember"
      decimals="INF"
      unitRef="Shares">23938</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixMember"
      decimals="-3"
      unitRef="USD">108000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSevenMember"
      decimals="INF"
      unitRef="USDPShares">4.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSevenMember"
      decimals="INF"
      unitRef="Shares">185300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSevenMember">P9Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEightMember"
      decimals="INF"
      unitRef="USDPShares">4.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEightMember"
      decimals="0"
      unitRef="Shares">6250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEightMember">P9Y10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineMember"
      decimals="INF"
      unitRef="USDPShares">4.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineMember"
      decimals="INF"
      unitRef="Shares">483337</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineMember">P5Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineMember"
      decimals="INF"
      unitRef="Shares">483337</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineMember"
      decimals="-3"
      unitRef="USD">2320000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTenMember"
      decimals="INF"
      unitRef="USDPShares">5.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTenMember"
      decimals="INF"
      unitRef="Shares">53250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTenMember">P8Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTenMember"
      decimals="INF"
      unitRef="Shares">39750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTenMember"
      decimals="-3"
      unitRef="USD">202000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceElevenMember"
      decimals="INF"
      unitRef="USDPShares">5.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceElevenMember"
      decimals="INF"
      unitRef="Shares">63000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceElevenMember">P9Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceElevenMember"
      decimals="INF"
      unitRef="Shares">7875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceElevenMember"
      decimals="-3"
      unitRef="USD">40000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwelveMember"
      decimals="INF"
      unitRef="USDPShares">5.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwelveMember"
      decimals="INF"
      unitRef="Shares">352550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwelveMember">P7Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwelveMember"
      decimals="INF"
      unitRef="Shares">290488</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwelveMember"
      decimals="-3"
      unitRef="USD">1740000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThirteenMember"
      decimals="INF"
      unitRef="USDPShares">6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThirteenMember"
      decimals="INF"
      unitRef="Shares">16667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThirteenMember">P3Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThirteenMember"
      decimals="INF"
      unitRef="Shares">16667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceThirteenMember"
      decimals="-3"
      unitRef="USD">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourteenMember"
      decimals="INF"
      unitRef="USDPShares">6.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourteenMember"
      decimals="INF"
      unitRef="Shares">17000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourteenMember">P9Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourteenMember"
      decimals="INF"
      unitRef="Shares">4250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFourteenMember"
      decimals="-3"
      unitRef="USD">29000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFifteenMember"
      decimals="INF"
      unitRef="USDPShares">7.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFifteenMember"
      decimals="INF"
      unitRef="Shares">83334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFifteenMember">P6Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFifteenMember"
      decimals="INF"
      unitRef="Shares">83334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceFifteenMember"
      decimals="-3"
      unitRef="USD">600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixteenMember"
      decimals="INF"
      unitRef="USDPShares">8.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixteenMember"
      decimals="INF"
      unitRef="Shares">250001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixteenMember">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixteenMember"
      decimals="INF"
      unitRef="Shares">250001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSixteenMember"
      decimals="-3"
      unitRef="USD">2090000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSeventeenMember"
      decimals="INF"
      unitRef="USDPShares">8.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSeventeenMember"
      decimals="INF"
      unitRef="Shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSeventeenMember">P7Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSeventeenMember"
      decimals="INF"
      unitRef="Shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceSeventeenMember"
      decimals="-3"
      unitRef="USD">134000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEighteenMember"
      decimals="INF"
      unitRef="USDPShares">9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEighteenMember"
      decimals="INF"
      unitRef="Shares">20834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEighteenMember">P2Y6M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEighteenMember"
      decimals="INF"
      unitRef="Shares">20834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceEighteenMember"
      decimals="-3"
      unitRef="USD">187000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineteenMember"
      decimals="INF"
      unitRef="USDPShares">9.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineteenMember"
      decimals="INF"
      unitRef="Shares">58908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineteenMember">P1Y6M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineteenMember"
      decimals="INF"
      unitRef="Shares">58908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceNineteenMember"
      decimals="-3"
      unitRef="USD">558000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwentyMember"
      decimals="INF"
      unitRef="USDPShares">10.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwentyMember"
      decimals="INF"
      unitRef="Shares">39267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwentyMember">P1Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwentyMember"
      decimals="INF"
      unitRef="Shares">39267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember_custom_ExercisePriceTwentyMember"
      decimals="-3"
      unitRef="USD">401000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Shares">2917667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember">P5Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="-3"
      unitRef="USD">4006000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="INF"
      unitRef="Shares">2299937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember"
      decimals="-3"
      unitRef="USD">9263000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesAndDirectorsMember"
      decimals="-3"
      unitRef="USD">1470000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToEmployeesAndDirectorsMember"
      decimals="-3"
      unitRef="USD">2107000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-012020-12-31_custom_MasthercellGlobalMember"
      decimals="INF"
      unitRef="Shares">450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2019-01-012019-12-31_custom_MasthercellGlobalMember"
      decimals="INF"
      unitRef="Shares">360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2020-12-31_custom_MasthercellGlobalMember"
      decimals="-3"
      unitRef="USD">1594000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2020-01-012020-12-31_custom_MasthercellGlobalMember">P2Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember">&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zrZwCVhUAEB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Below
is a table summarizing all the compensation granted to consultants and service providers during the years ended December 31, 2020
and December 31, 2019 and for the one-month period ended December 31, 2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8BE_zyaIvRYNcubb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify"&gt;SCHEDULE OF STOCK OPTIONS GRANTED TO CONSULTANTS&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;br/&gt;Year
    of grant&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;br/&gt;No.
    of options &lt;br/&gt; granted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;br/&gt;Exercise
    price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Vesting period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair
                                         value at grant&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(in
                                         thousands)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;br/&gt;Expiration
    &lt;br/&gt; period&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 8%; text-align: center"&gt;Non-employees &lt;br/&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: center"&gt;2020 &lt;br/&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zq9DlXJrIeng" style="width: 6%; text-align: right"&gt;62,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zanjnW2R8tDb"&gt;2.99&lt;/span&gt;-$&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z725VBpqLdzi"&gt;6.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 30%; text-align: center"&gt;Quarterly over a period of &lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zgFWgaOCBvi" title="Vesting peirod description"&gt;two&lt;/span&gt; years&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pp0p0_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z3QNkvR0SEUh" style="width: 14%; text-align: right"&gt;209&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: center"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zStftzty8WEh"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;Non-employees &lt;br/&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2019 &lt;br/&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_ztq9TlnZkUz1" style="text-align: right" title="No. of options granted"&gt;128,336&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z7jIjxUbX6rj" title="Exercise price"&gt;3.14&lt;/span&gt;-$&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zfRWQwgfkdrg" title="Exercise price"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Vest immediately-&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zJCsrnJgG7mi" title="Vesting period"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pp0p0_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zyvsGmIXHucc" style="text-align: right" title="Fair value at grant"&gt;394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zklPJev0kWDb" title="Expiration period"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Shares">62500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">2.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">6.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember">two</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="0"
      unitRef="USD">209</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember">P10Y</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Shares">128336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">3.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">7</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember">P5Y</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="0"
      unitRef="USD">394</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember">P10Y</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember">&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zcIP9njEhfD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The underlying data used for computing
the fair value of the options are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8B0_zJxkjABIydHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify"&gt;SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value of one common share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_907_eus-gaap--SharePrice_iI_pii_c20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zJVigMTWX45k" title="Value of one common share"&gt;2.99&lt;/span&gt;-$&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_pii_c20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zpRisG2jihca" title="Value of one common share"&gt;6.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_pii_c20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z4CFsUrPPvgd" title="Value of one common share"&gt;3.14&lt;/span&gt;-$&lt;span id="xdx_908_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z7Q6Fqa6nU5j" title="Value of one common share"&gt;5.07&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_uPercentage_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zCGG4SGYztWj" style="width: 18%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_uPercentage_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zIlUev5sQYfi" style="width: 18%; text-align: right" title="Dividend yield"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected stock price volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zEEBmNX0ugFa"&gt;86&lt;/span&gt;%-&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zzpOwg9Ve8De"&gt;89&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zqbMIBHnVT39" title="Expected stock price volatility"&gt;89&lt;/span&gt;%-&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zrpQJcpmFPL" title="Expected stock price volatility"&gt;92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zhYmeOySrEn9"&gt;0.73&lt;/span&gt;%-&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zKnvypQfvKO4"&gt;1.12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z4OaZ4mRlzf9" title="Risk free interest rate"&gt;1.52&lt;/span&gt;%-&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z3gtBPyAed2" title="Risk free interest rate"&gt;2.62&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zvBH53H5zF08"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zzioggVFdog1" title="Expected term (years)"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2020-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">2.99</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2020-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">6.84</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2019-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">3.14</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2019-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">5.07</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Percentage">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Percentage">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-012020-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Percentage">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-012020-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Percentage">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-01-012019-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Percentage">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-01-012019-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Percentage">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-012020-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Percentage">0.0073</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-012020-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Percentage">0.0112</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-01-012019-12-31_srt_MinimumMember_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Percentage">0.0152</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-01-012019-12-31_srt_MaximumMember_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Percentage">0.0262</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember">&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zbftw2pPvn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of the Company&#x2019;s stock options granted to consultants and service providers as of December 31, 2020, and December
31, 2019 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8BC_z5scIwsT27yf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify"&gt;SCHEDULE OF STOCK OPTIONS ACTIVITY&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: justify"&gt;Options outstanding at the &lt;br/&gt;beginning of the year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zMWWzXlkuf8b" style="width: 12%; text-align: right"&gt;598,310&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zMYVJ1dtg8vj" style="width: 12%; text-align: right"&gt;5.76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zQmxTi4o8My7" style="width: 12%; text-align: right" title="Number of Options - Options outstanding at the end of the year"&gt;469,974&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zLPGxTYap2vd" style="width: 12%; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the end of the year"&gt;5.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Changes during the year:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zsacUEIZps54" style="text-align: right"&gt;62,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z4m6jLMYhn81" style="text-align: right"&gt;3.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zjo8psJ0w978" style="text-align: right" title="Number of Options - Granted"&gt;128,336&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zD3WK7ymPaak" style="text-align: right" title="Weighted Average Exercise Price - Granted"&gt;5.65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zFGF3564i5qi" style="text-align: right" title="Number of Options - Exercised"&gt;(83,334&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zz9Bi03JMrgg" style="text-align: right" title="Weighted Average Exercise Price - Exercised"&gt;3.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zhSTkn5jm4vg" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2494"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zrhFkiUYRuvl" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2495"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zwKkzH5fQzUl" style="text-align: right"&gt;(8,335&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_ziOnnSoUSsUd" style="text-align: right"&gt;5.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zEmJt048ziR4" style="text-align: right" title="Number of Options - Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2499"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zDuFasT03jK" style="text-align: right" title="Weighted Average Exercise Price - Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2501"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zsYlJ5gHpanj" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(20,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_ziXt3pWgbXe5" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5.30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zbuZYe0hVNbb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options - Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2505"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zBmtnPDCceha" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price - Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2507"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Options outstanding at end of the year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zDPWZoMW9KL1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;549,141&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zBAZt4xBqfrl" style="border-bottom: Black 2.5pt double; text-align: right"&gt;5.89&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zL0TkJctr6g4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options outstanding at the end of the year"&gt;598,310&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z5X4sq1uxk27" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the end of the year"&gt;5.76&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Options exercisable at end of the year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zxZ8ISpM5Qkj" style="border-bottom: Black 2.5pt double; text-align: right"&gt;450,972&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zdHwM1ea4Ft1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;6.28&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zO82XaWp8604" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options exercisable at end of the year"&gt;539,515&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zCtk9ECpLhS3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options exercisable at end of the year"&gt;5.88&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Shares">598310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">5.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2018-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Shares">469974</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2018-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">5.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Shares">62500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">3.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Shares">128336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">5.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Shares">83334</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">3.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Shares">8335</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">5.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Shares">-20000</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod>
    <ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">5.30</ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Shares">549141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">5.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Shares">598310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">5.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Shares">450972</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">6.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2019-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Shares">539515</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">5.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember">&lt;p id="xdx_897_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zldnSpYcVwvi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table presents summary information concerning the options granted and exercisable to consultants and service providers
outstanding as of December 31, 2020 (in thousands, except per share data):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8B1_zvQLz8p6E7L2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify"&gt;SCHEDULE OF STOCK OPTIONS EXERCISABLE&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Value*&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Value $&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zjm9KeYw0zgf" style="width: 13%; text-align: right" title="Exercise Price"&gt;2.99&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zFsNJSwDApWg" style="width: 13%; text-align: right" title="Number of Outstanding Options"&gt;35,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zq3ZDJf4kH2" style="width: 13%; text-align: right" title="Weighted Average Remaining Contractual Life"&gt;9.22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zpIV6M23tDhk" style="width: 13%; text-align: right" title="Aggregate Intrinsic Value"&gt;53&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zonnfsenO1Ad" style="width: 13%; text-align: right" title="Number of Exercisable Options"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2531"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zvZhiXuQEK13" style="width: 13%; text-align: right" title="Aggregate Exercisable Options Value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2533"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zoWEcxO26Xr2" style="text-align: right"&gt;3.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z3K4Q79OQqbg" style="text-align: right" title="Number of Outstanding Options"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zVNabox3ktg7" style="text-align: right"&gt;8.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z9j6eSh0jVIa" style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zxoEyxXqf6yg" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2539"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zaSf0MMFK0hi" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2540"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zktbC9NK4TW6" style="text-align: right"&gt;3.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zCMVcnDHKi9f" style="text-align: right" title="Number of Outstanding Options"&gt;136,775&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zmtPk5bUnJpd" style="text-align: right"&gt;5.32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zn0bDOAAafo4" style="text-align: right"&gt;156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zIIhm7y6zio7" style="text-align: right"&gt;136,775&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zFHyytHLrxG4" style="text-align: right"&gt;460&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zOxNEUsbX702" style="text-align: right"&gt;4.09&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zgTFDIoUL233" style="text-align: right" title="Number of Outstanding Options"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zNJ3aWMz8Xl7" style="text-align: right"&gt;8.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zeEVsV31T7f3" style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zFOYn8Ir6nej" style="text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbZxy4FxBHnf" style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zWeNDczB3e78" style="text-align: right"&gt;4.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zeQON0tYgVP6" style="text-align: right" title="Number of Outstanding Options"&gt;10,325&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zdbqxxK1uYqg" style="text-align: right"&gt;6.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zSqHe0Ao7EQd" style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zR2WFvpSqTpl" style="text-align: right"&gt;10,325&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zhm9J98AUeX2" style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zkcADpZSds4k" style="text-align: right"&gt;4.5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zd5lv0i429O5" style="text-align: right" title="Number of Outstanding Options"&gt;13,335&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJSz7E0E76ob" style="text-align: right"&gt;8.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zBooPwUqqhOg" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2566"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zeeWGjZPl6y1" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2567"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_znd3nMZECIQ4" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2568"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zrP3TyPWJbJk" style="text-align: right"&gt;4.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zi0nUliJ5sgk" style="text-align: right" title="Number of Outstanding Options"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zJs5hiyQ5Q2f" style="text-align: right"&gt;9.96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zHHcqEqVmkIg" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2573"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zkzM1mNSEw66" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2574"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zVqIafo7IUal" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2575"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zaieSMzFpVql" style="text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zurwOxk9DNCl" style="text-align: right" title="Number of Outstanding Options"&gt;16,668&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zbWd7Mk8IIWj" style="text-align: right"&gt;5.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zSN3DyjkCwC8" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2580"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z9RaK704MHoj" style="text-align: right"&gt;16,668&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zY2FbABfI1Vg" style="text-align: right"&gt;80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zEg461Ebhqr5" style="text-align: right"&gt;5.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_ztlx2ItVxahe" style="text-align: right" title="Number of Outstanding Options"&gt;5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zO104xrrhPwg" style="text-align: right"&gt;8.19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z1rZAmEh70Lk" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2587"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zI6fMwT3gUIf" style="text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zjw3S2bpxcR" style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zNrlRTalEVHj" style="text-align: right"&gt;5.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zvkzRwm5Bruj" style="text-align: right" title="Number of Outstanding Options"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zAbI3yY5QC2e" style="text-align: right"&gt;7.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zEnyWF57eaU9" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2594"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z4Kpm9VUq672" style="text-align: right"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zVwvRKv5DJ3d" style="text-align: right"&gt;80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zgWb0dUriad6" style="text-align: right"&gt;5.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z1ji04xSMPxl" style="text-align: right" title="Number of Outstanding Options"&gt;16,670&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z3axaAYQ4rx8" style="text-align: right"&gt;7.81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_znaPAL9XofZ" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2601"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zxJraIVcjY8k" style="text-align: right"&gt;16,670&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zgI0vgGH2Y77" style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zZPMsU8ReXG1" style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zqO7LylWwdV4" style="text-align: right" title="Number of Outstanding Options"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_ze9lgJeZooXc" style="text-align: right"&gt;3.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zs0u9hDogXC" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2608"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zv9YQJLUgJmd" style="text-align: right"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zcF8hGPpjWG1" style="text-align: right"&gt;540&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zsQhIelhGvsf" style="text-align: right"&gt;6.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zAiTLyxIz4zb" style="text-align: right" title="Number of Outstanding Options"&gt;7,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zjP14kh3Zcs" style="text-align: right"&gt;9.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z7xRGhD5QDO5" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2615"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zqZETXPG2fUj" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2616"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z52vcHID7zy1" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2617"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z8BknISK8yNa" style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zlGerKsKT0Kb" style="text-align: right" title="Number of Outstanding Options"&gt;70,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z82nupvXIEC9" style="text-align: right"&gt;8.83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z7Qs3uB9N123" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2622"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zi3znQaa68cd" style="text-align: right"&gt;70,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zftRam9AvoSb" style="text-align: right"&gt;490&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zw4q5x4zBfXa" style="text-align: right"&gt;7.32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z4zo18qwcyS6" style="text-align: right" title="Number of Outstanding Options"&gt;8,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z6B57Re75uD2" style="text-align: right"&gt;1.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z4NJZnHEe9W4" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2629"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zJFfvXx4XJCh" style="text-align: right"&gt;8,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zGdeGtxb7y5e" style="text-align: right"&gt;61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_z0Ic6KJ8XcU8" style="text-align: right"&gt;8.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zeNExxZhoBk6" style="text-align: right" title="Number of Outstanding Options"&gt;8,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zJY5o9pyAd51" style="text-align: right"&gt;7.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_z31WZzfFzHle" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2636"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zDb2jKC1BLPa" style="text-align: right"&gt;8,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zLz7ySnhSeEa" style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zfaV4M7ePToa" style="text-align: right"&gt;8.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_znuZvBMVskeg" style="text-align: right" title="Number of Outstanding Options"&gt;8,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zgFzWN7WAT8e" style="text-align: right"&gt;7.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zp69PYYZoIUh" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2643"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zc90HE6kBMUg" style="text-align: right"&gt;4,999&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zg0koyS616p4" style="text-align: right"&gt;42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zttaeVMJ2mmc" style="text-align: right"&gt;11.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_z6ojrK2VDqe" style="text-align: right" title="Number of Outstanding Options"&gt;8,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zrmW1ph8Acba" style="text-align: right"&gt;2.26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zBIQUnU5xsl" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2650"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zIgegUeSGUC" style="text-align: right"&gt;8,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_z2cgXQaWRDM" style="text-align: right"&gt;96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zmFRHLn4lQU8" style="padding-bottom: 1.5pt; text-align: right"&gt;16.8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zpWfNgNoTnra" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Outstanding Options"&gt;39,267&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zpcmqwo8y4k4" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1.28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zAjvcELcwlfa" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2657"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zYAWvkc5Qpv8" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,267&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zvMnWacbflx2" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;660&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zXPtMpBpMvO4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding Options"&gt;549,141&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z4hKvDKamxN2" style="border-bottom: Black 2.5pt double; text-align: right"&gt;6.18&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z7jEda9Q4WG8" style="border-bottom: Black 2.5pt double; text-align: right"&gt;240&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zJN4C00E9KHf" style="border-bottom: Black 2.5pt double; text-align: right"&gt;450,972&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zAMCvEmSYO3" style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,834&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="USDPShares">2.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="Shares">35000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceOneMember">P9Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceOneMember"
      decimals="-3"
      unitRef="USD">53000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="USDPShares">3.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="Shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwoMember">P8Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwoMember"
      decimals="-3"
      unitRef="USD">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="USDPShares">3.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="Shares">136775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThreeMember">P5Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThreeMember"
      decimals="-3"
      unitRef="USD">156000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThreeMember"
      decimals="INF"
      unitRef="Shares">136775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThreeMember"
      decimals="-3"
      unitRef="USD">460000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourMember"
      decimals="INF"
      unitRef="USDPShares">4.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourMember">P8Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourMember"
      decimals="-3"
      unitRef="USD">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourMember"
      decimals="-3"
      unitRef="USD">102000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFiveMember"
      decimals="INF"
      unitRef="USDPShares">4.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFiveMember"
      decimals="INF"
      unitRef="Shares">10325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFiveMember">P6Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFiveMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFiveMember"
      decimals="INF"
      unitRef="Shares">10325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFiveMember"
      decimals="-3"
      unitRef="USD">46000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixMember"
      decimals="INF"
      unitRef="USDPShares">4.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixMember"
      decimals="INF"
      unitRef="Shares">13335</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixMember">P8Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSevenMember"
      decimals="INF"
      unitRef="USDPShares">4.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSevenMember"
      decimals="INF"
      unitRef="Shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSevenMember">P9Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEightMember"
      decimals="INF"
      unitRef="USDPShares">4.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEightMember"
      decimals="INF"
      unitRef="Shares">16668</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEightMember">P5Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEightMember"
      decimals="INF"
      unitRef="Shares">16668</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEightMember"
      decimals="-3"
      unitRef="USD">80000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineMember"
      decimals="INF"
      unitRef="USDPShares">5.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineMember"
      decimals="INF"
      unitRef="Shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineMember">P8Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineMember"
      decimals="INF"
      unitRef="Shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineMember"
      decimals="-3"
      unitRef="USD">5000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTenMember"
      decimals="INF"
      unitRef="USDPShares">5.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTenMember"
      decimals="INF"
      unitRef="Shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTenMember">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTenMember"
      decimals="INF"
      unitRef="Shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTenMember"
      decimals="-3"
      unitRef="USD">80000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceElevenMember"
      decimals="INF"
      unitRef="USDPShares">5.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceElevenMember"
      decimals="INF"
      unitRef="Shares">16670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceElevenMember">P7Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceElevenMember"
      decimals="INF"
      unitRef="Shares">16670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceElevenMember"
      decimals="-3"
      unitRef="USD">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwelveMember"
      decimals="INF"
      unitRef="USDPShares">6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwelveMember"
      decimals="INF"
      unitRef="Shares">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwelveMember">P3Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwelveMember"
      decimals="INF"
      unitRef="Shares">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceTwelveMember"
      decimals="-3"
      unitRef="USD">540000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThirteenMember"
      decimals="INF"
      unitRef="USDPShares">6.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThirteenMember"
      decimals="INF"
      unitRef="Shares">7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceThirteenMember">P9Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourteenMember"
      decimals="INF"
      unitRef="USDPShares">7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourteenMember"
      decimals="INF"
      unitRef="Shares">70000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourteenMember">P8Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourteenMember"
      decimals="INF"
      unitRef="Shares">70000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFourteenMember"
      decimals="-3"
      unitRef="USD">490000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFifteenMember"
      decimals="INF"
      unitRef="USDPShares">7.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFifteenMember"
      decimals="INF"
      unitRef="Shares">8334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFifteenMember">P1Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFifteenMember"
      decimals="INF"
      unitRef="Shares">8334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceFifteenMember"
      decimals="-3"
      unitRef="USD">61000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixteenMember"
      decimals="INF"
      unitRef="USDPShares">8.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixteenMember"
      decimals="INF"
      unitRef="Shares">8600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixteenMember">P7Y6M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixteenMember"
      decimals="INF"
      unitRef="Shares">8600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSixteenMember"
      decimals="-3"
      unitRef="USD">72000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSeventeenMember"
      decimals="INF"
      unitRef="USDPShares">8.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSeventeenMember"
      decimals="INF"
      unitRef="Shares">8333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSeventeenMember">P7Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSeventeenMember"
      decimals="INF"
      unitRef="Shares">4999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceSeventeenMember"
      decimals="-3"
      unitRef="USD">42000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEighteenMember"
      decimals="INF"
      unitRef="USDPShares">11.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEighteenMember"
      decimals="INF"
      unitRef="Shares">8334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEighteenMember">P2Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEighteenMember"
      decimals="INF"
      unitRef="Shares">8334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceEighteenMember"
      decimals="-3"
      unitRef="USD">96000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineteenMember"
      decimals="INF"
      unitRef="USDPShares">16.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineteenMember"
      decimals="INF"
      unitRef="Shares">39267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineteenMember">P1Y3M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineteenMember"
      decimals="INF"
      unitRef="Shares">39267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember_custom_ExercisePriceNineteenMember"
      decimals="-3"
      unitRef="USD">660000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Shares">549141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember">P6Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="-3"
      unitRef="USD">240000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="INF"
      unitRef="Shares">450972</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="-3"
      unitRef="USD">2834000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="-3"
      unitRef="USD">113000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-012019-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="-3"
      unitRef="USD">330000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2020-12-31_custom_OptionsGrantedToNonEmployeesMember"
      decimals="-3"
      unitRef="USD">231000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember">P4Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2020-01-192020-01-20_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">2200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2020-01-20_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="USDPShares">4.20</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-01-20_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-01-20_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="USDPShares">5.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ORGS:WarrantExercisableDescription contextRef="From2020-01-192020-01-20_custom_SecuritiesPurchaseAgreementMember">exercisable between June
2021 and January 2023.</ORGS:WarrantExercisableDescription>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2020-01-192020-01-20_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      unitRef="USD">9200000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2020-01-20_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      unitRef="USD">800000</us-gaap:DeferredOfferingCosts>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-01-192020-01-20_custom_SecuritiesPurchaseAgreementMember"
      decimals="-3"
      unitRef="USD">1911000</us-gaap:FairValueAdjustmentOfWarrants>
    <ORGS:AggregateAmountOfSubscriptionAgreement
      contextRef="AsOf2020-01-02_custom_PrivatePlacementSubscriptionAgreementsMember"
      decimals="-3"
      unitRef="USD">250000</ORGS:AggregateAmountOfSubscriptionAgreement>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2020-01-02_custom_PrivatePlacementSubscriptionAgreementsMember"
      decimals="INF"
      unitRef="USDPShares">7.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-01-02_custom_PrivatePlacementSubscriptionAgreementsMember"
      decimals="INF"
      unitRef="Shares">151428</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-01-02_custom_PrivatePlacementSubscriptionAgreementsMember"
      decimals="INF"
      unitRef="USDPShares">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-01-012020-01-02_custom_PrivatePlacementSubscriptionAgreementsMember"
      decimals="-3"
      unitRef="USD">210000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-012020-12-31_custom_NonEmployeesMember_custom_SeveralConsultantsMember"
      decimals="INF"
      unitRef="Shares">193178</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="From2020-01-012020-12-31_custom_NonEmployeesMember_custom_SeveralConsultantsMember"
      decimals="INF"
      unitRef="USDPShares">3.14</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2020-01-012020-12-31_custom_NonEmployeesMember_custom_SeveralConsultantsMember"
      decimals="INF"
      unitRef="USDPShares">5.34</us-gaap:WarrantExercisePriceIncrease>
    <ORGS:WarrantsAndRightsOutstandingTermDescription contextRef="From2020-01-012020-12-31_custom_NonEmployeesMember_custom_SeveralConsultantsMember">three years</ORGS:WarrantsAndRightsOutstandingTermDescription>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2020-01-012020-12-31_custom_NonEmployeesMember_custom_SeveralConsultantsMember"
      decimals="-3"
      unitRef="USD">378000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2020-01-012020-12-31_custom_NonEmployeesMember_custom_ConvertibleNotesAndPrivateInvestmentMember"
      decimals="-3"
      unitRef="USD">350000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-012020-12-31_custom_NonEmployeesMember_custom_ConvertibleNotesAndPrivateInvestmentMember"
      decimals="INF"
      unitRef="Shares">179428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <ORGS:ClassOfWarrantOrRightGrantsInPeriod
      contextRef="From2019-01-012019-12-31_custom_SeveralConsultantsMember"
      decimals="INF"
      unitRef="Shares">88499</ORGS:ClassOfWarrantOrRightGrantsInPeriod>
    <ORGS:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_srt_MinimumMember_custom_SeveralConsultantsMember"
      decimals="INF"
      unitRef="USDPShares">4.3</ORGS:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice>
    <ORGS:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_srt_MaximumMember_custom_SeveralConsultantsMember"
      decimals="INF"
      unitRef="USDPShares">7.00</ORGS:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice>
    <ORGS:ClassOfWarrantOrRightGrantsInPeriodFairValue
      contextRef="From2019-01-012019-12-31_custom_SeveralConsultantsMember"
      decimals="-3"
      unitRef="USD">155000</ORGS:ClassOfWarrantOrRightGrantsInPeriodFairValue>
    <ORGS:ClassOfWarrantOrRightGrantsInPeriodFairValue
      contextRef="From2019-01-012019-12-31_custom_SuccessFeeMember"
      decimals="-3"
      unitRef="USD">97000</ORGS:ClassOfWarrantOrRightGrantsInPeriodFairValue>
    <ORGS:ClassOfWarrantOrRightGrantsInPeriod
      contextRef="From2019-01-012019-12-31_custom_SuccessFeeMember"
      decimals="INF"
      unitRef="Shares">57142</ORGS:ClassOfWarrantOrRightGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2019-09-012019-09-30_custom_InvestorRelationContactMember"
      decimals="INF"
      unitRef="Shares">40174</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2019-09-012019-09-30_custom_HeldUntilSixMonthsAnniversaryMember_custom_InvestorRelationContactMember"
      decimals="INF"
      unitRef="Shares">20087</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2019-09-012019-09-30_custom_HeldUntilOneYearAnniversaryMember_custom_InvestorRelationContactMember"
      decimals="INF"
      unitRef="Shares">20087</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-09-092019-09-30_custom_InvestorRelationContactMember"
      decimals="-3"
      unitRef="USD">178000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <ORGS:FairValueOfSharesRecognizedOnGrantDate contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">96000</ORGS:FairValueOfSharesRecognizedOnGrantDate>
    <ORGS:FairValueOfSharesRecognizedOnGrantDate contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">82000</ORGS:FairValueOfSharesRecognizedOnGrantDate>
    <ORGS:JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted
      contextRef="From2019-03-012019-03-31_custom_FirstChoiceInternationalCompanyIncMember"
      decimals="INF"
      unitRef="Shares">525000</ORGS:JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-01-012019-12-31_custom_FirstChoiceInternationalCompanyIncMember"
      decimals="-5"
      unitRef="USD">2600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2018-12-012018-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <ORGS:NumberOfVestedShares
      contextRef="AsOf2018-12-31_custom_VestedOnSigningDateMember_custom_InvestorRelationContactMember_custom_ConsultantMember"
      decimals="INF"
      unitRef="Shares">2500</ORGS:NumberOfVestedShares>
    <ORGS:NumberOfVestedShares
      contextRef="AsOf2018-12-31_custom_VestMonthlyOver3MonthsMember_custom_InvestorRelationContactMember_custom_ConsultantMember"
      decimals="0"
      unitRef="Shares">7500</ORGS:NumberOfVestedShares>
    <ORGS:NumberOfVestedShares
      contextRef="AsOf2019-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember"
      decimals="INF"
      unitRef="Shares">10000</ORGS:NumberOfVestedShares>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-12-012019-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember"
      decimals="-3"
      unitRef="USD">51000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <ORGS:FairValueOfSharesOnVestingDatesRecognizedDuringYear
      contextRef="From2019-01-012019-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember"
      decimals="-3"
      unitRef="USD">37000</ORGS:FairValueOfSharesOnVestingDatesRecognizedDuringYear>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2018-12-012018-12-31_custom_SeparateInvestorRelationsContactMember_custom_ConsultantMember"
      decimals="INF"
      unitRef="Shares">40000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <ORGS:NumberOfVestedShares
      contextRef="AsOf2018-12-31_custom_VestedOnSigningDateMember_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember"
      decimals="INF"
      unitRef="Shares">6667</ORGS:NumberOfVestedShares>
    <ORGS:NumberOfVestedShares
      contextRef="AsOf2018-12-31_custom_VestMonthlyOver3MonthsMember_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember"
      decimals="0"
      unitRef="Shares">33333</ORGS:NumberOfVestedShares>
    <ORGS:NumberOfVestedShares
      contextRef="AsOf2019-12-31_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember"
      decimals="INF"
      unitRef="Shares">40000</ORGS:NumberOfVestedShares>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-12-012019-12-31_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember"
      decimals="-3"
      unitRef="USD">200000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <ORGS:FairValueOfSharesOnVestingDatesRecognizedDuringYear
      contextRef="From2019-01-012019-12-31_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember"
      decimals="-3"
      unitRef="USD">163000</ORGS:FairValueOfSharesOnVestingDatesRecognizedDuringYear>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2018-11-30_custom_SeveralConsultantsMember"
      decimals="INF"
      unitRef="Shares">78782</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="From2018-11-292018-11-30_custom_SeveralConsultantsMember"
      decimals="INF"
      unitRef="USDPShares">6.24</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2018-11-292018-11-30_custom_SeveralConsultantsMember"
      decimals="INF"
      unitRef="USDPShares">15.41</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2018-11-292018-11-30_custom_SeveralConsultantsMember"
      decimals="-3"
      unitRef="USD">350000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2018-01-012018-01-31_custom_ConsultingAgreementMember_custom_ConsultantMember"
      decimals="0"
      unitRef="USD">60</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2018-01-012018-01-31_custom_ConsultingAgreementMember_custom_ConsultantMember"
      decimals="INF"
      unitRef="Shares">19000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2018-01-31_custom_ConsultingAgreementMember_custom_ConsultantMember"
      decimals="INF"
      unitRef="USDPShares">6.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2018-01-012018-01-31_custom_ConsultingAgreementMember_custom_ConsultantMember"
      decimals="-3"
      unitRef="USD">171000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2018-01-012018-01-31_custom_ConsultingAgreementMember_custom_ConsultantMember"
      decimals="-3"
      unitRef="USD">62000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2018-07-012018-07-31_custom_ConsultingAgreementMember_custom_ConsultantMember"
      decimals="INF"
      unitRef="Shares">6629</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2018-07-31_custom_ConsultingAgreementMember_custom_ConsultantMember"
      decimals="INF"
      unitRef="Shares">6629</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2018-07-31_custom_ConsultingAgreementMember_custom_ConsultantMember"
      decimals="INF"
      unitRef="USDPShares">6.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2018-07-012018-07-31_custom_ConsultingAgreementMember_custom_ConsultantMember"
      decimals="0"
      unitRef="USD">88</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2017-12-012017-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember"
      decimals="INF"
      unitRef="Shares">195000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <ORGS:NumberOfVestedShares
      contextRef="AsOf2017-12-31_custom_VestedOnSigningDateMember_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember"
      decimals="INF"
      unitRef="Shares">50000</ORGS:NumberOfVestedShares>
    <ORGS:NumberOfVestedShares
      contextRef="AsOf2017-12-31_custom_VestMonthlyOver3MonthsMember_custom_SeparateInvestorRelationContactMember_custom_ConsultantMember"
      decimals="0"
      unitRef="Shares">145000</ORGS:NumberOfVestedShares>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2017-12-012017-12-31_custom_InvestorRelationContactMember_custom_ConsultantMember"
      decimals="-3"
      unitRef="USD">1439000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">270174</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <ORGS:NumberOfAdditionalSharesRestrictionsOnTransfer
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Shares">30000</ORGS:NumberOfAdditionalSharesRestrictionsOnTransfer>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_zgc6SFYi2Hbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
16 &#x2013; &lt;span id="xdx_823_zdBFmTGxF39h"&gt;TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;a.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Corporate
    taxation in the U.S.&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
corporate U.S. Federal Income tax rate applicable to the Company and its US subsidiaries is &lt;span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercentage_c20200101__20201231__srt--StatementGeographicalAxis__country--US_zvSqlUnoCDo5" title="Effective income tax rate reconciliation, at income tax rate"&gt;21%&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of December 31, 2020, the Company has an accumulated tax loss carryforward of approximately $ &lt;span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20201231_zvnQWbP5ivVg"&gt;18
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million (as of December 31, 2019,
approximately $&lt;span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20191231_zYrfI1zw54xj"&gt;34&lt;/span&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20200101__20201231__srt--StatementGeographicalAxis__country--US" title="Operating loss carryforwards, limitations on use"&gt;For
U.S. federal income tax purposes, net operating losses (&#x201c;NOLs&#x201d;) arising in tax years beginning after December 31,
2017, the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;) limits the ability to utilize NOL carryforwards to
80% of taxable income in tax years beginning after December 31, 2020.&lt;/span&gt; In addition, NOLs arising in tax years ending after December
31, 2017 can be carried forward indefinitely, but carryback is generally prohibited. NOLs generated in tax years beginning before
January 1, 2018 will not be subject to the taxable income limitation, and NOLs generated in tax years ending before January 1,
2018 will continue to have a two-year carryback and twenty-year carryforward period. Deferred tax assets for NOLs will need to
be measured at the applicable tax rate in effect when the NOL is expected to be utilized. The changes in the carryforward/carryback
periods as well as the new limitation on use of NOLs may significantly impact the Company&#x2019;s valuation allowance assessments
for NOLs generated after December 31, 2017.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
addition, utilization of the NOLs may be subject to substantial annual limitation under Section 382 of the Code due to an &#x201c;ownership
change&#x201d; within the meaning of Section 382(g) of the Code. An ownership change, subjects pre-ownership change NOLs carryforwards
to an annual limitation, which significantly restricts the ability to use them to offset taxable income in periods following the
ownership change. In general, the annual use limitation equals the aggregate value of the Company&#x2019;s stock at the time of
the ownership change multiplied by a specified tax-exempt interest rate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the &#x201c;CARES Act&#x201d;) was enacted into law. The
CARES Act is aimed at providing emergency relief and health care for individuals and businesses affected by the COVID-19 pandemic.
The CARES Act, among other things, includes provisions related to refundable payroll tax credits, deferral of the employer portion
of social security payments, expanded net operating loss application, modifications to the net interest deduction limitations,
and technical corrections to tax depreciation methods for qualified improvement property. The CARES act allowed the Company to
utilize 100% of NOLs arising in tax years after December 31, 2017. The Company assess all other provisions of the CARES Act and
notes no other material impact to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;b.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Corporate
    taxation in Israel&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Israeli Subsidiaries are taxed in accordance with Israeli tax laws. The corporate tax rate applicable to 2020 and 2019 are &lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercentage_c20200101__20201231__srt--StatementGeographicalAxis__country--IL_zfC2oMpOFwfl" title="Effective income tax rate reconciliation, at income tax rate"&gt;&lt;span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercentage_c20190101__20191231__srt--StatementGeographicalAxis__country--IL_z9mE9zgMWA27" title="Effective income tax rate reconciliation, at income tax rate"&gt;23%&lt;/span&gt;&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of December 31, 2020, the Israeli Subsidiaries has an accumulated tax loss carryforward of approximately $&lt;span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pin6_c20201231__srt--StatementGeographicalAxis__country--IL_zA26Da8kwIp8" title="Operating loss carryforwards"&gt;11&lt;/span&gt; million (as of December
31, 2019, approximately $&lt;span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pin6_c20191231__srt--StatementGeographicalAxis__country--IL_zao3Ibx3Xfhe" title="Operating loss carryforwards"&gt;10&lt;/span&gt; million). Under the Israeli tax laws, carryforward tax losses have no expiration date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;c.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Corporate
taxation in Belgium&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Belgian Subsidiary are taxed according to Belgian tax laws. The corporate tax rates applicable to  2020, 2019
are &lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercentage_c20200101__20201231__srt--StatementGeographicalAxis__country--BE__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyOneToTwoThousandTwentyMember_zPzwHLKe2y0h"&gt;25%
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and &lt;span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercentage_c20190101__20191231__srt--StatementGeographicalAxis__country--BE_zvMZu66v1zF5"&gt;29.58%,
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of December 31, 2020, the Belgian Subsidiary has an accumulated tax loss carryforward of approximately $ &lt;span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pin6_c20201231__srt--StatementGeographicalAxis__country--BE_ztKmAzH7EHcf"&gt;8
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million (&#x20ac; &lt;span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pin6_uEUR_c20201231__srt--StatementGeographicalAxis__country--BE__us-gaap--AwardTypeAxis__srt--EuropeMember_z64hQwO0QK2i"&gt;6
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million), (as of December 31, 2019 $&lt;span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pin6_c20191231__srt--StatementGeographicalAxis__country--BE_zhnpymgbxTc4"&gt;6
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million). Under the Belgian tax laws there
are limitation on accumulated tax loss carryforward deductions of Euro &lt;span id="xdx_905_ecustom--AccumulatedTaxLossCarryforwardDeductions_iI_pin6_uEUR_c20201231__srt--StatementGeographicalAxis__country--BE__us-gaap--AwardTypeAxis__srt--EuropeMember_z6nV2q6VzjY4"&gt;1
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million per year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;d.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Corporate
    taxation in Korea&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
basic Korean corporate tax rates are currently: &lt;span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember_zlmYfvNcz0y" title="Effective income tax rate reconciliation, at income tax rate"&gt;10%&lt;/span&gt; on the first KRW 200 million of the tax base, &lt;span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--UpToKrwTwoZeroBillionMember_znQrRJ88tJP5" title="Effective income tax rate reconciliation, at income tax rate"&gt;20%&lt;/span&gt; up to KRW 20 billion, &lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--UpToKrwThreeZeroZeroBillionMember_zKLZJPdoTzW7" title="Effective income tax rate reconciliation, at income tax rate"&gt;22%&lt;/span&gt;
up to KRW 300 billion and &lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--TaxBaseAboveKrwThreeZeroZeroBillionMember_zFjZ2f7e5r0l" title="Effective income tax rate reconciliation, at income tax rate"&gt;25%&lt;/span&gt; for tax base above KRW 300 billion. In addition, the local income tax rate is &lt;span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercentage_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember_zRBrOoNLT9f" title="Effective income tax rate reconciliation, at local income tax rate"&gt;1%&lt;/span&gt; on the first KRW
200 million of taxable income, &lt;span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercentage_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--UpToKrwTwoZeroBillionMember_z1LZEOs8cNjd" title="Effective income tax rate reconciliation, at local income tax rate"&gt;2%&lt;/span&gt; on taxable income over KRW 200 million up to KRW 20 billion, &lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercentage_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--UpToKrwThreeZeroZeroBillionMember_zO7j5qn1X9Sb" title="Effective income tax rate reconciliation, at local income tax rate"&gt;2.2%&lt;/span&gt; of taxable income over KRW
20 billion up to 300 billion and &lt;span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercentage_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--TaxBaseAboveKrwThreeZeroZeroBillionMember_zLHLaSVq83Tk" title="Effective income tax rate reconciliation, at local income tax rate"&gt;2.5%&lt;/span&gt; on taxable income over KRW 300 billion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of December 31, 2020, the Korean subsidiary has an accumulated tax loss carryforward of approximately $ &lt;span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_pin6_c20201231__srt--StatementGeographicalAxis__country--KR_zvKetHp1cF9l"&gt;4
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million (KRW &lt;span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pin6_uKRW_c20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--AwardTypeAxis__custom--SouthKoreanWonMember_zeUF2PMi5vZ9"&gt;3,813
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million), (as of December 31, 2019,
approximately $&lt;span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pin6_c20191231__srt--StatementGeographicalAxis__country--KR_zOzKCiGFCds5"&gt;3
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million). Under the Korean tax laws accumulated
tax loss can be carry forwarded for &lt;span id="xdx_90B_ecustom--AccumulatedTaxLossCarryForwardedPeriod_dtY_c20200101__20201231__srt--StatementGeographicalAxis__country--KR_zQEcnKBSHTHb"&gt;15
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;e.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Deferred
    Taxes&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zeqE89lKRzJ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table presents summary of information concerning the Company&#x2019;s deferred taxes as of the years ending December
31, 2019 and December 31, 2019 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B1_z766Or12sSuc" style="display: none"&gt;SCHEDULE OF DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20201231_zXZFQuv0fVj3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20191231_zDgTmK3N8vic" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;(U.S. dollars in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_msDTLztYm_zgBPVCDGywNa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Net operating loss carry forwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;9,606&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;14,033&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_msDTLztYm_zCrXy6rt04M4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,684&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_msDTLztYm_zTg18Jn9qUm6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Equity compensation &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,747&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2841"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_iI_pn3n3_msDTLztYm_zXn3SAkGPgU6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Employee benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;228&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsLeasesAsset_iI_pn3n3_msDTLztYm_z11i1Jih1eP9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leases asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;533&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2847"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--DeferredTaxAssetsLeaseLiability_iNI_pn3n3_di_maDTLztYm_zjVBpvnsc7q9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(324&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2850"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_pn3n3_di_maDTLztYm_zwCugWd6HsWa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,863&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(737&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_msDTLztYm_zkJGG3QCpJbc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;297&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_maDTLztYm_zcpm0JO7Gs46" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(11,932&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,939&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxLiabilities_iNTI_pn3n3_di_mtDTLztYm_zMJuAwQKEokj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2861"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(58&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A4_z1DdpOkxSl4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Realization
of deferred tax assets is contingent upon sufficient future taxable income during the period that deductible temporary differences
and carry forwards losses are expected to be available to reduce taxable income. As the achievement of required future taxable
income is not considered more likely than not achievable, the Company and all its subsidiaries except the Korean Subsidiary (previously
CureCell) have recorded full valuation allowance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--SummaryOfValuationAllowanceTextBlock_zaZcptbl3pD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
changes in valuation allowance are comprised as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BF_zI2Sac4A7VW4" style="display: none"&gt;SCHEDULE OF VALUATION ALLOWANCE, ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;(U.S dollars in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Balance at the beginning of year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20200101__20201231_z4UsOo810krg" style="width: 18%; text-align: right" title="Balance at the beginning of year"&gt;(14,939&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20190101__20191231_zj5TStugVh28" style="width: 18%; text-align: right" title="Balance at the beginning of year"&gt;(10,254&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20200101__20201231_zUge94j55QWg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change during the year"&gt;3,007&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20190101__20191231_zjtjNj8oM515" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change during the year"&gt;(4,685&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Balance at end of year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20200101__20201231_zKy9h85KJWOe" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of year"&gt;(11,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20190101__20191231_z0lEzw0xdTTf" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of year"&gt;(14,939&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AC_zaPljoTAvhri" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;f.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Reconciliation
    of the Theoretical Tax Expense to Actual Tax Expense&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
main reconciling item between the statutory tax rate of the Company and the effective rate is the provision for valuation allowance
with respect to tax benefits from carry forward tax losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;g.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Uncertain
    Tax Provisions&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;ASC
Topic 740, &#x201c;Income Taxes&#x201d; requires significant judgment in determining what constitutes an individual tax position
as well as assessing the outcome of each tax position. Changes in judgment as to recognition or measurement of tax positions can
materially affect the estimate of the effective tax rate and consequently, affect the operating results of the Company. As of
December 31, 2020, the Company has not accrued a provision for uncertain tax positions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2020-01-012020-12-31_country_US"
      decimals="INF"
      unitRef="Percentage">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2020-12-31" decimals="-6" unitRef="USD">18000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2019-12-31" decimals="-6" unitRef="USD">34000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse contextRef="From2020-01-012020-12-31_country_US">For
U.S. federal income tax purposes, net operating losses (&#x201c;NOLs&#x201d;) arising in tax years beginning after December 31,
2017, the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;) limits the ability to utilize NOL carryforwards to
80% of taxable income in tax years beginning after December 31, 2020.</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2020-01-012020-12-31_country_IL"
      decimals="INF"
      unitRef="Percentage">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2019-01-012019-12-31_country_IL"
      decimals="INF"
      unitRef="Percentage">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2020-12-31_country_IL"
      decimals="0"
      unitRef="USD">11000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2019-12-31_country_IL"
      decimals="0"
      unitRef="USD">10000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2020-01-012020-12-31_country_BE_custom_TwoThousandTwentyOneToTwoThousandTwentyMember"
      decimals="INF"
      unitRef="Percentage">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2019-01-012019-12-31_country_BE"
      decimals="INF"
      unitRef="Percentage">0.2958</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2020-12-31_country_BE"
      decimals="0"
      unitRef="USD">8000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2020-12-31_country_BE_srt_EuropeMember"
      decimals="0"
      unitRef="EUR">6000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2019-12-31_country_BE"
      decimals="0"
      unitRef="USD">6000000</us-gaap:OperatingLossCarryforwards>
    <ORGS:AccumulatedTaxLossCarryforwardDeductions
      contextRef="AsOf2020-12-31_country_BE_srt_EuropeMember"
      decimals="0"
      unitRef="EUR">1000000</ORGS:AccumulatedTaxLossCarryforwardDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2020-01-012020-12-31_country_KR_custom_TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember"
      decimals="INF"
      unitRef="Percentage">0.10</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2020-01-012020-12-31_country_KR_custom_UpToKrwTwoZeroBillionMember"
      decimals="INF"
      unitRef="Percentage">0.20</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2020-01-012020-12-31_country_KR_custom_UpToKrwThreeZeroZeroBillionMember"
      decimals="INF"
      unitRef="Percentage">0.22</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2020-01-012020-12-31_country_KR_custom_TaxBaseAboveKrwThreeZeroZeroBillionMember"
      decimals="INF"
      unitRef="Percentage">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2020-01-012020-12-31_country_KR_custom_TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember"
      decimals="INF"
      unitRef="Percentage">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2020-01-012020-12-31_country_KR_custom_UpToKrwTwoZeroBillionMember"
      decimals="INF"
      unitRef="Percentage">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2020-01-012020-12-31_country_KR_custom_UpToKrwThreeZeroZeroBillionMember"
      decimals="INF"
      unitRef="Percentage">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2020-01-012020-12-31_country_KR_custom_TaxBaseAboveKrwThreeZeroZeroBillionMember"
      decimals="INF"
      unitRef="Percentage">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2020-12-31_country_KR"
      decimals="0"
      unitRef="USD">4000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2020-12-31_country_KR_custom_SouthKoreanWonMember"
      decimals="0"
      unitRef="KRW">3813000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2019-12-31_country_KR"
      decimals="0"
      unitRef="USD">3000000</us-gaap:OperatingLossCarryforwards>
    <ORGS:AccumulatedTaxLossCarryForwardedPeriod contextRef="From2020-01-012020-12-31_country_KR">P15Y</ORGS:AccumulatedTaxLossCarryForwardedPeriod>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zeqE89lKRzJ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table presents summary of information concerning the Company&#x2019;s deferred taxes as of the years ending December
31, 2019 and December 31, 2019 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B1_z766Or12sSuc" style="display: none"&gt;SCHEDULE OF DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20201231_zXZFQuv0fVj3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20191231_zDgTmK3N8vic" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;(U.S. dollars in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_msDTLztYm_zgBPVCDGywNa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Net operating loss carry forwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;9,606&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;14,033&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_msDTLztYm_zCrXy6rt04M4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,684&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_msDTLztYm_zTg18Jn9qUm6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Equity compensation &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,747&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2841"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_iI_pn3n3_msDTLztYm_zXn3SAkGPgU6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Employee benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;228&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsLeasesAsset_iI_pn3n3_msDTLztYm_z11i1Jih1eP9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leases asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;533&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2847"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--DeferredTaxAssetsLeaseLiability_iNI_pn3n3_di_maDTLztYm_zjVBpvnsc7q9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(324&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2850"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_pn3n3_di_maDTLztYm_zwCugWd6HsWa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,863&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(737&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_msDTLztYm_zkJGG3QCpJbc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;297&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_maDTLztYm_zcpm0JO7Gs46" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(11,932&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,939&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxLiabilities_iNTI_pn3n3_di_mtDTLztYm_zMJuAwQKEokj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2861"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(58&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">9606000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">14033000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1684000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">1358000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">2747000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">252000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">228000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <ORGS:DeferredTaxAssetsLeasesAsset contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">533000</ORGS:DeferredTaxAssetsLeasesAsset>
    <ORGS:DeferredTaxAssetsLeaseLiability contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">324000</ORGS:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">2863000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">737000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOther contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">297000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">-1000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">11932000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">14939000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">58000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_891_eus-gaap--SummaryOfValuationAllowanceTextBlock_zaZcptbl3pD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
changes in valuation allowance are comprised as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BF_zI2Sac4A7VW4" style="display: none"&gt;SCHEDULE OF VALUATION ALLOWANCE, ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;(U.S dollars in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Balance at the beginning of year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20200101__20201231_z4UsOo810krg" style="width: 18%; text-align: right" title="Balance at the beginning of year"&gt;(14,939&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20190101__20191231_zj5TStugVh28" style="width: 18%; text-align: right" title="Balance at the beginning of year"&gt;(10,254&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20200101__20201231_zUge94j55QWg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change during the year"&gt;3,007&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20190101__20191231_zjtjNj8oM515" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change during the year"&gt;(4,685&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Balance at end of year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20200101__20201231_zKy9h85KJWOe" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of year"&gt;(11,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20190101__20191231_z0lEzw0xdTTf" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of year"&gt;(14,939&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">14939000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2018-12-31" decimals="-3" unitRef="USD">10254000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">3007000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-4685000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">11932000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">14939000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_802_eus-gaap--RevenueFromContractWithCustomerTextBlock_zatR1J2qiMTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
17 &#x2013; &lt;span id="xdx_822_zc9Tws1gKm7a"&gt;REVENUES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Disaggregation
of Revenue&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--DisaggregationOfRevenueTableTextBlock_zciVtxWIG3Cl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table disaggregates the Company&#x2019;s revenues by major revenue streams.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B6_z1gyYh8uIJzf" style="display: none"&gt;SCHEDULE OF DISAGGREGATION OF REVENUE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Revenue stream:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;POC and hospital services&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--Revenues_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--PointOfCareServicesMember_zhFWJCKZmbgk" style="width: 18%; text-align: right" title="Total"&gt;6,068&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Revenues_c20190101__20191231__srt--ProductOrServiceAxis__custom--PointOfCareServicesMember_pn3n3" style="width: 18%; text-align: right" title="Total"&gt;3,109&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cell process development services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--Revenues_c20200101__20201231__srt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total"&gt;1,584&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Revenues_c20190101__20191231__srt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total"&gt;790&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Revenues_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;7,652&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--Revenues_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;3,899&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AB_z22QlsUJnVD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;POC
development services are the result of agreements between Company and its partners (See Note 11). The Company provides certain
services in support of the partners&#x2019; clinical activity. The Company has signed Master Services Agreements with joint venture
partners in the aggregate amount of over $&lt;span id="xdx_90B_eus-gaap--Revenues_pin6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JointVenturePartnersMember_zrXXa7x58lKa" title="Revenue"&gt;38&lt;/span&gt; million for services to be provided from 2021 to 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--ScheduleOfBreakdownOfRevenuesPerCustomer_zY1gLtJVUKwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
breakdown of the revenues per customer what constituted at least 10% of revenues is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B2_zm38Kgu5iW3i" style="display: none"&gt;SCHEDULE OF BREAKDOWN OF REVENUES PER CUSTOMER&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Revenue earned:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;Customer A&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerAMember_pn3n3" style="width: 18%; text-align: right" title="Revenues"&gt;2,857&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--MajorCustomersAxis__custom--CustomerAMember_pn3n3" style="width: 18%; text-align: right" title="Revenues"&gt;1,420&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Customer B&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerBMember_pn3n3" style="text-align: right" title="Revenues"&gt;1,577&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--MajorCustomersAxis__custom--CustomerBMember_pn3n3" style="text-align: right" title="Revenues"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2904"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Customer C &#x2013; related party&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerCRelatedPartyMember_pn3n3" style="text-align: right" title="Revenues"&gt;1,475&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--MajorCustomersAxis__custom--CustomerCRelatedPartyMember_pn3n3" style="text-align: right" title="Revenues"&gt;1,270&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Customer D&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerDMember_pn3n3" style="text-align: right" title="Revenues"&gt;1,412&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--MajorCustomersAxis__custom--CustomerDMember_pn3n3" style="text-align: right" title="Revenues"&gt;857&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A7_zxdqTJw6Pdu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Contract
Assets and Liabilities&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Contract
assets are mainly comprised of trade receivables net of allowance for doubtful debts, which includes amounts billed and currently
due from customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zEx5HF4APUu1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
activity for trade receivables is comprised of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&lt;span id="xdx_8B3_zKMopYhtwfci" style="display: none"&gt;SCHEDULE OF ACTIVITY FOR TRADE RECEIVABLES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%"&gt;Balance as of beginning of period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AccountsReceivableNetCurrent_iS_pn3n3_c20200101__20201231_zgIuXzD8VVu3" style="width: 18%; text-align: right" title="Balance as of beginning of period"&gt;1,831&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccountsReceivableNetCurrent_iS_pn3n3_c20190101__20191231_zeumEvjYPYj7" style="width: 18%; text-align: right" title="Balance as of beginning of period"&gt;129&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Acquisition of Koligo&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--AccountsReceivableAcquisitionOfKoligo_c20200101__20201231_pn3n3" style="text-align: right" title="Acquisition of Koligo"&gt;228&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--AccountsReceivableAcquisitionOfKoligo_c20190101__20191231_pn3n3" style="text-align: right" title="Acquisition of Koligo"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2922"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--AccountsReceivableAdditions_c20200101__20201231_pn3n3" style="text-align: right" title="Additions"&gt;6,997&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--AccountsReceivableAdditions_c20190101__20191231_pn3n3" style="text-align: right" title="Additions"&gt;2,079&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Collections&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AccountsReceivableCollections_c20200101__20201231_pn3n3" style="text-align: right" title="Collections"&gt;(5,982&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--AccountsReceivableCollections_c20190101__20191231_pn3n3" style="text-align: right" title="Collections"&gt;(364&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Exchange rate differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ExchangeRateDifferencesOfAccountsReceivable_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate differences"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ExchangeRateDifferencesOfAccountsReceivable_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate differences"&gt;(13&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of end of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AccountsReceivableNetCurrent_iE_pn3n3_c20200101__20201231_z5EzxrYt23w8" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance as of end of period"&gt;3,085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccountsReceivableNetCurrent_iE_pn3n3_c20190101__20191231_zqbnSQSPLjwf" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance as of end of period"&gt;1,831&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A4_z4gg2OJ5ms8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_z7ZGBpL1HCgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
activity for contract liabilities is comprised of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B4_zWL501wjCgnk" style="display: none"&gt;SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%"&gt;Balance as of beginning of period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ContractWithCustomerLiabilityCurrent_iS_pn3n3_c20200101__20201231_zPJ5G2h1xHhl" style="width: 18%; text-align: right" title="Balance as of beginning of period"&gt;325&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ContractWithCustomerLiabilityCurrent_iS_pn3n3_c20190101__20191231_zJNOYDwWAI32" style="width: 18%; text-align: right" title="Balance as of beginning of period"&gt;56&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ContractWithCustomerLiabilityAddition_c20200101__20201231_pn3n3" style="text-align: right" title="Additions"&gt;597&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ContractWithCustomerLiabilityAddition_c20190101__20191231_pn3n3" style="text-align: right" title="Additions"&gt;1,126&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F43_z0M5U3m6Pdc7" style="padding-left: 10pt"&gt;Realizations*&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ContractWithCustomerLiabilityRealizations_pn3n3_c20200101__20201231_fKg_____zl72xmE3vlo9" style="text-align: right" title="Realizations"&gt;(862&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ContractWithCustomerLiabilityRealizations_pn3n3_c20190101__20191231_fKg_____zx18NKmAlo2j" style="text-align: right" title="Realizations"&gt;(854&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Exchange rate differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ContractWithCustomerLiabilityExchangeRateDifferences_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate differences"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ContractWithCustomerLiabilityExchangeRateDifferences_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate differences"&gt;(3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of end of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ContractWithCustomerLiabilityCurrent_iE_pn3n3_c20200101__20201231_zGOvVzvolUrf" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance as of end of period"&gt;59&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ContractWithCustomerLiabilityCurrent_iE_pn3n3_c20190101__20191231_zOKMpkkMhpv5" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance as of end of period"&gt;325&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td id="xdx_F06_zZk6RCpAn0lg" style="width: 3%"&gt;*&lt;/td&gt;
    &lt;td id="xdx_F1F_zKmYLsKShpMl" style="width: 97%"&gt;Out of which $ &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDVElWSVRZIEZPUiBDT05UUkFDVCBMSUFCSUxJVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn3n3_c20191231_zMzilnHXUcB9" title="Contract with customer liability"&gt;325&lt;/span&gt; thousand were realized from the beginning of the period for the year ended December 31, 2020.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_8AF_zgh8DGPfK7ic" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_899_eus-gaap--DisaggregationOfRevenueTableTextBlock_zciVtxWIG3Cl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table disaggregates the Company&#x2019;s revenues by major revenue streams.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B6_z1gyYh8uIJzf" style="display: none"&gt;SCHEDULE OF DISAGGREGATION OF REVENUE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Revenue stream:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;POC and hospital services&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--Revenues_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--PointOfCareServicesMember_zhFWJCKZmbgk" style="width: 18%; text-align: right" title="Total"&gt;6,068&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Revenues_c20190101__20191231__srt--ProductOrServiceAxis__custom--PointOfCareServicesMember_pn3n3" style="width: 18%; text-align: right" title="Total"&gt;3,109&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cell process development services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--Revenues_c20200101__20201231__srt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total"&gt;1,584&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Revenues_c20190101__20191231__srt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total"&gt;790&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Revenues_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;7,652&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--Revenues_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;3,899&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-12-31_custom_PointOfCareServicesMember"
      decimals="-3"
      unitRef="USD">6068000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-12-31_custom_PointOfCareServicesMember"
      decimals="-3"
      unitRef="USD">3109000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-12-31_custom_CellProcessDevelopmentServicesMember"
      decimals="-3"
      unitRef="USD">1584000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-12-31_custom_CellProcessDevelopmentServicesMember"
      decimals="-3"
      unitRef="USD">790000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">7652000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">3899000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-12-31_custom_MasterServicesAgreementsMember_custom_JointVenturePartnersMember"
      decimals="0"
      unitRef="USD">38000000</us-gaap:Revenues>
    <ORGS:ScheduleOfBreakdownOfRevenuesPerCustomer contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_898_ecustom--ScheduleOfBreakdownOfRevenuesPerCustomer_zY1gLtJVUKwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
breakdown of the revenues per customer what constituted at least 10% of revenues is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B2_zm38Kgu5iW3i" style="display: none"&gt;SCHEDULE OF BREAKDOWN OF REVENUES PER CUSTOMER&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Revenue earned:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;Customer A&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerAMember_pn3n3" style="width: 18%; text-align: right" title="Revenues"&gt;2,857&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--MajorCustomersAxis__custom--CustomerAMember_pn3n3" style="width: 18%; text-align: right" title="Revenues"&gt;1,420&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Customer B&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerBMember_pn3n3" style="text-align: right" title="Revenues"&gt;1,577&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--MajorCustomersAxis__custom--CustomerBMember_pn3n3" style="text-align: right" title="Revenues"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2904"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Customer C &#x2013; related party&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerCRelatedPartyMember_pn3n3" style="text-align: right" title="Revenues"&gt;1,475&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--MajorCustomersAxis__custom--CustomerCRelatedPartyMember_pn3n3" style="text-align: right" title="Revenues"&gt;1,270&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Customer D&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerDMember_pn3n3" style="text-align: right" title="Revenues"&gt;1,412&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--MajorCustomersAxis__custom--CustomerDMember_pn3n3" style="text-align: right" title="Revenues"&gt;857&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</ORGS:ScheduleOfBreakdownOfRevenuesPerCustomer>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_custom_CustomerAMember"
      decimals="-3"
      unitRef="USD">2857000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_custom_CustomerAMember"
      decimals="-3"
      unitRef="USD">1420000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_custom_CustomerBMember"
      decimals="-3"
      unitRef="USD">1577000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_custom_CustomerCRelatedPartyMember"
      decimals="-3"
      unitRef="USD">1475000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_custom_CustomerCRelatedPartyMember"
      decimals="-3"
      unitRef="USD">1270000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_custom_CustomerDMember"
      decimals="-3"
      unitRef="USD">1412000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_custom_CustomerDMember"
      decimals="-3"
      unitRef="USD">857000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89A_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zEx5HF4APUu1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
activity for trade receivables is comprised of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&lt;span id="xdx_8B3_zKMopYhtwfci" style="display: none"&gt;SCHEDULE OF ACTIVITY FOR TRADE RECEIVABLES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%"&gt;Balance as of beginning of period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AccountsReceivableNetCurrent_iS_pn3n3_c20200101__20201231_zgIuXzD8VVu3" style="width: 18%; text-align: right" title="Balance as of beginning of period"&gt;1,831&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccountsReceivableNetCurrent_iS_pn3n3_c20190101__20191231_zeumEvjYPYj7" style="width: 18%; text-align: right" title="Balance as of beginning of period"&gt;129&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Acquisition of Koligo&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--AccountsReceivableAcquisitionOfKoligo_c20200101__20201231_pn3n3" style="text-align: right" title="Acquisition of Koligo"&gt;228&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--AccountsReceivableAcquisitionOfKoligo_c20190101__20191231_pn3n3" style="text-align: right" title="Acquisition of Koligo"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2922"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--AccountsReceivableAdditions_c20200101__20201231_pn3n3" style="text-align: right" title="Additions"&gt;6,997&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--AccountsReceivableAdditions_c20190101__20191231_pn3n3" style="text-align: right" title="Additions"&gt;2,079&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Collections&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AccountsReceivableCollections_c20200101__20201231_pn3n3" style="text-align: right" title="Collections"&gt;(5,982&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--AccountsReceivableCollections_c20190101__20191231_pn3n3" style="text-align: right" title="Collections"&gt;(364&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Exchange rate differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ExchangeRateDifferencesOfAccountsReceivable_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate differences"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ExchangeRateDifferencesOfAccountsReceivable_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate differences"&gt;(13&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of end of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AccountsReceivableNetCurrent_iE_pn3n3_c20200101__20201231_z5EzxrYt23w8" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance as of end of period"&gt;3,085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccountsReceivableNetCurrent_iE_pn3n3_c20190101__20191231_zqbnSQSPLjwf" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance as of end of period"&gt;1,831&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">1831000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2018-12-31" decimals="-3" unitRef="USD">129000</us-gaap:AccountsReceivableNetCurrent>
    <ORGS:AccountsReceivableAcquisitionOfKoligo
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">228000</ORGS:AccountsReceivableAcquisitionOfKoligo>
    <ORGS:AccountsReceivableAdditions
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">6997000</ORGS:AccountsReceivableAdditions>
    <ORGS:AccountsReceivableAdditions
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">2079000</ORGS:AccountsReceivableAdditions>
    <ORGS:AccountsReceivableCollections
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-5982000</ORGS:AccountsReceivableCollections>
    <ORGS:AccountsReceivableCollections
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-364000</ORGS:AccountsReceivableCollections>
    <ORGS:ExchangeRateDifferencesOfAccountsReceivable
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">11000</ORGS:ExchangeRateDifferencesOfAccountsReceivable>
    <ORGS:ExchangeRateDifferencesOfAccountsReceivable
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-13000</ORGS:ExchangeRateDifferencesOfAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">3085000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">1831000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89D_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_z7ZGBpL1HCgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
activity for contract liabilities is comprised of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B4_zWL501wjCgnk" style="display: none"&gt;SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%"&gt;Balance as of beginning of period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ContractWithCustomerLiabilityCurrent_iS_pn3n3_c20200101__20201231_zPJ5G2h1xHhl" style="width: 18%; text-align: right" title="Balance as of beginning of period"&gt;325&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ContractWithCustomerLiabilityCurrent_iS_pn3n3_c20190101__20191231_zJNOYDwWAI32" style="width: 18%; text-align: right" title="Balance as of beginning of period"&gt;56&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ContractWithCustomerLiabilityAddition_c20200101__20201231_pn3n3" style="text-align: right" title="Additions"&gt;597&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ContractWithCustomerLiabilityAddition_c20190101__20191231_pn3n3" style="text-align: right" title="Additions"&gt;1,126&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F43_z0M5U3m6Pdc7" style="padding-left: 10pt"&gt;Realizations*&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ContractWithCustomerLiabilityRealizations_pn3n3_c20200101__20201231_fKg_____zl72xmE3vlo9" style="text-align: right" title="Realizations"&gt;(862&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ContractWithCustomerLiabilityRealizations_pn3n3_c20190101__20191231_fKg_____zx18NKmAlo2j" style="text-align: right" title="Realizations"&gt;(854&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Exchange rate differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ContractWithCustomerLiabilityExchangeRateDifferences_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate differences"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ContractWithCustomerLiabilityExchangeRateDifferences_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate differences"&gt;(3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of end of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ContractWithCustomerLiabilityCurrent_iE_pn3n3_c20200101__20201231_zGOvVzvolUrf" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance as of end of period"&gt;59&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ContractWithCustomerLiabilityCurrent_iE_pn3n3_c20190101__20191231_zOKMpkkMhpv5" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance as of end of period"&gt;325&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td id="xdx_F06_zZk6RCpAn0lg" style="width: 3%"&gt;*&lt;/td&gt;
    &lt;td id="xdx_F1F_zKmYLsKShpMl" style="width: 97%"&gt;Out of which $ &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDVElWSVRZIEZPUiBDT05UUkFDVCBMSUFCSUxJVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn3n3_c20191231_zMzilnHXUcB9" title="Contract with customer liability"&gt;325&lt;/span&gt; thousand were realized from the beginning of the period for the year ended December 31, 2020.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">325000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2018-12-31" decimals="-3" unitRef="USD">56000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ORGS:ContractWithCustomerLiabilityAddition
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">597000</ORGS:ContractWithCustomerLiabilityAddition>
    <ORGS:ContractWithCustomerLiabilityAddition
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">1126000</ORGS:ContractWithCustomerLiabilityAddition>
    <ORGS:ContractWithCustomerLiabilityRealizations
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact002950"
      unitRef="USD">-862000</ORGS:ContractWithCustomerLiabilityRealizations>
    <ORGS:ContractWithCustomerLiabilityRealizations
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      id="Fact002952"
      unitRef="USD">-854000</ORGS:ContractWithCustomerLiabilityRealizations>
    <ORGS:ContractWithCustomerLiabilityExchangeRateDifferences
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-1000</ORGS:ContractWithCustomerLiabilityExchangeRateDifferences>
    <ORGS:ContractWithCustomerLiabilityExchangeRateDifferences
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-3000</ORGS:ContractWithCustomerLiabilityExchangeRateDifferences>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">59000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">325000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">325000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_802_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zWlXHw6dGYq" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
18 &#x2013; &lt;span id="xdx_824_zMcviMJeQtY9"&gt;COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_z3cLO8fhyhdh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BC_zV30xjyeSrsl" style="display: none"&gt;SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Total expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OtherResearchAndDevelopmentExpense_c20200101__20201231_pn3n3" style="width: 18%; text-align: right" title="Total expenses"&gt;84,182&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OtherResearchAndDevelopmentExpense_c20190101__20191231_pn3n3" style="width: 18%; text-align: right" title="Total expenses"&gt;14,826&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Less grants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--GrantsIncome_pn3n3_c20200101__20201231_zLkNeA3LKiB4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less grants"&gt;(196&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--GrantsIncome_pn3n3_c20190101__20191231_zWqsZuYCF5S3" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(812&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, net"&gt;83,986&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, net"&gt;14,014&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A6_zBvXs2JHb9gf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_z3cLO8fhyhdh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BC_zV30xjyeSrsl" style="display: none"&gt;SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Total expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OtherResearchAndDevelopmentExpense_c20200101__20201231_pn3n3" style="width: 18%; text-align: right" title="Total expenses"&gt;84,182&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OtherResearchAndDevelopmentExpense_c20190101__20191231_pn3n3" style="width: 18%; text-align: right" title="Total expenses"&gt;14,826&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Less grants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--GrantsIncome_pn3n3_c20200101__20201231_zLkNeA3LKiB4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less grants"&gt;(196&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--GrantsIncome_pn3n3_c20190101__20191231_zWqsZuYCF5S3" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(812&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, net"&gt;83,986&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, net"&gt;14,014&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">84182000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">14826000</us-gaap:OtherResearchAndDevelopmentExpense>
    <ORGS:GrantsIncome
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-196000</ORGS:GrantsIncome>
    <ORGS:GrantsIncome
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-812000</ORGS:GrantsIncome>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">83986000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">14014000</us-gaap:ResearchAndDevelopmentExpense>
    <ORGS:FinancialExpensesNetTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_806_ecustom--FinancialExpensesNetTextBlock_zzoFwE69I6Xb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
19 &#x2013; &lt;span id="xdx_82C_zutiiOuEq0C3"&gt;FINANCIAL EXPENSES, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--ScheduleOfFinancialExpensesTableTextBlock_zn2kLRrF00z3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B8_zNbPtYGts483" style="display: none"&gt;SCHEDULE OF FINANCIAL EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20200101_20201231" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20190101_20191231" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue_maTFEzElv_zsM3s6BwG0hi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Increase in fair value of warrants and financial liabilities measured at fair value&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2984"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;63&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--InterestExpenseOnConvertibleLoans_maTFEzElv_zsyyLXxCWzI" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest expense on convertible loans&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,254&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;498&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--ForeignCurrencyTransactionsGainLossRealized_pn3n3_maTFEzElv_zBTjU4qtGp5a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign exchange loss, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;160&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--OtherIncome_iN_pn3n3_di_msTFEzElv_zVEnpzdXTn2c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(353&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(113&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--TotalFinancialExpenses_iT_mtTFEzElv_zqPwqivVUB6c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,061&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;843&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A6_zKCcIilTYR59" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ORGS:FinancialExpensesNetTextBlock>
    <ORGS:ScheduleOfFinancialExpensesTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89B_ecustom--ScheduleOfFinancialExpensesTableTextBlock_zn2kLRrF00z3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B8_zNbPtYGts483" style="display: none"&gt;SCHEDULE OF FINANCIAL EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20200101_20201231" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20190101_20191231" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue_maTFEzElv_zsM3s6BwG0hi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Increase in fair value of warrants and financial liabilities measured at fair value&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2984"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;63&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--InterestExpenseOnConvertibleLoans_maTFEzElv_zsyyLXxCWzI" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest expense on convertible loans&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,254&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;498&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--ForeignCurrencyTransactionsGainLossRealized_pn3n3_maTFEzElv_zBTjU4qtGp5a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign exchange loss, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;160&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--OtherIncome_iN_pn3n3_di_msTFEzElv_zVEnpzdXTn2c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(353&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(113&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--TotalFinancialExpenses_iT_mtTFEzElv_zqPwqivVUB6c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,061&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;843&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</ORGS:ScheduleOfFinancialExpensesTableTextBlock>
    <ORGS:IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">63000</ORGS:IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue>
    <ORGS:InterestExpenseOnConvertibleLoans
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1254000</ORGS:InterestExpenseOnConvertibleLoans>
    <ORGS:InterestExpenseOnConvertibleLoans
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">498000</ORGS:InterestExpenseOnConvertibleLoans>
    <ORGS:ForeignCurrencyTransactionsGainLossRealized
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">160000</ORGS:ForeignCurrencyTransactionsGainLossRealized>
    <ORGS:ForeignCurrencyTransactionsGainLossRealized
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">395000</ORGS:ForeignCurrencyTransactionsGainLossRealized>
    <us-gaap:OtherIncome
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">353000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">113000</us-gaap:OtherIncome>
    <ORGS:TotalFinancialExpenses
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1061000</ORGS:TotalFinancialExpenses>
    <ORGS:TotalFinancialExpenses
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">843000</ORGS:TotalFinancialExpenses>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_80A_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zmDO0XMqZorh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
20 &#x2013; &lt;span id="xdx_820_zciW7f3HFWe7"&gt;RELATED PARTIES TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;a.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Related
    Parties presented in the consolidated statements of comprehensive loss&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_89A_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_z0I8RBOqbpe4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B7_z38wGFN32fS9" style="display: none"&gt;SCHEDULE OF RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Continuing operations:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: left; padding-bottom: 2.5pt"&gt;Stock-based compensation expenses to executive officers&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right" title="Stock Based Compensation"&gt;221&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zScrlX5LwUYc" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right" title="Stock Based Compensation"&gt;898&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F4D_zDj1uemAftSe" style="text-align: left; padding-bottom: 2.5pt"&gt;Stock-based compensation expenses to Board Members*&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_fKg_____z5oDhlnYaApj" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock Based Compensation"&gt;209&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember_fKg_____zbufEPXtHTL9" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock Based Compensation"&gt;414&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Compensation of executive officers&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OfficersCompensation_pn3n3_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zeXQ9O2OeORf" style="border-bottom: Black 2.5pt double; text-align: right" title="Compensation"&gt;1,321&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OfficersCompensation_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zDt1hvYywZ2a" style="border-bottom: Black 2.5pt double; text-align: right"&gt;812&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Management and consulting fees to Board Members&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and consulting fees"&gt;264&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember_zZ5ZrtfncJ67" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and consulting fees"&gt;233&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Revenues from customer&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromRelatedParties_pn3n3_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zWmRrjlj5Fk2" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues from customer"&gt;1,475&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromRelatedParties_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_z3S6kt0Y6JN8" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues from customer"&gt;1,270&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Cost of research and development and research and development services, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet_pn3n3_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zMEkarZwPlOh" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost of research and development and research and development services, net"&gt;4,772&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost of research and development and research and development services, net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3024"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Financial income&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--FinancialIncome_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Financial income"&gt;169&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--FinancialIncome_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Financial income"&gt;112&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td id="xdx_F08_zUmcncmQEk2b" style="width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 95%"&gt;&lt;span id="xdx_F14_zdm5QhoDOrPa" style="font: 10pt Times New Roman, Times, Serif"&gt;Does not include $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEFURUQgUEFSVFkgVFJBTlNBQ1RJT05TIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--StockOptionPlanExpense_pn3n3_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaerusTherapeuticsLLCMember_zwN4HCMuUKA8" title="Stock Based Compensation expenses for options exercisable"&gt;192&lt;/span&gt; thousand
    for the year ended December 31, 2019 related to Stock Based Compensation expenses for options exercisable at an exercise price
    of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEFURUQgUEFSVFkgVFJBTlNBQ1RJT05TIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaerusTherapeuticsLLCMember_pii" title="Exercise price per share of options exercisable"&gt;7.00&lt;/span&gt; per share into &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEFURUQgUEFSVFkgVFJBTlNBQ1RJT05TIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_ecustom--NumberOfOrdinarySharesHeld_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaerusTherapeuticsLLCMember_pii" title="Number of ordinary shares held"&gt;70,000&lt;/span&gt; ordinary shares held by Caerus Therapeutics LLC for which the director does not have beneficial
    control.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Year ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Discontinued operations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F46_zSsDanWIU0i8" style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left; padding-bottom: 2.5pt"&gt;Stock-based compensation expenses to executive officers&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Stock Based Compensation"&gt;76&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Compensation of executive officers&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OfficersCompensation_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_z3PQzKHltDNa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Compensation"&gt;685&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AE_zt0eY1Dvex6j" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Related
    Parties presented in the consolidated balance sheets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_899_ecustom--ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock_z4a2KVSbG4S7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BC_zMe02VSe5zki" style="display: none"&gt;SCHEDULE OF RELATED PARTIES PRESENTED IN CONSOLIDATED BALANCE SHEETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Continuing operations:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: left; padding-bottom: 2.5pt"&gt;Executive officers&#x2019; payables&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_c20201231__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zKL8yC3duZL5" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right" title="Due to Related Parties"&gt;170&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_c20191231__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right" title="Due to Related Parties"&gt;1,251&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Non-executive directors&#x2019; payable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_c20201231__us-gaap--RelatedPartyTransactionAxis__custom--NonexecutiveDirectorsMember_zY02Lb952nXi" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to Related Parties"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_c20191231__us-gaap--RelatedPartyTransactionAxis__custom--NonexecutiveDirectorsMember_zN7cd3dfFGGj" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to Related Parties"&gt;202&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F4F_zU60oWJU4a1j" style="text-align: left; padding-bottom: 2.5pt"&gt;Loan to Related Party &lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DueFromRelatedPartiesNoncurrent1_iI_pn3n3_c20201231_fKg_____zEKOY0rnIym3" style="border-bottom: Black 2.5pt double; text-align: right" title="Loan to related party"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3051"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--DueFromRelatedPartiesNoncurrent1_iI_pn3n3_c20191231_fKg_____zQFt3aaF0ufj" style="border-bottom: Black 2.5pt double; text-align: right" title="Loan to related party"&gt;2,623&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Accounts receivable, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccountsReceivableNet_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts receivable, net"&gt;744&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AccountsReceivableNet_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts receivable, net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3057"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Contract liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ContractWithCustomerLiability_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Contract liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3059"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ContractWithCustomerLiability_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Contract liabilities"&gt;230&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AB_zgA9qYDvZ32e" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0"/&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89A_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_z0I8RBOqbpe4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B7_z38wGFN32fS9" style="display: none"&gt;SCHEDULE OF RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Continuing operations:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: left; padding-bottom: 2.5pt"&gt;Stock-based compensation expenses to executive officers&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right" title="Stock Based Compensation"&gt;221&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zScrlX5LwUYc" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right" title="Stock Based Compensation"&gt;898&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F4D_zDj1uemAftSe" style="text-align: left; padding-bottom: 2.5pt"&gt;Stock-based compensation expenses to Board Members*&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_fKg_____z5oDhlnYaApj" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock Based Compensation"&gt;209&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember_fKg_____zbufEPXtHTL9" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock Based Compensation"&gt;414&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Compensation of executive officers&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OfficersCompensation_pn3n3_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zeXQ9O2OeORf" style="border-bottom: Black 2.5pt double; text-align: right" title="Compensation"&gt;1,321&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OfficersCompensation_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zDt1hvYywZ2a" style="border-bottom: Black 2.5pt double; text-align: right"&gt;812&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Management and consulting fees to Board Members&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and consulting fees"&gt;264&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember_zZ5ZrtfncJ67" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and consulting fees"&gt;233&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Revenues from customer&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromRelatedParties_pn3n3_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zWmRrjlj5Fk2" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues from customer"&gt;1,475&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromRelatedParties_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_z3S6kt0Y6JN8" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues from customer"&gt;1,270&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Cost of research and development and research and development services, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet_pn3n3_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zMEkarZwPlOh" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost of research and development and research and development services, net"&gt;4,772&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost of research and development and research and development services, net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3024"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Financial income&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--FinancialIncome_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Financial income"&gt;169&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--FinancialIncome_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Financial income"&gt;112&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td id="xdx_F08_zUmcncmQEk2b" style="width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 95%"&gt;&lt;span id="xdx_F14_zdm5QhoDOrPa" style="font: 10pt Times New Roman, Times, Serif"&gt;Does not include $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEFURUQgUEFSVFkgVFJBTlNBQ1RJT05TIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--StockOptionPlanExpense_pn3n3_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaerusTherapeuticsLLCMember_zwN4HCMuUKA8" title="Stock Based Compensation expenses for options exercisable"&gt;192&lt;/span&gt; thousand
    for the year ended December 31, 2019 related to Stock Based Compensation expenses for options exercisable at an exercise price
    of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEFURUQgUEFSVFkgVFJBTlNBQ1RJT05TIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaerusTherapeuticsLLCMember_pii" title="Exercise price per share of options exercisable"&gt;7.00&lt;/span&gt; per share into &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEFURUQgUEFSVFkgVFJBTlNBQ1RJT05TIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_ecustom--NumberOfOrdinarySharesHeld_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaerusTherapeuticsLLCMember_pii" title="Number of ordinary shares held"&gt;70,000&lt;/span&gt; ordinary shares held by Caerus Therapeutics LLC for which the director does not have beneficial
    control.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Year ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Discontinued operations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F46_zSsDanWIU0i8" style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left; padding-bottom: 2.5pt"&gt;Stock-based compensation expenses to executive officers&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Stock Based Compensation"&gt;76&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Compensation of executive officers&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OfficersCompensation_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_z3PQzKHltDNa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Compensation"&gt;685&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-12-31_us-gaap_SegmentContinuingOperationsMember_srt_ExecutiveOfficerMember"
      decimals="-3"
      unitRef="USD">221000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-012019-12-31_us-gaap_SegmentContinuingOperationsMember_srt_ExecutiveOfficerMember"
      decimals="-3"
      unitRef="USD">898000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-12-31_custom_BoardMembersMember_us-gaap_SegmentContinuingOperationsMember"
      decimals="-3"
      id="Fact003007"
      unitRef="USD">209000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-012019-12-31_us-gaap_SegmentContinuingOperationsMember_custom_BoardMembersMember"
      decimals="-3"
      id="Fact003009"
      unitRef="USD">414000</us-gaap:ShareBasedCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2020-01-012020-12-31_us-gaap_SegmentContinuingOperationsMember_srt_ExecutiveOfficerMember"
      decimals="-3"
      unitRef="USD">1321000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2019-01-012019-12-31_us-gaap_SegmentContinuingOperationsMember_srt_ExecutiveOfficerMember"
      decimals="-3"
      unitRef="USD">812000</us-gaap:OfficersCompensation>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2020-01-012020-12-31_custom_BoardMembersMember_us-gaap_SegmentContinuingOperationsMember"
      decimals="-3"
      unitRef="USD">264000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2019-01-012019-12-31_us-gaap_SegmentContinuingOperationsMember_custom_BoardMembersMember"
      decimals="-3"
      unitRef="USD">233000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RevenueFromRelatedParties
      contextRef="From2020-01-012020-12-31_us-gaap_SegmentContinuingOperationsMember"
      decimals="-3"
      unitRef="USD">1475000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="From2019-01-012019-12-31_us-gaap_SegmentContinuingOperationsMember"
      decimals="-3"
      unitRef="USD">1270000</us-gaap:RevenueFromRelatedParties>
    <ORGS:CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet
      contextRef="From2020-01-012020-12-31_us-gaap_SegmentContinuingOperationsMember"
      decimals="-3"
      unitRef="USD">4772000</ORGS:CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet>
    <ORGS:FinancialIncome
      contextRef="From2020-01-012020-12-31_us-gaap_SegmentContinuingOperationsMember"
      decimals="-3"
      unitRef="USD">169000</ORGS:FinancialIncome>
    <ORGS:FinancialIncome
      contextRef="From2019-01-012019-12-31_us-gaap_SegmentContinuingOperationsMember"
      decimals="-3"
      unitRef="USD">112000</ORGS:FinancialIncome>
    <us-gaap:StockOptionPlanExpense
      contextRef="From2019-01-012019-12-31_custom_CaerusTherapeuticsLLCMember"
      decimals="-3"
      unitRef="USD">192000</us-gaap:StockOptionPlanExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_custom_CaerusTherapeuticsLLCMember"
      decimals="INF"
      unitRef="USDPShares">7.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <ORGS:NumberOfOrdinarySharesHeld
      contextRef="From2019-01-012019-12-31_custom_CaerusTherapeuticsLLCMember"
      decimals="INF"
      unitRef="Shares">70000</ORGS:NumberOfOrdinarySharesHeld>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-012019-12-31_us-gaap_SegmentDiscontinuedOperationsMember_srt_ExecutiveOfficerMember"
      decimals="-3"
      unitRef="USD">76000</us-gaap:ShareBasedCompensation>
    <us-gaap:OfficersCompensation
      contextRef="From2019-01-012019-12-31_us-gaap_SegmentDiscontinuedOperationsMember_srt_ExecutiveOfficerMember"
      decimals="-3"
      unitRef="USD">685000</us-gaap:OfficersCompensation>
    <ORGS:ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_899_ecustom--ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock_z4a2KVSbG4S7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BC_zMe02VSe5zki" style="display: none"&gt;SCHEDULE OF RELATED PARTIES PRESENTED IN CONSOLIDATED BALANCE SHEETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Continuing operations:&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: left; padding-bottom: 2.5pt"&gt;Executive officers&#x2019; payables&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_c20201231__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zKL8yC3duZL5" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right" title="Due to Related Parties"&gt;170&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_c20191231__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right" title="Due to Related Parties"&gt;1,251&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Non-executive directors&#x2019; payable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_c20201231__us-gaap--RelatedPartyTransactionAxis__custom--NonexecutiveDirectorsMember_zY02Lb952nXi" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to Related Parties"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_c20191231__us-gaap--RelatedPartyTransactionAxis__custom--NonexecutiveDirectorsMember_zN7cd3dfFGGj" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to Related Parties"&gt;202&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F4F_zU60oWJU4a1j" style="text-align: left; padding-bottom: 2.5pt"&gt;Loan to Related Party &lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DueFromRelatedPartiesNoncurrent1_iI_pn3n3_c20201231_fKg_____zEKOY0rnIym3" style="border-bottom: Black 2.5pt double; text-align: right" title="Loan to related party"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3051"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--DueFromRelatedPartiesNoncurrent1_iI_pn3n3_c20191231_fKg_____zQFt3aaF0ufj" style="border-bottom: Black 2.5pt double; text-align: right" title="Loan to related party"&gt;2,623&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Accounts receivable, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccountsReceivableNet_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts receivable, net"&gt;744&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AccountsReceivableNet_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts receivable, net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3057"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Contract liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ContractWithCustomerLiability_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Contract liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3059"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ContractWithCustomerLiability_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Contract liabilities"&gt;230&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</ORGS:ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2020-12-31_srt_ExecutiveOfficerMember"
      decimals="-3"
      unitRef="USD">170000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2019-12-31_srt_ExecutiveOfficerMember"
      decimals="-3"
      unitRef="USD">1251000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2020-12-31_custom_NonexecutiveDirectorsMember"
      decimals="-3"
      unitRef="USD">13000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2019-12-31_custom_NonexecutiveDirectorsMember"
      decimals="-3"
      unitRef="USD">202000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <ORGS:DueFromRelatedPartiesNoncurrent1 contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">2623000</ORGS:DueFromRelatedPartiesNoncurrent1>
    <us-gaap:AccountsReceivableNet contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">744000</us-gaap:AccountsReceivableNet>
    <us-gaap:ContractWithCustomerLiability contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">230000</us-gaap:ContractWithCustomerLiability>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000502"
          xlink:label="Fact000502"
          xlink:type="locator"/>
        <link:footnote id="Footnote000606" xlink:label="Footnote000606" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">out of which 30,000 shares
    have additional restrictions on transfer until services have been provided.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000502"
          xlink:to="Footnote000606"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001095"
          xlink:label="Fact001095"
          xlink:type="locator"/>
        <link:footnote id="Footnote001102" xlink:label="Footnote001102" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Fair value of the consideration is based on the company&#x2019;s market share price.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001095"
          xlink:to="Footnote001102"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001116"
          xlink:label="Fact001116"
          xlink:type="locator"/>
        <link:footnote id="Footnote001143" xlink:label="Footnote001143" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
                                         allocation of the purchase price to the net assets acquired and liabilities assumed resulted
                                         in the recognition of other intangible assets which comprised of: Kyslecel Technology
                                         of $<xhtml:span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_zkEyoPQjdj0e" title="Other intangible assets">9,340</xhtml:span> and IPR&amp;D of <xhtml:span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_zbaY6aSbgAC8" title="Other intangible assets">641</xhtml:span>. Kyslecel Technology has a useful life of <xhtml:span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_zYRTWIzaNSq8" title="Useful life">15</xhtml:span> years. The
                                         useful life of these intangible assets for amortization purposes was determined considering
                                         the period of expected cash flows generated by the assets used to measure the fair value
                                         of the intangible assets adjusted as appropriate for the entity-specific factors, including
                                         legal, regulatory, contractual, competitive, economic or other factors that may limit
                                         the useful life of intangible assets.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001116"
          xlink:to="Footnote001143"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001118"
          xlink:label="Fact001118"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001118"
          xlink:to="Footnote001143"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001122"
          xlink:label="Fact001122"
          xlink:type="locator"/>
        <link:footnote id="Footnote001150" xlink:label="Footnote001150" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The primary
items that generate goodwill include the value of the synergies between the acquired company and the Company and the acquired
assembled workforce, neither of which qualifies for recognition as an intangible asset. The Goodwill is not deductible for tax
purposes.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001122"
          xlink:to="Footnote001150"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001296"
          xlink:label="Fact001296"
          xlink:type="locator"/>
        <link:footnote id="Footnote001397" xlink:label="Footnote001397" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of <xhtml:span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_pii" title="Stock issued during period, conversion of convertible securities">148,838</xhtml:span> shares
and <xhtml:span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zfQ3X7ZtgEv7" title="Number of warrant may be converted">148,838</xhtml:span> <xhtml:span title="Warrants exercise, term"><xhtml:span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_z2olYqVdp0gb" title="Warrants exercise, term::XDX::P3Y"><xhtml:span style="-sec-ix-hidden: xdx2ixbrl1403">three-year</xhtml:span></xhtml:span></xhtml:span> warrants to purchase up to an additional <xhtml:span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxws5Qrjrwp2" title="Number of warrant may be converted">148,838</xhtml:span> shares of the Company&#x2019;s common stock at a per share
exercise price of $<xhtml:span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zHp9sXQK5nwg" title="Warrants exercise price">7</xhtml:span>. <xhtml:span>In the initial two years, the holders have the right to convert the outstanding principal amount and accrued
interest into shares of capital stock of Hemogenyx-Cell or Immugenyx, LLC according under the relevant note agreement, subsidiaries
of Hemogenyx Pharmaceuticals Plc, at a price per share based on a pre-money valuation of Hemogenyx-Cell or Immugenyx, LLC of $<xhtml:span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_ecustom--PreMoneyValuation_iI_pn6n6_c20201231__dei--LegalEntityAxis__custom--HemogenyxCelMember_zkLtkIqsJWR" title="Pre-money valuation">12</xhtml:span>
million and $<xhtml:span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_ecustom--PreMoneyValuation_iI_pn6n6_c20201231__dei--LegalEntityAxis__custom--ImmugenyxLLCMember_zqO6fr0KZyMe">8</xhtml:span> million, respectively, pursuant to the collaboration agreement with Hemogenyx Pharmaceuticals Plc and Immugenyx,
LLC.</xhtml:span> As of December 31, 2020, the loans are presented in current maturities of convertible notes in the balance sheet (See Notes
11(c) and 11(d).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001296"
          xlink:to="Footnote001397"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001338"
          xlink:label="Fact001338"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001338"
          xlink:to="Footnote001397"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001312"
          xlink:label="Fact001312"
          xlink:type="locator"/>
        <link:footnote id="Footnote001411" xlink:label="Footnote001411" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of <xhtml:span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pii" title="Stock issued during period, conversion of convertible securities">1,443,734</xhtml:span> shares
and <xhtml:span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pii" title="Number of warrant may be converted">1,053,503</xhtml:span> <xhtml:span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zRDvnnKx88Ag" title="Warrants exercise, term::XDX::P3Y"><xhtml:span style="-sec-ix-hidden: xdx2ixbrl1417">three-year</xhtml:span></xhtml:span> warrants to purchase up to an additional <xhtml:span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Number of warrant may be converted">1,053,503</xhtml:span> shares of the Company&#x2019;s common stock at a per
share exercise price of $<xhtml:span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pii" title="Warrants exercise price">7</xhtml:span>. As of December 31, 2020, $<xhtml:span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--ConvertibleDebtCurrent_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zScnFXulvOp2" title="Current maturities of convertible loans">2,500</xhtml:span> thousand of the principal amount is included in current maturities
of convertible loans in the balance sheet and the remainder in long-term convertible loans. See also Notes 7(b), 7(c), 7(e), 7(f)
and 7(g).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001312"
          xlink:to="Footnote001411"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001354"
          xlink:label="Fact001354"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001354"
          xlink:to="Footnote001411"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001324"
          xlink:label="Fact001324"
          xlink:type="locator"/>
        <link:footnote id="Footnote001424" xlink:label="Footnote001424" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of <xhtml:span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_pii" title="Stock issued during period, conversion of convertible securities">38,559</xhtml:span> shares
at a per share exercise price of $<xhtml:span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zEMHD8sLnPdi" title="Warrants exercise price">7</xhtml:span>. As of December 31, 2020, all the principal amount is included in long-term convertible loans
in the balance sheet See also Notes 7(h).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001324"
          xlink:to="Footnote001424"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002053"
          xlink:label="Fact002053"
          xlink:type="locator"/>
        <link:footnote id="Footnote002060" xlink:label="Footnote002060" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As
of December 31, 2020 and December 31, 2019, there are no warrants that are subject to exercise price adjustments.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002053"
          xlink:to="Footnote002060"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002055"
          xlink:label="Fact002055"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002055"
          xlink:to="Footnote002060"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002057"
          xlink:label="Fact002057"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002057"
          xlink:to="Footnote002060"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002059"
          xlink:label="Fact002059"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002059"
          xlink:to="Footnote002060"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002950"
          xlink:label="Fact002950"
          xlink:type="locator"/>
        <link:footnote id="Footnote002961" xlink:label="Footnote002961" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Out of which $ <xhtml:span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDVElWSVRZIEZPUiBDT05UUkFDVCBMSUFCSUxJVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn3n3_c20191231_zMzilnHXUcB9" title="Contract with customer liability">325</xhtml:span> thousand were realized from the beginning of the period for the year ended December 31, 2020.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002950"
          xlink:to="Footnote002961"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002952"
          xlink:label="Fact002952"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002952"
          xlink:to="Footnote002961"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003007"
          xlink:label="Fact003007"
          xlink:type="locator"/>
        <link:footnote id="Footnote003029" xlink:label="Footnote003029" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Does not include $<xhtml:span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEFURUQgUEFSVFkgVFJBTlNBQ1RJT05TIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--StockOptionPlanExpense_pn3n3_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaerusTherapeuticsLLCMember_zwN4HCMuUKA8" title="Stock Based Compensation expenses for options exercisable">192</xhtml:span> thousand
    for the year ended December 31, 2019 related to Stock Based Compensation expenses for options exercisable at an exercise price
    of $<xhtml:span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEFURUQgUEFSVFkgVFJBTlNBQ1RJT05TIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaerusTherapeuticsLLCMember_pii" title="Exercise price per share of options exercisable">7.00</xhtml:span> per share into <xhtml:span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEFURUQgUEFSVFkgVFJBTlNBQ1RJT05TIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_ecustom--NumberOfOrdinarySharesHeld_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaerusTherapeuticsLLCMember_pii" title="Number of ordinary shares held">70,000</xhtml:span> ordinary shares held by Caerus Therapeutics LLC for which the director does not have beneficial
    control.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003007"
          xlink:to="Footnote003029"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact003009"
          xlink:label="Fact003009"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact003009"
          xlink:to="Footnote003029"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676578688008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 09, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ORGENESIS
INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001460602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0583166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">20271
Goldenrod Lane<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Germantown<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">659-6404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ORGS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,399,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,199,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676578746056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 44,923<span></span>
</td>
<td class="nump">$ 107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">645<span></span>
</td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">3,085<span></span>
</td>
<td class="nump">1,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other receivables</a></td>
<td class="nump">1,070<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grants receivable</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets of discontinued operations (See Note 3)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">75,221<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">50,077<span></span>
</td>
<td class="nump">78,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesNoncurrent', window );">Loan to related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments in associates, net</a></td>
<td class="nump">175<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plants and equipment, net</a></td>
<td class="nump">3,073<span></span>
</td>
<td class="nump">2,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">13,023<span></span>
</td>
<td class="nump">3,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,474<span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">8,745<span></span>
</td>
<td class="nump">4,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">821<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">27,607<span></span>
</td>
<td class="nump">14,147<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">77,684<span></span>
</td>
<td class="nump">92,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,649<span></span>
</td>
<td class="nump">5,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_AccruedExpensesAndOtherPayablesCurrent', window );">Accrued expenses and other payables</a></td>
<td class="nump">792<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">7<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employees and related payables</a></td>
<td class="nump">1,463<span></span>
</td>
<td class="nump">1,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_AdvancePaymentsOnAccountOfGrant', window );">Advance payments on account of grant</a></td>
<td class="nump">692<span></span>
</td>
<td class="nump">523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Short-term loans and current maturities of long-term loans</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current maturities of finance leases</a></td>
<td class="nump">19<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturities of operating leases</a></td>
<td class="nump">485<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Current maturities of convertible loans</a></td>
<td class="nump">3,974<span></span>
</td>
<td class="nump">416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations (See Note 3)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">31,586<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">16,285<span></span>
</td>
<td class="nump">42,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG-TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating leases</a></td>
<td class="nump">1,020<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible loans</a></td>
<td class="nump">7,200<span></span>
</td>
<td class="nump">12,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Retirement benefits obligation</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term debt and finance leases</a></td>
<td class="nump">64<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">TOTAL LONG-TERM LIABILITIES</a></td>
<td class="nump">8,671<span></span>
</td>
<td class="nump">13,028<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">24,956<span></span>
</td>
<td class="nump">55,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RedeemableNoncontrollingInterestOfDiscontinuedOperation', window );">REDEEMABLE NON CONTROLLING INTEREST OF DISCONTINUED OPERATIONS (See Note 3)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">30,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock of $0.0001 par value, 145,833,334 shares authorized, 24,223,093 and 16,140,962 shares issued as of December 31, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">140,397<span></span>
</td>
<td class="nump">94,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">748<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock at December 31, 2020 55,309 shares</a></td>
<td class="num">(250)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(88,319)<span></span>
</td>
<td class="num">(89,429)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity attributable to Orgenesis Inc.</a></td>
<td class="nump">52,579<span></span>
</td>
<td class="nump">5,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">601<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">TOTAL EQUITY</a></td>
<td class="nump">52,728<span></span>
</td>
<td class="nump">6,078<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND EQUITY</a></td>
<td class="nump">$ 77,684<span></span>
</td>
<td class="nump">$ 92,495<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_AccruedExpensesAndOtherPayablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_AccruedExpensesAndOtherPayablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_AdvancePaymentsOnAccountOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advance payments on account of grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_AdvancePaymentsOnAccountOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_RedeemableNoncontrollingInterestOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable non-controlling interest of discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_RedeemableNoncontrollingInterestOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.11)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676738854344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">145,833,334<span></span>
</td>
<td class="nump">145,833,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">24,223,093<span></span>
</td>
<td class="nump">16,140,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">24,223,093<span></span>
</td>
<td class="nump">16,140,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">55,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676578172728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (Income) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 6,177<span></span>
</td>
<td class="nump">$ 2,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenues from related party</a></td>
<td class="nump">1,475<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">7,652<span></span>
</td>
<td class="nump">3,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Cost of research and development and research and development services, net</a></td>
<td class="nump">83,986<span></span>
</td>
<td class="nump">14,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">478<span></span>
</td>
<td class="nump">430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">18,973<span></span>
</td>
<td class="nump">11,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other income, net</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="nump">95,781<span></span>
</td>
<td class="nump">21,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Financial expenses, net</a></td>
<td class="nump">1,061<span></span>
</td>
<td class="nump">843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareInNetIncomeOfAssociatedCompanies', window );">Share in net income of associated companies</a></td>
<td class="num">(106)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operation before income taxes</a></td>
<td class="nump">96,736<span></span>
</td>
<td class="nump">22,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax income</a></td>
<td class="num">(1,609)<span></span>
</td>
<td class="num">(229)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net loss from continuing operation</a></td>
<td class="nump">95,127<span></span>
</td>
<td class="nump">22,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net loss (income) from discontinued operations, net of tax</a></td>
<td class="num">(95,706)<span></span>
</td>
<td class="nump">3,452<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss (income)</a></td>
<td class="num">(579)<span></span>
</td>
<td class="nump">26,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Net loss attributable to non-controlling interests (including redeemable) from continuing operation</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interests (including redeemable) from discontinued operations</a></td>
<td class="num">(492)<span></span>
</td>
<td class="num">(1,821)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss (income) attributable to Orgenesis Inc.</a></td>
<td class="num">$ (1,110)<span></span>
</td>
<td class="nump">$ 24,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss (income) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted from continuing operations</a></td>
<td class="nump">$ 4.46<span></span>
</td>
<td class="nump">$ 1.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare', window );">Basic and diluted from discontinued operations</a></td>
<td class="num">(4.75)<span></span>
</td>
<td class="nump">0.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="nump">$ 1.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares used in computation of Basic and Diluted loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">21,320,314<span></span>
</td>
<td class="nump">15,907,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss (income):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests', window );">Net loss from Continuing Operation</a></td>
<td class="nump">$ 95,127<span></span>
</td>
<td class="nump">$ 22,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_IncomeLossesFromDiscontinuedOperationNetOfTax', window );">Net loss (income) from Discontinued Operations, Net of Tax</a></td>
<td class="num">(95,706)<span></span>
</td>
<td class="nump">3,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Other Comprehensive (income) loss &#8211; Translation adjustment</a></td>
<td class="num">(341)<span></span>
</td>
<td class="nump">456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary', window );">Release of translation adjustment due to sale of subsidiary</a></td>
<td class="num">(194)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ComprehensiveIncomeNetOfTaxes', window );">Comprehensive loss (income)</a></td>
<td class="num">(1,114)<span></span>
</td>
<td class="nump">26,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations', window );">Comprehensive loss attributed to non-controlling interests (including redeemable)</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations', window );">Comprehensive loss attributed to non-controlling interests (including redeemable) from discontinued operations</a></td>
<td class="num">(492)<span></span>
</td>
<td class="num">(1,821)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss (income) attributed to Orgenesis Inc.</a></td>
<td class="num">$ (1,645)<span></span>
</td>
<td class="nump">$ 24,577<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Comprehensive income attributed to non-controlling interests (including redeemable) from continuing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Comprehensive income attributed to non-controlling interests (including redeemable) from discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ComprehensiveIncomeNetOfTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ComprehensiveIncomeNetOfTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_IncomeLossesFromDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_IncomeLossesFromDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net loss (income) from discontinued operations, net of tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ShareInNetIncomeOfAssociatedCompanies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share in net income of associated companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ShareInNetIncomeOfAssociatedCompanies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation, when the per share amount is the same.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676654722760">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Equity Attributed To Orgenesis Inc [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance, value at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 90,597<span></span>
</td>
<td class="nump">$ 669<span></span>
</td>
<td class="num">$ (65,163)<span></span>
</td>
<td class="nump">$ 26,105<span></span>
</td>
<td class="nump">$ 645<span></span>
</td>
<td class="nump">$ 26,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,540,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation to employees and directors</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,106<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,106<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">2,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock-based compensation to service providers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">893<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">893<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock-based compensation to service providers, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares', window );">Stock-based compensation for Tamir purchase agreement (See Note 3), shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_IssuanceOfSharesAndWarrantsShares', window );">Issuance of shares and warrants, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of shares related to acquisition of Koligo, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of treasury stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_StockbasedCompensationToStrategicCollaborations', window );">Stock-based compensation to strategic collaborations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,641<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_StockbasedCompensationToStrategicCollaborationsShares', window );">Stock-based compensation to strategic collaborations, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans', window );">Issuance and modification of warrants and Beneficial conversion feature of convertible loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp', window );">Transaction with non-controlling interest GPP (See Note 1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,034<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,034<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Adjustment to redemption value of redeemable non-controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(4,095)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,095)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,095)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive income (loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(456)<span></span>
</td>
<td class="num">(24,121)<span></span>
</td>
<td class="num">(24,577)<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="num">(24,679)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">94,691<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="num">(89,429)<span></span>
</td>
<td class="nump">5,477<span></span>
</td>
<td class="nump">601<span></span>
</td>
<td class="nump">6,078<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,140,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation to employees and directors</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,470<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,470<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,470<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock-based compensation to service providers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,377<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,377<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock-based compensation to service providers, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">270,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement', window );">Stock-based compensation for Tamir purchase agreement (See Note 4)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,748<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,748<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,748<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares', window );">Stock-based compensation for Tamir purchase agreement (See Note 3), shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature of convertible loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_IssuanceOfSharesAndWarrants', window );">Issuance of shares and warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,438<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,438<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,438<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_IssuanceOfSharesAndWarrantsShares', window );">Issuance of shares and warrants, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of shares related to acquisition of Koligo</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,172<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,172<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,172<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of shares related to acquisition of Koligo, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,128,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Sale of subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(413)<span></span>
</td>
<td class="num">(413)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of treasury stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(250)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(250)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of treasury stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(55,309)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Adjustment to redemption value of redeemable non-controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,160<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,160<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,160<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive income (loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">535<span></span>
</td>
<td class="nump">1,110<span></span>
</td>
<td class="nump">1,645<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="nump">1,606<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 140,397<span></span>
</td>
<td class="nump">$ 748<span></span>
</td>
<td class="num">$ (88,319)<span></span>
</td>
<td class="nump">$ 52,579<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">$ 52,728<span></span>
</td>
<td class="num">$ (250)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,167,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">out of which 30,000 shares
    have additional restrictions on transfer until services have been provided.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Transaction With noncontrolling interest GPP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance and modification of warrants and beneficial conversion feature of convertible loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_IssuanceOfSharesAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_IssuanceOfSharesAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_IssuanceOfSharesAndWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares and warrants, shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_IssuanceOfSharesAndWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation for Tamir purchase agreement, shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation for Tamir purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_StockbasedCompensationToStrategicCollaborations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation to strategic collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_StockbasedCompensationToStrategicCollaborations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_StockbasedCompensationToStrategicCollaborationsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation to strategic collaborations, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_StockbasedCompensationToStrategicCollaborationsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e34017-109320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676578472152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 579<span></span>
</td>
<td class="num">$ (26,041)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,847<span></span>
</td>
<td class="nump">3,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationOne', window );">Stock-based compensation for strategic collaborations</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationTwo', window );">Stock-based compensation for Tamir Purchase Agreement (See Notes 4)</a></td>
<td class="nump">17,048<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Capital loss (gain), net</a></td>
<td class="nump">22<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary', window );">Gain on disposal of subsidiaries</a></td>
<td class="num">(96,918)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareInNetIncomeOfAssociatedCompanies', window );">Share in income of associated company</a></td>
<td class="num">(106)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="nump">1,435<span></span>
</td>
<td class="nump">3,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances', window );">Effect of exchange differences on inter-company balances</a></td>
<td class="num">(618)<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_NetChangesInOperatingLeases', window );">Net changes in operating leases</a></td>
<td class="nump">14<span></span>
</td>
<td class="num">(339)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseShortTermBorrowings', window );">Interest expense accrued on loans and convertible loans (including amortization of beneficial conversion feature)</a></td>
<td class="nump">927<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>&#160;&#160;&#160;&#160;&#160;Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable</a></td>
<td class="num">(1,350)<span></span>
</td>
<td class="num">(5,308)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventory</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(414)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Increase in other assets</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Increase in prepaid expenses, other accounts receivable</a></td>
<td class="num">(1,073)<span></span>
</td>
<td class="num">(112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase in accounts payable</a></td>
<td class="nump">1,985<span></span>
</td>
<td class="nump">4,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_IncreaseDecreaseInAccuredExpensesAndOtherPayables', window );">Increase (decrease) in accrued expenses and other payable</a></td>
<td class="num">(1,156)<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Increase (decrease) in employee and related payables</a></td>
<td class="num">(170)<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease) in contract liabilities</a></td>
<td class="num">(166)<span></span>
</td>
<td class="nump">3,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant', window );">Change in advance payments and receivables on account of grant, net</a></td>
<td class="nump">140<span></span>
</td>
<td class="num">(247)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Increase (decrease) in deferred taxes</a></td>
<td class="num">(1,378)<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(78,046)<span></span>
</td>
<td class="num">(13,220)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForLongTermLoansForRelatedParties', window );">Increase in loan to JV partner, a related party</a></td>
<td class="num">(500)<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Repayment in loan to JV partner, a related party</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sale of property, plants and equipment</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plants and equipment</a></td>
<td class="num">(1,525)<span></span>
</td>
<td class="num">(12,129)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of Koligo, net of cash acquired (See Note 4)</a></td>
<td class="num">(955)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates', window );">Proceed from sale of subsidiaries, net</a></td>
<td class="nump">105,634<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_PaymentsForInvestments', window );">Investment in associated company</a></td>
<td class="num">(69)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Repayment (investment) in short term deposits</a></td>
<td class="nump">18<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used) in investing activities</a></td>
<td class="nump">105,610<span></span>
</td>
<td class="num">(13,778)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RepaymentOfTreasuryStock', window );">Repurchase of treasury stock</a></td>
<td class="num">(250)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Increase in redeemable non-controlling interests received from GPP</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">13,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of shares, warrants and exercise of options (net of transaction costs)</a></td>
<td class="nump">8,738<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible loans (net of transaction costs)</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">11,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible loans and convertible bonds</a></td>
<td class="num">(2,400)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of short and long-term debt</a></td>
<td class="num">(457)<span></span>
</td>
<td class="num">(772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of loans payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">5,881<span></span>
</td>
<td class="nump">24,098<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="nump">33,445<span></span>
</td>
<td class="num">(2,900)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">82<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF YEAR</a></td>
<td class="nump">12,041<span></span>
</td>
<td class="nump">14,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF YEAR</a></td>
<td class="nump">45,568<span></span>
</td>
<td class="nump">12,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW TRANSACTIONS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid in cash during the year</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes, net of refunds paid in cash during the year</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL NON-CASH FINANCING AND INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_FinanceLeasesOfPropertyPlantAndEquipment', window );">Finance Leases of property, plant and equipment</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities', window );">Right-of-use assets acquired in exchange for right-of-use liabilities</a></td>
<td class="nump">967<span></span>
</td>
<td class="nump">8,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable', window );">Purchase of property, plant and equipment included in accounts payable</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">1,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Transaction costs of issuance of convertible loans</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_AcquisitionOfOtherAssetInExchangeForCommonStocks', window );">Acquisition of other asset in exchange for common stocks</a></td>
<td class="nump">700<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo', window );">Issuance of common stocks in connection with the acquisition of Koligo</a></td>
<td class="nump">$ 11,172<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_AcquisitionOfOtherAssetInExchangeForCommonStocks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of other asset in exchange for common stocks.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_AcquisitionOfOtherAssetInExchangeForCommonStocks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_FinanceLeasesOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance leases of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_FinanceLeasesOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_IncreaseDecreaseInAccuredExpensesAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in accrued expenses and other payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_IncreaseDecreaseInAccuredExpensesAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effect of exchange differences on inter-company balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in advance payments and receivables on account of grant, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stocks in connection with the acquisition of Koligo.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_NetChangesInOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net changes in operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_NetChangesInOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_PaymentsForInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in associated company</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_PaymentsForInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of property, plant and equipment included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_RepaymentOfTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repurchase of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_RepaymentOfTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-use assets acquired in exchange for right-of-use liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ShareBasedCompensationOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation to for strategic collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ShareBasedCompensationOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ShareBasedCompensationTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation for Tamir Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ShareBasedCompensationTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ShareInNetIncomeOfAssociatedCompanies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share in net income of associated companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ShareInNetIncomeOfAssociatedCompanies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOrLossOnSaleOfStockInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate interest expense incurred on short-term borrowings including commercial paper and Federal funds purchased and securities sold under agreements to repurchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForLongTermLoansForRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow or outflow associated with long-term loans for related parties where one party can exercise control or significant influence over another party, including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from (Payments for) Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForLongTermLoansForRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676577603080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text"><p id="xdx_809_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z1wFQBsa56jj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
1 &#8211; <span id="xdx_82E_zKn9KP3uNTw5">DESCRIPTION OF BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>a.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>General</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
Inc., a Nevada corporation, is a global biotech company working to unlock the potential of cell and gene therapies in an affordable
and accessible format (&#8220;CGTs&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">CGTs
can be centered on autologous (using the patient&#8217;s own cells) or allogenic (using master banked donor cells) and are part
of a class of medicines referred to as advanced therapy medicinal products (ATMP). The Company mostly focusses on autologous therapies,
with processes and systems that are developed for each therapy using a closed and automated processing system approach that is
validated for compliant production near the patient at their point of care for treatment of the patient. This approach has the
potential to overcome the limitations of traditional commercial manufacturing methods that do not translate well to commercial
production of advanced therapies due to their cost prohibitive nature and complex logistics to deliver the treatments to patients
(ultimately limiting the number of patients that can have access to, or can afford, these therapies).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">To
achieve these goals, the Company has developed a Point of Care Platform comprised of three enabling components: a pipeline of
licensed <b>POCare Therapies</b> that are designed to be processed and produced in closed, automated <b>POCare Technology</b>
systems across a collaborative <b>POCare Network</b>. Via a combination of science, technology, engineering, and networking, the
Company is working to provide a more efficient and scalable pathway for advanced therapies to reach patients more rapidly at lowered
costs. The Company also draws on extensive medical expertise to identify promising new autologous therapies to leverage within
the POCare Platform either via ownership or licensing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
POCare Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide with a goal of
achieving harmonized, regulated clinical development and production of the therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Over
time, the Company has worked to develop and validate POCare Technologies that can be combined within mobile production units for
advanced therapies. In 2020, the Company made significant investments in the development of several types of Orgenesis Mobile
Processing Units and Labs (OMPULs) with the expectation of use and/or distribution through our POCare Network of partners, collaborators,
and joint ventures. As of the date of this report, the OMPULs are still in the development stage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">OMPULs
are designed for the purpose of validation, development, performance of clinical trials, manufacturing and/or processing of potential
or approved cell and gene therapy products in a safe, reliable, and cost-effective manner at the point of care, as well as the
manufacturing of such CGTs in a consistent and standardized manner in all locations. The design delivers a potential industrial
solution for the Company to deliver CGTs to practically any clinical institution at the point of care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Until
December 31, 2019, the Company operated the POCare Platform as one of two business separate business segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Historically,
the second separate business segment was operated as a Contract Development and Manufacturing Organization (&#8220;CDMO&#8221;)
platform, providing contract manufacturing and development services for biopharmaceutical companies (the &#8220;CDMO Business&#8221;).
The CDMO platform was historically operated mainly through majority owned Masthercell Global (which consisted of the following
two subsidiaries: MaSTherCell S.A. in Belgium (&#8220;MaSTherCell&#8221;), and Masthercell U.S., LLC in the United States (&#8220;Masthercell
U.S.&#8221;) (collectively, the &#8220;Masthercell Global Subsidiaries&#8221;)).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
February 2020, the Company and GPP-II Masthercell LLC (&#8220;GPP&#8221;) sold <span id="xdx_90F_ecustom--PercentageOfOutstandingEquityInterests_iI_pii_dp_uPercentage_c20200229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zc8EpBAWrAUa" title="Percentage of outstanding equity interests">100%</span> of the outstanding equity interests of Masthercell
(the &#8220;Masthercell Business&#8221;), which comprised the majority of the Company&#8217;s CDMO Business, to Catalent Pharma
Solutions, Inc. for an aggregate nominal purchase price of $<span id="xdx_907_ecustom--AggregateNominalPurchasePrice_pn5n6_c20200201__20200229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z7YHP7JDTwFk" title="Aggregate nominal purchase price of outstanding equity interests">315</span> million, (the &#8220;Masthercell Sale&#8221;). After accounting
for GPP&#8217;s liquidation preference and equity stake in Masthercell as well as other investor interests in our Belgian subsidiary
MaSTherCell, distributions to Masthercell option holders and transaction costs, the company received approximately $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20200201__20200229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zhYswqhZwNic" title="Proceeds from Issuance or Sale of Equity">126.7</span> million.
The Company incurred an additional approximately $<span id="xdx_906_ecustom--TransactionCostIncurred_pn5n6_c20200201__20200229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zV1ELPSMkbZ3" title="Transaction cost incurred">5.6</span> million in transaction costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company determined that the Masthercell Business (&#8220;Discontinued Operation&#8221;) meets the criteria to be classified as
a discontinued operation as of the first quarter of 2020. The Discontinued Operation includes the vast majority of the previous
CDMO Business, including majority-owned Masthercell, including MaSTherCell, Masthercell U.S. and all of the Masthercell Global
Subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Since
the Masthercell Sale, the Company has entered into new joint venture agreements with new partners in various jurisdictions. This
has allowed the Company to grow its infrastructure and expand its processing sites into new markets and jurisdictions. In addition,
the Company has engaged some of these joint venture partners to perform research and development services to further develop and
adapt its systems and devices for specific purposes. The Company has been investing manpower and financial resources to focus
on developing, manufacturing and rolling out several types of OMPULs to be used and/or distributed through our POCare Network
of partners, collaborators, and joint ventures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Chief Executive Officer (&#8220;CEO&#8221;) is the Company&#8217;s chief operating decision-maker who reviews financial
information prepared on a consolidated basis. Effective from the first quarter of 2020, all of our continuing operations
are in one segment, being the point-of-care business via our POCare Platform. Therefore, no segment report has been
presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company currently conducts its core CGT business operations through itself and its subsidiaries which are all wholly-owned except
as otherwise stated (collectively, the &#8220;Subsidiaries&#8221;). The Subsidiaries are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">United
    States: Orgenesis Maryland Inc. (the &#8220;U.S. Subsidiary&#8221;) is the center of activity in North America currently focused
    on setting up of the POCare Network.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Koligo
    Therapeutics Inc. (&#8220;Koligo&#8221;) is a Kentucky corporation that was acquired in 2020 and is currently focused on developing
    the POCare network and therapies (See Note 4 for the acquisition of Koligo).</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">European
    Union: Orgenesis Belgium SRL (the &#8220;Belgian Subsidiary&#8221;) is the center of activity in Europe currently focused
    on process development and preparation of European clinical trials.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Orgenesis
    Switzerland Sarl (the &#8220;Swiss subsidiary) incorporated in October 2020 is currently focused on providing management services
    to the Company.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Israel:
    Orgenesis Ltd. (the &#8220;Israeli Subsidiary&#8221;) is a provider of regulatory, clinical and pre-clinical services, and
    Orgenesis Biotech Israel Ltd. (&#8220;OBI&#8221;) previously known as Atvio Biotech Ltd. (&#8220;Atvio&#8221;) is a provider
    of cell-processing services in Israel.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Korea:
    Orgenesis Korea Co. Ltd. (the &#8220;Korean Subsidiary&#8221;), previously known as CureCell Co. Ltd., is a provider of processing
    and pre-clinical services in Korea. The Company owns <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CureCellCoLtdMember_zg6wD7RHx4Pb" title="Equity Method Investment, Ownership Percentage">94.12%</span> of the Korean Subsidiary.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">These
consolidated financial statements include the accounts of Orgenesis Inc. and its subsidiaries including the Discontinued Operation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
April 7, 2020, the Company entered into an Asset Purchase Agreement (the &#8220;Tamir Purchase Agreement&#8221;) with Tamir Biotechnology,
Inc. (&#8220;Tamir&#8221; or &#8220;Seller&#8221;), pursuant to which the Company agreed to acquire certain assets and liabilities
of Tamir related to the discovery, development and testing of therapeutic products for the treatment of diseases and conditions
in humans, including all rights to Ranpirnase and use for antiviral therapy (collectively, the &#8220;Purchased Assets and Assumed
Liabilities&#8221; and such acquisition, the &#8220;Tamir Transaction&#8221;). The Tamir Transaction closed on April 23, 2020.
As aggregate consideration for the acquisition, the Company paid $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pn5n6_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zd5O51mhgaTc" title="Stock issued during period value acquisitions">2.5</span> million in cash and issued an aggregate of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_pii" title="Shares issued, acquisition">3,400,000</span> shares
(the &#8220;Shares&#8221;) of Common Stock to Tamir resulting in a total consideration of $<span id="xdx_90F_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zJNhl0Q0aX61" title="Business Combination, Consideration Transferred">20.2</span> million (See Note 4).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s common stock, par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_c20201231_pii" title="Common Stock, Par or Stated Value Per Share">0.0001</span> per share (the &#8220;Common Stock&#8221;) is listed and traded on the Nasdaq
Capital Market under the symbol &#8220;ORGS.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
used in this report and unless otherwise indicated, the term &#8220;Company&#8221; refers to Orgenesis Inc. and its Subsidiaries.
Unless otherwise specified, all amounts are expressed in United States Dollars.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>b.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Liquidity</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020 ,the Company has accumulated losses of approximately $<span id="xdx_900_ecustom--AccumulatedDeficit_iI_pn5n6_c20201231_zdiUdTmPhuKi" title="Accumulated losses">88</span> Million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
February 10, 2020, the Company received approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20200209__20200210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zzFiFZu6z6j7">126.7
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million, of which $<span id="xdx_90B_ecustom--RepaymentOfIntercompanyLoansAndPayables_pn5n6_c20200209__20200210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z49SNnFE192l">7.2
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million was used for the repayment of
intercompany loans and payables, from the Masthercell Sale (See Note 3). In addition, on January 20, 2020, the Company
entered into a Securities Purchase Agreement with certain investors pursuant to which the Company received gross proceeds of approximately
$<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn4n6_uUSD_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zf3ZAztQ34Ul">9.24
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million before deducting related offering
expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company invested significant resources in research and development and research and development services in 2020. The Company
believes that these investments will enable it to substantially increase revenues in the next 12 months. Based on its current
cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and
expected level of expenditures for at least 12 months from the date of the issuance of these financial statements. If there are
further increases in operating costs for facilities expansion, research and development, commercial and clinical activity or decreases
in revenues from customers, the Company may decide to seek additional financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676575368488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zJBSMdfeMNv7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
2 - <span><span id="xdx_829_z2Cc0yIxfPkf">SIGNIFICANT ACCOUNTING POLICIES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements are prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_845_eus-gaap--UseOfEstimates_zoTqjeGUG1E3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>a.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86F_zmuEvKVDb2R9">Use of Estimates in the Preparation of Financial Statements</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30.6pt"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation of our consolidated financial statements in conformity with U.S. GAAP requires us to make estimates, judgments
and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure
of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, judgments and methodologies. We base our
estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form
the basis for making judgments about the carrying values of assets, liabilities and equity, the amount of revenues and expenses
and determining whether an acquisition is a business combination or a purchase of asset. Actual results could differ from those
estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial
condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning
COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and
international customers and markets. We examined the impact of COVID-19 on our financial statements, and although there is currently
no major impact, there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_84F_eus-gaap--BusinessCombinationsPolicy_zASBMmgcRifh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>b.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_864_zIV8aZ9zoWC7">Business Combination</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company allocates the purchase price of an acquired business to the tangible and intangible assets acquired and liabilities assumed
based upon their estimated fair values on the acquisition date. Any excess of the purchase price over the fair value of the net
assets acquired is recorded as goodwill. Acquired in-process backlog, customer relations, technology, IPR&amp;D, brand name and
know how are recognized at fair value. The purchase price allocation process requires management to make significant estimates
and assumptions, especially at the acquisition date with respect to intangible assets. Direct transaction costs associated with
the business combination are expensed as incurred. The allocation of the consideration transferred in certain cases may be subject
to revision based on the final determination of fair values during the measurement period, which may be up to one year from the
acquisition date. The Company includes the results of operations of the business that it has acquired in its consolidated results
prospectively from the date of acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">If
the business combination is achieved in stages, the acquisition date carrying value of the acquirer&#8217;s previously held equity
interest in the acquire is re-measured to fair value at the acquisition date; any gains or losses arising from such re-measurement
are recognized in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_849_ecustom--OtherInvestmentsPolicyTextBlock_zxa4jeXJtTJ5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>c.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_862_zEX2xcZFX5Og">Other Investments</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
other investments, the Company applies the measurement alternative upon the adoption of ASU 2016-01, and elected to record equity
investments without readily determinable fair values at cost, less impairment, adjusted for subsequent observable price changes.
In this measurement alternative method, changes in the carrying value of the equity investments are reflected in current earnings.
Changes in the carrying value of the equity investment are required to be made whenever there are observable price changes in
orderly transactions for the identical or similar investment of the same issuer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_848_eus-gaap--DiscontinuedOperationsPolicyTextBlock_z0tAJNQJEqF6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>d.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_866_zT2nEPd7Xj7l">Discontinued operations</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Upon
divestiture of a business, the Company classifies such business as a discontinued operation, if the divested business represents
a strategic shift that has (or will have) a major effect on an entity&#8217;s operations and financial results. For disposals
other than by sale such as abandonment, the results of operations of a business would not be recorded as a discontinued operation
until the period in which the business is actually abandoned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Masthercell Business divestiture qualifies as a discontinued operation and therefore has been presented as such.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
results of businesses that have qualified as a discontinued operation have been presented as such for all reporting periods. Results
of discontinued operations include all revenues and expenses directly derived from such businesses; general corporate overhead
is not allocated to discontinued operations. Any loss or gain that arose from the divestiture of a business that qualifies as
discontinued operations is included within the results of the discontinued operations. The Company included information regarding
cash flows from discontinued operations (See Note 3).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zGbbnJW7W7Ok" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>e.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_864_z5uAMJlNwL1">Cash Equivalents</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company considers cash equivalents to be all short-term, highly liquid investments, which include money market instruments, that
are not restricted as to withdrawal or use, and short-term bank deposits with original maturities of three months or less from
the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_841_eus-gaap--ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_z0k9DUhdcDQ3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>f.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_865_zd0MD2bxejCe">Cost of research and development and research and development services, net </span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Cost
of research and development and research and development services include costs directly attributable to the conduct of research
and development activities, including the cost of salaries, stock-based compensation expenses, payroll taxes and other employees&#8217;
benefits, lab expenses, consumable equipment, courier fees, travel expenses, professional fees and consulting fees. All costs
associated with research and developments are expensed as incurred. Participation from government departments and from research
foundations for development of approved projects is recognized as a reduction of expense as the related costs are incurred. Research
and development in-process acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative
future use, is expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_84D_eus-gaap--ConsolidationPolicyTextBlock_z58jOYQ7GVW2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>g.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86B_zFu2oE6YT6Md">Principles of Consolidation</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
consolidated financial statements include the accounts of the Company and its Subsidiaries. All intercompany transactions and
balances have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_849_eus-gaap--EquityMethodInvestmentsPolicy_z6a50xTL5SCf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>h.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_869_zNyNwcNiwFv5">Non-Marketable Equity Investments</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s investments in certain non-marketable equity securities in which it has the ability to exercise significant influence,
but it does not control through variable interests or voting interests. These are accounted for under the equity method of accounting
and presented as Investment in associates, net, in the Company&#8217;s consolidated balance sheets. Under the equity method, the
Company recognizes its proportionate share of the comprehensive income or loss of the investee. The Company&#8217;s share of income
and losses from equity method investments is included in share in losses of associated company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company reviews its investments accounted for under the equity method for possible impairment, which generally involves an analysis
of the facts and changes in circumstances influencing the investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p id="xdx_840_ecustom--FunctionalCurrencyPolicyTextBlock_zoWTiL5Cyoh8" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>i.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86E_zugML1cnvI3l">Functional Currency</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
currency of the primary economic environment in which the operations of the Company and part of its Subsidiaries are conducted
is the U.S. dollar (&#8220;$&#8221; or &#8220;dollar&#8221;). The functional currency of the Belgian Subsidiaries is the Euro
(&#8220;&#8364;&#8221; or &#8220;Euro&#8221;). The functional currency of Orgenesis Korea is the Won (&#8220;KRW&#8221;). Most
of the Company&#8217;s expenses are incurred in dollars, and the source of the Company&#8217;s financing has been provided in
dollars. Thus, the functional currency of the Company and its other subsidiaries is the dollar. Transactions and balances originally
denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using
historical and current exchange rates for nonmonetary and monetary balances, respectively. For foreign transactions and other
items reflected in the statements of operations, the following exchange rates are used: (1) for transactions &#8211; exchange
rates at transaction dates or average rates and (2) for other items (derived from nonmonetary balance sheet items such as depreciation)
&#8211; historical exchange rates. The resulting transaction gains or losses are recorded as financial income or expenses. The
financial statements of the Belgian Subsidiaries and Orgenesis Korea are included in the consolidated financial statements, translated
into U.S. dollars. Assets and liabilities are translated at year-end exchange rates, while revenues and expenses are translated
at yearly average exchange rates during the year. Differences resulting from translation of assets and liabilities are presented
as other comprehensive income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zbJ1zWty11Zh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>j.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86A_zLI2WVvdPIy5">Inventory</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s inventory consists of raw material for use for the services provided. The Company periodically evaluates the quantities
on hand. Cost of the raw materials is determined using the weighted average cost method. The inventory is recorded at the lower
of cost or net realizable value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrb5SiWXpmAg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>k.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_868_z7qU0zEBmU38">Property, plant and Equipment</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Property,
plant and equipment are recorded at cost and depreciated by the straight-line method over the estimated useful lives of the related
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_890_ecustom--ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock_zh1n2tVBzNya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Annual
rates of depreciation are presented in the table below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BF_z2zA03goEqb4" style="display: none">SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Useful Life (Years)</b></span></p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Production facility</td><td style="width: 2%">&#160;</td>
    <td style="width: 32%; text-align: center"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember__srt--RangeAxis__srt--MinimumMember_zrZKyWqXBHH3" title="Weighted Average Useful Life">5</span> - <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember__srt--RangeAxis__srt--MaximumMember_zvU9vrNQ1Hj2" title="Weighted Average Useful Life">10</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zxVC4f2PFcZh" title="Weighted Average Useful Life">2</span> - <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zY76Fk7sDRRg" title="Weighted Average Useful Life">7</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office equipment and computers</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zN3XZviUAKbe" title="Weighted Average Useful Life">3</span> - <span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zZhJXWuhWnrf" title="Weighted Average Useful Life">17</span></td></tr>
</table>

<p id="xdx_8A2_z9w1ZtH7Elsl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_845_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zMSnFezUZica" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>l.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_863_zJ3WcX5X9dV7">Intangible assets</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_898_ecustom--ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock_zbOYS9vpY4p6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Intangible
assets and their useful lives are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B8_zEKSONEQ5FDi" style="display: none">SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful Life (Years)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Amortization Recorded at Comprehensive</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Loss Line Item</p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Customer Relationships</td><td style="width: 2%">&#160;</td>
    <td style="width: 22%; text-align: center"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zO06hxwW9q0a" title="Intangible assets and useful lives (Years)">10</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 44%; text-align: center">Amortization of intangible assets</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Know-How</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowhowMember_zcXooVGZJTe5" title="Intangible assets and useful lives (Years)">12</span></td><td>&#160;</td>
    <td style="text-align: center">Amortization of intangible assets</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Technology</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TechnologyMember_zEsA4tuODn0k" title="Intangible assets and useful lives (Years)">15</span></td><td>&#160;</td>
    <td style="text-align: center">Amortization of intangible assets</td></tr>
</table>

<p id="xdx_8A6_z9WCdJJlXZr2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Intangible
assets are recorded at acquisition less accumulated amortization and impairment. Definite lived intangible assets are amortized
over their estimated useful life using the straight-line method, which is determined by identifying the period over which the
cash flows from the asset are expected to be generated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_843_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zi7iV6mHs2b9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>m.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_865_zd6VISbnwa5e">Goodwill</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Goodwill represents
the excess of consideration transferred over the value assigned to the net tangible and identifiable intangible assets of businesses
acquired. Goodwill is allocated to reporting units expected to benefit from the business combination. Goodwill is not amortized
but rather tested for impairment at least annually in the fourth quarter, or more frequently if events
or changes in circumstances indicate that goodwill may be impaired. Following the sale of Masthercell the Company manages
the business as one operating segment and one reporting unit. Goodwill impairment is recognized when the quantitative assessment
results in the carrying value exceeding the fair value, in which case an impairment charge is recorded to the extent the
carrying value exceeds the fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">There
were <span id="xdx_90E_eus-gaap--GoodwillImpairmentLoss_pn5n6_do_c20200101__20201231_zPR5LqcFQzkg">no</span></span> <span style="font: 10pt Times New Roman, Times, Serif">impairment
charges to goodwill during the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zrrNaOitkMu6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>n.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_866_zOv0AtkRWS3g">Impairment of Long-lived Assets</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company reviews its property, plants and equipment, intangible assets subject to amortization and other long-lived assets for
impairment whenever events or changes in circumstances indicate that the carrying amount of an asset class may not be recoverable.
Indicators of potential impairment include: an adverse change in legal factors or in the business climate that could affect the
value of the asset; an adverse change in the extent or manner in which the asset is used or is expected to be used, or in its
physical condition; and current or forecasted operating or cash flow losses that demonstrate continuing losses associated with
the use of the asset. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying
value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected
cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is
written down to fair value, based on the related estimated discounted cash flows. There were <span id="xdx_906_eus-gaap--AssetImpairmentCharges_pn5n6_do_c20200101__20201231_z1wGWkiwhMsg" title="Impairment of long-lived asset"><span id="xdx_904_eus-gaap--AssetImpairmentCharges_pn5n6_do_c20190101__20191231_zrB1t9GtR964" title="Impairment of long-lived asset">no</span></span> impairment charges in the year
ended December 31, 2020 and 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_843_eus-gaap--IncomeTaxPolicyTextBlock_zYJB765LFvch" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>o.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86D_zJoBX6muei4">Income Taxes</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">1)
With respect to deferred taxes, income taxes are computed using the asset and liability method. Under the asset and liability
method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and
tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is
recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">2)
The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the
tax position for recognition by determining if the available evidence indicates that it is more likely than not that the position
will be sustained on examination. If this threshold is met, the second step is to measure the tax position as the largest amount
that is greater than <span id="xdx_90E_ecustom--IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent_pii_dp_uPercentage_c20200101__20201231_zXxFP1WFAnW7" title="Income tax examination, likelihood of unfavorable settlement percent">50</span>% likely of being realized upon ultimate settlement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">3)
Taxes that would apply in the event of disposal of investment in Subsidiaries have not been taken into account in computing the
deferred income taxes, as it is the Company&#8217;s intention to hold these investments and not realize them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zSIop9rtFqEe" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>p.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_865_zPzQrxQKQuEf">Stock-based Compensation</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes
stock-based compensation for the estimated fair value of share-based awards. The Company measures compensation expense for share-based
awards based on estimated fair values on the date of grant using the Black-Scholes option-pricing model. This option pricing model
requires estimates as to the option&#8217;s expected term and the price volatility of the underlying stock. The Company amortizes
the value of share-based awards to expense over the vesting period on a straight-line basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_848_ecustom--RedeemableNoncontrollingInterestPolicyTextBlock_zsEnUDcEFlxj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>q.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_866_zgCh5Z6OyJih">Redeemable Non-controlling Interest</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Non-controlling
interests with embedded redemption features, whose settlement is not at the Company&#8217;s discretion, are considered redeemable
non-controlling interest. Redeemable non-controlling interests are considered to be temporary equity and are therefore presented
as a mezzanine section between liabilities and equity on the Company&#8217;s consolidated balance sheets. Subsequent adjustment
of the amount presented in temporary equity is required only if the Company&#8217;s management estimates that it is probable that
the instrument will become redeemable. Adjustments of redeemable non-controlling interest to its redemption value are recorded
through additional paid-in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zNJx6RzESn1i" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>r.
<span id="xdx_867_zU7V6Xvszvll">Loss (income) per Share of Common Stock</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Basic
net loss (income) per share is computed by dividing the net loss (income) for the period by the weighted average
number of shares of common stock outstanding for each period. Diluted net loss (income) per share is based upon the weighted
average number of common shares and of common shares equivalents outstanding when dilutive. Common share equivalents include:
(i) outstanding stock options and warrants which are included under the treasury share method when dilutive, and (ii) common shares
to be issued under the assumed conversion of the Company&#8217;s outstanding convertible loans and debt, which are included under
the if-converted method when dilutive (See Note 14).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_z9iIMxbJLEt3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>s.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86C_zAOs2P028xn">Concentration of Credit Risk</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Financial
instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents,
bank deposits and certain receivables. The Company held these instruments with highly rated financial institutions and the Company
has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant
credit risk on these instruments apart of accounts receivable. The Company performs ongoing credit evaluations of its customers
for the purpose of determining the appropriate allowance for doubtful accounts. An appropriate allowance for doubtful accounts
is included in the accounts and netted against accounts receivable. In the year ended December 31, 2020 the Company has not experienced
any material credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Bad
debt allowance is created when objective evidence exists of inability to collect all sums owed it under the original terms of
the debit balances. Material customer difficulties, the probability of their going bankrupt or undergoing economic reorganization
and insolvency or material delays in payments are all considered indicative of reduced debtor balance value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_84E_ecustom--TreasurySharesPolicyTextBlock_zLbbSVa2voY4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>t.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86D_zCEKwbqlGi5h">Treasury shares</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company repurchases its ordinary shares from time to time on the open market and holds such shares as treasury stock. The Company
presents the cost to repurchase treasury stock as a reduction of shareholders&#8217; equity. During the years ended December 31,
2020, the Company repurchased <span id="xdx_90D_eus-gaap--TreasuryStockShares_iI_pii_c20201231_zSfcLu6T32ck">55,309</span></span>
<span style="font: 10pt Times New Roman, Times, Serif">shares. The Company did not reissue nor cancel treasury
shares during the year ended December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p id="xdx_84E_ecustom--BeneficialConversionFeatureBcfPolicyTextBlock_zcdFRGpqeFm1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>u.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_861_zwdTIHksyfce">Beneficial Conversion Feature (&#8220;BCF&#8221;)</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">When
the Company issues convertible debt, if the stock price is greater than the effective conversion price (after allocation of the
total proceeds) on the measurement date, the conversion feature is considered &#8220;beneficial&#8221; to the holder. If there
is no contingency, this difference is treated as issued equity and reduces the carrying value of the host debt; the discount is
accreted as deemed interest on the debt (See Note 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_84C_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zqsBQb7xNxJc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>v.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_862_zmJDopxvL1Jk">Other Comprehensive Loss</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other
comprehensive loss represents adjustments of foreign currency translation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p id="xdx_841_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zI8Vwp6qBLh4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>w.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_864_zmzvFYMGY2lf">Revenue from Contracts with Customers</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes revenue from contracts with customers according to ASC 606, <i>Revenue from Contracts with Customers</i> and
the related amendments (&#8220;New Revenue Standard&#8221;) to all contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s agreements are primarily service contracts that range in duration from a few months to one year. The Company recognizes
revenue when control of these services is transferred to the customer for an amount, referred to as the transaction price, which
reflects the consideration to which the Company is expected to be entitled in exchange for those goods or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
contract with a customer exists only when:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    parties to the contract have approved it and are committed to perform their respective obligations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance
    obligations&#8221;);</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company can determine the transaction price for the goods or services to be transferred; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled
    in exchange for the goods or services that will be transferred to the customer.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company does not adjust the promised amount of consideration for the effects of a significant financing component since the Company
expects, at contract inception, that the period between the time of transfer of the promised goods or services to the customer
and the time the customer pays for these goods or services to be generally one year or less. The Company&#8217;s credit terms
to customers are in average between thirty and one hundred and fifty days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Nature
of Revenue Streams</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s main revenue streams from continuing operation are POC development services and Cell Process Development
Services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>POC
Development Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Revenue
recognized under contracts for POC development services may, in some contracts, represent multiple performance obligations (where
promises to the customers are distinct) in circumstances in which the work packages are not interrelated or the customer is able
to complete the services performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">For
arrangements that include multiple performance obligations, the transaction price is allocated to the identified performance obligations
based on their relative standalone selling prices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes revenue when, or as, it satisfies a performance obligation. At contract inception, the Company determines whether
the services are transferred over time or at a point in time. Performance obligations that have no alternative use and that the
Company has the right to payment for performance completed to date, at all times during the contract term, are recognized over
time. All other Performance obligations are recognized as revenues by the company at point of time (upon completion).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Included
in POC development services is Hospital supplies revenue which is derived principally from the sale or lease of products and the
performance of services to hospitals or other medical providers. Revenue is earned and recognized when product and services are
received by the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;Significant
Judgement and Estimates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Significant
judgment is required to</span> identifying the distinct performance obligations and estimating the standalone selling price of
each distinct performance obligation, and identifying which performance obligations create assets with alternative use to the
Company, which results in revenue recognized upon completion, and which performance obligations are transferred to the customer
over time.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Practical
Expedients</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">As
part of ASC 606, the Company has adopted several practical expedients including the Company&#8217;s determination that it need
not adjust the promised amount of consideration for the effects of a significant financing component since the Company expects,
at contract inception, that the period between when the Company transfers a promised service to the customer and when the customer
pays for that service will be one year or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>Cell
Process Development Services (mainly discontinued operations)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Revenue
recognized under contracts for cell process development services may, in some contracts, represent multiple performance obligations
(where promises to the customers are distinct) in circumstances in which the work packages and milestones are not interrelated
or the customer is able to complete the services performed independently or by using competitors of the Company. In other contracts
when the above circumstances are not met, the promises are not considered distinct and the contract represents one performance
obligation. All performance obligations are satisfied over time, as there is no alternative use to the services it performs, since,
in nature, those services are unique to the customer, which retain the ownership of the intellectual property created through
the process. Additionally, due to the non-refundable upfront payment the customer pays, together with the payment term and cancellation
fine, it has a right to payment (which include a reasonable margin), at all times, for work completed to date, which is enforceable
by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
arrangements that include multiple performance obligations, the transaction price is allocated to the identified performance obligations
based on their relative standalone selling prices. For these contracts, the standalone selling prices are based on the Company&#8217;s
normal pricing practices when sold separately with consideration of market conditions and other factors, including customer demographics
and geographic location.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company measures the revenue to be recognized over time on a contract by contract basis, determining the use of either a cost-based
input method or output method, depending on whichever best depicts the transfer of control over the life of the performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>Tech
Transfer Services (discontinued operations)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Revenue
recognized under contracts for tech transfer services are considered a single performance obligation, as all work packages (including
data collection, GMP documentation, validation runs) and milestones are interrelated. Additionally, the customer is unable to
complete services of work performed independently or by using competitors of the Company. Revenue is recognized over time using
a cost-based based input method where progress on the performance obligation is measured by the proportion of actual costs incurred
to the total costs expected to complete the contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>Cell
Manufacturing Services (discontinued operations)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Revenues
from cell manufacturing services represent a single performance obligation which is recognized over time. The progress towards
completion will continue to be measured on an output measure based on direct measurement of the value transferred to the customer
(units produced).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>Reimbursed
Expenses (discontinued operations)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company includes reimbursed expenses in revenues and costs of revenue as the Company is primarily responsible for fulfilling the
promise to provide the specified service, including the integration of the related services into a combined output to the customer,
which are inseparable from the integrated service. These costs include such items as consumable, reagents, transportation and
travel expenses, over which the Company has discretion in establishing prices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Change
Orders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Changes
in the scope of work are common and can result in a change in transaction price, equipment used and payment terms. Change orders
are evaluated on a contract-by-contract basis to determine if they should be accounted for as a new contract or as part of the
existing contract. Generally, services from change orders are not distinct from the original performance obligation. As a result,
the effect that the contract modification has on the contract revenue, and measure of progress, is recognized as an adjustment
to revenue when they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Costs
of Revenue (discontinued operations)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Costs
of revenue include (i) compensation and benefits for billable employees and personnel involved in production, data management
and delivery, and the costs of acquiring and processing data for the Company&#8217;s information offerings; (ii) costs of staff
directly involved with delivering services offerings and engagements; (iii) consumables used for the services; and (iv) other
expenses directly related to service contracts such as courier fees, laboratory supplies, professional services and travel expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zM949RtKzIP9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>x.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_864_zoYBMzuMVFJe">Leases</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company adopted
the new lease standard ASC 842 and all the related amendments on January 1, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2.
If any of these five criteria is met, The Company classifies the lease as a finance lease; otherwise, the Company classifies the
lease as an operating lease. <span id="xdx_904_ecustom--LeaseClassificationDiscription_c20200101__20201231" title="Lease classification discription">When determining lease classification, the Company&#8217;s approach in assessing two of the mentioned
criteria is: (i) generally 75% or more of the remaining economic life of the underlying asset is a major part of the remaining
economic life of that underlying asset; and (ii) generally 90% or more of the fair value of the underlying asset comprises substantially
all of the fair value of the underlying asset.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Operating
leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the consolidated
balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">ROU
assets represent Orgenesis&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation
to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date
based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the
information available at the commencement date to determine the present value of the lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
standard also provides practical expedients for an entity&#8217;s ongoing accounting. The Company elected the short-term lease
recognition exemption for all leases with a term shorter than 12 months. This means that for those leases, the Company does not
recognize ROU assets or lease liabilities, including not recognizing ROU assets or lease liabilities for existing short-term leases
of those assets in transition, but recognizes lease expenses over the lease term on a straight-line basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Lease
terms will include options to extend or terminate the lease when it is reasonably certain that Orgenesis will exercise or not
exercise the option to renew or terminate the lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_84F_ecustom--RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zUdPYL8yJYz5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>y.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86B_zlPuyTRD20wc">Recently issued accounting pronouncements, not yet adopted</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2016, the FASB issued ASU 2016-13 &#8220;Financial Instruments&#8212;Credit Losses&#8212;Measurement of Credit Losses on
Financial Instruments.&#8221; This guidance replaces the current incurred loss impairment methodology with a methodology that
reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform
credit loss estimates. The guidance will be effective for Smaller Reporting Companies (SRCs, as defined by the SEC) for the fiscal
year beginning on January 1, 2023, including interim periods within that year. The Company is currently evaluating this guidance
to determine the impact it may have on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, Debt with Conversion and Other Options (Subtopic
470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments
and Contracts in an Entity&#8217;s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation
models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument
with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required
for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it.
The ASU also simplifies the diluted net income per share calculation in certain areas. The new guidance is effective for annual
and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years beginning after December
15, 2020, and interim periods within those fiscal years. The Company is currently evaluating the impact that this new guidance
will have on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zA9T2OUm4Tfi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">z.</span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86D_zHRjqYLmA3cc">Newly issued and recently adopted accounting pronouncements</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company early adopted ASU 2019-12 on January 1, 2020, which did not have a material impact on the Consolidated Financial Statements
except for the removal of the exception related to intra-period tax allocations. Commencing from January 1, 2020, the Company
followed the general intra-period allocation of tax expenses. The Company had incurred a loss from continuing operations and subsequent
to the adoption of ASU 2019-12, the Company determined the amount attributable to continuing operations without regard to the
tax effect of other items. The ASU 2019-12 amendment related to the intra-period tax allocation was applied prospectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Had
the Company not adopted ASU 2019-12, an approximately $<span id="xdx_902_eus-gaap--IncomeTaxExpenseBenefit_pn5n6_c20200101__20201231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201912Member_zgebC0H9Ojm1" title="Income Tax Expense (Benefit)">20</span> million tax benefit would have been recognized along with corresponding
decreases to net loss from continuing operations with a corresponding increase in tax expenses and decrease in net income resulting
from discontinued operations. The Company had no intra-period tax allocation items in prior years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_84D_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zhAsVeCQvSik" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>aa.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86C_z1U2luzhxRDl">Reclassifications</span> </i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Certain
reclassifications have been made to the prior years&#8217; financial statements to conform to the current year presentation. These
reclassifications had no net effect on previously reported results of operations.</span></p>

<p id="xdx_852_zoOFYUCTqTvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676576400088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">DISCONTINUED OPERATION</a></td>
<td class="text"><p id="xdx_805_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_z5kixiFfTK2e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
3 &#8211; <span id="xdx_82A_zgDFcvg3IEmk">DISCONTINUED OPERATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
February 2, 2020, the Company entered into a Purchase Agreement with GPP, Masthercell and the Buyer. Pursuant to the terms and
conditions of the Purchase Agreement, Sellers agreed to sell <span id="xdx_909_ecustom--PercentageOfOutstandingEquityInterests_iI_pii_dp_c20200202__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zvcmOPmYYGjk" title="Percentage of outstanding equity interests">100%</span> of the outstanding equity interests of Masthercell to Buyer
for an aggregate nominal purchase price of $<span id="xdx_90A_ecustom--AggregateNominalPurchasePrice_pn5n6_c20200201__20200202__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zBxUQgH60ZFg" title="Aggregate nominal purchase price of outstanding equity interests">315</span> million. The Company has determined that the Masthercell Business meets the criteria
to be classified as discontinued operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
February 10, 2020, the Masthercell Sale was consummated in accordance with the terms of the Purchase Agreement. After accounting
for GPP&#8217;s liquidation preference and equity stake in Masthercell, as well as SFPI &#8211; FPIM&#8217;s interest in MaSTherCell,
distributions to Masthercell option holders and transaction costs, the Company received approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20200209__20200210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zXXsIlh7t9H2" title="Proceeds from Issuance or Sale of Equity">126.7</span> million at the closing
of the Masthercell Sale, of which $<span id="xdx_90E_ecustom--RepaymentOfIntercompanyLoansAndPayables_pn5n6_c20200209__20200210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zTNolHBnENQe" title="Repayment of intercompany loans and payables">7.2</span> million was used for the repayment of intercompany loans and payables, including $<span id="xdx_900_ecustom--RepaymentOfIntercompanyLoansAndPayables_pn5n6_c20200209__20200210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MasthercellSAMember_zPLBGhlZ7rM6" title="Repayment of intercompany loans and payables">4.6</span> million
of payables to MaSTherCell.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Due
to the sale of the controlling interest in Masthercell, the Company retrospectively reclassified the assets and liabilities of
these entities as assets and liabilities of discontinued operations and included the financial results of these entities as discontinued
operations in the Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Discontinued
operations relate to the Masthercell Business. The comprehensive loss and balance sheet for this operation are separately reported
as discontinued operations for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zmkQyrHutPYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
financial results of the Masthercell Business are presented as income (loss) from discontinued operations, net of income taxes
on the Company&#8217;s consolidated statement of comprehensive loss. The following table presents the financial results associated
with the Masthercell Business operation as reflected in the Company&#8217;s Consolidated Comprehensive loss (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;<span id="xdx_8B6_zpoTCAyl7kKi" style="display: none">SCHEDULE OF DISCONTINUED OPERATION AND BALANCE SHEETS</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"/><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">OPERATIONS</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231_zeOdHvQTFCM3" style="width: 14%; text-align: right" title="Revenues">2,556</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231_zDshnLGkj0M8" style="width: 14%; text-align: right" title="Revenues">31,053</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c20200101__20201231_pn3n3" style="text-align: right" title="Cost of revenues">1,482</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c20190101__20191231_pn3n3" style="text-align: right" title="Cost of revenues">18,318</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cost of research and development and research and development services, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet_c20200101__20201231_pn3n3" style="text-align: right" title="Cost of research and development and research and development services, net">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet_c20190101__20191231_pn3n3" style="text-align: right" title="Cost of research and development and research and development services, net">54</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amortization of intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DepreciationAndAmortizationDiscontinuedOperations_c20200101__20201231_pn3n3" style="text-align: right" title="Amortization of intangible assets">137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DepreciationAndAmortizationDiscontinuedOperations_c20190101__20191231_pn3n3" style="text-align: right" title="Amortization of intangible assets">1,631</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling, general and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c20200101__20201231_pn3n3" style="text-align: right" title="Selling, general and administrative expenses">1,896</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c20190101__20191231_pn3n3" style="text-align: right" title="Selling, general and administrative expenses">13,886</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other (income) expenses, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherExpenses_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other (income) expenses, net">305</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherExpenses_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other (income) expenses, net">(207</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_c20200101__20201231_pn3n3" style="text-align: right" title="Operating loss">1,271</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_c20190101__20191231_pn3n3" style="text-align: right" title="Operating loss">2,629</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Financial expenses (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet_pn3n3_c20200101__20201231_zGXmlGGliLjl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Financial expenses (income), net">(29</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet_pn3n3_c20190101__20191231_ztHwbrb670Ki" style="border-bottom: Black 1.5pt solid; text-align: right" title="Financial expenses (income), net">31</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_c20200101__20201231_pn3n3" style="text-align: right" title="Loss before income taxes">1,242</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_c20190101__20191231_pn3n3" style="text-align: right" title="Loss before income taxes">2,660</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax expenses (income)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DiscontinuedOperationTaxEffectOfDiscontinuedOperation_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Tax expenses (income)">(30</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DiscontinuedOperationTaxEffectOfDiscontinuedOperation_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Tax expenses (income)">792</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss from discontinuing operation, net of tax</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_ecustom--IncomeLossFromDiscontinuedOperationNetOfTax_c20200101__20201231_pn3n3" style="text-align: right" title="Net loss from discontinuing operation, net of tax">1,212</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--IncomeLossFromDiscontinuedOperationNetOfTax_c20190101__20191231_pn3n3" style="text-align: right" title="Net loss from discontinuing operation, net of tax">3,452</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">DISPOSAL</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on disposal before income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_c20200101__20201231_pn3n3" style="text-align: right" title="Gain on disposal before income taxes">96,918</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_c20190101__20191231_pn3n3" style="text-align: right" title="Gain on disposal before income taxes"><span style="-sec-ix-hidden: xdx2ixbrl0958">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Provision for income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Provision for income taxes"><span style="-sec-ix-hidden: xdx2ixbrl0960">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"/><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Provision for income taxes"><span style="-sec-ix-hidden: xdx2ixbrl0962">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on disposal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_c20200101__20201231_pn3n3" style="text-align: right" title="Gain on disposal">96,918</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_c20190101__20191231_pn3n3" style="text-align: right" title="Gain on disposal"><span style="-sec-ix-hidden: xdx2ixbrl0966">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net profit (loss) from discontinuing operation, net of tax</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--NetProfitLossFromDiscontinuingOperationNetOfTax_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net profit (loss) from discontinuing operation, net of tax">95,706</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--NetProfitLossFromDiscontinuingOperationNetOfTax_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net profit (loss) from discontinuing operation, net of tax">(3,452</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table is a summary of the assets and liabilities of discontinued operations (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 78%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_pn3n3_c20191231_zVVTRihLJ2J2" style="width: 18%; text-align: right" title="Cash and cash equivalents">11,281</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--DisposalGroupIncludingDiscontinuedOperationRestrictedCash_c20191231_pn3n3" style="text-align: right" title="Restricted cash">186</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_c20191231_pn3n3" style="text-align: right" title="Accounts receivable, net">6,654</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_c20191231_pn3n3" style="text-align: right" title="Prepaid expenses and other receivables">845</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Grants receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--DisposalGroupIncludingDiscontinuedOperationGrantsReceivable_c20191231_pn3n3" style="text-align: right" title="Grants receivable">1,979</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DisposalGroupIncludingDiscontinuedOperationInventory1_c20191231_pn3n3" style="text-align: right" title="Inventory">1,907</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--DisposalGroupIncludingDiscontinuedOperationsDeposits_c20191231_pn3n3" style="text-align: right" title="Deposits">326</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_c20191231_pn3n3" style="text-align: right" title="Property and equipment, net">22,149</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Intangible assets, net (mainly Know How)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_iI_pn3n3_c20191231_zGQWzg7mr6C4" style="text-align: right" title="Intangible assets, net (mainly Know How)">10,858</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets_c20191231_pn3n3" style="text-align: right" title="Operating lease right-of-use assets">8,860</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGoodwill1_c20191231_pn3n3" style="text-align: right" title="Goodwill">10,129</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherAssets_c20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other assets">47</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL CURRENT ASSETS OF DISCONTINUED OPERATIONS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperation_iI_pn3n3_c20191231_z50nh6viLcIc" style="border-bottom: Black 2.5pt double; text-align: right" title="TOTAL CURRENT ASSETS OF DISCONTINUED OPERATIONS">75,221</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 78%; text-align: left">Accounts payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayable_c20191231_pn3n3" style="width: 18%; text-align: right" title="Accounts payable">5,756</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_c20191231_pn3n3" style="text-align: right" title="Accrued expenses and other payables">372</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Employees and related payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables_c20191231_pn3n3" style="text-align: right" title="Employees and related payables">2,047</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Advance payments on account of grant</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant_c20191231_pn3n3" style="text-align: right" title="Advance payments on account of grant">2,227</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Short-term loans and current maturities of long- term loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans_c20191231_pn3n3" style="text-align: right" title="Short-term loans and current maturities of long- term loans">372</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Contract liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_c20191231_pn3n3" style="text-align: right" title="Contract liabilities">8,301</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Current maturities of long-term finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases_c20191231_pn3n3" style="text-align: right" title="Current maturities of long-term finance leases">291</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Current maturities of operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases_c20191231_pn3n3" style="text-align: right" title="Current maturities of operating leases">1,365</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Non-current operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases_c20191231_pn3n3" style="text-align: right" title="Non-current operating leases">7,069</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loans payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--DisposalGroupIncludingDiscontinuedOperationLoansPayable_c20191231_pn3n3" style="text-align: right" title="Loans payable">1,230</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Deferred taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_c20191231_pn3n3" style="text-align: right" title="Deferred taxes">1,868</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Long-term finance leases</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases_c20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Long-term finance leases">688</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL CURRENT LIABILITIES OF DISCONTINUED OPERATIONS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="TOTAL CURRENT LIABILITIES OF DISCONTINUED OPERATIONS">31,586</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Property,
plants and equipment, net and right-of-use assets by geographical location were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--PropertyPlantAndEquipmentNetAndRightOfUseAssets_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--US_zphmKqdJ6fB6" style="width: 26%; text-align: right" title="Property, plants and equipment, net and right-of-use assets">16,707</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Belgium</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--PropertyPlantAndEquipmentNetAndRightOfUseAssets_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--BE_zrqOc8vCk7Rc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property, plants and equipment, net and right-of-use assets">14,302</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--PropertyPlantAndEquipmentNetAndRightOfUseAssets_iI_pn3n3_c20191231_zJ5y9rAN0zs2" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, plants and equipment, net and right-of-use assets">31,009</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table represents the components of the cash flows from discontinued operations (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net cash flows used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_pn3n3_c20200101__20201231_zacoQ03y73D4" style="width: 14%; text-align: right" title="Net cash flows provided by (used in) operating activities">(2,409</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_c20190101__20191231_pn3n3" style="width: 14%; text-align: right" title="Net cash flows provided by (used in) operating activities">(1,248</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash flows used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_c20200101__20201231_pn3n3" style="text-align: right" title="Net cash flows used in investing activities">(579</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_c20190101__20191231_pn3n3" style="text-align: right" title="Net cash flows used in investing activities">(11,621</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash flows (used in) provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_c20200101__20201231_pn3n3" style="text-align: right" title="Net cash flows (used in) provided by financing activities">(51</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_c20190101__20191231_pn3n3" style="text-align: right" title="Net cash flows (used in) provided by financing activities">12,570</td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AB_zMbRXlROwq2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Disaggregation
of Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_896_ecustom--ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock_zCO9x69k1qOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table disaggregates the Company&#8217;s revenues by major revenue streams related to discontinued operations (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zm80mblxonAi" style="display: none">SCHEDULE OF DISAGGREGATION OF REVENUE RELATED TO DISCONTINUED OPERATIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Revenue stream:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Cell process development services</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesMember_zmYvscrkc938" style="width: 14%; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue">2,556</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231__srt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesMember_zi8SlHnnKwZ1" style="width: 14%; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue">20,834</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Tech transfer services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--TechTransferServicesMember_zcAyJvlL4sxc" style="text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue"><span style="-sec-ix-hidden: xdx2ixbrl1048">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231__srt--ProductOrServiceAxis__custom--TechTransferServicesMember_zbf29ju37tFf" style="text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue">5,396</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Cell manufacturing services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--CellManufacturingServicesMember_zdo3UKetmdie" style="border-bottom: Black 1.5pt solid; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231__srt--ProductOrServiceAxis__custom--CellManufacturingServicesMember_zo6KYpAjIKDb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue">4,823</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231_zDS1Tqq4vpk3" style="border-bottom: Black 2.5pt double; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue">2,556</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231_z3CT2nlfEL76" style="border-bottom: Black 2.5pt double; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue">31,053</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AE_zdgAKf1XHhVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Redeemable
Non-Controlling Interest of Discontinued Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>a.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Subscription
    and Shareholders Agreement with Belgian Sovereign Funds Soci&#233;t&#233; F&#233;d&#233;rale de Participations et
    d&#8217;Investissement (&#8220;SFPI&#8221;).</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
November 15, 2017, the Company, MaSTherCell and SFPI entered into a Subscription and Shareholders Agreement (&#8220;SFPI Agreement&#8221;)
pursuant to which SFPI made an equity investment in MaSTherCell.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Due
to the embedded redemption feature of the SPFI agreement whose settlement was not at the Company discretion, the Company had accounted
for the investment made by GPP as a redeemable non-controlling interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>b.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Stock
    Purchase Agreement and Stockholders&#8217; Agreement with Great Point Partners, LLC (&#8220;GPP&#8221;)</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
June 28, 2018, the Company, Masthercell Global GPP, and certain of GPP&#8217;s affiliates, entered into a series of
definitive strategic agreements intended to finance, strengthen and expand Orgenesis&#8217; CDMO business. Due to the
embedded redemption feature of the GPP agreement whose settlement was not at the Company discretion, the Company had
accounted for the investment made by GPP as a redeemable non-controlling interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676573204056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION AND REORGANIZATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisclosureAcquisitionAndReorganizationAbstract', window );"><strong>Acquisition And Reorganization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_AcquisitionAndReorganizationTextBlock', window );">ACQUISITION AND REORGANIZATION</a></td>
<td class="text"><p id="xdx_805_ecustom--AcquisitionAndReorganizationTextBlock_zApP4DXnF3ge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
4 &#8211; <span id="xdx_82F_zNMSOub0OWC3">ACQUISITION AND REORGANIZATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Tamir
Biotechnology, Inc.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
April 7, 2020, the Company entered into the Tamir Purchase Agreement with Tamir, pursuant to which the Company agreed to acquire
certain assets and liabilities of Tamir related to the discovery, development and testing of therapeutic products for the treatment
of diseases and conditions in humans, including all rights to Ranpirnase and use for antiviral therapy. The Tamir Transaction
closed on April 23, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
aggregate consideration for the acquisition, the Company paid $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pn5n6_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zBxjUOcsNzRi" title="Stock issued during period value acquisitions">2.5</span> million in cash and issued an aggregate of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pii_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zbTMUQ8HNTBi" title="Shares issued, acquisition">3,400,000</span> shares
(the &#8220;Shares&#8221;) of Common Stock to Tamir resulting in a total consideration of $<span id="xdx_90D_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zAvLQRdRVvGe" title="Business Combination, Consideration Transferred">20.2</span> million based on the Company&#8217;s
share price at the closing date. $<span id="xdx_907_eus-gaap--EscrowDeposit_iI_pn3n3_c20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zKluibrst0Wd" title="Escrow Deposit">59</span> thousand and <span id="xdx_901_ecustom--NumberOfSharesDepositInEscrowAccount_pii_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zRn641sDS4g2" title="Number of shares deposit in escrow account">340,000</span> Shares are being held in an escrow account for a period of 18 months
from closing to secure indemnification obligations of Tamir pursuant to the terms of the Tamir Purchase Agreement. $<span id="xdx_900_ecustom--BusinessCombinationConsiderationTransferred_pn5n6_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zTibqOyYTWCf" title="Total consideration">4.5</span> million
of the consideration was attributable to research and development related inventory and most of the remaining amount reflected
the cost of intangible assets. The Shares were registered for resale by the Company in November 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s acquired right to Tamir&#8217;s intellectual property represents a single identifiable asset sourced from the
agreement. Because substantially all (more than 90%) of the fair value of the gross assets acquired are concentrated in a single
asset being the right to Tamir&#8217;s intellectual property and related assets (&#8220;IPR&amp;D&#8221;), the Company determined
that the acquisition is not considered a business in accordance with ASC 805-10-55-5A. Therefore, the Company accounted the transaction
as an asset acquisition. The fair value associated with Tamir&#8217;s IPR&amp;D in the amount of $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_z0ewOEClv3wl" title="Research and Development Expense">19.5</span> million was charged to
research and development expenses under ASC 730. The remaining amount was attributed to the above-mentioned share in a private
company, which is presented in the balance sheet as long term &#8220;other assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Description
of Koligo Acquisition during 2020</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
September 26, 2020, the Company entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;)
by and among the Company, Orgenesis Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (&#8220;Merger
Sub&#8221;), Koligo Therapeutics Inc., a Kentucky corporation (&#8220;Koligo&#8221;), the shareholders of Koligo (collectively,
the &#8220;Shareholders&#8221;), and Long Hill Capital V, LLC (&#8220;Long Hill&#8221;), solely in its capacity as the representative,
agent and attorney-in-fact of the Shareholders. The Merger Agreement provides for the acquisition of Koligo by the Company through
the merger of Merger Sub with and into Koligo, with Koligo surviving as a wholly-owned subsidiary of the Company (the &#8220;Merger&#8221;).
The acquisition was completed on October 15, 2020 (the &#8220;Effective Time&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Koligo
is a privately-held US regenerative medicine company. Koligo&#8217;s first commercial product is KYSLECEL&#174; (autologous pancreatic
islets) for chronic and acute recurrent pancreatitis. Koligo&#8217;s 3D-V technology platform incorporates the use of advanced
3D bioprinting techniques and vascular endothelial cells to support development of transformational cell and tissue products for
serious diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the terms of the Merger Agreement, at the Effective Time, the shares of capital stock of Koligo that were issued and outstanding
immediately prior to the Effective Time were automatically cancelled and converted into the right to receive, subject to customary
adjustments, an aggregate of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pii_c20201014__20201015__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--MaterialDefinitiveAgreementMember_zGcVmhNbUwB3">2,061,713
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Company common stock which
have been issued to Koligo&#8217;s accredited investors (with certain non-accredited investors being paid solely in cash in
the amount of approximately $<span id="xdx_905_ecustom--CashPaidToAccreditedInvestors_pn3n3_c20201014__20201015__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--MaterialDefinitiveAgreementMember_zGpx3FcbLVmk" title="Cash paid to accredited investors">20
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand). In addition, we issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20201014__20201015__dei--LegalEntityAxis__custom--MaximaGroupLLCMember_zpCXUCeVXnr4">66,910</span>
shares to Maxim Group LLC for advisory services</span><span style="font: 10pt Times New Roman, Times, Serif"> in connection
with the Merger. The share price was $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pii_c20201015__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--MaterialDefinitiveAgreementMember_zm7taXrIMAj7">5.26
</span></span><span style="font: 10pt Times New Roman, Times, Serif">at the day of the closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Merger Agreement contains customary indemnification provisions whereby the Shareholders of Koligo will indemnify the Company and
certain affiliated parties for any losses arising out of breaches of the representations, warranties and covenants of Koligo and
the Shareholders under the Merger Agreement. As partial security for the indemnification and purchase price adjustment obligations
of Koligo shareholders under the Merger Agreement, $<span id="xdx_90F_eus-gaap--EscrowDeposit_iI_pn3n3_c20201015__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--MaterialDefinitiveAgreementMember_z40mcdEKpc7a" title="Cash held in escrow account">7</span> thousand in cash and <span id="xdx_909_ecustom--SharesHeldInEscrow_pii_c20201014__20201015__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--MaterialDefinitiveAgreementMember_zd5VTQj77s6g" title="Shares held in escrow">328,587</span> shares of Company common stock of the merger
consideration otherwise payable in the Merger to the Shareholders were placed in a third party escrow account. The aggregate indemnification
obligations of the Koligo shareholders under the Merger Agreement is capped at the amounts in escrow, subject to certain limited
exceptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, according to the agreement between the parties, the Company has also funded an additional cash consideration of $<span id="xdx_900_ecustom--AdditionalCashConsideration_pn3n3_c20201014__20201015__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--MaterialDefinitiveAgreementMember_zbdhd01wAtwh" title="Additional cash consideration">500</span>
thousand (with $<span id="xdx_90D_ecustom--ReductionInConsiderationPayable_pn3n3_c20201014__20201015__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--MaterialDefinitiveAgreementMember_zLTXPNlbeaGa" title="Reduction in consideration payable">100</span> thousand of such reducing the ultimate consideration payable to Koligo) for the acquisition of the assets
of Tissue Genesis, LLC (&#8220;Tissue Genesis&#8221;) by Koligo that was consummated on October 14, 2020. The Tissue Genesis assets
include the entire inventory of Tissue Genesis Icellator&#174; devices, related kits and reagents, a broad patent portfolio to
protect the technology, registered trademarks, clinical data, and existing business relationships for commercial and development
stage use of the Icellator technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with the Merger Agreement, the Company, Long Hill and Maxim Group LLC (&#8220;Maxim&#8221;) entered into a Registration
Rights and Lock-Up Agreement pursuant to which Long Hill will have one demand registration right to require the registration of
the shares of Company common stock received by Long Hill in the Merger and Long Hill and Maxim will have certain piggyback registration
rights. In addition, Long Hill agreed with the Company that, during the applicable Restriction Period (as defined below), it shall
not sell or transfer, subject to certain limited exceptions, the portion of the shares received in the Merger during the applicable
Restriction Period, subject to a limitation on the number of shares sold per any trading day not to exceed <span id="xdx_90D_ecustom--RestrictionOnSaleOfSharesPercentage_pii_dp_uPercentage_c20201014__20201015__dei--LegalEntityAxis__custom--LongHillAndMaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsandLockUpAgreementMember_z32ak6MQfMZ2" title="Restriction on sale of shares percentage">10</span>% of the average
daily trading volume of the Common Stock, as reported by Bloomberg Financial L.P. &#8220;Restriction Period&#8221; means <span id="xdx_904_ecustom--RestrictionPeriodDescription_c20201014__20201015__dei--LegalEntityAxis__custom--LongHillAndMaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsandLockUpAgreementMember_z1Y7fRHKmZ3b" title="Restriction period, description">(a) in
relation to 70% of all of the shares received in the Merger that Long Hill is entitled to receive under or in connection with
the Merger Agreement, the period beginning on the date of the closing and ending on the date that is the four month anniversary
thereof, and (b) in relation to the remaining 30% of all of the shares received in the Merger that Long Hill is entitled to receive
under or in connection with the Merger Agreement, the period beginning on the date of the closing and ending on the date that
is the twelve month anniversary thereof</span>. All of the shares required to be registered by the Company pursuant to the Registration
Rights and Lock-Up Agreement were registered by the Company in November 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, pursuant to separate Lock-Up Agreements entered into by the Shareholders other than Long Hill with the Company (the
&#8220;Shareholders Lock-Up Agreement&#8221;), such Shareholders agreed that they will not transfer any of their shares received
in the Merger except in accordance with the following lock-up release schedule whereby one fifth of such holder&#8217;s respective
shares will be released from such restriction every six months, starting six months from the closing of the Merger. Each holder&#8217;s
sales of such shares are subject to a resale limit of its pro rata portion of 10% of the average daily trading volume, allocated
to the Shareholders other than Long Hill pro-rata.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
acquisition was accounted in accordance with Accounting Standards Codification Topic 805, &#8220;Business Combinations&#8221;.
The allocation of the consideration transferred in certain cases may be subject to revision based on the final determination of
fair values during the measurement period, which may be up to one year from the acquisition date. The Company includes the results
of operations of the business that it has acquired in its consolidated results prospectively from the date of acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Fair
Value of Consideration Transferred</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zWeonuaKo7se" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the allocation of purchase price to the fair values of the assets acquired and liabilities assumed
as of the transaction date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B2_z8408OO7tIP9" style="display: none">SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20201231_z1qrVyAOpNob" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued_iI_pn3n3_maBCRIAzxgu_zpZljblX2cRk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%">Fair value of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_ecustom--FairValuePercentageofSharesIssued_iI_pii_dp_uPercentage_c20201231_zmr08iQJvnDa" title="Fair value percentage of shares issued">8.8</span>% of shared issued *</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"><span id="xdx_F47_zz9L2sR0yq73" style="display: none; font-family: Times New Roman, Times, Serif">*</span></td><td style="width: 18%; text-align: right">11,172</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments_iI_pn3n3_maBCRIAzxgu_ziNdtG7LgITh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash payment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,115</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_pn3n3_mtBCRIAzxgu_zxQF4lTwThg8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total consideration transferred</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,287</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td id="xdx_F01_zLuqe2CpwNid" style="width: 1.2%">*</td>
    <td id="xdx_F1F_zSzpzffwMp64" style="width: 50%">Fair value of the consideration is based on the company&#8217;s market share price.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Total assets acquired:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 78%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pn3n3_c20201231_zaA0VUMeje8b" style="width: 18%; text-align: right" title="Cash and cash equivalents">8</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Restricted Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_iI_pn3n3_c20201231_zzdW7jHhqefd" style="text-align: right" title="Restricted Cash">152</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts Receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_pn3n3_c20201231_zmNyRNKuCKLk" style="text-align: right" title="Accounts Receivable">228</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iI_pn3n3_c20201231_zq9T4Dy5pkpl" style="text-align: right" title="Inventory">34</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_iI_pn3n3_c20201231_ztTVWWU6d3Td" style="text-align: right" title="Other assets">25</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Property, plants and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pn3n3_c20201231_zYmz0iITYuui" style="text-align: right" title="Property, plants and equipment, net">482</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Kyslecel Technology (a)</td><td id="xdx_F46_zu1500R9cTqk" style="display: none">(a)</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_fYQ_____zKffF8VCEZO7" style="text-align: right" title="Other intangible assets">9,340</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">IPR&amp;D (a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_fYQ_____zidQJTdSBsef" style="text-align: right" title="Other intangible assets">641</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_iI_pn3n3_c20201231_z9LX9XnVFREh" style="text-align: right" title="Operating lease right-of-use assets">238</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Goodwill (b)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill_iI_pn3n3_c20201231_fYg_____zAz3kQsaxVRf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill">3,704</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_pn3n3_c20201231_zRe9GSXqKHJ" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total assets">14,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Total liabilities assumed:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease_iI_pn3n3_c20201231_zKR13To8FmJ7" style="text-align: right" title="Operating leases">238</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_pn3n3_c20201231_ze56KYhWrkt5" style="text-align: right" title="Accounts Payable">216</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_iI_pn3n3_c20201231_zgv0xezpFr98" style="text-align: right" title="Accrued Expenses">4</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Orgenesis Inc loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability_iI_pn3n3_c20201231_zuLlfxIelzwa" style="text-align: right" title="Orgenesis Inc loan">651</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Deferred taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_iI_pn3n3_c20201231_zu8WyHo2SLR9" style="text-align: right" title="Deferred taxes">1,293</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Notes Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_iI_pn3n3_c20201231_zvF4ICtmkrCe" style="text-align: right" title="Notes Payable">162</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_iI_pn3n3_c20201231_zWoir7e4LwZ3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other liabilities">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_pn3n3_c20201231_zcqPJQYzOgd3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total liabilities">2,565</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; padding-bottom: 2.5pt">Total consideration transferred</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pn3n3_c20201231_zIIXbRMFwIa4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred">12,287</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1.2%; text-align: right"><span id="xdx_F0D_zmsOFibs8cqa" style="font: 10pt Times New Roman, Times, Serif">a.</span></td><td style="text-align: justify; width: 50%"><span id="xdx_F16_zzszZc7HaF43" style="font: 10pt Times New Roman, Times, Serif">The
                                         allocation of the purchase price to the net assets acquired and liabilities assumed resulted
                                         in the recognition of other intangible assets which comprised of: Kyslecel Technology
                                         of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_zkEyoPQjdj0e" title="Other intangible assets">9,340</span> and IPR&amp;D of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_zbaY6aSbgAC8" title="Other intangible assets">641</span>. Kyslecel Technology has a useful life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_zYRTWIzaNSq8" title="Useful life">15</span> years. The
                                         useful life of these intangible assets for amortization purposes was determined considering
                                         the period of expected cash flows generated by the assets used to measure the fair value
                                         of the intangible assets adjusted as appropriate for the entity-specific factors, including
                                         legal, regulatory, contractual, competitive, economic or other factors that may limit
                                         the useful life of intangible assets.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">These
intangible assets were estimated using a discounted cash flow method with the application of the multi-period excess earnings
method. Under this method, an intangible asset&#8217;s fair value is equal to the present value of the incremental after-tax cash
flows attributable only to the subject intangible asset after deducting contributory asset charges. An income and expenses forecast
were built based upon revenue and expense estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1.2%; text-align: right"><span id="xdx_F08_zwXN3l4aZ3rl" style="font: 10pt Times New Roman, Times, Serif">b.</span></td><td style="text-align: justify; width: 50%"><span id="xdx_F14_zGdT76xRwTL" style="font: 10pt Times New Roman, Times, Serif">The primary
items that generate goodwill include the value of the synergies between the acquired company and the Company and the acquired
assembled workforce, neither of which qualifies for recognition as an intangible asset. The Goodwill is not deductible for tax
purposes.</span></td>
</tr></table>

<p id="xdx_8AF_znSjyyQGYlq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Pro
forma Impact of Business Combination</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
unaudited pro forma financial results have been prepared using the acquisition method of accounting and are based on the historical
financial information of the Company and Koligo. The unaudited pro forma condensed financial results have been prepared for illustrative
purposes only and do not purport to be indicative of the results of operations that actually would have resulted had the acquisition
of Koligo occurred at the beginning of the fiscal year, or of future results of the combined entities. The unaudited pro forma
condensed financial information does not reflect any operating efficiencies and expected realization of cost savings or synergies
associated with the acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p id="xdx_89A_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_z7erDNuy7OUf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Unaudited
supplemental pro forma combined results of operations (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8B1_zNvvKHaYkemd" style="display: none">SCHEDULE OF UNAUDITED SUPPLEMENTAL PRO FORMA</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20200101__20201231__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_zZnB1kWTVapb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20190101__20191231__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_zdjNqHXzKmgd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zQkIcQPJ7PDk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 2.5pt">Revenues</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">8,239</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">4,398</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--ProfitLoss_pn3n3_zeJXVLbN19e9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">318</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">27,263</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Loss per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--EarningsPerShareBasic_pii_zas48cbihrHe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Basic</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.05</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.91</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A7_zcChthqUgVvf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Koligo&#8217;s
related actual results from the date of acquisition to December 31, 2020 resulted in a loss of $<span id="xdx_90E_eus-gaap--NetIncomeLoss_pn3n3_c20200101__20201231__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_zViwJXPQHkK4" title="Net Loss">513</span> thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i/></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Koligo&#8217;s
Acquisition-related Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Acquisition-related
expenses consist of transaction costs which represent external costs directly related to the acquisition of Koligo and primarily
include expenditures for professional fees such as legal, accounting and other directly related incremental costs incurred to
close the acquisition by both the Company and Koligo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Acquisition-related
expenses for the year ended December 31, 2020 were $<span id="xdx_90B_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_pn3n3_c20200101__20201231__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_zzU5VvHDY1f7" title="Acquisition-related expenses">682</span> thousand. These expenses were recorded to selling and general administrative
expense in the consolidated statements of comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Cooperate
reorganization, description of the Transactions Korea and OBI during 2019</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
August 7, 2019, the Company, Masthercell Global and GPP-II Masthercell, LLC, a Delaware limited liability company (&#8220;GPP-II&#8221;),
(the &#8220;Parties&#8221;) entered into a Transfer Agreement (the &#8220;Transfer Agreement&#8221;). As a result of the Transfer
Agreement, Masthercell Global transferred all of its equity interests of OBI and the Korean Subsidiary to Orgenesis Inc in exchange
for one dollar ($<span id="xdx_906_eus-gaap--BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_pp0p0_c20190806__20190807__us-gaap--TypeOfArrangementAxis__custom--TransferAgreementMember_zZtK8opGDRxb" title="Transfer of equity interests">1.00</span>). The Transfer Agreement also contained agreements made with respect to certain intercompany loans. The
Company accounted for the Transfer Agreement as a transaction with non-controlling interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_AcquisitionAndReorganizationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition and Reorganization [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_AcquisitionAndReorganizationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisclosureAcquisitionAndReorganizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisclosureAcquisitionAndReorganizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676573131656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANTS AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANTS AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zJKxz2PJM8F6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
5 &#8211; <span id="xdx_827_z4crzAehKnS">PROPERTY, PLANTS AND EQUIPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_890_eus-gaap--PropertyPlantAndEquipmentTextBlock_zDHQPVL1geg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table represents the components of property, plants and equipment:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BC_z2GFvj6gaFHk" style="display: none">SCHEDULE OF COMPONENTS OF PROPERTY, PLANTS AND EQUIPMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cost:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Production facility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember_zWYVxVDMQvGc" style="width: 14%; text-align: right" title="Cost">2,801</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember_pn3n3" style="width: 14%; text-align: right" title="Cost">2,481</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and computers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndComputersMember_zgcO2T8iYmK7" style="text-align: right" title="Cost">697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndComputersMember_z0y9NA1IfI65" style="text-align: right" title="Cost">606</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lab equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zczCPRXCNbLl" style="text-align: right" title="Cost">1,483</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zL1npMPfGEH9" style="text-align: right" title="Cost">656</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Advance payment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancePaymentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost">281</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancePaymentMember_zkxBffHbarbg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231_zHLOZ4Rnt6ce" style="text-align: right" title="Cost">5,262</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20191231_pn3n3" style="text-align: right" title="Cost">3,743</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less &#8211; accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20201231_zLFFAiqJWJz4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated depreciation">(2,189</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20191231_zV8Gha4ReO47" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated depreciation">(1,438</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">3,073</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">2,305</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A8_zOGJHQuedg2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Depreciation
expense for the years ended December 31, 2020 and December 31, 2019 were $ <span id="xdx_90D_eus-gaap--Depreciation_pn3n3_c20200101__20201231_zzJYb6SVla56" title="Depreciation">705</span> thousand and $<span id="xdx_90B_eus-gaap--Depreciation_pn3n3_c20190101__20191231_zaQMBO8KTPCl" title="Depreciation">634</span> thousand, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_893_ecustom--ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock_zHA5Muxbbcp" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Property,
plants and equipment, net by geographical location were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;<span id="xdx_8BB_zNFBcntFHRU8" style="display: none">SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT BY GEOGRAPHICAL LOCATION</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Belgium</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--BE_z3FrDJDpS0dk" style="width: 14%; text-align: right" title="Property, plants and equipment, net">358</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--BE_zwfZfgF2Jwx4" style="width: 14%; text-align: right" title="Property, plants and equipment, net"><span style="-sec-ix-hidden: xdx2ixbrl1209">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Korea</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--KR_zlTQHJXo3AB5" style="text-align: right" title="Property, plants and equipment, net">839</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--KR_zAqptTq2mcBl" style="text-align: right" title="Property, plants and equipment, net">983</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Israel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--IL_zoo1isOf3lTe" style="text-align: right" title="Property, plants and equipment, net">1,386</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--IL_zLDcfeYHoMyc" style="text-align: right" title="Property, plants and equipment, net">1,322</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">U.S.</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--US_z6HzmHQklp0h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property, plants and equipment, net">490</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--US_zteNa7ACv2q1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property, plants and equipment, net"><span style="-sec-ix-hidden: xdx2ixbrl1221">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231_zHod0TYdk5Yh" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, plants and equipment, net">3,073</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231_zXe9lKeMKkqi" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, plants and equipment, net">2,305</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AA_z7TYMSt04WBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676572887720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND GOODWILL</a></td>
<td class="text"><p id="xdx_807_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zcFooncd3e82" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
6 &#8211; <span id="xdx_829_zqOazwDyQHXc">INTANGIBLE ASSETS AND GOODWILL</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfGoodwillTextBlock_zzQN5PNTZYI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Changes
in the carrying amount of the Company&#8217;s goodwill for the years ended December 31, 2020 and 2019 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B4_zJh07DxpbKv" style="display: none">SCHEDULE OF GOODWILL</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%">Goodwill as of December 31, 2018</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--Goodwill_iS_pn3n3_c20190101__20191231_zP0kjS9gsqp2" style="width: 22%; text-align: right"><span title="Goodwill, Beginning Balance">4,942</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Goodwill as acquired, (Koligo) see note 4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--GoodwillAcquiredDuringPeriod_c20190101__20191231_pn3n3" style="text-align: right" title="Goodwill as acquired"><span style="-sec-ix-hidden: xdx2ixbrl1232">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Translation differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Translation differences">(130</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Goodwill as of December 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--Goodwill_iE_pn3n3_c20190101__20191231_zJv4Jb2X2twb" style="text-align: right" title="Goodwill, Ending Balance">4,812</td><td style="text-align: left">&#160;</td></tr>
<tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Goodwill as of December 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--Goodwill_iS_pn3n3_c20200101__20201231_zitu3wy1HRq9" style="text-align: right" title="Goodwill, Beginning Balance">4,812</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Goodwill as acquired, (Koligo) see note 4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--GoodwillAcquiredDuringPeriod_c20200101__20201231_pn3n3" style="text-align: right" title="Goodwill as acquired">3,704</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Translation differences</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Translation differences">229</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Goodwill as of December 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--Goodwill_iE_pn3n3_c20200101__20201231_zFIXFDKo4AJ" style="border-bottom: Black 2.5pt double; text-align: right" title="Goodwill, Ending Balance">8,745</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AD_z1AC6UZDaZuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Goodwill
Impairment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">See
Note 2(m) for the Company&#8217;s goodwill impairment analysis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Other
Intangible Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zReGqiIAAmG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Other
intangible assets consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B6_zOKwaLRlcl2" style="display: none">SCHEDULE OF OTHER INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Gross Carrying Amount:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Know How</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowhowMember_zqboipEQbCYh" style="width: 14%; text-align: right" title="Gross Carrying Amount">3,170</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowhowMember_pn3n3" style="width: 14%; text-align: right" title="Gross Carrying Amount">2,991</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Customer relationships</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z7884oqAwQ25" style="text-align: right" title="Gross Carrying Amount">886</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Gross Carrying Amount">895</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Kyslecel Technology</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_pn3n3" style="text-align: right" title="Gross Carrying Amount">9,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_pn3n3" style="text-align: right" title="Gross Carrying Amount"><span style="-sec-ix-hidden: xdx2ixbrl1258">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">IPR&amp;D</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Carrying Amount">641</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Carrying Amount"><span style="-sec-ix-hidden: xdx2ixbrl1262">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231_pn3n3" style="text-align: right" title="Gross Carrying Amount">14,037</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231_pn3n3" style="text-align: right" title="Gross Carrying Amount">3,886</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less &#8211; Accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_c20201231_zacFdX1Y6U27" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(1,014</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_c20191231_zDlaRNPO6mWb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(538</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net carrying amount of other intangible assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying amount of other intangible assets">13,023</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying amount of other intangible assets">3,348</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A2_zkYJzhcRqgk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Intangible
assets amortization expenses were approximately $<span id="xdx_900_ecustom--AmortizationOfIntangibleAsset_pn3n3_c20200101__20201231_zLmIfKr0POxl">478 </span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand
and $<span id="xdx_90F_ecustom--AmortizationOfIntangibleAsset_pn3n3_c20190101__20191231_zbCZmQsUiNpl">430</span> thousand for the years ended December 31, 2020 and December 31, 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zbdoR2gR6af2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Estimated
aggregate amortization expenses for the five succeeding years ending on December 31<sup>st</sup> are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B2_zh9tGtGOqTY9" style="display: none">SCHEDULE OF ESTIMATED AGGREGATE AMORTIZATION EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 to 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Amortization expenses</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_c20201231_z73g2F3IBPG5" style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right" title="Amortization expenses, 2021">965</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive_iI_pn3n3_c20201231_zCHhoDKXPeGf" style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right" title="Amortization expenses, 2022  to 2025">3,910</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A2_zsqOQYGrAS07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676576390792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE LOANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE LOANS</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_za5Tuv2xnZU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
7 &#8211; <span id="xdx_823_z5Kds0JuJvy3">CONVERTIBLE LOANS</span></b></span></p>

<p id="xdx_898_eus-gaap--ConvertibleDebtTableTextBlock_zkusSwVXQFmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8B5_z8MbVmB5xC1k" style="display: none">SCHEDULE OF LONG TERM CONVERTIBLE LOANS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Long
    term convertible loans outstanding as of&#160;December 31, 2020 and December 31, 2019 are as follows:</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Principal</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Amount</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Issuance</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Year</p></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Interest</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Rate</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maturity Period</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>BCF</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b/></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">(in thousands)</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">(Years)</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="14" style="font-style: normal; font-weight: normal">Convertible Loans Outstanding as of <span style="font-style: normal; font-weight: normal">December
    31, 2020</span></td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zDFw3ZPfrvd7" style="width: 17%; text-align: right" title="Principal Amount">1,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td id="xdx_98A_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember" style="width: 16%; text-align: center" title="Issuance Year">2018</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zHPp0UkM80Yg" style="width: 16%; text-align: right" title="Interest Rate">2</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td id="xdx_987_eus-gaap--DebtInstrumentTerm_dtY_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zeg6ar17UK5g" style="width: 14%; text-align: right" title="Maturity Period">3</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_fKDEp_zb4zf47LSFJi" style="width: 14%; text-align: right" title="Exercise Price"><span style="font: 10pt Times New Roman, Times, Serif">7.00</span></td><td style="width: 1%; text-align: left">(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_pn3n3" style="width: 10%; text-align: right" title="BCF">71</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zDA1sBqe1EXi" style="text-align: right" title="Principal Amount">9,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_980_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember" style="text-align: center" title="Issuance Year">2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MinimumMember_zSPSlDj6sNgc" title="Interest Rate">6</span>%-<span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MaximumMember_z6yMje78exYf" title="Interest Rate">8</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MinimumMember_zV50gcduFWV4" title="Maturity Period">2</span>-<span id="xdx_906_eus-gaap--DebtInstrumentTerm_dtY_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MaximumMember_z7xBBiTsS0Nk" title="Maturity Period">5</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_fKDIp_z6v86nbfHkbe" style="text-align: right" title="Exercise Price"><span style="font: 10pt Times New Roman, Times, Serif">7.00</span></td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pn3n3" style="text-align: right" title="BCF"><span style="-sec-ix-hidden: xdx2ixbrl1314">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zyv1bKnywRHj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Principal Amount">250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td id="xdx_987_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember" style="padding-bottom: 1.5pt; text-align: center" title="Issuance Year">2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_z5xJOBpnNrOb" style="padding-bottom: 1.5pt; text-align: right" title="Interest Rate">8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td id="xdx_98A_eus-gaap--DebtInstrumentTerm_dtY_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zAxR13De8uzi" style="padding-bottom: 1.5pt; text-align: right" title="Maturity Period">2</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_fKDMp_zt8CAYylZ5w2" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Price"><span style="font: 10pt Times New Roman, Times, Serif">7.00</span></td><td style="padding-bottom: 1.5pt; text-align: left">(3)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_pn3n3" style="padding-bottom: 1.5pt; text-align: right" title="BCF"><span style="-sec-ix-hidden: xdx2ixbrl1326">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DebtInstrumentFaceAmount_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal Amount">10,750</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="18" style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Convertible
    Loans Outstanding as of </b><span style="font-style: normal; font-weight: normal">December 31, 2019</span></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_pn3n3" style="text-align: right" title="Principal Amount">1,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_989_ecustom--DebtInstrumentIssuanceYear_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember" style="text-align: center" title="Issuance Year">2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zle1KDDZKZqk" style="text-align: right" title="Interest Rate">2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td id="xdx_987_eus-gaap--DebtInstrumentTerm_dtY_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zYwCOa0umj1c" style="text-align: right" title="Maturity Period">3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_fKDEp_zxqPtxnJs8sb" style="text-align: right" title="Exercise Price"><span style="font: 10pt Times New Roman, Times, Serif">7.00</span></td><td id="xdx_F20_z1eDrS0SelJf" style="text-align: left">(1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn3n3_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zT8CBWNXlY6j" style="text-align: right" title="BCF">124</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal Amount">11,400</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td id="xdx_98E_ecustom--DebtInstrumentIssuanceYear_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember" style="padding-bottom: 2.5pt; text-align: center" title="Issuance Year">2019</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MinimumMember_zHMFCnuTzZxg" title="Interest Rate">6</span>%-<span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MaximumMember_zBK65LqIf8w" title="Interest Rate">8</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90D_eus-gaap--DebtInstrumentTerm_dtY_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MinimumMember_zyUY8X127l2h" title="Maturity Period">2</span>-<span id="xdx_90A_eus-gaap--DebtInstrumentTerm_dtY_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MaximumMember_zeuAtuVShXIf" title="Maturity Period">5</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_fKDIp_zx9JV7VEjKQ3" style="padding-bottom: 2.5pt; text-align: right" title="Exercise Price"><span style="font: 10pt Times New Roman, Times, Serif">7.00</span></td><td id="xdx_F2B_zfU9bW8ArPui" style="padding-bottom: 2.5pt; text-align: left">(2)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pn3n3" style="padding-bottom: 2.5pt; text-align: right" title="BCF"><span style="-sec-ix-hidden: xdx2ixbrl1356">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtInstrumentFaceAmount_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal Amount">12,900</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td colspan="18" style="text-align: left; font-weight: bold">Convertible Loans repaid during the year ended <span style="font-style: normal; font-weight: normal">December
    31, 2020</span></td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Principal</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Amount</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Issuance</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Year</p></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Interest</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Rate</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maturity Period</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>BCF</b></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 1%; text-align: center">&#160;</td><td id="xdx_984_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zIHKBs5PcDRf" style="width: 17%; text-align: right" title="Repaid, Principal Amount">500</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 1%">&#160;</td>
    <td id="xdx_98D_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zkow0ZZaa3H6" style="width: 16%; text-align: center" title="Issuance Year">2018</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td id="xdx_98C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zBotYCYosfuk" style="width: 16%; text-align: right" title="Interest Rate">2</td><td style="width: 1%; text-align: center">%</td><td style="text-align: center; width: 1%">&#160;</td>
    <td id="xdx_989_ecustom--DebtInstrumentRemainingTerm_dtM_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_z7cvCx8z5JW6" style="width: 14%; text-align: right" title="Repaid, Maturity Period">0.87</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">$</td><td id="xdx_987_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zK7dopUg33n6" style="width: 14%; text-align: right" title="Exercise Price">7</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td id="xdx_983_ecustom--DebtInstrumentConvertibleRepaidBeneficialConversionFeature_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zrQIEMx9Rx7k" style="width: 10%; text-align: right" title="Repaid, BCF">53</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td id="xdx_98D_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_zdo7o6rInVL6" style="text-align: right" title="Repaid, Principal Amount">500</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td id="xdx_980_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember" style="text-align: center" title="Issuance Year">2019</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_98A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_zaVwMTYQyCE2" style="text-align: right" title="Interest Rate">6</td><td style="text-align: center">%</td><td style="text-align: center">&#160;</td>
    <td id="xdx_986_ecustom--DebtInstrumentRemainingTerm_dtM_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_zvPfHqd4CFpe" style="text-align: right" title="Repaid, Maturity Period">0.28</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_zJcBzqlsDTrj" style="text-align: right" title="Exercise Price">7</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_986_ecustom--DebtInstrumentConvertibleRepaidBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_pn3n3" style="text-align: right" title="Repaid, BCF"><span style="-sec-ix-hidden: xdx2ixbrl1382">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td id="xdx_98B_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_zAKr0TKD3mxg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Repaid, Principal Amount">1,400</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td id="xdx_987_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_zdeDPXfx1Bn2" style="padding-bottom: 1.5pt; text-align: center" title="Issuance Year">2019</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td id="xdx_986_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_zM9WocadbgL7" style="padding-bottom: 1.5pt; text-align: right" title="Interest Rate">8</td><td style="padding-bottom: 1.5pt; text-align: center">%</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td id="xdx_980_ecustom--DebtInstrumentRemainingTerm_dtMp_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_zibWRPZBRSmg" style="padding-bottom: 1.5pt; text-align: right" title="Repaid, Maturity Period">0.76</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td id="xdx_98E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_z6FdnJQRu7Dc" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Price">7</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td id="xdx_98D_ecustom--DebtInstrumentConvertibleRepaidBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_pn3n3" style="padding-bottom: 1.5pt; text-align: right" title="Repaid, BCF"><span style="-sec-ix-hidden: xdx2ixbrl1394">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td id="xdx_981_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansMember_zRR7XZAJBEHa" style="text-align: right" title="Repaid, Principal Amount">2,400</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Apart
from the items mentioned below there were no repayments of convertible loans during the fiscal years ended December 31, 2019 and
December 31, 2020. In addition, there were no conversions during the fiscal years ended December 31, 2019 and December 31,
2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F08_zpSgWyVib4Qg" style="font: 10pt Times New Roman, Times, Serif">(1)</span></td><td style="text-align: justify"><span id="xdx_F12_zNRKLWCftCS9" style="font: 10pt Times New Roman, Times, Serif">The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_pii" title="Stock issued during period, conversion of convertible securities">148,838</span> shares
and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zfQ3X7ZtgEv7" title="Number of warrant may be converted">148,838</span> <span title="Warrants exercise, term"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_z2olYqVdp0gb" title="Warrants exercise, term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl1403">three-year</span></span></span> warrants to purchase up to an additional <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxws5Qrjrwp2" title="Number of warrant may be converted">148,838</span> shares of the Company&#8217;s common stock at a per share
exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zHp9sXQK5nwg" title="Warrants exercise price">7</span>. <span>In the initial two years, the holders have the right to convert the outstanding principal amount and accrued
interest into shares of capital stock of Hemogenyx-Cell or Immugenyx, LLC according under the relevant note agreement, subsidiaries
of Hemogenyx Pharmaceuticals Plc, at a price per share based on a pre-money valuation of Hemogenyx-Cell or Immugenyx, LLC of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_ecustom--PreMoneyValuation_iI_pn6n6_c20201231__dei--LegalEntityAxis__custom--HemogenyxCelMember_zkLtkIqsJWR" title="Pre-money valuation">12</span>
million and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_ecustom--PreMoneyValuation_iI_pn6n6_c20201231__dei--LegalEntityAxis__custom--ImmugenyxLLCMember_zqO6fr0KZyMe">8</span> million, respectively, pursuant to the collaboration agreement with Hemogenyx Pharmaceuticals Plc and Immugenyx,
LLC.</span> As of December 31, 2020, the loans are presented in current maturities of convertible notes in the balance sheet (See Notes
11(c) and 11(d).</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F0E_z5oVRsJ6GJOj" style="font: 10pt Times New Roman, Times, Serif">(2)</span></td><td style="text-align: justify"><span id="xdx_F15_zprCsjdBN534" style="font: 10pt Times New Roman, Times, Serif">The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pii" title="Stock issued during period, conversion of convertible securities">1,443,734</span> shares
and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pii" title="Number of warrant may be converted">1,053,503</span> <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zRDvnnKx88Ag" title="Warrants exercise, term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl1417">three-year</span></span> warrants to purchase up to an additional <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Number of warrant may be converted">1,053,503</span> shares of the Company&#8217;s common stock at a per
share exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pii" title="Warrants exercise price">7</span>. As of December 31, 2020, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--ConvertibleDebtCurrent_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zScnFXulvOp2" title="Current maturities of convertible loans">2,500</span> thousand of the principal amount is included in current maturities
of convertible loans in the balance sheet and the remainder in long-term convertible loans. See also Notes 7(b), 7(c), 7(e), 7(f)
and 7(g).</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F07_zKcMdD3eXmG9" style="width: 15pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td><td style="text-align: justify"><span id="xdx_F19_zABI8xDlieZ9" style="font: 10pt Times New Roman, Times, Serif">The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_pii" title="Stock issued during period, conversion of convertible securities">38,559</span> shares
at a per share exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zEMHD8sLnPdi" title="Warrants exercise price">7</span>. As of December 31, 2020, all the principal amount is included in long-term convertible loans
in the balance sheet See also Notes 7(h).</span></td>
</tr></table>

<p id="xdx_8AC_zLHNdcivKyDi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">b.
During April 2019, the Company entered into a convertible loan agreement with an offshore investor for an aggregate amount of
$<span id="xdx_902_eus-gaap--ProceedsFromConvertibleDebt_pn3n3_c20190401__20190430__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_z69O0G3tVKJk" title="Proceeds from Convertible Debt">500</span> thousand into the U.S. Subsidiary. The investor, at its option, may convert the outstanding principal amount and accrued
interest under this note into shares and <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20190430__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_z7n6mMUDIHE6" title="Warrants exercise, term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl1432">three-year</span></span> warrants to purchase shares of the Company&#8217;s common stock at a per share
exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20190430__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_pii" title="Warrants exercise price">7.00</span>; or into shares of the U.S. Subsidiary at a valuation of the U.S. Subsidiary of $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn6n6_c20190401__20190430__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zcRY4Opjzscf" title="Valuation of shares">50</span> million. During February
2020 the company repaid this convertible loan to the investor in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">c.
During May 2019, the Company entered into a private placement subscription agreement with an investor for $<span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn6n6_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zKQ4Zzo0IKrj" title="Aggregate amount of debt">5</span> million. The lender
shall be entitled, at any time prior to or no later than the maturity date, to convert the outstanding amount, into units of (1)
shares of common stock of the Company at a conversion price per share equal to $<span title="Convertible warrant exercise price"><span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20190531__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zV5pGv4Se0P2" title="Convertible warrant exercise price into common stock">7.00</span></span> and (2) warrants to purchase an equal number
of additional shares of the Company&#8217;s common stock at a price of $<span title="Conversion price per share"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20190531__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zW7aCDryPHCh" title="Warrant exercise price per share">7.00</span></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
transaction costs were approximately $<span id="xdx_902_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zk6UVIe2To5a" title="Transaction costs">497</span> thousand, out of which $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z0DLIX3eIO3k" title="Allocated share-based compensation expense">97</span> thousand are stock-based compensation due to issuance of
warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">d.
In May 2019, the Company had agreed to enter into a <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20190531__us-gaap--TypeOfArrangementAxis__custom--SixPercentageConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zHEYF4XfkfIh" title="Interest rate">6</span>% convertible loan agreement with an investor for an aggregate amount of
$<span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn6n6_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--SixPercentageConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z0bvHabdnThh" title="Aggregate amount of debt">5</span> million. The lender shall be entitled, at any time prior to or no later than the maturity date, to convert the outstanding
amount, into units of (1) shares of stock of the Company at a conversion price per share equal to $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20190531__us-gaap--TypeOfArrangementAxis__custom--SixPercentageConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zTiIhuplX0h6" title="Convertible warrant exercise price into common stock">7.00</span> and (2) warrants to purchase
an equal number of additional shares of the Company&#8217;s common stock at a price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20190531__us-gaap--TypeOfArrangementAxis__custom--SixPercentageConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zrHb12bwPml8" title="Warrant exercise price per share">7.00</span> per share. As of the date of the
filing of this Annual Report on Form 10-K, the loan had not yet been received by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">e.
In June 2019, the Company entered into private placement subscription agreements with investors for an aggregate amount of $<span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn6n6_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zpurUKFq14na" title="Aggregate amount of debt">2</span>
million. The lenders shall be entitled, at any time prior to or no later than the maturity date, to convert the outstanding amount,
into units of (1) shares of common stock of the Company at a conversion price per share equal to $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20190630__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zuliYvtAThb6" title="Convertible warrant exercise price into common stock">7.00</span> and (2) warrants to purchase
an equal number of additional shares of the Company&#8217;s common stock at a price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20190630__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zUPP9yQegI1k" title="Warrant exercise price per share">7.00</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">f.
During October 2019, the Company entered into a Private Placement Subscription Agreement and Convertible Credit Line Agreement
(collectively, the &#8220;Credit Line Agreements&#8221;) with four non-U.S. investors (the &#8220;Lenders&#8221;), pursuant to
which the Lenders furnished to the Company access to an aggregate $<span title="Aggregate credit line amount"><span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_zcjuaMXMr04c">5</span>.0</span> million credit line (which consists of $<span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_zUuI9OIxOmo2" title="Aggregate credit line amount"><span id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_z3MyOSmjrq59" title="Aggregate credit line amount"><span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_z8UUtvwWvQrj" title="Aggregate credit line amount"><span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_zWymxtcelJLd" title="Aggregate credit line amount">1.25</span></span></span></span> million from
each Lender) (collectively, the &#8220;Credit Line&#8221;). Pursuant to the Credit Line Agreements, the Company is entitled to
draw down an aggregate of $<span title="Proceeds from lines of credit"><span id="xdx_90A_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_zaPyjOXVPFU5" title="Proceeds from lines of credit"><span id="xdx_901_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20191101__20191130__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_zitzrlT2jfn3" title="Proceeds from lines of credit">1</span></span></span> million (consisting of $<span title="Proceeds from lines of credit"><span id="xdx_909_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_zWjb1tdLhk62" title="Proceeds from lines of credit"><span id="xdx_904_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_zCexVgm8IXNd" title="Proceeds from lines of credit"><span id="xdx_906_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_zw24EX7Nx9Z7" title="Proceeds from lines of credit"><span id="xdx_907_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191001__20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_zdCQdwaFdnwc" title="Proceeds from lines of credit"><span id="xdx_902_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191101__20191130__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_zezWyrEqHisl" title="Proceeds from lines of credit"><span id="xdx_90D_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191101__20191130__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_zm2F3SqPrmlc" title="Proceeds from lines of credit"><span id="xdx_905_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191101__20191130__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_znQSaazoCaDb" title="Proceeds from lines of credit"><span id="xdx_90D_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191101__20191130__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_zymaoZ7Qbk5g" title="Proceeds from lines of credit">250</span></span></span></span></span></span></span></span></span> thousand from each Lender) of the Credit Line in each of October 2019
and November 2019. In each of December 2019, January 2020 and February 2020, the Company may draw down an additional aggregate
of $<span title="Proceeds from lines of credit"><span id="xdx_90B_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_z1r7z6cMtRbj" title="Proceeds from lines of credit"><span id="xdx_908_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_zB0QdMgwrfec" title="Proceeds from lines of credit"><span id="xdx_90F_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_zQZC92nW2BE2" title="Proceeds from lines of credit">1</span></span></span></span> million (consisting of $<span title="Proceeds from lines of credit"><span id="xdx_905_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_z6Bw4wZHB7Al" title="Proceeds from lines of credit"><span id="xdx_909_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_z4LDdXOcIfd4" title="Proceeds from lines of credit"><span id="xdx_90D_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_zJEFVNtTRf9a" title="Proceeds from lines of credit"><span id="xdx_905_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_z55ZFm2vjlzi" title="Proceeds from lines of credit"><span id="xdx_903_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_z1jhgobBxpZc" title="Proceeds from lines of credit"><span id="xdx_908_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_zKRyE2bR8XCd" title="Proceeds from lines of credit"><span id="xdx_90F_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_z8csag846ioh" title="Proceeds from lines of credit"><span id="xdx_90E_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_zsFaN90115w5" title="Proceeds from lines of credit"><span id="xdx_901_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_zfEXCZRUReLk" title="Proceeds from lines of credit"><span id="xdx_900_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_zkiCMDD8vf34" title="Proceeds from lines of credit"><span id="xdx_90C_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_zIAVVEyOlkl7" title="Proceeds from lines of credit"><span id="xdx_901_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_z8ceT8CzTIOh" title="Proceeds from lines of credit">250</span></span></span></span></span></span></span></span></span></span></span></span></span> thousand from each Lender), until the total amount drawn down under the Credit Line reaches
an aggregate of $<span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_zW6lx0PuaOha" title="Aggregate credit line amount">5</span> million (consisting of $<span id="xdx_90F_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_zEVMX3fEW0kd" title="Aggregate credit line amount"><span id="xdx_900_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_zYpzfkrlPyhk" title="Aggregate credit line amount"><span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_zOZKMacdpBC6" title="Aggregate credit line amount"><span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn4n6_c20191031__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_z5SDJgoHqgH5" title="Aggregate credit line amount">1.25</span></span></span></span> million from each Lender), subject to the approval of the Lenders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the terms of the Credit Line Agreements and the Notes, the total loan amount, and all accrued but unpaid interest thereon,
shall become due and payable on the second anniversary of the Effective Date (the &#8220;Maturity Date&#8221;). The Maturity Date
may be extended by each Lender in its sole discretion and shall be in writing signed by the Company and the Lender. Interest on
any amount that has been drawn down under the Credit Line accrues at a per annum rate of eight percent (<span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zZJUkLpt2qGj" title="Interest rate">8</span>%). At any time prior
to or on the Maturity Date, by providing written notice to the Company, each of the Lenders is entitled to convert its respective
drawdown amounts and all accrued interest, into shares of the Company&#8217;s common stock, par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zwSUsnpyt1md" title="Common stock, par value"><span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zatdvznLc6Ji" title="Common stock, par value">0.0001</span></span> per share (the &#8220;Common
Stock&#8221;), at a conversion price equal to $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zjgrLDl3JEU5" title="Conversion price per share">7.00</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Furthermore,
upon the drawdown of $<span id="xdx_904_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_z6phx8coXCwf" title="Proceeds from lines of credit"><span id="xdx_903_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_zzz6tqDI2Xna" title="Proceeds from lines of credit"><span id="xdx_90C_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_zb2cTMQKoN6l" title="Proceeds from lines of credit"><span id="xdx_90F_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_zYdKUBTBiNX2" title="Proceeds from lines of credit">500</span></span></span></span> thousand from each Lender and, together with the other Lenders, a drawdown of an aggregate of $<span id="xdx_90B_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorMember_zi0HTrgMuR1d" title="Proceeds from lines of credit">2</span> million
under the Credit Line, the existing warrants of the Lenders to purchase shares of Common Stock shall be amended to extend their
exercise date to June 30, 2021 and the Company will issue to each of the Lenders warrants to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_pii" title="Number of warrant to purchase"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_pii" title="Number of warrant to purchase"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_pii" title="Number of warrant to purchase"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_pii" title="Number of warrant to purchase">50,000</span></span></span></span> shares of Common
Stock at an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_pii" title="Warrants exercise price"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_pii" title="Warrants exercise price"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_pii" title="Warrants exercise price"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_pii" title="Warrants exercise price">7.00</span></span></span></span> per share. The new warrants will be exercisable for three (<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorOneMember_zgdXXTXftPKj" title="Warrants exercise, term"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorTwoMember_zPfkchNgbST7" title="Warrants exercise, term"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorThreeMember_z6xdvaAGX202" title="Warrants exercise, term"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonUSInvestorFourMember_zKDnZs4JEHF3" title="Warrants exercise, term">3</span></span></span></span>) years from the Effective Date.
During October 2019, such drawdown was reached and the warrants were issued. The modification of the existing warrants in the
amount of $<span title="Transaction costs"><span id="xdx_90F_ecustom--ModificationOfExistingWarrants_iI_pn3n3_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zP7ls0iJyzUd" title="Modification of the existing warrants">145</span></span> thousands was recorded against the accumulated deficit and the value of the new warrants in the amount of $<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_z3xEr6nPszll" title="Warrants amount">370</span>
thousands was offset against the convertible loan amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
lender shall be entitled, at any time prior to or no later than the maturity date, to convert the outstanding amount, into units
of shares of common stock of the Company at a conversion price per share equal to $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zljxqb0hyRxg" title="Conversion price per share">7.00</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
at December 31, 2019, the Company had received $<span id="xdx_901_eus-gaap--ProceedsFromLinesOfCredit_pn3n6_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_ztDQtFSEVnda">3.65
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million from the Convertible Credit
Line investment comprised of $<span id="xdx_905_eus-gaap--ProceedsFromLinesOfCredit_pn4n6_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorOneMember_zkli2RKtYWPb">1.15
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million from one investor, $<span id="xdx_905_eus-gaap--ProceedsFromLinesOfCredit_pn6n6_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorTwoMember_zV1I2zV9YHxa">1
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million from a second investor, and $<span id="xdx_90A_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoOtherInvestorTwoMember_zTHnt9KwW958">750
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand from two of the other lenders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
transaction costs were approximately $<span id="xdx_90E_ecustom--ModificationOfExistingWarrants_iI_pn3n3_c20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zsLO4oYJWIB7">145
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 2020 the company repaid principal amount of $<span id="xdx_905_eus-gaap--RepaymentsOfLinesOfCredit_pn3n3_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zvAkWqq8xlFl" title="Repayments of lines o credit">2,400</span> thousand and a total interest amount of $<span id="xdx_90F_eus-gaap--InterestExpenseDebt_pn3n3_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CreditLineAgreementsMember_zH49qumtG5Hf" title="Interest expense">372</span> thousand
to certain of the credit line investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">g.
In December 2019, the Company entered into private placement subscription agreements with investors for an aggregate amount of
$<span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn3n3_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zMsWBG02UWQ" title="Aggregate amount of debt">250</span> thousand. The lenders shall be entitled, at any time prior to or no later than the maturity date, to convert the outstanding
amount, into units of 1 share of common stock of the Company at a conversion price per share equal to $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20191231__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_pii" title="Warrants exercise price">7.00</span> and warrants to purchase
<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20191231__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zUa5os2B7M3j" title="Number of warrant to purchase">183,481</span> additional shares of the Company&#8217;s common stock at a price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20191231__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z6Pw4KchltVg" title="Warrants exercise price">7.00</span> per share. The fair value of the warrants was
$<span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20191231__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z52UVplQdXbl" title="Warrants amount">124</span> thousand using the fair value of the shares on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">h.
On January 2, 2020, the Company entered into private placement subscription agreements with investors for an aggregate amount
of $<span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn3n3_c20191230__20200103__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zoIQtR4YckW" title="Aggregate amount of debt">250</span> thousand of convertible loans. The lenders shall be entitled, at any time prior to or no later than the maturity date,
to convert the outstanding amount, into shares of Common Stock of the Company at a conversion price per share equal to $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_pii" title="Warrants exercise price">7.00</span>.
In addition, the Company granted the investors <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_pii" title="Number of warrant to purchase">151,428</span> warrants to purchase an equal number of additional shares of Common Stock
at a price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zmheJnSvGEd9" title="Warrants exercise price">7.00</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">i.
In December 2018, the Company entered into a Controlled Equity Offering Sales Agreement, or Sales Agreement, with Cantor Fitzgerald
&amp; Co., or Cantor, pursuant to which the Company may offer and sell, from time to time through Cantor, shares of its common
stock having an aggregate offering price of up to $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zlMtfVU4VtSg" title="Proceeds from issuance of common stock">25.0</span> million. The Company will pay Cantor a commission rate equal to <span id="xdx_904_ecustom--PercentageOfCommission_pii_dp_uPercentage_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zhWvdCpBPosk" title="Percentage of commission">3.0</span>% of
the aggregate gross proceeds from each sale. Shares sold under the Sales Agreement will be offered and sold pursuant to the Company&#8217;s
Shelf Registration Statement on Form S-3 (Registration No. 333-223777) that was declared effective by the Securities and Exchange
Commission on March 28, 2018, or the Shelf Registration Statement, and a prospectus supplement and accompanying base prospectus
that the Company filed with the Securities and Exchange Commission on December 20, 2018. The Company has not yet sold any shares
of its common stock pursuant to the Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">j.
On November 2, 2016, the Company entered into unsecured convertible note agreements with accredited or offshore investors for
an aggregate amount of NIS <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn6n6_uNIS_c20161101__20161102__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember__srt--CurrencyAxis__currency--ILS_zPreb3R8Nm9g" title="Aggregate amount of debt">1</span> million ($<span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn3n3_c20161101__20161102__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember_zmz9g9CfIoD6" title="Aggregate amount of debt">280</span> thousand). The loan bears a monthly interest rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20161102__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember_zjANP8kHV3pb" title="Interest rate">2</span>% and mature on <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20161101__20161102__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember_zZ8BnkI6oK82" title="Debt instrument, maturity date">May 1, 2017</span>,
unless converted earlier. On April 27, 2017 and November 2, 2017, the Company entered into extension agreements through November
2, 2017 and May 2, 2018, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
March 2018, the investor submitted a notice of its intention to convert into shares of the Company&#8217;s common stock the principal
amount and accrued interest of approximately $<span id="xdx_902_eus-gaap--ConvertibleDebt_iI_pn3n3_c20180331__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember_znUx3t8cIbqh" title="Convertible debt">383</span> thousand outstanding. A related party of such investor at the same time, exercised
warrants issued in November 2016 to purchase shares of the Company&#8217;s Common Stock. The exercise price of the warrants and
conversion price were fixed at $<span id="xdx_902_ecustom--DebtInstrumentConvertibleWarrantExercisePrice_iI_pii_uUSDPShares_c20180331__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember_zxOnUi2aIdp8" title="Convertible warrant exercise price">0.52</span> per share (pre-reverse stock split implemented by the Company in November 2017). There is
a significant disagreement between the Company and these two entities as to the number of shares of Common Stock issuable to these
entities, and they contend that the number of shares of Common Stock issuable to them should not consider the reverse stock split.
The Company rejects these contentions in their entirety and, based on the advice of specially retained counsel, believes that
these claims are without legal merit and not made in good faith. The Company intends to vigorously defend its interests and pursue
other avenues of legal address. Through its counsel, the Company has advised these entities that unless they withdraw their request
within a specified period, the Company will cancel the above referenced agreements and these parties&#8217; right to receive any
shares of the Company&#8217;s Common Stock. In April 2018, the Company withdrew the agreements and deposited the shares in total
amount of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180401__20180430__us-gaap--TypeOfArrangementAxis__custom--ControlledEquityOfferingSalesAgreementMember_pii" title="Number of shares issued">107,985</span> issued under those agreements and the principal amount and accrued interest of the loan in escrow account. The
deposit of the principal amount and accrued interest presented as restricted cash in the balance sheet as of December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676577589528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisclosureLoansAbstract', window );"><strong>Loans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_LoansTextBlock', window );">LOANS</a></td>
<td class="text"><p id="xdx_800_ecustom--LoansTextBlock_zjrO7ATL8kll" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
8 &#8211; <span id="xdx_824_ztd02ZE3btW2">LOANS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfDebtTableTextBlock_zAYEB7Q4VzU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Terms
of Short-term Loans</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_8BF_z8OljQQ2hCri" style="display: none">SCHEDULE OF LOANS</span></i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Currency</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Interest Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 42%; text-align: left">Short term loans</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center">KRW</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoanOneMember__srt--CurrencyAxis__currency--KRW_zIsn6CtImNi3" style="width: 12%; text-align: right" title="Interest Rate">3.61</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--DebtCurrent_iI_pn3n3_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoanOneMember__srt--CurrencyAxis__currency--KRW_z6t9YdpT77kf" style="width: 10%; text-align: right" title="Total loans"><span style="-sec-ix-hidden: xdx2ixbrl1630">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtCurrent_iI_pn3n3_c20191231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoanOneMember__srt--CurrencyAxis__currency--KRW_zNr3uHWNlib8" style="width: 10%; text-align: right" title="Total loans">260</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short term loans</td><td>&#160;</td>
    <td style="text-align: center">KRW</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansTwoMember__srt--CurrencyAxis__currency--KRW_zMC4UvRNnTJl" style="text-align: right" title="Interest Rate">6.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtCurrent_iI_pn3n3_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansTwoMember__srt--CurrencyAxis__currency--KRW_zgLnnldJsKOg" style="text-align: right" title="Total loans"><span style="-sec-ix-hidden: xdx2ixbrl1636">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--DebtCurrent_iI_pn3n3_c20191231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansTwoMember__srt--CurrencyAxis__currency--KRW_zL8Jg8cz0a31" style="text-align: right" title="Total loans">131</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short term loans</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">USD</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansThreeMember_zETCATVnI7qh" style="padding-bottom: 1.5pt; text-align: right" title="Interest Rate">1.00</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--DebtCurrent_iI_pn3n3_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansThreeMember_zsvIRslKMeI2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total loans">145</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--DebtCurrent_iI_pn3n3_c20191231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansThreeMember_zrBmTvcLXsgg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total loans"><span style="-sec-ix-hidden: xdx2ixbrl1644">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DebtCurrent_iI_pn3n3_c20201231_zYcK5lHR21sh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total loans">145</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--DebtCurrent_iI_pn3n3_c20191231_ztWvQaA4gr9h" style="border-bottom: Black 2.5pt double; text-align: right" title="Total loans">391</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A7_zXo7VmyNKFee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisclosureLoansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisclosureLoansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_LoansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_LoansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676576294968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zr0ZpGQpiJUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
9 &#8211; <span id="xdx_82C_zRZf20zOsyz8">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company leases research and development facilities, equipment and offices under finance and operating leases. For leases with
terms greater than 12 months, the Company record the related asset and obligation at the present value of lease payments over
the term. Many of the leases include rental escalation clauses, renewal options and/or termination options that are factored into
the determination of lease payments when appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s leases do not provide a readily determinable implicit rate. Therefore, the Company estimated the incremental borrowing
rate to discount the lease payments based on information available at lease commencement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Manufacturing
facilities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company leases space for its manufacturing facilities in Israel under operating lease agreements. The leasing contracts are for
a period of <span id="xdx_903_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ManufacturingFacilityMember__srt--StatementGeographicalAxis__country--IL__srt--RangeAxis__srt--MinimumMember_zGQAXTREGjQa" title="Leasing contracts period">3</span> - <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ManufacturingFacilityMember__srt--StatementGeographicalAxis__country--IL__srt--RangeAxis__srt--MaximumMember_zZSthrCW7jG5" title="Leasing contracts period">5</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Research
and Development facilities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company leases space for its research and development facilities in South Korea under an operating lease agreement. The leasing
contracts are for a period of <span id="xdx_900_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchAndDevelopmentFacilitiesMember__srt--StatementGeographicalAxis__country--KR__srt--RangeAxis__srt--MinimumMember_zbob8PMMPKHc" title="Leasing contracts period">2</span> &#8211; <span id="xdx_900_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchAndDevelopmentFacilitiesMember__srt--StatementGeographicalAxis__country--KR__srt--RangeAxis__srt--MaximumMember_zWy4x1Grp6Ml" title="Leasing contracts period">5</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Offices</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company leases space for offices in Israel under operating leases. The leasing contracts are valid for terms of <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficesMember__srt--StatementGeographicalAxis__country--IL_zR0orHrT7INg" title="Leasing contracts period">5</span> years. These
contracts are considered as operational leasing and under operating lease right-of-use assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Lease
Position</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p id="xdx_890_ecustom--LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock_z1FhRdiiGaR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
table below presents the lease-related assets and liabilities recorded on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8B0_zZdKgRAHa2p5" style="display: none">SCHEDULE OF LEASE-RELATED ASSETS AND LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Operating Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Operating lease right-of-use assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231_zqRWSm2h1JEc" style="width: 22%; text-align: right" title="Operating lease right-of-use assets">1,474</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property, plants and equipment, gross</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_iI_pn3n3_c20201231_zJOUqZ8y7xm8" style="text-align: right" title="Property, plants and equipment, gross">99</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_iNI_pn3n3_di_c20201231_zWnCpv4ev9o7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated depreciation">(17</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_iI_pn3n3_c20201231_zvbDrAEhCeBj" style="text-align: right" title="Property and equipment, net">82</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current maturities of operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20201231_zWljfSHKPXta" style="text-align: right" title="Current maturities of operating leases">485</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current maturities of long-term finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityCurrent_iI_pn3n3_c20201231_zYVkaOFfyVm9" style="text-align: right" title="Current maturities of long-term finance leases">19</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Long-term liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_zvKMPRRBlAfi" style="text-align: right" title="Non-current operating leases">1,020</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long-term finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_z5cnGBu7KYX4" style="text-align: right" title="Long-term finance leases">64</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Weighted Average Remaining Lease Term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Weighted Average Remaining Lease Term, Operating leases"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zqn7w1LZqLPc" title="Weighted Average Remaining Lease Term, Operating leases">3.4</span> years</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_90C_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zFXvyLnurfwl" title="Weighted Average Remaining Lease Term, Finance leases">4.2</span> years</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average Discount Rate</b></span></p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercentage_c20201231_zKy8r14AXkhk" title="Weighted Average Discount Rate, Operating leases">6.7</span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercentage_c20201231_zuyJmNY7djsb" style="text-align: right" title="Weighted Average Discount Rate, Finance leases">2.0</td><td style="text-align: left">%</td></tr>
</table>

<p id="xdx_8A2_zGn7PpLH9Mbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Lease
Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_893_eus-gaap--LeaseCostTableTextBlock_z67WrxGKHnM5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
table below presents certain information related to lease costs and finance and operating leases during the year ended December
31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8BA_zuaKHrU7aoml" style="display: none">SCHEDULE OF LEASE COSTS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20200101__20201231_z0Sk6zz48Erk" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeaseCost_pn3n3_zexRgjt0MFr2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Operating lease cost:</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 18%; text-align: right">547</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Finance lease cost:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_pn3n3_maFLCzuMa_zmKVHsTFM7V3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amortization of leased assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--FinanceLeaseInterestExpense_pn3n3_maFLCzuMa_zbwkMID5of0e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Interest on lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_400_ecustom--FinanceLeaseCost_iT_pn3n3_mtFLCzuMa_zPKF1ljciKzb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total finance lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A7_z8Ud03dG2pu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zJyqjoP69R92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
table below presents supplemental cash flow information related to leases during the year ended December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8B1_z4qX6smYrA7h" style="display: none">SCHEDULE OF SUPPLEMENTAL CASHFLOW INFORMATION</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20200101__20201231_zl3kxCon0LI8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>December 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in Thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid for amounts included in the measurement of leases liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--OperatingLeasePayments_pn3n3_zSuJywrS7kae" style="vertical-align: bottom; background-color: White">
    <td style="width: 78%; text-align: left">Operating leases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">515</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--FinanceLeaseInterestPaymentOnLiability_pn3n3_zfrprXkaNqL7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">42</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_zZZo1JoAWpwc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">967</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_pn3n3_zFFFu9SrcNN" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">366</td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AC_zVemCYsqNhWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Undiscounted
Cash Flows</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89C_ecustom--LesseeLeaseLiabilityMaturityTableTextBlock_zPoAow1Vgmpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining years to the finance
lease liabilities and operating lease liabilities recorded on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8B7_zOMZCS7jzl36" style="display: none">SCHEDULE OF FINANCE LEASE LIABILITIES AND OPERATING LEASE LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Operating</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Leases</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Finance<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; font-weight: bold">Year ended December 31,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20201231_z6tF4FvykiI8" style="width: 14%; text-align: right" title="Operating Leases, 2021">526</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20201231_zBaLYRgihj6" style="width: 14%; text-align: right" title="Finance Lease, 2021">20</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20201231_zg24sOWglx32" style="text-align: right" title="Operating Leases, 2022">528</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20201231_zTxAWvVV5xtb" style="text-align: right" title="Finance Lease, 2022">20</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20201231_zHETN0cgwm34" style="text-align: right" title="Operating Leases, 2023">342</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20201231_zq4qcR8EzRKh" style="text-align: right" title="Finance Lease, 2023">20</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20201231_zFeR4t2KR6h" style="text-align: right" title="Operating Leases, 2024">188</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20201231_zwNV9GhUi5K3" style="text-align: right" title="Finance Lease, 2024">20</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20201231_zsJhVL2uRgn7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, 2025">59</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20201231_zuz522hVdfpj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Lease, 2025">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total minimum lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3_c20201231_zBMnPMPIbkLk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Total minimum lease payments">1,643</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_pn3n3_c20201231_zC1UR28KG7Mk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Leases, Total minimum lease payments">84</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: amount of lease payments representing interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20201231_ztGz3nCYll8h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Less: amount of lease payments representing interest">(138</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20201231_zHT9XriD7Lrl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Lease, Less: amount of lease payments representing interest">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Present value of future minimum lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20201231_zuJcxwl9X6Rg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Present value of future minimum lease payments">1,505</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20201231_zsOll1AEozka" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Lease, Present value of future minimum lease payments">83</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Current leases obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_c20201231_znjuy2SLuqd1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Less: Current leases obligations">(485</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_pn3n3_di_c20201231_z95tzskdOep5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Lease, Less: Current leases obligations">(19</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Long-term leases obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_zgG7HPpfTkOe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Long-term leases obligations">1,020</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_zkdo2MEdckRc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Lease, Long-term leases obligations">64</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A1_zOc9cENU1w82" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p id="xdx_895_ecustom--ScheduleOfRightofuseAssetsByGeographicalLocation_zGSgBueRb6dk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Right-of-use
assets by geographical location were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8B9_ziuqXQcrRCB3" style="display: none">SCHEDULE OF RIGHT-OF-USE ASSETS BY GEOGRAPHICAL LOCATION</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Korea</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--KR_zlXuLOn79WM6" style="width: 14%; text-align: right" title="Operating lease right-of-use assets">683</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--KR_zmzTrc2PUWRl" style="width: 14%; text-align: right" title="Operating lease right-of-use assets">145</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Israel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--IL_z19Lr1NnxPye" style="text-align: right" title="Operating lease right-of-use assets">496</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--IL_zcOn8zhaNaCb" style="text-align: right" title="Operating lease right-of-use assets">580</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">U.S.</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--US_z4mX8BUG13c9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating lease right-of-use assets">295</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--US_z76UwFBhrWG" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating lease right-of-use assets"><span style="-sec-ix-hidden: xdx2ixbrl1762">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231_zg2SXZvncJul" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use assets">1,474</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20191231_zhAh91WpnK6b" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use assets">725</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A4_zCsttVJJ5FFd" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676573083480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">COMMITMENTS</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--CommitmentsDisclosureTextBlock_zAn7Qlnnjvtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
10 &#8211; <span id="xdx_82E_zDzDwqP4TG81">COMMITMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">See
Note 11 for additional commitments for funding of the ventures of the company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>a.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Maryland
    Technology Development Corporation</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
June 30, 2014, the Company&#8217;s U.S. Subsidiary entered into a grant agreement with Maryland Technology Development Corporation
(&#8220;TEDCO&#8221;). TEDCO was created by the Maryland State Legislature in 1998 to facilitate the transfer and commercialization
of technology from Maryland&#8217;s research universities and federal labs into the marketplace and to assist in the creation
and growth of technology-based businesses in all regions of the State. Under the agreement, TEDCO paid to the U.S Subsidiary an
amount of $<span id="xdx_90D_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_c20140630__us-gaap--RelatedPartyTransactionAxis__custom--MarylandTechnologyDevelopmentCorporationMember__srt--RangeAxis__srt--MaximumMember_z61OWaxT90nb" title="Grants receivable, noncurrent">406</span> thousand (the &#8220;Grant&#8221;). On June 21, 2016 TEDCO has approved an extension until June 30, 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>b.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Department
    De La Gestion Financiere Direction De L&#8217;analyse Financiere (&#8220;DGO6&#8221;)</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">(1)
On November 17, 2014, the Belgian Subsidiary, received the formal approval from the DGO6 for a Euro <span id="xdx_900_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_uEUR_c20141117__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zpNwyBMCRF6h" title="Grants receivable, noncurrent">2</span> million ($<span id="xdx_900_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_uUSD_c20141117__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zxBTCocFltT" title="Grants receivable, noncurrent">2.4</span> million) support
program for the research and development of a potential cure for Type 1 Diabetes. The financial support was composed of Euro <span id="xdx_90F_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_uEUR_c20141117__us-gaap--OtherCommitmentsAxis__custom--IndustrialResearchPartOfResearchProgramMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zxlOqLLITAx2" title="Grants receivable, noncurrent">1,085</span>
thousand (<span id="xdx_90C_ecustom--GrantsReceivablePercentageOfBudgetedCosts_iI_pii_dp_uPercentage_c20141117__us-gaap--OtherCommitmentsAxis__custom--IndustrialResearchPartOfResearchProgramMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zQwJabUpFY3" title="Grants receivable, percentage of budgeted costs">70</span>% of budgeted costs) grant for the industrial research part of the research program and a further recoverable advance
of Euro <span id="xdx_907_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_uEUR_c20141117__us-gaap--OtherCommitmentsAxis__custom--ExperimentalDevelopmentPartOfResearchProgramMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zBOhOf3nRpw8" title="Grants receivable, noncurrent">930</span> thousand (<span id="xdx_901_ecustom--GrantsReceivablePercentageOfBudgetedCosts_iI_pii_dp_uPercentage_c20141117__us-gaap--OtherCommitmentsAxis__custom--ExperimentalDevelopmentPartOfResearchProgramMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zxIWdncDV2d9" title="Grants receivable, percentage of budgeted costs">60</span>% of budgeted costs) of the experimental development part of the research program. In December 2014, the
Belgian Subsidiary received advance payment of Euro <span id="xdx_90C_ecustom--AdvancePaymentsOnAccountOfGrant_iI_pn3n3_uEUR_c20141231__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zVKbZnE8j15e" title="Advance payments on account of grant">1,209</span> thousand under the grant. The grants are subject to certain conditions
with respect to the Belgian Subsidiary&#8217;s work in the Walloon Region. In addition, the DGO6 is also entitled to a royalty
upon revenue being generated from any commercial application of the technology. In 2017 the Company received by the DGO6 final
approval for Euro <span id="xdx_908_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_uEUR_c20171231__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zyEBoHcF3IB9" title="Grants receivable, noncurrent">1.8</span> million costs invested in the project out of which Euro <span id="xdx_905_eus-gaap--Revenues_pn5n6_c20170101__20171231__srt--ProductOrServiceAxis__custom--RevenueFromGrantsMember__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zwbh06oQeVx2" title="Revenues, total">1.2</span> million funded by the DGO6. As of December 31,
2020, the Company repaid to the DGO6 a total amount of $<span id="xdx_90F_eus-gaap--OtherExpenses_pn3n3_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zuJ1klvKPF3b" title="Other expenses">118</span> thousand (Euro <span id="xdx_904_eus-gaap--OtherExpenses_pn3n3_uEUR_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zqDcUUNqk98e" title="Other expenses">96</span> thousand) and amount of $<span id="xdx_905_eus-gaap--OtherCommitment_iI_pn3n3_c20201231__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zChk3zy27KRd" title="Other payables">106</span> thousand was recorded
in other payables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">(2)
In April 2016, the Belgian Subsidiary received the formal approval from DGO6 for a Euro <span id="xdx_906_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_uEUR_c20160430__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zwckrLTpKrOc">1.3
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million ($<span id="xdx_903_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_c20160430__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zcyDSi8mIuC2">1.5
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million) support program for the development
of a potential cure for Type 1 Diabetes. The financial support was awarded to the Belgium Subsidiary as a recoverable advance
payment at <span id="xdx_90F_ecustom--GrantsReceivablePercentageOfBudgetedCosts_iI_dp_uPercentage_c20160430__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zkYAYh5F1O06">55</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of budgeted costs, or for a total of Euro <span id="xdx_90D_eus-gaap--Revenues_pn3n3_uEUR_c20160401__20160430__srt--ProductOrServiceAxis__custom--RevenueFromGrantsMember__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zsgyX91xQ0Lh">717
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand ($<span id="xdx_909_eus-gaap--Revenues_pn3n3_c20160401__20160430__srt--ProductOrServiceAxis__custom--RevenueFromGrantsMember__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_z3OUrZmJYRT8">800
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand). The grant will be paid over
the project period. The Belgian Subsidiary received advance payment of Euro <span id="xdx_90B_eus-gaap--Revenues_pn3n3_uEUR_c20200101__20201231__srt--ProductOrServiceAxis__custom--RevenueFromGrantsMember__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_z00ID9zTlD19">438
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand ($<span id="xdx_905_eus-gaap--Revenues_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--RevenueFromGrantsMember__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zvPwZ8jIz1Ag">537
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand). Up through December 31,
2020, an amount of Euro <span id="xdx_903_ecustom--DeductionOfResearchAndDevelopmentExpenses_pn3n3_uEUR_c20200101__20201231__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zKrgXmU9kBO">358
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand ($<span id="xdx_901_ecustom--DeductionOfResearchAndDevelopmentExpenses_pn3n3_c20200101__20201231__us-gaap--OtherCommitmentsAxis__custom--DevelopmentOfPotentialCureForTypeOneDiabetesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zeOcc5Wz7Axc">437
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand) was recorded as deduction of
research and development expenses and an amount of Euro <span id="xdx_90E_ecustom--AdvancePaymentsOnAccountOfGrant_iI_pn3n3_uEUR_c20201231__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_z3HPJnLeeree">80
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand was recorded as advance payments
on account of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">(3)
On October 8, 2016, the Belgian Subsidiary received the formal approval from the DGO6 for a Euro <span id="xdx_907_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_uEUR_c20161008__us-gaap--OtherCommitmentsAxis__custom--GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zQ351sqZpTCh" title="Grants receivable, noncurrent">12.3 </span>million ($<span id="xdx_902_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_c20161008__us-gaap--OtherCommitmentsAxis__custom--GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zUtbRlRMhrlk" title="Grants receivable, noncurrent">12.8</span> million)
support program for the GMP production of AIP cells for two clinical trials that will be performed in Germany and Belgium. The
project will be conducted during a period of three years commencing January 1, 2017. The financial support is awarded to the Belgium
subsidiary at<span id="xdx_906_ecustom--GrantsReceivablePercentageOfBudgetedCosts_iI_dp_uPercentage_c20161008__us-gaap--OtherCommitmentsAxis__custom--GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zCAmTg3EXiOc" title="Grants receivable, percentage of budgeted costs"> 55</span>% of budgeted costs, a total of Euro <span id="xdx_90E_eus-gaap--Revenues_pn5n6_uEUR_c20161001__20161008__us-gaap--OtherCommitmentsAxis__custom--GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zdAUZJBCegKj" title="Revenues, total">6.8</span> million ($<span id="xdx_904_eus-gaap--Revenues_pn5n6_c20161001__20161008__us-gaap--OtherCommitmentsAxis__custom--GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zMVclOX9uG67" title="Revenues, total">7</span> million). The grant will be paid over the project period.
On December 19, 2016, the Belgian Subsidiary received a first payment of Euro <span id="xdx_909_eus-gaap--Revenues_pn5n6_uEUR_c20161201__20161219__us-gaap--OtherCommitmentsAxis__custom--GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zvG5mrnrBYTc" title="Revenues, total">1.7</span> million ($<span id="xdx_900_eus-gaap--Revenues_pn5n6_c20161201__20161219__us-gaap--OtherCommitmentsAxis__custom--GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zW6uSLNowGCg" title="Revenues, total">2</span> million). Up through December 31,
2020, an amount of Euro <span id="xdx_902_ecustom--DeductionOfResearchAndDevelopmentExpenses_pn5n6_c20200101__20201231__us-gaap--OtherCommitmentsAxis__custom--DeductionOfResearchAndDevelopmentExpensesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zOyIMtsiFh6" title="Deduction of research and development expenses">1.7</span> million was recorded as deduction of research and development expenses and an amount of Euro <span id="xdx_900_ecustom--DeductionOfResearchAndDevelopmentExpenses_pn3n3_uEUR_c20200101__20201231__us-gaap--OtherCommitmentsAxis__custom--DeductionOfResearchAndDevelopmentExpensesMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_z2oNMdoqLROj" title="Deduction of research and development expenses">53</span> thousand
was recorded as receivable on account of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><span style="font: 10pt Times New Roman, Times, Serif">(4)
In December 2020, the Belgian Subsidiary received the formal approval from DGO6 for a Euro <span id="xdx_901_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_uEUR_c20201231__us-gaap--OtherCommitmentsAxis__custom--ResearchOnDermatitisTreatmentsAndWoundHealingMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_z9uGjXhpGRB6" title="Grants receivable, noncurrent">2.9</span> million ($<span id="xdx_908_eus-gaap--GrantsReceivableNoncurrent_iI_pn5n6_c20201231__us-gaap--OtherCommitmentsAxis__custom--ResearchOnDermatitisTreatmentsAndWoundHealingMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zWmYSsiAhZL3" title="Grants receivable, noncurrent">3.5</span> million) support
program for research on Dermatitis Treatments and Wound Healing Using Cell Regenerative Technologies. The financial support was
awarded to the Belgium Subsidiary as a recoverable advance payment at <span id="xdx_908_ecustom--GrantsReceivablePercentageOfBudgetedCosts_iI_pii_dp_uPercentage_c20201231__us-gaap--OtherCommitmentsAxis__custom--ResearchOnDermatitisTreatmentsAndWoundHealingMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_ztxwQsGzHb75" title="Grants receivable, percentage of budgeted costs">60</span>% of budgeted costs, or for a total of Euro <span id="xdx_905_eus-gaap--Revenues_pn5n6_uEUR_c20201201__20201231__us-gaap--OtherCommitmentsAxis__custom--ResearchOnDermatitisTreatmentsAndWoundHealingMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zahfsZHia256" title="Revenues, total">1.7</span> million
($<span id="xdx_90E_eus-gaap--Revenues_pn5n6_c20201201__20201231__us-gaap--OtherCommitmentsAxis__custom--ResearchOnDermatitisTreatmentsAndWoundHealingMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zxDQaPfMmVV7" title="Revenues, total">2.1 </span>million). The grant will be paid over the project period. The Belgian Subsidiary received an advance payment of Euro <span id="xdx_907_eus-gaap--Revenues_pn3n3_uEUR_c20200101__20201231__us-gaap--OtherCommitmentsAxis__custom--ResearchOnDermatitisTreatmentsAndWoundHealingMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember__us-gaap--AwardTypeAxis__srt--EuropeMember_zH6NmnKczsj1" title="Revenues, total">301</span>
thousand ($<span id="xdx_902_eus-gaap--Revenues_pn3n3_c20200101__20201231__us-gaap--OtherCommitmentsAxis__custom--ResearchOnDermatitisTreatmentsAndWoundHealingMember__us-gaap--RelatedPartyTransactionAxis__custom--DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember_zqq9gnukmmSb" title="Revenues, total">366</span> thousand) in December 2020. The research program is to be started in 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>c.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Israel-U.S.
    Binational Industrial Research and Development Foundation (&#8220;BIRD&#8221;)</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
September 9, 2015, the Israeli Subsidiary entered into a pharma Cooperation and Project Funding Agreement (CPFA) with BIRD and
Pall Corporation, a U.S. company. BIRD awarded a conditional grant of $<span id="xdx_908_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_c20150909__us-gaap--RelatedPartyTransactionAxis__custom--IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember_zxoTJz8FASMl" title="Grants receivable, noncurrent">400</span> thousand each (according to terms defined in the agreement),
for a joint research and development project for the use Autologous Insulin Producing (AIP) Cells for the Treatment of Diabetes
(the &#8220;Project&#8221;). The Project started on March 1, 2015. Upon the conclusion of product development, the grant shall
be repaid at the rate of <span id="xdx_904_ecustom--RepaymentsOfGrantPercentageOfGrossSales_pii_dp_uPercentage_c20150901__20150909__us-gaap--RelatedPartyTransactionAxis__custom--IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember_zGZjuaY4Bu61" title="Repayments of grant, percentage of gross sales">5</span>% of gross sales. The grant will be used solely to finance the costs to conduct the research of the
project during a period of 18 months starting on March 1, 2015. On July 28, 2016, BIRD approved an extension for the project period
until May 31, 2017 and the final report was submitted to BIRD. As of December 31, 2020, the Israeli Subsidiary received a total
amount of $<span id="xdx_90E_eus-gaap--Revenues_pn3n3_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember_zlikKsnB5QBe" title="Revenues, total">299</span> thousand under the grant and the project was completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>d.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Korea-Israel
    Industrial Research and Development Foundation (&#8220;KORIL&#8221;)</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
May 26, 2016, the Israeli Subsidiary and the Korean Subsidiary entered into a pharma Cooperation and Project Funding Agreement
(CPFA) with KORIL. KORIL will give a conditional grant of up to $<span title="Grants receivable, noncurrent"><span id="xdx_905_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_c20160526__us-gaap--RelatedPartyTransactionAxis__custom--KoreaisraelIndustrialResearchAndDevelopmentFoundationMember_zWQSCLNRjLn" title="Grants receivable, noncurrent">400</span></span> thousand each (according to terms defined in the agreement),
for a joint research and development project for the use of AIP Cells for the Treatment of Diabetes (the &#8220;Project&#8221;).
The Project started on June 1, 2016. Upon the conclusion of product development, the grant shall be repaid at the yearly rate
of <span id="xdx_90F_ecustom--RepaymentsOfGrantPercentageOfGrossSales_pii_dp_uPercentage_c20160501__20160526__us-gaap--RelatedPartyTransactionAxis__custom--KoreaisraelIndustrialResearchAndDevelopmentFoundationMember_zlSFd6mGeR41" title="Repayments of grant, percentage of gross sales">2.5</span>% of gross sales. The grant will be used solely to finance the costs to conduct the research of the project during a period
of 18 months starting. On July 26, 2018 KORIL approved extension for the project period till May 31, 2019 and was further extended
to May 2020. During 2019, the grant was assigned to Cure Therapeutics from the Korean Subsidiary. As of December 31, 2020, the
Israeli Subsidiary and the Korean Subsidiary received $<span id="xdx_907_eus-gaap--Revenues_pn3n3_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--KoreaisraelIndustrialResearchAndDevelopmentFoundationMember_zzaKlScIBE09" title="Revenues, total">440</span> thousand under the grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>e.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">BIRD
    Secant</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
July 30, 2018, Orgenesis Inc and OBI entered into a collaboration agreement with Secant Group LLC (&#8220;Secant&#8221;). Under
the agreement, Secant will engineer and prototype 3D scaffolds based on novel biomaterials and technologies involving bioresorbable
polymer microparticles, while OBI will provide expertise in cell coatings, cell production, process development and support services.
Under the agreement, Orgenesis is authorized to utilize the jointly developed technology for its autologous cell therapy platform,
including its Autologous Insulin Producing (&#8220;AIP&#8221;) cell technology for patients with Type 1 Diabetes, acute pancreatitis
and other insulin deficient diseases. In the beginning of 2018, OBI entered into a Cooperation and Project Funding Agreement (CPFA)
with BIRD and Secant. BIRD will give a conditional grant up to $<span id="xdx_90A_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_c20180730__us-gaap--RelatedPartyTransactionAxis__custom--BirdSecantMember_zansRgRUxYM4" title="Grants receivable, noncurrent">450</span> thousand each to support the joint project (according to terms
defined in the agreement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, OBI received a total amount of $<span id="xdx_90E_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_c20201231__us-gaap--RelatedPartyTransactionAxis__custom--OBIMember_zi6QxgMyqHLb" title="Grants receivable, noncurrent">425</span> thousand under the grant. For the year ended December 31, 2020, an amount
of $<span id="xdx_906_ecustom--DeductionOfResearchAndDevelopmentExpenses_c20200101__20201231__us-gaap--OtherCommitmentsAxis__custom--DeductionOfResearchAndDevelopmentExpensesMember_pn3n3" title="Deduction of research and development expenses">28</span> thousand was recorded as deduction of research and development expenses.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676576390792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION AND LICENSE AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisclosureCollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration And License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationsLicenseAgreementsAndCommitmentsTextBlock', window );">COLLABORATION AND LICENSE AGREEMENTS</a></td>
<td class="text"><p id="xdx_80D_ecustom--CollaborationsLicenseAgreementsAndCommitmentsTextBlock_zAO0ynzstave" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
11 &#8211; <span id="xdx_82B_z4GMuU7NLpCh">COLLABORATION AND LICENSE AGREEMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>a.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Adva
    Biotechnology Ltd.</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
January 28, 2018, the Company and Adva Biotechnology Ltd. (&#8220;Adva&#8221;), entered into a Master Services Agreement (&#8220;MSA&#8221;),
under which the Company and/or its affiliates are to provide certain services relating to development of products to Adva, as
may be agreed between the parties from time to time. Under the MSA, the Company undertook to provide Adva with in kind funding
in the form of materials and services having an aggregate value of approximately $<span id="xdx_901_eus-gaap--OtherCommitment_iI_pn3n3_c20180128__custom--CollaborationAndLicenseAgreementsAxis__custom--AdvaBiotechnologyLtdMember_zl0mHKSUG3J9" title="Commitment">760</span> thousand at the Company&#8217;s own cost
in accordance with a project schedule and related mutually acceptable project budget. The Company entered into an agreement with
Orgenesis Biotech Israel (previously Atvio), to fulfill its obligations pursuant this MSA and it completed its contractual obligations
under the contract during 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
consideration for and subject to the fulfillment by the Company of such in-kind funding commitment, Adva agreed that upon completion
of the development of the products, the Company and/or its affiliates and Adva shall enter into a supply agreement pursuant to
which for a period of eight (8) years following execution of such supply agreement, the Company and/or its affiliates (as applicable)
is entitled (on a non-exclusive basis) to purchase the products from Adva at a specified discount pricing from their then standard
pricing. The Company and/or its affiliates were also granted a non-exclusive worldwide right to distribute such products, directly
or indirectly. <span id="xdx_90E_ecustom--TerminationDescription_c20180126__20180128__custom--CollaborationAndLicenseAgreementsAxis__custom--AdvaBiotechnologyLtdMember" title="Termination description">The MSA shall remain in effect for 10 years unless earlier terminated in accordance with its terms.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>b.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Tel
    Hashomer Medical Research, Infrastructure and Services Ltd (&#8220;THM&#8221;).</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
February 2, 2012, the Company&#8217;s Israeli Subsidiary entered into a licensing agreement with THM. According to the agreement,
the Israeli Subsidiary was granted a worldwide, royalty bearing, exclusive license to trans-differentiation of cells to insulin
producing cells, including the population of insulin producing cells, methods of making this population, and methods of using
this population of cells for cell therapy or diabetes treatment developed by Dr. Sarah Ferber of THM.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
consideration for the license, the Israeli Subsidiary will pay the following to THM:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">1)</span></td>
    <td colspan="3"><span style="font: 10pt Times New Roman, Times, Serif">A royalty of <span id="xdx_901_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20120201__20120202__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zPH6e54yVUwa" title="Royalty of net sales, percentage">3.5</span>% of net sales;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2)</span></td>
    <td colspan="3"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_ecustom--SublicensingFeesPercentage_pii_dp_uPercentage_c20120201__20120202__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zJkV0kE3qAJg" title="Sublicensing fees, percentage">16</span>% of all sublicensing fees received;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">3)</span></td>
    <td colspan="3" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An annual license fee of $<span id="xdx_908_eus-gaap--OtherCommitment_iI_pn3n3_c20120202__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zHgkyJiYWSCe" title="Commitment">15</span> thousand, which commenced on January 1, 2012 and shall be paid once every year thereafter. The annual fee is non-refundable, but it shall be paid each year against the royalty noted above, to the extent that such are payable, during that year; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">4)</span></td>
    <td colspan="3"><span style="font: 10pt Times New Roman, Times, Serif">Milestone payments as follows:</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">$<span id="xdx_90E_eus-gaap--OtherCommitment_iI_pn3n3_c20120202__us-gaap--OtherCommitmentsAxis__custom--OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zNC2gLJnbjO8" title="Commitment">50</span>
    thousand on the date of initiation of Phase I clinical trials in human subjects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">$<span id="xdx_903_eus-gaap--OtherCommitment_iI_pn3n3_c20120202__us-gaap--OtherCommitmentsAxis__custom--OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_z5sCowqt1tzf" title="Commitment">50</span>
    thousand on the date of initiation of Phase II clinical trials in human subjects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">c.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">$<span id="xdx_900_eus-gaap--OtherCommitment_iI_pn3n3_c20120202__us-gaap--OtherCommitmentsAxis__custom--OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zkpYvuhXP3Sd" title="Commitment">150</span>
    thousand on the date of initiation of Phase III clinical trials in human subjects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">d.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">$<span id="xdx_90A_eus-gaap--OtherCommitment_iI_pn3n3_c20120202__us-gaap--OtherCommitmentsAxis__custom--OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zjYrwyDrPJfc" title="Commitment">750</span>
    thousand on the date of initiation of issuance of an approval for marketing of the first product by the FDA; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">e.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">$<span id="xdx_903_eus-gaap--OtherCommitment_iI_pin6_c20120202__us-gaap--OtherCommitmentsAxis__custom--WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zSrPM8kKujtg" title="Commitment">2</span>
    million when worldwide net sales of Products (as defined in the agreement) have reached the amount of $<span id="xdx_90B_eus-gaap--ConvertibleDebt_iI_pin6_c20181018__dei--LegalEntityAxis__custom--HemogenyxPharmaceuticalsPLCMember__us-gaap--TypeOfArrangementAxis__custom--SalesMilestoneMember_zwf65DEtjjLg" title="Convertible loan">150</span> million for the
    first time, (the &#8220;Sales Milestone&#8221;).</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, the Israeli Subsidiary had not reached any of these milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><span style="font: 10pt Times New Roman, Times, Serif">In
the event of closing of an acquisition of all of the issued and outstanding share capital of the Israeli Subsidiary and/or consolidation
of the Israeli Subsidiary or the Company into or with another corporation (&#8220;Exit&#8221;), the THM shall be entitled to choose
whether to receive from the Israeli Subsidiary a one-time payment based, as applicable, on the value of either <span id="xdx_90E_ecustom--CommitmentSharesOfCommonStock_c20120202__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_pii" title="Commitment, shares of common stock">463,651</span> shares
of common stock of the Company at the time of the Exit or the value of <span id="xdx_900_ecustom--CommitmentSharesOfCommonStockOfSubsidiary_c20120202__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_pii" title="Commitment, shares of common stock of Israeli subsidiary">1,000</span> shares of common stock of the Israeli Subsidiary
at the time of the Exit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>c.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Hemogenyx
    Pharmaceuticals PLC.</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
October 18, 2018, the Company and Hemogenyx Pharmaceuticals PLC., a corporation with its registered office in the United Kingdom
and Hemogenyx-Cell (&#8220;H-Cell&#8221;), a corporation with its registered office in Belgium (together &#8220;Hemo&#8221;),
who are engaged in the development of cell replacement bone marrow therapy technology, entered into a Collaboration Agreement
(the &#8220;Hemo Agreement&#8221;) pursuant to which the parties will collaborate in the funding, continued development, and commercialization
of the Hemo technology via Hemo. Pursuant to the Hemo agreement the Company and Hemogenyx LLC (&#8220;Hemo-LLC&#8221;) (a wholly
owned US subsidiary of Hemo) entered into a loan agreement on November 7, 2018 according to which the Company agreed to loan Hemo-LLC
not less than $<span id="xdx_907_eus-gaap--ConvertibleDebt_iI_pn5n6_c20181018__dei--LegalEntityAxis__custom--HemogenyxPharmaceuticalsPLCMember_z3oC1AMftN38">1
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million by way of a convertible loan.
On November 25, 2018 the Company and Hemo entered into a License and Distribution agreement according to which Company received
the worldwide rights to market the products under the agreement in consideration for the payment of a <span id="xdx_907_ecustom--ReductionRateOfRoyaltyPercentage_pii_dp_uPercentage_c20181123__20181125__dei--LegalEntityAxis__custom--HemogenyxPharmaceuticalsPLCMember_zWPMYzAt6mEg">12</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
royalty all subject to the terms of the agreement. On November 25, 2018, the Company and H-Cell signed an Exclusive Manufacturing
agreement according to which the Company will receive the exclusive right to manufacture certain of H-Cell products. During 2018
and 2020 the Company advanced $<span id="xdx_90F_eus-gaap--ConvertibleDebt_iI_pn4n6_c20181231__dei--LegalEntityAxis__custom--HemogenyxPharmaceuticalsPLCMember__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentCostsMember_zh6QmUhapDl8">0.75
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million and $<span id="xdx_90A_eus-gaap--ConvertibleDebt_iI_pn4n6_c20201231__dei--LegalEntityAxis__custom--HemogenyxPharmaceuticalsPLCMember__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentCostsMember_zt5E6z96iXYi">0.25
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million, respectively,</span><span style="font: 10pt Times New Roman, Times, Serif">
to Hemo as a convertible loan and the entire loan was charged to expenses under ASC 730-10-50 and 20-50 and presented as research
and development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">See
Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>d.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Immugenyx
    LLC.</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
October 16, 2018, the Company and Immugenyx LLC., a corporation with its registered office in the USA (&#8220;Immu&#8221;), who
is engaged in the development of technology related to the production and use of humanized mice entered into a Collaboration Agreement
(the &#8220;Immu Agreement&#8221;) pursuant to which the parties will collaborate in the funding, continued development, and commercialization
of the Immu technology. Pursuant to the agreement, the Company received the worldwide rights to market the products under the
agreement in consideration for the payment of a <span id="xdx_90B_ecustom--ReductionRateOfRoyaltyPercentage_pii_dp_uPercentage_c20181015__20181016__custom--CollaborationAndLicenseAgreementsAxis__custom--ImmuAgreementMember__dei--LegalEntityAxis__custom--ImmugenyxLLCMember_zemHS3SecARd">12</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
royalty all subject to the terms of the agreement. Pursuant to the Immu agreement the Company and Immu entered into a loan agreement
on November 7, 2018 according to which the Company agreed to loan Immu not less than US$<span id="xdx_900_eus-gaap--ConvertibleDebt_iI_pn5n6_c20181016__dei--LegalEntityAxis__custom--ImmugenyxLLCMember_zuOVZyQekvyj">1
</span></span><span style="font: 10pt Times New Roman, Times, Serif">Million by way of a convertible loan.
During 2018 and 2020 the Company advanced $<span id="xdx_90F_eus-gaap--ConvertibleDebt_iI_pn4n6_c20181231__dei--LegalEntityAxis__custom--ImmugenyxLLCMember__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentCostsMember_zZMMGiDr48Nf">0.75
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million and $<span id="xdx_90F_eus-gaap--ConvertibleDebt_iI_pn4n6_c20201231__dei--LegalEntityAxis__custom--ImmugenyxLLCMember__us-gaap--OtherCommitmentsAxis__custom--ResearchAndDevelopmentCostsMember_zuuKQOo3fw09">0.25
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million, respectively,</span><span style="font: 10pt Times New Roman, Times, Serif">
to Immu as a convertible loan and the entire loan was charged to expenses under ASC 730-10-50 and 20-50 and presented as research
and development</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>e.
    </i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">BG
    Negev Technologies and Applications (&#8220;BGN&#8221;).</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
August 2, 2018, the Company&#8217;s U.S. Subsidiary entered into a licensing agreement with BGN. According to the agreement, the
U.S. Subsidiary was granted a worldwide, royalty bearing, exclusive license to develop and commercialize a novel alginate scaffold
technology for cell transplantation focused on autoimmune diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
November 25, 2018, the Company&#8217;s U.S. Subsidiary entered into a further licensing agreement with BGN. According to the agreement,
the U.S. Subsidiary was granted a worldwide, royalty bearing, exclusive license to develop and commercialize technology directed
to RAFT modification of polysaccharides and use of a bioreactor for supporting cell constructs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
consideration for the licenses, the U.S. Subsidiary will pay royalties of between <span id="xdx_90B_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20181124__20181125__custom--CollaborationAndLicenseAgreementsAxis__custom--BgNegevTechnologiesAndApplicationsBgnMember__srt--RangeAxis__srt--MinimumMember_zqWgvHHdLYjh" title="Royalty of net sales, percentage">4</span>% and <span id="xdx_909_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20181124__20181125__custom--CollaborationAndLicenseAgreementsAxis__custom--BgNegevTechnologiesAndApplicationsBgnMember__srt--RangeAxis__srt--MaximumMember_zxWcD51E429a" title="Royalty of net sales, percentage">7</span>% (subject to rate reductions to <span id="xdx_90D_ecustom--ReductionRateOfRoyaltyPercentage_pii_dp_uPercentage_c20181124__20181125__custom--CollaborationAndLicenseAgreementsAxis__custom--BgNegevTechnologiesAndApplicationsBgnMember__srt--RangeAxis__srt--MaximumMember_zVuLkYAhTSV7" title="Reduction rate of royalty percentage">5</span>%
and <span id="xdx_903_ecustom--ReductionRateOfRoyaltyPercentage_pii_dp_uPercentage_c20181124__20181125__custom--CollaborationAndLicenseAgreementsAxis__custom--BgNegevTechnologiesAndApplicationsBgnMember__srt--RangeAxis__srt--MinimumMember_zEet3ELPDQk5" title="Reduction rate of royalty percentage">4</span>%, respectively, in specific circumstances) of net sales of the licensed product, sub-license fees of <span id="xdx_901_ecustom--SublicensingFeesPercentage_pii_dp_uPercentage_c20181124__20181125__custom--CollaborationAndLicenseAgreementsAxis__custom--BgNegevTechnologiesAndApplicationsBgnMember_zd2gKaDZMjK2" title="Sublicensing fees, percentage">20</span>% of sub-license
income received, license fees of $<span id="xdx_901_eus-gaap--OtherCommitment_c20181125__custom--CollaborationAndLicenseAgreementsAxis__custom--BgNegevTechnologiesAndApplicationsBgnMember_pp0p0" title="Commitment">10,000</span> per year per license, and milestone and budget payments according to agreed upon work
plans to BGN.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>f.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Collaboration
    Agreement with Tarus Therapeutics, Inc.</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
February 27, 2019, the Company and Tarus Therapeutics Inc., a Delaware corporation, (&#8220;Tarus&#8221;) entered into a Collaboration
Agreement (the &#8220;Tarus Agreement&#8221;) for the collaboration in the funding, development and commercialization of certain
technologies, products and patents of Tarus in the areas of therapeutics for cancer and other diseases in the field of cell therapies
and their combination with checkpoint inhibitors comprised of Adenosine Receptor Antagonists. Under the terms of the Tarus Agreement
and subject to final due diligence and approved financing of the Company, the Company and/or one or more qualified investors (the
&#8220;Investors&#8221;) shall advance to Tarus a convertible loan in an amount of not less than $<span id="xdx_90A_eus-gaap--NotesReceivableNet_iI_pn3n3_c20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CollaborationAgreementMember__srt--RangeAxis__srt--MinimumMember_zHPmYRxJk323" title="Loans receivable net">1,750</span> thousand and up to $<span id="xdx_902_eus-gaap--NotesReceivableNet_iI_pn3n3_c20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CollaborationAgreementMember__srt--RangeAxis__srt--MaximumMember_zCCxlFU7M1Hi" title="Loans receivable net">3,000</span>
thousand (the &#8220;Loan Agreement&#8221;). As of December 31, 2020, the loan agreements have not been concluded, nor has any
financing been made to Tarus. As part of such Loan Agreement, and subject to approval by the board of directors of the Company,
the Investors shall have the right, within two years of the date of the Loan Agreement, to convert the outstanding convertible
loan into either (i) shares of Tarus at a price per share based on a pre- money valuation of $<span id="xdx_906_ecustom--PreMoneyValuation_iI_pn3n3_c20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CollaborationAgreementMember_z4v84TGEQ3a6" title="Pre-money valuation">12,500</span> thousand or (ii) shares of
the Company&#8217;s common stock at a price per share set in accordance with an approved financing of the Company, with such terms
as approved by the Company in its sole discretion. In the event the Investors elect to convert into shares of the Company&#8217;s
common stock, the Company shall have the right upon notice to Tarus to receive the same number of shares of capital stock of Tarus
that the Investors would have received had the Investors converted their convertible loans into shares of Tarus. Further, as part
of the Loan Agreement, the Company shall advance to Tarus up to $<span id="xdx_907_ecustom--AdditionalFundsInvest_iI_pn3n3_c20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CollaborationAgreementMember__srt--RangeAxis__srt--MinimumMember_zKcZnbLsBRrk" title="Additional Funds Invest">500</span> thousand within fourteen days of execution of the Loan Agreement.
Subject to the closing of the Loan Agreement, the Company and/or the Investors shall have an option, exercisable by sending written
notice to Tarus at any time through the second anniversary of the closing of the Loan Agreement, to invest additional funds in
an amount of up to $<span id="xdx_908_ecustom--AdditionalFundsInvest_iI_pn3n3_c20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CollaborationAgreementMember__srt--RangeAxis__srt--MaximumMember_zMc08MlHqtJ6" title="Additional Funds Invest">1,250</span> thousand and not less than $<span id="xdx_905_eus-gaap--ProceedsFromGrantors_pn3n3_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CollaborationAgreementMember_znoS8pAsopBf" title="Proceeds from advance payment of grant">500</span> thousand in Tarus. The Company will also have the right to appoint and/or
replace one member of board of directors of Tarus. Upon and subject to the execution of a definitive development and manufacturing
agreement between the Company and Tarus (&#8220;Manufacturing and Supply Agreement&#8221;), the Company, or one or more of its
affiliates, shall manufacture and supply to Tarus and any of its affiliates, licensees, assignees of interest all requirements
for all cell therapy elements of any combination therapy incorporating the technology of Tarus. Following the conclusion of the
clinical development stage of each product emanating from the technology of Tarus, the cell therapy component of any such product
borne out of the technology of Tarus shall be exclusively supplied by the Company under the Manufacturing and Supply Agreement.
If the Company and Tarus fail to sign such Manufacturing and Supply Agreement for any given Tarus product, Tarus shall pay the
Company an amount equal to four percent (<span id="xdx_906_ecustom--PercentageOfGrossRevenues_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CollaborationAgreementMember_ztrZuKxNxkvf" title="Percentage of gross revenues">4</span>%) of gross revenues derived by Tarus from such Tarus products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Apart
from the above, there was no activity in the Tarus collaboration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>g.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Sponsored
    Research and Exclusive License Agreement with Columbia University</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Effective
April 2, 2019, the Company and The Trustees of Columbia University in the City of New York, a New York corporation, (&#8220;Columbia&#8221;)
entered into a Sponsored Research Agreement (the &#8220;SRA&#8221;) whereby the Company will provide financial support for studying
the utility of serological tumor marker for tumor dynamics monitoring. Under the terms of the SRA, the Company shall pay $<span id="xdx_906_ecustom--PaymentForFinancialSupportToTrustForStudy_pn3n3_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--SponsoredResearchAgreementMember_zdTOfRjwJtMk" title="Payment for financial support to trust for study">300</span>
thousand per year for three years, or for a total of $<span id="xdx_906_ecustom--PaymentForFinancialSupportCumulativeAmountToTrustForStudy_pn3n3_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--SponsoredResearchAgreementMember_z60cQnMRYDS9" title="Payment for financial support cumulative amount to trust for study">900</span> thousand, with payments of $<span id="xdx_905_ecustom--PaymentForFinancialSupportToTrustForStudyDueEverySixMonths_pn3n3_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--SponsoredResearchAgreementMember_zQceikMC5Y1j" title="Payment for financial support to trust for study due every six months">150</span> thousand due every six months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Effective
April 2, 2019, the Company and Columbia entered into an Exclusive License Agreement (the &#8220;Columbia License Agreement&#8221;)
whereby Columbia granted to the Company an exclusive license to discover, develop, manufacture, sell, and otherwise distribute
certain product in the field of cancer therapy. In consideration of the licenses granted under the Columbia License Agreement,
the Company shall pay to Columbia (i) a royalty of <span id="xdx_909_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--ColumbiaLicenseAgreementMember_zxjZ2yTPKBpc" title="Royalty of net sales, percentage">5</span>% of net sales of any product sold which incorporates a licensed Columbia
patent and (ii) <span id="xdx_90B_ecustom--RoyaltyOfNetSalesOfOtherProductsPercentage_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--ColumbiaLicenseAgreementMember_zL4KLpOLHNMb" title="Royalty of net sales of other product percentage">2.5</span>% of net sales of other products. In addition, the Company shall pay a flat $<span id="xdx_904_ecustom--PaymentOfFeeUponAchievementOfEachRegulatoryMilestone_pn3n3_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--ColumbiaLicenseAgreementMember_zhNWLXIZRyyd" title="Payment of fee upon the achievement of each regulatory milestone">100</span> thousand fee to Columbia upon
the achievement of each regulatory milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>h.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>IRB
    Approval for Liver Cell Collection</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
April 29, 2019, the Company received Institutional Review Board (&#8220;IRB&#8221;) approval to collect liver biopsies from patients
at Rambam Medical Center located in Haifa, Israel for a planned study to confirm the suitability of liver cells for personalized
cell replacement therapy for patients with insulin-dependent diabetes resulting from total or partial pancreatectomy. The liver
cells are intended to be bio-banked for potential future clinical use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
goal of the proposed study, entitled &#8220;Collection of Human Liver Biopsy and Whole Blood Samples from Type 1 Diabetes Mellitus
(T1DM), Total or Partial Pancreatectomy Patients for Potential use as an Autologous Source for Insulin Producing Cells in Future
Clinical Studies,&#8221; is to confirm the suitability of the liver cells for personalized cell replacement therapy, as well as
eligibility of patients to participate in a future clinical study, as defined by successful AIP cell production from their own
liver biopsy. The secondary objective of the study is to evaluate patients&#8217; immune response to AIPs based on the patient&#8217;s
blood samples and followed by subcutaneous implantation into the patients&#8217; arm which would represent the first human trial.
The Company has developed a novel technology based on technology licensed from Tel Hashomer Medical Research Infrastructure and
Services Ltd., utilizing liver cells as a source for AIP cells as replacement therapy for islet transplantation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the study, liver samples will be collected and then processed and stored in specialized, clinical grade, tissue banks for potential
clinical use. The propagated cells will be maintained in a tissue bank and are intended to be utilized in a future clinical study,
in which the cells will be transdifferentiated and administered back to the patients as a potential treatment. This personalized
autologous process will be performed under our POC platform in which the patient liver samples are processed, cryopreserved and
potentially re-injected, all in the medical center under clinical grade/GMP level conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2019, the Company received additional Institutional Review Board (&#8220;IRB&#8221;) approval to collect liver biopsies from
patients at a leading medical center in USA for a planned study to confirm the suitability of liver cells for personalized cell
replacement therapy for patients with insulin-dependent diabetes resulting from total pancreatectomy (the granted Orphan Drug
Designation indication). The liver cells are intended to be bio-banked at the New York Blood Center, NYC for potential future
clinical use. In October 2019, a liver sample from the first recruited patient was collected and processed and stored at the New
York Blood Center, NYC in specialized, clinical grade, tissue banks for potential clinical use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>i.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>FDA
    Approval for Orphan Drug Designation for AIP Cells</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
June 11, 2019, the FDA granted Orphan Drug Designation for the Company&#8217;s AIP cells as a cell replacement therapy for the
treatment of severe hypoglycemia-prone diabetes resulting from total pancreatectomy (&#8220;TP&#8221;) due to chronic pancreatitis.
The incidence of diabetes following TP is <span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pii_dp_uPercentage_c20201231__srt--OwnershipAxis__custom--MarylandSubsidiaryMember__custom--CollaborationAndLicenseAgreementsAxis__custom--AIPCellsMember_zraQWOEaILP3" title="Percentage of ownership">100</span>%, resulting in immediate and lifelong insulin-dependence with the loss of both endogenous
insulin secretion and that of the counter-regulatory hormone, glucagon. Glycemic control after TP is notoriously difficult with
conventional insulin therapy due to complete insulin dependence and loss of glucagon-dependent counter-regulation. Patients with
this condition experience both severe hyperglycemic and hypoglycemic episodes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>j.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Regents
    of the University of California</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, the Company and the Regents of the University of California (&#8220;University&#8221;) entered into a joint research
agreement in the field of therapies and processing technologies according to an agreed upon work plan. According to the agreement,
the Company will pay the University royalties of up to <span id="xdx_901_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CaliforniaUniversityJointResearchAgreementMember__srt--RangeAxis__srt--MaximumMember_z7PbVj9GvJS8" title="Royalty of net sales, percentage">5</span>% (or up to <span id="xdx_90B_ecustom--SublicensingFeesPercentage_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--CaliforniaUniversityJointResearchAgreementMember__srt--RangeAxis__srt--MaximumMember_zbuTfjASQFHk" title="Sublicensing fees, percentage">20</span>% of sub-licensing sales) in the event of sales that includes
certain types of University owned IP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>k.
    </i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Caerus
    Therapeutics Inc (a related party)</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2019, the Company and Caerus Therapeutics (&#8220;Caerus&#8221;), a Virginia company, concluded a license agreement whereby
Caerus granted the Company an exclusive license to all Caerus IP relating to Advance Chemeric Antigen Vectors for Targeting Tumors
for the development and/or commercialization of certain licensed products. In consideration for the License granted to the Company
under this Agreement, the Company shall pay Caerus feasibility fees (including the grant to purchase <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231__srt--OwnershipAxis__custom--CaerusTherapeuticsIncMember_pii" title="Number of options issued">70,000</span> options in the Company,
annual maintenance fees and royalties of sales of up to <span id="xdx_904_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20200101__20201231__srt--OwnershipAxis__custom--CaerusTherapeuticsIncMember__srt--RangeAxis__srt--MaximumMember_zZUw2eJZY7Gc" title="Royalty of net sales, percentage">5</span>% and up to <span id="xdx_90B_ecustom--SublicensingFeesPercentage_pii_dp_uPercentage_c20200101__20201231__srt--OwnershipAxis__custom--CaerusTherapeuticsIncMember__srt--RangeAxis__srt--MaximumMember_zJHtmnyCjaSi" title="Sublicensing fees, percentage">18</span>% of sub-license fees. Expenses in the amount of approximately
$<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200101__20201231__srt--OwnershipAxis__custom--CaerusTherapeuticsIncMember_zALt5XPUoLB7" title="Research and development expense">200</span> thousand including the fair value of the options granted were recorded as research and development expenses. The Company
also has the right to instruct Caerus to transfer the license, development, development results and any other rights and licenses
granted to the Company to a joint venture (&#8220;JV&#8221;) in which Company shall have a <span id="xdx_904_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pii_dp_uPercentage_c20201231__srt--OwnershipAxis__custom--CaerusTherapeuticsIncMember_z3UaTBN68y08" title="Percentage of ownership">51</span>% controlling ownership stake in
the JV Entity. Upon Company&#8217;s election of such option, the development shall be carried out by Caerus for the JV and the
royalty, sublicense fees and annual maintenance fee shall be terminated. Company may provide requisite funding for the JV Entity
as determined by the Company and Caerus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>l.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Extracellular
    Vesicle (&#8220;EV&#8221;) Technology License</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the third quarter of 2020, the Company purchased the IP and related EV technology from a service provider (the &#8220;Service
Provider&#8221;) pursuant to an EV agreement (the &#8220;EV agreement&#8221;). According to the EV agreement, the Service Provider
sold to the Company all of its rights in the EV technology that it had produced, in the amount of $500 thousand, to be paid in
installments over the next 12 months from September 2020. The $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20201001__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ExtracellularVesicleMember__custom--CollaborationAndLicenseAgreementsAxis__custom--EVAmentMember_zJQDYFWWaCH2" title="Research and development expense">500</span> thousand was recorded in R&amp;D expenses. In addition, the
Service Provider granted the Company an exclusive worldwide license to use the EV IP technology for any purpose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>m.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Tamir
    Biotechnology acquisition</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Included
in the purchased assets of the Tamir Biotechnology Inc acquisition (See Note 4) was the assumption by the Company of a worldwide
license to a private company of certain Tamir technologies in the field of treatment, amelioration, mitigation or prevention of
diseases or conditions of the eye and its adnexa in return for certain development and sales milestone payments to be paid to
Tamir. This license fee and the right to receive future milestone payments (of up to $<span id="xdx_907_ecustom--FutureMilestonePayments_iI_pin6_c20200407__srt--RangeAxis__srt--MaximumMember__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_z17N0ufaqVYg" title="Future milestone payments">11</span> million assuming that certain milestones
are reached) and royalties (of up to $<span id="xdx_906_eus-gaap--RoyaltyExpense_pin6_c20200406__20200407__srt--RangeAxis__srt--MaximumMember__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zeDpymxqdJHj" title="Royalty Expense">35</span> million based on net sales milestones), were assumed by the Company in connection with
the Tamir Purchase Agreement together with a less than <span id="xdx_902_ecustom--RoyaltyPercentage_iI_pii_dp_uPercentage_c20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zrdusZxTjA9l" title="Royalty percentage">10</span>% share interest. To date, no milestones have been reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>n.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Tissue
    Genesis, LLC (&#8220;Tissue Genesis&#8221;)</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Included
in the Koligo acquisition (See Note 4) were the assets of Tissue Genesis. The Company is committed to paying the previous owners
of Tissue Genesis up to $<span id="xdx_90C_ecustom--FutureMilestonePayments_iI_pn3n3_c20201231__us-gaap--BusinessAcquisitionAxis__custom--TissueGenesisLLCMember__srt--RangeAxis__srt--MaximumMember_zf3DbvEYPCOl" title="Future milestone payments">500</span> thousand upon the achievement of certain performance milestones and earn-out payments on future sales
provided that in no event will the aggregate of the earn-out payments exceed $<span id="xdx_901_eus-gaap--RoyaltyExpense_pn5n6_c20201229__20201231__us-gaap--BusinessAcquisitionAxis__custom--TissueGenesisLLCMember__srt--RangeAxis__srt--MaximumMember_zUb1PGRVHhLl" title="Royalty Expense">4</span> million. To date, no milestones have been reached.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>o.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Joint
    venture agreements</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Additionally,
the Company has entered into joint venture agreements (&#8220;JVAs&#8221;) with its joint venture partners (Company and partner
are referred to as &#8220;parties&#8221;) to facilitate the collaboration in the field of CGT development and development of the
Company&#8217;s worldwide POCare network. The provisos and the table below summarize the major agreements. CGT and POCare activities
covered by the JVAs include the development, marketing, clinical development, and commercialization of the Company&#8217;s and
/ or partner&#8217;s products within defined territories. The extent of the collaboration is set out in each agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Unless
otherwise stated in the table below the JVAs include the following provisos (&#8220;Provisos&#8221;):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    incorporation of a joint venture entity (&#8220;JVE&#8221;) in which the Company will hold between <span id="xdx_90D_ecustom--InterestInJointVenture_iI_pii_dp_uPercentage_c20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--BroadenJointVentureAgreementMember__dei--LegalEntityAxis__custom--MarylandSubsidiaryMember__srt--RangeAxis__srt--MinimumMember_zNSbZAJGnWlf" title="Interest in joint venture">49</span>% and <span id="xdx_908_ecustom--InterestInJointVenture_iI_pii_dp_uPercentage_c20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--BroadenJointVentureAgreementMember__dei--LegalEntityAxis__custom--MarylandSubsidiaryMember__srt--RangeAxis__srt--MaximumMember_zzEeoNyOYN5" title="Interest in joint venture">50</span> % of the equity.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    partner will manage the joint venture activities until the JVE is incorporated.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    JVE will be managed by a steering committee consisting of 3 members which will act as the entity&#8217;s board of directors.
    The Company is entitled to appoint 1 member, the partner is entitled to appoint 1 member, and Company and partner will jointly
    appoint the third member.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    Company has the right to exercise a call option to acquire the partner&#8217;s share in the JVE based on the occurrence of
    certain events and according to an agreed upon mechanism.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    funding of the parties&#8217; investment in the joint venture share may be made in the form of cash investment and / or in-kind
    services. The Company&#8217;s cash investment may be in the form of additional shares, a convertible loan, and/or procured
    services.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Each
    of the parties may agree to provide additional funding to the JVE to cover the operation costs and such additional funding
    may be in the form of in-kind contributions. The Company&#8217;s investments may be made in the form of a cash investment
    for additional shares, a convertible loan, and/or procured services. Procured services refer to certain services that the
    Company has engaged the partner or the JVE to provide the Company with, in support of Company&#8217;s activity. All results
    of these procured services shall be owned by Company.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
    appropriate, the parties will grant to the JVE an exclusive or nonexclusive, sublicensable, royalty-bearing, right and license
    to the relevant party&#8217;s background IP as required solely to manufacture, distribute and market and sell the party&#8217;s
    products within the territory. Each party shall receive royalties in an amount of ten percent (<span id="xdx_906_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--BroadenJointVentureAgreementMember__dei--LegalEntityAxis__custom--MarylandSubsidiaryMember_zwmlyMD2ISV4" title="Royalty of net sales, percentage">10</span>%) of the net sales generated
    by the JVE and/or its sublicensees.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Once
    the JVE is profitable, the Company will be entitled (in addition to any of its rights as the holder of the JVE) to an additional
    share of fifteen percent (<span id="xdx_901_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__custom--CollaborationAndLicenseAgreementsAxis__custom--BroadenJointVentureAgreementMember__dei--LegalEntityAxis__custom--MarylandSubsidiaryMember_zJOSHZxgIH3b" title="Royalty of net sales, percentage">15</span>%) of the JVE&#8217;s GAAP profit after tax, over and above all rights granted pursuant to Company&#8217;s
    participating interest in the JVE.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name
    of party (and country of origin)</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Territory</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Theracell
    Advanced Biotechnology</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Greece,
    Turkey, Cyprus, Israel and Balkans</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Broaden
    Bioscience and Technology Corp</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Certain
    projects in China and the Middle East</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Mircod
                                         LLC</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(US)</span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Russia</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Image
    Securities FZC (UAE) (a related party)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">India</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cure
    Therapeutics</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Korea
    and Japan</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Kidney
    Cure Ltd</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Worldwide</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Sescom
    Ltd</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Worldwide</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(4)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Educell
                                         D.O.O</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(Slovenia)</span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Croatia,
    Serbia and Slovenia</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Med
                                         Centre for Gene and Cell Therapy FZ-LLC</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(UAE)</span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">UAE</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Mida
                                         Biotech B.V.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(Netherlands)</span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Netherlands,
    Lithuania, Spain, Switzerland, Germany, Belgium or any other countries within West Europe</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(5)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">First
                                         Choice International Company, Inc</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Panama
    and certain other Latin American countries</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(6)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">KinerjaPay
    Corp</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Singapore</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(7)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">SBH
    Sciences Inc</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Worldwide</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(8)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">HekaBio
    KK</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Japan</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(9)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    Theracell JVE was incorporated in Greece under the name of Theracell Laboratories Ltd. (See Note 12).</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
    the Mircod JVA, provisos 7 and 8 do not apply. Subject to payment by the Company ORGS of the contribution amount, the JVA
    will grant Company an exclusive, perpetual, irrevocable, royalty free and fully paid up and sublicensable license to use the
    Project IP for research and development and for the manufacturing, processing, supplying, and use of products based on point
    of care manufacturing and/or processing of treatments for patients and for use in hospitals, medical centers and academic
    institution settings solely outside the territory. The parties also, following proviso 6, concluded a convertible loan agreement
    pursuant to which Company shall lend Mircod up to $<span id="xdx_90D_ecustom--ConvertibleLoanAdvancedToJointVenture_pin6_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--JointVentureAgreementMember__srt--RangeAxis__srt--MinimumMember_zemq4si86All" title="Convertible loan advanced to joint venture">5</span> million based upon a development plan to be agreed upon. The loan bears
    simple interest in the amount of <span id="xdx_908_ecustom--ConvertibleLoanAdvancedToJointVentureInterestRate_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--JointVentureAgreementMember_zn2eHUwvtpOe" title="Convertible loan advanced to joint venture, interest rate">6</span>% annually. As at December 31, 2020, the development plan had not been finalized and no
    transfers under the loan agreement were made.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
    to the Kidney Cure JVA, the parties will collaborate in the (i) implementation of a point-of-care strategy; (ii) assessment
    of the options for development and manufacture of various cell-based types (including kidney derived cells, MSC cells, exosomes,
    gene therapies) development; and (iii) development of protocols and tests for kidney therapies (the &#8220;Project&#8221;).
    Provisos 7 and 8 do not apply to the Kidney Cure JVA. The Kidney Cure JVE was incorporated in Switzerland under the name of
    Butterfly Biosciences Sarl (See Note 12).</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
    the Sescom JVA, the parties will collaborate in the field of the assessment of relevant tools and technologies to be used
    in the Company&#8217;s information security system (the &#8220;ISS&#8221;); (ii) the implementation of the ISS within the
    Company and in the Company&#8217;s point-of-care network; and (iii) the operation and maintenance of the ISS. Provisos 7 and
    8 do not apply to this JVA. Company has agreed to provide the Sescom JVE with: (a) a non-exclusive, not transferable and non-sublicensable
    worldwide royalty-free license to use its background IP to the extent required for carrying out certain activities by the
    Sescom JVE; and (b) access to its point-of-care network and relevant data to be used for the certain activities.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
    the Mida JVA, commencing January 1, 2022 and thereafter Mida shall have the right to sell to Company its then issued and outstanding
    shares in the JVA, and if the JVA was not yet set up, its assets, contracts and liabilities relating to the project, for a
    consideration to be agreed between the parties in good faith, provided that such consideration is not lower than $<span id="xdx_909_eus-gaap--PaymentForContingentConsiderationLiabilityInvestingActivities_pn3n3_c20211231__20220101__custom--CollaborationAndLicenseAgreementsAxis__custom--JointVentureAgreementMember__srt--RangeAxis__srt--MaximumMember_zmMDqUsvnE44" title="Payment for consideration">500</span> thousand.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
    the First Choice JVA, each party shall, subject to fulfilment of the party&#8217;s JVA, grant the Panama JV Entity an exclusive
    license to certain intellectual property of the part to develop and commercialize the party&#8217;s products in the territory,
    subject to minimum sales obligations. In consideration of such license, the Panama JV shall pay the relevant part royalties
    at the rate of 15% of the Panama JVE net sales of party&#8217;s products sold in the territory.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"/>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">No
    activities have taken place since the JVA was signed. According to the JVA, Company was eligible to receive <span id="xdx_90E_ecustom--RoyaltyOfNetSalesPercentage_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--JointVentureAgreementMember__dei--LegalEntityAxis__custom--KinerjapayCorpMember_zNDhJ53IA2Ti" title="Royalty of net sales, percentage">51</span>% of the equity
    and <span id="xdx_900_ecustom--RoyaltyOfNetSalesOfOtherProductsPercentage_pii_dp_uPercentage_c20200101__20201231__custom--CollaborationAndLicenseAgreementsAxis__custom--JointVentureAgreementMember__dei--LegalEntityAxis__custom--KinerjapayCorpMember_zqrpDxVw2r2e" title="Royalty of net sales of other product percentage">10</span>% royalties on sales of products. The steering committee was to compromise 5 members of which Company could appoint
    2, and a third member to be an industry expert, to be appointed by Orgenesis. The JVA did not include the proviso 8.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
    to the SBH JVA the parties will collaborate in the field of gene and cell therapy development, process and services of bio-exosome
    therapy products and services in the areas of diabetes, liver cells and skin applications, including wound healing. The SBH
    JVE has not yet been incorporated. According to the JVA, the board of directors of the SBH JVE shall be comprised of three
    directors with one appointed by SBH and two appointed by the Company. All intellectual property conceived or developed resulting
    from the business of the SBH JV Entity, that is not SBH&#8217;s or the Company&#8217;s background intellectual property, shall
    be owned exclusively by the SBH JV Entity, although the Company shall be granted the right to exclusively license any intellectual
    property arriving from the development activities of the SBH JV Entity, or exclusively distribute products based thereon.
    Provisos 7 and 8 do not apply to the SBH JVA.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
    the third quarter of 2019, the Company transferred $<span id="xdx_900_eus-gaap--TransferToInvestments_pn3n3_c20191001__20191231__dei--LegalEntityAxis__custom--SBHSciencesIncMember_zrvWxhpaG5Qh" title="Transfer for prior establishment">50</span> thousand to SBH. Apart from the above, there was no material activity
    in the SBH Collaboration and the SBH JV entity had not been incorporated as at December 31, 2020.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
    the third quarter of 2020, the Company and HB agreed to terminate the license agreement. As of December 31, 2020, no activity
    had begun in the said JV and no investments were made therein.</span></td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_CollaborationsLicenseAgreementsAndCommitmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_CollaborationsLicenseAgreementsAndCommitmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisclosureCollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisclosureCollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676576498824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS IN ASSOCIATES, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract', window );"><strong>Investments in and Advances to Affiliates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock', window );">INVESTMENTS IN ASSOCIATES, NET</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock_zgkjvWqzjWV1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
12 &#8211;<span id="xdx_824_z0OkBUWj5wUj"> INVESTMENTS IN ASSOCIATES, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Theracell
    Laboratories Private Company</span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">During
October 2020, the Company and Theracell, pursuant to the Greek JVA (See Note 11) incorporated the Greek JVA entity known as Theracell
Laboratories Private Company (&#8220;TLABS&#8221;). The Theracell Project activities will be run through TLABS. The Company and
Theracell each hold a <span id="xdx_901_ecustom--InvestmentsInAssociatePercentageOfOwnership_iI_pii_dp_uPercentage_c20201031__dei--LegalEntityAxis__custom--TLABSMember_zCbE0weqp0i6" title="Investments in associate percentage of ownership">50</span>% participating interest in TLABS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Butterfly
    Biosciences Sarl</span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">During
October 2020, the Company and Kidney Cure, pursuant to the Kidney Cure JVA (See Note 11) incorporated the KC JV Entity known as
Butterfly Biosciences Sarl (&#8220;BB&#8221;) in Switzerland. BB will be involved in the (i) implementation of a point-of-care
strategy; (ii) assessment of the options for development and manufacture of various cell-based types (including kidney derived
cells, MSC cells, exosomes, gene therapies) development; and (iii) development of protocols and tests for kidney therapies (the
&#8220;BB Project&#8221;). The Company holds a <span id="xdx_906_ecustom--InvestmentsInAssociatePercentageOfOwnership_iI_pii_dp_uPercentage_c20201031__dei--LegalEntityAxis__custom--ButterflyBiosciencesSarlMember_zpeP14qqdOad" title="Investments in associate percentage of ownership">49</span>% participating interest on BB and Kidney Cure holds the remaining <span id="xdx_900_ecustom--InvestmentsInAssociatePercentageOfOwnership_iI_pii_dp_uPercentage_c20201031__dei--LegalEntityAxis__custom--KidneyCureJVAMember_zUdTmFSDZTm7" title="Investments in associate percentage of ownership">51</span>%.</span></p>

<p id="xdx_898_eus-gaap--InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_zmRmGgVbBzQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">c.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    table below sets forth a summary of the changes in the investments for the year ended&#160;December 31, 2020:</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B6_z5jPxicOzBo6" style="display: none">SCHEDULE OF CHANGES IN INVESTMENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20200101__20201231_zCZPdhPHQcI2" style="font-weight: bold; text-align: center">December 30,</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(In thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--EquityMethodInvestments_iS_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Opening balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1988">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--PaymentsToAcquireEquityMethodInvestments_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="width: 71%; text-align: left">Investments during the period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 25%; text-align: right">69</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--IncomeLossFromEquityMethodInvestments_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Share in net income of associated companies</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">106</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--EquityMethodInvestments_iE_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Ending balance</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">175</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the information summarizing investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates. It reflects specified information about ownership, financial results from, and financial position in such entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676576360296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zCWfL8IlyhK2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
13 &#8211; <span id="xdx_823_zOXiRXZlnMvg">EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Financings</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
January 20, 2020, the Company entered into a Securities Purchase Agreement (the &#8220;January Purchase Agreement&#8221;) with
certain investors pursuant to which the Company issued and sold, in a private placement (the &#8220;Offering&#8221;), <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pii" title="Sale of Stock, Number of Shares Issued in Transaction">2,200,000</span>
shares of Common Stock at a purchase price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_c20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pii" title="Sale of Stock, Price Per Share">4.20</span> per share (the &#8220;Shares&#8221;) and warrants to purchase up to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_znkdBizq9Ap7" title="Warrant to purchase of common stock">1,000,000</span>
shares of Common Stock at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pii" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">5.50</span> per share (the &#8220;Warrants&#8221;) which are <span id="xdx_90A_ecustom--WarrantExercisableDescription_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember" title="Warrant exercisable, description">exercisable between June
2021 and January 2023.</span> The Company received gross proceeds of approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn4n6_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zmILN4Kjidt1" title="Proceeds from Issuance of Private Placement">9.24</span> million before deducting related offering expenses
in the amount of $<span id="xdx_90C_ecustom--OfferingExpenses_pn5n6_c20200119__20200120_zEAiaVypijU7" title="Offering expenses">0.8</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>b.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Tamir
    Biotechnology, Inc.</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
the acquisition of Tamir, see Note 4.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
aggregate consideration for the acquisition, the Company paid $<span id="xdx_90E_eus-gaap--Cash_iI_pn5n6_c20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zcN3btyYhyof" title="Cash">2.5</span> million in cash and issued an aggregate of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pii_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zYhzVXccQFJh" title="Stock Issued During Period, Shares, Acquisitions">3,400,000</span> shares
(the &#8220;Shares&#8221;) of Common Stock to Tamir resulting in a total consideration of $<span id="xdx_906_eus-gaap--BusinessCombinationConsiderationTransferred1_pn5n6_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zP1lwZBdHHaf" title="Business Combination, Consideration Transferred">20.2</span> million based on the Company&#8217;s
share price at the closing date. $<span id="xdx_901_eus-gaap--EscrowDeposit_iI_pn3n3_c20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_zHhrr4v1e1V9" title="Escrow Deposit">59</span> thousand and <span id="xdx_901_ecustom--NumberOfSharesDepositInEscrowAccount_c20200406__20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_pii" title="Number of shares deposit in escrow account">340,000</span> Shares are being held in an escrow account for a period of 18 months
from closing to secure indemnification obligations of Tamir pursuant to the terms of the Tamir Purchase Agreement. The share price
was $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_c20200407__us-gaap--BusinessAcquisitionAxis__custom--TamirBiotechnologyIncMember__us-gaap--TypeOfArrangementAxis__custom--TamirPurchaseAgreementMember_pii" title="Shares Issued, Price Per Share">5.26</span> at the day of the closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>c.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Koligo
    Therapeutics Inc.</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
the acquisition of Koligo, see Note 4.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the terms of the Merger Agreement, at the Effective Time, the shares of capital stock of Koligo that were issued and outstanding
immediately prior to the Effective Time were automatically cancelled and converted into the right to receive, subject to customary
adjustments, an aggregate of <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20200924__20200926__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_pii">2,063,713
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Company common stock which
have been issued to Koligo&#8217;s accredited investors (with certain non-accredited investors being paid solely in cash in
the amount of approximately $<span id="xdx_906_eus-gaap--Cash_iI_pn3n3_c20200926__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_ztN69wJlqo8f">20
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand). In addition, we issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20201014__20201015__dei--LegalEntityAxis__custom--MaximaGroupLLCMember_zV4CliG3nq01">66,910</span>
shares to Maxim Group LLC for advisory services</span><span style="font: 10pt Times New Roman, Times, Serif"> in connection
with the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>d.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Warrants</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_892_ecustom--ScheduleOfWarrantsActivity_zYqchtHnoERa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the Company&#8217;s warrants granted to investors and as finder&#8217;s fees as of December 31, 2020, and December
31, 2019 and changes for the periods then ended is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zM9rIJbKhFS7" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Warrants </b></span></p> </div></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p> </div></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Warrants </b></span></p> </div></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p> </div></td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Warrants </b>outstanding at the</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">beginning of the period</span></p></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pii_c20200101__20201231_zy7hqsLWzaWe" style="width: 14%; text-align: right" title="Number of Warrants - Warrants outstanding at the beginning of the period">6,010,087</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231_zFSaEvQVhSc5" style="width: 14%; text-align: right" title="Weighted Average Exercise Price - Warrants outstanding at the beginning of the period">6.35</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pii_c20190101__20191231_zQls2BU5AEg9" style="width: 14%; text-align: right" title="Number of Warrants - Warrants outstanding at the beginning of the period">6,286,351</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pii_c20190101__20191231_zgeuftkOQsZf" style="width: 14%; text-align: right" title="Weighted Average Exercise Price - Warrants outstanding at the beginning of the period">6.29</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes during the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231_pii" style="text-align: right" title="Number of Warrants - Issued">1,344,606</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_c20200101__20201231_pii" style="text-align: right" title="Weighted Average Exercise Price - Issued">5.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20190101__20191231_pii" style="text-align: right" title="Number of Warrants - Issued">471,980</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_c20190101__20191231_pii" style="text-align: right" title="Weighted Average Exercise Price - Issued">6.95</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pii_di_c20200101__20201231_zIeUTF8pAYnl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants - Expired">(284,452</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_c20200101__20201231_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price - Expired">6.53</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pii_di_c20190101__20191231_z2bpJ9Ke5kE9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants - Expired">(748,244</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_c20190101__20191231_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price - Expired">6.24</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><b>Warrants</b> outstanding and exercisable at end of the period*</td><td style="padding-bottom: 2.5pt"><span id="xdx_F45_zkzKE0sZlZCe" style="font: 10pt Times New Roman, Times, Serif; display: none">*</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pii_c20200101__20201231_fKg_____zR6NfaZmUFu3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants - Warrants outstanding and exercisable at the end of the period">7,070,241</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice_iE_pii_c20200101__20201231_fKg_____z8LdBEn42ePi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Warrants outstanding and exercisable at the end of the period">6.20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pii_c20190101__20191231_fKg_____zUMeCU4HGJp6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants - Warrants outstanding and exercisable at the end of the period">6,010,087</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice_iE_pii_c20190101__20191231_fKg_____zDnl7acqCJ1h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Warrants outstanding and exercisable at the end of the period">6.35</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td id="xdx_F03_zyyC5iZXAPy1" style="width: 1%">*</td>
    <td id="xdx_F12_zEo56LSDClG5">As
of December 31, 2020 and December 31, 2019, there are no warrants that are subject to exercise price adjustments.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<p id="xdx_8AC_zFYvy87s8xN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>e.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Treasury
    shares</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p id="xdx_89E_ecustom--ScheduleOfTreasuryShares_z9FHh3sxwB8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the Company&#8217;s treasury shares purchased as of December 31, 2020 and changes for the period then ended is presented
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BA_zE0KGUTQTGYi" style="display: none">S<span>CHEDULE
OF TREASURY SHARES</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Treasury Shares </b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price Paid</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Treasury Shares at the beginning of the period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--TreasuryStockShare_iS_pii_c20200101__20201231_zCALmNDnKKKf" style="text-align: right" title="Number of Treasury Shares at the beginning of the period"><span style="-sec-ix-hidden: xdx2ixbrl2064">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--WeightedAveragePriceNumberOfSharesTreasuryStock_iS_pii_c20200101__20201231_z5s3B29Wptf2" style="text-align: right" title="Weighted Average Price Paid Treasury Shares at the beginning of the period"><span style="-sec-ix-hidden: xdx2ixbrl2066">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes during the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 56%; padding-bottom: 1.5pt">Purchased</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--TreasuryStockSharesAcquired_c20200101__20201231_pii" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Number of Treasury Shares Purchased">55,309</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--WeightedAveragePriceNumberOfSharesTreasuryStockPurchased_c20200101__20201231_pii" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Weighted Average Price Paid Treasury Shares Purchased">4.47</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Shares at end of the period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_ecustom--TreasuryStockShare_iE_pii_c20200101__20201231_zX5xyPjyZQt9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Treasury Shares at end of the period">53,309</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_ecustom--WeightedAveragePriceNumberOfSharesTreasuryStock_iE_pii_c20200101__20201231_zNaro5lNGmN9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Price Paid Treasury Shares at end of the period">4.47</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AB_zXvFBZTcCjGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676577865992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss (income) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">INCOME (LOSS) PER SHARE</a></td>
<td class="text"><p id="xdx_808_eus-gaap--EarningsPerShareTextBlock_zMOXj1KiIjXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
14 &#8211; <span id="xdx_826_z9nVLXal8zkh">INCOME (LOSS) PER SHARE</span></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zLfgzUn45W49" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth the calculation of basic and diluted loss per share for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B4_zW1mjJ0gKzSk" style="display: none">SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20200101__20201231_zWx4jwAIP616" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20190101__20191231_z79mK5xdaI01" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands, except per share data)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Basic and diluted:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net loss from continuing operations attributable to Orgenesis Inc.</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">95,088</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">22,490</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net (income) loss from discontinued operations attributable to Orgenesis Inc. for loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(96,198</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,631</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Adjustment of redeemable non-controlling interest to redemption amount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,160</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zL6pxqPyyqvd" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif">Basic: Net income (loss) available to common stockholders</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(101,358</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,726</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--NetIncomeLossToParentCompany_zFQJa5eUc912" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net (income) loss attributable to Orgenesis Inc. for loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,270</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,216</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i_pii" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Weighted average number of common shares outstanding</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,320,314</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,907,995</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pii_zUMbTmX4h8l1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss per common share from continuing operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4.46</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.41</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_pii_zcRAfqAQwP8e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net (income) loss common share from discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4.75</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.36</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--EarningsPerShareBasic_pii_uUSDPShares_zEEhZlScEMna" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Net (income) loss per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.29</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.77</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AB_z9AMcNjIP1Qc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
the year ended December 31, 2020, and December 31, 2019, all outstanding convertible notes, options and warrants have been excluded
from the calculation of the diluted net loss per share since their effect was anti-dilutive. Diluted loss per share does not include
<span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsAndWarrantsMember_zJs3Bb4BH4J9" title="Antidilutive securities excluded from computation of earnings per share amount">10,212,789</span> shares underlying outstanding options and warrants and <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesUponConversionOfConvertibleNotesMember_zt6AFC85gL54" title="Antidilutive securities excluded from computation of earnings per share amount">1,630,857</span> shares upon conversion of convertible loans for the
year ended December 31, 2020, because the effect of their inclusion in the computation would be anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676573629704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_800_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zsPEWaOODBTl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
15 &#8211; <span id="xdx_823_ziOCQJv1z6Sa">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>a.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Global
    Share Incentive Plan</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
May 11, 2017, the annual meeting of the Company&#8217;s stockholders approved the 2017 Equity Incentive Plan (the &#8220;2017
Plan&#8221;) under which, the Company had reserved a pool of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_c20170511__us-gaap--PlanNameAxis__custom--TwoZeroOneSevenEquityIncentivePlanMember_z2As6VSfKaFd" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">1,750,000</span> shares of the Company&#8217;s common stock, which may be
issued at the discretion of the Company&#8217;s board of directors from time to time. Under this Plan, each option is exercisable
into one share of common stock of the Company. The options may be exercised after vesting and in accordance with the vesting schedule
that will be determined by the Company&#8217;s board of directors for each grant. The maximum contractual life term of the options
is <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20170509__20170511__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoZeroOneSevenEquityIncentivePlanMember_zw9xbN8LIZ45" title="Share-based compensation, shares authorized under stock option plans, exercise price range, outstanding options, weighted average remaining contractual term">10</span> years. At the Company&#8217;s annual meeting of stockholders on November 26, 2019 the Company&#8217;s stockholders approved
an amendment to increase the number of shares authorized for issuance of awards under the Company&#8217;s 2017 Equity Incentive
Plan from <span>1,750,000</span> shares to an aggregate of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pii_c20170509__20170511__us-gaap--PlanNameAxis__custom--TwoZeroOneSevenEquityIncentivePlanMember_z9b3mV53BZ4j" title="Share-based compensation arrangement by share-based payment award, number of additional shares authorized">3,000,000</span> shares of Common Stock. As of December 31, 2020, total options granted
under this plan are <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--TwoZeroOneSevenEquityIncentivePlanMember_ze4AO8PDT6e7" title="Share-based compensation arrangement by share-based payment award, options, outstanding, number">1,362,133</span> and the total options that are available for grants under this plan are <span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--TwoZeroOneSevenEquityIncentivePlanMember_zFTUyslIemka" title="Share-based compensation arrangement by share-based payment award, options, available for grants">1,724,966</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
May 23, 2012, the Company&#8217;s board of directors adopted the Global Share Incentive Plan 2012 (the &#8220;2012 Plan&#8221;)
under which, the Company had reserved a pool of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_c20120523__us-gaap--PlanNameAxis__custom--GlobalShareIncentivePlanTwoZeroOneTwoMember_zClNYU8Q0NB1" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">1,000,000</span> shares of the Company&#8217;s common stock, which may be issued at the
discretion of the Company&#8217;s board of directors from time to time. Under this plan, each option is exercisable into one share
of common stock of the Company. The options may be exercised after vesting and in accordance with the vesting schedule that will
be determined by the Company&#8217;s board of directors for each grant. The maximum contractual life term of the options is <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20120521__20120523__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--GlobalShareIncentivePlanTwoZeroOneTwoMember_zXXYQyCIc3m6" title="Share-based compensation, shares authorized under stock option plans, exercise price range, outstanding options, weighted average remaining contractual term">10</span>
years. As of December 31, 2020, total options granted under this plan are <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20201231__us-gaap--PlanNameAxis__custom--GlobalShareIncentivePlanTwoZeroOneTwoMember_zjksD69k25pb" title="Share-based compensation arrangement by share-based payment award, options, outstanding, number">1,183,182</span> and the total options that are available for
grants under this plan are <span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--GlobalShareIncentivePlanTwoZeroOneTwoMember_zvSDZoIywWE4" title="Share-based compensation arrangement by share-based payment award, options, available for grants">248,024</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>b.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Options
    Granted to Employees and Directors</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZpsYXnnwH74" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Below
is a table summarizing all of the options grants to employees and Directors made during the years ended December 31, 2020, and
December 31, 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8BE_z2wZ5VoapHK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE
OF EMPLOYEE STOCK OWNERSHIP PLAN DISCLOSURES<span style="font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of options <br/> granted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Vesting period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Fair value at grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>(in thousands)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Expiration <br/> period</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%; text-align: center">Employees</td><td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: center">December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zK84ovmWCrVj" style="width: 10%; text-align: right">531,450</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">$<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember__srt--RangeAxis__srt--MinimumMember_zjlMlT6Y8Hp3" title="Exercise price">2.99</span>-$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember__srt--RangeAxis__srt--MaximumMember_z2N5Xc2nwZHd">6.84</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 28%; text-align: center">Quarterly over a period of <span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zOHsvZG0LJx4" title="Stock options vesting period description">two years</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_znd3sUJFCZqi" style="width: 12%; text-align: right" title="Fair value at grant">1,312</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zbvht2A920S9">10</span> years</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Directors</td><td>&#160;</td>
    <td style="text-align: center">December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zK3VPNSsvJ0f" style="text-align: right">145,050</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">$<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember__srt--RangeAxis__srt--MinimumMember_z5KfV2P0CSb" title="Exercise price">2.99</span>-$<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember__srt--RangeAxis__srt--MaximumMember_zUuysBuwVFX8">4.7</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90C_ecustom--StockOptionsGrantVestingPeriodPercentage_pii_dp_uPercentage_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--StatementScenarioAxis__custom--OneYearAnniversaryMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z6PmhEs4a4td">96</span>%
on the one-year anniversary, <span>and
the remaining </span><span id="xdx_902_ecustom--StockOptionsGrantVestingPeriodPercentage_pii_dp_uPercentage_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--StatementScenarioAxis__custom--ThreeEqualInstallmentsMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z5aJKhTktsA3">4</span><span>%
in three equal instalments on the first, second and third year anniversaries</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zAUSql0z2lgg" style="text-align: right" title="Fair value at grant">377</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z9CKhxzGeRSa">10</span> years</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Employees</td><td>&#160;</td>
    <td style="text-align: center">December 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zi9F5VeJtsja" style="text-align: right" title="No. of options granted">94,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zE36mXHDmjW4" title="Exercise price">3.14</span>-$<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zXVuc9s05iJh" title="Exercise price">5.07</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Quarterly over a period of <span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zIYrSjtXl9m9" title="Stock options vesting period description">two years</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zFxHlKP0XU9a" style="text-align: right" title="Fair value at grant">322</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z78KDbNzJeK6" title="Expiration period">10</span> years</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Directors</td><td>&#160;</td>
    <td style="text-align: center">December 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zVqCz3kgOwPk" style="text-align: right" title="No. of options granted">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zZyCgN1R4yXh" style="text-align: right" title="Exercise price">2.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zjOfThQtSbe6">One-year</span> anniversary</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zQJe3aZ6xA1i" style="text-align: right" title="Fair value at grant">103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zNiZVk9vlFY6" title="Expiration period">10</span> years</td></tr>
</table>

<p id="xdx_8A0_zb0bzOVrWTg8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value of each stock option grant is estimated at the date of grant using a Black Scholes option pricing model. The volatility
is based on historical volatility of the Company, by statistical analysis of the weekly share price for past periods based on
expected term. The expected option term is calculated using the simplified method<i>, </i>as the Company concludes that its historical
share option exercise experience does not provide a reasonable basis to estimate its expected option term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zarrDrkXzyxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The fair value of each
option grant is based on the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8BB_zu5YXeodfKUg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify">SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value of one common share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zxAkFRvFYom7" title="Value of one common share">2.99</span>-$<span id="xdx_905_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z1eFWEp56oF4" title="Value of one common share">6.84</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zG7neHReUXf4" title="Value of one common share">2.99</span>-$<span id="xdx_90E_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zQ5y9tjhJhr2" title="Value of one common share">5.07</span></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">Dividend yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_uPercentage_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zReH2dtA3zh4" style="width: 18%; text-align: right">0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_uPercentage_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZebSolkkqrl" style="width: 18%; text-align: right" title="Dividend yield">0</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected stock price volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zsS5PwD0W1D7">80</span>%-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zYePs3g60htc">86</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zNar8RrjmwB8" title="Expected stock price volatility">83</span>%-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zEDf0maq53rk" title="Expected stock price volatility">88</span></span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zOy9G7xKVGLf">0.36</span>%-<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zYye4pMhEvIe">1.71</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zLyjUsMQiYx4" title="Risk free interest rate">1.45</span>%-<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zjDBWHGiJmW1" title="Risk free interest rate">2.47</span></span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_ze3gE7h0Rb49">5.50</span>-<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zW6K9Y35RD4k">6.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zKAv9fglXGY2" title="Expected term (years)">5.38</span>-<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zleGTKeRrgcj" title="Expected term (years)">5.56</span></span></td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A8_zLejcaFxNxp1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zS3l2Iqv4Uv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the Company&#8217;s stock options granted to employees and directors as of December 31, 2020 and December 31, 2019
is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8BD_zoETxj5WpTca" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify">SCHEDULE OF STOCK OPTIONS ACTIVITY<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify">Options outstanding at the beginning of the period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pp0i_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zS0jFjN6KED9" style="width: 14%; text-align: right" title="Number of Options - Options outstanding at the beginning of the year">2,465,522</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z66PjItUwiM7" style="width: 14%; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the beginning of the year">4.44</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z1XpzuJYcAm4" style="width: 14%; text-align: right" title="Number of Options - Options outstanding at the beginning of the year">2,376,427</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zwin3PHg5uH5" style="width: 14%; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the beginning of the year">4.51</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes during the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" style="text-align: right" title="Number of Options - Granted">676,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" style="text-align: right" title="Weighted Average Exercise Price - Granted">3.74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zpPLI0D0IsI7" style="text-align: right" title="Number of Options - Granted">144,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zXaY3QgzSlJd" style="text-align: right" title="Weighted Average Exercise Price - Granted">4.15</td><td style="text-align: left">&#160;</td></tr>
<tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zkbmQpBqp9b8" style="text-align: right" title="Number of Options - Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2221">-</span></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zKYCsHeYQgBf" style="text-align: right" title="Weighted Average Exercise Price - Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2223">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_ztjVax01M9gf" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2224">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zi0koaWyMNhj" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2225">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zcE59Ue5eEM1" style="text-align: right" title="Number of Options - Expired">(11,876</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" style="text-align: right" title="Weighted Average Exercise Price - Expired">7.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zsvXWdYt2eEh" style="text-align: right" title="Number of Options - Expired">(16,750</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zOgPNHGEJ0pc" style="text-align: right" title="Weighted Average Exercise Price - Expired">6.01</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zx0am2zNCkf6" style="text-align: right" title="Number of Options - Forfeited">(57,042</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" style="text-align: right" title="Weighted Average Exercise Price - Forfeited">4.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zBs5z1ppkm2d" style="text-align: right" title="Number of Options - Forfeited">(38,655</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zL30qNRjUlL" style="text-align: right" title="Weighted Average Exercise Price - Forfeited">7.11</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zK1f3mUQl6Cc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options - Cancelled">(155,437</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price - Cancelled">8.38</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zHUFGhJj1qua" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options - Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl2247">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zyudtFueAWS" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price - Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl2249">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Options outstanding at end of the period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z024hYqGeUMe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options outstanding at the end of the year">2,917,667</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zFoCUILK0Q8c" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the end of the year">4.05</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zKrFiK6LLwvg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options outstanding at the end of the year">2,465,522</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zyCEU8TRgmZi" style="border-bottom: Black 2.5pt double; text-align: right">4.44</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Options exercisable at end of the period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pp0i_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZ2pJpCKwoxc" style="border-bottom: Black 2.5pt double; text-align: right">2,299,937</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zpUpqlzns8x4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options exercisable at end of the year">4.03</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZ0SvcxgDS9g" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options exercisable at end of the year">2,112,567</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zK7aIyGVpPbc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options exercisable at end of the year">4.21</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A9_zLojcCy90UR7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_892_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zxdA6Hu4y6M3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table presents summary information concerning the options granted and exercisable to employees and directors outstanding
as of December 31, 2020 (in thousands, except per share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8B5_z4X3q6LgMLN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify">SCHEDULE OF STOCK OPTIONS EXERCISABLE<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Life</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Value $</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(in thousands)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zGEALbelDWwh" style="width: 13%; text-align: right" title="Exercise Price">0.0012</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z6TqKbUflO2j" style="width: 13%; text-align: right" title="Number of Outstanding Options">230,189</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zuf78fMwa3f5" style="width: 13%; text-align: right" title="Weighted Average Remaining Contractual Life">3.64</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zY4WOMnLvNb6" style="width: 13%; text-align: right" title="Aggregate Intrinsic Value">1,036</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zAWBgIjsGEXb" style="width: 13%; text-align: right" title="Number of Exercisable Options">230,189</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_d0_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z0iITGcIcg7i" style="width: 13%; text-align: right" title="Aggregate Exercisable Options Value">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zsnXse1mShx5" style="text-align: right" title="Exercise Price">0.012</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zYWnvvAxbePf" style="text-align: right" title="Number of Outstanding Options">510,017</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zgtr2LszQ8T" style="text-align: right">1.09</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z7pAURfpw0B5" style="text-align: right" title="Aggregate Intrinsic Value">2,289</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zosR9KYJuJl9" style="text-align: right" title="Number of Exercisable Options">510,017</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z2evfla7Qt4" style="text-align: right" title="Aggregate Exercisable Options Value">6</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z8lU7wP9IYhf" style="text-align: right">2.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zZe7CuN7ybP6" style="text-align: right" title="Number of Outstanding Options">445,013</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zLhTnNHFK0j" style="text-align: right">9.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zwDNvdMzi6s2" style="text-align: right">672</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zNIKw2DIiwW6" style="text-align: right">174,208</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z1TXSnL3ru7k" style="text-align: right">521</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zziuggCyAbF3" style="text-align: right">3.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zXpaNqHvtX13" style="text-align: right" title="Number of Outstanding Options">3,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvuZtvKy57B3" style="text-align: right">6.27</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zE3q69EIIDYc" style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zSICuphcB5Ug" style="text-align: right">1,875</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zAxaQYg9prC5" style="text-align: right">6</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zzgKfDknX7re" style="text-align: right">4.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zHDBhdy1z2e8" style="text-align: right" title="Number of Outstanding Options">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zz9bcZ1HDAA" style="text-align: right">6.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zAfiKgfooTsa" style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zbM0gX99XZy7" style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTCxm0HfXDb9" style="text-align: right">221</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zua5M9f5Kwjc" style="text-align: right">4.5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zbIxZC0xCdFb" style="text-align: right" title="Number of Outstanding Options">34,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJJhg7ViLdEk" style="text-align: right">8.47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zxPzOGqt9tAf" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2314">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zKYpcnIP3CA2" style="text-align: right">23,938</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zuR3G4xzwGo8" style="text-align: right">108</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zrtz3nBOVSl4" style="text-align: right">4.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zi1Jq9uNwzg5" style="text-align: right" title="Number of Outstanding Options">185,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zNdSHSEvJXUh" style="text-align: right">9.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zqwyKX6tAvol" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2321">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zaB4oP2vrV6i" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2322">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_z3KEJ7E6TB4g" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2323">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zGoq2SXn28Vj" style="text-align: right">4.7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pp0i_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zTtdkdMRF9D5" style="text-align: right" title="Number of Outstanding Options">6,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zSVe3QPTBTk9" style="text-align: right">9.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zB5WBQL6dIUl" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2328">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z8M4560m5oEb" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2329">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z54JqtlcFFnd" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2330">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zaXCRz6LmYI9" style="text-align: right">4.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zByoI54r79j6" style="text-align: right" title="Number of Outstanding Options">483,337</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zX6XYi0wSKS2" style="text-align: right">5.94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z1RW0WBc41G6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2335">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zLUJ1ygYDy8i" style="text-align: right">483,337</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zhXjTw0gsvgl" style="text-align: right">2,320</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zfFNf1Lmh8yf" style="text-align: right">5.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zMF2XZBxa3jl" style="text-align: right" title="Number of Outstanding Options">53,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zzonyXwmtLAe" style="text-align: right">8.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zZ5sgYFnjkY" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2342">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zBTf2tpIvD94" style="text-align: right">39,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zU7QOoLUpS2a" style="text-align: right">202</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z6jBUGwNk8v6" style="text-align: right">5.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zBZdet3rU6Yh" style="text-align: right" title="Number of Outstanding Options">63,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zRHJmugJkFck" style="text-align: right">9.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zhXZzATa9Ss8" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2349">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zHilCuwxGo84" style="text-align: right">7,875</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zcodATh9AaOk" style="text-align: right">40</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z86G3JEOVNr9" style="text-align: right">5.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zwNp4pEw8fQ2" style="text-align: right" title="Number of Outstanding Options">352,550</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zfHNOptExar2" style="text-align: right">7.26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zA1mWFNXcNJ6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2356">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zP1LLSF4Mtuc" style="text-align: right">290,488</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zMpNwJzHG4Gd" style="text-align: right">1,740</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zuUYwnC0X5fa" style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zVwS6ErCiyTa" style="text-align: right" title="Number of Outstanding Options">16,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zSyQu6yR305h" style="text-align: right">3.59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z9tAjFEecGda" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2363">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zlZ9fmmDFEIc" style="text-align: right">16,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z39Brmi8we8l" style="text-align: right">100</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zv7NHJLAmtw8" style="text-align: right">6.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zVulO9w8euh5" style="text-align: right" title="Number of Outstanding Options">17,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z8RNlxcC2W1i" style="text-align: right">9.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zKnH7yGsrxn9" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2370">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zmIYUBzMpcYd" style="text-align: right">4,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zqlLmFqB3qi2" style="text-align: right">29</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zw8ubJhwHO17" style="text-align: right">7.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zONbllM7nOLc" style="text-align: right" title="Number of Outstanding Options">83,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zFDNG2zRevn7" style="text-align: right">6.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_znOihXEN96jl" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2377">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zBumwNDfbY28" style="text-align: right">83,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zj1GmtxQcMYc" style="text-align: right">600</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zyrN5fuMbMU2" style="text-align: right">8.36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zAcZWJKzTXu" style="text-align: right" title="Number of Outstanding Options">250,001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zDILxQGP3fzd" style="text-align: right">7.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_ztmamPyTtELk" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2384">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zsXyj2NXlY1i" style="text-align: right">250,001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zpJuHxdUimm6" style="text-align: right">2,090</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_z76gvrXQeJdf" style="text-align: right">8.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zDhBuuQ0yyL8" style="text-align: right" title="Number of Outstanding Options">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_z74nX1crcePc" style="text-align: right">7.46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_z7RM1Jq3y8Ah" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2391">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zXjHdoUuI6sd" style="text-align: right">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zQ3jAXaGiuv" style="text-align: right">134</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_z79o78OrNJ36" style="text-align: right">9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zfO8tkwF6Zn" style="text-align: right" title="Number of Outstanding Options">20,834</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_ztIvFWPvSzhi" style="text-align: right">2.54</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zvOuCFgoJyLe" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2398">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zUwzO0SsLsCi" style="text-align: right">20,834</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zm81PGWFTiC5" style="text-align: right">187</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zLDbWwX6rgF8" style="text-align: right">9.48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_z0aoY4XPQdl9" style="text-align: right" title="Number of Outstanding Options">58,908</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zzp1y3zqife6" style="text-align: right">1.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zNV3bqMD055k" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2405">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zOL8AZY6jqni" style="text-align: right">58,908</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zma966NkxPvl" style="text-align: right">558</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zGbmSBYIOg61" style="padding-bottom: 1.5pt; text-align: right">10.2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zgzKvQiMO9w6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Outstanding Options">39,267</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_z0i0XGzTN3O6" style="border-bottom: Black 1.5pt solid; text-align: right">1.42</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zgRRK1mvqLH2" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2412">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zbdB8XmT3Tx3" style="border-bottom: Black 1.5pt solid; text-align: right">39,267</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zbyxob0ZdTu4" style="border-bottom: Black 1.5pt solid; text-align: right">401</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zsDbzHu4diyh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding Options">2,917,667</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zx7nbitDplPd" style="border-bottom: Black 2.5pt double; text-align: right">5.98</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zdZNhbLeERj6" style="border-bottom: Black 2.5pt double; text-align: right">4,006</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z6RenwmsaOAi" style="border-bottom: Black 2.5pt double; text-align: right">2,299,937</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_ztKD6Ozzb14f" style="border-bottom: Black 2.5pt double; text-align: right">9,263</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A8_zy1aHQkP142g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Costs
incurred with respect to stock-based compensation for employees and directors for the years ended December 31, 2020 and December
31, 2019 were $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesAndDirectorsMember_zSI8D6O7pIsg">1,470
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pn3n3_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesAndDirectorsMember_z3SS4NEX4755">2,107
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand, respectively,</span><span style="font: 10pt Times New Roman, Times, Serif">
out of which <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20201231__dei--LegalEntityAxis__custom--MasthercellGlobalMember_z5y3Qqm3LChk">$450
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand</span><span style="font: 10pt Times New Roman, Times, Serif">
and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20190101__20191231__dei--LegalEntityAxis__custom--MasthercellGlobalMember_zpVzsmy5ta04">$360
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousand</span><span style="font: 10pt Times New Roman, Times, Serif">
related to options granted to employees of Masthercell Global, respectively, and presented as part of net loss from discontinued
operations in the consolidated statements of comprehensive loss. As of December 31, 2020, there was $<span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--MasthercellGlobalMember_zXKOSiT2ndna">1,594
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thousands of unrecognized compensation
costs related to non-vested employees and directors stock options, to be recorded over the next <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20200101__20201231__dei--LegalEntityAxis__custom--MasthercellGlobalMember_zS5SsYoLX809">2.02
</span></span><span style="font: 10pt Times New Roman, Times, Serif">years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>c.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Options
    Granted to Consultants and service providers</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zrZwCVhUAEB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Below
is a table summarizing all the compensation granted to consultants and service providers during the years ended December 31, 2020
and December 31, 2019 and for the one-month period ended December 31, 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8BE_zyaIvRYNcubb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify">SCHEDULE OF STOCK OPTIONS GRANTED TO CONSULTANTS<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><br/>Year
    of grant</b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><br/>No.
    of options <br/> granted</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><br/>Exercise
    price</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Vesting period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Fair
                                         value at grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(in
                                         thousands)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"><b><br/>Expiration
    <br/> period</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 8%; text-align: center">Non-employees <br/></td><td style="width: 2%">&#160;</td>
    <td style="width: 8%; text-align: center">2020 <br/></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zq9DlXJrIeng" style="width: 6%; text-align: right">62,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zanjnW2R8tDb">2.99</span>-$<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z725VBpqLdzi">6.84</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 30%; text-align: center">Quarterly over a period of <span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zgFWgaOCBvi" title="Vesting peirod description">two</span> years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pp0p0_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z3QNkvR0SEUh" style="width: 14%; text-align: right">209</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 10%; text-align: center"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zStftzty8WEh">10</span> years</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Non-employees <br/></td><td>&#160;</td>
    <td style="text-align: center">2019 <br/></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_ztq9TlnZkUz1" style="text-align: right" title="No. of options granted">128,336</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z7jIjxUbX6rj" title="Exercise price">3.14</span>-$<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zfRWQwgfkdrg" title="Exercise price">7</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Vest immediately-<span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zJCsrnJgG7mi" title="Vesting period">5</span> years</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pp0p0_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zyvsGmIXHucc" style="text-align: right" title="Fair value at grant">394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zklPJev0kWDb" title="Expiration period">10</span> years</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_8AD_zmELaunstzi7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value of options granted during 2020 and 2019 to consultants and service providers, was computed using the Black-Scholes
model. The fair value of each stock option grant is estimated at the date of grant using a Black Scholes option pricing model.
The volatility is based on historical volatility of the Company, by statistical analysis of the weekly share price for past periods
based on the expected term period, the expected term is the contractual term of each grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zcIP9njEhfD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The underlying data used for computing
the fair value of the options are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8B0_zJxkjABIydHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify">SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value of one common share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_907_eus-gaap--SharePrice_iI_pii_c20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zJVigMTWX45k" title="Value of one common share">2.99</span>-$<span id="xdx_90A_eus-gaap--SharePrice_iI_pii_c20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zpRisG2jihca" title="Value of one common share">6.84</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharePrice_iI_pii_c20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z4CFsUrPPvgd" title="Value of one common share">3.14</span>-$<span id="xdx_908_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z7Q6Fqa6nU5j" title="Value of one common share">5.07</span></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">Dividend yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_uPercentage_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zCGG4SGYztWj" style="width: 18%; text-align: right">0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_uPercentage_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zIlUev5sQYfi" style="width: 18%; text-align: right" title="Dividend yield">0</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected stock price volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zEEBmNX0ugFa">86</span>%-<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zzpOwg9Ve8De">89</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zqbMIBHnVT39" title="Expected stock price volatility">89</span>%-<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zrpQJcpmFPL" title="Expected stock price volatility">92</span></span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zhYmeOySrEn9">0.73</span>%-<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zKnvypQfvKO4">1.12</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z4OaZ4mRlzf9" title="Risk free interest rate">1.52</span>%-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z3gtBPyAed2" title="Risk free interest rate">2.62</span></span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zvBH53H5zF08">10</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zzioggVFdog1" title="Expected term (years)">10</span></td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A2_z57grP2rydpi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zbftw2pPvn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the Company&#8217;s stock options granted to consultants and service providers as of December 31, 2020, and December
31, 2019 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8BC_z5scIwsT27yf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify">SCHEDULE OF STOCK OPTIONS ACTIVITY<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify">Options outstanding at the <br/>beginning of the year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zMWWzXlkuf8b" style="width: 12%; text-align: right">598,310</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zMYVJ1dtg8vj" style="width: 12%; text-align: right">5.76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zQmxTi4o8My7" style="width: 12%; text-align: right" title="Number of Options - Options outstanding at the end of the year">469,974</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zLPGxTYap2vd" style="width: 12%; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the end of the year">5.75</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes during the year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zsacUEIZps54" style="text-align: right">62,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z4m6jLMYhn81" style="text-align: right">3.97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zjo8psJ0w978" style="text-align: right" title="Number of Options - Granted">128,336</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zD3WK7ymPaak" style="text-align: right" title="Weighted Average Exercise Price - Granted">5.65</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zFGF3564i5qi" style="text-align: right" title="Number of Options - Exercised">(83,334</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zz9Bi03JMrgg" style="text-align: right" title="Weighted Average Exercise Price - Exercised">3.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zhSTkn5jm4vg" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2494">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zrhFkiUYRuvl" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2495">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zwKkzH5fQzUl" style="text-align: right">(8,335</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_ziOnnSoUSsUd" style="text-align: right">5.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zEmJt048ziR4" style="text-align: right" title="Number of Options - Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2499">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zDuFasT03jK" style="text-align: right" title="Weighted Average Exercise Price - Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2501">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zsYlJ5gHpanj" style="border-bottom: Black 1.5pt solid; text-align: right">(20,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_ziXt3pWgbXe5" style="border-bottom: Black 1.5pt solid; text-align: right">5.30</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zbuZYe0hVNbb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options - Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl2505">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zBmtnPDCceha" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price - Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl2507">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Options outstanding at end of the year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zDPWZoMW9KL1" style="border-bottom: Black 2.5pt double; text-align: right">549,141</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zBAZt4xBqfrl" style="border-bottom: Black 2.5pt double; text-align: right">5.89</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zL0TkJctr6g4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options outstanding at the end of the year">598,310</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z5X4sq1uxk27" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the end of the year">5.76</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Options exercisable at end of the year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zxZ8ISpM5Qkj" style="border-bottom: Black 2.5pt double; text-align: right">450,972</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zdHwM1ea4Ft1" style="border-bottom: Black 2.5pt double; text-align: right">6.28</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zO82XaWp8604" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options exercisable at end of the year">539,515</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zCtk9ECpLhS3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options exercisable at end of the year">5.88</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A0_zNJjV3QAxgKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_897_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zldnSpYcVwvi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table presents summary information concerning the options granted and exercisable to consultants and service providers
outstanding as of December 31, 2020 (in thousands, except per share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8B1_zvQLz8p6E7L2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify">SCHEDULE OF STOCK OPTIONS EXERCISABLE</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Life</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Value*</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Value $</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(in thousands)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zjm9KeYw0zgf" style="width: 13%; text-align: right" title="Exercise Price">2.99</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zFsNJSwDApWg" style="width: 13%; text-align: right" title="Number of Outstanding Options">35,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zq3ZDJf4kH2" style="width: 13%; text-align: right" title="Weighted Average Remaining Contractual Life">9.22</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zpIV6M23tDhk" style="width: 13%; text-align: right" title="Aggregate Intrinsic Value">53</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zonnfsenO1Ad" style="width: 13%; text-align: right" title="Number of Exercisable Options"><span style="-sec-ix-hidden: xdx2ixbrl2531">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zvZhiXuQEK13" style="width: 13%; text-align: right" title="Aggregate Exercisable Options Value"><span style="-sec-ix-hidden: xdx2ixbrl2533">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zoWEcxO26Xr2" style="text-align: right">3.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z3K4Q79OQqbg" style="text-align: right" title="Number of Outstanding Options">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zVNabox3ktg7" style="text-align: right">8.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z9j6eSh0jVIa" style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zxoEyxXqf6yg" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2539">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zaSf0MMFK0hi" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2540">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zktbC9NK4TW6" style="text-align: right">3.36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zCMVcnDHKi9f" style="text-align: right" title="Number of Outstanding Options">136,775</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zmtPk5bUnJpd" style="text-align: right">5.32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zn0bDOAAafo4" style="text-align: right">156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zIIhm7y6zio7" style="text-align: right">136,775</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zFHyytHLrxG4" style="text-align: right">460</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zOxNEUsbX702" style="text-align: right">4.09</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zgTFDIoUL233" style="text-align: right" title="Number of Outstanding Options">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zNJ3aWMz8Xl7" style="text-align: right">8.76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zeEVsV31T7f3" style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zFOYn8Ir6nej" style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbZxy4FxBHnf" style="text-align: right">102</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zWeNDczB3e78" style="text-align: right">4.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zeQON0tYgVP6" style="text-align: right" title="Number of Outstanding Options">10,325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zdbqxxK1uYqg" style="text-align: right">6.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zSqHe0Ao7EQd" style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zR2WFvpSqTpl" style="text-align: right">10,325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zhm9J98AUeX2" style="text-align: right">46</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zkcADpZSds4k" style="text-align: right">4.5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zd5lv0i429O5" style="text-align: right" title="Number of Outstanding Options">13,335</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJSz7E0E76ob" style="text-align: right">8.53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zBooPwUqqhOg" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2566">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zeeWGjZPl6y1" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2567">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_znd3nMZECIQ4" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2568">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zrP3TyPWJbJk" style="text-align: right">4.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zi0nUliJ5sgk" style="text-align: right" title="Number of Outstanding Options">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zJs5hiyQ5Q2f" style="text-align: right">9.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zHHcqEqVmkIg" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2573">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zkzM1mNSEw66" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2574">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zVqIafo7IUal" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2575">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zaieSMzFpVql" style="text-align: right">4.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zurwOxk9DNCl" style="text-align: right" title="Number of Outstanding Options">16,668</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zbWd7Mk8IIWj" style="text-align: right">5.94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zSN3DyjkCwC8" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2580">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z9RaK704MHoj" style="text-align: right">16,668</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zY2FbABfI1Vg" style="text-align: right">80</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zEg461Ebhqr5" style="text-align: right">5.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_ztlx2ItVxahe" style="text-align: right" title="Number of Outstanding Options">5,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zO104xrrhPwg" style="text-align: right">8.19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z1rZAmEh70Lk" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2587">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zI6fMwT3gUIf" style="text-align: right">1,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zjw3S2bpxcR" style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zNrlRTalEVHj" style="text-align: right">5.3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zvkzRwm5Bruj" style="text-align: right" title="Number of Outstanding Options">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zAbI3yY5QC2e" style="text-align: right">7.70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zEnyWF57eaU9" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2594">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z4Kpm9VUq672" style="text-align: right">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zVwvRKv5DJ3d" style="text-align: right">80</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zgWb0dUriad6" style="text-align: right">5.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z1ji04xSMPxl" style="text-align: right" title="Number of Outstanding Options">16,670</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z3axaAYQ4rx8" style="text-align: right">7.81</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_znaPAL9XofZ" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2601">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zxJraIVcjY8k" style="text-align: right">16,670</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zgI0vgGH2Y77" style="text-align: right">100</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zZPMsU8ReXG1" style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zqO7LylWwdV4" style="text-align: right" title="Number of Outstanding Options">90,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_ze9lgJeZooXc" style="text-align: right">3.59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zs0u9hDogXC" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2608">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zv9YQJLUgJmd" style="text-align: right">90,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zcF8hGPpjWG1" style="text-align: right">540</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zsQhIelhGvsf" style="text-align: right">6.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zAiTLyxIz4zb" style="text-align: right" title="Number of Outstanding Options">7,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zjP14kh3Zcs" style="text-align: right">9.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z7xRGhD5QDO5" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2615">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zqZETXPG2fUj" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2616">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z52vcHID7zy1" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2617">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z8BknISK8yNa" style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zlGerKsKT0Kb" style="text-align: right" title="Number of Outstanding Options">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z82nupvXIEC9" style="text-align: right">8.83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z7Qs3uB9N123" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2622">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zi3znQaa68cd" style="text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zftRam9AvoSb" style="text-align: right">490</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zw4q5x4zBfXa" style="text-align: right">7.32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z4zo18qwcyS6" style="text-align: right" title="Number of Outstanding Options">8,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z6B57Re75uD2" style="text-align: right">1.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z4NJZnHEe9W4" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2629">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zJFfvXx4XJCh" style="text-align: right">8,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zGdeGtxb7y5e" style="text-align: right">61</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_z0Ic6KJ8XcU8" style="text-align: right">8.34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zeNExxZhoBk6" style="text-align: right" title="Number of Outstanding Options">8,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zJY5o9pyAd51" style="text-align: right">7.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_z31WZzfFzHle" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2636">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zDb2jKC1BLPa" style="text-align: right">8,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zLz7ySnhSeEa" style="text-align: right">72</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zfaV4M7ePToa" style="text-align: right">8.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_znuZvBMVskeg" style="text-align: right" title="Number of Outstanding Options">8,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zgFzWN7WAT8e" style="text-align: right">7.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zp69PYYZoIUh" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2643">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zc90HE6kBMUg" style="text-align: right">4,999</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zg0koyS616p4" style="text-align: right">42</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zttaeVMJ2mmc" style="text-align: right">11.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_z6ojrK2VDqe" style="text-align: right" title="Number of Outstanding Options">8,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zrmW1ph8Acba" style="text-align: right">2.26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zBIQUnU5xsl" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2650">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zIgegUeSGUC" style="text-align: right">8,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_z2cgXQaWRDM" style="text-align: right">96</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zmFRHLn4lQU8" style="padding-bottom: 1.5pt; text-align: right">16.8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zpWfNgNoTnra" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Outstanding Options">39,267</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zpcmqwo8y4k4" style="border-bottom: Black 1.5pt solid; text-align: right">1.28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zAjvcELcwlfa" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2657">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zYAWvkc5Qpv8" style="border-bottom: Black 1.5pt solid; text-align: right">39,267</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zvMnWacbflx2" style="border-bottom: Black 1.5pt solid; text-align: right">660</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zXPtMpBpMvO4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding Options">549,141</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z4hKvDKamxN2" style="border-bottom: Black 2.5pt double; text-align: right">6.18</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z7jEda9Q4WG8" style="border-bottom: Black 2.5pt double; text-align: right">240</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zJN4C00E9KHf" style="border-bottom: Black 2.5pt double; text-align: right">450,972</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zAMCvEmSYO3" style="border-bottom: Black 2.5pt double; text-align: right">2,834</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AC_znVadZXHR6yf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Costs
incurred with respect to options granted to consultants and service providers for the years ended December 31, 2020 and December
31, 2019 were $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zfzTc7v9MyA8">113</span> thousand and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pn3n3_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zTNhbHPzQjij" title="Stock-based compensation">330</span> thousand, respectively. As of December 31, 2020, there was $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z7kubgqN0Mtj">231</span> thousands of unrecognized
compensation costs related to non-vested consultants and service providers, to be recorded over the next <span><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zAgzhiocscYi">4.58</span></span> years.<br/>
<br/></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>d.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Warrants
    and Shares Issued to Non-Employees</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">The
fair value of Common Stock issued was the share price of the shares issued at the day of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">1)
On January 20, 2020, the Company entered into a Securities Purchase Agreement (the &#8220;January Purchase Agreement&#8221;) with
certain investors pursuant to which the Company issued and sold, in a private placement (the &#8220;Offering&#8221;), <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pii_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zGgaZxQiban3" title="Number of shares issued">2,200,000</span>
shares of Common Stock at a purchase price of $<span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_pii_c20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zqAUx3s3jtF3" title="Share issued price per share">4.20</span> per share (the &#8220;Shares&#8221;) and warrants to purchase up to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z1rqvrI0qa5" title="Number of warrants granted to purchase an equal number of additional shares of common stock">1,000,000</span>
shares of Common Stock at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z4fF0eCNDWb1" title="Warrants exercise price per share">5.50</span> per share (the &#8220;Warrants&#8221;) which are <span id="xdx_909_ecustom--WarrantExercisableDescription_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYrwZqyDlgT4">exercisable between June
2021 and January 2023.</span> The Company received gross proceeds of approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zK01S5AP0ag9" title="Proceeds from issuance of private placement">9.2</span> million before deducting related offering expenses
in the amount of $<span id="xdx_907_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z0GuOIhqqxO9" title="Offering expenses">0.8</span> million. The fair value of those warrants as of the date of grant using the Black-Scholes valuation model
was $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20200119__20200120__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zX1pH7Qz3im6" title="Warrants fair value">1,911</span> thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">2)
On January 2, 2020, the Company entered into private placement subscription agreements with investors for an aggregate amount
of $<span id="xdx_90B_ecustom--AggregateAmountOfSubscriptionAgreement_iI_pn3n3_c20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementsMember_zkXsyYGJbKrd" title="Aggregate amount of subscription agreement">250</span> thousand of convertible loans. The lenders shall be entitled, at any time prior to or no later than the maturity date,
to convert the outstanding amount, into shares of Common Stock of the Company at a conversion price per share equal to $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementsMember_zTN8O4MeTSca" title="Conversion price per share">7.00</span>.
In addition, the Company granted the investors <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementsMember_zxKxt3202ijl" title="Number of warrants granted to purchase an equal number of additional shares of common stock">151,428</span> warrants to purchase an equal number of additional shares of the Company&#8217;s
Common Stock at a price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementsMember_pii" title="Warrant exercise price">7.00</span> per share. The fair value of those warrants as of the date of grant using the Black-Scholes valuation
model was $<span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20200101__20200102__us-gaap--TypeOfArrangementAxis__custom--PrivatePlacementSubscriptionAgreementsMember_zZuxOd1WxtQ4">210</span> thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">3)
During the year ended December 31, 2020, the Company granted to several consultants <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20201231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_zw3LmohdRPAk" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross">193,178</span> warrants each exercisable between
$<span id="xdx_90B_eus-gaap--WarrantExercisePriceDecrease_c20200101__20201231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_pii" title="Warrant, Exercise Price, Decrease">3.14</span> and $<span id="xdx_906_eus-gaap--WarrantExercisePriceIncrease_c20200101__20201231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_pii" title="Warrant, Exercise Price, Increase">5.34</span> per share for <span id="xdx_904_ecustom--WarrantsAndRightsOutstandingTermDescription_c20200101__20201231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember" title="Warrants term">three years</span>. The fair value of those options as of the date of grant using the Black-Scholes valuation
model was $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20200101__20201231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_zLZWMYD6u1Oh" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value">378</span> thousand, out of which $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20200101__20201231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesAndPrivateInvestmentMember_zn9yzulEQCTb">350</span> thousand is related to <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20200101__20201231__srt--TitleOfIndividualAxis__custom--NonEmployeesMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesAndPrivateInvestmentMember_zMnNdbdHsQZa">179,428</span> warrants granted as a success fee with respect to the
issuance of the convertible notes and private Investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">4)
During the year ended December 31, 2019, the Company granted to several consultants <span id="xdx_907_ecustom--ClassOfWarrantOrRightGrantsInPeriod_pii_c20190101__20191231__srt--TitleOfIndividualAxis__custom--SeveralConsultantsMember_z38o6pCisXWa" title="Number of warrants - issued">88,499</span> warrants each exercisable between $<span id="xdx_902_ecustom--ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__srt--TitleOfIndividualAxis__custom--SeveralConsultantsMember_zUmPEII3LERa" title="Weighted Average Exercise Price - Issued">4.3</span>
and $<span id="xdx_901_ecustom--ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__srt--TitleOfIndividualAxis__custom--SeveralConsultantsMember_zSwNtPytmdxj" title="Weighted Average Exercise Price - Issued">7.00</span> per share for three years. The fair value of those options as of the date of grant using the Black-Scholes valuation
model was $<span id="xdx_909_ecustom--ClassOfWarrantOrRightGrantsInPeriodFairValue_pn3n3_c20190101__20191231__srt--TitleOfIndividualAxis__custom--SeveralConsultantsMember_zJNuZDCPnpOj" title="Class of warrant or right, grants in period, fair value">155</span> thousand, out of which $<span id="xdx_909_ecustom--ClassOfWarrantOrRightGrantsInPeriodFairValue_pn3n3_c20190101__20191231__us-gaap--AwardTypeAxis__custom--SuccessFeeMember_z0WGCbdKgHA9" title="Class of warrant or right, grants in period, fair value">97</span> thousand is related to <span id="xdx_908_ecustom--ClassOfWarrantOrRightGrantsInPeriod_pii_c20190101__20191231__us-gaap--AwardTypeAxis__custom--SuccessFeeMember_z75y90cjcXh5" title="Number of warrants - issued">57,142</span> warrants granted as a success fee with respect to the
issuance of the convertible notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">5)
In September 2019, the Company entered into an investor relation services, marketing and related services agreement. Under the
terms of the agreement, the Company agreed to issue the consultant <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pii_c20190901__20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember_zBrAJ1D5qcSf">40,174
</span></span><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">shares of restricted
common stock, of which the first <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pii_c20190901__20190930__us-gaap--VestingAxis__custom--HeldUntilSixMonthsAnniversaryMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember_zIFtiRK2GhCc">20,087
</span></span><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">shares will be
held in escrow by the Company until the six months anniversary of the agreement and <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pii_c20190901__20190930__us-gaap--VestingAxis__custom--HeldUntilOneYearAnniversaryMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember_zMwrXjnDdaij">20,087
</span></span><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">shares will be
issued on the six months anniversary of the agreement to be held in escrow by the company until the one-year anniversary of the
agreement. The fair value of the shares was $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn3n3_c20190909__20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember_z27lpOlmmtD2">178
</span></span><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">thousand using
the fair value of the shares on the grant date. $<span id="xdx_905_ecustom--FairValueOfSharesRecognizedOnGrantDate_iI_pn3n3_c20201231_zI6pjGp1Yf59">96
</span></span><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">and <span id="xdx_904_ecustom--FairValueOfSharesRecognizedOnGrantDate_iI_pn3n3_c20191231_zMsklUcFte4b">82
</span></span><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">thousand was recognized
during the year ended December 31, 2020 and December 31, 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">6)
In March 2019, the Company issued First Choice <span id="xdx_90B_ecustom--JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted_pii_c20190301__20190331__dei--LegalEntityAxis__custom--FirstChoiceInternationalCompanyIncMember_zV1gWUHfRjle" title="Joint venture agreement, shares issued for compensation of work already completed">525,000</span> shares of Common Stock. The value of Common Stock issued in the amount
of $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20190101__20191231__dei--LegalEntityAxis__custom--FirstChoiceInternationalCompanyIncMember_z48GvTEwiqIl" title="Research and development expense">2.6</span> million were charged to research and development expenses during the year ended December 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">7)
In December 2018, the Company entered into an investor relation services, marketing and related services agreement. Under the
terms of the agreement, the Company agreed to issue the consultant <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20181201__20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zs2Wvc0x5Cyd" title="Stock issued during period, shares, restricted stock">10,000</span> shares of restricted common stock, of which the first
<span id="xdx_90F_ecustom--NumberOfVestedShares_iI_pii_c20181231__us-gaap--VestingAxis__custom--VestedOnSigningDateMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zuTQasQOik18" title="Number of vested shares">2,500</span> shares vested on the signing date, and <span id="xdx_901_ecustom--NumberOfVestedShares_iI_pp0i_c20181231__us-gaap--VestingAxis__custom--VestMonthlyOver3MonthsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zI8ZVcqcj5F3" title="Number of vested shares">7,500</span> shares are to vest monthly over 3 months commencing January 2019. As of December
31, 2019, <span id="xdx_90F_ecustom--NumberOfVestedShares_iI_pii_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zHu65hMXBPb9" title="Number of vested shares">10,000</span> shares were fully vested. The fair value of the shares was $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn3n3_c20191201__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zbTATAZto1kj" title="Stock issued during period, value, issued for services">51</span> thousand using the fair value of the shares on
the vesting dates. $<span id="xdx_90B_ecustom--FairValueOfSharesOnVestingDatesRecognizedDuringYear_pn3n3_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zJyRPF4wQirh" title="Fair value of shares on vesting dates recognized during year">37</span> thousand was recognized during the year ended December 30, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">8)
In December 2018, the Company entered into a separate investor relations services, marketing and related services agreement. Under
the terms of the agreement, the Company agreed to issue the consultant <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20181201__20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationsContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zmLwbrAhBk88" title="Stock issued during period, shares, restricted stock">40,000</span> shares of restricted common stock, of which the
first <span id="xdx_908_ecustom--NumberOfVestedShares_iI_pii_c20181231__us-gaap--VestingAxis__custom--VestedOnSigningDateMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zQFuM1QM4ZW6">6,667</span> shares vested on the signing date, and <span id="xdx_903_ecustom--NumberOfVestedShares_iI_pp0i_c20181231__us-gaap--VestingAxis__custom--VestMonthlyOver3MonthsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zimv2xMOMZcb">33,333</span> shares vested monthly over five months commencing January 2019. As of
December 31, 2019, <span id="xdx_908_ecustom--NumberOfVestedShares_iI_pii_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zYjFXWrQxLW1">40,000</span> shares were fully vested. The fair value of the shares was $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn3n3_c20191201__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_z6rz8wsWwo77">200</span> thousand using the fair value of the
shares at the vesting dates. $<span id="xdx_907_ecustom--FairValueOfSharesOnVestingDatesRecognizedDuringYear_pn3n3_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zfwB15vDhaX3">163</span> thousand was recognized during the year ended December 30, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">9)
During the year ended November 30, 2018, the Company granted to several consultants <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_zv3Vyqf154q1" title="Number of warrants shares">78,782</span> warrants each exercisable between $<span id="xdx_903_eus-gaap--WarrantExercisePriceDecrease_c20181129__20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_zaUy9CQtXmM8" title="Warrant, exercise price, decrease">6.24</span>
and $<span id="xdx_90F_eus-gaap--WarrantExercisePriceIncrease_c20181129__20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_z1kBFaQUrea3" title="Warrant, exercise price, increase">15.41</span> per share for <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtxL_c20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_z8dp5Nk1tCb5" title="Warrant term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl2755">three</span></span> years. The fair value of those warrants as of the date of grant using the Black-Scholes valuation
model was $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20181129__20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeveralConsultantsMember_za1cOu0l2cN9" title="Fair value of warrants">350</span> thousand. The warrants granted as a success fee with respect to private placement and the issuance of convertible
loans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">10)
In January 2018, the Company entered into a consulting agreement with a financial advisor for a period of one year. Under the
terms of the agreement, the consultant was entitled to receive $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20180101__20180131__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zNSdiF9VL1I7" title="Number of common stock for services, value">60</span> thousand and <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pii_c20180101__20180131__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_z4FiHJj0Bn4c" title="Number of common stock for services">19,000</span> units of the Company securities. Each unit
is comprised of (i) one share of the Company&#8217;s common stock and (ii) a <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtxL_c20180131__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zcniQxloDrF3" title="Warrant term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl2763">three</span></span>-year warrant to purchase up to an additional
one share of the Company&#8217;s Common Stock at a per share exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20180131__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zkvmPiTNsOVf" title="Warrant exercise price">6.24</span>. The fair value of the units as of the date
of grant was $<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20180101__20180131__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_ze0x5BBacvIf" title="Fair value of granted">171</span> thousand, out of which $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20180101__20180131__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zCb0671DJAQ2" title="Fair value of warrants">62</span> thousand reflect the fair value of the warrants using the Black-Scholes valuation
model. In July 2018, the board approved an additional issuance of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180701__20180731__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zfLMK3gqVDG6" title="Number of common stock issued">6,629</span> shares and <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtxL_c20180731__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zxRaOQdO1T87" title="::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl2772">three</span></span>-year warrants to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20180731__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zkWvMiLL0GB" title="Number of warrants shares">6,629</span>
shares of the Company&#8217;s Common Stock at a per share exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20180731__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zBFFLzb7Wzk8" title="Warrant exercise price">6.24</span>. The fair value of the units as of the date
of grant was $<span id="xdx_900_eus-gaap--FairValueAdjustmentOfWarrants_c20180701__20180731__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zLNjkl2Zy4b1" title="Fair value of warrants">88</span> thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">11)
In December 2017, the Company entered into investor relations services, marketing and related services agreements. Under the terms
of the agreement, the Company agreed to grant the consultants a total of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20171201__20171231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zaVThk1Qtvj7" title="Stock issued during period, shares, restricted stock">195,000</span> shares of restricted common stock, out of which
the first <span id="xdx_90E_ecustom--NumberOfVestedShares_iI_pii_c20171231__us-gaap--VestingAxis__custom--VestedOnSigningDateMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zHFwRjEQ7kwf">50,000</span> shares will vest after 30 days from the signing date, and <span id="xdx_902_ecustom--NumberOfVestedShares_iI_pp0i_c20171231__us-gaap--VestingAxis__custom--VestMonthlyOver3MonthsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SeparateInvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_z5y4wtROY3G8">145,000</span> shares are to vest monthly over 15 months commencing
February 2018. As of December 31, 2019, all shares were vested. The fair value of the shares as of the date of grant was $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20171201__20171231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorRelationContactMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_zCHKCtFxVbXb" title="Stock issued during period, value, restricted stock">1,439</span>
thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">12)
During the twelve months ended December 31, 2020, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk9Sya5NOXuk" title="Number of common stock for services">270,174</span> shares of common stock to service providers. As of
December 31, 2020, <span id="xdx_90B_ecustom--NumberOfAdditionalSharesRestrictionsOnTransfer_pii_c20200101__20201231_zTNluHLhUpT3" title="Number of additional shares restrictions on transfer">30,000</span> shares have additional restrictions on transfer until such services have been provide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676577602312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES</a></td>
<td class="text"><p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_zgc6SFYi2Hbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
16 &#8211; <span id="xdx_823_zdBFmTGxF39h">TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>a.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Corporate
    taxation in the U.S.</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
corporate U.S. Federal Income tax rate applicable to the Company and its US subsidiaries is <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercentage_c20200101__20201231__srt--StatementGeographicalAxis__country--US_zvSqlUnoCDo5" title="Effective income tax rate reconciliation, at income tax rate">21%</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, the Company has an accumulated tax loss carryforward of approximately $ <span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20201231_zvnQWbP5ivVg">18
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million (as of December 31, 2019,
approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20191231_zYrfI1zw54xj">34</span></span> <span style="font: 10pt Times New Roman, Times, Serif">million).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20200101__20201231__srt--StatementGeographicalAxis__country--US" title="Operating loss carryforwards, limitations on use">For
U.S. federal income tax purposes, net operating losses (&#8220;NOLs&#8221;) arising in tax years beginning after December 31,
2017, the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) limits the ability to utilize NOL carryforwards to
80% of taxable income in tax years beginning after December 31, 2020.</span> In addition, NOLs arising in tax years ending after December
31, 2017 can be carried forward indefinitely, but carryback is generally prohibited. NOLs generated in tax years beginning before
January 1, 2018 will not be subject to the taxable income limitation, and NOLs generated in tax years ending before January 1,
2018 will continue to have a two-year carryback and twenty-year carryforward period. Deferred tax assets for NOLs will need to
be measured at the applicable tax rate in effect when the NOL is expected to be utilized. The changes in the carryforward/carryback
periods as well as the new limitation on use of NOLs may significantly impact the Company&#8217;s valuation allowance assessments
for NOLs generated after December 31, 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, utilization of the NOLs may be subject to substantial annual limitation under Section 382 of the Code due to an &#8220;ownership
change&#8221; within the meaning of Section 382(g) of the Code. An ownership change, subjects pre-ownership change NOLs carryforwards
to an annual limitation, which significantly restricts the ability to use them to offset taxable income in periods following the
ownership change. In general, the annual use limitation equals the aggregate value of the Company&#8217;s stock at the time of
the ownership change multiplied by a specified tax-exempt interest rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the &#8220;CARES Act&#8221;) was enacted into law. The
CARES Act is aimed at providing emergency relief and health care for individuals and businesses affected by the COVID-19 pandemic.
The CARES Act, among other things, includes provisions related to refundable payroll tax credits, deferral of the employer portion
of social security payments, expanded net operating loss application, modifications to the net interest deduction limitations,
and technical corrections to tax depreciation methods for qualified improvement property. The CARES act allowed the Company to
utilize 100% of NOLs arising in tax years after December 31, 2017. The Company assess all other provisions of the CARES Act and
notes no other material impact to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>b.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Corporate
    taxation in Israel</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Israeli Subsidiaries are taxed in accordance with Israeli tax laws. The corporate tax rate applicable to 2020 and 2019 are <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercentage_c20200101__20201231__srt--StatementGeographicalAxis__country--IL_zfC2oMpOFwfl" title="Effective income tax rate reconciliation, at income tax rate"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercentage_c20190101__20191231__srt--StatementGeographicalAxis__country--IL_z9mE9zgMWA27" title="Effective income tax rate reconciliation, at income tax rate">23%</span></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, the Israeli Subsidiaries has an accumulated tax loss carryforward of approximately $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pin6_c20201231__srt--StatementGeographicalAxis__country--IL_zA26Da8kwIp8" title="Operating loss carryforwards">11</span> million (as of December
31, 2019, approximately $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pin6_c20191231__srt--StatementGeographicalAxis__country--IL_zao3Ibx3Xfhe" title="Operating loss carryforwards">10</span> million). Under the Israeli tax laws, carryforward tax losses have no expiration date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>c.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Corporate
taxation in Belgium</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Belgian Subsidiary are taxed according to Belgian tax laws. The corporate tax rates applicable to  2020, 2019
are <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercentage_c20200101__20201231__srt--StatementGeographicalAxis__country--BE__us-gaap--AwardTypeAxis__custom--TwoThousandTwentyOneToTwoThousandTwentyMember_zPzwHLKe2y0h">25%
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercentage_c20190101__20191231__srt--StatementGeographicalAxis__country--BE_zvMZu66v1zF5">29.58%,
</span></span><span style="font: 10pt Times New Roman, Times, Serif">respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, the Belgian Subsidiary has an accumulated tax loss carryforward of approximately $ <span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pin6_c20201231__srt--StatementGeographicalAxis__country--BE_ztKmAzH7EHcf">8
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million (&#8364; <span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pin6_uEUR_c20201231__srt--StatementGeographicalAxis__country--BE__us-gaap--AwardTypeAxis__srt--EuropeMember_z64hQwO0QK2i">6
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million), (as of December 31, 2019 $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pin6_c20191231__srt--StatementGeographicalAxis__country--BE_zhnpymgbxTc4">6
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million). Under the Belgian tax laws there
are limitation on accumulated tax loss carryforward deductions of Euro <span id="xdx_905_ecustom--AccumulatedTaxLossCarryforwardDeductions_iI_pin6_uEUR_c20201231__srt--StatementGeographicalAxis__country--BE__us-gaap--AwardTypeAxis__srt--EuropeMember_z6nV2q6VzjY4">1
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million per year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>d.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Corporate
    taxation in Korea</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
basic Korean corporate tax rates are currently: <span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember_zlmYfvNcz0y" title="Effective income tax rate reconciliation, at income tax rate">10%</span> on the first KRW 200 million of the tax base, <span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--UpToKrwTwoZeroBillionMember_znQrRJ88tJP5" title="Effective income tax rate reconciliation, at income tax rate">20%</span> up to KRW 20 billion, <span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--UpToKrwThreeZeroZeroBillionMember_zKLZJPdoTzW7" title="Effective income tax rate reconciliation, at income tax rate">22%</span>
up to KRW 300 billion and <span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--TaxBaseAboveKrwThreeZeroZeroBillionMember_zFjZ2f7e5r0l" title="Effective income tax rate reconciliation, at income tax rate">25%</span> for tax base above KRW 300 billion. In addition, the local income tax rate is <span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercentage_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember_zRBrOoNLT9f" title="Effective income tax rate reconciliation, at local income tax rate">1%</span> on the first KRW
200 million of taxable income, <span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercentage_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--UpToKrwTwoZeroBillionMember_z1LZEOs8cNjd" title="Effective income tax rate reconciliation, at local income tax rate">2%</span> on taxable income over KRW 200 million up to KRW 20 billion, <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercentage_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--UpToKrwThreeZeroZeroBillionMember_zO7j5qn1X9Sb" title="Effective income tax rate reconciliation, at local income tax rate">2.2%</span> of taxable income over KRW
20 billion up to 300 billion and <span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercentage_c20200101__20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--IncomeTaxAuthorityNameAxis__custom--TaxBaseAboveKrwThreeZeroZeroBillionMember_zLHLaSVq83Tk" title="Effective income tax rate reconciliation, at local income tax rate">2.5%</span> on taxable income over KRW 300 billion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, the Korean subsidiary has an accumulated tax loss carryforward of approximately $ <span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_pin6_c20201231__srt--StatementGeographicalAxis__country--KR_zvKetHp1cF9l">4
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million (KRW <span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pin6_uKRW_c20201231__srt--StatementGeographicalAxis__country--KR__us-gaap--AwardTypeAxis__custom--SouthKoreanWonMember_zeUF2PMi5vZ9">3,813
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million), (as of December 31, 2019,
approximately $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pin6_c20191231__srt--StatementGeographicalAxis__country--KR_zOzKCiGFCds5">3
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million). Under the Korean tax laws accumulated
tax loss can be carry forwarded for <span id="xdx_90B_ecustom--AccumulatedTaxLossCarryForwardedPeriod_dtY_c20200101__20201231__srt--StatementGeographicalAxis__country--KR_zQEcnKBSHTHb">15
</span></span><span style="font: 10pt Times New Roman, Times, Serif">years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>e.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Deferred
    Taxes</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zeqE89lKRzJ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table presents summary of information concerning the Company&#8217;s deferred taxes as of the years ending December
31, 2019 and December 31, 2019 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B1_z766Or12sSuc" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20201231_zXZFQuv0fVj3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20191231_zDgTmK3N8vic" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(U.S. dollars in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_msDTLztYm_zgBPVCDGywNa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Net operating loss carry forwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">9,606</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">14,033</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_msDTLztYm_zCrXy6rt04M4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,684</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,358</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_msDTLztYm_zTg18Jn9qUm6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity compensation </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,747</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl2841">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_iI_pn3n3_msDTLztYm_zXn3SAkGPgU6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Employee benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">228</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--DeferredTaxAssetsLeasesAsset_iI_pn3n3_msDTLztYm_z11i1Jih1eP9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leases asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">533</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl2847">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--DeferredTaxAssetsLeaseLiability_iNI_pn3n3_di_maDTLztYm_zjVBpvnsc7q9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(324</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl2850">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_pn3n3_di_maDTLztYm_zwCugWd6HsWa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,863</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(737</td><td style="text-align: left">)</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_msDTLztYm_zkJGG3QCpJbc" style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">297</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_maDTLztYm_zcpm0JO7Gs46" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,932</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,939</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxLiabilities_iNTI_pn3n3_di_mtDTLztYm_zMJuAwQKEokj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2861">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(58</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<p id="xdx_8A4_z1DdpOkxSl4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Realization
of deferred tax assets is contingent upon sufficient future taxable income during the period that deductible temporary differences
and carry forwards losses are expected to be available to reduce taxable income. As the achievement of required future taxable
income is not considered more likely than not achievable, the Company and all its subsidiaries except the Korean Subsidiary (previously
CureCell) have recorded full valuation allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_891_eus-gaap--SummaryOfValuationAllowanceTextBlock_zaZcptbl3pD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
changes in valuation allowance are comprised as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BF_zI2Sac4A7VW4" style="display: none">SCHEDULE OF VALUATION ALLOWANCE, ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(U.S dollars in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Balance at the beginning of year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20200101__20201231_z4UsOo810krg" style="width: 18%; text-align: right" title="Balance at the beginning of year">(14,939</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20190101__20191231_zj5TStugVh28" style="width: 18%; text-align: right" title="Balance at the beginning of year">(10,254</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20200101__20201231_zUge94j55QWg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change during the year">3,007</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20190101__20191231_zjtjNj8oM515" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change during the year">(4,685</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Balance at end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20200101__20201231_zKy9h85KJWOe" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of year">(11,932</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20190101__20191231_z0lEzw0xdTTf" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of year">(14,939</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<p id="xdx_8AC_zaPljoTAvhri" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>f.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Reconciliation
    of the Theoretical Tax Expense to Actual Tax Expense</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
main reconciling item between the statutory tax rate of the Company and the effective rate is the provision for valuation allowance
with respect to tax benefits from carry forward tax losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>g.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Uncertain
    Tax Provisions</span></i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">ASC
Topic 740, &#8220;Income Taxes&#8221; requires significant judgment in determining what constitutes an individual tax position
as well as assessing the outcome of each tax position. Changes in judgment as to recognition or measurement of tax positions can
materially affect the estimate of the effective tax rate and consequently, affect the operating results of the Company. As of
December 31, 2020, the Company has not accrued a provision for uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676665272376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text"><p id="xdx_802_eus-gaap--RevenueFromContractWithCustomerTextBlock_zatR1J2qiMTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
17 &#8211; <span id="xdx_822_zc9Tws1gKm7a">REVENUES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Disaggregation
of Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_899_eus-gaap--DisaggregationOfRevenueTableTextBlock_zciVtxWIG3Cl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table disaggregates the Company&#8217;s revenues by major revenue streams.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B6_z1gyYh8uIJzf" style="display: none">SCHEDULE OF DISAGGREGATION OF REVENUE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Revenue stream:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">POC and hospital services</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--PointOfCareServicesMember_zhFWJCKZmbgk" style="width: 18%; text-align: right" title="Total">6,068</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Revenues_c20190101__20191231__srt--ProductOrServiceAxis__custom--PointOfCareServicesMember_pn3n3" style="width: 18%; text-align: right" title="Total">3,109</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cell process development services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--Revenues_c20200101__20201231__srt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">1,584</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--Revenues_c20190101__20191231__srt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">790</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">7,652</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--Revenues_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">3,899</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AB_z22QlsUJnVD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">POC
development services are the result of agreements between Company and its partners (See Note 11). The Company provides certain
services in support of the partners&#8217; clinical activity. The Company has signed Master Services Agreements with joint venture
partners in the aggregate amount of over $<span id="xdx_90B_eus-gaap--Revenues_pin6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JointVenturePartnersMember_zrXXa7x58lKa" title="Revenue">38</span> million for services to be provided from 2021 to 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_898_ecustom--ScheduleOfBreakdownOfRevenuesPerCustomer_zY1gLtJVUKwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">A
breakdown of the revenues per customer what constituted at least 10% of revenues is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B2_zm38Kgu5iW3i" style="display: none">SCHEDULE OF BREAKDOWN OF REVENUES PER CUSTOMER</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Revenue earned:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: justify">Customer A</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerAMember_pn3n3" style="width: 18%; text-align: right" title="Revenues">2,857</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--MajorCustomersAxis__custom--CustomerAMember_pn3n3" style="width: 18%; text-align: right" title="Revenues">1,420</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Customer B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerBMember_pn3n3" style="text-align: right" title="Revenues">1,577</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--MajorCustomersAxis__custom--CustomerBMember_pn3n3" style="text-align: right" title="Revenues"><span style="-sec-ix-hidden: xdx2ixbrl2904">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Customer C &#8211; related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerCRelatedPartyMember_pn3n3" style="text-align: right" title="Revenues">1,475</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--MajorCustomersAxis__custom--CustomerCRelatedPartyMember_pn3n3" style="text-align: right" title="Revenues">1,270</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Customer D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerDMember_pn3n3" style="text-align: right" title="Revenues">1,412</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--MajorCustomersAxis__custom--CustomerDMember_pn3n3" style="text-align: right" title="Revenues">857</td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A7_zxdqTJw6Pdu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Contract
Assets and Liabilities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Contract
assets are mainly comprised of trade receivables net of allowance for doubtful debts, which includes amounts billed and currently
due from customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89A_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zEx5HF4APUu1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
activity for trade receivables is comprised of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><span><span id="xdx_8B3_zKMopYhtwfci" style="display: none">SCHEDULE OF ACTIVITY FOR TRADE RECEIVABLES</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%">Balance as of beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AccountsReceivableNetCurrent_iS_pn3n3_c20200101__20201231_zgIuXzD8VVu3" style="width: 18%; text-align: right" title="Balance as of beginning of period">1,831</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AccountsReceivableNetCurrent_iS_pn3n3_c20190101__20191231_zeumEvjYPYj7" style="width: 18%; text-align: right" title="Balance as of beginning of period">129</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Acquisition of Koligo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--AccountsReceivableAcquisitionOfKoligo_c20200101__20201231_pn3n3" style="text-align: right" title="Acquisition of Koligo">228</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--AccountsReceivableAcquisitionOfKoligo_c20190101__20191231_pn3n3" style="text-align: right" title="Acquisition of Koligo"><span style="-sec-ix-hidden: xdx2ixbrl2922">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--AccountsReceivableAdditions_c20200101__20201231_pn3n3" style="text-align: right" title="Additions">6,997</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--AccountsReceivableAdditions_c20190101__20191231_pn3n3" style="text-align: right" title="Additions">2,079</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Collections</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--AccountsReceivableCollections_c20200101__20201231_pn3n3" style="text-align: right" title="Collections">(5,982</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--AccountsReceivableCollections_c20190101__20191231_pn3n3" style="text-align: right" title="Collections">(364</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Exchange rate differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ExchangeRateDifferencesOfAccountsReceivable_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate differences">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ExchangeRateDifferencesOfAccountsReceivable_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate differences">(13</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance as of end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AccountsReceivableNetCurrent_iE_pn3n3_c20200101__20201231_z5EzxrYt23w8" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance as of end of period">3,085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AccountsReceivableNetCurrent_iE_pn3n3_c20190101__20191231_zqbnSQSPLjwf" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance as of end of period">1,831</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A4_z4gg2OJ5ms8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_z7ZGBpL1HCgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
activity for contract liabilities is comprised of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B4_zWL501wjCgnk" style="display: none">SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%">Balance as of beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ContractWithCustomerLiabilityCurrent_iS_pn3n3_c20200101__20201231_zPJ5G2h1xHhl" style="width: 18%; text-align: right" title="Balance as of beginning of period">325</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ContractWithCustomerLiabilityCurrent_iS_pn3n3_c20190101__20191231_zJNOYDwWAI32" style="width: 18%; text-align: right" title="Balance as of beginning of period">56</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ContractWithCustomerLiabilityAddition_c20200101__20201231_pn3n3" style="text-align: right" title="Additions">597</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ContractWithCustomerLiabilityAddition_c20190101__20191231_pn3n3" style="text-align: right" title="Additions">1,126</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F43_z0M5U3m6Pdc7" style="padding-left: 10pt">Realizations*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ContractWithCustomerLiabilityRealizations_pn3n3_c20200101__20201231_fKg_____zl72xmE3vlo9" style="text-align: right" title="Realizations">(862</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ContractWithCustomerLiabilityRealizations_pn3n3_c20190101__20191231_fKg_____zx18NKmAlo2j" style="text-align: right" title="Realizations">(854</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Exchange rate differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--ContractWithCustomerLiabilityExchangeRateDifferences_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate differences">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--ContractWithCustomerLiabilityExchangeRateDifferences_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate differences">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ContractWithCustomerLiabilityCurrent_iE_pn3n3_c20200101__20201231_zGOvVzvolUrf" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance as of end of period">59</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ContractWithCustomerLiabilityCurrent_iE_pn3n3_c20190101__20191231_zOKMpkkMhpv5" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance as of end of period">325</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td id="xdx_F06_zZk6RCpAn0lg" style="width: 3%">*</td>
    <td id="xdx_F1F_zKmYLsKShpMl" style="width: 97%">Out of which $ <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDVElWSVRZIEZPUiBDT05UUkFDVCBMSUFCSUxJVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn3n3_c20191231_zMzilnHXUcB9" title="Contract with customer liability">325</span> thousand were realized from the beginning of the period for the year ended December 31, 2020.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p id="xdx_8AF_zgh8DGPfK7ic" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676577589528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET</a></td>
<td class="text"><p id="xdx_802_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zWlXHw6dGYq" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
18 &#8211; <span id="xdx_824_zMcviMJeQtY9">COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET</span></b></span></p>

<p id="xdx_891_eus-gaap--ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_z3cLO8fhyhdh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BC_zV30xjyeSrsl" style="display: none">SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Total expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--OtherResearchAndDevelopmentExpense_c20200101__20201231_pn3n3" style="width: 18%; text-align: right" title="Total expenses">84,182</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--OtherResearchAndDevelopmentExpense_c20190101__20191231_pn3n3" style="width: 18%; text-align: right" title="Total expenses">14,826</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less grants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--GrantsIncome_pn3n3_c20200101__20201231_zLkNeA3LKiB4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less grants">(196</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--GrantsIncome_pn3n3_c20190101__20191231_zWqsZuYCF5S3" style="border-bottom: Black 1.5pt solid; text-align: right">(812</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, net">83,986</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, net">14,014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A6_zBvXs2JHb9gf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676654716424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL EXPENSES, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisclosureFinancialExpensesNetAbstract', window );"><strong>Financial Expenses Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_FinancialExpensesNetTextBlock', window );">FINANCIAL EXPENSES, NET</a></td>
<td class="text"><p id="xdx_806_ecustom--FinancialExpensesNetTextBlock_zzoFwE69I6Xb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
19 &#8211; <span id="xdx_82C_zutiiOuEq0C3">FINANCIAL EXPENSES, NET</span></b></span></p>

<p id="xdx_89B_ecustom--ScheduleOfFinancialExpensesTableTextBlock_zn2kLRrF00z3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B8_zNbPtYGts483" style="display: none">SCHEDULE OF FINANCIAL EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20200101_20201231" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20190101_20191231" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_40B_ecustom--IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue_maTFEzElv_zsM3s6BwG0hi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Increase in fair value of warrants and financial liabilities measured at fair value</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2984">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">63</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--InterestExpenseOnConvertibleLoans_maTFEzElv_zsyyLXxCWzI" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense on convertible loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,254</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">498</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--ForeignCurrencyTransactionsGainLossRealized_pn3n3_maTFEzElv_zBTjU4qtGp5a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign exchange loss, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">160</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">395</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OtherIncome_iN_pn3n3_di_msTFEzElv_zVEnpzdXTn2c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(353</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(113</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr id="xdx_402_ecustom--TotalFinancialExpenses_iT_mtTFEzElv_zqPwqivVUB6c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,061</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">843</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A6_zKCcIilTYR59" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisclosureFinancialExpensesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisclosureFinancialExpensesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_FinancialExpensesNetTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_FinancialExpensesNetTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676577589528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES TRANSACTIONS</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zmDO0XMqZorh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
20 &#8211; <span id="xdx_820_zciW7f3HFWe7">RELATED PARTIES TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>a.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Related
    Parties presented in the consolidated statements of comprehensive loss</span></i></span></td></tr>
</table>
<p id="xdx_89A_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_z0I8RBOqbpe4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_z38wGFN32fS9" style="display: none">SCHEDULE OF RELATED PARTY TRANSACTIONS</span></span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold">(in thousands)</td><td style="font-size: 11pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Continuing operations:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left; padding-bottom: 2.5pt">Stock-based compensation expenses to executive officers</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right" title="Stock Based Compensation">221</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zScrlX5LwUYc" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right" title="Stock Based Compensation">898</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F4D_zDj1uemAftSe" style="text-align: left; padding-bottom: 2.5pt">Stock-based compensation expenses to Board Members*</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_fKg_____z5oDhlnYaApj" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock Based Compensation">209</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember_fKg_____zbufEPXtHTL9" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock Based Compensation">414</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Compensation of executive officers</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--OfficersCompensation_pn3n3_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zeXQ9O2OeORf" style="border-bottom: Black 2.5pt double; text-align: right" title="Compensation">1,321</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--OfficersCompensation_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zDt1hvYywZ2a" style="border-bottom: Black 2.5pt double; text-align: right">812</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Management and consulting fees to Board Members</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and consulting fees">264</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember_zZ5ZrtfncJ67" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and consulting fees">233</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Revenues from customer</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromRelatedParties_pn3n3_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zWmRrjlj5Fk2" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues from customer">1,475</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromRelatedParties_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_z3S6kt0Y6JN8" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues from customer">1,270</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Cost of research and development and research and development services, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet_pn3n3_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zMEkarZwPlOh" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost of research and development and research and development services, net">4,772</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost of research and development and research and development services, net"><span style="-sec-ix-hidden: xdx2ixbrl3024">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Financial income</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--FinancialIncome_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Financial income">169</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--FinancialIncome_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Financial income">112</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td id="xdx_F08_zUmcncmQEk2b" style="width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td>
    <td style="width: 95%"><span id="xdx_F14_zdm5QhoDOrPa" style="font: 10pt Times New Roman, Times, Serif">Does not include $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEFURUQgUEFSVFkgVFJBTlNBQ1RJT05TIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--StockOptionPlanExpense_pn3n3_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaerusTherapeuticsLLCMember_zwN4HCMuUKA8" title="Stock Based Compensation expenses for options exercisable">192</span> thousand
    for the year ended December 31, 2019 related to Stock Based Compensation expenses for options exercisable at an exercise price
    of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEFURUQgUEFSVFkgVFJBTlNBQ1RJT05TIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaerusTherapeuticsLLCMember_pii" title="Exercise price per share of options exercisable">7.00</span> per share into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEFURUQgUEFSVFkgVFJBTlNBQ1RJT05TIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_ecustom--NumberOfOrdinarySharesHeld_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaerusTherapeuticsLLCMember_pii" title="Number of ordinary shares held">70,000</span> ordinary shares held by Caerus Therapeutics LLC for which the director does not have beneficial
    control.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Year ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">December 31,</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2019</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(in thousands)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Discontinued operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F46_zSsDanWIU0i8" style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left; padding-bottom: 2.5pt">Stock-based compensation expenses to executive officers</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Stock Based Compensation">76</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Compensation of executive officers</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--OfficersCompensation_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_z3PQzKHltDNa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Compensation">685</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AE_zt0eY1Dvex6j" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Related
    Parties presented in the consolidated balance sheets</span></i></span></td></tr>
</table>
<p id="xdx_899_ecustom--ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock_z4a2KVSbG4S7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BC_zMe02VSe5zki" style="display: none">SCHEDULE OF RELATED PARTIES PRESENTED IN CONSOLIDATED BALANCE SHEETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Continuing operations:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left; padding-bottom: 2.5pt">Executive officers&#8217; payables</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_c20201231__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zKL8yC3duZL5" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right" title="Due to Related Parties">170</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_c20191231__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right" title="Due to Related Parties">1,251</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Non-executive directors&#8217; payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_c20201231__us-gaap--RelatedPartyTransactionAxis__custom--NonexecutiveDirectorsMember_zY02Lb952nXi" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to Related Parties">13</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_c20191231__us-gaap--RelatedPartyTransactionAxis__custom--NonexecutiveDirectorsMember_zN7cd3dfFGGj" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to Related Parties">202</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F4F_zU60oWJU4a1j" style="text-align: left; padding-bottom: 2.5pt">Loan to Related Party </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--DueFromRelatedPartiesNoncurrent1_iI_pn3n3_c20201231_fKg_____zEKOY0rnIym3" style="border-bottom: Black 2.5pt double; text-align: right" title="Loan to related party"><span style="-sec-ix-hidden: xdx2ixbrl3051">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--DueFromRelatedPartiesNoncurrent1_iI_pn3n3_c20191231_fKg_____zQFt3aaF0ufj" style="border-bottom: Black 2.5pt double; text-align: right" title="Loan to related party">2,623</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Accounts receivable, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AccountsReceivableNet_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts receivable, net">744</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AccountsReceivableNet_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts receivable, net"><span style="-sec-ix-hidden: xdx2ixbrl3057">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Contract liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ContractWithCustomerLiability_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Contract liabilities"><span style="-sec-ix-hidden: xdx2ixbrl3059">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ContractWithCustomerLiability_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Contract liabilities">230</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AB_zgA9qYDvZ32e" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0"/>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676578402600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates in the Preparation of Financial Statements</a></td>
<td class="text"><p id="xdx_845_eus-gaap--UseOfEstimates_zoTqjeGUG1E3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>a.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86F_zmuEvKVDb2R9">Use of Estimates in the Preparation of Financial Statements</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30.6pt"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation of our consolidated financial statements in conformity with U.S. GAAP requires us to make estimates, judgments
and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure
of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, judgments and methodologies. We base our
estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form
the basis for making judgments about the carrying values of assets, liabilities and equity, the amount of revenues and expenses
and determining whether an acquisition is a business combination or a purchase of asset. Actual results could differ from those
estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial
condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning
COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and
international customers and markets. We examined the impact of COVID-19 on our financial statements, and although there is currently
no major impact, there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combination</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--BusinessCombinationsPolicy_zASBMmgcRifh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>b.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_864_zIV8aZ9zoWC7">Business Combination</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company allocates the purchase price of an acquired business to the tangible and intangible assets acquired and liabilities assumed
based upon their estimated fair values on the acquisition date. Any excess of the purchase price over the fair value of the net
assets acquired is recorded as goodwill. Acquired in-process backlog, customer relations, technology, IPR&amp;D, brand name and
know how are recognized at fair value. The purchase price allocation process requires management to make significant estimates
and assumptions, especially at the acquisition date with respect to intangible assets. Direct transaction costs associated with
the business combination are expensed as incurred. The allocation of the consideration transferred in certain cases may be subject
to revision based on the final determination of fair values during the measurement period, which may be up to one year from the
acquisition date. The Company includes the results of operations of the business that it has acquired in its consolidated results
prospectively from the date of acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">If
the business combination is achieved in stages, the acquisition date carrying value of the acquirer&#8217;s previously held equity
interest in the acquire is re-measured to fair value at the acquisition date; any gains or losses arising from such re-measurement
are recognized in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_OtherInvestmentsPolicyTextBlock', window );">Other Investments</a></td>
<td class="text"><p id="xdx_849_ecustom--OtherInvestmentsPolicyTextBlock_zxa4jeXJtTJ5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>c.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_862_zEX2xcZFX5Og">Other Investments</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
other investments, the Company applies the measurement alternative upon the adoption of ASU 2016-01, and elected to record equity
investments without readily determinable fair values at cost, less impairment, adjusted for subsequent observable price changes.
In this measurement alternative method, changes in the carrying value of the equity investments are reflected in current earnings.
Changes in the carrying value of the equity investment are required to be made whenever there are observable price changes in
orderly transactions for the identical or similar investment of the same issuer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsPolicyTextBlock', window );">Discontinued operations</a></td>
<td class="text"><p id="xdx_848_eus-gaap--DiscontinuedOperationsPolicyTextBlock_z0tAJNQJEqF6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>d.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_866_zT2nEPd7Xj7l">Discontinued operations</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Upon
divestiture of a business, the Company classifies such business as a discontinued operation, if the divested business represents
a strategic shift that has (or will have) a major effect on an entity&#8217;s operations and financial results. For disposals
other than by sale such as abandonment, the results of operations of a business would not be recorded as a discontinued operation
until the period in which the business is actually abandoned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Masthercell Business divestiture qualifies as a discontinued operation and therefore has been presented as such.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
results of businesses that have qualified as a discontinued operation have been presented as such for all reporting periods. Results
of discontinued operations include all revenues and expenses directly derived from such businesses; general corporate overhead
is not allocated to discontinued operations. Any loss or gain that arose from the divestiture of a business that qualifies as
discontinued operations is included within the results of the discontinued operations. The Company included information regarding
cash flows from discontinued operations (See Note 3).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zGbbnJW7W7Ok" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>e.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_864_z5uAMJlNwL1">Cash Equivalents</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company considers cash equivalents to be all short-term, highly liquid investments, which include money market instruments, that
are not restricted as to withdrawal or use, and short-term bank deposits with original maturities of three months or less from
the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Cost of research and development and research and development services, net</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_z0k9DUhdcDQ3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>f.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_865_zd0MD2bxejCe">Cost of research and development and research and development services, net </span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Cost
of research and development and research and development services include costs directly attributable to the conduct of research
and development activities, including the cost of salaries, stock-based compensation expenses, payroll taxes and other employees&#8217;
benefits, lab expenses, consumable equipment, courier fees, travel expenses, professional fees and consulting fees. All costs
associated with research and developments are expensed as incurred. Participation from government departments and from research
foundations for development of approved projects is recognized as a reduction of expense as the related costs are incurred. Research
and development in-process acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative
future use, is expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--ConsolidationPolicyTextBlock_z58jOYQ7GVW2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>g.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86B_zFu2oE6YT6Md">Principles of Consolidation</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
consolidated financial statements include the accounts of the Company and its Subsidiaries. All intercompany transactions and
balances have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Non-Marketable Equity Investments</a></td>
<td class="text"><p id="xdx_849_eus-gaap--EquityMethodInvestmentsPolicy_z6a50xTL5SCf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>h.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_869_zNyNwcNiwFv5">Non-Marketable Equity Investments</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s investments in certain non-marketable equity securities in which it has the ability to exercise significant influence,
but it does not control through variable interests or voting interests. These are accounted for under the equity method of accounting
and presented as Investment in associates, net, in the Company&#8217;s consolidated balance sheets. Under the equity method, the
Company recognizes its proportionate share of the comprehensive income or loss of the investee. The Company&#8217;s share of income
and losses from equity method investments is included in share in losses of associated company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company reviews its investments accounted for under the equity method for possible impairment, which generally involves an analysis
of the facts and changes in circumstances influencing the investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_FunctionalCurrencyPolicyTextBlock', window );">Functional Currency</a></td>
<td class="text"><p id="xdx_840_ecustom--FunctionalCurrencyPolicyTextBlock_zoWTiL5Cyoh8" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>i.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86E_zugML1cnvI3l">Functional Currency</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
currency of the primary economic environment in which the operations of the Company and part of its Subsidiaries are conducted
is the U.S. dollar (&#8220;$&#8221; or &#8220;dollar&#8221;). The functional currency of the Belgian Subsidiaries is the Euro
(&#8220;&#8364;&#8221; or &#8220;Euro&#8221;). The functional currency of Orgenesis Korea is the Won (&#8220;KRW&#8221;). Most
of the Company&#8217;s expenses are incurred in dollars, and the source of the Company&#8217;s financing has been provided in
dollars. Thus, the functional currency of the Company and its other subsidiaries is the dollar. Transactions and balances originally
denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using
historical and current exchange rates for nonmonetary and monetary balances, respectively. For foreign transactions and other
items reflected in the statements of operations, the following exchange rates are used: (1) for transactions &#8211; exchange
rates at transaction dates or average rates and (2) for other items (derived from nonmonetary balance sheet items such as depreciation)
&#8211; historical exchange rates. The resulting transaction gains or losses are recorded as financial income or expenses. The
financial statements of the Belgian Subsidiaries and Orgenesis Korea are included in the consolidated financial statements, translated
into U.S. dollars. Assets and liabilities are translated at year-end exchange rates, while revenues and expenses are translated
at yearly average exchange rates during the year. Differences resulting from translation of assets and liabilities are presented
as other comprehensive income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zbJ1zWty11Zh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>j.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86A_zLI2WVvdPIy5">Inventory</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s inventory consists of raw material for use for the services provided. The Company periodically evaluates the quantities
on hand. Cost of the raw materials is determined using the weighted average cost method. The inventory is recorded at the lower
of cost or net realizable value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, plant and Equipment</a></td>
<td class="text"><p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrb5SiWXpmAg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>k.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_868_z7qU0zEBmU38">Property, plant and Equipment</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Property,
plant and equipment are recorded at cost and depreciated by the straight-line method over the estimated useful lives of the related
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_890_ecustom--ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock_zh1n2tVBzNya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Annual
rates of depreciation are presented in the table below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BF_z2zA03goEqb4" style="display: none">SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Useful Life (Years)</b></span></p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Production facility</td><td style="width: 2%">&#160;</td>
    <td style="width: 32%; text-align: center"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember__srt--RangeAxis__srt--MinimumMember_zrZKyWqXBHH3" title="Weighted Average Useful Life">5</span> - <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember__srt--RangeAxis__srt--MaximumMember_zvU9vrNQ1Hj2" title="Weighted Average Useful Life">10</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zxVC4f2PFcZh" title="Weighted Average Useful Life">2</span> - <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zY76Fk7sDRRg" title="Weighted Average Useful Life">7</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office equipment and computers</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zN3XZviUAKbe" title="Weighted Average Useful Life">3</span> - <span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zZhJXWuhWnrf" title="Weighted Average Useful Life">17</span></td></tr>
</table>

<p id="xdx_8A2_z9w1ZtH7Elsl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible assets</a></td>
<td class="text"><p id="xdx_845_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zMSnFezUZica" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>l.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_863_zJ3WcX5X9dV7">Intangible assets</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_898_ecustom--ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock_zbOYS9vpY4p6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Intangible
assets and their useful lives are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B8_zEKSONEQ5FDi" style="display: none">SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful Life (Years)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Amortization Recorded at Comprehensive</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Loss Line Item</p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Customer Relationships</td><td style="width: 2%">&#160;</td>
    <td style="width: 22%; text-align: center"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zO06hxwW9q0a" title="Intangible assets and useful lives (Years)">10</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 44%; text-align: center">Amortization of intangible assets</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Know-How</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowhowMember_zcXooVGZJTe5" title="Intangible assets and useful lives (Years)">12</span></td><td>&#160;</td>
    <td style="text-align: center">Amortization of intangible assets</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Technology</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TechnologyMember_zEsA4tuODn0k" title="Intangible assets and useful lives (Years)">15</span></td><td>&#160;</td>
    <td style="text-align: center">Amortization of intangible assets</td></tr>
</table>

<p id="xdx_8A6_z9WCdJJlXZr2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Intangible
assets are recorded at acquisition less accumulated amortization and impairment. Definite lived intangible assets are amortized
over their estimated useful life using the straight-line method, which is determined by identifying the period over which the
cash flows from the asset are expected to be generated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
<td class="text"><p id="xdx_843_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zi7iV6mHs2b9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>m.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_865_zd6VISbnwa5e">Goodwill</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Goodwill represents
the excess of consideration transferred over the value assigned to the net tangible and identifiable intangible assets of businesses
acquired. Goodwill is allocated to reporting units expected to benefit from the business combination. Goodwill is not amortized
but rather tested for impairment at least annually in the fourth quarter, or more frequently if events
or changes in circumstances indicate that goodwill may be impaired. Following the sale of Masthercell the Company manages
the business as one operating segment and one reporting unit. Goodwill impairment is recognized when the quantitative assessment
results in the carrying value exceeding the fair value, in which case an impairment charge is recorded to the extent the
carrying value exceeds the fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">There
were <span id="xdx_90E_eus-gaap--GoodwillImpairmentLoss_pn5n6_do_c20200101__20201231_zPR5LqcFQzkg">no</span></span> <span style="font: 10pt Times New Roman, Times, Serif">impairment
charges to goodwill during the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Long-lived Assets</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zrrNaOitkMu6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>n.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_866_zOv0AtkRWS3g">Impairment of Long-lived Assets</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company reviews its property, plants and equipment, intangible assets subject to amortization and other long-lived assets for
impairment whenever events or changes in circumstances indicate that the carrying amount of an asset class may not be recoverable.
Indicators of potential impairment include: an adverse change in legal factors or in the business climate that could affect the
value of the asset; an adverse change in the extent or manner in which the asset is used or is expected to be used, or in its
physical condition; and current or forecasted operating or cash flow losses that demonstrate continuing losses associated with
the use of the asset. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying
value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected
cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is
written down to fair value, based on the related estimated discounted cash flows. There were <span id="xdx_906_eus-gaap--AssetImpairmentCharges_pn5n6_do_c20200101__20201231_z1wGWkiwhMsg" title="Impairment of long-lived asset"><span id="xdx_904_eus-gaap--AssetImpairmentCharges_pn5n6_do_c20190101__20191231_zrB1t9GtR964" title="Impairment of long-lived asset">no</span></span> impairment charges in the year
ended December 31, 2020 and 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_843_eus-gaap--IncomeTaxPolicyTextBlock_zYJB765LFvch" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>o.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86D_zJoBX6muei4">Income Taxes</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">1)
With respect to deferred taxes, income taxes are computed using the asset and liability method. Under the asset and liability
method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and
tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is
recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">2)
The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the
tax position for recognition by determining if the available evidence indicates that it is more likely than not that the position
will be sustained on examination. If this threshold is met, the second step is to measure the tax position as the largest amount
that is greater than <span id="xdx_90E_ecustom--IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent_pii_dp_uPercentage_c20200101__20201231_zXxFP1WFAnW7" title="Income tax examination, likelihood of unfavorable settlement percent">50</span>% likely of being realized upon ultimate settlement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">3)
Taxes that would apply in the event of disposal of investment in Subsidiaries have not been taken into account in computing the
deferred income taxes, as it is the Company&#8217;s intention to hold these investments and not realize them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zSIop9rtFqEe" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>p.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_865_zPzQrxQKQuEf">Stock-based Compensation</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes
stock-based compensation for the estimated fair value of share-based awards. The Company measures compensation expense for share-based
awards based on estimated fair values on the date of grant using the Black-Scholes option-pricing model. This option pricing model
requires estimates as to the option&#8217;s expected term and the price volatility of the underlying stock. The Company amortizes
the value of share-based awards to expense over the vesting period on a straight-line basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RedeemableNoncontrollingInterestPolicyTextBlock', window );">Redeemable Non-controlling Interest</a></td>
<td class="text"><p id="xdx_848_ecustom--RedeemableNoncontrollingInterestPolicyTextBlock_zsEnUDcEFlxj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>q.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_866_zgCh5Z6OyJih">Redeemable Non-controlling Interest</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Non-controlling
interests with embedded redemption features, whose settlement is not at the Company&#8217;s discretion, are considered redeemable
non-controlling interest. Redeemable non-controlling interests are considered to be temporary equity and are therefore presented
as a mezzanine section between liabilities and equity on the Company&#8217;s consolidated balance sheets. Subsequent adjustment
of the amount presented in temporary equity is required only if the Company&#8217;s management estimates that it is probable that
the instrument will become redeemable. Adjustments of redeemable non-controlling interest to its redemption value are recorded
through additional paid-in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss (income) per Share of Common Stock</a></td>
<td class="text"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zNJx6RzESn1i" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>r.
<span id="xdx_867_zU7V6Xvszvll">Loss (income) per Share of Common Stock</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Basic
net loss (income) per share is computed by dividing the net loss (income) for the period by the weighted average
number of shares of common stock outstanding for each period. Diluted net loss (income) per share is based upon the weighted
average number of common shares and of common shares equivalents outstanding when dilutive. Common share equivalents include:
(i) outstanding stock options and warrants which are included under the treasury share method when dilutive, and (ii) common shares
to be issued under the assumed conversion of the Company&#8217;s outstanding convertible loans and debt, which are included under
the if-converted method when dilutive (See Note 14).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_z9iIMxbJLEt3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>s.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86C_zAOs2P028xn">Concentration of Credit Risk</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Financial
instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents,
bank deposits and certain receivables. The Company held these instruments with highly rated financial institutions and the Company
has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant
credit risk on these instruments apart of accounts receivable. The Company performs ongoing credit evaluations of its customers
for the purpose of determining the appropriate allowance for doubtful accounts. An appropriate allowance for doubtful accounts
is included in the accounts and netted against accounts receivable. In the year ended December 31, 2020 the Company has not experienced
any material credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Bad
debt allowance is created when objective evidence exists of inability to collect all sums owed it under the original terms of
the debit balances. Material customer difficulties, the probability of their going bankrupt or undergoing economic reorganization
and insolvency or material delays in payments are all considered indicative of reduced debtor balance value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_TreasurySharesPolicyTextBlock', window );">Treasury shares</a></td>
<td class="text"><p id="xdx_84E_ecustom--TreasurySharesPolicyTextBlock_zLbbSVa2voY4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>t.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86D_zCEKwbqlGi5h">Treasury shares</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company repurchases its ordinary shares from time to time on the open market and holds such shares as treasury stock. The Company
presents the cost to repurchase treasury stock as a reduction of shareholders&#8217; equity. During the years ended December 31,
2020, the Company repurchased <span id="xdx_90D_eus-gaap--TreasuryStockShares_iI_pii_c20201231_zSfcLu6T32ck">55,309</span></span>
<span style="font: 10pt Times New Roman, Times, Serif">shares. The Company did not reissue nor cancel treasury
shares during the year ended December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_BeneficialConversionFeatureBcfPolicyTextBlock', window );">Beneficial Conversion Feature (&#8220;BCF&#8221;)</a></td>
<td class="text"><p id="xdx_84E_ecustom--BeneficialConversionFeatureBcfPolicyTextBlock_zcdFRGpqeFm1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>u.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_861_zwdTIHksyfce">Beneficial Conversion Feature (&#8220;BCF&#8221;)</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">When
the Company issues convertible debt, if the stock price is greater than the effective conversion price (after allocation of the
total proceeds) on the measurement date, the conversion feature is considered &#8220;beneficial&#8221; to the holder. If there
is no contingency, this difference is treated as issued equity and reduces the carrying value of the host debt; the discount is
accreted as deemed interest on the debt (See Note 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive Loss</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zqsBQb7xNxJc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>v.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_862_zmJDopxvL1Jk">Other Comprehensive Loss</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other
comprehensive loss represents adjustments of foreign currency translation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue from Contracts with Customers</a></td>
<td class="text"><p id="xdx_841_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zI8Vwp6qBLh4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>w.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_864_zmzvFYMGY2lf">Revenue from Contracts with Customers</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes revenue from contracts with customers according to ASC 606, <i>Revenue from Contracts with Customers</i> and
the related amendments (&#8220;New Revenue Standard&#8221;) to all contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s agreements are primarily service contracts that range in duration from a few months to one year. The Company recognizes
revenue when control of these services is transferred to the customer for an amount, referred to as the transaction price, which
reflects the consideration to which the Company is expected to be entitled in exchange for those goods or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
contract with a customer exists only when:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    parties to the contract have approved it and are committed to perform their respective obligations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance
    obligations&#8221;);</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company can determine the transaction price for the goods or services to be transferred; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled
    in exchange for the goods or services that will be transferred to the customer.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company does not adjust the promised amount of consideration for the effects of a significant financing component since the Company
expects, at contract inception, that the period between the time of transfer of the promised goods or services to the customer
and the time the customer pays for these goods or services to be generally one year or less. The Company&#8217;s credit terms
to customers are in average between thirty and one hundred and fifty days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Nature
of Revenue Streams</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s main revenue streams from continuing operation are POC development services and Cell Process Development
Services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>POC
Development Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Revenue
recognized under contracts for POC development services may, in some contracts, represent multiple performance obligations (where
promises to the customers are distinct) in circumstances in which the work packages are not interrelated or the customer is able
to complete the services performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">For
arrangements that include multiple performance obligations, the transaction price is allocated to the identified performance obligations
based on their relative standalone selling prices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes revenue when, or as, it satisfies a performance obligation. At contract inception, the Company determines whether
the services are transferred over time or at a point in time. Performance obligations that have no alternative use and that the
Company has the right to payment for performance completed to date, at all times during the contract term, are recognized over
time. All other Performance obligations are recognized as revenues by the company at point of time (upon completion).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Included
in POC development services is Hospital supplies revenue which is derived principally from the sale or lease of products and the
performance of services to hospitals or other medical providers. Revenue is earned and recognized when product and services are
received by the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;Significant
Judgement and Estimates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Significant
judgment is required to</span> identifying the distinct performance obligations and estimating the standalone selling price of
each distinct performance obligation, and identifying which performance obligations create assets with alternative use to the
Company, which results in revenue recognized upon completion, and which performance obligations are transferred to the customer
over time.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Practical
Expedients</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">As
part of ASC 606, the Company has adopted several practical expedients including the Company&#8217;s determination that it need
not adjust the promised amount of consideration for the effects of a significant financing component since the Company expects,
at contract inception, that the period between when the Company transfers a promised service to the customer and when the customer
pays for that service will be one year or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>Cell
Process Development Services (mainly discontinued operations)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Revenue
recognized under contracts for cell process development services may, in some contracts, represent multiple performance obligations
(where promises to the customers are distinct) in circumstances in which the work packages and milestones are not interrelated
or the customer is able to complete the services performed independently or by using competitors of the Company. In other contracts
when the above circumstances are not met, the promises are not considered distinct and the contract represents one performance
obligation. All performance obligations are satisfied over time, as there is no alternative use to the services it performs, since,
in nature, those services are unique to the customer, which retain the ownership of the intellectual property created through
the process. Additionally, due to the non-refundable upfront payment the customer pays, together with the payment term and cancellation
fine, it has a right to payment (which include a reasonable margin), at all times, for work completed to date, which is enforceable
by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
arrangements that include multiple performance obligations, the transaction price is allocated to the identified performance obligations
based on their relative standalone selling prices. For these contracts, the standalone selling prices are based on the Company&#8217;s
normal pricing practices when sold separately with consideration of market conditions and other factors, including customer demographics
and geographic location.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company measures the revenue to be recognized over time on a contract by contract basis, determining the use of either a cost-based
input method or output method, depending on whichever best depicts the transfer of control over the life of the performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>Tech
Transfer Services (discontinued operations)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Revenue
recognized under contracts for tech transfer services are considered a single performance obligation, as all work packages (including
data collection, GMP documentation, validation runs) and milestones are interrelated. Additionally, the customer is unable to
complete services of work performed independently or by using competitors of the Company. Revenue is recognized over time using
a cost-based based input method where progress on the performance obligation is measured by the proportion of actual costs incurred
to the total costs expected to complete the contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>Cell
Manufacturing Services (discontinued operations)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Revenues
from cell manufacturing services represent a single performance obligation which is recognized over time. The progress towards
completion will continue to be measured on an output measure based on direct measurement of the value transferred to the customer
(units produced).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>Reimbursed
Expenses (discontinued operations)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company includes reimbursed expenses in revenues and costs of revenue as the Company is primarily responsible for fulfilling the
promise to provide the specified service, including the integration of the related services into a combined output to the customer,
which are inseparable from the integrated service. These costs include such items as consumable, reagents, transportation and
travel expenses, over which the Company has discretion in establishing prices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Change
Orders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Changes
in the scope of work are common and can result in a change in transaction price, equipment used and payment terms. Change orders
are evaluated on a contract-by-contract basis to determine if they should be accounted for as a new contract or as part of the
existing contract. Generally, services from change orders are not distinct from the original performance obligation. As a result,
the effect that the contract modification has on the contract revenue, and measure of progress, is recognized as an adjustment
to revenue when they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Costs
of Revenue (discontinued operations)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Costs
of revenue include (i) compensation and benefits for billable employees and personnel involved in production, data management
and delivery, and the costs of acquiring and processing data for the Company&#8217;s information offerings; (ii) costs of staff
directly involved with delivering services offerings and engagements; (iii) consumables used for the services; and (iv) other
expenses directly related to service contracts such as courier fees, laboratory supplies, professional services and travel expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zM949RtKzIP9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>x.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_864_zoYBMzuMVFJe">Leases</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company adopted
the new lease standard ASC 842 and all the related amendments on January 1, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2.
If any of these five criteria is met, The Company classifies the lease as a finance lease; otherwise, the Company classifies the
lease as an operating lease. <span id="xdx_904_ecustom--LeaseClassificationDiscription_c20200101__20201231" title="Lease classification discription">When determining lease classification, the Company&#8217;s approach in assessing two of the mentioned
criteria is: (i) generally 75% or more of the remaining economic life of the underlying asset is a major part of the remaining
economic life of that underlying asset; and (ii) generally 90% or more of the fair value of the underlying asset comprises substantially
all of the fair value of the underlying asset.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Operating
leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the consolidated
balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">ROU
assets represent Orgenesis&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation
to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date
based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the
information available at the commencement date to determine the present value of the lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
standard also provides practical expedients for an entity&#8217;s ongoing accounting. The Company elected the short-term lease
recognition exemption for all leases with a term shorter than 12 months. This means that for those leases, the Company does not
recognize ROU assets or lease liabilities, including not recognizing ROU assets or lease liabilities for existing short-term leases
of those assets in transition, but recognizes lease expenses over the lease term on a straight-line basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Lease
terms will include options to extend or terminate the lease when it is reasonably certain that Orgenesis will exercise or not
exercise the option to renew or terminate the lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Recently issued accounting pronouncements, not yet adopted</a></td>
<td class="text"><p id="xdx_84F_ecustom--RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zUdPYL8yJYz5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>y.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86B_zlPuyTRD20wc">Recently issued accounting pronouncements, not yet adopted</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2016, the FASB issued ASU 2016-13 &#8220;Financial Instruments&#8212;Credit Losses&#8212;Measurement of Credit Losses on
Financial Instruments.&#8221; This guidance replaces the current incurred loss impairment methodology with a methodology that
reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform
credit loss estimates. The guidance will be effective for Smaller Reporting Companies (SRCs, as defined by the SEC) for the fiscal
year beginning on January 1, 2023, including interim periods within that year. The Company is currently evaluating this guidance
to determine the impact it may have on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, Debt with Conversion and Other Options (Subtopic
470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments
and Contracts in an Entity&#8217;s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation
models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument
with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required
for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it.
The ASU also simplifies the diluted net income per share calculation in certain areas. The new guidance is effective for annual
and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years beginning after December
15, 2020, and interim periods within those fiscal years. The Company is currently evaluating the impact that this new guidance
will have on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Newly issued and recently adopted accounting pronouncements</a></td>
<td class="text"><p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zA9T2OUm4Tfi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">z.</span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86D_zHRjqYLmA3cc">Newly issued and recently adopted accounting pronouncements</span></i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company early adopted ASU 2019-12 on January 1, 2020, which did not have a material impact on the Consolidated Financial Statements
except for the removal of the exception related to intra-period tax allocations. Commencing from January 1, 2020, the Company
followed the general intra-period allocation of tax expenses. The Company had incurred a loss from continuing operations and subsequent
to the adoption of ASU 2019-12, the Company determined the amount attributable to continuing operations without regard to the
tax effect of other items. The ASU 2019-12 amendment related to the intra-period tax allocation was applied prospectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Had
the Company not adopted ASU 2019-12, an approximately $<span id="xdx_902_eus-gaap--IncomeTaxExpenseBenefit_pn5n6_c20200101__20201231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201912Member_zgebC0H9Ojm1" title="Income Tax Expense (Benefit)">20</span> million tax benefit would have been recognized along with corresponding
decreases to net loss from continuing operations with a corresponding increase in tax expenses and decrease in net income resulting
from discontinued operations. The Company had no intra-period tax allocation items in prior years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zhAsVeCQvSik" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>aa.</i></span> <span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_86C_z1U2luzhxRDl">Reclassifications</span> </i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Certain
reclassifications have been made to the prior years&#8217; financial statements to conform to the current year presentation. These
reclassifications had no net effect on previously reported results of operations.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_BeneficialConversionFeatureBcfPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial Conversion Feature [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_BeneficialConversionFeatureBcfPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_FunctionalCurrencyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Functional Currency [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_FunctionalCurrencyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_OtherInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Investments [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_OtherInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recently Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_RedeemableNoncontrollingInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_RedeemableNoncontrollingInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_TreasurySharesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Treasury Shares [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_TreasurySharesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19347-109286<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676573106040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock', window );">SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_890_ecustom--ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock_zh1n2tVBzNya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Annual
rates of depreciation are presented in the table below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BF_z2zA03goEqb4" style="display: none">SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Useful Life (Years)</b></span></p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Production facility</td><td style="width: 2%">&#160;</td>
    <td style="width: 32%; text-align: center"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember__srt--RangeAxis__srt--MinimumMember_zrZKyWqXBHH3" title="Weighted Average Useful Life">5</span> - <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember__srt--RangeAxis__srt--MaximumMember_zvU9vrNQ1Hj2" title="Weighted Average Useful Life">10</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zxVC4f2PFcZh" title="Weighted Average Useful Life">2</span> - <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zY76Fk7sDRRg" title="Weighted Average Useful Life">7</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office equipment and computers</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zN3XZviUAKbe" title="Weighted Average Useful Life">3</span> - <span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zZhJXWuhWnrf" title="Weighted Average Useful Life">17</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock', window );">SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE</a></td>
<td class="text"><p id="xdx_898_ecustom--ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock_zbOYS9vpY4p6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Intangible
assets and their useful lives are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B8_zEKSONEQ5FDi" style="display: none">SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful Life (Years)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Amortization Recorded at Comprehensive</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Loss Line Item</p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Customer Relationships</td><td style="width: 2%">&#160;</td>
    <td style="width: 22%; text-align: center"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zO06hxwW9q0a" title="Intangible assets and useful lives (Years)">10</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 44%; text-align: center">Amortization of intangible assets</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Know-How</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowhowMember_zcXooVGZJTe5" title="Intangible assets and useful lives (Years)">12</span></td><td>&#160;</td>
    <td style="text-align: center">Amortization of intangible assets</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Technology</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TechnologyMember_zEsA4tuODn0k" title="Intangible assets and useful lives (Years)">15</span></td><td>&#160;</td>
    <td style="text-align: center">Amortization of intangible assets</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Annual Depreciation Rates Property and Equipment [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Intangible Assets Useful Lives [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676570819576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">SCHEDULE OF DISCONTINUED OPERATION AND BALANCE SHEETS</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zmkQyrHutPYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
financial results of the Masthercell Business are presented as income (loss) from discontinued operations, net of income taxes
on the Company&#8217;s consolidated statement of comprehensive loss. The following table presents the financial results associated
with the Masthercell Business operation as reflected in the Company&#8217;s Consolidated Comprehensive loss (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;<span id="xdx_8B6_zpoTCAyl7kKi" style="display: none">SCHEDULE OF DISCONTINUED OPERATION AND BALANCE SHEETS</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"/><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">OPERATIONS</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231_zeOdHvQTFCM3" style="width: 14%; text-align: right" title="Revenues">2,556</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231_zDshnLGkj0M8" style="width: 14%; text-align: right" title="Revenues">31,053</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c20200101__20201231_pn3n3" style="text-align: right" title="Cost of revenues">1,482</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c20190101__20191231_pn3n3" style="text-align: right" title="Cost of revenues">18,318</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cost of research and development and research and development services, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet_c20200101__20201231_pn3n3" style="text-align: right" title="Cost of research and development and research and development services, net">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet_c20190101__20191231_pn3n3" style="text-align: right" title="Cost of research and development and research and development services, net">54</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amortization of intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DepreciationAndAmortizationDiscontinuedOperations_c20200101__20201231_pn3n3" style="text-align: right" title="Amortization of intangible assets">137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DepreciationAndAmortizationDiscontinuedOperations_c20190101__20191231_pn3n3" style="text-align: right" title="Amortization of intangible assets">1,631</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling, general and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c20200101__20201231_pn3n3" style="text-align: right" title="Selling, general and administrative expenses">1,896</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c20190101__20191231_pn3n3" style="text-align: right" title="Selling, general and administrative expenses">13,886</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other (income) expenses, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherExpenses_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other (income) expenses, net">305</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherExpenses_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other (income) expenses, net">(207</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_c20200101__20201231_pn3n3" style="text-align: right" title="Operating loss">1,271</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_c20190101__20191231_pn3n3" style="text-align: right" title="Operating loss">2,629</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Financial expenses (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet_pn3n3_c20200101__20201231_zGXmlGGliLjl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Financial expenses (income), net">(29</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet_pn3n3_c20190101__20191231_ztHwbrb670Ki" style="border-bottom: Black 1.5pt solid; text-align: right" title="Financial expenses (income), net">31</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_c20200101__20201231_pn3n3" style="text-align: right" title="Loss before income taxes">1,242</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_c20190101__20191231_pn3n3" style="text-align: right" title="Loss before income taxes">2,660</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax expenses (income)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DiscontinuedOperationTaxEffectOfDiscontinuedOperation_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Tax expenses (income)">(30</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DiscontinuedOperationTaxEffectOfDiscontinuedOperation_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Tax expenses (income)">792</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss from discontinuing operation, net of tax</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_ecustom--IncomeLossFromDiscontinuedOperationNetOfTax_c20200101__20201231_pn3n3" style="text-align: right" title="Net loss from discontinuing operation, net of tax">1,212</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--IncomeLossFromDiscontinuedOperationNetOfTax_c20190101__20191231_pn3n3" style="text-align: right" title="Net loss from discontinuing operation, net of tax">3,452</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">DISPOSAL</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on disposal before income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_c20200101__20201231_pn3n3" style="text-align: right" title="Gain on disposal before income taxes">96,918</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_c20190101__20191231_pn3n3" style="text-align: right" title="Gain on disposal before income taxes"><span style="-sec-ix-hidden: xdx2ixbrl0958">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Provision for income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Provision for income taxes"><span style="-sec-ix-hidden: xdx2ixbrl0960">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"/><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Provision for income taxes"><span style="-sec-ix-hidden: xdx2ixbrl0962">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on disposal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_c20200101__20201231_pn3n3" style="text-align: right" title="Gain on disposal">96,918</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_c20190101__20191231_pn3n3" style="text-align: right" title="Gain on disposal"><span style="-sec-ix-hidden: xdx2ixbrl0966">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net profit (loss) from discontinuing operation, net of tax</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--NetProfitLossFromDiscontinuingOperationNetOfTax_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net profit (loss) from discontinuing operation, net of tax">95,706</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--NetProfitLossFromDiscontinuingOperationNetOfTax_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net profit (loss) from discontinuing operation, net of tax">(3,452</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table is a summary of the assets and liabilities of discontinued operations (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 78%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_pn3n3_c20191231_zVVTRihLJ2J2" style="width: 18%; text-align: right" title="Cash and cash equivalents">11,281</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--DisposalGroupIncludingDiscontinuedOperationRestrictedCash_c20191231_pn3n3" style="text-align: right" title="Restricted cash">186</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_c20191231_pn3n3" style="text-align: right" title="Accounts receivable, net">6,654</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_c20191231_pn3n3" style="text-align: right" title="Prepaid expenses and other receivables">845</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Grants receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--DisposalGroupIncludingDiscontinuedOperationGrantsReceivable_c20191231_pn3n3" style="text-align: right" title="Grants receivable">1,979</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DisposalGroupIncludingDiscontinuedOperationInventory1_c20191231_pn3n3" style="text-align: right" title="Inventory">1,907</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--DisposalGroupIncludingDiscontinuedOperationsDeposits_c20191231_pn3n3" style="text-align: right" title="Deposits">326</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_c20191231_pn3n3" style="text-align: right" title="Property and equipment, net">22,149</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Intangible assets, net (mainly Know How)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_iI_pn3n3_c20191231_zGQWzg7mr6C4" style="text-align: right" title="Intangible assets, net (mainly Know How)">10,858</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets_c20191231_pn3n3" style="text-align: right" title="Operating lease right-of-use assets">8,860</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGoodwill1_c20191231_pn3n3" style="text-align: right" title="Goodwill">10,129</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherAssets_c20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other assets">47</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL CURRENT ASSETS OF DISCONTINUED OPERATIONS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperation_iI_pn3n3_c20191231_z50nh6viLcIc" style="border-bottom: Black 2.5pt double; text-align: right" title="TOTAL CURRENT ASSETS OF DISCONTINUED OPERATIONS">75,221</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 78%; text-align: left">Accounts payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayable_c20191231_pn3n3" style="width: 18%; text-align: right" title="Accounts payable">5,756</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_c20191231_pn3n3" style="text-align: right" title="Accrued expenses and other payables">372</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Employees and related payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables_c20191231_pn3n3" style="text-align: right" title="Employees and related payables">2,047</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Advance payments on account of grant</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant_c20191231_pn3n3" style="text-align: right" title="Advance payments on account of grant">2,227</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Short-term loans and current maturities of long- term loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans_c20191231_pn3n3" style="text-align: right" title="Short-term loans and current maturities of long- term loans">372</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Contract liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_c20191231_pn3n3" style="text-align: right" title="Contract liabilities">8,301</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Current maturities of long-term finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases_c20191231_pn3n3" style="text-align: right" title="Current maturities of long-term finance leases">291</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Current maturities of operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases_c20191231_pn3n3" style="text-align: right" title="Current maturities of operating leases">1,365</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Non-current operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases_c20191231_pn3n3" style="text-align: right" title="Non-current operating leases">7,069</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loans payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--DisposalGroupIncludingDiscontinuedOperationLoansPayable_c20191231_pn3n3" style="text-align: right" title="Loans payable">1,230</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Deferred taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_c20191231_pn3n3" style="text-align: right" title="Deferred taxes">1,868</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Long-term finance leases</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases_c20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Long-term finance leases">688</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL CURRENT LIABILITIES OF DISCONTINUED OPERATIONS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="TOTAL CURRENT LIABILITIES OF DISCONTINUED OPERATIONS">31,586</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Property,
plants and equipment, net and right-of-use assets by geographical location were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--PropertyPlantAndEquipmentNetAndRightOfUseAssets_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--US_zphmKqdJ6fB6" style="width: 26%; text-align: right" title="Property, plants and equipment, net and right-of-use assets">16,707</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Belgium</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--PropertyPlantAndEquipmentNetAndRightOfUseAssets_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--BE_zrqOc8vCk7Rc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property, plants and equipment, net and right-of-use assets">14,302</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--PropertyPlantAndEquipmentNetAndRightOfUseAssets_iI_pn3n3_c20191231_zJ5y9rAN0zs2" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, plants and equipment, net and right-of-use assets">31,009</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table represents the components of the cash flows from discontinued operations (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net cash flows used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_pn3n3_c20200101__20201231_zacoQ03y73D4" style="width: 14%; text-align: right" title="Net cash flows provided by (used in) operating activities">(2,409</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_c20190101__20191231_pn3n3" style="width: 14%; text-align: right" title="Net cash flows provided by (used in) operating activities">(1,248</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash flows used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_c20200101__20201231_pn3n3" style="text-align: right" title="Net cash flows used in investing activities">(579</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_c20190101__20191231_pn3n3" style="text-align: right" title="Net cash flows used in investing activities">(11,621</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash flows (used in) provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_c20200101__20201231_pn3n3" style="text-align: right" title="Net cash flows (used in) provided by financing activities">(51</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_c20190101__20191231_pn3n3" style="text-align: right" title="Net cash flows (used in) provided by financing activities">12,570</td><td style="text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock', window );">SCHEDULE OF DISAGGREGATION OF REVENUE RELATED TO DISCONTINUED OPERATIONS</a></td>
<td class="text"><p id="xdx_896_ecustom--ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock_zCO9x69k1qOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table disaggregates the Company&#8217;s revenues by major revenue streams related to discontinued operations (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zm80mblxonAi" style="display: none">SCHEDULE OF DISAGGREGATION OF REVENUE RELATED TO DISCONTINUED OPERATIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Revenue stream:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Cell process development services</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesMember_zmYvscrkc938" style="width: 14%; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue">2,556</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231__srt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesMember_zi8SlHnnKwZ1" style="width: 14%; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue">20,834</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Tech transfer services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--TechTransferServicesMember_zcAyJvlL4sxc" style="text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue"><span style="-sec-ix-hidden: xdx2ixbrl1048">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231__srt--ProductOrServiceAxis__custom--TechTransferServicesMember_zbf29ju37tFf" style="text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue">5,396</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Cell manufacturing services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--CellManufacturingServicesMember_zdo3UKetmdie" style="border-bottom: Black 1.5pt solid; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231__srt--ProductOrServiceAxis__custom--CellManufacturingServicesMember_zo6KYpAjIKDb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue">4,823</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20200101__20201231_zDS1Tqq4vpk3" style="border-bottom: Black 2.5pt double; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue">2,556</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_c20190101__20191231_z3CT2nlfEL76" style="border-bottom: Black 2.5pt double; text-align: right" title="Disposal Group, Including Discontinued Operation, Revenue">31,053</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Disaggregation of Revenue Related to Discontinued Operations [Table Text ]Block</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676573749912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION AND REORGANIZATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisclosureAcquisitionAndReorganizationAbstract', window );"><strong>Acquisition And Reorganization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zWeonuaKo7se" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the allocation of purchase price to the fair values of the assets acquired and liabilities assumed
as of the transaction date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B2_z8408OO7tIP9" style="display: none">SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20201231_z1qrVyAOpNob" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued_iI_pn3n3_maBCRIAzxgu_zpZljblX2cRk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%">Fair value of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_ecustom--FairValuePercentageofSharesIssued_iI_pii_dp_uPercentage_c20201231_zmr08iQJvnDa" title="Fair value percentage of shares issued">8.8</span>% of shared issued *</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"><span id="xdx_F47_zz9L2sR0yq73" style="display: none; font-family: Times New Roman, Times, Serif">*</span></td><td style="width: 18%; text-align: right">11,172</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments_iI_pn3n3_maBCRIAzxgu_ziNdtG7LgITh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash payment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,115</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_pn3n3_mtBCRIAzxgu_zxQF4lTwThg8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total consideration transferred</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,287</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td id="xdx_F01_zLuqe2CpwNid" style="width: 1.2%">*</td>
    <td id="xdx_F1F_zSzpzffwMp64" style="width: 50%">Fair value of the consideration is based on the company&#8217;s market share price.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Total assets acquired:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 78%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pn3n3_c20201231_zaA0VUMeje8b" style="width: 18%; text-align: right" title="Cash and cash equivalents">8</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Restricted Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_iI_pn3n3_c20201231_zzdW7jHhqefd" style="text-align: right" title="Restricted Cash">152</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts Receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_pn3n3_c20201231_zmNyRNKuCKLk" style="text-align: right" title="Accounts Receivable">228</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iI_pn3n3_c20201231_zq9T4Dy5pkpl" style="text-align: right" title="Inventory">34</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_iI_pn3n3_c20201231_ztTVWWU6d3Td" style="text-align: right" title="Other assets">25</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Property, plants and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pn3n3_c20201231_zYmz0iITYuui" style="text-align: right" title="Property, plants and equipment, net">482</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Kyslecel Technology (a)</td><td id="xdx_F46_zu1500R9cTqk" style="display: none">(a)</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_fYQ_____zKffF8VCEZO7" style="text-align: right" title="Other intangible assets">9,340</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">IPR&amp;D (a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_fYQ_____zidQJTdSBsef" style="text-align: right" title="Other intangible assets">641</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_iI_pn3n3_c20201231_z9LX9XnVFREh" style="text-align: right" title="Operating lease right-of-use assets">238</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Goodwill (b)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill_iI_pn3n3_c20201231_fYg_____zAz3kQsaxVRf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill">3,704</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_pn3n3_c20201231_zRe9GSXqKHJ" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total assets">14,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Total liabilities assumed:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease_iI_pn3n3_c20201231_zKR13To8FmJ7" style="text-align: right" title="Operating leases">238</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_pn3n3_c20201231_ze56KYhWrkt5" style="text-align: right" title="Accounts Payable">216</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_iI_pn3n3_c20201231_zgv0xezpFr98" style="text-align: right" title="Accrued Expenses">4</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Orgenesis Inc loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability_iI_pn3n3_c20201231_zuLlfxIelzwa" style="text-align: right" title="Orgenesis Inc loan">651</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Deferred taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_iI_pn3n3_c20201231_zu8WyHo2SLR9" style="text-align: right" title="Deferred taxes">1,293</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Notes Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_iI_pn3n3_c20201231_zvF4ICtmkrCe" style="text-align: right" title="Notes Payable">162</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_iI_pn3n3_c20201231_zWoir7e4LwZ3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other liabilities">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_pn3n3_c20201231_zcqPJQYzOgd3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total liabilities">2,565</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; padding-bottom: 2.5pt">Total consideration transferred</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pn3n3_c20201231_zIIXbRMFwIa4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred">12,287</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1.2%; text-align: right"><span id="xdx_F0D_zmsOFibs8cqa" style="font: 10pt Times New Roman, Times, Serif">a.</span></td><td style="text-align: justify; width: 50%"><span id="xdx_F16_zzszZc7HaF43" style="font: 10pt Times New Roman, Times, Serif">The
                                         allocation of the purchase price to the net assets acquired and liabilities assumed resulted
                                         in the recognition of other intangible assets which comprised of: Kyslecel Technology
                                         of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_zkEyoPQjdj0e" title="Other intangible assets">9,340</span> and IPR&amp;D of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_zbaY6aSbgAC8" title="Other intangible assets">641</span>. Kyslecel Technology has a useful life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_zYRTWIzaNSq8" title="Useful life">15</span> years. The
                                         useful life of these intangible assets for amortization purposes was determined considering
                                         the period of expected cash flows generated by the assets used to measure the fair value
                                         of the intangible assets adjusted as appropriate for the entity-specific factors, including
                                         legal, regulatory, contractual, competitive, economic or other factors that may limit
                                         the useful life of intangible assets.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">These
intangible assets were estimated using a discounted cash flow method with the application of the multi-period excess earnings
method. Under this method, an intangible asset&#8217;s fair value is equal to the present value of the incremental after-tax cash
flows attributable only to the subject intangible asset after deducting contributory asset charges. An income and expenses forecast
were built based upon revenue and expense estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1.2%; text-align: right"><span id="xdx_F08_zwXN3l4aZ3rl" style="font: 10pt Times New Roman, Times, Serif">b.</span></td><td style="text-align: justify; width: 50%"><span id="xdx_F14_zGdT76xRwTL" style="font: 10pt Times New Roman, Times, Serif">The primary
items that generate goodwill include the value of the synergies between the acquired company and the Company and the acquired
assembled workforce, neither of which qualifies for recognition as an intangible asset. The Goodwill is not deductible for tax
purposes.</span></td>
</tr></table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">SCHEDULE OF UNAUDITED SUPPLEMENTAL PRO FORMA</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_z7erDNuy7OUf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Unaudited
supplemental pro forma combined results of operations (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8B1_zNvvKHaYkemd" style="display: none">SCHEDULE OF UNAUDITED SUPPLEMENTAL PRO FORMA</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20200101__20201231__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_zZnB1kWTVapb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20190101__20191231__us-gaap--BusinessAcquisitionAxis__custom--KoligoTherapeuticsIncMember_zdjNqHXzKmgd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zQkIcQPJ7PDk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 2.5pt">Revenues</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">8,239</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">4,398</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--ProfitLoss_pn3n3_zeJXVLbN19e9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">318</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">27,263</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Loss per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--EarningsPerShareBasic_pii_zas48cbihrHe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Basic</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.05</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.91</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisclosureAcquisitionAndReorganizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisclosureAcquisitionAndReorganizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676570825864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANTS AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">SCHEDULE OF COMPONENTS OF PROPERTY, PLANTS AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_890_eus-gaap--PropertyPlantAndEquipmentTextBlock_zDHQPVL1geg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table represents the components of property, plants and equipment:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BC_z2GFvj6gaFHk" style="display: none">SCHEDULE OF COMPONENTS OF PROPERTY, PLANTS AND EQUIPMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cost:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Production facility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember_zWYVxVDMQvGc" style="width: 14%; text-align: right" title="Cost">2,801</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember_pn3n3" style="width: 14%; text-align: right" title="Cost">2,481</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and computers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndComputersMember_zgcO2T8iYmK7" style="text-align: right" title="Cost">697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndComputersMember_z0y9NA1IfI65" style="text-align: right" title="Cost">606</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lab equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zczCPRXCNbLl" style="text-align: right" title="Cost">1,483</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zL1npMPfGEH9" style="text-align: right" title="Cost">656</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Advance payment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancePaymentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost">281</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancePaymentMember_zkxBffHbarbg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20201231_zHLOZ4Rnt6ce" style="text-align: right" title="Cost">5,262</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20191231_pn3n3" style="text-align: right" title="Cost">3,743</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less &#8211; accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20201231_zLFFAiqJWJz4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated depreciation">(2,189</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20191231_zV8Gha4ReO47" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated depreciation">(1,438</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">3,073</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">2,305</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock', window );">SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT BY GEOGRAPHICAL LOCATION</a></td>
<td class="text"><p id="xdx_893_ecustom--ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock_zHA5Muxbbcp" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Property,
plants and equipment, net by geographical location were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;<span id="xdx_8BB_zNFBcntFHRU8" style="display: none">SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT BY GEOGRAPHICAL LOCATION</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Belgium</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--BE_z3FrDJDpS0dk" style="width: 14%; text-align: right" title="Property, plants and equipment, net">358</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--BE_zwfZfgF2Jwx4" style="width: 14%; text-align: right" title="Property, plants and equipment, net"><span style="-sec-ix-hidden: xdx2ixbrl1209">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Korea</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--KR_zlTQHJXo3AB5" style="text-align: right" title="Property, plants and equipment, net">839</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--KR_zAqptTq2mcBl" style="text-align: right" title="Property, plants and equipment, net">983</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Israel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--IL_zoo1isOf3lTe" style="text-align: right" title="Property, plants and equipment, net">1,386</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--IL_zLDcfeYHoMyc" style="text-align: right" title="Property, plants and equipment, net">1,322</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">U.S.</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--US_z6HzmHQklp0h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property, plants and equipment, net">490</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--US_zteNa7ACv2q1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property, plants and equipment, net"><span style="-sec-ix-hidden: xdx2ixbrl1221">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20201231_zHod0TYdk5Yh" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, plants and equipment, net">3,073</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20191231_zXe9lKeMKkqi" style="border-bottom: Black 2.5pt double; text-align: right" title="Property, plants and equipment, net">2,305</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676572892472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">SCHEDULE OF GOODWILL</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfGoodwillTextBlock_zzQN5PNTZYI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Changes
in the carrying amount of the Company&#8217;s goodwill for the years ended December 31, 2020 and 2019 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B4_zJh07DxpbKv" style="display: none">SCHEDULE OF GOODWILL</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%">Goodwill as of December 31, 2018</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--Goodwill_iS_pn3n3_c20190101__20191231_zP0kjS9gsqp2" style="width: 22%; text-align: right"><span title="Goodwill, Beginning Balance">4,942</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Goodwill as acquired, (Koligo) see note 4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--GoodwillAcquiredDuringPeriod_c20190101__20191231_pn3n3" style="text-align: right" title="Goodwill as acquired"><span style="-sec-ix-hidden: xdx2ixbrl1232">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Translation differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Translation differences">(130</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Goodwill as of December 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--Goodwill_iE_pn3n3_c20190101__20191231_zJv4Jb2X2twb" style="text-align: right" title="Goodwill, Ending Balance">4,812</td><td style="text-align: left">&#160;</td></tr>
<tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Goodwill as of December 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--Goodwill_iS_pn3n3_c20200101__20201231_zitu3wy1HRq9" style="text-align: right" title="Goodwill, Beginning Balance">4,812</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Goodwill as acquired, (Koligo) see note 4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--GoodwillAcquiredDuringPeriod_c20200101__20201231_pn3n3" style="text-align: right" title="Goodwill as acquired">3,704</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Translation differences</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Translation differences">229</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Goodwill as of December 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--Goodwill_iE_pn3n3_c20200101__20201231_zFIXFDKo4AJ" style="border-bottom: Black 2.5pt double; text-align: right" title="Goodwill, Ending Balance">8,745</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">SCHEDULE OF OTHER INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zReGqiIAAmG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Other
intangible assets consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B6_zOKwaLRlcl2" style="display: none">SCHEDULE OF OTHER INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Gross Carrying Amount:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Know How</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowhowMember_zqboipEQbCYh" style="width: 14%; text-align: right" title="Gross Carrying Amount">3,170</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowhowMember_pn3n3" style="width: 14%; text-align: right" title="Gross Carrying Amount">2,991</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Customer relationships</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z7884oqAwQ25" style="text-align: right" title="Gross Carrying Amount">886</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Gross Carrying Amount">895</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Kyslecel Technology</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_pn3n3" style="text-align: right" title="Gross Carrying Amount">9,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_pn3n3" style="text-align: right" title="Gross Carrying Amount"><span style="-sec-ix-hidden: xdx2ixbrl1258">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">IPR&amp;D</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Carrying Amount">641</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross Carrying Amount"><span style="-sec-ix-hidden: xdx2ixbrl1262">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231_pn3n3" style="text-align: right" title="Gross Carrying Amount">14,037</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_c20191231_pn3n3" style="text-align: right" title="Gross Carrying Amount">3,886</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less &#8211; Accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_c20201231_zacFdX1Y6U27" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(1,014</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_c20191231_zDlaRNPO6mWb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(538</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net carrying amount of other intangible assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying amount of other intangible assets">13,023</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying amount of other intangible assets">3,348</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">SCHEDULE OF ESTIMATED AGGREGATE AMORTIZATION EXPENSES</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zbdoR2gR6af2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Estimated
aggregate amortization expenses for the five succeeding years ending on December 31<sup>st</sup> are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B2_zh9tGtGOqTY9" style="display: none">SCHEDULE OF ESTIMATED AGGREGATE AMORTIZATION EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 to 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Amortization expenses</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_c20201231_z73g2F3IBPG5" style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right" title="Amortization expenses, 2021">965</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive_iI_pn3n3_c20201231_zCHhoDKXPeGf" style="border-bottom: Black 1.5pt solid; width: 20%; text-align: right" title="Amortization expenses, 2022  to 2025">3,910</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676577257336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE LOANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">SCHEDULE OF LONG TERM CONVERTIBLE LOANS</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ConvertibleDebtTableTextBlock_zkusSwVXQFmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8B5_z8MbVmB5xC1k" style="display: none">SCHEDULE OF LONG TERM CONVERTIBLE LOANS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Long
    term convertible loans outstanding as of&#160;December 31, 2020 and December 31, 2019 are as follows:</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Principal</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Amount</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Issuance</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Year</p></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Interest</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Rate</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maturity Period</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>BCF</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b/></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">(in thousands)</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">(Years)</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="14" style="font-style: normal; font-weight: normal">Convertible Loans Outstanding as of <span style="font-style: normal; font-weight: normal">December
    31, 2020</span></td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zDFw3ZPfrvd7" style="width: 17%; text-align: right" title="Principal Amount">1,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td id="xdx_98A_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember" style="width: 16%; text-align: center" title="Issuance Year">2018</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zHPp0UkM80Yg" style="width: 16%; text-align: right" title="Interest Rate">2</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td id="xdx_987_eus-gaap--DebtInstrumentTerm_dtY_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zeg6ar17UK5g" style="width: 14%; text-align: right" title="Maturity Period">3</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_fKDEp_zb4zf47LSFJi" style="width: 14%; text-align: right" title="Exercise Price"><span style="font: 10pt Times New Roman, Times, Serif">7.00</span></td><td style="width: 1%; text-align: left">(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_pn3n3" style="width: 10%; text-align: right" title="BCF">71</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zDA1sBqe1EXi" style="text-align: right" title="Principal Amount">9,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_980_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember" style="text-align: center" title="Issuance Year">2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MinimumMember_zSPSlDj6sNgc" title="Interest Rate">6</span>%-<span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MaximumMember_z6yMje78exYf" title="Interest Rate">8</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MinimumMember_zV50gcduFWV4" title="Maturity Period">2</span>-<span id="xdx_906_eus-gaap--DebtInstrumentTerm_dtY_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MaximumMember_z7xBBiTsS0Nk" title="Maturity Period">5</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_fKDIp_z6v86nbfHkbe" style="text-align: right" title="Exercise Price"><span style="font: 10pt Times New Roman, Times, Serif">7.00</span></td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pn3n3" style="text-align: right" title="BCF"><span style="-sec-ix-hidden: xdx2ixbrl1314">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zyv1bKnywRHj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Principal Amount">250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td id="xdx_987_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember" style="padding-bottom: 1.5pt; text-align: center" title="Issuance Year">2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_z5xJOBpnNrOb" style="padding-bottom: 1.5pt; text-align: right" title="Interest Rate">8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td id="xdx_98A_eus-gaap--DebtInstrumentTerm_dtY_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zAxR13De8uzi" style="padding-bottom: 1.5pt; text-align: right" title="Maturity Period">2</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_fKDMp_zt8CAYylZ5w2" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Price"><span style="font: 10pt Times New Roman, Times, Serif">7.00</span></td><td style="padding-bottom: 1.5pt; text-align: left">(3)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_pn3n3" style="padding-bottom: 1.5pt; text-align: right" title="BCF"><span style="-sec-ix-hidden: xdx2ixbrl1326">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DebtInstrumentFaceAmount_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal Amount">10,750</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="18" style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Convertible
    Loans Outstanding as of </b><span style="font-style: normal; font-weight: normal">December 31, 2019</span></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_pn3n3" style="text-align: right" title="Principal Amount">1,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_989_ecustom--DebtInstrumentIssuanceYear_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember" style="text-align: center" title="Issuance Year">2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zle1KDDZKZqk" style="text-align: right" title="Interest Rate">2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td id="xdx_987_eus-gaap--DebtInstrumentTerm_dtY_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zYwCOa0umj1c" style="text-align: right" title="Maturity Period">3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_fKDEp_zxqPtxnJs8sb" style="text-align: right" title="Exercise Price"><span style="font: 10pt Times New Roman, Times, Serif">7.00</span></td><td id="xdx_F20_z1eDrS0SelJf" style="text-align: left">(1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn3n3_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zT8CBWNXlY6j" style="text-align: right" title="BCF">124</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal Amount">11,400</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td id="xdx_98E_ecustom--DebtInstrumentIssuanceYear_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember" style="padding-bottom: 2.5pt; text-align: center" title="Issuance Year">2019</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MinimumMember_zHMFCnuTzZxg" title="Interest Rate">6</span>%-<span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MaximumMember_zBK65LqIf8w" title="Interest Rate">8</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90D_eus-gaap--DebtInstrumentTerm_dtY_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MinimumMember_zyUY8X127l2h" title="Maturity Period">2</span>-<span id="xdx_90A_eus-gaap--DebtInstrumentTerm_dtY_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__srt--RangeAxis__srt--MaximumMember_zeuAtuVShXIf" title="Maturity Period">5</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_fKDIp_zx9JV7VEjKQ3" style="padding-bottom: 2.5pt; text-align: right" title="Exercise Price"><span style="font: 10pt Times New Roman, Times, Serif">7.00</span></td><td id="xdx_F2B_zfU9bW8ArPui" style="padding-bottom: 2.5pt; text-align: left">(2)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pn3n3" style="padding-bottom: 2.5pt; text-align: right" title="BCF"><span style="-sec-ix-hidden: xdx2ixbrl1356">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtInstrumentFaceAmount_c20191231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal Amount">12,900</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td colspan="18" style="text-align: left; font-weight: bold">Convertible Loans repaid during the year ended <span style="font-style: normal; font-weight: normal">December
    31, 2020</span></td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Principal</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Amount</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Issuance</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Year</p></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Interest</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Rate</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maturity Period</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>BCF</b></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 1%; text-align: center">&#160;</td><td id="xdx_984_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zIHKBs5PcDRf" style="width: 17%; text-align: right" title="Repaid, Principal Amount">500</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 1%">&#160;</td>
    <td id="xdx_98D_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zkow0ZZaa3H6" style="width: 16%; text-align: center" title="Issuance Year">2018</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td id="xdx_98C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zBotYCYosfuk" style="width: 16%; text-align: right" title="Interest Rate">2</td><td style="width: 1%; text-align: center">%</td><td style="text-align: center; width: 1%">&#160;</td>
    <td id="xdx_989_ecustom--DebtInstrumentRemainingTerm_dtM_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_z7cvCx8z5JW6" style="width: 14%; text-align: right" title="Repaid, Maturity Period">0.87</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">$</td><td id="xdx_987_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zK7dopUg33n6" style="width: 14%; text-align: right" title="Exercise Price">7</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td id="xdx_983_ecustom--DebtInstrumentConvertibleRepaidBeneficialConversionFeature_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--TwoPercentageConvertibleLoansTwoMember_zrQIEMx9Rx7k" style="width: 10%; text-align: right" title="Repaid, BCF">53</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td id="xdx_98D_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_zdo7o6rInVL6" style="text-align: right" title="Repaid, Principal Amount">500</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td id="xdx_980_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember" style="text-align: center" title="Issuance Year">2019</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_98A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_zaVwMTYQyCE2" style="text-align: right" title="Interest Rate">6</td><td style="text-align: center">%</td><td style="text-align: center">&#160;</td>
    <td id="xdx_986_ecustom--DebtInstrumentRemainingTerm_dtM_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_zvPfHqd4CFpe" style="text-align: right" title="Repaid, Maturity Period">0.28</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_zJcBzqlsDTrj" style="text-align: right" title="Exercise Price">7</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_986_ecustom--DebtInstrumentConvertibleRepaidBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--SixPercentageConvertibleLoansTwoMember_pn3n3" style="text-align: right" title="Repaid, BCF"><span style="-sec-ix-hidden: xdx2ixbrl1382">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td id="xdx_98B_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_zAKr0TKD3mxg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Repaid, Principal Amount">1,400</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td id="xdx_987_ecustom--DebtInstrumentIssuanceYear_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_zdeDPXfx1Bn2" style="padding-bottom: 1.5pt; text-align: center" title="Issuance Year">2019</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td id="xdx_986_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_zM9WocadbgL7" style="padding-bottom: 1.5pt; text-align: right" title="Interest Rate">8</td><td style="padding-bottom: 1.5pt; text-align: center">%</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td id="xdx_980_ecustom--DebtInstrumentRemainingTerm_dtMp_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_zibWRPZBRSmg" style="padding-bottom: 1.5pt; text-align: right" title="Repaid, Maturity Period">0.76</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td id="xdx_98E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_z6FdnJQRu7Dc" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Price">7</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td id="xdx_98D_ecustom--DebtInstrumentConvertibleRepaidBeneficialConversionFeature_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--EightPercetageConvertibleLoansTwoMember_pn3n3" style="padding-bottom: 1.5pt; text-align: right" title="Repaid, BCF"><span style="-sec-ix-hidden: xdx2ixbrl1394">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td id="xdx_981_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansMember_zRR7XZAJBEHa" style="text-align: right" title="Repaid, Principal Amount">2,400</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Apart
from the items mentioned below there were no repayments of convertible loans during the fiscal years ended December 31, 2019 and
December 31, 2020. In addition, there were no conversions during the fiscal years ended December 31, 2019 and December 31,
2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F08_zpSgWyVib4Qg" style="font: 10pt Times New Roman, Times, Serif">(1)</span></td><td style="text-align: justify"><span id="xdx_F12_zNRKLWCftCS9" style="font: 10pt Times New Roman, Times, Serif">The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_pii" title="Stock issued during period, conversion of convertible securities">148,838</span> shares
and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zfQ3X7ZtgEv7" title="Number of warrant may be converted">148,838</span> <span title="Warrants exercise, term"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_z2olYqVdp0gb" title="Warrants exercise, term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl1403">three-year</span></span></span> warrants to purchase up to an additional <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxws5Qrjrwp2" title="Number of warrant may be converted">148,838</span> shares of the Company&#8217;s common stock at a per share
exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zHp9sXQK5nwg" title="Warrants exercise price">7</span>. <span>In the initial two years, the holders have the right to convert the outstanding principal amount and accrued
interest into shares of capital stock of Hemogenyx-Cell or Immugenyx, LLC according under the relevant note agreement, subsidiaries
of Hemogenyx Pharmaceuticals Plc, at a price per share based on a pre-money valuation of Hemogenyx-Cell or Immugenyx, LLC of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_ecustom--PreMoneyValuation_iI_pn6n6_c20201231__dei--LegalEntityAxis__custom--HemogenyxCelMember_zkLtkIqsJWR" title="Pre-money valuation">12</span>
million and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_ecustom--PreMoneyValuation_iI_pn6n6_c20201231__dei--LegalEntityAxis__custom--ImmugenyxLLCMember_zqO6fr0KZyMe">8</span> million, respectively, pursuant to the collaboration agreement with Hemogenyx Pharmaceuticals Plc and Immugenyx,
LLC.</span> As of December 31, 2020, the loans are presented in current maturities of convertible notes in the balance sheet (See Notes
11(c) and 11(d).</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F0E_z5oVRsJ6GJOj" style="font: 10pt Times New Roman, Times, Serif">(2)</span></td><td style="text-align: justify"><span id="xdx_F15_zprCsjdBN534" style="font: 10pt Times New Roman, Times, Serif">The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pii" title="Stock issued during period, conversion of convertible securities">1,443,734</span> shares
and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pii" title="Number of warrant may be converted">1,053,503</span> <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zRDvnnKx88Ag" title="Warrants exercise, term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl1417">three-year</span></span> warrants to purchase up to an additional <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Number of warrant may be converted">1,053,503</span> shares of the Company&#8217;s common stock at a per
share exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pii" title="Warrants exercise price">7</span>. As of December 31, 2020, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--ConvertibleDebtCurrent_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zScnFXulvOp2" title="Current maturities of convertible loans">2,500</span> thousand of the principal amount is included in current maturities
of convertible loans in the balance sheet and the remainder in long-term convertible loans. See also Notes 7(b), 7(c), 7(e), 7(f)
and 7(g).</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F07_zKcMdD3eXmG9" style="width: 15pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td><td style="text-align: justify"><span id="xdx_F19_zABI8xDlieZ9" style="font: 10pt Times New Roman, Times, Serif">The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_pii" title="Stock issued during period, conversion of convertible securities">38,559</span> shares
at a per share exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zEMHD8sLnPdi" title="Warrants exercise price">7</span>. As of December 31, 2020, all the principal amount is included in long-term convertible loans
in the balance sheet See also Notes 7(h).</span></td>
</tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676575826536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisclosureLoansAbstract', window );"><strong>Loans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">SCHEDULE OF LOANS</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfDebtTableTextBlock_zAYEB7Q4VzU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Terms
of Short-term Loans</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_8BF_z8OljQQ2hCri" style="display: none">SCHEDULE OF LOANS</span></i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Currency</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Interest Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 42%; text-align: left">Short term loans</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center">KRW</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoanOneMember__srt--CurrencyAxis__currency--KRW_zIsn6CtImNi3" style="width: 12%; text-align: right" title="Interest Rate">3.61</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--DebtCurrent_iI_pn3n3_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoanOneMember__srt--CurrencyAxis__currency--KRW_z6t9YdpT77kf" style="width: 10%; text-align: right" title="Total loans"><span style="-sec-ix-hidden: xdx2ixbrl1630">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtCurrent_iI_pn3n3_c20191231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoanOneMember__srt--CurrencyAxis__currency--KRW_zNr3uHWNlib8" style="width: 10%; text-align: right" title="Total loans">260</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short term loans</td><td>&#160;</td>
    <td style="text-align: center">KRW</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansTwoMember__srt--CurrencyAxis__currency--KRW_zMC4UvRNnTJl" style="text-align: right" title="Interest Rate">6.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtCurrent_iI_pn3n3_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansTwoMember__srt--CurrencyAxis__currency--KRW_zgLnnldJsKOg" style="text-align: right" title="Total loans"><span style="-sec-ix-hidden: xdx2ixbrl1636">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--DebtCurrent_iI_pn3n3_c20191231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansTwoMember__srt--CurrencyAxis__currency--KRW_zL8Jg8cz0a31" style="text-align: right" title="Total loans">131</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short term loans</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">USD</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_uPercentage_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansThreeMember_zETCATVnI7qh" style="padding-bottom: 1.5pt; text-align: right" title="Interest Rate">1.00</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--DebtCurrent_iI_pn3n3_c20201231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansThreeMember_zsvIRslKMeI2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total loans">145</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--DebtCurrent_iI_pn3n3_c20191231__us-gaap--ExtinguishmentOfDebtAxis__custom--ShortTermLoansThreeMember_zrBmTvcLXsgg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total loans"><span style="-sec-ix-hidden: xdx2ixbrl1644">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DebtCurrent_iI_pn3n3_c20201231_zYcK5lHR21sh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total loans">145</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--DebtCurrent_iI_pn3n3_c20191231_ztWvQaA4gr9h" style="border-bottom: Black 2.5pt double; text-align: right" title="Total loans">391</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisclosureLoansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisclosureLoansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676570484760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock', window );">SCHEDULE OF LEASE-RELATED ASSETS AND LIABILITIES</a></td>
<td class="text"><p id="xdx_890_ecustom--LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock_z1FhRdiiGaR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
table below presents the lease-related assets and liabilities recorded on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8B0_zZdKgRAHa2p5" style="display: none">SCHEDULE OF LEASE-RELATED ASSETS AND LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Operating Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Operating lease right-of-use assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231_zqRWSm2h1JEc" style="width: 22%; text-align: right" title="Operating lease right-of-use assets">1,474</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property, plants and equipment, gross</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_iI_pn3n3_c20201231_zJOUqZ8y7xm8" style="text-align: right" title="Property, plants and equipment, gross">99</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_iNI_pn3n3_di_c20201231_zWnCpv4ev9o7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated depreciation">(17</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_iI_pn3n3_c20201231_zvbDrAEhCeBj" style="text-align: right" title="Property and equipment, net">82</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current maturities of operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20201231_zWljfSHKPXta" style="text-align: right" title="Current maturities of operating leases">485</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current maturities of long-term finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityCurrent_iI_pn3n3_c20201231_zYVkaOFfyVm9" style="text-align: right" title="Current maturities of long-term finance leases">19</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Long-term liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_zvKMPRRBlAfi" style="text-align: right" title="Non-current operating leases">1,020</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long-term finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_z5cnGBu7KYX4" style="text-align: right" title="Long-term finance leases">64</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Weighted Average Remaining Lease Term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Weighted Average Remaining Lease Term, Operating leases"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zqn7w1LZqLPc" title="Weighted Average Remaining Lease Term, Operating leases">3.4</span> years</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_90C_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zFXvyLnurfwl" title="Weighted Average Remaining Lease Term, Finance leases">4.2</span> years</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average Discount Rate</b></span></p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercentage_c20201231_zKy8r14AXkhk" title="Weighted Average Discount Rate, Operating leases">6.7</span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercentage_c20201231_zuyJmNY7djsb" style="text-align: right" title="Weighted Average Discount Rate, Finance leases">2.0</td><td style="text-align: left">%</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">SCHEDULE OF LEASE COSTS</a></td>
<td class="text"><p id="xdx_893_eus-gaap--LeaseCostTableTextBlock_z67WrxGKHnM5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
table below presents certain information related to lease costs and finance and operating leases during the year ended December
31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8BA_zuaKHrU7aoml" style="display: none">SCHEDULE OF LEASE COSTS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20200101__20201231_z0Sk6zz48Erk" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeaseCost_pn3n3_zexRgjt0MFr2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Operating lease cost:</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 18%; text-align: right">547</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Finance lease cost:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_pn3n3_maFLCzuMa_zmKVHsTFM7V3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amortization of leased assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--FinanceLeaseInterestExpense_pn3n3_maFLCzuMa_zbwkMID5of0e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Interest on lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_400_ecustom--FinanceLeaseCost_iT_pn3n3_mtFLCzuMa_zPKF1ljciKzb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total finance lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">SCHEDULE OF SUPPLEMENTAL CASHFLOW INFORMATION</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zJyqjoP69R92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
table below presents supplemental cash flow information related to leases during the year ended December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8B1_z4qX6smYrA7h" style="display: none">SCHEDULE OF SUPPLEMENTAL CASHFLOW INFORMATION</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20200101__20201231_zl3kxCon0LI8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>December 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in Thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid for amounts included in the measurement of leases liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--OperatingLeasePayments_pn3n3_zSuJywrS7kae" style="vertical-align: bottom; background-color: White">
    <td style="width: 78%; text-align: left">Operating leases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">515</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--FinanceLeaseInterestPaymentOnLiability_pn3n3_zfrprXkaNqL7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">42</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_zZZo1JoAWpwc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">967</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_pn3n3_zFFFu9SrcNN" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">366</td><td style="text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_LesseeLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF FINANCE LEASE LIABILITIES AND OPERATING LEASE LIABILITIES</a></td>
<td class="text"><p id="xdx_89C_ecustom--LesseeLeaseLiabilityMaturityTableTextBlock_zPoAow1Vgmpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining years to the finance
lease liabilities and operating lease liabilities recorded on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8B7_zOMZCS7jzl36" style="display: none">SCHEDULE OF FINANCE LEASE LIABILITIES AND OPERATING LEASE LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Operating</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Leases</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Finance<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; font-weight: bold">Year ended December 31,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20201231_z6tF4FvykiI8" style="width: 14%; text-align: right" title="Operating Leases, 2021">526</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20201231_zBaLYRgihj6" style="width: 14%; text-align: right" title="Finance Lease, 2021">20</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20201231_zg24sOWglx32" style="text-align: right" title="Operating Leases, 2022">528</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20201231_zTxAWvVV5xtb" style="text-align: right" title="Finance Lease, 2022">20</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20201231_zHETN0cgwm34" style="text-align: right" title="Operating Leases, 2023">342</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20201231_zq4qcR8EzRKh" style="text-align: right" title="Finance Lease, 2023">20</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20201231_zFeR4t2KR6h" style="text-align: right" title="Operating Leases, 2024">188</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20201231_zwNV9GhUi5K3" style="text-align: right" title="Finance Lease, 2024">20</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20201231_zsJhVL2uRgn7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, 2025">59</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20201231_zuz522hVdfpj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Lease, 2025">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total minimum lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3_c20201231_zBMnPMPIbkLk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Total minimum lease payments">1,643</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_pn3n3_c20201231_zC1UR28KG7Mk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Leases, Total minimum lease payments">84</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: amount of lease payments representing interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20201231_ztGz3nCYll8h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Less: amount of lease payments representing interest">(138</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20201231_zHT9XriD7Lrl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Lease, Less: amount of lease payments representing interest">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Present value of future minimum lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20201231_zuJcxwl9X6Rg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Present value of future minimum lease payments">1,505</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20201231_zsOll1AEozka" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Lease, Present value of future minimum lease payments">83</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Current leases obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_c20201231_znjuy2SLuqd1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Less: Current leases obligations">(485</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_pn3n3_di_c20201231_z95tzskdOep5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Lease, Less: Current leases obligations">(19</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Long-term leases obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_zgG7HPpfTkOe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating Leases, Long-term leases obligations">1,020</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_c20201231_zkdo2MEdckRc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finance Lease, Long-term leases obligations">64</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ScheduleOfRightofuseAssetsByGeographicalLocation', window );">SCHEDULE OF RIGHT-OF-USE ASSETS BY GEOGRAPHICAL LOCATION</a></td>
<td class="text"><p id="xdx_895_ecustom--ScheduleOfRightofuseAssetsByGeographicalLocation_zGSgBueRb6dk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Right-of-use
assets by geographical location were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span><span id="xdx_8B9_ziuqXQcrRCB3" style="display: none">SCHEDULE OF RIGHT-OF-USE ASSETS BY GEOGRAPHICAL LOCATION</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Korea</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--KR_zlXuLOn79WM6" style="width: 14%; text-align: right" title="Operating lease right-of-use assets">683</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--KR_zmzTrc2PUWRl" style="width: 14%; text-align: right" title="Operating lease right-of-use assets">145</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Israel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--IL_z19Lr1NnxPye" style="text-align: right" title="Operating lease right-of-use assets">496</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--IL_zcOn8zhaNaCb" style="text-align: right" title="Operating lease right-of-use assets">580</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">U.S.</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231__srt--StatementGeographicalAxis__country--US_z4mX8BUG13c9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating lease right-of-use assets">295</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20191231__srt--StatementGeographicalAxis__country--US_z76UwFBhrWG" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating lease right-of-use assets"><span style="-sec-ix-hidden: xdx2ixbrl1762">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20201231_zg2SXZvncJul" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use assets">1,474</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20191231_zhAh91WpnK6b" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use assets">725</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Lease-Related Assets and Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_LesseeLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Finance Lease Liabilities and Operating Lease Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_LesseeLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ScheduleOfRightofuseAssetsByGeographicalLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Right-of-use Assets by Geographical Location [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ScheduleOfRightofuseAssetsByGeographicalLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676576950376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS IN ASSOCIATES, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract', window );"><strong>Investments in and Advances to Affiliates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock', window );">SCHEDULE OF CHANGES IN INVESTMENTS</a></td>
<td class="text"><p id="xdx_898_eus-gaap--InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_zmRmGgVbBzQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-decoration: none">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">c.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    table below sets forth a summary of the changes in the investments for the year ended&#160;December 31, 2020:</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B6_z5jPxicOzBo6" style="display: none">SCHEDULE OF CHANGES IN INVESTMENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20200101__20201231_zCZPdhPHQcI2" style="font-weight: bold; text-align: center">December 30,</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(In thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--EquityMethodInvestments_iS_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Opening balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1988">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--PaymentsToAcquireEquityMethodInvestments_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="width: 71%; text-align: left">Investments during the period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 25%; text-align: right">69</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--IncomeLossFromEquityMethodInvestments_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Share in net income of associated companies</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">106</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--EquityMethodInvestments_iE_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Ending balance</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">175</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676573144632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ScheduleOfWarrantsActivity', window );">SCHEDULE OF WARRANTS ACTIVITY</a></td>
<td class="text"><p id="xdx_892_ecustom--ScheduleOfWarrantsActivity_zYqchtHnoERa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the Company&#8217;s warrants granted to investors and as finder&#8217;s fees as of December 31, 2020, and December
31, 2019 and changes for the periods then ended is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zM9rIJbKhFS7" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Warrants </b></span></p> </div></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p> </div></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Warrants </b></span></p> </div></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p> </div></td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Warrants </b>outstanding at the</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">beginning of the period</span></p></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pii_c20200101__20201231_zy7hqsLWzaWe" style="width: 14%; text-align: right" title="Number of Warrants - Warrants outstanding at the beginning of the period">6,010,087</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231_zFSaEvQVhSc5" style="width: 14%; text-align: right" title="Weighted Average Exercise Price - Warrants outstanding at the beginning of the period">6.35</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pii_c20190101__20191231_zQls2BU5AEg9" style="width: 14%; text-align: right" title="Number of Warrants - Warrants outstanding at the beginning of the period">6,286,351</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pii_c20190101__20191231_zgeuftkOQsZf" style="width: 14%; text-align: right" title="Weighted Average Exercise Price - Warrants outstanding at the beginning of the period">6.29</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes during the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231_pii" style="text-align: right" title="Number of Warrants - Issued">1,344,606</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_c20200101__20201231_pii" style="text-align: right" title="Weighted Average Exercise Price - Issued">5.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20190101__20191231_pii" style="text-align: right" title="Number of Warrants - Issued">471,980</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_c20190101__20191231_pii" style="text-align: right" title="Weighted Average Exercise Price - Issued">6.95</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pii_di_c20200101__20201231_zIeUTF8pAYnl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants - Expired">(284,452</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_c20200101__20201231_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price - Expired">6.53</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pii_di_c20190101__20191231_z2bpJ9Ke5kE9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants - Expired">(748,244</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_c20190101__20191231_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price - Expired">6.24</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><b>Warrants</b> outstanding and exercisable at end of the period*</td><td style="padding-bottom: 2.5pt"><span id="xdx_F45_zkzKE0sZlZCe" style="font: 10pt Times New Roman, Times, Serif; display: none">*</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pii_c20200101__20201231_fKg_____zR6NfaZmUFu3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants - Warrants outstanding and exercisable at the end of the period">7,070,241</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice_iE_pii_c20200101__20201231_fKg_____z8LdBEn42ePi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Warrants outstanding and exercisable at the end of the period">6.20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pii_c20190101__20191231_fKg_____zUMeCU4HGJp6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants - Warrants outstanding and exercisable at the end of the period">6,010,087</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice_iE_pii_c20190101__20191231_fKg_____zDnl7acqCJ1h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Warrants outstanding and exercisable at the end of the period">6.35</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td id="xdx_F03_zyyC5iZXAPy1" style="width: 1%">*</td>
    <td id="xdx_F12_zEo56LSDClG5">As
of December 31, 2020 and December 31, 2019, there are no warrants that are subject to exercise price adjustments.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ScheduleOfTreasuryShares', window );">SCHEDULE OF TREASURY SHARES</a></td>
<td class="text"><p id="xdx_89E_ecustom--ScheduleOfTreasuryShares_z9FHh3sxwB8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the Company&#8217;s treasury shares purchased as of December 31, 2020 and changes for the period then ended is presented
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BA_zE0KGUTQTGYi" style="display: none">S<span>CHEDULE
OF TREASURY SHARES</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Treasury Shares </b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price Paid</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Treasury Shares at the beginning of the period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--TreasuryStockShare_iS_pii_c20200101__20201231_zCALmNDnKKKf" style="text-align: right" title="Number of Treasury Shares at the beginning of the period"><span style="-sec-ix-hidden: xdx2ixbrl2064">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--WeightedAveragePriceNumberOfSharesTreasuryStock_iS_pii_c20200101__20201231_z5s3B29Wptf2" style="text-align: right" title="Weighted Average Price Paid Treasury Shares at the beginning of the period"><span style="-sec-ix-hidden: xdx2ixbrl2066">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes during the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 56%; padding-bottom: 1.5pt">Purchased</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--TreasuryStockSharesAcquired_c20200101__20201231_pii" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Number of Treasury Shares Purchased">55,309</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--WeightedAveragePriceNumberOfSharesTreasuryStockPurchased_c20200101__20201231_pii" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Weighted Average Price Paid Treasury Shares Purchased">4.47</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Shares at end of the period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_ecustom--TreasuryStockShare_iE_pii_c20200101__20201231_zX5xyPjyZQt9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Treasury Shares at end of the period">53,309</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_ecustom--WeightedAveragePriceNumberOfSharesTreasuryStock_iE_pii_c20200101__20201231_zNaro5lNGmN9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Price Paid Treasury Shares at end of the period">4.47</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ScheduleOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Treasury Shares [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ScheduleOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ScheduleOfWarrantsActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Warrants Activity [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ScheduleOfWarrantsActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676577384504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss (income) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zLfgzUn45W49" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth the calculation of basic and diluted loss per share for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B4_zW1mjJ0gKzSk" style="display: none">SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20200101__20201231_zWx4jwAIP616" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20190101__20191231_z79mK5xdaI01" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands, except per share data)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Basic and diluted:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net loss from continuing operations attributable to Orgenesis Inc.</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">95,088</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">22,490</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net (income) loss from discontinued operations attributable to Orgenesis Inc. for loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(96,198</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,631</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Adjustment of redeemable non-controlling interest to redemption amount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,160</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zL6pxqPyyqvd" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif">Basic: Net income (loss) available to common stockholders</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(101,358</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,726</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--NetIncomeLossToParentCompany_zFQJa5eUc912" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net (income) loss attributable to Orgenesis Inc. for loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,270</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,216</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i_pii" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Weighted average number of common shares outstanding</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,320,314</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,907,995</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pii_zUMbTmX4h8l1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss per common share from continuing operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4.46</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.41</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_pii_zcRAfqAQwP8e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net (income) loss common share from discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4.75</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.36</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--EarningsPerShareBasic_pii_uUSDPShares_zEEhZlScEMna" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Net (income) loss per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.29</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.77</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676577263048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock', window );">SCHEDULE OF EMPLOYEE STOCK OWNERSHIP PLAN DISCLOSURES</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZpsYXnnwH74" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Below
is a table summarizing all of the options grants to employees and Directors made during the years ended December 31, 2020, and
December 31, 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8BE_z2wZ5VoapHK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE
OF EMPLOYEE STOCK OWNERSHIP PLAN DISCLOSURES<span style="font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of options <br/> granted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Vesting period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Fair value at grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>(in thousands)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Expiration <br/> period</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%; text-align: center">Employees</td><td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: center">December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zK84ovmWCrVj" style="width: 10%; text-align: right">531,450</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">$<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember__srt--RangeAxis__srt--MinimumMember_zjlMlT6Y8Hp3" title="Exercise price">2.99</span>-$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember__srt--RangeAxis__srt--MaximumMember_z2N5Xc2nwZHd">6.84</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 28%; text-align: center">Quarterly over a period of <span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zOHsvZG0LJx4" title="Stock options vesting period description">two years</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_znd3sUJFCZqi" style="width: 12%; text-align: right" title="Fair value at grant">1,312</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zbvht2A920S9">10</span> years</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Directors</td><td>&#160;</td>
    <td style="text-align: center">December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zK3VPNSsvJ0f" style="text-align: right">145,050</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">$<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember__srt--RangeAxis__srt--MinimumMember_z5KfV2P0CSb" title="Exercise price">2.99</span>-$<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember__srt--RangeAxis__srt--MaximumMember_zUuysBuwVFX8">4.7</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90C_ecustom--StockOptionsGrantVestingPeriodPercentage_pii_dp_uPercentage_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--StatementScenarioAxis__custom--OneYearAnniversaryMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z6PmhEs4a4td">96</span>%
on the one-year anniversary, <span>and
the remaining </span><span id="xdx_902_ecustom--StockOptionsGrantVestingPeriodPercentage_pii_dp_uPercentage_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--StatementScenarioAxis__custom--ThreeEqualInstallmentsMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z5aJKhTktsA3">4</span><span>%
in three equal instalments on the first, second and third year anniversaries</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zAUSql0z2lgg" style="text-align: right" title="Fair value at grant">377</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z9CKhxzGeRSa">10</span> years</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Employees</td><td>&#160;</td>
    <td style="text-align: center">December 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zi9F5VeJtsja" style="text-align: right" title="No. of options granted">94,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zE36mXHDmjW4" title="Exercise price">3.14</span>-$<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zXVuc9s05iJh" title="Exercise price">5.07</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Quarterly over a period of <span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zIYrSjtXl9m9" title="Stock options vesting period description">two years</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zFxHlKP0XU9a" style="text-align: right" title="Fair value at grant">322</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z78KDbNzJeK6" title="Expiration period">10</span> years</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Directors</td><td>&#160;</td>
    <td style="text-align: center">December 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zVqCz3kgOwPk" style="text-align: right" title="No. of options granted">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zZyCgN1R4yXh" style="text-align: right" title="Exercise price">2.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zjOfThQtSbe6">One-year</span> anniversary</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zQJe3aZ6xA1i" style="text-align: right" title="Fair value at grant">103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zNiZVk9vlFY6" title="Expiration period">10</span> years</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zarrDrkXzyxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The fair value of each
option grant is based on the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8BB_zu5YXeodfKUg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify">SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value of one common share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zxAkFRvFYom7" title="Value of one common share">2.99</span>-$<span id="xdx_905_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z1eFWEp56oF4" title="Value of one common share">6.84</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zG7neHReUXf4" title="Value of one common share">2.99</span>-$<span id="xdx_90E_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zQ5y9tjhJhr2" title="Value of one common share">5.07</span></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">Dividend yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_uPercentage_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zReH2dtA3zh4" style="width: 18%; text-align: right">0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_uPercentage_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZebSolkkqrl" style="width: 18%; text-align: right" title="Dividend yield">0</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected stock price volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zsS5PwD0W1D7">80</span>%-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zYePs3g60htc">86</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zNar8RrjmwB8" title="Expected stock price volatility">83</span>%-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zEDf0maq53rk" title="Expected stock price volatility">88</span></span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zOy9G7xKVGLf">0.36</span>%-<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zYye4pMhEvIe">1.71</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zLyjUsMQiYx4" title="Risk free interest rate">1.45</span>%-<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zjDBWHGiJmW1" title="Risk free interest rate">2.47</span></span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_ze3gE7h0Rb49">5.50</span>-<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zW6K9Y35RD4k">6.00</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zKAv9fglXGY2" title="Expected term (years)">5.38</span>-<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zleGTKeRrgcj" title="Expected term (years)">5.56</span></span></td><td style="text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTIONS ACTIVITY</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zS3l2Iqv4Uv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the Company&#8217;s stock options granted to employees and directors as of December 31, 2020 and December 31, 2019
is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8BD_zoETxj5WpTca" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify">SCHEDULE OF STOCK OPTIONS ACTIVITY<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify">Options outstanding at the beginning of the period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pp0i_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zS0jFjN6KED9" style="width: 14%; text-align: right" title="Number of Options - Options outstanding at the beginning of the year">2,465,522</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z66PjItUwiM7" style="width: 14%; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the beginning of the year">4.44</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z1XpzuJYcAm4" style="width: 14%; text-align: right" title="Number of Options - Options outstanding at the beginning of the year">2,376,427</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zwin3PHg5uH5" style="width: 14%; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the beginning of the year">4.51</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes during the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" style="text-align: right" title="Number of Options - Granted">676,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" style="text-align: right" title="Weighted Average Exercise Price - Granted">3.74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zpPLI0D0IsI7" style="text-align: right" title="Number of Options - Granted">144,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zXaY3QgzSlJd" style="text-align: right" title="Weighted Average Exercise Price - Granted">4.15</td><td style="text-align: left">&#160;</td></tr>
<tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zkbmQpBqp9b8" style="text-align: right" title="Number of Options - Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2221">-</span></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zKYCsHeYQgBf" style="text-align: right" title="Weighted Average Exercise Price - Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2223">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_ztjVax01M9gf" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2224">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zi0koaWyMNhj" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2225">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zcE59Ue5eEM1" style="text-align: right" title="Number of Options - Expired">(11,876</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" style="text-align: right" title="Weighted Average Exercise Price - Expired">7.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zsvXWdYt2eEh" style="text-align: right" title="Number of Options - Expired">(16,750</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zOgPNHGEJ0pc" style="text-align: right" title="Weighted Average Exercise Price - Expired">6.01</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zx0am2zNCkf6" style="text-align: right" title="Number of Options - Forfeited">(57,042</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" style="text-align: right" title="Weighted Average Exercise Price - Forfeited">4.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zBs5z1ppkm2d" style="text-align: right" title="Number of Options - Forfeited">(38,655</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zL30qNRjUlL" style="text-align: right" title="Weighted Average Exercise Price - Forfeited">7.11</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zK1f3mUQl6Cc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options - Cancelled">(155,437</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price - Cancelled">8.38</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zHUFGhJj1qua" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options - Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl2247">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zyudtFueAWS" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price - Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl2249">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Options outstanding at end of the period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z024hYqGeUMe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options outstanding at the end of the year">2,917,667</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zFoCUILK0Q8c" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the end of the year">4.05</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zKrFiK6LLwvg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options outstanding at the end of the year">2,465,522</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zyCEU8TRgmZi" style="border-bottom: Black 2.5pt double; text-align: right">4.44</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Options exercisable at end of the period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pp0i_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZ2pJpCKwoxc" style="border-bottom: Black 2.5pt double; text-align: right">2,299,937</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zpUpqlzns8x4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options exercisable at end of the year">4.03</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZ0SvcxgDS9g" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options exercisable at end of the year">2,112,567</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zK7aIyGVpPbc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options exercisable at end of the year">4.21</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">SCHEDULE OF STOCK OPTIONS EXERCISABLE</a></td>
<td class="text"><p id="xdx_892_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zxdA6Hu4y6M3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table presents summary information concerning the options granted and exercisable to employees and directors outstanding
as of December 31, 2020 (in thousands, except per share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8B5_z4X3q6LgMLN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify">SCHEDULE OF STOCK OPTIONS EXERCISABLE<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Life</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Value $</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(in thousands)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zGEALbelDWwh" style="width: 13%; text-align: right" title="Exercise Price">0.0012</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z6TqKbUflO2j" style="width: 13%; text-align: right" title="Number of Outstanding Options">230,189</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zuf78fMwa3f5" style="width: 13%; text-align: right" title="Weighted Average Remaining Contractual Life">3.64</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zY4WOMnLvNb6" style="width: 13%; text-align: right" title="Aggregate Intrinsic Value">1,036</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zAWBgIjsGEXb" style="width: 13%; text-align: right" title="Number of Exercisable Options">230,189</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_d0_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z0iITGcIcg7i" style="width: 13%; text-align: right" title="Aggregate Exercisable Options Value">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zsnXse1mShx5" style="text-align: right" title="Exercise Price">0.012</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zYWnvvAxbePf" style="text-align: right" title="Number of Outstanding Options">510,017</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zgtr2LszQ8T" style="text-align: right">1.09</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z7pAURfpw0B5" style="text-align: right" title="Aggregate Intrinsic Value">2,289</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zosR9KYJuJl9" style="text-align: right" title="Number of Exercisable Options">510,017</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z2evfla7Qt4" style="text-align: right" title="Aggregate Exercisable Options Value">6</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z8lU7wP9IYhf" style="text-align: right">2.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zZe7CuN7ybP6" style="text-align: right" title="Number of Outstanding Options">445,013</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zLhTnNHFK0j" style="text-align: right">9.15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zwDNvdMzi6s2" style="text-align: right">672</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zNIKw2DIiwW6" style="text-align: right">174,208</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z1TXSnL3ru7k" style="text-align: right">521</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zziuggCyAbF3" style="text-align: right">3.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zXpaNqHvtX13" style="text-align: right" title="Number of Outstanding Options">3,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvuZtvKy57B3" style="text-align: right">6.27</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zE3q69EIIDYc" style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zSICuphcB5Ug" style="text-align: right">1,875</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zAxaQYg9prC5" style="text-align: right">6</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zzgKfDknX7re" style="text-align: right">4.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zHDBhdy1z2e8" style="text-align: right" title="Number of Outstanding Options">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zz9bcZ1HDAA" style="text-align: right">6.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zAfiKgfooTsa" style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zbM0gX99XZy7" style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTCxm0HfXDb9" style="text-align: right">221</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zua5M9f5Kwjc" style="text-align: right">4.5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zbIxZC0xCdFb" style="text-align: right" title="Number of Outstanding Options">34,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJJhg7ViLdEk" style="text-align: right">8.47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zxPzOGqt9tAf" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2314">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zKYpcnIP3CA2" style="text-align: right">23,938</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zuR3G4xzwGo8" style="text-align: right">108</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zrtz3nBOVSl4" style="text-align: right">4.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zi1Jq9uNwzg5" style="text-align: right" title="Number of Outstanding Options">185,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zNdSHSEvJXUh" style="text-align: right">9.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zqwyKX6tAvol" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2321">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zaB4oP2vrV6i" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2322">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_z3KEJ7E6TB4g" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2323">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zGoq2SXn28Vj" style="text-align: right">4.7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pp0i_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zTtdkdMRF9D5" style="text-align: right" title="Number of Outstanding Options">6,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zSVe3QPTBTk9" style="text-align: right">9.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zB5WBQL6dIUl" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2328">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z8M4560m5oEb" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2329">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z54JqtlcFFnd" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2330">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zaXCRz6LmYI9" style="text-align: right">4.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zByoI54r79j6" style="text-align: right" title="Number of Outstanding Options">483,337</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zX6XYi0wSKS2" style="text-align: right">5.94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z1RW0WBc41G6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2335">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zLUJ1ygYDy8i" style="text-align: right">483,337</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zhXjTw0gsvgl" style="text-align: right">2,320</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zfFNf1Lmh8yf" style="text-align: right">5.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zMF2XZBxa3jl" style="text-align: right" title="Number of Outstanding Options">53,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zzonyXwmtLAe" style="text-align: right">8.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zZ5sgYFnjkY" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2342">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zBTf2tpIvD94" style="text-align: right">39,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zU7QOoLUpS2a" style="text-align: right">202</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z6jBUGwNk8v6" style="text-align: right">5.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zBZdet3rU6Yh" style="text-align: right" title="Number of Outstanding Options">63,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zRHJmugJkFck" style="text-align: right">9.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zhXZzATa9Ss8" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2349">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zHilCuwxGo84" style="text-align: right">7,875</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zcodATh9AaOk" style="text-align: right">40</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z86G3JEOVNr9" style="text-align: right">5.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zwNp4pEw8fQ2" style="text-align: right" title="Number of Outstanding Options">352,550</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zfHNOptExar2" style="text-align: right">7.26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zA1mWFNXcNJ6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2356">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zP1LLSF4Mtuc" style="text-align: right">290,488</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zMpNwJzHG4Gd" style="text-align: right">1,740</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zuUYwnC0X5fa" style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zVwS6ErCiyTa" style="text-align: right" title="Number of Outstanding Options">16,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zSyQu6yR305h" style="text-align: right">3.59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z9tAjFEecGda" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2363">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zlZ9fmmDFEIc" style="text-align: right">16,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z39Brmi8we8l" style="text-align: right">100</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zv7NHJLAmtw8" style="text-align: right">6.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zVulO9w8euh5" style="text-align: right" title="Number of Outstanding Options">17,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z8RNlxcC2W1i" style="text-align: right">9.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zKnH7yGsrxn9" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2370">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zmIYUBzMpcYd" style="text-align: right">4,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zqlLmFqB3qi2" style="text-align: right">29</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zw8ubJhwHO17" style="text-align: right">7.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zONbllM7nOLc" style="text-align: right" title="Number of Outstanding Options">83,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zFDNG2zRevn7" style="text-align: right">6.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_znOihXEN96jl" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2377">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zBumwNDfbY28" style="text-align: right">83,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zj1GmtxQcMYc" style="text-align: right">600</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zyrN5fuMbMU2" style="text-align: right">8.36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zAcZWJKzTXu" style="text-align: right" title="Number of Outstanding Options">250,001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zDILxQGP3fzd" style="text-align: right">7.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_ztmamPyTtELk" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2384">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zsXyj2NXlY1i" style="text-align: right">250,001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zpJuHxdUimm6" style="text-align: right">2,090</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_z76gvrXQeJdf" style="text-align: right">8.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zDhBuuQ0yyL8" style="text-align: right" title="Number of Outstanding Options">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_z74nX1crcePc" style="text-align: right">7.46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_z7RM1Jq3y8Ah" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2391">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zXjHdoUuI6sd" style="text-align: right">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zQ3jAXaGiuv" style="text-align: right">134</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_z79o78OrNJ36" style="text-align: right">9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zfO8tkwF6Zn" style="text-align: right" title="Number of Outstanding Options">20,834</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_ztIvFWPvSzhi" style="text-align: right">2.54</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zvOuCFgoJyLe" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2398">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zUwzO0SsLsCi" style="text-align: right">20,834</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zm81PGWFTiC5" style="text-align: right">187</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zLDbWwX6rgF8" style="text-align: right">9.48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_z0aoY4XPQdl9" style="text-align: right" title="Number of Outstanding Options">58,908</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zzp1y3zqife6" style="text-align: right">1.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zNV3bqMD055k" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2405">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zOL8AZY6jqni" style="text-align: right">58,908</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zma966NkxPvl" style="text-align: right">558</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zGbmSBYIOg61" style="padding-bottom: 1.5pt; text-align: right">10.2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zgzKvQiMO9w6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Outstanding Options">39,267</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_z0i0XGzTN3O6" style="border-bottom: Black 1.5pt solid; text-align: right">1.42</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zgRRK1mvqLH2" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2412">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zbdB8XmT3Tx3" style="border-bottom: Black 1.5pt solid; text-align: right">39,267</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zbyxob0ZdTu4" style="border-bottom: Black 1.5pt solid; text-align: right">401</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zsDbzHu4diyh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding Options">2,917,667</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zx7nbitDplPd" style="border-bottom: Black 2.5pt double; text-align: right">5.98</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zdZNhbLeERj6" style="border-bottom: Black 2.5pt double; text-align: right">4,006</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z6RenwmsaOAi" style="border-bottom: Black 2.5pt double; text-align: right">2,299,937</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_ztKD6Ozzb14f" style="border-bottom: Black 2.5pt double; text-align: right">9,263</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zcIP9njEhfD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The underlying data used for computing
the fair value of the options are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8B0_zJxkjABIydHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify">SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value of one common share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_907_eus-gaap--SharePrice_iI_pii_c20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zJVigMTWX45k" title="Value of one common share">2.99</span>-$<span id="xdx_90A_eus-gaap--SharePrice_iI_pii_c20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zpRisG2jihca" title="Value of one common share">6.84</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharePrice_iI_pii_c20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z4CFsUrPPvgd" title="Value of one common share">3.14</span>-$<span id="xdx_908_eus-gaap--SharePrice_iI_pii_uUSDPShares_c20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z7Q6Fqa6nU5j" title="Value of one common share">5.07</span></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">Dividend yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_uPercentage_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zCGG4SGYztWj" style="width: 18%; text-align: right">0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_uPercentage_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zIlUev5sQYfi" style="width: 18%; text-align: right" title="Dividend yield">0</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected stock price volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zEEBmNX0ugFa">86</span>%-<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zzpOwg9Ve8De">89</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zqbMIBHnVT39" title="Expected stock price volatility">89</span>%-<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zrpQJcpmFPL" title="Expected stock price volatility">92</span></span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zhYmeOySrEn9">0.73</span>%-<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zKnvypQfvKO4">1.12</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z4OaZ4mRlzf9" title="Risk free interest rate">1.52</span>%-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_uPercentage_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z3gtBPyAed2" title="Risk free interest rate">2.62</span></span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zvBH53H5zF08">10</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zzioggVFdog1" title="Expected term (years)">10</span></td><td style="text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTIONS ACTIVITY</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zbftw2pPvn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the Company&#8217;s stock options granted to consultants and service providers as of December 31, 2020, and December
31, 2019 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8BC_z5scIwsT27yf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify">SCHEDULE OF STOCK OPTIONS ACTIVITY<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><div style="font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt; margin-top: 0; margin-bottom: 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p> </div></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify">Options outstanding at the <br/>beginning of the year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zMWWzXlkuf8b" style="width: 12%; text-align: right">598,310</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zMYVJ1dtg8vj" style="width: 12%; text-align: right">5.76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zQmxTi4o8My7" style="width: 12%; text-align: right" title="Number of Options - Options outstanding at the end of the year">469,974</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zLPGxTYap2vd" style="width: 12%; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the end of the year">5.75</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes during the year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zsacUEIZps54" style="text-align: right">62,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z4m6jLMYhn81" style="text-align: right">3.97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zjo8psJ0w978" style="text-align: right" title="Number of Options - Granted">128,336</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zD3WK7ymPaak" style="text-align: right" title="Weighted Average Exercise Price - Granted">5.65</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zFGF3564i5qi" style="text-align: right" title="Number of Options - Exercised">(83,334</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zz9Bi03JMrgg" style="text-align: right" title="Weighted Average Exercise Price - Exercised">3.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zhSTkn5jm4vg" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2494">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zrhFkiUYRuvl" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2495">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zwKkzH5fQzUl" style="text-align: right">(8,335</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_ziOnnSoUSsUd" style="text-align: right">5.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zEmJt048ziR4" style="text-align: right" title="Number of Options - Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2499">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zDuFasT03jK" style="text-align: right" title="Weighted Average Exercise Price - Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2501">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zsYlJ5gHpanj" style="border-bottom: Black 1.5pt solid; text-align: right">(20,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_ziXt3pWgbXe5" style="border-bottom: Black 1.5pt solid; text-align: right">5.30</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zbuZYe0hVNbb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options - Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl2505">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zBmtnPDCceha" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price - Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl2507">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Options outstanding at end of the year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zDPWZoMW9KL1" style="border-bottom: Black 2.5pt double; text-align: right">549,141</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zBAZt4xBqfrl" style="border-bottom: Black 2.5pt double; text-align: right">5.89</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zL0TkJctr6g4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options outstanding at the end of the year">598,310</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z5X4sq1uxk27" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the end of the year">5.76</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Options exercisable at end of the year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zxZ8ISpM5Qkj" style="border-bottom: Black 2.5pt double; text-align: right">450,972</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zdHwM1ea4Ft1" style="border-bottom: Black 2.5pt double; text-align: right">6.28</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zO82XaWp8604" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options exercisable at end of the year">539,515</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zCtk9ECpLhS3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options exercisable at end of the year">5.88</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">SCHEDULE OF STOCK OPTIONS EXERCISABLE</a></td>
<td class="text"><p id="xdx_897_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zldnSpYcVwvi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table presents summary information concerning the options granted and exercisable to consultants and service providers
outstanding as of December 31, 2020 (in thousands, except per share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8B1_zvQLz8p6E7L2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify">SCHEDULE OF STOCK OPTIONS EXERCISABLE</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Life</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Intrinsic</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Value*</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Value $</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(in thousands)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zjm9KeYw0zgf" style="width: 13%; text-align: right" title="Exercise Price">2.99</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zFsNJSwDApWg" style="width: 13%; text-align: right" title="Number of Outstanding Options">35,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zq3ZDJf4kH2" style="width: 13%; text-align: right" title="Weighted Average Remaining Contractual Life">9.22</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zpIV6M23tDhk" style="width: 13%; text-align: right" title="Aggregate Intrinsic Value">53</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zonnfsenO1Ad" style="width: 13%; text-align: right" title="Number of Exercisable Options"><span style="-sec-ix-hidden: xdx2ixbrl2531">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zvZhiXuQEK13" style="width: 13%; text-align: right" title="Aggregate Exercisable Options Value"><span style="-sec-ix-hidden: xdx2ixbrl2533">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zoWEcxO26Xr2" style="text-align: right">3.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z3K4Q79OQqbg" style="text-align: right" title="Number of Outstanding Options">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zVNabox3ktg7" style="text-align: right">8.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z9j6eSh0jVIa" style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zxoEyxXqf6yg" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2539">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zaSf0MMFK0hi" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2540">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zktbC9NK4TW6" style="text-align: right">3.36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zCMVcnDHKi9f" style="text-align: right" title="Number of Outstanding Options">136,775</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zmtPk5bUnJpd" style="text-align: right">5.32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zn0bDOAAafo4" style="text-align: right">156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zIIhm7y6zio7" style="text-align: right">136,775</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zFHyytHLrxG4" style="text-align: right">460</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zOxNEUsbX702" style="text-align: right">4.09</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zgTFDIoUL233" style="text-align: right" title="Number of Outstanding Options">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zNJ3aWMz8Xl7" style="text-align: right">8.76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zeEVsV31T7f3" style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zFOYn8Ir6nej" style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbZxy4FxBHnf" style="text-align: right">102</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zWeNDczB3e78" style="text-align: right">4.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zeQON0tYgVP6" style="text-align: right" title="Number of Outstanding Options">10,325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zdbqxxK1uYqg" style="text-align: right">6.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zSqHe0Ao7EQd" style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zR2WFvpSqTpl" style="text-align: right">10,325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zhm9J98AUeX2" style="text-align: right">46</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zkcADpZSds4k" style="text-align: right">4.5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zd5lv0i429O5" style="text-align: right" title="Number of Outstanding Options">13,335</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJSz7E0E76ob" style="text-align: right">8.53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zBooPwUqqhOg" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2566">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zeeWGjZPl6y1" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2567">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_znd3nMZECIQ4" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2568">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zrP3TyPWJbJk" style="text-align: right">4.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zi0nUliJ5sgk" style="text-align: right" title="Number of Outstanding Options">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zJs5hiyQ5Q2f" style="text-align: right">9.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zHHcqEqVmkIg" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2573">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zkzM1mNSEw66" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2574">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zVqIafo7IUal" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2575">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zaieSMzFpVql" style="text-align: right">4.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zurwOxk9DNCl" style="text-align: right" title="Number of Outstanding Options">16,668</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zbWd7Mk8IIWj" style="text-align: right">5.94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zSN3DyjkCwC8" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2580">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z9RaK704MHoj" style="text-align: right">16,668</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zY2FbABfI1Vg" style="text-align: right">80</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zEg461Ebhqr5" style="text-align: right">5.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_ztlx2ItVxahe" style="text-align: right" title="Number of Outstanding Options">5,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zO104xrrhPwg" style="text-align: right">8.19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z1rZAmEh70Lk" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2587">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zI6fMwT3gUIf" style="text-align: right">1,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zjw3S2bpxcR" style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zNrlRTalEVHj" style="text-align: right">5.3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zvkzRwm5Bruj" style="text-align: right" title="Number of Outstanding Options">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zAbI3yY5QC2e" style="text-align: right">7.70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zEnyWF57eaU9" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2594">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z4Kpm9VUq672" style="text-align: right">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zVwvRKv5DJ3d" style="text-align: right">80</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zgWb0dUriad6" style="text-align: right">5.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z1ji04xSMPxl" style="text-align: right" title="Number of Outstanding Options">16,670</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z3axaAYQ4rx8" style="text-align: right">7.81</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_znaPAL9XofZ" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2601">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zxJraIVcjY8k" style="text-align: right">16,670</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zgI0vgGH2Y77" style="text-align: right">100</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zZPMsU8ReXG1" style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zqO7LylWwdV4" style="text-align: right" title="Number of Outstanding Options">90,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_ze9lgJeZooXc" style="text-align: right">3.59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zs0u9hDogXC" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2608">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zv9YQJLUgJmd" style="text-align: right">90,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zcF8hGPpjWG1" style="text-align: right">540</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zsQhIelhGvsf" style="text-align: right">6.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zAiTLyxIz4zb" style="text-align: right" title="Number of Outstanding Options">7,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zjP14kh3Zcs" style="text-align: right">9.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z7xRGhD5QDO5" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2615">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zqZETXPG2fUj" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2616">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z52vcHID7zy1" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2617">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z8BknISK8yNa" style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zlGerKsKT0Kb" style="text-align: right" title="Number of Outstanding Options">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z82nupvXIEC9" style="text-align: right">8.83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z7Qs3uB9N123" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2622">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zi3znQaa68cd" style="text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zftRam9AvoSb" style="text-align: right">490</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zw4q5x4zBfXa" style="text-align: right">7.32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z4zo18qwcyS6" style="text-align: right" title="Number of Outstanding Options">8,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z6B57Re75uD2" style="text-align: right">1.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z4NJZnHEe9W4" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2629">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zJFfvXx4XJCh" style="text-align: right">8,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zGdeGtxb7y5e" style="text-align: right">61</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_z0Ic6KJ8XcU8" style="text-align: right">8.34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zeNExxZhoBk6" style="text-align: right" title="Number of Outstanding Options">8,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zJY5o9pyAd51" style="text-align: right">7.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_z31WZzfFzHle" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2636">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zDb2jKC1BLPa" style="text-align: right">8,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zLz7ySnhSeEa" style="text-align: right">72</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zfaV4M7ePToa" style="text-align: right">8.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_znuZvBMVskeg" style="text-align: right" title="Number of Outstanding Options">8,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zgFzWN7WAT8e" style="text-align: right">7.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zp69PYYZoIUh" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2643">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zc90HE6kBMUg" style="text-align: right">4,999</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zg0koyS616p4" style="text-align: right">42</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zttaeVMJ2mmc" style="text-align: right">11.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_z6ojrK2VDqe" style="text-align: right" title="Number of Outstanding Options">8,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zrmW1ph8Acba" style="text-align: right">2.26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zBIQUnU5xsl" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2650">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zIgegUeSGUC" style="text-align: right">8,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_z2cgXQaWRDM" style="text-align: right">96</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zmFRHLn4lQU8" style="padding-bottom: 1.5pt; text-align: right">16.8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zpWfNgNoTnra" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Outstanding Options">39,267</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zpcmqwo8y4k4" style="border-bottom: Black 1.5pt solid; text-align: right">1.28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zAjvcELcwlfa" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2657">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zYAWvkc5Qpv8" style="border-bottom: Black 1.5pt solid; text-align: right">39,267</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zvMnWacbflx2" style="border-bottom: Black 1.5pt solid; text-align: right">660</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zXPtMpBpMvO4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding Options">549,141</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z4hKvDKamxN2" style="border-bottom: Black 2.5pt double; text-align: right">6.18</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z7jEda9Q4WG8" style="border-bottom: Black 2.5pt double; text-align: right">240</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zJN4C00E9KHf" style="border-bottom: Black 2.5pt double; text-align: right">450,972</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zAMCvEmSYO3" style="border-bottom: Black 2.5pt double; text-align: right">2,834</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTIONS GRANTED TO CONSULTANTS</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zrZwCVhUAEB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Below
is a table summarizing all the compensation granted to consultants and service providers during the years ended December 31, 2020
and December 31, 2019 and for the one-month period ended December 31, 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8BE_zyaIvRYNcubb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none; text-align: justify">SCHEDULE OF STOCK OPTIONS GRANTED TO CONSULTANTS<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><br/>Year
    of grant</b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><br/>No.
    of options <br/> granted</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><br/>Exercise
    price</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Vesting period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Fair
                                         value at grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(in
                                         thousands)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"><b><br/>Expiration
    <br/> period</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 8%; text-align: center">Non-employees <br/></td><td style="width: 2%">&#160;</td>
    <td style="width: 8%; text-align: center">2020 <br/></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zq9DlXJrIeng" style="width: 6%; text-align: right">62,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zanjnW2R8tDb">2.99</span>-$<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z725VBpqLdzi">6.84</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 30%; text-align: center">Quarterly over a period of <span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zgFWgaOCBvi" title="Vesting peirod description">two</span> years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pp0p0_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z3QNkvR0SEUh" style="width: 14%; text-align: right">209</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 10%; text-align: center"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20200101__20201231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zStftzty8WEh">10</span> years</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Non-employees <br/></td><td>&#160;</td>
    <td style="text-align: center">2019 <br/></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pii_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_ztq9TlnZkUz1" style="text-align: right" title="No. of options granted">128,336</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z7jIjxUbX6rj" title="Exercise price">3.14</span>-$<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20190101__20191231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zfRWQwgfkdrg" title="Exercise price">7</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Vest immediately-<span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zJCsrnJgG7mi" title="Vesting period">5</span> years</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pp0p0_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zyvsGmIXHucc" style="text-align: right" title="Fair value at grant">394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20190101__20191231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zklPJev0kWDb" title="Expiration period">10</span> years</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the details pertaining to each employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676573629704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF DEFERRED TAX ASSETS</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zeqE89lKRzJ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table presents summary of information concerning the Company&#8217;s deferred taxes as of the years ending December
31, 2019 and December 31, 2019 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B1_z766Or12sSuc" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20201231_zXZFQuv0fVj3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20191231_zDgTmK3N8vic" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(U.S. dollars in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_msDTLztYm_zgBPVCDGywNa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Net operating loss carry forwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">9,606</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">14,033</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_msDTLztYm_zCrXy6rt04M4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,684</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,358</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_msDTLztYm_zTg18Jn9qUm6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity compensation </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,747</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl2841">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_iI_pn3n3_msDTLztYm_zXn3SAkGPgU6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Employee benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">228</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--DeferredTaxAssetsLeasesAsset_iI_pn3n3_msDTLztYm_z11i1Jih1eP9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leases asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">533</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl2847">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--DeferredTaxAssetsLeaseLiability_iNI_pn3n3_di_maDTLztYm_zjVBpvnsc7q9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(324</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl2850">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_pn3n3_di_maDTLztYm_zwCugWd6HsWa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,863</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(737</td><td style="text-align: left">)</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_msDTLztYm_zkJGG3QCpJbc" style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">297</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_maDTLztYm_zcpm0JO7Gs46" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,932</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,939</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxLiabilities_iNTI_pn3n3_di_mtDTLztYm_zMJuAwQKEokj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2861">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(58</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">SCHEDULE OF VALUATION ALLOWANCE, ACTIVITY</a></td>
<td class="text"><p id="xdx_891_eus-gaap--SummaryOfValuationAllowanceTextBlock_zaZcptbl3pD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
changes in valuation allowance are comprised as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BF_zI2Sac4A7VW4" style="display: none">SCHEDULE OF VALUATION ALLOWANCE, ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(U.S dollars in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Balance at the beginning of year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20200101__20201231_z4UsOo810krg" style="width: 18%; text-align: right" title="Balance at the beginning of year">(14,939</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20190101__20191231_zj5TStugVh28" style="width: 18%; text-align: right" title="Balance at the beginning of year">(10,254</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20200101__20201231_zUge94j55QWg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change during the year">3,007</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20190101__20191231_zjtjNj8oM515" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change during the year">(4,685</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Balance at end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20200101__20201231_zKy9h85KJWOe" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of year">(11,932</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20190101__20191231_z0lEzw0xdTTf" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of year">(14,939</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676572932072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">SCHEDULE OF DISAGGREGATION OF REVENUE</a></td>
<td class="text"><p id="xdx_899_eus-gaap--DisaggregationOfRevenueTableTextBlock_zciVtxWIG3Cl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table disaggregates the Company&#8217;s revenues by major revenue streams.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B6_z1gyYh8uIJzf" style="display: none">SCHEDULE OF DISAGGREGATION OF REVENUE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Revenue stream:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">POC and hospital services</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--PointOfCareServicesMember_zhFWJCKZmbgk" style="width: 18%; text-align: right" title="Total">6,068</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Revenues_c20190101__20191231__srt--ProductOrServiceAxis__custom--PointOfCareServicesMember_pn3n3" style="width: 18%; text-align: right" title="Total">3,109</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cell process development services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--Revenues_c20200101__20201231__srt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">1,584</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--Revenues_c20190101__20191231__srt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">790</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">7,652</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--Revenues_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">3,899</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ScheduleOfBreakdownOfRevenuesPerCustomer', window );">SCHEDULE OF BREAKDOWN OF REVENUES PER CUSTOMER</a></td>
<td class="text"><p id="xdx_898_ecustom--ScheduleOfBreakdownOfRevenuesPerCustomer_zY1gLtJVUKwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">A
breakdown of the revenues per customer what constituted at least 10% of revenues is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B2_zm38Kgu5iW3i" style="display: none">SCHEDULE OF BREAKDOWN OF REVENUES PER CUSTOMER</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Revenue earned:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: justify">Customer A</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerAMember_pn3n3" style="width: 18%; text-align: right" title="Revenues">2,857</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--MajorCustomersAxis__custom--CustomerAMember_pn3n3" style="width: 18%; text-align: right" title="Revenues">1,420</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Customer B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerBMember_pn3n3" style="text-align: right" title="Revenues">1,577</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--MajorCustomersAxis__custom--CustomerBMember_pn3n3" style="text-align: right" title="Revenues"><span style="-sec-ix-hidden: xdx2ixbrl2904">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Customer C &#8211; related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerCRelatedPartyMember_pn3n3" style="text-align: right" title="Revenues">1,475</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--MajorCustomersAxis__custom--CustomerCRelatedPartyMember_pn3n3" style="text-align: right" title="Revenues">1,270</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Customer D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--MajorCustomersAxis__custom--CustomerDMember_pn3n3" style="text-align: right" title="Revenues">1,412</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--MajorCustomersAxis__custom--CustomerDMember_pn3n3" style="text-align: right" title="Revenues">857</td><td style="text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">SCHEDULE OF ACTIVITY FOR TRADE RECEIVABLES</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zEx5HF4APUu1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
activity for trade receivables is comprised of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><span><span id="xdx_8B3_zKMopYhtwfci" style="display: none">SCHEDULE OF ACTIVITY FOR TRADE RECEIVABLES</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%">Balance as of beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AccountsReceivableNetCurrent_iS_pn3n3_c20200101__20201231_zgIuXzD8VVu3" style="width: 18%; text-align: right" title="Balance as of beginning of period">1,831</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AccountsReceivableNetCurrent_iS_pn3n3_c20190101__20191231_zeumEvjYPYj7" style="width: 18%; text-align: right" title="Balance as of beginning of period">129</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Acquisition of Koligo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--AccountsReceivableAcquisitionOfKoligo_c20200101__20201231_pn3n3" style="text-align: right" title="Acquisition of Koligo">228</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--AccountsReceivableAcquisitionOfKoligo_c20190101__20191231_pn3n3" style="text-align: right" title="Acquisition of Koligo"><span style="-sec-ix-hidden: xdx2ixbrl2922">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--AccountsReceivableAdditions_c20200101__20201231_pn3n3" style="text-align: right" title="Additions">6,997</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--AccountsReceivableAdditions_c20190101__20191231_pn3n3" style="text-align: right" title="Additions">2,079</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Collections</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--AccountsReceivableCollections_c20200101__20201231_pn3n3" style="text-align: right" title="Collections">(5,982</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--AccountsReceivableCollections_c20190101__20191231_pn3n3" style="text-align: right" title="Collections">(364</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Exchange rate differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ExchangeRateDifferencesOfAccountsReceivable_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate differences">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ExchangeRateDifferencesOfAccountsReceivable_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate differences">(13</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance as of end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AccountsReceivableNetCurrent_iE_pn3n3_c20200101__20201231_z5EzxrYt23w8" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance as of end of period">3,085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AccountsReceivableNetCurrent_iE_pn3n3_c20190101__20191231_zqbnSQSPLjwf" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance as of end of period">1,831</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_z7ZGBpL1HCgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
activity for contract liabilities is comprised of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B4_zWL501wjCgnk" style="display: none">SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%">Balance as of beginning of period</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ContractWithCustomerLiabilityCurrent_iS_pn3n3_c20200101__20201231_zPJ5G2h1xHhl" style="width: 18%; text-align: right" title="Balance as of beginning of period">325</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ContractWithCustomerLiabilityCurrent_iS_pn3n3_c20190101__20191231_zJNOYDwWAI32" style="width: 18%; text-align: right" title="Balance as of beginning of period">56</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ContractWithCustomerLiabilityAddition_c20200101__20201231_pn3n3" style="text-align: right" title="Additions">597</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ContractWithCustomerLiabilityAddition_c20190101__20191231_pn3n3" style="text-align: right" title="Additions">1,126</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F43_z0M5U3m6Pdc7" style="padding-left: 10pt">Realizations*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ContractWithCustomerLiabilityRealizations_pn3n3_c20200101__20201231_fKg_____zl72xmE3vlo9" style="text-align: right" title="Realizations">(862</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ContractWithCustomerLiabilityRealizations_pn3n3_c20190101__20191231_fKg_____zx18NKmAlo2j" style="text-align: right" title="Realizations">(854</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Exchange rate differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--ContractWithCustomerLiabilityExchangeRateDifferences_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate differences">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--ContractWithCustomerLiabilityExchangeRateDifferences_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate differences">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ContractWithCustomerLiabilityCurrent_iE_pn3n3_c20200101__20201231_zGOvVzvolUrf" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance as of end of period">59</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ContractWithCustomerLiabilityCurrent_iE_pn3n3_c20190101__20191231_zOKMpkkMhpv5" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance as of end of period">325</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td id="xdx_F06_zZk6RCpAn0lg" style="width: 3%">*</td>
    <td id="xdx_F1F_zKmYLsKShpMl" style="width: 97%">Out of which $ <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDVElWSVRZIEZPUiBDT05UUkFDVCBMSUFCSUxJVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn3n3_c20191231_zMzilnHXUcB9" title="Contract with customer liability">325</span> thousand were realized from the beginning of the period for the year ended December 31, 2020.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ScheduleOfBreakdownOfRevenuesPerCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ScheduleOfBreakdownOfRevenuesPerCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676575138648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock', window );">SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_z3cLO8fhyhdh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BC_zV30xjyeSrsl" style="display: none">SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Total expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--OtherResearchAndDevelopmentExpense_c20200101__20201231_pn3n3" style="width: 18%; text-align: right" title="Total expenses">84,182</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--OtherResearchAndDevelopmentExpense_c20190101__20191231_pn3n3" style="width: 18%; text-align: right" title="Total expenses">14,826</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less grants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--GrantsIncome_pn3n3_c20200101__20201231_zLkNeA3LKiB4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less grants">(196</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--GrantsIncome_pn3n3_c20190101__20191231_zWqsZuYCF5S3" style="border-bottom: Black 1.5pt solid; text-align: right">(812</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, net">83,986</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, net">14,014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676573736168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL EXPENSES, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisclosureFinancialExpensesNetAbstract', window );"><strong>Financial Expenses Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ScheduleOfFinancialExpensesTableTextBlock', window );">SCHEDULE OF FINANCIAL EXPENSES</a></td>
<td class="text"><p id="xdx_89B_ecustom--ScheduleOfFinancialExpensesTableTextBlock_zn2kLRrF00z3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B8_zNbPtYGts483" style="display: none">SCHEDULE OF FINANCIAL EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20200101_20201231" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20190101_20191231" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr id="xdx_40B_ecustom--IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue_maTFEzElv_zsM3s6BwG0hi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Increase in fair value of warrants and financial liabilities measured at fair value</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2984">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">63</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--InterestExpenseOnConvertibleLoans_maTFEzElv_zsyyLXxCWzI" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense on convertible loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,254</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">498</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--ForeignCurrencyTransactionsGainLossRealized_pn3n3_maTFEzElv_zBTjU4qtGp5a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign exchange loss, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">160</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">395</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OtherIncome_iN_pn3n3_di_msTFEzElv_zVEnpzdXTn2c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(353</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(113</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr id="xdx_402_ecustom--TotalFinancialExpenses_iT_mtTFEzElv_zqPwqivVUB6c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,061</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">843</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisclosureFinancialExpensesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisclosureFinancialExpensesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ScheduleOfFinancialExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ScheduleOfFinancialExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676573111848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">SCHEDULE OF RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_z0I8RBOqbpe4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_z38wGFN32fS9" style="display: none">SCHEDULE OF RELATED PARTY TRANSACTIONS</span></span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold">(in thousands)</td><td style="font-size: 11pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Continuing operations:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left; padding-bottom: 2.5pt">Stock-based compensation expenses to executive officers</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right" title="Stock Based Compensation">221</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zScrlX5LwUYc" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right" title="Stock Based Compensation">898</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F4D_zDj1uemAftSe" style="text-align: left; padding-bottom: 2.5pt">Stock-based compensation expenses to Board Members*</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_fKg_____z5oDhlnYaApj" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock Based Compensation">209</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember_fKg_____zbufEPXtHTL9" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock Based Compensation">414</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Compensation of executive officers</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--OfficersCompensation_pn3n3_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zeXQ9O2OeORf" style="border-bottom: Black 2.5pt double; text-align: right" title="Compensation">1,321</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--OfficersCompensation_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zDt1hvYywZ2a" style="border-bottom: Black 2.5pt double; text-align: right">812</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Management and consulting fees to Board Members</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20200101__20201231__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and consulting fees">264</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember_zZ5ZrtfncJ67" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and consulting fees">233</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Revenues from customer</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromRelatedParties_pn3n3_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zWmRrjlj5Fk2" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues from customer">1,475</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromRelatedParties_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_z3S6kt0Y6JN8" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues from customer">1,270</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Cost of research and development and research and development services, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet_pn3n3_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zMEkarZwPlOh" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost of research and development and research and development services, net">4,772</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost of research and development and research and development services, net"><span style="-sec-ix-hidden: xdx2ixbrl3024">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Financial income</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--FinancialIncome_c20200101__20201231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Financial income">169</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--FinancialIncome_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Financial income">112</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td id="xdx_F08_zUmcncmQEk2b" style="width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td>
    <td style="width: 95%"><span id="xdx_F14_zdm5QhoDOrPa" style="font: 10pt Times New Roman, Times, Serif">Does not include $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEFURUQgUEFSVFkgVFJBTlNBQ1RJT05TIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--StockOptionPlanExpense_pn3n3_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaerusTherapeuticsLLCMember_zwN4HCMuUKA8" title="Stock Based Compensation expenses for options exercisable">192</span> thousand
    for the year ended December 31, 2019 related to Stock Based Compensation expenses for options exercisable at an exercise price
    of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEFURUQgUEFSVFkgVFJBTlNBQ1RJT05TIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaerusTherapeuticsLLCMember_pii" title="Exercise price per share of options exercisable">7.00</span> per share into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEFURUQgUEFSVFkgVFJBTlNBQ1RJT05TIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_ecustom--NumberOfOrdinarySharesHeld_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaerusTherapeuticsLLCMember_pii" title="Number of ordinary shares held">70,000</span> ordinary shares held by Caerus Therapeutics LLC for which the director does not have beneficial
    control.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Year ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">December 31,</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2019</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(in thousands)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Discontinued operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F46_zSsDanWIU0i8" style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left; padding-bottom: 2.5pt">Stock-based compensation expenses to executive officers</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_pn3n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Stock Based Compensation">76</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Compensation of executive officers</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--OfficersCompensation_pn3n3_c20190101__20191231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_z3PQzKHltDNa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Compensation">685</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock', window );">SCHEDULE OF RELATED PARTIES PRESENTED IN CONSOLIDATED BALANCE SHEETS</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock_z4a2KVSbG4S7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BC_zMe02VSe5zki" style="display: none">SCHEDULE OF RELATED PARTIES PRESENTED IN CONSOLIDATED BALANCE SHEETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Continuing operations:</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left; padding-bottom: 2.5pt">Executive officers&#8217; payables</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_c20201231__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zKL8yC3duZL5" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right" title="Due to Related Parties">170</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_c20191231__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_pn3n3" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right" title="Due to Related Parties">1,251</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Non-executive directors&#8217; payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_c20201231__us-gaap--RelatedPartyTransactionAxis__custom--NonexecutiveDirectorsMember_zY02Lb952nXi" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to Related Parties">13</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pn3n3_c20191231__us-gaap--RelatedPartyTransactionAxis__custom--NonexecutiveDirectorsMember_zN7cd3dfFGGj" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to Related Parties">202</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F4F_zU60oWJU4a1j" style="text-align: left; padding-bottom: 2.5pt">Loan to Related Party </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--DueFromRelatedPartiesNoncurrent1_iI_pn3n3_c20201231_fKg_____zEKOY0rnIym3" style="border-bottom: Black 2.5pt double; text-align: right" title="Loan to related party"><span style="-sec-ix-hidden: xdx2ixbrl3051">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--DueFromRelatedPartiesNoncurrent1_iI_pn3n3_c20191231_fKg_____zQFt3aaF0ufj" style="border-bottom: Black 2.5pt double; text-align: right" title="Loan to related party">2,623</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Accounts receivable, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AccountsReceivableNet_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts receivable, net">744</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AccountsReceivableNet_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts receivable, net"><span style="-sec-ix-hidden: xdx2ixbrl3057">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Contract liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ContractWithCustomerLiability_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Contract liabilities"><span style="-sec-ix-hidden: xdx2ixbrl3059">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ContractWithCustomerLiability_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Contract liabilities">230</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676579245320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 07, 2020</div></th>
<th class="th"><div>Feb. 10, 2020</div></th>
<th class="th"><div>Feb. 02, 2020</div></th>
<th class="th"><div>Jan. 20, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems', window );"><strong>Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,738<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period value acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_AccumulatedDeficit', window );">Accumulated losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems', window );"><strong>Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_TamirPurchaseAgreementMember', window );">Tamir Purchase Agreement [Member] | Tamir Biotechnology Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems', window );"><strong>Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period value acquisitions</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued, acquisition</a></td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business Combination, Consideration Transferred</a></td>
<td class="nump">$ 20,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_MasthercellMember', window );">Masthercell [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems', window );"><strong>Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_PercentageOfOutstandingEquityInterests', window );">Percentage of outstanding equity interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_AggregateNominalPurchasePrice', window );">Aggregate nominal purchase price of outstanding equity interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_TransactionCostIncurred', window );">Transaction cost incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RepaymentOfIntercompanyLoansAndPayables', window );">Repayment of intercompany loans and payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_CureCellCoLtdMember', window );">CureCell Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems', window );"><strong>Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.12%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_AccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_AccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_AggregateNominalPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate nominal purchase price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_AggregateNominalPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_PercentageOfOutstandingEquityInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding equity interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_PercentageOfOutstandingEquityInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_RepaymentOfIntercompanyLoansAndPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment of intercompany loans and payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_RepaymentOfIntercompanyLoansAndPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_TransactionCostIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction cost incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_TransactionCostIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ORGS_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ORGS_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ORGS_TamirPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ORGS_TamirPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ORGS_TamirBiotechnologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ORGS_TamirBiotechnologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_MasthercellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_MasthercellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_CureCellCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_CureCellCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676668162472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_ProductionFacilityMember', window );">Production Facility [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Weighted Average Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_ProductionFacilityMember', window );">Production Facility [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Weighted Average Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Weighted Average Useful Life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Weighted Average Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Weighted Average Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Weighted Average Useful Life</a></td>
<td class="text">17 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_ProductionFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_ProductionFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676574418232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets and useful lives (Years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_KnowhowMember', window );">Know-How [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets and useful lives (Years)</a></td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_TechnologyMember', window );">Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets and useful lives (Years)</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_KnowhowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_KnowhowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_TechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_TechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676578637064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent', window );">Income tax examination, likelihood of unfavorable settlement percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock, Shares</a></td>
<td class="nump">55,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_LeaseClassificationDiscription', window );">Lease classification discription</a></td>
<td class="text">When determining lease classification, the Company&#8217;s approach in assessing two of the mentioned
criteria is: (i) generally 75% or more of the remaining economic life of the underlying asset is a major part of the remaining
economic life of that underlying asset; and (ii) generally 90% or more of the fair value of the underlying asset comprises substantially
all of the fair value of the underlying asset.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 1,609<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member', window );">Accounting Standards Update 2019-12 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_LeaseClassificationDiscription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease classification discription.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_LeaseClassificationDiscription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676654736648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF DISCONTINUED OPERATION AND BALANCE SHEETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenues</a></td>
<td class="nump">$ 2,556<span></span>
</td>
<td class="nump">$ 31,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of revenues</a></td>
<td class="nump">1,482<span></span>
</td>
<td class="nump">18,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet', window );">Cost of research and development and research and development services, net</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations', window );">Amortization of intangible assets</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">1,896<span></span>
</td>
<td class="nump">13,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisposalGroupIncludingDiscontinuedOperationOtherExpenses', window );">Other (income) expenses, net</a></td>
<td class="nump">305<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Operating loss</a></td>
<td class="nump">1,271<span></span>
</td>
<td class="nump">2,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet', window );">Financial expenses (income), net</a></td>
<td class="num">(29)<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Loss before income taxes</a></td>
<td class="nump">1,242<span></span>
</td>
<td class="nump">2,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Tax expenses (income)</a></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_IncomeLossFromDiscontinuedOperationNetOfTax', window );">Net loss from discontinuing operation, net of tax</a></td>
<td class="nump">1,212<span></span>
</td>
<td class="nump">3,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax', window );">Gain on disposal before income taxes</a></td>
<td class="nump">96,918<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal', window );">Provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax', window );">Gain on disposal</a></td>
<td class="nump">96,918<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_NetProfitLossFromDiscontinuingOperationNetOfTax', window );">Net profit (loss) from discontinuing operation, net of tax</a></td>
<td class="nump">95,706<span></span>
</td>
<td class="num">(3,452)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisposalGroupIncludingDiscontinuedOperationRestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets', window );">Prepaid expenses and other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisposalGroupIncludingDiscontinuedOperationGrantsReceivable', window );">Grants receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisposalGroupIncludingDiscontinuedOperationsDeposits', window );">Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible assets, net (mainly Know How)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">TOTAL CURRENT ASSETS OF DISCONTINUED OPERATIONS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities', window );">Accrued expenses and other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables', window );">Employees and related payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant', window );">Advance payments on account of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans', window );">Short-term loans and current maturities of long- term loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases', window );">Current maturities of long-term finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases', window );">Current maturities of operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases', window );">Non-current operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisposalGroupIncludingDiscontinuedOperationLoansPayable', window );">Loans payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities', window );">Deferred taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases', window );">Long-term finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">TOTAL CURRENT LIABILITIES OF DISCONTINUED OPERATIONS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_PropertyPlantAndEquipmentNetAndRightOfUseAssets', window );">Property, plants and equipment, net and right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash flows provided by (used in) operating activities</a></td>
<td class="num">(2,409)<span></span>
</td>
<td class="num">(1,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash flows used in investing activities</a></td>
<td class="num">(579)<span></span>
</td>
<td class="num">(11,621)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash flows (used in) provided by financing activities</a></td>
<td class="num">$ (51)<span></span>
</td>
<td class="nump">12,570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_PropertyPlantAndEquipmentNetAndRightOfUseAssets', window );">Property, plants and equipment, net and right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BE', window );">BELGIUM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_PropertyPlantAndEquipmentNetAndRightOfUseAssets', window );">Property, plants and equipment, net and right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,302<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of research and development and research and development services, net to discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advance payments on account of grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current maturities of long-term finance leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current maturities of operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employees and related payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisposalGroupIncludingDiscontinuedOperationGrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group, including discontinued operation receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisposalGroupIncludingDiscontinuedOperationGrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisposalGroupIncludingDiscontinuedOperationLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group, including discontinued operation loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisposalGroupIncludingDiscontinuedOperationLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term finance leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-current operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discontinued operation financial (income) expenses, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease right-of-use assets to disposal group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisposalGroupIncludingDiscontinuedOperationOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisposalGroupIncludingDiscontinuedOperationOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisposalGroupIncludingDiscontinuedOperationRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as restricted cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisposalGroupIncludingDiscontinuedOperationRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-term loans and current maturities of long- term loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisposalGroupIncludingDiscontinuedOperationsDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deposits of discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisposalGroupIncludingDiscontinuedOperationsDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_IncomeLossFromDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_IncomeLossFromDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_NetProfitLossFromDiscontinuingOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net profit (loss) from discontinuing operation, net of tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_NetProfitLossFromDiscontinuingOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_PropertyPlantAndEquipmentNetAndRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, plants and equipment, net and right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_PropertyPlantAndEquipmentNetAndRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortizationDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax (expense) benefit on (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676578198728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF DISAGGREGATION OF REVENUE RELATED TO DISCONTINUED OPERATIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems', window );"><strong>SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Disposal Group, Including Discontinued Operation, Revenue</a></td>
<td class="nump">$ 2,556<span></span>
</td>
<td class="nump">$ 31,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ORGS_CellProcessDevelopmentServicesMember', window );">Cell Process Development Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems', window );"><strong>SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Disposal Group, Including Discontinued Operation, Revenue</a></td>
<td class="nump">2,556<span></span>
</td>
<td class="nump">20,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ORGS_TechTransferServicesMember', window );">Tech Transfer Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems', window );"><strong>SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Disposal Group, Including Discontinued Operation, Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ORGS_CellManufacturingServicesMember', window );">Cell Manufacturing Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems', window );"><strong>SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Disposal Group, Including Discontinued Operation, Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,823<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ORGS_CellProcessDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ORGS_CellProcessDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ORGS_TechTransferServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ORGS_TechTransferServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ORGS_CellManufacturingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ORGS_CellManufacturingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676578735512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATION (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 10, 2020</div></th>
<th class="th"><div>Feb. 02, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems', window );"><strong>Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,738<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_MasthercellMember', window );">Masthercell [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems', window );"><strong>Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_PercentageOfOutstandingEquityInterests', window );">Percentage of outstanding equity interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_AggregateNominalPurchasePrice', window );">Aggregate nominal purchase price of outstanding equity interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315,000<span></span>
</td>
<td class="nump">$ 315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="nump">$ 126,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RepaymentOfIntercompanyLoansAndPayables', window );">Repayment of intercompany loans and payables</a></td>
<td class="nump">7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_MasthercellSAMember', window );">Masthercell S A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems', window );"><strong>Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RepaymentOfIntercompanyLoansAndPayables', window );">Repayment of intercompany loans and payables</a></td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_AggregateNominalPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate nominal purchase price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_AggregateNominalPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_PercentageOfOutstandingEquityInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding equity interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_PercentageOfOutstandingEquityInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_RepaymentOfIntercompanyLoansAndPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment of intercompany loans and payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_RepaymentOfIntercompanyLoansAndPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_MasthercellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_MasthercellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ORGS_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ORGS_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_MasthercellSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_MasthercellSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676579135256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued', window );">Fair value of 8.8% of shared issued *</a></td>
<td class="nump">$ 11,172<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments', window );">Cash payment</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total consideration transferred</a></td>
<td class="nump">12,287<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">152<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts Receivable</a></td>
<td class="nump">228<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="nump">34<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other assets</a></td>
<td class="nump">25<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property, plants and equipment, net</a></td>
<td class="nump">482<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="nump">238<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill', window );">Goodwill</a></td>
<td class="nump">3,704<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets</a></td>
<td class="nump">14,852<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease', window );">Operating leases</a></td>
<td class="nump">238<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts Payable</a></td>
<td class="nump">216<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Accrued Expenses</a></td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability', window );">Orgenesis Inc loan</a></td>
<td class="nump">651<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred taxes</a></td>
<td class="nump">1,293<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt', window );">Notes Payable</a></td>
<td class="nump">162<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other liabilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities</a></td>
<td class="nump">2,565<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total consideration transferred</a></td>
<td class="nump">12,287<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_KyslecelTechnologyMember', window );">Kyslecel Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Other intangible assets</a></td>
<td class="nump">9,340<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_IPResearchAndDevelopmentMember', window );">IPR&amp;D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Other intangible assets</a></td>
<td class="nump">$ 641<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Fair value of the consideration is based on the company&#8217;s market share price.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The primary
items that generate goodwill include the value of the synergies between the acquired company and the Company and the acquired
assembled workforce, neither of which qualifies for recognition as an intangible asset. The Goodwill is not deductible for tax
purposes.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The
                                         allocation of the purchase price to the net assets acquired and liabilities assumed resulted
                                         in the recognition of other intangible assets which comprised of: Kyslecel Technology
                                         of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_zkEyoPQjdj0e" title="Other intangible assets">9,340</span> and IPR&amp;D of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_zbaY6aSbgAC8" title="Other intangible assets">641</span>. Kyslecel Technology has a useful life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_zYRTWIzaNSq8" title="Useful life">15</span> years. The
                                         useful life of these intangible assets for amortization purposes was determined considering
                                         the period of expected cash flows generated by the assets used to measure the fair value
                                         of the intangible assets adjusted as appropriate for the entity-specific factors, including
                                         legal, regulatory, contractual, competitive, economic or other factors that may limit
                                         the useful life of intangible assets.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of shared issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_KyslecelTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_KyslecelTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_IPResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_IPResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676578873032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_FairValuePercentageofSharesIssued', window );">Fair value percentage of shares issued</a></td>
<td class="nump">8.80%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_KyslecelTechnologyMember', window );">Kyslecel Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Other intangible assets</a></td>
<td class="nump">$ 9,340<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_IPResearchAndDevelopmentMember', window );">IPR&amp;D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Other intangible assets</a></td>
<td class="nump">$ 641<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The
                                         allocation of the purchase price to the net assets acquired and liabilities assumed resulted
                                         in the recognition of other intangible assets which comprised of: Kyslecel Technology
                                         of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_zkEyoPQjdj0e" title="Other intangible assets">9,340</span> and IPR&amp;D of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IPResearchAndDevelopmentMember_zbaY6aSbgAC8" title="Other intangible assets">641</span>. Kyslecel Technology has a useful life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNVTU1BUlkgT0YgQVNTRVRTIEFDUVVJUkVEIEFORCBMSUFCSUxJVElFUyBBU1NVTUVEIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KyslecelTechnologyMember_zYRTWIzaNSq8" title="Useful life">15</span> years. The
                                         useful life of these intangible assets for amortization purposes was determined considering
                                         the period of expected cash flows generated by the assets used to measure the fair value
                                         of the intangible assets adjusted as appropriate for the entity-specific factors, including
                                         legal, regulatory, contractual, competitive, economic or other factors that may limit
                                         the useful life of intangible assets.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_FairValuePercentageofSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Percentage of Shares Issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_FairValuePercentageofSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_KyslecelTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_KyslecelTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_IPResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_IPResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676569312920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF UNAUDITED SUPPLEMENTAL PRO FORMA (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 6,177<span></span>
</td>
<td class="nump">$ 2,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (579)<span></span>
</td>
<td class="nump">$ 26,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="nump">$ 1.77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ORGS_KoligoTherapeuticsIncMember', window );">Koligo Therapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8,239<span></span>
</td>
<td class="nump">$ 4,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">$ 318<span></span>
</td>
<td class="nump">$ 27,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 1.91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ORGS_KoligoTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ORGS_KoligoTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676583126872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION AND REORGANIZATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 15, 2020</div></th>
<th class="th"><div>Apr. 07, 2020</div></th>
<th class="th"><div>Aug. 07, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period value acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,986,000<span></span>
</td>
<td class="nump">$ 14,014,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,110,000)<span></span>
</td>
<td class="nump">$ 24,121,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ORGS_MaximaGroupLLCMember', window );">Maxima Group L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued, acquisition</a></td>
<td class="nump">66,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_RegistrationRightsandLockUpAgreementMember', window );">Registration Rightsand Lock Up Agreement [Member] | Long Hill And Maxim Group L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RestrictionOnSaleOfSharesPercentage', window );">Restriction on sale of shares percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RestrictionPeriodDescription', window );">Restriction period, description</a></td>
<td class="text">(a) in
relation to 70% of all of the shares received in the Merger that Long Hill is entitled to receive under or in connection with
the Merger Agreement, the period beginning on the date of the closing and ending on the date that is the four month anniversary
thereof, and (b) in relation to the remaining 30% of all of the shares received in the Merger that Long Hill is entitled to receive
under or in connection with the Merger Agreement, the period beginning on the date of the closing and ending on the date that
is the twelve month anniversary thereof<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_TransferAgreementMember', window );">Transfer Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Transfer of equity interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ORGS_TamirBiotechnologyIncMember', window );">Tamir Biotechnology Inc [Member] | Tamir Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period value acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued, acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business Combination, Consideration Transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Cash held in escrow account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_NumberOfSharesDepositInEscrowAccount', window );">Number of shares deposit in escrow account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_BusinessCombinationConsiderationTransferred', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ORGS_KoligoTherapeuticsIncMember', window );">Koligo Therapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 682,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ORGS_KoligoTherapeuticsIncMember', window );">Koligo Therapeutics Inc [Member] | Material Definitive Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued, acquisition</a></td>
<td class="nump">2,061,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Cash held in escrow account</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CashPaidToAccreditedInvestors', window );">Cash paid to accredited investors</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 5.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_SharesHeldInEscrow', window );">Shares held in escrow</a></td>
<td class="nump">328,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_AdditionalCashConsideration', window );">Additional cash consideration</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ReductionInConsiderationPayable', window );">Reduction in consideration payable</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_AdditionalCashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional cash consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_AdditionalCashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_BusinessCombinationConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination consideration transferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_BusinessCombinationConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_CashPaidToAccreditedInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid to accredited investors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_CashPaidToAccreditedInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_NumberOfSharesDepositInEscrowAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares deposit in escrow account.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_NumberOfSharesDepositInEscrowAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ReductionInConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ReductionInConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_RestrictionOnSaleOfSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restriction on sale of shares percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_RestrictionOnSaleOfSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_RestrictionPeriodDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_RestrictionPeriodDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_SharesHeldInEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares held in escrow.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_SharesHeldInEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=116868678&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ORGS_MaximaGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ORGS_MaximaGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ORGS_RegistrationRightsandLockUpAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ORGS_RegistrationRightsandLockUpAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ORGS_LongHillAndMaximGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ORGS_LongHillAndMaximGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ORGS_TransferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ORGS_TransferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ORGS_TamirBiotechnologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ORGS_TamirBiotechnologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ORGS_TamirPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ORGS_TamirPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ORGS_KoligoTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ORGS_KoligoTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ORGS_MaterialDefinitiveAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ORGS_MaterialDefinitiveAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676578492968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF COMPONENTS OF PROPERTY, PLANTS AND EQUIPMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 5,262<span></span>
</td>
<td class="nump">$ 3,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(2,189)<span></span>
</td>
<td class="num">(1,438)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">3,073<span></span>
</td>
<td class="nump">2,305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_ProductionFacilityMember', window );">Production Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">2,801<span></span>
</td>
<td class="nump">2,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_OfficeFurnitureAndComputersMember', window );">Office Furniture and Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">697<span></span>
</td>
<td class="nump">606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_LabEquipmentMember', window );">Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">1,483<span></span>
</td>
<td class="nump">656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_AdvancePaymentMember', window );">Advance Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 281<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_ProductionFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_ProductionFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_OfficeFurnitureAndComputersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_OfficeFurnitureAndComputersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_AdvancePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_AdvancePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676578392120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT BY GEOGRAPHICAL LOCATION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plants and equipment, net</a></td>
<td class="nump">$ 3,073<span></span>
</td>
<td class="nump">$ 2,305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BE', window );">BELGIUM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plants and equipment, net</a></td>
<td class="nump">358<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KR', window );">KOREA, REPUBLIC OF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plants and equipment, net</a></td>
<td class="nump">839<span></span>
</td>
<td class="nump">983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">ISRAEL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plants and equipment, net</a></td>
<td class="nump">1,386<span></span>
</td>
<td class="nump">1,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plants and equipment, net</a></td>
<td class="nump">$ 490<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676576294968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANTS AND EQUIPMENT (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 705<span></span>
</td>
<td class="nump">$ 634<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676570774152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF GOODWILL (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning Balance</a></td>
<td class="nump">$ 4,812<span></span>
</td>
<td class="nump">$ 4,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill as acquired</a></td>
<td class="nump">3,704<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation differences</a></td>
<td class="nump">229<span></span>
</td>
<td class="num">(130)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Ending Balance</a></td>
<td class="nump">$ 8,745<span></span>
</td>
<td class="nump">$ 4,812<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676578771720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF OTHER INTANGIBLE ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 14,037<span></span>
</td>
<td class="nump">$ 3,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,014)<span></span>
</td>
<td class="num">(538)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount of other intangible assets</a></td>
<td class="nump">13,023<span></span>
</td>
<td class="nump">3,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_KnowhowMember', window );">Know-How [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">3,170<span></span>
</td>
<td class="nump">2,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">886<span></span>
</td>
<td class="nump">895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_KyslecelTechnologyMember', window );">Kyslecel Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">9,340<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_IPResearchAndDevelopmentMember', window );">IPR&amp;D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 641<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_KnowhowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_KnowhowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_KyslecelTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_KyslecelTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_IPResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_IPResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676575530792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ESTIMATED AGGREGATE AMORTIZATION EXPENSES (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Amortization expenses, 2021</a></td>
<td class="nump">$ 965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive', window );">Amortization expenses, 2022 to 2025</a></td>
<td class="nump">$ 3,910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization expenses, 2022  to 2025.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676572900072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_AmortizationOfIntangibleAsset', window );">Amortization of Intangible Assets</a></td>
<td class="nump">$ 478<span></span>
</td>
<td class="nump">$ 430<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_AmortizationOfIntangibleAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of Intangible Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_AmortizationOfIntangibleAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676573855832">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF LONG TERM CONVERTIBLE LOANS (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repaid, Principal Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansOneMember', window );">Convertible Loans One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DebtInstrumentIssuanceYear', window );">Issuance Year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2018<span></span>
</td>
<td class="text">2018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Exercise Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">BCF</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansTwoMember', window );">Convertible Loans Two [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9,500<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DebtInstrumentIssuanceYear', window );">Issuance Year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2019<span></span>
</td>
<td class="text">2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Exercise Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">BCF</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansTwoMember', window );">Convertible Loans Two [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansTwoMember', window );">Convertible Loans Two [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansThreeMember', window );">Convertible Loans Three [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DebtInstrumentIssuanceYear', window );">Issuance Year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Exercise Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">BCF</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansMember', window );">Convertible Loans [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10,750<span></span>
</td>
<td class="nump">$ 12,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repaid, Principal Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ORGS_TwoPercentageConvertibleLoansTwoMember', window );">Two Percentage Convertible Loans Two [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DebtInstrumentIssuanceYear', window );">Issuance Year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Exercise Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repaid, Principal Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DebtInstrumentRemainingTerm', window );">Repaid, Maturity Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DebtInstrumentConvertibleRepaidBeneficialConversionFeature', window );">Repaid, BCF</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ORGS_SixPercentageConvertibleLoansTwoMember', window );">Six Percentage Convertible Loans Two [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DebtInstrumentIssuanceYear', window );">Issuance Year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Exercise Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repaid, Principal Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DebtInstrumentRemainingTerm', window );">Repaid, Maturity Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DebtInstrumentConvertibleRepaidBeneficialConversionFeature', window );">Repaid, BCF</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ORGS_EightPercetageConvertibleLoansTwoMember', window );">Eight Percetage Convertible Loans Two [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DebtInstrumentIssuanceYear', window );">Issuance Year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Exercise Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repaid, Principal Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DebtInstrumentRemainingTerm', window );">Repaid, Maturity Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DebtInstrumentConvertibleRepaidBeneficialConversionFeature', window );">Repaid, BCF</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_pii" title="Stock issued during period, conversion of convertible securities">148,838</span> shares
and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zfQ3X7ZtgEv7" title="Number of warrant may be converted">148,838</span> <span title="Warrants exercise, term"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_z2olYqVdp0gb" title="Warrants exercise, term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl1403">three-year</span></span></span> warrants to purchase up to an additional <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxws5Qrjrwp2" title="Number of warrant may be converted">148,838</span> shares of the Company&#8217;s common stock at a per share
exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zHp9sXQK5nwg" title="Warrants exercise price">7</span>. <span>In the initial two years, the holders have the right to convert the outstanding principal amount and accrued
interest into shares of capital stock of Hemogenyx-Cell or Immugenyx, LLC according under the relevant note agreement, subsidiaries
of Hemogenyx Pharmaceuticals Plc, at a price per share based on a pre-money valuation of Hemogenyx-Cell or Immugenyx, LLC of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_ecustom--PreMoneyValuation_iI_pn6n6_c20201231__dei--LegalEntityAxis__custom--HemogenyxCelMember_zkLtkIqsJWR" title="Pre-money valuation">12</span>
million and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_ecustom--PreMoneyValuation_iI_pn6n6_c20201231__dei--LegalEntityAxis__custom--ImmugenyxLLCMember_zqO6fr0KZyMe">8</span> million, respectively, pursuant to the collaboration agreement with Hemogenyx Pharmaceuticals Plc and Immugenyx,
LLC.</span> As of December 31, 2020, the loans are presented in current maturities of convertible notes in the balance sheet (See Notes
11(c) and 11(d).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pii" title="Stock issued during period, conversion of convertible securities">1,443,734</span> shares
and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pii" title="Number of warrant may be converted">1,053,503</span> <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zRDvnnKx88Ag" title="Warrants exercise, term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl1417">three-year</span></span> warrants to purchase up to an additional <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Number of warrant may be converted">1,053,503</span> shares of the Company&#8217;s common stock at a per
share exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_pii" title="Warrants exercise price">7</span>. As of December 31, 2020, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--ConvertibleDebtCurrent_iI_pn3n3_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zScnFXulvOp2" title="Current maturities of convertible loans">2,500</span> thousand of the principal amount is included in current maturities
of convertible loans in the balance sheet and the remainder in long-term convertible loans. See also Notes 7(b), 7(c), 7(e), 7(f)
and 7(g).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_pii" title="Stock issued during period, conversion of convertible securities">38,559</span> shares
at a per share exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zEMHD8sLnPdi" title="Warrants exercise price">7</span>. As of December 31, 2020, all the principal amount is included in long-term convertible loans
in the balance sheet See also Notes 7(h).</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DebtInstrumentConvertibleRepaidBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, convertible, repaid beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DebtInstrumentConvertibleRepaidBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DebtInstrumentIssuanceYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, issuance year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DebtInstrumentIssuanceYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DebtInstrumentRemainingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repaid maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DebtInstrumentRemainingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ORGS_TwoPercentageConvertibleLoansTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ORGS_TwoPercentageConvertibleLoansTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ORGS_SixPercentageConvertibleLoansTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ORGS_SixPercentageConvertibleLoansTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ORGS_EightPercetageConvertibleLoansTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ORGS_EightPercetageConvertibleLoansTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676581202904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF LONG TERM CONVERTIBLE LOANS (Details) (Parenthetical) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Current maturities of convertible loans</a></td>
<td class="nump">$ 3,974<span></span>
</td>
<td class="nump">$ 416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ORGS_HemogenyxCelMember', window );">Hemogenyx Cel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_PreMoneyValuation', window );">Pre-money valuation</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ORGS_ImmugenyxLLCMember', window );">Immugenyx, Llc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_PreMoneyValuation', window );">Pre-money valuation</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansOneMember', window );">Convertible Loans One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued during period, conversion of convertible securities</a></td>
<td class="nump">148,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrant may be converted</a></td>
<td class="nump">148,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercise, term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansOneMember', window );">Convertible Loans One [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrant may be converted</a></td>
<td class="nump">148,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansTwoMember', window );">Convertible Loans Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued during period, conversion of convertible securities</a></td>
<td class="nump">1,443,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrant may be converted</a></td>
<td class="nump">1,053,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercise, term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Current maturities of convertible loans</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansTwoMember', window );">Convertible Loans Two [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrant may be converted</a></td>
<td class="nump">1,053,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansThreeMember', window );">Convertible Loans Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued during period, conversion of convertible securities</a></td>
<td class="nump">38,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_PreMoneyValuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre-money valuation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_PreMoneyValuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ORGS_HemogenyxCelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ORGS_HemogenyxCelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ORGS_ImmugenyxLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ORGS_ImmugenyxLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676562932616">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE LOANS (Details Narrative)<br> $ / shares in Units, $ in Thousands, &#8362; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="11">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 02, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 02, 2016 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 02, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansOneMember', window );">Convertible Loans One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercise, term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrant to purchase | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_ConvertibleLoanAgreementMember', window );">Convertible Loan Agreement [Member] | Investor [Member] | Convertible Loans One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercise, term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Valuation of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_PrivatePlacementSubscriptionAgreementMember', window );">Private Placement Subscription Agreement [Member] | Investor [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Aggregate amount of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrant to purchase | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,481<span></span>
</td>
<td class="nump">151,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_SixPercentageConvertibleLoanAgreementMember', window );">Six Percentage Convertible Loan Agreement [Member] | Investor [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Aggregate amount of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_CreditLineAgreementsMember', window );">Credit Line Agreements [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ModificationOfExistingWarrants', window );">Modification of the existing warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of lines o credit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_CreditLineAgreementsMember', window );">Credit Line Agreements [Member] | Non U S Investor [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate credit line amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_CreditLineAgreementsMember', window );">Credit Line Agreements [Member] | Non U S Investor Three [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercise, term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate credit line amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrant to purchase | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_CreditLineAgreementsMember', window );">Credit Line Agreements [Member] | Non U S Investor One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercise, term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate credit line amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrant to purchase | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_CreditLineAgreementsMember', window );">Credit Line Agreements [Member] | Non U S Investor Two [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercise, term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate credit line amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrant to purchase | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_CreditLineAgreementsMember', window );">Credit Line Agreements [Member] | Non U S Investor Four [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercise, term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate credit line amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrant to purchase | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_CreditLineAgreementsMember', window );">Credit Line Agreements [Member] | Investor One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_CreditLineAgreementsMember', window );">Credit Line Agreements [Member] | Investor Two [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_CreditLineAgreementsMember', window );">Credit Line Agreements [Member] | Two Other Investor Two [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_ControlledEquityOfferingSalesAgreementMember', window );">Controlled Equity Offering Sales Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Aggregate amount of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  01,  2017<span></span>
</td>
<td class="text">May  01,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DebtInstrumentConvertibleWarrantExercisePrice', window );">Convertible warrant exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_ControlledEquityOfferingSalesAgreementMember', window );">Controlled Equity Offering Sales Agreement [Member] | Israel, New Shekels</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Aggregate amount of debt | &#8362;</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_ControlledEquityOfferingSalesAgreementMember', window );">Controlled Equity Offering Sales Agreement [Member] | Cantor Fitzgerald &amp; Co. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_PercentageOfCommission', window );">Percentage of commission</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="19"></td></tr>
<tr><td colspan="19"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The holders,
at their option, may convert the outstanding principal amount and accrued interest under this note into a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_pii" title="Stock issued during period, conversion of convertible securities">148,838</span> shares
and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zfQ3X7ZtgEv7" title="Number of warrant may be converted">148,838</span> <span title="Warrants exercise, term"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_z2olYqVdp0gb" title="Warrants exercise, term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl1403">three-year</span></span></span> warrants to purchase up to an additional <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxws5Qrjrwp2" title="Number of warrant may be converted">148,838</span> shares of the Company&#8217;s common stock at a per share
exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zHp9sXQK5nwg" title="Warrants exercise price">7</span>. <span>In the initial two years, the holders have the right to convert the outstanding principal amount and accrued
interest into shares of capital stock of Hemogenyx-Cell or Immugenyx, LLC according under the relevant note agreement, subsidiaries
of Hemogenyx Pharmaceuticals Plc, at a price per share based on a pre-money valuation of Hemogenyx-Cell or Immugenyx, LLC of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_ecustom--PreMoneyValuation_iI_pn6n6_c20201231__dei--LegalEntityAxis__custom--HemogenyxCelMember_zkLtkIqsJWR" title="Pre-money valuation">12</span>
million and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIExPTkcgVEVSTSBDT05WRVJUSUJMRSBMT0FOUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_ecustom--PreMoneyValuation_iI_pn6n6_c20201231__dei--LegalEntityAxis__custom--ImmugenyxLLCMember_zqO6fr0KZyMe">8</span> million, respectively, pursuant to the collaboration agreement with Hemogenyx Pharmaceuticals Plc and Immugenyx,
LLC.</span> As of December 31, 2020, the loans are presented in current maturities of convertible notes in the balance sheet (See Notes
11(c) and 11(d).</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DebtInstrumentConvertibleWarrantExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Warrant Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DebtInstrumentConvertibleWarrantExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ModificationOfExistingWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Modification of the existing warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ModificationOfExistingWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_PercentageOfCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_PercentageOfCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ORGS_ConvertibleLoansOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ORGS_ConvertibleLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ORGS_ConvertibleLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ORGS_PrivatePlacementSubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ORGS_PrivatePlacementSubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ORGS_SixPercentageConvertibleLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ORGS_SixPercentageConvertibleLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ORGS_CreditLineAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ORGS_CreditLineAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_NonUSInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_NonUSInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_NonUSInvestorThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_NonUSInvestorThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_NonUSInvestorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_NonUSInvestorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_NonUSInvestorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_NonUSInvestorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_NonUSInvestorFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_NonUSInvestorFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_InvestorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_InvestorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_InvestorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_InvestorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_TwoOtherInvestorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_TwoOtherInvestorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ORGS_ControlledEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ORGS_ControlledEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_ILS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_ILS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ORGS_CantorFitzgeraldAndCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ORGS_CantorFitzgeraldAndCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676578248040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF LOANS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Total loans</a></td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">$ 391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=ORGS_ShortTermLoanOneMember', window );">Short Term Loan One [Member] | Korea (South), Won</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Total loans</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=ORGS_ShortTermLoansTwoMember', window );">Short Term Loans Two [Member] | Korea (South), Won</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Total loans</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=ORGS_ShortTermLoansThreeMember', window );">Short Term Loans Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Total loans</a></td>
<td class="nump">$ 145<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=ORGS_ShortTermLoanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=ORGS_ShortTermLoanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_KRW">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_KRW</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=ORGS_ShortTermLoansTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=ORGS_ShortTermLoansTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=ORGS_ShortTermLoansThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=ORGS_ShortTermLoansThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676577703240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF LEASE-RELATED ASSETS AND LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 1,474<span></span>
</td>
<td class="nump">$ 725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plants and equipment, gross</a></td>
<td class="nump">99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Accumulated depreciation</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturities of operating leases</a></td>
<td class="nump">485<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current maturities of long-term finance leases</a></td>
<td class="nump">19<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating leases</a></td>
<td class="nump">1,020<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance leases</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted Average Remaining Lease Term, Operating leases</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted Average Remaining Lease Term, Finance leases</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted Average Discount Rate, Operating leases</a></td>
<td class="nump">6.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted Average Discount Rate, Finance leases</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676573016024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF LEASE COSTS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost:</a></td>
<td class="nump">$ 547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of leased assets</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_FinanceLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total finance lease cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676570645464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF SUPPLEMENTAL CASHFLOW INFORMATION (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating leases</a></td>
<td class="nump">$ 515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Finance leases</a></td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance leases</a></td>
<td class="nump">$ 366<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676573377160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FINANCE LEASE LIABILITIES AND OPERATING LEASE LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Operating Leases, 2021</a></td>
<td class="nump">$ 526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Finance Lease, 2021</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Operating Leases, 2022</a></td>
<td class="nump">528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">Finance Lease, 2022</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Operating Leases, 2023</a></td>
<td class="nump">342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">Finance Lease, 2023</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Operating Leases, 2024</a></td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">Finance Lease, 2024</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Operating Leases, 2025</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">Finance Lease, 2025</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Operating Leases, Total minimum lease payments</a></td>
<td class="nump">1,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Finance Leases, Total minimum lease payments</a></td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Operating Leases, Less: amount of lease payments representing interest</a></td>
<td class="num">(138)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Finance Lease, Less: amount of lease payments representing interest</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Leases, Present value of future minimum lease payments</a></td>
<td class="nump">1,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance Lease, Present value of future minimum lease payments</a></td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Leases, Less: Current leases obligations</a></td>
<td class="num">(485)<span></span>
</td>
<td class="num">$ (357)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance Lease, Less: Current leases obligations</a></td>
<td class="num">(19)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Leases, Long-term leases obligations</a></td>
<td class="nump">1,020<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance Lease, Long-term leases obligations</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676577517160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF RIGHT-OF-USE ASSETS BY GEOGRAPHICAL LOCATION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 1,474<span></span>
</td>
<td class="nump">$ 725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KR', window );">KOREA, REPUBLIC OF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">683<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">ISRAEL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">496<span></span>
</td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateLineItems', window );"><strong>SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 295<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676580965208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Details Narrative)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing Facility [Member] | ISRAEL | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Leasing contracts period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing Facility [Member] | ISRAEL | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Leasing contracts period</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_ResearchAndDevelopmentFacilitiesMember', window );">Research And Development Facilities [Member] | KOREA, REPUBLIC OF | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Leasing contracts period</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_ResearchAndDevelopmentFacilitiesMember', window );">Research And Development Facilities [Member] | KOREA, REPUBLIC OF | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Leasing contracts period</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_OfficesMember', window );">Offices [Member] | ISRAEL</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Leasing contracts period</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_ResearchAndDevelopmentFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_ResearchAndDevelopmentFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_OfficesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ORGS_OfficesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676561982360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS (Details Narrative)<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 08, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 08, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 09, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 19, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 19, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 26, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 08, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 30, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 17, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 17, 2014 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_AdvancePaymentsOnAccountOfGrant', window );">Advance payments on account of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=ORGS_DeductionOfResearchAndDevelopmentExpensesMember', window );">Deduction Of Research And Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DeductionOfResearchAndDevelopmentExpenses', window );">Deduction of research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_MarylandTechnologyDevelopmentCorporationMember', window );">Maryland Technology Development Corporation [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableNoncurrent', window );">Grants receivable, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember', window );">Department De La Gestion Financiere Direction De Lanalyse Financiere [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember', window );">Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_AdvancePaymentsOnAccountOfGrant', window );">Advance payments on account of grant | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other expenses | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember', window );">Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Research And Development Of Potential Cure For Type One Diabetes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableNoncurrent', window );">Grants receivable, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember', window );">Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Research And Development Of Potential Cure For Type One Diabetes [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableNoncurrent', window );">Grants receivable, noncurrent | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember', window );">Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Research And Development Of Potential Cure For Type One Diabetes [Member] | Europe [Member] | Revenue from grants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember', window );">Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Industrial research part of research program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_GrantsReceivablePercentageOfBudgetedCosts', window );">Grants receivable, percentage of budgeted costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember', window );">Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Industrial research part of research program [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableNoncurrent', window );">Grants receivable, noncurrent | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember', window );">Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Experimental development part of research program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_GrantsReceivablePercentageOfBudgetedCosts', window );">Grants receivable, percentage of budgeted costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember', window );">Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Experimental development part of research program [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableNoncurrent', window );">Grants receivable, noncurrent | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember', window );">Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Development Of Potential Cure For Type One Diabetes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableNoncurrent', window );">Grants receivable, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_GrantsReceivablePercentageOfBudgetedCosts', window );">Grants receivable, percentage of budgeted costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DeductionOfResearchAndDevelopmentExpenses', window );">Deduction of research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember', window );">Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Development Of Potential Cure For Type One Diabetes [Member] | Revenue from grants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember', window );">Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Development Of Potential Cure For Type One Diabetes [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableNoncurrent', window );">Grants receivable, noncurrent | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DeductionOfResearchAndDevelopmentExpenses', window );">Deduction of research and development expenses | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember', window );">Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Development Of Potential Cure For Type One Diabetes [Member] | Europe [Member] | Revenue from grants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues, total | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember', window );">Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | GMP production of AIP cells for two clinical trials that will be performed in Germany and Belgium [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableNoncurrent', window );">Grants receivable, noncurrent</a></td>
<td class="nump">$ 12,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_GrantsReceivablePercentageOfBudgetedCosts', window );">Grants receivable, percentage of budgeted costs</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues, total</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember', window );">Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | GMP production of AIP cells for two clinical trials that will be performed in Germany and Belgium [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableNoncurrent', window );">Grants receivable, noncurrent | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues, total | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember', window );">Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Deduction Of Research And Development Expenses [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DeductionOfResearchAndDevelopmentExpenses', window );">Deduction of research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember', window );">Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Research On Dermatitis Treatments And Wound Healing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableNoncurrent', window );">Grants receivable, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_GrantsReceivablePercentageOfBudgetedCosts', window );">Grants receivable, percentage of budgeted costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember', window );">Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Research On Dermatitis Treatments And Wound Healing [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableNoncurrent', window );">Grants receivable, noncurrent | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues, total | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember', window );">Israelus Binational Industrial Research And Development Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableNoncurrent', window );">Grants receivable, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RepaymentsOfGrantPercentageOfGrossSales', window );">Repayments of grant, percentage of gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember', window );">Koreaisrael Industrial Research And Development Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableNoncurrent', window );">Grants receivable, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RepaymentsOfGrantPercentageOfGrossSales', window );">Repayments of grant, percentage of gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_BirdSecantMember', window );">BIRD Secant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableNoncurrent', window );">Grants receivable, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_OBIMember', window );">O B I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableNoncurrent', window );">Grants receivable, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_AdvancePaymentsOnAccountOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advance payments on account of grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_AdvancePaymentsOnAccountOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DeductionOfResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deduction of research and development expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DeductionOfResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_GrantsReceivablePercentageOfBudgetedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grants receivable, percentage of budgeted costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_GrantsReceivablePercentageOfBudgetedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_RepaymentsOfGrantPercentageOfGrossSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments of grant, percentage of gross sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_RepaymentsOfGrantPercentageOfGrossSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=ORGS_DeductionOfResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=ORGS_DeductionOfResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ORGS_MarylandTechnologyDevelopmentCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ORGS_MarylandTechnologyDevelopmentCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=ORGS_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=ORGS_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ORGS_RevenueFromGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ORGS_RevenueFromGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=ORGS_IndustrialResearchPartOfResearchProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=ORGS_IndustrialResearchPartOfResearchProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=ORGS_ExperimentalDevelopmentPartOfResearchProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=ORGS_ExperimentalDevelopmentPartOfResearchProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=ORGS_DevelopmentOfPotentialCureForTypeOneDiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=ORGS_DevelopmentOfPotentialCureForTypeOneDiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=ORGS_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=ORGS_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=ORGS_ResearchOnDermatitisTreatmentsAndWoundHealingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=ORGS_ResearchOnDermatitisTreatmentsAndWoundHealingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ORGS_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ORGS_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ORGS_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ORGS_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ORGS_BirdSecantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ORGS_BirdSecantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ORGS_OBIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ORGS_OBIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676557476296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION AND LICENSE AGREEMENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 07, 2020</div></th>
<th class="th"><div>Nov. 25, 2018</div></th>
<th class="th"><div>Nov. 25, 2018</div></th>
<th class="th"><div>Oct. 16, 2018</div></th>
<th class="th"><div>Jan. 28, 2018</div></th>
<th class="th"><div>Feb. 02, 2012</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 18, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,986,000<span></span>
</td>
<td class="nump">$ 14,014,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ORGS_CaerusTherapeuticsIncMember', window );">Caerus Therapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Tissue Genesis L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_FutureMilestonePayments', window );">Future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Caerus Therapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RoyaltyOfNetSalesPercentage', window );">Royalty of net sales, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_SublicensingFeesPercentage', window );">Sublicensing fees, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_TamirPurchaseAgreementMember', window );">Tamir Purchase Agreement [Member] | Tamir Biotechnology Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_TamirPurchaseAgreementMember', window );">Tamir Purchase Agreement [Member] | Maximum [Member] | Tamir Biotechnology Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_FutureMilestonePayments', window );">Future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ORGS_HemogenyxPharmaceuticalsPLCMember', window );">Hemogenyx Pharmaceuticals PLC. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ReductionRateOfRoyaltyPercentage', window );">Reduction rate of royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ORGS_HemogenyxPharmaceuticalsPLCMember', window );">Hemogenyx Pharmaceuticals PLC. [Member] | Sales Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ORGS_ImmugenyxLLCMember', window );">Immugenyx, Llc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_PreMoneyValuation', window );">Pre-money valuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ORGS_SBHSciencesIncMember', window );">SBH Sciences, Inc [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransferToInvestments', window );">Transfer for prior establishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=ORGS_ResearchAndDevelopmentCostsMember', window );">Research And Development Costs [Member] | Hemogenyx Pharmaceuticals PLC. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=ORGS_ResearchAndDevelopmentCostsMember', window );">Research And Development Costs [Member] | Immugenyx, Llc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_AdvaBiotechnologyLtdMember', window );">Adva Biotechnology Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_TerminationDescription', window );">Termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The MSA shall remain in effect for 10 years unless earlier terminated in accordance with its terms.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember', window );">Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RoyaltyOfNetSalesPercentage', window );">Royalty of net sales, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_SublicensingFeesPercentage', window );">Sublicensing fees, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CommitmentSharesOfCommonStock', window );">Commitment, shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CommitmentSharesOfCommonStockOfSubsidiary', window );">Commitment, shares of common stock of Israeli subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember', window );">Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member] | On the date of initiation of phase I clinical trials in human subjects [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember', window );">Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member] | On the date of initiation of phase II clinical trials in human subject [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember', window );">Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member] | On the date of initiation of phase III clinical trials in human subjects [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember', window );">Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member] | On the date of initiation of issuance of an approval for marketing of the first product by the FDA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember', window );">Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member] | When Worldwide Net Sales Of Products Have Reached The Amount Of One Five Zero Million For The First Time [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_ImmuAgreementMember', window );">Immu Agreement [Member] | Immugenyx, Llc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ReductionRateOfRoyaltyPercentage', window );">Reduction rate of royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_BgNegevTechnologiesAndApplicationsBgnMember', window );">BG Negev Technologies and Applications (BGN) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_SublicensingFeesPercentage', window );">Sublicensing fees, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_BgNegevTechnologiesAndApplicationsBgnMember', window );">BG Negev Technologies and Applications (BGN) [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RoyaltyOfNetSalesPercentage', window );">Royalty of net sales, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ReductionRateOfRoyaltyPercentage', window );">Reduction rate of royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_BgNegevTechnologiesAndApplicationsBgnMember', window );">BG Negev Technologies and Applications (BGN) [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RoyaltyOfNetSalesPercentage', window );">Royalty of net sales, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ReductionRateOfRoyaltyPercentage', window );">Reduction rate of royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_CollaborationAgreementMember', window );">Collaboration agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_PreMoneyValuation', window );">Pre-money valuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromGrantors', window );">Proceeds from advance payment of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_PercentageOfGrossRevenues', window );">Percentage of gross revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_CollaborationAgreementMember', window );">Collaboration agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Loans receivable net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_AdditionalFundsInvest', window );">Additional Funds Invest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_CollaborationAgreementMember', window );">Collaboration agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Loans receivable net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_AdditionalFundsInvest', window );">Additional Funds Invest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_SponsoredResearchAgreementMember', window );">Sponsored Research Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_PaymentForFinancialSupportToTrustForStudy', window );">Payment for financial support to trust for study</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_PaymentForFinancialSupportCumulativeAmountToTrustForStudy', window );">Payment for financial support cumulative amount to trust for study</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_PaymentForFinancialSupportToTrustForStudyDueEverySixMonths', window );">Payment for financial support to trust for study due every six months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_ColumbiaLicenseAgreementMember', window );">Columbia License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RoyaltyOfNetSalesPercentage', window );">Royalty of net sales, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RoyaltyOfNetSalesOfOtherProductsPercentage', window );">Royalty of net sales of other product percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_PaymentOfFeeUponAchievementOfEachRegulatoryMilestone', window );">Payment of fee upon the achievement of each regulatory milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_AIPCellsMember', window );">A I P Cells [Member] | Maryland Subsidiary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_CaliforniaUniversityJointResearchAgreementMember', window );">California University Joint Research Agreement [member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RoyaltyOfNetSalesPercentage', window );">Royalty of net sales, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_SublicensingFeesPercentage', window );">Sublicensing fees, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_EVAmentMember', window );">E V Ament [Member] | Extracellular Vesicle [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_BroadenJointVentureAgreementMember', window );">Broaden Joint Venture Agreement [Member] | Maryland Subsidiary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RoyaltyOfNetSalesPercentage', window );">Royalty of net sales, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_BroadenJointVentureAgreementMember', window );">Broaden Joint Venture Agreement [Member] | Maryland Subsidiary [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RoyaltyOfNetSalesPercentage', window );">Royalty of net sales, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_InterestInJointVenture', window );">Interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_BroadenJointVentureAgreementMember', window );">Broaden Joint Venture Agreement [Member] | Maryland Subsidiary [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_InterestInJointVenture', window );">Interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_JointVentureAgreementMember', window );">Joint Venture Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ConvertibleLoanAdvancedToJointVentureInterestRate', window );">Convertible loan advanced to joint venture, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_JointVentureAgreementMember', window );">Joint Venture Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ConvertibleLoanAdvancedToJointVenture', window );">Convertible loan advanced to joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_JointVentureAgreementMember', window );">Joint Venture Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities', window );">Payment for consideration</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_JointVentureAgreementMember', window );">Joint Venture Agreement [Member] | Kinerjapay Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RoyaltyOfNetSalesPercentage', window );">Royalty of net sales, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_RoyaltyOfNetSalesOfOtherProductsPercentage', window );">Royalty of net sales of other product percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_AdditionalFundsInvest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents additional amount invested in company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_AdditionalFundsInvest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_CommitmentSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment, shares of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_CommitmentSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_CommitmentSharesOfCommonStockOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment, shares of common stock of subsidiary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_CommitmentSharesOfCommonStockOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ConvertibleLoanAdvancedToJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible loan advanced to joint venture</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ConvertibleLoanAdvancedToJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ConvertibleLoanAdvancedToJointVentureInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible loan advanced to joint venture, interest rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ConvertibleLoanAdvancedToJointVentureInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_FutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_FutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_InterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in joint venture</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_InterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_PaymentForFinancialSupportCumulativeAmountToTrustForStudy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of cumulative financial support provided to trust for study.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_PaymentForFinancialSupportCumulativeAmountToTrustForStudy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_PaymentForFinancialSupportToTrustForStudy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of financial support provided to trust for study.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_PaymentForFinancialSupportToTrustForStudy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_PaymentForFinancialSupportToTrustForStudyDueEverySixMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of financial support to trust for study due in six month.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_PaymentForFinancialSupportToTrustForStudyDueEverySixMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_PaymentOfFeeUponAchievementOfEachRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of payment of fee to Columbia upon the achievement of each regulatory milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_PaymentOfFeeUponAchievementOfEachRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_PercentageOfGrossRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of gross revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_PercentageOfGrossRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_PreMoneyValuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre-money valuation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_PreMoneyValuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ReductionRateOfRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction rate of royalty percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ReductionRateOfRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_RoyaltyOfNetSalesOfOtherProductsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty of net sales of other products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_RoyaltyOfNetSalesOfOtherProductsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_RoyaltyOfNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty of net sales, percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_RoyaltyOfNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_SublicensingFeesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sublicensing fees, percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_SublicensingFeesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_TerminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Termination description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_TerminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromGrantors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from grantors during the current period related to operating activities. This element represents receipts from a guarantor for the amount of guarantee provided.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromGrantors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransferToInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of investments transferred to the entity's investments in noncash transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransferToInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ORGS_CaerusTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ORGS_CaerusTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ORGS_TissueGenesisLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ORGS_TissueGenesisLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ORGS_TamirPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ORGS_TamirPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ORGS_TamirBiotechnologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ORGS_TamirBiotechnologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ORGS_HemogenyxPharmaceuticalsPLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ORGS_HemogenyxPharmaceuticalsPLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ORGS_SalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ORGS_SalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ORGS_ImmugenyxLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ORGS_ImmugenyxLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ORGS_SBHSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ORGS_SBHSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=ORGS_ResearchAndDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=ORGS_ResearchAndDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_AdvaBiotechnologyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_AdvaBiotechnologyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=ORGS_OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=ORGS_OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=ORGS_OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=ORGS_OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=ORGS_OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=ORGS_OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=ORGS_OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=ORGS_OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=ORGS_WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=ORGS_WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_ImmuAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_ImmuAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_BgNegevTechnologiesAndApplicationsBgnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_BgNegevTechnologiesAndApplicationsBgnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_SponsoredResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_SponsoredResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_ColumbiaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_ColumbiaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_AIPCellsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_AIPCellsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ORGS_MarylandSubsidiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ORGS_MarylandSubsidiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_CaliforniaUniversityJointResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_CaliforniaUniversityJointResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_EVAmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_EVAmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_ExtracellularVesicleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ORGS_ExtracellularVesicleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_BroadenJointVentureAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_BroadenJointVentureAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ORGS_MarylandSubsidiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ORGS_MarylandSubsidiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_JointVentureAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_CollaborationAndLicenseAgreementsAxis=ORGS_JointVentureAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ORGS_KinerjapayCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ORGS_KinerjapayCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676576295688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF CHANGES IN INVESTMENTS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract', window );"><strong>Investments in and Advances to Affiliates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Opening balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Investments during the period</a></td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net income of associated companies</a></td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending balance</a></td>
<td class="nump">$ 175<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676573114344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVESTMENTS IN ASSOCIATES, NET (Details Narrative)<br></strong></div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ORGS_TLABSMember', window );">T L A B S [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_InvestmentsInAssociatePercentageOfOwnership', window );">Investments in associate percentage of ownership</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ORGS_ButterflyBiosciencesSarlMember', window );">Butterfly Biosciences Sarl [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_InvestmentsInAssociatePercentageOfOwnership', window );">Investments in associate percentage of ownership</a></td>
<td class="nump">49.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ORGS_KidneyCureJVAMember', window );">Kidney Cure J V A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_InvestmentsInAssociatePercentageOfOwnership', window );">Investments in associate percentage of ownership</a></td>
<td class="nump">51.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_InvestmentsInAssociatePercentageOfOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments in associate percentage of ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_InvestmentsInAssociatePercentageOfOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ORGS_TLABSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ORGS_TLABSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ORGS_ButterflyBiosciencesSarlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ORGS_ButterflyBiosciencesSarlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ORGS_KidneyCureJVAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ORGS_KidneyCureJVAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676572875768">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANTS ACTIVITY (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants - Warrants outstanding at the beginning of the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,010,087<span></span>
</td>
<td class="nump">6,286,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Warrants outstanding at the beginning of the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.35<span></span>
</td>
<td class="nump">$ 6.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants - Issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,344,606<span></span>
</td>
<td class="nump">471,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5.64<span></span>
</td>
<td class="nump">$ 6.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Warrants - Expired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(284,452)<span></span>
</td>
<td class="num">(748,244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Expired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.53<span></span>
</td>
<td class="nump">$ 6.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber', window );">Number of Warrants - Warrants outstanding and exercisable at the end of the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,070,241<span></span>
</td>
<td class="nump">6,010,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Warrants outstanding and exercisable at the end of the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6.20<span></span>
</td>
<td class="nump">$ 6.35<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As
of December 31, 2020 and December 31, 2019, there are no warrants that are subject to exercise price adjustments.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price - warrants expiration in periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price - warrants granted in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Warrants - Warrants outstanding and exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise pPrice - warrants outstanding and exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price - warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676578353096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF TREASURY SHARES (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_TreasuryStockShare', window );">Number of Treasury Shares at the beginning of the period | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock', window );">Weighted Average Price Paid Treasury Shares at the beginning of the period | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Number of Treasury Shares Purchased | shares</a></td>
<td class="nump">55,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_WeightedAveragePriceNumberOfSharesTreasuryStockPurchased', window );">Weighted Average Price Paid Treasury Shares Purchased | $ / shares</a></td>
<td class="nump">$ 4.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_TreasuryStockShare', window );">Number of Treasury Shares at end of the period | shares</a></td>
<td class="nump">53,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock', window );">Weighted Average Price Paid Treasury Shares at end of the period | $ / shares</a></td>
<td class="nump">$ 4.47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_TreasuryStockShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_TreasuryStockShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Price Paid Treasury Shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_WeightedAveragePriceNumberOfSharesTreasuryStockPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Price Paid Treasury Shares Purchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_WeightedAveragePriceNumberOfSharesTreasuryStockPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676578735704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>EQUITY (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 15, 2020</div></th>
<th class="th"><div>Sep. 26, 2020</div></th>
<th class="th"><div>Apr. 07, 2020</div></th>
<th class="th"><div>Jan. 20, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_OfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ORGS_MaximaGroupLLCMember', window );">Maxima Group L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock Issued During Period, Shares, Acquisitions</a></td>
<td class="nump">66,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_WarrantExercisableDescription', window );">Warrant exercisable, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">exercisable between June
2021 and January 2023.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_TamirPurchaseAgreementMember', window );">Tamir Purchase Agreement [Member] | Tamir Biotechnology Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock Issued During Period, Shares, Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business Combination, Consideration Transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_NumberOfSharesDepositInEscrowAccount', window );">Number of shares deposit in escrow account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_MergerAgreementMember', window );">Merger Agreement [Member] | Koligo Therapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,063,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_NumberOfSharesDepositInEscrowAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares deposit in escrow account.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_NumberOfSharesDepositInEscrowAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_OfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_OfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_WarrantExercisableDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant exercisable description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_WarrantExercisableDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ORGS_MaximaGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ORGS_MaximaGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ORGS_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ORGS_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ORGS_TamirPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ORGS_TamirPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ORGS_TamirBiotechnologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ORGS_TamirBiotechnologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ORGS_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ORGS_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ORGS_KoligoTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ORGS_KoligoTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676581142776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss (income) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic', window );">Net loss from continuing operations attributable to Orgenesis Inc.</a></td>
<td class="nump">$ 95,088<span></span>
</td>
<td class="nump">$ 22,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic', window );">Net (income) loss from discontinued operations attributable to Orgenesis Inc. for loss per share</a></td>
<td class="num">(96,198)<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount', window );">Adjustment of redeemable non-controlling interest to redemption amount</a></td>
<td class="num">(5,160)<span></span>
</td>
<td class="nump">4,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Basic: Net income (loss) available to common stockholders</a></td>
<td class="num">(101,358)<span></span>
</td>
<td class="nump">5,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_NetIncomeLossToParentCompany', window );">Net (income) loss attributable to Orgenesis Inc. for loss per share</a></td>
<td class="num">$ (6,270)<span></span>
</td>
<td class="nump">$ 28,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">21,320,314<span></span>
</td>
<td class="nump">15,907,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Loss per common share from continuing operations</a></td>
<td class="nump">$ 4.46<span></span>
</td>
<td class="nump">$ 1.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare', window );">Net (income) loss common share from discontinued operations</a></td>
<td class="num">(4.75)<span></span>
</td>
<td class="nump">0.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (income) loss per share</a></td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="nump">$ 1.77<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment of redeemable non-controlling interest to redemption amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_NetIncomeLossToParentCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income Loss To Parent Company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_NetIncomeLossToParentCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from discontinued operations available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676573117464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME (LOSS) PER SHARE (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ORGS_OptionsAndWarrantsMember', window );">Options and Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">10,212,789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ORGS_SharesUponConversionOfConvertibleNotesMember', window );">Shares Upon Conversion of Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">1,630,857<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ORGS_OptionsAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ORGS_OptionsAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ORGS_SharesUponConversionOfConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ORGS_SharesUponConversionOfConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676578738872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF EMPLOYEE STOCK OWNERSHIP PLAN DISCLOSURES (Details) - Options Granted To Employees [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">No. of options granted</a></td>
<td class="nump">676,500<span></span>
</td>
<td class="nump">144,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 3.74<span></span>
</td>
<td class="nump">$ 4.15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">No. of options granted</a></td>
<td class="nump">531,450<span></span>
</td>
<td class="nump">94,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description', window );">Stock options vesting period description</a></td>
<td class="text">two years<span></span>
</td>
<td class="text">two years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue', window );">Fair value at grant</a></td>
<td class="nump">$ 1,312<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Employees [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="nump">$ 3.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Employees [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 6.84<span></span>
</td>
<td class="nump">$ 5.07<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">No. of options granted</a></td>
<td class="nump">145,050<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description', window );">Stock options vesting period description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">One-year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue', window );">Fair value at grant</a></td>
<td class="nump">$ 377<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Director [Member] | One Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_StockOptionsGrantVestingPeriodPercentage', window );">Stock options grant vesting period percentage</a></td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Director [Member] | Three Equal Installments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_StockOptionsGrantVestingPeriodPercentage', window );">Stock options grant vesting period percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Director [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Director [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value at grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_StockOptionsGrantVestingPeriodPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock options grant vesting period percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_StockOptionsGrantVestingPeriodPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ORGS_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ORGS_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ORGS_OneYearAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ORGS_OneYearAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ORGS_ThreeEqualInstallmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ORGS_ThreeEqualInstallmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676578341976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Options Granted To Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value of one common share</a></td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.36%<span></span>
</td>
<td class="nump">1.45%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 4 months 17 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Options Granted To Non Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value of one common share</a></td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="nump">$ 3.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.73%<span></span>
</td>
<td class="nump">1.52%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Options Granted To Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.71%<span></span>
</td>
<td class="nump">2.47%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 6 months 21 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Options Granted To Non Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value of one common share</a></td>
<td class="nump">$ 6.84<span></span>
</td>
<td class="nump">$ 5.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">89.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.12%<span></span>
</td>
<td class="nump">2.62%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676576220872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTIONS ACTIVITY (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options - Options outstanding at the end of the year</a></td>
<td class="nump">2,465,522<span></span>
</td>
<td class="nump">2,376,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Options outstanding at the end of the year</a></td>
<td class="nump">$ 4.44<span></span>
</td>
<td class="nump">$ 4.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Options - Granted</a></td>
<td class="nump">676,500<span></span>
</td>
<td class="nump">144,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Granted</a></td>
<td class="nump">$ 3.74<span></span>
</td>
<td class="nump">$ 4.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options - Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Options - Expired</a></td>
<td class="num">(11,876)<span></span>
</td>
<td class="num">(16,750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Expired</a></td>
<td class="nump">$ 7.88<span></span>
</td>
<td class="nump">$ 6.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options - Forfeited</a></td>
<td class="num">(57,042)<span></span>
</td>
<td class="num">(38,655)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Forfeited</a></td>
<td class="nump">$ 4.52<span></span>
</td>
<td class="nump">$ 7.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod', window );">Number of Options - Cancelled</a></td>
<td class="num">(155,437)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Cancelled</a></td>
<td class="nump">$ 8.38<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options - Options outstanding at the end of the year</a></td>
<td class="nump">2,917,667<span></span>
</td>
<td class="nump">2,465,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Options outstanding at the end of the year</a></td>
<td class="nump">$ 4.05<span></span>
</td>
<td class="nump">$ 4.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options - Options exercisable at end of the year</a></td>
<td class="nump">2,299,937<span></span>
</td>
<td class="nump">2,112,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Options exercisable at end of the year</a></td>
<td class="nump">$ 4.03<span></span>
</td>
<td class="nump">$ 4.21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options - Options outstanding at the end of the year</a></td>
<td class="nump">598,310<span></span>
</td>
<td class="nump">469,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Options outstanding at the end of the year</a></td>
<td class="nump">$ 5.76<span></span>
</td>
<td class="nump">$ 5.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Options - Granted</a></td>
<td class="nump">62,500<span></span>
</td>
<td class="nump">128,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Granted</a></td>
<td class="nump">$ 3.97<span></span>
</td>
<td class="nump">$ 5.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options - Exercised</a></td>
<td class="num">(83,334)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Exercised</a></td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options - Forfeited</a></td>
<td class="num">(8,335)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Forfeited</a></td>
<td class="nump">$ 5.99<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod', window );">Number of Options - Cancelled</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Cancelled</a></td>
<td class="nump">$ 5.30<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options - Options outstanding at the end of the year</a></td>
<td class="nump">549,141<span></span>
</td>
<td class="nump">598,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Options outstanding at the end of the year</a></td>
<td class="nump">$ 5.89<span></span>
</td>
<td class="nump">$ 5.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options - Options exercisable at end of the year</a></td>
<td class="nump">450,972<span></span>
</td>
<td class="nump">539,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Options exercisable at end of the year</a></td>
<td class="nump">$ 6.28<span></span>
</td>
<td class="nump">$ 5.88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Cancellations in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Cancellations in Period, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676555950328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTIONS EXERCISABLE (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 4.05<span></span>
</td>
<td class="nump">$ 4.44<span></span>
</td>
<td class="nump">$ 4.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">2,917,667<span></span>
</td>
<td class="nump">2,465,522<span></span>
</td>
<td class="nump">2,376,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">5 years 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 4,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">2,299,937<span></span>
</td>
<td class="nump">2,112,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 9,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member] | Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.0012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">230,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">3 years 7 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 1,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">230,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ (0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member] | Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">510,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">1 year 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 2,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">510,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member] | Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">445,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">9 years 1 month 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">174,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member] | Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">6 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">1,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member] | Exercise Price Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 4.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">6 years 11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member] | Exercise Price Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">8 years 5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">23,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member] | Exercise Price Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">185,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">9 years 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member] | Exercise Price Eighteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">6,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">9 years 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member] | Exercise Price Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">483,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">5 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">483,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 2,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member] | Exercise Price Ten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 5.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">53,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">8 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">39,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member] | Exercise Price Eleven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">9 years 8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">7,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member] | Exercise Price Twelve [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 5.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">352,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">7 years 3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">290,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 1,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member] | Exercise Price Thirteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">16,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">3 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">16,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member] | Exercise Price Fourteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 6.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">9 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">4,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member] | Exercise Price Fifteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">83,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">6 years 5 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">83,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member] | Exercise Price Sixteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 8.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">250,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">250,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 2,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member] | Exercise Price Seventeen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 8.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">7 years 5 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member] | Exercise Price Eighteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">20,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">2 years 6 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">20,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member] | Exercise Price Nineteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 9.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">58,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">1 year 6 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">58,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember', window );">Options Granted To Employees [Member] | Exercise Price Twenty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">39,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">1 year 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">39,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 5.89<span></span>
</td>
<td class="nump">$ 5.76<span></span>
</td>
<td class="nump">$ 5.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">549,141<span></span>
</td>
<td class="nump">598,310<span></span>
</td>
<td class="nump">469,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">6 years 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">450,972<span></span>
</td>
<td class="nump">539,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 2,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member] | Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">9 years 2 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member] | Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">8 years 10 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member] | Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">136,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">5 years 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">136,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member] | Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 4.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">8 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member] | Exercise Price Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 4.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">10,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">6 years 11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">10,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member] | Exercise Price Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">13,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">8 years 6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member] | Exercise Price Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">9 years 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member] | Exercise Price Eighteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">16,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">5 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">16,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member] | Exercise Price Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 5.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">8 years 2 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member] | Exercise Price Ten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member] | Exercise Price Eleven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 5.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">16,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">7 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">16,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member] | Exercise Price Twelve [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">3 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member] | Exercise Price Thirteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 6.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">9 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member] | Exercise Price Fourteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">8 years 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member] | Exercise Price Fifteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 7.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">8,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">1 year 10 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">8,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member] | Exercise Price Sixteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 8.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">7 years 6 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member] | Exercise Price Seventeen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 8.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">8,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">7 years 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">4,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member] | Exercise Price Eighteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 11.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">8,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">2 years 3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">8,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member] | Exercise Price Nineteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 16.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options</a></td>
<td class="nump">39,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">1 year 3 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Exercisable Options</a></td>
<td class="nump">39,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Exercisable Options Value</a></td>
<td class="nump">$ 660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ORGS_ExercisePriceTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676581222232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTIONS GRANTED TO CONSULTANTS (Details) - Options Granted To Non Employees [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">No. of options granted</a></td>
<td class="nump">62,500<span></span>
</td>
<td class="nump">128,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 3.97<span></span>
</td>
<td class="nump">$ 5.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription', window );">Vesting peirod description</a></td>
<td class="text">two<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue', window );">Fair value at grant</a></td>
<td class="nump">$ 209<span></span>
</td>
<td class="nump">$ 394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="nump">$ 3.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 6.84<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value at grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676564825992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 20, 2020</div></th>
<th class="th"><div>Jan. 02, 2020</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>May 11, 2017</div></th>
<th class="th"><div>May 23, 2012</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,847,000<span></span>
</td>
<td class="nump">$ 3,057,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Number of common stock for services, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,377,000<span></span>
</td>
<td class="nump">893,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_FairValueOfSharesRecognizedOnGrantDate', window );">[custom:FairValueOfSharesRecognizedOnGrantDate-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,000<span></span>
</td>
<td class="nump">82,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,986,000<span></span>
</td>
<td class="nump">$ 14,014,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_NumberOfAdditionalSharesRestrictionsOnTransfer', window );">Number of additional shares restrictions on transfer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ORGS_SuccessFeeMember', window );">Success fee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ClassOfWarrantOrRightGrantsInPeriod', window );">Number of warrants - issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ClassOfWarrantOrRightGrantsInPeriodFairValue', window );">Class of warrant or right, grants in period, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_SeveralConsultantsMember', window );">Several Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant, exercise price, decrease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant, exercise price, increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_InvestorRelationContactMember', window );">Investor Relation Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of common stock for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Number of common stock for services, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_InvestorRelationContactMember', window );">Investor Relation Contact [Member] | Held Until Six Months Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of common stock for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_InvestorRelationContactMember', window );">Investor Relation Contact [Member] | Held Until One Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of common stock for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ORGS_NonEmployeesMember', window );">Non-Employees [Member] | Convertible Notes And Private Investment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ORGS_NonEmployeesMember', window );">Non-Employees [Member] | Several Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant, exercise price, decrease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant, exercise price, increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_WarrantsAndRightsOutstandingTermDescription', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">three years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ORGS_SeveralConsultantsMember', window );">Several Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ClassOfWarrantOrRightGrantsInPeriod', window );">Number of warrants - issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ClassOfWarrantOrRightGrantsInPeriodFairValue', window );">Class of warrant or right, grants in period, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ORGS_ConsultantMember', window );">Consultant [Member] | Investor Relation Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Number of common stock for services, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock issued during period, shares, restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_NumberOfVestedShares', window );">Number of vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_FairValueOfSharesOnVestingDatesRecognizedDuringYear', window );">Fair value of shares on vesting dates recognized during year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock issued during period, value, restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ORGS_ConsultantMember', window );">Consultant [Member] | Investor Relation Contact [Member] | vested on signing date[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_NumberOfVestedShares', window );">Number of vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ORGS_ConsultantMember', window );">Consultant [Member] | Investor Relation Contact [Member] | Vest Monthly Over 3 Months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_NumberOfVestedShares', window );">Number of vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ORGS_ConsultantMember', window );">Consultant [Member] | Separate Investor Relations Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock issued during period, shares, restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ORGS_ConsultantMember', window );">Consultant [Member] | Separate Investor Relation Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Number of common stock for services, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_NumberOfVestedShares', window );">Number of vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_FairValueOfSharesOnVestingDatesRecognizedDuringYear', window );">Fair value of shares on vesting dates recognized during year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ORGS_ConsultantMember', window );">Consultant [Member] | Separate Investor Relation Contact [Member] | vested on signing date[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_NumberOfVestedShares', window );">Number of vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ORGS_ConsultantMember', window );">Consultant [Member] | Separate Investor Relation Contact [Member] | Vest Monthly Over 3 Months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_NumberOfVestedShares', window );">Number of vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share issued price per share</a></td>
<td class="nump">$ 4.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrant may be converted</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_WarrantExercisableDescription', window );">[custom:WarrantExercisableDescription]</a></td>
<td class="text">exercisable between June
2021 and January 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="nump">$ 9,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering expenses</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 1,911,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_PrivatePlacementSubscriptionAgreementsMember', window );">Private Placement Subscription Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrant may be converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_AggregateAmountOfSubscriptionAgreement', window );">Aggregate amount of subscription agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.24<span></span>
</td>
<td class="nump">$ 6.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">$ 62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of common stock for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Number of common stock for services, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ORGS_MasthercellGlobalMember', window );">Masthercell Global [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,594,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ORGS_FirstChoiceInternationalCompanyIncMember', window );">First Choice International Company, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted', window );">Joint venture agreement, shares issued for compensation of work already completed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesAndDirectorsMember', window );">Options Granted to Employees and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,470,000<span></span>
</td>
<td class="nump">2,107,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember', window );">Options Granted To Non Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based compensation, shares authorized under stock option plans, exercise price range, outstanding options, weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,000<span></span>
</td>
<td class="nump">$ 330,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 231,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Several Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Several Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ORGS_TwoZeroOneSevenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation arrangement by share-based payment award, number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based compensation arrangement by share-based payment award, number of additional shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,362,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants', window );">Share-based compensation arrangement by share-based payment award, options, available for grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,724,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ORGS_TwoZeroOneSevenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based compensation, shares authorized under stock option plans, exercise price range, outstanding options, weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ORGS_GlobalShareIncentivePlanTwoZeroOneTwoMember', window );">Global Share Incentive Plan 2012 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation arrangement by share-based payment award, number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,183,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants', window );">Share-based compensation arrangement by share-based payment award, options, available for grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ORGS_GlobalShareIncentivePlanTwoZeroOneTwoMember', window );">Global Share Incentive Plan 2012 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based compensation, shares authorized under stock option plans, exercise price range, outstanding options, weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_AggregateAmountOfSubscriptionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of subscription agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_AggregateAmountOfSubscriptionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ClassOfWarrantOrRightGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Grants in Period, Net of Forfeitures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ClassOfWarrantOrRightGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ClassOfWarrantOrRightGrantsInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Grants in Period, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ClassOfWarrantOrRightGrantsInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Grants in Period, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_FairValueOfSharesOnVestingDatesRecognizedDuringYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of fair value of shares on vesting dates recognized during year .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_FairValueOfSharesOnVestingDatesRecognizedDuringYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_FairValueOfSharesRecognizedOnGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_FairValueOfSharesRecognizedOnGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint venture agreement, shares issued for compensation of work already completed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_NumberOfAdditionalSharesRestrictionsOnTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_NumberOfAdditionalSharesRestrictionsOnTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_NumberOfVestedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of vested shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_NumberOfVestedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Available for grants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_WarrantExercisableDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant exercisable description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_WarrantExercisableDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_WarrantsAndRightsOutstandingTermDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_WarrantsAndRightsOutstandingTermDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ORGS_SuccessFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ORGS_SuccessFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_SeveralConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_SeveralConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_InvestorRelationContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_InvestorRelationContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=ORGS_HeldUntilSixMonthsAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=ORGS_HeldUntilSixMonthsAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=ORGS_HeldUntilOneYearAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=ORGS_HeldUntilOneYearAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ORGS_NonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ORGS_NonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ORGS_ConvertibleNotesAndPrivateInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ORGS_ConvertibleNotesAndPrivateInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ORGS_SeveralConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ORGS_SeveralConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ORGS_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ORGS_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=ORGS_VestedOnSigningDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=ORGS_VestedOnSigningDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=ORGS_VestMonthlyOver3MonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=ORGS_VestMonthlyOver3MonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_SeparateInvestorRelationsContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_SeparateInvestorRelationsContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_SeparateInvestorRelationContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_SeparateInvestorRelationContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ORGS_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ORGS_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ORGS_PrivatePlacementSubscriptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ORGS_PrivatePlacementSubscriptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ORGS_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ORGS_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ORGS_MasthercellGlobalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ORGS_MasthercellGlobalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ORGS_FirstChoiceInternationalCompanyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ORGS_FirstChoiceInternationalCompanyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToEmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=ORGS_OptionsGrantedToNonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ORGS_TwoZeroOneSevenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ORGS_TwoZeroOneSevenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ORGS_GlobalShareIncentivePlanTwoZeroOneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ORGS_GlobalShareIncentivePlanTwoZeroOneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676663864424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 9,606<span></span>
</td>
<td class="nump">$ 14,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development expenses</a></td>
<td class="nump">1,684<span></span>
</td>
<td class="nump">1,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Equity compensation</a></td>
<td class="nump">2,747<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits', window );">Employee benefits</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DeferredTaxAssetsLeasesAsset', window );">Leases asset</a></td>
<td class="nump">533<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="num">(324)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(2,863)<span></span>
</td>
<td class="num">(737)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">297<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(11,932)<span></span>
</td>
<td class="num">(14,939)<span></span>
</td>
<td class="num">$ (10,254)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DeferredTaxAssetsLeasesAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DeferredTaxAssetsLeasesAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676577386472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF VALUATION ALLOWANCE, ACTIVITY (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at the beginning of year</a></td>
<td class="num">$ (14,939)<span></span>
</td>
<td class="num">$ (10,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change during the year</a></td>
<td class="nump">3,007<span></span>
</td>
<td class="num">(4,685)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at end of year</a></td>
<td class="num">$ (11,932)<span></span>
</td>
<td class="num">$ (14,939)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676579151464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="nump">$ 34,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective income tax rate reconciliation, at income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards, limitations on use</a></td>
<td class="text">For
U.S. federal income tax purposes, net operating losses (&#8220;NOLs&#8221;) arising in tax years beginning after December 31,
2017, the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) limits the ability to utilize NOL carryforwards to
80% of taxable income in tax years beginning after December 31, 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">ISRAEL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective income tax rate reconciliation, at income tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BE', window );">BELGIUM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective income tax rate reconciliation, at income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.58%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BE', window );">BELGIUM | 2021-2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective income tax rate reconciliation, at income tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BE', window );">BELGIUM | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_AccumulatedTaxLossCarryforwardDeductions', window );">[custom:AccumulatedTaxLossCarryforwardDeductions-0] | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KR', window );">KOREA, REPUBLIC OF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_AccumulatedTaxLossCarryForwardedPeriod', window );">[custom:AccumulatedTaxLossCarryForwardedPeriod]</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KR', window );">KOREA, REPUBLIC OF | The First KRW 200 Million Of The Tax Base [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective income tax rate reconciliation, at income tax rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Effective income tax rate reconciliation, at local income tax rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KR', window );">KOREA, REPUBLIC OF | Up To KRW 20 Billion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective income tax rate reconciliation, at income tax rate</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Effective income tax rate reconciliation, at local income tax rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KR', window );">KOREA, REPUBLIC OF | Up To KRW 300 Billion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective income tax rate reconciliation, at income tax rate</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Effective income tax rate reconciliation, at local income tax rate</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KR', window );">KOREA, REPUBLIC OF | Tax Base Above KRW 300 Billion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective income tax rate reconciliation, at income tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Effective income tax rate reconciliation, at local income tax rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KR', window );">KOREA, REPUBLIC OF | South Korean Won [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards | &#8361;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 3,813,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_AccumulatedTaxLossCarryForwardedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated tax loss carry forwarded period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_AccumulatedTaxLossCarryForwardedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_AccumulatedTaxLossCarryforwardDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated tax loss carryforward deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_AccumulatedTaxLossCarryforwardDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ORGS_TwoThousandTwentyOneToTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ORGS_TwoThousandTwentyOneToTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=ORGS_TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=ORGS_TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=ORGS_UpToKrwTwoZeroBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=ORGS_UpToKrwTwoZeroBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=ORGS_UpToKrwThreeZeroZeroBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=ORGS_UpToKrwThreeZeroZeroBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=ORGS_TaxBaseAboveKrwThreeZeroZeroBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=ORGS_TaxBaseAboveKrwThreeZeroZeroBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ORGS_SouthKoreanWonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ORGS_SouthKoreanWonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676578832168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF DISAGGREGATION OF REVENUE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">$ 7,652<span></span>
</td>
<td class="nump">$ 3,899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ORGS_PointOfCareServicesMember', window );">POC and Hospital Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">6,068<span></span>
</td>
<td class="nump">3,109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ORGS_CellProcessDevelopmentServicesMember', window );">Cell Process Development Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">$ 1,584<span></span>
</td>
<td class="nump">$ 790<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ORGS_PointOfCareServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ORGS_PointOfCareServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ORGS_CellProcessDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ORGS_CellProcessDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676654750424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF BREAKDOWN OF REVENUES PER CUSTOMER (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 6,177<span></span>
</td>
<td class="nump">$ 2,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ORGS_CustomerAMember', window );">Customer A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,857<span></span>
</td>
<td class="nump">1,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ORGS_CustomerBMember', window );">Customer B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,577<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ORGS_CustomerCRelatedPartyMember', window );">Customer C Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,475<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ORGS_CustomerDMember', window );">Customer D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,412<span></span>
</td>
<td class="nump">$ 857<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ORGS_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ORGS_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ORGS_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ORGS_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ORGS_CustomerCRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ORGS_CustomerCRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ORGS_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ORGS_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676577179208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ACTIVITY FOR TRADE RECEIVABLES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Balance as of beginning of period</a></td>
<td class="nump">$ 1,831<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_AccountsReceivableAcquisitionOfKoligo', window );">Acquisition of Koligo</a></td>
<td class="nump">228<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_AccountsReceivableAdditions', window );">Additions</a></td>
<td class="nump">6,997<span></span>
</td>
<td class="nump">2,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_AccountsReceivableCollections', window );">Collections</a></td>
<td class="num">(5,982)<span></span>
</td>
<td class="num">(364)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ExchangeRateDifferencesOfAccountsReceivable', window );">Exchange rate differences</a></td>
<td class="nump">11<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Balance as of end of period</a></td>
<td class="nump">$ 3,085<span></span>
</td>
<td class="nump">$ 1,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_AccountsReceivableAcquisitionOfKoligo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accounts receivable acquisition of Koligo.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_AccountsReceivableAcquisitionOfKoligo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_AccountsReceivableAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accounts receivable additions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_AccountsReceivableAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_AccountsReceivableCollections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accounts receivable collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_AccountsReceivableCollections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ExchangeRateDifferencesOfAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exchange rate differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ExchangeRateDifferencesOfAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676665289720">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance as of beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 325<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ContractWithCustomerLiabilityAddition', window );">Additions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">597<span></span>
</td>
<td class="nump">1,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ContractWithCustomerLiabilityRealizations', window );">Realizations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(862)<span></span>
</td>
<td class="num">(854)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ContractWithCustomerLiabilityExchangeRateDifferences', window );">Exchange rate differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance as of end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Out of which $ <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDVElWSVRZIEZPUiBDT05UUkFDVCBMSUFCSUxJVElFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn3n3_c20191231_zMzilnHXUcB9" title="Contract with customer liability">325</span> thousand were realized from the beginning of the period for the year ended December 31, 2020.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ContractWithCustomerLiabilityAddition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition of contract with customer liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ContractWithCustomerLiabilityAddition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ContractWithCustomerLiabilityExchangeRateDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from contract with customer liability exchange rate differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ContractWithCustomerLiabilityExchangeRateDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ContractWithCustomerLiabilityRealizations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from contract with customer liability realizations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ContractWithCustomerLiabilityRealizations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676575107000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES (Details) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with customer liability</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676573101272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 7,652,000<span></span>
</td>
<td class="nump">$ 3,899,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ORGS_MasterServicesAgreementsMember', window );">Master Services Agreements [Member] | Joint Venture Partners [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ORGS_MasterServicesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ORGS_MasterServicesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_JointVenturePartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_JointVenturePartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676573141384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Total expenses</a></td>
<td class="nump">$ 84,182<span></span>
</td>
<td class="nump">$ 14,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_GrantsIncome', window );">Less grants</a></td>
<td class="num">(196)<span></span>
</td>
<td class="num">(812)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Cost of research and development and research and development services, net</a></td>
<td class="nump">$ 83,986<span></span>
</td>
<td class="nump">$ 14,014<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_GrantsIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_GrantsIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676576217800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FINANCIAL EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DisclosureFinancialExpensesNetAbstract', window );"><strong>Financial Expenses Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue', window );">Increase in fair value of warrants and financial liabilities measured at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_InterestExpenseOnConvertibleLoans', window );">Interest expense on convertible loans</a></td>
<td class="nump">1,254<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_ForeignCurrencyTransactionsGainLossRealized', window );">Foreign exchange loss, net</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="num">(353)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_TotalFinancialExpenses', window );">Total</a></td>
<td class="nump">$ 1,061<span></span>
</td>
<td class="nump">$ 843<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DisclosureFinancialExpensesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DisclosureFinancialExpensesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_ForeignCurrencyTransactionsGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_ForeignCurrencyTransactionsGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in fair value of warrants and financial liabilities measured at fair value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_InterestExpenseOnConvertibleLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest expense on convertible loans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_InterestExpenseOnConvertibleLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_TotalFinancialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total financial expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_TotalFinancialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676655708056">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RELATED PARTY TRANSACTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock Based Compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,847<span></span>
</td>
<td class="nump">$ 3,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenues from customer</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,475<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenues from customer</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,475<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet', window );">Cost of research and development and research and development services, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,772<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_FinancialIncome', window );">Financial income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">169<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations [Member] | Executive Officer [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock Based Compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">221<span></span>
</td>
<td class="nump">898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,321<span></span>
</td>
<td class="nump">812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations [Member] | Board Members [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock Based Compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">209<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Management and consulting fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations [Member] | Executive Officer [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock Based Compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 685<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Does not include $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEFURUQgUEFSVFkgVFJBTlNBQ1RJT05TIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--StockOptionPlanExpense_pn3n3_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaerusTherapeuticsLLCMember_zwN4HCMuUKA8" title="Stock Based Compensation expenses for options exercisable">192</span> thousand
    for the year ended December 31, 2019 related to Stock Based Compensation expenses for options exercisable at an exercise price
    of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEFURUQgUEFSVFkgVFJBTlNBQ1RJT05TIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaerusTherapeuticsLLCMember_pii" title="Exercise price per share of options exercisable">7.00</span> per share into <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTEFURUQgUEFSVFkgVFJBTlNBQ1RJT05TIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_ecustom--NumberOfOrdinarySharesHeld_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaerusTherapeuticsLLCMember_pii" title="Number of ordinary shares held">70,000</span> ordinary shares held by Caerus Therapeutics LLC for which the director does not have beneficial
    control.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of research and development and research and development services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_FinancialIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_FinancialIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ORGS_BoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ORGS_BoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676578270024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RELATED PARTY TRANSACTIONS (Details) (Parenthetical) - Caerus Therapeutics LLC [Member]<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock Based Compensation expenses for options exercisable | $</a></td>
<td class="nump">$ 192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise price per share of options exercisable | $ / shares</a></td>
<td class="nump">$ 7.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_NumberOfOrdinarySharesHeld', window );">Number of ordinary shares held | shares</a></td>
<td class="nump">70,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_NumberOfOrdinarySharesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of ordinary shares held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_NumberOfOrdinarySharesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_CaerusTherapeuticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ORGS_CaerusTherapeuticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139676662879896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF RELATED PARTIES PRESENTED IN CONSOLIDATED BALANCE SHEETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ORGS_DueFromRelatedPartiesNoncurrent1', window );">Loan to related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">744<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=srt_ExecutiveOfficerMember', window );">Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ORGS_NonexecutiveDirectorsMember', window );">Nonexecutive Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 202<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ORGS_DueFromRelatedPartiesNoncurrent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ORGS_DueFromRelatedPartiesNoncurrent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ORGS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ORGS_NonexecutiveDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ORGS_NonexecutiveDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>122
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M[LN5;;6=?M^EW4'KI0RA<'6GU@)@6]AV1<U+RY<FWQ(#,QR1UI^R?;E<N7.
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M-&0C5%3'6M6%$KOR9&@EE!)9^7/+6<P++0#/'X10QPO]@N9P<?$?4$L#!!0
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M QW[GJZNSIH@S8%,$+A#->J-MET3]9: YMT,7]CB"[OQ+2WPU>.C:LB@-YZ
M6>F+(TW/P'6<UD82JOH&R-PWT+2^M8':K'2QT[B/VSH)L@4T[V+VPA9;V(5M
M:8&M[NJJK8#,;84K3SE0LW0=8MS6W4!5Z8K,I:N=AJ29Y)H4M5G=N4@-;$MD
M,UM \PY6+VR1A1W(EA;(ZO%45='(7$5?.!;3!L_/EXUE\#2KU*&+&[=O2W0S
M6T#S3G8O;-&%G>B6%NCJ(505\^@?.UE%S6(>(<.=&5>U/+9^=*H+4:RI+2$,
MU"W.;,P5,6H+:-[-\(4MOK ;W]("7ST@JBH<FZMPRV?IN%E)(HB&/FIY?@57
M-2"^4 .2Y&#D_BF+HYCPN,4"2Z?!$UM 4UM ,UM <UM "]RLC/NNVND-.TDM
M+1A5#ZVSIQ_-9;CI,0QMB%DJ0">V@*:V@&:V@.:X65OWD:=62;;HPDYTRTM2
M]?BIRG1L+M/?^A@/UCQ(X'G8:3D#PE7]C<WU]S]VUFOFO2;RFU6M!WVU]K=%
M-[,%-.]D]\(67=B);FF!KAYH5?6/S=7_SYT8F\&OB29+0%/<;$]X6#G'GVF$
M9$ZG.&6NDVH\SK_02/7Q2+U_ZJ#4I\&7%B:A'@55\P6;FR]=CIR1HXV H'&$
MHZ0%$XT(=!W<>%M#(]=HY<XT0OWA$$/US%DCYR$O&*G>T]G6\)X.*T!JH:HS
MK?W>5#4R\'6/ VB/E%N<HSG%=Z$?!,.6=AW.:^/ZJQY58>J:"U/]T<O]!2VV
M%\6SB9MXM0'8^2 KY'*$_P+RWX;(78E4KZ#EMS4>%\^S92 _/LJ?;WNF'.Q3
M$2?'HZ3LH/=$:7H\58H^ZA;*X.RMOBWEZ^(MT@RLF(0[O'QS^O7TINI]\4*G
M^CL>?0KQ2'-%3L"G\/!RZZ"B.+P:^QOAZU@.)*'/DL[Y&,C8X8>W30]?!-L5
M[Q4^,2'8MOBXH22B/!>0UY\9$\<O.<'IG=^[_P-02P,$%     @ _&%I4M$(
M8X'5"@  :3   !@   !X;"]W;W)K<VAE971S+W-H965T-BYX;6RE6VUWVCH2
M_BLZV7OVI.>$QI9M7KI)SJ&4M-Q-23;0WMV/BA'@O<;BRB8O^^MW)!MDK!<@
M_=* &4OSC$;SS(S4JQ?&_\R7E!;H=95F^?79LBC6GRXO\WA)5R3_R-8T@U_F
MC*]( 5_YXC)?<TIF\J55>HD]KWVY(DEV=G,EGSWPFRNV*=(DHP\<Y9O5BO"W
MSS1E+]=G_MGVP6.R6!;BP>7-U9HLZ(06/]8/'+Y=[D:9)2N:Y0G+$*?SZ[.^
M_VG0]L0+4N)G0E_RVF<DH#PQ]J?X,II=GWE"(YK2N!!#$/CS3 <T3<5(H,=?
MU:!GNSG%B_7/V]%O)7@ \T1R.F#I'\FL6%Z?=<_0C,[))BT>V<LW6@&*Q'@Q
M2W/Y+WJI9+TS%&_R@JVJET&#59*5?\EK98C:"W[;\@*N7L#-%T++"T'U0B"!
MEII)6%](06ZN.'M!7$C#:.*#M(U\&] DF5C&2<'AUP3>*VX&+,M9FLQ(06=H
M4L ?6*,B1VR.!B1?HEM8YQRUT(_)%W3^VP?T&THR-%VR34ZR67YU68 .8J3+
MN)KO<SD?MLSG8_2=9<4R1\-L1F?[ UR"\CL$>(O@,W:.^(7&'U'@7R#L8<^@
MT.#HU_V>0YU@9]! CA?8#-J??$.W=_=_3-#MX_UW=/\P?.Q/1^.OJ#^8CGZ.
MIJ/AY)-CGG W3RCG"2WSC&&+)UG,5A2=IRS//YC6HAPBDD.(#?U\$W4 Y'/=
M/+I,"[>]T-^)[:D7[=2+G&;HS_X+SEOZ$J=_;1(._E4P^!RS+$Y2BK(F /&S
M>!@+O]OD( ^N!O&*DR+)%N6&3XJ$YB[SM7?ZM9WFFQ0L_K,E L ,@0X0%7,B
MXHK)BN5([9J%<#?L-,RH"P5>U#$;L;-3LO,N)1&$;Y078!BZ2&+X*4W)$^/R
M-^.>=$XCF.)3OB8QO3X#*L@I?Z9G-\BTE3JZ)=HV3^GN0';?#W)*5@E'#QL>
M+T$ ]1><R@"%SB>4HC$K:(Y"H^MW-57]CA=V&ZOF5.THP^QA[NTP]YR8!V2=
M%"1%PN_1^0+8]L.%\'T3D)YN<]Q H8NT<,^\*KZGB,%SZOB5B.V7H5F2KUD.
MR@(EY)NG/)DEA,,N-,9^3]>DU^[Y3;.[IS[=[GZ-[GRWMRT)IR*P5*$'0)$\
M9W$B"5#X'\G>C-!\'9KOM9O G+._ QA6P+ 3V!<*(PH8,CG*9HBL&"^2_Y4/
MZ*O85Y9%P_I6"8.HB4R7"KHU_/MJ*[;T Z?:P_D<$CJQ#/05]GBVH.!P\(S3
M+(:]S<1"%92WJI6!E"TEXA<CD$!?HK;N>[H4]D,+#L7&_F$Z+O7/]VDKI<1F
M]]!@]Z:RNDPK"&Q[6Y&S'SFU'0F;TKS8^@60:\PWL ' WBDC62X]")CZF8(/
M/0%;ET_/8=>DFYFDX[I[P?(]T8S.$W# M'I/)OIS2HH-I\8(7>E8Q];#35HU
M" 5="ZWZBOS]MBL[,>_#O__-;WO_L/T[,"TNA Y:E,9*$_*4I ?S$U]QO^\F
M_U$6<^$[8D98'K8I4ZF8)L\$5L1H49V?6WX0>4V;&L2BP.M:K*J(W'<S>5WC
M!%P@*Q@WQU*=G%M=S?4-0J%UHRKF]=W46U>2%4O*JT4TZFDB5DU/@U!HB8M8
ML2]VLV]=37#1-4EFNR!^L57\.*_ !E+VO4[0P&$4\[$%B")<["9<HQNOR9M5
M6YUG_5ZWR48&J;"-;597)(K=)+I3]GQ&RT\?*KUE=-PN@-SPY1JXD.B,"0:-
MFBF#00QW+#DU5KR*W;QJ04)7ZY2]0>HL$'":RJRGPF#< MC J9!(-S'H4F''
MLE6QXE3LYE0+!J 7*'T@::B%7*/J!N[TVYKY=:D@"FR>I!@6NQFVI OI/+-G
MD;$(*Y?E<&GZ[8Z5.4ZU,02/+CC)"FLQ@'4Z]$-M-70A"%L6TL2*-+&[9+8L
MQXQ"MB:K>_)J60B]-@9:ZC03,X-8X-F<2-$H=M/H^)B.@E%K TMVNEZH.9"1
M=#'V+)HK.L7=DSI)H_'/X>2$3A)6G(B/YT21Z(E.S.\_P6-YD5%^@4@M5/#"
M2.G8P(*1IWFF0<JOB^VWW!1;!FZV?*35[OH%!('.?X&G(7 K<GJ!%R@B#0Y4
MKB25Y>J:"P\NWB[0&DJA*IZ(#MM:&,"(3"?+9IIM$K%4&8%BT\#-IKNVS?NT
M-M%GA)N9@%$,^[;^1U#KX[H9M!^#=GFRK6_^R=)DP61@%E]E2"%QU=C<=:,L
MS:C P**]2(/B5.@=OJ68-G S[0-G,04<<\Y6**\<K=[LL1)28"ABO:@=-+-D
MMP+OP*:8.#A4ZS[3LA,MV?BH9D]@8-!VLW'NGO<=D!03!VXF5N'N/-FADV2<
M+Z$J1U#<KX"7UPS<U\AM@4ZU6I_$(-/"V%(D!HJ/@R/Y&"+"<S*#=7AZ0^>"
MG#]LZ\;\"'8.=-85?N=K\=K(SIV.#8=BY^ T=KX=C?OCP?'L'"AV#MSL#*M=
M"Z2%8.H-?T.YZ)L;36.J6K4F@'O2T[TW5&0='E_:0O"D="7R8)2QK"53>Y:F
M8OV3JD>U+6^WX>GKPX/QJ.O7B;DZ#]/S $CG;#E*J/@[=/-W%6/S$D62YQM9
M%HA *WK2$&)?".>*&U\ICY-RS=E:GNR@\XI\H/S)<E*>@\<,3&0^_-,YO=L)
MFMO<K?4[_$"E!^&!],!J$$/C\33DAI):VP &(1]J*=LZJ[PA=.<-*C@;D30;
MJT_,<HX>&G(&'&H)J5N;=ZQ?[0#:G33L 2V)1S9"6;9H50ST9,P90D-A'D;-
ME-0DU>E8^E&A2@="=SI@][IR?1P-'??(IX08/;W '9OCJ:P@=&<%1F:=)QG@
M.\RGH<[V4;?K-]?$<!0>>CT+F88J*0@/) 7#*1I\ZX^_#J'*19):^^,OY8?A
MOWZ,?O;OAN/I1#Y\A"+X<328#LO?C6!TT@^",&SFVP:Q%NY9(X!*#4)W'WQX
M>SL<3-']+1K^NT+UV)\.*X03=.^ :(2C=\*[S2-@@TPKLJV+2CW" ^?4IZP$
MZD_1Y^'7T7@LLB! _Y]A_]&(1T]0?%R_<5)!,HB%O9ZEL(M4_A&Y\P^AZ\71
MB(;PV($ETK.%,(K:398UB.U#WL>BDHK(=V:ADQ\/#W?#[P"@?X>^C":#N_O)
MC\>AT'B7H*+I8W\\$5GI_=B9DD:*NJ-#??+J_%">2XB>K(@[LPT7@:984O1&
M"3>:RSGN"2$T,K"W[;I-I+@[.M@U%Y<"9"=S5^IS.M\ 1Y^.]=>9N<*J9P+U
M8X1]K(J^H_!XUQG?CUNEPZ@R!AS?U')T.5#M=IB;A6\E+5%T)T_'#0VBP_VA
MR' RK'7W34*UOLN^]HIIHP/UM[@;VF+SUD8<G5=GP-M>D#AEV5YE$%>8>%WX
MP)%%I/-KK]U,C Q"76SK=T6*@R,W!SNZ=?N+@<I+ "748X[T(L.U,2W:&X3\
MJ&MI_T>*BR,W%T^;!8. YZPUC A^_9Y8A5*GZ<AV6!PIFH[<--UH5=:.M35O
MA/BV BG9/#!#U5FWHQ4=;GU.+SK:BKS;!YH'>TM7PU*=#&;5]?"7I%C*Z$Q,
M;5SC+<]RXOI%6-_W.\U$RZW?"= O:Y>V5Y0OY%WV',GM5-Y^WCW=W9?ORUOB
MC>>?_4^#\M:[&J:\A/^=\$4"-4U*YS"D][$#X'AYK[W\4K"UO!K^Q(J"K>3'
M)24SRH4 _#YGK-A^$1/L_G?!S?\!4$L#!!0    ( /QA:5)CL*C>+P\  -0F
M   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&ULI5I9<]LX$G[GKT!Y9K:<
M*EF6%><^JFS'R7@GB5V1L_NPM0\0"4D8DX0& "UK?OU^W0!XV')FM_8A,0^@
MT7=_W=3;C;$W;J64%W=56;MW>ROOUZ\/#UV^4I5T8[-6-=XLC*VDQZU='KJU
M5;+@355Y.)U,GA]64M=[[]_RLRO[_JUI?*EK=66%:ZI*VNVI*LWFW=[17GKP
M32]7GAX<OG^[EDLU4_[[^LKB[K"E4NA*U4Z;6EBU>+=W<O3Z])C6\X)_:+5Q
MO6M!DLR-N:&;B^+=WH084J7*/5&0^'.KSE19$B&P\4>DN=<>21O[UXGZ1Y8=
MLLRE4V>F_*<N_.K=WLL]4:B%;$K_S6Q^55&>9T0O-Z7C_\4FKIWLB;QQWE1Q
M,SBH=!W^RKNHA_]FPS1NF#+?X2#F\H/T\OU;:S;"TFI0HPL6E7>#.5V346;>
MXJW&/O_^P_GL[-O%U?7%Y5=Q^5&<?I]=?#V?S=X>>A"G)8=Y)'0:"$T?(70T
M%5],[5=.G->%*H8$#L%5R]HTL78Z_2'%#RH?BZ='(S&=3"<_H/>T%?4ITWOZ
M"+U+NY2U_E.2-XS$F:F=*74A@W/4A;BRRJG:AP=F(3[J6M:YEJ68X:&")WHG
M_G4R=]["E_[] XZ.6XZ.F:/C_U_Y/R1$D?O:K66NWNVM20I[J_;>?[V\/L^.
MQ-]^>CD].GHC'CDLDV/Q2=7*0DYH"%=.N^RBSL<C(<57=2L+*7)CU\9&S6F'
M%\O2S+%CKHU7^0H+JK6LMQR"NEX*;T13ER:_$7ZEQ!J+:D^:A%IS1"#KF\ZB
MUU:NM7)"DQ6$7"#1%')>JHS6R#Q7SFG<BI" Q#[),YV\.?MT[?CRZ,V3L:"[
M+,?^N<(!M5=6%8+LVGA3FJ5IG-AO''-&_$ 2+&+-O'CCA-G4S)9[(HP5LL0.
M5>L\;4$6!$$$?WT#JH6IL2@N9QXM4;0^@W!052F=(SDK5>@<=G*4NY0EAJ 5
M">45M_ KNF79MVDEU+.VIFARN-G^R?67*\AU#6[/HFXKXWRYA1Z0%AS(#L5K
M%3G*-MJOB!2I#NN(1[>%"!6M@@J)X4+=(B&OP07T*I2$#1,[06B2Q#B\9Q%Q
M#I2/NTB65@2:0J[Q+.P';?C.K>2PBJ3),THM:Y^$H^BJE;1]2PCLQ*VV<!6-
M6W(3XI((>-0:3\%'3WM[2#GDBNGXE60E9)VS0=WF5EEPP'XF2EWI$-YL((1Q
MH>D.2[&FPDK:5<FZ62# &\NV5WYEBJBXPHC:>-I8NQ(2B@WY,H[IMF<]*<D?
MAK8F/R\:15N"N#EL2HI9Z;FF\B1JB8,5*YTUI^X$#*R=U[FC;84JL2PHK]4,
MOXEJ<=D^"I(F:\%96.3D]G53S;$5;*6U02R*FY7$X2':0&Q$<9"WX3BB[:X7
MK.29)H/6-=PHOEP:63I>V7HLF:1S-"FNDG'/R+A74"$%-0MJ-?D:6]@J)52-
M%$!\TSM3$Z^O06"MUXIR'Q9FI4:@TZ:K2R9WW6HX/4!BJBD\MNG)5^4I0='2
M[-ZC.5F;1%\JDK+5T A&S[VQN-!U@7ILMQSL2)AX1+E66CB?KF$AW_@8;BOC
MUG"UTE%"+ N4=/@*1:5D-1'[07DDXDK:RJ PJ8((+IN28R>'G#K'VJA C@"B
M/70P]H,D^5A<PC<R6%\]- 2)&7)0I,C44K ^4!HILO4.RJJFFD/S!<N!7%V9
MN496[G'3U!H>!8MF#[U^+"YJKN-#OBH)Q3B]K/4"LD) 7=\J%WT:A]#:OOP0
MV.&6:I7?KA6'<5NT@#^(I>RJ2U'?F262\[.<(ZM>?KGZ_AEIFVU!Q-7=&O"P
M+?F-X] [A/<7B#FKYPV_@E.:9KD2IK'W?8FC*?D#T%@IYU0IR6.X@OW./G\+
M[A'7T,.)2V9CM?.UIAJ! NN#=@*7G*;A5<@P.S3A/"#S."[-0D8G1<:LRWFR
M0=%V?$2T,I?O'I616"O+=176XJ2;G ZB<S0/DV%43:\&D/0IWV94.RD;WY+[
M[JCRVZZ^4;$73BX4N3S* PK\*"8]YP_48J$8K=/YT&PL#\/B,*):R@DX)OXA
MK^0J#2*3D$$X+D?>AU%3'$&#=2%M08&7SJ%U( C@$LI$*,!!LRGU$OKI:DQ,
M"B0^X&3PEF2 Y.6]M,W<4+(F"$F:1HZF):WB4R)A4+I#ZC%\&CZ1 1PKSN8!
M(!^]&@86$J[E-$(/H\>V^582=@BNMS%B3O6>TKY3<&3RR=Z3)8?B6/P*Q1D;
M&!YE1-0IZ+-X?)/8T#&)#8(]!+D9.HL/]U+:EX'E^CB]@WL?OEPFN)>MHR0C
M<JA;781"$8D_<-EAW  ;HW!PGB+TNJ;L"^#<L#4BCJ7<MT]"]@X7IU' %G1F
M#,[H5>*'95[U5-4I@/ICW*=$4LG?L<9O"7HJ4H"C$.&@^120]?YFI1E8!Z<M
M4M98(,68#43+R'BNF3O(+RU8?@TR,ZJ"U..*V?AD3/Z,OGNIFZI59&]-DF04
MC=#Q\'T\ _S__/DLI1Y*I."!&R'7H]5NR6A+(BCV*1&&$(:_B)XJ=T@ZZ\F0
M*#RA@I%]5'/;2%3<AY6#./YT=75P<3%@G%A.W.%URQ!BLQ!'D\DOB)=GXFCZ
M?/Q"/!L_9R202!8**+_B&L>%CX[KTTX.T![P03OR.ETWV'+)EH;+MF=6Z,DY
M,XD<IE;($13Y5$JI14#%X[C())6:CHY)=#A,H\VU!4S\ ZKP ;^1/D)NVLT#
MS):73:'"\;<0HN=Q$45;H \T#MG N4=Q9VA[PHZ#!S[:7]7SI]$#'PK-0UFF
M0Q]:/^M;?RQF(*RR^TMGLMP!:%*;A^P(7*XVPU(KY!) ,B )+O>T(E5J<NM;
M'$F-T^](% X-6)OPT<(0>6H#-S&#]C+YDGI\S25L8<&C;?(6L0--T!]ZV^^3
MM.?V-G)92>"PB$KNG0V,)(O0DX0D.Q1WB9*/C$OM3- GBOM0YE8^*C&AM'<8
M]=%4B,6+QC+L[4%#H#BY]BQ,ZAXCA39_.H G0FX):KAAPTI<SY6J(ZH+/E6O
MH57+I!;M@ 4\ EHE7JC!S4R=F,&^'4!$6*08+O2-WP$* X0*\=;$-G8 Z]BR
MCZ&Z[ >H3NQ"=9Q' .@7XOQ.Y0UCE\L%5 -1VQ)VWE8PFJ'T[-L.(G(F$5,
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M43;(I;PB;J(A;HI6F$C9GBD;ZQH:N('%4.,&S16='CY7A$0+;[->TG2$9 E
MD*8VND1:1)Q"NX$UJ\+T,@8N=S: 9MO1@[SD(R(,Q2-5AFY"E++O8/P/>DJF
M;QI4Z75 (N!LU2"!#/H7JMB6/LHR#OP&Y*EM+<.$CR=]= 1T@/3*V#'.J!XO
MWLDZ13!IX *73844_+E31U(_3YEH!M6K( ."06?7]#E!YOW>,03!@]?IDPRN
M@O]-GP8''&<GX&8)LRUI%L-#@R+U@COJV-!AUU(7XF<Q'3\33T?'D\EH,IF
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M?A^GTY&-Z\T83C@XX#S0M@@SZ-2V+9%]$/$ZHCG>=2VMN"B6GT .SP)AL4Y
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M9/\(X-Q>K0Z?&6K6Y0:M!EH/1.0:S9=)(LIM -V#@-NA17KZ[3./5O -&BH
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M<G]-4IJ!Y0K/6#5L\B(5!/C9]#H)15$-;--0I4<29.'M5I[\.H)D+*#HEYD
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M9A/(?G<Q)0@"KB/?G-V_+*,4RPNPYPV4RIVL)2'V#!Q.$!]5L&*V&2,N!-:
MIU-*=Y54!?JD3V;,,ND&TAK"NBUD$Z5;A.*&_1TP%ZV.Y5E73L*?5(:>/GDX
MMQ[Q"S*BZ6.G\ 6P"[#I^\I_BMW%)JG>9$X.SC^(@1#12!0/MQ3F4R]YZ@ZG
MEDP2Q1&X^(JF(N>(G.I1+>K,Y#6?-$;,6N!E5U&!_\A,H%X5M6_B!DC92!5K
M-\HAXKBJ'R+Q))LR6H\6&WE+ZEI)ZYIDD^+$LRWHDYHP.DNM=-+NWA1S'(AH
M/>N3T?0FQ6';3&RN"%5UNF)$SUX2#JN,?6B!EKE=<(B\%IJ$CDT3Y-'0(8R<
M/HI. %$]>B5PJ&A(18^*BA';8=%C\%UAPUS47QEO1E5'_6:$69!@)!8I>=U/
MX^"J":E6\ QQIA?P*XDNO5(A.Y")4S<<J97DYW_JR%D5)B<]040'3QGK,TJ#
M(B'S6?$Y#A@AU[?$E<CVP1-SGS5[BXU%H4!O"9H3&9@JO0>DB%O$;Y^(LE A
M@F>-,W#]M%O **W3F-O7 26:GD*?OUIB!EM[T%C[IS8LV.#:@]]\ZH8=A=)H
M:?XZE$QUKNW68"AQQ-1PKZO'ZBXJJ.GBD8#-7=S16>R*NUAO6U"=;K#7Q#%%
M%+%),2!'(UK;+MA/$F[NL? FU1#CF+ 6KW)<N,62_2*.Y=A6M>42:OQ7M"C>
M):,U\E3%"CZ9U'.H^O2);MHS\8WFA:0R@NV>",[HV8D*7UH&EP7^%H4D%A]8
M!GEI@I]@&(,,DW<OQ=5+^_3I[/')][*77 "5E?J9I#GA;XR4 L[K +01'(Q*
M) [Q[=P.P!J46R)I?A$5[TMV)$+5V/.+EUHU9G\#=C&Y#/8#>9=1$[/^%8N7
M4<DNV3@V0'XMQ:R1KA+5S\./BA4.W6N=!1NB1]L3ZZ1=Z1\J?:2M>6C8S^2<
MP[3B(8V"FK++1<"%UN")S\GGK3'6SG%S3;PV8TFW/6#F,P3M**0@ @9C#&SM
M)#X.,Y"_)QR[0?)$3#Z3@*"7T 8F%-%=XZG1M.?T+AORZIJCO(LFS+=@P=QH
M<^=$LIQ^,'G-"UFW,9>:>$(D%4>5;G=IN<W<WJ)72 4_S,X7Z'10!2E9%!?A
M6H,/T]6\7?KP,G\XN1.!;IDA:F_M^?6%_>;DF]E?7SB8E@509W:A#=:A8J^*
MU.@DD)!EUVD2!7@NZ4 H@-!NM9$FZ:">'PK^Z&Y)%VE)-].!3PJ$B*ABTEH;
M3%1_4%>:MM!@(6 <)_&ZM&:-6$RL9"/5?RH8LS1Y=A%(9GBEB0EJ=JS9U @U
M6VP!H>V#V47*8NEFP)PQBDVY(BCN1'4O.LZ(DQ_,W_[M^V^^_9Y8P:#55KD0
M$@JS4%0P=&U4?0@FH -2]0*KF'*B3&.U)-@ =;5F6^Y9ME[H_L($K90SB%,(
MD$3JZ=#'\[$)3?D6I,2RW\> AD"2$U6!*S"B?#<)6"J$#X,7T@G3QQU<Y*\
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M>51.46#>&HX9)O3<7'T "E"GAT1'XD2H=O!ZTYC)$!R*L;.JN(KKU;$8T>[
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M\5S'^<2.[\6FB74KEFF.L&.NL:C-LHU@(QEO>?+"1)*)%'8)DTPRSF9YZF^
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M4IJ [RLIL_*%-JC^473U'U!+ P04    " #\86E215-0$UD1  #"+   &0
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MZ>,H$Y*#<(K4>3?BAR,D9L5A57^/=!:\ET&*7!M@UE)KK;ZNQK;*+%[*W)%
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M"55B56BUY"L%G<X9=+HMY^-6T;6!.4PQ798B%]D6NHTP\H@^P_N'=ZQ8O1_
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M"J51H.\+0=.ZVQ@']5NM]R]02P,$%     @ _&%I4G)T7F/9"   UQ<  !D
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M,V.:@>!A.)L.N[B"'^%JC>AP35_ -8HFP6@43EY%!@%1>#@</F,7+4HN$Y;
MT$!@4\$>R1&"TO09$_V__;>EUK _G[$W;,:FXZ!C:IJ(YAC>#SJ*SMWX[,"-
M1V[\M.3:!DNM<J>(M"(W#-6!N!W:+*B\T QB<DV/0CGU'VF),_UNY'?LL@0Y
M0&\RCWEBGTZ\%TFPDQM]V(7Q))$$)'R"P)])!>PWG;8U&KC3 HJ+KY"1JBR!
MZ##@EF1*S53I(>3\L5'6G=9-\+)U,?<NIE-X'.L*&&3CX J0-/9* R7@:TPH
MQIE5%AMARM%D'L['\_;7IEJ(?1=;S=",S.(<5< RV&;7RBOL;-3 9RF_%VY
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M^(3RW<%N0!]L'2N<D+]6A?B1NK]66>.U;50UKS@"ND0=+,O6^C>Q5<3)/_3
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M]]LQ =E48A-H4;G;OQ3:U)(;9N;Q0FD!9GTEA-X%=H/V.8Q_ U!+ P04
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M4CPRCUO\4J%"'\#]-><J>]$&\E^.'OX!4$L#!!0    ( /QA:5)T<RQ+D <
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M$WY-"#=.5_X$/]/.Z96_7$J!(&4!O)]K3'C-#6_0_J1S^F]02P,$%     @
M_&%I4F"3@ZKN'0  35@  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
MS5QI<QLWTOZ.7X'RFWU+K*)H4;)LYZRB9/E(+%MERD[M?@-G0!+1',P<DIE?
MOT\WCL$,*=G)'K55NS%%#H!&=^/I$_/#75G=U&NM&_DYSXKZQT?KIME\]_AQ
MG:QUKNI)N=$%?EF65:X:_%FM'M>;2JN4!^79X^.CHZ>/<V6*1S_]P-]=53_]
M4+9-9@I]5<FZS7-5;<]T5M[]^&CZR'_QP:S6#7WQ^*<?-FJEY[KYN+FJ\-?C
M,$MJ<EW4IBQDI9<_/II-OSM[0L_S Y^,OJNCSY)VLBC+&_KC3?KCHR,B2&<Z
M:6@&A7]N];G.,IH(9/SNYGP4EJ2!\6<_^TO>._:R4+4^+[-?3=JL?WST_)%,
M]5*U6?.AO'NMW7Y.:;ZDS&K^K[RSSYX\>R23MF[*W T&!;DI[+_JL^-#-.#Y
MT3T#CMV 8Z;;+L14OE"-^NF'JKR3%3V-V>@#;Y5'@SA3D%#F385?#<8U/YV_
M?_MV=O;^P^SZS?MW<O;NA7S[YOSBW?Q"SEY]N+BXO'AW/?_A<8.5Z/G'B9OU
MS,YZ?,^LTV-Y61;-NI871:K3_@2/06*@\]C3>7;\X(PO=#*1)].Q/#XZ/GI@
MOI.P[Q.>[^2^?9=9IA9EI5@W9D4JWYH$NJ;E;%5I#;5KZ@>6>1*6><++//DW
ML_?A6=^]O[X0TZG\__][?CR=?B^_9A6A)G*6WBIQ9LI&)^NBS,K55KYMTHE\
M7XB?5='B4,KCY\3B*?[;K+4\+_.-*K92@3\T6.X9?$!4'!]]3[_SQ^GWH[$$
M_W2E4VF*II1*7JH:?\NYKF[!YKIC<AA^.9^%T:*%UE3R;FV2]9".QV4E35-+
MM5R:S*@&DZE*2ZRRJ<I;DVJ9Z*H!&LG:+U;I#&(N5O10JF\!1!M>NES2F+1-
M,!U^H@V,I:I%KK9RH:4B&E-\:NZT+IB.C:H:@QF759G+!N!$X^C?B?S()--#
MV$F?>[R;!L 44\GLO#/-&BR2-P8,7N(Y4"F,78L ET@$\NC*J*QF*81-K=4M
M;4D!V%8@=(6GY*W*6DUCU ;+?#8T--O*;^2SIT?R32&2$F *6JS28P$[9;OX
M#1C)6Z%UVPR<S9A#BVUO(YBY;A.B^#"F6"9EGIN&1HSMOASKFK5J9+O!6GAB
MDVE:5F 2FG,@".:N$\:.[NV3N=?(>JVRS*J;5[:ZW6RP;15T;--6=:L*VJ*P
M2L5[EQLPMDQI>09O>?!\)+=:51 PX*&\H[WISSIIF5]^]\/IOX;< U634#*3
MJ$6F1\+41+)I,G#I@(R3+,KB4'].LK:&E2)#8^H1ZTM;)6N8G1Z'K ):5C>T
MXXU.S-)@LM342=G2GBN3$/U65=?:L'+B5#2@4%6I< ],Y/47J;_#49;0P%*N
M*K 1RPSIA>G-TCO2ZXHY22?-U$UE%BWTDMG623<U%?0MVPI:J?!_64)P>)Q(
M*TT^!9T.O5R2?I+,ID=.0&V1Z1I,5%5FZ-SI"L91-8PX,/5)6:6J2+0[873
M\40]$0LLHS/Q6M7K,L? 2YU")IG\H&O,E:S'."?+"FA5@=:6M@U%"[ %P N
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M-:!,>J"JK5X=C-RX3;J4AO:R>\SH0PB5%:#W*TF1WAVL@<.GU?A?4$L#!!0
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MG< B \D%^1YM4*/%'Z!%,=PJ:=<&,EGPXC5 @*8=[(N?[1O$1Q%'/#^%)&I
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MGOF@ZW>[7EBU<6_E0EDL-S==XZ\.UR2 YTNE[/."" X_3[U_ 5!+ P04
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MP->T#5A=T^(Z\@U>IL,UPCNV@Y&J,I^75=F5."Q.VMW/X(5;6_<P.XYN/X.
M<_)#:RO:45&Z1=6XOK4&!H-]((G @F1<>C8:^BA[#_(%#J=>-4A+("9*F.\.
M-G6;5ST,28<VMD,::F.[=5,T5;.BP7ZS)&CP'>/?@<&S=0GRH"T7<-*X[+:T
M]<+2"/#'V[PM&SC/!LZDW3TT6,S<5B5L/<M;/+3<-74^K^Q,#M&!'*.SNUN7
MBW6&-V?P+[09_!&O"7<7K7T.<IY>7^1M>X]_Q/W:?5? !RZW@*_QC>'3HW="
MUU_8S@(1U3CZW=KR[E"<PSBN)**$]>79O'? #\[!=6WF0)%,KO!LMNW;Q3IG
M)J!5'65GBZZ'4]1=@Q2H\-:!J-ILV38;6%WC;#C](V*$95_AR7=("4"V?%"X
MC_/W_[Y\=7CR8[:%%=M-N2 :+8#$%UUUCZLH:_]3N0$>[8@B=,VS^/Q!XS*S
M\6%X[C) AP5M&$BKA)44%HZ)[G[9=T"K\(M;4+-;OARZ=;SJ'HBD[4!!SV 5
MBZHO\"1S/#*>%.>L07V6-2MY/#?/9\#-[<HB"\ @> ?&[Q471Y>X$#(#+J[Q
M7)!?8+JL['#G'9!:YT]HAC/?@1+&_^+;%IYN\,3T6.JL:H#"\4A6,"[^BR\3
M[@NF-&4-].!_PRK2ML)(>?L)B(Y8R'[.@6HLKU$'7X:K0NJ *Q@37C,:+*^
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MG2V!SO[O+8K&,G][+$^+[,UZZ9AW<+/SOLOEHL0C+?I%L@&S,RDZ71(.#\%
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M'64O=4S,'</)@V;1I2NQD=:O9 :,=\@<&*=8F0@V0OROX=_/+ FREE*Q*&5
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M]HG8+<+UH!T&&T!,'8W5M"2YM@V2%_G'$4.P)_N,ABS@3:>@-(KMVA5Z+>"
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M6H;N%V$T'1D6H5/S6BCV,OQE7/,0+XZB? 4N"+S6(SU<7D/\CH9"S$'Y,!E
M]KL-F Y0(BU%CSA D4 " GX->SZ XKZ7N23'ERR'$3X')<R8;,:(DXNE?/&0
M4K\O%0HNJL0>LGF\@;B>H6IRV41AYQX]M[L#YOSEH;QKB]'U1_4S)]]-%]"<
M!GS<Z30^[AS;;-1=Z+5S#D("A--UZ<89\!N <@X)8?\TH0V0B4I>6$SZ.!K(
M6!\<C*P0[OV1#KW@H5L<6M !%))CT#0-17$&BD\-"GAF)BV4H6?$$0-!:4LJ
M*!W8C%2VK19YV !I<BG]:0=H%7RN[/I Y=&FC.+=0\>=@@JX8X2O;%+B8>R]
MN C+342GF%]MPQ.?',?T&L?*>C"\B<^PJ4<VEWO4OLX8CF<'6(%%8\[W*I*Q
MK7?AG4(:?6L5XP5GW^(:.=$>W%9B3_2CX5+1J@XQ "IV:/IYAXE 71MF[?_*
M\V: O^W6@Y,%44ORFV!2W?@97-8>U)-9[$:6O8*_DHS5?F+)A8S<NN$$C0!:
MONG*V<Z(;GJ$B/;>,B(!"X.R*XFRX'L<>T7QU!!7HGSRL0/[61$Y6,CNH>H+
M,$N0@:D\KD>*N,/S[2*9Z[&(>-<X A>=V3D\I8C H^RM/Q)-E6.4JEP@5DK;
M,;!I%3LTX)!ILZSZ4]MO*2I-4_.O/3BWM4V[ BN4DP^&V[XXQ#D3=+,-5P(.
M6'Y/=['-[T,]3TYU0-X8EE *'A';:SUR-!YKTWKC],OXG=. QSJ=QF-]2)3A
M:*AS>H1Q.=XA_#09>9#ZT<(=3O\T6!V:AV<YA%UNN'P,_RNF"#9\U*)'JN!I
MJD)0C6J#N$C![_BB1E/5@@]D@S<L9_#N2'4338/3@NP1K2ZF/IA7*4#/C3"S
M069."^7#[$7VY,GL\?&/LI=4.!:E1FW(_(!_8T($Z*'RBS9R!@.@X#Z9,DU"
M 0)V.@T!>TD)<])5Y\'^><T^J$=?OSQ_K>CK42+[!EA8#T+GK\Z=_0:"R*3:
MS?44Q G&&)M@XJ@Q(7#D8Q@GI/ 1)=:08R/KCQ\_R)?XZ$Y_'C C.W29L,+-
M%NZA4G?<9 /]T9E0J1]6'/M!YD5V.?=GH3AZ">TPM6HBJ+5<A1XZ!RZHX1WB
M6WP G\*+(KHQWL@&;^2:LVAR$SFC-3(7GN1S20XX"7,B0@.C##PT>J0,XF'_
M4R-@J$F"%?OT"T9L@)6=3L/*N-'++JAJE":_ 5UVJ[UD1G!;] >3@FO)"PL(
MFBC*0$IQ *F_CW&]TR<2,$*GTQBA:\8FL\P]QY  %>.02:KXLO'C^08 T1W&
MB+YBOH&V\(58;?SR(GTYZK:W6)!&62$'G-V<9]\??S_[ZQ-[IRT'IK=!9W.)
M#E:D"U X6@FY(JTFT$$01R6Y.?#OG9;+1]VOCO:%KG6W9#QI-1ZSEXM0RL2K
M 5RE%==J\%!7#"V4QQJ)\)RD1&(X/TDN\3^-%$:HMDS@7$F+R<13B)/2U&RE
M8MO8P]G99$=C'5$PA&#0S8#];?0T^6KRL!,U%C&,AF?RS/SC/W[\_NF/)&$,
MNAFE]0%M/PHE7GP9<]GYT"*Z]F4G:Q7?0ZR_4$@"1FM5KMCY>)[,YWL\()!(
ML( 2;H&5!.II,7KB0A,,%8<@?!?=[@EH0#2Z4=5CLD94^B9:ENJV_<OS&=OQ
MZ_;!IZ]8#($UDHFB@Z:(UP:K3+',HI\S>D:P #M1S(1T*(2I9O\$N94^VNEI
MR^S2UNA6*)$G[TXP3%H=Z=TDELSJ,&Q*9XL(^I.NUJ>6R#:0CC^Q.Q5*PU =
M@"# M@HEGE7LW3,O8<JO"^2,3VTY1!_2J1(TC)+N;#4O_49#?:&L??2NXW,P
M&FQ@0SP6*5MT96238UR<P%DQBN(;_4F7D/$J6'$RR:'#4%LDT;FH50.08:-E
M*P8)SK &%TVQ)\MR"7\I8*%'V3NRFC!LKSK@!HV;S;BTWW $AQ]T\J!7.((N
MBIH@P=*NWI^/=\C E6!7=ZQ0(%CLJ_"4N?$R#]XWT5\R_8NN-P8KL <<- Y>
MP][Y-_D]P1X=9@;\.[-@<60;](2WE<TBX1++O.S@CFQ&H9L=*A%(B(BSAV/(
MN4A18!=\H)[%)P22^EXP9/PIVD=8Q],:8G<QZT11@0VLE+$+49$.+YSQK$"U
M+:G?*#+H6^9\8:NS/=)QB!ZF$*P@DN$W>T8S,3:FU&:HMU1<6!=YU5#FBK,O
M-(\;EF7O6#VH\PA*ER,T"*X9!G3<W&G/*D"=[A,=D6>IVL%I#VN3'+"O4TO0
MVR67\B&2/]LV)0,8\+= SGM(*?3Z2KMN^&X_*M!,'.G"M9 .)37-P1,N.X^F
M4=+@CEKD.^4</L(E)2ZQ/P[NN#1H78F;,[P-[%_!4-)]&QJVJ?57Y32!HZTO
M*$!=2DM /+H#2J_(LK$*D\!A%$=$?;:7HX$8?VT<Y=A PTH'RD @OE*!L8!Q
M)-OC AGGW1((G3LT<1F0#R^;A)B6B5A?R^0D[_ET@/4(T"G5<JT+1CX:A'E;
MBTP>8KQE7FY %5&;X>!HJ,H*JODFBCS_LR\D8TK58#YK&C^C_>"3/"QLXPHI
M %=M+D#)%B5)BS-G-%;MO89AW)7Z>%I<[RTU>=OJ0&3YRD!I]Z*=+'O21%=S
MO+6%F_]_8VAD:FB8OVAH>*2^3[*(F"")I(M7+VGHF%#*3D?P5D=D6^2>[KW=
MMFM(H'HU(^HU*-$#U.C8M6^\V=S#K]6R5!"A;8G^F]2M876;_;>H6X0-EG!J
M75/OT;YFC_;-OJQ],79-/?\9DXGQZGN!+A% "FQUP59'!$.Y#RTZEN,RGB;R
M>8-AM61_NFJ/ /0GI7^)(F/>RU)3UA-W%')!DAKWK%@%[#.,<#[5P)%2G(E7
MS6&Z$44G-QHD>N<37S/FS1EJ@)J,UIDXRHDR[NORCWZ'GS1IW%H&@V*X_ X,
M<*P)#%UH.DLN5L_RFHHN?))&8!U&CG5!_'7F,1X5$'<1YD4(26N7V#T,*:3?
M@H)!.(QHZ!V' ;;2K/@3&>38TRSZL*+,.*+- 2YL#&!GOGGWKA%PD+9$S*,/
MAV"28%76#U,S8$9\3%PQ8C!X[6FQ=^6"T+H&B+C*[_[_-RU?>V\MDDL<W][S
M#I%: O >*#+05K"VRJ,,116R&8E"L$+93U_G010P!^D2]054*<D<7PP2=^J3
M"I>X&V!(X]E-LVKS+=P9-^Y?6?TYTW![:E![O"89E&*@L*,ZL/]\RBD/ H,J
M.O3?_ F=89I9RDIL28O/*;TDZ,^RWO:=+R=O$082?C&3CZ607RGBF^J2YI9"
MZ-M20W"Q,^_C@0J4I%I6]?+W> -8QFL^Z"A!0_Y=U8A]]L+J$F$5B6,T3>K5
M7BXAR8F\FJJM W_[!O@TUR 1O?#+VZNL:!:4@Y8Q;G/?X*[M<0LC:B]6>4,)
M-U1_?2T*T'@%Z/>''R2BM?Y-)1B9RZ.DR*UR8HH2QDSHREL.JY8J<.L)4LA"
M3W=O98<.9XS6("7!;1NU"Y+1#YU0 HO_%D=\$QM!241LM+=YW2-'LR?V];3G
M# =?+%6PQF/X>PCVU1=(+,CXL7.6+XOH 78-H9)-<-(T2LFKU:[R>HS<7MRS
M-I<A> '*[5&3')^0 :?-)B*2YH#+E-E?LL5#I)AR,^];E"T7VD]F_TG&8M!_
M0Z/U0X26-"'RI7U+M5^*4&B>E!UP2%>S(1@T1V:G(A<LX^NK9<D:A9Q*-M1(
M@;.GR/H'/[%"VDZN<]C\%9EU%10&2V^.%46=:#&;(17:N'F^A*&%9&)8':LF
M6JQZQCI5&%J[&7HV('5/@ /NJ)2[J$\L6OKY*NHLA/SDZU+-3K/8M%= XF<&
M*#:E3ARV!BG!E(M4.G\8P;QOJ<&T?";!: NK!1" %U":[I "6<P)R/>U2M)R
MH>1S-Q44>GU0D2<WEPMFFU](1I]*<-1Z6JN,BE2+'L[O#U,MRD5OFIW@E#O"
M0*C>9C[L($EF('X.S _"OU2O'<F,DD0"KQ3Q\XO&H6>!8EBFQ OW#H3W&CQ=
M>*S1WBA;^&+9S 2'/#C.?L&;IB#?7)K9>S$=>2;$:;.HRDN#-"269B,->.L8
MG<Z?\ F)0SK19@$"G'L1N3@0OE]F^$=U,"7^ T;%AI(7ZBTG/93IFN; ]5PB
MIJV6F6K@D)NZMI7V@M0/Q0B\9I:1?@](>&D+C#7<[?TL<N)$*'&G!ZV($X\%
M?Z1Q-#:R6R(5.M,W"'C SXP\5[2O# W\MER:\%D\73 9L;*D1 7YD;CDH%[)
M'GAD&EJEA%1+#[M-/1?0\>U#:4ZW^]T!E7L(SMM)/6MOM[1!=14Z^6BX<-"D
M.DE6#$34-,8@-" XG6Y \ 8CC>,@@F_H,_#Y*.,!TRHC#LP1]Z&(X.@F>S=M
M00&]'[X[E8_G58D:R>&B"L%<U-D_P<9 +!JAI$Y^'*0#0ZR\Y(+_X!/RIQYY
MWCR*G\ER_1=1%MX"XR;=;($M"4+4EH071,:0%1^>'!^>/CD\/3*72P+?>@#
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MZ#4:05&?)Z<"XI)B6S#2-+D9D$T\R"#1*EB2$$V):<9GY)+O0@=?B,&_H0O
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M*CR"T.%B&E_%=/*$)(]^09<;I^M'=DLGF]?((<LQ*<O:-Z:1,8]YS+URC#[
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M$5:D+""J(5#K5.Z4*.>.3*U(UY)\+.5N(AE$#L]:.H"O^OP )AB*>%< @B"
MN"1'#+ #$@%K &$L<6BBP-Q0^@0/I7%I@Q+Y*VQ:/ &L[A"'GHV*KI-EL=R/
M3()>R6/$@41"> K & Y"IRC5L(*_P1<X9#228ZZ+HSK&Z2=OJW+]T>^HLK$J
M,'MER'&W,=1"]IJ!3 ,-5#>$W94%?8S8<6XP<@.38+%JEWG1@%4:;W?B3+[\
M%S>0GTPIQ. "$>:!PS>"IQ!!]5R0(" 0P::!XXDL4 D41;Q#..YD@#98YB*^
MS&5LRRZ59VYGPO:0[_%4:3$-MG10)+S1.L:DA80&AK"<J@9!#'R]JU_4'N<A
M.(_V F.V2+HF&"[!;@ *Z%58+=ND,X$NKE^\[P@9.9Q@<$*WQ:%C 5"+D@ZT
MJ*M *>5)KF3A^A[ A3F4[\+#J@MAJE-E=S$G*A*#F618?9G"D#;>&/O=:NQW
MWQ[[UY]'P\7MB*;>XGZP&([G..]FB\GD=G0WNI\/;OED^L!O'J9W@T,#_TWI
MM*3W328"N*@YI.I'J%TN4I&'DFK?Y%A .Z1F6G&WMU,>EBAHUR3<R%99V:D,
MWY^R.+=_P05&ZQCN9-X9^X)ER8'6/8[+&N83<X<+VS.*:0%)-^KJ?OL,?SOU
M]EF/W2/<8V7HHNWU\+]_6O=/VNR6SM#08K+VV94P,L#K5J/5I:[:.//XH9PU
MGZW$"2+4+?Z&NP94;,?5:?5M,2A6ZA_DQ8?)'1:AQ"#%L$+65N,4$Z2+9;]X
ML2IS"_9265S7W6.$WT>@B0#O5PIG2_E""JHOKLO_ %!+ P04    " #\86E2
MJ< $89,#   '"   &0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6R=5=MN
MVS@0?==7#+3%(@'<Z.:+G+4-.([;&.O$WMAI42SV@98HFZA$JB05-W^_0\I6
MTR(Q@KY('))SYLR-,]@+^57M*-7PO<BY&KH[K<M+SU/)CA9$78B2<CS)A"R(
M1E%N/55*2E*K5.1>Z/M=KR",NZ.!W5O*T4!4.F><+B6HJBB(?+JBN=@/W< ]
M;MRS[4Z;#6\T*,F6KJA^*)<2):]!25E!N6*"@Z39T!T'EU<=<]]>^,3H7CU;
M@_%D(\17(\S2H>L;0C2GB38(!'^/=$+SW  AC6\'3+<Q:12?KX_H'ZSOZ,N&
M*#H1^6>6ZMW0C5U(:4:J7-^+_0T]^&,))B)7]@O[^FZWYT)2*2V*@S(R*!BO
M_^3[(0[/%&+_%87PH!!:WK4AR_*::#(:2+$':6XCFEE85ZTVDF/<)&6E)9XR
MU-.CY?UB.;U??VG!<CZ^6Z]@?'<-TW\>9LO;Z=T:SM9DDU-U/O T&C,J7G(
MOJJ!PU> @Q!N!=<[!5.>TO1G  ]9-E3#(]6K\"3B-4TN( I:$/JA?P(O:ER/
M+%[TFNL22UOJ)W0])UP#X2E,OU6LQ)K3\.]XH[3$HOGOA*EV8ZIM3;5?,;6:
MW$RO'^936'R R>)VN;B;FEBC=#K^+X7]I"73PY>J) D=NMBDBLI'ZH[6.^ID
M(L<&9'P+VJ04&\J><ZU [R@DHB@%MZ+(H&Q"4YK0*!L;>HS-)?RN/P[FD!8;
M*DT>'9-'3&;0=\X81Q:B4FA'G3L3H?2E@_E)J[IW,Y*PG.DG> =A*_8#^V_'
M@;/(,I90R"K)F:XDM42-+Y6F4D&WWX.NWW7F9/.#/@2H&D&WTW7&Z2/AJ%^2
M)WL2Q@&\=U;51@M-<NBTPFX(4:O7CIPY50K^_",.@^ O?$N2JJARHFF*3P &
M,F'$$CT+6T'<AW,X0R-1#.?.VB*]0Q2_%UG>D=^!$S75:6JJ\^::^B7JOS3Q
MU1?X.%U\O!\O;V:3\1SFB\EX/5O<O51=)VV^7%U-'SDO%4L+.(Z6S1-LJ=A*
M4NY8@O'(15(';$]-TA34Y:E^+JW?<^N-188#:<NJPJ2F$^/WO?.WP+$&<=2'
M?APY,R4)S;%8HKAKOF'H/%RL+J#=]_'NV]/J/7N<"RJW=@0I+-**Z_J=;G:;
M*3>N'_<?U^L1>4ODEG$%.<U0U;_H8;9D/79J08O2/O4;H7%PV.4.)S65Y@*>
M9T+HHV ,-+-_]#]02P,$%     @ _&%I4M<'<G0^!   , H  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&ULG59M<]HX$/[.K]CA,IUDA@M^XRT%9AR@
MA$D"&:#7F[NY#\)>C*>V12510G_]K63BD@9HIQ_ DJU]=O?1L]*VMUQ\EBM$
M!<]IDLE.>:74^J9:E<$*4R:O^1HS^K+D(F6*IB*JRK5 %AJC-*DZEE6OIBS.
MRMVV>?<DNFV^44F<X9, N4E3)G:WF/!MIVR77UY,XVBE](MJM[UF$<Y0?5P_
M"9I5"Y0P3C&3,<] X+)3]NV;V[I>;Q;\%>-6'HQ!9[+@_+.>C,).V=(!88*!
MT@B,'E^QATFB@2B,+WO,<N%2&QZ.7] _F-PIEP63V./)ISA4JTZY6880EVR3
MJ"G?WN$^GYK&"W@BS3]L\[4UKPS!1BJ>[HTI@C3.\B=[WO-P8-"T3A@X>P/'
MQ)T[,E'VF6+=MN!;$'HUH>F!2=584W!QIC=EI@1]C<E.=4?CN3\>CFX?!N#/
M9H/Y#/QQ'X:32?_3Z.$!+N=LD:"\:E<5.=,FU6 /?)L#.R> ;0<>>:96$@99
MB.%K@"I%683JO(1ZZYQ%[&-P#:Y= <=RK#-X;I&Z:_#<$WA#SL-MG"3 LA!&
MF6)9%%.RX$N)2D(_ED'"Y48@_.LOI!(DH/_.N/4*MYYQZYUP.^O=#?H?B>_)
MAX+G8_2>1=&U>B/7+,!.F8I1HOB*Y6YO13F@+,49J!5"P(38Q5D$+.6;3 %?
MFM<]GJY9MGOW1].Q&^\E1"\\4(F;!3MD0@+J;0,B'=,%BH)XPY9CV2U@Q R3
M9)509<L;.)98Z=+$PC>2S.15Z3OG4H?S [K=A OP*BW/>;60!5\VL<"P I?W
M/(DC?@42$3*N$#SXLS07+),),U4>QLLE"LP"E'!INQ;\U&?+^&S:SN\M/!^<
M6VE8WLD ':?U$Z?$]P4T*PVO!F>D5RND5_MEZ4WF=X,IO"G_8TH\"WI<B1/2
MD2 =%D7%\J(*.!WG4I&P]F+,U4,B?:V?$]&5#NDI&7KTQKQ1F>!20N]%_KZ1
M_TWI/B.Z[NAW0?MB-S2U3J75LDL]<\X2JL!\E^0J7DMH-NO0;-5*]SM)EP@F
M,,=@E?&$1SMH55S/(NV-GJ;O6+I^WX>Z9]-\MEDHKE@"ME>QW 8Y(I32 U(\
MIN#L]^ 'P2;=D"-B@2I3J/A;+HU+NV+9'ES!9<UMDG#'="<?J6&NN86WW%Z
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M>'[5\4'5&Z,6C*S<E,ZEH9EWQYR6+"IK0/<+*<U.L Z:M3WX!U!+ P04
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M^5+_7*@8$< #T'^=YU4K\ +=L_[!?P!02P,$%     @ _&%I4M]/[KS; P
M:P@  !D   !X;"]W;W)K<VAE971S+W-H965T-# N>&ULC59M;^(X$/Z>7S'B
M3B>0V"8DO/8H$H54B\2V%=#NG4[WP20#L3:Q6=N4]M_?V($<E5KN/D!B>YYG
MWCT9'J3ZH3-$ Z]%+O1-+3-F=^W[.LFP8/I*[E#0R4:J@AE:JJVO=PI9ZD!%
M[H=!T/4+QD5M-'1[CVHTE'N3<X&/"O2^*)AZN\5<'FYJK=II8\&WF;$;_FBX
M8UM<HGG:/2I:^15+R@L4FDL!"C<WM7'K^K9CY9W ,\>#/GL'Z\E:RA]V,4MO
M:H$U"'-,C&5@]'C!">:Y)2(S?AXY:Y5*"SQ_/['?.=_)ES73.)'Y=YZ:[*;6
MKT&*&[;/S4(>ON+1'V=@(G/M_N%0RK;#&B1[;61Q!),%!1?ED[T>XW &Z >?
M ,(C('1VEXJ<E5-FV&BHY &4E28V^^)<=6@RC@N;E*51=,H)9T:K\1_Q$NHK
MMLY1-X:^(4Y[XB='_&V)#S_!MT+X)H7)-,0BQ?0]@4_&5!:%)XMNPXN,4TRN
M(&HU(0S"X )?5'D8.;[H$[Z92&2!L&*O,.4ZR:7>*X2_QFMM%-7$WQ=4M"L5
M;:>B_8F*Y>1K/'V:Q_!P!]/X+EXLXBE09&&\7,:KY4=1O4RXRM#;R)PZAHLM
M&)L<H)[3*(P^]0_(#7!1MJ6M[T2*!)5P@ QA(HL=$V^__=(/6[W?M:U45 I3
M8GM%#4Q;O!5\0Z8TH$@MDH*/Q1J55R:@-0 FTFH7JMTZ%P26>TW'NG$-_Q$!
MS^;2(;USKK/M^M/5\@I2\ME:\X[=NZ>[B6XA17Z2B91 #0E3% %R_L!4JN%7
M&#2[09>>K78SB")O0;%B*LF<^2F^T.6SHZO$ +[2=:8I *UFM]^F_ZC3]^*?
M>V[>*(*%/2S#&39[[1Y\\>)BE\LW1%BCP VG^(>=$,*P[\V1:1=)3?9UHHB$
MW1;DG*UY;AGK4=B&!AW,A&%BRVT>G;R&>MCL=R,ZK/>B'C2\!\J%@G#0@WJ+
MEG/4^AJ>6;XOS6&V&!AEF(Y;S4$46B0Y.X@&4$;H/,&5"1QM<+[0K][I0^-"
MK7>J6N_\[UI_'L^?QJO9PSV,Y_.'[^/[2=R$\60U>YZM_ORHZB]3VZI/,HH3
MN@IX^<!Y1JUKTZ2X)D^IB,LNT>\K\*)=ERKPDP*\97FIW;B.6>.6"]=HU$*V
M?6QX3[EP[T$S[%#BO8GS!M*].K6E$X^:04!Y;E,)=N =/;7A.])3JL\4?)1#
M_VP %*BV;LQ1E\B],.4LJ':K23HN!\B_XN48_L84>:<AQPU!@ZL>Y4R5HZU<
M&+ESXV0M#0TG]YK1UP J*T#G&RG-:6$55-\7HW\ 4$L#!!0    ( /QA:5(?
M#)T_F00  +P+   9    >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;+5647/:
M.!!^]Z_8X7HWI,,%VV!LTH09 V[+-"T9(.ET;NY!V +K:ENN)$)SO_Y6,CCD
MAG!I9^[%LE;:3[O[[:YTN>7BJTPI5? ]SPIYU4B5*B_:;1FG-"?RG)>TP)45
M%SE1.!7KMBP%)8E1RK.V:]N]=DY8T1A<&MF-&%SRC<I806\$R$V>$_$PI!G?
M7C6<QEXP8^M4:4%[<%F2-9U3=5O>")RU:Y2$Y;20C!<@Z.JJ$3H70U_O-QON
M&-W*@W_0GBPY_ZHGD^2J86N#:$9CI1$(#O=T1+-, Z$9WW:8C?I(K7CXOT=_
M:WQ'7Y9$TA'//K-$I5>-H $)79%-IF9\^Y[N_/$T7LPS:;ZPK?9V_0;$&ZEX
MOE-&"W)65"/YOHO#@4)@/Z/@[A1<8W=UD+%R3!097 J^!:%W(YK^,:X:;32.
M%9J4N1*XRE!/#6;17?3I-II#<T&6&95GEVV%L'JQ'>\@AA6$^PR$X\)'7JA4
M0E0D-'D*T$9[:J/<O5%#]R3BF,;GT'%:X-JN?0*O4SO9,7B=YYRD][384%@)
MGL,(;168#!AHE<+(A)@*^"-<2B/_\\2!W?K KCFP^\R!\]'[:'Q['<'T+8PG
M\_#=NUGT+EQ,II^T9!?S8Y$^":L+]$*6)*97#:Q 2<4];0P6*;56/,/J8L4:
ME&81$B;)>BWHFB@J0:44O<Y+4CS\]DO@.OX;B?5D0B)A^8#I]!<7>PE@%"C)
MY3F\R GK"R6B(AZ0-IHO,99(G:6I0_Z<OM5D!9K -Y(4B3RS9D_.N;!NIB/
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MFW$T6\[-#P#*U, \#X30FTU*4/Q2M/\ 4$L#!!0    ( /QA:5)ZA5R&GP(
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M.!"^\RNZ,C-;4 7$=@@A3$@5!(9-%62H">P<IO:@V.U8BRQY)87 OY^6'$P
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MZ ;J]R7G\NU&3W#XZ.;Z_U!+ P04    " #\86E2:L>L0% #  #T"@  &0
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M,SV6HC *^G[-N7HZF #MH#OZ%U!+ P04    " #\86E2+/;C9H(#  #4"P
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M'-C@EN6Q7HK#7U@$U#9\H8B5?<*AL/4<"'.E15* 24'"T^.;?2T2<0+P6U<
M00$(Z@*:!:!9%] J *VZ@'8!:-<%= I Q^;^F"R;Z0G3;-B7X@#26!.;^;#E
MLFA*,$_-REII2;.<<'HXF:W&C_.GV?SY?@*/B_OEZ&GV.(?W$]2,QPKF3$IF
MBO\!_H#GU03>O_L [X"G\!2)7+%TH_JN)B&&S@T+IW='I\$5IU-<-\#W?H?
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M!ZCW"\;DRT3W7%6//?P/4$L#!!0    ( /QA:5+=3V==0@,  - +   9
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M/IC#)U1<P.R5/:R*[.+ZFXWKA:LE'+/<PT7$G"ZZ(+OP&279#*6O+^_8VX<
M'8&C)%D65WK@\G+(+&:XN.$Z"M0W%*,GQCM%-.!Z./= OGS(HVD$<83R-]O6
MP0UU(8$A6I(HA'$.;N*P!VBJ8.W\YNK</GLI$OT)O:,#!KT6)_PVY^:4/E.9
MM\ P@=_44?M;+T))$)X5KUW*:9AI#%>/K&^N;M[M]+%X)\[N]2!X/PF"AE]8
MAWT_*=\'U><W6;U.:@SQC$Z.0(P>Z0T'AZQ"QZL7-*V^D&Q1O(SE(2,D2XJ/
M<P1I\)D _?TQHV$OO[ ;;-Z3=?Q_4$L#!!0    ( /QA:5*+OHXM\P(  + *
M   9    >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;+5644_B0!#^*Y/&2S3Q
M:+>E* ::*&@TXFD$SP?CPP(#W=AVN=T%O.1^_.VVM=0<5#SB"]WMSC??S.S7
M85I++EYDB*C@-8X2V;9"I68GMBU'(<94UO@,$WTRX2*F2F_%U)8S@72<@N+(
M=AVG8<>4)5;02M_=B:#%YRIB"=X)D/,XIN+W&49\V;:(]?;BGDU#95[806M&
MI]A']3"[$WIG%U[&+,9$,IZ P$G;.B4G'>(;0&KQD^%2EM9@4AER_F(V5^.V
MY9B(,,*1,BZH?BRP@U%D/.DX?N5.K8+3 ,OK-^\7:?(ZF2&5V.'1(QNKL&T=
M6S#&"9U'ZIXO+S%/* UPQ".9_L(RL_4]"T9SJ7B<@W4$,4NR)WW-"U$"D/H&
M@)L#W&T!7@[PTD2SR-*TNE31H"7X$H2QUM[,(JU-BM;9L,1<8U\)?<HT3@7]
MSN5Y]Z%W#K<7T+L]_=&'_2XJRB)Y -_AH=^%_;T#V .6P"#D<TF3L6S92C,;
MO#W*6<XR%G<#2Q='-?#((;B.ZZR!=[:&D^9[N*WS+9)VBZ3=U)^WP=_YJV+)
M=,YDJ 6I@$^@BT,%3SUM!U<*8_E<P>(5+%[*4M_ ,N"*1A!QFJRM6 ;V4[#Y
MV!8!J?LM>U$NR[\V7I,4-N^BJA=1U2NCZH=<*!B@B*&G0X-;G?+3#<9#%,_P
M!ZZY;@:PW]=??'AP"(\\J:B$7W#Z7UCO1L'2J,SL*E$H4"JXIPK75;P:[M4:
MY%M%&$=%&$>[7'LEV#3M$SFC(VQ;NBM+% NT ECWQ61^&B5IN UGO32.B\B/
M/R,-"8,E_V]M- O2YA=J@SBK/N?LIHX/\(V:XU3)@Y0Z+ME%(-7H3R@D=U26
M"/$V= ^R:IW$_:1(0H&K%E)5H57C)-Y7:F+5"DEU+_Q8$]5X\I$F5@V2^#MI
MPM_BSZ*:8BOA9-';I7'"S'(W5$R9OND()]JS4SO21"(;C[*-XK-TPAARI>>5
M=!GJD1*%,=#G$\[5V\8,+<60&OP%4$L#!!0    ( /QA:5*6K A/H@,  /(+
M   9    >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;*U66V_B.!3^*T?1K#0C
M%7(AX5(!$@6J06*G%="=A]4^N,& -8F=L1V8_OL]#FE*24B9U;Y G/A\Y_N.
M?2[]@Y _U(Y2#;_BB*N!M=,ZN;5M%>YH3%13))3CEXV0,=&XE%M;)9*2=684
M1[;G.&T[)HQ;PW[V[E$.^R+5$>/T48)*XYC(ESL:B</ <JW7%PNVW6GSPA[V
M$[*E2ZJ?DD>)*[M 6;.8<L4$!TDW VODWHY=WQAD._YB]*!.GL%(>1;BAUG,
MU@/+,8QH1$-M( C^[>F81I%!0AX_<U"K\&D,3Y]?T>\S\2CFF2@Z%M%WMM:[
M@=6U8$TW)(WT0AR^TEQ08/!"$:GL%P[Y7L>",%5:Q+DQ,H@9/_Z37WD@3@R\
MX(*!EQMX9P88F6J#5F[0RH0>F66R)D2385^* TBS&]',0Q:;S!K5,&Z.<:DE
M?F5HIX?+\=?IY&D^A8=[F$]'RVEC,9V/5M,)C);+Z6H)HV\3F,]&=[/Y;#6;
M+N'SA&K"(O4%&O"TG,#G3U_@$S .JYU(%>%KU;<U$C/P=IB3N#N2\"Z0F-"P
M"2WW!CS'<RK,QU>;N[WWYC:&HXB)5\3$R_!:%_#F%.^%@K]'STI+O&?_U&"V
M"LQ6ANE?P'Q(J"2:\2U$!AVDN5X-L6FDN"!*45T9MR-HD(&:C-P/7;_C]^W]
M:73*FSI>4.QY1]<OZ/JU=!\E%@JI7VX@B0C7"O!@@?Y,68(IK&]@*X6J)'R$
M;9]PZ?6JJ00%E:"6RB@,TSB-B*9KS$^L52$CI@)4>0]*WAMNI]I]NW#?OBH2
MYQ'@5%<Q:)<8=+UJ IV"0*>6P#B5$CUBTNM4,LWP9HH-B/?WJ?(L.B4N?C<X
MNSOE/:W@0L2Z!>'N?R <";YM:"ICV#!.>$AKB'=+I-S>&>]:"J;WW:J$A'1@
MX8515.ZI-82:-.X5VGJUVKX)W@AS?=<<0:^L)"MQ[[24-_G!A?QUG;>Z[M0R
MG?]&O'.HTPK2/B\R]>Y^/^+N28=R:Y5\SUHQ9O]HCP'?4EA0,Y^8P&>5&E:H
M\@8>KCB.#SRUX(42J<"'6'"]4^#YL"8OJD[&6U-QO?]#QOW'IU7OQ\]%>*\B
M7.]#$6]=S*UO8R41$Z9"D6(V++! 7WD(]2[:S8[S1QW9MQ[FUC>QC\A>$>IZ
M!U[3J:9JGPQD9AK^D\@MXPH];1#(:78PU>1QP#PNM$BR&>U9:)SXLL<=#N54
MF@WX?2.$?EV8L:\8\X?_ E!+ P04    " #\86E22WCK4G,"  #4!0  &0
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M1%,%7+<R91>4#3#KI92X'UB#MI"G?P!02P,$%     @ _&%I4NNHIQ]; @
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MY=_T<KK-,#\0*E1!>P5M-CRES,N)40:2Y:9+=TRJGC?+1 U9X#I!G>\9D^=
M"]1C._@#4$L#!!0    ( /QA:5(9F*5FR ,  -L/   9    >&PO=V]R:W-H
M965T<R]S:&5E=#<P+GAM;*U776_B.!3]*U8T#S/2TL1. J$") IT!XEM46EW
M'U;[8," -4G,V@[,_/NUDS1A&P?AT;R G>3><XX_SK4'9\:_B0,A$GQ/XE0,
MG8.4QWO7%9L#2;"X8T>2JC<[QA,L59?O77'D!&_SH"1VD>=UW033U!D-\F=+
M/AJP3,8T)4L.1)8DF/]X(#$[#QWHO#]XH?N#U _<T>"(]V1%Y-MQR57/K;)L
M:4)205D*.-D-G3&\GR"D _(O_J3D+"[:0$M9,_9-=^;;H>-I1B0F&ZE38/5W
M(A,2QSJ3XO%OF=2I,'7@9?L]^V,N7HE98T$F+/Z+;N5AZ$0.V)(=SF+YPLY?
M22DHU/DV+!;Y+SB7WWH.V&1"LJ0,5@P2FA;_^'LY$!<!,&@)0&4 NC7 +P/\
M7&C!+)<UQ1*/!IR= ==?JVRZD8]-'JW4T%1/XTIR]9:J.#E:3;[.IF^+&7A^
M!(_SI_'39 86L_%*_<['#_/%_'4^6X'QTQ0\+V<OX]?YT^^&]Y^G1&(:BR^@
M ]Y64_#YTQ?P"= 4O!Y8)G"Z%0-7*K8:T]V4S!X*9JB%V91L[H /?P/(0YXA
M?')S..S_/]Q58U0-%*H&"N7Y_)9\"Z(6BP!_C]="<K7X_KF2TZ]R^GG.H"7G
M\Y%P+&FZ!T7V7"LT#561)\SSZ)UY&H6H.W!/!O"@ @^N@C_2%*<;4D"W(Q=)
MNA?(>C9,P&$%'-JK1B;LL($=HL@,WJW NY:JC<C=FU7W*N">O6K?A-UK8/L!
M,H-'%7ADJ=J('-VLNE\!]^U5!R;L?@,;1BUS#;W:W#Q+W4;L,LLMPN&%L4)[
MZ:$1'C;7>;\%OK8KB"REF[%1 SMH@:Y=#=K:VBN3.-;EBR99 F+]%!SQ#W4<
MD.;*X#=70S?P6XC5C@<M+.]G:#7-,&H;K=H-H:T=+H@0]P G+$LE8+L/Q-3A
M21W8A&KJ&)I*HGK22+?IGQWHMVVJVD&AE87^,K9-S^W %JZUZ4);UUT6;, )
MQQG1?'>9S#BQ605-@X:A%[90K2T:6GGT+^#9M/.H;0O5?@YM#;V8_TG&N:8;
M%\<DMH[I'NN#NIE:T^T[050/87G ZS=./1T_[)DEH+HH(*NB\#/\4;-@=&#_
M _WK-/3][%X<\88,G7R'\!-Q1N#:2;4N/<BV]"Q8NN^HO9?<*K!9DJ!W41-+
MA<VO@K!E(Z"+@[95Y;*FCAJKIAM\)'Z5@<74N!<W+WWM_0/S/4V%HKI3F;V[
MGJ+!BYMDT9'LF%_&UDRJJUW>/*C;-^'Z _5^QYA\[^C[776?'_T'4$L#!!0
M   ( /QA:5(0 TLP#0,  /@)   9    >&PO=V]R:W-H965T<R]S:&5E=#<Q
M+GAM;,U6VV[B,!#]E5&T#ZT$S85PJP IA+2-EA9$8%>KU3ZX,$#4),[:!KI_
MOW9(T[1<U)=*?4E\F7-\9HX3N[.C[(FO$04\QU'"N]I:B/1:U_E\C3'A5S3%
M1,XL*8N)D%VVTGG*D"PR4!SIEF$T])B$B=;K9&-CUNO0C8C"!,<,^":."?O7
MQXCNNIJIO0Q,PM5:J &]UTG)"@,4LW3,9$\O6!9AC D/:0(,EUW-,:]=TU*
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M7,NK&3(5(.>7E(J7CCK\B\M>[S]02P,$%     @ _&%I4I4N"6&V @  90H
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M%CAGW\P*DJ&2O26/)W1!,(IKH2P]L2W+/\E0DA^=?JX_NR6GGXNJ3),<WQ)
MJRQ#Y.4,I\73ER-XM/[@>_(X+_D')Z>?%^@1W^'R]\4M8>].-EKB),,Y38H<
M$#S[<C2"O]Y MY:HB_Q(\!.57@/^+ ]%\9._F<9?CBS>))SBJ.0Z$/MOB<<X
M3;DJUI#_-%J/-I5R0?GU6OM%_?3L:1X0Q>,B_2.)R_F7H^$1B/$,56GYO7BZ
MQ,T3>5Q?5*2T_A<\-66M(Q!5M"RR1IBU($ORU?_HN>D)20"Z'0)V(V";"CB-
M@&,JX#8"KJF UPAXI@)^(^";"@P:@<$K@<YN'38"0],:@D8@,!6 UMIREK'(
MQMC&UH9K<T-C>\.UP:&QQ>':Y-#8YG!M])7#GZP\OAXNYZA$IY])\00(+\_T
M\1?UF*OEV2A)<LZ'NY*P;Q,F5YZ.;\)P=';S?70_O;D&H^MS$$['D^N["1A]
M_3Z97$VN[^_ AW-<HB2EX!H1@OAX_@A^ ;_?G8,/__CX^:1D[>#:3J*FSK-5
MG79'G=]0?@PL^ G8EFVWB(_5XN<X.@;.2MQJ$3]7BX\6A-4^Z!2?J,6OB^4Q
ML#TN#H<MXA=O$_^J%K^)RF, _4[Q2X.>MX>=XE.U^ 5^8%UGU^)MAOOV-L/]
M9BP.@Q;Q\&VU7[VM]FMS\;:>OS&Q>ZOA3MB(WPQ[>S/L[5J?TZ%ODI=)^0+"
MA)9)_DC!GR$K *8ESNB_%>J=C7JG5N]VJ/^.*48DF@.4QVRR7K(P9,&"BA+@
M9Q;84-QFO95&K];(HYKEZ= )AKYE,6,M93OM%H2NQ?Y*!;<:[6X:[2H;/4:8
M5!3<SS%!"UR5243!-(_ GU<X>\!$U2_>I@JOCV[W-^I]Y1/<8A*Q7F9Q'2AF
MH'C*,:'S9-&&6+4B#QY;UC_;1OB!<N'^<EL],-CTP$"IZ+KBIJJ??L'#3PH2
M2BL<MS5II<F7_&A@=3K1<-. X;M[_G#'H6VKNR7!IB6!LB57Z#G)JFSCON"_
MX+[N#/ 5YY@F%(3LS]C$O:$EH@FK#P>'4K@"E4]U4945P2P62C&+CICN!7KA
M_4M;XPBXT[/>=L\VTY99N5!?;ONI!(VAK?::X@6EK-\FG4XR;C3([NI:JLH%
MJZ$:UBV.\@840H%;Z/;B*P*VT#/J54:#G*VT*6(^\PDL-I!LC2'4*CT-IZ!
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M%?:59ICA?P40V@&?+SA7NXE>H/GW,?P/4$L#!!0    ( /QA:5+T)*^EM@(
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MC?Y2V?BQD3M-10*;5Q_6 ]> ^]8)-SZZ.BY<)6=<Q01]D\)L-)J)A"4?#;C
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M&QB^F;("\'XEI3DM[ 'E.#_\%U!+ P04    " #\86E2U6]-@9X"  #S!@
M&0   'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6S-E4MOVD 0Q[_*R*=&JF)C
MPJ.100)"E4@A0: TAZB'Q1[P*OMP=]>0?OONKHT#;4"]M1>\K_G/;V:6V60G
MU:O.$0V\<2;T(,B-*:[#4*<Y<J(O98'"[JREXL38J=J$NE!(,F_$61A'43?D
MA(I@F/BUN1HFLC2,"IPKT"7G1/T<(Y.[0= *]@L+NLF-6PB'24$VN$3S5,R5
MG86-2D8Y"DVE (7K03!J78_[[KP_\(WB3A^,P46RDO+53>ZR01 Y(&28&J=
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M&MLD_3"WKQ(J=\#NKZ4M?SUQ#IIW;O@+4$L#!!0    ( /QA:5(AX-.N^@0
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M;%T=1'Z[FK\HOC 7E ]<*<[,XYR2B(JL@_Y]RKEZ><D&*.ZX!_\#4$L#!!0
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ME!1CD_'R91(SVI>ZJ4NACE(0@0]YQM8%N,N69'F:P.2X&_#H /X&:3/>DL@
M&/X.D(4L!:#I#S>'@08.;OH25_GLCGRS3?EF%N /&F:,+,%##N[239)_)Z0
M?WT@Z2.A?VOJV$T=NZJ#.^H<DH(%RZ-O8+;+""W6\0;,DS #K^X6L_EK<!L7
M49(76UK6?L\S@'M&TD)7WVGJ.UJ>'[<E$Y"OP('Q17/%5XJ"A=DRSIY R !;
M$T"R91E;7GXG(56].'4]MZI7+CS/$V2[CH/0V'P^'D]%'/9<&WE-W DAMR'D
M:@E]K28['['K9T+YX@7N7@B-XH* .8TC,IA>7=T_@FT;MMWBI@IRH)J8UQ#S
M>H_4_NU4X?2D[G4]U[&L%E(Y#-KV<=@)5K_!Z@\<! UR7^H\;'CM'I:#; ,Z
M:M1!@SKHW<,'X$JDVG2E:%\6FS B5R.NR@6ASV0T :JE;7B>$[[0$H)A#1PG
M+7]]]AX=\!,2G?; D63",\9\$],.QE":+Q<0^I[;>CV5<:[G=,PKB 1>-'C$
MNM$C:=9XAN^WL<M1KF%UK%Y0""K4*ZJJI[E[6Y&X8QW8YSOI0\>S[+:0J.*P
MSR6G [&09F@/[&L]?ENE A)Z.<HS8%=O"UF'_75]&F81]]@=:&4]OH".8V.O
M#5A;^(RY*I0=#I5V/4-9E7T#^];1/]CFJ@5T!E<A]K"_V@\S+E"6>A1 SW6E
M 58$MAS<*2GA"N!06S"0HLH56$Z;GRKJR,*=DA/F ?9W#X<K4O,,'Q-2TOD1
M*H$\""@( GDZ*@(A1([;X:.1, =HJ#DXG]Z^=&ND<(N;,@IUK(U(:#[2:[YB
M;_<QS_KM[Y!0;(1^R0X/">5%_95WV$1#LN0Z@8]A>W>AB+/=(/ Z)AL2THR&
M2O- @K(J.X;D\M11';X#">U&_;5;LU]"LG*[2-[I*<(@\C%V.^ *649#95D'
M7A9E; 3M14X1Y1AN5T<+D47]15:[X4&R-%[P+L3MW:F^;G_?@(3$HJ$2JR>H
MVGQ+K[T6PAGLA,:B_AJK]>!(5L=RP-J60%^V/R,L1!8/%5DM/RPKI&,$08N>
M'L,9](34XO[;:ZU)QXJ-,RJM>9N2MNX9E(2>XZ$[<#U!>7?M&&WCHX=P!KNC
MS][_MU? "J]@!]!N[[54<:>>XI22\ KXUWH%K'(!OC0'_\-1G)(37@&?__V^
MORW'LD>P'2OPVA\M%'$.#IRN#[!8> G\L[[>GT%.-A&N@=I?OQ11SO$WLIJ8
M>71*EQ+Z5!U>%B#*MQFKS[R:I\T!Z75U+-AZ?@,OI_4QITA3G[I^".E3S(DF
M9,536MQ7C@"M#S+K&Y9OJK/ QYRQ/*TNUR1<$EH&\-]7><X.-V6!YCAY\B]0
M2P,$%     @ _&%I4K9AX/@4%   (<(  !D   !X;"]W;W)K<VAE971S+W-H
M965T.#4N>&ULQ9UM;^/&U8;_"F'T0P+TD7G.</@2> UL;*<-FL2+>-,6*/I!
M:].V$%GR(\GK+- ?7\I+>H[,.7.&Y+#TAUV_D$=##74->7/NN4^>UYO?M_=E
MN8O^>%BNMN^.[G>[Q^^.C[?7]^7#?#M;/Y:KZB^WZ\W#?%?]N+D[WCYNROG-
MRTX/RV.,X_3X8;Y8'9V>O/SNP^;T9/VT6RY6Y8=-M'UZ>)AOOGQ?+M?/[X[@
MJ/G%KXN[^]W^%\>G)X_SN_*JW/WV^&%3_73\6N5F\5"NMHOU*MJ4M^^.WL-W
MYTK%^SU>-OG[HGS>DN^C_;%\6J]_W__PX\V[HWC?I')97N_V->;5?Y_+LW*Y
MW)>J&O+_==6CUQ?=[TB_;ZK_\'+TU=%\FF_+L_7R'XN;W?V[H_PHNBEOYT_+
MW:_KY[^6]1'I?;WK]7+[\F_T7&\;'T773]O=^J'>N6K!PV+U]?_Y'_4[07;
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M,L2>;YFEQ?R;5U>E[UZ!J6):0\8I&$Z^Z#_1(3FBRXI*'EP$-.W 2<@(9@@
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MG2"X.ST@FK>%>7[572!V3A#\G-VQE]MFK?,B+3%S@N#F',HHH7SQEE'R"E-
M+*"0AQ3F\[9XH[DP#N("!<$&VIU1[H(]KB:)=10$[VCOD('0SUV)RQ0$(^@
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M_GZ[7N^:'_8O\+S>_/[2O-/_ E!+ P04    " #\86E2LUZCOGL#  !O"P
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M9KE2$S%R;:">+QB3VXUV4,[8@U]02P,$%     @ _&%I4DF3E]TG#@  +UP
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M/<YI-8ZM&.<33@Z!;8WH7]N2D)\9D%NVDOQ<3WZ;/AX"5(X. PGYA9Y\C+<
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M8/P,!#H+NK@,7:B\%PXX+ =Z6#8&H+.@ZVDK\A "#L>!'HZ-5?,LZ.9XVYK
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M"B.@_R\Y5R\;,R,U0_3X?U!+ P04    " #\86E2Z/-5C*8"  !]!@  &0
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M#C/]=8#"&.CG*>?J;6("5-\;HS]02P,$%     @ _&%I4@:M_X4@ P  Z@@
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M,M4?(RB,@WZ><*Y>-B9!]7DS_ 502P,$%     @ _&%I4C7_"GA& @  .P4
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M*$T [:^$T#O#'-!\I<+?4$L#!!0    ( /QA:5+;@O0ZL (  )<&   9
M>&PO=V]R:W-H965T<R]S:&5E=#DW+GAM;(U5:V_:,!3]*U?1/K12VSP(&:T
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MJZ]*$Z_:8#61;&4ZR9Q)U9?,,%-_#N0Z0.TO&).[B4[0_(N&?P%02P,$%
M  @ _&%I4J>25V0# P  [0<  !D   !X;"]W;W)K<VAE971S+W-H965T.3@N
M>&ULC95M;]HP$,>_RBGJBU9JFR<(M (D'E6DEJ+2;GMKDH-8=6QF&^B^_>P$
M,@:![0W$SMW_?G=V[EI;(3]5BJCA*V-<M9U4Z]6CZZHXQ8RH>[%";MXLA,R(
M-DNY=-5*(DERIXRY@>=%;D8H=SJM?&\J.RVQUHQRG$I0ZRPC\E</F=BV'=_9
M;[S19:KMAMMIK<@29Z@_5E-I5FZIDM ,N:*"@\1%V^GZC_VFM<\-OE'<JH-G
ML)G,A?BTBW'2=CP+A QC;16(^=M@'QFS0@;CYT[3*4-:Q\/GO?HHS]WD,B<*
M^X)]IXE.VT[3@0079,WTF]@^X2Z?NM6+!5/Y+VQWMIX#\5IID>V<#4%&>?%/
MOG9U.'#PHS,.P<XA.':HG7$(=PYAGFA!EJ<U()IT6E)L05IKHV8?\MKDWB8;
MRNTISK0T;ZGQTYU9_VDX^'@>PNL(1N-)=](?=Y]A^&,ZG,R&,[@>H":4J1NX
M@X_9 *ZO;N **(?W5*P5X8EJN=I@6#$WWH7L%2&#,R'] %X$UZF"(4\P^5O
M-?QE$L$^B5YP47& \3V$_BT$7N!5 /7_V]U_N( 3EC4-<[WPC-Z(<L)C2A@,
MO\S7IE#!!/4%X5HI7,N%:V>$QSPV7ZI">P +0B5L"%LCB 5LB92$:P7F2&!1
MQF>4S"FCFAJ$S'BN)29 ](%SU?%=A+!MY5&M2(QMQ_0-A7*#3@>JJE[HU',=
MVTTVG2ALN9N* M3+ M3_40"-)J8&+ H+IA'$@F]0:CIG"$P07GDC"]GH ,4/
MZK42IN ]-:H]-*N!HQ(XN@AL6HUI)-SPQBGA2TNHU"WPX^M04$:GE)%W!'EJ
M$S[4JR$;)63C(N2K3E&:.Q6+K/(^-$Y"WH7U\(BKPLCWSQQWLP1K7@1[%YJP
M*J+FR<WRO<@_(CHU:M:.@=R#SIFA7.8#19D[M>:ZZ#_E;CFSNGFK/MKOF5E6
MC)X_,L4@?"%R2;D"A@LCZ=TW#)$LADNQT&*5]^>YT*;;YX^IF<<HK8%YOQ!"
M[Q<V0#GA.[\!4$L#!!0    ( /QA:5(;G;\84P0  &L0   9    >&PO=V]R
M:W-H965T<R]S:&5E=#DY+GAM;+586V_B.!3^*U8T#S-2MXF=0* ")"!44ZF=
M5D!WM:KFP4T.$#6)6=M 1]H?OW:2)I1<VM6T+R6VS^4[%W^V.S@P_B0V !(]
MQU$BAL9&RNV%:0I_ S$5YVP+B5I9,1Y3J89\;8HM!QJD2G%D$LOJFC$-$V,T
M2.?N^&C =C(*$[CC2.SBF/)?$XC886A@XV5B'JXW4D^8H\&6KF$!\GY[Q]7(
M+*P$80R)"%F".*R&QAA?>,31"JG$GR$<Q-$WTJ$\,O:D!U?!T+ T(HC E]H$
M53][F$(4:4L*QS^Y4:/PJ16/OU^L7Z;!JV >J8 IB_X* [D9&CT#!;"BNTC.
MV>$[Y %UM#V?12+]BPZ9K-LUD+\3DL6YLD(0ATGV2Y_S1!PIV)T&!9(KD!,%
MW.3!SA7L4P6G0<')%=)4FUDH:1X\*NEHP-D!<2VMK.F/-)FIM@H_3'3=%Y*K
MU5#IR=%B^GWFW5_/T.TEFL^NQ\N9A^[&\^7?:#D?_UB,I\NKVQ\+]-4#2<-(
M?$-_H/N%A[Y^^8:^H#!!RPW;"9H$8F!*!4<;-?W<]31S31I<8X)N6"(W LV2
M (+7!DP51Q$,>0EF2EHM>N"?(QN?(6(1JP:0]VYUW&^!8Q>YM5-[=H.].414
M0H#N*)>_T)+31-"LVQ^NE2BZDA"+GRV.G,*1DSIRFHHHF?^$)JK] S1EL>($
M0;6?NIIDECJI)4T*^Q'I.>[ W!_GJ2ID6YU2Z!7(3@&RTPIR#GM(=B#0BK,X
M;VW@=1 S.]TC[]AQ.R<0:X2(:]5#[!80NZT0IZH=PV07)FMTNP6>YE"@AQN(
M'X&W%<HM'+B?VQ&]PE'O@Y+=>T^R:X0:D]TO(/;?2+:0B*W4X2& <G^#%(LH
MQMZKHVBK#A:9CAL7!?!]Z(,X0PG(NKCZ%<B.ZY*3N%H1ZB/W0FRI#T-CJX'P
M/1@CU%(=;)6L:[4&?QDF-/%#&BD.]55I:MG3JF:]VS^)H$X(D_K*X*-# ?_&
M1D#_HMDS^#M]8J/;U4K5@;]GEV!2^B>?NT]PR='8_C#NS$T=)YL0?%J1JE"O
MWVNH2,GPN)WBWX3F5/O KF*K2O4:NZ4D=MS.[&]VRX11'J!L_"X^Q25CX^XG
M=TK)W=C]J$Z9O&'J ?^L+:);[2^KLN.K0@YV&FI8GA>X_<"XH8FZYA>\ZZL*
MJINS+ND*H/YRUZO>)+K.*=CJR4%LNP%L>7+@]J/#"X6?]9PJQ0<2%"GYFUB?
MVW:DY&+2SL7_H^V\W-1QNMUN?;9)2<:$_ [U>+GZ<2-T>YT&KYJ77\^4%$C:
M*;!^TTS>T/*8N@4E3.J#-MH%H)XMN$^0>VY9R+7.+,NJJY)Y]*)2%Z=U^C(5
M:EOL$IG=RXO9XO4[2=]\)_-3]2K&-?-C8E],B5VSH@)2*]GKKG2=/<-O*%^'
MJM$C6"D8UKFKDLZSEVTVD&R;OO4>F50WOO1S S0 K@74^HHQ^3+0#HK_+XS^
M U!+ P04    " #\86E2:=ZP?L@"   F!@  &@   'AL+W=O<FMS:&5E=',O
M<VAE970Q,# N>&UL?95M;]HP$,>_RBGJBU;J&@B%KA4@\52M$FT1#YNFJB],
M<A"KCIW93FFE??B='4C95N!%8E_N[O_SV3[:&Z5?3(IHX2T3TG2"U-K\)@Q-
MG&+&S(7*4=*7E=(9LS35Z]#D&EGB@S(11K5:*\P8ET&W[6T3W6VKP@HN<:+!
M%%G&]'L?A=IT@GJP,TSY.K7.$';;.5OC#.TBGVB:A566A&<H#5<2-*XZ0:]^
MTV\Y?^_PG>/&[(W!K62IU(N;W"6=H.: 4&!L709&KU<<H! N$6'\VN8,*DD7
MN#_>9;_U:Z>U+)G!@1(_>&+33O U@ 17K!!VJC;?<+N>ILL7*V'\$S9;WUH
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M= <@+032.AUD6CT 2!N!M-5">I2[,8L2%@8DG)'IDK. <@[@1@C<2"T<9_.
MS9CK! EQ7#=<!@D+YB0*?>8R"B''".18<0LR[H82;$D]$D8T=F1C K8)PC91
MR^:X?RX99\W==0*/Q#2,YT[ _GK-..AC<;NOEC**9;,EMQ](Y(M;S1M4*LBC
M!0T22(G:1;%>6) XP9Q-?4H<SNDSYCP,O6OF^Y 24\Q M6/"X$JT98/IATX
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MJK<%Z&U5;PO0VZG>#J"W4[T=0&^G>CN WJYZ6 +0VZG>#J"W4[T=0&^G>CN
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ML^J= 7H7U;L ]"ZJ=P'H753O M"[J-X%H'=1O0M [Z)Z%X#>1?4N +V+ZET
M>A?5NP#T+M5A'8#>IJN/ZP#\-EUU8*?[3L''Z7/?C[>BKW45\)U>3Y?/]K?O
MORZ_+M:WX4IT>Y\Q/OT%4$L#!!0    ( /QA:5)_X$/,6P(  $TY   3
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MK"5%UI(B:TF156XHM,K-_[3U^S@>_G'\\DS[JAU>\L7R+\J;GU!+ 0(4 Q0
M   ( /QA:5('04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ _&%I4J\IC)/O    *P(  !$
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M970R+GAM;%!+ 0(4 Q0    ( /QA:5)=LE4BB0(  !0'   8
M  " @>86  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #\
M86E2@':TNM$&  !H'   &               @(&E&0  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ _&%I4C2L!$%K"0  _SL  !@
M         ("!K"   'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( /QA:5+1"&.!U0H  &DP   8              " @4TJ  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #\86E28["HWB\/  #4)@
M&               @(%8-0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ _&%I4A1.*H)C*0  PGX  !@              ("!O40  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( /QA:5)I5. 8= H
M #0:   8              " @59N  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    " #\86E215-0$UD1  #"+   &0              @($
M>0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( /QA:5*W
MGP=IJ0,  *8'   9              " @9"*  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ _&%I4J@OA/E>!   MPD  !D
M     ("!<(X  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /QA:5)@DX.J[AT  $U8   9              "
M@?RM  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ _&%I
M4CTUW")L!   C D  !D              ("!(<P  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    " #\86E2.<J9+^D%   D#0  &0
M        @('$T   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( /QA:5)#RFA1/P0  &8)   9              " @>36  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ _&%I4LU^24%@#P  ;RT
M !D              ("!6ML  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    " #\86E2C6W,?&0*   T&0  &0              @('QZ@
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( /QA:5)2$.ST
M204  )D+   9              " @8SU  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ _&%I4MM8NJ>9 @  W@4  !D
M ("!#/L  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #\
M86E2U#?E?\$"  "\!0  &0              @('<_0  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( /QA:5*GN"(Z]@,  $@)   9
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M970S,"YX;6Q02P$"% ,4    " #\86E2J< $89,#   '"   &0
M    @('Z00$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M /QA:5+7!W)T/@0  # *   9              " @<1% 0!X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ _&%I4N0W:$*A!   R L  !D
M             ("!.4H! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    " #\86E21NFZ2V$"   :!0  &0              @($13P$ >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( /QA:5)69I(L\ 4
M ' 0   9              " @:E1 0!X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ _&%I4MRQFZC" @  P@4  !D              ("!
MT%<! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #\86E2
M\RUG=<@#   +"0  &0              @(')6@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( /QA:5*4.??LO@,  #H(   9
M      " @<A> 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ _&%I4L.4I-T\"@  XA\  !D              ("!O6(! 'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #\86E2WT_NO-L#  !K"
M&0              @($P;0$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( /QA:5(?#)T_F00  +P+   9              " @4)Q 0!X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ _&%I4D>;68..
M @  ;@4  !D              ("!$G8! 'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    " #\86E2ZW)-UKL"  "E!0  &0
M@('7> $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( /QA
M:5+<CW:[U ,  &P)   9              " @<E[ 0!X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ _&%I4H)Z[EPK!0  MA,  !D
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M=#0Y+GAM;%!+ 0(4 Q0    ( /QA:5)JQZQ 4 ,  /0*   9
M  " @0V8 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
M_&%I4BSVXV:" P  U L  !D              ("!E)L! 'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6Q02P$"% ,4    " #\86E27A7$,0D&  #(%0  &0
M            @(%-GP$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4
M Q0    ( /QA:5+3P7NMD@,  $4*   9              " @8VE 0!X;"]W
M;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ _&%I4DW-GH0@ P
M$@D  !D              ("!5JD! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6Q02P$"% ,4    " #\86E2]BE//5\&  ",&@  &0              @(&M
MK $ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( /QA:5*'
MJXIM50,  &\+   9              " @4.S 0!X;"]W;W)K<VAE971S+W-H
M965T-38N>&UL4$L! A0#%     @ _&%I4MU/9UU" P  T L  !D
M     ("!S[8! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /QA:5(4.DK/80(  $ %   9              "
M@>3% 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ _&%I
M4D8,TZS8!P  VBL  !D              ("!?,@! 'AL+W=O<FMS:&5E=',O
M<VAE970V,RYX;6Q02P$"% ,4    " #\86E2A4 0P5L$   M$P  &0
M        @(&+T $ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0
M   ( /QA:5(VF8[L. P  #-+   9              " @1W5 0!X;"]W;W)K
M<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ _&%I4HN^CBWS @  L H
M !D              ("!C.$! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q0
M2P$"% ,4    " #\86E2EJP(3Z(#  #R"P  &0              @(&VY $
M>&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( /QA:5)+>.M2
M<P(  -0%   9              " @8_H 0!X;"]W;W)K<VAE971S+W-H965T
M-C@N>&UL4$L! A0#%     @ _&%I4NNHIQ]; @  P@4  !D
M ("!.>L! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " #\
M86E2&9BE9L@#  #;#P  &0              @('+[0$ >&PO=V]R:W-H965T
M<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( /QA:5(0 TLP#0,  /@)   9
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M970W-2YX;6Q02P$"% ,4    " #\86E2'KH&,F\"  !!!P  &0
M    @(&*$@( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    (
M /QA:5*"4Z$FM ,  (D,   9              " @3 5 @!X;"]W;W)K<VAE
M971S+W-H965T-S<N>&UL4$L! A0#%     @ _&%I4O0DKZ6V @  %0@  !D
M             ("!&QD" 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"
M% ,4    " #\86E2^F,+?=8$   D$@  &0              @($(' ( >&PO
M=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( /QA:5*%Y-<%ZP,
M -H+   9              " @14A @!X;"]W;W)K<VAE971S+W-H965T.# N
M>&UL4$L! A0#%     @ _&%I4M5O38&> @  \P8  !D              ("!
M-R4" 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4    " #\86E2
M(>#3KOH$   M%P  &0              @($,* ( >&PO=V]R:W-H965T<R]S
M:&5E=#@R+GAM;%!+ 0(4 Q0    ( /QA:5)\S,UE?P0  .\6   9
M      " @3TM @!X;"]W;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%
M  @ _&%I4B?H=..;!0  6AX  !D              ("!\S$" 'AL+W=O<FMS
M:&5E=',O<VAE970X-"YX;6Q02P$"% ,4    " #\86E2MF'@^!04   AP@
M&0              @('%-P( >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+
M 0(4 Q0    ( /QA:5*S7J.^>P,  &\+   9              " @1!, @!X
M;"]W;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @ _&%I4DF3E]TG
M#@  +UP  !D              ("!PD\" 'AL+W=O<FMS:&5E=',O<VAE970X
M-RYX;6Q02P$"% ,4    " #\86E2PJ@BBX(#  !0"P  &0
M@($@7@( >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    ( /QA
M:5+H\U6,I@(  'T&   9              " @=EA @!X;"]W;W)K<VAE971S
M+W-H965T.#DN>&UL4$L! A0#%     @ _&%I4JRQ?-;R!0  W!X  !D
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M=#DT+GAM;%!+ 0(4 Q0    ( /QA:5(U_PIX1@(  #L%   9
M  " @=9W @!X;"]W;W)K<VAE971S+W-H965T.34N>&UL4$L! A0#%     @
M_&%I4A9K=L&- @  L08  !D              ("!4WH" 'AL+W=O<FMS:&5E
M=',O<VAE970Y-BYX;6Q02P$"% ,4    " #\86E2VX+T.K "  "7!@  &0
M            @($7?0( >&PO=V]R:W-H965T<R]S:&5E=#DW+GAM;%!+ 0(4
M Q0    ( /QA:5*GDE=D P,  .T'   9              " @?Y_ @!X;"]W
M;W)K<VAE971S+W-H965T.3@N>&UL4$L! A0#%     @ _&%I4AN=OQA3!
M:Q   !D              ("!.(," 'AL+W=O<FMS:&5E=',O<VAE970Y.2YX
M;6Q02P$"% ,4    " #\86E2:=ZP?L@"   F!@  &@              @('"
MAP( >&PO=V]R:W-H965T<R]S:&5E=#$P,"YX;6Q02P$"% ,4    " #\86E2
MAQ7"FP@#   F"0  &@              @('"B@( >&PO=V]R:W-H965T<R]S
M:&5E=#$P,2YX;6Q02P$"% ,4    " #\86E2'%'/=8T"  !\#P  #0
M        @ $"C@( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( /QA:5*7BKL<
MP    !,"   +              "  ;J0 @!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( /QA:5*_[JQ&? <  !-"   /              "  :.1 @!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " #\86E28\012MT"  !<.P  &@
M    @ %,F0( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" #\86E2?^!#S%L"  !-.0  $P              @ %AG ( 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     ;0!M /0=  #MG@(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>502</ContextCount>
  <ElementCount>651</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>185</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Comprehensive Loss (Income)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/StatementsOfComprehensiveLossIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (Income)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/StatementsOfChangesInEquity</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/DescriptionOfBusiness</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - DISCONTINUED OPERATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/DiscontinuedOperation</Role>
      <ShortName>DISCONTINUED OPERATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - ACQUISITION AND REORGANIZATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/AcquisitionAndReorganization</Role>
      <ShortName>ACQUISITION AND REORGANIZATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - PROPERTY, PLANTS AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/PropertyPlantsAndEquipment</Role>
      <ShortName>PROPERTY, PLANTS AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - CONVERTIBLE LOANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ConvertibleLoans</Role>
      <ShortName>CONVERTIBLE LOANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - LOANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/Loans</Role>
      <ShortName>LOANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/Commitments</Role>
      <ShortName>COMMITMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/CollaborationAndLicenseAgreements</Role>
      <ShortName>COLLABORATION AND LICENSE AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - INVESTMENTS IN ASSOCIATES, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/InvestmentsInAssociatesNet</Role>
      <ShortName>INVESTMENTS IN ASSOCIATES, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/Equity</Role>
      <ShortName>EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - INCOME (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/IncomeLossPerShare</Role>
      <ShortName>INCOME (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/Stock-basedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/Taxes</Role>
      <ShortName>TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/Revenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet</Role>
      <ShortName>COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - FINANCIAL EXPENSES, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/FinancialExpensesNet</Role>
      <ShortName>FINANCIAL EXPENSES, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - RELATED PARTIES TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/RelatedPartiesTransactions</Role>
      <ShortName>RELATED PARTIES TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://orgenesis.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - DISCONTINUED OPERATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/DiscontinuedOperationTables</Role>
      <ShortName>DISCONTINUED OPERATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://orgenesis.com/role/DiscontinuedOperation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - ACQUISITION AND REORGANIZATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/AcquisitionAndReorganizationTables</Role>
      <ShortName>ACQUISITION AND REORGANIZATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://orgenesis.com/role/AcquisitionAndReorganization</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - PROPERTY, PLANTS AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/PropertyPlantsAndEquipmentTables</Role>
      <ShortName>PROPERTY, PLANTS AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://orgenesis.com/role/PropertyPlantsAndEquipment</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://orgenesis.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - CONVERTIBLE LOANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ConvertibleLoansTables</Role>
      <ShortName>CONVERTIBLE LOANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://orgenesis.com/role/ConvertibleLoans</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - LOANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/LoansTables</Role>
      <ShortName>LOANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://orgenesis.com/role/Loans</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://orgenesis.com/role/Leases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - INVESTMENTS IN ASSOCIATES, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/InvestmentsInAssociatesNetTables</Role>
      <ShortName>INVESTMENTS IN ASSOCIATES, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://orgenesis.com/role/InvestmentsInAssociatesNet</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/EquityTables</Role>
      <ShortName>EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://orgenesis.com/role/Equity</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - INCOME (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/IncomeLossPerShareTables</Role>
      <ShortName>INCOME (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://orgenesis.com/role/IncomeLossPerShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/Stock-basedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://orgenesis.com/role/Stock-basedCompensation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/TaxesTables</Role>
      <ShortName>TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://orgenesis.com/role/Taxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/RevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://orgenesis.com/role/Revenues</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNetTables</Role>
      <ShortName>COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://orgenesis.com/role/CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - FINANCIAL EXPENSES, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/FinancialExpensesNetTables</Role>
      <ShortName>FINANCIAL EXPENSES, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://orgenesis.com/role/FinancialExpensesNet</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - RELATED PARTIES TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/RelatedPartiesTransactionsTables</Role>
      <ShortName>RELATED PARTIES TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://orgenesis.com/role/RelatedPartiesTransactions</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative</Role>
      <ShortName>DESCRIPTION OF BUSINESS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://orgenesis.com/role/DescriptionOfBusiness</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails</Role>
      <ShortName>SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfIntangibleAssetsAndTheirUsefulLiveDetails</Role>
      <ShortName>SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/SignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://orgenesis.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - SCHEDULE OF DISCONTINUED OPERATION AND BALANCE SHEETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails</Role>
      <ShortName>SCHEDULE OF DISCONTINUED OPERATION AND BALANCE SHEETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - SCHEDULE OF DISAGGREGATION OF REVENUE RELATED TO DISCONTINUED OPERATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsDetails</Role>
      <ShortName>SCHEDULE OF DISAGGREGATION OF REVENUE RELATED TO DISCONTINUED OPERATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - DISCONTINUED OPERATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative</Role>
      <ShortName>DISCONTINUED OPERATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://orgenesis.com/role/DiscontinuedOperationTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails</Role>
      <ShortName>SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical</Role>
      <ShortName>SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - SCHEDULE OF UNAUDITED SUPPLEMENTAL PRO FORMA (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfUnauditedSupplementalProFormaDetails</Role>
      <ShortName>SCHEDULE OF UNAUDITED SUPPLEMENTAL PRO FORMA (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - ACQUISITION AND REORGANIZATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative</Role>
      <ShortName>ACQUISITION AND REORGANIZATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://orgenesis.com/role/AcquisitionAndReorganizationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - SCHEDULE OF COMPONENTS OF PROPERTY, PLANTS AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails</Role>
      <ShortName>SCHEDULE OF COMPONENTS OF PROPERTY, PLANTS AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT BY GEOGRAPHICAL LOCATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT BY GEOGRAPHICAL LOCATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - PROPERTY, PLANTS AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/PropertyPlantsAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY, PLANTS AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://orgenesis.com/role/PropertyPlantsAndEquipmentTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - SCHEDULE OF GOODWILL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfGoodwillDetails</Role>
      <ShortName>SCHEDULE OF GOODWILL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - SCHEDULE OF OTHER INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfOtherIntangibleAssetsDetails</Role>
      <ShortName>SCHEDULE OF OTHER INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - SCHEDULE OF ESTIMATED AGGREGATE AMORTIZATION EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfEstimatedAggregateAmortizationExpensesDetails</Role>
      <ShortName>SCHEDULE OF ESTIMATED AGGREGATE AMORTIZATION EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/IntangibleAssetsAndGoodwillDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://orgenesis.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - SCHEDULE OF LONG TERM CONVERTIBLE LOANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails</Role>
      <ShortName>SCHEDULE OF LONG TERM CONVERTIBLE LOANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - SCHEDULE OF LONG TERM CONVERTIBLE LOANS (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical</Role>
      <ShortName>SCHEDULE OF LONG TERM CONVERTIBLE LOANS (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - CONVERTIBLE LOANS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ConvertibleLoansDetailsNarrative</Role>
      <ShortName>CONVERTIBLE LOANS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://orgenesis.com/role/ConvertibleLoansTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>00000066 - Disclosure - SCHEDULE OF LOANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfLoansDetails</Role>
      <ShortName>SCHEDULE OF LOANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>00000067 - Disclosure - SCHEDULE OF LEASE-RELATED ASSETS AND LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfLease-relatedAssetsAndLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF LEASE-RELATED ASSETS AND LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>00000068 - Disclosure - SCHEDULE OF LEASE COSTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfLeaseCostsDetails</Role>
      <ShortName>SCHEDULE OF LEASE COSTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>00000069 - Disclosure - SCHEDULE OF SUPPLEMENTAL CASHFLOW INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfSupplementalCashflowInformationDetails</Role>
      <ShortName>SCHEDULE OF SUPPLEMENTAL CASHFLOW INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>00000070 - Disclosure - SCHEDULE OF FINANCE LEASE LIABILITIES AND OPERATING LEASE LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF FINANCE LEASE LIABILITIES AND OPERATING LEASE LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>00000071 - Disclosure - SCHEDULE OF RIGHT-OF-USE ASSETS BY GEOGRAPHICAL LOCATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfRight-of-useAssetsByGeographicalLocationDetails</Role>
      <ShortName>SCHEDULE OF RIGHT-OF-USE ASSETS BY GEOGRAPHICAL LOCATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>00000072 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://orgenesis.com/role/LeasesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>00000073 - Disclosure - COMMITMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/CommitmentsDetailsNarrative</Role>
      <ShortName>COMMITMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://orgenesis.com/role/Commitments</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>00000074 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative</Role>
      <ShortName>COLLABORATION AND LICENSE AGREEMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://orgenesis.com/role/CollaborationAndLicenseAgreements</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>00000075 - Disclosure - SCHEDULE OF CHANGES IN INVESTMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfChangesInInvestmentsDetails</Role>
      <ShortName>SCHEDULE OF CHANGES IN INVESTMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>00000076 - Disclosure - INVESTMENTS IN ASSOCIATES, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/InvestmentsInAssociatesNetDetailsNarrative</Role>
      <ShortName>INVESTMENTS IN ASSOCIATES, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://orgenesis.com/role/InvestmentsInAssociatesNetTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>00000077 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfWarrantsActivityDetails</Role>
      <ShortName>SCHEDULE OF WARRANTS ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>00000078 - Disclosure - SCHEDULE OF TREASURY SHARES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfTreasurySharesDetails</Role>
      <ShortName>SCHEDULE OF TREASURY SHARES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>00000079 - Disclosure - EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/EquityDetailsNarrative</Role>
      <ShortName>EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://orgenesis.com/role/EquityTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>00000080 - Disclosure - SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfBasicAndDilutedLossPerShareDetails</Role>
      <ShortName>SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>00000081 - Disclosure - INCOME (LOSS) PER SHARE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/IncomeLossPerShareDetailsNarrative</Role>
      <ShortName>INCOME (LOSS) PER SHARE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://orgenesis.com/role/IncomeLossPerShareTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>00000082 - Disclosure - SCHEDULE OF EMPLOYEE STOCK OWNERSHIP PLAN DISCLOSURES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails</Role>
      <ShortName>SCHEDULE OF EMPLOYEE STOCK OWNERSHIP PLAN DISCLOSURES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>00000083 - Disclosure - SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>00000084 - Disclosure - SCHEDULE OF STOCK OPTIONS ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTIONS ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>00000085 - Disclosure - SCHEDULE OF STOCK OPTIONS EXERCISABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTIONS EXERCISABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>00000086 - Disclosure - SCHEDULE OF STOCK OPTIONS GRANTED TO CONSULTANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTIONS GRANTED TO CONSULTANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>00000087 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://orgenesis.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>00000088 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails</Role>
      <ShortName>SCHEDULE OF DEFERRED TAX ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>00000089 - Disclosure - SCHEDULE OF VALUATION ALLOWANCE, ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfValuationAllowanceActivityDetails</Role>
      <ShortName>SCHEDULE OF VALUATION ALLOWANCE, ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>00000090 - Disclosure - TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/TaxesDetailsNarrative</Role>
      <ShortName>TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://orgenesis.com/role/TaxesTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>00000091 - Disclosure - SCHEDULE OF DISAGGREGATION OF REVENUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueDetails</Role>
      <ShortName>SCHEDULE OF DISAGGREGATION OF REVENUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>00000092 - Disclosure - SCHEDULE OF BREAKDOWN OF REVENUES PER CUSTOMER (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfBreakdownOfRevenuesPerCustomerDetails</Role>
      <ShortName>SCHEDULE OF BREAKDOWN OF REVENUES PER CUSTOMER (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>00000093 - Disclosure - SCHEDULE OF ACTIVITY FOR TRADE RECEIVABLES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfActivityForTradeReceivablesDetails</Role>
      <ShortName>SCHEDULE OF ACTIVITY FOR TRADE RECEIVABLES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>00000094 - Disclosure - SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>00000095 - Disclosure - SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetailsParenthetical</Role>
      <ShortName>SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>00000096 - Disclosure - REVENUES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/RevenuesDetailsNarrative</Role>
      <ShortName>REVENUES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://orgenesis.com/role/RevenuesTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>00000097 - Disclosure - SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails</Role>
      <ShortName>SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>00000098 - Disclosure - SCHEDULE OF FINANCIAL EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfFinancialExpensesDetails</Role>
      <ShortName>SCHEDULE OF FINANCIAL EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>00000099 - Disclosure - SCHEDULE OF RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails</Role>
      <ShortName>SCHEDULE OF RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>00000100 - Disclosure - SCHEDULE OF RELATED PARTY TRANSACTIONS (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical</Role>
      <ShortName>SCHEDULE OF RELATED PARTY TRANSACTIONS (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>00000101 - Disclosure - SCHEDULE OF RELATED PARTIES PRESENTED IN CONSOLIDATED BALANCE SHEETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://orgenesis.com/role/ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails</Role>
      <ShortName>SCHEDULE OF RELATED PARTIES PRESENTED IN CONSOLIDATED BALANCE SHEETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="form10-k.htm">form10-k.htm</File>
    <File>ex10-45.htm</File>
    <File>ex10-46.htm</File>
    <File>ex21-1.htm</File>
    <File>ex23-1.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ex32-2.htm</File>
    <File>orgs-20201231.xsd</File>
    <File>orgs-20201231_cal.xml</File>
    <File>orgs-20201231_def.xml</File>
    <File>orgs-20201231_lab.xml</File>
    <File>orgs-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>form10-k_004.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>128
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-k.htm": {
   "axisCustom": 1,
   "axisStandard": 29,
   "contextCount": 502,
   "dts": {
    "calculationLink": {
     "local": [
      "orgs-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "orgs-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "orgs-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "orgs-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "orgs-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 937,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 158,
    "http://orgenesis.com/20201231": 42,
    "http://xbrl.sec.gov/dei/2020-01-31": 6,
    "total": 206
   },
   "keyCustom": 178,
   "keyStandard": 473,
   "memberCustom": 158,
   "memberStandard": 25,
   "nsprefix": "ORGS",
   "nsuri": "http://orgenesis.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://orgenesis.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ORGS:AcquisitionAndReorganizationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - ACQUISITION AND REORGANIZATION",
     "role": "http://orgenesis.com/role/AcquisitionAndReorganization",
     "shortName": "ACQUISITION AND REORGANIZATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ORGS:AcquisitionAndReorganizationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2019-01-012019-12-31_custom_CaerusTherapeuticsLLCMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockOptionPlanExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000100 - Disclosure - SCHEDULE OF RELATED PARTY TRANSACTIONS (Details) (Parenthetical)",
     "role": "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical",
     "shortName": "SCHEDULE OF RELATED PARTY TRANSACTIONS (Details) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2019-01-012019-12-31_custom_CaerusTherapeuticsLLCMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockOptionPlanExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ORGS:ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ORGS:DueFromRelatedPartiesNoncurrent1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000101 - Disclosure - SCHEDULE OF RELATED PARTIES PRESENTED IN CONSOLIDATED BALANCE SHEETS (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails",
     "shortName": "SCHEDULE OF RELATED PARTIES PRESENTED IN CONSOLIDATED BALANCE SHEETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ORGS:ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ORGS:DueFromRelatedPartiesNoncurrent1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - PROPERTY, PLANTS AND EQUIPMENT",
     "role": "http://orgenesis.com/role/PropertyPlantsAndEquipment",
     "shortName": "PROPERTY, PLANTS AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - INTANGIBLE ASSETS AND GOODWILL",
     "role": "http://orgenesis.com/role/IntangibleAssetsAndGoodwill",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - CONVERTIBLE LOANS",
     "role": "http://orgenesis.com/role/ConvertibleLoans",
     "shortName": "CONVERTIBLE LOANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ORGS:LoansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - LOANS",
     "role": "http://orgenesis.com/role/Loans",
     "shortName": "LOANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ORGS:LoansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - LEASES",
     "role": "http://orgenesis.com/role/Leases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - COMMITMENTS",
     "role": "http://orgenesis.com/role/Commitments",
     "shortName": "COMMITMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ORGS:CollaborationsLicenseAgreementsAndCommitmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS",
     "role": "http://orgenesis.com/role/CollaborationAndLicenseAgreements",
     "shortName": "COLLABORATION AND LICENSE AGREEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ORGS:CollaborationsLicenseAgreementsAndCommitmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - INVESTMENTS IN ASSOCIATES, NET",
     "role": "http://orgenesis.com/role/InvestmentsInAssociatesNet",
     "shortName": "INVESTMENTS IN ASSOCIATES, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - EQUITY",
     "role": "http://orgenesis.com/role/Equity",
     "shortName": "EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "role": "http://orgenesis.com/role/BalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - INCOME (LOSS) PER SHARE",
     "role": "http://orgenesis.com/role/IncomeLossPerShare",
     "shortName": "INCOME (LOSS) PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://orgenesis.com/role/Stock-basedCompensation",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - TAXES",
     "role": "http://orgenesis.com/role/Taxes",
     "shortName": "TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - REVENUES",
     "role": "http://orgenesis.com/role/Revenues",
     "shortName": "REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET",
     "role": "http://orgenesis.com/role/CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet",
     "shortName": "COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ORGS:FinancialExpensesNetTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - FINANCIAL EXPENSES, NET",
     "role": "http://orgenesis.com/role/FinancialExpensesNet",
     "shortName": "FINANCIAL EXPENSES, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ORGS:FinancialExpensesNetTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - RELATED PARTIES TRANSACTIONS",
     "role": "http://orgenesis.com/role/RelatedPartiesTransactions",
     "shortName": "RELATED PARTIES TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ORGS:ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://orgenesis.com/role/SignificantAccountingPoliciesTables",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ORGS:ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - DISCONTINUED OPERATION (Tables)",
     "role": "http://orgenesis.com/role/DiscontinuedOperationTables",
     "shortName": "DISCONTINUED OPERATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://orgenesis.com/role/BalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ORGS:AcquisitionAndReorganizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - ACQUISITION AND REORGANIZATION (Tables)",
     "role": "http://orgenesis.com/role/AcquisitionAndReorganizationTables",
     "shortName": "ACQUISITION AND REORGANIZATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ORGS:AcquisitionAndReorganizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - PROPERTY, PLANTS AND EQUIPMENT (Tables)",
     "role": "http://orgenesis.com/role/PropertyPlantsAndEquipmentTables",
     "shortName": "PROPERTY, PLANTS AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "role": "http://orgenesis.com/role/IntangibleAssetsAndGoodwillTables",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - CONVERTIBLE LOANS (Tables)",
     "role": "http://orgenesis.com/role/ConvertibleLoansTables",
     "shortName": "CONVERTIBLE LOANS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ORGS:LoansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - LOANS (Tables)",
     "role": "http://orgenesis.com/role/LoansTables",
     "shortName": "LOANS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ORGS:LoansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ORGS:LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - LEASES (Tables)",
     "role": "http://orgenesis.com/role/LeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ORGS:LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - INVESTMENTS IN ASSOCIATES, NET (Tables)",
     "role": "http://orgenesis.com/role/InvestmentsInAssociatesNetTables",
     "shortName": "INVESTMENTS IN ASSOCIATES, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ORGS:ScheduleOfWarrantsActivity",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - EQUITY (Tables)",
     "role": "http://orgenesis.com/role/EquityTables",
     "shortName": "EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ORGS:ScheduleOfWarrantsActivity",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - INCOME (LOSS) PER SHARE (Tables)",
     "role": "http://orgenesis.com/role/IncomeLossPerShareTables",
     "shortName": "INCOME (LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://orgenesis.com/role/Stock-basedCompensationTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Consolidated Statements of Comprehensive Loss (Income)",
     "role": "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome",
     "shortName": "Consolidated Statements of Comprehensive Loss (Income)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - TAXES (Tables)",
     "role": "http://orgenesis.com/role/TaxesTables",
     "shortName": "TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - REVENUES (Tables)",
     "role": "http://orgenesis.com/role/RevenuesTables",
     "shortName": "REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET (Tables)",
     "role": "http://orgenesis.com/role/CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNetTables",
     "shortName": "COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ORGS:FinancialExpensesNetTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ORGS:ScheduleOfFinancialExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - FINANCIAL EXPENSES, NET (Tables)",
     "role": "http://orgenesis.com/role/FinancialExpensesNetTables",
     "shortName": "FINANCIAL EXPENSES, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ORGS:FinancialExpensesNetTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ORGS:ScheduleOfFinancialExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - RELATED PARTIES TRANSACTIONS (Tables)",
     "role": "http://orgenesis.com/role/RelatedPartiesTransactionsTables",
     "shortName": "RELATED PARTIES TRANSACTIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative)",
     "role": "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative",
     "shortName": "DESCRIPTION OF BUSINESS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-5",
      "lang": null,
      "name": "ORGS:AccumulatedDeficit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ORGS:ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_ProductionFacilityMember_srt_MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails",
     "shortName": "SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ORGS:ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_ProductionFacilityMember_srt_MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ORGS:ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_us-gaap_CustomerRelationshipsMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfIntangibleAssetsAndTheirUsefulLiveDetails",
     "shortName": "SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ORGS:ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_us-gaap_CustomerRelationshipsMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "role": "http://orgenesis.com/role/SignificantAccountingPoliciesDetailsNarrative",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - SCHEDULE OF DISCONTINUED OPERATION AND BALANCE SHEETS (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails",
     "shortName": "SCHEDULE OF DISCONTINUED OPERATION AND BALANCE SHEETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2018-12-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Equity",
     "role": "http://orgenesis.com/role/StatementsOfChangesInEquity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2018-12-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - SCHEDULE OF DISAGGREGATION OF REVENUE RELATED TO DISCONTINUED OPERATIONS (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsDetails",
     "shortName": "SCHEDULE OF DISAGGREGATION OF REVENUE RELATED TO DISCONTINUED OPERATIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ORGS:ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_CellProcessDevelopmentServicesMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - DISCONTINUED OPERATION (Details Narrative)",
     "role": "http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative",
     "shortName": "DISCONTINUED OPERATION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-02-092020-02-10_custom_MasthercellSAMember",
      "decimals": "-5",
      "lang": null,
      "name": "ORGS:RepaymentOfIntercompanyLoansAndPayables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ORGS:AcquisitionAndReorganizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details)",
     "role": "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails",
     "shortName": "SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ORGS:AcquisitionAndReorganizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ORGS:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ORGS:AcquisitionAndReorganizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ORGS:FairValuePercentageofSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percentage",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) (Parenthetical)",
     "role": "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical",
     "shortName": "SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ORGS:AcquisitionAndReorganizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ORGS:FairValuePercentageofSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percentage",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - SCHEDULE OF UNAUDITED SUPPLEMENTAL PRO FORMA (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfUnauditedSupplementalProFormaDetails",
     "shortName": "SCHEDULE OF UNAUDITED SUPPLEMENTAL PRO FORMA (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ORGS:AcquisitionAndReorganizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_KoligoTherapeuticsIncMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueAcquisitions",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000055 - Disclosure - ACQUISITION AND REORGANIZATION (Details Narrative)",
     "role": "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative",
     "shortName": "ACQUISITION AND REORGANIZATION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ORGS:AcquisitionAndReorganizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-10-142020-10-15_custom_LongHillAndMaximGroupLLCMember_custom_RegistrationRightsandLockUpAgreementMember",
      "decimals": "INF",
      "lang": null,
      "name": "ORGS:RestrictionOnSaleOfSharesPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percentage",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000056 - Disclosure - SCHEDULE OF COMPONENTS OF PROPERTY, PLANTS AND EQUIPMENT (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails",
     "shortName": "SCHEDULE OF COMPONENTS OF PROPERTY, PLANTS AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000057 - Disclosure - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT BY GEOGRAPHICAL LOCATION (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails",
     "shortName": "SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT BY GEOGRAPHICAL LOCATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ORGS:ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_country_BE",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000058 - Disclosure - PROPERTY, PLANTS AND EQUIPMENT (Details Narrative)",
     "role": "http://orgenesis.com/role/PropertyPlantsAndEquipmentDetailsNarrative",
     "shortName": "PROPERTY, PLANTS AND EQUIPMENT (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000059 - Disclosure - SCHEDULE OF GOODWILL (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfGoodwillDetails",
     "shortName": "SCHEDULE OF GOODWILL (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2018-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://orgenesis.com/role/StatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2019-01-012019-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "ORGS:ShareBasedCompensationOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000060 - Disclosure - SCHEDULE OF OTHER INTANGIBLE ASSETS (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfOtherIntangibleAssetsDetails",
     "shortName": "SCHEDULE OF OTHER INTANGIBLE ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000061 - Disclosure - SCHEDULE OF ESTIMATED AGGREGATE AMORTIZATION EXPENSES (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfEstimatedAggregateAmortizationExpensesDetails",
     "shortName": "SCHEDULE OF ESTIMATED AGGREGATE AMORTIZATION EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ORGS:AmortizationOfIntangibleAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000062 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)",
     "role": "http://orgenesis.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ORGS:AmortizationOfIntangibleAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfConvertibleDebt",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000063 - Disclosure - SCHEDULE OF LONG TERM CONVERTIBLE LOANS (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails",
     "shortName": "SCHEDULE OF LONG TERM CONVERTIBLE LOANS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_custom_ConvertibleLoansOneMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConvertibleDebtCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000064 - Disclosure - SCHEDULE OF LONG TERM CONVERTIBLE LOANS (Details) (Parenthetical)",
     "role": "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical",
     "shortName": "SCHEDULE OF LONG TERM CONVERTIBLE LOANS (Details) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_custom_HemogenyxCelMember",
      "decimals": "-6",
      "lang": null,
      "name": "ORGS:PreMoneyValuation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000065 - Disclosure - CONVERTIBLE LOANS (Details Narrative)",
     "role": "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
     "shortName": "CONVERTIBLE LOANS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2019-04-012019-04-30_custom_ConvertibleLoanAgreementMember_us-gaap_InvestorMember_custom_ConvertibleLoansOneMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ORGS:LoansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000066 - Disclosure - SCHEDULE OF LOANS (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfLoansDetails",
     "shortName": "SCHEDULE OF LOANS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ORGS:LoansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000067 - Disclosure - SCHEDULE OF LEASE-RELATED ASSETS AND LIABILITIES (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfLease-relatedAssetsAndLiabilitiesDetails",
     "shortName": "SCHEDULE OF LEASE-RELATED ASSETS AND LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ORGS:LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000068 - Disclosure - SCHEDULE OF LEASE COSTS (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfLeaseCostsDetails",
     "shortName": "SCHEDULE OF LEASE COSTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000069 - Disclosure - SCHEDULE OF SUPPLEMENTAL CASHFLOW INFORMATION (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfSupplementalCashflowInformationDetails",
     "shortName": "SCHEDULE OF SUPPLEMENTAL CASHFLOW INFORMATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - DESCRIPTION OF BUSINESS",
     "role": "http://orgenesis.com/role/DescriptionOfBusiness",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ORGS:LesseeLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000070 - Disclosure - SCHEDULE OF FINANCE LEASE LIABILITIES AND OPERATING LEASE LIABILITIES (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails",
     "shortName": "SCHEDULE OF FINANCE LEASE LIABILITIES AND OPERATING LEASE LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ORGS:LesseeLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000071 - Disclosure - SCHEDULE OF RIGHT-OF-USE ASSETS BY GEOGRAPHICAL LOCATION (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfRight-of-useAssetsByGeographicalLocationDetails",
     "shortName": "SCHEDULE OF RIGHT-OF-USE ASSETS BY GEOGRAPHICAL LOCATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ORGS:ScheduleOfRightofuseAssetsByGeographicalLocation",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_country_KR",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_ManufacturingFacilityMember_country_IL_srt_MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000072 - Disclosure - LEASES (Details Narrative)",
     "role": "http://orgenesis.com/role/LeasesDetailsNarrative",
     "shortName": "LEASES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_ManufacturingFacilityMember_country_IL_srt_MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ORGS:AdvancePaymentsOnAccountOfGrant",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000073 - Disclosure - COMMITMENTS (Details Narrative)",
     "role": "http://orgenesis.com/role/CommitmentsDetailsNarrative",
     "shortName": "COMMITMENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_DeductionOfResearchAndDevelopmentExpensesMember",
      "decimals": "-3",
      "lang": null,
      "name": "ORGS:DeductionOfResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000074 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS (Details Narrative)",
     "role": "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
     "shortName": "COLLABORATION AND LICENSE AGREEMENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ORGS:CollaborationsLicenseAgreementsAndCommitmentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_CaerusTherapeuticsIncMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
       "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000075 - Disclosure - SCHEDULE OF CHANGES IN INVESTMENTS (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfChangesInInvestmentsDetails",
     "shortName": "SCHEDULE OF CHANGES IN INVESTMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
       "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-10-31_custom_TLABSMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ORGS:InvestmentsInAssociatePercentageOfOwnership",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percentage",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000076 - Disclosure - INVESTMENTS IN ASSOCIATES, NET (Details Narrative)",
     "role": "http://orgenesis.com/role/InvestmentsInAssociatesNetDetailsNarrative",
     "shortName": "INVESTMENTS IN ASSOCIATES, NET (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-10-31_custom_TLABSMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ORGS:InvestmentsInAssociatePercentageOfOwnership",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percentage",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ORGS:ScheduleOfWarrantsActivity",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000077 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfWarrantsActivityDetails",
     "shortName": "SCHEDULE OF WARRANTS ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ORGS:ScheduleOfWarrantsActivity",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ORGS:ScheduleOfTreasuryShares",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000078 - Disclosure - SCHEDULE OF TREASURY SHARES (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfTreasurySharesDetails",
     "shortName": "SCHEDULE OF TREASURY SHARES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ORGS:ScheduleOfTreasuryShares",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-192020-01-20",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ORGS:OfferingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000079 - Disclosure - EQUITY (Details Narrative)",
     "role": "http://orgenesis.com/role/EquityDetailsNarrative",
     "shortName": "EQUITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-192020-01-20",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ORGS:OfferingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://orgenesis.com/role/SignificantAccountingPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000080 - Disclosure - SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfBasicAndDilutedLossPerShareDetails",
     "shortName": "SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_OptionsAndWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000081 - Disclosure - INCOME (LOSS) PER SHARE (Details Narrative)",
     "role": "http://orgenesis.com/role/IncomeLossPerShareDetailsNarrative",
     "shortName": "INCOME (LOSS) PER SHARE (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_OptionsAndWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000082 - Disclosure - SCHEDULE OF EMPLOYEE STOCK OWNERSHIP PLAN DISCLOSURES (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails",
     "shortName": "SCHEDULE OF EMPLOYEE STOCK OWNERSHIP PLAN DISCLOSURES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember_custom_EmployeesMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percentage",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000083 - Disclosure - SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails",
     "shortName": "SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percentage",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31_custom_OptionsGrantedToEmployeesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000084 - Disclosure - SCHEDULE OF STOCK OPTIONS ACTIVITY (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails",
     "shortName": "SCHEDULE OF STOCK OPTIONS ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_custom_OptionsGrantedToEmployeesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000085 - Disclosure - SCHEDULE OF STOCK OPTIONS EXERCISABLE (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails",
     "shortName": "SCHEDULE OF STOCK OPTIONS EXERCISABLE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_OptionsGrantedToEmployeesMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000086 - Disclosure - SCHEDULE OF STOCK OPTIONS GRANTED TO CONSULTANTS (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails",
     "shortName": "SCHEDULE OF STOCK OPTIONS GRANTED TO CONSULTANTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_OptionsGrantedToNonEmployeesMember",
      "decimals": null,
      "lang": "en-US",
      "name": "ORGS:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000087 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)",
     "role": "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative",
     "shortName": "STOCK-BASED COMPENSATION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "ORGS:FairValueOfSharesRecognizedOnGrantDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000088 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails",
     "shortName": "SCHEDULE OF DEFERRED TAX ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000089 - Disclosure - SCHEDULE OF VALUATION ALLOWANCE, ACTIVITY (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfValuationAllowanceActivityDetails",
     "shortName": "SCHEDULE OF VALUATION ALLOWANCE, ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - DISCONTINUED OPERATION",
     "role": "http://orgenesis.com/role/DiscontinuedOperation",
     "shortName": "DISCONTINUED OPERATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000090 - Disclosure - TAXES (Details Narrative)",
     "role": "http://orgenesis.com/role/TaxesDetailsNarrative",
     "shortName": "TAXES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000091 - Disclosure - SCHEDULE OF DISAGGREGATION OF REVENUE (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueDetails",
     "shortName": "SCHEDULE OF DISAGGREGATION OF REVENUE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_PointOfCareServicesMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000092 - Disclosure - SCHEDULE OF BREAKDOWN OF REVENUES PER CUSTOMER (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfBreakdownOfRevenuesPerCustomerDetails",
     "shortName": "SCHEDULE OF BREAKDOWN OF REVENUES PER CUSTOMER (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ORGS:ScheduleOfBreakdownOfRevenuesPerCustomer",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_CustomerAMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000093 - Disclosure - SCHEDULE OF ACTIVITY FOR TRADE RECEIVABLES (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfActivityForTradeReceivablesDetails",
     "shortName": "SCHEDULE OF ACTIVITY FOR TRADE RECEIVABLES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2018-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000094 - Disclosure - SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetails",
     "shortName": "SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "ORGS:ContractWithCustomerLiabilityAddition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000095 - Disclosure - SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES (Details) (Parenthetical)",
     "role": "http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetailsParenthetical",
     "shortName": "SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES (Details) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000096 - Disclosure - REVENUES (Details Narrative)",
     "role": "http://orgenesis.com/role/RevenuesDetailsNarrative",
     "shortName": "REVENUES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_MasterServicesAgreementsMember_custom_JointVenturePartnersMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000097 - Disclosure - SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails",
     "shortName": "SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ORGS:ScheduleOfFinancialExpensesTableTextBlock",
       "ORGS:FinancialExpensesNetTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2019-01-012019-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ORGS:IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000098 - Disclosure - SCHEDULE OF FINANCIAL EXPENSES (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfFinancialExpensesDetails",
     "shortName": "SCHEDULE OF FINANCIAL EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ORGS:ScheduleOfFinancialExpensesTableTextBlock",
       "ORGS:FinancialExpensesNetTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2019-01-012019-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ORGS:IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000099 - Disclosure - SCHEDULE OF RELATED PARTY TRANSACTIONS (Details)",
     "role": "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails",
     "shortName": "SCHEDULE OF RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_us-gaap_SegmentContinuingOperationsMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 185,
   "tag": {
    "ORGS_AIPCellsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AIP Cells [Member]",
        "label": "A I P Cells [Member]"
       }
      }
     },
     "localname": "AIPCellsMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_AccountsReceivableAcquisitionOfKoligo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accounts receivable acquisition of Koligo.",
        "label": "Acquisition of Koligo"
       }
      }
     },
     "localname": "AccountsReceivableAcquisitionOfKoligo",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfActivityForTradeReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_AccountsReceivableAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accounts receivable additions.",
        "label": "Additions"
       }
      }
     },
     "localname": "AccountsReceivableAdditions",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfActivityForTradeReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_AccountsReceivableCollections": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accounts receivable collections.",
        "label": "Collections"
       }
      }
     },
     "localname": "AccountsReceivableCollections",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfActivityForTradeReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_AccruedExpensesAndOtherPayablesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other payables.",
        "label": "Accrued expenses and other payables"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherPayablesCurrent",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_AccumulatedDeficit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated losses.",
        "label": "Accumulated losses"
       }
      }
     },
     "localname": "AccumulatedDeficit",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_AccumulatedTaxLossCarryForwardedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated tax loss carry forwarded period.",
        "label": "[custom:AccumulatedTaxLossCarryForwardedPeriod]"
       }
      }
     },
     "localname": "AccumulatedTaxLossCarryForwardedPeriod",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "ORGS_AccumulatedTaxLossCarryforwardDeductions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated tax loss carryforward deductions.",
        "label": "[custom:AccumulatedTaxLossCarryforwardDeductions-0]"
       }
      }
     },
     "localname": "AccumulatedTaxLossCarryforwardDeductions",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_AcquisitionAndReorganizationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition and Reorganization [Text Block]",
        "label": "ACQUISITION AND REORGANIZATION"
       }
      }
     },
     "localname": "AcquisitionAndReorganizationTextBlock",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_AcquisitionOfOtherAssetInExchangeForCommonStocks": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of other asset in exchange for common stocks.",
        "label": "Acquisition of other asset in exchange for common stocks"
       }
      }
     },
     "localname": "AcquisitionOfOtherAssetInExchangeForCommonStocks",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_AdditionalCashConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional cash consideration.",
        "label": "Additional cash consideration"
       }
      }
     },
     "localname": "AdditionalCashConsideration",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_AdditionalFundsInvest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents additional amount invested in company.",
        "label": "Additional Funds Invest"
       }
      }
     },
     "localname": "AdditionalFundsInvest",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment of redeemable non-controlling interest to redemption amount.",
        "label": "Adjustment of redeemable non-controlling interest to redemption amount"
       }
      }
     },
     "localname": "AdjustmentOfRedeemableNoncontrollingInterestToRedemptionAmount",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfBasicAndDilutedLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Transaction With noncontrolling interest GPP.",
        "label": "Transaction with non-controlling interest GPP (See Note 1)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalTransactionWithNoncontrollingInterestGpp",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_AdvaBiotechnologyLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adva Biotechnology Ltd.",
        "label": "Adva Biotechnology Ltd. [Member]"
       }
      }
     },
     "localname": "AdvaBiotechnologyLtdMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_AdvancePaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advance Payment [Member]"
       }
      }
     },
     "localname": "AdvancePaymentMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_AdvancePaymentsOnAccountOfGrant": {
     "auth_ref": [],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance payments on account of grant.",
        "label": "Advance payments on account of grant"
       }
      }
     },
     "localname": "AdvancePaymentsOnAccountOfGrant",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets",
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_AggregateAmountOfSubscriptionAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of subscription agreement.",
        "label": "Aggregate amount of subscription agreement"
       }
      }
     },
     "localname": "AggregateAmountOfSubscriptionAgreement",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_AggregateNominalPurchasePrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of aggregate nominal purchase price.",
        "label": "Aggregate nominal purchase price of outstanding equity interests"
       }
      }
     },
     "localname": "AggregateNominalPurchasePrice",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative",
      "http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_AmortizationOfIntangibleAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of Intangible Assets.",
        "label": "Amortization of Intangible Assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAsset",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_BeneficialConversionFeatureBcfPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficial Conversion Feature [Policy Text Block]",
        "label": "Beneficial Conversion Feature (\u201cBCF\u201d)"
       }
      }
     },
     "localname": "BeneficialConversionFeatureBcfPolicyTextBlock",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_BgNegevTechnologiesAndApplicationsBgnMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BG Negev Technologies and Applications (BGN)",
        "label": "BG Negev Technologies and Applications (BGN) [Member]"
       }
      }
     },
     "localname": "BgNegevTechnologiesAndApplicationsBgnMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_BirdSecantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIRD Secant",
        "label": "BIRD Secant [Member]"
       }
      }
     },
     "localname": "BirdSecantMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_BoardMembersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Board Members",
        "label": "Board Members [Member]"
       }
      }
     },
     "localname": "BoardMembersMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_BroadenJointVentureAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Broaden Joint Venture Agreement [Member]",
        "label": "Broaden Joint Venture Agreement [Member]"
       }
      }
     },
     "localname": "BroadenJointVentureAgreementMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_BusinessCombinationConsiderationTransferred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination consideration transferred.",
        "label": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments": {
     "auth_ref": [],
     "calculation": {
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payment.",
        "label": "Cash payment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashPayments",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Expenses.",
        "label": "Accrued Expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued": {
     "auth_ref": [],
     "calculation": {
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of shared issued.",
        "label": "Fair value of 8.8% of shared issued *"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFairValueofSharesIssued",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill.",
        "label": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan liability.",
        "label": "Orgenesis Inc loan"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanLiability",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases.",
        "label": "Operating leases"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLease",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease right-of-use assets.",
        "label": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash.",
        "label": "Restricted Cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_ButterflyBiosciencesSarlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Butterfly Biosciences Sarl [Member]",
        "label": "Butterfly Biosciences Sarl [Member]"
       }
      }
     },
     "localname": "ButterflyBiosciencesSarlMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/InvestmentsInAssociatesNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_CaerusTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Caerus Therapeutics Inc [Member].",
        "label": "Caerus Therapeutics Inc [Member]"
       }
      }
     },
     "localname": "CaerusTherapeuticsIncMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_CaerusTherapeuticsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Caerus Therapeutics LLC",
        "label": "Caerus Therapeutics LLC [Member]"
       }
      }
     },
     "localname": "CaerusTherapeuticsLLCMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_CaliforniaUniversityJointResearchAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California University Joint Research Agreement [member]",
        "label": "California University Joint Research Agreement [member]"
       }
      }
     },
     "localname": "CaliforniaUniversityJointResearchAgreementMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_CantorFitzgeraldAndCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cantor Fitzgerald &amp; Co. [Member]",
        "label": "Cantor Fitzgerald &amp; Co. [Member]"
       }
      }
     },
     "localname": "CantorFitzgeraldAndCoMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_CashPaidToAccreditedInvestors": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid to accredited investors.",
        "label": "Cash paid to accredited investors"
       }
      }
     },
     "localname": "CashPaidToAccreditedInvestors",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_CellManufacturingServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cell Manufacturing Services [Member]",
        "label": "Cell Manufacturing Services [Member]"
       }
      }
     },
     "localname": "CellManufacturingServicesMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_CellProcessDevelopmentServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cell Process Development Services [Member]",
        "label": "Cell Process Development Services [Member]"
       }
      }
     },
     "localname": "CellProcessDevelopmentServicesMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueDetails",
      "http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ClassOfWarrantOrRightGrantsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Grants in Period, Net of Forfeitures",
        "label": "Number of warrants - issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightGrantsInPeriod",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ORGS_ClassOfWarrantOrRightGrantsInPeriodFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Grants in Period, Fair Value",
        "label": "Class of warrant or right, grants in period, fair value"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightGrantsInPeriodFairValue",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Grants in Period, Weighted Average Exercise Price",
        "label": "Class Of Warrant Or Right Grants In Period Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price - Issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "ORGS_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement",
        "label": "Collaboration agreement [Member]"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_CollaborationAndLicenseAgreementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and License Agreements",
        "label": "Collaboration and License Agreements [Axis]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAxis",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ORGS_CollaborationAndLicenseAgreementsDomain": {
     "auth_ref": [],
     "localname": "CollaborationAndLicenseAgreementsDomain",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_CollaborationsLicenseAgreementsAndCommitmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COLLABORATION AND LICENSE AGREEMENTS"
       }
      }
     },
     "localname": "CollaborationsLicenseAgreementsAndCommitmentsTextBlock",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_ColumbiaLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Columbia License Agreement [Member]",
        "label": "Columbia License Agreement [Member]"
       }
      }
     },
     "localname": "ColumbiaLicenseAgreementMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_CommitmentSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment, shares of common stock",
        "label": "Commitment, shares of common stock"
       }
      }
     },
     "localname": "CommitmentSharesOfCommonStock",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ORGS_CommitmentSharesOfCommonStockOfSubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment, shares of common stock of subsidiary",
        "label": "Commitment, shares of common stock of Israeli subsidiary"
       }
      }
     },
     "localname": "CommitmentSharesOfCommonStockOfSubsidiary",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Comprehensive income attributed to non-controlling interests (including redeemable) from continuing operation.",
        "label": "Comprehensive loss attributed to non-controlling interests (including redeemable)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestContinuingOperations",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Comprehensive income attributed to non-controlling interests (including redeemable) from discontinued operation.",
        "label": "Comprehensive loss attributed to non-controlling interests (including redeemable) from discontinued operations"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestDiscontinuedOperations",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_ComprehensiveIncomeNetOfTaxes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Comprehensive loss (income)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxes",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_ConsultantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultant [Member]",
        "label": "Consultant [Member]"
       }
      }
     },
     "localname": "ConsultantMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ConsultingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting Agreement [Member]",
        "label": "Consulting Agreement [Member]"
       }
      }
     },
     "localname": "ConsultingAgreementMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ContractWithCustomerLiabilityAddition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition of contract with customer liability.",
        "label": "ContractWithCustomerLiabilityAddition",
        "verboseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAddition",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_ContractWithCustomerLiabilityExchangeRateDifferences": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue from contract with customer liability exchange rate differences.",
        "label": "ContractWithCustomerLiabilityExchangeRateDifferences",
        "verboseLabel": "Exchange rate differences"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityExchangeRateDifferences",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_ContractWithCustomerLiabilityRealizations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue from contract with customer liability realizations.",
        "label": "Realizations"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRealizations",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_ControlledEquityOfferingSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Controlled Equity Offering Sales Agreement [Member]"
       }
      }
     },
     "localname": "ControlledEquityOfferingSalesAgreementMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ConvertibleLoanAdvancedToJointVenture": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible loan advanced to joint venture",
        "label": "Convertible loan advanced to joint venture"
       }
      }
     },
     "localname": "ConvertibleLoanAdvancedToJointVenture",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_ConvertibleLoanAdvancedToJointVentureInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible loan advanced to joint venture, interest rate",
        "label": "Convertible loan advanced to joint venture, interest rate"
       }
      }
     },
     "localname": "ConvertibleLoanAdvancedToJointVentureInterestRate",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ORGS_ConvertibleLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Loan Agreement [Member]"
       }
      }
     },
     "localname": "ConvertibleLoanAgreementMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ConvertibleLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Loans [Member]",
        "label": "Convertible Loans [Member]"
       }
      }
     },
     "localname": "ConvertibleLoansMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ConvertibleLoansOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Loans One [Member]"
       }
      }
     },
     "localname": "ConvertibleLoansOneMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ConvertibleLoansThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Loans Three [Member]"
       }
      }
     },
     "localname": "ConvertibleLoansThreeMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ConvertibleLoansTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Loans Two [Member]"
       }
      }
     },
     "localname": "ConvertibleLoansTwoMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ConvertibleNotesAndPrivateInvestmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes And Private Investment [Member]"
       }
      }
     },
     "localname": "ConvertibleNotesAndPrivateInvestmentMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of research and development and research and development services, net to discontinued operation.",
        "label": "CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet",
        "verboseLabel": "Cost of research and development and research and development services, net"
       }
      }
     },
     "localname": "CostOfResearchAnDisposalGroupIncludingDiscontinuedOperationdDevelopmentAndResearchAndDevelopmentServicesNet",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of research and development and research and development services.",
        "label": "Cost of research and development and research and development services net",
        "verboseLabel": "Cost of research and development and research and development services, net"
       }
      }
     },
     "localname": "CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_CreditLineAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Line Agreements [Member]"
       }
      }
     },
     "localname": "CreditLineAgreementsMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_CureCellCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CureCell Co. Ltd [Member]",
        "label": "CureCell Co. Ltd [Member]"
       }
      }
     },
     "localname": "CureCellCoLtdMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customers A [Member]",
        "label": "Customer A [Member]"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfBreakdownOfRevenuesPerCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customers B [Member]",
        "label": "Customer B [Member]"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfBreakdownOfRevenuesPerCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_CustomerCRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customers C - Related Party [Member]",
        "label": "Customer C Related Party [Member]"
       }
      }
     },
     "localname": "CustomerCRelatedPartyMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfBreakdownOfRevenuesPerCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_CustomerDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customers D [Member]",
        "label": "Customer D [Member]"
       }
      }
     },
     "localname": "CustomerDMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfBreakdownOfRevenuesPerCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_DebtInstrumentConvertibleRepaidBeneficialConversionFeature": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, convertible, repaid beneficial conversion feature.",
        "label": "Repaid, BCF"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRepaidBeneficialConversionFeature",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_DebtInstrumentConvertibleWarrantExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Warrant Exercise Price",
        "label": "Convertible warrant exercise price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleWarrantExercisePrice",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "ORGS_DebtInstrumentIssuanceYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, issuance year.",
        "label": "Issuance Year"
       }
      }
     },
     "localname": "DebtInstrumentIssuanceYear",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "ORGS_DebtInstrumentRemainingTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repaid maturity period.",
        "label": "Repaid, Maturity Period"
       }
      }
     },
     "localname": "DebtInstrumentRemainingTerm",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ORGS_DeductionOfResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deduction of research and development expenses",
        "label": "Deduction of research and development expenses"
       }
      }
     },
     "localname": "DeductionOfResearchAndDevelopmentExpenses",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_DeductionOfResearchAndDevelopmentExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deduction Of Research And Development Expenses [Member]"
       }
      }
     },
     "localname": "DeductionOfResearchAndDevelopmentExpensesMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease liability.",
        "label": "DeferredTaxAssetsLeaseLiability",
        "negatedLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_DeferredTaxAssetsLeasesAsset": {
     "auth_ref": [],
     "calculation": {
      "http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases asset.",
        "label": "Leases asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeasesAsset",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Department De La Gestion Financiere Direction De Lanalyse Financiere [Member]",
        "label": "Department De La Gestion Financiere Direction De Lanalyse Financiere [Member]"
       }
      }
     },
     "localname": "DepartmentDeLaGestionFinanciereDirectionDeLanalyseFinanciereMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_DevelopmentOfPotentialCureForTypeOneDiabetesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development of a potential cure for Type 1 Diabetes [Member]",
        "label": "Development Of Potential Cure For Type One Diabetes [Member]"
       }
      }
     },
     "localname": "DevelopmentOfPotentialCureForTypeOneDiabetesMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_DisclosureAcquisitionAndReorganizationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition And Reorganization"
       }
      }
     },
     "localname": "DisclosureAcquisitionAndReorganizationAbstract",
     "nsuri": "http://orgenesis.com/20201231",
     "xbrltype": "stringItemType"
    },
    "ORGS_DisclosureCollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration And License Agreements"
       }
      }
     },
     "localname": "DisclosureCollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://orgenesis.com/20201231",
     "xbrltype": "stringItemType"
    },
    "ORGS_DisclosureFinancialExpensesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Expenses Net",
        "verboseLabel": "Schedule Of Financial Expenses"
       }
      }
     },
     "localname": "DisclosureFinancialExpensesNetAbstract",
     "nsuri": "http://orgenesis.com/20201231",
     "xbrltype": "stringItemType"
    },
    "ORGS_DisclosureLoansAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans"
       }
      }
     },
     "localname": "DisclosureLoansAbstract",
     "nsuri": "http://orgenesis.com/20201231",
     "xbrltype": "stringItemType"
    },
    "ORGS_DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance payments on account of grant.",
        "label": "DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant",
        "verboseLabel": "Advance payments on account of grant"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAdvancePaymentsOnAccountOfGrant",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current maturities of long-term finance leases.",
        "label": "Current maturities of long-term finance leases"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfLongtermFinanceLeases",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current maturities of operating leases.",
        "label": "DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases",
        "verboseLabel": "Current maturities of operating leases"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCurrentMaturitiesOfOperatingLeases",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and related payables.",
        "label": "DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables",
        "verboseLabel": "Employees and related payables"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationEmployeesAndRelatedPayables",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_DisposalGroupIncludingDiscontinuedOperationGrantsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group, including discontinued operation receivable.",
        "label": "DisposalGroupIncludingDiscontinuedOperationGrantsReceivable",
        "verboseLabel": "Grants receivable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGrantsReceivable",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_DisposalGroupIncludingDiscontinuedOperationLoansPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group, including discontinued operation loans payable.",
        "label": "Loans payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationLoansPayable",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term finance leases.",
        "label": "Long-term finance leases"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationLongtermFinanceLeases",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-current operating leases.",
        "label": "DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases",
        "verboseLabel": "Non-current operating leases"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationNoncurrentOperatingLeases",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discontinued operation financial (income) expenses, net.",
        "label": "Financial expenses (income), net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingFinancialIncomeExpensesNet",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease right-of-use assets to disposal group.",
        "label": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofuseAssets",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_DisposalGroupIncludingDiscontinuedOperationOtherExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Other (income) expenses, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpenses",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_DisposalGroupIncludingDiscontinuedOperationRestrictedCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as restricted cash equivalents attributable to disposal group held for sale or disposed of.",
        "label": "repayment of intercompany loans and payables",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRestrictedCash",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term loans and current maturities of long- term loans.",
        "label": "Short-term loans and current maturities of long- term loans"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationShorttermLoansAndCurrentMaturitiesOfLongTermLoans",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_DisposalGroupIncludingDiscontinuedOperationsDeposits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deposits of discontinued operations.",
        "label": "DisposalGroupIncludingDiscontinuedOperationsDeposits",
        "verboseLabel": "Deposits"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationsDeposits",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_DueFromRelatedPartiesNoncurrent1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due after one year (or one business cycle).",
        "label": "Loan to Related Party",
        "verboseLabel": "Loan to related party"
       }
      }
     },
     "localname": "DueFromRelatedPartiesNoncurrent1",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_EVAmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EV Agreement [Member]",
        "label": "E V Ament [Member]"
       }
      }
     },
     "localname": "EVAmentMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_EightPercetageConvertibleLoansTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eight Percetage Convertible Loans Two [Member]"
       }
      }
     },
     "localname": "EightPercetageConvertibleLoansTwoMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees [Member]",
        "label": "Employees [Member]"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_EquityAttributedToOrgenesisIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Attributed To Orgenesis Inc [Member]",
        "label": "Equity Attributed To Orgenesis Inc [Member]"
       }
      }
     },
     "localname": "EquityAttributedToOrgenesisIncMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExchangeRateDifferencesOfAccountsReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange rate differences.",
        "label": "Exchange rate differences"
       }
      }
     },
     "localname": "ExchangeRateDifferencesOfAccountsReceivable",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfActivityForTradeReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_ExercisePriceEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Eighteen [Member]",
        "label": "Exercise Price Eighteen [Member]"
       }
      }
     },
     "localname": "ExercisePriceEightMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExercisePriceEighteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Eighteen [Member]",
        "label": "Exercise Price Eighteen [Member] [Default Label]",
        "verboseLabel": "Exercise Price Eighteen [Member]"
       }
      }
     },
     "localname": "ExercisePriceEighteenMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExercisePriceElevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Eleven [Member]",
        "label": "Exercise Price Eleven [Member]"
       }
      }
     },
     "localname": "ExercisePriceElevenMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExercisePriceFifteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Fifteen [Member]",
        "label": "Exercise Price Fifteen [Member]"
       }
      }
     },
     "localname": "ExercisePriceFifteenMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExercisePriceFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Five [Member]",
        "label": "Exercise Price Five [Member]"
       }
      }
     },
     "localname": "ExercisePriceFiveMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExercisePriceFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Four [Member]",
        "label": "Exercise Price Four [Member]"
       }
      }
     },
     "localname": "ExercisePriceFourMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExercisePriceFourteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Fourteen [Member]",
        "label": "Exercise Price Fourteen [Member]"
       }
      }
     },
     "localname": "ExercisePriceFourteenMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExercisePriceNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Nine [Member]",
        "label": "Exercise Price Nine [Member]"
       }
      }
     },
     "localname": "ExercisePriceNineMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExercisePriceNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Nineteen [Member]",
        "label": "Exercise Price Nineteen [Member]"
       }
      }
     },
     "localname": "ExercisePriceNineteenMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExercisePriceOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price 1",
        "label": "Exercise Price One [Member]"
       }
      }
     },
     "localname": "ExercisePriceOneMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExercisePriceSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Seven [Member]",
        "label": "Exercise Price Seven [Member]"
       }
      }
     },
     "localname": "ExercisePriceSevenMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExercisePriceSeventeenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Seventeen [Member]",
        "label": "Exercise Price Seventeen [Member]"
       }
      }
     },
     "localname": "ExercisePriceSeventeenMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExercisePriceSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Six [Member]",
        "label": "Exercise Price Six [Member]"
       }
      }
     },
     "localname": "ExercisePriceSixMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExercisePriceSixteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Sixteen [Member]",
        "label": "Exercise Price Sixteen [Member]"
       }
      }
     },
     "localname": "ExercisePriceSixteenMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExercisePriceTenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Ten [Member]",
        "label": "Exercise Price Ten [Member]"
       }
      }
     },
     "localname": "ExercisePriceTenMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExercisePriceThirteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Thirteen [Member]",
        "label": "Exercise Price Thirteen [Member]"
       }
      }
     },
     "localname": "ExercisePriceThirteenMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExercisePriceThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Three [Member]",
        "label": "Exercise Price Three [Member]"
       }
      }
     },
     "localname": "ExercisePriceThreeMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExercisePriceTwelveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Twelve [Member]",
        "label": "Exercise Price Twelve [Member]"
       }
      }
     },
     "localname": "ExercisePriceTwelveMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExercisePriceTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Twenty [Member]",
        "label": "Exercise Price Twenty [Member]"
       }
      }
     },
     "localname": "ExercisePriceTwentyMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExercisePriceTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price 2",
        "label": "Exercise Price Two [Member]"
       }
      }
     },
     "localname": "ExercisePriceTwoMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExperimentalDevelopmentPartOfResearchProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Experimental development part of the research program [Member]",
        "label": "Experimental development part of research program [Member]"
       }
      }
     },
     "localname": "ExperimentalDevelopmentPartOfResearchProgramMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ExtracellularVesicleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extracellular Vesicle [Member]",
        "label": "Extracellular Vesicle [Member]"
       }
      }
     },
     "localname": "ExtracellularVesicleMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_FairValueOfSharesOnVestingDatesRecognizedDuringYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of fair value of shares on vesting dates recognized during year .",
        "label": "Fair value of shares on vesting dates recognized during year"
       }
      }
     },
     "localname": "FairValueOfSharesOnVestingDatesRecognizedDuringYear",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_FairValueOfSharesRecognizedOnGrantDate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:FairValueOfSharesRecognizedOnGrantDate-0]"
       }
      }
     },
     "localname": "FairValueOfSharesRecognizedOnGrantDate",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_FairValuePercentageofSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Percentage of Shares Issued.",
        "label": "Fair value percentage of shares issued"
       }
      }
     },
     "localname": "FairValuePercentageofSharesIssued",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical"
     ],
     "xbrltype": "percentItemType"
    },
    "ORGS_FinanceLeaseCost": {
     "auth_ref": [],
     "calculation": {
      "http://orgenesis.com/role/ScheduleOfLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total finance lease cost",
        "label": "Finance Lease Cost",
        "totalLabel": "Total finance lease cost"
       }
      }
     },
     "localname": "FinanceLeaseCost",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_FinanceLeasesOfPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance leases of property, plant and equipment.",
        "label": "Finance Leases of property, plant and equipment"
       }
      }
     },
     "localname": "FinanceLeasesOfPropertyPlantAndEquipment",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_FinancialExpensesNetTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FINANCIAL EXPENSES, NET"
       }
      }
     },
     "localname": "FinancialExpensesNetTextBlock",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/FinancialExpensesNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_FinancialIncome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial income.",
        "label": "Financial income"
       }
      }
     },
     "localname": "FinancialIncome",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization expenses, 2022  to 2025.",
        "label": "Amortization expenses, 2022 to 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoToFive",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfEstimatedAggregateAmortizationExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_FirstChoiceInternationalCompanyIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Choice International Company, Inc.",
        "label": "First Choice International Company, Inc. [Member]"
       }
      }
     },
     "localname": "FirstChoiceInternationalCompanyIncMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ForeignCurrencyTransactionsGainLossRealized": {
     "auth_ref": [],
     "calculation": {
      "http://orgenesis.com/role/ScheduleOfFinancialExpensesDetails": {
       "order": 3.0,
       "parentTag": "ORGS_TotalFinancialExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.",
        "label": "Foreign exchange loss, net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsGainLossRealized",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfFinancialExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_FunctionalCurrencyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Functional Currency [Policy Text Block]",
        "label": "Functional Currency"
       }
      }
     },
     "localname": "FunctionalCurrencyPolicyTextBlock",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_FutureMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future milestone.",
        "label": "Future milestone payments"
       }
      }
     },
     "localname": "FutureMilestonePayments",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_GlobalShareIncentivePlanTwoZeroOneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global share incentive plan (2012) [Member]",
        "label": "Global Share Incentive Plan 2012 [Member]"
       }
      }
     },
     "localname": "GlobalShareIncentivePlanTwoZeroOneTwoMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GMP production of AIP cells for two clinical trials that will be performed in Germany and Belgium",
        "label": "GMP production of AIP cells for two clinical trials that will be performed in Germany and Belgium [Member]"
       }
      }
     },
     "localname": "GmpProductionOfAipCellsForTwoClinicalTrialsThatWillBePerformedInGermanyAndBelgiumMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_GrantsIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Less grants"
       }
      }
     },
     "localname": "GrantsIncome",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_GrantsReceivablePercentageOfBudgetedCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grants receivable, percentage of budgeted costs",
        "label": "Grants receivable, percentage of budgeted costs"
       }
      }
     },
     "localname": "GrantsReceivablePercentageOfBudgetedCosts",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ORGS_HeldUntilOneYearAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information of shares held until one year anniversary.",
        "label": "Held Until One Year Anniversary [Member]"
       }
      }
     },
     "localname": "HeldUntilOneYearAnniversaryMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_HeldUntilSixMonthsAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information of shares held until six months anniversary.",
        "label": "Held Until Six Months Anniversary [Member]"
       }
      }
     },
     "localname": "HeldUntilSixMonthsAnniversaryMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_HemogenyxCelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hemogenyx Cel [Member]"
       }
      }
     },
     "localname": "HemogenyxCelMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_HemogenyxPharmaceuticalsPLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hemogenyx Pharmaceuticals PLC. [Member]",
        "label": "Hemogenyx Pharmaceuticals PLC. [Member]"
       }
      }
     },
     "localname": "HemogenyxPharmaceuticalsPLCMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_IPResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IPR&amp;D [Member]",
        "label": "IPR&amp;D [Member]"
       }
      }
     },
     "localname": "IPResearchAndDevelopmentMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfOtherIntangibleAssetsDetails",
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ImmuAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immu Agreement [Member]",
        "label": "Immu Agreement [Member]"
       }
      }
     },
     "localname": "ImmuAgreementMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ImmugenyxLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immugenyx, LLC",
        "label": "Immugenyx, Llc [Member]"
       }
      }
     },
     "localname": "ImmugenyxLLCMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Net loss from Continuing Operation"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_IncomeLossFromDiscontinuedOperationNetOfTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Net loss from discontinuing operation, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationNetOfTax",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_IncomeLossesFromDiscontinuedOperationNetOfTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Net loss (income) from Discontinued Operations, Net of Tax"
       }
      }
     },
     "localname": "IncomeLossesFromDiscontinuedOperationNetOfTax",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax examination, likelihood of unfavorable settlement percent"
       }
      }
     },
     "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlementPercent",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ORGS_IncreaseDecreaseInAccuredExpensesAndOtherPayables": {
     "auth_ref": [],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in accrued expenses and other payables.",
        "label": "Increase (decrease) in accrued expenses and other payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccuredExpensesAndOtherPayables",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances": {
     "auth_ref": [],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect of exchange differences on inter-company balances.",
        "label": "Effect of exchange differences on inter-company balances"
       }
      }
     },
     "localname": "IncreaseDecreaseInEffectOfExchangeDifferencesOnIntercompanyBalances",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant": {
     "auth_ref": [],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in advance payments and receivables on account of grant, net.",
        "label": "Change in advance payments and receivables on account of grant, net"
       }
      }
     },
     "localname": "IncreaseDecreaseIncreaseDecreaseInAdvancePaymentOnAccountOfGrant",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://orgenesis.com/role/ScheduleOfFinancialExpensesDetails": {
       "order": 1.0,
       "parentTag": "ORGS_TotalFinancialExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in fair value of warrants and financial liabilities measured at fair value",
        "label": "Increase in fair value of warrants and financial liabilities measured at fair value"
       }
      }
     },
     "localname": "IncreasesInFairValueOfWarrantsAndFinancialLiabilitiesMeasuredAtFairValue",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfFinancialExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_IndustrialResearchPartOfResearchProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Industrial research part of the research program [Member]",
        "label": "Industrial research part of research program [Member]"
       }
      }
     },
     "localname": "IndustrialResearchPartOfResearchProgramMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_InterestExpenseOnConvertibleLoans": {
     "auth_ref": [],
     "calculation": {
      "http://orgenesis.com/role/ScheduleOfFinancialExpensesDetails": {
       "order": 2.0,
       "parentTag": "ORGS_TotalFinancialExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense on convertible loans",
        "label": "Interest expense on convertible loans"
       }
      }
     },
     "localname": "InterestExpenseOnConvertibleLoans",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfFinancialExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_InterestInJointVenture": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest in joint venture",
        "label": "Interest in joint venture"
       }
      }
     },
     "localname": "InterestInJointVenture",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ORGS_InvestmentsInAssociatePercentageOfOwnership": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in associate percentage of ownership.",
        "label": "Investments in associate percentage of ownership"
       }
      }
     },
     "localname": "InvestmentsInAssociatePercentageOfOwnership",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/InvestmentsInAssociatesNetDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ORGS_InvestorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor One [Member]"
       }
      }
     },
     "localname": "InvestorOneMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_InvestorRelationContactMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investor Relation Contact [Member]",
        "label": "Investor Relation Contact [Member]"
       }
      }
     },
     "localname": "InvestorRelationContactMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_InvestorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor Two [Member]"
       }
      }
     },
     "localname": "InvestorTwoMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Israel-U.S Binational Industrial Research and Development Foundation",
        "label": "Israelus Binational Industrial Research And Development Foundation [Member]"
       }
      }
     },
     "localname": "IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance and modification of warrants and beneficial conversion feature of convertible loans.",
        "label": "Issuance and modification of warrants and Beneficial conversion feature of convertible loans"
       }
      }
     },
     "localname": "IssuanceAndModificationOfWarrantsAndBeneficialConversionFeatureOfConvertibleLoans",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stocks in connection with the acquisition of Koligo.",
        "label": "Issuance of common stocks in connection with the acquisition of Koligo"
       }
      }
     },
     "localname": "IssuanceOfCommonStocksInConnectionWithAcquisitionOfKoligo",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_IssuanceOfSharesAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of shares and warrants.",
        "label": "Issuance of shares and warrants"
       }
      }
     },
     "localname": "IssuanceOfSharesAndWarrants",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_IssuanceOfSharesAndWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of shares and warrants, shares",
        "label": "Issuance of shares and warrants, shares"
       }
      }
     },
     "localname": "IssuanceOfSharesAndWarrantsShares",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ORGS_JointVentureAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint Venture Agreement [Member]",
        "label": "Joint Venture Agreement [Member]"
       }
      }
     },
     "localname": "JointVentureAgreementMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint venture agreement, shares issued for compensation of work already completed",
        "label": "Joint venture agreement, shares issued for compensation of work already completed"
       }
      }
     },
     "localname": "JointVentureAgreementSharesIssuedForCompensationOfWorkAlreadyCompleted",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ORGS_JointVenturePartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Joint Venture Partners [Member]"
       }
      }
     },
     "localname": "JointVenturePartnersMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/RevenuesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_KidneyCureJVAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kidney Cure JVA [Member]",
        "label": "Kidney Cure J V A [Member]"
       }
      }
     },
     "localname": "KidneyCureJVAMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/InvestmentsInAssociatesNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_KinerjapayCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "KinerjaPay Corp member.",
        "label": "Kinerjapay Corp [Member]"
       }
      }
     },
     "localname": "KinerjapayCorpMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_KnowhowMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Know How [Member]",
        "label": "Know-How [Member]"
       }
      }
     },
     "localname": "KnowhowMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfIntangibleAssetsAndTheirUsefulLiveDetails",
      "http://orgenesis.com/role/ScheduleOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_KoligoTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Koligo therapeutics inc.",
        "label": "Koligo Therapeutics Inc [Member]"
       }
      }
     },
     "localname": "KoligoTherapeuticsIncMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative",
      "http://orgenesis.com/role/EquityDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfUnauditedSupplementalProFormaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_KoreaisraelIndustrialResearchAndDevelopmentFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Korea-Israel Industrial Research and Development Foundation",
        "label": "Koreaisrael Industrial Research And Development Foundation [Member]"
       }
      }
     },
     "localname": "KoreaisraelIndustrialResearchAndDevelopmentFoundationMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_KyslecelTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kyslecel Technology [Member]",
        "label": "Kyslecel Technology [Member]"
       }
      }
     },
     "localname": "KyslecelTechnologyMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfOtherIntangibleAssetsDetails",
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab Equipment [Member]",
        "label": "Lab Equipment [Member]"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_LeaseClassificationDiscription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease classification discription.",
        "label": "Lease classification discription"
       }
      }
     },
     "localname": "LeaseClassificationDiscription",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ORGS_LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Lease-Related Assets and Liabilities [Table Text Block]",
        "label": "SCHEDULE OF LEASE-RELATED ASSETS AND LIABILITIES"
       }
      }
     },
     "localname": "LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_LesseeLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finance Lease Liabilities and Operating Lease Liabilities [Table Text Block]",
        "label": "SCHEDULE OF FINANCE LEASE LIABILITIES AND OPERATING LEASE LIABILITIES"
       }
      }
     },
     "localname": "LesseeLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_LoansTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loans.",
        "label": "LOANS"
       }
      }
     },
     "localname": "LoansTextBlock",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Loans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_LongHillAndMaximGroupLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long hill and maximum group.",
        "label": "Long Hill And Maxim Group L L C [Member]"
       }
      }
     },
     "localname": "LongHillAndMaximGroupLLCMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_MarylandSubsidiaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maryland Subsidiary [Member]",
        "label": "Maryland Subsidiary [Member]"
       }
      }
     },
     "localname": "MarylandSubsidiaryMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_MarylandTechnologyDevelopmentCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maryland Technology Development Corporation [Member]",
        "label": "Maryland Technology Development Corporation [Member]"
       }
      }
     },
     "localname": "MarylandTechnologyDevelopmentCorporationMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_MasterServicesAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Master Services Agreements [Member]"
       }
      }
     },
     "localname": "MasterServicesAgreementsMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/RevenuesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_MasthercellGlobalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Masthercell Global [Member]",
        "label": "Masthercell Global [Member]"
       }
      }
     },
     "localname": "MasthercellGlobalMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_MasthercellMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MaSTherCell [Member]",
        "label": "Masthercell [Member]"
       }
      }
     },
     "localname": "MasthercellMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative",
      "http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_MasthercellSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Masthercell SA [Member]",
        "label": "Masthercell S A [Member]"
       }
      }
     },
     "localname": "MasthercellSAMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_MaterialDefinitiveAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Material dewfinitive agreement.",
        "label": "Material Definitive Agreement [Member]"
       }
      }
     },
     "localname": "MaterialDefinitiveAgreementMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_MaximaGroupLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maxima Group L L C [Member]"
       }
      }
     },
     "localname": "MaximaGroupLLCMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative",
      "http://orgenesis.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_MergerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger Agreement [Member]",
        "label": "Merger Agreement [Member]"
       }
      }
     },
     "localname": "MergerAgreementMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ModificationOfExistingWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modification of the existing warrants",
        "label": "Modification of the existing warrants"
       }
      }
     },
     "localname": "ModificationOfExistingWarrants",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_NetChangesInOperatingLeases": {
     "auth_ref": [],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net changes in operating leases.",
        "label": "NetChangesInOperatingLeases",
        "negatedLabel": "Net changes in operating leases"
       }
      }
     },
     "localname": "NetChangesInOperatingLeases",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_NetIncomeLossToParentCompany": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Income Loss To Parent Company.",
        "label": "Net (income) loss attributable to Orgenesis Inc. for loss per share"
       }
      }
     },
     "localname": "NetIncomeLossToParentCompany",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfBasicAndDilutedLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_NetProfitLossFromDiscontinuingOperationNetOfTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net profit (loss) from discontinuing operation, net of tax.",
        "label": "Net profit (loss) from discontinuing operation, net of tax"
       }
      }
     },
     "localname": "NetProfitLossFromDiscontinuingOperationNetOfTax",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_NonEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Employees [Member]",
        "label": "Non-Employees [Member]"
       }
      }
     },
     "localname": "NonEmployeesMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_NonUSInvestorFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non U S Investor Four [Member]"
       }
      }
     },
     "localname": "NonUSInvestorFourMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_NonUSInvestorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non U S Investor [Member]"
       }
      }
     },
     "localname": "NonUSInvestorMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_NonUSInvestorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non U S Investor One [Member]"
       }
      }
     },
     "localname": "NonUSInvestorOneMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_NonUSInvestorThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non U S Investor Three [Member]"
       }
      }
     },
     "localname": "NonUSInvestorThreeMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_NonUSInvestorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non U S Investor Two [Member]"
       }
      }
     },
     "localname": "NonUSInvestorTwoMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_NonexecutiveDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-executive directors",
        "label": "Nonexecutive Directors [Member]"
       }
      }
     },
     "localname": "NonexecutiveDirectorsMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_NumberOfAdditionalSharesRestrictionsOnTransfer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of additional shares restrictions on transfer"
       }
      }
     },
     "localname": "NumberOfAdditionalSharesRestrictionsOnTransfer",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ORGS_NumberOfOrdinarySharesHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of ordinary shares held.",
        "label": "Number of ordinary shares held"
       }
      }
     },
     "localname": "NumberOfOrdinarySharesHeld",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "ORGS_NumberOfSharesDepositInEscrowAccount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares deposit in escrow account.",
        "label": "Number of shares deposit in escrow account"
       }
      }
     },
     "localname": "NumberOfSharesDepositInEscrowAccount",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative",
      "http://orgenesis.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ORGS_NumberOfVestedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of vested shares",
        "label": "Number of vested shares"
       }
      }
     },
     "localname": "NumberOfVestedShares",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ORGS_OBIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "O B I [Member]"
       }
      }
     },
     "localname": "OBIMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_OfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering expenses.",
        "label": "Offering expenses"
       }
      }
     },
     "localname": "OfferingExpenses",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_OfficeFurnitureAndComputersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Furniture and Computers [Member]",
        "label": "Office Furniture and Computers [Member]"
       }
      }
     },
     "localname": "OfficeFurnitureAndComputersMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_OfficesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offices [Member]"
       }
      }
     },
     "localname": "OfficesMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On the date of initiation of issuance of an approval for marketing of the first product by the FDA",
        "label": "On the date of initiation of issuance of an approval for marketing of the first product by the FDA [Member]"
       }
      }
     },
     "localname": "OnTheDateOfInitiationOfIssuanceOfAnApprovalForMarketingOfTheFirstProductByTheFdaMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On the date of initiation of phase I clinical trials in human subjects",
        "label": "On the date of initiation of phase I clinical trials in human subjects [Member]"
       }
      }
     },
     "localname": "OnTheDateOfInitiationOfPhaseIClinicalTrialsInHumanSubjectsMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On the date of initiation of phase II clinical trials in human subject",
        "label": "On the date of initiation of phase II clinical trials in human subject [Member]"
       }
      }
     },
     "localname": "OnTheDateOfInitiationOfPhaseIiClinicalTrialsInHumanSubjectMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On the date of initiation of phase III clinical trials in human subjects",
        "label": "On the date of initiation of phase III clinical trials in human subjects [Member]"
       }
      }
     },
     "localname": "OnTheDateOfInitiationOfPhaseIiiClinicalTrialsInHumanSubjectsMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_OneYearAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Year Anniversary [Member]",
        "label": "One Year Anniversary [Member]"
       }
      }
     },
     "localname": "OneYearAnniversaryMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_OptionsAndWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options and Warrants [Member]",
        "label": "Options and Warrants [Member]"
       }
      }
     },
     "localname": "OptionsAndWarrantsMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/IncomeLossPerShareDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_OptionsGrantedToEmployeesAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options Granted to Employees and Directors",
        "label": "Options Granted to Employees and Directors [Member]"
       }
      }
     },
     "localname": "OptionsGrantedToEmployeesAndDirectorsMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_OptionsGrantedToEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options Granted To Employees [Member]",
        "label": "Options Granted To Employees [Member]"
       }
      }
     },
     "localname": "OptionsGrantedToEmployeesMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails",
      "http://orgenesis.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_OptionsGrantedToNonEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Granted To Non Employees [Member]"
       }
      }
     },
     "localname": "OptionsGrantedToNonEmployeesMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative",
      "http://orgenesis.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net loss (income) from discontinued operations, net of tax.",
        "label": "Release of translation adjustment due to sale of subsidiary"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeReleaseOfTranslationAdjustmentDueToSaleOfSubsidiary",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_OtherInvestmentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Investments [Policy Text Block]",
        "label": "Other Investments"
       }
      }
     },
     "localname": "OtherInvestmentsPolicyTextBlock",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_PaymentForFinancialSupportCumulativeAmountToTrustForStudy": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of cumulative financial support provided to trust for study.",
        "label": "Payment for financial support cumulative amount to trust for study"
       }
      }
     },
     "localname": "PaymentForFinancialSupportCumulativeAmountToTrustForStudy",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_PaymentForFinancialSupportToTrustForStudy": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of financial support provided to trust for study.",
        "label": "Payment for financial support to trust for study"
       }
      }
     },
     "localname": "PaymentForFinancialSupportToTrustForStudy",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_PaymentForFinancialSupportToTrustForStudyDueEverySixMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of financial support to trust for study due in six month.",
        "label": "Payment for financial support to trust for study due every six months"
       }
      }
     },
     "localname": "PaymentForFinancialSupportToTrustForStudyDueEverySixMonths",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_PaymentOfFeeUponAchievementOfEachRegulatoryMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of payment of fee to Columbia upon the achievement of each regulatory milestone.",
        "label": "Payment of fee upon the achievement of each regulatory milestone"
       }
      }
     },
     "localname": "PaymentOfFeeUponAchievementOfEachRegulatoryMilestone",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_PaymentsForInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in associated company",
        "label": "PaymentsForInvestments",
        "negatedLabel": "Investment in associated company"
       }
      }
     },
     "localname": "PaymentsForInvestments",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_PercentageOfCommission": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission.",
        "label": "Percentage of commission"
       }
      }
     },
     "localname": "PercentageOfCommission",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ORGS_PercentageOfGrossRevenues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of gross revenues.",
        "label": "Percentage of gross revenues"
       }
      }
     },
     "localname": "PercentageOfGrossRevenues",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ORGS_PercentageOfOutstandingEquityInterests": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of outstanding equity interests.",
        "label": "Percentage of outstanding equity interests"
       }
      }
     },
     "localname": "PercentageOfOutstandingEquityInterests",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative",
      "http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ORGS_PointOfCareServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "POC and Hospital Services [Member]",
        "label": "POC and Hospital Services [Member]"
       }
      }
     },
     "localname": "PointOfCareServicesMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_PreMoneyValuation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-money valuation",
        "label": "Pre-money valuation"
       }
      }
     },
     "localname": "PreMoneyValuation",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_PrivatePlacementSubscriptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Subscription Agreement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementSubscriptionAgreementMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_PrivatePlacementSubscriptionAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Placement Subscription Agreements [Member]",
        "label": "Private Placement Subscription Agreements [Member]"
       }
      }
     },
     "localname": "PrivatePlacementSubscriptionAgreementsMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ProductionFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Production Facility [Member]",
        "label": "Production Facility [Member]"
       }
      }
     },
     "localname": "ProductionFacilityMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails",
      "http://orgenesis.com/role/ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_PropertyPlantAndEquipmentNetAndRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, plants and equipment, net and right-of-use assets.",
        "label": "Property, plants and equipment, net and right-of-use assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAndRightOfUseAssets",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of property, plant and equipment included in accounts payable.",
        "label": "Purchase of property, plant and equipment included in accounts payable"
       }
      }
     },
     "localname": "PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayable",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block]",
        "label": "Recently issued accounting pronouncements, not yet adopted"
       }
      }
     },
     "localname": "RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_RedeemableNoncontrollingInterestOfDiscontinuedOperation": {
     "auth_ref": [],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable non-controlling interest of discontinued operation.",
        "label": "REDEEMABLE NON CONTROLLING INTEREST OF DISCONTINUED OPERATIONS (See Note 3)"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestOfDiscontinuedOperation",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_RedeemableNoncontrollingInterestPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest [Policy Text Block]",
        "label": "Redeemable Non-controlling Interest"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestPolicyTextBlock",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_ReductionInConsiderationPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in consideration.",
        "label": "Reduction in consideration payable"
       }
      }
     },
     "localname": "ReductionInConsiderationPayable",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_ReductionRateOfRoyaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction rate of royalty percentage.",
        "label": "Reduction rate of royalty percentage"
       }
      }
     },
     "localname": "ReductionRateOfRoyaltyPercentage",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ORGS_RegistrationRightsandLockUpAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registration rights and lock up agreement.",
        "label": "Registration Rightsand Lock Up Agreement [Member]"
       }
      }
     },
     "localname": "RegistrationRightsandLockUpAgreementMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_RepaymentOfIntercompanyLoansAndPayables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment of intercompany loans and payables.",
        "label": "Repayment of intercompany loans and payables"
       }
      }
     },
     "localname": "RepaymentOfIntercompanyLoansAndPayables",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative",
      "http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_RepaymentOfTreasuryStock": {
     "auth_ref": [],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchase of treasury stock.",
        "label": "RepaymentOfTreasuryStock",
        "negatedLabel": "Repurchase of treasury stock"
       }
      }
     },
     "localname": "RepaymentOfTreasuryStock",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_RepaymentsOfGrantPercentageOfGrossSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments of grant, percentage of gross sales",
        "label": "Repayments of grant, percentage of gross sales"
       }
      }
     },
     "localname": "RepaymentsOfGrantPercentageOfGrossSales",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ORGS_ResearchAndDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Costs [Member]",
        "label": "Research And Development Costs [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCostsMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ResearchAndDevelopmentFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development Facilities [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentFacilitiesMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development of a potential cure for Type 1 Diabetes [Member]",
        "label": "Research And Development Of Potential Cure For Type One Diabetes [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentOfPotentialCureForTypeOneDiabetesMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ResearchOnDermatitisTreatmentsAndWoundHealingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research On Dermatitis Treatments And Wound Healing [Member]"
       }
      }
     },
     "localname": "ResearchOnDermatitisTreatmentsAndWoundHealingMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_RestrictionOnSaleOfSharesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restriction on sale of shares percentage.",
        "label": "Restriction on sale of shares percentage"
       }
      }
     },
     "localname": "RestrictionOnSaleOfSharesPercentage",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ORGS_RestrictionPeriodDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restriction period, description"
       }
      }
     },
     "localname": "RestrictionPeriodDescription",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ORGS_RevenueFromGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from grants [Member]",
        "label": "Revenue from grants [Member]"
       }
      }
     },
     "localname": "RevenueFromGrantsMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use assets acquired in exchange for right-of-use liabilities.",
        "label": "Right-of-use assets acquired in exchange for right-of-use liabilities"
       }
      }
     },
     "localname": "RightofuseAssetsAcquiredInExchangeForRightofuseLiabilities",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_RoyaltyOfNetSalesOfOtherProductsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty of net sales of other products.",
        "label": "Royalty of net sales of other product percentage"
       }
      }
     },
     "localname": "RoyaltyOfNetSalesOfOtherProductsPercentage",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ORGS_RoyaltyOfNetSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty of net sales, percentage",
        "label": "Royalty of net sales, percentage"
       }
      }
     },
     "localname": "RoyaltyOfNetSalesPercentage",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ORGS_RoyaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty percentage.",
        "label": "Royalty percentage"
       }
      }
     },
     "localname": "RoyaltyPercentage",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ORGS_SBHSciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SBH Sciences, Inc [member]",
        "label": "SBH Sciences, Inc [member]"
       }
      }
     },
     "localname": "SBHSciencesIncMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_SalesMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Milestone [Member]"
       }
      }
     },
     "localname": "SalesMilestoneMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Annual Depreciation Rates Property and Equipment [Table Text Block]",
        "label": "SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_ScheduleOfBreakdownOfRevenuesPerCustomer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF BREAKDOWN OF REVENUES PER CUSTOMER"
       }
      }
     },
     "localname": "ScheduleOfBreakdownOfRevenuesPerCustomer",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Disaggregation of Revenue Related to Discontinued Operations [Table Text ]Block",
        "label": "SCHEDULE OF DISAGGREGATION OF REVENUE RELATED TO DISCONTINUED OPERATIONS"
       }
      }
     },
     "localname": "ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsTableTextBlock",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/DiscontinuedOperationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_ScheduleOfFinancialExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FINANCIAL EXPENSES"
       }
      }
     },
     "localname": "ScheduleOfFinancialExpensesTableTextBlock",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/FinancialExpensesNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Intangible Assets Useful Lives [Table Text Block]",
        "label": "SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsUsefulLivesTableTextBlock",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT BY GEOGRAPHICAL LOCATION"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/PropertyPlantsAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RELATED PARTIES PRESENTED IN CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/RelatedPartiesTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_ScheduleOfRightofuseAssetsByGeographicalLocation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Right-of-use Assets by Geographical Location [Table Text Block]",
        "label": "SCHEDULE OF RIGHT-OF-USE ASSETS BY GEOGRAPHICAL LOCATION"
       }
      }
     },
     "localname": "ScheduleOfRightofuseAssetsByGeographicalLocation",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_ScheduleOfTreasuryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Treasury Shares [Table Text Block]",
        "label": "SCHEDULE OF TREASURY SHARES"
       }
      }
     },
     "localname": "ScheduleOfTreasuryShares",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_ScheduleOfWarrantsActivity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Warrants Activity [Table Text Block]",
        "label": "SCHEDULE OF WARRANTS ACTIVITY"
       }
      }
     },
     "localname": "ScheduleOfWarrantsActivity",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement [Member]",
        "label": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative",
      "http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative",
      "http://orgenesis.com/role/EquityDetailsNarrative",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_SeparateInvestorRelationContactMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separate Investor Relation Contact [Member]",
        "label": "Separate Investor Relation Contact [Member]"
       }
      }
     },
     "localname": "SeparateInvestorRelationContactMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_SeparateInvestorRelationsContactMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separate Investor Relations Contact [Member]",
        "label": "Separate Investor Relations Contact [Member]"
       }
      }
     },
     "localname": "SeparateInvestorRelationsContactMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_SeveralConsultantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Several Consultants [Member]",
        "label": "Several Consultants [Member]"
       }
      }
     },
     "localname": "SeveralConsultantsMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options vesting period description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price - warrants expiration in periods.",
        "label": "Weighted Average Exercise Price - Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price - warrants granted in period.",
        "label": "Weighted Average Exercise Price - Issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Warrants - Warrants outstanding and exercisable.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber",
        "periodEndLabel": "Number of Warrants - Warrants outstanding and exercisable at the end of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise pPrice - warrants outstanding and exercisable.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice",
        "periodEndLabel": "Weighted Average Exercise Price - Warrants outstanding and exercisable at the end of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price - warrants outstanding.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
        "periodStartLabel": "Weighted Average Exercise Price - Warrants outstanding at the beginning of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Available for grants",
        "label": "Share-based compensation arrangement by share-based payment award, options, available for grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrants",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Cancellations in Period",
        "label": "Number of Options - Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Cancellations in Period, Weighted Average Exercise Price",
        "label": "Weighted Average Exercise Price - Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration period",
        "label": "Expiration period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value at grant",
        "label": "Fair value at grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting period",
        "label": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriod",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ORGS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting peirod description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ORGS_ShareBasedCompensationOne": {
     "auth_ref": [],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation to for strategic collaborations.",
        "label": "Stock-based compensation for strategic collaborations"
       }
      }
     },
     "localname": "ShareBasedCompensationOne",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_ShareBasedCompensationTwo": {
     "auth_ref": [],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation for Tamir Purchase Agreement.",
        "label": "Stock-based compensation for Tamir Purchase Agreement (See Notes 4)"
       }
      }
     },
     "localname": "ShareBasedCompensationTwo",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_ShareInNetIncomeOfAssociatedCompanies": {
     "auth_ref": [],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share in net income of associated companies.",
        "label": "ShareInNetIncomeOfAssociatedCompanies",
        "negatedLabel": "Share in net income of associated companies",
        "negatedTerseLabel": "Share in income of associated company"
       }
      }
     },
     "localname": "ShareInNetIncomeOfAssociatedCompanies",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows",
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_SharesHeldInEscrow": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares held in escrow.",
        "label": "Shares held in escrow"
       }
      }
     },
     "localname": "SharesHeldInEscrow",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ORGS_SharesUponConversionOfConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Upon Conversion of Convertible Notes [Member]",
        "label": "Shares Upon Conversion of Convertible Notes [Member]"
       }
      }
     },
     "localname": "SharesUponConversionOfConvertibleNotesMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/IncomeLossPerShareDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ShortTermLoanOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short Term Loan One [Member]"
       }
      }
     },
     "localname": "ShortTermLoanOneMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ShortTermLoansThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short Term Loans Three [Member]"
       }
      }
     },
     "localname": "ShortTermLoansThreeMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ShortTermLoansTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short Term Loans Two [Member]"
       }
      }
     },
     "localname": "ShortTermLoansTwoMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_SixPercentageConvertibleLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Six Percentage Convertible Loan Agreement [Member]"
       }
      }
     },
     "localname": "SixPercentageConvertibleLoanAgreementMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_SixPercentageConvertibleLoansTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Six Percentage Convertible Loans Two [Member]"
       }
      }
     },
     "localname": "SixPercentageConvertibleLoansTwoMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_SouthKoreanWonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "KRW [Member]",
        "label": "South Korean Won [Member]"
       }
      }
     },
     "localname": "SouthKoreanWonMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_SponsoredResearchAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsored Research Agreement [Member]",
        "label": "Sponsored Research Agreement [Member]"
       }
      }
     },
     "localname": "SponsoredResearchAgreementMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation for Tamir purchase agreement, shares",
        "label": "Stock-based compensation for Tamir purchase agreement (See Note 3), shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationTamirPurchaseAgreementShares",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ORGS_StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation for Tamir purchase agreement.",
        "label": "Stock-based compensation for Tamir purchase agreement (See Note 4)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationTamirPurchaseAgreement",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_StockOptionsGrantVestingPeriodPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options grant vesting period percentage.",
        "label": "Stock options grant vesting period percentage"
       }
      }
     },
     "localname": "StockOptionsGrantVestingPeriodPercentage",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ORGS_StockbasedCompensationToStrategicCollaborations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation to strategic collaborations.",
        "label": "Stock-based compensation to strategic collaborations"
       }
      }
     },
     "localname": "StockbasedCompensationToStrategicCollaborations",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_StockbasedCompensationToStrategicCollaborationsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation to strategic collaborations, shares.",
        "label": "Stock-based compensation to strategic collaborations, shares"
       }
      }
     },
     "localname": "StockbasedCompensationToStrategicCollaborationsShares",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ORGS_SublicensingFeesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublicensing fees, percentage",
        "label": "Sublicensing fees, percentage"
       }
      }
     },
     "localname": "SublicensingFeesPercentage",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "ORGS_SuccessFeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success fee",
        "label": "Success fee [Member]"
       }
      }
     },
     "localname": "SuccessFeeMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_TLABSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TLABS [Member]",
        "label": "T L A B S [Member]"
       }
      }
     },
     "localname": "TLABSMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/InvestmentsInAssociatesNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_TamirBiotechnologyIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tamir Biotechnology, Inc. [Member]",
        "label": "Tamir Biotechnology Inc [Member]"
       }
      }
     },
     "localname": "TamirBiotechnologyIncMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative",
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative",
      "http://orgenesis.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_TamirPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tamir Purchase Agreement [Member]",
        "label": "Tamir Purchase Agreement [Member]"
       }
      }
     },
     "localname": "TamirPurchaseAgreementMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative",
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative",
      "http://orgenesis.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_TaxBaseAboveKrwThreeZeroZeroBillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Base Above KRW 300 Billion [Member]",
        "label": "Tax Base Above KRW 300 Billion [Member]"
       }
      }
     },
     "localname": "TaxBaseAboveKrwThreeZeroZeroBillionMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_TechTransferServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tech Transfer Services [Member]",
        "label": "Tech Transfer Services [Member]"
       }
      }
     },
     "localname": "TechTransferServicesMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_TechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology [Member]",
        "label": "Technology [Member]"
       }
      }
     },
     "localname": "TechnologyMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfIntangibleAssetsAndTheirUsefulLiveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member]",
        "label": "Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member]"
       }
      }
     },
     "localname": "TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_TerminationDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination description.",
        "label": "Termination description"
       }
      }
     },
     "localname": "TerminationDescription",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ORGS_TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The First KRW 200 Million Of The Tax Base [Member]",
        "label": "The First KRW 200 Million Of The Tax Base [Member]"
       }
      }
     },
     "localname": "TheFirstKrwTwoZeroZeroMillionOfTheTaxBaseMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_ThreeEqualInstallmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Equal Installments [Member]",
        "label": "Three Equal Installments [Member]"
       }
      }
     },
     "localname": "ThreeEqualInstallmentsMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_TissueGenesisLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tissue Genesis, LLC [Member]",
        "label": "Tissue Genesis L L C [Member]"
       }
      }
     },
     "localname": "TissueGenesisLLCMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_TotalFinancialExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://orgenesis.com/role/ScheduleOfFinancialExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total financial expenses",
        "label": "Total Financial Expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "TotalFinancialExpenses",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfFinancialExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_TransactionCostIncurred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction cost incurred.",
        "label": "Transaction cost incurred"
       }
      }
     },
     "localname": "TransactionCostIncurred",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ORGS_TransferAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transfer Agreement [Member]"
       }
      }
     },
     "localname": "TransferAgreementMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_TreasurySharesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury Shares [Policy Text Block]",
        "label": "Treasury shares"
       }
      }
     },
     "localname": "TreasurySharesPolicyTextBlock",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ORGS_TreasuryStockShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares repurchased.",
        "label": "Shares repurchased",
        "periodEndLabel": "Number of Treasury Shares at end of the period",
        "periodStartLabel": "Number of Treasury Shares at the beginning of the period"
       }
      }
     },
     "localname": "TreasuryStockShare",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfTreasurySharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ORGS_TwoOtherInvestorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Other Investor Two [Member]"
       }
      }
     },
     "localname": "TwoOtherInvestorTwoMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_TwoPercentageConvertibleLoansTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Percentage Convertible Loans Two [Member]"
       }
      }
     },
     "localname": "TwoPercentageConvertibleLoansTwoMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_TwoThousandTwentyOneToTwoThousandTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021-2020 [Member]",
        "label": "2021-2020 [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyOneToTwoThousandTwentyMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_TwoZeroOneSevenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Equity Incentive Plan [Member]",
        "label": "2017 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoZeroOneSevenEquityIncentivePlanMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_UpToKrwThreeZeroZeroBillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Up to KRW 300 billion",
        "label": "Up To KRW 300 Billion [Member]"
       }
      }
     },
     "localname": "UpToKrwThreeZeroZeroBillionMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_UpToKrwTwoZeroBillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Up to KRW 20 billion",
        "label": "Up To KRW 20 Billion [Member]"
       }
      }
     },
     "localname": "UpToKrwTwoZeroBillionMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_VestMonthlyOver3MonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information of Vest Monthly Over 3 Months.",
        "label": "Vest Monthly Over 3 Months [Member]"
       }
      }
     },
     "localname": "VestMonthlyOver3MonthsMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_VestedOnSigningDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vested on the signing date",
        "label": "vested on signing date[Member]"
       }
      }
     },
     "localname": "VestedOnSigningDateMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ORGS_WarrantExercisableDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant exercisable description.",
        "label": "Warrant exercisable, description",
        "verboseLabel": "[custom:WarrantExercisableDescription]"
       }
      }
     },
     "localname": "WarrantExercisableDescription",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/EquityDetailsNarrative",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ORGS_WarrantsAndRightsOutstandingTermDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants term.",
        "label": "Warrants term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTermDescription",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ORGS_WeightedAveragePriceNumberOfSharesTreasuryStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Price Paid Treasury Shares.",
        "label": "WeightedAveragePriceNumberOfSharesTreasuryStock",
        "periodEndLabel": "Weighted Average Price Paid Treasury Shares at end of the period",
        "periodStartLabel": "Weighted Average Price Paid Treasury Shares at the beginning of the period"
       }
      }
     },
     "localname": "WeightedAveragePriceNumberOfSharesTreasuryStock",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfTreasurySharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ORGS_WeightedAveragePriceNumberOfSharesTreasuryStockPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Price Paid Treasury Shares Purchased.",
        "label": "Weighted Average Price Paid Treasury Shares Purchased"
       }
      }
     },
     "localname": "WeightedAveragePriceNumberOfSharesTreasuryStockPurchased",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfTreasurySharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ORGS_WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "When worldwide net sales of Products have reached the amount of $150 million for the first time",
        "label": "When Worldwide Net Sales Of Products Have Reached The Amount Of One Five Zero Million For The First Time [Member]"
       }
      }
     },
     "localname": "WhenWorldwideNetSalesOfProductsHaveReachedTheAmountOfOneFiveZeroMillionForTheFirstTimeMember",
     "nsuri": "http://orgenesis.com/20201231",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "country_BE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BELGIUM"
       }
      }
     },
     "localname": "BE",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails",
      "http://orgenesis.com/role/ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails",
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ISRAEL"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/LeasesDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails",
      "http://orgenesis.com/role/ScheduleOfRight-of-useAssetsByGeographicalLocationDetails",
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "country_KR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KOREA, REPUBLIC OF"
       }
      }
     },
     "localname": "KR",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/LeasesDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails",
      "http://orgenesis.com/role/ScheduleOfRight-of-useAssetsByGeographicalLocationDetails",
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails",
      "http://orgenesis.com/role/ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails",
      "http://orgenesis.com/role/ScheduleOfRight-of-useAssetsByGeographicalLocationDetails",
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_ILS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israel, New Shekels"
       }
      }
     },
     "localname": "ILS",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_KRW": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Korea (South), Won"
       }
      }
     },
     "localname": "KRW",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r633",
      "r635",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative",
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
      "http://orgenesis.com/role/EquityDetailsNarrative",
      "http://orgenesis.com/role/InvestmentsInAssociatesNetDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Listings [Line Items]"
       }
      }
     },
     "localname": "EntityListingsLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative",
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
      "http://orgenesis.com/role/EquityDetailsNarrative",
      "http://orgenesis.com/role/InvestmentsInAssociatesNetDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]"
       }
      }
     },
     "localname": "DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative",
      "http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative",
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails",
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r225",
      "r328",
      "r333",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfBreakdownOfRevenuesPerCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r350",
      "r353",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r586",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/CommitmentsDetailsNarrative",
      "http://orgenesis.com/role/LeasesDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails",
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r350",
      "r353",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r586",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/LeasesDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails",
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MortgageLoansOnRealEstateLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails",
      "http://orgenesis.com/role/ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails",
      "http://orgenesis.com/role/ScheduleOfRight-of-useAssetsByGeographicalLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r225",
      "r328",
      "r333",
      "r589"
     ],
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfBreakdownOfRevenuesPerCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r222",
      "r328",
      "r331",
      "r518",
      "r585",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueDetails",
      "http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r222",
      "r328",
      "r331",
      "r518",
      "r585",
      "r587"
     ],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueDetails",
      "http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r342",
      "r350",
      "r353",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r586",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/CommitmentsDetailsNarrative",
      "http://orgenesis.com/role/LeasesDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails",
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r342",
      "r350",
      "r353",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r586",
      "r590"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/CommitmentsDetailsNarrative",
      "http://orgenesis.com/role/LeasesDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails",
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]"
       }
      }
     },
     "localname": "ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r351"
     ],
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r223",
      "r224",
      "r328",
      "r332",
      "r588",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620"
     ],
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/LeasesDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails",
      "http://orgenesis.com/role/ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails",
      "http://orgenesis.com/role/ScheduleOfRight-of-useAssetsByGeographicalLocationDetails",
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r223",
      "r224",
      "r328",
      "r332",
      "r588",
      "r608",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/LeasesDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails",
      "http://orgenesis.com/role/ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails",
      "http://orgenesis.com/role/ScheduleOfRight-of-useAssetsByGeographicalLocationDetails",
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r285",
      "r351",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r226",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "auth_ref": [
      "r421",
      "r422",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.",
        "label": "Accounting Standards Update 2019-12 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201912Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "SCHEDULE OF ACTIVITY FOR TRADE RECEIVABLES"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r59",
      "r561"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r34",
      "r59",
      "r227",
      "r228"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning of period"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets",
      "http://orgenesis.com/role/ScheduleOfActivityForTradeReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r53",
      "r540",
      "r563"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Income tax payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r73",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r62",
      "r97",
      "r98",
      "r99",
      "r565",
      "r598",
      "r602"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r96",
      "r99",
      "r100",
      "r166",
      "r167",
      "r168",
      "r461",
      "r593",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfIntangibleAssetsAndTheirUsefulLiveDetails",
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredIndefiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfUnauditedSupplementalProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r421",
      "r422",
      "r423",
      "r424",
      "r520",
      "r521",
      "r522",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": {
     "auth_ref": [
      "r299",
      "r304",
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.",
        "label": "Beneficial conversion feature of convertible loans"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).",
        "label": "Adjustment to redemption value of redeemable non-controlling interest"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r354",
      "r356",
      "r395",
      "r396"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock-based compensation to employees and directors"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments required to reconcile net income (loss) to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r356",
      "r382",
      "r394"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r146",
      "r256",
      "r264"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive securities excluded from computation of earnings per share amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/IncomeLossPerShareDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/IncomeLossPerShareDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/IncomeLossPerShareDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/IncomeLossPerShareDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative",
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative",
      "http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative",
      "http://orgenesis.com/role/EquityDetailsNarrative",
      "http://orgenesis.com/role/RevenuesDetailsNarrative",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r146",
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Impairment of long-lived asset"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r158",
      "r210",
      "r214",
      "r220",
      "r233",
      "r454",
      "r462",
      "r468",
      "r538",
      "r562"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r35",
      "r36",
      "r94",
      "r158",
      "r233",
      "r454",
      "r462",
      "r468"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r158",
      "r233",
      "r454",
      "r462",
      "r468"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r1",
      "r2",
      "r22",
      "r24",
      "r28",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.",
        "label": "TOTAL CURRENT ASSETS OF DISCONTINUED OPERATIONS"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r22",
      "r24",
      "r28",
      "r271",
      "r276"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Current assets of discontinued operations (See Note 3)"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r357",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative",
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r349",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative",
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative",
      "http://orgenesis.com/role/EquityDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfUnauditedSupplementalProFormaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r349",
      "r352",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative",
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative",
      "http://orgenesis.com/role/EquityDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfUnauditedSupplementalProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "SCHEDULE OF UNAUDITED SUPPLEMENTAL PRO FORMA"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Acquisition-related expenses"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r445",
      "r446",
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative",
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative",
      "http://orgenesis.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r445",
      "r446"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Transfer of equity interests"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Total assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Accounts Receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Accounts Payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "verboseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r441",
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Other intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r441",
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Total liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r441",
      "r442"
     ],
     "calculation": {
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Total consideration transferred",
        "totalLabel": "Total consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Notes Payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Other liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r441",
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "verboseLabel": "Property, plants and equipment, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r155",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combination"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r31",
      "r165",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/DescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r68",
      "r603",
      "r604"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r32",
      "r68",
      "r148"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r43",
      "r149",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r141",
      "r148",
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF YEAR",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF YEAR"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r141",
      "r469"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net cash flows (used in) provided by financing activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r20",
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net cash flows used in investing activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r20",
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net cash flows provided by (used in) operating activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Warrants exercise price",
        "terseLabel": "Warrant exercise price",
        "verboseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
      "http://orgenesis.com/role/EquityDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Number of warrants shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Number of warrant may be converted",
        "terseLabel": "Warrant to purchase of common stock",
        "verboseLabel": "Number of warrant to purchase"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
      "http://orgenesis.com/role/EquityDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/EquityDetailsNarrative",
      "http://orgenesis.com/role/RevenuesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r86",
      "r284",
      "r546",
      "r570"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments Disclosure [Text Block]",
        "verboseLabel": "COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Commitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical",
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value",
        "verboseLabel": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheetsParenthetical",
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r58",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock of $0.0001 par value, 145,833,334 shares authorized, 24,223,093 and 16,140,962 shares issued as of December 31, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r103",
      "r105",
      "r106",
      "r116",
      "r554",
      "r578"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive loss (income) attributed to Orgenesis Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive loss (income):"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Other Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r199",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r155",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r309",
      "r310",
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r309",
      "r310",
      "r329"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract liabilities",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning of period",
        "verboseLabel": "Contract with customer liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets",
      "http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetails",
      "http://orgenesis.com/role/ScheduleOfActivityForContractLiabilitiesDetailsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r54",
      "r541",
      "r564"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible debt",
        "verboseLabel": "Convertible loan"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Current maturities of convertible loans"
       }
      }
     },
     "localname": "ConvertibleDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible loans"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.",
        "label": "SCHEDULE OF LONG TERM CONVERTIBLE LOANS"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfIntangibleAssetsAndTheirUsefulLiveDetails",
      "http://orgenesis.com/role/ScheduleOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r151",
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Aggregate amount of debt"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Total loans"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "CONVERTIBLE LOANS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r52",
      "r53",
      "r54",
      "r539",
      "r541",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.",
        "label": "BCF"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleBeneficialConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Exercise Price",
        "verboseLabel": "Conversion price per share"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r478",
      "r479"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Principal Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Interest Rate",
        "verboseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfLoansDetails",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r83",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.",
        "label": "Debt instrument, maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r84",
      "r161",
      "r300",
      "r301",
      "r302",
      "r303",
      "r477",
      "r478",
      "r479",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Maturity Period"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r151",
      "r152",
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Transaction costs of issuance of convertible loans"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r403",
      "r404"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r93",
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "verboseLabel": "Offering expenses"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r417",
      "r418"
     ],
     "calculation": {
      "http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r417",
      "r418"
     ],
     "calculation": {
      "http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carry forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r417",
      "r418"
     ],
     "calculation": {
      "http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": {
     "auth_ref": [
      "r417",
      "r418"
     ],
     "calculation": {
      "http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.",
        "label": "Employee benefits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r417",
      "r418"
     ],
     "calculation": {
      "http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Equity compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: Valuation allowance",
        "negatedPeriodEndLabel": "Balance at end of year",
        "negatedPeriodStartLabel": "Balance at the beginning of year"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails",
      "http://orgenesis.com/role/ScheduleOfValuationAllowanceActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r404",
      "r412"
     ],
     "calculation": {
      "http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r417",
      "r418"
     ],
     "calculation": {
      "http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Deposits"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r146",
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/PropertyPlantsAndEquipmentDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r146",
      "r272"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortizationDiscontinuedOperations": {
     "auth_ref": [
      "r21",
      "r146"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.",
        "label": "Depreciation and Amortization, Discontinued Operations",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "DepreciationAndAmortizationDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfBreakdownOfRevenuesPerCustomerDetails",
      "http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r328",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfBreakdownOfRevenuesPerCustomerDetails",
      "http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "SCHEDULE OF DISAGGREGATION OF REVENUE"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r357",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "SCHEDULE OF STOCK OPTIONS EXERCISABLE"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r18",
      "r113",
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Loss before income taxes"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.",
        "label": "Net (income) loss common share from discontinued operations"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfBasicAndDilutedLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax": {
     "auth_ref": [
      "r7",
      "r9",
      "r11"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.",
        "label": "Gain on disposal before income taxes"
       }
      }
     },
     "localname": "DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax": {
     "auth_ref": [
      "r7",
      "r9",
      "r11",
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.",
        "label": "Gain on disposal"
       }
      }
     },
     "localname": "DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r11",
      "r18",
      "r25",
      "r405",
      "r426",
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Tax expenses (income)"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal": {
     "auth_ref": [
      "r9",
      "r11",
      "r25",
      "r430"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax (expense) benefit on (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.",
        "label": "Provision for income taxes"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxExpenseBenefitFromProvisionForGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r29",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.",
        "label": "Discontinued operations"
       }
      }
     },
     "localname": "DiscontinuedOperationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "auth_ref": [
      "r1",
      "r2",
      "r22",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable": {
     "auth_ref": [
      "r1",
      "r2",
      "r22",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities": {
     "auth_ref": [
      "r1",
      "r2",
      "r22",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities",
        "verboseLabel": "Accrued expenses and other payables"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "auth_ref": [
      "r1",
      "r2",
      "r22",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r19",
      "r28"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Cost of revenues"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities": {
     "auth_ref": [
      "r1",
      "r2",
      "r22",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities",
        "verboseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": {
     "auth_ref": [
      "r1",
      "r2",
      "r22",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": {
     "auth_ref": [
      "r1",
      "r2",
      "r22",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.",
        "label": "Intangible assets, net (mainly Know How)"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": {
     "auth_ref": [
      "r1",
      "r2",
      "r22",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Operating loss"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": {
     "auth_ref": [
      "r1",
      "r2",
      "r22",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": {
     "auth_ref": [
      "r1",
      "r2",
      "r22",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets": {
     "auth_ref": [
      "r1",
      "r2",
      "r22",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets",
        "verboseLabel": "Prepaid expenses and other receivables"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r1",
      "r2",
      "r22",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r19",
      "r28"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsDetails",
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r30",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "DISCONTINUED OPERATION"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/DiscontinuedOperation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DueFromRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r69",
      "r163",
      "r501"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due after one year (or one business cycle).",
        "label": "Loan to related party"
       }
      }
     },
     "localname": "DueFromRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r163",
      "r501",
      "r545",
      "r572"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss (income) per share:",
        "verboseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r117",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r181",
      "r183",
      "r186",
      "r187",
      "r188",
      "r192",
      "r193",
      "r555",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic",
        "verboseLabel": "Net (income) loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfBasicAndDilutedLossPerShareDetails",
      "http://orgenesis.com/role/ScheduleOfUnauditedSupplementalProFormaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r155",
      "r189",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Loss (income) per Share of Common Stock"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "INCOME (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/IncomeLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r469"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r406",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective income tax rate reconciliation, at income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r406",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective income tax rate reconciliation, at local income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employees and related payables"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of employee stock ownership plan.",
        "label": "Employee Stock Ownership Plan (ESOP) Name [Axis]"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative",
      "http://orgenesis.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails",
      "http://orgenesis.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entities identify multiple employee stock ownership plans by unique name."
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative",
      "http://orgenesis.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r170",
      "r178",
      "r180",
      "r196",
      "r237",
      "r299",
      "r304",
      "r389",
      "r390",
      "r391",
      "r423",
      "r424",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r476",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical",
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r70",
      "r211",
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Opening balance"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfChangesInInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r70",
      "r140",
      "r155",
      "r232",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Non-Marketable Equity Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EscrowDeposit": {
     "auth_ref": [
      "r544"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.",
        "label": "Cash held in escrow account",
        "verboseLabel": "Escrow Deposit"
       }
      }
     },
     "localname": "EscrowDeposit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative",
      "http://orgenesis.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAxis": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.",
        "label": "Extinguishment of Debt [Axis]"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ExtinguishmentOfDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Extinguishment of Debt [Line Items]"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ExtinguishmentOfDebtTypeDomain": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of debt extinguished."
       }
      }
     },
     "localname": "ExtinguishmentOfDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r146",
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair value of warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r483",
      "r489",
      "r497"
     ],
     "calculation": {
      "http://orgenesis.com/role/ScheduleOfLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "ORGS_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r484",
      "r491"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfSupplementalCashflowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r482",
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Present value of future minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Current maturities of finance leases",
        "negatedLabel": "Finance Lease, Less: Current leases obligations",
        "verboseLabel": "Current maturities of long-term finance leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets",
      "http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails",
      "http://orgenesis.com/role/ScheduleOfLease-relatedAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Long-term debt and finance leases",
        "terseLabel": "Finance Lease, Long-term leases obligations",
        "verboseLabel": "Long-term finance leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets",
      "http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails",
      "http://orgenesis.com/role/ScheduleOfLease-relatedAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Leases, Total minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, 2021"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, 2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, 2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, 2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, 2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Finance Lease, Less: amount of lease payments representing interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r483",
      "r489",
      "r497"
     ],
     "calculation": {
      "http://orgenesis.com/role/ScheduleOfLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "ORGS_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Amortization of leased assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r494",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Weighted Average Discount Rate, Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLease-relatedAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r493",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Lease Term, Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLease-relatedAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Intangible assets and useful lives (Years)",
        "verboseLabel": "Useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfIntangibleAssetsAndTheirUsefulLiveDetails",
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Amortization expenses, 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfEstimatedAggregateAmortizationExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r257",
      "r259",
      "r263",
      "r266",
      "r519",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfIntangibleAssetsAndTheirUsefulLiveDetails",
      "http://orgenesis.com/role/ScheduleOfOtherIntangibleAssetsDetails",
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r263",
      "r523"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r257",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfIntangibleAssetsAndTheirUsefulLiveDetails",
      "http://orgenesis.com/role/ScheduleOfOtherIntangibleAssetsDetails",
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r263",
      "r519"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Net carrying amount of other intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Capital loss (gain), net"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainOrLossOnSaleOfStockInSubsidiary": {
     "auth_ref": [
      "r119",
      "r120",
      "r146",
      "r549",
      "r580"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.",
        "label": "Gain (Loss) on Disposition of Stock in Subsidiary",
        "negatedLabel": "Gain on disposal of subsidiaries"
       }
      }
     },
     "localname": "GainOrLossOnSaleOfStockInSubsidiary",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r246",
      "r248",
      "r537"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets",
      "http://orgenesis.com/role/ScheduleOfGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill as acquired"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "INTANGIBLE ASSETS AND GOODWILL"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/IntangibleAssetsAndGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r155",
      "r252",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Translation differences"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r146",
      "r247",
      "r250",
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantsReceivableCurrent": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Grants receivable"
       }
      }
     },
     "localname": "GrantsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantsReceivableNoncurrent": {
     "auth_ref": [
      "r51",
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants receivable, noncurrent"
       }
      }
     },
     "localname": "GrantsReceivableNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment of Long-lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "auth_ref": [
      "r449",
      "r451"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss attributable to non-controlling interests (including redeemable) from continuing operation"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r111",
      "r210",
      "r213",
      "r216",
      "r219",
      "r221",
      "r536",
      "r550",
      "r557",
      "r581"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss from continuing operation before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r158",
      "r169",
      "r210",
      "r213",
      "r216",
      "r219",
      "r221",
      "r233",
      "r451",
      "r468"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net loss from continuing operation"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.",
        "label": "Basic and diluted from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r109",
      "r117",
      "r169",
      "r173",
      "r174",
      "r175",
      "r176",
      "r183",
      "r186",
      "r187",
      "r547",
      "r551",
      "r555",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Loss per common share from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfBasicAndDilutedLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r25",
      "r28",
      "r431",
      "r575"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Net loss (income) from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r18",
      "r25",
      "r449",
      "r451"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss attributable to non-controlling interests (including redeemable) from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation, when the per share amount is the same.",
        "label": "Basic and diluted from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r112",
      "r146",
      "r208",
      "r230",
      "r548",
      "r573"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Share in net income of associated companies"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfChangesInInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r407",
      "r409",
      "r414",
      "r425",
      "r428",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Taxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r159",
      "r179",
      "r180",
      "r209",
      "r405",
      "r426",
      "r429",
      "r582"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Tax income"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r155",
      "r401",
      "r402",
      "r409",
      "r410",
      "r413",
      "r419",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income taxes, net of refunds paid in cash during the year"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase in accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Increase in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (decrease) in contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Increase (decrease) in deferred taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (decrease) in employee and related payables"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Increase in inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedLabel": "Increase in other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Increase in prepaid expenses, other accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r155",
      "r262",
      "r515",
      "r516",
      "r517",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r255",
      "r261"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r126",
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseShortTermBorrowings": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate interest expense incurred on short-term borrowings including commercial paper and Federal funds purchased and securities sold under agreements to repurchase.",
        "label": "Interest expense accrued on loans and convertible loans (including amortization of beneficial conversion feature)"
       }
      }
     },
     "localname": "InterestExpenseShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r138",
      "r143",
      "r150"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest paid in cash during the year"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r33",
      "r91"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r39",
      "r92",
      "r155",
      "r195",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments.",
        "label": "SCHEDULE OF CHANGES IN INVESTMENTS"
       }
      }
     },
     "localname": "InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/InvestmentsInAssociatesNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments in associates, net"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAndAdvancesToAffiliatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in and Advances to Affiliates [Abstract]"
       }
      }
     },
     "localname": "InvestmentsInAndAdvancesToAffiliatesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the information summarizing investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates. It reflects specified information about ownership, financial results from, and financial position in such entities.",
        "label": "INVESTMENTS IN ASSOCIATES, NET"
       }
      }
     },
     "localname": "InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/InvestmentsInAssociatesNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestorMember": {
     "auth_ref": [
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.",
        "label": "Investor [Member]"
       }
      }
     },
     "localname": "InvestorMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "SCHEDULE OF LEASE COSTS"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "LEASES"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Operating Leases, Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Operating Leases, 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Operating Leases, 2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Operating Leases, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Operating Leases, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Operating Leases, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Operating Leases, Less: amount of lease payments representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Leasing contracts period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r79",
      "r158",
      "r215",
      "r233",
      "r455",
      "r462",
      "r463",
      "r468"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r65",
      "r158",
      "r233",
      "r468",
      "r543",
      "r568"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r81",
      "r158",
      "r233",
      "r455",
      "r462",
      "r463",
      "r468"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r54",
      "r55",
      "r158",
      "r233",
      "r455",
      "r462",
      "r463",
      "r468"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "TOTAL LONG-TERM LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LONG-TERM LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r1",
      "r2",
      "r22",
      "r24",
      "r28",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.",
        "label": "TOTAL CURRENT LIABILITIES OF DISCONTINUED OPERATIONS"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r22",
      "r24",
      "r28",
      "r271",
      "r276"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Current liabilities of discontinued operations (See Note 3)"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Aggregate credit line amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r84",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ManufacturingFacilityMember": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure used in the manufacturing of goods.",
        "label": "Manufacturing Facility [Member]"
       }
      }
     },
     "localname": "ManufacturingFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r90",
      "r158",
      "r233",
      "r468",
      "r542",
      "r567"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Non-controlling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Percentage of ownership"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used) in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r141",
      "r144",
      "r147"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r28",
      "r101",
      "r104",
      "r114",
      "r147",
      "r158",
      "r169",
      "r173",
      "r174",
      "r175",
      "r176",
      "r179",
      "r180",
      "r184",
      "r210",
      "r213",
      "r216",
      "r219",
      "r221",
      "r233",
      "r468",
      "r552",
      "r576"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Loss",
        "totalLabel": "Net loss (income) attributable to Orgenesis Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative",
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r181",
      "r182",
      "r185",
      "r188",
      "r210",
      "r213",
      "r216",
      "r219",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Basic: Net income (loss) available to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfBasicAndDilutedLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": {
     "auth_ref": [
      "r182",
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.",
        "label": "Net loss from continuing operations attributable to Orgenesis Inc."
       }
      }
     },
     "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfBasicAndDilutedLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from discontinued operations available to common shareholders.",
        "label": "Net (income) loss from discontinued operations attributable to Orgenesis Inc. for loss per share"
       }
      }
     },
     "localname": "NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfBasicAndDilutedLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Newly issued and recently adopted accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL NON-CASH FINANCING AND INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest": {
     "auth_ref": [
      "r305",
      "r453",
      "r459"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.",
        "label": "Noncontrolling Interest, Increase from Sale of Parent Equity Interest",
        "negatedLabel": "Sale of subsidiaries"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r304",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesReceivableNet": {
     "auth_ref": [
      "r59",
      "r227",
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.",
        "label": "Loans receivable net"
       }
      }
     },
     "localname": "NotesReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OfficersCompensation": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Compensation"
       }
      }
     },
     "localname": "OfficersCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r210",
      "r213",
      "r216",
      "r219",
      "r221"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r490",
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating lease cost:"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Leases, Present value of future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Current maturities of operating leases",
        "negatedLabel": "Operating Leases, Less: Current leases obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets",
      "http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails",
      "http://orgenesis.com/role/ScheduleOfLease-relatedAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Non-current operating leases",
        "verboseLabel": "Operating Leases, Long-term leases obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets",
      "http://orgenesis.com/role/ScheduleOfFinanceLeaseLiabilitiesAndOperatingLeaseLiabilitiesDetails",
      "http://orgenesis.com/role/ScheduleOfLease-relatedAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r485",
      "r491"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfSupplementalCashflowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets",
      "http://orgenesis.com/role/ScheduleOfLease-relatedAssetsAndLiabilitiesDetails",
      "http://orgenesis.com/role/ScheduleOfRight-of-useAssetsByGeographicalLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r494",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted Average Discount Rate, Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLease-relatedAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r493",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Lease Term, Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLease-relatedAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.",
        "label": "Operating loss carryforwards, limitations on use"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other payables",
        "verboseLabel": "Commitment"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation."
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r451",
      "r452",
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive (income) loss \u2013 Translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r102",
      "r105",
      "r108",
      "r115",
      "r299",
      "r470",
      "r475",
      "r476",
      "r553",
      "r577"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Comprehensive income (loss) for the period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpenses": {
     "auth_ref": [
      "r125",
      "r584"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense classified as other.",
        "label": "Other expenses"
       }
      }
     },
     "localname": "OtherExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r583"
     ],
     "calculation": {
      "http://orgenesis.com/role/ScheduleOfFinancialExpensesDetails": {
       "order": 4.0,
       "parentTag": "ORGS_TotalFinancialExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "negatedLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfFinancialExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r37",
      "r38",
      "r80"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Short-term loans and current maturities of long-term loans"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Financial expenses, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncome": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Operating Income",
        "negatedLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherOperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other research and development expense.",
        "label": "Total expenses"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.",
        "label": "Payment for consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromInvestments": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.",
        "label": "Payments for (Proceeds from) Investments",
        "negatedLabel": "Repayment (investment) in short term deposits"
       }
      }
     },
     "localname": "PaymentsForProceedsFromInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Transaction costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition of Koligo, net of cash acquired (See Note 4)"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Investments during the period"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfChangesInInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property, plants and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r56",
      "r339",
      "r340",
      "r341"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.",
        "label": "Retirement benefits obligation"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r357",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r35",
      "r66",
      "r67"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other receivables"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from issuance of convertible loans (net of transaction costs)",
        "verboseLabel": "Proceeds from Convertible Debt"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.",
        "label": "Proceed from sale of subsidiaries, net"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromGrantors": {
     "auth_ref": [
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from grantors during the current period related to operating activities. This element represents receipts from a guarantor for the amount of guarantee provided.",
        "label": "Proceeds from advance payment of grant"
       }
      }
     },
     "localname": "ProceedsFromGrantors",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from issuance of loans payable"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "verboseLabel": "Proceeds from issuance of private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative",
      "http://orgenesis.com/role/EquityDetailsNarrative",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from issuance of shares, warrants and exercise of options (net of transaction costs)",
        "verboseLabel": "Proceeds from Issuance or Sale of Equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative",
      "http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative",
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r134",
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from lines of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Increase in redeemable non-controlling interests received from GPP"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForLongTermLoansForRelatedParties": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow or outflow associated with long-term loans for related parties where one party can exercise control or significant influence over another party, including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from (Payments for) Advances to Affiliates.",
        "label": "Increase in loan to JV partner, a related party"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForLongTermLoansForRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.",
        "label": "Repayment in loan to JV partner, a related party"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Sale of property, plants and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r28",
      "r101",
      "r104",
      "r139",
      "r158",
      "r169",
      "r179",
      "r180",
      "r210",
      "r213",
      "r216",
      "r219",
      "r221",
      "r233",
      "r451",
      "r457",
      "r458",
      "r465",
      "r466",
      "r468",
      "r557"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net loss",
        "negatedLabel": "Net income (loss)",
        "totalLabel": "Net loss (income)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfUnauditedSupplementalProFormaDetails",
      "http://orgenesis.com/role/StatementsOfCashFlows",
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r274",
      "r483",
      "r489"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLease-relatedAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r95",
      "r275",
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLease-relatedAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r47",
      "r273",
      "r481"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, plants and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLease-relatedAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r73",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/LeasesDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails",
      "http://orgenesis.com/role/ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r279",
      "r610",
      "r611",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "PROPERTY, PLANTS AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/PropertyPlantsAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r72",
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails",
      "http://orgenesis.com/role/ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r47",
      "r48",
      "r275",
      "r569"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, plants and equipment, net",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets",
      "http://orgenesis.com/role/ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails",
      "http://orgenesis.com/role/ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r71",
      "r155",
      "r275",
      "r610",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r47",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "SCHEDULE OF COMPONENTS OF PROPERTY, PLANTS AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/PropertyPlantsAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r47",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/LeasesDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails",
      "http://orgenesis.com/role/ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Weighted Average Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r343",
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative",
      "http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative",
      "http://orgenesis.com/role/RevenuesDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r500",
      "r504"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Management and consulting fees"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r343",
      "r500",
      "r501",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails",
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails",
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails",
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails",
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r343",
      "r500",
      "r504",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative",
      "http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative",
      "http://orgenesis.com/role/RevenuesDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r498",
      "r499",
      "r501",
      "r505",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "RELATED PARTIES TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/RelatedPartiesTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repaid, Principal Amount",
        "negatedLabel": "Repayment of convertible loans and convertible bonds"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetails",
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Repayment of short and long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r136",
      "r162"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of lines o credit"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r400",
      "r622"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Cost of research and development and research and development services, net",
        "terseLabel": "Research and development expense",
        "verboseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative",
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails",
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "COST OF RESEARCH AND DEVELOPMENT AND RESEARCH AND DEVELOPMENT SERVICES, NET"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "auth_ref": [
      "r74",
      "r155",
      "r267",
      "r268",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.",
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "verboseLabel": "Cost of research and development and research and development services, net"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r32",
      "r43",
      "r154"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r61",
      "r304",
      "r392",
      "r566",
      "r597",
      "r602"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r170",
      "r178",
      "r180",
      "r237",
      "r389",
      "r390",
      "r391",
      "r423",
      "r424",
      "r593",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r206",
      "r207",
      "r212",
      "r217",
      "r218",
      "r222",
      "r223",
      "r225",
      "r327",
      "r328",
      "r518"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfBreakdownOfRevenuesPerCustomerDetails",
      "http://orgenesis.com/role/ScheduleOfUnauditedSupplementalProFormaDetails",
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r156",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contracts with Customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r330",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r121",
      "r605"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenues from related party",
        "verboseLabel": "Revenues from customer"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails",
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r110",
      "r158",
      "r206",
      "r207",
      "r212",
      "r217",
      "r218",
      "r222",
      "r223",
      "r225",
      "r233",
      "r468",
      "r557"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues, total",
        "terseLabel": "Revenue",
        "totalLabel": "Total revenues",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative",
      "http://orgenesis.com/role/RevenuesDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueDetails",
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r492",
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "verboseLabel": "Finance leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfSupplementalCashflowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r492",
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfSupplementalCashflowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Valuation of shares"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/EquityDetailsNarrative",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "verboseLabel": "Share issued price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/EquityDetailsNarrative",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/IncomeLossPerShareDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "SCHEDULE OF SUPPLEMENTAL CASHFLOW INFORMATION"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/EquityDetailsNarrative",
      "http://orgenesis.com/role/RevenuesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "SCHEDULE OF LOANS"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/LoansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "SCHEDULE OF DEFERRED TAX ASSETS"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/TaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative",
      "http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r2",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r23",
      "r26",
      "r27",
      "r28",
      "r277",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "SCHEDULE OF DISCONTINUED OPERATION AND BALANCE SHEETS"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/DiscontinuedOperationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/IncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the details pertaining to each employee stock ownership plan.",
        "label": "Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails",
      "http://orgenesis.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the details pertaining to each employee stock ownership plan.",
        "label": "SCHEDULE OF EMPLOYEE STOCK OWNERSHIP PLAN DISCLOSURES"
       }
      }
     },
     "localname": "ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfExtinguishmentOfDebtTable": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to debt extinguished, including the amount of gain (loss) on the debt extinguished, the income tax effect on the gain (loss), and the amount of gain (loss), net of the related income tax.",
        "label": "Schedule of Extinguishment of Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfExtinguishmentOfDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r257",
      "r262",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfIntangibleAssetsAndTheirUsefulLiveDetails",
      "http://orgenesis.com/role/ScheduleOfOtherIntangibleAssetsDetails",
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://orgenesis.com/role/SummaryOfAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r257",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "SCHEDULE OF OTHER INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r252",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "SCHEDULE OF GOODWILL"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/InvestmentsInAssociatesNetDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.",
        "label": "Schedule of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/InvestmentsInAssociatesNetDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r73",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentDetails",
      "http://orgenesis.com/role/ScheduleOfComponentsOfPropertyPlantsAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "SUMMARY OF ASSETS ACQUIRED AND LIABILITIES ASSUMED"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r160",
      "r502",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsDetails",
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails",
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "SCHEDULE OF RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/RelatedPartiesTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.",
        "label": "SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CostOfResearchAndDevelopmentAndResearchAndDevelopmentServicesNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r280",
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfUnauditedSupplementalProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r357",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r363",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "SCHEDULE OF STOCK OPTIONS ACTIVITY"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.",
        "label": "SCHEDULE OF STOCK OPTIONS GRANTED TO CONSULTANTS"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "SCHEDULE OF ESTIMATED AGGREGATE AMORTIZATION EXPENSES"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentContinuingOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity expected to operate in the foreseeable future.",
        "label": "Continuing Operations [Member]"
       }
      }
     },
     "localname": "SegmentContinuingOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations [Member]"
       }
      }
     },
     "localname": "SegmentDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operations of an entity including continuing and discontinued operations."
       }
      }
     },
     "localname": "SegmentOperatingActivitiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://orgenesis.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation",
        "verboseLabel": "Stock Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails",
      "http://orgenesis.com/role/StatementsOfCashFlows",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations",
        "negatedLabel": "Number of Warrants - Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Number of Warrants - Issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r364",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodStartLabel": "Number of Warrants - Warrants outstanding at the beginning of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based compensation arrangement by share-based payment award, number of additional shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based compensation arrangement by share-based payment award, number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Number of Exercisable Options",
        "periodEndLabel": "Number of Options - Options exercisable at end of the year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Exercise price per share of options exercisable",
        "periodEndLabel": "Weighted Average Exercise Price - Options exercisable at end of the year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical",
      "http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of Options - Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options - Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "No. of options granted",
        "verboseLabel": "Number of Options - Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of options issued",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r365",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Number of Outstanding Options",
        "periodEndLabel": "Number of Options - Options outstanding at the end of the year",
        "periodStartLabel": "Number of Options - Options outstanding at the end of the year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price - Options outstanding at the end of the year",
        "periodStartLabel": "Weighted Average Exercise Price - Options outstanding at the end of the year",
        "verboseLabel": "Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r355",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CommitmentsDetailsNarrative",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative",
      "http://orgenesis.com/role/TaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted Average Exercise Price - Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price - Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted Average Exercise Price - Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Exercise price",
        "verboseLabel": "Weighted Average Exercise Price - Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfEmployeeStockOwnershipPlanDisclosuresDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://orgenesis.com/role/ScheduleOfStockOptionsGrantedToConsultantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r155",
      "r357",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Value of one common share"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r377",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Aggregate Exercisable Options Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Contractual Life",
        "verboseLabel": "Share-based compensation, shares authorized under stock option plans, exercise price range, outstanding options, weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsExercisableDetails",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Fair value of granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative",
      "http://orgenesis.com/role/EquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r89",
      "r166",
      "r167",
      "r168",
      "r170",
      "r178",
      "r180",
      "r196",
      "r237",
      "r299",
      "r304",
      "r389",
      "r390",
      "r391",
      "r423",
      "r424",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r476",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical",
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by continuing and discontinuing operations.",
        "label": "Operating Activities [Axis]"
       }
      }
     },
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r196",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfDisaggregationOfRevenueRelatedToDiscontinuedOperationsDetails",
      "http://orgenesis.com/role/ScheduleOfDiscontinuedOperationAndBalanceSheetsDetails",
      "http://orgenesis.com/role/ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationDetails",
      "http://orgenesis.com/role/ScheduleOfRight-of-useAssetsByGeographicalLocationDetails",
      "http://orgenesis.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r57",
      "r58",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Issuance of shares related to acquisition of Koligo, shares",
        "terseLabel": "Stock Issued During Period, Shares, Acquisitions",
        "verboseLabel": "Shares issued, acquisition"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative",
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative",
      "http://orgenesis.com/role/EquityDetailsNarrative",
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r88",
      "r299",
      "r300",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock issued during period, conversion of convertible securities"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock-based compensation to service providers, shares",
        "verboseLabel": "Number of common stock for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r57",
      "r58",
      "r299",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Number of shares issued",
        "verboseLabel": "Number of common stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r299",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock issued during period, shares, restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r57",
      "r58",
      "r299",
      "r304",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Exercise of options, shares",
        "negatedLabel": "Number of Options - Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r89",
      "r299",
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Issuance of shares related to acquisition of Koligo",
        "verboseLabel": "Stock issued during period value acquisitions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative",
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative",
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock-based compensation to service providers",
        "verboseLabel": "Number of common stock for services, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r57",
      "r58",
      "r299",
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock issued during period, value, restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r89",
      "r299",
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionPlanExpense": {
     "auth_ref": [
      "r146"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for option under share-based payment arrangement.",
        "label": "Stock Based Compensation expenses for options exercisable"
       }
      }
     },
     "localname": "StockOptionPlanExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r57",
      "r58",
      "r299",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Repurchase of treasury stock, shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r57",
      "r58",
      "r299",
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchase of treasury stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r58",
      "r63",
      "r64",
      "r158",
      "r229",
      "r233",
      "r468"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Equity attributable to Orgenesis Inc."
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EQUITY:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r158",
      "r166",
      "r167",
      "r168",
      "r170",
      "r178",
      "r233",
      "r237",
      "r304",
      "r389",
      "r390",
      "r391",
      "r423",
      "r424",
      "r449",
      "r450",
      "r464",
      "r468",
      "r470",
      "r471",
      "r476",
      "r594",
      "r595"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "TOTAL EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets",
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r157",
      "r304",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "SCHEDULE OF VALUATION ALLOWANCE, ACTIVITY"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/TaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW TRANSACTIONS:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransferToInvestments": {
     "auth_ref": [
      "r151",
      "r152",
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of investments transferred to the entity's investments in noncash transactions.",
        "label": "Transfer for prior establishment"
       }
      }
     },
     "localname": "TransferToInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r87",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r87",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury stock, shares",
        "verboseLabel": "Treasury Stock, Shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheetsParenthetical",
      "http://orgenesis.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r58",
      "r299",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Number of Treasury Shares Purchased"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfTreasurySharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r87",
      "r306",
      "r307"
     ],
     "calculation": {
      "http://orgenesis.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock at December 31, 2020 55,309 shares"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r421",
      "r422",
      "r423",
      "r424",
      "r520",
      "r521",
      "r522",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/AcquisitionAndReorganizationDetailsNarrative",
      "http://orgenesis.com/role/CollaborationAndLicenseAgreementsDetailsNarrative",
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
      "http://orgenesis.com/role/DescriptionOfBusinessDetailsNarrative",
      "http://orgenesis.com/role/DiscontinuedOperationDetailsNarrative",
      "http://orgenesis.com/role/EquityDetailsNarrative",
      "http://orgenesis.com/role/RevenuesDetailsNarrative",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates in the Preparation of Financial Statements"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Change during the year"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfValuationAllowanceActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.",
        "label": "Warrant, exercise price, decrease"
       }
      }
     },
     "localname": "WarrantExercisePriceDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.",
        "label": "Warrant, exercise price, increase"
       }
      }
     },
     "localname": "WarrantExercisePriceIncrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants amount"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants exercise, term",
        "verboseLabel": "Warrant term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ConvertibleLoansDetailsNarrative",
      "http://orgenesis.com/role/ScheduleOfLongTermConvertibleLoansDetailsParenthetical",
      "http://orgenesis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted average number of common shares outstanding",
        "verboseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/ScheduleOfBasicAndDilutedLossPerShareDetails",
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares used in computation of Basic and Diluted loss per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://orgenesis.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868656-224227"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080555-108585"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=27011391&loc=d3e105025-122735"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "51",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e34017-109320"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(g))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.7)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.7)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611133-123010"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "http://asc.fasb.org/subtopic&trid=2197926"
  },
  "r624": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r625": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r626": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r627": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r628": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r629": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r631": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r632": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r633": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r634": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r635": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r636": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r637": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r638": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r639": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r641": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r642": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.11)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>129
<FILENAME>0001493152-21-005653-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-21-005653-xbrl.zip
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M7Z2FZSX2OH ,IT5"BMX(X.*8?D/%+(%J#K;$OP!^5\GS#3\)Y"$1,[N8@!
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MYSIF]2W.IGUQH0V0"CU$26%J69<-XGV"I<HP-S.$#D(VZULD,J5=4D. +_X
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M@8<1?7:1]>9Q\3*[8K-L7&</.GLP7WOP>N'MP1F?NN-F]Y:[W\&)JF^P;2U
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MT">#S");\XLL1>PMHWD9X#S7X'3/]K(I$4#4K?:O"/)=,8XF!\1';-NZ;.&
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M$^'5(!BQ%-QZR:MC$2=F)>MA/+P"!/6#BVO]J[&*\E"Q.YJMUI5YV?[I:V2
MVX;IS#)YLQAC&:>)2G,3A!H]=#@9P%/$( +Q2%&ZMX(G2J+'Q<%%@_'CEFP.
MNYJ.X7X@.,2PT3\=QIL\"LNNZ$47%=?UW(^?E_JC#SA$-";2FUJ :(K5 [#(
M^IS,S:I\?NJK?/HJG]NO\GFQK54^?5;E7F15OE<(1Q/H5NF#<F5HM6$UN+9F
M'K=WUN$.PT 064=\<>#LUB2X?K#6AF"]\[V[@V9# G3=F3,T<Y@[L"7F4K<&
MN%7);6<HWN_=3DZ$1&3#0S4O>Z.DUX+[7<6!@![L?G[YX@:;T ;:G <$VS[7
M23/#Z_"Y41KF3"6,(;-/,L.ZC0+C-A.3!#P9G_Y,I/ &8&IA,,\,J-<6_$?+
M>:IM$TM'MH]E( YC-D^Q49=Q+I.6L<BL_^N' 6Y1YB7Y/.BFI40]Q93YV#]M
M7O46"V0?.5[!"#W.B6?\H#[/?"A@_',.CH(DAGO*4BH#0Q9Q-X-,W0KW=4Z@
M/OZXX?CC8?<CD#?4W!+S'* W5$*]8,E K"K#&EA74_]9UU^<4<2DP&Q]G4_<
M$:Z9@\8>8&\^N'@W%U^WU$#G!.KUTL;U4N=]ZYOHI3"E; 0F/%"]:&F(-@IU
M4]/&"MZFV"J;>E=,A9;3-,:V$PU,E0\ZJYH*<0U%,W*3*TWZ1BM&H&&[C(4R
M*5J>+(,L@(-H>2ZXO89/(ID;)A%Q?$!!2O3EA9F6T?W6ONAN/L"8!+,OU]+"
M&0N#VQ.A5A346<.<S&N8 A%;0]=. 9:*3-.97-2=_,*YMQ,CO-J^VJDW\,S-
M6(37ZK2T 5__R1,"A]\S7[\O"KF56HO#+2H*.6ZD';W@G<FCXS)!^1A?8]XJ
M5+:'!6J'TTK&,OA@W>$KRT:N?>_^7_^O_W?EO\T;T=UR9SHGT'WVK[KU)#HG
M4%=SHD4]>QL3"&4+38!!;ORO(P;AWS9KLWR,#/(PQIEU01HI5ZJ7*L/TZTG+
MTFG#&J?,]AG'"!6&Q[R"6FPFA1Q3<TX3C9V":K(94J-$['@L%#75I9Q $5[+
MN'K6K\N[P\*5D#$W(\85'D6*467KV>B",&6-N\3W811L!B6P&KSS&0DS2=.(
M&J11LFB>5WN951)&UILFGBX?Y]7.<*6!O+WRWV'G^(U@S3C]2CA=$,8(G32T
MXN<R5&.%:UUBOZ]>\VZ?0/VAW)4GT3F!.GHH%X";5G(LI^L=S!>.;(02%<D=
M9&/)^?#PBV3.4ULH:S'195:<#  *(O*AR\=DB:^FDP\_']C#I'*"^1W'E;.N
MBAHO9N1ZAU_E7/6; JZC'G 5^0A)(BLQ9 NB'W!33Y@*Q#$H[F0/YU05K072
M5!HD^]<:NXHFDX_'<+@YWLSR+F@2-5'GW$4,OM)Z3/74'=?#?+_H,=\]YOOV
M,=_[>SWH>Y-PQVMKX#O]UY4\R_[M9D=NR1B[J^3-%N XUW,VM08?USO'KZ\
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M_?(S+ -;BX\SQ,'JL8I139,$T8##LG_E"O3T'4<%6UNH;!38L=\#.WI@QQT
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M2V/!<]D$QRXDQ"RC)0SI+4QX1O+:CE"#*15L8: @BHY_5JX%&1%+EIN2%TU
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MZ+'4M3H9T&H59/T5Q5203+T5B+RO\J.O_ESO-%*5V^V\_[]"OX9"GQ\]K$)
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M3X8QY?JI6A=UUQN8BR(M6\ELJ&QF&3O(UM ;ZNE.]KA'/17Z"U!+ P04
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MGN3HE-\+0A+,3K"?J0:FH.G 2GE#]T8YU]BO'8)4>R(:8NQ1-FU*+$">LL0
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MK$'P7&Q69"Y:@#KY8ZET]<K),GKE)/VT(H%^@?ZTQ?E)RJ[T)(QG;;,*&"]
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M7@Z2 /_MSA^'+'W";30,2,*@P&&)7RQFU/@^A05+(8$9B88#KB!*7^!Y]#!
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MZ%D6V!DTUYQD%N9CI!P:.!#1-]-*V)UQ!<F[\7V;,EDG"N/TA2L7E4A3E.I
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M4&#1,+C53@\+Q!Z)7,-DJ:*!D#$M1(EU>^L"Y;ZV@\MB;:COJA0AM^<7"S+
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M0B^/F3= 17,4DAE7,:(0(2[6@$U^OH(P$#"602B.&=<E62M0S!W&4M@58\0
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M2NY Q+3+$]%^.=I9%>YV2_'WWN#9_C>#%\_WPP(69L?6"NZ(S#=F^($9ID^
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M7"#3J+.)O &?[$-'KJ,3QIE:MHV*.?!'D'Q_%.E-\]F3<Y8!2\#68Z6(=%^
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MV7AP)W=O\+\N@_^CII+4XG,C9F_,;\^8A_<=0: TB<'-%(Q.*M&#7JF%T_R
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M@9-XC.P#2C0+HLIA,2;'C-P'<,5'KJ7!X\RY3"%Q)'UM&C$[/>O_X2(X)GC
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M8#Q../.9/3]5-#UK?>Q(1GN]G,TN;B.M":.RJ&@W+HM,0HL1"Y*D99T[A(U
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MS$5K7)X\XK9>!#UM> ,3EEZ(9(/R J*K<_,8HNWXYZ=[WR %,&?(;]4,_Z$
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MJ: G+3:@6>OG0CP&\]T3ES-<7)J6 +MZY,-ZOX4><Y#NZ$!!,[72(W.IA/9
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M/-V?%4M#D:VK >O,<N[3P *0D<"O25B0# ?<%!2)B6IA)]93!90T!\LY64$
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M5/-/6M$BP.TMPN*\&UFD<9,MC5 ]M:B-CQ;AVUD$R40ZWL)F <P-TAI>]UT
M0>7:2K%)^A.?U&!(L*7TIEL!=LM5@T!K)"XP:) TTNA=XQQ;7]=2'H8XI-XL
MGYAJSZ<ULLV^V[.LUOYONDA5Y\TR"=1JJZ[E^F:3W!%"D$8!V%/G@=NOX"AY
M]O:?+Y_O'3Q-+;P'B&1DK>NJS$[SNFONC@Q_5U@M^8#&<4' :0IRN&""BD4!
MT&1?%#E P: B=U&Q).#G [Z0 9A@Q5#L)=FBN2HFC2#P*Z24FSO:KJZTU5/!
MMZ)\FDVU.\F:#;J<Z_=#Z8F)UUQ,;C%1RFW2GW<6T;S)]=?;.(D_D:G>W6GI
M;^Q0Y4LAV^2J(SID/JTL7M^E.=H%B^_)[ J>36J6 Y7TJ'1_[L)@VY%J[ <=
ML1I*M]I/J#5.@'CG=*14C8C] O<=4(C R]Q2T:=C@O$".!D8T<ST!Z8T9"68
M=H+7L>6=..^I]865J+SW6*F*RM)MUNYJM+X!0Y1^W 0$]J"F;Y5JU'S*6<%M
M=R?8)%YE@!-2\N^-?>+H+@9V"I@T\+*S#KQEJJIF*\(A"G?N)B-Z GUH(8E0
MV"/3180ZO!;J:"A\F#/.VJG[,M24@CA,HA/:+5AO#XA-;A?J$&70L6'*L%&H
M"I9:H):6#EH3WYNH7'EV[H-!MU6V/K%;-)UASI!;Q\*$$B[.*LD\_.XY8N"F
M7[LL=,Q+6+G!T'7 ]^&(BEZ]R%:K$$XKRSE+N(W&A.J7I7%</I$^A67\=LFM
M6*L"5%S2"YN=T8BP0R;GLL]6"O.*+"TKS9X[+L*@">ZS#;HP[[C%F%-4O]'"
M-0Q\C?O57'/7>&)__>F<__T]7#!0KCJ\!=I)/F U[CWGRC5G<&+"%ZNO_9RV
MGJ'X^6]_S<<C]]+A>/]X34:F$1Z@PM)8DX4N>*?3Q\FK?,HBCD=6#WYT?O[0
M\[TC7Z'CUC5-'($?TC&3#HZXA"ST49J\K8$);&C*7K7BEB0OFSHS19X<=Y,F
MG^7H11**1\NU'>0NH&=J"J>VB8I]J'Q*QZT^G<UJT6$#9M'2'G'PSQIPHW?D
MSW"";9Y[>ER](S\SHBO'="9M0\-/"P'>7 @BR-&9 [BU,2S]"P?)W<$12_G/
M#;*)\$O"Y2UTG$P1(+_>W=D<\(FRQLYL']CF8\NDG-5@Q"J9%4+\&F4-U>8?
M3E/.MUUB5L'?5#9Y(S_5'^+J"";IW$7'L@B@0+37/I'<<9]?U-&B;[S<P&**
M'V=W)W@>U[1%(^P+CIQWI6#6S_/PA;D!EMXH<2^4M_8]#I[<2V;9NHG?0][!
M->C+[=F%Y[>I.R74@# R)VK=R]*@+U>MM55@OLUD?=&9OT;_.JU_ETR6?;)E
M6[D=1>N@)=\L4P8WE0Z,8P_A (3'SSX,_@_Y/[HYG$>#'-.I^#!X%X@+F=.P
MIXXO:&;^<IAYR\YSX45Y!,('A%#12@:'O21A('!KT?]0<E=K)2JP/!FV#]&"
M21S)@&Y!1_\B'I_3=J'?0N_JG).BU[\H.795GD;RU>\:F4@!(KGUL&5KV\L%
MEPI$HH$YRVJW<<G%7[EX0S/VM+MYK# ?&(H5G']PUK#R KE]K@KA-%@'-F\H
M,.EAZENL;?)EQE826%]H;<\]0VZ;!WM!=]']L;OHFKN+[H_=1=]O=]%-][8O
MG=&8#Q UH#A!0J((*0F;954RE8V1@@]*?E/-]--S=*Q&T"SR>3M@C[,BF:M2
M!"]!27QP<SF2)TH6$H:^=%S=H>.$5U5Y M8XLY1L#'(IA_=^H%<5_MHIZ+(R
MONY>D7\T_/G!#RR74]"FD..%JY1RZT!X4ER>F8;4^[L[PNM@<S1Y$S9<X=P+
MA\72T:N^$2LB\=7IQ)5&)?40YIVPVPJ*>.BAX)&!CY [O<43K)?T]9.BFZ).
MK[AQ/NOX MJ[SBC6TUS>7CVE]7[R(U*#>N+37TR'40+O;ZL%?F-UDK@)AD<9
M2@---]E;5:O.RPWP].C \>@'PYXW!3)[JX4AOX6,I; EZ[NFP@_!73'L^ NC
MF.3+,-QT 9T%)4-K(=@VJ\J*G7OZ\5\9YW=61F_1<GI,@J\*8UY;K2<FR@Y^
M94>*R7QU(/<LP=6II0A1T@=R@4R1"X, <KX<41@CHO/^2K^)VT=^K"IGR5OB
M1>GK9_YU6?)4V97M\DH#1LE>NU[^N\5T.$FLH&](FW8:)='*0)$]$5HG[YH%
M%=RQ)^?/W),3#? ?0RBX)SK\/MN$'$WG1IN0Z^9S!]5/SX_2Y,7KH^%N'F5O
M:1V$2@39./@&!R*XQ:%3E;.3Z")*;P&L#*(/8;2/L(T9OZTQ^?[@4Y>V;K_#
MA>H/#M]1-C/H5+$<LWG3VIQ3;0KANU<N1@W;Z93(Z4ACO%9FSUY7F H/>O.)
M?(K3RC+ .5?"7<(H'E"^/D$HR<X!1_-RX7%]_IG79[SR! XZ-Q$A9F7S,XT)
MV(L\"JVHRI,]9-SH$O =][J5<"051>"^+RJ;]HJD2\?5]V=:?9Q_=6O/!61<
M^\_GB64)2R/]6B!9\V"!6F ;O&RIC 2)RY V?%QH?]J%MG$,]V#0(?EQ1,!2
MFA9--JJ8PZ)QS(%=55:N3^-C%3#,6@;VYYS5!XVO\+:"P7 Y'JY_LE7GV'K<
MNO.,/U)&V83@SUL3JA"@N#04W8!31]0*N1JCDMB<_OX>T?OC*MO^9$O/]&J-
MFW"4<FLU#)9?:TU7GYJ\*$1-'2$'*M) ^C7-4M773^I,R-Q5@LL!T&R+B:25
M<]'\I!6)JOZL\Z0=G"JLNQ._6JW(YFWI%_C;Q*VYFXP0&D2D/0\R$9CA]]YZ
M' 5,1PQ<BPKT[Q0B^<SE+V\V4NUZ)^FR 6OO*7S*:H E)"40I8\F>;4"0VHV
MY=RY["#%M2*=OS"JU8WMNQYQ;%=260M [QZ^;EF@+9LT4]@JB5"Y$)6F./>W
MHLW'P&G +%!90+EME:\,0Y%%9;C/-\:H-EN]\K%/L0Z?Q"X)1_6[9*5RA>LS
M'8-@?6P>T^-=6"[3&OJ@;W2-<BS.#W<7CYQVCR?5(BLH*:AI= +(13>HTUP#
M6N-Q*A,CS>=A4Y$0*0O?1&OED[/=G1,>,[S%1QJR!3G>"@@2V>98W]*.64"1
MMOE,J04*V9#2H[77CF]-!VU_=\?J96M;3KP6%#BCTD.3+B]DS.T$IX$O-^#'
M]=D?I9RT^?1158D?T<JS--T$"E;,*!?\;MZ)WC3SSLE(ETY+2#K)4-]42+JU
M*'BCI9F%%B<T32PZ9D,9?'>KG8H,&H4_D*:-E;X\%(X9)QTKWN9RX]?5"<:N
M<.7LQ+5&<%44XJ\:A(DWC&6%[)5H*\US= ZPTSPP$=+T,C$T%2;><:><DF7\
M&ST3[1+>$J>@ UQ7'3_]Q=2?4?\+N5/J?ZU])NW<%>LZA*34&L*EK'SY6Q$!
MXC/%;VYLMAQ="&(\%M498^QH0S*-BSIX' %OGP':,&N*,=P4B)48>$IL8)?$
MB8ZT.EKCDD2<2S,RXINLZ76R8I5*]G"LBO[)JZ(W->QBO0Y.F=L#?JO#$.ZS
M<_?Y]Y<>NJFS=Z:4.?W.1K@@9+OU/$=@O.1CI+.XFP@U;-NWK&P"-^&-,WPC
M9MCOS\V#RLXZ;U/!(4-BS1Y=X3%&7T?F9)RWZYJW;,NL\:3!;5"%RJ;M9AQ)
MP*MA74-&;L =A=EEOF;II&P"-1CZ.)NB7D0/.=6(!.JI4]R!5:HLE1;'&VN%
MN'E-77NI,_A0KDED:4P;*A8&'B8D=E"?&E?0=:T@*T7%,L'6R+O(L%".C%,;
MD-:&6["V47]/FJHPTGY=<(G(57C&&;VN&751,)>)@TC8897%I$,'DS8GS],$
M<=RIJ<UFF[UB9X!&$-E1:Q[,)PI &&,J#3;C#%_7#'-@*WN5"UI<3MUR""A7
MMY0<[+Y%O LQ0=[2*A3(+4T;R57^QN:5K>4O*T:P,$H0<2GL^;@.;L3IKXXZ
M%TP+D:<TGO1!_+@@K?=OM*1I6;7MY850R&<>#:G@?Y]5T]L\R3)7Z&AI%(*&
M%+MSP]#7G F63)IB;=H2\R^9W,K*JR>JKYZMF?8_GVN9U+EKMZ8N>1M+*6 "
MBC*=6D6NIM.N=N6*"3?@3*6$F4UHLI4*)S3>MNCB#@<V^I6S_PWOZ$V^(F8H
ML$F8U$7JJ6]U[24H+TC'6EKLLT'50E<MM^J%NSL1VY/7.PPU9J4I1?I$IL+7
M=QMHULXKPE[0^?I@['R]YL[7!V/GZ]CY^IWA*%Z J!@A&SC&9G2/V@'F4&1:
MD/NPR&92WN.J7$AU -.=,DN8+TQ:CJV>Z&S(PARF"H+S*05F($25;J!)0ZC?
MB-JX?(&Y GB%N"#-3.@EQP!UI*)F[,))A3/$?$HY*BA$4]Z@9HU)/(&K4"XE
M]6_7U3ZHV(4:>_]X/W7-I*L:DA8KK!((=TO3A,]!<#.:;8'-.)_$68=6J7KP
MC>= SKU@NG A=SF*>R_N:!OU\Q='VC!]5\3G0<X=/"W='Q2%0O2'5 FM_8PI
M0TZS>MW'(^A7!X6UE(;/09"JP409AE?"L0!^/W.RU1+7@S,07'@_&3+>-#L_
M517M37YEO,.SJEER@_'1M!6W_EG%@ER@/#H6I(-EN_?=?'.]&$:@4_A,,%>-
M*-HG0CCH59^V?ET'4=3<YX4<DD(CP[6 D!F%_[E2K7 H++#<4$H7K^2SVD 8
M<'?GHS$K^801"6F(/&"1]+R1:]75LE*%[JPPFS9$NPN%XB4  ?UJB:1\U[E*
MN+ _O+NCX(9@"Z"ML9JA(;QDOOCP\G3@6II(QAC,6.D]H,T,U+6#L=GR>+3L
MI#6;FS%YF;\(&S*#+DRO.5,*%^CF0S9*63// :M2R$7&.): _T<Q^UCV+M*#
M5*H;&B;ULHY^&FU/NT:&MHA[L-KL.80KMYF0]?!_J<UI;LYDR$!JTX8OP!')
MS C+E7%2]!@YP>XV8>.*[JZ!MQ/5GI;[$39:&D0;PAF,Z<^OWUF+$?%*AR/R
MDP5=6,EX]\A^@%RZE(=$2)BDN;^:D#T[M0M/2)'H/Z9Y&R^8LZP6N')A6AH#
M3<1+4!0&0DN:^#G%1J)J$A) :30'$B'- PH1K7W<?7[2DXZ^!QA6HZ1#RHF1
M]9^ 895X!1J4LI"&W=.\TF'!HM9!#!:$=QJFCKHB@K"%C)\6JJ2GBQ!=\2$Q
M73"G%ED)2TVE\;#3,F2V72N]1.>B"0Z'3-]6R8*9;6QB+#I,?PMT6Q_$[7G$
ME2=K:-?2K^V..*]Q&L;'/2V-0(,M2S.X,%G1LE2QPK!HZ]!<TH">]<EAK>6T
MPHUL.#,FV-",,!YR5F=G ,VY%1@^S_2FQ\JWT:7Z@+Q\S?EVZ29H<H'5E5,G
MX55T,W8REA7L/^:%_H5U@QV5*4NR77ZK;D*V.,<)Z+6@>:9EY>2_XZ!)05Z+
M_VFK5BF,N7;#_7\-A,;TK/(2&=:VA(=EVONV6C#7.RTV.@3AZE&A%BS8:=BI
M3G#A-^5*:22NF))5$M1 S4PDG#-JS+23O7E4KL6:NE'C[D8*-.A+W-QX<1J)
MAJ ?D&S05Z>>\3=QA+_R@%FS2.;H4[-^@C6IT[R>=DOUJX(S$'9DH0H1=J>O
M^=2B,:L^PD;0V-$F)X-V0NL#.S_J^: [':O#Y1<+79 ./;**R.M.JE.7^\M.
MZ8\6+&D?0J@Q,^Z2AZV;@3G'I !  MN,-^]6E5 6J9B.X]KD\98?,$98I1&*
M\ 1U*$E%/W,1OW_BK^$GEK.LGC5"NPTR97>)O/'LU!8@Q$9Z'<649QDM]]R>
M<($2 V*56*IZ-%^7;KY>=! ZHI^_1HV O8$CF5KK&KUX[6,I15<+;=/@J4@3
M+)?<#YMKG..G<1P81W M.-ZATRTLLEDA$HM8JQ0_9<)BJ; S?(6\A8*MI,,V
M<PPCY^@6)YLICT#L1 \'TX+6!"4?;W/H$60?#2-E!),^V%C("NVHGK=GH)%W
M0>!^X@BN_>\48,R&3%GC@<4)%9+%TQ2>SCGS+E5B,%(1(W)ZRF'*G4=$TH7R
M90Z-4,%S01-M6'@$O#G%_<O:H1>2/@XVKA.\D#56-$L]%V+<>U?0Y&3G@Y:!
M76%J\LDQS]8X_FQ["LYN4^9*W15R90T Q,'LY2"9'G-.ZR8-J4F=76=?W^Z>
MVF^J2%6<NP>84)8V:-D.]XA+3XN/C\-;Q! P?^4QUW?Y,BL" R271+@??(P2
M)/%@]?;@/G1+GAW7Y^KXN.TZT449QDUJ)-E*J0C2@'TA^ZK'2MBEAW!=J 2E
M:<M9?U"^M8NU]MZ>5#7B)&020O*+ 'W:?[DH:]E(!+GYHD'&9@GG10W>MNCM
M7V;H_6V>([#+^C@3LZY80J."0I7F((JUU:'JJP9KHU+@#_%IQ%E6$0WN96(0
MHFHGO*267#.=M_\3&@^R I)50A*6KR?G<AJVX(2OY-6LSFF+YCC'-L-8+_R\
M7NFHO/SYS=)]$DHR;)IA&VZ>3HZ*PBY;G(PGE5!(T2 CK:6':,@VP8[P><-^
M'2;INLW)+3&O%Q3''X[%\6LNCC\<B^-C<?R[<(V^WE]WA-)*@TRGIF\>%^$T
M2ZOI>'VM!\74-JD36@OD).W%-M(BT34=QMMSY&C%*N@2E\Q/U$E<K&VM7ION
MA#?81P_PX"6Z"WSPRYO//]72<@LD<PO##_3 JF@<AYLT!P<T;AG:L1F5H2H8
M?LUQ"69PX<6+1+J>AU::_1$]%1,-A*NNF=JZJJV]V 4FU_F<-<8U"VY>UM4U
MDCB/[<HW&G,M&)<VH$Q6K@"G,B.[L:S*X5 T[J)(M_1+C9T2U];?>B$%=I]H
M3F/^W[6H/1_&\?@2-JM'\:K9C%/'>;ZN>=ZDKFSHBC3U;+6Y*$##Q_\8S%<Z
MY:<A'+M/J(9<A;IN'*U<1(@B3R&L*$+&JA)<6%2+?-58DO10UY:3#N$=6*?Z
MK.P]<DR%*"36==:T=<=HLG'17=>B*[*NG'K:RB&2HHM,Q_8:T_EV*4U,SJE.
MT6JS"XZ)&92#E3P'\B=PT20L^%?UN$"^T>FS04-J2Y1#0-'&6@\66A&'8L5S
M/\[?M;7@S6;D 3;!#E\GVC>/S+33+K9NH$YPX 2.DW5MDQ7P!Z4Z75R%$*>=
M*6CTU&8 E-<J*LW9Z*-_PXDKS4FEHFCR1//LM*K%]C%22;%"_DCC^E?!FI<\
MNQYK6S,*3XJ7K-GA3EJF>^1TZSBQUS2Q@7.<NF;F%OA=&T>+-*XC**CJ=EX5
M>85S$5BTHC""6 -6QZ ]61@G0I=<Z2E2.B>SF5'A.$VQ?BRKL[U%=38VKE_K
MJ:G<+V[6%WGM9KPV-EQB[!9CTVEJFZHL33&VF%]A5AH,K;L[N>9Z>\B.B$53
M6D4<%Q *YN?FI]%70D<O6KI $5("Z\" @2"?#!P&8&X.4*^M&7U2UW+M;[;Q
M<)+*UKI\H]")G!4;&V,!%X*QU_2-9Z2U"(?='84>,AP"K56\+KF[*FXB2Q/M
MVN%VG$$TO>L=FU5+M/9,E:$7;3$IPT.$A076+0KBF1[5 Z5H6+)U(S?DCB.F
M2K3II#3,-P9/ E5*P?$J+"+W^!!!2 KB4.;3(U#\9(&K=@MG[P6,O(P386_7
M+J=MV9.*.5>ETF#A)E(]D&Y0 $VRNDT]3+EAHN2YZM;@)HT57:7SNP9GE96V
M<<?[=LI: 3XK3\:J1K./%<71QTT%'Q.52%!WRY>3KFZTA40I>/%[K<AH.Q*B
M>%'Q#'>&:H_+G4"VHP^^9J UZV^ZDA"3\&FL(04\X8+V0E"Y .BRF!U8M.NQ
M[@"63K6Y9Z;(?+^/MH*:^+KD,U5GC!&CM<H7Y WD5K\C^%D'P^A55/D-78CJ
M+\BWM21CO)M6BW5#ZXYN,EU4+ 0?_')WQ[<AI2$[A:M6;:V)2BG4PMF]V)91
M2FH[#I8&&VN=1U.1]/8.P ?%Y5MI+D1?QH!9"AX3C%J;==@1*7O92-E_+7"$
MG>E&L^S0/1Q@.L!M$B+UF'E>('IJ;VC_:/^;6_TC%O72Y^^93A,9&NV"S1L]
MRQFIB5E('#I3;&R ">U*[<9IUP'->'+298Q5-YXF?0,M:$\=70'<;]U8'*:R
MVG !!T7UI)DNS*R#7P/;P<17?$-9&'(;%C?(ZB*XF0I@T9T6IEAQSA\-A8Q#
MS+EIS\FBDC^QN\-6)7GYYOE&Z0'=Y3G*%<GAO<-[^\D_R)HR$<^9>VMNEJC/
M8U*?+//6WH#/3HA]TPCOS>ML:;39>\L%^=>-;0?3BVC'A^VP]#U0V@G;1^,R
M)2BMK?WD-3D(PB1D+3+W7SM0,G\ME<Y2Z97(ZMPZ+N+C28,:SY5T _.! '/?
MN^U^<N0:2G&REGS*L(O27Q:L%B $2_9T%XUS>!ZVA]T"=;2)9&-I#;)9[R<O
M E@KOK+BDZ4-7:P*)RX,S]HN/QWOP5JR-A".J(D1-7'S GY'2XERZR;,*.A!
MZ?%'2QA#UH3U>"O]S[:NI+>)#9DWHR+1L+%-QEK[M=?:"PI6[8PC/IA*/5Q[
M4,E8RUDWQ N! Y8YJ6<&#OTX:]]HUB*<P;/7SY([SQ9FB=S'.DU>Q\PM0CK#
M%#/-70VY(3L$.@;:XTV+8Q9MTN&67(=N!*Z 3E$EF[=$(@/Q^K@@KMUJPXWC
M>-BZ<IU3[(J:;]C#$LO, 7+FX7%Y2<_2=C;Q9*VV]3_G@:<92!-Y(43FGZKM
MX;&]*NY<Z$U65)8UUM2>ZTT<?$!HC9!S-G7Q")YB/$6^K3T*TXW:BO;2SQFM
MN_?"0O%CE=4SSDV]?/^CYX>"!X]S:,,&Y>T(B+J^$CQZW#G;IW:>HD>Z ?VU
MSFIN*5Y1]):543ORHBHV4I366_B,'F?I@/0<)6)S(O)B<1GI2A1*S9B#D+N;
M:9G1RN'D[I;O#:Z<RZE'76N?W*.Q3^Z:^^0>C7UR8Y_<F",9<R0.%.$:2I!
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MCX_)H(6<Z3R.A,RS-O[(6Z"!"%WA01I(AHGM9EH"AR+ECOE LZY:<:@5A^]
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MWKN=WRWG:U9\8>&B,?=!!<R*CS0;>^^HYB/RV"*D0< *5!?I5L3]%,L#93!
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MU\*MP6"1R\F(!AUTJL\:YN)V\IX^X\Y3:(^8%5(6#=IO=7:Q.D6!X1 BG(A
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M6"*K_F%?7\IO1-D![H2_7'#:,S3N?:-(].-F>R7CU$]8%ESH)*KXV\U^R0R
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MG;>6)/D2JF0?'+9 #.-U%#U5!R*YXQX6@US5Y1\FT_JUL8ZMAT.-K[FTIJB
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M^$K#:#'?.G3=M("#S!SYM4]]Z8:ET[]5=E4VG/XEAKMXFK #>IX>5>RB5C)
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M?84'B@'D/KKDV6$_XUHP/.&9R=(A+QSJH2/0=K7Q-:#6L/VD*"JTOFXE%6C
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M+=";1GVS0,1.J%,C6L#I!(?"\"&P@("\P*@EH%W%4Z? 521NI6_VV778R#-
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M3N1DXU!.'L!SZ-1X#FO&<^C4> XUGL.KT50YKRW+:9M35A^3O51EW73SJE-
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MF1JL&U/8UTI_40UU!D""Z!2!N>FL79R<(,&,$*AA1#V+L _)(/Q;YC)@@#N
MO3!5C1=A E=R$F:J7C8#J8GW+/A[-L%#X[,F#XD(PDL!0KWP<]3)E;TL0-OE
M+!9-+C#^F97%@B-]RK<5@CE_>MLMYK<XBQ)<G%Q^"[R^>%'G[=1+*;[,4[0=
MAM#ACC;%( S/.]PT)>6!I)B].BEFS4DQ>W523)T44RFKX\7,TKP"MR*;-+,_
MG07F)RI M?VY;A-.H5$P$L5F&:";>,_(\N3-?JKAV3ZR+4\>2QE:_7 G%R%1
M^B)Z?],>VH2N@Q>=DII8(3P/T&U[XEICF4$PVZ,?@6[Y27A^IC]F<_825H$M
M7SW'PK3-:[XXR=Z$K35-+I'2@JWWY&="EJ;4II!G%I2%>#)08O9BRP0U;> [
M"5J^.D6+S 9+W56Z)K_&/@3UK,H15P$)=)?C?'FG2-6E3B,Z 5MG=YM?[ZM?
MPTD),@R"$#&4O^94[F9#VY=FH%P>D;*#8]4,F'B=GA]JU79..>AT*=<B)-IQ
M_!7[@.)K)3X=I$/13SBL@="FL>K3,/38M'5&8@K<.[G# *O>!&[6JZT7]5X5
MY3(]'NU4I]\^7*N<?B_(,JP.].'OV8<[!AF.F?[%732]0 6')GQM.&AS=4S;
M_[;5I??@<E.TM90<48U4@7C""3H)%I4*U'+C134(PYA6I$" R4L=I+,$@AUV
MEI$J";06RYAM^%IS6(OFH#%[&*^G5AW6HCKP9C]>=<C*X]AO?61EVAPS6\Z&
M-EDVY.!!D:%/E>*5YT$0WG*2ALZ/MG*$?-@1#-N&:1+#)>_GBLNR?!'3G9DG
M3A)/@MP*9['3][&+&XK0?7=W%Y-$0A!HF''RA;ND]Z,0KO8M8N3D7'X\6&RM
MK3._MKQ[WBSP$O2*0#D]P1(FM^IYH-M=OXW"+Y@;\_'C*0H7T&&TPQO3:O/#
ME@WY#HMA4?:C?PHCO;8G[5HK*1];'UNG+>>]4B+:2HG8SRT!\VS(66IWS.[&
M<=)2[KB()#"C +P5 <?;$^=LXN%'L?F,E4#CAD51[@6WH7_+^>O8P0UX98P)
MN]BZGL][C$!$R(&!UVL..X8S@'$Y_0R5@.Z929\V3<T%>A 3)@#R/K P !41
MU XU(]^;>+KM,0; S=Q8&0,E)(R28>A[(1=J_G;]SOFA<^CT0(?![H[V-BDG
MYNF8FE7!LR8SMS_+/)3Y+.#B;Q.E/9R#FEIW$WPY?8%N?W9ZSU0:#&5:/@<R
M7$R8A$PD('"R/HB6LLPII(M<W_$<\S*U%YZ)HM1T\1(-[ 3WKQN*B>?/YAB0
MME/05%)21_1"(!%ID ="W7$&9(N5EQ;Q,QC+<U0ZF()0P5@#6)S8/S2@BA @
MJG!"_2P+H](X9MB6<YE&<0K<@E+P BL(1ZHI\5/X1L\Z919W/D'E]1J&CE3^
MU]_]EK.%>E1G]PU]2_]NO]EV,4:Z;&=A8)Q^R'U]S2 4Z$(&'>$&FJX]RMJ$
M*]/>_1$7-<*,,XQO>8FN:$>Y, (I2!WF*>L,W=BX4KUQMOX!'Y??49LYXY#9
MK@]SFTGS4PFOJ*8XJMWH1$HN#E$&GRJ1XF126DN E2P)_I9N=T*MB^O+^2P5
M7Z$0:@3"S=+Q-ST_1>_Z$\H%5.G5B6[ES>KP9V"1JL"NL\M*I?T.TOKG$%R:
M#5V[A['7T)]-?:SY$R:S08,Z4#&<IPJM,*%MJ%+[@:.,9,!]Q3B1@JL X4-I
M<BK@[7?XE=")K2J3%\,#JG(!%60VVUND1(>FT)%R>]'&GT<LN?SXT<[#I7EC
M]H%A?)S/@N AK.:3&H);H5QON./-QL D^#I3D$)8 .E861"XKD"F43B0N";,
M'@!),?!@";$J]@PG/8\U8F98PBP<O76(F[%X %B^BO5W/UZKP@ T@V*%&P&<
MO>9Q*[U\E$9$N1BLEA*QB7ZB:@$N__WA$QWZ.[!*4(^X%$"Y^AX8W9,.>IC"
M5Y=$\!^1JK%EO0?F"N;8LMS[H>WNO<V>PEQP1=_-AL*\H?'G$&[ )H2Y8$V*
MIGKZ%?EB+;/PYM.Y\Q%#;-?J"ID2!:O.&A9*!0[Y5+4/1(I^LZ&M2O@97GIZ
M&?"3D2]W?HME/HGD[6_DZJ5V\%'H&\/2+-WGJF;-/=@X)%Y#?X'J!"I('.,%
M\ Q,#'OU5+&S3M?9-*)_(*%COT[H6'-"QWZ=T%$G=+Q>*9:7(20)/([ LFC"
M3XQI."<W/EW?.-U ^#/6FCC[DV*I;%>>@;(RE5@4)'P9&[\C<G9ZD7X6Q8?*
MI26Y@%4[KA*H!1FD!(X93<NO2V!TY%!%]4T+%>4&Y4Q:3#M&9V&@Q<T4TTUY
M6+99;5_IM0PP_+Q8Y.D9N"7R4XDW4 MP)NXB^:;T1W96YV4<2&DC[;5#2A8*
MM#S$7M"!7IAT ,>LP]HF"(\KR *_0_*BR_Q\LYR:EM/%]Z%G0$M?3_GQ0=B>
M7V;.52X4(D_ P+7TBD@ET)KI4XUP>W_3)/%F7%PR;8C,=>@2JVAC0CSQ53ZL
M I;-@ A+LJKBK*J'[OVICQ<7U%5*5(;7=E-,JI@GFRTP! .Q[8*M#Z0=DS#Z
M*'K.%IM*VUS7&272!U5OZZWT1UXZV:Y)X>5=Y-IDKYWD&^DG>@XH"ITJG<2&
M(*-LXJ4CY)F2^V.*YRDMC0 OX'LL#MDZW%:L&/2#+HC++." <4@5-; P 0*8
M[9QCF\9*POX7? (':C:ZB2,%X83?]T,NO5;),?A*8 79^^_&%$F7T80\:QC+
MF'H(&8KY5K[L)S;O,&'1!#:$R(Q^0IE8P!D4M^%\G =6D^'*ZB$JS  VD4JS
MTIMFPSAO![#9(PJJ*"_JO+])'\] #LDLR/H%A+T_\9QN216=*%PS4EBGJOS.
M*C++ZJ10,"!P+SS5%U$T4R#.*()L-9'+PD".H/NJ#]_&H#M/=*)$7\1C9PCT
MXCI2"17X%%5>,T9H(R40NDR4>OQZD%##H>I^ !.G*;"7%3W2?=)<(CE*?:Z)
MC"2ILA-&_;@I1[@&?3WJ>^2^3;#8:HK:=DRB#BO")M;F]V8*OD3[LWC#*)\!
ME.T=O'O9WKE68AJA]C(,H-I"3-:D0BL=S>)?F4?(L2[H.K$G#]5$K+7KL0&#
M2\.3YGP8%-/6 TJZ ^< U0'#E?U*2^4-B(YE25'G<*>G$B]V7U9;B]A$7K=(
M(GN,9X&9GP/.=Y^(/\-(P05ZYDR23""2_8ZX4PAB29Q0!],\ZPA9IIZJ*%%*
M41BN3(:K91P)]A/(Y*ZPNO7@</=@2VQC-T^=#P>J J5HHR9-N"Q8]0A??!;Q
M0/SE7-.5_,2AK9IP5IQ*H@EG3. GNEJ8LPU1N4*"LE$X.$#R";@M$@M70;F<
MR^P:TTM5T7*FDDK8L,A-I6UP>-% +97205).!YA3>,N)D[DI(SG:J3 FIX1B
MA(:624!G"1XN94V@)$.7%"53#T*).1@)(\D@[A'+3)R/%G[SE^C/=#"B"#/A
MUVIAGR9%90/-0+J/)D7FNZ?KY\@99?:=ZOY V&UB+1D-"W.,JKW793QD]8M9
M))60TYCD64)1<[K4ULZ<'SJR3^VF:N8;!>SP.=_5*\OG_9!U]<I&4Y!ZQ,YR
M\K!4 N+M%7U0_ =9 A5=X-27]XDFK=MJE7HH!^2)C$T"6[/AB[M8H4Z2OLTP
M?C>$@D?FL8%RRV\(F:-Y,*0B%^;<!^; 98/2!2G=TWL'YS(5_(1?4SK?)0[$
MNI_T1CT^R0EWN==<V:W!+-2XN<58];GT0WMM+\]I:[9P[V+.!(*MFEYNRE"6
ML:,@YYV["+\(,&T)T\VSI",RX8VY#7;EHDS*4Q#C?%>5D%>O4B/&G#PK;H7G
MTU55"@@G5(11ID%0O8329G&H.]F+/82WY^H^4&[\L"\46MPX2:8__?O?=W=W
MK3#"1*78BUOP\@K+]OL\NP_D8QS4^1AKSL<XJ/,QZGR,*D9LUB,W<H_1"P>R
M'S(6U4\L/+!N^Q\_D^YD:QMF ZK*AE^5?">?PKS^NB6V'1%S4&A!TT10UH:I
MC^7V%!A%8YSJT+&8(AS^Y&QYV_0H15D4!"L:YR/MST(!;2H=R>V=L!?[7_\\
M/ME_ P/ "-KJM\LC,";@VVKYO!M<*03H+P[SKW&RMZ@!?%('!EZ,-9HI6/W\
M]F8#7F^O0,>)8K40RU6FUF);)]3W&W9)+04?V?)N>3C0GS#E6BSU**?;;/6V
M$3MN"FI0K'PF&#Y@S(.\M4/9K&>G>C] "5.9.)P8CF\#A>SK+-L)!H9+H[F0
M5X75H-=__RA/YD0?!5\V(%'AJ_J'<U"L06@SD$"9 6H0Z+,(CAR8 N,L3.9A
M+AL%?>X$W4JCS0.IDYV=(8>K&2!TH)I&%FWB(@-V0^?\D?E>T?/3)#QURNDJ
M&/8O9]<[I68]!CWF-G7QTHI(_H'VF]+]M8R8C/=08HIQIEJ@41,I IV2<@X'
MXNSO'FT-MK<.R.=^92;I7._\RE!2-"7J!,IPVA-"GV'H$Y7+!Q.$MZM)&;;M
M%IL9QWD70+-A.67F"Z1B/7LN3^34P+@?>5/FC:%N">[+6ZP?-' 7NFQ:9^9@
M+'X!>5BJ0,V#5AH^Z,+>!B%E0ZA:*X4?BNV*I<:G15% '340*U[EAVB0=9L%
M4,(K]47!YP<F<ZKLGEO5E4#E+-+)LZ7J417ZNY)]Y,@7@W":L-^@7 .IB6/U
ML:42_CR?"DRI#Y:F-Z=@L69"[:2Y0S'A"<NQ\(?W=."F4'Z*CB8N99Z()"'.
MI'H 4$Z@XI9S<S0YW]K_A/&B6(F1>^G'N8"9SXU&\-'\+%5I%]=NE2:Z&1V3
MS(@D]E[1W"ZW2:K!S!?&M<:137M"!>$C[(9QV*U0!B,"B>AAQ-:\?IH"G^98
M%FN$%+2** 5"UQS1DO@@\"NE<-(/:7?I!Z[2$6B_8.F4C,O '5R=#2_=X@IH
M4QC-7K=,5M^W"FZYB -9V5U*%1'^-L<E2090K*\P%**BY,>:I+%9ECFB)"PC
MBM*SY0&4,D3J!:5_2LIAS^\)IZ+D=T7A>/BP'<$.[['Y:LMDN[N4+TJA"Q&K
MP#N?I($5-MEKD0R'VPY5TNM#,H[2O%*DC0*W3"NRE!W4;%RE(LTK.#6[7"6[
M7-J]80=Q+-6F=G*\E Q;$#5#?\3#+@UT!(R%2O9.XF(: -TX_!2>T=B$YFW8
MD S%80ELA]WW%"9,S@V5'"CC17Z!XCBN\B7@XV* .3\Q"4K\-?%9=AB@<A?0
M@[GY45J>8@Q*;2.Y&8PXSYTX,?](\57>)<2WD&!'#6HFLC9Z%5I[24&U\B9H
MML_;YB&#3CH'CW 4E+\-^R4_PF'@/,%?T#Y9F)TZQFX-2W@/%NP4F]_/]"$T
M&ZMP(M37XYO(V"R=@=G?_0DFM>A]*5;VJ#R?$FD,UQ7%-%6PP@1QG*PD#.;I
MW7J#%$'X2&<F.*M,II++?CN7#*O;HUC5LI900SF9Q)FKCL4R#:&K774=2B8\
MT: I$\OHWF\V)F& >CIMP/_/WK<_-6XDC_].%?_#?/>2*_9*.);\WLVER@OL
MALLN<$!RE\\OJ;$]QKJ5)4</6/+7?[M[1B];!C]D(QMQ5QNPI9F>GGY/3W?D
M &,1+<_#W^3$8CB45Q,P!UXI]/O4K 1:\M*"/ 8)L7D78Y/F& 3R7&" 111!
M9!7[>MIKH>[%]7<]NL<RK;Y3 ?:%=.1R0"ZE.E6YM W%WTN"?1'5>1WUTYZ;
MHU?JRTU)E$7R([.49.+@/?H\BH/.N*QX"(ZQ2"&2UT#"Y]'T3T"1;%8'RN7.
MY6.EH^+B#B6OO@@I/$PE8IMQ83S0%OH*Q[$+,'\^WM4B&@+[9[^PBMA2*O S
MJ9K-,E5SRZF:S3)5LTS5+)B"R3T?L_?3Z=GG\XM__WIV<7MX<'-V<GM^><'T
M)N;Z79]=75[?WI37L%X^'^Q&7F$X/) [$Z;TQ:KQ[)N,V+-NGXZ6]4Y-5L_D
M&,\';7^$+ZC$G^3#4?7M,#G0FW,\0><8R1O#U#")JHM3!0[6$[: %TUN68]8
MACO1Y!7]6W@490 [TJO?OTT$;[&UJS0$L)>&*L2C,I?P0!;6ETK1I(2H>*YT
MP>_4>$<?L8AM[:TR5*,<3RSD$Q]O+#Z4!SXYWH-OO(W-&N"82I0SI26P)8MY
M4J%QB0,L/IXL:4*7G!3.*20@$S2CM"[$0.#:8-7AH3M-V*<K,;)(D67)@YFA
MH\Z-'PEA>V,.%=P\IWN1>%Z&5YQ=,;3HY(]N+UM6E(FK^H>)Y$[+DWW<*TQJ
MB$OJ*Q9G2W$XV.@1BVMR(CDRIIM03I=%!:!-#WM3]L5$ >D_."&0F*\"JCU9
MFO:.RUXA0XQFILMQ)*:P*&\+"/>4WYN#Y.5R;"LC1W]B<'PH,;9&GDP\,G($
M=6T,KZ5G#8HNRM*C?@H>HROOE)*S'K1X(50.+%M%R;N0I3>\3@FP1-[IB3.0
M?6L<F[KUX8Z=^<!795&PK94@H4Z$*O,R<;53[4Q4N*>?V")!6Z0D(A7-]\)[
M%XF$AY2E(?MBX8D+ICF%=4+EW03XVYQ0MO34(8N6^#+.-\SX,I$WENAO0B6(
MP!4B 1,V2P$-F\B.\\RQ:7$7>]GWU5WOZ:NI830]Q$@&(E)W5352YUA4@M)*
MX.]@0DT$P,7TL/+$X0$B6=E!E^$]5%6BUJ@:+9U]0BO"=IT!^\QM&.&3P"P1
M'TP8C7TYQ:?:K:;&NKYOH\_;=X7/5<]AA&7B>'[<>'[VTBS%71:^-3M[79;"
M/+2+WNP@F'W@1D6S8*BNO&1RK;(3;8;F%AB[U>-?DD4\Z,8*Y37:,=*I-!76
M]@A3ETV;,F8D\'9J7NI0,W]&AA-6V'\$M5Q *@0Z'\A:<YYLUT:&+^I;:4JJ
MA)CX0&6^N-+"OCP/G'IS4NT"2B:*[RAI4P#ONA;I86' EU0E])HY^.<;_D=5
M[[P)]<7Y[=D7("^]PL[^>W;RZ^WY;V?LY/++U=G%31<=X!U'>\'4"H6RXUJ)
M,G#EC9P'>8#A.SX5@TNFI'&3&E6!T'8#O(D7YP]96" 8S==$(I''I(][*OHR
MDEW394^84.50OY?#@YE;+O(TE)K!?(R4A_JN O8<J<'I0369I2M-8=M1Z=,9
MV7WH% -T-MJ(L2_\G5ZM4K_'.4E1\Y9"+2UP2B\N49Z54B@+=E*E)!1(1U0T
M1#G^-L=<XMFWPB# KLF;9V+FK3)FON68>:N,F9<Q\T)ILG7<T)M@#(,_3F7C
MWB*Z\W8^<T;C4H2^.+B+L<2;GQ""N3P@9>F;D%1CTG]>&F</E<E1*V^&E!?5
M&=%?G2,F5SYX0>&)6GWJ?(7M .A7H5N=!^Q9$N^9]:P%N\K[G )]6C\IOHGF
M)#K,!I84P(- Q25=GGF$FA+>,?D#$R$8_WQC3.N>)UAA34!^!U-SZTM>;:[-
MXW(1L1(Q3?&Y\X9;H+5VD#6/OGN;'U>6]%@4>OS@V(%7DF-)CL4@1SK1WT&C
MJ_N ];1+/BKYJ!CT>#G),*-+1MHL([$?O6#RTY$.'(6_E'RU?WQUX=C'9]3C
M9@=YZSRL,;"#L%]9?!?%61B</-Y!V//2(*5%4TK>?"1O=+5\![GI%/-@W)T$
M/7G"LH/@GW$7:POLJ%%9RK+]DV5=RV*7F)FR@]Q46C0OZ%H:N^-:[N+!VRUE
MN_W8<]D/  D)WVV?PF'6R (G]%D7?=R[WI%1K6M&K:T9C<;;C%-\E0A@M*/4
M&/S\'<,6L)@S-'M6_QL5^#SA6$M'869.MI#Q_9R=3#^F?Y\US9-I4--94"H-
M"3/OYKRQPB3;![]!J88[O()Z===7(-]Y^M_C'5Z?WJR!..CL\ H6V:']VK/7
MMV)#;VC-^B[+$5VK&FVMW5J=TS:K]V?G/CF[/*I%]LV3V%H419DJ6I]!R7/#
M;0R6;'W[8N!D*\^7 F=&?KP4(.T6,%.M611P"H.7P@#2:FD9AO=+0:-KM4Y;
MJS:6))@UQ.U_9#V%I1>Q*0P\_V )30E-"4T)S<M!LVWK=L58ZX4P\=HY]7F[
M$R[#:A<?+^$I5W!L->FRO_/QY#U+73#:M)E8'%T+Z(=MT L#3FE!9P+2:&FU
MXNQ28=!2 C)#*+JA-9I&L45Y5![E5<4J])K6;-2* DYA*+8P@!B&UFF5JJ<$
MY%E"J36UIK$D)RL9JXH'%/?^>O*^^O1]]J7!3=5MF'N9?>K^^N)KF=G4Q2'+
M+!2AP&U\OT8!I/1M@=B?6 /6)&%%]8(4K)TU@#VW)5#3Y>.I,"J6CY?-RO@8
M"[G%Q<-@VX*QG2C"*=B0FR[#/GHBK'!VYV*9S8&JYDCM:B>R*2M=!I'?8Z$>
M!$!5]9JJEJ,QV)\^EF>59?:GP>S>G+!;9V+V64MO5\*:MJH'-E7N(8@&#.OE
MJ1X-F%YR?-,?.5@<?^P,A%61(-R&,!\3S(D%1?70;(&-A+AK4D_:>/%JW4/F
MC3B6\Y4%V\;\$>N.8OMF\S[NFSL,_, 5J0:&21Q@Q3-"4.4)B!1"O=2"IW8'
M&P90C]0^]T;4\]OVXO:Y84EA+!<HIU<+\F:V,VNNV3VFCJI8I0GKP<0HX]1D
M25;M0SAZW,+]DXN+9Y$@9$[U@.W4+?,KUE6]QX)Z0]<92[+L^UA13H*)'ZCF
MM@KC'O:FXH$G9A^6312B9=@!%GZ*8 AG!CIT^Z:GFO%1AWC9.&'BFG%SR'1!
M93E@2/7A"!4L=@?;@47M L]+],#BGA>,)ZH (,X_Y@,1DHKL2YEX.H49C6$K
MD0L'IM(;[/DR>]'>)XI>25T0EKZ2$(3UKRJI8,B,A[ %(9V7BLM=^.8(V(L@
M-E/[K:GRC(VKO)4!_.@HTH[*NJ%;B/77)]ATQU9"+U40CSJW>'W7[*'^P$9-
M\ADNE9@J[Q;E_*::8JKB;B!_+.<ADXTB([! Y9>R[<+BP/>CB2G6AP>S^"[K
M$F^E@"0VHS4'5,,_KO>*!;M=JALLNZUCFT>;NNH-TPR%VB=503+%C&&MV<A,
MFK/5D74CGU+UPMALN3#&>\X]*-[KF,=#,Y9J7<( N/ISS^7",MG-2("%X;&C
MB_.;MU@(\^;!]$ E?P0+YZNLEMQW;)2:LOXNAU^QRIL(:\2[U$ ZJ6)S+>U8
M5BO++5/\#=4!>\IW?R+;.S-7?.O)[MG5I+)>G9/;GC'B\\&/)\?<+ YVXP)0
M .,Z/6RB(GM^CL>!#92]HS?LK@4YWCL(^9ET=G?Q;N!WDG46^J$HTY-7AE;C
MWI+]5]JZ&P>+6>\@NWR@?DS^WK.+4;)+@:B.KN7M(LEMAHBV<D6PULR\LI"\
M#CB]G(U?OM"-W;X(. ]^O:;IK9DTC%U: >R 5F^V=WH):UY"RC&C?&OY<\5)
M>-'Q]E1A+GTTVII>KQ<%FE4N7)09!&4&0<$R".+PJ@0. Z!?L&$;&1,:XT#&
MG(Y0T\&1?C(X$IY.>^618WGDN!]'CK>8R:&2:UQYM.A2*H%L5NB[9B^060:]
MQW1"AL,\CMVFZ'P?3QGLOM 8\@=U01V8'@<N,GW96="TO8 >8<AO'L..@"['
M?M#JM$8EV)BV.NJ@MVX>3/\OX<(; XW%G1_%(% ,.0PP/0(?A;7Q.U@3MQ)S
MT=>RERMX#D)@ULX]5^].^".F=YCA@4N87A*=PX1G+@H2SXL72B/C"*HYWU.S
M)S 1?0<X"R83BWK[8?/*<$%*. 7R&"?"ONQ337$;@"%L_%N!313)7 TZQU6'
MP.K@]X*[+J>.7J>R42'F]&!/X;D'4A($?%W7W[.DRU51Y\4[?5#\3&.P=MD8
M;,N-P=IE8[ U-RXKDE/PQF Q,Z[G&(0K>\F3ZQ_-GRX#W_-!1E/C<5FAF<E:
MXG@&/].QL> MPG+8\$VV!R7-!;PCDZ&<&/5,2,RKQ-T1T#):+93O,:>_9=RI
M65HU?*:QY^%!.L>P>-M5I!R)U:WL-;(IY*0+=Q3.TEQ9F19+#KO,^<DVE_:)
M<I]/N;_-!:YT0)3'/E*&-/+P#:6XA]44$:Y?T2ZV'F$)Z4^C].GDQY<JM_KH
M;V^3'Y_)9V6?QPUCL]RI=78J>KK<J[7W2O5SF>4#D?SLBFX;9-0MW5%LOS2&
M)Z;+IS^-Q?C*L;$E5._RELD:F_/T+JP^5,[P9/#@"\/V^A:8_]JV#%'A>"1W
M:;)B_L?RQVV-.;&HIW)%EI[EN82 _,!>T3.L&L<?1>]8-WXT9\[E9JH%%0@-
M2V10+#_XG#BAT6IK>F>F1$VQ@-\/5,\40B@6V/N!Y&JEJL_D;Q4+].W)3R4(
M#6-7]5K6HC9B"^4"V8KJRC".N\'=L5[?A+K:Q'KSX8;,"BU536_/9,*]')0[
MA;TU],NKQANHC+5TQBX@+Q112M88]5(C%%@C5#O'IZ)_K#=?O4;0FTVMV6SM
M-W.6&J%@>*M7VC-)WON%NLA#D)+&:);ZH,CZH'G\K\ ^UENO7A^T:UJM-G,=
M9+]XLU0'!<-;JS)[YV>_4!>I REHC%:I#@JL#HRV5 ?M5Z\.YC02VR_F+/5!
MP?#6KLPV1=LOU$7A(BEIC':I#XJL#XSCR[Z?U >U5ZH/ZH;6*-5!B;SM(Z]1
MZ>SYN57B" &E3:D3"JT3],[Q%^X>@^-JSMR[?ETZH:9K[59COWES<V*MINE&
MB;P5O=-7HQ/T-DF;6G6+.F%>\]]]503%@VQCC)/GD$5EG1)Y)?**(U#VPXJ?
M:AI<1*27&4'E"7 9\=\UO)4)03NM%XJ+[E75@?2W],ZKC^XT@6+VG#4WEUS;
MUEHE\E8.^%?W/"TY4@E2V!B=4B446"64 ?^(,[5F&;)>$7<=K5:>E93A_I7"
M_66%^^)7N*]6C'5J4&ZKROV* &99$@_RF(BJ9R*(J4[SPP"+;M\+CQJ$8KE+
MM2:V(H+2Q3)Q/BIQFAQL+HAQ6<VRZGLQ:08)!;NS<_9GP%T?R_+!VYX)A ,8
M@X\G,*)#Y>+]!T=US(TZWX?]Y>^P!N7+-TW8Q"[77MDN#[%<[M+;O#/EX0M5
M_-B%;2*A;3MJJUA8 I/Z,>!6S"EL[+%!X&)-9'PFT<Z:"1N;5T^5I-8[JL%U
ML2L=%X=VP..,.BL<'BS:6J'L_[X6SGNRJ-OA05C5K5=B,U>1<VD?'G2#.QB9
MZ762"_ O"I /#G=)^I^:KNC[#HB7OF,/31=ECS_B/O522I;<TT#7.&S$004*
M]UZ9FC#2E2L\$V&5K:='IAAB,5DEO"ZE\#H\H)8GS$3?RQPK5>29V!<BDEQ&
MC2"$?Q]@;#Z9./CX<A/E*NQ*^D'Z 2^Y/V*U*FU."S9']M&*>VTQ\J@%M@0"
M88E_CR>60XUT&+]S!?7$P38\%KFN:'RXXMYT B_[230^!DR2[>&!84BZ94=H
MF*@F.-VQU'H*@+-XF&XXC&IM\[8BBT^36;/ :TCF)JS7=YRO3 R'P!S 0A/7
MM)@>8B!>.C75:;W'AD5V@*U\N(6* CO]F': M.NS[V#;\8(?FESTW!A[!?7^
M!R.C<N$#W#@" O[Z3MT&C!]FP02[""'XE@D[C!; ,-FX*8(A[B/$)+>=?>N/
MN'TG*NS29E_X(VSY_$T<!BX,"I,J',WBZ_ @"V%L$KA>P"7X$G>)47NB#P,B
MA9B^A:/"@J55J;H:X30($O5M" M_)W;ZW(85 69E/>5P4P$?#DX,Z_,$D^D4
MS*.RX_.P@WW?'&0!I_\5MX5,8/E.9(,!86+%:_$G[B7,@.-\Y*8+R'._"E\V
M$F)'W#L\&(BA:1/-DW"B):@^(><VQIA0*%TA"I*KH<>N%.'@0MXN!"[\,FN5
M'QZ 02FWB_8AW,"P_984XST!LL)&J@%(E=D(4+33-#C!E^ ;U1*LGS1T$!+3
M]X709C?V\""ULT!U@X&);\%8RKY-L6W\;6H_068Y=X*@?S#]$<&0WGB-)891
M!>)C8I@B)4([]@,,)@A6R%(Q?:21.YQN@]83LN.(W%XO )*6#<4\HIFD\0VZ
M"8:UK,.#'J+-!K7FXV9$R[@BU0G#4-.2/I+KNL3'$K073@%(6)F0 -6*)!*=
M6984-X<'%]P;\#\7$(ZHW%U.+>D2 J]4W+DJ[H\.V%P)9C1MX(>Q9&A7W %Q
MX\YF[)6B$R6)9>,=[ <HB 82;9%8NBN2C%#SGG,ORJW,W0:[ +22C:QW9,.I
MA<RPR#@>A$;^R)S$AI:F[!M\0K9)NH2':!8M);8C*QL=X\1(,[:6)G6.%X!T
M _X6GFK4B):?\!8UP5)S7[DF"/)9J^[PX"IA=^ +L2^0#61*?3V8EA69:=3Z
M$IV:E"( E)@@\4]&((-Q/< Y2A*2\T0"-_:>DC#3]R&DLM,CZ@A 1%\@?*8M
M504H+<F1J*M0^2$09"'/GY:4+,G3PP-@Y !$JOIB*$2H$:2VPO>^:S6D.<D?
MB4&G>GZB7B)]$T<)31LXW+*H#29^SP?WV-^2M$0H4 B5H=<.O/"(*E, "Y@X
M!Z[&=NQC%Q4$A:R\B:!.EQ&@'BX1G0#Q@$8R8$B:(&*0A# R04Y"$V1J!Y)(
MSWXAM0OPM)V>%?$_-.-9:=S9I;+T2DEM8MA"F3BJ/9F,G@+O$D7B?X$72-V"
MP> *>C2A2V>!W37!^4SGS4[9>7/+G3<[9>?-_>V\^:J,GH1^B4S3B>.94MX^
MH1YC5_ Y>R"4YK#'8].FF!-J+E2+0,T>^C38:](DMS2A!!PWI4(Q/,,Z5?"I
M'CUTX>#K!Q?%N0U*T*<&6@DM=2$_NJ+3M]AL2OOLB>$/#Q#*"$3EC,K0J R;
MI7&!OB4ZL:A]U'D1CI::-NGY]X%#N+1'I+[#'M0X1S@EM;!^"N%D20$:53-N
MGGR3B7M @SE,HL\58YB0# #.0@LF-%!30U?8KXC;%"13]HLSS/)A$E%%AW8/
ML"J-K#X/P-&&7V"<9.PKM>_L 3;!<[ SN"8M((D:P!>@ A[K]OLN!O<N>\
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M/ *7KMD,8"R,,%*4UF;AC3EY\:C"8(9$1=8,A_SP((XWPP(G@47&>AP&CB/
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M"8Z^C'!8DLS3%$&7YJ*[J7IS 1-_ZMPKD2T_98IK6=X +IBL:RD%4%88RA]
M+%/L7L8580.GKOL;U0KKTCOIXBT2Y'#M.(R#AP[?&6V&$40/D4!X5]$5_#NP
M::J(,N,(\=/\^:H\S'7J#%PYOG3=#P^NI!90Q#T;M(.MN4T$-^-874:$KZQ%
MD+N3'[BI.%Q$ZI[414]6ZPC%OFF#CL:7B&T2<F,Z-2H1Q=:D#@;M;O90E,M
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M?61#UQE+$N[[ ;?4N_@![#H(IG ?U/[WA&P@/O/&0 !B!M&R[( :<@(,X<Q
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M/'9*/AES9GI@7[AC+SQ0PGE[SKVHL ^/S,3C/?Q6PJH@P&.Q,<A:.JI#]KZ
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M^%A,>X/ 59FRAP=#<!7!O'D4 )BPT5B9B4WNNI?2<ZS!BT9LZ#5S\,\W_ ]
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MBTUAFNIYP#=X7GJ[LY*%O]#/4A[-LUA<"HW+0JG\MW ^O=D$!VC5T%RXX"6
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MN!*-2G51PWX5S$@_HK6^0;","O2?,@C"#('G#0(R[);>E.F$J2?M@6JK&/:
M_H0Y0)NWO)^[!!X6L :6F']ZA:4U4%H#+V<-M+8:3]RR!5#K:,;:<2$2_TO,
MO9J>TZL5(R%C(D%7Q[/]UIZ%0,C<F5DL&B9MK=58-A?C96*<Z"PO,?/T:N\Q
MO$6))PMOQ3+H?W89,W&(&7LC?&\U+9>8+5XZSDM9(J;M.ZQ5S5S_2%B4(W_"
MA1MXF(_H\HD(0(PN(P&PGP9:!T KH%V_N)6P^M0@7"=EW"?2^_L@FUS'JI2:
MM]2\V]"\[7W6O$95:^?C>V]<\W9*M6N G;1T"N3+J=UX#4M6"E])[3X#W'*\
M,>OME\JF5#:;5S:=?58VS9I6JZZH;+0PWD9BO]'6.M7VGHG]3J7>SA3[4LGM
MA-A/JZZ5Q/XJKN7+)$-,G<.J#;M_N\3L.2NYY;S/4LF52NXEE%RB;MJ+)T=B
M9;AE)'A^C!KG<:R2(J,."',0'SF>B)7BHQ0?6Q ?!:Z<DGEUU-"J[5J^HJ->
M:66%0_1TRMP*M]#7C4)3XA<6A4F=>"]QB LKJSZ7TF7:\E8[$W\&W((_ 7P+
MZY-X=/-=?<EMVX2_/.Z:(1R+694PFBMKG]CL7]P.<-/DC53CJ7N0.WA3JU'>
MU-KR3:U&>5.KO*E5Z*)V4;M<DIK=P!\Y+NS=@$3[N:H4PG[%TG;L[!LH.Y24
M9W\&6,7JQ!E/A.UQ2OJYLKA=]!ZZ.72>- $3^&ZUTC#ME<&['8G#@R'PC_-
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M(A@-."EOWKT$42Q?]7@MHD !N7D*V',4ZIT=9*)M53AL3F?JR-P1&3G_B&8
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M')M]! L1(#G^1<8]74'U7U5]NP'#9A785[#W*.O38] T5U-/(<[8TAZ7TK"
MTG"P1]*0W2C/J!2+&X3TPL'2@#.",')+93%VV>)F:**;RJF)AK^((.R)/@\\
M#-F*1Y*(&.<!-]D"]J/NDRZC#FKX<73(0_THH_>2KC=ZZ13*?< HE8K=AY)U
M$[)T.W3QS#6,=GD-8\O7,-KE-8SR&D9I!NVN&22*90:=?1N9/=-?[@*$TH;@
M+ES++ =4@#?'ORQE#&VQWG3AZE_/9=0D8TXS[GJ,.E?8YE9N5C$IB<?-5/*(
M.+ U8_VL&YGO@;59264DK%?Q:$Z%D&@%.HJ0EZBZLG:0O??3J8BZR4UC;/4B
M)[F7*5XYU4W/A03R*IWUK(&S]H9R-G+%\)]O1KX_\=[]\,/#PT/%$_W*G7/_
M0]?MC\Q[X?T@!G?<_6' ??Z#7F]6FU7CAVJUJE>;1J=3,^#7:EUO_""D-C&.
M]<K('T<BZQB&.P:0L4?;.Z8>>O.3;*]X%3;Z[(;=G30V4*44>VY G=QE77)-
MYFT-L%V1?<<N7<R.\4Q8RKG=KVCLT]75\?DY^\(]=,10?++/GT^TU >?+*<'
M'B&^(+L\P(HLNEPRXN#*L1O'"E1"(#YSE(J3)>-C>'ZJE"<#F@F/4Z_I6!X;
M4,;-)%5CERDOM U.J/1:*4D(7\;+%OAUN.Z:7/=;$$Q\[]C,*-EL83:K=VIZ
MPP VT]LMW0 V6Y##(I:2MZTPH=49LB^4 TL?70O'O>.V^1>7+<,DX\D4PQLQ
M\65B@M%4C0&R^4^Q7_RWFN FZ(6L^0NHK#L'DQU</A' 8?WP+:)[;*PZ OM+
MR*X2ZFF<ZC/.]#/>E#CA$Q.K3/VF2:X&+2@L; !(^0I]CI:3_\CHNM'$%1ZL
MFJLN2[.3/,W7@":%0J8Z'8;-F=P9'M84$\-'EWW?(70IMMT_KJV5RG$EKJUW
MZCIP;?W86(AK<5$8WJ3[CR&=RIZ6'C"?[-NQ+ F[2C.1LQ8'4T-2OCEN)TBY
M&]QAGE%KCRFYU#^+4[+>;#2,E@Z>9+7=J0(EUX"2_6_^LY2L:%6J&B*Z ?OP
M:/&'#8G@A,Z2;6OT>;1;!.J=\FC7R$O/1RPOXY]NA+3S<45T^"5T1>J+&4JK
M-KF//6%I,0&1FM0T>%GJ5HVNW8R3JHBX92_E3B23U8[S/:;K?(3TGM!UU6C6
MMD/71'Q T/_A+KJRFY'5_^*V].Z-IRGZY>EY#0*N[:J5D;/A6]\"M<IXTJ44
MQ['KFQ/Q/F,@[QOIZM72UUM:2NNU:K59:QJAE ;]O9#'=^+8M#P\!OKL<'LV
M%AHUH*-0C%[39-3PBQB8?,+=KZQ;^539C)R.IM;5W'OH#@*U[ZP_N!&RK6U0
M7I\#L7O^F&[USR=TO9:B]%\<H/2O413PD^L$$XH$KDGT5+%J0:K?0QG_*NV3
MN52_22OE.AE_N\8D+.\),;\EZE]"Y.\A\==WE?A?SL"I8S2PVD[PS$)^:&BB
M>T$OCICPO$WT-!'+<$F="+B^GS9+HR3@]0EX(0L])."'349$7@'%-G>58G,B
MO0X=GRPE.]<HY1E85 YBQLSH3ES3DNDE>EV9&%UO(M#Q!!I^9)_-L>FO<,BX
M$)G+V5L1F>^A9=$JR7Q9";LBLK.#?B6A;XG0VZ^;T(U:J[DE>?Z,"4VD/=R&
ME2*IVFCO,UEW7C=9U^J-SO;,E&="WU_X(S,Z*1%^8=J"Q6%$;[-B' &H5?>9
MW/7JKM+[BSJ2]6I#7Y9-;F1=N<3Y9$_X#WB%.<Z?O;FZ_DPY4U_X#:;,GF#F
M^DVE6PE9XE^!]1A:-1LZG,<96OOLB>KE\>9*--^HM9:._D67^)]T2N61NIZ2
M]&?W\$3@)5[4V%7E9$-'G0J$QE[3_<X>=!:)[A=R::^H3#20_1G5%B=I_RS9
MJSL6LUHANK-T(4RL:0'L >P@W)(55F:%G3W]?#E6:(%W4&LN[?2>?1/]@*[C
M/,4+,@"N;&VP/IY@@M^H].T)IRK]RW+ GP%W@7:H-OMTPNV_IZT@0P;D6WO*
M \4Z!,TLXYMYT[Q0/+#8O1Z\#4&$?^%44.#'_JT>D3Q=*UV$5^0EO=WDF*@L
M1%R$(5%5(:2DA4H0=<H21%LN0=0I2Q"5)8CFBO_\"IV5Y56V7%YE<Q=YRO(J
M2V#J^?(J.V]SEGE+JX0@FK7.TJ<R5/4 +,K^B-MW&356+IQ[F>E96SS^,!V5
MEH54\"]9W^&1_>Q8U(;MILN.4!"*/IJS8!EB412C^CXQ GVBOW]+@X3]*[%>
M@S=5%"(YZT8B'A$J].I>!SUV-@7KY9BO@4F#[:7CWMW! #R^8#SM[Z'+1I<>
M]08Y?#DSJ9;D%>WE&4LN6$82&WO*5#N;\%4DIEHHBG(&UI'S\%2UL%;(6L]P
MR7/,\)QNDR/T''OPW ")P@"W+K<]X"EV$M=U*=EN5;;;V?2SEV6[%0+X4W;@
M!X>[ Z3W[N#>]!S7>_)H5Y*BNDS4V"2YZZV]IO>=S4M[47IOZGIM+=O-F+'$
M]!VWWU;PBFK[S%E&F0&WRC$8,%;J*E5C$=;ZEV,"U?V&B3UN!K<H02[/D)J+
M!"1.8!PB_Q,'F.>S/U@^/6A^_:4$+\0F9GN?CX2-8F7&+7HD'$>%Z7SI'3,J
M!D6%PX_Q'";\],49IY.Z>+Z02GJ6;Z)SY(6XINO?FP[[8#J^ 'Y;B6L6/166
M5P;TSEYS3;'RZEX#URR6A.>:]]B>^<KB?=6\*WF#9H:-HK)DS05R*L['>/":
M<.\__M_R)1E*+DIP4;%2\EX#%RU4ZF=.[E)D$742^4OHI)1<MU-<MYM)@,MR
M74[LTVA5?Z >A ,QU.M\@Y?CD.+8V9\!%K8'ZH=]QJS JU42^ !6TS;I_8GK
M?'MDJ1+@83]+<+NZ,S&U,+MP/^^^&<5*1M@_C=/&BW+-QK+>S@DF4/7"$Q+J
M!6'";F<UBI&IL/\*;,&D8]Y^4GU\,=V^,UCYSNBBBB-L!Z%"A>T]51W%2B?8
M3_9IM9:.7R]K@$W'>9]FH>Z]C0U>'-LV;6?#Z3A&=:_YIUB9 Z^!?S82-HC)
M55^ ?P 9O-]WQ8 TD$F5#)P-W>2+(6OO-2,5*Q=@/QFI4UNZ?-G*C*3<CN(P
MTE0-[GWEHV+E&.PE'S6JC:43<);EH[B&;V'Y2)WQ[BDCU8J54K"?C*0;*P06
M;-_%2PF#,+1V.02BIIQ.CFWWYK.2L0@KG7 ;6>>CZ?]U)UQN#=C?^1C0>N)L
MND'#?GM*M3(M8;/\U*E6C>KRF:%STA(B%L'CH!-G#,N2*0D?3=?SV<G(P3)8
MYT@5-L7XJ#P0/2:[QJ;3@600K;.Q:!UF3TC_J+/,M?47OV+[]/7X=K6\'K_=
MZ_'M:GD]OKP>7UZ/W[_K\=,SCLW!P!+EM?GRVGP.)+.68;R;F8<%LW77;-27
MX1&"Y?IH4;Y2Z!K^[GABR*[Y.%6>OA"V[7YRQFYF$Q:,,Q9*$%S6"_S%M(7[
M/WX%I(DW82N))'897N](G,M_2\[(FS-V,^/OI3FC;NA+5X%XOL*]4@,R>M>9
MN;LQS3KGJT;GL[ABF,$5T1%<ZU6RQFXF!!:,-9;JJO;T219=;&J5S%$(YMC-
M=+^",<="%M7BS%$K-4<QF&,W<_D*QAP+-6%>C#DH);SY$LR1Y6R\<N;8S?R\
MEV:.6JV^=+?EJ,;4G)L2JK>#(L.0+_C8L>] GWC &"Z&_]DGR^EQ2\M*<OAT
M=75\?IY\>I%VY,MVGU"YZ*^-4XJ5@;<SM4A6N)=7N MVKXC,Z\7*C]L%,C?@
MUZK17/HR4.*J]%4 ,_&L6W31%6RB1OPWI1BFS27\.S29O TUH0LA,B1$KXP_
MBI7OMJ/\L5 <ZEK<F9ZOKII>8_I-1A9HR1\%XX]B'7OO"G_HK=;2=WBZGB?\
M#-6Q0)6I6SXVW;#*E.U8SIU,[]0RCL"-ZB8[5DMGXM5Q2;&.P(O-)76L%VH
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MA J*FB#B5%R;;'RPE 3!XN/LR"!DO,&G8.J';!2&R6/7B3R_&#ZE >@$ OP
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M&83_WS/VC/P;0]<Q_SW_#JSR)'ZH85C,G[XQ8U'0^W!\]I]O#*GLT\0IHOB
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M1/$!KUDG?QSK*YRKC"CF%^1;^=R..A-IWYCF9(@AR*M\6^Q\8ZI805+$5A5
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M!+MY9YI_SIUK>1C!BD'7L$?04G<->P2#IWX%!#8*Y"UYLFE(#9\WVZ:\**;
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M5.EB#M4\+",O,C_\&7[9 7=NA(]+7XU=9,4\-<-;QS[J"$\Z8JEB_!)Z]Z%
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M1/!V[(H(TYPQ5I&MB%*MF]<TI2-"]KQ 2LDP,2T2?GY8;S:OTK4_8GNOG@G
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MFB=R2'N&3-A+B;X :-K]O8:H]E.Q;';SZ,;#D$[1O\1@!%4RQN8"*JW9E.0
M7,#_093P#8-'%LUHNBIV8$4WU'_+POPO;)^L(U54A,6I)J5W8PN=N=?SGM<1
MW?79$JFT(U).?_O3_-FH9JLE(1CCQU7"N%IJ,H7K?/6JQ%2J#$D?YZM%^D/I
MYT/E,7];JC8;Y)?WI4;SOE)HENC?]QN="??FPNP\3<22R>A.Y=[@T.S_6@(>
M5Q;+^=UI;B]F7=P)#$>MR3LAM6)NQ2R*VE#1>.D*"Y(A_@;^-V!/E$=(,(:W
M*++6FOYZ276JH_R/O!YV]4JI7"X5FDRMS)2>#*%TGV^6# '58&IK)-3>ZLWV
M?V5A)K>\1 WV7<(6S1L*5DZE EQ<%ZHX$ANM:?NR_8P>GFX2]8 FG;F03BM=
MPZUL)B;?9"Y+5Y5J%6KRL*#[7<K??V!W8W],EM=J7;\[@=GDT=4\H+O/^C@.
M.);+;>Z_\LU%+>Y-VI9:TR&?ZE6YT6V:];/NPI.(C<]$;,RU?"WA7[N4K'&/
MW$6^QPC*J"TA[^RU^BD'P5^^)N]BJ?3V(:#X;K+U>/L'K5E=W?Y,NOII-T:X
M=2%:T&P:@=P8#8<2@@0X+P&-EB5E7)$I16$:F&NKT=^:$RE;_Y&]]E),NU-@
MHO%0K]^6[K#6R=\RQ4JC<%MK/-R70,U8'3=,\SY?;4";3:UZ[+'Q1AJ)N=G]
MM%R_SHM"%='*@6GRY4F:/K2+&<'++CO?JL],V!BR%A8VZD!N4!BID S4^XB9
M(%X-,B+E,OF?2I%4_<9ZJI#B-)O&P\]=>'@UEIXJAS:1,CN_AL(<;S]'S>)M
M3A_]O)+B4O@5SA0FNCG"&M6DHBY^@19YLLX>%%DO7GZ(E.W?BJ6C^101'3FW
M04*1@45GS=BR8&7R*SH:S/<E%]ZZO<2T_CR:^CG0<7L#JEJKGE.S:=:=C'UV
MI\GT4;R4:$&S@D3,5F5*#N@6$JG:IB&]T_0?[6:$QF\]=9_6E0$S0X%V& 'J
MRP10[Y*=M"Z[16R8E0.>%A3N23WNC,1@UA)ZFKWH8ER5-3H <*)T1QK*:QK2
M-7.^9$4VLY,P3M_ZT/Q28,RA*>'Q_N%M\*+^"FZ9]\H.! #K7.F>8\!@.AN"
M?E%SKB<L S9. -= +]_\\.Y[1G<D-.]H#W/P9SKTV=J10FL@'(UUD:?YO9MX
M.F>;LFC,UE@CP&C %1!C[%O4C!7GE*O;U:O25:>LL.6]C@E9,W5[7N5B;J?G
M(7,:C1,M-D2$2XJ[7$*8[7<N MW1XG&_$1N,IQM+98/8 6Z/XD#WAMG+48#^
M;GSL$6PO+)( B>&+U52R!8>7C'\W9UWAE-=O)N^9QO-EKU3S<Q>8.P9O+K:H
M Z>O[6Z/0+0GDSB@:,_.1!(:RZ0\[1W<Q#"IF5JT386O=6MZ'ZG$2)BS#0K*
M8*#(9.:38>#FGWYU9.&A."GN=63*PDA[!<"G-N^2I=LA9V#(,*T]F;?;HCK,
M=3'AKU'R5?ADO J?#8&965>@_6(J<D&19430]$O4^W,72_<J4#;Y>:7?\%FU
M<]WULBQP-RTRASL2_NOR U&:?&6:X@!I3!6-F7MEP,LQ^HL8TT"JV#W[7IG3
M-'!J"@%E'9)PL$[/C/'Q2=*!=]HNL7 EWF%:[HW==JC!-F_[C_OA!I[?L6X]
MO%>B"W-4*A?C')O37?*@CY1P)*QYPG(I,[.L76;NX=H,T?M%!Q\$_X1_'MH?
M347;^@=_8P:\VA,Q?.R\#.P@R%,[ .SFJ4O@#G<'SS,H/@.!'Q.-<Y!KQ_<D
M288^^^\9>T;^C3_7,?]-B_+(CUO#/!8%O0\?9?\Y6Y\?U96A@YXUOL]>Q%.B
M;)[;-!/*V(B>MMD:>KIZ$'_?)K>&[^S[I__[["AX%M_$Y5K3GGA?+I=N?B;&
M70]O F73511=AHU.\-RR\0^6Q8( ZX/W@?15X@'G2#Y_:)Q]M_8_)8CU+,ZJ
MO1@5]7A5,(L-!%LMHKE47I&U"Z(:S'=^W\#X^^(MRN;^,[NOLJC91Z<G$+XC
MVU4 [X!2C>%5;'7)9&!J3^4ELB*63+CK(PV!)4!: LAF%F,& OZ0IN-?D%$V
M%Y$]L.-]8 #_Y_R<*8M($KXR=;Z'ON'/OXX0-I2^,CD,P2,OC?"/''-^;O*2
M(+Z9K]_<.D$/8WTB#57'+J74_#NP^2[Q0PW#8OXT)XN^,41Q:N(447S :]:)
M)D?KWEE+4\POB+[RN1UU)M*^,<W)$$.05_FVV/G&5+$!2A%;50"%6?N7OIC?
M@K_,N-CDX7^_8$P[(5U%_,MY&V'A@9\]))=FH!F?R\2Q17@6.=D+OH?S3[<#
M!<#2V]ZO /&3D_!'_>6F?]LV?<*WV$3*TL78VRA52XU*X_2D4BU@@=#VU=H(
MXBC56K.$P6W6F$*MVJC=5HIYZ"HQ:E3RMTRCB7]Q1WN-@S[.\TC3Q>YDE_.8
M!+0,*O6LJJ,!_FS'M6.'L,,V!*&@CM#90M337)Q8Q!]213(R."\+E[PFDJP^
MUAJR3K1W$[_I4H()[\"<IAV2A6R:%6??_F&M*3<N_[S4^%3Z^=F#.1?L10!A
MG9YPS/_^OVR<X[XQ\S98-EYJ37_(N1_UQ*C:'&,6*I8:A?M*'>K(H<#\\J%1
MP:S4L&XQZK3G++EFZLZNWA;5WRZ6^#=FI99<,-+=/]Z=.;\UN.P%MOM])C3Q
M.P^F\?>U$0?WD/H,VQ62L0$O+0*X9+%'C)8QY"8YB^&PG?%+4180/)10BF?P
M:VH/XQT+3JR&Y<Y%C.'Q9]]X@<><H0X5ZE'%&!&;_$Q/4MK8C&^+V 7H],V5
MB\Q845^(1Z8P(QF$+?'-AOA#,B2P2"@7,S&I#X"7P9]5?B@B$L_%0/-=;*,)
M<+W8U\ ?POX&%NXDPT@]/^832,8X^ZUPU=3(C]RWS[[Z$&')N.@3!*#X]*2#
MO]I&ALT$SC6^I9&N2$I/&6FPU\MTP8>80/"'B.;*?-,892Q3$?Z9P:X[+^%O
M(!G;$,97!KR&'\BT>?D%/U509,B.T8^3FU<1<25/3S#18!*4>(TDH =($#N@
M\J'_ $&R%*B-QT0IO$&T6C!H:F)^$EQ251%&'1U#FV_>U3]?,-B790H&S0X4
M39<FF+PZ(XU4D,Z=SR+0V.D)23(,85@C^2! J4TTJ)S&'\.D"2 +Z U)RA"<
M77P>Q'?Z%CSTV' 41<-_)X?$+QH0U]AX+'R"/I/AA_AW]/OXV<"5;[SE2--,
MXE 2H=K&.!X)WR->M5\&@[^*_RFJF E%8_XU@ D/@,T^NCDCV/8=0 \PN?G^
M/D_0<'HRXV.,<05K.]H4TH>2O8%(S2S-&&XOD(P _BBD;F!#!/X1D]BHRW=T
MVB(R0'I?$0S4"0I$$^A4? D?D1F#F,"OF7T=OW]V3J")^?L&&2*,$'R''AA*
M%@ U?;&-87E#V J%M<3&M&^,._3.X$L6,=]T-/B:@"3\,8H^"S?D+P9B\!5\
M&DFZ"#>&*88<VB1^>31HX^]"+93Q87HPX)X^_X8,28:?%@-NZ%BR+F8$2JQ3
M'*59,-*LJ4#XJB]B!C50WE-X22/XMX0!T/J,A7FF;G)- ;BFCDD3U!"A'U4$
M+B:LHR+$(!EK+: &^)LB P5\Q0\8BD-,5C)D,4]/)!%+4?@6-O3K-?+(IGGM
M8*K;Q0B,ZJ&R#0M?4^A0J4'Y@-;346$2LTD2V[.Q:I9!D$W@X:<GIK#B.ZJB
M@18G%F^;:':,E-D7JT@'30[?NF >19Y\=-#&LM1D/JTC0A@&(\]Z1PRC -\G
M0L#=,0*H3)]#_DTDB(EF+%YLIH(Q)A6_9:#@MZ-N5^Q0X042%AO4Q!O ?-4?
M\Q,BNAQX'S]')>+6XC_R,/BK@)D5XU52QJ# L$:#4IMY)8 ) 0L E1\3^8^)
M#M\3X(3H$"RZT#L4L\&:&_P>$<@1DR< /A")S)8QU3EI#?BXA.E)A1 1Z ]1
M/CT!@C,P;5$4$DG1R!M&-M:;2-7ZXA $!249_(JC5 A&*@!9SI,]TP8*AJOK
M(7(I)D7%L)KJZ(J*?\ OQ\"H$V*BP'7%&(@U\"HF0%'&8.HCW3 1^HHVQ,I1
M(B0O"6.@=&))\$0 $<% Y1(04I]7!XHL3H&G5=0;272E.18AA X-V30PN6->
M)1+-99+>D6""\9(P,V,6QK];UAQ /51F&_=$[L@TVYA%L4SD@VDD@(E-9"Q^
M !446("U10G9[QB*'S20@)ADED3@!5.1&0C"S0,VX#'!@381L5CE23FVM4\9
M- C)GMG("J0[D5C8_IH,:4N5Y1HR=P0FS#(S>_6!  4GO>7;V,:NW=4?;K$5
M;]7D@/#LZ);N( TALO %2S=!A)DC[1'Y$]:CRJC79Y21RBQP)#&K3$:;:2U@
M1>HG/A,]_8;AQR8>QD1>,_F!8)[\+(++@/U8G>*'@DFT+:82;&TZX$+3L=P^
M,E(PC$3PCZ_/;NX0OP1<D9$Z5&AO@<$^)/9@NYL8@S4RB0F8-6*FC,041>RZ
M>7?#H#B;GP5$97HTV,M4J<<#FQZ=8A23F1<)H0I&X[L(1#1T*TDH9K@5FGZ.
MR !)8CSPL@R%H+H1!;$Y8#'P6(F/8SI7\] "$XZP+@$7G+X/$JF86RRS2,?_
M'_+?6%.8+X+/X2=*2L=(?A,3A^+6]&[ [)OY<88:(PC0%(GRH7D'I@"QN48$
M'&*Q0:$51C985O@C%NY-W0?/<3KWD9<"X:4'?)WX"HNH@X@;FN!B#-1_SVL"
M6A9!5<:2 <J#Y4LEY1C['$9:!:L"+'A!A-I^T_,_<7^\2A/N:\SDBDIY*T9]
M!0UAYA=67P4SALLS+Q="8?C*9=+*SQ07#,:[.3&#]3J/C4VJFJW(:O&N9D96
M3T^&!H'$##>-NKC&TY=$[+SV1.H;=E^(P0*AXB$8MWP'C8CH,(+&8 1]@E/:
MWLZ863TKP'MZ0KPU^)L)$#EUWX:M&0H&O"CC?YL&Q8!_)JMFB6<%*-! I!,A
M?T7CV)_&?9&$L:F,%4SCH8M-#66,SX8O G.%-FIK& .\BH'^BI_3 .^] ,]I
M7.0O0/Y>(JDGC@86+FV?,<\2,^YA!L3#1>,BQMS>%DP3!"PJ#$0#BF0TV[.L
MKYR>P'?,)S*?P"2B2@<3#6/#IL-9&[9#F$\XQIR"8>8*]O;+J*V.>.PJ+IOF
M0 A7]?IYI3)'#T )YJ7C/UO7C#6TL) 0SK%E6VLI?%\&D[76K8UT8B+ )'RR
MU-8<F*2UQ$IK*(HM8=@:S;[1Z@!X;#R>:[5L.^Z(^PGM1Q-;UY%V.;'_)?\N
M:JV6"83M('=$&=F>!Y4^M6X>M@?W2/77_%<;^"0J:?@UVPCS/161#QJ/FG:R
MI>%E_I>:?^#/&&QIP'7,#D&:;V8')RVHF.VM7=[K6Q==86_%;$LV?HXQ1P_2
M6D:!\8>-!W19$5^IEJV2^/.XK29^=H:S[YQ#+\T_!@N9\FT=LN S<R+GTPJY
MLBBL8XPI3<T@*7QQ)H2[=AZPLD5S<C\&1F:!U\D 2J9.],;I2<.P4/&?(4%)
M(X'8SNSUH!94AR7N YKO,5N3\?NI<_"?1;;)V%K/S.]7Z=?-NZG#EUM#.26G
M3>Y@N5;K(/@D\_NZGKDI-L?E%XM/\B[PY)E[UB)Q54-(G+0IALX^YRF+>])+
M,STXIYD>E&D&HB01-W05)\ 2<<MD8?)=R&\:#>_$A@""-00ZH7E)Q"BFOBV^
M DAGDMI&LWL>(Q]?Q@L"L\#^&IOK2%L-:42'U$>;S(N_ G$48H^ YC*5_N3T
MQ&:3Q.8B,,2UL[^([G-G^ECO$,\1P[6TMYIJ-+, 0,4>B @N-/&EW\U4V1+[
MK=KQ[;R0_4"9L/];&[_V_XRK8F>FK.;V1,YZW%1"/,""Q@[ZP+;81Y#IN'CZ
MPFF:R1S;F3Z F4(R6J6)!A"L=/,&NDO/Q+Z-1J#WVFR]/E!:>^1*M_7&W4O[
M3\*BM<4&?@MG:R7Y"KP<$#FE+IR:U>>(B7A:BZ+L$)T@6J&+R-8K]'UM;P+W
MC:D1@8Y]5_R2!NWAM!H6<L>&!5\:%G*'T[! N,2DG4.A^ -P^YOV6@<!P<)U
MDM<CR3XPEYS<)\OEMX_59ZRY^E848( 0*2["W(4%*7XA;Q2)D!(YL2N2&.#I
M";^B)XZ8C49X2U2Q5G@=865%:Y= D-.L@3,0YB@G^OXW?(HEOP[;L6^B,L(
M+'ATHKE&P/K*^5(\SOZI.3-U,5Q&J^<DR7SK<IP+NXNV0-<ABO8#(/0&OBY$
M@]2+?M!R=MPL(,5.BD(*9N:2MMB--^P C6:.X1-FTA?4]1N^2*BM><;V@R:(
M'2O%!:61\'RH,!T;T09;[JJG*F-&)"Y15\5 JJ..50>(WH?P'_BKO0!3U$E!
ML@$FQND+,C+<"R^OS&Q/(U8_?^ >%K18WT"9I-41.7]JZX205:,)S5DER<J
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MO)14^%A72(Y'Q1T9 F*_A0$_(4),('C7$'JQSPTT3ASY/4MK=S5_F5O6_#V
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M  +3@:MXDOA@OU8O",B:"6N7RV<! JYY*V<FRU#&333&;6Z$@ E0KLXU$(>
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M]9A+RW?+"46ZXRIPHHP(E=$)Q4<15MN@$M$&81RXZ8AE(H:3!WM5HMA&KK4
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M[T*X.'670FHZ_[7 ^!J 1 8EEK[Q_>Z.F%JH'I6Z-G8#@\:4ZH3'LP+#".#
M)1JH\K+ZL<;*!<5Y3:?Q$MB-Z,7G5U:J[B)3?JIO-J50**9,.BI+! ]L;(6P
M*&W3,X0\]WV"T$5UYU#%M,@$=&-X&&JGL'$@ALI//T)C2@X^_!#*#T#Q&X+7
M,#@?AE3D _.07'RML_!MAU D)Z\X*VS#5=C7<KJ!34TIQYVAM185?]ND1^JC
MQI?,Z+L_S&1^;4L-G=\)::NE^NCJ,OO]86#<7@X+>Y_DGKWIJ*_G2\,#8-!
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M="G0;:G^B_VJE7I<;,&FA[5_<"I1]1R_2?%9FJ (]SI##\OL0$4N],=\#!5
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M)+-P/C/FS51[])>KLZ#BAE?P"V8AWLTF@PC'Z(? \BG?9(Q7F1WF91@P(W-
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MNW/9PO[%LNIQY!&/(3%5.A.OY) 2/C>8)LLIX1]]9&+NR?1(.%LF_/SN3C"
M+30]*GGQTX.QUGKYH.L8;L!I:/UGX%PS<8-8=[UT)IVIUT6?O3T-R^O]WU[L
MWAG!PWO+2A.EM]KTZ;&^4B$LC14SJ52LCH,U6W6$16(*(U.+_"='>%*!<NC3
MP R4H_R VEU05^VP\ \VC75<$KA@ =L>ZCJKPFLP_F]A?B6F3C+J[.J_H>Y
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MNNOW$,@&_U;U>BH<V#_!>R1?*&IV$5Y_7ZY<-J^0;<U!UZEVJ?9&7WY',*N
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M%GI2=#VL_Z*\R0S>!(*):@C. '['XAP\QQX=@EW'()92%9/G1W+I?U$JW1[
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M^ N#<_&HZ08]6S A;$ LAS7^8FGD$[X4W5K0?9, <8IX,<RRTKKCTRC9"]"
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M#-M[D;DO"<!9>EY)4]MK%EI8A%6.3Z+$6I%ZO&,G*..)U HL+\<%Q?1N')]
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M^+YN;U.L[2:]CCI4O&AI_  Q-T%OM4S+A-2%5%1/]>A+L3G7[HY!6J9M^N8
MP:KTUVVS&6@M'BH*"-JF#_*^#"F$M=IM.B&FY9+G'OQ1<=O$)IXIZ>_T[+JB
M-?H>)6'/.]"H_J0Q]6EW9P[]"=685:I/NSM2?](249]"XK1GF?Y^E;1A;"%%
M\4,MPS21K;@Y44_>BG.;2DUJRG@F]B6&QMF.V]9M<X0,<$+*4KH0I"S-]7A]
M5.K=YL]^V.>Y-MDL?^-_&I]N*K7R[DY>PSN3^:A%$FBRY_71S76UTF^D*]]/
M<WN?2J??[B^KEY@;4[HYT^[*="-+-Y>_, -&'M\6Y/^MV6'PDJG6]*[I[NZ<
MF(Y/FAW;L9SV$*,.!ULQ_6UWS91ZKFEIAR 8L^DP6P\)-O@"CRI.24(5"+]-
M:>/^%75,%#HH\'3@+RX55T+$\AK](.V4#L(@L=A[E6P_&!$S_JBV3(E%Q:S#
MXSXO0<&$G4O98Y_JU !Q!WB#)P44))"@?,($63H@MAYB<M^Q#9.Y&NG4.GVZ
M>W3?3!D+TZFN@($K#^9SI]L]T[5A4^!AJ"L*[Z"[8 Y,E^H3;!K# ZTFMQ'1
M72Q61/? <B#QG IJ=A[9'#N0;70A; 'AESRJKXCL4SAKSS1X!$<2AQ[(O_"U
MZ.FFH?UW6)8<I]-*D!;MA4O/ZQ/C#/$?M_2UCH'.$D6L0@6R@EWDX(!\NLC
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M/^O2_6+WF HQ(66]ON4S.XS::3[ L2(<DCX[QOY49**@(OJ"!K5JL6NT.H#
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MV)=-I/!I,C0_VYA 1P;K!Z$J(>#/UWW?-1M]%A6E= C=(W0Z5>2HJ@=%^%G
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MA^WF7XEQQLWK18RP6$P=9R8&9CFD W5 ?#4K.8-F)@9BC8'I0?PI*-WW$H)
M]N38-N'.;>1R@=+"#$P59 +FUQBK.E6)!*?/SN$6'J''@)\AOD01V1O)GKJ'
MOO[#O;PN_3Z<26^3%CH!5[(9XI@RF%M!B86#['B-J!5Q&J[B&KJT]CE,8!M-
MD$42P/-O">"K3@#/OB6 _XN,:8RXC_DT@:52S=L+;,PQE!&Z/3T$&3U!5)?[
M-ZOQ'N G\..*(<*>4*H@*1DX(JO5H%3C8O8-2V,9:I2A86J,:R+^B=K@,#Y0
M6K-#O  8$OAX'4B8>=)!0.%(S,@>$%L'5$ P.9S!V.19]"[.I7"@E3PV/7 8
M@&,+G,Q!SFEXH^"M/0&MXMA1::ZK8"TU7.3--Y/4N'9P/B?B=%-U@GRZVS3*
M7WO-0SULL@C(W'P@PT4PJ)MHE1S.QJ&J61M1*CA6&O^A_O&9[IZ 5VZ3+\<H
M/-2^_3X\](KM:"Y&F""F6JWC>["QINH$@&GV*%4XFDP4,]PQG#EV>0 PDDP!
M&( G$[B3/D2]A\,'.+?AOL@0<T1G9H\J4P*[Y'=,E_'L8>2&,JLF\$A&^"/E
M>F&\*KQK,2X(08JFWNN!']57X#U>0!UAQRD7-I;9-1$Q2%4(@A'[-Y=],EK&
M)2"YI/^#X<0XB!F/2YYD@_A/X"Z$3[D"$"WT0.6XY3E:JX]U*_3 L0+Q&>"'
MLU.%%!!S23X,0B:$T]TN5U_#Z!CIS%/)?^I(1EF:MC-3&>:4;=E8SCDUKV,R
M.!]4/RY1F=LY+K-,',0=@7@???HRC.F^99QSNTCFJO;C]L9J$/U"5W"!?('<
M5Z7<)"X=IM+-C/W92MK)3$GLD*0#^3#]9@>JRO2; K@+:8S=\?QN(69E,.3]
M).P(?H3@/#0.:BSJ?,'00F$T3/@[F65)S;)0)!/Q'+;7[W;U**(CSQ/^686
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MP^RXG\D*&7]<EN\$+H!S^:LY1NSNKUL$7-Z<AWG&+<[%V_N4/D@OGJ[W;Y8
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M?'M,QHYGX,$!6<?! <G>,GW'*HG;Z>W7(OGC3ZG9>*H @QE6_M>;A4;'959
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MLS;(S8[@M.-2^>.9(VU-#@N'_3E4$3EGGT=BO/MD-(O'U]P+264%:K1#V4H
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MX0KSL3_ 1D9F.[B9!\Q-G4G8^D4&LVXO$"/ZBT-?(',*\L0@IL+YF6$K(-O
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MRDXO"?"%S8RH=;4&=F<X/^-HH,Y@M?H7X4G1UY7T*Z*U-E' WAI8-55XQ?
M(MV>E>D9P4HS<55AWTCZ7FTJ 9D;=N6A5[I+ FM'";@V14<7JZ>:3.B>ZCAR
M?YWSTZW%>_/EJ55]3#NTV]@*&=(W9$@#,J2O\N6]0H97E[+0I=X'8M(S9#SW
M(5F!C8.SGDSHSOK]V3<N_OF0-T<:FR.MY=0'VAP9D 4:O.^G9L!IL="=6$W>
M(T$9"</Q9C46P^7YO4^J;'WTD:&"<IO4]P*.Q5HI<?.GX3A7>VFP08&3^6;
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M"(3 R@;YZS2O#6+QWA_X K !F0 28<IMFKW6KCHE=%,'W@,4VZ:,S_<)W@B
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M00XA1??/F+%9AYP6Y*&'1XQO@!GR^F,N],<O\.F@#QJ1^GWN&%PG3046>9O
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M[]!+)/ *>1'E:A.0<0-! 8E;P.]@!'JJ0$B G[@9^$V:X&(OL);_P+Y+X)$
M#NA:_2=4S@3+M  D54FO/<=+8+F5.S86.QMQ(BXLGLC\J57]/@C"J-[2D(&5
M4!T=.((O'N $#8Z>9GE4(Z>='<Q A265/,/CCAM:S20L*UAK/@"6/J;-MLB,
MC IZ !X!]4.69FA^%6I+HDJPOA)5Z)B8:>*%443(BUAW0 3P1?,"6@VM:C?
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M%<KLCC151\0=4,5I37#3HK/L7A'=J*W.JNPFW$1W8K],7 \>Z:@-KK/@==6
M@F]V?M?V)L3[4C_7NK]OW=TPH;)S+53I<5\Z8P>KCE:<4TZ,W=Z[]3?@PZIX
M?UZDYN2U/,G<"S'"AY.@CZ\DB4#0-[%3\B3+CT66ZU[D+?:UJU7]!;;%HJ=A
MM[*-<"X=AAEKZ!C$I%JV$Y)\(W>SM<8P"GZZNC33/MHGDX1G"KNZK1ZGWH(-
M-Q;2$ $-[M*/'XUZM77#H,#LI32XG$*]#L8)3JSX0*P8(<3Y60LVE@+'=\0L
M&6Q&/XS-/83=+6<EY%O$[;,ZL'N6&?Y57%NE6%OJ^']8;TE61VV6YZ_I=C0-
M5/8H=7![D#Y0%F=Z8% QXRF7*_%$W%9-X.F^;C[BR*/9K7&EEUD$7"5:!K+6
MBR716[ZQ=\-VX8:F)FE/O5A@=/ZR7:D7NI4R4>AT*MT.46B4B7JM4*S5:]V:
M)78?;7\6K4L7S%?Y3=!35?+2LB4#2_^T.V5<N@]O]=O%Y?@:&VSTV]MKEX.
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M!F=B,N<35V&.>9$?3\=:G':BP3ANR)T)P"3M78/W8NN^5>M_U#]<F*,;:.+
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MZX[C(=P;H= N,R:0U]@C@&S3^##]D0>D1&_%-:X>8 N@['P94SC:7I$$3EA
M,L51%4[#83A'#,X5Q/5RJQ,S\6P^L[C.II2.S!%C -61@BD&_KQ),DV1N)V"
MEU-&J3D6+"B6C]TEX%@X$=&23L&K/I?SLZFH\@)X\@)F$>(!@9!SJ%J<"$Z"
M-AIZ*],^,#-5'"."[[*;ZV1)/K 1N99$=&36G9^YC'%Q<$Z&--,I#!(4^(\[
M12RF'XK<?@W76$@T*N]_"J>!749I*8VJ12<"#+;$W-0$AH6N&5OT^9/%N2^+
MD_T.%N>=!)0HC?O@Y0>T,^^:[5K]9&@>S-"$0I/*6"NO; 2>SN[0J8LA6I]
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M77#7PI$T6YA)475/&0PM>PCN6J>'GX5/!!FUYKAYO^06V#58KB' J[BW<P[
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MO5\#7"B6\Z !A%F_!2$PD53<[J'V\\#42 IJ3VMICFG9<-G TDC,JZM4,5T
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M.'J36UW0(G1C,[HAZB5)%^.3:K6'CFH@V&&M+^&>$B>5]$0Q#!5O&S6B:84
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MV[\4']4F(="AM"<UC(=U ^AX42=":2)VJU<SF>]8EVRC#(MI#JUG-,HHM='
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M8>$I3?;4#A&OI%U(5S, _1WXI0%?,PF-I:/=!=[MZKM>#DI[) $JT4:M3=?
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MN;!SGGDP9TJ&>LN9:QS_)-P!+'#GC\E*H<?0T67H^M QB*YSPE^CC_A$?</
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M:1(0[!KP*5WKXK7"S^=S8].!W0APB(*?0[0FDWC+3^+,)R9EFOD2TJY17]7
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M;$?5=<)#YZ;=DGIZUKMY=NQJ(;VT&SOGQ=)O=$"!$S')X<'C4Q ,4-'(",D
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M5'6PC\:R33<,Z TT2>FZ+!N;BZ3AARVWE2!,G'0YP0/ E"6UZ67='^D50YM
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M$3P*"=YIKQGSSH#MCGFVT=N0JVKR3/."YJCF1R!JZ'#JWY_@Q8RLFO<\C%R
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M.L\=M++*C, \Y&OTF]C[\ &VRN!$]+!5-H:M@F*6V:W$5%\ZG^^Y"#N8AEH
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MH8646Z+"\.:_0YU5%Y5W%FRF(_8%>+%ANM.0HXY!O\;M_G<=OU<^M_%**.1
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ML5"I"_T:>%+1]"#M?D+(: .,])![(CR^MA\H;O+2WR8!FY_LQWS S.9!0$1
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M FQSR#(0X>GJ;?S,$8?N;</1W*J[C$T'K!8V0FX#AP#'\'66?;S PY:\N+S
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M-S6F^?*=(UM?I\ZWT;BW21?_UD7?FGW<([NH1!RS=D_76L+8<C#96J7@L[4
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M#4:2+]69X51G$H=69T9?/QD%Q=$6<F=/Z_\9+2<;](>YO.#!__P_4$L#!!0
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M*.)8?E53CY"RCB-7DA Y+"R%PK#V+_VB_57VW\%2_B_9/V#_=$T HF#0SO+
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MFM7C,XRRD&P<.S"N[5^S0&:\:PPTT65V62"<43LGW_P_E>+V^%\ 4$L#!!0
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M"_^^:?G[PHJ591U1:UO2^#H\"O2\?;C1OA@8&>J+ZMH_NZC1W9>:C1M/'F^
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M8AKJ]#HZV6]+:9GQB^J=8YY6P?!A9CPA !8+$+", + YA7EQ PB0)P"(0UD
M , ":T.3 P5 "42Y!D" (!(7'N=F1:#)("0! &\$'1H( " !,'KD9P6 E 92
M5W<R8@'2U9AF\DE^Y -C8(EIK7*@>J#B8)1TN*+!->Q1%LD1 'E(T9Z10SD)
M+$"0""B0S3M;1X<F![)+Y![\!J#TT7\#- >\4,=T=5?'"7&] 48-E@).-MX
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M/)4N2S$I&CLV#8GM3(9G9VP0Z:TKVL-TY$4;>LZ#>N[S'_**UW;(3LAV832
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MV'-7AX1<"B]E=#GIN>TH$DV3CSS)7\\W1#\L-JBJJ0NG8QQ28E1M+LG*4W^
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M;\IH?I2(I:"%G32K?7M%NT"%$?\Y&"&-V\QU3O.!%>-QU\B#Z\$DKH5G?#=
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MGUZ$%I_;[3D>S.."\BB[*D&M/IDL_AK=<R!D'O$:=(<_L/]I5$/D3(:_4+'
M;J6!O/.IVI0B/:=9C]8===@S /!=3-,-.Y+7J@FD^A5PER0BR*='GL,R5UE=
MPX#$/JL1MK&>,\N411>78+V#=2#>B9/[X5C7^[)]6/(Z9]GRTBAJJ]">'%_X
M<KS3:6!KSR,=[_ ][U0;NZ*[XZ[P]>:W)$=LH&,*WZT9DQJB4/-3LL,4@4R5
MO5HWUW9_4*"3&)1BZ3^-V^%W/X-;T-L;]%3O:QC^Z'ZW2*IX'XMS*#MPQ!*4
M8BI6;2KO?G <9EJ;JC$CDK_\<6F!:0G WB/P(O!2QEK,;&:XRV81+A5C!B:&
M%K)C[O!&9&+2J*GD!-]G6-A8ZF6^_E6NR0*YZWRO ]3!"W724=Y\$C/>>)K4
M'?@F1(G'(][(8T(2>DR&21!:PB]/D.N!ZI):VG6N496VZP.DR]D8A#N-^)$B
MJ:S# D)%5>U5Y;#^9:MTXW*5&R#X&?;LBA]U:Z) U%0&Q68.[T,C9RU>HT>=
MO8.802DK9<;U=0UE\/;^_MDD8E7]T"#+^,M%!C(,\G/$:D!:R6B2JR?$6X3_
M<<4@K^RDTTKMRP":-Q,>.YV__*GKF,K 0=T"42(.E!7\^'!T;@!T#]@"\K_*
MU]AT(IFN.C%IOD:J\QS<K6!LJ$?_BN1U=:ZLGH_8CI\B?K@T7QG)]\S=,K\=
M-*%T6_(-BFN2(*N8H5P!*X1)X.W)=?&GKWZ/(K\+Q_)*E_/TCVM\L=R#7*@P
M?[;B0DI.]B2:AN;-28/54'DL@M'2A>94?2>EG"6G6G>X)GAK*'2^' W(LZZ"
MA#M>:(8$.[DZK2:5O-F+0.(.S$WM8&Y)1*:81KZ_*WOT?DCE.S*.!5IV:*H]
M'/V[)_J)/8BJLEV1.NZN%3C7(>Z[,O:*;6W+ /BX'S)*^CS^J8DAH].D6 O%
M.>]C.LUHTI@ RHH\T-RQJ)=ZK,'& \J<'JO<-T1XW@G^I ,M6WP8[IVBPNV
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M!OXS0$\3K?'"V9_8M@%\I&<,!Y:XX$#75%[Z\EJ9\!>1Q^ N['2[)-+K+W"
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M(5RPKR:0]IRQEBW&(G^;7\=5?ZT330VKP((L+\ G3"^ZX< MK3\9PN.)1V_
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MCSZGH*#VHHF'(9^4KKK:91K9:<5RBC7Q\\FVO?["$36?[= )G;A;;!Z'MOR
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M;+>SDI;#. S'UVF?+) >]=G'AT8_,L35(7>!G1G[^2\^2F%02ES!-'+&$7J
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M ['X+CAPROYE?6E-$](^- J!)D+O#EMN=:@/JZJ-KS9\X,!KKE^G\%7%"%=
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M/;,B]H%N^"8HX[<-S-2T;R-)0"U6P3!O&3C@WT7]UYKHWYAXF3>1GWN#H6_
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M ^(RS7&=H)26@R5\_CRT&PG>2+R=N8G"7?)JFG::Q=^WFA44%0EW]3G'A([
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MF],?W?5DV'7(GZ;GN9;%^<@Q/.<+ V,\RDU">AZ$^+B,M%-5@B4C@,A3Z+V
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MB8-%5&\6 1T[STUQ12AMG%9[?,S_21/&BQ#L$!I,,U^\_L'93-')P\BMH"5
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M)(B:R,W4X\(W*TK[=&7OV-9V2]U\]>.2H6F8H7.-GM :HB)699G$EA0F,W)
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M7%Q60@O'-J=F_*Y)0U4%)VH/F53\'HF#\N%%R=?RO&**X3LGCW/C>MO,D8'
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MN3EYYT]+M/!A0<=$!KKUJ!W_T6O##Q$4@N&Y%WGY!&]9\!,TZR/&5D/RL3Y
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M[-M%X055>O:R9539@K25W$C]T$BQ/>7%E' >CS2(<2T#?'A0+)_)16MB._'
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M_+VUFC??8=!*X/#$8;?A,M#Y("K13I@!@)A5:==V)YVUQ ]VKSBN>6)<_WG
M^3"C]@Q =3+/Y-1='@,U2RD^H%T_ ^I^0]M6ESR ^KDV'?:;]6J\ A%#V@MB
M4T/+KZ)V]_7FUS)16,/,B:VX+K[G>?F(>J+M775@[GL(Z>FFE]E'WI%F%A^
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MO%NZ)6A$0J)9X9\J;=&8G#-\=8#JT+E]TOR&;GWHGOM<^-=2D7\ ;/#[OP"
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M*@D)PS,^J'O\]]M-7^EZX3W*,3Q%<0#^!4K?ZCW3PBFLY1FP+^1\#?/R.V^
MR]RT_+='3PID &_0FL(]70;Q,^"W:B4\5&N/*?.,[BEN'!,RQSC[[[^4G/
M+\P!4'O=U^0,#,7]^@:,04.I;'=4R<>_O)UF$']UX%WJ4^6,^?J:Y/>4)6<8
M)[-#7;$JM0.V!)2:D0/9_G2::R+Y;>K&L&S=HA/Y@MRT[S$)ZMR7$9*W$F\0
M'"! F3CXNS9V@P2+]FE;4KM47],&DTMJHN&/I->DSEOV,G"BFH2IE05-&K<<
M]SE_T>6=TR6L:??^"95W;BK+/9,'Q/FC4 IS2EJ<KY9S@VM>(RY^<?>.$G[%
M0GH4EW6/NOQ6)VK\QUIKTC1?\Z4,&BFNGKS;++MFCPA.;I8SQ EDFS<,?PY'
M;6/ZKS12_ TH['-VFG%M2/K-A>!I\-L*YE96>HKVJ=A266=Y6>I<%K?'4$55
M4--.I?&]@8"O8\#+93!/PX\IIW<R%M!#Z$*R/Z"$!/R*^?,3L7$++D0,A2]6
M7<R/A+_2R<]]]9-*;3'H&= ?9+IX)X-:MML0ZV3+G2.X41_Y 8&4#<7\_2#I
M[E5QWMF"=#'7QHU)G6=>J^>WTA_)HEW+X7[QRE&*$GY%AUAX%LWAT<P@<XT3
M:8T/"<A2V]_3@@P%SGP:^4:MU3]FNQD>0(>_RLE^2S"IAFVYS.D6?T %LKTW
M0"3%V@T]H#=X6?)Y;&7H;0X'0%S) F:7JB]=:'7#U75]CHT2HGWJ$Q?>S5"8
MX8$'^H$KJ'7&3)O';<O3ND1BBR*B3$(]FC-J*@676H1U6FCS'>U6I-87T80*
MK[[//]'[:0QVTD%A3D44EW\KZ/P,"-])(V%LT \,L/CU \ZA!0T3% TI4/$4
M,>O\#%44TF1I&F"!6]GIW>>G5 ;FHSKM4@TSWT]V^#CAOJP3G3$7]7P#5WCF
MQ DLK6*W AL:90S;0I&E'^2E-'+M[$]W?.([-&[:R1IJ9PQ;I?,_OC?$VR3M
M"WG*13GGKI+"?IFJ&"_L!F"B>@8HM<)G=#_*_2!HO/"Z-VFDH3&75NS<BOUT
MU<>D5\.-25E12=U>VQH[=D[-_E[Q,\K773##VMJ%8'BF%B"B+K$JE*B."%U_
ML#&8.3Y_J?3ON:_HEO.)_2BS"/5TA8TUR_&"9L:V4.\\+EEI>I/MR04J_YXD
M-_H>[^NUIBCU1ETQ;O.%[5R)E?!/C.I$ &SVR(QK]#L9SAM:[?U E_&=M!Q"
M=]Y34ZSP8D/W?B1[A4^6>A-U1F5S@W;0"U$E=\.%/75!G2)J80\?]W*9TL*Y
M@DPK@XCD7\,T3;;J#CT^IN5*1/]6Y3]-[_^TF04G;FZ/'8B0H1K&C[8Q?5Q\
MKW KI21]7-?&],VM8$S07,\X/?-HW]Y^2VR*&:V;WQ %L;(=V6+B3EL^=(C^
MJ^=.Z(JV^8D&%KN2F"S"_8S"ND/HH%GQDE8_\YO7G:IJ'$BZ6?Z20XMN S>;
MH1[HBLVS8>5<BTQ-UKD)^^43!&Z;IB&:OHSO^Q$I HY01_7C=*IE76*,Z6"4
MY2KX0D--FU="4.?Q0"59SS!!88F-H3];] DKM,IIC)5#/<8FJI\>7$:_>K']
MN,_CK?'^M<0]5[?0^.XW1?V1V7N:S=F+7-&9'R"BN8)$S.41QRTM24<'@Z \
M6;L]DAT*2,RHY?PA0</M+$'"AJFG8[TZ.YOH'(K-9A>?@1T3N0+*QI LDYS:
M 73%T[BA4?6+$84*S@^DJ%_Q %(/M97,0LE"[\)A%UL16_X&%T%5.^'VET56
M[/!OC13(')/*'P3-JT0'E )EO#DTGN;TA$=29RJV^*B%NZZSWKI*G_-GRC6V
MSZ1,T829LXOJ#.,VD&MGOU].0XAL"]*SQ5[H1[*YF2UFCC2*7"Y?''5 EB=L
M1$R[*H&<A;J/<\VFI/?<RL?D.09^,7^J7RGT^V&P/+X]JI'XN279($5.3QEB
M<V38A)V%H $84B>B6 /JO."NA'?N'!Y;%JIIU:/,52T57A%%4H*_(.&8T#^;
M+^FY20(V3RJOFQK%^\W\>Q2Q-##^YH=B5-*9&U[IVJ,C8M[M+*<4'/P^<F)Q
M13S.KK.SFZ)S7YHWZ$.+14$SM")C_RD]-L\\0__7]BQZN(,"_YCY!#<S*"3+
M@B4WE%<2G(UTOL00L8',:S<G_+O-P_FJ^&H59W^AO--_?NOM^?VD>TS\N_YH
M7E:/2,D=QN8[0WZ31_'KK09U%L:6 15Z$Q4G5, >.S50)T47JQO;W.$D4FI+
M)5R<\('+?*C]*(N #[$RGQBYX!A/4>J[.-XW9.2V\B6+YJ#XLG<:7^@B-8FU
MY]'HYQM\)1U;KG)6>UVF-+3D:,MG,X7(/3]AR%%+)/=M^MW*\YUX,YYD9\\?
M)$8KN!/%&_[0\"K\IAIP/ 8YS8068[V5 P2577LFT6F\;HW])<E!%:O.#W0S
MOKS?R?"?"7;[,V/):T]4D#!%9)AN0Q&2I\_2)9CDUTGT "V\^1LB32H7+SVU
M%)T7<=I@(_QII?41^NTLV'>0+++8$6S-A;,XC*IBE>//\>8]QB=^;M 3U3G+
M'+ON*%EB*MZH.;Y,31\>PPN/7[!*UA$CY[EFL#3(,6H?"H)3 R-W^#@HK43V
M7[UK;]P][R]W8G2EM\*)2<,9=9R\DQ,Z+#9K3Y!H=$LZCL ]D6XE0 .8#G09
MC3'E9/N_^)GH/R\>[M7_VV@7O5M\!M!ZZCX#&B PNLCVCLIH$9YGP*#>+.1X
M]1D@O9F%5?CTYAE <]FM?X-6]PR8E-5][0A'>@;$NJ]7/K[6>@;LY5?X^_YS
M3?]U=)W;+H!J6'R&'6_<,6&_5QM<D<6)^L1ME? QV#K)'0>RWE)>EZOH'+#-
M#]JB^JY\':6QIK2E[_>[;1S;S)Q*==SP-AU;?4?BGI?!I)D@'D[52<M,1#;J
MCSSI+[5UJ=N?D$QG>)EV/BML04R4+E-KKE(QA1:.LW]5:*\Q=+9\?0S/9$YL
MES9.CN6G<K(^8!^<&T$TH_#U5.OEH,_]P4ZJ6&;>AH\,>&*X^O'/^/P;=@GJ
M#?4LC(,0##GO$IU^VJOSIZHR=[0DEO T [-(+&4UJG.RX^Y/5@M!Z676-(>P
MO$GX"82Y" '!ZI4KZ87D@/WQ[" 21\^D]#LAZV$F>@J8./7"XB# 7XK*38*=
MA(*1?3K4%3^245A?J;$Y3)F0'8$@T66;@'-[S"CZM?V8J-4K@?/K@H;0.B*N
M*L>WN84'',.%;5#**'2;-8;WW;BU"?U\_$ =EP:"Z&6M86LJGQ.IA0^+70L2
MJ.2_%L'HVGQ"2101ZN9J?\+KD9&]S1LU=KB%956F*Z&O4U9DZ_T!INQL.H/V
MOY]2JSI!^AX&S7]9G9=%%K3GNA<LE3I/HM>^9IJ]Y>"U\S$$:1W)4)/&*WE+
MY1K:+-<YINV2/2C:_3[X-WNJGSZYNYH4Y,YSR=K3]K"5RN3'NPZ42 /"S^0L
M__555&@W!;!1IX]]J*95"\5.=;BI^O+YJU&(37)S9G*7ZD#_$!8H_G,96%V=
MW(&G& S>/HA>1'_7&/]+)NUDS*$[QB_<QWE)VA9I+(J9O25[B).>UB?C5P38
MYC)D 34\RT#JFTT_-+W7*%Z$N8E@PAV,<>M7*?1H_+@FWF'>KQB+[7AX^DU_
M947/S3XOK(? ]5UK?24\ AL&W5>G1J@).-T#5VM02F>8A!"HKZ?1OVXOB!74
M=FNXM_N2.K:SX&LC4@@-"XJ4JTLMNGYO%;3<%BJ\-33KR/#]E]3 -Z(U]B6%
M KPU%3OPPECVA?;2?/_VPCA[Z@!K3=+60EFN*UIW!OSOG*PMTGG2]@]^G$B9
M9O\WU[U"$KX ' GD2;_%Z7WQ/SW$SH-MTRRL\V+)Z])HD8N^?##+48I_^^2^
M]56:^A_Z_+\QOK!26+3&<)GJF!E\;P'* (HK](<+S!O4?TM42[\S1AY#X1OL
MYR-3^%UA \$^8..JKV^.2,CJ/]JVV0S;#A^D%RO##Q9ZUYUV/NJ\LX$9V6=^
M0[=*^X/P<%^1XG=]W24UP:0V;H?#L0K=K#!#\-9IJWCQG*20HYX6HH73(%<+
MOIY4H.6]BBD@I@4),<TI/_3BX+3'10$)KL,$<4![33>JB/9[3 $E$U[G=',Y
M9UDE-10S%#-RX)H%XB#+"W^,K/N>7Q<IU2V-UOJ3_@V@ZN8Z9]WHU]EL<)VU
M]K> XS<V%"F\[E3O),A?80$ VU'9 Z0/3A5]-<RV5XNIB> ORDRR-!Q2,5&M
M/U'L@04>?_=.#.(U<S-X5?D,*U!1)B:ZWDW*16KLR)TW-S\4#Q0J_7^BJCX
M)(%L58([;DZ? 7GGL[/7_W/V<4*X^H_/ RNPNGRXSLHK_;R$;>TW=(G?;TRS
MQ$IM=81H$GW)\D<WQG;KM8'\<5U["4K$5Z GHNYG0.\WE$_BCL^ L_0[$/Q'
M&]8S )GM&7"N\I]E_UGVGV7_-Y?IO(W*U5T")DK7UR^6##LX8][]*DJ.Y-GD
MI]X^# ?^:>A8%SR#P# ]@'",[\^ C:)G0.!IUS/@BGL/<L?^\QD0^F)DQL/^
M7,SO$5NQSR_(L=3N@%,-7?('*7^R1$HMH0[TXQ/?>3SP1I[M0V,E6(U3'YE&
MR'6^QZM@2RVV4,3UB3A&>2O<R3\!GP&?]5[>+X (<E<"^@\7;=08K)IPMF;%
M3UCY,](:XHQ3'^E0C)J@>_!I<8 ,M?.FE$#K-335Q5].8%Q9(A)).T2'Z=-V
MEA* T6V F7TI[>'OZ?_Z"F.I?USE2 >MH#=]FA\U!H$HMQUV:5CR6/F?'-?#
MVB085"S4!*Q,D?RR0N6&16@EA@T0?/%]3R_)XZN> 6]6 UYL)?C?#I!&+V#C
M2S[1^;P<LRO_;7,9#GI2)40GJ"VG>^14G%FAWPB=VI%Z.1 ! M'Z$?UBF;2:
M_OWHZ?_W\Q5C[-%70."X'2C/@(G9?WM5]@'AC%'_\2S _^%53%M8$1T7ZG6K
MCZ[/@"FWP_W_)S#W1ALP6$;AN:QFZ^\6_Q.H K7QA!2-1 ].P ]24FS)=5'@
M\_Q_ 5!+ P04    " #\86E2Y($=)+(I  #'[0$ $0   &]R9W,M,C R,#$R
M,S$N>'-D[7W9=ALYEN#SS#GS#QP_99\N699=Z2J[,[L/-TDL4PP.24GI>ND#
M18 DRL$ .Q9)S*^?>Q$+8P4C*,J 3>9#E45<(.Z"Y6ZX^.V_GE=VZY&Z'N/.
M[V\NWKY[TZ*.R2WF+'Y_<SL]:T^[@\&;UG_]Y__YWRWX[[?_>W;6NF34MCZW
M>MP\&SAS_A^M$5G1SZTKZE"7^-S]C]8=L0/\A5\RF[JM+E^M;>I3: B_]+GU
MZ]N/9NOLK,:P=]2QN'L[&23#+GU__?G\_.GIZ:W#'\D3=[]Y;TV^JC?>U"=^
MX"6#O7M^%_U7K_L-\\RD\Z>/-VOO;\\3]L>".G\/>L1Y\N[)ID\>QI_^_/6?
M?[^GWY:/]YV/#Z;]\7IS&UQ>S1\'W?D_[M__^^KF_J^]\)._>>:2KD@+1.%X
MO[])D??TX2UW%^?OW[V[./_C9C@5<&]"P,_/-G.^E8%??/KTZ5RTQJ %R.<'
MUXZ'_G".S0_$H\G(T,HD\,SQ?.*8&7C+3SJD@7\]#QLSH*P4]&,(RF)0B^;@
M/&J^7?#'<V@ ^/?OSMY=G'VXB,$#[VQ!R#KI,B?>@Q@Z:BCIXKE^$1Q^+ <]
M\S=KZI5V")M*NCG<<8)5.2LMWSW'?N< = 90U&5FTF]WIVP'8W(U37H (*Q%
MCXE5(;"Z>(\X49NNJ.-?<G?5HW,2V$#^_P3$9G-&K3<MGT _'Z>YMR8FW35<
MO%B(XW!84["LHU_PM_6:P:*!'_[7;SB[/KO<IC/ NX7_@,5<,3BVGG<Y;$AO
M6LSZ_4WX3QP&!A4#673.'":^%JW;B]89KM( 28-_BBZ_G>>!4T,$'K4,YS_%
MO]<N]:"?0'\(/T0=(Y"*3B:QS<!NUF>+2FF7Z(>83?LQKD-L7);3):6^%S(P
M^Y.<D>^!>[@[TH23CL=M9L$O5BL:J!6.=.*O-R8N$+:D/@-T2YB=;9=S_D-]
MSK=^R0S\;\<IB819GC%'[<*E2^IX[)$.N><-0(%9T5 D=0#ELOFK3#;;X5M\
MWLI\H(5?:/T2?N,DIGEW29P%!9[W_R=@_J9$/#D N5A^;2"6<. 6<UKAT"=A
M=(FWO+3YDU<BAJ1)+H"/#00 0[;$F,?)^1[U3)>M\2/&O!-X#-HCSI<WR3G_
M-U1XP RQN1>X%/_H3[N3P7@V,$8MX[+5N9T.1OWI]#B9/64+!Q1:DSA^VS1Y
MX/A@RXYA9IJ,QM-="B)G_M_SS)\.KD:#RT&W/9JUVMVN<3N:#497K;$Q''0'
M_2,5 G*((UL#&':-;@'X7#3C2YOD3/]4F/&#:== 1M_V>RUCW)^T<?(?)Z_;
M)AQJGOA(V[$F%$"(P_Y,L5P*(>7\Q;L\Y]O=_W<[F [$7M,>]5J3/IB>[='@
MGT<L@;'+82+[FS$HZKX'+$8U8XW'7\A_2;N<^Q=Y[H\G.-EG7__2&@]APYD*
M$?1!(N.;_FAVG-P? "'.@CW8M.UY5/#WBG/KB=F1628#D//_?9[_@]&L/;H:
M=(;]5GLZ[4<"N#*,WOU@.#Q._H/B]PBS&_D[Y,3Q8L]-[E<YIS_D.0W;^QW,
M=,'JH=$>'>E!FN)H'3;^-<_&8V8=)5ZL\47_EC/OUP+S^NWIL6IP7;Y:,5^8
M</&"WOX@Y^/'XEJ^N1G,\(0Z6F;:-GG@H:X+Q\^0F=3Q:'OA4IIA\2XP.>,+
MAF'7& [;'2/4CL51!49)?S2%T^MJTN\?L40&<#IYX6P>.* 6<),1GWHCZL<Z
M0V6[7 8%^W  Y]@TG/SP;U0;C.Z@/>M/_](:]8]494N[ .MX^RX*!B#JO+.O
MQ\F]T*6,[N4Q=:=+XM)XSA9^EW+U?<&X&XQ@J^ZW?AD:T^F_M<#2:$VOVY/^
M<;)YZG/SVQG&Q2UT[,-.G#*IJQKE#"_8<].9T?URU@$UHX>GY!CVYB.VHV?D
M.5;8PG_*N5FPSF;M/XY579O01^H$,?>2O^0,+!A=D_Y=?W1[K#SL<L\WYA.@
MB+CF$O2O'K#1YL)1(_QF90U3ZCZ"FK;5'%X\BEQF!0NO:TQGZ/6?]*?]]J1[
M+=2\'@AR: BG4.2EJVB<]B=WH!(>LS)RR1SB@'IG]Y]Q'T^)LK1%+IZ"#7DY
M&+5'H/ -6_T_<'L_:E9/J(WAP3%Q?4:]F4O@V#3QD\F^5=DN9WO!Y)STAZ!C
M]UKC]F0VZ$];LTD;CM8NGJU'NKM)@UX-XF/UXF3O"[;HCCA9ZY=XX&/-E9 Q
M?48>[%K2B0#ELFD:PVS]$@Y[I)(IC5BF)2(#D$NB9F#SR 4@BU^FY5 #3BJ.
M#PVCG4<NENJP9EHH.Z'D(FD8 CURD4A"G6F9[ :3"Z5A7/3(A9(/A:8E4=$F
M9__N8.F1<[S YOJ\+8^@'CL_1?@TP]#T+W*.5H15CYREU0&F[$:] TK.^H)9
M+ ]&';E(PDA4FOV97^2L+MB[883JR%E:#$EE9W=%JYS5)2'6TK#5D?.^(D25
M<25(0>12*)BN5;&L(Q>#B&2EF9[^0<KBOQ;,41'@.G)^QK&M-$MSO\FY6K H
MXZC7D3/VI8&KK%ESD+'D@BQ8H0<,A1WY7"B+?*7E*VF7RZQ@NE;$QXZ<_]6!
ML.RVMP-*+HN"J2L+FAVY0$KOZ?6H3YCMC8B++O]'*KG25P"5BZ9@,U=<\6O]
M$@W<2D8^4@%A;10KL*DQ;SM.0.P>!?+06H:O3M!FCOW0:0]TQ+Q(&7[)"')Q
M%NSP:?>ZW[L=]E&6[='H%K:_7G\\Z:,QCB*>A#9Y[.O.^[BCKQZ]J$O\V+,E
M9>ZM1^>!/8354"'A^AWE@BU&N5."+7>*SZ[[@TGK=MJ_O!VVAH.[_M&+4Q;/
M+M]BFW61B[!Y,/RTY>;786D '-94IB!*Q5)LU%<NRJ)+(K4:*R+KN"0[[2'H
MH/W6]+J/J_38UV-:-&2Q<.F"A,I,9&9':N>,EXI.(N<7#"85_*\%1TE.\.VK
MJTG_JAUK3Y'!G^B[,Z-B=AS]7"@52H7:6PM4+L>":Z8J'>:T!4=K-5BMB+L!
ME3548S !QJ66N#M&'IC-T#"$MF!%K>RZW*.C7'8%;\ST]N:F/?DJ5-Q(_<%L
MF@E(,KR)UNX,A@-A:$+[[0W\?N2K;0^AE%0A>_$H<CD7/#@OD?.IFEGVQ+UU
M2& Q. ^GP7H=5FLD-MB=6+*15!RLM?K(95KP!*7/S]M1^[8WP'-R>CL>#\6M
M4;!7P39M71J3F_:QKUI9UF'Y4=FHAUQR!4?1KHS%T\F97W,8^>1.6/RL.EFQ
M8O$UZRR7I=1+A!%58R02-^"O74F0Q[TBM^+)B"0MD<[FBO*%2]9+/'>&W$PO
MOKR0]QQ%+FVIZR@GWYQX.U];5WWC:M(>7P^ZL!4/C6YV=1^IW'<NP-P^W !>
M+LN"#ZGF^CSMPLD:B_./*Y9@OEDN#ZDC:)N5?-RK9<M< _1O-^\2KQ"$%%8J
ME8]2+XTQN^Y/2ESF)R%%C.][/ENAJZP=>=%H>\5=/U(;XSA\A=2:=9:+L5C$
M("7&_G0VN!%.M=CG!I*\,2:S6 &-H_S'+EC)%8SRPZI)![D &]_>.)U6^<4X
MY,YB1MU5_OI&Q?+;!2Z75]'CDEIP0V-TU9KU)S=EET".>XG5YG^9$VV_OG)!
M2MTLM01Y\I>57:@JWS!W0LF%5?"L5(OEM#&F5HML%ZR]Y4E=(:?-+<MRO(IU
MYH9QU$0W2/GZJ\11MY]<5%(_AKCJ=1;'65/*13HJ<))D6B*8.BT5609 +IMB
M;DM>-B)G^B2"A,/I& H^6S&W^1,^_^:N9 ["FKWDPI(Z+3*AEVY[>GTY-.Y!
M<1<1F)/O+RW",#>=BK62CG@Z<5J"L\BW58CU!2-)1?TWJ2<DS(CO1^LS$SX=
M)4D0H"L6VT]3(!+<A"V6_AF?G\$7PI.MD;^_:7>YL*7^DLG@ZGIV9ER>W4X3
MX_ODWI?=0B]7]BO:Y)(I.$+BF^DGO;Y0!+S*QJH&D/.^I(9%4B3\)(#:A<.K
MQ-*TFUQ8)44G=Q<6/TFQ)-<@?N,N5=BA*K-  BJ75L%SD<DCN&Z/KOJB^D.Z
M&,21'RW5=3:JG/&UX>6R:ERAX[2F\FOJ'CF!\7L3V,'\3<5ZJ@*3RT?JW;AO
M3R9A=+\[&]R):A_'O8RVW)ZYH) %[D94]:C:XLJ!Y *1NC1F$U#@;B=?P_H?
M1[^KA>5KRG>PBC8Y\RN>83CM2L4%T"$>,[&^ ;,#GUKI(C<5JZ%&#ZET_B[U
M*G3:TT$WK'DP&-ZB-Q:KY:2+Y1SW6BG6(JHZ^7?"R:54< =45B\Z+:I"#LQJ
M;?,-I:)ND?'D4-=;LC6F[VTY6ID"TZ2O7(3%JR[I#)B;\=#XVN^']9!:QOVH
M/YE>#\8B$U!<: )!WYY.I[3378A$5$SP[H@=A&8KWE )?ZORNM?L)A>F-+LB
MDJ&HNP :^%U[>!N9O'B397RZ(U@IQQW:N Q4+B]I$D5&7B>U7"JA_C-U3>9A
M59<:0BJ!ELM)ZH7(RJG_1W_2'4S;F%EQ$E4)\Z_0<L5+TEWX([!]4NTVJMM-
M+CQI_D56>%=H H>7J+OP]^UPUCXYE*J*+U:4LZ@)+)=9T55169#QI%D62AW0
M.75=6"OD69K^7@DGEXW4:]'K7_8G>%UVUO[CE/:>$\Q6L;-M_H3A^!V:Q>X.
M<E%)TS!2"N!P:-QCG/XO)S4C7>FT?(<K;Y(*XE-5]=/3YE6S3DNS0BRU5L<G
M:3)#=:65(U\9*2>?2\DWBS]M^8Y^I&[@^7Q%W2K/8*U.<L%)?1:=2;_]I6?<
MIV46^@:[MZ!%W, _3A*,BP-&I\DE=V<NL>B$FI0]BMJ8%>*KT4,N.ZF+(CE]
M+HT)5NSL85VC;G]PA^;429$HDP*80[Y+3']W!F"]3G+I21T6&>EAJ:,)_')*
MZMM;@-*K/'N,(!>MU,?10+2G:ST\5=F]7(6L;)6+J.1ET+C:^TF1+.3-EM9E
MWW&WN%XGN92D:1:5%=M/=XG+<]]3==FEF>TE<'(Q2=T8Q4KN)[ELUTA2J7V3
MKM->N:3DX'(I23T8Z1KO7W,5WD_2JL5^J8[1J*],CA?OI/D<=>1X4BLJY8H/
M68=$4FO@8'R$V\S"UCHUB_<?2"YQ^561W.L,8SP71>AE,!*A%V,XZ F(G[^>
M,?X/QDLF=-YZ%K_XT/[[&X^MUC8HC.%O2Y?.?W\#4\([>__N_;N+]Q\N_AM(
M>_N\LF,0'#J9/$]/3V^?'US[+70Y?__NW8=P N6Y$7TX'@)TG\(H3Q_$&!>?
M/GTZ%U PB*@U!=/E/$8^'L!G/G8?IS[3PN_ M#L_!,DV>6A*,G2A]BO2.L3Q
M#THDS+ZF1.8F["N1VMU^Y: $P])I2G!VM;T2O;WD(VER6^*_W\[)>LV<.8]^
M@;\=AX=3/OX)".>NWW+(BGIK8LJ(8H[GXQ;[IN7!UKPB\;T\21?\ZRSN=X8_
MG5V\/_MP\?;9L[:8-D%BRX9F2,3]]D B/=JOXB_+K_WYN -^]]=&7_2H^7;!
M'V$:L7.<AF?O+@#I\@][59WP'V?;WG41F!/O05 0>&<+0M8[$8B_7]KQG-J^
M%__R0FQPO7H'0D>,M0<^&1E;OGN. YT[W#ES@A5UF5EO=J1[CL*..$L^X>R\
M^/A"9/9#9&\L,I-//!'B;IK/VG3'^(\]Y),=,W!!*3?WP2;=,_GK)?/7<_WF
M4S?N%$Y;^.N%&.R[A(IX[%@_-*S1()1Y8W(U_>_P$D3;]UWV$(A,*2.V'P:.
M>4-7#]1](["/+TSLA&5X\Q+/0=\-\&@$C-EG.#(9MV;B9+>"\%KFFU9XTL-:
M@UG^V>(KPIR!3U<(!AP('CPX40,$O7)YL/[]33@6 Q 933?$PQ*-)K7M+ %E
M#<JQG5*8QL+]/@Y<<TE2EU2SV-<!5$Y-%ZRV+O"WRX>^E<6_O$DYQC.R8FZ'
M<9^:2X?;?+$I3'PYB!X4[)@\.V"4TS!VN14(/]$E,3$<M<GB+VE7COL7AS\M
M^5,6X?R/RK&<)9,W-S.*ORO'-;513]N5>WBJ23G&N+'!'#7%0Y>%]WQS&V$]
M6.4TX<P0#MPY=<LID4(HQQ_Y?$.<8$Y,'TY.9U$M#CF8<DJ^<)LM^ SF/5E3
MZ&X6E3,YB'(*;H@/7\,G14/?R&/5054'4 -JGMF*B"[#83=/0&F;<IRQBNLU
M8-%V+(%B.?8[H933,:$+YOGA-T29*H\X%MA)WV[7%5.J40_E]'W9>#:%XZWJ
MO):T*\=],"Y/A<A2L!-*.1WQF5:E3%<V*\?<F,_AZ+H,7-@[P=X"!N-]&K#6
MW=RI5P=0.35#\I \2)+;I\I:E./;MA[1JSXFFR+&%6W*<<X7B38<FM./) #:
M83][XG+LTP#Z8;^$#64'_AD0[2B0(Z\/WC -QFA%.CY9T)V3J#:T<KJF[+D!
M7;6AE=/51[U-X%J+L/K@RBF[IBN^H,[F&>S0+!&E+<KQ':Q6@<"J8#N4MBC'
M-R?\"I5N)Y1R.L8N>P3;>&P34[1,82#39>*>>P51S;HHIU"V&U7%1!IU44YA
MUZ46\X?,214BS<U#&81R_$?<N9V&E1^YFT6\O$DOC$O4*TF[7K@7U/+*5KWP
M+AS-E:UZX7W) ]D,SS0KQ[QRDF@Y/RJGAI:S I")7GRLP%H&H!Q[<<N/VS:U
MPNP-8SZG(L9!;.I5ZT)-^JBGD3BX(IG_YX*ZQ+:$+RM'DA1$.073)7=]?&(-
M]9;"(JYLU0OO$O.RLEDWS(N*@0Q .?;E_O,H,X+E YRUH973%3JE2SW5&F%Y
M0]R-31QK&X%)L;7+W77T[$ ^+MBPEW(ZR^>-,1]S'_Z?$1LSNK"D WP&MJ4>
M(P_4KS?YZ@^BG L]NB:N'SZ)/B17<,1C$E)X>Y2Z@+!+15X2MCK$WGATVYAE
MQ4%&4LZ/@6,%GH\A^EBT> EL>PEZ[.(S0:N\9M>LDW(J\5:PR\+WS%+SM@:I
M>_543F]46^#2Y2M1,[&PBJN:E6.^_];T8^Y'5ZOU-AG2F+?9&A.8O$MA>'1M
MYN!%UQDN-=!:B'\/"'?HF+KX%A]>T+P"G88X&]B/.]1>L" W?5]O>.6<Z]&$
M+'G%AOPT:=I-.:4QG@:<)>(%1I]Y^-1$^%X+8'_/ \>ZI@3DN2@_KYMU54[Q
MP',)M0.O R<F=B9V\<C)Z;](1XF>=I"1E//C"P>9,4'*OHQXV1#*.=!AKC6E
M)LE[-TI^5XZKT1GD;)[4#\JQP\R5S.V'PM4.*81R_&?4OB;>$BL%WE +SZ]X
M%@^<N4M@8@=FE ,5I_X"_K-E[F1\^3#*.6$XLR7M$9\:\P$FUT;U+\=X*620
M/=P'SG4 !_DT>/@76"5YD_SEX^C-"R8CH@$OZHVC.2^D1#29&75'TI4? \\+
M,(</U&*GO5Z[_)'8H!C?$/<;Q:>0C3ETNV2NYT<J=&>#/UBD%H]>/KIROMTO
MJ7//7=MZ8A8=45]$#$#Z(;[>-7FD$TJPB Q@WE[A;6)C#E;6)7ND_Z0NOP$*
MT">"H=B0U!E8TEGNO?(WE/,PR?J!-0,*N"DN<\!B&>?3;>H *J=&2 =8CI&Q
M0ERCO$TYSN4Z;I=[1:_(;D#EU&!65D6@K[Q).<:=Q8@NZ&/B* \?G(<MT6;A
M;7BOL\C9*LVZ**<P^SIQ5116"J.<AND:*WVYU$I6046*UFXXY;0 KX/5 R/Y
M5Z(+$I%#*:<CCC%AHA^S&/Q5'H,J:5>.>WLP%I[&G&69_U4YGEUBLSEW'49N
M'5 I7(_YFW]PYO@[UL$>_32@E;J!)[UW*@=13D'_&8M<PPP*;.+>48^9=DX+
MD4*HQ_^N79Q*^1^58SEC8+O0J[ 63"$OO+)5.=X=EQ.+.F(9WD$+>F_*5V\M
M2.7TU"!$<PJ^,(>Z_R)KLL&4B)Q#NKQ-.<[3SO749!1,]^+V6-&F'.?9L-V9
MYI9IYB?E&'8"WZ?NW-YT&/<B%DZ)F[LCLQ-*.1U?F.70#4:5_W'7SD_HLB;E
M&-]0=U%Y][FJ43G6\5.JCG6/KQD44A@D[<IQ%Z]H>[=@*85W6#SA$$S=9QGQ
M0O9"PS[*:9P]<72_&0Z=8C))F%H,>R)F73SB':6<2=\ 7CEM5S9_(+:02 ;#
M+0V%W-AF7913F']/-7Y+O'R12<"44U*!N8:8PASX"I9AVPGMQ8(U+VE7CKM(
MF(8UB]D3GD]LN^2NVPX8Y33D)_.(.S6G?2FD<GJB!ZSIV&4F+=PRJ&S5"^_B
M5>^J5LWP+EXQD+3KA7OQ+EQULV:8P\XHPSS=K!?F4_8L03S=JAG>J*S),,^T
MZX6[J!HAP3W;KA?N(R;=T#/->F$^D\Z7F;ZSQ=XQU7, >F$_>Z*V=&_, 6B&
M_9*Y/I5/G#R(7A3@H;F#@@*(9A2P^2X"<A!ZX0]GZ [\\Q":X8^[RRX*"C!Z
MT2!.5#D)!1"]*,"#=0<%!1"]*("-WLF76Y<!*,>^TLF$>5CB$B4O5+MLU$4Y
MA:DBYZ&?,)_&4=6L'/-:):=RPFG81SF-U7X@/?T^> BXQ,:7&0/;+T9&).W*
M<<_',V"]1M,E++=2EJ75H(=R^J:!B>\ 7!;*3Q1_5XYK7.!&O/W)1-S))_GK
M$+N E%-Q36WKUO&9C3X40&[I53K8ZX'J0]&N@$$=0.74B)3\[I*#XC& P]J-
M;V%B>6KB%!_GJ0]/'K *O.G'M*FG=;OE%O:P_._*<;V#98VOTD[9PF'. N^O
M9)&6 6B!O5C"]L: *?\A7,Y% B0PRFF88OV0Y!S;;K%>Z49<&UI;NAJ1I1U5
MT1J&E5!=9JT20#GVLR<^6_( 7\H(S3],2."%7PLI&XTZJ:<RN@'VQ7V*\BY2
M-\3$?;L9>>X0+[?3->^FG-+;]8QOT>V$J&:IDH-H0P'&26.62^F0 2JG)IH@
M[0?^2&M1U:2#<NJF//"7HGZ$<Y\GI*)-.<YC3(PVYEWBTO)WPF0 RK%'E]#V
M#;8J3\M.*.5TI-/3L6264WBX1@JA'/]N $K)BKJY3-_BS]I@VBG'M*,?IEVA
MZU$+I;XIQ[H<1!L*>N58]_3!M,.)&Y5NR:V[TA;E^!:OGQ6N'\E!E%,PX@Y]
MIF: "< 5T0LYB'(*VJ8)7[;B,FAMQQ+UL,=D@WAY7?%*NQ\34QMZ)UT,LT81
M-&QZ(#:6S_C]C2G>4(BI#1M7P$*?N)M#D)MYR,LS'* HK#(APDL)G3O!="5P
M0BW0"XAPH#MF5 P<S%3A7@.CVYCWF(>_,P<$:0#&T?2*JR+LVUU7AD19^B/J
M#X"@%59H\3QN,CQI0C<CHU[F7D8-X ;+]OM2&Z(]Y)Z'Y3Z[H:"P_DPL*;S)
M9@<6_#3FK@C2^;[+'@(?Z1')SR523_CS>L/_ !RE@NC2^0\3QIB#E5?D4[U.
MVE(OMG><^2Y=PI8/9UA(&JAJ%"Q:P!^?TPR]>&WK7T$8HNL%(&NL$&/,M]4*
MDG#^08?4EG,E%,8"W^XWNX!^1.KVV0'*=I(:/#K@IXZ%TZ4[T6OQNO)CVG)[
MZG/S&Q9SHU9/O"<_%DC=$3N@0CE /YY0!8!' L,963%W'+@F5LE+O#*)0G&X
M\7XTGH5W7)L0&?;8P;H7#-O8V HA/-'_$*I$4B0P1"EUG3E1'*0@VDX!"=I9
MH=8!5"TF,?$>"G.+3_$9>KI@9J:Z5W:^-NJFK3@;DE*R;O?HK%KL\=2$*7G#
M+3:/BL\9\WB"BK+X#H4&)A+NHGO[EY2@.SMS?5^\.Y2?\X<<6-NIL]78O1EO
M6_ ID= S)LP:.%VR9CX6D 4BB"C+?\_\9;GN<+5>;[TQ!QU36]Z5'VJ&0S/N
MB0J _:FRZ,-W)VKVQ.5$A0"Z$@7*L(O&:H^&_S]P^O,Y-4%3[C^#\N$L:(_A
MPWNBI(WAB/EGACEMG1##M$OE $/IRBBP'KJ""&_@1!: LQ@BG0D#Y"#:+M:B
MW-JF"=MUI7.\6N"[.^HJWB(M!=HRGO0J?_L!QM&517$,X9*[VQSV9#)4MFH[
M[R=T'<E@CD_+>(&[$1K?-H)0V:XM3>%3;33<=$0Y<L#*WV!)'Q]6(Y8O6J>M
M^@;PVM(\P:MY?!Z H>QY%)10$[!V\16H^-R!.;D%&C+R$#TYF4CZ)2-HRY?8
M?2 1:^@*0T*C7<B+MNID5;]L#&UY(R3LL=!Z$6>4D'Q&X*#$P1?%DD]FRA[]
MM.7!UH.1QGB .<P.3>R/#,5?N,T6/&\.[C. MEQ!3Z_-/:Q+ND4<YON$<G=!
M'/9G&,Z)+G'$K&C:Z^670"*?@8_^Q,,NB +:,_KL=^S4R5@7>-^<$#\>XZ#R
M%!Z':L'EFK634/@"=%X4A5_UXGGV^0#'RA>ME\BC05?M9)5U#!8QQW??5RL6
M>8+R,MV[MUZRCYX-)G9L#H)]7"UN.;1V$BY#MR#(74 ZR$LH,2F+;0PGM+DI
MD+(;3 =B+@/'#%VJ80*?N:D@IPZ@#@3MRF*K(*]Y-QV(3:QL$0BI(&T7D Z$
M2&(@'7->05C33CH0.J%8,]C>A,'MR/[# +?+'?AG6$C#&W'_*VSF%E]C3GS5
MC#W 2#JP9(IOO@6V>#_/"?#Q];5+S?!UO0GQ8<I&AG3:AIZ)W),\3PXSE%Y,
M@1T(S&0, (:NEEN/S@-[R.!@V<6$)EWU(AJT'+( _6T1A4NC=^RC6R(S7IY=
MM(L?!QI5+U95NIDZFRO*%RY9+_%YP2$WHSP9.8]>.IP.S(F=LT,*TYY&H;+I
MDE)_JSU73);]NNI!-&(L\(_=K9L;/ SA_ZMH;=!#!Q*WLS3O?RZ?G,797;N?
M7N0FV2*@@C^"=(J$E4#H14)6"RT24&C7"_T.H/?-XD_;4\,;4S>^"%@D9R>\
M7N05[.Y=Q\3N#GH1F+I?RE -I![%BH+"]>Z!6FQA:WJ[W\F! XRH XO&6(\0
M],0%D&0$/M[3PDSO^-F6W"6@VM#UKX1%E %9ZW#P0_CF(RT/C/D5PW2Q*"@G
MRF(F/OD=0+IF%:32W?#)XH%CHD/&VIK[5<W:1I P"685B.74$Q9]^M)IL477
MZX:I](=TJE88)G&L?#)0?7!=9V)X2V1&GOO/!)<0#C!DWZC-EIQ;QOS6F9-'
M[B+N4^K[8?=H"\E>E]M[C.9;Z$$W&J$\=VWB>4EN+]H)41'4C%$A@U+MF\>-
M D^T^%ETP&[-/6*+09+;/Z7F<?H%=1':+'M:/:Y<,J*)W+_O)W5=00VH%O&$
M6-M*18/V[?\SL"1.&4VTT7 W206/]F%4K5%U95_VFG;#&\L_]'UEP''L\CGS
MBY2D;WSFJ6_>35L.-)CDL&G"X6%B;0/B+?=8)84!]M;*M-E.1#JQAW$5]IA.
MZ7O9$#\^7[P>!5#F[W/JI/O^^)S(WE'(.Q-?<M94#?CC\RS]9$/B,\E:0@<;
M35?+L &!-:L4'73$GX!MTR5W\47Q56P^1_6HHG@&$S$=[BQF,<@>C-SG&S\!
M:RNH1$9D+D/LP=$&0_^<C*RX%W?H07\"YF%:5DCJRWDF&^LG8)78>W+74O;O
M_E,PY##;U8^V-U7F<F"F,.A/J&X:\]N\_MJ\FZ9::B?PF$,]K\M7#Y%K&4PS
MOG#8G]0:6 #+YHPDZ5'Q)3:1.I]<6(.V8$6M2\)<4;J'1^5+PKR[)!?QNWSJ
M"/B,WH1857T-YN;&/P*.EKMZ7O4+1\#5$LN]9"O]KE\\ JY?<6X] 9VOP=_4
MV$? R>QL>OWYJK&:=-#C);0KT@W9NMFO<J;5^.@Q,!\MER23]348G?^ KDQ-
M-,AMOE:YVEH'4&TJURC <OEQS< HFC!P^I[I\J?(DYF$\NK!JJXV5S(C,6>0
M69&9*3*XYC2=U-6LB[8!RE#Y9M:,XP:%G\*$R?!!N&TAVAU VE(73CM\K#.>
M<TG6:%F+ZFFXK::'',],IR3]3@JBK2 FU I$ N0@NTIR/K'=8+HF><0&%T80
MG:@R>GB[,]G&MT36 56<1I="<BP^VJ.%)+H=,*I3Z"Z9 R!XM\[*7[MKK[!L
M=ECL(]+(\!5??%^17T*'U.7W%PRAJ<V2QKQP(S'99W8 Z;H.>_0!] N80X&H
MZQ15]T'))-YE&<2><W:!W0^._83BLT(L#%^6HY\'V1/_^->#DY JEHO)U4Q6
M6K><PH8C:'L"CEUZ Z-M4+?/G.AE#9KN'-F"R?UGYJ$S(5\U?2>4KC9:^BJ-
MJ$[C>6DY5;4J/JDKETO$\?XS?(KE;MHT[;2GQ1F^X'20HSP)[V&:>NI\SO^N
MZ\&4ST-,3Z=.8"VH>-0J=;&K20>U#H%>K+6G;P^D,_\+.?(-.N@JS^2ND!=E
M;:7E R-Y'JKVQ:M%.\$5;R>[2Y;!AKZ],E(+^#M7OK+\SQ9;X;,YH4;S(G)[
MXFW'V@3'X"\G^>#O9(.&&#FJ2FRYRE;55MR$;XCM;XSYB/IBB908U%(0Q>MI
M&CS88I+@]15:AKX40OEN$!?I"UT4F3*IVT4A!VIZ.AW8JR9%K^Q-O"8=%-.6
M.,RPEA*<IN%**/,Y[813/-.VCLW+P+&\T+U<]'IF&S6UDPIG>UQPHLR6R ,H
MED.4B7/)W>2RW318K[GKS_C,#3QLF?J!E:R6)AWTM<XKB>B&M]W9(VVO,%K5
MF N[!_@!N9(CHA?0/EB0FRE[ON&.O\R_J+#?"-KRI:!P1'74QR[';;:.BB+K
MH<<.8,Q!&;E=@YIK+AEL3^%O?6(N)W2!,YJ[FQMF8Q!P^R;2GGUU-?(N W0K
M)ICFLR"KFW5U<54K"/MH!*_J58AKUPR<?W#F^'?0F'(25[:J13KW.%QTT<N:
M\3(:Z@)KNP_6(B"6%&J>C2C/=52\*Z;J1@^<Y!WZM")G/#G4]99LO9VC3;JH
MG;CE[[ZUT1F\$*"=S18DVNC:3\2U1GAE5@1!HXI3L5/92U6CNJ>8&TNM-D@=
M""]U22O%0+%_^Q5H%TY&:BGB?+VO[[ND-69[_WG-HGOVBEA?'X.?D/VI%8_7
MI$*"D<@P$?'[[#457U;L*OJ>-*O?[QOAHWCWS[S,)P9-O/)E+8KG48Z7@H?9
M--_2EPB;=U,LE88(Q[4JK3T)3O=7O3%GDP 0E9*(T2X@U8$C ]_IQ4JHN>!S
MR>^ZNA^V3VUCH%S^',J,(\1*<#]T-&Z=YR\<15?VC/#1PKA0VHR/"5ZYZ88U
M.Y,+"'(8;4WKO4]'\3]W5.1<A5FY%R6+]_6&5[WL]Z8LU"E"RP7L]9 X\5</
MK/;D6LZ+.5C_.S_?Y"RE?6NPA'^_#H=+OJ(^63:,**?0S:RLDE2!^O"JTQY>
M*+PN3F3;#NW8P8%G1M7@JN__O I=KVJ+O>##JI7<PVXOF85XR .WZ==^KO,W
M0^AWX*4>I\(+Z6L_$B9HN.3N528U_U5&5NR/2!Z-".V5,#\K7A!)8F9B#-6%
MUC6"FSPK%)5]2CN],(FSVE*OV47U!B*J\B?/)QFN0#F[9),P8BU0U:=Z#2SK
MG-$O'T;UB5N#@H*9U;"/MB93@F3L_-M6O#"<Q/I+$DOJ0NNZ2Z7C^,FNFJYB
M 0=(^@@""7/W6]MV*;$VV&#C]9:8'0<;3?56$/M_4>>@5O;AM8HVQ:=K828:
M3J0PX0Q,S<M>@/M_^J+M?EVU7<&Q?+:YR/'23&[! X5QV8^\5&OW4CU%>S0L
M6C(CS^%%]["F9N9R^ X83;.RR[$N5"?:#:;KIIMZF@N01X=W%X[-S9R[J,(G
ME^Z2':<!_ ]&\F5( K6R^F)M:/4V8%0;*77_4Y3!\EAXOGWA-EOP%%VU@'4-
MY)3@'VV7GH3$%,B/0QA>(*2%92@%TO9$[#^;2W0<8()FCV%8E<)G05LO4A33
MVJR+MI1W,7)*3/^>^<OX!=GDA(@G9BK9M1:PKI-8BO^$$CLJ$^/5(CC7X<<4
M<<4TKL6 ZK[:\B*VMS&.'M.8^TU;W %#5VBG R=ED*1<8LG%I%1QR1N1F$.M
MME]P2!QP/%T7?)P,$F7(&$XN7=_;\F(WH*Y$@M)'V2)ZK,/<I-[H]:X(<X;B
M4B9N5:G2G(VZZ$KXC/O$+CP6GF0<5K7J2D[^U=)#O7[Z$SUIFGLU,YG.A9]U
M)2!VHABN!3B[FVWQSKR;I11"N4LEH/B*9?9Y^NV+-Q>)YV$WG*:NE6W%!*^S
M0<0WV2HQY:T:EX6)'[6;H*:6*7E3UJ(Q(2)CZ"$?\4T?76GBZD)K3' L'\.A
M-S1]YZ.L07E1GN2M]0ZP\QO-5E>J:-28^;4MOS:8_+WLA=#&'77U2::73FH+
M3/^FZT$;ER'!8R@60W)#O+Q-5U*BTH!E*@_5WVK=AHO* T58-B/2/;=I_DVZ
MJ-:)+IGK@5[M,*S@"CS+[M65K<HW;'%"AD'G,&P9Q@Q"?3.5GAOG7EB9H[5A
MQ^\GI-_./7-)5P3^^?\!4$L#!!0    ( /QA:5+7MGQ1HAX  +Q\ 0 5
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M5ZYA.)\T/LJ6!I58Y423(,H*X%2)=Z@A=JNH64X40*7C!6A-KFJ&F=^I&ZO
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M!%3LF;)7*2]MS3&PLF++W1:"&VR1<]L="%QJ=H4Z2?9R;"DL#D;T7\YJ@PT
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MW2WZO#7;(7/[UP1,:I8%*C8O;9(P=8;T_M'GB8Z#&^H9V2S?F!X"+_?(HJP
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MB6M]:8Z3HEYSML91,2YWSU>[#V,(RI7Z7#+Z6/$/&FOV90DMN[N/%/1;#P&
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M@G22]XN%2TZM](Q7>OIR#R4S>DQ419B=ZKI@EW6#7K5R=(@1^*>-?^Z_2*V
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M=*R+@HYGOI7UW!2<"\G!Z![;<26>)/W,+I>A9W>01P1*LR6<N WH8\'\$O'
M.5+:=_0&OAIVP> .R?X9'J=2)EL#=2CEVW5WCX^ /LC\A-ZJ()U34 M4/\0H
MYC,.<#_/:QL/H2_BI3@!$57K?X*>(]"7VT,4CA8S\QD&DZ>W]CAR,P%"F/$Y
M_?WU$7_DZW_6\NS=#%:W+OX)Y%'X*/#@G8S42H>J[,5^;D'*?-(_T:04NYRN
M] =CVIWTQ[/^:-@:W;8Z#]/^T)A.J\POP*I@F$_UYV.JI_V[8?^VWVT/9ZUV
MMSMZ&,[ZP[O6>#3H=_M&E=3GEKG+I_K+B:S[T^Z(4OI@]%JCL3%I4[%72"RK
MB%@NS3=OCFEN=__[H3_MQ_K1'O9:$X/LT>UA_W^JIAVN-Y5/^<TQY>,)%?'L
MC[^VQ@.B)].8?(-P,[XWAK,**6<4"\HG_>TQZ?WAK#V\ZW<&1JL]G1HI[7>C
M4>][?S"H-)U-_N'DD-YWQ_02K?Y&1!T3/!BUAU5.0 9=[X_IJIR6N,)$/C$?
M3H@QVM-*EZ9,/8E\DCZ>XG9_WY_1Z5 M707%(O*I/=FJNJ/!H-T9):MF/"/(
M:F\,IV22W$T,HVHVX((+^?2?;%I],DFFB;3)O^G,'G7[[9DQ_6MK:%2Y(#&2
M]]R<;%)TA9S]4:D<C[/GYU+V]F0KZ@^)OAJM7P>CZ?0O+;*VMZ9?VQ.CTE1(
MN;FS\^D]V8"FLU'W]U<=,NM[=*:-B:I6O6G&F9SSR3O99&;M?U:Z'&U3MN:3
M<[*'3(QO!C&,JEV(@A!*Q1K;1WE_V(9^0_/\[<FNTQU-9]26GAA3HSWI?HV7
MJAYA;S"*38_4C@+^.#4FW\BR5OFB<)+1%63P9">[[0_;0[)T#5K&/ZE65T_L
M83K0;.+3?))/=KJ),2 K;:\U;A,SQ9BV9A-B&;2[=#HJ.^LPSSQO3[:_@C-/
MZ]?M>)4FAV,Q%">& M@1/<*U?DU&JY*9W+,<BPG.$UT=M+..=@P6W@D>\.I@
M!3[IL1@1/._5P0CCX,?B1/#X5P<GQ^= %OG%I\$Z*"XD,_]P6 MI\2F111MP
M5JQ'9Z%3#8O@D_V5?;:I@Y'DD,,B^F1'38XZ]4CY^,S#(C3GY)A[\JF#<N (
MQ"+_9)>$#D)[^A5F%P1+GQG3T3A3_FQ0G"6VS%@J [DXZK\=$5Z4;[;TB-ID
MIBVO#\=Q8F=*MQDY;KEYZ\3F'3OS;:G!U.7#/1=@?#[SH*IHK!1Q6<FB)*[<
M(ZC)NGL.6"*PG\I*O_2\M8&M<Q+?^A6BFFR_0(#;<?'++9%PWDK:K:"7LJRQ
MHE,.B[$$+LJ2GR@>TS+$7CE<3CLJRP,K$1J *W 959QZK80U01:H#B'I3[D&
M^79496E-55K@!\Q#JJ)VP\W4)=XE+AF;F_@2ZZ?IVT5EKV,C5$AW9'SG@K1)
MFCCTM-[S&,VZ?O(JDI^C4V)C7Z0>E1 !N(TIU9V]'"#VVO0YQS*)^^EL\J<2
MAR))_E#CM:H*>8"'B^8L3UZR++<?'WU$+S;(+R?.<A4&,;N5KEYE/MUX-:Q'
M0I!B9I(;U/IT((ZZ8MR(O#^Y=(]CK^JXOMD&8;&H.[E)WX9BU7/3?%Y,%HNQ
MDXMUB9%9=<@F+T2+Q>_)33P0J%6/XD$16RP.3B[I67%;M80(Y3VM 8O0'_!R
M<JD//+5I_9J.U]H-*/%"-/##S-Y*?CK>5\FO8K.-QG(A^S:BSVF)GNV>0,5
M.MYRAL<^?D+VR'%I7(L9T*GI/[$O1LG@LL;6PN3H4<U"Z4ODD&Z009G;4:YA
MU%^)2D2OP%H0D&LS[D4SR]\FN_AU-MF_L*]#1<;0X!94!,/C$E&BPM+-9Y*E
ML^BZ*Z^MFEO,$G*'@=/\FO(\A'2^>JP Q5KO%N_-@#X:MY +%Z&D#4_:*:H+
MRE!Z7$"M[,4+D&B7++A=\N$N'H0V4Z8Y+55=_?&)%2)8TUN]&?G :)%QO;%W
M?*!YHS=WI@AT\U]GG:3$EAUBS]S_)KNX%E9<%1U(C07 !@>?QY*FEH JC'6V
M(2K4@UIMB2FR(M^A'J>3RAW,?;"PGR);H^R<PX*LR5Z- 7CR:ZHPD6%U457^
M6 (JA6R!,T;M!KEU@6:?'S)-&K!#HXV: C'H=F>:1R[])U&[HK,P1U<UIDL1
M!,6 Y4I .W.E2NQT-DDDXUNK&1*O[AT'A\A:>=C%RTU1G7E&#U6['/^4.=[7
M&'R "$AV@8RIZ\4+S259YC,E?P_SXT.Y=_DZSS_7C$MEUS&"/$,8RDZJNR1F
MT=(,T1"O'9H+-+66QKYCY=VRQ;EC67TN"[!B5O6\*B&\6@C9 2U=L:LVY"=%
M+ X359UN:,5]+P=C,9;K.L#M#S<T<(>L[9'OYU86C#>#_-:7@U$1DWJ>!A*U
MN4?A"MO[] _[L+_=3@!/1.XA+@?K4IQ#"J!E*? JZJ1=&OQ"C$/H:U!YJ:ZR
M:B\$?X!S2 '4%G#:'NRZ>/V#6([)SD4.[?8V QK=T1:([F(WQ<X%GE$N3@V$
MF8<T06VQ<)HQ. W*'YL^,2MI[OID,3O.S7JJ !R=+PYW7IXAN"57DVI;5K2.
MXKB)7EP:)Z]*8GQ8/&EX.= P^(-@D%P3:H(>DT=4HT7L*;'P^M'T-G%*.L+$
MV-P<A+P?8</9^[( $V$:]&.H=<SGGLP78]]Y(FHX=DT+9?W;G,Z,D_Z7 [LX
MVR#P&0]6O35B=E>';<^+3+>',D_7:-K$;2K3;!+3]'7'CIV#1R(GB12GW:]&
M[V%@T!<B[>'PH3UH]8SQQ*#9%.G#D4F25'&;[/0XR6GZ,949]0[2N68%<:(9
MN7.BL*\6#T% 0KG?@!2-H/[YAP F^6<E06DUXV4'R$MG0Z.HV-$07)TUB(S@
M!.QD9>>5C(:7$@"_Y,M%U^Q<G=4$28A P@GFJ42T"YFH&DV=PR8J1;S6( I"
MCQW%]RJWIN6XL=>=$4$!-5<4N2DR?S ?%WHNG3O&BL*ECQJJ>F=2 A@& ^ *
MJ!:4T6+A6(@;FMSFJI*1E <(9@.\AY,*$]=;^PD-% :L1/+WS)\;9P<>DB\[
M).%,D8-S8$NUHI<XN4+#^:358V])EZF6]A*_W*NQ>LJ+_I[(;1VM6<(_:%*W
M!01H+8:ITV>IN#>?"V6;;5)[#N-BX9Z0!]J-:I^2@'O+0X 6D3MP%@P_&D?G
M^2?-[)<B?QDO3Q">;Y1[Q7,*8,U6R/&W##PAIC/\M.1=QAF>7Q1K]M7H3UH/
M4^/V8= :]+\96KC TSAY^Y:*&%&^[6/1G"A#SOM2H5&T<(LS2.5VC!>/H8UK
MO S.H).<5W;-<),SN.EL[LU_8;_KFD' =I<+#:+!<8D;0ER>33V]0 P6]@P,
MS76A^U5X(#6.]3*0<8/.DIAVSG95R&MYJ%2E'34>4<6##*,@Q&OD)Y$CV*-A
M\H6Y-1B=%#GTR\Y7+,*7[,4=N%KYW<,_5_@G\S[EH(VJ4CUG"CV?#U#(DJ4\
MV[V!93_]/6JFZF)$@JQS6='TB@1FE\?_P--;U06*A%,)-WO:^2)8]>GY\C:+
M5ZJO,G^SL%X/T<\,YS[VR#^3F,I@Y'=7U'?8][(M',]R'EW$X9"0,+32=T]F
MB'A"]([::>-MD(;LR9NF/,$TP\W0MO\5I>7+;['/D!#;T2 XC#I70SY4^!QF
M]'0HI!GI;!SGWB\Z+N2W5N,:*"?^W*29N=QKYP$X'RJ=S_)5P:GSD7W/XI3F
M@3%].WAXM,G20XXX7V[>%B;&Y.FN*JT1<VKADGR .*I=1.\PMG\ZKMM?/YJ.
M']]!XH"Q#>:WGW]0@U15]@Z#2X[CC(KI2 ]>>VH)Z^3@P[)F<MM?&HP,+FMR
MH_4]<NY$,_/9>#;7Z3/P@?,G<IT54;'1XL%;F$_8IZ;:%(5ALN.D&4( 9] Y
M0UX,P%($ 1I+:FTE'YE!Y&_B)^1)U@B&J73:^&(P+F 1W%#ESN !^3J*'9NQ
MTXB*D+I^THI?P!QE=[H8A#A9A9!2F^(HLWS$I?/2'+_P7 ,Z7 R:'&Q"2'Y0
MY<O=)VJF#](IHQ&R1X]ICI6V9W=,ESX?GZX0"@-F:-D75FA9KS_MCJA3]\'H
MM>B[ZN2I-8TOZ[0'[6'7:$V_&C3DK(+@,KZP5.R'2W.)XOP((V^"3-<(J"^(
MY;6EP: <_:XNV7*E\?@QT=??RJ5\.WKO$%[ZYN.*[ 0N_(*%T5Q3ORF;Z%K\
MHWQ )-J8)1$,JJ$\P<WK?^-2+&#,0W@]+M!:T=#2^2D+L>J\G,%6 @&R?EOB
MI]>Q+>1O$N#2'XYQ2W\]?YCF@)3^\6%:NVN22^=Q'I65.![/$FW'@$7;,6J/
MB2@AVI1*\&"CUJ=+K-A'')CNG8\C:LZ[$<W3GFLAI\7?8;M*?*SYQ_KQ*VUH
ME61/3R>P #,T#W4P6E _=S#%;EYZ;G$)'0]ZJ9J0RV=-#F7Z[=&"9E(C'UFU
M/0&R[1[18!?'[\7(R7@_1O8/4^0_.18*A@CR/]=(03,42(50]'1=9Y/=$?K;
M:R)+YS\[G^ )ZPS'MO!0S="5L[B3[?&N?=>Y0Q[Y%\T&V;;7!)@@3((A4T^C
ME$VHX!O-4A.Y;,OVPP-;E #5(UH .R412GY;=KAF('TVAQPN>;T7A?0?WC*Y
M>&"'GYPW;C-40AZKD&Z4+2X@8<)O*;UU/-,C.Z";D+Q5:=CLE/N19FA"17Q#
M:J&VTD N2WN%ILF@<YMTT +[:'=KR5P[9'R@&:I3 <^0VI2M6%"AVM#;Z\4"
M62%P,2RH)$7#-5\EN#B$%$!RK00.]20KV6B1/]GWD6%<(S0#NC),L>Z,=9NO
MM%" 0Z^C;K%/.;PC$ASMG"CGK?!"8S=#'>2R"RJ*\EN,_'7J("R)SH4LRY1=
MRO:>Y1)KO> 7FJ\T99D&54>Q'U)\8C!VE/*SK5F;C"0^09V0')A+/DJH(KIZ
MNB62(Q"OJ2 X2C.0+,L8")W:2%V1JSDSH#<G]']H;L0GTZ7QL')N-W.';H9"
M2.46U)*R+L?SW4H3%(2^8X4H)OA\#]+A>,W ^'P606#5%B,58"H-=P^&.$0T
MM6@LO0FR$%'@'R[*]RZ*3X[BSS1#92KC'-0DY2Y&7D;'/GHT'9NP&%^Y)#EQ
MI"A/[LB7JB\PLZ"*2"Z *G*'ZIM$M??:?/X^<CQB,V"6P20(;UEG8>TK0-][
M(B8/]C>,"M>EAFN&$IS-(1BB)+D(E "%00^1ID[N0BZH]+NAFH'F6=R!2"IW
M$/)O0T#>?$D[.C!Z,W1#-L.@NBAW"O*O9(>Y$"5M (>#7JIRY/()ZH1DIV"9
M:(GX!?O$6:Y"O(@"&/*RT1BYXS<#??DL@XK0&!?C-C>0'+-P-UHS%.)<!D'X
MFQ.N*-D=\ *< +Q'_[=J_8P)A7$ #"]GL :4&*Q1\)?E#\2^,9[!K0MT;&[8
M*2G*C]DH33B335 AE(<5"G#EDY\'COF#EF-V6/FZSAKV@M4BCU-0,R3'&PI0
M:JP?7;Q!\=5'7)\#V:DN2S@P, 9O!O*2^87PEUU%7D13[2>:38J0F>39VJYH
MHT7L!#]?!PH^<)%ZP,,SJ N2GU<+D#U=$<&$R%_'@J&Q$I'OTYKB9ACY\2HV
M6@RPMYQMFYRO'<*?O$A]*2<%4(,:XY6,CU&RK8SC09NA,9+X!'5"G5<2T&6J
M[LFK+A3[UB0L)KQ?:H9&5,D\J";J'D[GT'_H?*U&08Z^\5)4(X]M4"G414$.
ML6<EQ$O7!7#HBU0!-K<@\NJ>5<>2@!U2@NQG1[M(?$\8!"%MC%>RAQ:(:*P]
M,Y]EFXCY0S=#,:1R"VJ)NI#%BFS#EV,(EK#ZU$8P9I12TE55V1&;H0\RF(14
M(2]3Z3D3'XRK&J(X-1P-J!@M'@IB5 1':0:,91D#H5,;NTC?W,1O*FUD=S:$
M9+N_CYYI6Z'S%*MJ?G F/)7/&K89BB"-4U SU#H$\QBCD=6!?,W@'K;QFB'&
M*:@9:A,MYC&69GJ2K1G<PS9>,\0X!34CXPE45P#'7"Y]M$S<W8LT775ZL3K#
M4)P_7!'GPYN"BCCMN[N)<9=4PB&_F1C?C.&#0?YWT)X9O=9L!)3-45<D9X(<
MC_ 27S?Z:.U$:UJQM;_]71>O'TV/J$!G0_3$CJQM8O@3S3HLW"!AV&N)G7(E
M=J0AVO */"EW(S_-% T7W\EOJ6_='19G.I3<2>FC%]';+-VL(B^,YO67W&'*
M]@0"F$4MJNW( D+7:COG@E5-H1VH3@%R74()^7B0D\8>+ \>Y]+GZ#JOW^PL
MG@18G ?9RQB Q@Q9JQG9$(,%\KDP@#O,\V:V3J(O(!U<L&07ZB :<&]ZT<*T
MZ$6RM^36?48O%;61A/6^B'Y-77("3N$JJB9]J1_9JFSGDMQ#>O%&T=D:N!Z,
M#ZY#TZ<_/^T-UH.3\\WQR1FH'[L]![=VX]5](HZ9C(@18M]&9,;2##[437+K
MXI]![#L@R,TP]9H0(3BTOL2=&= :-?X3"@J.Q;+&5GDVWOM7J&(A.\V/2:\@
M@CW"0='166P8+4[6<C7C^'A=1JY*3M_"*K-[RN"'F]@.(5LA=;5U-MF_ .?S
M=!"1,=2=W$MAB$LS6LN1_RRXP>-F#K>*#OWEY0X#5Z\OH&:$M/0&5(=BK4Z"
M>S.@8?D6/32P3D4G[>H^_A<K/2Z@MJ:#?N;;TS:O3+<M:R]J7%:L!P2#RJIV
M7YB1#XP6;6+6>\MX.K-W?*!YHS=WI@ATJUV9(9.Z.H;8,_>_R2ZNX*S:9D80
M'4B-!< &!Y_'DJ:6@"J,=;8A*M2#6FV)*;+2]SKCR+=69H#:2Q_%E#'WP<)^
MBFR-LG,."[(F>S6&0EOISNV%YI(HVR@*@]#TJ%.0AG"&FSY16;*7P!&M7)WG
M'^IWH5;C)!'DF<-Q*@/"=AI>A(9X[7BFNU6JL>]8T*LC9I_+ JR853T=&/$U
M);+C&B']((BHZW_D3TUJ^R7:!N^#Q7TO!V,QEFM:5B?H,4F;,5K$:X(5W]EL
MMID1"I+3</:^' Q%F0:-%U7AGM%Z;?H;8J_%+QS:%E$X']'T^IGW+>1OT1K9
MS-#.MR>AG0_W]^W)'S2.LSV=&K-IJ]W][X?^Q.BUVL->:]!O=_J#_JQO3.G?
M'^[)[RL(XA2WZ%,)W%()HX'S1&-Z#_//GBA#CCDO-(H6UU$,4KGOHHK'4'\1
M50JA@BLG7MDUX[Z)P4UG<V_^"_M=UPP"MOM):! -G%+<$.+R;.IIKC%8V#,P
M-->HZ*I#>" U?JHRD'&#SI*8=MXK5<CK[+VJ73MJ]6G]O@E<9"&7AC1ZV,7+
M#=.5!36O $ N%U;9B8<Y60(7:,F7:OTQ/5B0+]"*B)EP7B88[$ZU1]'*@X2#
M,7 !E0Q,)PJ(T1<$7;S^X7AI0*&%EY[S'\*?38AR%HZYXY!Y7+HU'?^;Z48(
M+Z8KTT<!/=SO3V9'Z-;PY=IC?268VG6*IB:OITQVX@>H:9K3&A0K^[FK-N7(
M0T\+7R;+S(JGDC_41!6K4!)ZACG(GD]I&I;"0MO5?O>J>BS!<'BQ==LIN0IZ
M5_?!)NI3#1*!%$EM[2ZI,RA)^YFTW)>TK6MA [[>1'6L6SR0;JHM+":3_5U]
MW7J4<?>YJ_;ER -2-[4ES"J;;7'Z? 6+8/S=JP*R! -IHMK4Q3(9+U&]N9;/
M7_620SZ0>JHM[R9W8]C*OB8S,?/!JPKF2@12.LF5XV2RD%,[N3C5;WT$-%'1
M%$B(%3BDJ^9M*S37H&/;3UVUZ4@6TJ^R]=LFP86L@OV@N6M6M<( U4QR6'IU
MJV[M&V$3E:@&B8":I#9'=@7G[>P?>$M_UTI&$S54F9Q O95<RZ]RSFC%;./Y
M$7EPP9]::6BB%JH1$JB"DBL'RN2,OH[:_C;O_D&V) ^^=U6M/(& :G0Y5Q"B
M1>VJ_W835;%>X8!J>3GW$?ORH)F_;2N.]]"/ND+NBLBX*JN G$"]O9R+BEQ!
MU'BS"W__JJD\ @)55&U%2JEF3MW;_'5O+Y((&,>L*B]WB20(8Y-.JA4*'<O<
MW7,<9D1X)S,C0NO7@R]>,R1<,R1<,R3H^'#ZFB'AFB&A#.37# F%-L$+0OZ:
M(>&:(>&:(>&:(4&_# F[!_3[=*)<^0T*^]6>$U#2G0P?8Q \:K>WBPE:;J#N
MU""1IEG3#P%:1.[ 63".TCR]&ZP.W.R!Z[WRNO$/GAG9A E[&CT^)D:E24N7
MWF)_;3)SB+YGE8=_&+8?>GU:!G[Z,!X/C'MC.&L/6N/)J'4[FMRWM<H>VO=2
MT9[M'^,?20L?6?S&.TI+=9)%*JW$TL6!@).,8Q#MO&2BB(.>,FX)-L-5MMW?
M8CD%"4),MQC800,7&#\V^9L\( 3==N@\<A,U+_1S<'15X],J@J 8L%P):.>Q
MJA([G;U2DO&MU^>$76>)9RODFX\H"ATKZ'L6V^T$]U!4789_QF!N-O1<'=,*
MT[1<0Y<HJ6]:X7<G7'6C(,1KY!O/:7EJNO&3_Z,A;?"<*S&8JJ)ZDBR=LASK
MZ4$AYYJ%$PYPP+!H]FT:#MT1(WI.3\/T/:(^P1CYL1>N8P:.!8.3V[SA.,$\
MZ>8UR.X6U)PF34S/^4_L!DN/\[M"]OD^@P_'/H,XIF;:G_5'PSBL9F*0G:8]
M[/]/._[5UDO0VHU[]1=<_057?\'57W#U%^AXYKSZ"YJ+W=5?4(V_8&:N';_C
MX' 7H5'D+V#T:)*_H( -V:MC+>X:15$ITOTUE02AR%GCF!6I3]<UH'F#[0EV
M26[-$LJKJJFNRM*HL%ZZME:'*HQUMD@JU(/ZK1.@/CS+/&&4E%?ABBLYTXZM
M%097LI=? (][LD7XCNGV4J$]<8)2V$^5Z2(!&C[>0("DU]Q>.F1C3X+_:!+(
MP/3L ;;^?'CD@XI_ &6A<>=C)L@D!-X'R>#%Q"^0S[G2Y;>>?VHL+"R.( P^
MG7,>"+9L!\CZ;8F?7MO(22P/\H]C@X/\:CY 2],UO- )-X#A3UJ=-&JBN9_'
M![CMUPE!0A#H4")-#EO4;(DSY(8!"BLQK"N6JY;6K[#L:S5F[\UG9VW>^3AZ
M' RZ!?;2:=/:+Y(A/<4<=((RE>P_HYEROCJN2U:TF!8NZ;([U6[6<,B9@V+0
M1E'K+YN&Q*I*'B_UXKUG3(QE;,>OG#+^0H8+C7>$^9=&!UH(L0F!K=83 ["0
M/& ["^S3(2X3;8!/O:]J,\_-NH1BQT;)P6IKS1-IW13?_/&,TG#0A5G5TZEN
M!$1V/WOH$1,=943#99LU'+E37F0?A0#[9AA1]D;I(^"4@+Z7T).FD :L')ZN
M385%B#\(JNJ3:D.S&T!,8(0F R?*)FC9*@[=S\NBD.;2AE=%9K>FHLK-&P1E
MV:S0P%2D-8''IF//,$UQCN(7Q+1"9D &@/+1,_LT%1@^QD#7JMK31";OQ=AW
M++0-06><'J N3<6/BR\(OK*Y@8%)E1#Q%;GV=I,%9M)IPZ:*G\$-)'3)1?S:
MMAV+R'3I-#[8)@'I,WHT&88BML CLF0G[@3947R-U3\T6N"J.\E]([-7DX'A
M80T$1[(W.+[D<F)J1M[4I/=>R?3=YU," 2KLV6R0^-@#@9(>I;"C)W%\]1!9
M6IU'QKK&ZG(AT.3S!6*BMIC9$)'#MH77B/U@]:!94W$">0&Q*>M;J,PSF_$I
M9Z_^A?RRP!@-1U6041!RM>X( :<*+8$>;HB8$-D PO180<[L]!_"E0/+?N3R
ME.8L28!:E?&,*,K!1EA\Q!Z-ZAHMQCY^1'ZX&;MF$N5%F8N]/,QD;!]9R=BZ
MH_OQ:&@,9U/ZTW@R&AN3V1]_;8T';?H[^N[:^.^'_I@F:=,B,=N!$+(R.%&:
MW/P-A7VU>$P-$LK]DKIH!&V>4?/C"3Z<YI-6,UY-@[QT-O19 ?N]$U=G#<(A
M.0$[R5G"*QG=[NIA?LF7BQ[G<G56\^!)!!).,$\EHMV3IZK1U#*XLP[$:XT'
M)?2DKK-;TXI+IS*C%J'FBAXUB<P?S,>%[*43D/MHL7 L=!OY1$+$'"6T4Q,W
M(O8Y_$20=BSLI^H14TDH^/@!ET#9D;SFCQW=[.C=DX:J:N.5E#O  "3H]Y(%
MW;:?3,]"8W-3*.J\IO./C1(VR (D[H^:&FIW?E%B0$:_^8VB&C*ESU8\_$ 0
M*GZ/;EG1.HJ]ACWTZ"/+25/0/;HHEK5GM]?8#]/4=""C,-:ROM \K9#+><..
M:D/$T E6K^;A7,P-:)8H]Y<R#BAW""]]\W%%RZX.J 8YN]24^8[33RS'Z9&K
M],A3VOFC=6>,[B;M\==^MSUH#4;=PZR5$EVH@1]F])O\=*S;Y%?S>S(OE^82
M#;#I!2-O@DS7"$*3.N!AMRGIR--/Z:,70@J/8_2HG7KW)Z=L\UV?N5PK<7!R
M*=^.WNP4!%R9I#VCN3KG9;[(,0_1M>QT?$ DVI@E$71849[@YC4['+D$C'D(
MK\>I6"L:6CH,92%6C5,P]XU^_&C%WR3 I3\<XY;^>MXQ<D!*_]@QZO8*<JD\
MSB&RBJ7I++G^/H'E^OND=A]?"<&F5$KWW)TMVOX %FU_4+L;KX1H4RJE^^K.
M%NW#%!;MP[1VIUT)T:94-LTOUZ!3^3D&?_D3^1M%)_+"6*6":A"?C\_>G*%)
MV6H0>\ZK\S?<86S_=%R7Z4CXPG(DW(U&O>_]P2#C&JB#\%&X0OYQX!V+BX]O
M6%R,9E^-2:L_G+6'=_T.^5U[.C4(2CJ$C(E4<16I4ZM=#0X&J=R!8\5CJ/>=
M""&3[T$1EEDSPL<8W'0V^R+U[# RH4$T""?CAI"W0C,H*]UN*Q@L[!D8FNO"
ML"3A@=0$G)6!C!MTEL2T"T)3A;R6OB95VE%O;5$/_USAG^SR%-DVBD+3RLXP
MS&!#S]5W6^DR?J5$TX6MG,?"//>,3JHBV,Y$C),QZ0XQ:)YL A=9R)WM2LNP
MIPS07%58FXSIPV))NO,,@*$_SD](PP2#W4E5\)L$2#@8T]3UQF"^("BNJ*>R
MP)@SSHU\/'$XX_1",A/9E8W@*H4M,-:%H<WD4D]SA<$-TXW.[G=AN#8@Q,T(
M0F<=*]YRZ:,E^5=6 ].$;VQ7[@W+E6M,9_W[]LSHM=IW=Q/CCORSU;X?36;;
MRLO&/\?&<&I,:_%8GTP\SS[RN;-O$CZ^/>;UU$E-KQ).W/!UWR30+.,SY*^[
MV'M"!$["<7Q/Q 3R'0O(P6AXUYH9D_M6=S3\9A  *<^#47NHAU^^AWZ$?8]6
MQN!\OPUV4+BJ'M)4X&;/;:R-/[T CZ-%E,%X,WSE=,*%9,)11HK?5N>W5N;]
M9DD?<Q"NIXER3&N1\Q)JK\8[S90T&Q3-O<UR<-'9=WPV=K7Z@H]MA)&'F'X5
ML+TB'W&!^F-.RF4O8IS2GOW$0M+>M5?EX"TO[D/2ZW+AGE!!6HLI>*;'_'/C
MA'Y$/"3VSQ6+74CBN_JT39-VEG#8?)4L:C*O]LD_1=<7OLYDQNH.A0@CL&4D
M&9JI\UP>&K[.\[?:;P0BC(#0R-X7#%HL-B:K##:<O>=O%=W\\8,CQ F(SEGA
M\N5>/$UH15KXX5_FSSH?K \IY7 4URE=< ILJ=XVJ/\%WZG0<#YI]9R"I<M4
MR_,MO]RK>VE7\LDZD=LZ6K.$?]!$Q0NF/+7%#/(@\;ZO?[6(2YD6B#?;I/;*
MK,7B/2$/$F_I4O%5W!'<FA:]L<NO'9>["^U[S-\J.LV><S=P3#Z$DF0GV2$1
M<<)GST)_(!,R$.$.NHN=AWH]/?Y'5*=YNB=FB.+7XS:S=DBND%ACZ(YC289J
M,4'/O1DE)QONBU'2MI%0[0D'[2B-(,D<')-_!G'6+L="C(K!W$,T$L!"?D #
M3D]<.\@C K<<T]VS<XM,FG&T!,2,T9J.=B%KH&FI%/@)>DQR:P:T5,2.&\HF
MC"^C4T-@+.0 0DMRJ=-#JB>(<NHD85Q<-N9!#]UEST4^)/BRU4RY!)]1 :H9
MCBVV[)TR)C)@\V 3YPZ\@53[_HJ^NQ@MOM,X32\<^1/J%C>>B7'L!"C>M'=_
M#-*_!@S+IM1PNJ-_/F\0]IE:JXH"H0LB9L>F3R2S0B%-?K/CXR!\]OW9X;.M
M7P\^<PVGO8;37L-IK^&T>CC7KN&TD&/L&DY[#:>]AM,V/9RV[AM)B>&TS-O*
M:SAMH\)I):>R3TK6[@N_L@VI@FX-L*BX&-?M<NN(UJ(='&BNQK#B$SCF84!3
M TL&.CJ;5](0K#'F2]R]A]=K[$U#;/U9F%3IN*FJES;L:8(YB 9GU#GKW4ER
M:QLY"1#D'\?R)[^:#]#2= TO),P VP]I==)(Y\TFCUY0\>L4=4(0N$21)H<M
M:MXS&'+# (65; H5RU7+U5Y8]K6>FK^B-5XB;_/<12[S-'':<)Y'2Y7+,Z2C
MN)!*4)JR\Z6MUU'\^<&@R\Z1=M*P]L!G#FD"5$+2E/L6I<39BVS"-&02V;W(
M=[SE&/D.MJ<KTT?!_D[T(-A@BBS2-'00\W!VSKC*'E.*W5S(8!+2"\46:-ZM
MZ3"BLALM]BQT3==%=F=S?($J>-7,/W!#%$,*EWK>K&QI;7MV0NPH"H/0]&PX
M^B?M6M2S(=CRL2';=P/LG6,?W9/SUN:;Z490XD+:\*2=[L)F$%W%V>5"0G(T
M!_5\WD K2K&_YB 0LQOY/F*]<<IOWQ3T&,2#]SJ*(J: ^*B"O(D?CF.CX"BH
M;*I$74*'3@"\QC]=XY^J1(Y>2HX6;;I@+V,)L>_M@.8ZNU#9E.MIJ&?(I+;J
M$'OF_C<S\J_ M.)J!457#,(#J;G;8X.#SV-)T]L^51AKZ3.N7@]4AF:UESZ*
MR1()7SGJI"A(J^QL@R-;<OB2O0B#!V[GR0S1V#6MF(!I]".P?.<Q%B 71 (C
MJ+K+E0"8*)?@ EMCCC,^_ 1&4%5)1P)^HEQ*O]Z 5D4?V4YL4N^H*,C6"'90
M%<\G8SED,P6!44':S) P[B([B?X8+1:(7H-,31<%W!L6]Q#S#Y^:BY@PGZ O
MY9/:<T5<Y0S98],/-UG>.YOL7]A'0)$Q&G N%!>);D&=63J+8@;SVJHY\I60
M.PR<YH&=YR&D\X&M A1U#N[L$ULJ(&,7'<D/VRDZNC$F""Z@MJ8;4+(9/TP+
M94J;YK1490(6BY5%,&C>52G:XJ<S4//YE\8(^9AJ2-)?JI1TT1N\_,;*;@]+
MB/F(:/BNHU*%+GA\E]]86=&_,MI\2#0HYILJQ7R+(X%E>=]Z?J/(^55"T,=4
M@Y(N_90!"IWE7#).)]Y[K1=E@%[0R21[/>9=(TYGV@>M5V& 7M#5('L!)M\=
MA2OD\\H7;#__H/4R7$ W*._2*_$UD4EEB4S4AA5>$YGHZ8ZY)C+A8TZZ$^::
MR*1,(I-:WW6^[">TYX0B7Y_05K/>7Y_0ZO:$MFMZ].#LA/]9(M]T[;9G=PN2
M(<$]ZK\8YG@'6D@O> KX)/44P%42)XGBMZ#UFC0Y;*'S8GU"+"AHF2N*E7XR
MD?7VIV-9;W\_;[MN2J2# G"=V3;/;5WS6@Z)%7.06L^B7C<$6B[[Y6&J[M+T
M7*3Z@RD#&?+7^8>Z+_)XU!T#=(+K4>D+/#EGVK&/+83LX)9PR5U2@=%I_E%1
M_*/8^YM"#B"\U'H@*GR(W0S<^-@ [V*NKX6; ?,9O(%FA]J4*R9-X1_G#B'+
M3> 0DN+7[1-D(><IKG&6"8."01<;IR%HEV%*3\]]_#AZEP,FW5B0O1=%4ABR
MH. 8SP@-@5:,G2K<:PTK(]<<6 7XJ>(P+L'TW175VN5THC5$NSA@)3-B]6H(
M>L4L0("5+2@FZ>6K&P^.DF1;'3- -LT]2D[/\79A/--_,A((\/5O"(@BS$!P
MEBU3ULABN,V 590A"%JUM<HHEZ-%\F+MUK0<UPDW:?WR#O9]_),<U[KF(_E+
MN&'<GPN,TA!XQ5F" /ZBC=N(\A1LF>)S&AUT:0AT!?2#/@=MTHJ/37_D)ZL(
MS:Z&R%(2[QT,%T-QYX: Q\T)"*.&OB,=<G,V!'X97(*J(3E@]A[;SL*Q8C-N
MM#">G2 DN\*6)N"FG-U)=YAX.0 A4.OV87FER[GD=0>,FP40,;4^G6Q);4[[
M!>S2$*P*Z >!4NNDV9Z TO,L^UXRIW%#P $I!V%1ZXK)&L-;_Q%->;ZSLOC.
M ;E=&P(9)Q\@@))KQ.\= PD13A#DWR3%F9IR&^LN^"+*05&K=88<<G=/"\W3
M($)R .'U:V7[Z X2)P,@5FK]&MPA,,T,>Q$*=2D=J >L4."E46I%'MSO PN7
MT!BZ@U*2(1 OC:O*#-'/^$]EJ\?L^NN.:0EF0#PS?H5:,ZA/K16R(QJ3D4V@
MOB/T(&_ZQ^.\Z=/N5Z/W,#!:H]NCO.DJLZ4;S]29$#G!BJ(W6E T3S#,*97)
M[J9RMNTPRJ.Q(),Z5V=M,JMS87<\__C%D^^RURW?>AX;[*?:< ]E#SE$4,&<
MS( @:@<7SY/AHGYJGG072K\8K 8\[ZX&,RT?C%2!:ZU/":<K[(<TX)M:*$7O
MOO,;*WKTS3DY, _YLM<^'F$'1?E;@-;*:E2?)^\C!J2?O?A$7IB'#VRO*AWY
MV6(_8@$2O-Q2JI?U;K:$N<7]CO:<YQ3*'W%>W]$JAT!+L^@2W]'^/OG.0(;\
MM6X[J,0KVI3**M:BQH4Q*\KA6,8)(\@5!*_:4R%7<<]L4<R& 90EF^,\H<H1
MC<P O?*31(SM($!QS-' ,7_0$&JZ@+"<U)^83FJC/35>38Q!>V;T6NWIU)A-
M6^UAKS7HMSO]07_6-[(^[+TD*N8V?H[#9.MS(5NM[F@ZJYOZ:?3XF&RUIMLU
M@]7"Q3_[W@+[ZSBVC\G2%Q9+TX?Q>&#<&\-9>]#JMJ=?;P>C[ZW^\'8TN6_/
M^J-AS8S>.AX-^HC1RJ@B4<S18_R$U5L>_XW%_*<W+.9O^\/VL&NDN&9UD^KJ
M:&Q,B B&=SE_KU<H<1S@*[QX%04HF:B=S1W"2]]\7#F6Z0ZP5:@&GVY8DICT
M[[[.7HUN7ST01M/YVOFC=6>,[B;M\==^EVC'8-0]UHAZ#XGWY#"[)#M;FJYO
M@DS7".BN=[(F'QX=>?HIO>0EI)QD8<J[S#ULI_XRB5.VP&UN'M=*+HZXE&]'
M;W;BP>X*1G-UOHM\D6,>HFNY$N(#(M'&+(G@89GR!#>OWV%1+&#,0W@]ESVU
MHJ&K[T(*8G5Z,FCJ!W_KR$A^./%C)+^>_S[)\V(D?_Q]4K</@TOE<0Z152Q-
M9\FU/X#EVA_4?FE30K IE=)O9LX6[4-N KODCP_3VB]F2H@VI;*>NQ=A6_3P
MD!6?.T:+A_34 9NFS&ZU>V_.,4N+.>%PJ=7JT(D)W1Z"AS3"-72>]M;=P1GP
M[?$9,#[9[H^SK5U_E8&% T2$G;@ >FA7[9IUR-MF BCJJ#)]0RYM!4<^9B?U
MYS]>L>?.- Z!-".,<.QCLFB$F[%K>F';BPL3/U*!=3;T=IX=4<C56=F)D0>C
MDQ=<O,+0+;X0))TG8(VKLYI(0Q%(.,%L0.1AU6AJ>6"M W&=:P+?FUZT,*TP
M?AZRRP544""8T4E1/*/(O,,BO,A>>(%(NPD*$!E^14COH2?DXICXE!P'!<RP
M.[[.JD(?2T CR)3T0S< TFBQ<*P"+ [:J I[+"GR4]KK.7._E-L$ =NPW-5"
M_=5;KE<+UZN%Z]5"#2YP_=VT"9%5+$U57MDTX&HAI1*4;/VK_L3TEI"7AOP]
M\^>&[+4G#.6L#&JD#!J;6ZJW#>K?/T^%AO-)TVB'%)&IKKL@I]QK]#KPQ:(1
MN:VC-4OX!TT4;'EY6HMAZO19*M+DS4S99IM4H-KG"O>$/-#SHK@L>KRQ'%YZ
MTO>"-!$8V:U-BW'I6]QW_E%1$>@S+J0*^8&05'7_&V=L"^,DE'R7P.^.+X&[
MH_O[_HS&@&MW$XR#@ J?P)&\:3K!,*]"/-Q'Y4P[)JOHZA=HK\^M;R$V)]7M
M61)HQEWO)'DM,S;]<).IG\6^XV5V4G>F8,-QG.BVD&_=KG,!DHNN_@JZJ;G"
MY1$_%V":7]I6@9F6!Y]J<*TU7<R]Z6]<T[-GR%IYV,7+3>9FJXO]1YQ4'&1>
M,(D-HN@ZEF\NX7.XDKV$@NE"'PD3E(H>&IAW**!4)$_N'.2CGN.CA#7R5\]T
M-P':_Y&)X_D#UWZ(*PNN)%9!Q"57ON@'OHG<*.@0(BA9IMOW["@(?<=T@5MI
M''EV\=0]?^#YNP\-P5P6K^#:_$'R1/\=^\AT8JHEP7W&B/-W=5>5+XOSV4R"
M '^6#'#'\>TILDPO9*)VW&S^OBG+;#[ED'S?EZXE!47'=/KLR)CMW^?O%44B
M"4OTB&10E')S7E_,%1S7<9GO]DW1'>?U]NUZ^W8AMV^B-T1Z7Q!IFX=K%*Z0
MG[E@8/LY\UMKOF(S::_E3O1L5(K<8U![-;Y,IJ39H&CNO92#BY9;A2SL:O50
MYA_<1HLQ#LG_DI-=-_+1+?9I'/G(0SV'(!26>IW .:8J'U?!/"I\IR#"'NC7
MDGQ .SV?TY/0:+'[R:<!B;")$+MU1,:8YZFG5N")LP/.1,E@T1*,OI.DK\OH
ME3ABX@/-%?D8^6$KR1.$G6Q7HK2EL\R"HOV<*\L4N$S*GGIW:_J RHYBY]!H
MT78>N\AU TK=3]PE_6G$]HPN&L%L98;?'=?MT/KM-+<DLOO>'?+7IK<A&T('
MN4N'<>BBGZOH:_.WBIQL_(I0*>>@P2O[46 /[3C(-P728KI%,UUHE/E;1?<#
M(M.\!$<@:K(O [8DC;P>BC/"ADXP\Y&9&NF>_9U>5GQ%)AEJR67>"HPT?ZLH
M.[.X52O,%8C@%[6Q3>V?IF\7)Q<Y:M8,3TPN;SG7%&ISMM*BDQTS0#910#KS
MS42,/O7ZQ5K5V>S;C),B\3%G>_8\F[YH'IKKPG04U7Q-C?LG'UY< [^:>HV:
MKTHZ>ZQ4J9MN-R9&1+,HL"Y,LBU4.:HJG?@89A4^C=4.5'J(&/E3Y#\Y%N-6
M/+^EYIL\2#?HSE"% +4+4PIA3_Z>G;SF]=^C,V5[ @',HA87[+* T')_D@!6
MS9<I3\B+T"UAX(XLQV'1-4EN:Q6I8(MU'?/1#4E:\5DPH7."+.0\T15WB#VK
MJ+82W&?^7I&_7/@Y61$/$%R2Y\4Q&?L"7*-%)[*7**3&3!#F;>*QWY"W?P.0
M*<$/:'G)1:EM/]&R0JG%&(R\MA7G(QDM8GH!; IZ-001+B[ ;5_Q>[!X.6:^
MK4Q:- "+7(K![5M]),O6I5T0P+)MUAP$<LC6T\MXY.'FCB1J&!3'A,L^"IY[
MUW7N+5<#X"C!#X321]GGCL?MQI7L5UF#XLXG'$Y-%\2(LW=#$!+B!L+GD[(\
M)2X!)WWY&A<:M:@VM9<^0@+92]Z?9B\9#-J=T22I39@4&>T:0UK'\&YB&/+3
MFIPD\+.1DZSIY!_'2SGYU=P@^(:;@1-0F)DI3$AKL+'**XK&5BAD"33_+D!)
M64)@[2N<,H!SF';F[*O,7<PN1BC 04TGR.+E"W)-<O&BR&4L+F<1@"KS*:O$
M2$MO<ATXUNINIDZ+CH/#70:-06@S/<YPA[H??Y69&IB7D9I6NQEROYK!"J^1
M?X]L&KJX/1+TO85O!F2OHT4F4,:I3LB<K=C1H6>.6GMZXS.1E,$NN'3*?DZQ
M7D<[GMB/)DY;SF_J+@UQ)C(@#^#T*ETC LK?L!RB)7K:90A*:MRW'Q]=)ZGE
M'G26[(0< B/,;^H.L#T3'V'>0-QDA]H>,L4U85A=Z@]L/Q.98F; %4OVDC5]
M)'J ?63OO%5<<!1UF[^M.VOMF9#P,03"\E'^#(G6/QSSF(.B.<+H-'_[J5F0
M\+ # O))]MUG?QP_16&;SP>-ZG^1<:[1G$,^*.#/DE.L=4W766#?<\P'SWE"
M?N"$F__"1 !B"Y/H,/4_O#AW5I1B$(2Q=-P-]$CU6[L0HX,V\W=U/T\\$X <
MZL'S_#O)DZ3C8]-&7HSW-T($/?=P38OBCO-W#9L(O"R!X,A6?7%46+2_;]BT
M*.0%PN%]Z<>ZU_0\!1< I=+RZ)4LZ9J61X\'5M>T/'S,U>7:'WFS%>J1R3]:
M]*GPS"3F9+PR ]0_?"G?][Y&:].;1C_^A:R"D/-SAU55WI;_&;,4#L&]3'8"
M51:Q#HO:\BAS#*M_.A@I'$(HRTX.PR:62>T9LYEK8%7%IV0AS<TCA+5LQQY
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M0!MD:^;40*8Y_)3+NF&!ZMA3)@B0#_H#3XX45LX[&R"5434R23>TD,?3B,4
M4D(72<,1PD(@39.SJC, F:2C7D*ZPR\6 T@'W?X]WS^,OUW? 'A+'#?D0UW4
M#2%XL&)&5'( *<&!TW*":HR^GV\R6K@<*/1C!-#AP71DL#DB& T&+L<!_1
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M*B%-W6A04:<$AX2&2 4A7KD"JC0 +'YG7_'N3-H#7AX._@Z+ZY"J!&TM@M5
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M!<$02H6N3:!*EE$(!FWR(Z9DC7>8$/HQP/<X5;-'K6)U,#0 WQ@3%?)@*&4
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MS!MI@F%E)[A<(8-,^0H]9>JL@_0:!LIB4C"(R@*8RQ1LV?I;\F;$HM;S/TC
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MN/_5BV,OE-R!58G;N\*G!UU=V)/+.B>;(< V>0J-6A(,NIG^)=>RSQ3Y0M)
M"0)K)(L]K09X!BD79!H>P1K25?/PR2X[K1)$&G=7!S EE3IENJ2JZSKG:$_
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MMME5=)UL29_UG@,Q=JP><Y97F5QG&387U3:$<7-6F7#;C^J=4W>I<GWGK+X
MM"&GB_JCC,M% M:<S6#GPE-Z_]3;914&SDD:'7%<O %9F%%G*VY);>2BFM=*
M$X"I;8+;D-V[W%1]X]7:K((;B_8O]'B7C#WL@F4Q05H>[FA&(+/QK*M-AW..
M?NXKIB#=##HG^)!><+&@630!G9-DZK3+SJ[N9/UXL81C40;YO)J>MCU1HX#"
M1OGW4:QOLZ"VK?>UPQQ%J.NV'U>XH^Z]!8KP]RCDH T[['UN *54%P9'S:\3
M2]Y3%P,P+XJ+*&NN;;4K3J/4"U2L[8Q;&(RCN_$(FKKTL"89(N>!TA  *ALX
M:D!IA17GLXR+H>MR'LSO/\\V77(>V&,W<7:'\3ZA)17R^5-R&\6+*'RBT4PL
M1R?Y=[Y$7GFQHH_N:<LFQR]RMY4<HKLA,$R_!+UJ]YE&JM$+[?_QF4RFXS3$
M\17R:ELB<0KDM+K^ M:XF/@O#S6/7VG]18/WIU9W16X3IV1\5NF"I+ !8$$E
MA$SES=)6</UQ$NYU5U@[67!%7D/79/S5J(.DL!EF64VC4ZYWA4Y!F1D;%\I
MN)LWT6W$*IO%N#-U.QBPRMS.CC6(:ZP-;>NB,_(V>\N, 6^5P=?GQ ]QDN L
MZ2M=/.2_R.K9=S/AE,4&SBEYK- 'SV0]=B[SD[C8(LWL1&L0T*T.+[=02ZD.
M)2M&?22Z\=ER-RO74%7>V]1NIM,[JX>#']"+SB:+P>XF7<T\^CHOFXITM0=R
M;M+3":Z[STPB^O91(JC&.,B9BN1HL;;*S?9SV+]$QTTR26O'@&JHY>&>6 Q*
MUZJ'R.\C%!+L3 YH(H6:2_4F(N=4%T47X[W>$=$H+]>"0L#.B.4[!-_ZI3 [
M8$OH74]$NL$CVN-31$;]-W=4<?$..-2CB<N.)-[$*9L<M_24[92;0(^OZ%MZ
MY/9=<8,H>4MG;K=^Z(6[ <[<E(8 $-O 40."*ZR F6?VAJX[<[N=WT_NIP.?
MN4DFE^50L3QLZ5G(.7YE2<!$<R*YK+4)I@YN.<64"4(9XTU OKTZW/5IRB<_
MC&(_?66IQO(",P8K-K&:JT6UR@G9PEFD Z;3,@2J.BDU*$Y67",KELQWJQ4\
M@A:%.I=Q=H*153\R>&\R15<D53LBHZE8"R11E5 E>S5)QCR_J,9*-VQ8[:.K
M9A%6_!7'.S_K4B-6AB]!W^9[GVFMW.0N(K0&N.=9JTIK>.K/:;CBK02ZC+ M
M<9!,%6,TIZ@@=Q)P+M8#&,RXJ-2PR44#Z'4N*L2AS"K-H<JWC(0L;.?U>HS"
M/9 %=]U70]:YI9H)OZ"3RI1)V7XCRWT5A4_O\HW'1RBGXJ(YAHI$*@7GLS\I
ML>32(,=0(43S(33KL$#=R#;?*;IXJPGJ'N!E>W]O8G-;CMMH<_M0J(/;TJ;.
MTO]+EUTO9 '&DLPE:>SO:*YY&F 2[IM_J$FN6#W;]EVQV=<\(6B19'E-1I\L
M8;+DI=L&8;,9N7G!]:9H%P&LYNS$=ZY+F&W1]./D_FZ&YO>(G0A,[F^R_YC]
MY\/\\V0QN]]NV!_7L\UV/9]N9]GO,#J)=M9TZO$RO.C=EH7(;_(R(W=Q=#X1
M#?)ONNOHAV>\SR_N1:%L[(0 S&9G L%?OH-QCPK,7!?,J^ *%MS>SJ9;M+Q%
MLS_E?=%ZLIWE_=(&+14=$XQ."$!W\_?;L;CN0OYN.XL3FT-L4B].1YNG#--#
M=)J7H,D67<_NYO?W-)2!]"J_S29K1^72_S_%74O5RAKLG87*O4,G_HO8>V5,
MW1GYLP%I+9:O/I]. :M.Z@7T#=T&T9=Y>(CB8U:-2QU.9JQMM<!U-Y<:%:_-
M5,',^KKAY6Y+/JQ6B]DGPM?) MW,-]/%<O.PGE&"EM%C:+N>W&]HR-CR'DJ.
MAN+*Q<KS]_=87A^E)>6BW$\+HJBV3RX"AE-B7-*J/2SQ,TV+1[<>]^>8[C6F
MSQB]8B^&0I<R<92.,;R@Y4Q?$J"MM%XM*4#4D4 31'[1 J$L(5=Y*9!\\G.X
M3]X H^[)MR3@JL#S<%_NT\]3?-1&89OK6SUXZ>I6X]S%5!D,6[LB5@Z?]\O[
M=]F@6<59D[F>*-/12$'7&7:<U?PS3X314==:4'97=\H@;5-%YSSL@[;-P5P=
M9?J"Q '#Y@V0Q?O[3\]I=#@G."L94=P-GX?%=B1-GE0*R5.%7VS-WIV!BUVN
M;A7T-@6#PA?CYX)]J.R[Z/#N3*M!YI7NBF0!-+]X4?F6+'107!<>/R5SD:-#
MT52SG07JO[JHR #V[-W!'L#MZJ;V!<9@4'X #SHD?VGVX<C/+8]1WF28^3$-
ML2H"KJ8TK)B\#%H^:W_#9O/YQ&L9LT1Z7I#_>UL%(TMF; /8M3F?'NPUU.?9
M%QMUWH*&]J3=DK;MH';:I)3Q\".-%;4<.,M#55&K,2Y.H^,Q"MD%/>%DJ+L-
M:V-"7_?*<:"K >?,O02U)D%2K5P@-\79,6O9E<S12DV4\;%U[*QP1HA96Z*E
M,QJ^9SF=1*_H F/VBDM<ZG!55:*O)1A\OA0^M[?7Z&EKS,V+I^1&T1=BE>WK
M>:)483 F,LOXR0OSPO+D?20$VCX[60GW*_(5Z,%+]DKRG2,OV)"_L!,9W2;@
M0+9M3F@&?1WU2<T@AITWIS&\:;>NNNTKU+#.E@EU^[0UE4] U2/0GXN'_#>,
M9E:D%[S!R2[V3_FKNO82GVV)51YM\=?T.N S25QBR&8#ZN]HO;5TMP*F:?2&
MWFX'-[/-=#U?T6-I>EY]_;"9W\\V0"(&\Q4_6<2L2.O<Z=/RJ!1L\E,/O,Y#
MN308OFDA\M/R0@$5&N"ZRXW_%/H'?T=WG#C_=%VDJ;+5B)U.#C4"=HPTP="Q
M$USNO'%^=S^_G4\G]ULTF4Z7#_?L8'&U7,RG QPK#K3U)XR>R\+JJC [77_8
MV8K5;;U^+C8V\;J9 ,/??KBYL;MF!55FV/RU,(0R2^#ZWJ:C]2!2P8NA?PVB
MY!QC7:]\N5G++6"0E]!J$A?9A-1&AG"$:S3SS71)>_R'V0U:KF;K"9W[CK0;
M6,&J[?NP:.JHMOZ4=.*]+%C;]^OG6KG9UTW=.2G[8U;M5Q-=U%0>_P2%PROK
M4KLHNC@KT3LB.B"1:\'@6!>H'+6F__DPW\S96CZ[-T%,3N[G_S5(%S=85A?Q
M.;]F)FN@9SG'BYD;K50O:B7G%.R*5)#X)0^X6)4!%Z4NN#FHU$OS^68W$R 8
M:CB/[*(/G[?F\\/5FDX*M[\1"B\FQ0TT>B-M12.481#W+HKV7_P@(![.PY2@
MIR$86=!@;8ZB[E [VK!)W5[NU;G;R0 8\O9!W69O88/UO)45E)E!E1UPG;&1
M][KNN*L1<*Q6=LG=++PM7NNZY?G]=G)_-[]>S-!DLYGE_?+=<GGSZWRQ@$%A
M&HAGW/_*A&T'5IKUJ&)),!13PN-V@(@PY)ZPZ8QVQU,F[8Y(ZOU)L2A0*NFZ
MI>GR_C.9+;)^:;&<W(]U*:U"Q&JHF^T8MD0=; T*P0KV !MRSJE@ *[-@\6(
MX<_,MG*7KBUA[4N+H94?N/DSC.\JQ,1]SB&:\C"C078C43.9: O9[/O% .M=
M?E/".0V4L#@F9!="H<T1BGNN"UI,&)O/%@ST['/'P V>3@HE8 S3(^5(-YML
MH 2BT&!V/RMH219P4W;T^H1#&FACO-;I:,-JWKP^[C62AW4Q (:9?5!S<]_*
M!MMN:EB!O,"J 3?O.75*CDAKV&>J-:S2\@7'CU&"%V;L[+(4^_1IOOTT1+Y3
M[2)L&@7$>!07MQ$6_@Z'"9X\Q5AY9Z6_&0>+M\Y."A9VQC:<]XP7 N<[QYH^
M"_3(+:#*Q$@T;3PZX8'3_KYL7\IU95]+ULAZF:LE7_N9@4'9B[#S?>AB,;E>
M9C%Q;(=],9_.[C<S-+E;SV:#=*Y#):,KZZS/:?N<[%_H9<ED&TT.!S_PO52[
M:.YFPFX"N^[.-5/;F>L[9_$%H/ET>*4)EM2#]+J%%91&J+(#;DIJXOQF]XSW
M9UIBLR:MF[8.81@:]<U>1-<&H;;ZIIJ)D2O\"2M-L<>Z>%KE9++9+*?SR7:V
MN4+W,R"!+UEM64V_WA:R6M]#"+!1:Z,A 8960EA<#0HF!*[S9)D6\A+9&<3[
M*.VP*=I!W^IMOJYN-2[TF2J#86!7Q!PY__-AOOW-40F#F1>'?OA$*TZQ@NW*
M'D B:[DT@,$^C!8I]PUR!40T$%,!UUFT?=)U#@IYJP.+#K:*8? :NPXA/SF9
M+C_-T+>+Y6;S'5K-UFCS<;*>P:!4U4>QW#\GL@)GJ_$U#FC97I:3C7GYZ"5X
MO\KK]!I<W;W$J.V;O)>_@/;%WOX6P=!\$#>X^^M4X1W30+D*FL0Q37,&\IJ%
M\4NXKK\$@YN^EUD%V4#4KZ!7"Q&;?'M-1.D'UT:VR^DO[ZXG&UHS:/EI-;O?
M +H$5]9W,#Y!5VHXJ:UA=CJN$ ?#0#U&2=D-H@+YF%O@EWZW4*7BF&>:'3ZY
M/&2FZ3JR[>1/4"*!UO@%AV=\2[X3#?6@3*<9+:?G)"5>Q9H>S%C;)LLZNE0G
MG*$J&.YUP\N5$LBT$7U]J-#/4H\6%L#U?QJ/=7VAN3H@QBK[2%/=M\)97=^Y
MGGV>W3_ Z3X33-XC+:9Y0_P*(I.T!SHEN]0S<:!).)4&()H9P.1[Q$PIR[95
MJ0'L!C.@===84,CIG.)X$QW2+V1U93Y'O,">"[;V=EM$Y,[&P'&\KP=\I-"&
M%:-?SS:SR7J:%9Z^(1WN8LD2)12%>\4_;F;KS_/I0$?+VFC-,G?S["O=7L#)
M/9;UNYTT'<1DFK@B",-4J3FG:'>LXNIM-#EWH8.(TJCU 9OXE%&4&@7+E0 U
MP%OE_R32,#AC I&C2E96<K) LS_174%0X2WYGB<MU/.ZK:KOZ(Z*]&IV!UXS
M)YKCJUK'.=\Z N4GBTP-,3U45P0X711[V&6"V,$"!&8:3P*-U<'SU7RBMYXM
M)MO9#5I-UK3H;J../0S&/M#Z@;,D]8\T]E'R(MI"-GDG!EBG5E,"#'N$L-H$
M><AJ+99B-/*:EB-:Q?CDQ<H"*C#X4]32((NA1P*2M0^62_Y5\EI4"BZJH,B!
MBZJ=\-)@^*:%V.9>H8!J&B--^UF%NEHX=89+.?'7JEB;^AN"+R?_&GGGA.D
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M$M$GO OH(_*J7D :7W&WT73Q)1-W<LO4:/$EEH5#2#5 ^25F#(1"U37_>B*
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MN V+AH+T84#R!-80B28[O#$\'-%L_>SY/@U]6D3CIA,F,_RB9WM];#=.\DS
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MM%O=L\WG@/./O/"Y[5*?TJI1]W3#HIE@R\FJ.7WF(Z_(/A+7KW% :#'\BKQ
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M!P@K-EMQ#'U%]TD6PGU_QM"_R?,I1?$V2+B4/8!C)?V?HX)Z,W%4'PALGLK
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MB%RO):K3W?6=]PQMD?<=ITHJ""ZM&/EKJX$!DA+2Z5<7_:CA,721)F^:( 9
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MS-$NB@7PG[<$HOX7G:@WT:85[/_*L+J#XF /P;O6& CY3SHA9U"H%76J1M-
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MUF*?<LG3"/@L]LD;^87OBK>1>ELHY%JL4CZ!&C%?.J]C#]-&LYL0J,30,[M
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MV4^##X.CLYUFE3TEQ!T4_0?% &UE[B!R*R=YHJS)D@]KQ]GE<H>"-#G\I2J
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MZLUT,T&EU[IF9'A[0.0RC:O 59OJSF;3AAU,BLW0K1GU1$3,$733G?6F#:-
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MO@ P4&:L$5THV)-RD\@K33R.0OQ/-\\^-HW2WU!J>=$N/3B2Q?9;]X&AC#3
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M_-M@-IH/%I^M^<B(/:624@FPNS![&&'L5J=WXR2^2P/.@RQM$X8K.:#N/4W
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MQU&V WAOI0=Z=^FV7,0M6:;%SPN+)H[B=.VL$<UJ8(=SY 2CA$R/Y[PED;N
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M-V@5Q>AX[2IY+=?F SI3W'?9/OJ$UV"9(7?OJQ5R4\;]MJ2$B(?3F1Z_7WF
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M!*VP/'M%&EMRD9"<>)B([&2Y8<Q0V'LRH^5(UVAE4WJS,$7>788/))(*CC@
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M3N/JL7?T&5^XIG.B 3KVZC%!E(-L"@3=-&]_S7RHK"@0Y69L<;,XPI--][/
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M4)-E9*U6>!WA'917B[X81FX4C6MN]'\S++ /*-U$'FC5,3OH>G_0"O'&Y2C
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MSTOZY$41,SQ1>U=H!8GUC-$F'IEEA#6';132^6^B *^WA(H F^K>/J#[P;Z
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M5+<F$RS]YQ;$R:F4W@=V?5YE;].=0-=>LI3"8Z8(8>="^FD&;>-+QXMN'?^
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M:LIN+\:*2%$;"0"@R&UQ&L$J %^ $PDS@-R/NRB??OA9Q"L"'PT0[%;!QGM
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M!Y14LKJ_]UP0$34E;$QJJWN!XY*T0A5D.LV*'.$7H1/MLC?1T\-P#?4?TA9
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M S!I:K=VZ2MCD*(@V?* E-/J?A7MX+X[RH8<_PI\TN$06H>^N7U9]!CN>?!
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M+30U+FAT;5!+ 0(4 Q0    ( /QA:5+<2S\03#D  %59 @ +
M  "  3D8  !E>#$P+30V+FAT;5!+ 0(4 Q0    ( /QA:5(C^$;SK@(  '0>
M   *              "  :Y1  !E>#(Q+3$N:'1M4$L! A0#%     @ _&%I
M4C&G60"5 P  9!0   H              ( !A%0  &5X,C,M,2YH=&U02P$"
M% ,4    " #\86E2GWF-)S,(  "^/@  "@              @ %!6   97@S
M,2TQ+FAT;5!+ 0(4 Q0    ( /QA:5+<N.+C3 @  +P^   *
M  "  9Q@  !E>#,Q+3(N:'1M4$L! A0#%     @ _&%I4K%+)K&=!   '!H
M  H              ( !$&D  &5X,S(M,2YH=&U02P$"% ,4    " #\86E2
M=AX]L-,$  !R'@  "@              @ '5;0  97@S,BTR+FAT;5!+ 0(4
M Q0    ( /QA:5(@T^W#G&0$ /*Y+0 ,              "  =!R  !F;W)M
M,3 M:RYH=&U02P$"% ,4    " #\86E2UR1SUA(+  #/"P  $
M    @ &6UP0 9F]R;3$P+6M?,# Q+FIP9U!+ 0(4 Q0    ( /QA:5*HTNBM
M-U@  !UB   0              "  =;B! !F;W)M,3 M:U\P,#(N:G!G4$L!
M A0#%     @ _&%I4G(D0#2>2P  )F(  !               ( !.SL% &9O
M<FTQ,"UK7S P,RYJ<&=02P$"% ,4    " #\86E2 >!*I#][  !N@0  $
M            @ $'AP4 9F]R;3$P+6M?,# T+FIP9U!+ 0(4 Q0    ( /QA
M:5+D@1TDLBD  ,?M 0 1              "  70"!@!O<F=S+3(P,C Q,C,Q
M+GAS9%!+ 0(4 Q0    ( /QA:5+7MGQ1HAX  +Q\ 0 5              "
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8;6Q02P4&     !( $@ _!   [C$(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
